[33m[nodemon] 1.19.1[39m
[33m[nodemon] to restart at any time, enter `rs`[39m
[33m[nodemon] watching: *.*[39m
[32m[nodemon] starting `node ./index.js`[39m
'characteristic','C1521970','Characteristic','Characteristics','false'
'placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'gemfibrozil n $nmbr$','C0017245','Gemfibrosil','Gemfibrozil','true'
'age yr','C0001779','AGE','Age','false'
'age yr','C0439234','yr','year','false'
'age $nmbr$ yr','C0001779','AGE','Age','false'
'age $nmbr$ yr','C0439234','yr','year','false'
'race white','C0007457','WHITE','Caucasoid Race','true'
'race white','C0043157','WHITE','Caucasians','true'
'race white','C0220938','WHITE','White color','false'
'black','C0005680','Black','Black race','true'
'black','C0027567','Black','African race','true'
'black','C0085756','BLACK','African American','true'
'black','C0439541','Black','Black color','false'
'education $nmbr$ yr','C0013621','Education','Knowledge acquisition','true'
'education $nmbr$ yr','C0439234','yr','year','false'
'education $nmbr$ yr','C0013622','education','Educational aspects','true'
'education $nmbr$ yr','C0013658','Education, NOS','Educational Status','true'
'education $nmbr$ yr','C0039401','Education','Educational process of instructing','true'
'current smoker','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker','C3241966','Current Smoker','Current Smoker','false'
'alcohol consumption','C0001948','ALCOHOL CONSUMPTION','Alcohol consumption','true'
'$nmbr$ $nmbr$ drinks dav','C0452428','Drinks','Drink (dietary substance)','false'
'$nmbr$ drinks dav','C0452428','Drinks','Drink (dietary substance)','false'
'hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'diabetes','C0011847','Diabetes','Diabetes','false'
'diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'prior myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'prior myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'prior myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'prior myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'prior myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'time since most recent myocardial','C0040223','TIME','Time','true'
'time since most recent myocardial','C3541383','Time','Time (foundation metadata concept)','false'
'infarction yr history of congestive heart failure','C0455531','History of - heart failure','H/O: heart failure','false'
'cabg or ptca','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'cabg or ptca','C2936173','PTCA','Percutaneous Transluminal Coronary Angioplasty','true'
'medication use aspirin','C0240320','MEDICATION USE','medication use','false'
'medication use aspirin','C0004057','ASPIRIN','Aspirin','true'
'calcium channel blockers','C0006684','CALCIUM CHANNEL BLOCKERS','Calcium Channel Blockers','true'
'calcium channel blockers','C2757014','Calcium Channel Blockers','Calcium Channel Antagonists [MoA]','false'
'ace inhibitors','C0003015','ACE INHIBITORS','Angiotensin-Converting Enzyme Inhibitors','true'
'beta blockers','C0001645','Beta blockers','Adrenergic beta-Antagonists','true'
'any antianginal drug','C0013227','Drug','Pharmaceutical Preparations','true'
'any antianginal drug','C1254351','DRUG','Pharmacologic Substance','false'
'body mass index','C0005893','Body mass index','Body mass index procedure','false'
'body mass index','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index','C1305855','BODY MASS INDEX','Body mass index','true'
'waist to hip ratio','C0205682','Waist to Hip Ratio','Waist-Hip Ratio','true'
'blood pressure mm hg systolic','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure mm hg systolic','C0039155','Systolic','Systole','true'
'blood pressure mm hg systolic','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure mm hg systolic','C1272641','Blood pressure','Systemic arterial pressure','true'
'diastolic','C0012000','Diastolic','Diastole','true'
'plasma lipids mg dl $nmbr$ total cholesterol mean','C0444504','Mean','Statistical mean','false'
'plasma lipids mg dl $nmbr$ total cholesterol mean','C2347634','Mean','Population Mean','false'
'plasma lipids mg dl $nmbr$ total cholesterol mean','C2348143','Mean','Sample Mean','false'
'interquartile range','C1711350','Interquartile Range','Interquartile Range','false'
'ldl cholesterol mean','C0444504','Mean','Statistical mean','false'
'ldl cholesterol mean','C2347634','Mean','Population Mean','false'
'ldl cholesterol mean','C2348143','Mean','Sample Mean','false'
'hdl cholesterol mean','C0444504','Mean','Statistical mean','false'
'hdl cholesterol mean','C2347634','Mean','Population Mean','false'
'hdl cholesterol mean','C2348143','Mean','Sample Mean','false'
'triglycerides mean','C0444504','Mean','Statistical mean','false'
'triglycerides mean','C2347634','Mean','Population Mean','false'
'triglycerides mean','C2348143','Mean','Sample Mean','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0042295','Values','Values','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1704970','Means','Means','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0190211','coronary artery angioplasty','Coronary angioplasty','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0920394','angiotensin hypertension','angiotensin hypertension','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0011847','Diabetes','Diabetes','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0011849','Diabetes','Diabetes Mellitus','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0011198','DE','Delaware','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0017480','DE','Germany','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C3541240','DE','Device Events Domain','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0205232','Fine','Fine - adjective','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0687757','fine','Legal fine','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0745732','List','List','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C3272378','LIST','Sequence Data Type','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0040028','ET','Thrombocythemia, Essential','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0028125','Nitrates','Nitrates','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0332257','include','Including (qualifier)','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1552866','include','include - SetOperator','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C2700399','Include','Include (action)','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1521827','Preparation','Preparation','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C3812761','Preparation','Prepared Material','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0013227','Drug','Pharmaceutical Preparations','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1254351','DRUG','Pharmacologic Substance','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0699857','Nitrate','Nitrate','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C3848573','Nitrate','nitrate ion','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0006684','Calcium Channel Blocker','Calcium Channel Blockers','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C3536851','Calcium Channel Blocker','Calcium Channel Blocker [EPC]','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C4521885','Calcium channel blocker','Calcium channel blocker (disposition)','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0001645','Beta Blocker','Adrenergic beta-Antagonists','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0005893','Body mass index','Body mass index procedure','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0578022','Body Mass Index','Finding of body mass index','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1305855','BODY MASS INDEX','Body mass index','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0005910','Weight','Body Weight','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0043100','Weight','Weight','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1305866','weight','Weighing patient','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1705104','Weight','Importance Weight','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0332849','Divided','Divide','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0205120','SQUARE','Square shape','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1552595','Square','Style Type - Square','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0441074','Meters','Meters (physical object)','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0008377','CHOLESTEROL','Cholesterol','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0439190','millimoles','millimole','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0475211','Litre','liter','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1719797','Multiply','Multiply - dosing instruction fragment','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C2911648','Multiply','Multiplication','false'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C0041004','TRIGLYCERIDES','Triglycerides','true'
'plus minus values are means sd cabg denotes coronary artery by pass graft ptca percutaneous transluminal coronary angioplasty and ace angiotensin converting enzyme hypertension and diabetes were de fined by clinical history a more complete list of base line characteristics is given in rubins et al $nmbr$ nitrates includes all preparations except as needed nitroglycerin any antianginal drug includes any nitrate as defined above calcium channel blocker or beta blocker the body mass index is the weight in kilograms divided by the square of the height in meters to convert values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$','C1532563','Millimole per Liter','Millimole per Liter','false'
'characteristics','C1521970','Characteristics','Characteristics','false'
'chlorthalidone group','C0441833','Group','Groups','false'
'chlorthalidone group','C0687744','group','Social group','false'
'chlorthalidone group','C1257890','Group','Population Group','true'
'chlorthalidone group','C1519504','Group','Stage Grouping','false'
'chlorthalidone group','C1705428','Group','Group Object','false'
'chlorthalidone group','C1705429','Group','User Group','false'
'doxazosin group','C0441833','Group','Groups','false'
'doxazosin group','C0687744','group','Social group','false'
'doxazosin group','C1257890','Group','Population Group','true'
'doxazosin group','C1519504','Group','Stage Grouping','false'
'doxazosin group','C1705428','Group','Group Object','false'
'doxazosin group','C1705429','Group','User Group','false'
'no of subjects','C0681850','Subject','Study Subject','false'
'no of subjects','C1550501','{Subject}','Subject -direct target','false'
'no of subjects','C1706203','Subject','Subject - topic','false'
'no of subjects','C2349001','Subject','Human Study Subject','false'
'no of subjects','C2697811','Subject','Investigative Subject','false'
'age y','C0001779','AGE','Age','false'
'women','C0043210','Women','Woman','true'
'race ethnicity white non hispanic','C1533020','Hispanic, white','Hispanic white finding','false'
'race ethnicity white non hispanic','C1533021','Hispanic, white','Hispanic white racial group','false'
'black non hispanic','C1533017','Hispanic, black','Hispanic black finding','false'
'black non hispanic','C1533018','Hispanic, black','Hispanic black racial group','false'
'white hispanic','C1533020','Hispanic, white','Hispanic white finding','false'
'white hispanic','C1533021','Hispanic, white','Hispanic white racial group','false'
'black hispanic','C1533017','Hispanic, black','Hispanic black finding','false'
'black hispanic','C1533018','Hispanic, black','Hispanic black racial group','false'
'other race','C0034510','RACE','Racial group','true'
'other race','C1706779','RACE','AMACR wt Allele','false'
'other race','C3853635','Race','Race','false'
'education y','C0013621','Education','Knowledge acquisition','true'
'education y','C0013622','education','Educational aspects','true'
'education y','C0013658','Education, NOS','Educational Status','true'
'education y','C0039401','Education','Educational process of instructing','true'
'blood pressure mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure mm hg','C0439475','mmHG','mmHg','false'
'blood pressure mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'treated for hypertension','C1522326','Treated','Treating','false'
'treated for hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'treated for hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'eligibility risk factors t ascvo','C0035648','Risk Factors','risk factors','true'
'eligibility risk factors t ascvo','C1553898','risk factors','risk factors - observation list','false'
'st t wave changes','C0392747','changes','Changing','false'
'st t wave changes','C0443172','changes','Changed status','false'
'type $nmbr$ diabetes','C1320657','type diabetes','Diabetes type','false'
'cigarette smoking','C0239059','cigarette smoking','Cigarette smoke (substance)','false'
'cigarette smoking','C0700219','CIGARETTE SMOKING','Cigarette smoking behavior','true'
'hdl c','C3715113','HDL','HSD11B1 wt Allele','false'
'lvh from electrocardiogram','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh from electrocardiogram','C0013798','Electrocardiogram','Electrocardiogram','true'
'lvh from electrocardiogram','C1547122','Electro-Cardiogram','Electro-Cardiogram','false'
'lvh from electrocardiogram','C1623258','Electrocardiogram','Electrocardiography','true'
'lvh from echocardiogram','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh from echocardiogram','C0013516','Echocardiogram','Echocardiography','true'
'lvh from echocardiogram','C2243117','Echocardiogram','Echocardiogram (image)','false'
'serum biochemistry potassium mmol l','C0302353','Serum Potassium','Serum potassium measurement','false'
'serum biochemistry potassium mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum biochemistry potassium mmol l','C0543465','serum potassium','Serum Potassium result','false'
'fasting glucose mg dl','C0015663','FASTING','Fasting','true'
'fasting glucose mg dl','C0439269','mg dl','mg/dL','false'
'creatinine mg dl','C0010294','CREATININE','Creatinine','true'
'creatinine mg dl','C0439269','mg dl','mg/dL','false'
'creatinine mg dl','C1561535','Creatinine','Creatinine, CTCAE','false'
'cholesterol mg dl','C0008377','CHOLESTEROL','Cholesterol','true'
'cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'ldl c mg dl','C0439269','mg dl','mg/dL','false'
'hdl c mg dl','C3715113','HDL','HSD11B1 wt Allele','false'
'hdl c mg dl','C0439269','mg dl','mg/dL','false'
'fasting triglycerides mg dl','C0015663','FASTING','Fasting','true'
'fasting triglycerides mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'fasting triglycerides mg dl','C0439269','mg dl','mg/dL','false'
'variable','C0439828','Variable','Variable (uniformity)','false'
'variable','C4553760','Variable','Study Variable','false'
'abciximab n $nmbr$','C0288672','ABCIXIMAB','abciximab','true'
'p value','C1709380','P-Value','P-Value','false'
'male sex','C0086582','MALE SEX','Males','true'
'weight kg','C0022718','KG','Kyrgyzstan','true'
'weight kg','C0439209','kg','Kilogram','false'
'weight kg','C4054209','/kg','Per Kilogram','false'
'clinical characteristics','C0683325','clinical characteristics','clinical aspects','false'
'hyperlipidemia','C0020473','Hyperlipidaemia, NOS','Hyperlipidemia','true'
'hyperlipidemia','C0428465','Hyperlipidemia','Serum lipids high (finding)','false'
'hyperlipidemia','C4555212','Hyperlipidemia','Hyperlipidemia, CTCAE','false'
'history of hypertension','C0455527','History of - hypertension','H/O: hypertension','false'
'histor y of myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'histor y of myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'histor y of myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'histor y of myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'histor y of myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'histor y of unstable angina','C0002965','Angina, Unstable','Angina, Unstable','true'
'histor y of stable angina','C0340288','Angina, Stable','Stable angina','true'
'histor y of heart failure','C0018801','Failure, Heart','Heart failure','true'
'histor y of heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'histor y of heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'congestive heart failure','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'cardiogenic shock during first $nmbr$ hr after randomization','C0036980','CARDIOGENIC SHOCK','Shock, Cardiogenic','true'
'cardiogenic shock during first $nmbr$ hr after randomization','C0205435','First','First (number)','false'
'cardiogenic shock during first $nmbr$ hr after randomization','C1279901','First','Firstly','false'
'cardiogenic shock during first $nmbr$ hr after randomization','C0034656','Randomization','Randomization','true'
'previous intervention','C0184661','Intervention','Interventional procedure','true'
'previous intervention','C0886296','intervention','Nursing interventions','false'
'previous intervention','C1273869','Intervention','Intervention regimes','false'
'percutaneous transluminal coronary angioplasty','C2936173','Percutaneous Transluminal Coronary Angioplasty','Percutaneous Transluminal Coronary Angioplasty','true'
'coronar y artery bypass grafting','C0332835','grafting','Transplanted tissue','true'
'coronar y artery bypass grafting','C1527362','grafting','grafting qualifier','true'
'coronar y artery bypass grafting','C1961139','Grafting','Grafting procedure','false'
'administration of study drug','C0150270','Drug administration','Medication Management','false'
'administration of study drug','C0262754','Administration drug','drug management','false'
'administration of study drug','C3469597','Drug administration','Administration of medication','false'
'bolus','C1186706','Bolus','Bolus of ingested food','false'
'bolus','C1511237','Bolus','bolus infusion','false'
'bolus','C1705509','{Bolus}','Bolus Dosing Unit','false'
'bolus','C3812160','Bolus','Radiotherapy Bolus','false'
'bolus and infusion','C1186706','Bolus','Bolus of ingested food','false'
'bolus and infusion','C1511237','Bolus','bolus infusion','false'
'bolus and infusion','C1705509','{Bolus}','Bolus Dosing Unit','false'
'bolus and infusion','C3812160','Bolus','Radiotherapy Bolus','false'
'bolus and infusion','C0574032','Infusion','Infusion procedures','false'
'bolus and infusion','C1827465','Infusion','Infusion route','false'
'infarct territory','C1301808','Territory','Geographic state','false'
'infarct territory','C2983136','Territory','Territory','false'
'$nmbr$ $nmbr$ f','C0016327','F-','Fluorides','true'
'anterior','C0205094','ANTERIOR','Anterior','false'
'inferior','C0542339','INFERIOR','Inferior','false'
'inferior','C0678975','inferior','inferiority','false'
'infarct related vessel','C0021308','INFARCT','Infarction','true'
'infarct related vessel','C0005847','Vessel','Blood Vessel','true'
'l eft anterior descending','C0439394','l's','liter/second','false'
'l eft anterior descending','C0205094','ANTERIOR','Anterior','false'
'l eft anterior descending','C1706495','L-','upper case letter ell','false'
'l eft anterior descending','C3642217','/L','Per Liter','false'
'l eft anterior descending','C0205386','Descending','Descending','false'
'l eft anterior descending','C1547177','Descending','Sequencing - Descending','false'
'r ight coronary','C0205090','R-','Right','false'
'r ight coronary','C0018787','coronary','Heart','true'
'r ight coronary','C0684010','R.','Rabbi','true'
'r ight coronary','C2603358','R'','R prime','false'
'circumflex','C1880089','Circumflex','Circumflex','false'
'graft','C0181074','{Graft}','Graft material','false'
'graft','C0332835','GRAFT','Transplanted tissue','true'
'graft','C1961139','Graft, NOS','Grafting procedure','false'
'age yrs','C0001779','AGE','Age','false'
'digoxin','C0012265','DIGOXIN','Digoxin','true'
'placebo','C0032042','Placebo','Placebos','true'
'placebo','C1696465','PLACEBO','placebo','false'
'placebo','C1706408','PLACEBO','Placebo Control','false'
'n','C0369718','N NOS','N not otherwise specified Antibody','false'
'n','C0441922','N+','N+ (tumor staging)','false'
'male','C0086582','MALE','Males','true'
'male','C1706180','Male','Male Gender, Self Report','false'
'male','C1706428','MALE','Male Phenotype','false'
'male','C1706429','Male','Male, Self-Reported','false'
'prior mi','C0332152','Prior','Before','false'
'prior mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'prior mi','C2826257','PRIOR','Prior Medication Usage','false'
'diabetes etiology','C0015127','etiology','Etiology aspects','true'
'diabetes etiology','C1314792','Etiology','Etiology','true'
'diabetes etiology','C1524003','Etiology','Science of Etiology','false'
'ischemic','C0475224','Ischemic','Ischemic','false'
'heart rate min_ $nmbr$ mean','C0444504','Mean','Statistical mean','false'
'heart rate min_ $nmbr$ mean','C2347634','Mean','Population Mean','false'
'heart rate min_ $nmbr$ mean','C2348143','Mean','Sample Mean','false'
'systolic bp mm hg mean nyha class','C0488053','BP mean','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic bp mm hg mean nyha class','C1882083','NYHA Class','New York Heart Association Class','false'
'ttf fv','C1332112','TTF','RHOH gene','false'
'ttf fv','C1705840','TTF','RHOH wt Allele','false'
'ttf fv','C4087167','TTF','Tumour treating fields therapy','false'
'ct ratio $nmbr$ $nmbr$','C0456603','RATIO','Ratio','false'
'ct ratio $nmbr$ $nmbr$','C1547037','Ratio','data type - ratio','false'
'ejection fraction mean','C0444504','Mean','Statistical mean','false'
'ejection fraction mean','C2347634','Mean','Population Mean','false'
'ejection fraction mean','C2348143','Mean','Sample Mean','false'
'creatinine $nmbr$ $nmbr$ mg dl medications','C0013227','Medications','Pharmaceutical Preparations','true'
'creatinine $nmbr$ $nmbr$ mg dl medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'creatinine $nmbr$ $nmbr$ mg dl medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'creatinine $nmbr$ $nmbr$ mg dl medications','C4284232','Medications','Medications','false'
'diuretics','C0012798','DIURETICS','Diuretics','true'
'losartan n $nmbr$','C0126174','LOSARTAN','Losartan','true'
'atenolol n $nmbr$','C0004147','ATENOLOL','Atenolol','true'
'all with diabetes n $nmbr$','C0011847','Diabetes','Diabetes','false'
'all with diabetes n $nmbr$','C0011849','Diabetes','Diabetes Mellitus','true'
'all without diabetes n $nmbr$','C0011847','Diabetes','Diabetes','false'
'all without diabetes n $nmbr$','C0011849','Diabetes','Diabetes Mellitus','true'
'demographic and clinical characteristics','C0011298','demographic','Demography','true'
'demographic and clinical characteristics','C0683325','clinical characteristics','clinical aspects','false'
'age years','C1510829','Age-Years','Age-Years','false'
'ethnic origin white','C0007457','WHITE','Caucasoid Race','true'
'ethnic origin white','C0043157','WHITE','Caucasians','true'
'ethnic origin white','C0220938','WHITE','White color','false'
'hispanic','C0086409','HISPANIC','Hispanics','true'
'asian','C0078988','ASIAN','Asians','true'
'heart rate bpm','C0018810','Heart Rate','heart rate','true'
'bmi kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'cornell voltage duration product mmxmsec','C0598352','Voltage','voltage','false'
'cornell voltage duration product mmxmsec','C0449238','Duration','Duration (temporal concept)','false'
'cornell voltage duration product mmxmsec','C2926735','Duration','Duration','false'
'sokolow lyon mm','C4330985','/mm','Per Millimeter','false'
'sokolow lyon mm','C4554674','MM','MM genotype','false'
'framingham risk score','C0035647','Risk','Risk','true'
'framingham risk score','C0449820','SCORE','Score','false'
'framingham risk score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'framingham risk score','C4552904','risk','Subject Risk','false'
'current smokers','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smokers','C3241966','Current Smoker','Current Smoker','false'
'medical history','C0262926','Medical History','Medical History','false'
'medical history','C1704706','Medical History','Medical History Domain','false'
'any vascular diasease','C0005847','Vascular','Blood Vessel','true'
'any vascular diasease','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'any vascular diasease','C1801960','Vascular','Vascular','false'
'coronary heart disease','C0010054','coronary heart disease','Coronary Arteriosclerosis','true'
'coronary heart disease','C0010068','Coronary Heart Disease','Coronary heart disease','true'
'coronary heart disease','C1956346','coronary heart disease','Coronary Artery Disease','true'
'cerebrovascular disease','C0007820','CEREBROVASCULAR DISEASE','Cerebrovascular Disorders','true'
'peripheral vascular disease','C0085096','PERIPHERAL VASCULAR DISEASE','Peripheral Vascular Diseases','true'
'atrial fibrillation','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'isolated systolic hypertension^','C0745133','isolated systolic hypertension','isolated systolic hypertension','false'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C0039224','Table','Table - furniture','false'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C0815172','patient characteristics','patient characteristics','false'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C1706074','Table','Data Table','true'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C0332293','Treated with','Treated with','false'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C0126174','LOSARTAN','Losartan','true'
'table $nmbr$ characteristics of patients treated with losartan and atenolol','C0004147','ATENOLOL','Atenolol','true'
'women no','C0043210','Women','Woman','true'
'ethnicity no','C0015031','Ethnicity','Ethnic group','true'
'ethnicity no','C0243103','ethnicity','Ethnicity aspects','true'
'white','C0007457','WHITE','Caucasoid Race','true'
'white','C0043157','WHITE','Caucasians','true'
'white','C0220938','WHITE','White color','false'
'systolic','C0039155','Systolic','Systole','true'
'heart rate beats min','C0439385','beats/min','beats per minute','false'
'body mass index kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m $nmbr$','C0439209','kg','Kilogram','false'
'body mass index kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'cornell voltage duration product mm x ms','C2349943','Ms.','Ms. - Title','false'
'cornell voltage duration product mm x ms','C3539704','MS','MTR wt Allele','false'
'cornell voltage duration product mm x ms','C3713294','MS','MTR protein, human','true'
'framingham risk score arbitrary units','C0035647','Risk','Risk','true'
'framingham risk score arbitrary units','C0439183','Arbitrary Unit','Arbitrary unit','false'
'framingham risk score arbitrary units','C4552904','risk','Subject Risk','false'
'current smoker no','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker no','C3241966','Current Smoker','Current Smoker','false'
'medical history no','C0262926','Medical History','Medical History','false'
'medical history no','C1704706','Medical History','Medical History Domain','false'
'previously untreated isolated systolic hypertension','C0745133','isolated systolic hypertension','isolated systolic hypertension','false'
'overall n $nmbr$','C0282416','Overall','Overall Publication Type','true'
'overall n $nmbr$','C1561607','Overall','Overall','false'
'rate control group n $nmbr$','C0441848','Group N','Group N','false'
'rhythm control group n $nmbr$','C0441848','Group N','Group N','false'
'female sex no','C0086287','FEMALE SEX','Females','true'
'ethnic minority group no','C0015031','Ethnic Group','Ethnic group','true'
'ethnic minority group no','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'predominant cardiac diagnosis no','C0011900','DIAGNOSIS','Diagnosis','true'
'predominant cardiac diagnosis no','C1704338','diagnosis','diagnosis aspect','true'
'predominant cardiac diagnosis no','C1704656','DIAGNOSIS','Diagnosis Study','false'
'coronar y artery disease','C0852949','artery disease','Arteriopathic disease','false'
'cardiomyopathy','C0878544','CARDIOMYOPATHY','Cardiomyopathies','true'
'valvular disease','C3258293','Valvular disease','Valvular disease','false'
'no apparent heart disease','C0750489','apparent','apparent','false'
'no apparent heart disease','C0018799','HEART DISEASE, NOS','Heart Diseases','true'
'histor y of congestive heart failure no','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'duration of qualifying atrial fibrillation $nmbr$ days no','C0449238','Duration','Duration (temporal concept)','false'
'duration of qualifying atrial fibrillation $nmbr$ days no','C2926735','Duration','Duration','false'
'duration of qualifying atrial fibrillation $nmbr$ days no','C1514624','Qualifying','Qualifying','false'
'duration of qualifying atrial fibrillation $nmbr$ days no','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'duration of qualifying atrial fibrillation $nmbr$ days no','C0439228','DAYS','day','false'
'duration of qualifying atrial fibrillation $nmbr$ days no','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'duration of qualifying atrial fibrillation $nmbr$ days no','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'first episode of atrial fibrillation vs recurrent episode no f','C0332189','Episode of','Episode of','false'
'first episode of atrial fibrillation vs recurrent episode no f','C0439615','First episode','First episode','false'
'first episode of atrial fibrillation vs recurrent episode no f','C0443287','Recurrent episode','Recurrent episode','false'
'first episode of atrial fibrillation vs recurrent episode no f','C0016327','F-','Fluorides','true'
'any prerandomization failure of an antiarrhythmic drug no','C0231174','FAILURE','Failure (biologic function)','false'
'any prerandomization failure of an antiarrhythmic drug no','C0680095','failure','Personal failure','false'
'size of left atrium normal no','C0225860','Atrium, Left','Left atrial structure','true'
'size of left atrium normal no','C0332506','Normal size','Normal size','false'
'left ventricular ejection fraction','C0428772','Left Ventricular Ejection Fraction','Left ventricular ejection fraction','false'
'left ventricular ejection fraction','C0488728','Left ventricular Ejection fraction','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'normal left ventricular ejection fraction no j','C0428772','Left Ventricular Ejection Fraction','Left ventricular ejection fraction','false'
'normal left ventricular ejection fraction no j','C0488728','Left ventricular Ejection fraction','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'no of participants','C0679646','participants','Participant','false'
'$nmbr$ chlorthalidone n $nmbr$','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine n $nmbr$','C0051696','AMLODIPINE','Amlodipine','true'
'i lisinopril n $nmbr$','C0021966','I-','Iodides','true'
'i lisinopril n $nmbr$','C0065374','Lysinopril','Lisinopril','true'
'i lisinopril n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'age mean sd y','C0001779','AGE','Age','false'
'age mean sd y','C0444504','Mean','Statistical mean','false'
'age mean sd y','C2347634','Mean','Population Mean','false'
'age mean sd y','C2348143','Mean','Sample Mean','false'
'age range y','C0001779','AGE','Age','false'
'age range y','C1514721','Range','Range','false'
'age range y','C2348147','Range','Sample Range','false'
'age range y','C3542016','Range','Concept model range (foundation metadata concept)','false'
'ethnicity','C0015031','Ethnicity','Ethnic group','true'
'ethnicity','C0243103','ethnicity','Ethnicity aspects','true'
'white non hispanic','C1533020','Hispanic, white','Hispanic white finding','false'
'white non hispanic','C1533021','Hispanic, white','Hispanic white racial group','false'
'education mean sd y','C0013621','Education','Knowledge acquisition','true'
'education mean sd y','C0013622','education','Educational aspects','true'
'education mean sd y','C0013658','Education, NOS','Educational Status','true'
'education mean sd y','C0039401','Education','Educational process of instructing','true'
'receiving antihypertensive','C1514756','RECEIVING','Receive','false'
'receiving antihypertensive','C0003364','anti hypertensive','Antihypertensive Agents','true'
'treatment','C0039798','treatment','therapeutic aspects','true'
'treatment','C0087111','Treatment','Therapeutic procedure','true'
'treatment','C1522326','Treatment','Treating','false'
'treatment','C1533734','Treatment','Administration procedure','false'
'treatment','C1705169','Treatment','Biomaterial Treatment','false'
'treatment','C3538994','TREATMENT','Treatment Epoch','false'
'treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'blood pressure mean sd mm hg','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure mean sd mm hg','C0439475','mmHG','mmHg','false'
'treated at baseline','C1522326','Treated','Treating','false'
'treated at baseline','C0168634','baseline','BaseLine dental cement','true'
'treated at baseline','C1442488','Baseline','Baseline','false'
'untreated at baseline','C0332155','untreated','Did not receive therapy or drug for','false'
'untreated at baseline','C0168634','baseline','BaseLine dental cement','true'
'untreated at baseline','C1442488','Baseline','Baseline','false'
'eligibility risk factors','C0035648','Risk Factors','risk factors','true'
'eligibility risk factors','C1553898','risk factors','risk factors - observation list','false'
'cigarette smoker','C0337667','Cigarette Smoker','Cigarette smoker (finding)','false'
'atherosclerotic cvdj','C0333482','Atherosclerotic','atherosclerotic','false'
'history of ml or stroke','C0019664','History','History','true'
'history of ml or stroke','C0019665','history','Historical aspects qualifier','true'
'history of ml or stroke','C0262512','History, NOS','History of present illness','false'
'history of ml or stroke','C0262926','History','Medical History','false'
'history of ml or stroke','C1705255','History','Concept History','false'
'history of ml or stroke','C2004062','History','History of previous events','false'
'history of ml or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'history of ml or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'history of coronary','C0019664','History','History','true'
'history of coronary','C0019665','history','Historical aspects qualifier','true'
'history of coronary','C0262512','History, NOS','History of present illness','false'
'history of coronary','C0262926','History','Medical History','false'
'history of coronary','C1705255','History','Concept History','false'
'history of coronary','C2004062','History','History of previous events','false'
'revascularization','C0581603','Revascularization','Revascularization - action','false'
'other atherosclerotic cvd','C0333482','Atherosclerotic','atherosclerotic','false'
'other atherosclerotic cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'major st depression or','C0041696','Major Depression','Unipolar Depression','true'
'major st depression or','C1269683','MAJOR DEPRESSION','Major Depressive Disorder','true'
't wave inversion','C0520888','T Wave Inversion','Inverted T wave','false'
'lvh by electrocardiogram','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by electrocardiogram','C0013798','Electrocardiogram','Electrocardiogram','true'
'lvh by electrocardiogram','C1547122','Electro-Cardiogram','Electro-Cardiogram','false'
'lvh by electrocardiogram','C1623258','Electrocardiogram','Electrocardiography','true'
'lvh by echocardiogram','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by echocardiogram','C0013516','Echocardiogram','Echocardiography','true'
'lvh by echocardiogram','C2243117','Echocardiogram','Echocardiogram (image)','false'
'history of chd at baseline','C0019664','History','History','true'
'history of chd at baseline','C0019665','history','Historical aspects qualifier','true'
'history of chd at baseline','C0262512','History, NOS','History of present illness','false'
'history of chd at baseline','C0262926','History','Medical History','false'
'history of chd at baseline','C1705255','History','Concept History','false'
'history of chd at baseline','C2004062','History','History of previous events','false'
'history of chd at baseline','C0168634','baseline','BaseLine dental cement','true'
'history of chd at baseline','C1442488','Baseline','Baseline','false'
'body mass index mean sd','C0005893','Body mass index','Body mass index procedure','false'
'body mass index mean sd','C2699239','SD','SD, Rat Strain','false'
'body mass index mean sd','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index mean sd','C1305855','BODY MASS INDEX','Body mass index','true'
'current medication use','C0240320','MEDICATION USE','medication use','false'
'aspirin','C0004057','ASPIRIN','Aspirin','true'
'estrogen supplementation','C0014939','Oestrogen, NOS','Estrogens','true'
'estrogen supplementation','C0242297','Supplementation','Dietary Supplementation','false'
'estrogen supplementation','C2936882','Estrogen','Estrogen [EPC]','false'
'estrogen supplementation','C4542544','Estrogen','Estrogen (disposition)','false'
'women only','C0043210','Women','Woman','true'
'lioid trial participants','C1997894','Trial participant','Clinical trial participant (person)','false'
'lioid trial participants','C2242969','Trial participant','clinical trial participant (history)','false'
'patients treated with losartan n $nmbr$','C0030705','Patients','Patients','true'
'patients treated with losartan n $nmbr$','C0332293','Treated with','Treated with','false'
'patients treated with losartan n $nmbr$','C0126174','LOSARTAN','Losartan','true'
'patients treated with atenoloi n $nmbr$','C0030705','Patients','Patients','true'
'patients treated with atenoloi n $nmbr$','C0332293','Treated with','Treated with','false'
'aii patients n $nmbr$','C1424250','AII','NLRP3 gene','false'
'aii patients n $nmbr$','C0030705','Patients','Patients','true'
'aii patients n $nmbr$','C2698414','AII','NLRP3 wt Allele','false'
'age x','C0001779','AGE','Age','false'
'women n','C0043210','Women','Woman','true'
'ethnicity n','C0015031','Ethnicity','Ethnic group','true'
'ethnicity n','C0243103','ethnicity','Ethnicity aspects','true'
'bmi kg m^','C0022718','KG','Kyrgyzstan','true'
'bmi kg m^','C0439209','kg','Kilogram','false'
'bmi kg m^','C4054209','/kg','Per Kilogram','false'
'cornell voltage x duration product mm x ms','C2349943','Ms.','Ms. - Title','false'
'cornell voltage x duration product mm x ms','C3539704','MS','MTR wt Allele','false'
'cornell voltage x duration product mm x ms','C3713294','MS','MTR protein, human','true'
'sokolow lyon voltage mm','C4330985','/mm','Per Millimeter','false'
'sokolow lyon voltage mm','C4554674','MM','MM genotype','false'
'current smokers n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smokers n','C3241966','Current Smoker','Current Smoker','false'
'atrial fibrillation n','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation n','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation n','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'isolated systolic hypertension n','C0745133','isolated systolic hypertension','isolated systolic hypertension','false'
'diabetes n','C0011847','Diabetes','Diabetes','false'
'diabetes n','C0011849','Diabetes','Diabetes Mellitus','true'
'patients with clinically evident vascular disease','C0683521','patient Disease','patient condition','false'
'patients without clinically evident vascular disease','C0683521','patient Disease','patient condition','false'
'treated with losartan n $nmbr$','C0332293','Treated with','Treated with','false'
'treated with losartan n $nmbr$','C0126174','LOSARTAN','Losartan','true'
'treated with atenolol n $nmbr$','C0332293','Treated with','Treated with','false'
'treated with atenolol n $nmbr$','C0004147','ATENOLOL','Atenolol','true'
'adjusted hazard ratio $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'adjusted hazard ratio $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'unadjusted hazard ratio $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'unadjusted hazard ratio $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'unadjusted hazard ratio $nmbr$ ci','C0008107','CI','Chile','true'
'unadjusted hazard ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'patients','C0030705','Patients','Patients','true'
'primary composite end points','C0205199','Composite','Composite','false'
'primary composite end points','C2349179','End Point','End Point','false'
'primary composite end points','C1547335','Composite','Data types- Composite','false'
'cardiovascular mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'cardiovascular mortality','C0026566','mortality','Aspects of mortality statistics','true'
'stroke','C0038454','STROKE','Cerebrovascular accident','true'
'stroke','C4554100','Stroke','Stroke, CTCAE','false'
'myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'total mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'total mortality','C0026566','mortality','Aspects of mortality statistics','true'
'hospitalization','C0019993','hospitalisation','Hospitalization','true'
'angina pectoris','C0002962','ANGINA PECTORIS','Angina Pectoris','true'
'heart failure','C0018801','Failure, Heart','Heart failure','true'
'heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'new onset diabetes','C0011847','Diabetes','Diabetes','false'
'new onset diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'candesartan group n $nmbr$','C0717550','CANDESARTAN','candesartan','true'
'candesartan group n $nmbr$','C0441848','Group N','Group N','false'
'control group n $nmbr$','C0441848','Group N','Group N','false'
'mean age y','C0444504','Mean','Statistical mean','false'
'mean age y','C0001779','AGE','Age','false'
'mean age y','C2347634','Mean','Population Mean','false'
'mean age y','C2348143','Mean','Sample Mean','false'
'ejection fraction','C0489482','ejection fraction','Ejection fraction (procedure)','false'
'ejection fraction','C2700378','Ejection fraction','Ejection fraction (finding)','false'
'history of','C0019664','History','History','true'
'history of','C0019665','history','Historical aspects qualifier','true'
'history of','C0262512','History, NOS','History of present illness','false'
'history of','C0262926','History','Medical History','false'
'history of','C1705255','History','Concept History','false'
'history of','C2004062','History','History of previous events','false'
'smoking status','C1519386','Smoking Status','Smoking Status','false'
'exsmoker','C0337671','Ex-smoker','Former smoker','false'
'exsmoker','C4555205','Exsmoker','Ex-Smokers','true'
'hypercholesterolemia','C0020443','HYPERCHOLESTEROLEMIA','Hypercholesterolemia','true'
'hypercholesterolemia','C1522133','Hypercholesterolemia','Hypercholesterolemia result','false'
'type of lipid lowering regimen','C0332307','TYPE','Type - attribute','false'
'type of lipid lowering regimen','C1547052','*Type','*Type - Kind of quantity','false'
'type of lipid lowering regimen','C0441994','lowering','Lower - spatial qualifier','false'
'type of lipid lowering regimen','C2003888','Lowering','Lower (action)','false'
'type of lipid lowering regimen','C0040808','Regimen','Treatment Protocols','true'
'type of lipid lowering regimen','C2945654','regimen','Regimen - CHV concept','false'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C0024671','MG','Mammography','true'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C0026410','MG','Mongolia','true'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C0439269','mg%','mg/dL','false'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C1960952','mg %','Milligram percent','false'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C4321396','MG','MG','false'
'i moderate $nmbr$ mg of pravastatin n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C0024671','MG','Mammography','true'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C0026410','MG','Mongolia','true'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C0439269','mg%','mg/dL','false'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C1960952','mg %','Milligram percent','false'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C4321396','MG','MG','false'
'i intensive $nmbr$ mg of atorvastatin n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0444504','Mean','Statistical mean','false'
'mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$','C2699239','SD','SD, Rat Strain','false'
'mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$','C2347634','Mean','Population Mean','false'
'mean sd $nmbr$ $nmbr$ $nmbr$ $nmbr$','C2348143','Mean','Sample Mean','false'
'cholesterol mg dl total','C0201950','Cholesterol/Total','Cholesterol measurement test','false'
'cholesterol mg dl total','C0543421','Cholesterol.total','Total cholesterol','false'
'low density lipoprotein','C0023823','LOW DENSITY LIPOPROTEIN','Low-Density Lipoproteins','true'
'high density lipoprotein','C0023821','High Density Lipoprotein','High Density Lipoproteins','true'
'triglycerides mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'triglycerides mg dl','C0439269','mg dl','mg/dL','false'
'apolipoprotein b $nmbr$ mg dl','C0003593','Apolipoprotein B','Apolipoproteins B','true'
'apolipoprotein b $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'c reactive protein mg l','C0006560','C Reactive Protein','C-reactive protein','true'
'c reactive protein mg l','C0439268','mg/L','Microgram per Milliliter','false'
'c reactive protein mg l','C1413716','C-reactive protein','CRP gene','false'
'c reactive protein mg l','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'men n $nmbr$','C0025266','Men','Male population group','true'
'white n $nmbr$','C0007457','WHITE','Caucasoid Race','true'
'white n $nmbr$','C0043157','WHITE','Caucasians','true'
'white n $nmbr$','C0220938','WHITE','White color','false'
'smoking status current smoker n $nmbr$','C1519386','Smoking Status','Smoking Status','false'
'smoking status current smoker n $nmbr$','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'smoking status current smoker n $nmbr$','C3241966','Current Smoker','Current Smoker','false'
'past or nonsmoker n $nmbr$','C0337672','nonsmoker','Non-smoker','false'
'past or nonsmoker n $nmbr$','C0425293','Non-Smoker','Never smoked tobacco','false'
'past or nonsmoker n $nmbr$','C4554605','Nonsmoker','Non-Smokers -- population group','true'
'history of hypertension n $nmbr$','C0455527','History of - hypertension','H/O: hypertension','false'
'prior statin use n $nmbr$','C0332152','Prior','Before','false'
'prior statin use n $nmbr$','C0042153','use','utilization qualifier','true'
'prior statin use n $nmbr$','C0457083','Use','Usage','false'
'prior statin use n $nmbr$','C1947944','Use','Use - dosing instruction imperative','false'
'prior statin use n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'history of diabetes mellitus n $nmbr$','C0455488','History of - diabetes mellitus','H/O: diabetes mellitus','false'
'metabolic syndrome n $nmbr$','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'subgroup','C1515021','Subgroup','Subgroup','false'
'test for interaction p value','C0022885','Test','Laboratory Procedures','false'
'test for interaction p value','C0039593','Test','Testing','false'
'test for interaction p value','C0392366','test','Tests (qualifier value)','false'
'test for interaction p value','C0456984','Test','Test Result','false'
'test for interaction p value','C1515976','test','Anatomic Structure, System, or Substance','false'
'test for interaction p value','C3831328','Test','Blood Products Laboratory Testing','false'
'test for interaction p value','C4318744','Test','Test - temporal region','false'
'demographics','C0011298','Demographics','Demography','true'
'demographics','C1704791','Demographics','Demographics Domain','false'
'age','C0001779','AGE','Age','false'
'gender','C0079399','Gender','Gender','true'
'gender','C1522384','Gender','sex','true'
'country','C0454664','COUNTRY','Country','false'
'country','C1511538','Country','Country Code','false'
'ethnic group','C0015031','Ethnic Group','Ethnic group','true'
'ethnic group','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'disease history','C0683519','Disease history','disease history','false'
'mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'ihd','C0151744','IHD','Myocardial Ischemia','true'
'angina','C0002962','ANGINA','Angina Pectoris','true'
'microalbuminuria','C0730345','Microalbuminuria','Microalbuminuria','false'
'alcohol intake','C0001948','Alcohol intake','Alcohol consumption','true'
'exercise status','C0015259','Exercise','Exercise','true'
'exercise status','C0449438','Status','Status','false'
'exercise status','C1522704','Exercise','Exercise Pain Management','false'
'bmi','C0578022','BMI','Finding of body mass index','false'
'systolic bp','C0871470','systolic bp','Systolic Pressure','true'
'diastolic bp','C0428883','diastolic bp','Diastolic blood pressure','true'
'total cholesterol','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol','C0543421','Total cholesterol','Total cholesterol','false'
'hdl cholesterol','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'ecg lvh cornell','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'ecg lvh sokolow lyon','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'a worldwide black and non black patients','C0005680','Black','Black race','true'
'a worldwide black and non black patients','C0027567','Black','African race','true'
'a worldwide black and non black patients','C0085756','BLACK','African American','true'
'a worldwide black and non black patients','C0439541','Black','Black color','false'
'a worldwide black and non black patients','C1829939','{Non-patient}','{Non-patient}','false'
'worldwide black patients','C0005680','Black','Black race','true'
'worldwide black patients','C0030705','Patients','Patients','true'
'worldwide black patients','C0027567','Black','African race','true'
'worldwide black patients','C0085756','BLACK','African American','true'
'worldwide black patients','C0439541','Black','Black color','false'
'crude rate','C0871208','Rate','Rating (action)','false'
'crude rate','C1521828','Rate','Rate','false'
'adjusted hazard ratio $nmbr$ ci','C0008107','CI','Chile','true'
'adjusted hazard ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'rate','C0871208','Rate','Rating (action)','false'
'rate','C1521828','Rate','Rate','false'
'composite','C0205199','Composite','Composite','false'
'composite','C1547335','Composite','Data types- Composite','false'
'components of primary composite end point secondary end points','C1882460','Primary Component','Principal Component','false'
'mi fatal nonfatal','C1302234','Fatal','Fatal','false'
'mi fatal nonfatal','C1705232','FATAL','Death Related to Adverse Event','false'
'stroke fatal nonfatal','C0038454','STROKE','Cerebrovascular accident','true'
'stroke fatal nonfatal','C1302234','Fatal','Fatal','false'
'stroke fatal nonfatal','C1705232','FATAL','Death Related to Adverse Event','false'
'stroke fatal nonfatal','C4554100','Stroke','Stroke, CTCAE','false'
'worldwide non black patients','C1829939','{Non-patient}','{Non-patient}','false'
'worldwide non black patients','C0005680','Black','Black race','true'
'worldwide non black patients','C0027567','Black','African race','true'
'worldwide non black patients','C0085756','BLACK','African American','true'
'worldwide non black patients','C0439541','Black','Black color','false'
'losartan n $nmbr$ $nmbr$','C0126174','LOSARTAN','Losartan','true'
'atenolol n $nmbr$ $nmbr$','C0004147','ATENOLOL','Atenolol','true'
'b u s black and non black patients','C0005680','Black','Black race','true'
'b u s black and non black patients','C0027567','Black','African race','true'
'b u s black and non black patients','C0085756','BLACK','African American','true'
'b u s black and non black patients','C0439541','Black','Black color','false'
'b u s black and non black patients','C1829939','{Non-patient}','{Non-patient}','false'
'u s black patients','C0041703','U S','United States','true'
'u s black patients','C0030705','Patients','Patients','true'
'u s non black patients','C0041703','U S','United States','true'
'u s non black patients','C1829939','{Non-patient}','{Non-patient}','false'
'sex no','C0009253','Sex','Coitus','true'
'sex no','C0036864','Sex','Sex Behavior','true'
'sex no','C0079399','sex','Gender','true'
'sex no','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex no','C1314687','Sex','Sexual intercourse - finding','false'
'sex no','C1522384','SEX','sex','true'
'female','C0043210','female','Woman','true'
'female','C0086287','FEMALE','Females','true'
'female','C1705497','Female','Female, Self-Report','false'
'female','C1705498','FEMALE','Female Phenotype','false'
'race no','C0034510','RACE','Racial group','true'
'race no','C1706779','RACE','AMACR wt Allele','false'
'race no','C3853635','Race','Race','false'
'patients receiving immunotherapy no','C0030705','Patients','Patients','true'
'patients receiving immunotherapy no','C1514756','RECEIVING','Receive','false'
'patients receiving immunotherapy no','C0005525','Immunotherapy','Biological Response Modifiers','true'
'patients receiving immunotherapy no','C0021083','IMMUNOTHERAPY','Immunotherapy','true'
'allergic rhinitis duration mean sd y','C1334103','allergic rhinitis','IL13 gene','false'
'allergic rhinitis duration mean sd y','C2607914','ALLERGIC RHINITIS','Allergic rhinitis (disorder)','true'
'allergic rhinitis duration mean sd y','C4552864','Allergic rhinitis','Allergic Rhinitis, CTCAE','false'
'baseline daytime nasal symptoms score mean sd','C0231918','NASAL SYMPTOMS','Nose symptoms','false'
'baseline daytime nasal symptoms score mean sd','C2699239','SD','SD, Rat Strain','false'
'pollen exposure','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'pollen exposure','C0332157','Exposure','Exposure to','false'
'patients included in analysis','C0030705','Patients','Patients','true'
'patients included in analysis','C0332257','included','Including (qualifier)','false'
'patients included in analysis','C0002778','Analysis','Analysis of substances','false'
'patients included in analysis','C0936012','ANALYSIS','Analysis','false'
'patients included in analysis','C1524024','analysis','analysis aspect','true'
'daytime nasal symptoms score change from baseline mean se','C0436315','Symptom change','Symptom modification','false'
'ls mean difference $nmbr$ cl','C0023668','LS','Liechtenstein','true'
'ls mean difference $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'monteiukast vs placebo','C0032042','Placebo','Placebos','true'
'monteiukast vs placebo','C1696465','PLACEBO','placebo','false'
'monteiukast vs placebo','C1706408','PLACEBO','Placebo Control','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ to $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'factor','C1521761','Factor','Factor','false'
'factor','C2827422','Factor','Mathematical Factor','false'
'no of strokes no of patients in category and','C0038454','Strokes','Cerebrovascular accident','true'
'no of strokes no of patients in category and','C0030705','Patients','Patients','true'
'no of strokes no of patients in category and','C0683312','Category','Categories','false'
'no of strokes no of patients in category and','C3889287','Category','Digital Content Category','false'
'hazard ratio and $nmbr$ ci','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio and $nmbr$ ci','C0008107','CI','Chile','true'
'hazard ratio and $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'factor present','C0150312','PRESENT','Present','false'
'factor present','C0449450','Present','Presentation','false'
'factor absent','C1521761','Factor','Factor','false'
'factor absent','C2827422','Factor','Mathematical Factor','false'
'factor absent','C0332197','ABSENT','Absent','false'
'factor absent','C4285062','Absent','Pharyngeal Stripping Wave Absent','false'
'adjusted','C0456081','Adjusted','Adjustment Action','false'
'diabetes mellitus','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'myocardial infarction or angina','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'myocardial infarction or angina','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'myocardial infarction or angina','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'myocardial infarction or angina','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'myocardial infarction or angina','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'myocardial infarction or angina','C0002962','ANGINA','Angina Pectoris','true'
'smoking in the past year','C0037369','SMOKING','Smoking','true'
'smoking in the past year','C0453996','Smoking','Tobacco smoking behavior','true'
'smoking in the past year','C1881674','Smoking','Medical Device Emits Smoke','false'
'ica stenosis $nmbr$ $nmbr$ f','C0201519','ICA','Antibody to islet cells of pancreas measurement','false'
'ica stenosis $nmbr$ $nmbr$ f','C0016327','F-','Fluorides','true'
'irregular or ulcerated ica plaquef','C0205271','Irregular','Irregular','false'
'irregular or ulcerated ica plaquef','C0041582','Ulcerated','Ulcer','true'
'irregular or ulcerated ica plaquef','C0201519','ICA','Antibody to islet cells of pancreas measurement','false'
'irregular or ulcerated ica plaquef','C3887532','Ulcerated','Ulceration','false'
'infarct on brain imaging^','C0021308','INFARCT','Infarction','true'
'infarct on brain imaging^','C0203860','imaging brain','Imaging of brain','false'
'intracranial disease of major artery disease t','C0752138','Intracranial artery disease','Intracranial Arterial Diseases','true'
'duration of symptoms $nmbr$ min','C0436359','Duration of symptom','Time symptom lasts','false'
'duration of symptoms $nmbr$ min','C0702093','/min','Per Minute','false'
'duration of symptoms $nmbr$ min','C1524029','MIN NOS','Mouse MIN NOS','false'
'duration of symptoms $nmbr$ min','C3813700','%/min','Percent per Minute','false'
'none n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'none n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ $nmbr$ week n $nmbr$','C0332174','/week','Weekly','false'
'$nmbr$ $nmbr$ week n $nmbr$','C0439230','Week','week','false'
'$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$','C0332174','/week','Weekly','false'
'$nmbr$ $nmbr$ week n $nmbr$ $nmbr$ $nmbr$ week n $nmbr$','C0439230','Week','week','false'
'$nmbr$ week n $nmbr$','C0332174','/week','Weekly','false'
'$nmbr$ week n $nmbr$','C0439230','Week','week','false'
'age years s d','C1510829','Age-Years','Age-Years','false'
'female n','C0043210','female','Woman','true'
'female n','C0086287','FEMALE','Females','true'
'female n','C1705497','Female','Female, Self-Report','false'
'female n','C1705498','FEMALE','Female Phenotype','false'
'white n','C0007457','WHITE','Caucasoid Race','true'
'white n','C0043157','WHITE','Caucasians','true'
'white n','C0220938','WHITE','White color','false'
'black n','C0005680','Black','Black race','true'
'black n','C0027567','Black','African race','true'
'black n','C0085756','BLACK','African American','true'
'black n','C0439541','Black','Black color','false'
'hispanic n','C0086409','HISPANIC','Hispanics','true'
'asian n','C0078988','ASIAN','Asians','true'
'other race n','C0034510','RACE','Racial group','true'
'other race n','C1706779','RACE','AMACR wt Allele','false'
'other race n','C3853635','Race','Race','false'
'cigarette smoking n','C0239059','cigarette smoking','Cigarette smoke (substance)','false'
'cigarette smoking n','C0700219','CIGARETTE SMOKING','Cigarette smoking behavior','true'
'never','C2003901','NEVER','Never (frequency)','false'
'previous smokers','C0337671','Previous smokers','Former smoker','false'
'$nmbr$ $nmbr$ day','C0332173','/day','Daily','false'
'$nmbr$ $nmbr$ day','C0439228','Day','day','false'
'$nmbr$ $nmbr$ day','C0439505','/day','per day','false'
'$nmbr$ day','C0332173','/day','Daily','false'
'$nmbr$ day','C0439228','Day','day','false'
'$nmbr$ day','C0439505','/day','per day','false'
'exercise n','C0015259','Exercise','Exercise','true'
'exercise n','C1522704','Exercise','Exercise Pain Management','false'
'p $nmbr$ min twice week','C0332174','/week','Weekly','false'
'p $nmbr$ min twice week','C0439230','Week','week','false'
'$nmbr$ min twice week','C0332174','/week','Weekly','false'
'$nmbr$ min twice week','C0439230','Week','week','false'
'enoxaparin n $nmbr$','C0206460','Enoxaparine','Enoxaparin','true'
'unfractionated heparin n $nmbr$','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin n $nmbr$','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'age median iqr y','C0001779','AGE','Age','false'
'age median iqr y','C0549183','Median','Midline (qualifier value)','false'
'age median iqr y','C0876920','Median','Median Statistical Measurement','false'
'age median iqr y','C2347635','Median','Population Median','false'
'age median iqr y','C2348144','Median','Sample Median','false'
'age median iqr y','C2939193','Median','Median (qualifier value)','false'
'female sex no total','C0086287','FEMALE SEX','Females','true'
'female sex no total','C0439175','% total','% of total','false'
'female sex no total','C0439810','Total','Total','false'
'region no total','C0017446','Region','Geographic Locations','true'
'region no total','C0205147','Region','regional','false'
'region no total','C0439175','% total','% of total','false'
'region no total','C0439810','Total','Total','false'
'austral ia new zealand','C0027978','NEW ZEALAND','New Zealand','true'
'austral ia new zealand','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'europe','C0015176','Europe','Europe','true'
'north america','C0028405','North America','North America','true'
'south america','C0037713','South America','South America','true'
'race no total','C0034510','RACE','Racial group','true'
'race no total','C1706779','RACE','AMACR wt Allele','false'
'race no total','C3853635','Race','Race','false'
'race no total','C0439175','% total','% of total','false'
'race no total','C0439810','Total','Total','false'
'american indian','C0002460','AMERICAN INDIAN','American Indians','true'
'pacific islander','C0242191','Pacific Islander','Pacific Islander Americans','true'
'clinical variables median iqr','C0205210','Clinical','Clinical','false'
'clinical variables median iqr','C0439828','variables','Variable (uniformity)','false'
'medical history and risk factors no total','C0262926','Medical History','Medical History','false'
'medical history and risk factors no total','C1704706','Medical History','Medical History Domain','false'
'medical history and risk factors no total','C0035648','Risk Factors','risk factors','true'
'medical history and risk factors no total','C1553898','risk factors','risk factors - observation list','false'
'medical history and risk factors no total','C0439175','% total','% of total','false'
'medical history and risk factors no total','C0439810','Total','Total','false'
'killip class $nmbr$','C1881332','Killip Class','Killip Class','false'
'iii','C0439070','III','Roman Numeral III','false'
'iii','C1705160','III','III (suffix)','false'
'iv','C0022326','IV','Ivory Coast','true'
'iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'prior angina','C0332152','Prior','Before','false'
'prior angina','C0002962','ANGINA','Angina Pectoris','true'
'prior angina','C2826257','PRIOR','Prior Medication Usage','false'
'prior infarction','C0332152','Prior','Before','false'
'prior infarction','C0021308','Infarction','Infarction','true'
'prior infarction','C2826257','PRIOR','Prior Medication Usage','false'
'prior oabg surgery','C0455610','Prior Surgery','H/O: surgery','false'
'prior pci','C0332152','Prior','Before','false'
'prior pci','C4049621','PCI','Peritoneal Cancer Index','false'
'prior pci','C2826257','PRIOR','Prior Medication Usage','false'
'g $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0439267','g%','Gram per Deciliter','false'
'prior congestive heart failure','C0332152','Prior','Before','false'
'prior congestive heart failure','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'prior congestive heart failure','C2826257','PRIOR','Prior Medication Usage','false'
'prior stroke','C0038454','STROKE','Cerebrovascular accident','true'
'prior stroke','C4554100','Stroke','Stroke, CTCAE','false'
'history of peripheral vascular disease','C1881056','History of Peripheral Vascular Disease','History of peripheral vascular disease','false'
'current','C0521116','CURRENT','Current (present time)','false'
'current','C1705970','Current','Electrical Current','false'
'previous','C0205156','Previous','Previous','false'
'previous','C1552607','previous','Act Relationship Subset - previous','false'
'family history of cad','C0241889','FAMILY HISTORY','Family history','true'
'family history of cad','C1504769','CAD','DFFB protein, human','true'
'family history of cad','C2239547','CAD','ACOD1 gene','false'
'family history of cad','C3813548','CAD','CALD1 wt Allele','false'
'family history of cad','C4284121','CAD','DFFB wt Allele','false'
'time from symptom onset to enrollment','C0449244','onset time','Time of onset','false'
'time from symptom onset to enrollment','C1516879','Enrollment','Enrollment','false'
'time from symptom onset to enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'time from symptom onset to enrollment','C3888021','enrollment','enrollment - coverage','false'
'median iqr h','C0033727','H+','Protons','true'
'median iqr h','C0369286','H NOS','H NOS Antibodies','false'
'median iqr h','C0441932','H+','Hepatic Involvement','false'
'median iqr h','C0564385','/h','/hour','false'
'median iqr h','C4528284','h*%','Hour Times Percent','false'
'time from hospital admission to enrollment','C3854258','Admission time','Admission time:ClockTime:Pt:^Patient:Qn','false'
'time from hospital admission to enrollment','C3854259','Admission time','Admission time','false'
'time from hospital admission to enrollment','C1516879','Enrollment','Enrollment','false'
'time from hospital admission to enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'time from hospital admission to enrollment','C3888021','enrollment','enrollment - coverage','false'
'niacin n $nmbr$','C0027996','NIACIN','Niacin','true'
'niacin n $nmbr$','C1142562','Niacin','Vitamin B3 Assay','false'
'p','C0369773','P NOS','P Blood group antibodies','false'
'p','C2603361','P'','P prime','false'
'male gender n','C0086582','Male Gender','Males','true'
'male gender n','C1706180','Male Gender','Male Gender, Self Report','false'
'age mean sd','C0001779','AGE','Age','false'
'age mean sd','C2699239','SD','SD, Rat Strain','false'
'type $nmbr$ diabetes mellitus n','C1320657','type Diabetes Mellitus','Diabetes type','false'
'hypertension n','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension n','C1963138','Hypertension','Hypertension, CTCAE','false'
'tobacco use n','C0040335','Tobacco use NOS','Encounter due to tobacco use','false'
'tobacco use n','C0543414','TOBACCO USE','Tobacco use','true'
'tobacco use n','C0841002','Tobacco use','History of tobacco use','false'
'tobacco use n','C3853727','Tobacco use','Tobacco user','false'
'family history ot chd n','C0241889','FAMILY HISTORY','Family history','true'
'family history ot chd n','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'family history ot chd n','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'metabolic syndrome n','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'history ot chd n','C0019664','History','History','true'
'history ot chd n','C0019665','history','Historical aspects qualifier','true'
'history ot chd n','C0262512','History, NOS','History of present illness','false'
'history ot chd n','C0262926','History','Medical History','false'
'history ot chd n','C1705255','History','Concept History','false'
'history ot chd n','C2004062','History','History of previous events','false'
'ml','C0439526','/mL','/mL','false'
'ml','C1705224','ML','THPO wt Allele','false'
'ml','C3887665','ML','Thrombopoietin, human','false'
'percutaneous coronary revascularization','C1532338','Revascularization, Percutaneous Coronary','Percutaneous Coronary Intervention','true'
'cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'angina with documented ischemia','C0002962','ANGINA','Angina Pectoris','true'
'angina with documented ischemia','C0022116','Ischaemia, NOS','Ischemia','true'
'angina with documented ischemia','C4321499','Ischemia','Ischemia Procedure','false'
'medications n','C0013227','Medications','Pharmaceutical Preparations','true'
'medications n','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications n','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications n','C4284232','Medications','Medications','false'
'angiotensin converting enzyme inhibitor','C0003015','Angiotensin-Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'angiotensin converting enzyme inhibitor','C2757044','Angiotensin Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors [MoA]','false'
'angiotensin converting enzyme inhibitor','C3536837','Angiotensin Converting Enzyme Inhibitor','Angiotensin Converting Enzyme Inhibitor [EPC]','false'
'angiotensin converting enzyme inhibitor','C4541021','Angiotensin-converting enzyme inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'vitamin e','C0042874','VITAMIN E','Vitamin E','true'
'vitamin e','C3714803','VITAMIN E','Vitamin E Drug Class','false'
'vitamin c','C0003968','VITAMIN C','Ascorbic Acid','true'
'vitamin c','C2349136','Vitamin C','Vitamin C Vitamins','false'
'vitamin c','C3714687','VITAMIN C','Vitamin C Drug Class','false'
'vitamin c','C4522080','Vitamin C','Vitamin C [EPC]','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0392747','Change','Changing','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0443172','change','Changed status','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0439231','MONTHS','month','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0030705','Patients','Patients','true'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0332293','Treated with','Treated with','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0032042','Placebo','Placebos','true'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0027996','NIACIN','Niacin','true'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1142562','Niacin','Vitamin B3 Assay','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C0332197','absence','Absent','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1689985','Absence','Absence (morphologic abnormality)','false'
'figure $nmbr$ change in imt across $nmbr$ months in patients treated with placebo and extended release niacin in presence or absence of metabolic syndrome or type $nmbr$ diabetes mellitus','C1320657','type Diabetes Mellitus','Diabetes type','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C1504308','Cis','Genus Cis','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C1742862','CIS','CISH protein, human','true'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C2349179','End Point','End Point','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C1709595','Pooled','Pooled Sample','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C1532737','EZETIMIBE/SIMVASTATIN','ezetimibe / Simvastatin','true'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C2349200','Pooled','Pool (action)','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C4522255','Pooled','Pooled Blood Products','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C0074554','SIMVASTATIN','Simvastatin','true'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C0449450','Presented','Presentation','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C2985777','Group Number','Group Number','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C0237753','Numbers','Numbers','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C0449788','numbers','Count of entities','false'
'figure $nmbr$ mean percent change $nmbr$ cis from baseline to end point in plasma concentration of low density lipoprotein cho lesterol ldl c for pooled ezetimibe simvastatin eze simva and pooled simvastatin simva presented by sub group numbers in parentheses indicate numbers for the pooled simva and pooled eze simva groups respec tively ht hypertension dm diabetes mellitus bmi body mass index ldl c low density lipoprotein cholesterol chd coronary heart disease tg triglycerides hdl c high density lipoprotein cholesterol','C0552369','LDL Cholesterol/HDL Cholesterol','LDL Cholesterol to HDL Cholesterol Ratio Measurement','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C0205307','NORMAL','Normal','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C0231683','Normal','Gait normal','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C0439166','% normal','Percent normal','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C2347086','% Normal','Mean Percent of Normal','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C4553972','Normal','How Often Felt Normal question','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C1417190','MLN','MLN gene','false'
'normal or increased gfr $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C3815103','MLN','MRLN gene','false'
'mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C0392756','Decrease','Reduced','false'
'mild decrease in gfr $nmbr$ $nmbr$ ml mln per $nmbr$ $nmbr$ m^','C0547047','Decrease','Decrease','false'
'moderate or severe decrease in gfr','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate or severe decrease in gfr','C1881878','Moderate','Moderation','false'
'moderate or severe decrease in gfr','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate or severe decrease in gfr','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate or severe decrease in gfr','C4085643','Moderate','Moderate Response','false'
'moderate or severe decrease in gfr','C4321335','Moderate','Moderate Level','false'
'moderate or severe decrease in gfr','C0392756','Decrease','Reduced','false'
'moderate or severe decrease in gfr','C0547047','Decrease','Decrease','false'
'$nmbr$ chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine','C0051696','AMLODIPINE','Amlodipine','true'
'ii lisinopril i','C0021966','I-','Iodides','true'
'ii lisinopril i','C0221138','I NOS','Blood group antibody I','false'
'chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'ii lisinopril','C1710602','II','VIPR1 wt Allele','false'
'ii lisinopril','C0065374','Lysinopril','Lisinopril','true'
'ii lisinopril','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'$nmbr$ lisinopril','C0065374','Lysinopril','Lisinopril','true'
'no randomized','C0034656','Randomized','Randomization','true'
'no randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'age mean sd y ethnicity no','C0015031','Ethnicity','Ethnic group','true'
'age mean sd y ethnicity no','C0243103','ethnicity','Ethnicity aspects','true'
'biack non hispanic','C1518424','Non-Hispanic','Not Hispanic or Latino','false'
'biack hispanic','C0086409','HISPANIC','Hispanics','true'
'bmi mean sd','C0444504','Mean','Statistical mean','false'
'bmi mean sd','C2699239','SD','SD, Rat Strain','false'
'bmi mean sd','C2347634','Mean','Population Mean','false'
'bmi mean sd','C2348143','Mean','Sample Mean','false'
'baseline systolic blood pressure mean sd mm hg','C4274438','Baseline systolic blood pressure','Baseline systolic blood pressure','false'
'baseline systolic blood pressure mean sd mm hg','C0439475','mmHG','mmHg','false'
'baseline diastolic blood pressure mean sd mm hg','C4274392','Baseline diastolic blood pressure','Baseline diastolic blood pressure','false'
'baseline diastolic blood pressure mean sd mm hg','C0439475','mmHG','mmHg','false'
'history of coronary heart disease no','C0683519','History of disease','disease history','false'
'history of coronary heart disease no','C0730226','History of Disease','H/O: Disorder','false'
'history of coronary heart disease no','C0850708','History of disease','History of disease','false'
'history of coronary heart disease no','C0944983','History of Disease','History of symptoms & diseases:Finding:Point in time:^Patient:Nominal:Observed','false'
'estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^','C0444504','Mean','Statistical mean','false'
'estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^','C2347634','Mean','Population Mean','false'
'estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^','C2348143','Mean','Sample Mean','false'
'estimated gfr mean sd mlvmin per $nmbr$ $nmbr$ m^','C1424601','GFR','RAPGEF5 gene','false'
'eligibility risk factors no t','C0035648','Risk Factors','risk factors','true'
'eligibility risk factors no t','C1553898','risk factors','risk factors - observation list','false'
'eligibility risk factors no t','C2603360','T'','T prime','false'
'current cigarette smoking','C0239059','cigarette smoking','Cigarette smoke (substance)','false'
'current cigarette smoking','C0700219','CIGARETTE SMOKING','Cigarette smoking behavior','true'
'atherosclerotic cardiovascular disease','C0004153','Atherosclerotic Cardiovascular Disease','Atherosclerosis','true'
'history of coronary revascularization','C0019664','History','History','true'
'history of coronary revascularization','C0019665','history','Historical aspects qualifier','true'
'history of coronary revascularization','C0262512','History, NOS','History of present illness','false'
'history of coronary revascularization','C0262926','History','Medical History','false'
'history of coronary revascularization','C1705255','History','Concept History','false'
'history of coronary revascularization','C2004062','History','History of previous events','false'
'st segment depression or t wave inversion on ecg','C0520887','ST Segment Depression','ST segment depression (finding)','false'
'st segment depression or t wave inversion on ecg','C0520888','T Wave Inversion','Inverted T wave','false'
'type $nmbr$ diabetes meiiitus','C1320657','type diabetes','Diabetes type','false'
'low hdl c','C0151691','Low HDL','Decreased HDL cholesterol concentration','false'
'lvh by ecg','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'lvh by echocardiography','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by echocardiography','C0013516','ECHOCARDIOGRAPHY','Echocardiography','true'
'total no of events total no of participants','C0439175','% total','% of total','false'
'total no of events total no of participants','C0439810','Total','Total','false'
'total no of events total no of participants','C0679646','participants','Participant','false'
'mean se $nmbr$ year rates per $nmbr$ population','C0871208','Rate','Rating (action)','false'
'mean se $nmbr$ year rates per $nmbr$ population','C1521828','Rate','Rate','false'
'rr $nmbr$ cl [ value]','C4554402','RR','RR genotype','false'
'rr $nmbr$ cl [ value]','C0596019','Cl -','Chloride Ion','false'
'rr $nmbr$ cl [ value]','C1522609','Value','Numerical value','false'
'$nmbr$ chlorthalidone amlodipine','C0008294','Chlortalidone','Chlorthalidone','true'
'$nmbr$ chlorthalidone amlodipine','C0051696','AMLODIPINE','Amlodipine','true'
'lisinopril','C0065374','Lysinopril','Lisinopril','true'
'ii chiorthaiidone amiodipine','C1710602','II','VIPR1 wt Allele','false'
'ii chiorthaiidone amiodipine','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone','C0051696','AMLODIPINE','Amlodipine','true'
'ii $nmbr$ amlodipine lisinopril chlorthalidone chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'total by baseline diabetic status','C0439175','% total','% of total','false'
'total by baseline diabetic status','C0439810','Total','Total','false'
'diabetic participants','C0241863','DIABETIC','diabetic','false'
'diabetic participants','C0679646','participants','Participant','false'
'nondiabetic participants','C0679646','participants','Participant','false'
'by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m','C0017654','GFR','Glomerular Filtration Rate','true'
'by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m','C0439445','mL/min','mL/min','false'
'by gfr stratum for all participants ml min per $nmbr$ $nmbr$ m','C1424601','GFR','RAPGEF5 gene','false'
'by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m','C0017654','GFR','Glomerular Filtration Rate','true'
'by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m','C0241863','DIABETIC','diabetic','false'
'by gfr stratum for diabetic participants mt min per $nmbr$ $nmbr$ m','C1424601','GFR','RAPGEF5 gene','false'
'total no of events of participants total no of participants','C0439175','% total','% of total','false'
'total no of events of participants total no of participants','C0439810','Total','Total','false'
'total no of events of participants total no of participants','C0679646','participants','Participant','false'
'rr $nmbr$ aci [p value]','C0814206','ACI','Alcohol Clinical Index','false'
'rr $nmbr$ aci [p value]','C1510682','ACI','ACI, Rat Strain','false'
'rr $nmbr$ aci [p value]','C2346870','aCi','Attocurie','false'
'rr $nmbr$ aci [p value]','C4050575','ACI','Acceleration index:Accel:Pt:Aorta:Qn','false'
'rr $nmbr$ aci [p value]','C1709380','P-Value','P-Value','false'
'$nmbr$ amlodipine chlorthalidone','C0051696','AMLODIPINE','Amlodipine','true'
'$nmbr$ amlodipine chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'$nmbr$ lisinopril chlorthalidone','C0065374','Lysinopril','Lisinopril','true'
'$nmbr$ lisinopril chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'total','C0439175','% total','% of total','false'
'total','C0439810','Total','Total','false'
'by baseline diabetic status','C0168634','baseline','BaseLine dental cement','true'
'by baseline diabetic status','C0449438','Status','Status','false'
'by baseline diabetic status','C1442488','Baseline','Baseline','false'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C0076836','TOR','Toremifene','true'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C1199517','Tor','Tor','false'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C1419603','TOR','RORC gene','false'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C3539732','TOR','RORC wt Allele','false'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C0679646','participants','Participant','false'
'by gfr stratum tor all participants ml min per $nmbr$ $nmbr$ m^','C0439445','mL/min','mL/min','false'
'by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m','C0017654','GFR','Glomerular Filtration Rate','true'
'by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m','C0439445','mL/min','mL/min','false'
'by gfr stratum tor diabetic participants ml min per $nmbr$ $nmbr$ m','C1424601','GFR','RAPGEF5 gene','false'
'vertebral fracture and or t score s $nmbr$ $nmbr$','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'vertebral fracture and or t score s $nmbr$ $nmbr$','C0718146','t s','A/T/S','false'
'vertebral fracture and or t score $nmbr$ $nmbr$','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'vertebral fracture and or t score $nmbr$ $nmbr$','C3854607','T-Score','T-Score','false'
'alendronate n $nmbr$','C0102118','ALENDRONATE','Alendronate','true'
'mean age years','C0444504','Mean','Statistical mean','false'
'mean age years','C1510829','Age-Years','Age-Years','false'
'mean age years','C2347634','Mean','Population Mean','false'
'mean age years','C2348143','Mean','Sample Mean','false'
'mean years since menopause','C0439234','YEARS','year','false'
'mean years since menopause','C0025320','MENOPAUSE','Menopause','true'
'mean years since menopause','C0567312','Menopause','Menopause present (finding)','false'
'mean femoral neck t score','C3533236','Mean score','Mean score','false'
'mean femoral neck t score','C0015815','Femoral Neck','Structure of neck of femur','true'
'mean lumbar spine t score','C3533236','Mean score','Mean score','false'
'mean lumbar spine t score','C0024091','Lumbar spine','Bone structure of lumbar vertebra','true'
'mean lumbar spine t score','C3887615','LUMBAR SPINE','Lumbar spine structure','false'
'number of prevalent vertebral fractures','C0237753','*Number','Numbers','false'
'number of prevalent vertebral fractures','C0449788','Number','Count of entities','false'
'history of falls in year before randomization','C1561668','History of fall','History of fall','false'
'history of falls in year before randomization','C2919132','History of fall','Encounter due to history of falling','false'
'history of falls in year before randomization','C0439234','Year','year','false'
'history of falls in year before randomization','C0439508','/Year','per year','false'
'prior clinical fracture since age $nmbr$','C0016658','FRACTURE','Fracture','true'
'prior clinical fracture since age $nmbr$','C0001779','AGE','Age','false'
'age group','C0027362','Age Group','Human Age Group','true'
'age group','C2348001','Age Group','Age Cohort','false'
'hip','C0019552','HIP','Hip structure','true'
'hip','C0022122','Hip','Bone structure of ischium','true'
'hip','C1505163','HIP','HHIP protein, human','true'
'hip','C3538851','HIP','REG3A wt Allele','false'
'hip','C4284725','HIP','HHIP wt Allele','false'
'spine','C0037949','Spine','Vertebral column','true'
'spine','C2752558','spine','Neuron spine','false'
'wrist','C0043262','Wrist','Wrist','true'
'wrist','C1322271','Wrist','Wrist joint','true'
'hip wrist or spine','C0043262','Wrist','Wrist','true'
'hip wrist or spine','C1322271','Wrist','Wrist joint','true'
'hip wrist or spine','C0037949','Spine','Vertebral column','true'
'hip wrist or spine','C2752558','spine','Neuron spine','false'
'alendronate','C0102118','ALENDRONATE','Alendronate','true'
'sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml','C1419891','SDC','SDC1 gene','false'
'sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml','C0439275','ng/mL','Microgram per Liter','false'
'sdc $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml','C3273112','SDC','SDC1 wt Allele','false'
'race non white','C0007457','WHITE','Caucasoid Race','true'
'race non white','C0043157','WHITE','Caucasians','true'
'race non white','C0220938','WHITE','White color','false'
'previous digoxin use','C0042153','use','utilization qualifier','true'
'previous digoxin use','C0457083','Use','Usage','false'
'previous digoxin use','C1947944','Use','Use - dosing instruction imperative','false'
'previous mi','C0205156','Previous','Previous','false'
'previous mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'previous mi','C1552607','previous','Act Relationship Subset - previous','false'
'current angina','C0521116','CURRENT','Current (present time)','false'
'current angina','C0002962','ANGINA','Angina Pectoris','true'
'current angina','C1705970','Current','Electrical Current','false'
'ischemic etiology','C0015127','etiology','Etiology aspects','true'
'ischemic etiology','C1314792','Etiology','Etiology','true'
'ischemic etiology','C1524003','Etiology','Science of Etiology','false'
'nyha functional class','C1882083','NYHA Class','New York Heart Association Class','false'
'nyha functional class','C0205245','Functional','Functional','false'
'nyha functional class','C0542341','Functional','Function (attribute)','false'
'nyha functional class','C2700217','Functional','Functional Relationship','false'
'i','C0021966','I-','Iodides','true'
'i','C0221138','I NOS','Blood group antibody I','false'
'ace inhibitor','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'diuretic','C0012798','Diuretic','Diuretics','true'
'nitrate','C0028125','Nitrate','Nitrates','true'
'nitrate','C0699857','Nitrate','Nitrate','false'
'nitrate','C3848573','Nitrate','nitrate ion','false'
'vasodilator therapy','C0039798','therapy','therapeutic aspects','true'
'vasodilator therapy','C0087111','Therapy','Therapeutic procedure','true'
'vasodilator therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'lvef u','C0428772','LVEF','Left ventricular ejection fraction','false'
'lvef u','C0439148','{U}','Unit','false'
'lvef u','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'duration of chf months','C0449238','Duration','Duration (temporal concept)','false'
'duration of chf months','C2926735','Duration','Duration','false'
'sbp mm hg','C0085805','SBP','Androgen Binding Protein','true'
'sbp mm hg','C0439475','mmHG','mmHg','false'
'dbp mm hg','C0536221','DBP','HSD17B4 protein, human','true'
'dbp mm hg','C0439475','mmHG','mmHg','false'
'dbp mm hg','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp mm hg','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'ct ratio','C0456603','RATIO','Ratio','false'
'ct ratio','C1547037','Ratio','data type - ratio','false'
'chf score u','C0018802','CHF','Congestive heart failure','true'
'chf score u','C0439148','{U}','Unit','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'sdc ng ml','C1419891','SDC','SDC1 gene','false'
'sdc ng ml','C0439275','ng/mL','Microgram per Liter','false'
'sdc ng ml','C3273112','SDC','SDC1 wt Allele','false'
'na','C0597484','Na+','Sodium Cation','false'
'na','C1272460','{NA}','Not Applicable','false'
'na','C1546968','NA','No Application Type','false'
'na','C1879645','NA','Adverse Event by CTCAE Category','false'
'na','C4049872','NA','Package Type Not Applicable','false'
'na','C4552882','NA','XK wt Allele','false'
'time sample drawn h','C0033727','H+','Protons','true'
'time sample drawn h','C0369286','H NOS','H NOS Antibodies','false'
'time sample drawn h','C0441932','H+','Hepatic Involvement','false'
'time sample drawn h','C0564385','/h','/hour','false'
'time sample drawn h','C4528284','h*%','Hour Times Percent','false'
'lrg','C1428862','LRG','LRG1 gene','false'
'hrg','C1437978','HRG','NRG1 protein, human','true'
'hrg','C1705020','HRG','NRG1 wt Allele','false'
'losartan','C0126174','LOSARTAN','Losartan','true'
'atenolol','C0004147','ATENOLOL','Atenolol','true'
'ns','C0038944','NS','Suriname','true'
'ns','C1112705','NS','Nuclear non-senile cataract','false'
'ns','C1705982','NS','KRAS wt Allele','false'
'sex women n [ ]','C0009253','Sex','Coitus','true'
'sex women n [ ]','C0036864','Sex','Sex Behavior','true'
'sex women n [ ]','C0079399','sex','Gender','true'
'sex women n [ ]','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex women n [ ]','C1314687','Sex','Sexual intercourse - finding','false'
'sex women n [ ]','C1522384','SEX','sex','true'
'race white n [ ]','C0034510','RACE','Racial group','true'
'race white n [ ]','C0007457','WHITE','Caucasoid Race','true'
'race white n [ ]','C0043157','WHITE','Caucasians','true'
'race white n [ ]','C0220938','WHITE','White color','false'
'race white n [ ]','C1706779','RACE','AMACR wt Allele','false'
'race white n [ ]','C3853635','Race','Race','false'
'heart rate min $nmbr$','C0702093','/min','Per Minute','false'
'heart rate min $nmbr$','C1524029','MIN NOS','Mouse MIN NOS','false'
'heart rate min $nmbr$','C3813700','%/min','Percent per Minute','false'
'cornell voltage duration mv ms','C2349943','Ms.','Ms. - Title','false'
'cornell voltage duration mv ms','C3539704','MS','MTR wt Allele','false'
'cornell voltage duration mv ms','C3713294','MS','MTR protein, human','true'
'sokolow lyon voltage mv','C1454484','MV','VCL protein, human','true'
'sokolow lyon voltage mv','C1705503','MV','VCL wt Allele','false'
'sokolow lyon voltage mv','C4281602','MV','Minute volume measurement','false'
'smoking','C0037369','SMOKING','Smoking','true'
'smoking','C0453996','Smoking','Tobacco smoking behavior','true'
'smoking','C1881674','Smoking','Medical Device Emits Smoke','false'
'serum glucose mmol l','C0202041','Serum Glucose','Glucose measurement, serum','false'
'serum glucose mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum glucose mmol l','C3534430','Serum glucose','Serum glucose','false'
'total cholesterol mmol l','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol mmol l','C1532563','mmol/L','Millimole per Liter','false'
'total cholesterol mmol l','C0543421','Total cholesterol','Total cholesterol','false'
'hdl cholesterol mmol l','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mmol l','C1532563','mmol/L','Millimole per Liter','false'
'hdl cholesterol mmol l','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'serum creatinine mmol l','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum creatinine mmol l','C0600061','serum creatinine','Serum creatinine level','false'
'urine albumin creatinine mg mmol','C0567349','mg/mmol','milligram/millimole (mg/mmol)','false'
'urine albumin creatinine mg mmol','C2348885','mg/mmol','Gram per Mole (g/mol)','false'
'bp component mm hg','C0037623','BP','Solomon Islands','true'
'bp component mm hg','C0439475','mmHG','mmHg','false'
'bp component mm hg','C1415692','Bp','HP gene','false'
'bp component mm hg','C1708288','BP','HP wt Allele','false'
'bp component mm hg','C4318478','BP','Base Pair Unit','false'
'sbp baseline','C0168634','baseline','BaseLine dental cement','true'
'sbp baseline','C1442488','Baseline','Baseline','false'
'sbp last','C0085805','SBP','Androgen Binding Protein','true'
'sbp difference','C1705241','*Difference','Delta (difference)','false'
'sbp difference','C1705242','Difference','Different','false'
'difference in sbp between treatment','C1705241','*Difference','Delta (difference)','false'
'difference in sbp between treatment','C1705242','Difference','Different','false'
'difference in sbp between treatment','C0039798','treatment','therapeutic aspects','true'
'difference in sbp between treatment','C0087111','Treatment','Therapeutic procedure','true'
'difference in sbp between treatment','C1522326','Treatment','Treating','false'
'difference in sbp between treatment','C1533734','Treatment','Administration procedure','false'
'difference in sbp between treatment','C1705169','Treatment','Biomaterial Treatment','false'
'difference in sbp between treatment','C3538994','TREATMENT','Treatment Epoch','false'
'difference in sbp between treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'mean arterial pressure baseline','C0443150','Pressure.baseline','Baseline pressure','false'
'mean arterial pressure last','C0428886','Mean Arterial Pressure','Mean blood pressure','true'
'mean arterial pressure difference','C0563547','Pressure Difference','Pressure change','false'
'end point','C2349179','End Point','End Point','false'
'end point','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'higher risk n $nmbr$','C0332167','HIGH RISK','High risk of','false'
'higher risk n $nmbr$','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'higher risk n $nmbr$','C4050568','High Risk','High Risk Acute Leukemia','false'
'higher risk n $nmbr$','C4319571','High risk','High risk','false'
'lower risk n $nmbr$','C3272281','Low Risk','American College of Cardiology/American Heart Association Lesion Complexity Score A','false'
'lower risk n $nmbr$','C3538919','LOW RISK','Low Risk','false'
'adjusted hr','C0456081','Adjusted','Adjustment Action','false'
'unadjusted hr','C1439367','unadjusted','unadjusted','false'
'$nmbr$ ci','C0008107','CI','Chile','true'
'$nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'primary composite end point','C2986535','Primary Endpoint','Primary Endpoint','false'
'primary composite end point','C0205199','Composite','Composite','false'
'primary composite end point','C1547335','Composite','Data types- Composite','false'
'components','C0449432','Components','Component object','false'
'other prespecified end points','C2349179','End Point','End Point','false'
'hospitalization for','C0019993','hospitalisation','Hospitalization','true'
'sudden cardiac death','C0085298','SUDDEN CARDIAC DEATH','Sudden Cardiac Death','true'
'new onset atrial fibrillation','C0741281','new onset atrial fibrillation','atrial fibrillation new onset','false'
'endpoint','C2349179','End Point','End Point','false'
'endpoint','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'primary composite endpoint','C2986535','Primary Endpoint','Primary Endpoint','false'
'primary composite endpoint','C0205199','Composite','Composite','false'
'primary composite endpoint','C1547335','Composite','Data types- Composite','false'
'demographic and clinical','C0011298','demographic','Demography','true'
'demographic and clinical','C0205210','Clinical','Clinical','false'
'cornell voltage duration product mm ms','C2349943','Ms.','Ms. - Title','false'
'cornell voltage duration product mm ms','C3539704','MS','MTR wt Allele','false'
'cornell voltage duration product mm ms','C3713294','MS','MTR protein, human','true'
'medical history n','C0262926','Medical History','Medical History','false'
'medical history n','C1704706','Medical History','Medical History Domain','false'
'any vascular disease','C0042373','Disease, Vascular','Vascular Diseases','true'
'isolated systolic hypertension','C0745133','isolated systolic hypertension','isolated systolic hypertension','false'
'with aspirin n $nmbr$ $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'without aspirin n $nmbr$ $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'sys ns dia','C0038944','NS','Suriname','true'
'sys ns dia','C1706546','DIA','LIF wt Allele','false'
'sys ns dia','C1112705','NS','Nuclear non-senile cataract','false'
'sys ns dia','C1705982','NS','KRAS wt Allele','false'
'pioglitazone n $nmbr$','C0071097','PIOGLITAZONE','pioglitazone','true'
'patients characteristics','C0815172','patient characteristics','patient characteristics','false'
'age years mean sd','C1510829','Age-Years','Age-Years','false'
'age years mean sd','C2699239','SD','SD, Rat Strain','false'
'time since diagnosis of diabetes years median iqr','C0556970','time year','times/year','false'
'time since diagnosis of diabetes years median iqr','C0011847','Diabetes','Diabetes','false'
'time since diagnosis of diabetes years median iqr','C0011849','Diabetes','Diabetes Mellitus','true'
'body mass index kg m $nmbr$ mean sd','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m $nmbr$ mean sd','C0439209','kg','Kilogram','false'
'body mass index kg m $nmbr$ mean sd','C4054209','/kg','Per Kilogram','false'
'body mass index kg m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'body mass index kg m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'body mass index kg m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'body mass index kg m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'blood pressure systolic diastolic mm hg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure systolic diastolic mm hg mean sd','C2699239','SD','SD, Rat Strain','false'
'past smoker','C0337664','Smoker','Smoker','true'
'microvascular disease','C0443258','Microvascular','Microvascular','false'
'microvascular disease','C0012634','Disease','Disease','true'
'blood glucose lowering treatment','C0005802','Blood Glucose','Blood Glucose','true'
'blood glucose lowering treatment','C0441994','lowering','Lower - spatial qualifier','false'
'blood glucose lowering treatment','C2003888','Lowering','Lower (action)','false'
'blood glucose lowering treatment','C0039798','treatment','therapeutic aspects','true'
'blood glucose lowering treatment','C0087111','Treatment','Therapeutic procedure','true'
'blood glucose lowering treatment','C1522326','Treatment','Treating','false'
'blood glucose lowering treatment','C1533734','Treatment','Administration procedure','false'
'blood glucose lowering treatment','C1705169','Treatment','Biomaterial Treatment','false'
'blood glucose lowering treatment','C3538994','TREATMENT','Treatment Epoch','false'
'blood glucose lowering treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'metformin only','C0025598','METFORMIN','Metformin','true'
'sulphonylureas only','C0038766','sulphonylureas','Sulfonylurea Compounds','true'
'metformin sulphonylureas','C0025598','METFORMIN','Metformin','true'
'metformin sulphonylureas','C0038766','sulphonylureas','Sulfonylurea Compounds','true'
'insulin only','C0021641','INSULIN','Insulin','true'
'insulin only','C1533581','INSULIN','Recombinant Insulin','false'
'insulin only','C1579433','Insulin','Insulin [EPC]','false'
'insulin only','C3714501','INSULIN','Insulin Drug Class','false'
'insulin metformin','C0021641','INSULIN','Insulin','true'
'insulin metformin','C0025598','METFORMIN','Metformin','true'
'insulin metformin','C1533581','INSULIN','Recombinant Insulin','false'
'insulin metformin','C1579433','Insulin','Insulin [EPC]','false'
'insulin metformin','C3714501','INSULIN','Insulin Drug Class','false'
'insulin sulphonylureas','C0021641','INSULIN','Insulin','true'
'insulin sulphonylureas','C0038766','sulphonylureas','Sulfonylurea Compounds','true'
'insulin sulphonylureas','C1533581','INSULIN','Recombinant Insulin','false'
'insulin sulphonylureas','C1579433','Insulin','Insulin [EPC]','false'
'insulin sulphonylureas','C3714501','INSULIN','Insulin Drug Class','false'
'insulin metformin sulphonylureas','C0021641','INSULIN','Insulin','true'
'insulin metformin sulphonylureas','C0038766','sulphonylureas','Sulfonylurea Compounds','true'
'insulin metformin sulphonylureas','C1533581','INSULIN','Recombinant Insulin','false'
'insulin metformin sulphonylureas','C1579433','Insulin','Insulin [EPC]','false'
'insulin metformin sulphonylureas','C3714501','INSULIN','Insulin Drug Class','false'
'other combination','C0205195','Combination','Combined','false'
'other combination','C1947911','Combination','combination of objects','false'
'other combination','C3811910','Combination','combination - answer to question','false'
'diet only','C0012155','Diet','Diet','true'
'diet only','C0012159','Diet','Diet therapy','true'
'diet only','C1519433','DIET','Special Diet Therapy','false'
'diet only','C2983588','DIET','Basal Diet','false'
'diet only','C3668949','Diet','Diet (animal life circumstance)','false'
'laboratory data','C1511726','Data','Data','false'
'laboratory data','C3245479','data','Data call receiving device','false'
'laboratory data','C3714741','Data','Data (eukaryote)','false'
'hba $nmbr$ c median iqr','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c median iqr','C0549183','Median','Midline (qualifier value)','false'
'hba $nmbr$ c median iqr','C0876920','Median','Median Statistical Measurement','false'
'hba $nmbr$ c median iqr','C2347635','Median','Population Median','false'
'hba $nmbr$ c median iqr','C2348144','Median','Sample Median','false'
'hba $nmbr$ c median iqr','C2939193','Median','Median (qualifier value)','false'
'hba $nmbr$ c median iqr','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c median iqr','C3538758','HBA','SCN2A wt Allele','false'
'ldl cholesterol mmol l median iqr','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol mmol l median iqr','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'hdl cholesterol mmol l median iqr','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mmol l median iqr','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'triglycerides mmol l median iqr','C0041004','TRIGLYCERIDES','Triglycerides','true'
'triglycerides mmol l median iqr','C1532563','mmol/L','Millimole per Liter','false'
'creatinine ^mol l median iqr','C0010294','CREATININE','Creatinine','true'
'creatinine ^mol l median iqr','C0347982','mol/L','Mole per Liter','false'
'creatinine ^mol l median iqr','C1561535','Creatinine','Creatinine, CTCAE','false'
'micral test result','C0456984','Test Result','Test Result','false'
'micral test result','C0587081','Test Result','Laboratory test finding','false'
'negative','C0205160','Negative','Negative','false'
'negative','C1513916','NEGATIVE','Negative Finding','false'
'negative','C2825415','Negative','Negative Number','false'
'negative','C2825491','Negative','Negative Charge','false'
'negative','C3853545','Negative','Negative - answer','false'
'about $nmbr$ mg l','C0439268','mg/L','Microgram per Milliliter','false'
'about $nmbr$ mg l or more','C0439268','mg/L','Microgram per Milliliter','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0439165','Percentage','Percent (qualifier value)','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1549488','Percentage','Amount type - Percentage','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0008976','Clinical Trial','Clinical Trials','true'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1096775','Clinical Trial','Clinical Trial [Publication Type]','true'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0441833','Panel','Groups','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1706365','Panel','Device Panel','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1999270','Panel','Laboratory Order Panels','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0544452','Remission','Disease remission','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0687702','remission','Cancer Remission','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0545082','Visit','Visit','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C1512346','visit','Patient Visit','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C2826704','VISIT','Visit Name','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0332174','/week','Weekly','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0441837','Panel C','Group C','false'
'figure $nmbr$ facing page percentage of patients in the enact $nmbr$ trial with a clinical response at each visit panel a in remission at each visit panel b with a response at week $nmbr$ panel c and in remission at week $nmbr$ panel d','C0439230','Week','week','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0871261','Response','Response process','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1704632','Response','Disease Response','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1706817','Response','Response (statement)','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C2911692','Response','Response (communication)','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1704788','Defined','Definition','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C3539106','Defined','Sufficiently defined concept definition status (core metadata concept)','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0168634','baseline','BaseLine dental cement','true'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1442488','Baseline','Baseline','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0011198','DE','Delaware','true'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0017480','DE','Germany','true'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C3541240','DE','Device Events Domain','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0205232','Fine','Fine - adjective','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0687757','fine','Legal fine','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0449820','SCORE','Score','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0237881','significant','Statistical Significance','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0750502','Significant','Significant','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1546944','Significant','Event Seriousness - Significant','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0039798','treatment','therapeutic aspects','true'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C0087111','Treatment','Therapeutic procedure','true'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1522326','Treatment','Treating','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1533734','Treatment','Administration procedure','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1705169','Treatment','Biomaterial Treatment','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C3538994','TREATMENT','Treatment Epoch','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C3887704','treatment','treatment - ActInformationManagementReason','false'
'a response was defined as a decrease from baseline in the cdai score of at least $nmbr$ points remission was de fined as a decrease in the cdai score to less than $nmbr$ points significant differences between the treatment groups are shown','C1547282','Show','Show','false'
'clopidogrel n $nmbr$ $nmbr$','C0070166','CLOPIDOGREL','clopidogrel','true'
'placebo n $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'age at entry years','C1510829','Age-Years','Age-Years','false'
'age at entry years','C1705654','Entry','Entry (data)','false'
'mean sd','C0444504','Mean','Statistical mean','false'
'mean sd','C2699239','SD','SD, Rat Strain','false'
'mean sd','C2347634','Mean','Population Mean','false'
'mean sd','C2348143','Mean','Sample Mean','false'
'sex','C0009253','Sex','Coitus','true'
'sex','C0036864','Sex','Sex Behavior','true'
'sex','C0079399','sex','Gender','true'
'sex','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex','C1314687','Sex','Sexual intercourse - finding','false'
'sex','C1522384','SEX','sex','true'
'time since onset h','C0449244','onset time','Time of onset','false'
'time since onset h','C0033727','H+','Protons','true'
'time since onset h','C0369286','H NOS','H NOS Antibodies','false'
'time since onset h','C0441932','H+','Hepatic Involvement','false'
'time since onset h','C0564385','/h','/hour','false'
'time since onset h','C4528284','h*%','Hour Times Percent','false'
'systolic blood pressure mm hg','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic blood pressure mm hg','C0439475','mmHG','mmHg','false'
'systolic blood pressure mm hg','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'systolic blood pressure mm hg','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'ecg abnormality at entry','C1623258','ECG NOS','Electrocardiography','true'
'ecg abnormality at entry','C1704258','Abnormality','Abnormality','false'
'st elevation','C0520886','ST ELEVATION','ST segment elevation (finding)','false'
'bundle branch block','C0006384','BUNDLE BRANCH BLOCK','Bundle-Branch Block','true'
'bundle branch block','C1879286','BUNDLE BRANCH BLOCK','Hereditary bundle branch system defect','true'
'st depression without st elevation','C0520887','ST DEPRESSION','ST segment depression (finding)','false'
'killip class','C1881332','Killip Class','Killip Class','false'
'ii or iii','C0439070','III','Roman Numeral III','false'
'ii or iii','C1705160','III','III (suffix)','false'
'previous disease and drug use','C0205156','Previous','Previous','false'
'previous disease and drug use','C0012634','Disease','Disease','true'
'previous disease and drug use','C1552607','previous','Act Relationship Subset - previous','false'
'previous disease and drug use','C0242510','Drug use','Drug usage','false'
'previous hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'previous hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'aspirin before admission','C0004057','ASPIRIN','Aspirin','true'
'aspirin before admission','C0184666','Admission','Hospital admission','false'
'aspirin before admission','C0809949','Admission','Admission activity','false'
'$nmbr$ blocker before admission','C0184666','Admission','Hospital admission','false'
'$nmbr$ blocker before admission','C0809949','Admission','Admission activity','false'
'fibrinolytic agent before randomisation','C0016018','Fibrinolytic agent','Fibrinolytic Agents','true'
'fibrinolytic agent before randomisation','C0034656','Randomization','Randomization','true'
'non trial treatment during hospital stay','C0019948','Hospital Treatment','Hospital Administration','true'
'non trial treatment during hospital stay','C3166479','Treatment hospital','Treatment hospital','false'
'non trial antiplatelet','C1518422','Non','Negation','false'
'non trial antiplatelet','C0008976','Trial','Clinical Trials','true'
'fibrinolytic agents before or after entry','C0016018','Fibrinolytic Agents','Fibrinolytic Agents','true'
'fibrinolytic agents before or after entry','C1705654','Entry','Entry (data)','false'
'anticoagulant','C0003280','Anticoagulant','Anticoagulants','true'
'anticoagulant','C0848112','anti coagulant','on anti-coagulants','false'
'anticoagulant','C3536711','Anticoagulant','Anti-coagulant [EPC]','false'
'antiarrhythmic','C0003195','Antiarrhythmic','Anti-Arrhythmia Agents','true'
'antiarrhythmic','C3537142','Antiarrhythmic','Antiarrhythmic [EPC]','false'
'nitrate oral or intravenous','C0442027','Oral','Oral','false'
'nitrate oral or intravenous','C4521986','Oral','Oral (intended site)','false'
'nitrate oral or intravenous','C0348016','Intravenous','Intravenous','false'
'calcium antagonist','C0006684','calcium antagonist','Calcium Channel Blockers','true'
'metoprolol n $nmbr$ $nmbr$','C0025859','METOPROLOL','Metoprolol','true'
'ai $nmbr$','C0003504','ai','Aortic Valve Insufficiency','true'
'ai $nmbr$','C4551710','AI','Anguilla island','false'
'p blocker before admission','C0369773','P NOS','P Blood group antibodies','false'
'p blocker before admission','C0184666','Admission','Hospital admission','false'
'p blocker before admission','C0809949','Admission','Admission activity','false'
'p blocker before admission','C2603361','P'','P prime','false'
'non trial p blocker','C1518422','Non','Negation','false'
'non trial p blocker','C0008976','Trial','Clinical Trials','true'
'score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'mean age y range','C1514721','Range','Range','false'
'mean age y range','C2348147','Range','Sample Range','false'
'mean age y range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'gender male','C0086582','MALE','Males','true'
'gender male','C1706180','Male','Male Gender, Self Report','false'
'gender male','C1706428','MALE','Male Phenotype','false'
'gender male','C1706429','Male','Male, Self-Reported','false'
'mean baseline nasal congestion score','C3533236','Mean score','Mean score','false'
'mean baseline nasal congestion score','C0027424','NASAL CONGESTION','Nasal congestion (finding)','false'
'mean baseline nasal congestion score','C4554631','Nasal congestion','Nasal Congestion, CTCAE','false'
'tenecteplase and pci n $nmbr$','C0872913','TENECTEPLASE','Tenecteplase','true'
'tenecteplase and pci n $nmbr$','C4049621','PCI','Peritoneal Cancer Index','false'
'pci alone n $nmbr$','C0205171','Alone','Singular','false'
'pci alone n $nmbr$','C0439044','Alone','Living Alone','false'
'pci alone n $nmbr$','C0679994','alone','alone - group size','false'
'age $nmbr$ years','C1510829','Age-Years','Age-Years','false'
'height cm','C0489786','Height','Height','false'
'ii iii','C0439070','III','Roman Numeral III','false'
'ii iii','C1705160','III','III (suffix)','false'
'congestive heart failure at randomisation','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'congestive heart failure at randomisation','C0034656','Randomization','Randomization','true'
'infarct location','C0450429','Location','Location','false'
'infarct location','C1515974','Location','Anatomic Site','false'
'infarct location','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'infarct location','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'previous infarction','C0205156','Previous','Previous','false'
'previous infarction','C0021308','Infarction','Infarction','true'
'previous infarction','C1552607','previous','Act Relationship Subset - previous','false'
'previous congestive heart failure','C0205156','Previous','Previous','false'
'previous congestive heart failure','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'previous congestive heart failure','C1552607','previous','Act Relationship Subset - previous','false'
'previous pci','C0205156','Previous','Previous','false'
'previous pci','C4049621','PCI','Peritoneal Cancer Index','false'
'previous pci','C1552607','previous','Act Relationship Subset - previous','false'
'previous coronary artery bypass graft','C2144990','previous Coronary artery bypass graft','previous Aortocoronary Bypass','false'
'outcome','C1274040','Outcome','Result','false'
'glucosamine','C0017718','GLUCOSAMINE','Glucosamine','true'
'chondroitin sulfate','C0008466','Chondroitin sulphate','Chondroitin Sulfates','true'
'glucosamine chondroitin sulfate','C0017720','GLUCOSAMINE SULFATE','Glucosamine Sulfate','true'
'celecoxib','C0538927','CELECOXIB','celecoxib','true'
'all randomized patients','C0034656','Randomized','Randomization','true'
'all randomized patients','C0030705','Patients','Patients','true'
'all randomized patients','C3815594','RANDOMIZED','Subject is Randomized','false'
'no of patients','C0030705','Patients','Patients','true'
'primary outcome $nmbr$ decrease in womac pain score','C0392756','Decrease','Reduced','false'
'primary outcome $nmbr$ decrease in womac pain score','C0547047','Decrease','Decrease','false'
'at end of follow up no','C0444930','End','End','false'
'at end of follow up no','C2746065','End','Stop (qualifier value)','false'
'secondary outcomes','C0027627','secondary','Neoplasm Metastasis','true'
'secondary outcomes','C1274040','Outcome','Result','false'
'secondary outcomes','C0175668','Secondary','Secondary to','false'
'secondary outcomes','C0205436','Secondary','second (number)','false'
'omeract oarsi response','C0871261','Response','Response process','false'
'omeract oarsi response','C1704632','Response','Disease Response','false'
'omeract oarsi response','C1706817','Response','Response (statement)','false'
'omeract oarsi response','C2911692','Response','Response (communication)','false'
'$nmbr$ decrease in womac pain score','C0392756','Decrease','Reduced','false'
'$nmbr$ decrease in womac pain score','C0547047','Decrease','Decrease','false'
'womac pain score','C0582148','Pain score','Pain score','false'
'change from baseline','C0392747','Change','Changing','false'
'change from baseline','C0443172','change','Changed status','false'
'change from baseline','C1705241','Change','Delta (difference)','false'
'change from baseline','C4319952','Change','Change -- procedure','false'
'at end of follow up','C0444930','End','End','false'
'at end of follow up','C2746065','End','Stop (qualifier value)','false'
'womac stiffness score','C0449820','SCORE','Score','false'
'womac stiffness score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'womac function score','C0449820','SCORE','Score','false'
'womac function score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'normalized womac score','C0449820','SCORE','Score','false'
'normalized womac score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'haq alternative disability score','C0449820','SCORE','Score','false'
'haq alternative disability score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'haq pain score','C0102923','HAQ','ametantrone','true'
'haq pain score','C0582148','Pain score','Pain score','false'
'haq pain score','C0451208','HAQ','Health assessment questionnaire','false'
'patient s global assessment of response to therapy score','C0030705','*^patient','Patients','true'
'patient s global assessment of response to therapy score','C0281858','Global Assessment','global assessment','false'
'patient s global assessment of response to therapy score','C0871261','Response','Response process','false'
'patient s global assessment of response to therapy score','C1704632','Response','Disease Response','false'
'patient s global assessment of response to therapy score','C1706817','Response','Response (statement)','false'
'patient s global assessment of response to therapy score','C2911692','Response','Response (communication)','false'
'patient s global assessment of response to therapy score','C0449820','SCORE','Score','false'
'patient s global assessment of response to therapy score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patient s global assessment of disease status score','C0030705','*^patient','Patients','true'
'patient s global assessment of disease status score','C0281858','Global Assessment','global assessment','false'
'patient s global assessment of disease status score','C3176928','Disease status','Condition status','false'
'physician s global assessment of disease status score','C0031831','PHYSICIAN','Physicians','true'
'physician s global assessment of disease status score','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'physician s global assessment of disease status score','C0281858','Global Assessment','global assessment','false'
'physician s global assessment of disease status score','C3176928','Disease status','Condition status','false'
'joint swelling effusion or both on clinical examination','C1253936','JOINT EFFUSION','Hydrarthrosis','true'
'joint swelling effusion or both on clinical examination','C1963136','Joint-effusion','Joint Effusion, CTCAE 3.0','false'
'joint swelling effusion or both on clinical examination','C4554335','Joint effusion','Joint Effusion, CTCAE 5.0','false'
'joint swelling effusion or both on clinical examination','C0031809','Clinical examination','Physical Examination','true'
'at baseline no','C0168634','baseline','BaseLine dental cement','true'
'at baseline no','C1442488','Baseline','Baseline','false'
'at end of follow up no total no','C0444930','End','End','false'
'at end of follow up no total no','C2746065','End','Stop (qualifier value)','false'
'at end of follow up no total no','C0439175','% total','% of total','false'
'at end of follow up no total no','C0439810','Total','Total','false'
'no of $nmbr$ mg tablets of acetaminophen','C0024671','MG','Mammography','true'
'no of $nmbr$ mg tablets of acetaminophen','C1243102','Acetaminophen Tablets','Acetaminophen Oral Tablet','false'
'no of $nmbr$ mg tablets of acetaminophen','C0026410','MG','Mongolia','true'
'no of $nmbr$ mg tablets of acetaminophen','C0439269','mg%','mg/dL','false'
'no of $nmbr$ mg tablets of acetaminophen','C1960952','mg %','Milligram percent','false'
'no of $nmbr$ mg tablets of acetaminophen','C2346927','Mg++','Magnesium Cation','false'
'no of $nmbr$ mg tablets of acetaminophen','C4321396','MG','MG','false'
'no of $nmbr$ mg tablets of acetaminophen','C4521761','MG','United States Military Commissioned Officer O8','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C1881878','Moderate','Moderation','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C4085643','Moderate','Moderate Response','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C4321335','Moderate','Moderate Level','false'
'patients with moderate to severe pain womac pain score $nmbr$ $nmbr$','C0582148','Pain score','Pain score','false'
'no of $nmbr$ mg acetaminophen tablets day','C0439422','mg day','milligram/day','false'
'no of $nmbr$ mg acetaminophen tablets day','C1243102','Acetaminophen Tablets','Acetaminophen Oral Tablet','false'
'at baseline','C0168634','baseline','BaseLine dental cement','true'
'at baseline','C1442488','Baseline','Baseline','false'
'patients with mild pain womac pain score $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'patients with mild pain womac pain score $nmbr$ $nmbr$','C0278138','Mild pain','Mild pain','false'
'patients with mild pain womac pain score $nmbr$ $nmbr$','C4522280','Mild Pain','Neck Pain Score 2','false'
'baseline characteristic','C0168634','baseline','BaseLine dental cement','true'
'baseline characteristic','C1521970','Characteristic','Characteristics','false'
'baseline characteristic','C1442488','Baseline','Baseline','false'
'mtx plus placebo','C0025677','MTX','Methotrexate','true'
'mtx plus placebo','C1417487','MTX','MTX1 gene','false'
'mtx plus infliximab','C0025677','MTX','Methotrexate','true'
'mtx plus infliximab','C1417487','MTX','MTX1 gene','false'
'coefficient','C1707429','*Coefficient','Coefficient','false'
'swollen joint count $nmbr$ $nmbr$','C0451521','Swollen joint count','Swollen joint count','false'
'tender joint count $nmbr$ $nmbr$','C0451530','Tender joint count','Tender joint count','false'
'rf mg dl','C0035448','RF','Rheumatoid Factor','true'
'rf mg dl','C0439269','mg dl','mg/dL','false'
'rf mg dl','C0201660','RF','Rheumatoid Factor Measurement','false'
'rf mg dl','C0748398','RF','RF','false'
'rf mg dl','C1547111','RF','Radio fluoroscopy','false'
'crp mg dl','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp mg dl','C0439269','mg dl','mg/dL','false'
'crp mg dl','C4048285','CRP','C-Reactive Protein, human','false'
'esr mm hour','C0439227','HOUR','Hour','false'
'esr mm hour','C0564385','/hour','/hour','false'
'baseline shs $nmbr$ $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline shs $nmbr$ $nmbr$','C1442488','Baseline','Baseline','false'
'j $nmbr$ coefficient','C1707429','*Coefficient','Coefficient','false'
'or $nmbr$ ci','C0008107','CI','Chile','true'
'or $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'age per $nmbr$ years','C1510829','Age-Years','Age-Years','false'
'sex male','C0086582','Sex Male','Males','true'
'swollen joint count $nmbr$ $nmbr$ per swollen joint','C0451521','Swollen joint count','Swollen joint count','false'
'swollen joint count $nmbr$ $nmbr$ per swollen joint','C0152031','SWOLLEN JOINT','Joint swelling','false'
'swollen joint count $nmbr$ $nmbr$ per swollen joint','C4554794','Swollen joint','Swollen joint:Anatomy:Point in time:^Patient:Nominal','false'
'swollen joint count $nmbr$ $nmbr$ per swollen joint','C4696257','Swollen joint #','Swollen joint:Num:Pt:^Patient:Qn','false'
'tender joint count $nmbr$ $nmbr$ per tender joint','C0451530','Tender joint count','Tender joint count','false'
'tender joint count $nmbr$ $nmbr$ per tender joint','C0240094','Tender joint','Joint tenderness','false'
'tender joint count $nmbr$ $nmbr$ per tender joint','C4554549','Tender joint','Tender joint:Anatomy:Point in time:^Patient:Nominal','false'
'tender joint count $nmbr$ $nmbr$ per tender joint','C4696258','Tender joint #','Tender joint:Num:Pt:^Patient:Qn','false'
'rf mg dl per unit','C0439269','mg dl','mg/dL','false'
'crp mg dl per unit','C0439269','mg dl','mg/dL','false'
'esr mm hour per unit','C3811131','ESR','Estrogen Receptor Measurement','false'
'esr mm hour per unit','C0456685','Unit per Hour','U/hour','false'
'shs $nmbr$ $nmbr$ per $nmbr$ score','C0449820','SCORE','Score','false'
'shs $nmbr$ $nmbr$ per $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'baseline inflammation markers','C0021368','INFLAMMATION','Inflammation','true'
'baseline inflammation markers','C0005516','Marker','Biological Markers','true'
'changes in shs','C0392747','changes','Changing','false'
'changes in shs','C0443172','changes','Changed status','false'
'normal crp and','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'normal crp and','C4048285','CRP','C-Reactive Protein, human','false'
'esr','C3811131','ESR','Estrogen Receptor Measurement','false'
'high crp or esr','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'high crp or esr','C4048285','CRP','C-Reactive Protein, human','false'
'high crp or esr','C3811131','ESR','Estrogen Receptor Measurement','false'
'high crp and esr','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'high crp and esr','C4048285','CRP','C-Reactive Protein, human','false'
'high crp and esr','C3811131','ESR','Estrogen Receptor Measurement','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0392747','Change','Changing','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0443172','change','Changed status','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0449820','SCORE','Score','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0332174','/week','Weekly','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0439230','Week','week','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0681867','Controlled Study','Controlled Study','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C1514756','RECEIVING','Receive','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0666743','INFLIXIMAB','infliximab','true'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C3899278','Early Rheumatoid Arthritis','Early Rheumatoid Arthritis','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde vdh s score from baseline to week $nmbr$ in the active controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset aspire trial','C0008976','Trial','Clinical Trials','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1547282','Show','Show','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0168634','baseline','BaseLine dental cement','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0201657','CRP - C-reactive protein level','C-reactive protein measurement','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1442488','Baseline','Baseline','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1176468','Erythrocyte Sedimentation Rate','Erythrocyte sedimentation rate measurement','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1619634','Erythrocyte sedimentation rate','erythrocyte sedimentation rate result','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0441837','Group C','Group C','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0032042','Placebo','Placebos','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1696465','PLACEBO','placebo','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C1706408','PLACEBO','Placebo Control','false'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0025677','METHOTREXATE','Methotrexate','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0666743','INFLIXIMAB','infliximab','true'
'shown are tertiles of baseline c reactive protein crp levels a erythrocyte sedimentation rate esr b and vdh s score c by treatment group methotrexate [mtx] plus placebo [placebo] or mtx plus infliximab [infliximab] p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group','C0072053','p i p','procollagen Type I N-terminal peptide','true'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0392747','Change','Changing','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0443172','change','Changed status','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0557775','Van','Van (physical object)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0449820','SCORE','Score','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0332174','/week','Weekly','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0439230','Week','week','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C0008976','Trial','Clinical Trials','true'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ in the aspire trial by tertile of week $nmbr$ $nmbr$ joint disease activity scores das $nmbr$','C4706353','DAS - Disease Activity Score','DAS - Disease Activity Score','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0392747','Change','Changing','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0443172','change','Changed status','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0557775','Van','Van (physical object)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0449820','SCORE','Score','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0332174','/week','Weekly','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0439230','Week','week','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0441889','Levels','Levels (qualifier value)','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C4048285','CRP','C-Reactive Protein, human','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C3811131','ESR','Estrogen Receptor Measurement','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0451521','Swollen joint count','Swollen joint count','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C1510992','Average','Average','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C2825518','AVERAGE','Average of Value Derivation Technique','false'
'figure $nmbr$ change in radiographic progression by modified sharp van der heijde score from baseline to week $nmbr$ by tertiles of crp levels a esr b and swollen joint count c averaged over time during the aspire trial','C0008976','Trial','Clinical Trials','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C3811131','ESR','Estrogen Receptor Measurement','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C4048285','CRP','C-Reactive Protein, human','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0451521','Swollen joint count','Swollen joint count','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C1510992','Average','Average','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C2825518','AVERAGE','Average of Value Derivation Technique','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0008976','Trial','Clinical Trials','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0750572','Estimated','Estimated','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0017446','Area','Geographic Locations','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0205146','AREA','Area','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0025663','Method','Methods','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0021966','I-','Iodides','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0221138','I NOS','Blood group antibody I','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0449851','Method','Techniques','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0871511','METHOD','Test Method','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0025677','MTX','Methotrexate','true'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C1417487','MTX','MTX1 gene','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C1550452','definition','definition - ActMoodCompletionTrack','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C1704788','Definition','Definition','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C3539107','Definition','Definition (core metadata concept)','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C3888054','DEFINITION','DEFINITION - NCI Thesaurus Property','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0681841','Explanation','explanation','false'
'crp esr and swollen joint counts averaged over time during the trial were estimated by the area under the curve method p $nmbr$ $nmbr$ i p $nmbr$ $nmbr$ versus the mtx plus placebo group see figure $nmbr$ for definitions and explanation of treatment groups','C0374505','Group Treatment','Group Therapies','false'
'enoxaparin n $nmbr$ $nmbr$','C0206460','Enoxaparine','Enoxaparin','true'
'fondaparinux n $nmbr$ $nmbr$','C1098510','FONDAPARINUX','fondaparinux','true'
'male sex no','C0086582','MALE SEX','Males','true'
'time from onset of pain to randomization hr','C0449244','Time of onset','Time of onset','false'
'time from onset of pain to randomization hr','C0034656','Randomization','Randomization','true'
'diagnosis at study entry no','C1704656','Diagnosis Study','Diagnosis Study','false'
'diagnosis at study entry no','C4068481','Study diagnosis','Study diagnosis','false'
'unstable angina','C0002965','Angina, Unstable','Angina, Unstable','true'
'suspected myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'suspected myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'suspected myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'suspected myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'suspected myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'cabg or pci','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'cabg or pci','C4049621','PCI','Peritoneal Cancer Index','false'
'current or former smoker','C0521116','CURRENT','Current (present time)','false'
'current or former smoker','C1705970','Current','Electrical Current','false'
'current or former smoker','C0337671','Former Smoker','Former smoker','false'
'any electrocardiographic abnormality no','C0522055','Electrocardiographic abnormality','Electrocardiogram abnormal','false'
'st segment depression $nmbr$ mm no','C4330985','/mm','Per Millimeter','false'
'st segment depression $nmbr$ mm no','C4554674','MM','MM genotype','false'
'medications at the time of randomization no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications at the time of randomization no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications at the time of randomization no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications at the time of randomization no','C4284232','Medications','Medications','false'
'clopidogrel or ticlopidine','C0070166','CLOPIDOGREL','clopidogrel','true'
'clopidogrel or ticlopidine','C0040207','TICLOPIDINE','Ticlopidine','true'
'unfractionated heparin','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'low molecular weight heparin','C0019139','Heparin, Low-Molecular-Weight','Heparin, Low-Molecular-Weight','true'
'low molecular weight heparin','C3536766','Low Molecular Weight Heparin','Low Molecular Weight Heparin [EPC]','false'
'ace inhibitor or arb','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor or arb','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'ace inhibitor or arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'beta blocker','C0001645','Beta Blocker','Adrenergic beta-Antagonists','true'
'calcium channel blocker','C0006684','Calcium Channel Blocker','Calcium Channel Blockers','true'
'calcium channel blocker','C3536851','Calcium Channel Blocker','Calcium Channel Blocker [EPC]','false'
'calcium channel blocker','C4521885','Calcium channel blocker','Calcium channel blocker (disposition)','false'
'lipid lowering agent','C0086440','Lipid lowering agent','Hypolipidemic Agents','true'
'medications in the hospital after randomization no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications in the hospital after randomization no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications in the hospital after randomization no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications in the hospital after randomization no','C4284232','Medications','Medications','false'
'medications in the hospital after randomization no','C0034656','Randomization','Randomization','true'
'procedures in the hospital no','C0025664','procedures','Methods aspects','true'
'procedures in the hospital no','C0184661','PROCEDURES','Interventional procedure','true'
'procedures in the hospital no','C2700391','Procedures','Procedure (set of actions)','false'
'procedures in the hospital no','C3538935','Procedures','Procedure Domain','false'
'coronary angiography','C0085532','CORONARY ANGIOGRAPHY','Coronary angiography','true'
'coronary angiography','C1548829','Coronary Angiography','Consent Type - Coronary Angiography','false'
'pci','C4049621','PCI','Peritoneal Cancer Index','false'
'procedures after discharge no','C0012621','Discharge','Body Fluid Discharge','false'
'procedures after discharge no','C0030685','Discharge','Patient Discharge','true'
'procedures after discharge no','C2926602','Discharge','Discharge, body substance','false'
'panel a','C0441833','Panel','Groups','false'
'panel a','C1706365','Panel','Device Panel','false'
'panel a','C1999270','Panel','Laboratory Order Panels','false'
'percentage of patients with event','C0439165','Percentage','Percent (qualifier value)','false'
'percentage of patients with event','C1549488','Percentage','Amount type - Percentage','false'
'percentage of patients with event','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'percentage of patients with event','C0441471','Event','Event','false'
'percentage of patients with event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'interaction p value','C1704675','Interaction','Interaction','false'
'interaction p value','C1709380','P-Value','P-Value','false'
'enoxaparin','C0206460','Enoxaparine','Enoxaparin','true'
'fondaparinux','C1098510','FONDAPARINUX','fondaparinux','true'
'$nmbr$ yr','C0439234','yr','year','false'
'creatinine','C0010294','CREATININE','Creatinine','true'
'creatinine','C1561535','Creatinine','Creatinine, CTCAE','false'
'at or above median','C0549183','Median','Midline (qualifier value)','false'
'at or above median','C0876920','Median','Median Statistical Measurement','false'
'at or above median','C2347635','Median','Population Median','false'
'at or above median','C2348144','Median','Sample Median','false'
'at or above median','C2939193','Median','Median (qualifier value)','false'
'less than median','C0549183','Median','Midline (qualifier value)','false'
'less than median','C0876920','Median','Median Statistical Measurement','false'
'less than median','C2347635','Median','Population Median','false'
'less than median','C2348144','Median','Sample Median','false'
'less than median','C2939193','Median','Median (qualifier value)','false'
'heparin at randomization','C0019134','HEPARIN','heparin','true'
'heparin at randomization','C0770546','HEPARIN','heparin, porcine','false'
'yes','C1549445','Yes','Yes - Yes/no indicator','false'
'yes','C1705108','YES','Yes (indicator)','false'
'yes','C1710701','Yes','YES1 wt Allele','false'
'revascularization in $nmbr$ days','C0581603','Revascularization','Revascularization - action','false'
'revascularization in $nmbr$ days','C0439228','DAYS','day','false'
'catheterization laboratory in center','C0007430','Catheterization','Catheterization','true'
'catheterization laboratory in center','C0022877','LABORATORY','Laboratory','true'
'catheterization laboratory in center','C3244292','laboratory','Laboratory domain','false'
'catheterization laboratory in center','C4283904','Laboratory','Laboratory observation','false'
'panel b','C0441833','Panel','Groups','false'
'panel b','C1706365','Panel','Device Panel','false'
'panel b','C1999270','Panel','Laboratory Order Panels','false'
'percentage of p','C0439165','Percentage','Percent (qualifier value)','false'
'percentage of p','C1549488','Percentage','Amount type - Percentage','false'
'percentage of p','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'atients with event','C0441471','Event','Event','false'
'atients with event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'catheterization laboratory in','C0007430','Catheterization','Catheterization','true'
'catheterization laboratory in','C0022877','LABORATORY','Laboratory','true'
'catheterization laboratory in','C3244292','laboratory','Laboratory domain','false'
'catheterization laboratory in','C4283904','Laboratory','Laboratory observation','false'
'center','C0205099','Centre','Central','false'
'center','C3810851','Center','Center of town','false'
'unfractionated heparin n $nmbr$ $nmbr$','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin n $nmbr$ $nmbr$','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'median','C0549183','Median','Midline (qualifier value)','false'
'median','C0876920','Median','Median Statistical Measurement','false'
'median','C2347635','Median','Population Median','false'
'median','C2348144','Median','Sample Median','false'
'median','C2939193','Median','Median (qualifier value)','false'
'age $nmbr$ yr no','C0001779','AGE','Age','false'
'age $nmbr$ yr no','C0439234','yr','year','false'
'white race no total no f','C0007457','white race','Caucasoid Race','true'
'white race no total no f','C0043157','white race','Caucasians','true'
'white race no total no f','C0439175','% total','% of total','false'
'white race no total no f','C0439810','Total','Total','false'
'white race no total no f','C0016327','F-','Fluorides','true'
'hypertension no total no','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension no total no','C1963138','Hypertension','Hypertension, CTCAE','false'
'hypertension no total no','C0439175','% total','% of total','false'
'hypertension no total no','C0439810','Total','Total','false'
'hyperlipidemia no total no','C0020473','Hyperlipidaemia, NOS','Hyperlipidemia','true'
'hyperlipidemia no total no','C0428465','Hyperlipidemia','Serum lipids high (finding)','false'
'hyperlipidemia no total no','C4555212','Hyperlipidemia','Hyperlipidemia, CTCAE','false'
'hyperlipidemia no total no','C0439175','% total','% of total','false'
'hyperlipidemia no total no','C0439810','Total','Total','false'
'current smoker no total no','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker no total no','C3241966','Current Smoker','Current Smoker','false'
'current smoker no total no','C0439175','% total','% of total','false'
'current smoker no total no','C0439810','Total','Total','false'
'diabetes mellitus no total no','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'diabetes mellitus no total no','C0439175','% total','% of total','false'
'diabetes mellitus no total no','C0439810','Total','Total','false'
'prior myocardial infarction no total no','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'prior myocardial infarction no total no','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'prior myocardial infarction no total no','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'prior myocardial infarction no total no','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'prior myocardial infarction no total no','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'prior myocardial infarction no total no','C0439175','% total','% of total','false'
'prior myocardial infarction no total no','C0439810','Total','Total','false'
'prior angina pectoris no total no','C0332152','Prior','Before','false'
'prior angina pectoris no total no','C0002962','ANGINA PECTORIS','Angina Pectoris','true'
'prior angina pectoris no total no','C2826257','PRIOR','Prior Medication Usage','false'
'prior angina pectoris no total no','C0439175','% total','% of total','false'
'prior angina pectoris no total no','C0439810','Total','Total','false'
'prior percutaneous coronary intervention no total no','C0332152','Prior','Before','false'
'prior percutaneous coronary intervention no total no','C1532338','Intervention, Percutaneous Coronary','Percutaneous Coronary Intervention','true'
'prior percutaneous coronary intervention no total no','C2826257','PRIOR','Prior Medication Usage','false'
'prior percutaneous coronary intervention no total no','C0439175','% total','% of total','false'
'prior percutaneous coronary intervention no total no','C0439810','Total','Total','false'
'anterior myocardial infarction no total no','C0340293','Anterior myocardial infarction','Anterior myocardial infarction','true'
'anterior myocardial infarction no total no','C0439175','% total','% of total','false'
'anterior myocardial infarction no total no','C0439810','Total','Total','false'
'long term treatment with aspirin no total no','C0023977','long-term treatment','long-term care','true'
'long term treatment with aspirin no total no','C0004057','ASPIRIN','Aspirin','true'
'long term treatment with aspirin no total no','C0439175','% total','% of total','false'
'long term treatment with aspirin no total no','C0439810','Total','Total','false'
'unfractionated heparin within $nmbr$ hr before randomization no total no','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin within $nmbr$ hr before randomization no total no','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'unfractionated heparin within $nmbr$ hr before randomization no total no','C0034656','Randomization','Randomization','true'
'unfractionated heparin within $nmbr$ hr before randomization no total no','C0439175','% total','% of total','false'
'unfractionated heparin within $nmbr$ hr before randomization no total no','C0439810','Total','Total','false'
'lmwh within $nmbr$ days before randomization no total no','C0019139','LMWH','Heparin, Low-Molecular-Weight','true'
'lmwh within $nmbr$ days before randomization no total no','C3536766','LMWH','Low Molecular Weight Heparin [EPC]','false'
'lmwh within $nmbr$ days before randomization no total no','C0034656','Randomization','Randomization','true'
'lmwh within $nmbr$ days before randomization no total no','C0439175','% total','% of total','false'
'lmwh within $nmbr$ days before randomization no total no','C0439810','Total','Total','false'
'creatinine clearance ml min','C0812399','Creatinine clearance','Creatinine clearance','false'
'creatinine clearance ml min','C0439445','mL/min','mL/min','false'
'killip class no i','C1881332','Killip Class','Killip Class','false'
'killip class no i','C0021966','I-','Iodides','true'
'killip class no i','C0221138','I NOS','Blood group antibody I','false'
'data missing','C1511726','Data','Data','false'
'data missing','C3245479','data','Data call receiving device','false'
'data missing','C3714741','Data','Data (eukaryote)','false'
'data missing','C1551393','Missing','Container status - Missing','false'
'data missing','C1705492','Missing','Missing','false'
'data missing','C3272743','MISSING','Missing Study Animal','false'
'timi risk score no total no c','C0035647','Risk','Risk','true'
'timi risk score no total no c','C0449820','SCORE','Score','false'
'timi risk score no total no c','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score no total no c','C4552904','risk','Subject Risk','false'
'timi risk score no total no c','C0439175','% total','% of total','false'
'timi risk score no total no c','C0439810','Total','Total','false'
'time from symptom onset to start of fibrinolytic therapy hr','C0449244','onset time','Time of onset','false'
'time from symptom onset to start of fibrinolytic therapy hr','C0439659','Start','Beginning','false'
'time from symptom onset to start of fibrinolytic therapy hr','C0040044','Therapy, Fibrinolytic','Thrombolytic Therapy','true'
'fibrinolytic therapy no','C0040044','Therapy, Fibrinolytic','Thrombolytic Therapy','true'
'tenecteplase','C0872913','TENECTEPLASE','Tenecteplase','true'
'alteplase','C0032143','ALTEPLASE','alteplase','true'
'reteplase','C0256103','RETEPLASE','Reteplase','true'
'streptokinase','C0038418','STREPTOKINASE','Streptokinase','true'
'time from fibrinolytic therapy to study drug administration no total no','C0040223','TIME','Time','true'
'time from fibrinolytic therapy to study drug administration no total no','C3541383','Time','Time (foundation metadata concept)','false'
'time from fibrinolytic therapy to study drug administration no total no','C0150270','Drug administration','Medication Management','false'
'time from fibrinolytic therapy to study drug administration no total no','C3469597','Drug administration','Administration of medication','false'
'time from fibrinolytic therapy to study drug administration no total no','C0439175','% total','% of total','false'
'time from fibrinolytic therapy to study drug administration no total no','C0439810','Total','Total','false'
'$nmbr$ min','C0702093','/min','Per Minute','false'
'$nmbr$ min','C1524029','MIN NOS','Mouse MIN NOS','false'
'$nmbr$ min','C3813700','%/min','Percent per Minute','false'
'$nmbr$ $nmbr$ min','C0702093','/min','Per Minute','false'
'$nmbr$ $nmbr$ min','C1524029','MIN NOS','Mouse MIN NOS','false'
'$nmbr$ $nmbr$ min','C3813700','%/min','Percent per Minute','false'
'cardiac medications during index hospitalization no','C0013227','Medications','Pharmaceutical Preparations','true'
'cardiac medications during index hospitalization no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'cardiac medications during index hospitalization no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'cardiac medications during index hospitalization no','C4284232','Medications','Medications','false'
'clopidogrel','C0070166','CLOPIDOGREL','clopidogrel','true'
'ace inhibitors or angiotensin receptor blockers','C0003015','ACE INHIBITORS','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitors or angiotensin receptor blockers','C0521942','Angiotensin Receptor Blockers','Angiotensin II receptor antagonist','true'
'ace inhibitors or angiotensin receptor blockers','C0815017','Angiotensin Receptor Blockers','Angiotensin Receptor Antagonists','true'
'statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'baseline to year $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline to year $nmbr$','C1442488','Baseline','Baseline','false'
'relative risk $nmbr$ cl','C0242492','Relative Risk','Relative Risk','true'
'relative risk $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'age $nmbr$','C0001779','AGE','Age','false'
'age a $nmbr$','C0001779','AGE','Age','false'
'non black','C0005680','Black','Black race','true'
'non black','C0027567','Black','African race','true'
'non black','C0085756','BLACK','African American','true'
'non black','C0439541','Black','Black color','false'
'men','C0025266','Men','Male population group','true'
'diabetic','C0241863','DIABETIC','diabetic','false'
'non diabetic','C1518422','Non','Negation','false'
'non diabetic','C0241863','DIABETIC','diabetic','false'
'year $nmbr$','C0439234','Year','year','false'
'year $nmbr$','C0439508','/Year','per year','false'
'figure $nmbr$ subgroup analyses for primary outcome event','C2986480','Subgroup Analysis','Subset Analysis','false'
'figure $nmbr$ subgroup analyses for primary outcome event','C1624730','Event outcome','Event outcome','false'
'estimated gfr at baseline ml min $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr at baseline ml min $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'female sex n of patients','C0086287','FEMALE SEX','Females','true'
'race white n of patients','C0007457','white race','Caucasoid Race','true'
'race white n of patients','C0043157','white race','Caucasians','true'
'medical history n of patients','C0262926','History of MEDICAL','Medical History','false'
'history of diabetes','C0019664','History','History','true'
'history of diabetes','C0019665','history','Historical aspects qualifier','true'
'history of diabetes','C0262512','History, NOS','History of present illness','false'
'history of diabetes','C0262926','History','Medical History','false'
'history of diabetes','C1705255','History','Concept History','false'
'history of diabetes','C2004062','History','History of previous events','false'
'documented mi','C1301725','Documented','Documented','false'
'documented mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'documented mi','C1609436','Documented','Document completion status - Documented','false'
'ptca','C2936173','PTCA','Percutaneous Transluminal Coronary Angioplasty','true'
'current cigarette n','C0521116','CURRENT','Current (present time)','false'
'current cigarette n','C0677453','Cigarette','Cigarette','true'
'current cigarette n','C1704760','CIGARETTE','Cigarette Dosage Form','false'
'current cigarette n','C3890423','CIGARETTE','Cigarette Dosing Unit','false'
'current cigarette n','C1705970','Current','Electrical Current','false'
'mean blood pressure mm hg','C0428886','Mean blood pressure','Mean blood pressure','true'
'mean blood pressure mm hg','C0439475','mmHG','mmHg','false'
'mean blood pressure mm hg','C0488053','Mean blood pressure','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'laboratory determinations','C0022877','LABORATORY','Laboratory','true'
'laboratory determinations','C0680730','determinations','Adjudication','false'
'laboratory determinations','C3244292','laboratory','Laboratory domain','false'
'laboratory determinations','C4283904','Laboratory','Laboratory observation','false'
'mean serum creatinine mg dl','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'mean serum creatinine mg dl','C0439269','mg dl','mg/dL','false'
'mean serum creatinine mg dl','C0600061','serum creatinine','Serum creatinine level','false'
'lv ejection fraction $nmbr$ and','C0489482','ejection fraction','Ejection fraction (procedure)','false'
'lv ejection fraction $nmbr$ and','C2700378','Ejection fraction','Ejection fraction (finding)','false'
'n of patients','C0369718','N NOS','N not otherwise specified Antibody','false'
'n of patients','C0441922','N+','N+ (tumor staging)','false'
'lv ejection fraction n $nmbr$','C0489482','ejection fraction','Ejection fraction (procedure)','false'
'lv ejection fraction n $nmbr$','C2700378','Ejection fraction','Ejection fraction (finding)','false'
'medications n of patients','C0013227','Medications','Pharmaceutical Preparations','true'
'medications n of patients','C0030705','Patients','Patients','true'
'medications n of patients','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications n of patients','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications n of patients','C4284232','Medications','Medications','false'
'aspirin antiplatelet medication','C0085826','Antiplatelet Medication','Antiplatelet Agents','true'
'lipid lowering drug','C0086440','Lipid lowering drug','Hypolipidemic Agents','true'
'diuretic any','C0012798','Diuretic','Diuretics','true'
'hrt use','C0042153','use','utilization qualifier','true'
'hrt use','C0457083','Use','Usage','false'
'hrt use','C1947944','Use','Use - dosing instruction imperative','false'
'egfr category','C0683312','Category','Categories','false'
'egfr category','C3889287','Category','Digital Content Category','false'
'trandolapril n $nmbr$','C0076891','TRANDOLAPRIL','trandolapril','true'
'multivariable adjusted hr $nmbr$ ci','C0008107','CI','Chile','true'
'multivariable adjusted hr $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'events n','C0441471','Events','Event','false'
'events n','C3541888','EVENTS','CDISC Events Class','false'
'hr $nmbr$ ci','C0008107','CI','Chile','true'
'hr $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'trandolapril','C0076891','TRANDOLAPRIL','trandolapril','true'
'egfr $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ $nmbr$ $nmbr$ $nmbr$ vs egfr $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'reference','C1514811','Reference','Bibliographic Reference','false'
'reference','C1706462','Reference','Reference Object','false'
'cardiovascular mortality or mi','C0026565','Mortality','Mortality Vital Statistics','true'
'cardiovascular mortality or mi','C0026566','mortality','Aspects of mortality statistics','true'
'cardiovascular mortality or mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'cardiovascular mortality mi or revascularization','C0007226','Cardiovascular','Cardiovascular system','true'
'cardiovascular mortality mi or revascularization','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'cardiovascular mortality mi or revascularization','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'cardiovascular mortality mi or revascularization','C0581603','Revascularization','Revascularization - action','false'
'no pretreatment','C1550147','Pretreatment','Pretreatment (substance)','false'
'no pretreatment','C2709094','pre treatment','pre treatment','false'
'no pretreatment','C3539075','Pretreatment','Pretreatment Period','false'
'no pretreatment','C3539076','Pretreatment','Pretreatment','false'
'enoxaparin only','C0206460','Enoxaparine','Enoxaparin','true'
'unadjusted p value','C1439367','unadjusted','unadjusted','false'
'unadjusted p value','C1709380','P-Value','P-Value','false'
'region','C0017446','Region','Geographic Locations','true'
'region','C0205147','Region','regional','false'
'australia new zealand','C0027978','NEW ZEALAND','New Zealand','true'
'australia new zealand','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'latin america','C0023122','Latin America','Latin America','true'
'race','C0034510','RACE','Racial group','true'
'race','C1706779','RACE','AMACR wt Allele','false'
'race','C3853635','Race','Race','false'
'caucasian','C0007457','Caucasian','Caucasoid Race','true'
'caucasian','C0043157','Caucasian','Caucasians','true'
'diastolic blood pressure mm hg','C0428883','Diastolic Blood Pressure','Diastolic blood pressure','true'
'diastolic blood pressure mm hg','C0439475','mmHG','mmHg','false'
'diastolic blood pressure mm hg','C1305849','diastolic blood pressure','Diastolic blood pressure measurement','false'
'ecg at time of qualifying symptoms','C1623258','ECG NOS','Electrocardiography','true'
'ecg at time of qualifying symptoms','C0040223','TIME','Time','true'
'ecg at time of qualifying symptoms','C3541383','Time','Time (foundation metadata concept)','false'
'ecg at time of qualifying symptoms','C1514624','Qualifying','Qualifying','false'
'ecg at time of qualifying symptoms','C0683368','symptoms','Symptoms aspect','true'
'ecg at time of qualifying symptoms','C1457887','SYMPTOMS','Symptoms','false'
'st segment elevation','C0520886','ST Segment Elevation','ST segment elevation (finding)','false'
'st segment depression','C0520887','ST Segment Depression','ST segment depression (finding)','false'
'inclusion criteria','C1512693','Inclusion Criteria','Inclusion','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C0001779','AGE','Age','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C0237881','significant','Statistical Significance','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C0855329','ecg change','Electrocardiographic changes','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C0750502','Significant','Significant','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C1546944','Significant','Event Seriousness - Significant','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C1704489','ERS','Extended Rotated Sidebent','false'
'age is $nmbr$ vrs significant ecg changes and no positive bi omark ers','C2931783','ERS','Amelogenesis imperfecta nephrocalcinosis','true'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C0001779','AGE','Age','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C0439178','% Positive','percent positive cells','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C0005516','Biomarkers','Biological Markers','true'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C1446409','Positive','Positive','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C1514241','POSITIVE','Positive Finding','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C2825490','Positive','Positive Charge','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C3812269','Positive','Positive Number','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C4050619','FI','Flexibility Index','false'
'age is $nmbr$ vrs positive biomarkers and no si gni fi canr ecg changes','C0855329','ecg change','Electrocardiographic changes','false'
'si gni fi canr ecg changes positive biomarkers and age','C0855329','ecg change','Electrocardiographic changes','false'
'si gni fi canr ecg changes positive biomarkers and age','C0005516','Biomarkers','Biological Markers','true'
'si gni fi canr ecg changes positive biomarkers and age','C0001779','AGE','Age','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0001779','AGE','Age','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0237881','significant','Statistical Significance','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0855329','ecg change','Electrocardiographic changes','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0750502','Significant','Significant','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C1546944','Significant','Event Seriousness - Significant','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0439178','% Positive','percent positive cells','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C0005516','Biomarkers','Biological Markers','true'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C1446409','Positive','Positive','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C1514241','POSITIVE','Positive Finding','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C2825490','Positive','Positive Charge','false'
'age is $nmbr$ vrs significant ecg changes and positive biomarkers','C3812269','Positive','Positive Number','false'
'time to randomization h','C0040223','TIME','Time','true'
'time to randomization h','C3541383','Time','Time (foundation metadata concept)','false'
'current smoking','C0037369','SMOKING','Smoking','true'
'current smoking','C0453996','Smoking','Tobacco smoking behavior','true'
'current smoking','C1881674','Smoking','Medical Device Emits Smoke','false'
'familv historv of cad','C1504769','CAD','DFFB protein, human','true'
'familv historv of cad','C2239547','CAD','ACOD1 gene','false'
'familv historv of cad','C3813548','CAD','CALD1 wt Allele','false'
'familv historv of cad','C4284121','CAD','DFFB wt Allele','false'
'medical historv','C0199168','Medical','Medical service','false'
'medical historv','C0205476','Medical','Medical','false'
'chf','C0018802','CHF','Congestive heart failure','true'
'transient ischemic attack','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'transient ischemic attack','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'with t $nmbr$ dm n $nmbr$','C2986835','T/N','Tumor to Normal','false'
'with t $nmbr$ dm n $nmbr$','C0011816','DM','Dextromethorphan','true'
'with t $nmbr$ dm n $nmbr$','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'without t $nmbr$ dm n $nmbr$','C2986835','T/N','Tumor to Normal','false'
'without t $nmbr$ dm n $nmbr$','C0011816','DM','Dextromethorphan','true'
'without t $nmbr$ dm n $nmbr$','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'eze simva $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'rosuva $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'rosuva $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'rosuva $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'rosuva $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'rosuva $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'rosuva $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'rosuva $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'gender n','C0079399','Gender','Gender','true'
'gender n','C1522384','Gender','sex','true'
'race n','C0034510','RACE','Racial group','true'
'race n','C1706779','RACE','AMACR wt Allele','false'
'race n','C3853635','Race','Race','false'
'fpg mg dl','C0439269','mg dl','mg/dL','false'
'duration of hypercholesterolemia yr','C0449238','Duration','Duration (temporal concept)','false'
'duration of hypercholesterolemia yr','C2926735','Duration','Duration','false'
'current smoker n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker n','C3241966','Current Smoker','Current Smoker','false'
'nob systolic blood pressure mm hg','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'nob systolic blood pressure mm hg','C0439475','mmHG','mmHg','false'
'nob systolic blood pressure mm hg','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'nob systolic blood pressure mm hg','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'history of hypertension n','C0455527','History of - hypertension','H/O: hypertension','false'
'history of chd n','C0019664','History','History','true'
'history of chd n','C0019665','history','Historical aspects qualifier','true'
'history of chd n','C0262512','History, NOS','History of present illness','false'
'history of chd n','C0262926','History','Medical History','false'
'history of chd n','C1705255','History','Concept History','false'
'history of chd n','C2004062','History','History of previous events','false'
'history of pvd n','C4534349','History of PVD','History of PVD','false'
'statin potency stratum n','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'low potencyc','C0205251','Low','low','false'
'low potencyc','C1550472','low','low confidentiality','false'
'low potencyc','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low potencyc','C4048187','low','low exposure','false'
'low potencyc','C4321351','Low','Low Level','false'
'low potencyc','C4522223','Low','IPSS Risk Category Low','false'
'high potencyc','C0205250','High','High','false'
'high potencyc','C1299351','High','Abnormally high','false'
'high potencyc','C2700149','HIGH','Value Above Reference Range','false'
'high potencyc','C3887512','high','high - ActExposureLevelCode','false'
'high potencyc','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high potencyc','C4321237','High','High Level','false'
'high potencyc','C4522209','High','IPSS Risk Category High','false'
'concomitant medications','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications','C4284232','Medications','Medications','false'
'drugs used in diabetes n','C0013227','Drugs','Pharmaceutical Preparations','true'
'drugs used in diabetes n','C3687832','Drugs','Drugs - dental services','false'
'drugs used in diabetes n','C1273517','used','Used by','false'
'drugs used in diabetes n','C0011847','Diabetes','Diabetes','false'
'drugs used in diabetes n','C0011849','Diabetes','Diabetes Mellitus','true'
'antithrombotic agents n','C1704311','ANTITHROMBOTIC AGENTS','Antithrombotic Agents','true'
'antihypertensive agents n','C0003364','Antihypertensive Agents','Antihypertensive Agents','true'
'cardiac therapy n d','C3654025','CARDIAC THERAPY','CARDIAC THERAPY DRUGS','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0021149','Incidence','Incidence','true'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0220856','incidence','incidence of cases','true'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0449618','Target vessel','Target vessel','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0001779','AGE','Age','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C1522326','Treatment','Treating','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'figure $nmbr$ incidence of major bleeding top $nmbr$ day mortality middle and $nmbr$ day combined incidence of death myocardial infarction and urgent target vessel revascularization tvr according to age quartiles and assigned treatment mi denotes myocardial infarction and tvr target vessel revascularization','C0581603','Revascularization','Revascularization - action','false'
'age dependent effect of abcixima','C1280500','Effect','Effect','false'
'age dependent effect of abcixima','C1518681','effect','Outcome of Therapy','false'
'age dependent effect of abcixima','C2348382','Effect','Effect, Appearance','false'
'unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$','C0206460','Enoxaparine','Enoxaparin','true'
'unfractionated heparin or enoxaparin plus glycoprotein iib iiia inhibitors n $nmbr$','C0016011','Glycoprotein IIb/IIIa','Platelet Glycoprotein GPIIb-IIIa Complex','true'
'bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$','C0168273','BIVALIRUDIN','bivalirudin','true'
'bivalirudin plus glycoprotein iib iiia inhibitors n $nmbr$','C0016011','Glycoprotein IIb/IIIa','Platelet Glycoprotein GPIIb-IIIa Complex','true'
'bivalirudin alone n $nmbr$','C0168273','BIVALIRUDIN','bivalirudin','true'
'bivalirudin alone n $nmbr$','C0205171','Alone','Singular','false'
'bivalirudin alone n $nmbr$','C0439044','Alone','Living Alone','false'
'bivalirudin alone n $nmbr$','C0679994','alone','alone - group size','false'
'range','C1514721','Range','Range','false'
'range','C2348147','Range','Sample Range','false'
'range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'male sex no medical history no total no','C0086582','MALE SEX','Males','true'
'male sex no medical history no total no','C0262926','Medical History','Medical History','false'
'male sex no medical history no total no','C1704706','Medical History','Medical History Domain','false'
'male sex no medical history no total no','C0439175','% total','% of total','false'
'male sex no medical history no total no','C0439810','Total','Total','false'
'insulin requiring diabetes','C0011847','Diabetes','Diabetes','false'
'insulin requiring diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'percutaneous coronary intervention','C1532338','Intervention, Percutaneous Coronary','Percutaneous Coronary Intervention','true'
'coronary artery bypass grafting','C0010055','Coronary Artery Bypass Grafting','Coronary Artery Bypass Surgery','true'
'renal insufficiency','C0035078','Renal Insufficiency','Kidney Failure','true'
'renal insufficiency','C1565489','RENAL INSUFFICIENCY','Renal Insufficiency','true'
'elevation of cardiac biomarker levels no total no','C0439775','Elevation','Elevation procedure','false'
'elevation of cardiac biomarker levels no total no','C0702240','Elevation','Elevation','false'
'elevation of cardiac biomarker levels no total no','C0439175','% total','% of total','false'
'elevation of cardiac biomarker levels no total no','C0439810','Total','Total','false'
'elevation of troponin levels no total no','C0439775','Elevation','Elevation procedure','false'
'elevation of troponin levels no total no','C0702240','Elevation','Elevation','false'
'elevation of troponin levels no total no','C0439175','% total','% of total','false'
'elevation of troponin levels no total no','C0439810','Total','Total','false'
'st segment deviation $nmbr$ mm no total no','C4330985','/mm','Per Millimeter','false'
'st segment deviation $nmbr$ mm no total no','C4554674','MM','MM genotype','false'
'st segment deviation $nmbr$ mm no total no','C0439175','% total','% of total','false'
'st segment deviation $nmbr$ mm no total no','C0439810','Total','Total','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C0439775','Elevation','Elevation procedure','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C0702240','Elevation','Elevation','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C4330985','/mm','Per Millimeter','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C4554674','MM','MM genotype','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C0439175','% total','% of total','false'
'elevation of cardiac biomarker levels or st seg ment deviation $nmbr$ mm no total no','C0439810','Total','Total','false'
'timi risk score no total no f','C0035647','Risk','Risk','true'
'timi risk score no total no f','C0449820','SCORE','Score','false'
'timi risk score no total no f','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score no total no f','C4552904','risk','Subject Risk','false'
'timi risk score no total no f','C0439175','% total','% of total','false'
'timi risk score no total no f','C0439810','Total','Total','false'
'timi risk score no total no f','C0016327','F-','Fluorides','true'
'i $nmbr$ mg d n $nmbr$','C0024671','MG','Mammography','true'
'i $nmbr$ mg d n $nmbr$','C0026410','MG','Mongolia','true'
'i $nmbr$ mg d n $nmbr$','C0439269','mg%','mg/dL','false'
'i $nmbr$ mg d n $nmbr$','C1960952','mg %','Milligram percent','false'
'i $nmbr$ mg d n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'i $nmbr$ mg d n $nmbr$','C4321396','MG','MG','false'
'i $nmbr$ mg d n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'i $nmbr$ mg d n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'i $nmbr$ mg d n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ mg d n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg d n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg d n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg d n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg d n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg d n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg d n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg d n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ mg d n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'body mass index mean sd t','C0005893','Body mass index','Body mass index procedure','false'
'body mass index mean sd t','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index mean sd t','C1305855','BODY MASS INDEX','Body mass index','true'
'general health self reported','C0424575','General health','General health','false'
'general health self reported','C4018875','General health','General Health:Find:Pt:^Patient:Ord','false'
'general health self reported','C0681906','self reported','Patient Self-Report','false'
'general health self reported','C2700446','Self-reported','Self-Report','true'
'very good or excellent','C3641222','Very Good','Very good','false'
'very good or excellent','C1548784','Excellent','Excellent - Specimen Quality','false'
'very good or excellent','C1961136','Excellent','Excellent (qualifier value)','false'
'good','C0205170','Good','Good','false'
'fair or poor','C2911689','Fair','Fair (qualifier)','false'
'fair or poor','C0032854','Poor','Poverty','true'
'fair or poor','C0542537','Poor','Poor - grade value','false'
'fair or poor','C2700379','Poor','Poor - qualifier','false'
'walk for exercise','C0080331','Walk','Walking (activity)','true'
'walk for exercise','C0015259','Exercise','Exercise','true'
'walk for exercise','C1522704','Exercise','Exercise Pain Management','false'
'fall in last $nmbr$ mo','C0085639','FALL','Falls','false'
'fall in last $nmbr$ mo','C0238715','Fall','Autumn','false'
'fall in last $nmbr$ mo','C4553726','Fall','Fall, CTCAE','false'
'baseline vertebral fracture','C0168634','baseline','BaseLine dental cement','true'
'baseline vertebral fracture','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'baseline vertebral fracture','C1442488','Baseline','Baseline','false'
'history of clinical fracture $nmbr$ years old','C1272071','History of - fracture','H/O: fracture','false'
'history of clinical fracture $nmbr$ years old','C0205210','Clinical','Clinical','false'
'high fracture risk stratum','C0332167','HIGH RISK','High risk of','false'
'high fracture risk stratum','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'high fracture risk stratum','C4050568','High Risk','High Risk Acute Leukemia','false'
'high fracture risk stratum','C4319571','High risk','High risk','false'
'former','C0205156','FORMER','Previous','false'
'former','C0750523','FORMER','FORMER','false'
'duration of alendronate use mean sd y','C1881378','DURATION OF USE','Limitation of Use Based on Duration of Use','false'
'duration of alendronate use mean sd y','C2826775','Duration of Use','Duration of Use','false'
'current alendronate use','C0042153','use','utilization qualifier','true'
'current alendronate use','C0457083','Use','Usage','false'
'current alendronate use','C1947944','Use','Use - dosing instruction imperative','false'
'current use of hormone therapy','C1524063','Use of','Use of','false'
'current use of hormone therapy','C0279025','Hormone Therapy','Hormone Therapy','false'
'or raloxifene','C0244404','RALOXIFENE','Raloxifene','true'
'time since start of fit mean sd y','C1301880','Start Time','Start time','false'
'time since start of fit mean sd y','C0036572','Fit, NOS','Seizures','true'
'time since start of fit mean sd y','C2349186','Fit','Fit (action)','false'
'time since start of fit mean sd y','C4048158','Fit NOS','Convulsions','true'
'time since start of fit mean sd y','C4553125','Fit','Prosthesis fit','false'
'time since end of fit mean sd y','C1522314','End Time','End Time','false'
'time since end of fit mean sd y','C0036572','Fit, NOS','Seizures','true'
'time since end of fit mean sd y','C2349186','Fit','Fit (action)','false'
'time since end of fit mean sd y','C4048158','Fit NOS','Convulsions','true'
'time since end of fit mean sd y','C4553125','Fit','Prosthesis fit','false'
'flex baseline bmd mean sd g cm $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'flex baseline bmd mean sd g cm $nmbr$','C0439267','g%','Gram per Deciliter','false'
'flex baseline bmd mean sd g cm $nmbr$','C1442488','Baseline','Baseline','false'
'total hip','C0019552','HIP','Hip structure','true'
'total hip','C0022122','Hip','Bone structure of ischium','true'
'total hip','C1505163','HIP','HHIP protein, human','true'
'total hip','C3538851','HIP','REG3A wt Allele','false'
'total hip','C4284725','HIP','HHIP wt Allele','false'
'femoral neck','C0015815','Femoral Neck','Structure of neck of femur','true'
'lumbar spine','C0024091','Lumbar spine','Bone structure of lumbar vertebra','true'
'lumbar spine','C3887615','LUMBAR SPINE','Lumbar spine structure','false'
'forearm','C0016536','FOREARM','Forearm','true'
'total body','C0229960','Total body','Entire body as a whole','false'
'flex baseline bmd t score','C0449820','SCORE','Score','false'
'flex baseline bmd t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'at femoral neck mean sd','C0015815','Femoral Neck','Structure of neck of femur','true'
'at femoral neck mean sd','C2699239','SD','SD, Rat Strain','false'
'serum bone specific alkaline','C0205369','Specific','Specific qualifier value','false'
'serum bone specific alkaline','C1552740','specific','Entity Determiner - specific','false'
'serum bone specific alkaline','C1979842','Alkaline','Alkaline','false'
'phosphatase mean sd ng mlf','C0017887','NG','Nitroglycerin','true'
'phosphatase mean sd ng mlf','C0066495','MLF','fluorouracil/leucovorin calcium/methotrexate protocol','true'
'phosphatase mean sd ng mlf','C0028074','NG','Niger','true'
'serum c terminal telopeptide of','C0229671','SERUM','Serum','true'
'serum c terminal telopeptide of','C1707271','C-Terminal','Carboxy-Terminal Amino Acid','false'
'serum c terminal telopeptide of','C1546774','Serum','Specimen Source Codes - Serum','false'
'serum c terminal telopeptide of','C1550100','Serum','Specimen Type - Serum','false'
'type $nmbr$ collagen mean sd ng ml','C0009325','Collagen','Collagen','true'
'type $nmbr$ collagen mean sd ng ml','C0439275','ng/mL','Microgram per Liter','false'
'serum n propeptide of type $nmbr$ collagen','C1709708','Propeptide','Proprotein','false'
'serum n propeptide of type $nmbr$ collagen','C1875696','PRO-PEPTIDE','PRO-PEPTIDE','false'
'mean sd ng ml','C0444504','Mean','Statistical mean','false'
'mean sd ng ml','C0439275','ng/mL','Microgram per Liter','false'
'mean sd ng ml','C2347634','Mean','Population Mean','false'
'mean sd ng ml','C2348143','Mean','Sample Mean','false'
'dietary calcium intake mean sd mg d','C0024671','MG','Mammography','true'
'dietary calcium intake mean sd mg d','C0026410','MG','Mongolia','true'
'dietary calcium intake mean sd mg d','C0439269','mg%','mg/dL','false'
'dietary calcium intake mean sd mg d','C1960952','mg %','Milligram percent','false'
'dietary calcium intake mean sd mg d','C2346927','Mg++','Magnesium Cation','false'
'dietary calcium intake mean sd mg d','C4321396','MG','MG','false'
'dietary calcium intake mean sd mg d','C4521761','MG','United States Military Commissioned Officer O8','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1705117','Increment','Increment','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C4035091','End-systolic volume','End-systolic volume','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0425043','Death of relative','Death of relative','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0581603','Revascularization','Revascularization - action','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0439231','MONTHS','month','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0441833','Group','Groups','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0687744','group','Social group','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1257890','Group','Population Group','true'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1519504','Group','Stage Grouping','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1705428','Group','Group Object','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1705429','Group','User Group','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1707455','Compared','Comparison','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C0680395','primary group','primary group','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1707156','BARS','CTBP1 wt Allele','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C3274014','BARS','Brief Ataxia Rating Scale','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C3541345','BARS','Barnes Akathisia Rating Scale Questionnaire','false'
'figure $nmbr$ increment in endsystolic volume index and the relative risk of death reinfarction or revascularization at $nmbr$ months in the early routine post brinolysis group when compared with the primary angioplasty group according to various characteristics horizontal bars indicate the $nmbr$ con dence intervals','C1272706','intervals','Interval','false'
'vildagliptin $nmbr$ mg daily','C0024671','MG','Mammography','true'
'vildagliptin $nmbr$ mg daily','C0332173','Daily','Daily','false'
'vildagliptin $nmbr$ mg daily','C0026410','MG','Mongolia','true'
'vildagliptin $nmbr$ mg daily','C0439269','mg%','mg/dL','false'
'vildagliptin $nmbr$ mg daily','C1960952','mg %','Milligram percent','false'
'vildagliptin $nmbr$ mg daily','C2346927','Mg++','Magnesium Cation','false'
'vildagliptin $nmbr$ mg daily','C4321396','MG','MG','false'
'vildagliptin $nmbr$ mg daily','C4521761','MG','United States Military Commissioned Officer O8','false'
'rosiglitazone $nmbr$ mg daik','C0024671','MG','Mammography','true'
'rosiglitazone $nmbr$ mg daik','C0026410','MG','Mongolia','true'
'rosiglitazone $nmbr$ mg daik','C0439269','mg%','mg/dL','false'
'rosiglitazone $nmbr$ mg daik','C1960952','mg %','Milligram percent','false'
'rosiglitazone $nmbr$ mg daik','C2346927','Mg++','Magnesium Cation','false'
'rosiglitazone $nmbr$ mg daik','C4321396','MG','MG','false'
'rosiglitazone $nmbr$ mg daik','C4521761','MG','United States Military Commissioned Officer O8','false'
'hispanic or latino','C0086409','HISPANIC','Hispanics','true'
'hispanic or latino','C0086528','Latino','Latinos','true'
'bmi group kg m^','C0022718','KG','Kyrgyzstan','true'
'bmi group kg m^','C0439209','kg','Kilogram','false'
'bmi group kg m^','C4054209','/kg','Per Kilogram','false'
'alc','C1424945','ALC','ALLC gene','false'
'alc','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'alc group','C0441833','Group','Groups','false'
'alc group','C0687744','group','Social group','false'
'alc group','C1257890','Group','Population Group','true'
'alc group','C1519504','Group','Stage Grouping','false'
'alc group','C1705428','Group','Group Object','false'
'alc group','C1705429','Group','User Group','false'
'fpg mmol $nmbr$','C0439190','mmol','millimole','false'
'disease duration years','C0872146','disease duration','disease length','false'
'disease duration years','C0439234','YEARS','year','false'
'rosiglitazone $nmbr$ mg daily','C0024671','MG','Mammography','true'
'rosiglitazone $nmbr$ mg daily','C0332173','Daily','Daily','false'
'rosiglitazone $nmbr$ mg daily','C0026410','MG','Mongolia','true'
'rosiglitazone $nmbr$ mg daily','C0439269','mg%','mg/dL','false'
'rosiglitazone $nmbr$ mg daily','C1960952','mg %','Milligram percent','false'
'rosiglitazone $nmbr$ mg daily','C2346927','Mg++','Magnesium Cation','false'
'rosiglitazone $nmbr$ mg daily','C4321396','MG','MG','false'
'rosiglitazone $nmbr$ mg daily','C4521761','MG','United States Military Commissioned Officer O8','false'
'adjusted mean change kg','C0022718','KG','Kyrgyzstan','true'
'adjusted mean change kg','C0439209','kg','Kilogram','false'
'adjusted mean change kg','C4054209','/kg','Per Kilogram','false'
'whole cohort','C0009247','COHORT','Cohort Studies','true'
'whole cohort','C0599755','Cohort','Cohort','false'
'bmi $nmbr$','C0578022','BMI','Finding of body mass index','false'
'etoricoxib $nmbr$ mg n $nmbr$ n','C0024671','MG','Mammography','true'
'etoricoxib $nmbr$ mg n $nmbr$ n','C0026410','MG','Mongolia','true'
'etoricoxib $nmbr$ mg n $nmbr$ n','C0439269','mg%','mg/dL','false'
'etoricoxib $nmbr$ mg n $nmbr$ n','C1960952','mg %','Milligram percent','false'
'etoricoxib $nmbr$ mg n $nmbr$ n','C2346927','Mg++','Magnesium Cation','false'
'etoricoxib $nmbr$ mg n $nmbr$ n','C4321396','MG','MG','false'
'etoricoxib $nmbr$ mg n $nmbr$ n','C4521761','MG','United States Military Commissioned Officer O8','false'
'diclofenac $nmbr$ mg n $nmbr$ n','C0012091','Diclophenac','Diclofenac','true'
'diclofenac $nmbr$ mg n $nmbr$ n','C0024671','MG','Mammography','true'
'diclofenac $nmbr$ mg n $nmbr$ n','C0026410','MG','Mongolia','true'
'diclofenac $nmbr$ mg n $nmbr$ n','C0439269','mg%','mg/dL','false'
'diclofenac $nmbr$ mg n $nmbr$ n','C1960952','mg %','Milligram percent','false'
'diclofenac $nmbr$ mg n $nmbr$ n','C2346927','Mg++','Magnesium Cation','false'
'diclofenac $nmbr$ mg n $nmbr$ n','C4321396','MG','MG','false'
'diclofenac $nmbr$ mg n $nmbr$ n','C4521761','MG','United States Military Commissioned Officer O8','false'
'age mean yrs sd','C0001779','AGE','Age','false'
'age mean yrs sd','C2699239','SD','SD, Rat Strain','false'
'sex n','C0009253','Sex','Coitus','true'
'sex n','C0036864','Sex','Sex Behavior','true'
'sex n','C0079399','sex','Gender','true'
'sex n','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex n','C1314687','Sex','Sexual intercourse - finding','false'
'sex n','C1522384','SEX','sex','true'
'native american','C0282204','NATIVE AMERICAN','Native Americans','true'
'native american','C1515945','Native American','American Indian or Alaska Native','false'
'body mass index mean kg m^ sd','C0022718','KG','Kyrgyzstan','true'
'body mass index mean kg m^ sd','C0439209','kg','Kilogram','false'
'body mass index mean kg m^ sd','C4054209','/kg','Per Kilogram','false'
'body mass index mean kg m^ sd','C2699239','SD','SD, Rat Strain','false'
'primary study joint n','C0205225','Primary','Primary','false'
'primary study joint n','C0022417','JOINT','Joints','true'
'primary study joint n','C0392905','Joint, NOS','Articular system','false'
'primary study joint n','C1706309','Joint','Joint Device','false'
'primary study joint n','C0439612','Primary','True primary (qualifier value)','false'
'primary study joint n','C0439631','Primary','Primary operation','false'
'knee','C0022742','Knee','Knee','true'
'knee','C0022745','Knee','Knee joint','true'
'knee','C1963703','Knee, NOS','Knee region structure','false'
'hand','C0018563','HAND','Hand','true'
'hand','C1552914','hand','hand - unit of measure','false'
'left shoulder','C0524469','Left shoulder','Structure of left shoulder region','false'
'acr functional class n','C0205245','Functional','Functional','false'
'acr functional class n','C0456387','Class','Class','false'
'acr functional class n','C1518526','class','Object Class','false'
'acr functional class n','C1705943','Class','Class (taxonomic)','false'
'acr functional class n','C0542341','Functional','Function (attribute)','false'
'acr functional class n','C2700217','Functional','Functional Relationship','false'
'class i','C0441885','Class I','Class 1','false'
'class i','C1319793','Class I','New York Heart Association Classification - Class I','false'
'class i','C2698967','Class I','Canadian Cardiovascular Society Grading Scale Class I','false'
'class ii','C0441886','Class II','Class 2','false'
'class ii','C2698968','Class II','Canadian Cardiovascular Society Grading Scale Class II','false'
'class $nmbr$','C0456387','Class','Class','false'
'class $nmbr$','C1518526','class','Object Class','false'
'class $nmbr$','C1705943','Class','Class (taxonomic)','false'
'prior antiinflammatory antirheumatic products n','C0003209','Antiinflammatory','Anti-Inflammatory Agents','true'
'prior antiinflammatory antirheumatic products n','C0003191','Antirheumatic','Antirheumatic Agents','true'
'prior antiinflammatory antirheumatic products n','C1515999','Anti-inflammatory','Anti-inflammatory effect','false'
'rofecoxib','C0762662','ROFECOXIB','rofecoxib','true'
'valdecoxib','C0913246','VALDECOXIB','valdecoxib','true'
'ibuprofen','C0020740','IBUPROFEN','Ibuprofen','true'
'naproxen','C0027396','NAPROXEN','Naproxen','true'
'prior analgesic products n','C0332152','Prior','Before','false'
'prior analgesic products n','C0002771','Analgesic product','Analgesics','true'
'prior analgesic products n','C2826257','PRIOR','Prior Medication Usage','false'
'acetaminophen','C0000970','ACETAMINOPHEN','Acetaminophen','true'
'acetaminophen','C2917659','Acetaminophen','Acetaminophen [EPC]','false'
'history of upper gl events perforations ulcers bleeding n','C0019664','History','History','true'
'history of upper gl events perforations ulcers bleeding n','C0019665','history','Historical aspects qualifier','true'
'history of upper gl events perforations ulcers bleeding n','C0262512','History, NOS','History of present illness','false'
'history of upper gl events perforations ulcers bleeding n','C0262926','History','Medical History','false'
'history of upper gl events perforations ulcers bleeding n','C1705255','History','Concept History','false'
'history of upper gl events perforations ulcers bleeding n','C2004062','History','History of previous events','false'
'low dose aspirin use strata n','C2608320','Low-Dose Aspirin','Low-Dose Aspirin','false'
'low dose aspirin use strata n','C0042153','use','utilization qualifier','true'
'low dose aspirin use strata n','C0457083','Use','Usage','false'
'low dose aspirin use strata n','C1947944','Use','Use - dosing instruction imperative','false'
'user','C1548600','User','user - Facility type','false'
'user','C1706077','User','user - individual','false'
'increased risk for thrombotic cardiovascular event^ n','C1273410','Cardiovascular event risk','Cardiovascular event risk','false'
'history of diagnosed hypertension prior to randomization n','C0455527','History of - hypertension','H/O: hypertension','false'
'history of diagnosed hypertension prior to randomization n','C0011900','Diagnosed','Diagnosis','true'
'history of diagnosed hypertension prior to randomization n','C0034656','Randomization','Randomization','true'
'baseline aspirin use strata','C0004057','ASPIRIN','Aspirin','true'
'baseline aspirin use strata','C0042153','use','utilization qualifier','true'
'baseline aspirin use strata','C0457083','Use','Usage','false'
'baseline aspirin use strata','C1947944','Use','Use - dosing instruction imperative','false'
'rr $nmbr$ ci','C0008107','CI','Chile','true'
'rr $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'patient years','C0030705','*^patient','Patients','true'
'patient years','C0439234','YEARS','year','false'
'pt years $nmbr$','C0032743','PT','Positron-Emission Tomography','true'
'pt years $nmbr$','C0439234','YEARS','year','false'
'pt years $nmbr$','C0699718','PT','Physical therapy (field)','false'
'continued use of gpa','C0549178','Continued','Continuous','false'
'continued use of gpa','C1524063','Use of','Use of','false'
'new use of gpa','C0205314','New','New','false'
'new use of gpa','C1524063','Use of','Use of','false'
'$nmbr$ years','C0439234','YEARS','year','false'
'non caucasian','C0007457','Caucasian','Caucasoid Race','true'
'non caucasian','C0043157','Caucasian','Caucasians','true'
'no of individuals','C0027361','Individual','Persons','true'
'no of individuals','C0237401','Individual','Individual','false'
'i rosuvastatin n $nmbr$','C0021966','I-','Iodides','true'
'i rosuvastatin n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'i placebo n $nmbr$','C0021966','I-','Iodides','true'
'i placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'i placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'i placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'i placebo n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'white race','C0007457','white race','Caucasoid Race','true'
'white race','C0043157','white race','Caucasians','true'
'blood pressure mean sd mm hgt','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure mean sd mm hgt','C2699239','SD','SD, Rat Strain','false'
'fasting blood glucose mean sd mg dlt','C1413248','DLT','CDAN1 gene','false'
'fasting blood glucose mean sd mg dlt','C3273706','DLT','CDAN1 wt Allele','false'
'impaired renal function','C1565489','Impaired renal function','Renal Insufficiency','true'
'estimated glomerular filtration rate','C3811844','Estimated Glomerular Filtration Rate','Estimated Glomerular Filtration Rate','false'
'normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$','C0205307','NORMAL','Normal','false'
'normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$','C0231683','Normal','Gait normal','false'
'normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$','C0439166','% normal','Percent normal','false'
'normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'normal $nmbr$ mlvmin per $nmbr$ $nmbr$ m $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'mild decrease $nmbr$','C0392756','Decrease','Reduced','false'
'mild decrease $nmbr$','C0547047','Decrease','Decrease','false'
'moderate decrease $nmbr$','C0392756','Decrease','Reduced','false'
'moderate decrease $nmbr$','C0547047','Decrease','Decrease','false'
'concomitant medication use','C0521115','Concomitant','Simultaneous','false'
'concomitant medication use','C0240320','MEDICATION USE','medication use','false'
'antihypertensive','C0003364','anti hypertensive','Antihypertensive Agents','true'
'the metabolic syndrome^','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'body mass index $nmbr$ t','C0005893','Body mass index','Body mass index procedure','false'
'body mass index $nmbr$ t','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index $nmbr$ t','C1305855','BODY MASS INDEX','Body mass index','true'
'triglycerides $nmbr$ mg dl $nmbr$ $nmbr$ mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'diastolic blood pressure $nmbr$ mm hg','C0428883','Diastolic Blood Pressure','Diastolic blood pressure','true'
'diastolic blood pressure $nmbr$ mm hg','C0439475','mmHG','mmHg','false'
'diastolic blood pressure $nmbr$ mm hg','C1305849','diastolic blood pressure','Diastolic blood pressure measurement','false'
'systolic blood pressure $nmbr$ mm hg','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic blood pressure $nmbr$ mm hg','C0439475','mmHG','mmHg','false'
'systolic blood pressure $nmbr$ mm hg','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'systolic blood pressure $nmbr$ mm hg','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'or taking antihypertensive medication','C1290952','Taking medication','Taking medication (activity)','false'
'fasting blood glucose $nmbr$ mg dl $nmbr$ $nmbr$ mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'$nmbr$ chd risk factors','C0035648','Risk Factors','risk factors','true'
'$nmbr$ chd risk factors','C1282512','chd risk','At risk of coronary heart disease','false'
'$nmbr$ chd risk factors','C1553898','risk factors','risk factors - observation list','false'
'chd risk factors','C0035648','Risk Factors','risk factors','true'
'chd risk factors','C1282512','chd risk','At risk of coronary heart disease','false'
'chd risk factors','C1553898','risk factors','risk factors - observation list','false'
'family history of premature chd','C0241889','FAMILY HISTORY','Family history','true'
'family history of premature chd','C0151526','Premature','Premature Birth','true'
'family history of premature chd','C0205252','Premature','Immature','false'
'family history of premature chd','C4018905','Premature','Too early','false'
'smoking during the previous month','C2114448','previous smoking','previous Smoking History','false'
'smoking during the previous month','C0332177','/month','Monthly (qualifier value)','false'
'smoking during the previous month','C0439231','Month','month','false'
'hypertension $nmbr$ $nmbr$ mm hg or taking','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension $nmbr$ $nmbr$ mm hg or taking','C0439475','mmHG','mmHg','false'
'hypertension $nmbr$ $nmbr$ mm hg or taking','C1963138','Hypertension','Hypertension, CTCAE','false'
'antihypertensive medication','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'$nmbr$ mg dl $nmbr$ $nmbr$ mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'mean of maximum cimt mean sd mm','C0444504','Mean','Statistical mean','false'
'mean of maximum cimt mean sd mm','C0806909','Maximum','Maximum','false'
'mean of maximum cimt mean sd mm','C1552615','maximum','Act Relationship Subset - maximum','false'
'mean of maximum cimt mean sd mm','C2826546','MAXIMUM','Maximum Value Derivation Technique','false'
'mean of maximum cimt mean sd mm','C2347634','Mean','Population Mean','false'
'mean of maximum cimt mean sd mm','C2348143','Mean','Sample Mean','false'
'$nmbr$ carotid artery sites','C0007272','CAROTID ARTERY','Carotid Arteries','true'
'$nmbr$ carotid artery sites','C0205145','Sites','Site','false'
'$nmbr$ carotid artery sites','C0162859','Carotid artery','Common carotid artery','true'
'common carotid artery sites','C0007272','Common Carotid Artery','Carotid Arteries','true'
'common carotid artery sites','C0205145','Sites','Site','false'
'common carotid artery sites','C0162859','Common Carotid Artery','Common carotid artery','true'
'carotid bulb sites','C0007281','Carotid bulb','Structure of carotid sinus','true'
'carotid bulb sites','C0205145','Sites','Site','false'
'internal carotid artery sites','C0007276','Internal Carotid Artery','Internal carotid artery structure','true'
'internal carotid artery sites','C0205145','Sites','Site','false'
'mean of mean cimt mean sd mm','C0444504','Mean','Statistical mean','false'
'mean of mean cimt mean sd mm','C2347634','Mean','Population Mean','false'
'mean of mean cimt mean sd mm','C2348143','Mean','Sample Mean','false'
'tolvaptan n $nmbr$','C1176308','TOLVAPTAN','tolvaptan','true'
'systolic blood pressure mean sd mm hg','C0428886','blood Pressure mean','Mean blood pressure','true'
'systolic blood pressure mean sd mm hg','C0439475','mmHG','mmHg','false'
'ejection fraction mean sd','C0489482','ejection fraction','Ejection fraction (procedure)','false'
'ejection fraction mean sd','C2699239','SD','SD, Rat Strain','false'
'ejection fraction mean sd','C2700378','Ejection fraction','Ejection fraction (finding)','false'
'ischemic heart failure etiology','C0015127','etiology','Etiology aspects','true'
'ischemic heart failure etiology','C1314792','Etiology','Etiology','true'
'ischemic heart failure etiology','C1524003','Etiology','Science of Etiology','false'
'previous hospitalization for heart failure','C0205156','Previous','Previous','false'
'previous hospitalization for heart failure','C3898876','HEART FAILURE HOSPITALIZATION','Hospitalization Due to Heart Failure','false'
'previous hospitalization for heart failure','C1552607','previous','Act Relationship Subset - previous','false'
'nyha class','C1882083','NYHA Class','New York Heart Association Class','false'
'chronic renal insufficiency','C0403447','Chronic Renal Insufficiency','Chronic Kidney Insufficiency','true'
'chronic renal insufficiency','C1561643','Chronic Renal Insufficiency','Chronic Kidney Diseases','true'
'valvular disease mitral','C3258293','Valvular disease','Valvular disease','false'
'valvular disease mitral','C0746591','mitral','mitral','false'
'baseline therapy','C0039798','therapy','therapeutic aspects','true'
'baseline therapy','C0087111','Therapy','Therapeutic procedure','true'
'baseline therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'ace inhibitors arbs','C0003015','ACE INHIBITORS','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitors arbs','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'p blockers','C0369773','P NOS','P Blood group antibodies','false'
'p blockers','C2603361','P'','P prime','false'
'aldosterone blockers','C0002006','ALDOSTERONE','Aldosterone','true'
'baseline cardiovascular assessment','C4684571','Baseline Assessment','Baseline Assessment','false'
'dyspnea frequent continuous','C0013404','DYSPNOEA','Dyspnea','true'
'dyspnea frequent continuous','C0549178','CONTINUOUS','Continuous','false'
'dyspnea frequent continuous','C1963100','Dyspnea','Dyspnea, CTCAE','false'
'orthopnea frequent continuous','C0085619','Orthopnoea','Orthopnea','false'
'orthopnea frequent continuous','C0549178','CONTINUOUS','Continuous','false'
'rales','C0034642','RALES','Rales','true'
'rales','C0240859','Rales','Basilar Rales','false'
'pedal edema slight moderate marked','C0205081','Moderate','Moderate (severity modifier)','false'
'pedal edema slight moderate marked','C1881878','Moderate','Moderation','false'
'pedal edema slight moderate marked','C4049705','Moderate','Moderate Extremity Pain','false'
'pedal edema slight moderate marked','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'pedal edema slight moderate marked','C4085643','Moderate','Moderate Response','false'
'pedal edema slight moderate marked','C4321335','Moderate','Moderate Level','false'
'pedal edema slight moderate marked','C0522501','Marked','Massive','false'
'pedal edema slight moderate marked','C1706089','Marked','Marked','false'
'jugular venous distention $nmbr$ cm','C0425687','Jugular venous distension','Jugular venous engorgement','false'
'younger subjects aged','C0681850','Subject','Study Subject','false'
'younger subjects aged','C1550501','{Subject}','Subject -direct target','false'
'younger subjects aged','C1706203','Subject','Subject - topic','false'
'younger subjects aged','C2349001','Subject','Human Study Subject','false'
'younger subjects aged','C2697811','Subject','Investigative Subject','false'
'younger subjects aged','C0001779','Aged','Age','false'
'younger subjects aged','C0001792','Aged','Elderly (population group)','true'
'younger subjects aged','C1999167','aged','Old age','false'
'older subjects aged $nmbr$ years','C0001779','Aged','Age','false'
'older subjects aged $nmbr$ years','C0439234','YEARS','year','false'
'older subjects aged $nmbr$ years','C0001792','Aged','Elderly (population group)','true'
'older subjects aged $nmbr$ years','C1999167','aged','Old age','false'
'sertraline','C0074393','SERTRALINE','Sertraline','true'
'sertraline','C0524265','Sertraline','Sertraline measurement','false'
'female sex','C0086287','FEMALE SEX','Females','true'
'married','C0024841','Married','Marriage, life event','true'
'married','C0555047','MARRIED','Married (finding)','false'
'education years','C0013621','Education','Knowledge acquisition','true'
'education years','C0439234','YEARS','year','false'
'education years','C0013622','education','Educational aspects','true'
'education years','C0013658','Education, NOS','Educational Status','true'
'education years','C0039401','Education','Educational process of instructing','true'
'no of events sample size i i','C0242618','Sample Size','Sample Size','true'
'no of events sample size i i','C3811654','Sample Events','Biospecimen Events Domain','false'
'kaplan meier rates i i','C0021966','I-','Iodides','true'
'kaplan meier rates i i','C0221138','I NOS','Blood group antibody I','false'
'ranolazine','C0073633','RANOLAZINE','ranolazine','true'
'hr $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'pfor interaction','C1151635','PFOR','pyruvate synthase activity','false'
'pfor interaction','C1704675','Interaction','Interaction','false'
'timi risk score','C0035647','Risk','Risk','true'
'timi risk score','C0449820','SCORE','Score','false'
'timi risk score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score','C4552904','risk','Subject Risk','false'
'index diagnosis','C0011900','DIAGNOSIS','Diagnosis','true'
'index diagnosis','C1704338','diagnosis','diagnosis aspect','true'
'index diagnosis','C1704656','DIAGNOSIS','Diagnosis Study','false'
'non st elevation ml','C0439526','/mL','/mL','false'
'non st elevation ml','C1705224','ML','THPO wt Allele','false'
'non st elevation ml','C3887665','ML','Thrombopoietin, human','false'
'st segment depression $nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'st segment depression $nmbr$ mm','C4554674','MM','MM genotype','false'
'creatinine clearance','C0812399','Creatinine clearance','Creatinine clearance','false'
'early invasive','C0205281','Invasive','Invasive','false'
'early invasive','C1334278','Invasive','Invasive Lesion','false'
'overall','C0282416','Overall','Overall Publication Type','true'
'overall','C1561607','Overall','Overall','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1705242','Difference','Different','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0441889','Levels','Levels (qualifier value)','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C4048285','CRP','C-Reactive Protein, human','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0030705','*^patient','Patients','true'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0042295','Values','Values','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C2360800','Number of patients','Number of patients','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1709595','Pooled','Pooled Sample','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0074554','SIMVASTATIN','Simvastatin','true'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C2349200','Pooled','Pool (action)','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C4522255','Pooled','Pooled Blood Products','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0441833','Groups','Groups','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0687744','groups','Social group','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1257890','Group','Population Group','true'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1519504','Group','Stage Grouping','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1552839','groups','Table Rules - groups','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1705428','Group','Group Object','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1705429','Group','User Group','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1522326','Treatment','Treating','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0369773','P NOS','P Blood group antibodies','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C2603361','P'','P prime','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C0332529','Consistency','Consistency','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1547017','Consistency','Kind of quantity - Consistency','false'
'figure $nmbr$ geometric mean percentage difference between treatment groups in crp levels from baseline across patient subgroups values in parentheses represent the number of patients in the pooled simvastatin and pooled ezetimibe simvastatin groups respectively the treatment by subgroup interaction term was p $nmbr$ $nmbr$ for all subgroups indicating consistency of the treatment effect across subgroups','C1079230','subgroups','Subgroup A Nepoviruses','false'
'tiotropium','C0213771','TIOTROPIUM','tiotropium','true'
'total randomised n','C0439175','% total','% of total','false'
'total randomised n','C0439810','Total','Total','false'
'male n','C0086582','MALE','Males','true'
'male n','C1706180','Male','Male Gender, Self Report','false'
'male n','C1706428','MALE','Male Phenotype','false'
'male n','C1706429','Male','Male, Self-Reported','false'
'smoking history pack years','C1519384','Smoking History','Smoking History','false'
'smoking history pack years','C1277691','Pack years','Pack years','false'
'screening visit $nmbr$','C0545082','Visit','Visit','false'
'screening visit $nmbr$','C1512346','visit','Patient Visit','false'
'screening visit $nmbr$','C2826704','VISIT','Visit Name','false'
'fev $nmbr$ l pre bronchodilator','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ l pre bronchodilator','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'fev $nmbr$ predicted normal','C0520835','FEV normal','FEV normal','false'
'fev $nmbr$ predicted normal','C0681842','Predicted','prediction','false'
'fev $nmbr$ predicted normal','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fev $nmbr$ fvc','C3714541','FEV','Forced Vital Capacity','true'
'fvc l','C3714541','FVC','Forced Vital Capacity','true'
'nice classification of copd severity of obstruction n [ $nmbr$ ]','C0008902','Classification','Classification','true'
'nice classification of copd severity of obstruction n [ $nmbr$ ]','C0008903','classification','Taxonomic','true'
'nice classification of copd severity of obstruction n [ $nmbr$ ]','C0678229','classification','Classification of information','false'
'mild fev $nmbr$ predicted','C0681842','Predicted','prediction','false'
'mild fev $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'moderate $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate $nmbr$','C1881878','Moderate','Moderation','false'
'moderate $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate $nmbr$','C4085643','Moderate','Moderate Response','false'
'moderate $nmbr$','C4321335','Moderate','Moderate Level','false'
'severe fev','C0205082','Severe','Severe (severity modifier)','false'
'severe fev','C3714541','FEV','Forced Vital Capacity','true'
'severe fev','C4050465','Severe','Severe Extremity Pain','false'
'severe fev','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'pulmonary medication during baseline','C0013227','Medication','Pharmaceutical Preparations','true'
'pulmonary medication during baseline','C3244316','medication','medication - HL7 publishing domain','false'
'pulmonary medication during baseline','C4284232','Medication','Medications','false'
'laba no ics n','C0815320','ICS','Impaired Control Scale','false'
'laba no ics n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics n','C0815320','ICS','Impaired Control Scale','false'
'ics n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics no laba n','C0815320','ICS','Impaired Control Scale','false'
'ics no laba n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'laba plus ics n','C0815320','ICS','Impaired Control Scale','false'
'laba plus ics n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'no laba no ics n','C0815320','ICS','Impaired Control Scale','false'
'no laba no ics n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'saba use occasions weekt','C0042153','use','utilization qualifier','true'
'saba use occasions weekt','C0457083','Use','Usage','false'
'saba use occasions weekt','C1947944','Use','Use - dosing instruction imperative','false'
'trough fev response l','C0444506','Trough','Trough','false'
'trough fev response l','C0871261','Response','Response process','false'
'trough fev response l','C1704632','Response','Disease Response','false'
'trough fev response l','C1706817','Response','Response (statement)','false'
'trough fev response l','C2911692','Response','Response (communication)','false'
'trough fvc response l','C0444506','Trough','Trough','false'
'trough fvc response l','C0871261','Response','Response process','false'
'trough fvc response l','C1704632','Response','Disease Response','false'
'trough fvc response l','C1706817','Response','Response (statement)','false'
'trough fvc response l','C2911692','Response','Response (communication)','false'
'effect size^','C0814843','effect size','effect size','false'
'laba tiotropium n $nmbr$ placebo n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'laba tiotropium n $nmbr$ placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'laba tiotropium n $nmbr$ placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'laba tiotropium n $nmbr$ placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'ics tiotropium n $nmbr$ placebo n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'ics tiotropium n $nmbr$ placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'ics tiotropium n $nmbr$ placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'ics tiotropium n $nmbr$ placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C0815320','ICS','Impaired Control Scale','false'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'ics no laba tiotropium n $nmbr$ placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'laba plus ics tiotropium n $nmbr$ placebo n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'laba plus ics tiotropium n $nmbr$ placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'laba plus ics tiotropium n $nmbr$ placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'laba plus ics tiotropium n $nmbr$ placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'no laba no ics tiotropium n $nmbr$ placebo n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'no laba no ics tiotropium n $nmbr$ placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'no laba no ics tiotropium n $nmbr$ placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'no laba no ics tiotropium n $nmbr$ placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'trough fev response l i','C0021966','I-','Iodides','true'
'trough fev response l i','C0221138','I NOS','Blood group antibody I','false'
'effect size','C0814843','effect size','effect size','false'
'fev $nmbr$ predicted','C0681842','Predicted','prediction','false'
'fev $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'tiotropium n $nmbr$ placebo n','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium n $nmbr$ placebo n','C0032042','Placebo','Placebos','true'
'tiotropium n $nmbr$ placebo n','C1696465','PLACEBO','placebo','false'
'tiotropium n $nmbr$ placebo n','C1706408','PLACEBO','Placebo Control','false'
'fev','C3714541','FEV','Forced Vital Capacity','true'
'placebo group n $nmbr$ j','C0441844','Group J','Group J','false'
'certolizumab group n $nmbr$','C1872109','CERTOLIZUMAB','certolizumab pegol','true'
'certolizumab group n $nmbr$','C0441848','Group N','Group N','false'
'mean age yr range','C1514721','Range','Range','false'
'mean age yr range','C2348147','Range','Sample Range','false'
'mean age yr range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'mean body mass indexj','C0444504','Mean','Statistical mean','false'
'mean body mass indexj','C0518010','body mass','body mass','false'
'mean body mass indexj','C2347634','Mean','Population Mean','false'
'mean body mass indexj','C2348143','Mean','Sample Mean','false'
'duration of disease yr^ mean','C0872146','disease duration','disease length','false'
'duration of disease yr^ mean','C0439234','yr','year','false'
'cdai score','C0449820','SCORE','Score','false'
'cdai score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'mean','C0444504','Mean','Statistical mean','false'
'mean','C2347634','Mean','Population Mean','false'
'mean','C2348143','Mean','Sample Mean','false'
'geometric mean ofcrp mg liter range','C1514721','Range','Range','false'
'geometric mean ofcrp mg liter range','C2348147','Range','Sample Range','false'
'geometric mean ofcrp mg liter range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'disease site no ^','C0205145','Site','Site','false'
'disease site no ^','C1515974','Site','Anatomic Site','false'
'disease site no ^','C2825164','Site','Study Site','false'
'terminal ileum','C0227327','Terminal Ileum','Distal part of ileum','false'
'colon','C0009368','COLON','Colon structure (body structure)','true'
'colon','C3888384','Colon','Colon <insect>','false'
'previous infliximab therapy','C0205156','Previous','Previous','false'
'previous infliximab therapy','C4076075','Infliximab therapy','Infliximab therapy','false'
'previous infliximab therapy','C1552607','previous','Act Relationship Subset - previous','false'
'any therapy no','C0039798','therapy','therapeutic aspects','true'
'any therapy no','C0087111','Therapy','Therapeutic procedure','true'
'any therapy no','C1363945','Therapy','Therapy Object (animal model)','false'
'median infusions no range','C0549183','Median','Midline (qualifier value)','false'
'median infusions no range','C0574032','infusions','Infusion procedures','false'
'median infusions no range','C0876920','Median','Median Statistical Measurement','false'
'median infusions no range','C2347635','Median','Population Median','false'
'median infusions no range','C2348144','Median','Sample Median','false'
'median infusions no range','C2939193','Median','Median (qualifier value)','false'
'median infusions no range','C1514721','Range','Range','false'
'median infusions no range','C2348147','Range','Sample Range','false'
'median infusions no range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'previous hypersensitivity reaction no','C0205156','Previous','Previous','false'
'previous hypersensitivity reaction no','C0020517','HYPERSENSITIVITY REACTION (NOS)','Hypersensitivity','true'
'previous hypersensitivity reaction no','C1552607','previous','Act Relationship Subset - previous','false'
'resection performed no','C0015252','resection','removal technique','false'
'resection performed no','C0728940','Resection','Excision','false'
'resection performed no','C0884358','PERFORMED','Performed','false'
'concurrent treatment at study entry no','C0679827','treatment entry','treatment entry','false'
'concurrent treatment at study entry no','C1521826','study treatment','Protocol Agent','false'
'concurrent treatment at study entry no','C3161471','Treatment Study','Treatment Study','false'
'glucocorticoids only','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'glucocorticoids only','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'glucocorticoids only','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'immunosuppressive agents only','C0021081','Immunosuppressive Agents','Immunosuppressive Agents','true'
'glucocorticoids combined with immunosuppressive agents','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'glucocorticoids combined with immunosuppressive agents','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'glucocorticoids combined with immunosuppressive agents','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'glucocorticoids combined with immunosuppressive agents','C0205195','Combined','Combined','false'
'glucocorticoids combined with immunosuppressive agents','C0021081','Immunosuppressive Agents','Immunosuppressive Agents','true'
'neither glucocorticoids nor immunosuppressive agents','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'neither glucocorticoids nor immunosuppressive agents','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'neither glucocorticoids nor immunosuppressive agents','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'neither glucocorticoids nor immunosuppressive agents','C0021081','Immunosuppressive Agents','Immunosuppressive Agents','true'
'placebo group','C0032042','Placebo','Placebos','true'
'placebo group','C0441833','Group','Groups','false'
'placebo group','C0687744','group','Social group','false'
'placebo group','C1257890','Group','Population Group','true'
'placebo group','C1519504','Group','Stage Grouping','false'
'placebo group','C1705428','Group','Group Object','false'
'placebo group','C1705429','Group','User Group','false'
'placebo group','C1696465','PLACEBO','placebo','false'
'placebo group','C1706408','PLACEBO','Placebo Control','false'
'certolizumab group','C0441833','Group','Groups','false'
'certolizumab group','C0687744','group','Social group','false'
'certolizumab group','C1257890','Group','Population Group','true'
'certolizumab group','C1519504','Group','Stage Grouping','false'
'certolizumab group','C1705428','Group','Group Object','false'
'certolizumab group','C1705429','Group','User Group','false'
'no total','C0439175','% total','% of total','false'
'no total','C0439810','Total','Total','false'
'a decrease of $nmbr$ points in the cdai score','C0392756','Decrease','Reduced','false'
'a decrease of $nmbr$ points in the cdai score','C0547047','Decrease','Decrease','false'
'a decrease of $nmbr$ points in the cdai score','C0449820','SCORE','Score','false'
'a decrease of $nmbr$ points in the cdai score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'with baseline crp level of $nmbr$ mg liter','C0441889','Level','Levels (qualifier value)','false'
'with baseline crp level of $nmbr$ mg liter','C0456079','Level','Disease classification level','false'
'with baseline crp level of $nmbr$ mg liter','C1547707','Level','Floor - story of building','false'
'with baseline crp level of $nmbr$ mg liter','C2946261','Level','Level','false'
'at week $nmbr$','C0332174','/week','Weekly','false'
'at week $nmbr$','C0439230','Week','week','false'
'at weeks $nmbr$ and $nmbr$','C0439230','WEEKS','week','false'
'all patients','C0030705','Patients','Patients','true'
'no immunosuppressive agents at baseline','C0021081','Immunosuppressive Agents','Immunosuppressive Agents','true'
'no immunosuppressive agents at baseline','C0168634','baseline','BaseLine dental cement','true'
'no immunosuppressive agents at baseline','C1442488','Baseline','Baseline','false'
'immunosuppressive agents at baseline','C0021081','Immunosuppressive Agents','Immunosuppressive Agents','true'
'immunosuppressive agents at baseline','C0168634','baseline','BaseLine dental cement','true'
'immunosuppressive agents at baseline','C1442488','Baseline','Baseline','false'
'no glucocorticoids at baseline','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'no glucocorticoids at baseline','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'no glucocorticoids at baseline','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'glucocorticoids at baseline','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'glucocorticoids at baseline','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'glucocorticoids at baseline','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'no previous treatment with infliximab','C0039798','treatment','therapeutic aspects','true'
'no previous treatment with infliximab','C0087111','Treatment','Therapeutic procedure','true'
'no previous treatment with infliximab','C1522326','Treatment','Treating','false'
'no previous treatment with infliximab','C1533734','Treatment','Administration procedure','false'
'no previous treatment with infliximab','C1705169','Treatment','Biomaterial Treatment','false'
'no previous treatment with infliximab','C3538994','TREATMENT','Treatment Epoch','false'
'no previous treatment with infliximab','C3887704','treatment','treatment - ActInformationManagementReason','false'
'previous treatment with infliximab','C0039798','treatment','therapeutic aspects','true'
'previous treatment with infliximab','C0087111','Treatment','Therapeutic procedure','true'
'previous treatment with infliximab','C1522326','Treatment','Treating','false'
'previous treatment with infliximab','C1533734','Treatment','Administration procedure','false'
'previous treatment with infliximab','C1705169','Treatment','Biomaterial Treatment','false'
'previous treatment with infliximab','C3538994','TREATMENT','Treatment Epoch','false'
'previous treatment with infliximab','C3887704','treatment','treatment - ActInformationManagementReason','false'
'patients with remission','C1277626','patients remission','patient in remission','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1280519','Efficacy','Effectiveness','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1707887','EFFICACY','Efficacy Study','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1872109','CERTOLIZUMAB PEGOL','certolizumab pegol','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0030705','Patients','Patients','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0871261','Response','Response process','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1704632','Response','Disease Response','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1706817','Response','Response (statement)','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C2911692','Response','Response (communication)','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0441837','Panel C','Group C','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1547282','Show','Show','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0034746','Response Time','Reaction Time','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0032659','Population','geographic population','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1257890','Population','Population Group','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0332174','/week','Weekly','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0439230','Week','week','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0441889','Level','Levels (qualifier value)','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0456079','Level','Disease classification level','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1547707','Level','Floor - story of building','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C2946261','Level','Level','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0441833','Panel','Groups','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1706365','Panel','Device Panel','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1999270','Panel','Laboratory Order Panels','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0439165','Percentage','Percent (qualifier value)','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1549488','Percentage','Amount type - Percentage','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0205210','Clinical','Clinical','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1704788','Defined','Definition','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C3539106','Defined','Sufficiently defined concept definition status (core metadata concept)','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0087111','TREAT','Therapeutic procedure','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1292734','treat','Treatment intent','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1522326','Treat','Treating','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0024671','MG','Mammography','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0026410','MG','Mongolia','true'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0439269','mg%','mg/dL','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C1960952','mg %','Milligram percent','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C2346927','Mg++','Magnesium Cation','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C4321396','MG','MG','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C4521761','MG','United States Military Commissioned Officer O8','false'
'figure $nmbr$ facing page efficacy of maintenance therapy with certolizumab pegol in patients with a response to induction therapy at week $nmbr$ panel c shows the response over time in patients in the intention to treat population who had a response to induction therapy at week $nmbr$ as well as the response in the subgroup of patients with a crp level of at least $nmbr$ mg per liter panel d shows the percentage of patients with clinical remis sion defined as a cdai score $nmbr$ at week $nmbr$ in the intention to treat population and in the subgroup of those with baseline crp serum levels of at least $nmbr$ mg per liter','C0475211','Litre','liter','false'
'fondaparinux n $nmbr$','C1098510','FONDAPARINUX','fondaparinux','true'
'age median range years','C1510829','Age-Years','Age-Years','false'
'age median range years','C0549183','Median','Midline (qualifier value)','false'
'age median range years','C0876920','Median','Median Statistical Measurement','false'
'age median range years','C2347635','Median','Population Median','false'
'age median range years','C2348144','Median','Sample Median','false'
'age median range years','C2939193','Median','Median (qualifier value)','false'
'gender male female','C0043210','female','Woman','true'
'gender male female','C0086287','FEMALE','Females','true'
'gender male female','C1705497','Female','Female, Self-Report','false'
'gender male female','C1705498','FEMALE','Female Phenotype','false'
'weight mean sd kg','C0022718','KG','Kyrgyzstan','true'
'weight mean sd kg','C0439209','kg','Kilogram','false'
'weight mean sd kg','C4054209','/kg','Per Kilogram','false'
'body mass index mean sd kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'body mass index mean sd kg m $nmbr$','C0439209','kg','Kilogram','false'
'body mass index mean sd kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'risk factor for venous thromboembolism no','C3495424','Risk for venous thromboembolism','Risk for venous thromboembolism:Impression/interpretation of study:Point in time:^Patient:Ordinal','false'
'risk factor for venous thromboembolism no','C3496592','Risk for venous thromboembolism','Risk for venous thromboembolism','false'
'obesity','C0028754','OBESITY','Obesity','true'
'obesity','C1963185','Obesity','Obesity, CTCAE','false'
'history of venous','C0019664','History','History','true'
'history of venous','C0019665','history','Historical aspects qualifier','true'
'history of venous','C0262512','History, NOS','History of present illness','false'
'history of venous','C0262926','History','Medical History','false'
'history of venous','C1705255','History','Concept History','false'
'history of venous','C2004062','History','History of previous events','false'
'thromboembolism','C0040038','THROMBOEMBOLISM','Thromboembolism','true'
'nyha grade iii or iv','C0205617','Grade III','Poorly differentiated','false'
'nyha grade iii or iv','C0450094','Grade III','Grade three rank','false'
'nyha grade iii or iv','C0475271','Grade III','Tumor grade G3','false'
'nyha grade iii or iv','C0687697','grade 3','Third grade in elementary school','false'
'nyha grade iii or iv','C3889290','GRADE 3','West Haven Hepatic Encephalopathy Grade 3','false'
'nyha grade iii or iv','C4050000','Grade III','Clavien-Dindo Grade III','false'
'nyha grade iii or iv','C4283820','Grade III','Simpson Grade 3','false'
'nyha grade iii or iv','C4283821','Grade 3','Bayer Corneal Epitheliopathy Grade 3','false'
'nyha grade iii or iv','C4283822','Grade 3','Bayer Visual Acuity Changes Grade 3','false'
'nyha grade iii or iv','C0022326','IV','Ivory Coast','true'
'nyha grade iii or iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'chronic obstructive pulmonary','C0205191','CHRONIC','chronic','false'
'chronic obstructive pulmonary','C0549186','Obstructive','Obstructed','false'
'chronic obstructive pulmonary','C0024109','pulmonary','Lung','true'
'chronic obstructive pulmonary','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'chronic obstructive pulmonary','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'chronic obstructive pulmonary','C4522268','Pulmonary','Pulmonary (intended site)','false'
'disease','C0012634','Disease','Disease','true'
'inflammatory bowel disease','C0021390','INFLAMMATORY BOWEL DISEASE','Inflammatory Bowel Diseases','true'
'cancer surgery','C0920424','cancer surgery','cancer surgery','false'
'no of risk factors for venous thromboembolism no','C0035648','Risk Factors','risk factors','true'
'no of risk factors for venous thromboembolism no','C1553898','risk factors','risk factors - observation list','false'
'no of risk factors for venous thromboembolism no','C1861172','VENOUS THROMBOEMBOLISM','Venous Thromboembolism','true'
'creatinine clearance no','C0812399','Creatinine clearance','Creatinine clearance','false'
'$nmbr$ $nmbr$ ml min $nmbr$','C0439445','mL/min','mL/min','false'
'$nmbr$ ml min $nmbr$','C0439445','mL/min','mL/min','false'
'sample size n','C0242618','Sample Size','Sample Size','true'
'age in years mean','C1510829','Age, in Years','Age-Years','false'
'age in years mean','C0444504','Mean','Statistical mean','false'
'age in years mean','C2347634','Mean','Population Mean','false'
'age in years mean','C2348143','Mean','Sample Mean','false'
'education in years mean','C0013621','Education','Knowledge acquisition','true'
'education in years mean','C0013622','education','Educational aspects','true'
'education in years mean','C0013658','Education, NOS','Educational Status','true'
'education in years mean','C0039401','Education','Educational process of instructing','true'
'clinic research experience n','C0002424','Clinic','Ambulatory Care Facilities','true'
'clinic research experience n','C0035168','Research','research','true'
'clinic research experience n','C0242481','Research','Research Activities','true'
'clinic research experience n','C0442592','Clinic','Clinic','false'
'on bp medication n','C0037623','BP','Solomon Islands','true'
'on bp medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'on bp medication n','C3244316','medication','medication - HL7 publishing domain','false'
'on bp medication n','C4284232','Medication','Medications','false'
'on bp medication n','C1415692','Bp','HP gene','false'
'on bp medication n','C1708288','BP','HP wt Allele','false'
'on bp medication n','C4318478','BP','Base Pair Unit','false'
'hx of diabetes n','C0262926','Hx','Medical History','false'
'hx of diabetes n','C3814444','HX','HPX wt Allele','false'
'chd n','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'chd n','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'baseline ecg with lvh n','C0168634','baseline','BaseLine dental cement','true'
'baseline ecg with lvh n','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'baseline ecg with lvh n','C1442488','Baseline','Baseline','false'
'ascvd n','C3665365','ASCVD','Arteriosclerotic cardiovascular disease, NOS','false'
'bmi kg m $nmbr$ mean','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ mean','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ mean','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ mean','C0444504','Mean','Statistical mean','false'
'bmi kg m $nmbr$ mean','C2347634','Mean','Population Mean','false'
'bmi kg m $nmbr$ mean','C2348143','Mean','Sample Mean','false'
'glucose mg dl mean','C0444504','Mean','Statistical mean','false'
'glucose mg dl mean','C2347634','Mean','Population Mean','false'
'glucose mg dl mean','C2348143','Mean','Sample Mean','false'
'potassium meq dl mean','C0444504','Mean','Statistical mean','false'
'potassium meq dl mean','C2347634','Mean','Population Mean','false'
'potassium meq dl mean','C2348143','Mean','Sample Mean','false'
'creatinine mg dl mean','C0444504','Mean','Statistical mean','false'
'creatinine mg dl mean','C2347634','Mean','Population Mean','false'
'creatinine mg dl mean','C2348143','Mean','Sample Mean','false'
'geographic region','C0017446','Geographic Region','Geographic Locations','true'
'south n','C1710133','South','South','false'
'pr virgin islands n','C0279759','PR+','progesterone receptor positive','false'
'pr virgin islands n','C0042752','VIRGIN ISLANDS','United States Virgin Islands','true'
'pr virgin islands n','C0279766','PR-','progesterone receptor negative','false'
'pr virgin islands n','C1418864','PR@','PR@ gene cluster','false'
'pr virgin islands n','C3538934','PR','STANDARDS Pain Relief Questionnaire','false'
'pr virgin islands n','C3538935','PR','Procedure Domain','false'
'pr virgin islands n','C3889640','PR','Progesterone Receptor Measurement','false'
'pr virgin islands n','C4048189','PR','Per rectum','false'
'pr virgin islands n','C4082178','PR','Progesterone Receptor, human','false'
'pr virgin islands n','C4082184','PR','peristromal region viral factory','false'
'pr virgin islands n','C4085573','PR','TMEM37 wt Allele','false'
'pr virgin islands n','C4552913','PR','Lugano Lymphoma Response Classification Partial Remission by CT','false'
'pr virgin islands n','C4552914','PR','Lugano Lymphoma Response Classification Partial Remission by PET','false'
'others n','C1955473','Others','Others - Allergy','false'
'others n','C3539125','others','other medicated shampoos in ATC','false'
'time in trial','C0040223','TIME','Time','true'
'time in trial','C3541383','Time','Time (foundation metadata concept)','false'
'time in trial','C0150312','In','Present','false'
'time in trial','C0008976','Trial','Clinical Trials','true'
'time in trial','C0332285','In','Within','false'
'time in trial','C1707101','IN','CD44 wt Allele','false'
'no with visit','C0545082','Visit','Visit','false'
'no with visit','C1512346','visit','Patient Visit','false'
'no with visit','C2826704','VISIT','Visit Name','false'
'sbp dbp mean','C0444504','Mean','Statistical mean','false'
'sbp dbp mean','C2347634','Mean','Population Mean','false'
'sbp dbp mean','C2348143','Mean','Sample Mean','false'
'no of drugs','C0013227','Drugs','Pharmaceutical Preparations','true'
'no of drugs','C3687832','Drugs','Drugs - dental services','false'
'on step $nmbr$ drug','C0013227','Drug','Pharmaceutical Preparations','true'
'on step $nmbr$ drug','C1254351','DRUG','Pharmacologic Substance','false'
'sd','C2699239','SD','SD, Rat Strain','false'
'baseline','C0168634','baseline','BaseLine dental cement','true'
'baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ mo','C0026544','MO','Morocco','true'
'$nmbr$ mo','C0332177','/mo','Monthly (qualifier value)','false'
'figure percentage of subgroup with bp controlled sbp','C0439165','Percentage','Percent (qualifier value)','false'
'figure percentage of subgroup with bp controlled sbp','C1549488','Percentage','Amount type - Percentage','false'
'figure percentage of subgroup with bp controlled sbp','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'figure percentage of subgroup with bp controlled sbp','C0037623','BP','Solomon Islands','true'
'figure percentage of subgroup with bp controlled sbp','C0085805','SBP','Androgen Binding Protein','true'
'figure percentage of subgroup with bp controlled sbp','C1415692','Bp','HP gene','false'
'figure percentage of subgroup with bp controlled sbp','C1708288','BP','HP wt Allele','false'
'figure percentage of subgroup with bp controlled sbp','C4318478','BP','Base Pair Unit','false'
'aged','C0001779','Aged','Age','false'
'aged','C0001792','Aged','Elderly (population group)','true'
'aged','C1999167','aged','Old age','false'
'aged a $nmbr$ years','C0001779','Aged','Age','false'
'aged a $nmbr$ years','C0001792','Aged','Elderly (population group)','true'
'aged a $nmbr$ years','C1999167','aged','Old age','false'
'aged a $nmbr$ years','C0439234','YEARS','year','false'
'diff_measure dm added this as table had multiple headings','C0011816','DM','Dextromethorphan','true'
'diff_measure dm added this as table had multiple headings','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'diff_measure dm added this as table had multiple headings','C1524062','Added','Additional','false'
'diff_measure dm added this as table had multiple headings','C0039224','Table','Table - furniture','false'
'diff_measure dm added this as table had multiple headings','C1706074','Table','Data Table','true'
'diff_measure dm added this as table had multiple headings','C0439064','MULTIPLE','Numerous','false'
'bl','C0005918','BL','Bolivia','true'
'bl','C0006413','BL','Burkitt Lymphoma','true'
'bl','C1552663','BL','Boolean','false'
'bl','C2827109','BL','Saint Barthelemy','false'
'diff_measure','C0079809','Measure','Measures','true'
'diff_measure','C0242485','Measure','Measurement','false'
'am_delta','C0439097','Delta','Delta - greek letter','false'
'am_delta','C1705241','Delta','Delta (difference)','false'
'am_delta','C3146239','Delta','Delta <Insecta>','false'
'am_delta','C3538806','DELTA','Axial R','false'
'am_delta','C3540585','DELTA','YY1 wt Allele','false'
'am_delta','C3815527','Delta','Delta-Like Protein 1, human','false'
'$nmbr$ $nmbr$ o lt','C0023376','LT','Lesotho','true'
'$nmbr$ $nmbr$ o lt','C0230426','LT','Structure of left thigh','false'
'$nmbr$ $nmbr$ o lt','C3887647','LT','Lymphotoxin-Alpha, human','false'
'$nmbr$ $nmbr$ o lt','C4521399','LT','United States Military Commissioned Officer O3','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'body weight kg','C0022718','KG','Kyrgyzstan','true'
'body weight kg','C0439209','kg','Kilogram','false'
'body weight kg','C4054209','/kg','Per Kilogram','false'
'$nmbr$ $nmbr$ l ot','C1318464','OT','Occupational therapy regime','true'
'$nmbr$ $nmbr$ l ot','C1418208','OT','OXT gene','false'
'$nmbr$ $nmbr$ l ot','C1705587','OT','OXT wt Allele','false'
'responder analyses achieving alc','C0002778','Analysis','Analysis of substances','false'
'responder analyses achieving alc','C0936012','ANALYSIS','Analysis','false'
'responder analyses achieving alc','C1524024','analysis','analysis aspect','true'
'responder analyses achieving alc','C1424945','ALC','ALLC gene','false'
'responder analyses achieving alc','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'n responders','C0369718','N NOS','N not otherwise specified Antibody','false'
'n responders','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'baseline alc','C1424945','ALC','ALLC gene','false'
'baseline alc','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'fasting lipids mmol $nmbr$','C0015663','FASTING','Fasting','true'
'fasting lipids mmol $nmbr$','C0023779','Lipids','Lipids','true'
'fasting lipids mmol $nmbr$','C0439190','mmol','millimole','false'
'am_ delta','C0439097','Delta','Delta - greek letter','false'
'am_ delta','C1705241','Delta','Delta (difference)','false'
'am_ delta','C3146239','Delta','Delta <Insecta>','false'
'am_ delta','C3538806','DELTA','Axial R','false'
'am_ delta','C3540585','DELTA','YY1 wt Allele','false'
'am_ delta','C3815527','Delta','Delta-Like Protein 1, human','false'
'triglycerides','C0041004','TRIGLYCERIDES','Triglycerides','true'
'hdl','C3715113','HDL','HSD11B1 wt Allele','false'
'non hdl','C1518422','Non','Negation','false'
'non hdl','C3715113','HDL','HSD11B1 wt Allele','false'
'vldl','C0523560','VLDL','VLDL cholesterol measurement','false'
'blood pressure mmhg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure mmhg','C0439475','mmHG','mmHg','false'
'blood pressure mmhg','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure mmhg','C1272641','Blood pressure','Systemic arterial pressure','true'
'mean_delta','C0439097','Delta','Delta - greek letter','false'
'mean_delta','C1705241','Delta','Delta (difference)','false'
'mean_delta','C3146239','Delta','Delta <Insecta>','false'
'mean_delta','C3538806','DELTA','Axial R','false'
'mean_delta','C3540585','DELTA','YY1 wt Allele','false'
'mean_delta','C3815527','Delta','Delta-Like Protein 1, human','false'
'subgroup analyses','C2986480','Subgroup Analysis','Subset Analysis','false'
'bl alc','C1424945','ALC','ALLC gene','false'
'bl alc','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'bl bmioo kg m^','C0022718','KG','Kyrgyzstan','true'
'bl bmioo kg m^','C0439209','kg','Kilogram','false'
'bl bmioo kg m^','C4054209','/kg','Per Kilogram','false'
'bl bml $nmbr$ kg m^','C0022718','KG','Kyrgyzstan','true'
'bl bml $nmbr$ kg m^','C0439209','kg','Kilogram','false'
'bl bml $nmbr$ kg m^','C4054209','/kg','Per Kilogram','false'
'bl bm $nmbr$','C0005918','BL','Bolivia','true'
'bl bm $nmbr$','C0006416','BM','Myanmar','true'
'bl bm $nmbr$','C0006413','BL','Burkitt Lymphoma','true'
'bl bm $nmbr$','C1552663','BL','Boolean','false'
'bl bm $nmbr$','C2827109','BL','Saint Barthelemy','false'
'bl bml','C0005918','BL','Bolivia','true'
'bl bml','C0006413','BL','Burkitt Lymphoma','true'
'bl bml','C1552663','BL','Boolean','false'
'bl bml','C2827109','BL','Saint Barthelemy','false'
'bl bml $nmbr$ ke m^','C0005918','BL','Bolivia','true'
'bl bml $nmbr$ ke m^','C0022558','KE','Kenya','true'
'bl bml $nmbr$ ke m^','C0006413','BL','Burkitt Lymphoma','true'
'bl bml $nmbr$ ke m^','C1552663','BL','Boolean','false'
'bl bml $nmbr$ ke m^','C2827109','BL','Saint Barthelemy','false'
'treatment group','C0039798','treatment','therapeutic aspects','true'
'treatment group','C0087111','Treatment','Therapeutic procedure','true'
'treatment group','C1522326','Treatment','Treating','false'
'treatment group','C1533734','Treatment','Administration procedure','false'
'treatment group','C1705169','Treatment','Biomaterial Treatment','false'
'treatment group','C3538994','TREATMENT','Treatment Epoch','false'
'treatment group','C3887704','treatment','treatment - ActInformationManagementReason','false'
'air n $nmbr$','C0001861','AIR','Air (substance)','true'
'air n $nmbr$','C3536832','AIR','Air','false'
'ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'air ig n $nmbr$','C0001861','AIR','Air (substance)','true'
'air ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'air ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'air ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'air ig n $nmbr$','C3536832','AIR','Air','false'
'gender [n ]','C0079399','Gender','Gender','true'
'gender [n ]','C1522384','Gender','sex','true'
'gender [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'gender [n ]','C0441922','N+','N+ (tumor staging)','false'
'origin [n ]','C0079946','origin','National origin','false'
'origin [n ]','C0439659','Origin','Beginning','false'
'origin [n ]','C1550512','origin','Participation Type - origin','false'
'origin [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'origin [n ]','C0441922','N+','N+ (tumor staging)','false'
'african','C0027567','AFRICAN','African race','true'
'duration of diabetes years','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes years','C2926735','Duration','Duration','false'
'oam use [n ]','C0042153','use','utilization qualifier','true'
'oam use [n ]','C0457083','Use','Usage','false'
'oam use [n ]','C1947944','Use','Use - dosing instruction imperative','false'
'oam use [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'oam use [n ]','C0441922','N+','N+ (tumor staging)','false'
'insulin secretagogue','C0021641','INSULIN','Insulin','true'
'insulin secretagogue','C4704833','Secretogogue','Secretagogues','true'
'insulin secretagogue','C1533581','INSULIN','Recombinant Insulin','false'
'insulin secretagogue','C1579433','Insulin','Insulin [EPC]','false'
'insulin secretagogue','C3714501','INSULIN','Insulin Drug Class','false'
'biguanides','C0005382','Biguanides','Biguanides','true'
'biguanides','C0360396','Biguanides','Biguanide antimalarial','false'
'biguanides','C3540012','Biguanides','biguanide blood glucose lower drugs','false'
'baseline insulin dose u kg [lsm se ]','C0366513','Insulin Dose','Insulin regular:Mass:Pt:Dose:Qn','false'
'baseline insulin dose u kg [lsm se ]','C1300561','U/kg','Unit/kilogram','false'
'baseline insulin dose u kg [lsm se ]','C0036919','SE','Seychelles','true'
'baseline a $nmbr$ c [lsm se ]','C0168634','baseline','BaseLine dental cement','true'
'baseline a $nmbr$ c [lsm se ]','C0036919','SE','Seychelles','true'
'baseline a $nmbr$ c [lsm se ]','C1442488','Baseline','Baseline','false'
'a $nmbr$ c [n ]','C1272460','a n','Not Applicable','false'
'prior insulin use years','C0240016','INSULIN USE','Insulin used','false'
'prior insulin use years','C0439234','YEARS','year','false'
'algorithm $nmbr$','C0002045','Algorithm','algorithm','true'
'algorithm $nmbr$','C1553907','algorithm','Observation Method - algorithm','false'
'number','C0237753','*Number','Numbers','false'
'number','C0449788','Number','Count of entities','false'
'female male','C0086582','MALE','Males','true'
'female male','C1706180','Male','Male Gender, Self Report','false'
'female male','C1706428','MALE','Male Phenotype','false'
'female male','C1706429','Male','Male, Self-Reported','false'
'duration since diagnosis years','C0449238','Duration','Duration (temporal concept)','false'
'duration since diagnosis years','C2926735','Duration','Duration','false'
'time since start insulin years','C1301880','Start Time','Start time','false'
'hba $nmbr$ c baseline','C0168634','baseline','BaseLine dental cement','true'
'hba $nmbr$ c baseline','C1442488','Baseline','Baseline','false'
'fbg baseline','C0168634','baseline','BaseLine dental cement','true'
'fbg baseline','C1442488','Baseline','Baseline','false'
'mg dl','C0439269','mg dl','mg/dL','false'
'mmol l','C1532563','mmol/L','Millimole per Liter','false'
'premixed insulin only','C0021641','INSULIN','Insulin','true'
'premixed insulin only','C1533581','INSULIN','Recombinant Insulin','false'
'premixed insulin only','C1579433','Insulin','Insulin [EPC]','false'
'premixed insulin only','C3714501','INSULIN','Insulin Drug Class','false'
'premixed insulin with oads','C0021641','INSULIN','Insulin','true'
'premixed insulin with oads','C1533581','INSULIN','Recombinant Insulin','false'
'premixed insulin with oads','C1579433','Insulin','Insulin [EPC]','false'
'premixed insulin with oads','C3714501','INSULIN','Insulin Drug Class','false'
'insulin glargine oad','C0907402','INSULIN GLARGINE','Insulin Glargine','true'
'insulin glargine oad od prandial','C0229089','OD','Right eye','false'
'insulin glargine oad od prandial','C0439164','OD','Optical density units','false'
'insulin glargine oad od prandial','C1512019','OD','Doctor of Optometry','false'
'insulin glargine oad od prandial','C3273373','OD','South Sudan','true'
'insulin glargine oad od prandial','C3665488','OD','Familial Osteochondritis Dissecans','true'
'insulin glargine oad od prandial','C1998602','Meals','Meal (occasion for eating)','true'
'insulin glargine oad od prandial','C4553624','Meals','With meals','false'
'insulin glargine oad bd prandial','C0005126','BD','Bermuda','true'
'insulin glargine oad bd prandial','C2344255','BD','BD Alcohol','false'
'insulin glargine oad bd prandial','C4050145','BD','Block Design Subtest (WPPSI-IV)','false'
'insulin glargine oad bd prandial','C1998602','Meals','Meal (occasion for eating)','true'
'insulin glargine oad bd prandial','C4553624','Meals','With meals','false'
'hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'change','C0392747','Change','Changing','false'
'change','C0443172','change','Changed status','false'
'change','C1705241','Change','Delta (difference)','false'
'change','C4319952','Change','Change -- procedure','false'
'fbg mg dl','C0439269','mg dl','mg/dL','false'
'fbg mmol l','C1532563','mmol/L','Millimole per Liter','false'
'assigned to topiramate','C1516050','Assigned','Assignment - action','false'
'assigned to topiramate','C1552601','assigned','PersonNameUse - assigned','false'
'assigned to placebo','C1516050','Assigned','Assignment - action','false'
'assigned to placebo','C1552601','assigned','PersonNameUse - assigned','false'
'migraine occurrence days month','C0149931','MIGRAINE','Migraine Disorders','true'
'migraine occurrence days month','C0556971','days month','days/month','false'
'migraine duration h','C0033727','H+','Protons','true'
'migraine duration h','C0369286','H NOS','H NOS Antibodies','false'
'migraine duration h','C0441932','H+','Hepatic Involvement','false'
'migraine duration h','C0564385','/h','/hour','false'
'migraine duration h','C4528284','h*%','Hour Times Percent','false'
'migraine severity score','C0149931','MIGRAINE','Migraine Disorders','true'
'migraine severity score','C0457451','Severity score','Severity score','false'
'acute medication intake days month','C0013227','Medication','Pharmaceutical Preparations','true'
'acute medication intake days month','C0556971','days month','days/month','false'
'acute medication intake days month','C3244316','medication','medication - HL7 publishing domain','false'
'acute medication intake days month','C4284232','Medication','Medications','false'
'midas score','C0449820','SCORE','Score','false'
'midas score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients assessed','C0030705','Patients','Patients','true'
'patients assessed','C1516048','Assessed','Assessed','false'
'hit $nmbr$ score','C0449820','SCORE','Score','false'
'hit $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'sf $nmbr$ mcs score','C0449820','SCORE','Score','false'
'sf $nmbr$ mcs score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'sf $nmbr$ pcs score','C0449820','SCORE','Score','false'
'sf $nmbr$ pcs score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'participants with metabolic syndrome','C0679646','participants','Participant','false'
'participants with metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'participants without metabolic syndrome','C0679646','participants','Participant','false'
'participants without metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'number randomized','C0237753','*Number','Numbers','false'
'number randomized','C0449788','Number','Count of entities','false'
'number randomized','C0034656','Randomized','Randomization','true'
'number randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'years of education','C0439234','YEARS','year','false'
'years of education','C0013621','Education','Knowledge acquisition','true'
'years of education','C0013622','education','Educational aspects','true'
'years of education','C0013658','Education, NOS','Educational Status','true'
'years of education','C0039401','Education','Educational process of instructing','true'
'antihypertensive treatments','C0003364','anti hypertensive','Antihypertensive Agents','true'
'antihypertensive treatments','C0087111','Treatments','Therapeutic procedure','true'
'sbp mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp mmhg','C0439475','mmHG','mmHg','false'
'dbp mmhg','C0536221','DBP','HSD17B4 protein, human','true'
'dbp mmhg','C0439475','mmHG','mmHg','false'
'dbp mmhg','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp mmhg','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'atherosclerotic cvd','C0333482','Atherosclerotic','atherosclerotic','false'
'atherosclerotic cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'history ol mi or stroke','C0019664','History','History','true'
'history ol mi or stroke','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'history ol mi or stroke','C0019665','history','Historical aspects qualifier','true'
'history ol mi or stroke','C0262512','History, NOS','History of present illness','false'
'history ol mi or stroke','C0262926','History','Medical History','false'
'history ol mi or stroke','C1705255','History','Concept History','false'
'history ol mi or stroke','C2004062','History','History of previous events','false'
'history ol mi or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'history ol mi or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'history ol coronary revascularization','C0019664','History','History','true'
'history ol coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'history ol coronary revascularization','C0019665','history','Historical aspects qualifier','true'
'history ol coronary revascularization','C0262512','History, NOS','History of present illness','false'
'history ol coronary revascularization','C0262926','History','Medical History','false'
'history ol coronary revascularization','C1705255','History','Concept History','false'
'history ol coronary revascularization','C2004062','History','History of previous events','false'
'other ascvd','C3665365','ASCVD','Arteriosclerotic cardiovascular disease, NOS','false'
'st t wave','C0036056','ST','Saint Lucia','true'
'st t wave','C0429103','T wave','T wave feature','false'
'st t wave','C3272372','ST','Character String Data Type','false'
'lelt ventricular hypertrophy','C0340279','Ventricular hypertrophy','Ventricular hypertrophy','false'
'history ol chd at baselines','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'history ol chd at baselines','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'bmi kg m','C0022718','KG','Kyrgyzstan','true'
'bmi kg m','C0439209','kg','Kilogram','false'
'bmi kg m','C4054209','/kg','Per Kilogram','false'
'fasting glucose','C0015663','FASTING','Fasting','true'
'fasting glucose','C0017725','GLUCOSE','Glucose','true'
'$nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'cardiovascular metabolic syndrome risk lactors','C0007226','Cardiovascular','Cardiovascular system','true'
'cardiovascular metabolic syndrome risk lactors','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'cardiovascular metabolic syndrome risk lactors','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'fasting glucose $nmbr$ mg dl','C0015663','FASTING','Fasting','true'
'fasting glucose $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'bmi $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'fasting triglycerides $nmbr$ mg dl','C0015663','FASTING','Fasting','true'
'fasting triglycerides $nmbr$ mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'fasting triglycerides $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'low hdl cholesterol','C0151691','Low HDL-cholesterol','Decreased HDL cholesterol concentration','false'
'high blood pressure','C0020538','Blood Pressure, High','Hypertensive disease','true'
'high blood pressure','C2926615','High blood pressure','Ever told by doctor or nurse that you have high blood pressure:Finding:Point in time:^Patient:Ordinal','false'
'lipid trial participantss','C0023779','Lipid','Lipids','true'
'lipid trial participantss','C0008976','Trial','Clinical Trials','true'
'table_group','C0441833','Group','Groups','false'
'table_group','C0687744','group','Social group','false'
'table_group','C1257890','Group','Population Group','true'
'table_group','C1519504','Group','Stage Grouping','false'
'table_group','C1705428','Group','Group Object','false'
'table_group','C1705429','Group','User Group','false'
'comparison','C1707455','Comparison','Comparison','false'
'with metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'without metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'chd','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'chd','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'amlodipine chlorthalidone','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'all cause mortality','C0015127','cause','Etiology aspects','true'
'all cause mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'all cause mortality','C0026566','mortality','Aspects of mortality statistics','true'
'all cause mortality','C1524003','Cause','Science of Etiology','false'
'combined cvd','C0205195','Combined','Combined','false'
'combined cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'esrd','C0022661','ESRD','Kidney Failure, Chronic','true'
'esrd','C0035078','ESRD','Kidney Failure','true'
'esrd','C2316810','ESRD','Chronic kidney disease stage 5','false'
'lisinopril chlorthalidone','C0065374','Lysinopril','Lisinopril','true'
'lisinopril chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'baseline characteristics','C4684572','Baseline Characteristics','Baseline Characteristics','false'
'categories of urinary acr ^g mg','C0683312','Categories','Categories','false'
'categories of urinary acr ^g mg','C1300563','mg/g','Gram per Kilogram','false'
'p for trend','C0369773','P NOS','P Blood group antibodies','false'
'p for trend','C2603361','P'','P prime','false'
'lowest normal n $nmbr$','C0205307','NORMAL','Normal','false'
'lowest normal n $nmbr$','C0231683','Normal','Gait normal','false'
'lowest normal n $nmbr$','C0439166','% normal','Percent normal','false'
'lowest normal n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'lowest normal n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'low normal n $nmbr$','C0205251','Low','low','false'
'low normal n $nmbr$','C0205307','NORMAL','Normal','false'
'low normal n $nmbr$','C0231683','Normal','Gait normal','false'
'low normal n $nmbr$','C0439166','% normal','Percent normal','false'
'low normal n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'low normal n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'low normal n $nmbr$','C1550472','low','low confidentiality','false'
'low normal n $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low normal n $nmbr$','C4048187','low','low exposure','false'
'low normal n $nmbr$','C4321351','Low','Low Level','false'
'low normal n $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'medium normal n $nmbr$','C0009458','Medium','Communications Media','true'
'medium normal n $nmbr$','C0205307','NORMAL','Normal','false'
'medium normal n $nmbr$','C0231683','Normal','Gait normal','false'
'medium normal n $nmbr$','C0439166','% normal','Percent normal','false'
'medium normal n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'medium normal n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'medium normal n $nmbr$','C0439536','MEDIUM','Medium','false'
'medium normal n $nmbr$','C1705217','Medium','Medium (Substance)','false'
'medium normal n $nmbr$','C3244283','medium','medium exposure','false'
'medium normal n $nmbr$','C4085196','Medium','Medium Growth Rate','false'
'medium normal n $nmbr$','C4522282','Medium','A Medium Amount of Time','false'
'medium normal n $nmbr$','C4522283','Medium','A Medium Amount','false'
'high normal n $nmbr$','C0205250','High','High','false'
'high normal n $nmbr$','C0205307','NORMAL','Normal','false'
'high normal n $nmbr$','C0231683','Normal','Gait normal','false'
'high normal n $nmbr$','C0439166','% normal','Percent normal','false'
'high normal n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'high normal n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'high normal n $nmbr$','C1299351','High','Abnormally high','false'
'high normal n $nmbr$','C2700149','HIGH','Value Above Reference Range','false'
'high normal n $nmbr$','C3887512','high','high - ActExposureLevelCode','false'
'high normal n $nmbr$','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high normal n $nmbr$','C4321237','High','High Level','false'
'high normal n $nmbr$','C4522209','High','IPSS Risk Category High','false'
'low medium microalbuminuria n $nmbr$','C0205251','Low','low','false'
'low medium microalbuminuria n $nmbr$','C0009458','Medium','Communications Media','true'
'low medium microalbuminuria n $nmbr$','C0439536','MEDIUM','Medium','false'
'low medium microalbuminuria n $nmbr$','C1705217','Medium','Medium (Substance)','false'
'low medium microalbuminuria n $nmbr$','C3244283','medium','medium exposure','false'
'low medium microalbuminuria n $nmbr$','C4085196','Medium','Medium Growth Rate','false'
'low medium microalbuminuria n $nmbr$','C4522282','Medium','A Medium Amount of Time','false'
'low medium microalbuminuria n $nmbr$','C4522283','Medium','A Medium Amount','false'
'low medium microalbuminuria n $nmbr$','C1550472','low','low confidentiality','false'
'low medium microalbuminuria n $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low medium microalbuminuria n $nmbr$','C4048187','low','low exposure','false'
'low medium microalbuminuria n $nmbr$','C4321351','Low','Low Level','false'
'low medium microalbuminuria n $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C0205250','High','High','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C0730345','Microalbuminuria','Microalbuminuria','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C1299351','High','Abnormally high','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C2700149','HIGH','Value Above Reference Range','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C3887512','high','high - ActExposureLevelCode','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C4321237','High','High Level','false'
'high microalbuminuria to macroalbuminuria n $nmbr$','C4522209','High','IPSS Risk Category High','false'
'male acr definition ^ g mg','C0024671','MG','Mammography','true'
'male acr definition ^ g mg','C0026410','MG','Mongolia','true'
'male acr definition ^ g mg','C0439269','mg%','mg/dL','false'
'male acr definition ^ g mg','C1960952','mg %','Milligram percent','false'
'male acr definition ^ g mg','C2346927','Mg++','Magnesium Cation','false'
'male acr definition ^ g mg','C4321396','MG','MG','false'
'male acr definition ^ g mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'female acr definition ^g mg','C0024671','MG','Mammography','true'
'female acr definition ^g mg','C0026410','MG','Mongolia','true'
'female acr definition ^g mg','C0439269','mg%','mg/dL','false'
'female acr definition ^g mg','C1960952','mg %','Milligram percent','false'
'female acr definition ^g mg','C2346927','Mg++','Magnesium Cation','false'
'female acr definition ^g mg','C4321396','MG','MG','false'
'female acr definition ^g mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'female sex n','C0086287','FEMALE SEX','Females','true'
'white n medical history n','C0262926','Medical History','Medical History','false'
'white n medical history n','C1704706','Medical History','Medical History Domain','false'
'prior angina pectoris','C0332152','Prior','Before','false'
'prior angina pectoris','C0002962','ANGINA PECTORIS','Angina Pectoris','true'
'prior angina pectoris','C2826257','PRIOR','Prior Medication Usage','false'
'prior cabg','C0332152','Prior','Before','false'
'prior cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'prior cabg','C2826257','PRIOR','Prior Medication Usage','false'
'prior ptca or cabg','C0332152','Prior','Before','false'
'prior ptca or cabg','C2936173','PTCA','Percutaneous Transluminal Coronary Angioplasty','true'
'prior ptca or cabg','C2826257','PRIOR','Prior Medication Usage','false'
'prior ptca or cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'current smoker n of patients','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker n of patients','C3241966','Current Smoker','Current Smoker','false'
'dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations','C0536221','DBP','HSD17B4 protein, human','true'
'dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations','C0439475','mmHG','mmHg','false'
'dbp $nmbr$ or sbp $nmbr$ mm hg laboratory determinations','C0680730','determinations','Adjudication','false'
'egfr ml mn $nmbr$ $nmbr$ m $nmbr$','C0026327','MN','MNSs Blood-Group System','true'
'egfr ml mn $nmbr$ $nmbr$ m $nmbr$','C0026405','MN','Monaco','true'
'egfr ml mn $nmbr$ $nmbr$ m $nmbr$','C4285072','mN','Millinewton','false'
'mean serum potassium mg dl','C0302353','Serum Potassium','Serum potassium measurement','false'
'mean serum potassium mg dl','C0439269','mg dl','mg/dL','false'
'mean serum potassium mg dl','C0543465','serum potassium','Serum Potassium result','false'
'mean serum cholesterol mg dl','C0587184','Serum cholesterol NOS','Serum cholesterol measurement','false'
'mean serum cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'lv function $nmbr$ $nmbr$ and','C0031843','function','physiological aspects','true'
'lv function $nmbr$ $nmbr$ and','C0542341','Function','Function (attribute)','false'
'lv function $nmbr$ $nmbr$ and','C0700205','FUNCTION','Function Axis','false'
'lv function $nmbr$ $nmbr$ and','C1705273','Function','Mathematical Operator','false'
'potassium sparing diuretic','C0304490','Potassium-Sparing Diuretic','Potassium Sparing Diuretics','true'
'potassium sparing diuretic','C3536751','Potassium-sparing Diuretic','Potassium-sparing Diuretic [EPC]','false'
'other diuretic','C0012798','Diuretic','Diuretics','true'
'digitalis','C0012252','Digitalis','Genus: Digitalis','true'
'digitalis','C0304520','DIGITALIS','Digitalis preparation','false'
'active treatment','C1704532','Active Treatment','Active Method','false'
'hr and $nmbr$ ci','C0008107','CI','Chile','true'
'hr and $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'low to medium microalbuminuria n $nmbr$','C0205251','Low','low','false'
'low to medium microalbuminuria n $nmbr$','C1550472','low','low confidentiality','false'
'low to medium microalbuminuria n $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low to medium microalbuminuria n $nmbr$','C4048187','low','low exposure','false'
'low to medium microalbuminuria n $nmbr$','C4321351','Low','Low Level','false'
'low to medium microalbuminuria n $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'urinary acr','C1412134','ACR','ACR gene','false'
'urinary acr','C1515941','ACR','American College of Radiology','false'
'males','C0086582','Males','Males','true'
'females','C0086287','Females','Females','true'
'primary outcome n $nmbr$','C0205225','Primary','Primary','false'
'primary outcome n $nmbr$','C0439612','Primary','True primary (qualifier value)','false'
'primary outcome n $nmbr$','C0439631','Primary','Primary operation','false'
'$nmbr$ $nmbr$ reference','C1514811','Reference','Bibliographic Reference','false'
'$nmbr$ $nmbr$ reference','C1706462','Reference','Reference Object','false'
'cardiovascular death n $nmbr$','C0007226','Cardiovascular','Cardiovascular system','true'
'cardiovascular death n $nmbr$','C0011065','DEATH','Cessation of life','true'
'cardiovascular death n $nmbr$','C1306577','Death','Death (finding)','false'
'cardiovascular death n $nmbr$','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cardiovascular death n $nmbr$','C4552775','Death NOS','Death NOS, CTCAE','false'
'cardiovascular death n $nmbr$','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'all cause mortality n $nmbr$','C0015127','cause','Etiology aspects','true'
'all cause mortality n $nmbr$','C0026565','Mortality','Mortality Vital Statistics','true'
'all cause mortality n $nmbr$','C0026566','mortality','Aspects of mortality statistics','true'
'all cause mortality n $nmbr$','C1524003','Cause','Science of Etiology','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0520511','Distribution','Distributing','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1704711','Distribution','Distribution','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1522706','MRS','magnetic resonance spectroscopic imaging','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C2349188','Mrs.','Mrs - title','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C3714939','MRS','Modified Rankin Scale Questionnaire','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C3854213','mRS','Modified rankin scale:Score:Point in time:^Patient:Ordinal','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1274040','Result','Result','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1546471','Result','What subject filter - Result','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C2825142','Result','Experimental Result','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1524063','Using','Use of','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0002778','Analysis','Analysis of substances','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0030705','Patients','Patients','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0936012','ANALYSIS','Analysis','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1524024','analysis','analysis aspect','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C4684790','enrolled','Study Subject Enrolled','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0009247','COHORT','Cohort Studies','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0599755','Cohort','Cohort','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1522326','Treated','Treating','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0288672','ABCIXIMAB','abciximab','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0032042','Placebo','Placebos','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0871208','Rate','Rating (action)','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1521828','Rate','Rate','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1442488','Baseline','Baseline','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C0449820','SCORE','Score','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ the distribution of scores on the mrs a and the ef cacy results at $nmbr$ months using the adjusted dichotomous responder analysis b in patients enrolled in the primary cohort is demonstrated for patients treated either with abciximab or placebo in addition the rates of favorable outcomes for patients with a baseline nihss score of $nmbr$ to $nmbr$ desired mrs score $nmbr$ $nmbr$ to $nmbr$ desired mrs score of $nmbr$ to $nmbr$ or $nmbr$ to $nmbr$ desired mrs score $nmbr$ to $nmbr$ are shown b','C1547282','Show','Show','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C1079230','subgroups','Subgroup A Nepoviruses','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C1527178','Based','Basis - conceptual entity','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C1705938','Based','Base - General Qualifier','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C0683970','demographic characteristics','demographic characteristics','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C0235828','LACK OF EFFICACY','Lack of Efficacy','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C0205225','Primary','Primary','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C1274040','Outcome','Result','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C0439612','Primary','True primary (qualifier value)','false'
'subgroups based on clinical and demographic characteristics also demonstrated a lack of efficacy in the primary outcomes','C0439631','Primary','Primary operation','false'
'black participants','C0005680','Black','Black race','true'
'black participants','C0679646','participants','Participant','false'
'black participants','C0027567','Black','African race','true'
'black participants','C0085756','BLACK','African American','true'
'black participants','C0439541','Black','Black color','false'
'nonblack participants','C0679646','participants','Participant','false'
'i with mets n $nmbr$','C0021966','I-','Iodides','true'
'i with mets n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'i without mets n $nmbr$','C0021966','I-','Iodides','true'
'i without mets n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'years of education mean sd','C0439234','YEARS','year','false'
'years of education mean sd','C0013621','Education','Knowledge acquisition','true'
'years of education mean sd','C0013622','education','Educational aspects','true'
'years of education mean sd','C0013658','Education, NOS','Educational Status','true'
'years of education mean sd','C0039401','Education','Educational process of instructing','true'
'aspirin use','C0042153','use','utilization qualifier','true'
'aspirin use','C0457083','Use','Usage','false'
'aspirin use','C1947944','Use','Use - dosing instruction imperative','false'
'antihypertensive treatment','C0003364','anti hypertensive','Antihypertensive Agents','true'
'antihypertensive treatment','C0039798','treatment','therapeutic aspects','true'
'antihypertensive treatment','C0087111','Treatment','Therapeutic procedure','true'
'antihypertensive treatment','C1522326','Treatment','Treating','false'
'antihypertensive treatment','C1533734','Treatment','Administration procedure','false'
'antihypertensive treatment','C1705169','Treatment','Biomaterial Treatment','false'
'antihypertensive treatment','C3538994','TREATMENT','Treatment Epoch','false'
'antihypertensive treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treated','C1522326','Treated','Treating','false'
'untreated','C0332155','untreated','Did not receive therapy or drug for','false'
'history of mi or stroke d','C0019664','History','History','true'
'history of mi or stroke d','C0019665','history','Historical aspects qualifier','true'
'history of mi or stroke d','C0262512','History, NOS','History of present illness','false'
'history of mi or stroke d','C0262926','History','Medical History','false'
'history of mi or stroke d','C1705255','History','Concept History','false'
'history of mi or stroke d','C2004062','History','History of previous events','false'
'history of mi or stroke d','C0038454','STROKE','Cerebrovascular accident','true'
'history of mi or stroke d','C4554100','Stroke','Stroke, CTCAE','false'
'history of coronary revascularization d','C0019664','History','History','true'
'history of coronary revascularization d','C0019665','history','Historical aspects qualifier','true'
'history of coronary revascularization d','C0262512','History, NOS','History of present illness','false'
'history of coronary revascularization d','C0262926','History','Medical History','false'
'history of coronary revascularization d','C1705255','History','Concept History','false'
'history of coronary revascularization d','C2004062','History','History of previous events','false'
'other atherosclerotic cvdd e','C0333482','Atherosclerotic','atherosclerotic','false'
'other atherosclerotic cvdd e','C1859330','CVDD','Cardiac Valvular Defect, Developmental','true'
'st t wave abnormality d','C0036056','ST','Saint Lucia','true'
'st t wave abnormality d','C1839341','T Wave Abnormality','Abnormal T-wave','false'
'st t wave abnormality d','C3272372','ST','Character String Data Type','false'
'lvh by ecg or echocardiographyd','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'glycemic status f','C0449438','Status','Status','false'
'glycemic status f','C0016327','F-','Fluorides','true'
'impaired fasting glucose','C1272092','Impaired fasting glucose','Impaired fasting glycaemia','false'
'normoglycemic','C0580545','Normoglycemic','Blood glucose normal','false'
'history of chd at baseline d g','C0019664','History','History','true'
'history of chd at baseline d g','C0019665','history','Historical aspects qualifier','true'
'history of chd at baseline d g','C0262512','History, NOS','History of present illness','false'
'history of chd at baseline d g','C0262926','History','Medical History','false'
'history of chd at baseline d g','C1705255','History','Concept History','false'
'history of chd at baseline d g','C2004062','History','History of previous events','false'
'history of chd at baseline d g','C0168634','baseline','BaseLine dental cement','true'
'history of chd at baseline d g','C1442488','Baseline','Baseline','false'
'history of chd at baseline d g','C0439267','g%','Gram per Deciliter','false'
'lipid trial participants','C1997894','Trial participant','Clinical trial participant (person)','false'
'lipid trial participants','C2242969','Trial participant','clinical trial participant (history)','false'
'blood pressure','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure','C1272641','Blood pressure','Systemic arterial pressure','true'
'systolic mean sd mm hg h','C0456680','mm/h','mm/h','false'
'diastolic mean sd mm hg','C0012000','Diastolic','Diastole','true'
'diastolic mean sd mm hg','C0439475','mmHG','mmHg','false'
'serum potassium level mean sd meq l','C0302353','Serum potassium level','Serum potassium measurement','false'
'serum potassium level mean sd meq l','C0439375','mEq/L','mEq/L','false'
'serum potassium level mean sd meq l','C0543465','serum potassium level','Serum Potassium result','false'
'fasting serum glucose level mean sd mg dl','C0202045','fasting glucose level','Glucose measurement, fasting','false'
'fasting serum glucose level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'serum creatinine level mean sd mg dl','C0600061','Serum creatinine level','Serum creatinine level','false'
'serum creatinine level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'tc level mean sd mg dl','C0039411','TC','Technetium','true'
'tc level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'tc level mean sd mg dl','C0040642','TC','Transcobalamin','true'
'tc level mean sd mg dl','C0041405','TC','Turks and Caicos Islands','true'
'tc level mean sd mg dl','C0041698','TC','United Arab Emirates','true'
'tc level mean sd mg dl','C1824670','TC','CD55 gene','false'
'tc level mean sd mg dl','C3272447','TC','CD55 wt Allele','false'
'tc level mean sd mg dl','C4522122','TC','TC Regimen','false'
'ldl c level mean sd mg dl','C0441889','Level','Levels (qualifier value)','false'
'ldl c level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'ldl c level mean sd mg dl','C0456079','Level','Disease classification level','false'
'ldl c level mean sd mg dl','C1547707','Level','Floor - story of building','false'
'ldl c level mean sd mg dl','C2946261','Level','Level','false'
'hdl c level mean sd mg dl','C0441889','Level','Levels (qualifier value)','false'
'hdl c level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'hdl c level mean sd mg dl','C0456079','Level','Disease classification level','false'
'hdl c level mean sd mg dl','C1547707','Level','Floor - story of building','false'
'hdl c level mean sd mg dl','C2946261','Level','Level','false'
'hdl c level $nmbr$ mg dld','C1414063','DLD','DLD gene','false'
'hdl c level $nmbr$ mg dld','C2826331','DLD','Division of Lung Diseases','false'
'fasting triglyceride level mean sd mg dl','C0015663','FASTING','Fasting','true'
'fasting triglyceride level mean sd mg dl','C0428475','Triglyceride level','Triglyceride level - finding','false'
'fasting triglyceride level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'cv mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'cv mortality','C0026566','mortality','Aspects of mortality statistics','true'
'combined chd','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'combined chd','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'non black participants','C0005680','Black','Black race','true'
'non black participants','C0679646','participants','Participant','false'
'non black participants','C0027567','Black','African race','true'
'non black participants','C0085756','BLACK','African American','true'
'non black participants','C0439541','Black','Black color','false'
'i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0021966','I-','Iodides','true'
'i $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'ii $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1710602','II','VIPR1 wt Allele','false'
'ii $nmbr$ $nmbr$ $nmbr$ $nmbr$','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'doxazosin','C0114873','DOXAZOSIN','Doxazosin','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1707455','Comparison','Comparison','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0077770','Doxazosin mesilate','Doxazosin Mesylate','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1511726','Data','Data','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C3245479','data','Data call receiving device','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C3714741','Data','Data (eukaryote)','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C2985465','Hazard Ratio','Hazard Ratio','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0009667','Confidence Intervals','Confidence Intervals','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0871208','Rate','Rating (action)','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1521828','Rate','Rate','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C4330837','Number of Events','Number of Events','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0013227','Drug','Pharmaceutical Preparations','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1254351','DRUG','Pharmacologic Substance','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0034510','RACE','Racial group','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1706779','RACE','AMACR wt Allele','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C3853635','Race','Race','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0010054','coronary heart disease','Coronary Arteriosclerosis','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0010068','Coronary Heart Disease','Coronary heart disease','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C1956346','coronary heart disease','Coronary Artery Disease','true'
'figure $nmbr$ comparisons of doxazosin mesylate with chlorthalidone data are expressed as hazard ratios $nmbr$ confidence intervals with event rates [ses] and numbers of events given for each drug by race and metabolic cardiometabolic syndrome mets status chd indicates coronary heart disease cv cardiovascular cvd cv disease and esrd end stage renal disease','C0022661','ESRD - End stage renal disease','Kidney Failure, Chronic','true'
'p women vs men','C0369773','P NOS','P Blood group antibodies','false'
'p women vs men','C0043210','Women','Woman','true'
'p women vs men','C2603361','P'','P prime','false'
'p women vs men','C0025266','Men','Male population group','true'
'systoiic biood pressure mm hg','C0033095','Pressure','Pressure- physical agent','true'
'systoiic biood pressure mm hg','C0439475','mmHG','mmHg','false'
'systoiic biood pressure mm hg','C0460139','Pressure','Pressure (finding)','false'
'systoiic biood pressure mm hg','C1306345','Pressure','Pressure - action','false'
'systoiic biood pressure mm hg','C4284008','Pressure','Pressure (property)','false'
'diastoiic biood pressure mm hg','C0033095','Pressure','Pressure- physical agent','true'
'diastoiic biood pressure mm hg','C0439475','mmHG','mmHg','false'
'diastoiic biood pressure mm hg','C0460139','Pressure','Pressure (finding)','false'
'diastoiic biood pressure mm hg','C1306345','Pressure','Pressure - action','false'
'diastoiic biood pressure mm hg','C4284008','Pressure','Pressure (property)','false'
'body mass index kg m^','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m^','C0439209','kg','Kilogram','false'
'body mass index kg m^','C4054209','/kg','Per Kilogram','false'
'corneii product mm ms','C2349943','Ms.','Ms. - Title','false'
'corneii product mm ms','C3539704','MS','MTR wt Allele','false'
'corneii product mm ms','C3713294','MS','MTR protein, human','true'
'sokoiow lyon voitage mv','C1454484','MV','VCL protein, human','true'
'sokoiow lyon voitage mv','C1705503','MV','VCL wt Allele','false'
'sokoiow lyon voitage mv','C4281602','MV','Minute volume measurement','false'
'current smokers n medicai history n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smokers n medicai history n','C3241966','Current Smoker','Current Smoker','false'
'isoiated systoiic hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'isoiated systoiic hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'cerebrovascuiar disease','C0012634','Disease','Disease','true'
'peripherai arteriai disease','C0012634','Disease','Disease','true'
'adjusted hr losartan vs atenolol','C0456081','Adjusted','Adjustment Action','false'
'adjusted hr losartan vs atenolol','C0126174','LOSARTAN','Losartan','true'
'adjusted hr losartan vs atenolol','C0004147','ATENOLOL','Atenolol','true'
'women n $nmbr$ events','C0441471','Events','Event','false'
'women n $nmbr$ events','C3541888','EVENTS','CDISC Events Class','false'
'women n $nmbr$','C0043210','Women','Woman','true'
'events','C0441471','Events','Event','false'
'events','C3541888','EVENTS','CDISC Events Class','false'
'primary composite^','C0205199','Composite','Composite','false'
'primary composite^','C1547335','Composite','Data types- Composite','false'
'myocardiai infarction','C0021308','Infarction','Infarction','true'
'hospitaiization for angina','C0002962','ANGINA','Angina Pectoris','true'
'hospitaiization for heart faiiure','C0018787','HEART','Heart','true'
'vildagliptin $nmbr$ mg daily glimepiride','C0024671','MG','Mammography','true'
'vildagliptin $nmbr$ mg daily glimepiride','C0061323','GLIMEPIRIDE','glimepiride','true'
'vildagliptin $nmbr$ mg daily glimepiride','C0026410','MG','Mongolia','true'
'vildagliptin $nmbr$ mg daily glimepiride','C0439269','mg%','mg/dL','false'
'vildagliptin $nmbr$ mg daily glimepiride','C1960952','mg %','Milligram percent','false'
'vildagliptin $nmbr$ mg daily glimepiride','C2346927','Mg++','Magnesium Cation','false'
'vildagliptin $nmbr$ mg daily glimepiride','C4321396','MG','MG','false'
'vildagliptin $nmbr$ mg daily glimepiride','C4521761','MG','United States Military Commissioned Officer O8','false'
'viidagliptin $nmbr$ mg daily glimepiride','C0024671','MG','Mammography','true'
'viidagliptin $nmbr$ mg daily glimepiride','C0061323','GLIMEPIRIDE','glimepiride','true'
'viidagliptin $nmbr$ mg daily glimepiride','C0026410','MG','Mongolia','true'
'viidagliptin $nmbr$ mg daily glimepiride','C0439269','mg%','mg/dL','false'
'viidagliptin $nmbr$ mg daily glimepiride','C1960952','mg %','Milligram percent','false'
'viidagliptin $nmbr$ mg daily glimepiride','C2346927','Mg++','Magnesium Cation','false'
'viidagliptin $nmbr$ mg daily glimepiride','C4321396','MG','MG','false'
'viidagliptin $nmbr$ mg daily glimepiride','C4521761','MG','United States Military Commissioned Officer O8','false'
'placebo glimepiride','C0032042','Placebo','Placebos','true'
'placebo glimepiride','C0061323','GLIMEPIRIDE','glimepiride','true'
'placebo glimepiride','C1696465','PLACEBO','placebo','false'
'placebo glimepiride','C1706408','PLACEBO','Placebo Control','false'
'age years mean s d','C1510829','Age-Years','Age-Years','false'
'age years mean s d','C0444504','Mean','Statistical mean','false'
'age years mean s d','C2347634','Mean','Population Mean','false'
'age years mean s d','C2348143','Mean','Sample Mean','false'
'hispanic latino','C0086409','HISPANIC','Hispanics','true'
'hispanic latino','C0086528','Latino','Latinos','true'
'bmi kg m^ mean s d','C0022718','KG','Kyrgyzstan','true'
'bmi kg m^ mean s d','C0439209','kg','Kilogram','false'
'bmi kg m^ mean s d','C4054209','/kg','Per Kilogram','false'
'bmi kg m^ mean s d','C0444504','Mean','Statistical mean','false'
'bmi kg m^ mean s d','C2347634','Mean','Population Mean','false'
'bmi kg m^ mean s d','C2348143','Mean','Sample Mean','false'
'hbaic mean s d','C0444504','Mean','Statistical mean','false'
'hbaic mean s d','C2347634','Mean','Population Mean','false'
'hbaic mean s d','C2348143','Mean','Sample Mean','false'
'hbaic group','C0441833','Group','Groups','false'
'hbaic group','C0687744','group','Social group','false'
'hbaic group','C1257890','Group','Population Group','true'
'hbaic group','C1519504','Group','Stage Grouping','false'
'hbaic group','C1705428','Group','Group Object','false'
'hbaic group','C1705429','Group','User Group','false'
'fpg mmol l mean s d','C0439433','mmol/d','mmol/24h','false'
'disease duration years mean s d','C0872146','disease duration','disease length','false'
'disease duration years mean s d','C0439234','YEARS','year','false'
'duration of sulphonylurea use months mean s d','C1881378','DURATION OF USE','Limitation of Use Based on Duration of Use','false'
'duration of sulphonylurea use months mean s d','C2826775','Duration of Use','Duration of Use','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0444504','Mean','Statistical mean','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C2347634','Mean','Population Mean','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C2348143','Mean','Sample Mean','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0392747','Change','Changing','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0443172','change','Changed status','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C1705241','Change','Delta (difference)','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C4319952','Change','Change -- procedure','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C2349179','End Point','End Point','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0001779','Aged','Age','false'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C0001792','Aged','Elderly (population group)','true'
'fig $nmbr$ a mean s e change from baseline to end point in haemoglobin a $nmbr$ c hba $nmbr$ c in patients aged','C1999167','aged','Old age','false'
'mets','C0812270','METS','ETV3 gene','false'
'mets','C1705694','METS','ETV3 wt Allele','false'
'mets','C2939420','mets','Metastatic Neoplasm','false'
'non mets','C0812270','METS','ETV3 gene','false'
'non mets','C1705694','METS','ETV3 wt Allele','false'
'non mets','C2939420','mets','Metastatic Neoplasm','false'
'placebo dr $nmbr$','C0013014','DR','Dominican Republic','true'
'placebo dr $nmbr$','C0031831','DR','Physicians','true'
'placebo dr $nmbr$','C1707664','DR','Delayed Release Dosage Form','false'
'placebo dr $nmbr$','C2348314','Dr.','Doctor - Title','false'
'placebo dr $nmbr$','C3540849','DR','Device to Subject Relationship Domain','false'
'eze simva $nmbr$ $nmbr$ mg dr $nmbr$','C0013014','DR','Dominican Republic','true'
'eze simva $nmbr$ $nmbr$ mg dr $nmbr$','C0031831','DR','Physicians','true'
'eze simva $nmbr$ $nmbr$ mg dr $nmbr$','C1707664','DR','Delayed Release Dosage Form','false'
'eze simva $nmbr$ $nmbr$ mg dr $nmbr$','C2348314','Dr.','Doctor - Title','false'
'eze simva $nmbr$ $nmbr$ mg dr $nmbr$','C3540849','DR','Device to Subject Relationship Domain','false'
'feno $nmbr$ dn $nmbr$','C1333964','DN','Liver Dysplastic Nodule','false'
'feno $nmbr$ dn $nmbr$','C1707618','DN','DN Term Type','false'
'eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$','C1333964','DN','Liver Dysplastic Nodule','false'
'eze simva $nmbr$ $nmbr$ mg feno $nmbr$ mg dn $nmbr$','C1707618','DN','DN Term Type','false'
'placebo dn $nmbr$','C1333964','DN','Liver Dysplastic Nodule','false'
'placebo dn $nmbr$','C1707618','DN','DN Term Type','false'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C0024671','MG','Mammography','true'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C0026410','MG','Mongolia','true'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C0439269','mg%','mg/dL','false'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C1960952','mg %','Milligram percent','false'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C4321396','MG','MG','false'
'eze simva $nmbr$ $nmbr$ mg dn $nmbr$ c $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'feno $nmbr$ mg dn $nmbr$','C1333964','DN','Liver Dysplastic Nodule','false'
'feno $nmbr$ mg dn $nmbr$','C1707618','DN','DN Term Type','false'
'bmi kg m $nmbr$ mean sd','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ mean sd','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ mean sd','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'bmi kg m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'bmi kg m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'bmi kg m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'waist circumference cm mean sd','C0455829','Waist Circumference','Waist Circumference','true'
'waist circumference cm mean sd','C2699239','SD','SD, Rat Strain','false'
'diagnosis of diabetes n','C0011900','DIAGNOSIS','Diagnosis','true'
'diagnosis of diabetes n','C1704338','diagnosis','diagnosis aspect','true'
'diagnosis of diabetes n','C1704656','DIAGNOSIS','Diagnosis Study','false'
'tg mg dl','C0337445','TG','Thyroglobulin measurement','false'
'tg mg dl','C0439269','mg dl','mg/dL','false'
'non hdl c mg dl','C1518422','Non','Negation','false'
'non hdl c mg dl','C0439269','mg dl','mg/dL','false'
'apo b mg dl','C0003593','Apo B','Apolipoproteins B','true'
'apo b mg dl','C0439269','mg dl','mg/dL','false'
'apo b mg dl','C3252643','APOB','APOB protein, human','true'
'tc mg dl','C0039411','TC','Technetium','true'
'tc mg dl','C0439269','mg dl','mg/dL','false'
'tc mg dl','C0040642','TC','Transcobalamin','true'
'tc mg dl','C0041405','TC','Turks and Caicos Islands','true'
'tc mg dl','C0041698','TC','United Arab Emirates','true'
'tc mg dl','C1824670','TC','CD55 gene','false'
'tc mg dl','C3272447','TC','CD55 wt Allele','false'
'tc mg dl','C4522122','TC','TC Regimen','false'
'apo a i mg dl','C0085201','ApoA-I','Apolipoprotein A-I','true'
'apo a i mg dl','C0439269','mg dl','mg/dL','false'
'apo a i mg dl','C1677784','ApoA-I','APOA1 protein, human','true'
'data are expressed as median sd except','C1511726','Data','Data','false'
'data are expressed as median sd except','C3245479','data','Data call receiving device','false'
'data are expressed as median sd except','C3714741','Data','Data (eukaryote)','false'
'data are expressed as median sd except','C0549183','Median','Midline (qualifier value)','false'
'data are expressed as median sd except','C0876920','Median','Median Statistical Measurement','false'
'data are expressed as median sd except','C2347635','Median','Population Median','false'
'data are expressed as median sd except','C2348144','Median','Sample Median','false'
'data are expressed as median sd except','C2939193','Median','Median (qualifier value)','false'
'data are expr','C1511726','Data','Data','false'
'data are expr','C3245479','data','Data call receiving device','false'
'data are expr','C3714741','Data','Data (eukaryote)','false'
'ssed as ls means','C0023668','LS','Liechtenstein','true'
'ssed as ls means','C1704970','Means','Means','false'
'by treatment arm','C1522541','Treatment Arm','Protocol Treatment Arm','false'
'icd','C0021122','ICD','Disruptive, Impulse Control, and Conduct Disorders','true'
'syncope','C0039070','SYNCOPE','Syncope','true'
'syncope','C3541349','Syncope','Syncope (amphibian)','false'
'syncope','C4554644','Syncope','Syncope, CTCAE 5.0','false'
'amiodarone','C0002598','AMIODARONE','Amiodarone','true'
'by cause of death','C0007465','Cause of Death','Cause of Death','true'
'by cause of death','C4050444','Cause of death','Cause of death:Find:Pt:^Patient:Nom','false'
'sudden death','C0011071','Death, Sudden','Sudden death','true'
'sudden death','C1964022','Sudden death','Sudden Death Not Associated with More Specific CTCAE Term, CTCAE','false'
'sudden death','C4554103','Sudden death NOS','Sudden Death NOS, CTCAE','false'
'figure $nmbr$ subgroup analyses for the primary outcome','C2986480','Subgroup Analysis','Subset Analysis','false'
'figure $nmbr$ subgroup analyses for the primary outcome','C0205225','Primary','Primary','false'
'figure $nmbr$ subgroup analyses for the primary outcome','C0439612','Primary','True primary (qualifier value)','false'
'figure $nmbr$ subgroup analyses for the primary outcome','C0439631','Primary','Primary operation','false'
'sal n $nmbr$ $nmbr$','C0036140','Salts','Salts','true'
'sal n $nmbr$ $nmbr$','C0037494','Salt','Sodium Chloride','true'
'sal n $nmbr$ $nmbr$','C0206136','Salt','Sodium Chloride, Dietary','true'
'fp n $nmbr$ $nmbr$','C0016704','FP','French Polynesia','true'
'fp n $nmbr$ $nmbr$','C1419068','FP','PTGFR gene','false'
'fp n $nmbr$ $nmbr$','C1419906','FP','SDHA gene','false'
'fp n $nmbr$ $nmbr$','C3541238','Fp','Succinate Dehydrogenase [Ubiquinone] Flavoprotein Subunit, Mitochondrial','false'
'fp n $nmbr$ $nmbr$','C3541412','FP','SDHA wt Allele','false'
'sfc n $nmbr$ $nmbr$','C4521536','SFC','United States Military enlisted E7','false'
'mean age sd yr','C0001779','AGE','Age','false'
'mean age sd yr','C0439234','yr','year','false'
'mean body mass index sd kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean body mass index sd kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean body mass index sd kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'baseline post bronchodilator fev $nmbr$ sd ml','C0439526','/mL','/mL','false'
'baseline post bronchodilator fev $nmbr$ sd ml','C1705224','ML','THPO wt Allele','false'
'baseline post bronchodilator fev $nmbr$ sd ml','C3887665','ML','Thrombopoietin, human','false'
'predicted post bronchodilator fev sd ml','C0439526','/mL','/mL','false'
'predicted post bronchodilator fev sd ml','C1705224','ML','THPO wt Allele','false'
'predicted post bronchodilator fev sd ml','C3887665','ML','Thrombopoietin, human','false'
'region n','C0017446','Region','Geographic Locations','true'
'region n','C0205147','Region','regional','false'
'united states','C0041703','UNITED STATES','United States','true'
'asia pacific','C0003980','Asia','Asia','true'
'eastern europe','C0015177','Eastern Europe','Europe, Eastern','true'
'western europe','C0043129','Western Europe','Western Europe','true'
'number of subjects in analysis','C0237753','*Number','Numbers','false'
'number of subjects in analysis','C0449788','Number','Count of entities','false'
'number of subjects in analysis','C0002778','Analysis','Analysis of substances','false'
'number of subjects in analysis','C0936012','ANALYSIS','Analysis','false'
'number of subjects in analysis','C1524024','analysis','analysis aspect','true'
'baseline mean fev $nmbr$ sd ml','C0439526','/mL','/mL','false'
'baseline mean fev $nmbr$ sd ml','C1705224','ML','THPO wt Allele','false'
'baseline mean fev $nmbr$ sd ml','C3887665','ML','Thrombopoietin, human','false'
'adjusted rate of fev $nmbr$ decline se ml yr','C0456081','Adjusted','Adjustment Action','false'
'adjusted rate of fev $nmbr$ decline se ml yr','C0871208','Rate','Rating (action)','false'
'adjusted rate of fev $nmbr$ decline se ml yr','C1521828','Rate','Rate','false'
'effect of covariates on slopes','C1280500','Effect','Effect','false'
'effect of covariates on slopes','C1518681','effect','Outcome of Therapy','false'
'effect of covariates on slopes','C2348382','Effect','Effect, Appearance','false'
'effect of covariates on slopes','C0807955','slopes','slope','false'
'p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'current n $nmbr$ $nmbr$','C0521116','CURRENT','Current (present time)','false'
'current n $nmbr$ $nmbr$','C1705970','Current','Electrical Current','false'
'former n $nmbr$ $nmbr$','C0205156','FORMER','Previous','false'
'former n $nmbr$ $nmbr$','C0750523','FORMER','FORMER','false'
'female n $nmbr$ $nmbr$','C0043210','female','Woman','true'
'female n $nmbr$ $nmbr$','C0086287','FEMALE','Females','true'
'female n $nmbr$ $nmbr$','C1705497','Female','Female, Self-Report','false'
'female n $nmbr$ $nmbr$','C1705498','FEMALE','Female Phenotype','false'
'male n $nmbr$ $nmbr$','C0086582','MALE','Males','true'
'male n $nmbr$ $nmbr$','C1706180','Male','Male Gender, Self Report','false'
'male n $nmbr$ $nmbr$','C1706428','MALE','Male Phenotype','false'
'male n $nmbr$ $nmbr$','C1706429','Male','Male, Self-Reported','false'
'$nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'predicted fev $nmbr$','C0681842','Predicted','prediction','false'
'predicted fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'predicted fev $nmbr$','C1882327','%{Predicted}','Percent of Predicted Value','false'
'$nmbr$ n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'united states n $nmbr$ $nmbr$','C0041703','UNITED STATES','United States','true'
'asia pacific n $nmbr$','C0003980','Asia','Asia','true'
'eastern europe n $nmbr$ $nmbr$','C0015177','Eastern Europe','Europe, Eastern','true'
'western europe n $nmbr$ $nmbr$','C0043129','Western Europe','Western Europe','true'
'other n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'other n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'ethnic origin','C0015031','Ethnic Origin','Ethnic group','true'
'white n $nmbr$ $nmbr$','C0007457','WHITE','Caucasoid Race','true'
'white n $nmbr$ $nmbr$','C0043157','WHITE','Caucasians','true'
'white n $nmbr$ $nmbr$','C0220938','WHITE','White color','false'
'black n $nmbr$','C0005680','Black','Black race','true'
'black n $nmbr$','C0027567','Black','African race','true'
'black n $nmbr$','C0085756','BLACK','African American','true'
'black n $nmbr$','C0439541','Black','Black color','false'
'asian n $nmbr$','C0078988','ASIAN','Asians','true'
'american hispanic n $nmbr$','C0596070','American','Americas Ethnicity','false'
'american hispanic n $nmbr$','C0086409','HISPANIC','Hispanics','true'
'$nmbr$ to $nmbr$ n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ to $nmbr$ n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'exacerbations in the year before study','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in the year before study','C0439234','Year','year','false'
'exacerbations in the year before study','C0439508','/Year','per year','false'
'exacerbations in the year before study','C0557651','Study','Room of building - Study','false'
'exacerbations in the year before study','C2603343','Study','Study','false'
'baseline sgrq total score','C0168634','baseline','BaseLine dental cement','true'
'baseline sgrq total score','C2964552','Total Score','Total score','false'
'baseline sgrq total score','C1442488','Baseline','Baseline','false'
'intensive therapy n $nmbr$','C0039798','therapy','therapeutic aspects','true'
'intensive therapy n $nmbr$','C0087111','Therapy','Therapeutic procedure','true'
'intensive therapy n $nmbr$','C1363945','Therapy','Therapy Object (animal model)','false'
'standard therapy n $nmbr$','C2936643','standard therapy','Standard of Care','true'
'median duration of diabetes yr','C0449238','Duration','Duration (temporal concept)','false'
'median duration of diabetes yr','C2926735','Duration','Duration','false'
'previous cardiovascular event','C0205156','Previous','Previous','false'
'previous cardiovascular event','C1320716','Cardiovascular event','Cardiovascular event','false'
'previous cardiovascular event','C1552607','previous','Act Relationship Subset - previous','false'
'race or ethnic group f','C0034510','RACE','Racial group','true'
'race or ethnic group f','C1706779','RACE','AMACR wt Allele','false'
'race or ethnic group f','C3853635','Race','Race','false'
'race or ethnic group f','C0441840','Group F','Group F','false'
'education','C0013621','Education','Knowledge acquisition','true'
'education','C0013622','education','Educational aspects','true'
'education','C0013658','Education, NOS','Educational Status','true'
'education','C0039401','Education','Educational process of instructing','true'
'less than high school','C0599395','High School','High Schools','false'
'less than high school','C0683862','High school','high school level','false'
'less than high school','C0870649','High School','High School Graduate','false'
'high school graduate','C0870649','High School Graduate','High School Graduate','false'
'high school graduate','C1549971','High School Graduate','High School Graduate - Degree/license/certificate','false'
'some college','C0557806','College','College','false'
'college degree or higher','C0441889','Degree','Levels (qualifier value)','false'
'college degree or higher','C0449286','Degree','Degree or extent','false'
'college degree or higher','C0542560','Degree','Academic degree','false'
'college degree or higher','C2348088','Degree','Degree Unit of Plane Angle','false'
'college degree or higher','C0205250','Higher','High','false'
'cigarette smoking status','C1519386','Smoking Status','Smoking Status','false'
'waist circumference cm','C0455829','Waist Circumference','Waist Circumference','true'
'medications','C0013227','Medications','Pharmaceutical Preparations','true'
'medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications','C4284232','Medications','Medications','false'
'insulin','C0021641','INSULIN','Insulin','true'
'insulin','C1533581','INSULIN','Recombinant Insulin','false'
'insulin','C1579433','Insulin','Insulin [EPC]','false'
'insulin','C3714501','INSULIN','Insulin Drug Class','false'
'metformin','C0025598','METFORMIN','Metformin','true'
'any sulfonylurea','C0038766','Sulphonylurea','Sulfonylurea Compounds','true'
'any sulfonylurea','C3536898','Sulfonylurea','Sulfonylurea [EPC]','false'
'any thiazolidinedione','C0289779','Thiazolidinedione','2,4-thiazolidinedione','true'
'any thiazolidinedione','C1257987','Thiazolidinedione','Thiazolidinediones','true'
'any thiazolidinedione','C3537039','Thiazolidinedione','Thiazolidinedione [EPC]','false'
'any antihypertensive agent','C0003364','Antihypertensive Agent','Antihypertensive Agents','true'
'any thiazide diuretic','C0012802','Thiazide Diuretic','Thiazide Diuretics','true'
'any thiazide diuretic','C3536861','Thiazide Diuretic','Thiazide Diuretic [EPC]','false'
'glycated hemoglobin','C0017853','Glycated hemoglobin','Hemoglobin, Glycosylated','true'
'fasting serum glucose mg dl','C0202041','Serum Glucose','Glucose measurement, serum','false'
'fasting serum glucose mg dl','C0439269','mg dl','mg/dL','false'
'fasting serum glucose mg dl','C3534430','Serum glucose','Serum glucose','false'
'median triglyceride mg dl','C0041004','Triglyceride','Triglycerides','true'
'median triglyceride mg dl','C0439269','mg dl','mg/dL','false'
'potassium mg dl','C0032821','POTASSIUM','Potassium','true'
'potassium mg dl','C0439269','mg dl','mg/dL','false'
'potassium mg dl','C0202194','Potassium+','Potassium measurement','false'
'potassium mg dl','C0304475','POTASSIUM','Potassium supplement','false'
'potassium mg dl','C0597277','Potassium','Potassium Ion','false'
'potassium mg dl','C3714637','POTASSIUM','Potassium Drug Class','false'
'serum creatinine mg dl','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine mg dl','C0439269','mg dl','mg/dL','false'
'serum creatinine mg dl','C0600061','serum creatinine','Serum creatinine level','false'
'oxypurinol n $nmbr$','C0030086','OXYPURINOL','Oxypurinol','true'
'age yrs mean sd','C0001779','AGE','Age','false'
'age yrs mean sd','C2699239','SD','SD, Rat Strain','false'
'male gender','C0086582','Male Gender','Males','true'
'male gender','C1706180','Male Gender','Male Gender, Self Report','false'
'nyha functional class iii','C1882086','NYHA CLASS III','New York Heart Association Class III','false'
'nyha functional class iii','C0205245','Functional','Functional','false'
'nyha functional class iii','C0542341','Functional','Function (attribute)','false'
'nyha functional class iii','C2700217','Functional','Functional Relationship','false'
'lvef mean sd','C0428772','LVEF','Left ventricular ejection fraction','false'
'lvef mean sd','C2699239','SD','SD, Rat Strain','false'
'lvef mean sd','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'medication use','C0240320','MEDICATION USE','medication use','false'
'arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'carvedilol','C0054836','CARVEDILOL','carvedilol','true'
'spironolactone','C0037982','SPIRONOLACTONE','Spironolactone','true'
'nitrates','C0028125','Nitrates','Nitrates','true'
'etiology','C0015127','etiology','Etiology aspects','true'
'etiology','C1314792','Etiology','Etiology','true'
'etiology','C1524003','Etiology','Science of Etiology','false'
'idiopathic','C0332240','Idiopathic','Unknown (origin) (qualifier value)','false'
'hypertensive','C0857121','hypertensive','Hypertensive (finding)','false'
'entry criteria','C1705654','Entry','Entry (data)','false'
'entry criteria','C0243161','Criteria','criteria','true'
'hospitalized','C0701159','HOSPITALIZED','Patient in hospital','false'
'er visit','C0545082','Visit','Visit','false'
'er visit','C1512346','visit','Patient Visit','false'
'er visit','C2826704','VISIT','Visit Name','false'
'new hf medication','C0013227','Medication','Pharmaceutical Preparations','true'
'new hf medication','C3244316','medication','medication - HL7 publishing domain','false'
'new hf medication','C4284232','Medication','Medications','false'
'on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl','C0013227','Medications','Pharmaceutical Preparations','true'
'on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl','C0439269','mg dl','mg/dL','false'
'on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'on maximum tolerated medications median $nmbr$ th to $nmbr$ th quartile sua mg dl','C4284232','Medications','Medications','false'
'mean $nmbr$ th to $nmbr$ thquartile bnp pg ml','C0039725','TH','Thailand','true'
'mean $nmbr$ th to $nmbr$ thquartile bnp pg ml','C0039738','Th','Thallium','true'
'mean $nmbr$ th to $nmbr$ thquartile bnp pg ml','C1420718','TH','TH gene','false'
'mean $nmbr$ th to $nmbr$ thquartile bnp pg ml','C4282123','TH','TH','false'
'mean $nmbr$ th to $nmbr$ thquartile bnp pg ml','C4285344','TH','Tyrosine 3-Monooxygenase, human','false'
'sildenafil n $nmbr$','C0529793','SILDENAFIL','sildenafil','true'
'mean sd age y mean bmi category','C0683312','Category','Categories','false'
'mean sd age y mean bmi category','C3889287','Category','Digital Content Category','false'
'missing ed duration y','C1551393','Missing','Container status - Missing','false'
'missing ed duration y','C0449238','Duration','Duration (temporal concept)','false'
'missing ed duration y','C2926735','Duration','Duration','false'
'missing ed duration y','C1705492','Missing','Missing','false'
'missing ed duration y','C3272743','MISSING','Missing Study Animal','false'
'range ed etiology n','C0015127','etiology','Etiology aspects','true'
'range ed etiology n','C1314792','Etiology','Etiology','true'
'range ed etiology n','C1524003','Etiology','Science of Etiology','false'
'mixed','C0205430','MIXED','Mixed (qualifier value)','false'
'mixed','C3160715','Mixed','Mixed Cell Morphology','false'
'organic','C0747055','Organic','organic','false'
'psychogenic','C0458006','Psychogenic','Psychogenic','false'
'mean iief ef score mean iief domain score by bmi','C3533236','Mean score','Mean score','false'
'mean iief ef score mean iief domain score by bmi','C0578022','BMI','Finding of body mass index','false'
'ef domain','C1880389','Domain','Domain (area of knowledge)','false'
'ef domain','C1883221','Domain','Superkingdom (taxonomic category)','false'
'ef domain','C3541951','Domain','Concept model domain','false'
'os domain','C1880389','Domain','Domain (area of knowledge)','false'
'os domain','C1883221','Domain','Superkingdom (taxonomic category)','false'
'os domain','C3541951','Domain','Concept model domain','false'
'is domain luts severity','C0439793','Severity','Severities','false'
'is domain luts severity','C0522510','Severity','With intensity','false'
'moderate','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate','C1881878','Moderate','Moderation','false'
'moderate','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate','C4085643','Moderate','Moderate Response','false'
'moderate','C4321335','Moderate','Moderate Level','false'
'severe','C0205082','Severe','Severe (severity modifier)','false'
'severe','C4050465','Severe','Severe Extremity Pain','false'
'severe','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'mean total ipss mean ipss by bmi','C0439175','% total','% of total','false'
'mean total ipss mean ipss by bmi','C0439810','Total','Total','false'
'storage subscore','C0337174','Storage','Storage area','false'
'storage subscore','C1698986','Storage','Storage','false'
'storage subscore','C1753314','storage','cellular entity storage','false'
'voiding subscore','C0042034','Voiding','Urination','true'
'voiding subscore','C4067975','Voiding','Voids','false'
'mean qmax score by bmi','C3533236','Mean score','Mean score','false'
'mean qmax score by bmi','C0578022','BMI','Finding of body mass index','false'
'sd standard deviation bmi body mass index ed erectile','C1305855','BMI - Body mass index','Body mass index','true'
'sd standard deviation bmi body mass index ed erectile','C3538926','ED','Endocrine System Findings Domain','false'
'sd standard deviation bmi body mass index ed erectile','C0030847','Erectile','Penile Erection','true'
'dysfunction ef erectile function iief i','C0021966','I-','Iodides','true'
'dysfunction ef erectile function iief i','C0221138','I NOS','Blood group antibody I','false'
'nternational index of','C0600653','Index','Indexes','true'
'nternational index of','C0918012','Index','Index','true'
'nternational index of','C1552854','index','Html Link Type - index','false'
'nternational index of','C1637833','% index','% index','false'
'nternational index of','C2986546','Index','Target Lesion Identification','false'
'erectile function ipss','C1019118','Ips','Ips <Invertebrate>','false'
'erectile function ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'erectile function ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'erectile function ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'international prostate symptom score','C1998280','International Prostate Symptom Score','International Prostate Symptom Score','false'
'luts lower urinary tract symptoms is','C0574785','LUTS - Lower urinary tract symptoms','Lower Urinary Tract Symptoms','true'
'intercourse satisfac','C0009253','Intercourse','Coitus','true'
'tion os overall satisfaction qmax maximal urinary flow rate','C4086680','Overall Satisfaction','Overall Satisfaction with Treatment Received for Prostate Cancer','false'
'tion os overall satisfaction qmax maximal urinary flow rate','C0429784','Maximal urinary flow rate','Maximal urinary flow rate','false'
'total n $nmbr$','C0439175','% total','% of total','false'
'total n $nmbr$','C0439810','Total','Total','false'
'famotidine $nmbr$ mg n $nmbr$','C0015620','FAMOTIDINE','Famotidine','true'
'famotidine $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'famotidine $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'famotidine $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'famotidine $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'famotidine $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'famotidine $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'famotidine $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'sex male female n','C0086287','Sex Female','Females','true'
'weight kg bmi kg m $nmbr$','C0005910','Weight','Body Weight','true'
'weight kg bmi kg m $nmbr$','C1319635','kg/kg','mg/mg','false'
'weight kg bmi kg m $nmbr$','C0043100','Weight','Weight','true'
'weight kg bmi kg m $nmbr$','C1305866','weight','Weighing patient','false'
'weight kg bmi kg m $nmbr$','C1705104','Weight','Importance Weight','false'
'smoking status ongoing n','C1519386','Smoking Status','Smoking Status','false'
'smoking status ongoing n','C0549178','ONGOING','Continuous','false'
'smoking status previous n','C1519386','Smoking Status','Smoking Status','false'
'smoking status previous n','C0205156','Previous','Previous','false'
'smoking status previous n','C1552607','previous','Act Relationship Subset - previous','false'
'alcohol consumption yes n','C0001948','ALCOHOL CONSUMPTION','Alcohol consumption','true'
'alcohol consumption yes n','C1549445','Yes','Yes - Yes/no indicator','false'
'alcohol consumption yes n','C1705108','YES','Yes (indicator)','false'
'alcohol consumption yes n','C1710701','Yes','YES1 wt Allele','false'
'caffeine consumption yes n','C0948365','caffeine consumption','caffeine consumption','false'
'caffeine consumption yes n','C1549445','Yes','Yes - Yes/no indicator','false'
'caffeine consumption yes n','C1705108','YES','Yes (indicator)','false'
'caffeine consumption yes n','C1710701','Yes','YES1 wt Allele','false'
'hiatal hernia yes n','C3489393','HIATAL HERNIA','Hiatal Hernia','true'
'hiatal hernia yes n','C1549445','Yes','Yes - Yes/no indicator','false'
'hiatal hernia yes n','C1705108','YES','Yes (indicator)','false'
'hiatal hernia yes n','C1710701','Yes','YES1 wt Allele','false'
'helicobacter pylori infection n','C0850666','Helicobacter Pylori Infection','Infection caused by Helicobacter pylori','false'
'pepsinogen i ii ratio','C0456603','RATIO','Ratio','false'
'pepsinogen i ii ratio','C1547037','Ratio','data type - ratio','false'
'days with heartburna days','C0439228','DAYS','day','false'
'severity of heartburnb','C0439793','Severity','Severities','false'
'severity of heartburnb','C0522510','Severity','With intensity','false'
'$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0008107','CI','Chile','true'
'$nmbr$ $nmbr$ $nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C3259781','CI','Coagulation Index Measurement','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0205307','NORMAL','Normal','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0231683','Normal','Gait normal','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439166','% normal','Percent normal','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'normal or increased baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'mildlydecreased baseline gfr $nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'pravastatin','C0085542','PRAVASTATIN','Pravastatin','true'
'usual care','C3538928','Usual','Usual','false'
'usual care','C1947933','Care','care activity','false'
'patients randomly assigned','C0030705','Patients','Patients','true'
'patients randomly assigned','C1516050','Assigned','Assignment - action','false'
'patients randomly assigned','C1552601','assigned','PersonNameUse - assigned','false'
'age at lipid randomization y','C0001779','AGE','Age','false'
'age at lipid randomization y','C0065033','lipid Y','lipid Y','true'
'body mass index kg m $nmbr$ baseline systolic blood','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m $nmbr$ baseline systolic blood','C0439209','kg','Kilogram','false'
'body mass index kg m $nmbr$ baseline systolic blood','C4054209','/kg','Per Kilogram','false'
'body mass index kg m $nmbr$ baseline systolic blood','C0005767','Blood','Blood','true'
'body mass index kg m $nmbr$ baseline systolic blood','C0005768','BLOOD','In Blood','true'
'body mass index kg m $nmbr$ baseline systolic blood','C0229664','BLOOD','peripheral blood','false'
'pressure mm hg','C0033095','Pressure','Pressure- physical agent','true'
'pressure mm hg','C0439475','mmHG','mmHg','false'
'pressure mm hg','C0460139','Pressure','Pressure (finding)','false'
'pressure mm hg','C1306345','Pressure','Pressure - action','false'
'pressure mm hg','C4284008','Pressure','Pressure (property)','false'
'baseline diastolic blood','C0005767','Blood','Blood','true'
'baseline diastolic blood','C0005768','BLOOD','In Blood','true'
'baseline diastolic blood','C0229664','BLOOD','peripheral blood','false'
'history of coronary heart disease at','C0683519','History of disease','disease history','false'
'history of coronary heart disease at','C0730226','History of Disease','H/O: Disorder','false'
'history of coronary heart disease at','C0850708','History of disease','History of disease','false'
'history of coronary heart disease at','C0944983','History of Disease','History of symptoms & diseases:Finding:Point in time:^Patient:Nominal:Observed','false'
'history of mi or stroke history of coronary','C0019664','History','History','true'
'history of mi or stroke history of coronary','C0019665','history','Historical aspects qualifier','true'
'history of mi or stroke history of coronary','C0262512','History, NOS','History of present illness','false'
'history of mi or stroke history of coronary','C0262926','History','Medical History','false'
'history of mi or stroke history of coronary','C1705255','History','Concept History','false'
'history of mi or stroke history of coronary','C2004062','History','History of previous events','false'
'other atherosclerotic cvd st depression on','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'other atherosclerotic cvd st depression on','C0520887','ST DEPRESSION','ST segment depression (finding)','false'
'electrocardiogram','C0013798','Electrocardiogram','Electrocardiogram','true'
'electrocardiogram','C1547122','Electro-Cardiogram','Electro-Cardiogram','false'
'electrocardiogram','C1623258','Electrocardiogram','Electrocardiography','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile','C0439445','mL/min','mL/min','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile','C1424601','GFR','RAPGEF5 gene','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile','C1979963','Profile','Profile (lab procedure)','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ lipid baseline lipid profile','C2003903','Profile','Profiling (action)','false'
'ldl cholesterol','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'fasting triglycerides','C0015663','FASTING','Fasting','true'
'fasting triglycerides','C0041004','TRIGLYCERIDES','Triglycerides','true'
'randomly assigned to ace','C1516050','Assigned','Assignment - action','false'
'randomly assigned to ace','C1552601','assigned','PersonNameUse - assigned','false'
'inhibitor','C1999216','Inhibitor','Inhibitor','false'
'randomly assigned to calcium channel blocker','C1516050','Assigned','Assignment - action','false'
'randomly assigned to calcium channel blocker','C1552601','assigned','PersonNameUse - assigned','false'
'randomly assigned to diuretic','C1516050','Assigned','Assignment - action','false'
'randomly assigned to diuretic','C1552601','assigned','PersonNameUse - assigned','false'
'esrd or $nmbr$ dedine in gfr','C0022661','ESRD','Kidney Failure, Chronic','true'
'esrd or $nmbr$ dedine in gfr','C0035078','ESRD','Kidney Failure','true'
'esrd or $nmbr$ dedine in gfr','C2316810','ESRD','Chronic kidney disease stage 5','false'
'esrd or $nmbr$ dedine in gfr','C0017654','GFR','Glomerular Filtration Rate','true'
'esrd or $nmbr$ dedine in gfr','C1424601','GFR','RAPGEF5 gene','false'
'esrd or $nmbr$ decline in gfr','C0022661','ESRD','Kidney Failure, Chronic','true'
'esrd or $nmbr$ decline in gfr','C0035078','ESRD','Kidney Failure','true'
'esrd or $nmbr$ decline in gfr','C2316810','ESRD','Chronic kidney disease stage 5','false'
'esrd or $nmbr$ decline in gfr','C0017654','GFR','Glomerular Filtration Rate','true'
'esrd or $nmbr$ decline in gfr','C1424601','GFR','RAPGEF5 gene','false'
'gfr $nmbr$ $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'gfr $nmbr$ $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'gfr','C0017654','GFR','Glomerular Filtration Rate','true'
'gfr','C1424601','GFR','RAPGEF5 gene','false'
'parameter mean s d','C0549193','Parameter','Parameter Value','false'
'parameter mean s d','C0444504','Mean','Statistical mean','false'
'parameter mean s d','C2347634','Mean','Population Mean','false'
'parameter mean s d','C2348143','Mean','Sample Mean','false'
'parameter mean s d','C1704769','Parameter','Programming Parameter','false'
'parameter mean s d','C2350001','Parameter','Population Parameter','false'
'total study itt population n $nmbr$','C3258257','Total population','Total population','false'
'asian itt population total n $nmbr$','C0078988','ASIAN','Asians','true'
'asian itt population total n $nmbr$','C0032659','Population','geographic population','true'
'asian itt population total n $nmbr$','C1257890','Population','Population Group','true'
'asian itt population by treatment group','C1257890','Population Group','Population Group','true'
'combination n $nmbr$','C0205195','Combination','Combined','false'
'combination n $nmbr$','C1947911','Combination','combination of objects','false'
'combination n $nmbr$','C3811910','Combination','combination - answer to question','false'
'dutasteride n $nmbr$','C0754659','DUTASTERIDE','Dutasteride','true'
'tamsulosin n $nmbr$','C0257343','TAMSULOSIN','tamsulosin','true'
'time since first luts years','C0556970','time year','times/year','false'
'time since first luts years','C0205435','First','First (number)','false'
'time since first luts years','C1279901','First','Firstly','false'
'prostate volume cm $nmbr$','C1441416','Prostate volume','Prostate volume','false'
'mean s d','C0444504','Mean','Statistical mean','false'
'mean s d','C2347634','Mean','Population Mean','false'
'mean s d','C2348143','Mean','Sample Mean','false'
'mean total serum psa','C2986589','Total PSA','Total PSA','false'
'mean total serum psa','C0229671','SERUM','Serum','true'
'mean total serum psa','C1546774','Serum','Specimen Source Codes - Serum','false'
'mean total serum psa','C1550100','Serum','Specimen Type - Serum','false'
'ngml total mean ipss score','C2964552','Total Score','Total score','false'
'qmax ml s','C0439526','/mL','/mL','false'
'qmax ml s','C1705224','ML','THPO wt Allele','false'
'qmax ml s','C3887665','ML','Thrombopoietin, human','false'
'bii score','C0449820','SCORE','Score','false'
'bii score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'bph related health status','C0005001','BPH','Benign prostatic hypertrophy','true'
'bph related health status','C0018759','Health Status','Health Status','true'
'bph related health status','C1704272','BPH','Benign Prostatic Hyperplasia','true'
'sexually active','C0241028','SEXUALLY ACTIVE','Sexually active','false'
'previous a blocker use','C0205156','Previous','Previous','false'
'previous a blocker use','C1552607','previous','Act Relationship Subset - previous','false'
'previous a blocker use','C0042153','use','utilization qualifier','true'
'previous a blocker use','C0457083','Use','Usage','false'
'previous a blocker use','C1947944','Use','Use - dosing instruction imperative','false'
'previous $nmbr$ ari use','C0042153','use','utilization qualifier','true'
'previous $nmbr$ ari use','C0457083','Use','Usage','false'
'previous $nmbr$ ari use','C1947944','Use','Use - dosing instruction imperative','false'
'chondroitin','C0008454','CHONDROITIN','Chondroitin','true'
'g c','C0439267','g%','Gram per Deciliter','false'
'structural','C0678594','Structural','structure','false'
'gait','C0016928','Gait','Gait','true'
'subjects n','C0681850','Subject','Study Subject','false'
'subjects n','C1550501','{Subject}','Subject -direct target','false'
'subjects n','C1706203','Subject','Subject - topic','false'
'subjects n','C2349001','Subject','Human Study Subject','false'
'subjects n','C2697811','Subject','Investigative Subject','false'
'age in years mean sd','C1510829','Age, in Years','Age-Years','false'
'age in years mean sd','C0444504','Mean','Statistical mean','false'
'age in years mean sd','C2347634','Mean','Population Mean','false'
'age in years mean sd','C2348143','Mean','Sample Mean','false'
'haq pain scale mean','C0444504','Mean','Statistical mean','false'
'haq pain scale mean','C2347634','Mean','Population Mean','false'
'haq pain scale mean','C2348143','Mean','Sample Mean','false'
'years duration oa','C0029408','OA','Degenerative polyarthritis','true'
'years duration oa','C3887876','OA','OSTEOARTHRITIS SUSCEPTIBILITY 1','false'
'symptoms mean sd','C0444504','Mean','Statistical mean','false'
'symptoms mean sd','C2699239','SD','SD, Rat Strain','false'
'symptoms mean sd','C2347634','Mean','Population Mean','false'
'symptoms mean sd','C2348143','Mean','Sample Mean','false'
'percentages','C0439165','Percentage','Percent (qualifier value)','false'
'percentages','C1549488','Percentage','Amount type - Percentage','false'
'percentages','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'bmi $nmbr$ $nmbr$ overweight','C0578022','BMI','Finding of body mass index','false'
'bmi $nmbr$ $nmbr$ overweight','C0497406','OVERWEIGHT','Overweight','true'
'bmi $nmbr$ obese','C0578022','BMI','Finding of body mass index','false'
'bmi $nmbr$ obese','C0028754','OBESE','Obesity','true'
'knees n','C0022742','knees','Knee','true'
'kl $nmbr$','C1366480','KL','KITLG gene','false'
'kl $nmbr$','C1416656','KL','KL gene','false'
'kl $nmbr$','C1704887','KL','KITLG wt Allele','false'
'mean of jsw mm','C0444504','Mean','Statistical mean','false'
'mean of jsw mm','C2347634','Mean','Population Mean','false'
'mean of jsw mm','C2348143','Mean','Sample Mean','false'
'median of jsw','C0549183','Median','Midline (qualifier value)','false'
'median of jsw','C0876920','Median','Median Statistical Measurement','false'
'median of jsw','C2347635','Median','Population Median','false'
'median of jsw','C2348144','Median','Sample Median','false'
'median of jsw','C2939193','Median','Median (qualifier value)','false'
'interquartile range mm','C4330985','/mm','Per Millimeter','false'
'interquartile range mm','C4554674','MM','MM genotype','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C1518681','Treatment Effect','Outcome of Therapy','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C3875154','Relative to','Relative to','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C1517945','Loss','Loss','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C0205363','Stratified','Stratified','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C0224497','Joint space','Articular space','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C1547282','Show','Show','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C0681850','Subject','Study Subject','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C1550501','{Subject}','Subject -direct target','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C1706203','Subject','Subject - topic','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C2349001','Subject','Human Study Subject','false'
'figure $nmbr$ treatment effect relative to placebo for jsw loss stratified by kellgren and lawrence grade adjusted mean two year loss in joint space is shown for $nmbr$ subjects and $nmbr$ knees jsw joint space width','C2697811','Subject','Investigative Subject','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1522326','Treatment','Treating','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0032042','Placebo','Placebos','true'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0028873','Odds Ratio','Odds Ratio','true'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C1511726','Data','Data','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C3245479','data','Data call receiving device','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C3714741','Data','Data (eukaryote)','false'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0022742','knees','Knee','true'
'figure $nmbr$ treatment versus placebo odds ratio for jsw progression $nmbr$ $nmbr$ mm by kellgren and lawrence grade data from $nmbr$ subjects and $nmbr$ knees are shown here as a odds ratio of progression jsw joint space width','C0224497','Joint space','Articular space','false'
'colesevelam hydrochloride group n $nmbr$','C0541154','COLESEVELAM HYDROCHLORIDE','Colesevelam hydrochloride','true'
'colesevelam hydrochloride group n $nmbr$','C0441848','Group N','Group N','false'
'placebo group n $nmbr$','C0032042','Placebo','Placebos','true'
'placebo group n $nmbr$','C0441848','Group N','Group N','false'
'placebo group n $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo group n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'height cm mean sd','C0444504','Mean','Statistical mean','false'
'height cm mean sd','C2699239','SD','SD, Rat Strain','false'
'height cm mean sd','C2347634','Mean','Population Mean','false'
'height cm mean sd','C2348143','Mean','Sample Mean','false'
'weight kg mean sd','C0005910','Weight','Body Weight','true'
'weight kg mean sd','C2699239','SD','SD, Rat Strain','false'
'weight kg mean sd','C0043100','Weight','Weight','true'
'weight kg mean sd','C1305866','weight','Weighing patient','false'
'weight kg mean sd','C1705104','Weight','Importance Weight','false'
'hbalc mean sd','C0444504','Mean','Statistical mean','false'
'hbalc mean sd','C2699239','SD','SD, Rat Strain','false'
'hbalc mean sd','C2347634','Mean','Population Mean','false'
'hbalc mean sd','C2348143','Mean','Sample Mean','false'
'fasting plasma glucose mg dl mean sd','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fasting plasma glucose mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'fasting plasma glucose mg dl mean sd','C0455280','plasma glucose','Plasma glucose result','false'
'oral anti dm drug status no','C0442027','Oral','Oral','false'
'oral anti dm drug status no','C4521986','Oral','Oral (intended site)','false'
'metformin alone','C0025598','METFORMIN','Metformin','true'
'metformin alone','C0205171','Alone','Singular','false'
'metformin alone','C0439044','Alone','Living Alone','false'
'metformin alone','C0679994','alone','alone - group size','false'
'metformin other oral anti dm drugs','C0025598','METFORMIN','Metformin','true'
'metformin other oral anti dm drugs','C0029167','Oral Drugs','Oral Medicine','true'
'metformin other oral anti dm drugs','C0175795','oral Drugs','oral medication','false'
'metformin other oral anti dm drugs','C0304289','Oral Drugs','Oral drug preparation, NOS','false'
'concomitant medications in $nmbr$ of subjects no','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications in $nmbr$ of subjects no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications in $nmbr$ of subjects no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications in $nmbr$ of subjects no','C4284232','Medications','Medications','false'
'angiotensin ii antagonists','C0003009','Angiotensin 2','angiotensin II','true'
'angiotensin ii antagonists','C0243076','antagonists','antagonists','true'
'angiotensin ii antagonists','C1366631','ANGIOTENSIN II','AGT gene','false'
'angiotensin ii antagonists','C3714928','Angiotensin-2','Angiotensin-2, Human','false'
'p blocking agents selective','C0233660','Blocking','Mental blocking','false'
'p blocking agents selective','C0332206','Blocking','Blocking','false'
'hmg coa reductase inhibitors','C0360714','HMG-COA REDUCTASE INHIBITORS','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'hmg coa reductase inhibitors','C2756999','HMG-CoA Reductase Inhibitors','Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]','false'
'hmg coa reductase inhibitors','C3539119','HMG CoA reductase inhibitors','HMG CoA reductase inhibitors, plain lipid modifying drugs','false'
'multivitamins','C0301532','MULTIVITAMINS','Multivitamin preparation','false'
'multivitamins','C3714835','MULTIVITAMINS','Multivitamin Drug Class','false'
'other plain vitamin preparations','C0042890','VITAMIN PREPARATIONS','Vitamins','true'
'platelet aggregation inhibitors excluding heparin','C0032177','PLATELET AGGREGATION INHIBITORS','Platelet Aggregation Inhibitors','true'
'platelet aggregation inhibitors excluding heparin','C0019134','HEPARIN','heparin','true'
'platelet aggregation inhibitors excluding heparin','C0770546','HEPARIN','heparin, porcine','false'
'propionic acid derivatives','C0033482','Propionic Acid Derivatives','Propionic Acids','true'
'propionic acid derivatives','C0695274','Propionic acid derivatives','Poisoning by propionic acid derivatives','false'
'propionic acid derivatives','C3540752','Propionic acid derivatives','Propionic acid derivatives, antiinflammatory and antirheumatic products','false'
'proton pump inhibitors','C0358591','Inhibitors, Proton Pump','Proton Pump Inhibitors','true'
'proton pump inhibitors','C1384478','Proton Pump Inhibitors','Proton Pump Inhibitors [MoA]','false'
'proton pump inhibitors','C3540020','Proton pump inhibitors','Proton pump inhibitors for peptic ulcer and GORD','false'
'thiazides','C0541746','Thiazides','Thiazides','true'
'thyroid hormone','C0040135','Thyroid Hormone','Thyroid Hormones','true'
'thyroid hormone','C4522017','Thyroid hormone','Thyroid hormone (disposition)','false'
'concomitant oral anti dm drugs no a','C0029167','Oral Drugs','Oral Medicine','true'
'concomitant oral anti dm drugs no a','C0175795','oral Drugs','oral medication','false'
'concomitant oral anti dm drugs no a','C0304289','Oral Drugs','Oral drug preparation, NOS','false'
'a glucosidase inhibitors $nmbr$','C1512211','Glucosidase Inhibitor','Glucosidase Inhibitor','false'
'nateglinide and repaglinide','C0903898','NATEGLINIDE','nateglinide','true'
'nateglinide and repaglinide','C0246689','REPAGLINIDE','repaglinide','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0022709','ACE - Angiotensin-converting enzyme','Peptidyl-Dipeptidase A','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1305855','BMI - Body mass index','Body mass index','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0444686','Calculated','Calculated','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1441506','Calculated','Calculation','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0439209','kilograms','Kilogram','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0332849','Divided','Divide','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0489786','Height','Height','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0681850','Subject','Study Subject','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1550501','{Subject}','Subject -direct target','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1706203','Subject','Subject - topic','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C2349001','Subject','Human Study Subject','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C2697811','Subject','Investigative Subject','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1515187','Take','Take','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0442027','Oral','Oral','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C4521986','Oral','Oral (intended site)','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0013227','Drug','Pharmaceutical Preparations','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1254351','DRUG','Pharmacologic Substance','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C4288115','Total Number','Total Number','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C3687832','Drugs','Drugs - dental services','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0042295','Values','Values','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0541154','COLESEVELAM HYDROCHLORIDE','Colesevelam hydrochloride','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0032042','Placebo','Placebos','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0441833','Group','Groups','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0687744','group','Social group','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1257890','Group','Population Group','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1519504','Group','Stage Grouping','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1705428','Group','Group Object','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1705429','Group','User Group','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1696465','PLACEBO','placebo','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1706408','PLACEBO','Placebo Control','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0332257','include','Including (qualifier)','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1552866','include','include - SetOperator','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C2700399','Include','Include (action)','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0008287','Clorpropamid','Chlorpropamide','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0017642','GLIPIZIDE','Glipizide','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0040372','TOLAZAMIDE','Tolazamide','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0872972','PIOGLITAZONE HYDROCHLORIDE','Pioglitazone hydrochloride','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0289313','ROSIGLITAZONE','rosiglitazone','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0795660','ROSIGLITAZONE MALEATE','Rosiglitazone maleate','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C1512211','Glucosidase Inhibitor','Glucosidase Inhibitor','false'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0050393','ACARBOSE','Acarbose','true'
'abbreviations ace angiotensin converting enzyme bmi body mass index calculated as weight in kilograms divided by height in meters squared dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg coa $nmbr$ hydroxy $nmbr$ methylglutaryl coenzyme a asome subjects took more than $nmbr$ oral anti dm drug in addition to metformin and thus the total number of concomitant oral anti dm drugs in the columns exceed the n values in the colesevelam hydrochloride and placebo group headings bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate d glucosidase inhibitors include acarbose or miglitol','C0066535','MIGLITOL','miglitol','true'
'rolofylline dose','C0178602','DOSE','Dosage','false'
'rolofylline dose','C0869039','Dose','Unit dose','false'
'rolofylline dose','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'$nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'male n n','C0086582','MALE','Males','true'
'male n n','C1706180','Male','Male Gender, Self Report','false'
'male n n','C1706428','MALE','Male Phenotype','false'
'male n n','C1706429','Male','Male, Self-Reported','false'
'ischemic heart disease','C0010054','ischaemic heart disease','Coronary Arteriosclerosis','true'
'ischemic heart disease','C0151744','Ischaemic heart disease, NOS','Myocardial Ischemia','true'
'atrial fibrillation atrial flutter','C0155709','Atrial fibrillation/flutter','Atrial fibrillation and flutter','false'
'nyha class when patient was last in stable condition before admission','C1882083','NYHA Class','New York Heart Association Class','false'
'nyha class when patient was last in stable condition before admission','C0030705','*^patient','Patients','true'
'nyha class when patient was last in stable condition before admission','C0677946','Stable condition','Stable Disease','false'
'nyha class when patient was last in stable condition before admission','C3538874','Stable condition','Stable chronic Graft vs Host Disease','false'
'nyha class when patient was last in stable condition before admission','C0184666','Admission','Hospital admission','false'
'nyha class when patient was last in stable condition before admission','C0809949','Admission','Admission activity','false'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C0054015','BNP','Nesiritide','true'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C0439297','pg/mL','Nanogram per Liter','false'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C1095989','BNP','Brain natriuretic peptide measurement','false'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C1417808','BNP','NPPB gene','false'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C2982014','BNP','NPPB wt Allele','false'
'bnp o $nmbr$ pg ml or nt pro bnp o $nmbr$ pg ml n','C4284038','NT/N','NTS wt Allele','false'
'creatinine clearance by c g ml min','C0151280','Creatinine clearance, ml/min','Creatinine clearance, ml/min','false'
'medications on admission','C0013227','Medications','Pharmaceutical Preparations','true'
'medications on admission','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications on admission','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications on admission','C4284232','Medications','Medications','false'
'medications on admission','C0457453','On admission','On admission','false'
'aldosterone inhibitor','C0002007','aldosterone inhibitor','Aldosterone Antagonists','true'
'iv nitrates','C0022326','IV','Ivory Coast','true'
'iv nitrates','C0028125','Nitrates','Nitrates','true'
'iv nitrates','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'rank based on treatment placebo','C0032042','Placebo','Placebos','true'
'rank based on treatment placebo','C1696465','PLACEBO','placebo','false'
'rank based on treatment placebo','C1706408','PLACEBO','Placebo Control','false'
'baseline variable','C0439828','Variable','Variable (uniformity)','false'
'baseline variable','C4553760','Variable','Study Variable','false'
'treatment lipid interaction','C0023779','Lipid','Lipids','true'
'treatment lipid interaction','C1704675','Interaction','Interaction','false'
'unadjusted hr $nmbr$ ci for $nmbr$ sd increment','C0008107','CI','Chile','true'
'unadjusted hr $nmbr$ ci for $nmbr$ sd increment','C3259781','CI','Coagulation Index Measurement','false'
'likelihood test','C0022885','Test','Laboratory Procedures','false'
'likelihood test','C0039593','Test','Testing','false'
'likelihood test','C0392366','test','Tests (qualifier value)','false'
'likelihood test','C0456984','Test','Test Result','false'
'likelihood test','C1515976','test','Anatomic Structure, System, or Substance','false'
'likelihood test','C3831328','Test','Blood Products Laboratory Testing','false'
'likelihood test','C4318744','Test','Test - temporal region','false'
'unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment','C0008107','CI','Chile','true'
'unadjusted hr $nmbr$ ci for $nmbr$ standard deviation increment','C3259781','CI','Coagulation Index Measurement','false'
'apob apoa i','C0085201','ApoA-I','Apolipoprotein A-I','true'
'apob apoa i','C1677784','ApoA-I','APOA1 protein, human','true'
'ldlc hdlc','C1416822','LDLC','COG2 gene','false'
'ldlc hdlc','C1704429','HDLC','Hypoalphalipoproteinemia, Familial','true'
'ldlc','C1416822','LDLC','COG2 gene','false'
'apob','C0003593','Apo B','Apolipoproteins B','true'
'apob','C3252643','APOB','APOB protein, human','true'
'apoa i','C0085201','ApoA-I','Apolipoprotein A-I','true'
'apoa i','C1677784','ApoA-I','APOA1 protein, human','true'
'non hdlc','C1518422','Non','Negation','false'
'non hdlc','C1704429','HDLC','Hypoalphalipoproteinemia, Familial','true'
'tc hdlc','C0039411','TC','Technetium','true'
'tc hdlc','C1704429','HDLC','Hypoalphalipoproteinemia, Familial','true'
'tc hdlc','C0040642','TC','Transcobalamin','true'
'tc hdlc','C0041405','TC','Turks and Caicos Islands','true'
'tc hdlc','C0041698','TC','United Arab Emirates','true'
'tc hdlc','C1824670','TC','CD55 gene','false'
'tc hdlc','C3272447','TC','CD55 wt Allele','false'
'tc hdlc','C4522122','TC','TC Regimen','false'
'cholesterol','C0008377','CHOLESTEROL','Cholesterol','true'
'febuxostat $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'febuxostat $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'febuxostat $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'febuxostat $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'febuxostat $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'febuxostat $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'febuxostat $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'allopurinol $nmbr$ mg n $nmbr$','C0002144','ALLOPURINOL','Allopurinol','true'
'allopurinol $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'allopurinol $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'allopurinol $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'allopurinol $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'allopurinol $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'allopurinol $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'allopurinol $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age mean sd years','C1510829','Age-Years','Age-Years','false'
'age mean sd years','C0444504','Mean','Statistical mean','false'
'age mean sd years','C2347634','Mean','Population Mean','false'
'age mean sd years','C2348143','Mean','Sample Mean','false'
'minority','C0026192','Minority','Minority Groups','true'
'bmi mean sd kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi mean sd kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi mean sd kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'cardiovascular disease','C0007222','Cardiovascular Disease','Cardiovascular Diseases','true'
'gout history mean sd years','C0018099','GOUT','Gout','true'
'gout history mean sd years','C0439234','YEARS','year','false'
'history presence of tophi','C0150312','Presence','Present','false'
'history presence of tophi','C0392148','Presence','Providing presence (regime/therapy)','false'
'history presence of tophi','C3854307','Presence','Presence (property)','false'
'recent use of allopurinol within $nmbr$ days of','C1524063','Use of','Use of','false'
'recent use of allopurinol within $nmbr$ days of','C0002144','ALLOPURINOL','Allopurinol','true'
'recent use of allopurinol within $nmbr$ days of','C0439228','DAYS','day','false'
'randomization','C0034656','Randomization','Randomization','true'
'low dose aspirin use','C0042153','use','utilization qualifier','true'
'low dose aspirin use','C0457083','Use','Usage','false'
'low dose aspirin use','C1947944','Use','Use - dosing instruction imperative','false'
'mild to moderate renal impairment','C1299392','Mild to moderate','Mild to moderate','false'
'mild to moderate renal impairment','C1565489','Renal Impairment','Renal Insufficiency','true'
'chlorthalidone vs amlodipine','C0008294','Chlortalidone','Chlorthalidone','true'
'chlorthalidone vs amlodipine','C0051696','AMLODIPINE','Amlodipine','true'
'chlorthalidone vs lisinopril','C0008294','Chlortalidone','Chlorthalidone','true'
'chlorthalidone vs lisinopril','C0065374','Lysinopril','Lisinopril','true'
'chlorthalidone vs doxazosin','C0008294','Chlortalidone','Chlorthalidone','true'
'chlorthalidone vs doxazosin','C0114873','DOXAZOSIN','Doxazosin','true'
'hr $nmbr$ ci univariate cox proportional hazard regression','C0684320','Regression','Disease regression','false'
'hr $nmbr$ ci univariate cox proportional hazard regression','C0684321','REGRESSION','Regression - mental defense mechanism','true'
'hr $nmbr$ ci univariate cox proportional hazard regression','C1836830','Regression','Developmental regression','false'
'pef','C0030771','PEF','Pefloxacin','true'
'pef','C1518922','PEF','peak expiratory flow (procedure)','false'
'pef','C1542834','PEF','Peak expiratory flow rate','false'
'ref','C1425988','REF','ALYREF gene','false'
'no ef data','C1511726','Data','Data','false'
'no ef data','C3245479','data','Data call receiving device','false'
'no ef data','C3714741','Data','Data (eukaryote)','false'
'hr $nmbr$ ci multivariate cox proportional hazard regression','C0684320','Regression','Disease regression','false'
'hr $nmbr$ ci multivariate cox proportional hazard regression','C0684321','REGRESSION','Regression - mental defense mechanism','true'
'hr $nmbr$ ci multivariate cox proportional hazard regression','C1836830','Regression','Developmental regression','false'
'hospitalized hf','C0018488','Hf','Hafnium','true'
'hospitalized hf','C1313497','HF','GZMA protein, human','true'
'hospitalized hf','C1538440','HF','CFH gene','false'
'hospitalized hf','C3273279','HF','CFH wt Allele','false'
'atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'atorvastatin $nmbr$ mg ezetimibe $nmbr$ mg n $nmbr$','C3643658','ATORVASTATIN/EZETIMIBE','atorvastatin / ezetimibe','false'
'atorvastatin $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'atorvastatin $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'atorvastatin $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'atorvastatin $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'atorvastatin $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'atorvastatin $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'atorvastatin $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'mean age yrs','C0444504','Mean','Statistical mean','false'
'mean age yrs','C0001779','AGE','Age','false'
'mean age yrs','C2347634','Mean','Population Mean','false'
'mean age yrs','C2348143','Mean','Sample Mean','false'
'mean body mass index kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean body mass index kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean body mass index kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'ncep atp iii risk factors','C0035648','Risk Factors','risk factors','true'
'ncep atp iii risk factors','C1553898','risk factors','risk factors - observation list','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0439269','mg dl','mg/dL','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0205195','Combined','Combined','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0441833','Group','Groups','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0687744','group','Social group','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C1257890','Group','Population Group','true'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C1519504','Group','Stage Grouping','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C1705428','Group','Group Object','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C1705429','Group','User Group','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C2360800','Number of patients','Number of patients','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0332257','included','Including (qualifier)','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C1442160','Cutoff','Cutoff','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0025266','Men','Male population group','true'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0043210','Women','Woman','true'
'the $nmbr$ substrata with baseline bl ldl cholesterol $nmbr$ to $nmbr$ mg dl and $nmbr$ to $nmbr$ mg dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg dl bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg dl for men and $nmbr$ or $nmbr$ mg dl for women bars indicate se bmi body mass index e ezetimibe $nmbr$ mg hdl c hdl cholesterol ldl c ldl cholesterol tg triglycerides','C0062152','hdl triglycerides','HDL-triglyceride','true'
'other forms of atherosclerosis^','C0348078','forms','Qualitative form','false'
'other forms of atherosclerosis^','C0376315','Forms','Manufactured form','true'
'multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$','C0035648','Risk Factors','risk factors','true'
'multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$','C1282512','chd risk','At risk of coronary heart disease','false'
'multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$','C1553898','risk factors','risk factors - observation list','false'
'multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$','C0439234','Year','year','false'
'multiple $nmbr$ chd risk factors that confer a $nmbr$ year risk of chd $nmbr$','C0439508','/Year','per year','false'
'family history of premature chdj','C0241889','FAMILY HISTORY','Family history','true'
'family history of premature chdj','C0151526','Premature','Premature Birth','true'
'family history of premature chdj','C0205252','Premature','Immature','false'
'family history of premature chdj','C4018905','Premature','Too early','false'
'metabolic syndrome $nmbr$ of $nmbr$ characteristics','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'metabolic syndrome $nmbr$ of $nmbr$ characteristics','C1521970','Characteristics','Characteristics','false'
'waist circumference s $nmbr$ men or $nmbr$ cm women','C0455829','Waist Circumference','Waist Circumference','true'
'waist circumference s $nmbr$ men or $nmbr$ cm women','C0025266','Men','Male population group','true'
'waist circumference s $nmbr$ men or $nmbr$ cm women','C0043210','Women','Woman','true'
'triglycerides $nmbr$ mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'triglycerides $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'fasting blood glucose $nmbr$ mg dl','C0428568','Fasting blood glucose','Fasting blood glucose measurement','false'
'fasting blood glucose $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'fasting blood glucose $nmbr$ mg dl','C1261430','fasting blood glucose','Fasting blood sugar result','false'
'visit $nmbr$ ldl cholesterol strata','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'visit $nmbr$ ldl cholesterol strata','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0042295','Values','Values','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0444504','Mean','Statistical mean','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C2347634','Mean','Population Mean','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C2348143','Mean','Sample Mean','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0205448','Two','Two','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0030705','Patients','Patients','true'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1881192','Index Value','Index Value','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0348078','forms','Qualitative form','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0376315','Forms','Manufactured form','true'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0277793','Attack','Onset of illness','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1261512','attack','Attack behavior','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1304680','Attack','Observation of attack','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0260518','Family history of stroke','Encounter due to family history of stroke','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1261367','Family history of stroke','Family history of stroke','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0439475','mmHG','mmHg','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C0011900','DIAGNOSIS','Diagnosis','true'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1704338','diagnosis','diagnosis aspect','true'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1704656','DIAGNOSIS','Diagnosis Study','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1527178','Based','Basis - conceptual entity','false'
'values expressed as mean sd or number percent two patients were missing values for body mass index other forms of atherosclerosis are peripheral arterial disease abdom inal aortic aneurysm symptomatic carotid artery disease transient isch emic attack and stroke family history of premature chd de ned as chd in male rst degree relative aged $nmbr$ years or female rst degree relative $nmbr$ years blood pressure $nmbr$ $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel','C1705938','Based','Base - General Qualifier','false'
'benazepril amlodipine group n $nmbr$','C0051696','AMLODIPINE','Amlodipine','true'
'benazepril amlodipine group n $nmbr$','C0441848','Group N','Group N','false'
'benazepril hydrochlorothiazide group n $nmbr$','C0717481','BENAZEPRIL/HYDROCHLOROTHIAZIDE','benazepril / Hydrochlorothiazide','false'
'benazepril hydrochlorothiazide group n $nmbr$','C0441848','Group N','Group N','false'
'$nmbr$ yr no','C0439234','yr','year','false'
'race or ethnic group no f','C0034510','RACE','Racial group','true'
'race or ethnic group no f','C1706779','RACE','AMACR wt Allele','false'
'race or ethnic group no f','C3853635','Race','Race','false'
'race or ethnic group no f','C0015031','Ethnic Group','Ethnic group','true'
'race or ethnic group no f','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'race or ethnic group no f','C0016327','F-','Fluorides','true'
'region no','C0017446','Region','Geographic Locations','true'
'region no','C0205147','Region','regional','false'
'nordic countries','C0036273','Nordic Countries','Nordic Countries','true'
'body mass index blood pressure mm hg','C0005893','Body mass index','Body mass index procedure','false'
'body mass index blood pressure mm hg','C0439475','mmHG','mmHg','false'
'body mass index blood pressure mm hg','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index blood pressure mm hg','C1305855','BODY MASS INDEX','Body mass index','true'
'pulse beats min','C0232117','PULSE','Pulse Rate','true'
'pulse beats min','C0439385','beats/min','beats per minute','false'
'pulse beats min','C0391850','Pulse','Physiologic pulse','false'
'pulse beats min','C1947910','Pulse','Pulse phenomenon','false'
'estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C3811844','Estimated Glomerular Filtration Rate','Estimated Glomerular Filtration Rate','false'
'estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C0439445','mL/min','mL/min','false'
'estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C0005902','Body Surface Area','Body Surface Area','true'
'serum values^','C0229671','SERUM','Serum','true'
'serum values^','C0042295','Values','Values','false'
'serum values^','C1546774','Serum','Specimen Source Codes - Serum','false'
'serum values^','C1550100','Serum','Specimen Type - Serum','false'
'glucose mg dl','C0017725','GLUCOSE','Glucose','true'
'glucose mg dl','C0439269','mg dl','mg/dL','false'
'potassium mmol liter','C0032821','POTASSIUM','Potassium','true'
'potassium mmol liter','C0475211','Litre','liter','false'
'potassium mmol liter','C0202194','Potassium+','Potassium measurement','false'
'potassium mmol liter','C0304475','POTASSIUM','Potassium supplement','false'
'potassium mmol liter','C0597277','Potassium','Potassium Ion','false'
'potassium mmol liter','C3714637','POTASSIUM','Potassium Drug Class','false'
'total cholesterol mg dl','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'total cholesterol mg dl','C0543421','Total cholesterol','Total cholesterol','false'
'high density lipoprotein cholesterol mg dl','C0023822','High Density Lipoprotein Cholesterol','High Density Lipoprotein Cholesterol','true'
'high density lipoprotein cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'previous antihypertensive treatment no','C0003364','anti hypertensive','Antihypertensive Agents','true'
'previous antihypertensive treatment no','C0039798','treatment','therapeutic aspects','true'
'previous antihypertensive treatment no','C0087111','Treatment','Therapeutic procedure','true'
'previous antihypertensive treatment no','C1522326','Treatment','Treating','false'
'previous antihypertensive treatment no','C1533734','Treatment','Administration procedure','false'
'previous antihypertensive treatment no','C1705169','Treatment','Biomaterial Treatment','false'
'previous antihypertensive treatment no','C3538994','TREATMENT','Treatment Epoch','false'
'previous antihypertensive treatment no','C3887704','treatment','treatment - ActInformationManagementReason','false'
'no of agents','C0450442','Agent','Agent','false'
'no of agents','C1254351','Agent','Pharmacologic Substance','false'
'no of agents','C1521826','Agent','Protocol Agent','false'
'lipid lowering agents','C0086440','Lipid lowering agents','Hypolipidemic Agents','true'
'antiplatelets agents','C0085826','Antiplatelet Agents','Antiplatelet Agents','true'
'risk factors no','C0035648','Risk Factors','risk factors','true'
'risk factors no','C1553898','risk factors','risk factors - observation list','false'
'previous myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'previous myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'previous myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'previous myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'previous myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'previous stroke','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke','C4554100','Stroke','Stroke, CTCAE','false'
'previous hospitalization for unstable angina','C0019993','hospitalisation','Hospitalization','true'
'previous hospitalization for unstable angina','C0002965','Angina, Unstable','Angina, Unstable','true'
'renal disease','C0022658','RENAL DISEASE, NOS','Kidney Diseases','true'
'previous coronary revascularization','C0205156','Previous','Previous','false'
'previous coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'previous coronary revascularization','C1552607','previous','Act Relationship Subset - previous','false'
'left ventricular hypertrophy','C0149721','Hypertrophy, Left Ventricular','Left Ventricular Hypertrophy','true'
'left ventricular hypertrophy','C3484363','Left ventricular hypertrophy','Left ventricular hypertrophy:Finding:Point in time:^Patient:Ordinal','false'
'dyslipidemia','C0242339','Dyslipidemia','Dyslipidemias','true'
'week o baseline mean sd','C0168634','baseline','BaseLine dental cement','true'
'week o baseline mean sd','C2699239','SD','SD, Rat Strain','false'
'week o baseline mean sd','C1442488','Baseline','Baseline','false'
'week $nmbr$ mean sd','C0332174','/week','Weekly','false'
'week $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'week $nmbr$ mean sd','C0439230','Week','week','false'
'ls mean change from baseline $nmbr$ ci','C0392747','Change','Changing','false'
'ls mean change from baseline $nmbr$ ci','C0443172','change','Changed status','false'
'ls mean change from baseline $nmbr$ ci','C1705241','Change','Delta (difference)','false'
'ls mean change from baseline $nmbr$ ci','C4319952','Change','Change -- procedure','false'
'ls mean difference between treatment groups $nmbr$ ci','C1705241','*Difference','Delta (difference)','false'
'ls mean difference between treatment groups $nmbr$ ci','C2347634','Group Mean','Population Mean','false'
'ls mean difference between treatment groups $nmbr$ ci','C1705242','Difference','Different','false'
'fasting indices','C0015663','FASTING','Fasting','true'
'fasting indices','C4033634','Indices','Blood Indices','false'
'fasting insulin miu ml','C0015663','FASTING','Fasting','true'
'fasting insulin miu ml','C0021641','INSULIN','Insulin','true'
'fasting insulin miu ml','C0439457','mIU/mL','International Unit per Liter','false'
'fasting insulin miu ml','C1533581','INSULIN','Recombinant Insulin','false'
'fasting insulin miu ml','C1579433','Insulin','Insulin [EPC]','false'
'fasting insulin miu ml','C3714501','INSULIN','Insulin Drug Class','false'
'placebo $nmbr$','C0032042','Placebo','Placebos','true'
'placebo $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'sitagliptin $nmbr$','C1565750','SITAGLIPTIN','sitagliptin','true'
'fasting proinsulin pmol l','C0015663','FASTING','Fasting','true'
'fasting proinsulin pmol l','C0033362','Proinsulin','Proinsulin','true'
'fasting proinsulin pmol l','C0439284','pmol/L','Picomole per Liter','false'
'fasting proinsulin pmol l','C3813208','Proinsulin','Proinsulin, human','false'
'fasting c peptide ng ml','C0015663','FASTING','Fasting','true'
'fasting c peptide ng ml','C0006558','C peptide','C-Peptide','true'
'fasting c peptide ng ml','C0439275','ng/mL','Microgram per Liter','false'
'homa ir','C0022065','IR','Iran','true'
'homa ir','C0022071','Ir','Iridium','true'
'homa ir','C1448132','IR','INSR protein, human','true'
'postprandial indices','C0376674','Postprandial','Postprandial Period','true'
'postprandial indices','C4033634','Indices','Blood Indices','false'
'$nmbr$ h postprandial insulin miu ml','C0021641','INSULIN','Insulin','true'
'$nmbr$ h postprandial insulin miu ml','C0439457','mIU/mL','International Unit per Liter','false'
'$nmbr$ h postprandial insulin miu ml','C1533581','INSULIN','Recombinant Insulin','false'
'$nmbr$ h postprandial insulin miu ml','C1579433','Insulin','Insulin [EPC]','false'
'$nmbr$ h postprandial insulin miu ml','C3714501','INSULIN','Insulin Drug Class','false'
'$nmbr$ h postprandial proinsulin pmol l','C2827799','h*pmol/L','Hour Times Femtomole per Milliliter','false'
'$nmbr$ h postprandial proinsulin pmol l','C0033362','Proinsulin','Proinsulin','true'
'$nmbr$ h postprandial proinsulin pmol l','C3813208','Proinsulin','Proinsulin, human','false'
'$nmbr$ h postprandial c peptide ng ml','C2827809','h*ng/mL','Hour Times Nanogram per Milliliter','false'
'$nmbr$ h postprandial c peptide ng ml','C0006558','C peptide','C-Peptide','true'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C0600653','Index','Indexes','true'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C0702093','/min','Per Minute','false'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C1524029','MIN NOS','Mouse MIN NOS','false'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C3813700','%/min','Percent per Minute','false'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C0918012','Index','Index','true'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C1552854','index','Html Link Type - index','false'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C1637833','% index','% index','false'
'insulinogenic index dinsulino_ $nmbr$ o min dglucoseo $nmbr$ o min','C2986546','Index','Target Lesion Identification','false'
'placebo $nmbr$ o $nmbr$','C0032042','Placebo','Placebos','true'
'placebo $nmbr$ o $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo $nmbr$ o $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'composite index of insulin sensitivity isi','C0600653','Index','Indexes','true'
'composite index of insulin sensitivity isi','C0918012','Index','Index','true'
'composite index of insulin sensitivity isi','C1552854','index','Html Link Type - index','false'
'composite index of insulin sensitivity isi','C1637833','% index','% index','false'
'composite index of insulin sensitivity isi','C2986546','Index','Target Lesion Identification','false'
'disposition index','C0743223','Disposition','Disposition','false'
'disposition index','C0600653','Index','Indexes','true'
'disposition index','C0918012','Index','Index','true'
'disposition index','C1552854','index','Html Link Type - index','false'
'disposition index','C1637833','% index','% index','false'
'disposition index','C2986546','Index','Target Lesion Identification','false'
'disposition index','C1705555','Disposition','Disposition Domain','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1705242','Difference','Different','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1142985','EZETIMIBE','ezetimibe','true'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0032042','Placebo','Placebos','true'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0392747','Change','Changing','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0443172','change','Changed status','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C4048285','CRP','C-Reactive Protein, human','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1522326','Treatment','Treating','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ treatment differences [ezetimibe statin] [placebo statin] in least squares ls mean percentage change from baseline in crp among subgroups of patients with ongoing statin treatment there were no signif icant treatment by subgroup interactions bmi body mass index dm diabetes mellitus hdl c high density lipoprotein cholesterol ldl c ldl cholesterol tg triglycerides','C0062152','hdl lipoprotein triglycerides','HDL-triglyceride','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C3484017','Change in systolic blood pressure','Change in systolic blood pressure:Pressure Difference:Point in time:^Patient:Quantitative','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C3484018','Change in systolic blood pressure','Change in systolic blood pressure','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1442488','Baseline','Baseline','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0679199','Strategy','strategy','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1522326','Treatment','Treating','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1079230','subgroups','Subgroup A Nepoviruses','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0005680','Black','Black race','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0027567','Black','African race','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0085756','BLACK','African American','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0439541','Black','Black color','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1305855','BMI - Body mass index','Body mass index','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0745133','isolated systolic hypertension','isolated systolic hypertension','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0237753','*Number','Numbers','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0449788','Number','Count of entities','false'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C0030705','Patients','Patients','true'
'figure $nmbr$ change in mean sitting systolic blood pressure mssbp mm hg from baseline to week $nmbr$ by treatment strategy and selected subgroups in black patients with stage $nmbr$ hypertension bmi body mass index ci confidence interval ish isolated systolic hypertension n is the number of intent to treat patients of the respective subgroup','C1292734','treat','Treatment intent','false'
'no draining fistulas','C0013103','drain','Drainage procedure','true'
'no draining fistulas','C0180499','DRAIN','Drain device','false'
'no draining fistulas','C4265177','Drain #','Drain number:ID:Pt:^Patient:Nom','false'
'no draining fistulas','C0016169','Fistulas','pathologic fistula','true'
'week $nmbr$ of patients','C0332174','/week','Weekly','false'
'week $nmbr$ of patients','C0439230','Week','week','false'
'week $nmbr$ of patients','C0030705','Patients','Patients','true'
'no baseline immunosuppressant use','C0042153','use','utilization qualifier','true'
'no baseline immunosuppressant use','C0457083','Use','Usage','false'
'no baseline immunosuppressant use','C1947944','Use','Use - dosing instruction imperative','false'
'both adalimumab groups n $nmbr$ baseline immunosuppressant use','C0042153','use','utilization qualifier','true'
'both adalimumab groups n $nmbr$ baseline immunosuppressant use','C0457083','Use','Usage','false'
'both adalimumab groups n $nmbr$ baseline immunosuppressant use','C1947944','Use','Use - dosing instruction imperative','false'
'$nmbr$ p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'both adalimumab groups n $nmbr$ no baseline cd related antibiotic use','C1122087','ADALIMUMAB','adalimumab','true'
'both adalimumab groups n $nmbr$ no baseline cd related antibiotic use','C0441848','Group N','Group N','false'
'both adalimumab groups n $nmbr$ no baseline cd related antibiotic use','C0042153','use','utilization qualifier','true'
'both adalimumab groups n $nmbr$ no baseline cd related antibiotic use','C0457083','Use','Usage','false'
'both adalimumab groups n $nmbr$ no baseline cd related antibiotic use','C1947944','Use','Use - dosing instruction imperative','false'
'both adalimumab groups n $nmbr$ baseline cd related antibiotic use','C0042153','use','utilization qualifier','true'
'both adalimumab groups n $nmbr$ baseline cd related antibiotic use','C0457083','Use','Usage','false'
'both adalimumab groups n $nmbr$ baseline cd related antibiotic use','C1947944','Use','Use - dosing instruction imperative','false'
'both adalimumab groups n $nmbr$','C1122087','ADALIMUMAB','adalimumab','true'
'both adalimumab groups n $nmbr$','C0441848','Group N','Group N','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0565965','Change values','Change values','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0019016','HBA','Hemoglobin A','true'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C1825777','HBA','KRT90P gene','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C3538758','HBA','SCN2A wt Allele','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C1442488','Baseline','Baseline','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0042295','Values','Values','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0167117','EXENATIDE','exenatide','true'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0332173','QD','Daily','false'
'figure $nmbr$ b mean change in hba $nmbr$ c values from baseline was plotted against baseline hba $nmbr$ c values of $nmbr$ $nmbr$ for exenatide biasp $nmbr$ qd and biasp $nmbr$ bid number of subject data values used exenatide $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively biasp $nmbr$ qd $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively and biasp $nmbr$ bid $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ for baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ and $nmbr$ respectively','C0243174','Number data','numerical data','true'
'dexlansoprazole mr','C0024485','MR','Magnetic Resonance Imaging','true'
'dexlansoprazole mr','C1417249','MR','MRC1 gene','false'
'dexlansoprazole mr','C2347167','Mr.','Mr. - Title','false'
'dexlansoprazole mr','C3254418','MR','NR3C2 protein, human','true'
'dexlansoprazole mr','C4050513','MR','Minor Response','false'
'$nmbr$ mg qd n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg qd n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg qd n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg qd n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg qd n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg qd n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg qd n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'non hispanic or latino','C1518424','Non-Hispanic','Not Hispanic or Latino','false'
'non hispanic or latino','C0086528','Latino','Latinos','true'
'american indian or alaskan native','C0002460','AMERICAN INDIAN','American Indians','true'
'american indian or alaskan native','C0238611','ALASKAN','alaskan','false'
'american indian or alaskan native','C0302891','Native','Native (qualifier value)','false'
'native hawaiian or other pacific islander','C0337920','Hawaiian, Native','Hawaiian population','true'
'native hawaiian or other pacific islander','C0242191','Pacific Islander','Pacific Islander Americans','true'
'multiracial','C1881928','Multiracial','Multiracial','false'
'age y mean s d','C0001779','AGE','Age','false'
'age y mean s d','C0444504','Mean','Statistical mean','false'
'age y mean s d','C2347634','Mean','Population Mean','false'
'age y mean s d','C2348143','Mean','Sample Mean','false'
'weight kg mean s d','C0005910','Weight','Body Weight','true'
'weight kg mean s d','C1275571','kg/s','kg/sec','false'
'weight kg mean s d','C0043100','Weight','Weight','true'
'weight kg mean s d','C1305866','weight','Weighing patient','false'
'weight kg mean s d','C1705104','Weight','Importance Weight','false'
'height cm mean s d','C0439392','cm/s','cm/s','false'
'height cm mean s d','C0444504','Mean','Statistical mean','false'
'height cm mean s d','C2347634','Mean','Population Mean','false'
'height cm mean s d','C2348143','Mean','Sample Mean','false'
'bm $nmbr$ kg m $nmbr$ mean s d','C0022718','KG','Kyrgyzstan','true'
'bm $nmbr$ kg m $nmbr$ mean s d','C0439209','kg','Kilogram','false'
'bm $nmbr$ kg m $nmbr$ mean s d','C4054209','/kg','Per Kilogram','false'
'bm $nmbr$ kg m $nmbr$ mean s d','C0444504','Mean','Statistical mean','false'
'bm $nmbr$ kg m $nmbr$ mean s d','C2347634','Mean','Population Mean','false'
'bm $nmbr$ kg m $nmbr$ mean s d','C2348143','Mean','Sample Mean','false'
'helicobacter pylori negative n','C4688581','Helicobacter pylori Negative','Helicobacter pylori Negative','false'
'eo severity by la classification at baseline baseline of the healing study n','C0439793','Severity','Severities','false'
'eo severity by la classification at baseline baseline of the healing study n','C0522510','Severity','With intensity','false'
'eo severity by la classification at baseline baseline of the healing study n','C0168634','baseline','BaseLine dental cement','true'
'eo severity by la classification at baseline baseline of the healing study n','C0043240','Healing','Wound Healing','true'
'eo severity by la classification at baseline baseline of the healing study n','C0205249','Healing','Healed','false'
'eo severity by la classification at baseline baseline of the healing study n','C1442488','Baseline','Baseline','false'
'duration of treatment in the healing study n','C0444921','Duration of treatment','Duration of treatment','false'
'duration of treatment in the healing study n','C0043240','Healing','Wound Healing','true'
'duration of treatment in the healing study n','C0205249','Healing','Healed','false'
'$nmbr$ week','C0332174','/week','Weekly','false'
'$nmbr$ week','C0439230','Week','week','false'
'previous treatment in the healing study n','C1521826','study treatment','Protocol Agent','false'
'previous treatment in the healing study n','C3161471','Treatment Study','Treatment Study','false'
'dexlansoprazole mr $nmbr$ mg qd','C0024485','MR','Magnetic Resonance Imaging','true'
'dexlansoprazole mr $nmbr$ mg qd','C0332173','QD','Daily','false'
'dexlansoprazole mr $nmbr$ mg qd','C1417249','MR','MRC1 gene','false'
'dexlansoprazole mr $nmbr$ mg qd','C2347167','Mr.','Mr. - Title','false'
'dexlansoprazole mr $nmbr$ mg qd','C3254418','MR','NR3C2 protein, human','true'
'dexlansoprazole mr $nmbr$ mg qd','C4050513','MR','Minor Response','false'
'lansoprazole $nmbr$ mg qd','C0024671','MG','Mammography','true'
'lansoprazole $nmbr$ mg qd','C0332173','QD','Daily','false'
'lansoprazole $nmbr$ mg qd','C0026410','MG','Mongolia','true'
'lansoprazole $nmbr$ mg qd','C0439269','mg%','mg/dL','false'
'lansoprazole $nmbr$ mg qd','C1960952','mg %','Milligram percent','false'
'lansoprazole $nmbr$ mg qd','C2346927','Mg++','Magnesium Cation','false'
'lansoprazole $nmbr$ mg qd','C4321396','MG','MG','false'
'lansoprazole $nmbr$ mg qd','C4521761','MG','United States Military Commissioned Officer O8','false'
'characteristic age mean sd yr','C0001779','AGE','Age','false'
'characteristic age mean sd yr','C0439234','yr','year','false'
'dronedarone n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0766326','DRONEDARONE','dronedarone','true'
'placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'all n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'atrial fibrillation or flutter no','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation or flutter no','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation or flutter no','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'atrial fibrillation or flutter no','C0016385','Flutter','Cardiac Flutter','false'
'atrial fibrillation or flutter no','C2242390','FLUTTER','Flutter (respiratory device)','false'
'structural heart disease no f','C1290384','Structural Heart disease','Structural disorder of heart','false'
'structural heart disease no f','C0016327','F-','Fluorides','true'
'hypertension no','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension no','C1963138','Hypertension','Hypertension, CTCAE','false'
'coronary heart disease no','C0010054','coronary heart disease','Coronary Arteriosclerosis','true'
'coronary heart disease no','C0010068','Coronary Heart Disease','Coronary heart disease','true'
'coronary heart disease no','C1956346','coronary heart disease','Coronary Artery Disease','true'
'valvular heart disease no','C0018824','Heart Disease, Valvular','Heart valve disease','true'
'valvular heart disease no','C1963123','Valvular heart disease','Valvular Heart Disease, CTCAE','false'
'nonischemic cardiomyopathy no','C0878544','CARDIOMYOPATHY','Cardiomyopathies','true'
'history of chf nyha class ii or iii no','C0019664','History','History','true'
'history of chf nyha class ii or iii no','C0019665','history','Historical aspects qualifier','true'
'history of chf nyha class ii or iii no','C0262512','History, NOS','History of present illness','false'
'history of chf nyha class ii or iii no','C0262926','History','Medical History','false'
'history of chf nyha class ii or iii no','C1705255','History','Concept History','false'
'history of chf nyha class ii or iii no','C2004062','History','History of previous events','false'
'history of chf nyha class ii or iii no','C0439070','III','Roman Numeral III','false'
'history of chf nyha class ii or iii no','C1705160','III','III (suffix)','false'
'lvef no i','C0428772','LVEF','Left ventricular ejection fraction','false'
'lvef no i','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'lvef no i','C0021966','I-','Iodides','true'
'lvef no i','C0221138','I NOS','Blood group antibody I','false'
'lone atrial fibrillation no','C0340489','Lone atrial fibrillation','Lone atrial fibrillation','false'
'pacemaker no','C0030163','PACEMAKER','Artificial cardiac pacemaker','true'
'pacemaker no','C0810633','Pacemaker','Pacemakers','false'
'pacemaker no','C1546728','Pacemaker','Specimen Source Codes - Pacemaker','false'
'pacemaker no','C3275122','PACEMAKER','Pacemaker Procedure','false'
'pacemaker no','C3853703','Pacemaker','Pacemaker ECG Assessment','false'
'medications in use at baseline no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications in use at baseline no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications in use at baseline no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications in use at baseline no','C4284232','Medications','Medications','false'
'medications in use at baseline no','C0150312','In','Present','false'
'medications in use at baseline no','C0042153','use','utilization qualifier','true'
'medications in use at baseline no','C0457083','Use','Usage','false'
'medications in use at baseline no','C1947944','Use','Use - dosing instruction imperative','false'
'medications in use at baseline no','C0332285','In','Within','false'
'medications in use at baseline no','C1707101','IN','CD44 wt Allele','false'
'calcium antagonists','C0006684','Calcium--Antagonists','Calcium Channel Blockers','true'
'statins','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'vitamin k antagonists','C3653316','Vitamin K antagonists','Vitamin K antagonists','false'
'early eptifibatide group n $nmbr$','C0253563','EPTIFIBATIDE','eptifibatide','true'
'early eptifibatide group n $nmbr$','C0441848','Group N','Group N','false'
'delayed eptifibatide group n $nmbr$','C0205421','Delayed','Deferred','false'
'delayed eptifibatide group n $nmbr$','C0441848','Group N','Group N','false'
'delayed eptifibatide group n $nmbr$','C1545665','Delayed','Views delayed','false'
'delayed eptifibatide group n $nmbr$','C3272602','Delayed','Delayed Testing','false'
'median yr','C0549183','Median','Midline (qualifier value)','false'
'median yr','C0439234','yr','year','false'
'median yr','C0876920','Median','Median Statistical Measurement','false'
'median yr','C2347635','Median','Population Median','false'
'median yr','C2348144','Median','Sample Median','false'
'median yr','C2939193','Median','Median (qualifier value)','false'
'interquartile range yr','C1711350','Interquartile Range','Interquartile Range','false'
'interquartile range yr','C0439234','yr','year','false'
'region ofenrollment','C0017446','Region','Geographic Locations','true'
'region ofenrollment','C0205147','Region','regional','false'
'middle east africa or asia pacific','C0001741','East Africa','Africa, Eastern','true'
'middle east africa or asia pacific','C0003980','Asia','Asia','true'
'previous cabg','C0205156','Previous','Previous','false'
'previous cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'previous cabg','C1552607','previous','Act Relationship Subset - previous','false'
'estimated creatinine clearance','C0750572','Estimated','Estimated','false'
'estimated creatinine clearance','C0812399','Creatinine clearance','Creatinine clearance','false'
'median ml min','C0549183','Median','Midline (qualifier value)','false'
'median ml min','C0439445','mL/min','mL/min','false'
'median ml min','C0876920','Median','Median Statistical Measurement','false'
'median ml min','C2347635','Median','Population Median','false'
'median ml min','C2348144','Median','Sample Median','false'
'median ml min','C2939193','Median','Median (qualifier value)','false'
'interquartile range ml min','C1711350','Interquartile Range','Interquartile Range','false'
'interquartile range ml min','C0439445','mL/min','mL/min','false'
'killip class ii iii or iv','C2697846','KILLIP CLASS III','Killip Class III','false'
'killip class ii iii or iv','C0022326','IV','Ivory Coast','true'
'killip class ii iii or iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'qualifying high risk features','C1514624','Qualifying','Qualifying','false'
'qualifying high risk features','C0035648','risk Feature','risk factors','true'
'age $nmbr$ yr elevated biomarkers and st segment changes','C0001779','AGE','Age','false'
'age $nmbr$ yr elevated biomarkers and st segment changes','C0005516','Biomarkers','Biological Markers','true'
'age $nmbr$ yr elevated biomarkers and st segment changes','C0232326','ST segment changes','EKG ST segment changes','false'
'age $nmbr$ yr and elevated biomarkers','C0001779','AGE','Age','false'
'age $nmbr$ yr and elevated biomarkers','C0439234','yr','year','false'
'age $nmbr$ yr and elevated biomarkers','C0205250','Elevated','High','false'
'age $nmbr$ yr and elevated biomarkers','C0005516','Biomarkers','Biological Markers','true'
'age $nmbr$ yr and elevated biomarkers','C3163633','Elevated','Elevated','false'
'elevated biomarkers and st segment changes','C0205250','Elevated','High','false'
'elevated biomarkers and st segment changes','C0005516','Biomarkers','Biological Markers','true'
'elevated biomarkers and st segment changes','C3163633','Elevated','Elevated','false'
'elevated biomarkers and st segment changes','C0232326','ST segment changes','EKG ST segment changes','false'
'age $nmbr$ yr and st segment changes','C0001779','AGE','Age','false'
'age $nmbr$ yr and st segment changes','C0439234','yr','year','false'
'age $nmbr$ yr and st segment changes','C0232326','ST segment changes','EKG ST segment changes','false'
'age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular','C0001779','AGE','Age','false'
'age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular','C0005516','Biomarkers','Biological Markers','true'
'age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular','C0005847','Vascular','Blood Vessel','true'
'age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'age $nmbr$ $nmbr$ yr elevated biomarkers and previous vascular','C1801960','Vascular','Vascular','false'
'elevated troponin','C0205250','Elevated','High','false'
'elevated troponin','C0041199','Troponin','Troponin','true'
'elevated troponin','C3163633','Elevated','Elevated','false'
'presentation to tertiary care hospital','C0449450','Presentation','Presentation','false'
'presentation to tertiary care hospital','C0337954','Tertiary care hospital','Tertiary care hospital','false'
'randomized','C0034656','Randomized','Randomization','true'
'randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'low $nmbr$ $nmbr$','C0205251','Low','low','false'
'low $nmbr$ $nmbr$','C1550472','low','low confidentiality','false'
'low $nmbr$ $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low $nmbr$ $nmbr$','C4048187','low','low exposure','false'
'low $nmbr$ $nmbr$','C4321351','Low','Low Level','false'
'low $nmbr$ $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'intermediate $nmbr$ $nmbr$','C0205103','INTERMEDIATE','Intermediate','false'
'intermediate $nmbr$ $nmbr$','C1550465','Intermediate','Observation Interpretation - intermediate','false'
'intermediate $nmbr$ $nmbr$','C2827755','INTERMEDIATE','Antimicrobial Intermediate Susceptibility Result','false'
'intermediate $nmbr$ $nmbr$','C3889971','Intermediate','Intermediate Mitosis-Karyorrhexis Index','false'
'high $nmbr$ $nmbr$','C0205250','High','High','false'
'high $nmbr$ $nmbr$','C1299351','High','Abnormally high','false'
'high $nmbr$ $nmbr$','C2700149','HIGH','Value Above Reference Range','false'
'high $nmbr$ $nmbr$','C3887512','high','high - ActExposureLevelCode','false'
'high $nmbr$ $nmbr$','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high $nmbr$ $nmbr$','C4321237','High','High Level','false'
'high $nmbr$ $nmbr$','C4522209','High','IPSS Risk Category High','false'
'medical therapy during index hospitalization','C0418981','Medical therapy','Medical therapy','false'
'medical therapy during index hospitalization','C0019993','hospitalisation','Hospitalization','true'
'antithrombin','C0003438','Antithrombin','Antithrombin III','true'
'antithrombin','C0003440','Antithrombin','Antithrombins','true'
'antithrombin','C4521254','Antithrombin','Therapeutic Human Antithrombin-III','false'
'unfractionated heparin only','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin only','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'low molecular weight heparin only','C0019139','Heparin, Low-Molecular-Weight','Heparin, Low-Molecular-Weight','true'
'low molecular weight heparin only','C3536766','Low Molecular Weight Heparin','Low Molecular Weight Heparin [EPC]','false'
'both unfractionated heparin and low molecular weight heparin','C0019134','Unfractionated Heparin','heparin','true'
'both unfractionated heparin and low molecular weight heparin','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'both unfractionated heparin and low molecular weight heparin','C0019139','Heparin, Low-Molecular-Weight','Heparin, Low-Molecular-Weight','true'
'both unfractionated heparin and low molecular weight heparin','C3536766','Low Molecular Weight Heparin','Low Molecular Weight Heparin [EPC]','false'
'neither unfractionated heparin nor low molecular weight heparin','C0019134','Unfractionated Heparin','heparin','true'
'neither unfractionated heparin nor low molecular weight heparin','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'neither unfractionated heparin nor low molecular weight heparin','C0019139','Heparin, Low-Molecular-Weight','Heparin, Low-Molecular-Weight','true'
'neither unfractionated heparin nor low molecular weight heparin','C3536766','Low Molecular Weight Heparin','Low Molecular Weight Heparin [EPC]','false'
'at any time','C0040223','TIME','Time','true'
'at any time','C3541383','Time','Time (foundation metadata concept)','false'
'early use intended','C0042153','use','utilization qualifier','true'
'early use intended','C0457083','Use','Usage','false'
'early use intended','C1947944','Use','Use - dosing instruction imperative','false'
'early use intended','C1283828','Intended','intent','false'
'early use intended','C1551357','intended','intended - ParticipationSignature','false'
'angiotensin receptor blocker','C0034787','Angiotensin Receptor','Angiotensin Receptor','true'
'angiotensin receptor blocker','C1622222','Angiotensin Receptor','MAS1 protein, human','true'
'temporal data and management strategy','C1511726','Data','Data','false'
'temporal data and management strategy','C3245479','data','Data call receiving device','false'
'temporal data and management strategy','C3714741','Data','Data (eukaryote)','false'
'temporal data and management strategy','C0001554','Management','Administration occupational activities','true'
'temporal data and management strategy','C0679199','Strategy','strategy','false'
'temporal data and management strategy','C0376636','management','Disease Management','true'
'temporal data and management strategy','C1273870','Management','Management procedure','false'
'temporal data and management strategy','C3273539','Management','Management Occupations','false'
'time from onset of symptoms to presentation hr','C1320528','Time of symptom onset','Time of symptom onset','false'
'time from onset of symptoms to presentation hr','C0449450','Presentation','Presentation','false'
'time from presentation to randomization hr','C0040223','TIME','Time','true'
'time from presentation to randomization hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from presentation to randomization hr','C0034656','Randomization','Randomization','true'
'time from randomization to study drug initiation hr','C0040223','TIME','Time','true'
'time from randomization to study drug initiation hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from randomization to study drug initiation hr','C0013175','study drug','Drug Evaluation','true'
'time from randomization to study drug initiation hr','C0589507','Initiation','Cognitive function: initiation','false'
'time from randomization to study drug initiation hr','C1158830','Initiation','Transcription Initiation','false'
'time from randomization to study drug initiation hr','C1704686','Initiation','Initiation','false'
'time from randomization to coronary angiography hr','C0040223','TIME','Time','true'
'time from randomization to coronary angiography hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from randomization to coronary angiography hr','C0085532','CORONARY ANGIOGRAPHY','Coronary angiography','true'
'time from randomization to coronary angiography hr','C1548829','Coronary Angiography','Consent Type - Coronary Angiography','false'
'pci no','C4049621','PCI','Peritoneal Cancer Index','false'
'time from randomization to pci hr','C0040223','TIME','Time','true'
'time from randomization to pci hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from randomization to pci hr','C4049621','PCI','Peritoneal Cancer Index','false'
'duration of infusion before pci hr','C0449238','Duration','Duration (temporal concept)','false'
'duration of infusion before pci hr','C2926735','Duration','Duration','false'
'duration of infusion before pci hr','C4049621','PCI','Peritoneal Cancer Index','false'
'duration of infusion after pci hr','C0449238','Duration','Duration (temporal concept)','false'
'duration of infusion after pci hr','C2926735','Duration','Duration','false'
'duration of infusion after pci hr','C4049621','PCI','Peritoneal Cancer Index','false'
'cabg no','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'time from randomization to cabg hr','C0040223','TIME','Time','true'
'time from randomization to cabg hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from randomization to cabg hr','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'duration of infusion before cabg hr','C0449238','Duration','Duration (temporal concept)','false'
'duration of infusion before cabg hr','C2926735','Duration','Duration','false'
'duration of infusion before cabg hr','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'medical management only no','C0199168','Medical','Medical service','false'
'medical management only no','C0001554','Management','Administration occupational activities','true'
'medical management only no','C0376636','management','Disease Management','true'
'medical management only no','C1273870','Management','Management procedure','false'
'medical management only no','C3273539','Management','Management Occupations','false'
'medical management only no','C0205476','Medical','Medical','false'
'duration of infusion during medical management hr','C0449238','Duration','Duration (temporal concept)','false'
'duration of infusion during medical management hr','C2926735','Duration','Duration','false'
'duration of infusion during medical management hr','C0199168','Medical','Medical service','false'
'duration of infusion during medical management hr','C0001554','Management','Administration occupational activities','true'
'duration of infusion during medical management hr','C0376636','management','Disease Management','true'
'duration of infusion during medical management hr','C1273870','Management','Management procedure','false'
'duration of infusion during medical management hr','C3273539','Management','Management Occupations','false'
'duration of infusion during medical management hr','C0205476','Medical','Medical','false'
'total no of patients','C0439175','% total','% of total','false'
'total no of patients','C0439810','Total','Total','false'
'total no of patients','C0030705','Patients','Patients','true'
'early eptifibatide','C1279919','Early','Early','false'
'early eptifibatide','C0253563','EPTIFIBATIDE','eptifibatide','true'
'delayed eptifibatide','C0205421','Delayed','Deferred','false'
'delayed eptifibatide','C0253563','EPTIFIBATIDE','eptifibatide','true'
'delayed eptifibatide','C1545665','Delayed','Views delayed','false'
'delayed eptifibatide','C3272602','Delayed','Delayed Testing','false'
'troponin','C0041199','Troponin','Troponin','true'
'positive','C0439178','% Positive','percent positive cells','false'
'positive','C1446409','Positive','Positive','false'
'positive','C1514241','POSITIVE','Positive Finding','false'
'positive','C2825490','Positive','Positive Charge','false'
'positive','C3812269','Positive','Positive Number','false'
'early clopidogrel intended','C1279919','Early','Early','false'
'early clopidogrel intended','C0070166','CLOPIDOGREL','clopidogrel','true'
'early clopidogrel intended','C1283828','Intended','intent','false'
'early clopidogrel intended','C1551357','intended','intended - ParticipationSignature','false'
'time to randomization','C0040223','TIME','Time','true'
'time to randomization','C3541383','Time','Time (foundation metadata concept)','false'
'heparin use','C0239945','HEPARIN USE','heparin use','false'
'low molecular weight only','C0041667','LOW WEIGHT','Underweight','true'
'type of hospital care','C0332307','TYPE','Type - attribute','false'
'type of hospital care','C1547052','*Type','*Type - Kind of quantity','false'
'primary','C0205225','Primary','Primary','false'
'primary','C0439612','Primary','True primary (qualifier value)','false'
'primary','C0439631','Primary','Primary operation','false'
'tertiary','C0205372','Tertiary','Tertiary','false'
'region of the world','C0017446','Region','Geographic Locations','true'
'region of the world','C0205147','Region','regional','false'
'region ofthe world','C0017446','Region','Geographic Locations','true'
'region ofthe world','C2700280','World','World','false'
'region ofthe world','C0205147','Region','regional','false'
'clopidogrel plus aspirin n $nmbr$','C0070166','CLOPIDOGREL','clopidogrel','true'
'clopidogrel plus aspirin n $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'aspirin n $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'body mass indexf','C0518010','body mass','body mass','false'
'chads $nmbr$ ^','C0007928','CHAD','Chad','true'
'chads $nmbr$ ^','C1413373','CHAD','CHAD gene','false'
'mean score','C3533236','Mean score','Mean score','false'
'score no','C0449820','SCORE','Score','false'
'score no','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'history of atrial fibrillation type no','C0729790','History of - atrial fibrillation','H/O: atrial fibrillation','false'
'history of atrial fibrillation type no','C0332307','TYPE','Type - attribute','false'
'history of atrial fibrillation type no','C1547052','*Type','*Type - Kind of quantity','false'
'permanent','C0205355','Permanent','Permanent','false'
'paroxysmal','C0205311','Paroxysmal','Paroxysmal','false'
'persistent','C0205322','Persistent','Persistent','false'
'persistent','C0332996','PERSISTENT','Persistent embryonic structure','false'
'atrial fibrillation duration no','C0449238','Duration','Duration (temporal concept)','false'
'atrial fibrillation duration no','C2926735','Duration','Duration','false'
'$nmbr$ mo to $nmbr$ yr','C0026544','MO','Morocco','true'
'$nmbr$ mo to $nmbr$ yr','C0332177','/mo','Monthly (qualifier value)','false'
'history of hypertension no','C0455527','History of - hypertension','H/O: hypertension','false'
'history of stroke or tia no','C0019664','History','History','true'
'history of stroke or tia no','C0019665','history','Historical aspects qualifier','true'
'history of stroke or tia no','C0262512','History, NOS','History of present illness','false'
'history of stroke or tia no','C0262926','History','Medical History','false'
'history of stroke or tia no','C1705255','History','Concept History','false'
'history of stroke or tia no','C2004062','History','History of previous events','false'
'history of stroke or tia no','C0007787','TIA','Transient Ischemic Attack','true'
'history of stroke or tia no','C0917805','TIA','Transient Cerebral Ischemia','true'
'history of stroke or tia no','C1054154','tia','Tacca leontopetaloides','false'
'history of ischemic heart disease no','C0683519','History of disease','disease history','false'
'history of ischemic heart disease no','C0730226','History of Disease','H/O: Disorder','false'
'history of ischemic heart disease no','C0850708','History of disease','History of disease','false'
'history of ischemic heart disease no','C0944983','History of Disease','History of symptoms & diseases:Finding:Point in time:^Patient:Nominal:Observed','false'
'cad','C1504769','CAD','DFFB protein, human','true'
'cad','C2239547','CAD','ACOD1 gene','false'
'cad','C3813548','CAD','CALD1 wt Allele','false'
'cad','C4284121','CAD','DFFB wt Allele','false'
'diabetes mellitus no','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'peripheral artery disease no','C1704436','Peripheral Artery Disease','Peripheral Arterial Diseases','true'
'peripheral artery disease no','C4025272','Peripheral artery disease','Peripheral arterial stenosis','false'
'congestive heart failure no','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'cardiac pacemaker no','C0030163','Cardiac Pacemaker','Artificial cardiac pacemaker','true'
'cardiac pacemaker no','C0037189','Cardiac pacemaker','Sinoatrial Node','true'
'ecg findings at baseline no','C0438154','ecg findings','Electrocardiogram finding','false'
'ecg findings at baseline no','C0168634','baseline','BaseLine dental cement','true'
'ecg findings at baseline no','C1442488','Baseline','Baseline','false'
'atrial flutter','C0004239','ATRIAL FLUTTER','Atrial Flutter','true'
'atrial flutter','C0344423','Atrial Flutter','Atrial Flutter by ECG Finding','false'
'atrial flutter','C1963068','Atrial flutter','Atrial Flutter, CTCAE','false'
'sinus rhythm','C0232201','SINUS RHYTHM','Sinus rhythm','false'
'medication use at baseline no','C0240320','MEDICATION USE','medication use','false'
'medication use at baseline no','C0168634','baseline','BaseLine dental cement','true'
'medication use at baseline no','C1442488','Baseline','Baseline','false'
'antiarrhythmic agent','C0003195','Antiarrhythmic Agent','Anti-Arrhythmia Agents','true'
'antiarrhythmic agent','C0301380','anti arrhythmic agent','Cardiac depressant drug, NOS','false'
'reason for enrollment in active a no','C0392360','Reason','Indication of (contextual qualifier)','false'
'reason for enrollment in active a no','C0205177','Active','Active','false'
'reason for enrollment in active a no','C3853793','active','active (HL7 RoleLink)','false'
'reason for enrollment in active a no','C3888249','Active','Active License','false'
'specific risk of bleeding^','C0205369','Specific','Specific qualifier value','false'
'specific risk of bleeding^','C3251812','Bleeding risk','Bleeding risk','false'
'specific risk of bleeding^','C1552740','specific','Entity Determiner - specific','false'
'physician s judgment that vka inappropriate]','C0031831','PHYSICIAN','Physicians','true'
'physician s judgment that vka inappropriate]','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'physician s judgment that vka inappropriate]','C0022423','Judgment','Judgment','true'
'physician s judgment that vka inappropriate]','C1548788','Inappropriate','Inappropriate','false'
'physician s judgment that vka inappropriate]','C3537135','Inappropriate','Inappropriate Specimen','false'
'physician s judgment that vka inappropriate]','C3542467','Inappropriate','Inappropriate component (foundation metadata concept)','false'
'patient s preference not to take vka only reason','C0030705','*^patient','Patients','true'
'patient s preference not to take vka only reason','C0558295','Preference','preference','false'
'patient s preference not to take vka only reason','C1549513','Preference','Diet Code Specification Type - Preference','false'
'patient s preference not to take vka only reason','C1518422','Not','Negation','false'
'patient s preference not to take vka only reason','C1515187','Take','Take','false'
'patient s preference not to take vka only reason','C0392360','Reason','Indication of (contextual qualifier)','false'
'western europe and israel','C0043129','Western Europe','Western Europe','true'
'western europe and israel','C0022271','ISRAEL','Israel','true'
'south africa','C0037712','SOUTH AFRICA','South Africa','true'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tadalafil $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'tadalafil $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tadalafil $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tadalafil $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tadalafil $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tadalafil $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tadalafil $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tadalafil $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'ed severity visit $nmbr$','C0545082','Visit','Visit','false'
'ed severity visit $nmbr$','C1512346','visit','Patient Visit','false'
'ed severity visit $nmbr$','C2826704','VISIT','Visit Name','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C0205307','NORMAL','Normal','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C0231683','Normal','Gait normal','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C0439166','% normal','Percent normal','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C2347086','% Normal','Mean Percent of Normal','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C4553972','Normal','How Often Felt Normal question','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C2945599','Mild','Mild (qualifier value)','false'
'normal or mild iief ef $nmbr$ $nmbr$ n','C3641331','IIEF','International Index of Erectile Function Questionnaire','false'
'moderate iief ef $nmbr$ $nmbr$ n','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate iief ef $nmbr$ $nmbr$ n','C1881878','Moderate','Moderation','false'
'moderate iief ef $nmbr$ $nmbr$ n','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate iief ef $nmbr$ $nmbr$ n','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate iief ef $nmbr$ $nmbr$ n','C4085643','Moderate','Moderate Response','false'
'moderate iief ef $nmbr$ $nmbr$ n','C4321335','Moderate','Moderate Level','false'
'severe iief ef $nmbr$ $nmbr$ n','C0205082','Severe','Severe (severity modifier)','false'
'severe iief ef $nmbr$ $nmbr$ n','C3641331','IIEF','International Index of Erectile Function Questionnaire','false'
'severe iief ef $nmbr$ $nmbr$ n','C4050465','Severe','Severe Extremity Pain','false'
'severe iief ef $nmbr$ $nmbr$ n','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'ed duration visit $nmbr$','C0545082','Visit','Visit','false'
'ed duration visit $nmbr$','C1512346','visit','Patient Visit','false'
'ed duration visit $nmbr$','C2826704','VISIT','Visit Name','false'
'$nmbr$ yr n','C0439234','yr','year','false'
'iief ef domain score visit $nmbr$','C0545082','Visit','Visit','false'
'iief ef domain score visit $nmbr$','C1512346','visit','Patient Visit','false'
'iief ef domain score visit $nmbr$','C2826704','VISIT','Visit Name','false'
'iief ef domain score visit $nmbr$ y','C0449820','SCORE','Score','false'
'iief ef domain score visit $nmbr$ y','C0545082','Visit','Visit','false'
'iief ef domain score visit $nmbr$ y','C1512346','visit','Patient Visit','false'
'iief ef domain score visit $nmbr$ y','C2826704','VISIT','Visit Name','false'
'iief ef domain score visit $nmbr$ y','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'tadalafil','C1176316','TADALAFIL','tadalafil','true'
'p values','C1709380','P-Value','P-Value','false'
'$nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'interaction','C1704675','Interaction','Interaction','false'
'$nmbr$ yr n $nmbr$','C0439234','yr','year','false'
'$nmbr$ kg m $nmbr$ n $nmbr$','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg m $nmbr$ n $nmbr$','C0439209','kg','Kilogram','false'
'$nmbr$ kg m $nmbr$ n $nmbr$','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg m $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ kg m $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'bph luts severity','C0439793','Severity','Severities','false'
'bph luts severity','C0522510','Severity','With intensity','false'
'moderate ipss','C1019118','Ips','Ips <Invertebrate>','false'
'moderate ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'moderate ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'moderate ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'severe ipss $nmbr$ n $nmbr$','C0205082','Severe','Severe (severity modifier)','false'
'severe ipss $nmbr$ n $nmbr$','C1019118','Ips','Ips <Invertebrate>','false'
'severe ipss $nmbr$ n $nmbr$','C1998280','IPSS','International Prostate Symptom Score','false'
'severe ipss $nmbr$ n $nmbr$','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'severe ipss $nmbr$ n $nmbr$','C3811063','IPS','SLC27A4 wt Allele','false'
'severe ipss $nmbr$ n $nmbr$','C4050465','Severe','Severe Extremity Pain','false'
'severe ipss $nmbr$ n $nmbr$','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'psa','C3810537','PSA','PSAT1 wt Allele','false'
'psa','C3813209','PSA','PROS1 wt Allele','false'
'$nmbr$ $nmbr$ ng ml n $nmbr$','C0439275','ng/mL','Microgram per Liter','false'
'prior a blocker use','C0332152','Prior','Before','false'
'prior a blocker use','C2826257','PRIOR','Prior Medication Usage','false'
'prior a blocker use','C0042153','use','utilization qualifier','true'
'prior a blocker use','C0457083','Use','Usage','false'
'prior a blocker use','C1947944','Use','Use - dosing instruction imperative','false'
'yes n $nmbr$','C1549445','Yes','Yes - Yes/no indicator','false'
'yes n $nmbr$','C1705108','YES','Yes (indicator)','false'
'yes n $nmbr$','C1710701','Yes','YES1 wt Allele','false'
'no n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'no n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'prior ed therapy','C1514463','Prior Therapy','Prior Therapy','false'
'prior ed therapy','C3538926','ED','Endocrine System Findings Domain','false'
'age y gender n','C0001779','AGE','Age','false'
'age y gender n','C0079399','Gender','Gender','true'
'age y gender n','C1522384','Gender','sex','true'
'african descent','C0205386','Descent','Descending','false'
'african descent','C0680043','Descent','Descent','false'
'weight kg duration of pah n','C0449238','Duration','Duration (temporal concept)','false'
'weight kg duration of pah n','C2926735','Duration','Duration','false'
'$nmbr$ y pathogenesis n','C0543483','pathogenesis','pathogenic aspects','true'
'$nmbr$ y pathogenesis n','C0699748','Pathogenesis','Pathogenesis','false'
'idiopathic familial','C0015576','Familial','Family','true'
'idiopathic familial','C0241888','FAMILIAL','Familial','false'
'anorexigen use','C0042153','use','utilization qualifier','true'
'anorexigen use','C0457083','Use','Usage','false'
'anorexigen use','C1947944','Use','Use - dosing instruction imperative','false'
'connective tissue disease','C0009782','CONNECTIVE TISSUE DISEASE','Connective Tissue Diseases','true'
'associated with an atrial septal defect','C0332281','Associated with','Associated with','false'
'associated with an atrial septal defect','C0018817','ATRIAL SEPTAL DEFECT','Atrial Septal Defects','true'
'surgical repair of vsd or pda $nmbr$ year duration','C0374711','Surgical repair','Surgical repair','false'
'surgical repair of vsd or pda $nmbr$ year duration','C0018818','VSD','Ventricular Septal Defects','true'
'surgical repair of vsd or pda $nmbr$ year duration','C0449238','Duration','Duration (temporal concept)','false'
'surgical repair of vsd or pda $nmbr$ year duration','C2926735','Duration','Duration','false'
'concomitant use of bosentan n','C1524063','Use of','Use of','false'
'concomitant use of bosentan n','C0252643','BOSENTAN','bosentan','true'
'six minute walk distance m','C3900196','SIX MINUTE WALK','6 Minute Walk Functional Test','false'
'borg dyspnea score who functional class n','C0013404','DYSPNOEA','Dyspnea','true'
'borg dyspnea score who functional class n','C0205245','Functional','Functional','false'
'borg dyspnea score who functional class n','C0542341','Functional','Function (attribute)','false'
'borg dyspnea score who functional class n','C2700217','Functional','Functional Relationship','false'
'borg dyspnea score who functional class n','C1963100','Dyspnea','Dyspnea, CTCAE','false'
'class iii','C0441887','Class III','Class 3','false'
'class iii','C2698969','Class III','Canadian Cardiovascular Society Grading Scale Class III','false'
'class iv','C0441888','Class IV','Class 4','false'
'class iv','C2698970','Class IV','Canadian Cardiovascular Society Grading Scale Class IV','false'
'hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy','C0019010','Hemodynamic','Hemodynamics','true'
'hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy','C0449381','Parameters','Observation parameter','false'
'hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy','C4281788','hemodynamic','hemodynamics (procedure)','false'
'hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy','C0030705','Patients','Patients','true'
'hemodynamic parameters at baseline in the patients enrolled in the hemodynamic substudy','C4684790','enrolled','Study Subject Enrolled','false'
'mean pulmonary artery pressure mm hg','C0428642','Pulmonary Artery Pressure','Pulmonary artery pressure','false'
'mean pulmonary artery pressure mm hg','C0439475','mmHG','mmHg','false'
'cardiac index l mn m $nmbr$','C0026327','MN','MNSs Blood-Group System','true'
'cardiac index l mn m $nmbr$','C0026405','MN','Monaco','true'
'cardiac index l mn m $nmbr$','C4285072','mN','Millinewton','false'
'pulmonary vascular resistance dyne s cm $nmbr$','C0308914','DYNE','Dyne veterinary drug','false'
'pulmonary vascular resistance dyne s cm $nmbr$','C0600130','Dyne','Dyne - unit of force','false'
'bosentan use','C0042153','use','utilization qualifier','true'
'bosentan use','C0457083','Use','Usage','false'
'bosentan use','C1947944','Use','Use - dosing instruction imperative','false'
'pah etiology','C0015127','etiology','Etiology aspects','true'
'pah etiology','C1314792','Etiology','Etiology','true'
'pah etiology','C1524003','Etiology','Science of Etiology','false'
'repaired s p shunts','C0205340','Repaired','Repaired','false'
'repaired s p shunts','C0232180','Shunt','Cardiac shunt','false'
'repaired s p shunts','C0542331','Shunt','Shunt Device','false'
'repaired s p shunts','C1442858','Shunt','Surgical fistula','false'
'others','C1955473','Others','Others - Allergy','false'
'others','C3539125','others','other medicated shampoos in ATC','false'
'baseline $nmbr$ mlnute walk distance','C0168634','baseline','BaseLine dental cement','true'
'baseline $nmbr$ mlnute walk distance','C0429886','Walk distance','Walking distance','false'
'baseline $nmbr$ mlnute walk distance','C1442488','Baseline','Baseline','false'
'$nmbr$ meters','C0441074','Meters','Meters (physical object)','false'
'medan $nmbr$ year old','C0439234','Year','year','false'
'medan $nmbr$ year old','C0580836','Old','Old','false'
'medan $nmbr$ year old','C0439508','/Year','per year','false'
'baseline who function class','C0456387','Class','Class','false'
'baseline who function class','C1518526','class','Object Class','false'
'baseline who function class','C1705943','Class','Class (taxonomic)','false'
'lor ii','C1710602','II','VIPR1 wt Allele','false'
'lor ii','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'iii or iv','C0439070','III','Roman Numeral III','false'
'iii or iv','C1705160','III','III (suffix)','false'
'iii or iv','C0022326','IV','Ivory Coast','true'
'iii or iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'table $nmbr$ not standard baseline characteristics table','C0039224','Table','Table - furniture','false'
'table $nmbr$ not standard baseline characteristics table','C1706074','Table','Data Table','true'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C3272907','Percent Change From Baseline','Percent Change From Baseline','false'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C0023824','Cholesterol.in LDL','LDL Cholesterol Lipoproteins','true'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C0445604','subclasses','Subclass','false'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C1079230','subgroup','Subgroup A Nepoviruses','false'
'fig $nmbr$ per cent change from baseline in ldl cholesterol subclasses in the mitt population panel a subgroup with tgs','C1515021','Subgroup','Subgroup','false'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C0025598','METFORMIN','Metformin','true'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'saxa $nmbr$ mg $nmbr$ metformin n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'saxa $nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'metformin n $nmbr$ $nmbr$','C0025598','METFORMIN','Metformin','true'
'age $nmbr$ years t','C1510829','Age-Years','Age-Years','false'
'black african american','C0085756','Black/African American','African American','true'
'diabetes duration years','C0011847','Diabetes','Diabetes','false'
'diabetes duration years','C0439234','YEARS','year','false'
'diabetes duration years','C0011849','Diabetes','Diabetes Mellitus','true'
'$nmbr$ t','C2603360','T'','T prime','false'
'fpg mg dl x','C0439269','mg dl','mg/dL','false'
'figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin','C0019016','HBA','Hemoglobin A','true'
'figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin','C2986480','Subgroup Analysis','Subset Analysis','false'
'figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin','C1825777','HBA','KRT90P gene','false'
'figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin','C3538758','HBA','SCN2A wt Allele','false'
'figure $nmbr$ hba $nmbr$ c adjusted mean change subgroup analysis by baseline hba $nmbr$ c hba $nmbr$ c glucosylated haemoglobin saxa saxagliptin','C1611934','SAXAGLIPTIN','saxagliptin','true'
'golimumab','C2353893','GOLIMUMAB','golimumab','true'
'proportion of patients who achieved acr $nmbr$ n n','C1709707','Proportion','Proportion','false'
'proportion of patients who achieved acr $nmbr$ n n','C0030705','Patients','Patients','true'
'odds ratio $nmbr$ ci','C0008107','CI','Chile','true'
'odds ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'$nmbr$ mg','C0024671','MG','Mammography','true'
'$nmbr$ mg','C0026410','MG','Mongolia','true'
'$nmbr$ mg','C0439269','mg%','mg/dL','false'
'$nmbr$ mg','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg','C4321396','MG','MG','false'
'$nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'combined golimumab groups','C0441833','Groups','Groups','false'
'combined golimumab groups','C0687744','groups','Social group','false'
'combined golimumab groups','C1257890','Group','Population Group','true'
'combined golimumab groups','C1519504','Group','Stage Grouping','false'
'combined golimumab groups','C1552839','groups','Table Rules - groups','false'
'combined golimumab groups','C1705428','Group','Group Object','false'
'combined golimumab groups','C1705429','Group','User Group','false'
'dmard at baseline','C0242708','DMARD','Antirheumatic Drugs, Disease-Modifying','true'
'dmard at baseline','C0168634','baseline','BaseLine dental cement','true'
'dmard at baseline','C1442488','Baseline','Baseline','false'
'number of previous tnfa inhibitors','C0237753','*Number','Numbers','false'
'number of previous tnfa inhibitors','C0449788','Number','Count of entities','false'
'anti ccp antibodies','C1624602','Anti-Antibodies','Anti-Antibodies','true'
'rheumatoid factor','C0035448','RHEUMATOID FACTOR','Rheumatoid Factor','true'
'rheumatoid factor','C0201660','Rheumatoid factor NOS','Rheumatoid Factor Measurement','false'
'reason for discontinuation of previous tnfa inhibitor','C0392360','Reason','Indication of (contextual qualifier)','false'
'reason for discontinuation of previous tnfa inhibitor','C0205156','Previous','Previous','false'
'reason for discontinuation of previous tnfa inhibitor','C1552607','previous','Act Relationship Subset - previous','false'
'patient assessment of pain $nmbr$ $nmbr$ cm vas','C0679830','patient assessment','patient assessment','false'
'lack of effectiveness','C0235828','Lack of Effectiveness','Lack of Efficacy','false'
'patient global assessment of disease activity $nmbr$ $nmbr$ cm vas','C4054228','Patient Global Assessment of Disease Activity','Patient Global Assessment of Disease Activity','false'
'patient global assessment of disease activity $nmbr$ $nmbr$ cm vas','C0042815','VAS','Visual Analog Pain Scale','true'
'patient global assessment of disease activity $nmbr$ $nmbr$ cm vas','C3536884','VAS','Visual Analog Scale','true'
'patient global assessment of disease activity $nmbr$ $nmbr$ cm vas','C3827561','VAS','Vibroacoustic Stimulation','false'
'unrelated to effectiveness','C0445356','Unrelated','Unrelated (finding)','false'
'unrelated to effectiveness','C1704623','Unrelated','Unrelated to Intervention','false'
'physician global assessment of disease activity $nmbr$ $nmbr$ cm vas','C4050369','Physician Global Assessment of Disease Activity','Physician Global Assessment of Disease Activity','false'
'physician global assessment of disease activity $nmbr$ $nmbr$ cm vas','C0042815','VAS','Visual Analog Pain Scale','true'
'physician global assessment of disease activity $nmbr$ $nmbr$ cm vas','C3536884','VAS','Visual Analog Scale','true'
'physician global assessment of disease activity $nmbr$ $nmbr$ cm vas','C3827561','VAS','Vibroacoustic Stimulation','false'
'assessment of physical function $nmbr$ $nmbr$ haq di','C0031809','Physical Assessment','Physical Examination','true'
'c reactive protein concentration mg l','C0006560','C Reactive Protein','C-reactive protein','true'
'c reactive protein concentration mg l','C0439268','mg/L','Microgram per Milliliter','false'
'c reactive protein concentration mg l','C1413716','C-reactive protein','CRP gene','false'
'c reactive protein concentration mg l','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'erythrocyte sedimentation rate mm h','C1176468','Erythrocyte Sedimentation Rate','Erythrocyte sedimentation rate measurement','false'
'erythrocyte sedimentation rate mm h','C0456680','mm/h','mm/h','false'
'erythrocyte sedimentation rate mm h','C1619634','Erythrocyte sedimentation rate','erythrocyte sedimentation rate result','true'
'das $nmbr$ score','C0449820','SCORE','Score','false'
'das $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'facit f score','C3272505','FACIT-F','FACIT Fatigue Scale','false'
'facit f score','C0449820','SCORE','Score','false'
'facit f score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'methotrexate treatment','C0746573','methotrexate treatment','methotrexate treatment','false'
'hydroxychloroquine treatment','C0039798','treatment','therapeutic aspects','true'
'hydroxychloroquine treatment','C0087111','Treatment','Therapeutic procedure','true'
'hydroxychloroquine treatment','C1522326','Treatment','Treating','false'
'hydroxychloroquine treatment','C1533734','Treatment','Administration procedure','false'
'hydroxychloroquine treatment','C1705169','Treatment','Biomaterial Treatment','false'
'hydroxychloroquine treatment','C3538994','TREATMENT','Treatment Epoch','false'
'hydroxychloroquine treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'sulfasalazine treatment','C0039798','treatment','therapeutic aspects','true'
'sulfasalazine treatment','C0087111','Treatment','Therapeutic procedure','true'
'sulfasalazine treatment','C1522326','Treatment','Treating','false'
'sulfasalazine treatment','C1533734','Treatment','Administration procedure','false'
'sulfasalazine treatment','C1705169','Treatment','Biomaterial Treatment','false'
'sulfasalazine treatment','C3538994','TREATMENT','Treatment Epoch','false'
'sulfasalazine treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C0025677','METHOTREXATE','Methotrexate','true'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C0020336','HYDROXYCHLOROQUINE','Hydroxychloroquine','true'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C0039798','treatment','therapeutic aspects','true'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C0087111','Treatment','Therapeutic procedure','true'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C1522326','Treatment','Treating','false'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C1533734','Treatment','Administration procedure','false'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C1705169','Treatment','Biomaterial Treatment','false'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C3538994','TREATMENT','Treatment Epoch','false'
'no methotrexate hydroxychloroquine or sulfasalazine treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment for latent tuberculosis^','C0749724','tuberculosis treatment','tuberculosis treatment','false'
'zoledronic acid','C0257685','ZOLEDRONIC ACID','zoledronic acid','true'
'$nmbr$ $nmbr$ yr','C0439234','yr','year','false'
'age at menopause yr','C1625754','Age at menopause','Age at menopause:Time:Point in time:^Patient:Quantitative','false'
'age at menopause yr','C1629609','Age at Menopause','Age at menopause','false'
'americas','C0002454','Americas','Americas','true'
'americas','C0596070','Americas','Americas Ethnicity','false'
'asia','C0003980','Asia','Asia','true'
'bmi kg m $nmbr$ a','C0578022','BMI','Finding of body mass index','false'
'bmi kg m $nmbr$ a','C1532718','kg-m','kg-m','false'
'$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'$nmbr$ $nmbr$ $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'$nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'weight kg a','C0022718','KG','Kyrgyzstan','true'
'weight kg a','C0439209','kg','Kilogram','false'
'weight kg a','C4054209','/kg','Per Kilogram','false'
'height loss','C0424641','height loss','Decrease in height','false'
'baseline vfx','C0168634','baseline','BaseLine dental cement','true'
'baseline vfx','C1442488','Baseline','Baseline','false'
'history of falls','C1561668','History of fall','History of fall','false'
'history of falls','C2919132','History of fall','Encounter due to history of falling','false'
'unknown','C0439673','UNKNOWN','Unknown','false'
'unknown','C3541433','unknown','unknown vaccine or immune globulin','false'
'unknown','C4050014','UNKNOWN','Unknown GENC','false'
'physical activity hours walking wk','C0015259','Physical Activity','Exercise','true'
'physical activity hours walking wk','C0439227','HOURS','Hour','false'
'physical activity hours walking wk','C0026606','Physical Activity','Physical activity','true'
'physical activity hours walking wk','C0080331','Walking','Walking (activity)','true'
'physical activity hours walking wk','C4283795','Walking','Symptoms Interfered with Walking','false'
'physical activity hours walking wk','C4321241','Walking','Usually Need Help from Another Person for Walking','false'
'physical activity hours walking wk','C4321242','Walking','Hard to Walk More Than One Block','false'
'physical activity hours walking wk','C0332174','/wk','Weekly','false'
'physical activity hours walking wk','C0439230','wk','week','false'
'prior bisphosphonate usage','C0012544','Bisphosphonate','Diphosphonates','true'
'prior bisphosphonate usage','C0457083','Usage','Usage','false'
'prior bisphosphonate usage','C2267018','Bisphosphonate','Bisphosphonate [EPC]','false'
'total hip bmd g cm $nmbr$','C0019552','HIP','Hip structure','true'
'total hip bmd g cm $nmbr$','C0022122','Hip','Bone structure of ischium','true'
'total hip bmd g cm $nmbr$','C1505163','HIP','HHIP protein, human','true'
'total hip bmd g cm $nmbr$','C3538851','HIP','REG3A wt Allele','false'
'total hip bmd g cm $nmbr$','C4284725','HIP','HHIP wt Allele','false'
'standardized total hip bmd g cm $nmbr$','C0019552','HIP','Hip structure','true'
'standardized total hip bmd g cm $nmbr$','C0022122','Hip','Bone structure of ischium','true'
'standardized total hip bmd g cm $nmbr$','C1505163','HIP','HHIP protein, human','true'
'standardized total hip bmd g cm $nmbr$','C3538851','HIP','REG3A wt Allele','false'
'standardized total hip bmd g cm $nmbr$','C4284725','HIP','HHIP wt Allele','false'
'femoral neck bmd g cm $nmbr$','C0015815','Femoral Neck','Structure of neck of femur','true'
'femoral neck bmd g cm $nmbr$','C0439267','g%','Gram per Deciliter','false'
'femoral neck t score','C0449820','SCORE','Score','false'
'femoral neck t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ ml min','C0439445','mL/min','mL/min','false'
'category','C0683312','Category','Categories','false'
'category','C3889287','Category','Digital Content Category','false'
'mean change in fn bmd','C0392747','Change','Changing','false'
'mean change in fn bmd','C0443172','change','Changed status','false'
'mean change in fn bmd','C1705241','Change','Delta (difference)','false'
'mean change in fn bmd','C4319952','Change','Change -- procedure','false'
'least squares mean between treatment difference $nmbr$ ci','C0023189','Least Squares','Least-Squares Analysis','true'
'least squares mean between treatment difference $nmbr$ ci','C0444504','Mean','Statistical mean','false'
'least squares mean between treatment difference $nmbr$ ci','C2347634','Mean','Population Mean','false'
'least squares mean between treatment difference $nmbr$ ci','C2348143','Mean','Sample Mean','false'
'p value within category','C1709380','P-Value','P-Value','false'
'p value within category','C0683312','Category','Categories','false'
'p value within category','C3889287','Category','Digital Content Category','false'
'p value interaction','C1709380','P-Value','P-Value','false'
'p value interaction','C1704675','Interaction','Interaction','false'
'and vfx status','C0449438','Status','Status','false'
'height loss cm','C0424641','height loss','Decrease in height','false'
'prior bp use','C0042153','use','utilization qualifier','true'
'prior bp use','C0457083','Use','Usage','false'
'prior bp use','C1947944','Use','Use - dosing instruction imperative','false'
'crcl ml min','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl ml min','C0439445','mL/min','mL/min','false'
'infliximab','C0666743','INFLIXIMAB','infliximab','true'
'p valuea','C0369773','P NOS','P Blood group antibodies','false'
'p valuea','C2603361','P'','P prime','false'
'$nmbr$ mg kg','C0439272','mg kg','ug/g','false'
'combined','C0205195','Combined','Combined','false'
'patients randomized n','C0030705','Patients','Patients','true'
'patients randomized n','C0034656','Randomized','Randomization','true'
'patients randomized n','C3815594','RANDOMIZED','Subject is Randomized','false'
'male sex n','C0086582','MALE SEX','Males','true'
'white race n','C0007457','white race','Caucasoid Race','true'
'white race n','C0043157','white race','Caucasians','true'
'disease duration y','C0872146','disease duration','disease length','false'
'colonic area involved','C0017446','Area','Geographic Locations','true'
'colonic area involved','C0205146','AREA','Area','false'
'colonic area involved','C1314939','Involved','Involvement with','false'
'left side n','C0205091','Left side','Left','false'
'extensive n','C0205231','Extensive','Extensive','false'
'mayo clinic scoreb','C0002424','Clinic','Ambulatory Care Facilities','true'
'mayo clinic scoreb','C0442592','Clinic','Clinic','false'
'c reactive proteinc','C0205332','Reactive','Reactive','false'
'mean mg dl','C0444504','Mean','Statistical mean','false'
'mean mg dl','C0439269','mg dl','mg/dL','false'
'mean mg dl','C2347634','Mean','Population Mean','false'
'mean mg dl','C2348143','Mean','Sample Mean','false'
'median mg dl','C0549183','Median','Midline (qualifier value)','false'
'median mg dl','C0439269','mg dl','mg/dL','false'
'median mg dl','C0876920','Median','Median Statistical Measurement','false'
'median mg dl','C2347635','Median','Population Median','false'
'median mg dl','C2348144','Median','Sample Median','false'
'median mg dl','C2939193','Median','Median (qualifier value)','false'
'elevated crp n','C0742906','Elevated CRP','Elevated C-reactive protein','false'
'concomitant medication n','C0521115','Concomitant','Simultaneous','false'
'concomitant medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'concomitant medication n','C3244316','medication','medication - HL7 publishing domain','false'
'concomitant medication n','C4284232','Medication','Medications','false'
'any ulcerative colitis medication','C0013227','Medication','Pharmaceutical Preparations','true'
'any ulcerative colitis medication','C3244316','medication','medication - HL7 publishing domain','false'
'any ulcerative colitis medication','C4284232','Medication','Medications','false'
'corticosteroids','C0001617','Corticosteroids','Adrenal Cortex Hormones','true'
'corticosteroids','C3539185','Corticosteroids','Corticosteroid nasal preparations for topical use','false'
'corticosteroids','C3540725','CORTICOSTEROIDS','Corticosteroid otologicals','false'
'corticosteroids','C3540726','CORTICOSTEROIDS','Corticosteroid ophthalmologic and otologic preparations','false'
'corticosteroids','C3540727','Corticosteroids','Corticosteroids, topical for treatment of hemorrhoids and anal fissures','false'
'$nmbr$ mg day','C0439422','mg day','milligram/day','false'
'aminosalicylates','C0368663','Aminosalicylates','aminosalicylate','false'
'immunomodulators','C0001551','immunomodulators','Immunologic Adjuvants','true'
'immunomodulators','C0005525','Immunomodulators','Biological Response Modifiers','true'
'immunomodulators','C1527392','Immunomodulators','Immunomodulators','true'
'azathioprine','C0004482','AZATHIOPRINE','Azathioprine','true'
'$nmbr$ mercaptopurine','C0000618','MERCAPTOPURINE','mercaptopurine','true'
'refractory to corticosteroids n','C0205269','Refractory','Unresponsive to Treatment','false'
'refractory to corticosteroids n','C0001617','Corticosteroids','Adrenal Cortex Hormones','true'
'refractory to corticosteroids n','C3539185','Corticosteroids','Corticosteroid nasal preparations for topical use','false'
'refractory to corticosteroids n','C3540725','CORTICOSTEROIDS','Corticosteroid otologicals','false'
'refractory to corticosteroids n','C3540726','CORTICOSTEROIDS','Corticosteroid ophthalmologic and otologic preparations','false'
'refractory to corticosteroids n','C3540727','Corticosteroids','Corticosteroids, topical for treatment of hemorrhoids and anal fissures','false'
'smoking status n','C1519386','Smoking Status','Smoking Status','false'
'nonsmoker','C0337672','nonsmoker','Non-smoker','false'
'nonsmoker','C0425293','Non-Smoker','Never smoked tobacco','false'
'nonsmoker','C4554605','Nonsmoker','Non-Smokers -- population group','true'
'prior smoker','C0337671','Prior Smoker','Former smoker','false'
'infliiimab i','C0021966','I-','Iodides','true'
'infliiimab i','C0221138','I NOS','Blood group antibody I','false'
'hazard inleraction','C0598697','Hazard','hazard','false'
'ratio','C0456603','RATIO','Ratio','false'
'ratio','C1547037','Ratio','data type - ratio','false'
'$nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'study','C0557651','Study','Room of building - Study','false'
'study','C2603343','Study','Study','false'
'act $nmbr$','C0079613','ACT','Adoptive Immunotherapy','true'
'act $nmbr$','C1704930','ACT','ACTG2 wt Allele','false'
'act $nmbr$','C1869853','ACT','SERPINA3 protein, human','true'
'act $nmbr$','C3890007','ACT','SERPINA3 wt Allele','false'
'act $nmbr$','C4048375','ACT','Asthma Control Test Questionnaire','false'
'nap','C0870935','Nap','Napping','false'
'nap','C1423800','NAP','CTNNBL1 gene','false'
'nap','C4283878','NAP','Neutrophil Activation Probe Imaging Agent','false'
'inflotmas io mgluj versus piecew','C1046794','Io','Genus Io','false'
'inflotmas io mgluj versus piecew','C3146236','Io','Io <angiosperm>','false'
'cortteosterom relrsclory status','C0449438','Status','Status','false'
'uc disease durslion','C0012634','Disease','Disease','true'
'ss years','C2699257','SS','SS, Rat Strain','false'
'ss years','C0439234','YEARS','year','false'
'ss years','C3891295','SS','Subject Status Domain','false'
'ss years','C4551874','Ss','BLOOD GROUP, Ss','false'
'$nmbr$ yearstos is years','C0439234','YEARS','year','false'
'ibs $nmbr$ $nmbr$','C0022104','IBS','Irritable Bowel Syndrome','true'
'ibs $nmbr$ $nmbr$','C0432306','IBS','Ichthyosis Bullosa of Siemens','true'
'is years','C0439234','YEARS','year','false'
'exlertl ot disease','C1318464','OT','Occupational therapy regime','true'
'exlertl ot disease','C0012634','Disease','Disease','true'
'exlertl ot disease','C1418208','OT','OXT gene','false'
'exlertl ot disease','C1705587','OT','OXT wt Allele','false'
'batellna c reective protein','C0033684','PROTEIN','Proteins','true'
'$nmbr$ $nmbr$ tng cll','C0023434','CLL','Chronic Lymphocytic Leukemia','true'
'baseline mayo score','C0449820','SCORE','Score','false'
'baseline mayo score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'center location','C0450429','Location','Location','false'
'center location','C1515974','Location','Anatomic Site','false'
'center location','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'center location','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'czech repumc','C0337799','Czech','Czech','false'
'nc','C0027964','NC','New Caledonia','true'
'nc','C0028407','NC','North Carolina','true'
'nc','C0067895','NC','Chimerin 1','true'
'nc','C0265987','NC','Nevus comedonicus','false'
'israel','C0022271','ISRAEL','Israel','true'
'southern hemisphere','C1710133','Southern','South','false'
's asa compounds at baseline','C0205198','Compound','Compound','false'
's asa compounds at baseline','C1706082','Compound','Compound (substance)','false'
'$nmbr$ $nmbr$ s s','C0565930','/s','per second','false'
'$nmbr$ $nmbr$ s s','C2603362','S'','S prime','false'
'coiticosieroids at baseline','C0168634','baseline','BaseLine dental cement','true'
'coiticosieroids at baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ mgday p eq','C0205163','EQ','Equal','false'
'$nmbr$ mgday p eq','C0439185','eq','Equivalent Weight','false'
'ssomgdayp eq','C0205163','EQ','Equal','false'
'ssomgdayp eq','C0439185','eq','Equivalent Weight','false'
'$nmbr$ up and or aza at baseline','C0004482','AZA','Azathioprine','true'
'$nmbr$ up and or aza at baseline','C0168634','baseline','BaseLine dental cement','true'
'$nmbr$ up and or aza at baseline','C1442488','Baseline','Baseline','false'
'not receiving','C1518422','Not','Negation','false'
'not receiving','C1514756','RECEIVING','Receive','false'
'conieosieroids and or $nmbr$ mp','C0024944','MP','Mauritius','true'
'and or aza at baseline','C0004482','AZA','Azathioprine','true'
'and or aza at baseline','C0168634','baseline','BaseLine dental cement','true'
'and or aza at baseline','C1442488','Baseline','Baseline','false'
'combined infliximab','C0205195','Combined','Combined','false'
'combined infliximab','C0666743','INFLIXIMAB','infliximab','true'
'hazard interaction','C0598697','Hazard','hazard','false'
'hazard interaction','C1704675','Interaction','Interaction','false'
'baseline age','C0168634','baseline','BaseLine dental cement','true'
'baseline age','C0001779','AGE','Age','false'
'baseline age','C1442488','Baseline','Baseline','false'
'baseline smoking status','C0168634','baseline','BaseLine dental cement','true'
'baseline smoking status','C1519386','Smoking Status','Smoking Status','false'
'baseline smoking status','C1442488','Baseline','Baseline','false'
'non smoker','C0337672','Non-smoker','Non-smoker','false'
'non smoker','C0425293','Non-Smoker','Never smoked tobacco','false'
'non smoker','C4554605','Non-Smoker','Non-Smokers -- population group','true'
'previous segments resection s','C0015252','resection','removal technique','false'
'previous segments resection s','C0728940','Resection','Excision','false'
'other uc related gi surgical procedure','C0439849','Related','Relationships','false'
'other uc related gi surgical procedure','C0543467','Surgical Procedure','Operative Surgical Procedures','true'
'other uc related gi surgical procedure','C0445223','Related','Related personal status','false'
'itt patients n','C0030705','Patients','Patients','true'
'mean age s d years','C0444504','Mean','Statistical mean','false'
'mean age s d years','C0001779','AGE','Age','false'
'mean age s d years','C2347634','Mean','Population Mean','false'
'mean age s d years','C2348143','Mean','Sample Mean','false'
'mean age s d years','C0439234','YEARS','year','false'
'mean bmi s d kg m $nmbr$','C0444504','Mean','Statistical mean','false'
'mean bmi s d kg m $nmbr$','C0578022','BMI','Finding of body mass index','false'
'mean bmi s d kg m $nmbr$','C2347634','Mean','Population Mean','false'
'mean bmi s d kg m $nmbr$','C2348143','Mean','Sample Mean','false'
'mean bmi s d kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean bmi s d kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean bmi s d kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'mean hba $nmbr$ c s d','C0444504','Mean','Statistical mean','false'
'mean hba $nmbr$ c s d','C0019016','HBA','Hemoglobin A','true'
'mean hba $nmbr$ c s d','C1825777','HBA','KRT90P gene','false'
'mean hba $nmbr$ c s d','C3538758','HBA','SCN2A wt Allele','false'
'mean hba $nmbr$ c s d','C2347634','Mean','Population Mean','false'
'mean hba $nmbr$ c s d','C2348143','Mean','Sample Mean','false'
'treatment with sulphonylurea n','C0039798','treatment','therapeutic aspects','true'
'treatment with sulphonylurea n','C0087111','Treatment','Therapeutic procedure','true'
'treatment with sulphonylurea n','C1522326','Treatment','Treating','false'
'treatment with sulphonylurea n','C1533734','Treatment','Administration procedure','false'
'treatment with sulphonylurea n','C1705169','Treatment','Biomaterial Treatment','false'
'treatment with sulphonylurea n','C3538994','TREATMENT','Treatment Epoch','false'
'treatment with sulphonylurea n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment with sulphonylurea biguanide n','C0039798','treatment','therapeutic aspects','true'
'treatment with sulphonylurea biguanide n','C0087111','Treatment','Therapeutic procedure','true'
'treatment with sulphonylurea biguanide n','C1522326','Treatment','Treating','false'
'treatment with sulphonylurea biguanide n','C1533734','Treatment','Administration procedure','false'
'treatment with sulphonylurea biguanide n','C1705169','Treatment','Biomaterial Treatment','false'
'treatment with sulphonylurea biguanide n','C3538994','TREATMENT','Treatment Epoch','false'
'treatment with sulphonylurea biguanide n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0392747','Change','Changing','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0443172','change','Changed status','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1705241','Change','Delta (difference)','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C4319952','Change','Change -- procedure','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0168634','baseline','BaseLine dental cement','true'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1442488','Baseline','Baseline','false'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0013175','study drug','Drug Evaluation','true'
'fig $nmbr$ change in hba $nmbr$ c from baseline to study endpoint intention to treat population hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1710181','Standard Error','Standard Error','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0444504','Mean','Statistical mean','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C2347634','Mean','Population Mean','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C2348143','Mean','Sample Mean','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0019016','HBA','Hemoglobin A','true'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0033727','H+','Protons','true'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0369286','H NOS','H NOS Antibodies','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0441932','H+','Hepatic Involvement','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0564385','/h','/hour','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C4528284','h*%','Hour Times Percent','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1825777','HBA','KRT90P gene','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C3538758','HBA','SCN2A wt Allele','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C2348070','Total Daily Dose','Daily Dose','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0455280','plasma glucose','Plasma glucose result','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C0015663','FASTING','Fasting','true'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1955477','Glucose (oral)','Glucose (oral)','false'
'fig $nmbr$ mean s e hba $nmbr$ c levels fpg levels $nmbr$ h ppg levels and total daily glulisine dose in itt population $nmbr$ h ppg $nmbr$ hour postprandial plasma glucose fpg fasting morning plasma glucose hba $nmbr$ c glycosylated haemoglobin a $nmbr$ c oad oral antidiabetic drugs s e standard error','C1710181','Standard Error','Standard Error','false'
'placebo pioglitazone n $nmbr$','C0032042','Placebo','Placebos','true'
'placebo pioglitazone n $nmbr$','C0071097','PIOGLITAZONE','pioglitazone','true'
'placebo pioglitazone n $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo pioglitazone n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C3535925','ALOGLIPTIN/PIOGLITAZONE','alogliptin / pioglitazone','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C0024671','MG','Mammography','true'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C0026410','MG','Mongolia','true'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C0439269','mg%','mg/dL','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C1960952','mg %','Milligram percent','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C4321396','MG','MG','false'
'alogliptin $nmbr$ $nmbr$ mg pioglitazone n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C3535925','ALOGLIPTIN/PIOGLITAZONE','alogliptin / pioglitazone','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C0024671','MG','Mammography','true'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C0026410','MG','Mongolia','true'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C0439269','mg%','mg/dL','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C1960952','mg %','Milligram percent','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C4321396','MG','MG','false'
'alogliptin $nmbr$ mg pioglitazone n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'black or african american','C0005680','Black','Black race','true'
'black or african american','C0027567','Black','African race','true'
'black or african american','C0085756','BLACK','African American','true'
'black or african american','C0439541','Black','Black color','false'
'non hispanic','C1518424','Non-Hispanic','Not Hispanic or Latino','false'
'diabetes history mean sd years','C0011847','Diabetes','Diabetes','false'
'diabetes history mean sd years','C0439234','YEARS','year','false'
'diabetes history mean sd years','C0011849','Diabetes','Diabetes Mellitus','true'
'pioglitazone dose mean sd mg','C0024671','MG','Mammography','true'
'pioglitazone dose mean sd mg','C0026410','MG','Mongolia','true'
'pioglitazone dose mean sd mg','C0439269','mg%','mg/dL','false'
'pioglitazone dose mean sd mg','C1960952','mg %','Milligram percent','false'
'pioglitazone dose mean sd mg','C2346927','Mg++','Magnesium Cation','false'
'pioglitazone dose mean sd mg','C4321396','MG','MG','false'
'pioglitazone dose mean sd mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'other hypoglycemic agent n','C0020616','Hypoglycemic agent','Hypoglycemic Agents','true'
'sulfonylurea','C0038766','Sulphonylurea','Sulfonylurea Compounds','true'
'sulfonylurea','C3536898','Sulfonylurea','Sulfonylurea [EPC]','false'
'median range','C1514721','Range','Range','false'
'median range','C2348147','Range','Sample Range','false'
'median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'$nmbr$ n of patients','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ n of patients','C0441922','N+','N+ (tumor staging)','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0392747','changes','Changing','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0443172','changes','Changed status','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0332174','/week','Weekly','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0439230','Week','week','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0439780','Forward','Forward','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0062259','hemoglobin C, glycosylated','hemoglobin C, glycosylated','true'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0042295','Values','Values','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0019016','HBA','Hemoglobin A','true'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C1825777','HBA','KRT90P gene','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C3538758','HBA','SCN2A wt Allele','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0369773','P NOS','P Blood group antibodies','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C1520214','Yp','Yp','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C2603361','P'','P prime','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C0032042','Placebo','Placebos','true'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ least squares ls mean changes from baseline to week $nmbr$ last observations carried forward in glycosylated hemoglobin hba $nmbr$ c in patients with baseline values of hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ and $nmbr$ $nmbr$ p $nmbr$ $nmbr$ yp $nmbr$ $nmbr$ vs placebo','C1706408','PLACEBO','Placebo Control','false'
'with tamsulosin','C0257343','TAMSULOSIN','tamsulosin','true'
'without tamsulosin','C0257343','TAMSULOSIN','tamsulosin','true'
'no japanese','C0376247','Japanese','Japanese language','false'
'no japanese','C1556094','JAPANESE','Japanese race','true'
'time since bph diagnosis years','C0556970','time year','times/year','false'
'time since bph diagnosis years','C0005001','BPH','Benign prostatic hypertrophy','true'
'time since bph diagnosis years','C1704272','BPH','Benign Prostatic Hyperplasia','true'
'no previous alpha blocker use','C0042153','use','utilization qualifier','true'
'no previous alpha blocker use','C0457083','Use','Usage','false'
'no previous alpha blocker use','C1947944','Use','Use - dosing instruction imperative','false'
'ipss unit','C0439148','Unit','Unit','false'
'ipss unit','C0439453','Unit','International Unit','false'
'ipss unit','C1509845','Unit','Unit device','false'
'ipss unit','C1519795','Unit','Unit of Measure','false'
'ipss unit','C1704753','Unit','Storage Unit','false'
'ipss unit','C1880519','Unit','Enzyme Unit','false'
'ipss unit','C3853603','Unit','Unit - NCI Thesaurus Property','false'
'prostate volume ml','C0439526','/mL','/mL','false'
'prostate volume ml','C1705224','ML','THPO wt Allele','false'
'prostate volume ml','C3887665','ML','Thrombopoietin, human','false'
'figure $nmbr$ primary e cacy results by patient subgroup','C0205225','Primary','Primary','false'
'figure $nmbr$ primary e cacy results by patient subgroup','C1547647','Patient Result','Patient Outcome','false'
'figure $nmbr$ primary e cacy results by patient subgroup','C0439612','Primary','True primary (qualifier value)','false'
'figure $nmbr$ primary e cacy results by patient subgroup','C0439631','Primary','Primary operation','false'
'shfm annual mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'shfm annual mortality','C0026566','mortality','Aspects of mortality statistics','true'
'quintile $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$','C1508496','Quintile','Quintile','false'
'randomized treatment n','C0034656','Randomized','Randomization','true'
'randomized treatment n','C0039798','treatment','therapeutic aspects','true'
'randomized treatment n','C0087111','Treatment','Therapeutic procedure','true'
'randomized treatment n','C1522326','Treatment','Treating','false'
'randomized treatment n','C1533734','Treatment','Administration procedure','false'
'randomized treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'randomized treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'randomized treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'randomized treatment n','C3815594','RANDOMIZED','Subject is Randomized','false'
'nyha class iii n','C1882086','NYHA CLASS III','New York Heart Association Class III','false'
'ischemic hf n','C0475224','Ischemic','Ischemic','false'
'ischemic hf n','C0018488','Hf','Hafnium','true'
'ischemic hf n','C1313497','HF','GZMA protein, human','true'
'ischemic hf n','C1538440','HF','CFH gene','false'
'ischemic hf n','C3273279','HF','CFH wt Allele','false'
'serum sodium meq l','C0523891','Serum sodium','Serum sodium measurement','false'
'serum sodium meq l','C0439375','mEq/L','mEq/L','false'
'systolic bp mm hg','C0871470','systolic bp','Systolic Pressure','true'
'systolic bp mm hg','C0439475','mmHG','mmHg','false'
'furosemide equivalent mg kg','C0016860','FUROSEMIDE','Furosemide','true'
'furosemide equivalent mg kg','C0439272','mg kg','ug/g','false'
'digoxin n','C0012265','DIGOXIN','Digoxin','true'
'ace i or arb n','C0021966','I-','Iodides','true'
'ace i or arb n','C0221138','I NOS','Blood group antibody I','false'
'ace i or arb n','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'statin n','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'carvedilol n','C0054836','CARVEDILOL','carvedilol','true'
'qrs $nmbr$ ms n','C2349943','Ms.','Ms. - Title','false'
'qrs $nmbr$ ms n','C3539704','MS','MTR wt Allele','false'
'qrs $nmbr$ ms n','C3713294','MS','MTR protein, human','true'
'qrs width ms','C2349943','Ms.','Ms. - Title','false'
'qrs width ms','C3539704','MS','MTR wt Allele','false'
'qrs width ms','C3713294','MS','MTR protein, human','true'
'$nmbr$ min walk distance ft','C1881534','ft.','Make - Instruction Imperative','false'
'$nmbr$ min walk distance ft','C3890579','FT','Functional Tests Domain','false'
'quintile n','C1508496','Quintile','Quintile','false'
'total deaths n','C0439175','% total','% of total','false'
'total deaths n','C0011065','deaths','Cessation of life','true'
'total deaths n','C1306577','DEATHS','Death (finding)','false'
'total deaths n','C0439810','Total','Total','false'
'placebo mortality rate events per $nmbr$ person y','C0441471','Events','Event','false'
'placebo mortality rate events per $nmbr$ person y','C3541888','EVENTS','CDISC Events Class','false'
'relative risk comparing icd therapy and placebo','C0242492','Relative Risk','Relative Risk','true'
'relative risk comparing icd therapy and placebo','C1707455','Compare','Comparison','false'
'relative risk comparing icd therapy and placebo','C0039798','therapy','therapeutic aspects','true'
'relative risk comparing icd therapy and placebo','C0087111','Therapy','Therapeutic procedure','true'
'relative risk comparing icd therapy and placebo','C1363945','Therapy','Therapy Object (animal model)','false'
'relative risk comparing icd therapy and placebo','C0032042','Placebo','Placebos','true'
'relative risk comparing icd therapy and placebo','C1696465','PLACEBO','placebo','false'
'relative risk comparing icd therapy and placebo','C1706408','PLACEBO','Placebo Control','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0242492','Relative Risk','Relative Risk','true'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0596019','Cl -','Chloride Ion','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1707455','Compare','Comparison','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0039798','therapy','therapeutic aspects','true'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0087111','Therapy','Therapeutic procedure','true'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1363945','Therapy','Therapy Object (animal model)','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0032042','Placebo','Placebos','true'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1696465','PLACEBO','placebo','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1706408','PLACEBO','Placebo Control','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1524063','Using','Use of','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C0233324','Term','Term Birth','true'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1515273','Term','Term (temporal)','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C1705313','Term','Term (lexical)','false'
'relative risk $nmbr$ cl comparing icd therapy and placebo using a linear interaction term in the model shfmxicd','C2826302','TERM','Reported Term','false'
'rr $nmbr$ cl','C4554402','RR','RR genotype','false'
'rr $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'ii $nmbr$','C1710602','II','VIPR1 wt Allele','false'
'ii $nmbr$','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'iii $nmbr$','C0439070','III','Roman Numeral III','false'
'iii $nmbr$','C1705160','III','III (suffix)','false'
'iv $nmbr$','C0022326','IV','Ivory Coast','true'
'iv $nmbr$','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'dabigatran $nmbr$ mg','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'warfarin','C0043031','WARFARIN','Warfarin','true'
'male sex no total no','C0086582','MALE SEX','Males','true'
'male sex no total no','C0439175','% total','% of total','false'
'male sex no total no','C0439810','Total','Total','false'
'type of atrial fibrillation no total no','C0332307','TYPE','Type - attribute','false'
'type of atrial fibrillation no total no','C1547052','*Type','*Type - Kind of quantity','false'
'type of atrial fibrillation no total no','C0439175','% total','% of total','false'
'type of atrial fibrillation no total no','C0439810','Total','Total','false'
'chads $nmbr$ scoref','C0007928','CHAD','Chad','true'
'chads $nmbr$ scoref','C1413373','CHAD','CHAD gene','false'
'$nmbr$ or $nmbr$ no total no','C0439175','% total','% of total','false'
'$nmbr$ or $nmbr$ no total no','C0439810','Total','Total','false'
'$nmbr$ no total no','C0439175','% total','% of total','false'
'$nmbr$ no total no','C0439810','Total','Total','false'
'$nmbr$ $nmbr$ no total no','C0439175','% total','% of total','false'
'$nmbr$ $nmbr$ no total no','C0439810','Total','Total','false'
'previous stroke or transient ischemic attack no total','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or transient ischemic attack no total','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or transient ischemic attack no total','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'previous stroke or transient ischemic attack no total','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'previous stroke or transient ischemic attack no total','C0439175','% total','% of total','false'
'previous stroke or transient ischemic attack no total','C0439810','Total','Total','false'
'heart failure no total no','C0018801','Failure, Heart','Heart failure','true'
'heart failure no total no','C0018802','Heart Failure','Congestive heart failure','true'
'heart failure no total no','C4554158','Heart failure','Heart Failure, CTCAE','false'
'heart failure no total no','C0439175','% total','% of total','false'
'heart failure no total no','C0439810','Total','Total','false'
'medications in use at baseline no total no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications in use at baseline no total no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications in use at baseline no total no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications in use at baseline no total no','C4284232','Medications','Medications','false'
'medications in use at baseline no total no','C0150312','In','Present','false'
'medications in use at baseline no total no','C0042153','use','utilization qualifier','true'
'medications in use at baseline no total no','C0457083','Use','Usage','false'
'medications in use at baseline no total no','C1947944','Use','Use - dosing instruction imperative','false'
'medications in use at baseline no total no','C0332285','In','Within','false'
'medications in use at baseline no total no','C1707101','IN','CD44 wt Allele','false'
'medications in use at baseline no total no','C0439175','% total','% of total','false'
'medications in use at baseline no total no','C0439810','Total','Total','false'
'arb or ace inhibitor','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'arb or ace inhibitor','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'arb or ace inhibitor','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'stating','C1301808','State','Geographic state','false'
'stating','C1442792','State','State','false'
'stating','C3148680','State','US State','false'
'proton pump inhibitor','C0358591','Proton Pump Inhibitor','Proton Pump Inhibitors','true'
'proton pump inhibitor','C3536754','Proton Pump Inhibitor','Proton Pump Inhibitor [EPC]','false'
'proton pump inhibitor','C4521480','Proton pump inhibitor','H+/K+-exchanging ATPase inhibitor (disposition)','false'
'h $nmbr$ receptor antagonist','C0033727','H+','Protons','true'
'h $nmbr$ receptor antagonist','C4543207','Receptor antagonist','Receptor antagonist (disposition)','false'
'h $nmbr$ receptor antagonist','C0369286','H NOS','H NOS Antibodies','false'
'h $nmbr$ receptor antagonist','C0441932','H+','Hepatic Involvement','false'
'h $nmbr$ receptor antagonist','C0564385','/h','/hour','false'
'h $nmbr$ receptor antagonist','C4528284','h*%','Hour Times Percent','false'
'long term vka therapy','C0039798','therapy','therapeutic aspects','true'
'long term vka therapy','C0087111','Therapy','Therapeutic procedure','true'
'long term vka therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'patients total no','C0439175','% total','% of total','false'
'patients total no','C0439810','Total','Total','false'
'dabigatran $nmbr$ mg $nmbr$ mg per yr','C1319635','mg/mg','mg/mg','false'
'dabigatran $nmbr$ mg $nmbr$ mg per yr','C0439234','yr','year','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C0024671','MG','Mammography','true'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C0026410','MG','Mongolia','true'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C0439269','mg%','mg/dL','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C1960952','mg %','Milligram percent','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C2346927','Mg++','Magnesium Cation','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C4321396','MG','MG','false'
'hazard ratio with dabigatran $nmbr$ mg $nmbr$ cl','C4521761','MG','United States Military Commissioned Officer O8','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C1709380','P-Value','P-Value','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C0178602','Dosage','Dosage','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C2986497','dosage','Cumulative Dose','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C0024671','MG','Mammography','true'
'p value for interaction dosage with dabigatran $nmbr$ mg','C0026410','MG','Mongolia','true'
'p value for interaction dosage with dabigatran $nmbr$ mg','C0439269','mg%','mg/dL','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C4321396','MG','MG','false'
'p value for interaction dosage with dabigatran $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'b i','C0021966','I-','Iodides','true'
'b i','C0221138','I NOS','Blood group antibody I','false'
'g','C0439267','g%','Gram per Deciliter','false'
'weight','C0005910','Weight','Body Weight','true'
'weight','C0043100','Weight','Weight','true'
'weight','C1305866','weight','Weighing patient','false'
'weight','C1705104','Weight','Importance Weight','false'
'$nmbr$ $nmbr$ kg','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ $nmbr$ kg','C0439209','kg','Kilogram','false'
'$nmbr$ $nmbr$ kg','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg','C0439209','kg','Kilogram','false'
'$nmbr$ kg','C4054209','/kg','Per Kilogram','false'
'european or arab','C0239307','EUROPEAN','ethnic european','false'
'european or arab','C1535514','EUROPEAN','European race','false'
'european or arab','C0282540','Arab','arab ethnic group','true'
'european or arab','C1561448','ARAB','Arab race','false'
'r','C0205090','R-','Right','false'
'r','C0684010','R.','Rabbi','true'
'r','C2603358','R'','R prime','false'
'$nmbr$ $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'chads $nmbr$ score','C0449820','SCORE','Score','false'
'chads $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'h','C0033727','H+','Protons','true'
'h','C0369286','H NOS','H NOS Antibodies','false'
'h','C0441932','H+','Hepatic Involvement','false'
'h','C0564385','/h','/hour','false'
'h','C4528284','h*%','Hour Times Percent','false'
'symptomatic heart fail','C0018787','HEART','Heart','true'
'symptomatic heart fail','C0231175','Fail','failed','false'
'stroke ortia','C0038454','STROKE','Cerebrovascular accident','true'
'stroke ortia','C4554100','Stroke','Stroke, CTCAE','false'
'k','C0597277','K+','Potassium Ion','false'
'k','C1708601','K'','K Prime','false'
'u','C0439148','{U}','Unit','false'
'central europe','C0682369','Central Europe','central europe','false'
'south asia','C1710133','South','South','false'
'south asia','C0003980','Asia','Asia','true'
'east asia','C0015631','East Asia','Far East','true'
'aspirin use at baseline','C0042153','use','utilization qualifier','true'
'aspirin use at baseline','C0457083','Use','Usage','false'
'aspirin use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'b h','C0033727','H+','Protons','true'
'b h','C0369286','H NOS','H NOS Antibodies','false'
'b h','C0441932','H+','Hepatic Involvement','false'
'b h','C0564385','/h','/hour','false'
'b h','C4528284','h*%','Hour Times Percent','false'
'amiodarone use at baseline yes $nmbr$ $nmbr$','C0042153','use','utilization qualifier','true'
'amiodarone use at baseline yes $nmbr$ $nmbr$','C0457083','Use','Usage','false'
'amiodarone use at baseline yes $nmbr$ $nmbr$','C1947944','Use','Use - dosing instruction imperative','false'
'ppi use at baseline','C0042153','use','utilization qualifier','true'
'ppi use at baseline','C0457083','Use','Usage','false'
'ppi use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'dexlansoprazole mr n $nmbr$','C0024485','MR','Magnetic Resonance Imaging','true'
'dexlansoprazole mr n $nmbr$','C1417249','MR','MRC1 gene','false'
'dexlansoprazole mr n $nmbr$','C2347167','Mr.','Mr. - Title','false'
'dexlansoprazole mr n $nmbr$','C3254418','MR','NR3C2 protein, human','true'
'dexlansoprazole mr n $nmbr$','C4050513','MR','Minor Response','false'
'lansoprazole n $nmbr$','C0050940','LANSOPRAZOLE','lansoprazole','true'
'mean age s d year','C0444504','Mean','Statistical mean','false'
'mean age s d year','C0001779','AGE','Age','false'
'mean age s d year','C2347634','Mean','Population Mean','false'
'mean age s d year','C2348143','Mean','Sample Mean','false'
'mean age s d year','C0439234','Year','year','false'
'mean age s d year','C0439508','/Year','per year','false'
'missing','C1551393','Missing','Container status - Missing','false'
'missing','C1705492','Missing','Missing','false'
'missing','C3272743','MISSING','Missing Study Animal','false'
'mean bmii s d kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean bmii s d kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean bmii s d kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'alcohol users n','C0556297','alcohol users','Current drinker','false'
'smokers n','C0337664','Smokers','Smoker','true'
'caffeine users n','C3532939','Caffeine user','Caffeine user','false'
'observation','C0302523','Observation','Observation in research','true'
'observation','C0700325','Observation','Patient observation','true'
'observation','C1964257','OBSERVATION','Observation - diagnostic procedure','false'
'observation','C3889687','observation','Clinical Observation','false'
'$nmbr$ mg a','C0024671','MG','Mammography','true'
'$nmbr$ mg a','C0026410','MG','Mongolia','true'
'$nmbr$ mg a','C0439269','mg%','mg/dL','false'
'$nmbr$ mg a','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg a','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg a','C4321396','MG','MG','false'
'$nmbr$ mg a','C4521761','MG','United States Military Commissioned Officer O8','false'
'participants','C0679646','participants','Participant','false'
'demographic characteristics','C0683970','demographic characteristics','demographic characteristics','false'
'mean sd age y','C0444504','Mean','Statistical mean','false'
'mean sd age y','C0001779','AGE','Age','false'
'mean sd age y','C2347634','Mean','Population Mean','false'
'mean sd age y','C2348143','Mean','Sample Mean','false'
'minimum maximum','C0806909','Maximum','Maximum','false'
'minimum maximum','C1552615','maximum','Act Relationship Subset - maximum','false'
'minimum maximum','C2826546','MAXIMUM','Maximum Value Derivation Technique','false'
'study eye characteristics','C1568011','Study Characteristics','Study Characteristics','true'
'study eye characteristics','C0015392','?Eye','Eye','true'
'study eye characteristics','C0700042','Eye','Orbital region','false'
'mean sd e etdrs visual acuity letter score snellen equivalent','C0205163','Equivalent','Equal','false'
'mean sd e etdrs visual acuity letter score snellen equivalent','C0439185','equivalent','Equivalent Weight','false'
'duration of macular edema mo','C0449238','Duration','Duration (temporal concept)','false'
'duration of macular edema mo','C2926735','Duration','Duration','false'
'iop mm hg','C0578862','IOP','Intraocular pressure finding','false'
'iop mm hg','C0439475','mmHG','mmHg','false'
'iop lowering medication','C0578862','IOP','Intraocular pressure finding','false'
'iop lowering medication','C0441994','lowering','Lower - spatial qualifier','false'
'iop lowering medication','C2003888','Lowering','Lower (action)','false'
'iop lowering medication','C0013227','Medication','Pharmaceutical Preparations','true'
'iop lowering medication','C3244316','medication','medication - HL7 publishing domain','false'
'iop lowering medication','C4284232','Medication','Medications','false'
'imaging data mean sd','C0011923','Imaging','Diagnostic Imaging','true'
'imaging data mean sd','C2699239','SD','SD, Rat Strain','false'
'imaging data mean sd','C0079595','Imaging','Imaging Techniques','false'
'oct center point thickness pm','C0030266','PM','Panama','true'
'oct center point thickness pm','C4049155','PM','Infusion pump Alert priority PM','false'
'total macular volume mean sd mm $nmbr$','C4330985','/mm','Per Millimeter','false'
'total macular volume mean sd mm $nmbr$','C4554674','MM','MM genotype','false'
'area of retinal thickening within the grid mean sd dab','C0017446','Area','Geographic Locations','true'
'area of retinal thickening within the grid mean sd dab','C0205146','AREA','Area','false'
'area of retinal thickening within the grid mean sd dab','C0086162','Dab','Dab fish','false'
'area of retinal thickening within the grid mean sd dab','C1081457','dab','Limanda limanda','false'
'area of retinal hemorrhage within the grid mean sd dab','C0017446','Area','Geographic Locations','true'
'area of retinal hemorrhage within the grid mean sd dab','C0205146','AREA','Area','false'
'area of retinal hemorrhage within the grid mean sd dab','C0086162','Dab','Dab fish','false'
'area of retinal hemorrhage within the grid mean sd dab','C1081457','dab','Limanda limanda','false'
'area of fluorescein leakage within the grid mean sd dab','C0017446','Area','Geographic Locations','true'
'area of fluorescein leakage within the grid mean sd dab','C0205146','AREA','Area','false'
'area of fluorescein leakage within the grid mean sd dab','C0086162','Dab','Dab fish','false'
'area of fluorescein leakage within the grid mean sd dab','C1081457','dab','Limanda limanda','false'
'$nmbr$ da of capillary nonperfusion in the eyec','C0011318','DA','Denmark','true'
'$nmbr$ da of capillary nonperfusion in the eyec','C3668815','DA','Displacement of abomasum','false'
'mean sd nonstudy eye e etdrs visual acuity letter score','C3533236','Mean score','Mean score','false'
'mean sd nonstudy eye e etdrs visual acuity letter score','C0042812','Visual Acuity','Visual Acuity','true'
'other clinical characteristics','C0683325','clinical characteristics','clinical aspects','false'
'coronary artery disease','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'coronary artery disease','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'coronary artery disease','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'history of cancer','C0455471','History of Cancer','H/O: malignant neoplasm','false'
'abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography','C3161471','Treatment Study','Treatment Study','false'
'abbreviations da disc area e etdrs electronic early treatment diabetic retinopathy study iop intraocular pressure oct optical coherence tomography','C0920367','OCT - Optical coherence tomography','Tomography, Optical Coherence','true'
'age gd lesion','C0221198','Lesion','Lesion','false'
'age gd lesion','C1546698','Lesion','Specimen Source Codes - Lesion','false'
'effect estimate','C1280500','Effect','Effect','false'
'effect estimate','C0750572','Estimate','Estimated','false'
'effect estimate','C1518681','effect','Outcome of Therapy','false'
'effect estimate','C2348382','Effect','Effect, Appearance','false'
'age $nmbr$ gd lesion $nmbr$ n $nmbr$','C0001779','AGE','Age','false'
'age $nmbr$ gd lesion $nmbr$ n $nmbr$','C0221198','Lesion','Lesion','false'
'age $nmbr$ gd lesion $nmbr$ n $nmbr$','C1546698','Lesion','Specimen Source Codes - Lesion','false'
'hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0596019','Cl -','Chloride Ion','false'
'age $nmbr$ n $nmbr$','C0001779','AGE','Age','false'
'cutoffs','C1442160','Cutoff','Cutoff','false'
'combo facilitated pci','C4049621','PCI','Peritoneal Cancer Index','false'
'abciximab facilitated pci','C0288672','ABCIXIMAB','abciximab','true'
'abciximab facilitated pci','C4049621','PCI','Peritoneal Cancer Index','false'
'primary pci','C0205225','Primary','Primary','false'
'primary pci','C0439612','Primary','True primary (qualifier value)','false'
'primary pci','C0439631','Primary','Primary operation','false'
'combo vs primary','C0205225','Primary','Primary','false'
'combo vs primary','C0439612','Primary','True primary (qualifier value)','false'
'combo vs primary','C0439631','Primary','Primary operation','false'
'abciximab vs primary','C0288672','ABCIXIMAB','abciximab','true'
'abciximab vs primary','C0205225','Primary','Primary','false'
'abciximab vs primary','C0439612','Primary','True primary (qualifier value)','false'
'abciximab vs primary','C0439631','Primary','Primary operation','false'
'timi $nmbr$ and spoke and time $nmbr$ h','C0033727','H+','Protons','true'
'timi $nmbr$ and spoke and time $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'timi $nmbr$ and spoke and time $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'timi $nmbr$ and spoke and time $nmbr$ h','C0564385','/h','/hour','false'
'timi $nmbr$ and spoke and time $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C0028873','Odds Ratios','Odds Ratio','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C2986535','Primary Endpoint','Primary Endpoint','false'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C0011900','DIAGNOSIS','Diagnosis','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C1704338','diagnosis','diagnosis aspect','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C1704656','DIAGNOSIS','Diagnosis Study','false'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C0087111','TREAT','Therapeutic procedure','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C0032659','Population','geographic population','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C1257890','Population','Population Group','true'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C1292734','treat','Treatment intent','false'
'figure $nmbr$ odds ratios for the primary end point according to diagnosis at enrollment in the modified intention to treat population','C1522326','Treat','Treating','false'
'lm $nmbr$ $nmbr$','C1261082','LM','Left coronary artery structure','false'
'lm $nmbr$ $nmbr$','C1551056','lm','Units Of Measure - lumen','false'
'glargine $nmbr$','C0907402','Glargine','Insulin Glargine','true'
'sex male female','C0086287','Sex Female','Females','true'
'race ethnicity zz','C0015031','Ethnicity','Ethnic group','true'
'race ethnicity zz','C2347310','ZZ','Mutually Defined','false'
'race ethnicity zz','C0243103','ethnicity','Ethnicity aspects','true'
'black african','C0337824','Black African','Black African','false'
'descent','C0205386','Descent','Descending','false'
'descent','C0680043','Descent','Descent','false'
'concomitant oral glucose lowering agents zz','C0442027','Oral','Oral','false'
'concomitant oral glucose lowering agents zz','C0017725','GLUCOSE','Glucose','true'
'concomitant oral glucose lowering agents zz','C4521986','Oral','Oral (intended site)','false'
'concomitant oral glucose lowering agents zz','C0441994','lowering','Lower - spatial qualifier','false'
'concomitant oral glucose lowering agents zz','C2003888','Lowering','Lower (action)','false'
'concomitant oral glucose lowering agents zz','C0450442','Agent','Agent','false'
'concomitant oral glucose lowering agents zz','C2347310','ZZ','Mutually Defined','false'
'concomitant oral glucose lowering agents zz','C1254351','Agent','Pharmacologic Substance','false'
'concomitant oral glucose lowering agents zz','C1521826','Agent','Protocol Agent','false'
'met su tzd','C0428210','MET','Methionine measurement','false'
'met su tzd','C0038642','SU','Sudan','true'
'met su tzd','C1705534','SU','Substance Use Domain','false'
'met su tzd','C1550543','Met','Fulfill','false'
'met su tzd','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'su tzd','C0038642','SU','Sudan','true'
'su tzd','C1705534','SU','Substance Use Domain','false'
'su met','C0428210','MET','Methionine measurement','false'
'su met','C1550543','Met','Fulfill','false'
'su met','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'met tzd','C0428210','MET','Methionine measurement','false'
'met tzd','C1550543','Met','Fulfill','false'
'met tzd','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'mmf n $nmbr$','C0083765','MMF','fluorouracil/methotrexate/mitoxantrone protocol','true'
'mmf n $nmbr$','C0209368','MMF','mycophenolate mofetil','true'
'mmf n $nmbr$','C3848524','MMF','monomethyl fumarate','true'
'ivc n $nmbr$','C4085887','IVC','Inspiratory Vital Capacity Test','false'
'age at diagnosis of sle years','C1828181','Age at diagnosis','Age at diagnosis','false'
'age at diagnosis of sle years','C3173302','Age at diagnosis','Age at diagnosis:Time:Pt:^Patient:Qn','false'
'time since diagnosis of sle years','C0556970','time year','times/year','false'
'time since diagnosis of sle years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since diagnosis of sle years','C1704338','diagnosis','diagnosis aspect','true'
'time since diagnosis of sle years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'age at diagnosis of ln years','C1828181','Age at diagnosis','Age at diagnosis','false'
'age at diagnosis of ln years','C3173302','Age at diagnosis','Age at diagnosis:Time:Pt:^Patient:Qn','false'
'time since diagnosis of ln years','C0556970','time year','times/year','false'
'time since diagnosis of ln years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since diagnosis of ln years','C1704338','diagnosis','diagnosis aspect','true'
'time since diagnosis of ln years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'renal biopsy class','C0456387','Class','Class','false'
'renal biopsy class','C1518526','class','Object Class','false'
'renal biopsy class','C1705943','Class','Class (taxonomic)','false'
'class iii iii v','C0441887','Class III','Class 3','false'
'class iii iii v','C2698969','Class III','Canadian Cardiovascular Society Grading Scale Class III','false'
'class iv iv v','C0441888','Class IV','Class 4','false'
'class iv iv v','C2698970','Class IV','Canadian Cardiovascular Society Grading Scale Class IV','false'
'class iv only','C0441888','Class IV','Class 4','false'
'class iv only','C2698970','Class IV','Canadian Cardiovascular Society Grading Scale Class IV','false'
'class v only','C0456387','Class','Class','false'
'class v only','C1518526','class','Object Class','false'
'class v only','C1705943','Class','Class (taxonomic)','false'
'scarring on renal biopsy','C0194073','Renal Biopsy','Kidney biopsy','false'
'urine p cr','C0201975','Cr','Creatinine measurement','false'
'urine p cr','C3539604','CR','CR2 wt Allele','false'
'urine p cr','C3711669','CR','CALB2 protein, human','true'
'urine p cr','C4084730','CR','CALB2 wt Allele','false'
'urine p cr','C4553336','CR','Lugano Lymphoma Response Classification Complete Remission by PET','false'
'urine p cr','C4553337','CR','Lugano Lymphoma Response Classification Complete Remission by CT','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ f','C0016327','F-','Fluorides','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'serum albumin concentration g l','C0439294','g l','Kilogram per Cubic Meter','false'
'serum albumin concentration g l','C0456615','G/L','Billion per Liter','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ g','C0439267','g%','Gram per Deciliter','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0033727','H+','Protons','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0564385','/h','/hour','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'patients with negative anti dsdna','C0030705','Patients','Patients','true'
'patients with negative anti dsdna','C0741099','anti ds dna','anti ds dna','false'
'antibody binding level at baseline','C0428536','Antibody level','Immunoglobulin level - finding','false'
'geometric anti dsdna antibody binding level','C0428536','Antibody level','Immunoglobulin level - finding','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ i','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ i','C0221138','I NOS','Blood group antibody I','false'
'patients with low','C0030705','Patients','Patients','true'
'patients with low','C0205251','Low','low','false'
'patients with low','C1550472','low','low confidentiality','false'
'patients with low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'patients with low','C4048187','low','low exposure','false'
'patients with low','C4321351','Low','Low Level','false'
'patients with low','C4522223','Low','IPSS Risk Category Low','false'
'concentrations at baseline','C0086045','Concentrations','Mental concentration','true'
'concentrations at baseline','C0168634','baseline','BaseLine dental cement','true'
'concentrations at baseline','C1442488','Baseline','Baseline','false'
'geometric c $nmbr$ concentration mg dl','C0086045','Concentration','Mental concentration','true'
'geometric c $nmbr$ concentration mg dl','C0439269','mg dl','mg/dL','false'
'geometric c $nmbr$ concentration mg dl','C1446561','Concentration','Concentration measurement','false'
'geometric c $nmbr$ concentration mg dl','C3827302','Concentration','Able to Concentrate Question','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ k','C0597277','K+','Potassium Ion','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ k','C1708601','K'','K Prime','false'
'selena sledai total score','C0451528','SLEDAI','Systemic lupus erythematosus disease activity index','false'
'selena sledai total score','C2964552','Total Score','Total score','false'
'dabigatran n $nmbr$','C2348066','DABIGATRAN','dabigatran','true'
'warfarin n $nmbr$','C0043031','WARFARIN','Warfarin','true'
'race no f','C0034510','RACE','Racial group','true'
'race no f','C1706779','RACE','AMACR wt Allele','false'
'race no f','C3853635','Race','Race','false'
'race no f','C0016327','F-','Fluorides','true'
'estimated creatinine clearance ml min','C0812399','Creatinine clearance','Creatinine clearance','false'
'estimated creatinine clearance ml min','C0439445','mL/min','mL/min','false'
'type of index event no','C1561488','TYPE OF EVENT','HL7 2.5 Event type','false'
'type of index event no','C0600653','Index','Indexes','true'
'type of index event no','C0918012','Index','Index','true'
'type of index event no','C1552854','index','Html Link Type - index','false'
'type of index event no','C1637833','% index','% index','false'
'type of index event no','C2986546','Index','Target Lesion Identification','false'
'deep vein thrombosis only','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'pulmonary embolism only','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'both deep vein thrombosis and pulmonary embolism','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'both deep vein thrombosis and pulmonary embolism','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'neither deep vein thrombosis nor pulmonary embolism^','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'neither deep vein thrombosis nor pulmonary embolism^','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'cancer no','C0006826','CANCER','Malignant Neoplasms','true'
'cancer no','C0998265','Cancer','Cancer Genus','false'
'cancer no','C1306459','Cancer','Primary malignant neoplasm','false'
'previous venous thromboembolism no','C0205156','Previous','Previous','false'
'previous venous thromboembolism no','C1861172','VENOUS THROMBOEMBOLISM','Venous Thromboembolism','true'
'previous venous thromboembolism no','C1552607','previous','Act Relationship Subset - previous','false'
'parenteral anticoagulation','C0003281','anticoagulation','Anticoagulation Therapy','false'
'parenteral anticoagulation','C2917212','Anticoagulation','Negative Regulation of Coagulation','false'
'parenteral anticoagulation','C2919015','ANTICOAGULATION','ANTICOAGULATION (finding)','false'
'parenteral anticoagulation','C3537050','Anticoagulation','Decreased Coagulation Activity [PE]','false'
'treatment before randomization days','C0039798','treatment','therapeutic aspects','true'
'treatment before randomization days','C0087111','Treatment','Therapeutic procedure','true'
'treatment before randomization days','C1522326','Treatment','Treating','false'
'treatment before randomization days','C1533734','Treatment','Administration procedure','false'
'treatment before randomization days','C1705169','Treatment','Biomaterial Treatment','false'
'treatment before randomization days','C3538994','TREATMENT','Treatment Epoch','false'
'treatment before randomization days','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment after randomization in the single dummy phase days]','C0039798','treatment','therapeutic aspects','true'
'treatment after randomization in the single dummy phase days]','C0087111','Treatment','Therapeutic procedure','true'
'treatment after randomization in the single dummy phase days]','C1522326','Treatment','Treating','false'
'treatment after randomization in the single dummy phase days]','C1533734','Treatment','Administration procedure','false'
'treatment after randomization in the single dummy phase days]','C1705169','Treatment','Biomaterial Treatment','false'
'treatment after randomization in the single dummy phase days]','C3538994','TREATMENT','Treatment Epoch','false'
'treatment after randomization in the single dummy phase days]','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment after randomization in the single dummy phase days]','C0037179','Single','Unmarried person','true'
'treatment after randomization in the single dummy phase days]','C0439228','DAYS','day','false'
'treatment after randomization in the single dummy phase days]','C0087136','single','Unmarried','true'
'treatment after randomization in the single dummy phase days]','C0205171','SINGLE','Singular','false'
'unfractionated heparin no','C0019134','Unfractionated Heparin','heparin','true'
'unfractionated heparin no','C2825026','Unfractionated Heparin','Unfractionated Heparin [EPC]','false'
'low molecular weight heparin no','C0019139','Heparin, Low-Molecular-Weight','Heparin, Low-Molecular-Weight','true'
'low molecular weight heparin no','C3536766','Low Molecular Weight Heparin','Low Molecular Weight Heparin [EPC]','false'
'fondaparinux no','C1098510','FONDAPARINUX','fondaparinux','true'
'double dummy phase','C0205390','Phase','Phase','false'
'double dummy phase','C1710475','phase','Trial Phase','false'
'exposure to study drug days','C0332157','Exposure to','Exposure to','false'
'adherence to study regimen no','C1510802','Adherence','Adherence (attribute)','false'
'adherence to study regimen no','C0040808','Regimen','Treatment Protocols','true'
'adherence to study regimen no','C2945654','regimen','Regimen - CHV concept','false'
'percent of the time that inr was in the therapeutic range','C0439165','PERCENT','Percent (qualifier value)','false'
'percent of the time that inr was in the therapeutic range','C0040223','TIME','Time','true'
'percent of the time that inr was in the therapeutic range','C3541383','Time','Time (foundation metadata concept)','false'
'percent of the time that inr was in the therapeutic range','C0525032','INR','International Normalized Ratio','true'
'percent of the time that inr was in the therapeutic range','C1704538','INR','Integrated Neuromusculoskeletal Release','false'
'percent of the time that inr was in the therapeutic range','C0460097','therapeutic range','Within therapeutic range','false'
'dabigatran','C2348066','DABIGATRAN','dabigatran','true'
'percentages of patients with event','C0439165','Percentage','Percent (qualifier value)','false'
'percentages of patients with event','C1549488','Percentage','Amount type - Percentage','false'
'percentages of patients with event','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'percentages of patients with event','C0441471','Event','Event','false'
'percentages of patients with event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'p value for interaction','C1709380','P-Value','P-Value','false'
'p value for interaction','C1704675','Interaction','Interaction','false'
'\ge category','C0683312','Category','Categories','false'
'\ge category','C3889287','Category','Digital Content Category','false'
'weight category','C0683312','Category','Categories','false'
'weight category','C3889287','Category','Digital Content Category','false'
'bmi category kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi category kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi category kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'creatinine clearance category [ml min]','C0683312','Category','Categories','false'
'creatinine clearance category [ml min]','C3889287','Category','Digital Content Category','false'
'creatinine clearance category [ml min]','C0439445','mL/min','mL/min','false'
'$nmbr$ ml mln','C1417190','MLN','MLN gene','false'
'$nmbr$ ml mln','C3815103','MLN','MRLN gene','false'
'previous vte','C0205156','Previous','Previous','false'
'previous vte','C0630906','vte','vinyltriethoxysilane','true'
'previous vte','C1552607','previous','Act Relationship Subset - previous','false'
'initial symptomatic pe','C0070939','PE','phosphoethanolamine','true'
'initial symptomatic pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'initial symptomatic pe','C4284304','PE','PENK wt Allele','false'
'active cancer at baseline','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer at baseline','C0998265','Cancer','Cancer Genus','false'
'active cancer at baseline','C1306459','Cancer','Primary malignant neoplasm','false'
'measure','C0079809','Measure','Measures','true'
'measure','C0242485','Measure','Measurement','false'
'fenofibric acid','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'low dose statin','C0445550','Low dose','Low dose','false'
'low dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'low dose statin','C1708745','Low-Dose','Low-Dose Treatment','false'
'fenofibric acid low dose statin','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'fenofibric acid low dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'mean percentage change from baseline to final visit','C0392747','Change','Changing','false'
'mean percentage change from baseline to final visit','C0443172','change','Changed status','false'
'mean percentage change from baseline to final visit','C1705241','Change','Delta (difference)','false'
'mean percentage change from baseline to final visit','C4319952','Change','Change -- procedure','false'
'mean percentage change from baseline to final visit','C0545082','Visit','Visit','false'
'mean percentage change from baseline to final visit','C1512346','visit','Patient Visit','false'
'mean percentage change from baseline to final visit','C2826704','VISIT','Visit Name','false'
'final','C0205088','Final','End-stage','false'
'final','C1546485','Final','Diagnosis Type - Final','false'
'final','C3853528','Final','Final','false'
'tg','C0337445','TG','Thyroglobulin measurement','false'
'efficacy variable','C0439828','Variable','Variable (uniformity)','false'
'efficacy variable','C4553760','Variable','Study Variable','false'
'fenofibric acid i low dose statin','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'fenofibric acid i low dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'non hdl c','C1518422','Non','Negation','false'
'non hdl c','C3715113','HDL','HSD11B1 wt Allele','false'
'baseline mean','C0444504','Mean','Statistical mean','false'
'baseline mean','C2347634','Mean','Population Mean','false'
'baseline mean','C2348143','Mean','Sample Mean','false'
'final mean','C0444504','Mean','Statistical mean','false'
'final mean','C2347634','Mean','Population Mean','false'
'final mean','C2348143','Mean','Sample Mean','false'
'change mean se','C0392747','Change','Changing','false'
'change mean se','C0036919','SE','Seychelles','true'
'change mean se','C0443172','change','Changed status','false'
'change mean se','C1705241','Change','Delta (difference)','false'
'change mean se','C4319952','Change','Change -- procedure','false'
'change meanlse','C0392747','Change','Changing','false'
'change meanlse','C0443172','change','Changed status','false'
'change meanlse','C1705241','Change','Delta (difference)','false'
'change meanlse','C4319952','Change','Change -- procedure','false'
'baseline median','C0549183','Median','Midline (qualifier value)','false'
'baseline median','C0876920','Median','Median Statistical Measurement','false'
'baseline median','C2347635','Median','Population Median','false'
'baseline median','C2348144','Median','Sample Median','false'
'baseline median','C2939193','Median','Median (qualifier value)','false'
'change median q $nmbr$ q $nmbr$','C0392747','Change','Changing','false'
'change median q $nmbr$ q $nmbr$','C0443172','change','Changed status','false'
'change median q $nmbr$ q $nmbr$','C1705241','Change','Delta (difference)','false'
'change median q $nmbr$ q $nmbr$','C4319952','Change','Change -- procedure','false'
'vldl c','C0523560','VLDL','VLDL cholesterol measurement','false'
'total c','C0439175','% total','% of total','false'
'total c','C0439810','Total','Total','false'
'moderate dose statin','C1709056','Moderate-Dose','Moderate-Dose Treatment','false'
'moderate dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'fenofibric acid moderate dose statin','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'fenofibric acid moderate dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'change meantse','C0392747','Change','Changing','false'
'change meantse','C0443172','change','Changed status','false'
'change meantse','C1705241','Change','Delta (difference)','false'
'change meantse','C4319952','Change','Change -- procedure','false'
'safety variable','C0439828','Variable','Variable (uniformity)','false'
'safety variable','C4553760','Variable','Study Variable','false'
'fenofibric acid $nmbr$ low dose statin','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'fenofibric acid $nmbr$ low dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'fenofibric acid i moderate dose statin','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'fenofibric acid i moderate dose statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'investigator reported aes','C1412268','AES','AES gene','false'
'investigator reported aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'any treatment emergent ae','C0039798','treatment','therapeutic aspects','true'
'any treatment emergent ae','C3887670','AE','AE synonym fragment','false'
'any treatment emergent ae','C0087111','Treatment','Therapeutic procedure','true'
'any treatment emergent ae','C1522326','Treatment','Treating','false'
'any treatment emergent ae','C1533734','Treatment','Administration procedure','false'
'any treatment emergent ae','C1705169','Treatment','Biomaterial Treatment','false'
'any treatment emergent ae','C3538994','TREATMENT','Treatment Epoch','false'
'any treatment emergent ae','C3887704','treatment','treatment - ActInformationManagementReason','false'
'myalgia','C0231528','MYALGIA','Myalgia','true'
'myalgia','C4552646','Myalgia','Myalgia, CTCAE 5','false'
'rhabdomyolysis','C0035410','RHABDOMYOLYSIS','Rhabdomyolysis','true'
'rhabdomyolysis','C4552660','Rhabdomyolysis','Rhabdomyolysis, CTCAE','false'
'laboratory evaluations','C0022877','LABORATORY','Laboratory','true'
'laboratory evaluations','C0220825','evaluations','Evaluation','false'
'laboratory evaluations','C3244292','laboratory','Laboratory domain','false'
'laboratory evaluations','C4283904','Laboratory','Laboratory observation','false'
'alt $nmbr$ x uln on two consecutive visits','C1519815','ULN','Upper Limit of Normal','false'
'alt $nmbr$ x uln on two consecutive visits','C0205448','Two','Two','false'
'ast $nmbr$ x uln on two consecutive visits','C1519815','ULN','Upper Limit of Normal','false'
'ast $nmbr$ x uln on two consecutive visits','C0205448','Two','Two','false'
'ck $nmbr$ xuln','C0009212','CK','Cocos (Keeling) Islands','true'
'ck $nmbr$ xuln','C0010287','CK','Creatine Kinase','true'
'ck $nmbr$ xuln','C1872855','CK','CHKA protein, human','true'
'creatinine $nmbr$ $nmbr$ x baseline and above uln','C0168634','baseline','BaseLine dental cement','true'
'creatinine $nmbr$ $nmbr$ x baseline and above uln','C1442488','Baseline','Baseline','false'
'creatinine $nmbr$ $nmbr$ x baseline and above uln','C1519815','ULN','Upper Limit of Normal','false'
'creatinine $nmbr$ x baseline','C0168634','baseline','BaseLine dental cement','true'
'creatinine $nmbr$ x baseline','C1442488','Baseline','Baseline','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C0392747','Change','Changing','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C0443172','change','Changed status','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C1705241','Change','Delta (difference)','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C4319952','Change','Change -- procedure','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C0428568','Fasting blood glucose','Fasting blood glucose measurement','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C1261430','fasting blood glucose','Fasting blood sugar result','false'
'mean change s in fasting blood glucose [mg dl mmol l ]','C0439268','mg/L','Microgram per Milliliter','false'
'f $nmbr$ $nmbr$ i $nmbr$ $nmbr$','C0021966','I-','Iodides','true'
'f $nmbr$ $nmbr$ i $nmbr$ $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'age y mean sd','C0001779','AGE','Age','false'
'age y mean sd','C2699239','SD','SD, Rat Strain','false'
'men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0025266','Men','Male population group','true'
'men with ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3538926','ED','Endocrine System Findings Domain','false'
'men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0025266','Men','Male population group','true'
'men without ed n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3538926','ED','Endocrine System Findings Domain','false'
'age $nmbr$ y','C0001779','AGE','Age','false'
'previous a blocker','C0205156','Previous','Previous','false'
'previous a blocker','C1552607','previous','Act Relationship Subset - previous','false'
'use','C0042153','use','utilization qualifier','true'
'use','C0457083','Use','Usage','false'
'use','C1947944','Use','Use - dosing instruction imperative','false'
'sexually active $nmbr$','C0241028','SEXUALLY ACTIVE','Sexually active','false'
'comorbidities','C0009488','comorbidities','Comorbidity','true'
'coronary artery','C0205042','Artery, Coronary','Coronary artery','true'
'calcium channel','C0006685','Calcium Channel','Calcium Channel','true'
'angiotensin','C0003018','Angiotensin','Angiotensins','true'
'angiotensin','C4521302','Angiotensin','Angiotensin-1, human','false'
'converting enzyme inhibitor','C0014432','Enzyme inhibitor','Enzyme Inhibitors','true'
'converting enzyme inhibitor','C0919438','Enzyme Inhibitor','Enzyme Inhibitor Drugs','false'
'converting enzyme inhibitor','C4521603','Enzyme inhibitor','Enzyme inhibitor (disposition)','false'
'angiotensin receptor','C0034787','Angiotensin Receptor','Angiotensin Receptor','true'
'angiotensin receptor','C1622222','Angiotensin Receptor','MAS1 protein, human','true'
'oral diabetic agent','C0450442','Agent','Agent','false'
'oral diabetic agent','C1254351','Agent','Pharmacologic Substance','false'
'oral diabetic agent','C1521826','Agent','Protocol Agent','false'
'ipss mean sd','C0444504','Mean','Statistical mean','false'
'ipss mean sd','C2699239','SD','SD, Rat Strain','false'
'ipss mean sd','C2347634','Mean','Population Mean','false'
'ipss mean sd','C2348143','Mean','Sample Mean','false'
'ipss qol','C1019118','Ips','Ips <Invertebrate>','false'
'ipss qol','C0518214','QOL','Perceived quality of life','false'
'ipss qol','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss qol','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss qol','C3811063','IPS','SLC27A4 wt Allele','false'
'bii mean sd','C0444504','Mean','Statistical mean','false'
'bii mean sd','C2699239','SD','SD, Rat Strain','false'
'bii mean sd','C2347634','Mean','Population Mean','false'
'bii mean sd','C2348143','Mean','Sample Mean','false'
'$nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'$nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'$nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'$nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'$nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'$nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'moderate to','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate to','C1881878','Moderate','Moderation','false'
'moderate to','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate to','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate to','C4085643','Moderate','Moderate Response','false'
'moderate to','C4321335','Moderate','Moderate Level','false'
'mild ed','C2945599','Mild','Mild (qualifier value)','false'
'mild ed','C3538926','ED','Endocrine System Findings Domain','false'
'severe ed','C0205082','Severe','Severe (severity modifier)','false'
'severe ed','C3538926','ED','Endocrine System Findings Domain','false'
'severe ed','C4050465','Severe','Severe Extremity Pain','false'
'severe ed','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'mild ed severe ed','C2945599','Mild','Mild (qualifier value)','false'
'mild ed severe ed','C0205082','Severe','Severe (severity modifier)','false'
'mild ed severe ed','C4050465','Severe','Severe Extremity Pain','false'
'mild ed severe ed','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'p interaction','C0369773','P NOS','P Blood group antibodies','false'
'p interaction','C1704675','Interaction','Interaction','false'
'p interaction','C2603361','P'','P prime','false'
'n $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'n $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'ipss ls mean se','C0023668','LS','Liechtenstein','true'
'ipss ls mean se','C0036919','SE','Seychelles','true'
'ipss qol ls','C0518214','QOL','Perceived quality of life','false'
'ipss qol ls','C0023668','LS','Liechtenstein','true'
'mean se bii ls mean se','C0036919','SE','Seychelles','true'
'mean se bii ls mean se','C0023668','LS','Liechtenstein','true'
'a $nmbr$ e $nmbr$ n $nmbr$','C1272460','a n','Not Applicable','false'
'a $nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'a $nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'mean age years race','C0034510','RACE','Racial group','true'
'mean age years race','C1706779','RACE','AMACR wt Allele','false'
'mean age years race','C3853635','Race','Race','false'
'body mass index $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'body mass index $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'body mass index $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'$nmbr$ concomitant medication','C0013227','Medication','Pharmaceutical Preparations','true'
'$nmbr$ concomitant medication','C3244316','medication','medication - HL7 publishing domain','false'
'$nmbr$ concomitant medication','C4284232','Medication','Medications','false'
'other forms of atherosclerosis','C0348078','forms','Qualitative form','false'
'other forms of atherosclerosis','C0376315','Forms','Manufactured form','true'
'diabetes mellitus type $nmbr$ or $nmbr$','C1320657','Diabetes Mellitus type','Diabetes type','false'
'metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'metabolic syndrome visit $nmbr$ low density lipoprotein cholesterol strata','C0023824','Low Density Lipoprotein Cholesterol','LDL Cholesterol Lipoproteins','true'
'$nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'mn na ve population','C0597484','Na+','Sodium Cation','false'
'mn na ve population','C1272460','{NA}','Not Applicable','false'
'mn na ve population','C1546968','NA','No Application Type','false'
'mn na ve population','C1879645','NA','Adverse Event by CTCAE Category','false'
'mn na ve population','C4049872','NA','Package Type Not Applicable','false'
'mn na ve population','C4552882','NA','XK wt Allele','false'
'mn na ve population','C0032659','Population','geographic population','true'
'mn na ve population','C1257890','Population','Population Group','true'
'uplift population','C0032659','Population','geographic population','true'
'uplift population','C1257890','Population','Population Group','true'
'all mn na ve patients','C0597484','Na+','Sodium Cation','false'
'all mn na ve patients','C1272460','{NA}','Not Applicable','false'
'all mn na ve patients','C1546968','NA','No Application Type','false'
'all mn na ve patients','C1879645','NA','Adverse Event by CTCAE Category','false'
'all mn na ve patients','C4049872','NA','Package Type Not Applicable','false'
'all mn na ve patients','C4552882','NA','XK wt Allele','false'
'all mn na ve patients','C0030705','Patients','Patients','true'
'all non mn','C0026327','MN','MNSs Blood-Group System','true'
'all non mn','C0026405','MN','Monaco','true'
'all non mn','C4285072','mN','Millinewton','false'
'sex m f','C0009253','Sex','Coitus','true'
'sex m f','C0036864','Sex','Sex Behavior','true'
'sex m f','C0079399','sex','Gender','true'
'sex m f','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex m f','C1314687','Sex','Sexual intercourse - finding','false'
'sex m f','C1522384','SEX','sex','true'
'sex m f','C0016327','F-','Fluorides','true'
'active smokers','C0205177','Active','Active','false'
'active smokers','C0337664','Smokers','Smoker','true'
'active smokers','C3853793','active','active (HL7 RoleLink)','false'
'active smokers','C3888249','Active','Active License','false'
'copd history yrs','C0019664','History','History','true'
'copd history yrs','C0019665','history','Historical aspects qualifier','true'
'copd history yrs','C0262512','History, NOS','History of present illness','false'
'copd history yrs','C0262926','History','Medical History','false'
'copd history yrs','C1705255','History','Concept History','false'
'copd history yrs','C2004062','History','History of previous events','false'
'pre fev $nmbr$ pred','C0032952','PRED','Prednisone','true'
'pre fev $nmbr$ pred','C0044955','Pred','prednylidene','true'
'post fev $nmbr$ pred','C0032952','PRED','Prednisone','true'
'post fev $nmbr$ pred','C0044955','Pred','prednylidene','true'
'pre fvc pred','C0032952','PRED','Prednisone','true'
'pre fvc pred','C0044955','Pred','prednylidene','true'
'post fvc pred','C0032952','PRED','Prednisone','true'
'post fvc pred','C0044955','Pred','prednylidene','true'
'gold stage','C0205390','Stage','Phase','false'
'gold stage','C1300072','Stage','Tumor stage','false'
'gold stage','C1306673','Stage','Stage','false'
'usa','C0041703','USA','United States','true'
'$nmbr$ day l','C0332173','/day','Daily','false'
'$nmbr$ day l','C0439228','Day','day','false'
'$nmbr$ day l','C0439505','/day','per day','false'
'$nmbr$ month l','C0332177','/month','Monthly (qualifier value)','false'
'$nmbr$ month l','C0439231','Month','month','false'
'decline ml yr $nmbr$','C0439526','/mL','/mL','false'
'decline ml yr $nmbr$','C0439234','yr','year','false'
'decline ml yr $nmbr$','C1705224','ML','THPO wt Allele','false'
'decline ml yr $nmbr$','C3887665','ML','Thrombopoietin, human','false'
'pre fev $nmbr$','C0332152','Pre','Before','false'
'pre fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'pre fev $nmbr$','C0740175','Pre','Before values','false'
'pre fev $nmbr$','C2257086','PRE','photoreactivating enzyme activity','false'
'pre fev $nmbr$','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'post fev $nmbr$','C0687676','Post','Post','false'
'post fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'post fev $nmbr$','C1704687','Post','Post Device','false'
'post fev $nmbr$','C3469826','POST','SLC35G1 gene','false'
'pre fvc','C0332152','Pre','Before','false'
'pre fvc','C3714541','FVC','Forced Vital Capacity','true'
'pre fvc','C0740175','Pre','Before values','false'
'pre fvc','C2257086','PRE','photoreactivating enzyme activity','false'
'pre fvc','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'post fvc','C0687676','Post','Post','false'
'post fvc','C3714541','FVC','Forced Vital Capacity','true'
'post fvc','C1704687','Post','Post Device','false'
'post fvc','C3469826','POST','SLC35G1 gene','false'
'pre svc','C0332152','Pre','Before','false'
'pre svc','C0231957','SVC','Slow vital capacity','false'
'pre svc','C0740175','Pre','Before values','false'
'pre svc','C2257086','PRE','photoreactivating enzyme activity','false'
'pre svc','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'post svc','C0687676','Post','Post','false'
'post svc','C0231957','SVC','Slow vital capacity','false'
'post svc','C1704687','Post','Post Device','false'
'post svc','C3469826','POST','SLC35G1 gene','false'
'glipizide n $nmbr$','C0017642','GLIPIZIDE','Glipizide','true'
'rosiglitazone n $nmbr$','C0289313','ROSIGLITAZONE','rosiglitazone','true'
'duration of diabetes mellitus median iqr y','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes mellitus median iqr y','C2926735','Duration','Duration','false'
'dyslipidemia n','C0242339','Dyslipidemia','Dyslipidemias','true'
'prior myocardial infarction n','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'prior myocardial infarction n','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'prior myocardial infarction n','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'prior myocardial infarction n','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'prior myocardial infarction n','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'presenting condition n','C0449450','Presenting','Presentation','false'
'presenting condition n','C0012634','condition','Disease','true'
'presenting condition n','C0348080','Condition','Condition','false'
'presenting condition n','C1705253','Condition','Logical Condition','false'
'presenting condition n','C3864998','Condition','Condition:Find:Pt:^Patient:Nom','false'
'acute coronary syndrome','C0948089','Acute Coronary Syndrome','Acute Coronary Syndrome','true'
'elective procedure','C0747973','Elective procedure','Elective procedure','false'
'baseline procedure n','C0168634','baseline','BaseLine dental cement','true'
'baseline procedure n','C0184661','Procedure','Interventional procedure','true'
'baseline procedure n','C2700391','Procedure','Procedure (set of actions)','false'
'baseline procedure n','C3274430','PROCEDURE','Physical Medical Procedure','false'
'baseline procedure n','C3539779','Procedure','CDISC SDTM Procedure Terminology','false'
'baseline procedure n','C1442488','Baseline','Baseline','false'
'medication use n','C0240320','MEDICATION USE','medication use','false'
'fibrate or other lipid lowering agent','C0086440','Lipid lowering agent','Hypolipidemic Agents','true'
'serum creatinine mean sd mg dl','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine mean sd mg dl','C0439269','mg dl','mg/dL','false'
'serum creatinine mean sd mg dl','C0600061','serum creatinine','Serum creatinine level','false'
'hemoglobin a $nmbr$ c mean sd','C0019020','Hemoglobin C','Hemoglobin C','true'
'hemoglobin a $nmbr$ c mean sd','C2699239','SD','SD, Rat Strain','false'
'hemoglobin a $nmbr$ c mean sd','C3889898','HEMOGLOBIN C','HEMOGLOBIN C PHENOTYPE','false'
'bnp median iqr pg ml','C0054015','BNP','Nesiritide','true'
'bnp median iqr pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'bnp median iqr pg ml','C1095989','BNP','Brain natriuretic peptide measurement','false'
'bnp median iqr pg ml','C1417808','BNP','NPPB gene','false'
'bnp median iqr pg ml','C2982014','BNP','NPPB wt Allele','false'
'fasting insulin median iqr gu ml','C0015663','FASTING','Fasting','true'
'fasting insulin median iqr gu ml','C0439526','/mL','/mL','false'
'fasting insulin median iqr gu ml','C1705224','ML','THPO wt Allele','false'
'fasting insulin median iqr gu ml','C3887665','ML','Thrombopoietin, human','false'
'ldl cholesterol mean sd mg dl','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol mean sd mg dl','C0439269','mg dl','mg/dL','false'
'ldl cholesterol mean sd mg dl','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'hdl cholesterol mean sd mg dl','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mean sd mg dl','C0439269','mg dl','mg/dL','false'
'hdl cholesterol mean sd mg dl','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'triglycerides median iqr mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'triglycerides median iqr mg dl','C0439269','mg dl','mg/dL','false'
'hscrp median iqr mg l','C0549183','Median','Midline (qualifier value)','false'
'hscrp median iqr mg l','C0439268','mg/L','Microgram per Milliliter','false'
'hscrp median iqr mg l','C0876920','Median','Median Statistical Measurement','false'
'hscrp median iqr mg l','C2347635','Median','Population Median','false'
'hscrp median iqr mg l','C2348144','Median','Sample Median','false'
'hscrp median iqr mg l','C2939193','Median','Median (qualifier value)','false'
'mmp $nmbr$ median iqr gg l','C0017454','GG','Georgia, Western Asia','true'
'mmp $nmbr$ median iqr gg l','C0018370','GG','Guernsey (geographic location)','true'
'subgroups','C1079230','subgroups','Subgroup A Nepoviruses','false'
'treatment difference $nmbr$ cl','C0039798','treatment','therapeutic aspects','true'
'treatment difference $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'treatment difference $nmbr$ cl','C0087111','Treatment','Therapeutic procedure','true'
'treatment difference $nmbr$ cl','C1522326','Treatment','Treating','false'
'treatment difference $nmbr$ cl','C1533734','Treatment','Administration procedure','false'
'treatment difference $nmbr$ cl','C1705169','Treatment','Biomaterial Treatment','false'
'treatment difference $nmbr$ cl','C3538994','TREATMENT','Treatment Epoch','false'
'treatment difference $nmbr$ cl','C3887704','treatment','treatment - ActInformationManagementReason','false'
'eu','C0015179','EU','European Union','true'
'eu','C3665627','EU','Ehrlich units per deciliter','false'
'sa','C0036243','SA','Saudi Arabia','true'
'sa','C0038702','SA','Sulfanilamide','true'
'sa','C1539696','SA','RPSA gene','false'
'sa','C1825840','SA','ACSM3 gene','false'
'sa','C3539736','Sa','Axial S','false'
'sa','C4521691','SA','United States Military enlisted E2','false'
'cardiac procedure','C1279986','cardiac procedure','Procedure on heart','false'
'prior oad','C0332152','Prior','Before','false'
'prior oad','C2826257','PRIOR','Prior Medication Usage','false'
'drug naive','C0013227','Drug','Pharmaceutical Preparations','true'
'drug naive','C1254351','DRUG','Pharmacologic Substance','false'
'low dose combination therapy','C0009429','Combination Therapy','Combined Modality Therapy','true'
'low dose combination therapy','C0556895','Combination therapy','Combination electrotherapy','false'
'metformin monotherapy','C0025598','METFORMIN','Metformin','true'
'su monotherapy','C0038642','SU','Sudan','true'
'su monotherapy','C1705534','SU','Substance Use Domain','false'
'systolic bp at baseline','C0871470','systolic bp','Systolic Pressure','true'
'systolic bp at baseline','C0168634','baseline','BaseLine dental cement','true'
'systolic bp at baseline','C1442488','Baseline','Baseline','false'
's $nmbr$ mmhg','C0439475','mmHG','mmHg','false'
'$nmbr$ mmhg','C0439475','mmHG','mmHg','false'
'statin use at baseline','C0042153','use','utilization qualifier','true'
'statin use at baseline','C0457083','Use','Usage','false'
'statin use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'diabetes duration','C0449238','Duration','Duration (temporal concept)','false'
'diabetes duration','C2926735','Duration','Duration','false'
's median','C0549183','Median','Midline (qualifier value)','false'
's median','C0876920','Median','Median Statistical Measurement','false'
's median','C2347635','Median','Population Median','false'
's median','C2348144','Median','Sample Median','false'
's median','C2939193','Median','Median (qualifier value)','false'
'hba $nmbr$ c at baseline','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c at baseline','C0168634','baseline','BaseLine dental cement','true'
'hba $nmbr$ c at baseline','C1442488','Baseline','Baseline','false'
'hba $nmbr$ c at baseline','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c at baseline','C3538758','HBA','SCN2A wt Allele','false'
'hdl c at baseline','C3715113','HDL','HSD11B1 wt Allele','false'
'hdl c at baseline','C0168634','baseline','BaseLine dental cement','true'
'hdl c at baseline','C1442488','Baseline','Baseline','false'
'ldl c at baseline','C0168634','baseline','BaseLine dental cement','true'
'ldl c at baseline','C1442488','Baseline','Baseline','false'
'triglycerides at baseline','C0041004','TRIGLYCERIDES','Triglycerides','true'
'triglycerides at baseline','C0168634','baseline','BaseLine dental cement','true'
'triglycerides at baseline','C1442488','Baseline','Baseline','false'
'hscrp at baseline','C0168634','baseline','BaseLine dental cement','true'
'hscrp at baseline','C1442488','Baseline','Baseline','false'
'percent atheroma volume at baseline','C1690016','Percent volume','% volume (qualifier value)','false'
'percent atheroma volume at baseline','C3887614','Volume Percent','Percent Volume per Volume','false'
'without baseline vertebral fracture','C0168634','baseline','BaseLine dental cement','true'
'without baseline vertebral fracture','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'without baseline vertebral fracture','C1442488','Baseline','Baseline','false'
'with baseline vertebral fracture','C0168634','baseline','BaseLine dental cement','true'
'with baseline vertebral fracture','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'with baseline vertebral fracture','C1442488','Baseline','Baseline','false'
'flex pbo','C0031962','PBO','Piperonyl Butoxide','true'
'flex ain','C0347129','AIN','Anal intraepithelial neoplasia','false'
'flex aln^','C0729594','ALN','Axillary lymph node group','false'
'flex aln^','C2681220','ALN','C4orf3 gene','false'
'body mass index kg m^ meanisd','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m^ meanisd','C0439209','kg','Kilogram','false'
'body mass index kg m^ meanisd','C4054209','/kg','Per Kilogram','false'
'fall in last $nmbr$ months','C0085639','FALL','Falls','false'
'fall in last $nmbr$ months','C0238715','Fall','Autumn','false'
'fall in last $nmbr$ months','C4553726','Fall','Fall, CTCAE','false'
'history of clinical fracture $nmbr$ years','C1272071','History of - fracture','H/O: fracture','false'
'history of clinical fracture $nmbr$ years','C0205210','Clinical','Clinical','false'
'duration alendronate use years meanisd','C0102118','ALENDRONATE','Alendronate','true'
'duration alendronate use years meanisd','C0042153','use','utilization qualifier','true'
'duration alendronate use years meanisd','C0457083','Use','Usage','false'
'duration alendronate use years meanisd','C1947944','Use','Use - dosing instruction imperative','false'
'using alendronate at baseline','C1524063','Using','Use of','false'
'using alendronate at baseline','C0102118','ALENDRONATE','Alendronate','true'
'using alendronate at baseline','C0168634','baseline','BaseLine dental cement','true'
'using alendronate at baseline','C1442488','Baseline','Baseline','false'
'using hrt or raloxifene at baseline','C1524063','Using','Use of','false'
'using hrt or raloxifene at baseline','C0282402','HRT','Hormone replacement therapy','true'
'using hrt or raloxifene at baseline','C0244404','RALOXIFENE','Raloxifene','true'
'using hrt or raloxifene at baseline','C0168634','baseline','BaseLine dental cement','true'
'using hrt or raloxifene at baseline','C1442488','Baseline','Baseline','false'
'time since start of fit years meanisd','C1301880','Start Time','Start time','false'
'time from end of fit years meanisd','C1522314','End Time','End Time','false'
'flex baseline bmd g cm^ meanisd','C0168634','baseline','BaseLine dental cement','true'
'flex baseline bmd g cm^ meanisd','C0439267','g%','Gram per Deciliter','false'
'flex baseline bmd g cm^ meanisd','C1442488','Baseline','Baseline','false'
'flex baseline bmd t score at femoral neck meanisd','C0449820','SCORE','Score','false'
'flex baseline bmd t score at femoral neck meanisd','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ $nmbr$ fn t score','C0449820','SCORE','Score','false'
'$nmbr$ $nmbr$ fn t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'$nmbr$ $nmbr$ fn t score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'fn t score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'fn t score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'flex baseline bmd t score at lumbar spine meanisd','C0449820','SCORE','Score','false'
'flex baseline bmd t score at lumbar spine meanisd','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ $nmbr$ ls t score','C0449820','SCORE','Score','false'
'$nmbr$ $nmbr$ ls t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'$nmbr$ $nmbr$ ls t score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'ls t score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'ls t score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'change in femoral neck bmd from fit baseline to flex baseline','C0742135','Cervical Change','cervical changes','false'
'change in femoral neck bmd from fit baseline to flex baseline','C0036572','Fit, NOS','Seizures','true'
'change in femoral neck bmd from fit baseline to flex baseline','C0168634','baseline','BaseLine dental cement','true'
'change in femoral neck bmd from fit baseline to flex baseline','C1442488','Baseline','Baseline','false'
'change in femoral neck bmd from fit baseline to flex baseline','C2349186','Fit','Fit (action)','false'
'change in femoral neck bmd from fit baseline to flex baseline','C4048158','Fit NOS','Convulsions','true'
'change in femoral neck bmd from fit baseline to flex baseline','C4553125','Fit','Prosthesis fit','false'
'gained bmd','C1517378','Gained','Gain','false'
'lost bmd','C0745777','Lost','Lost','false'
'lost bmd','C3815882','LOST','Lost Medical Device','false'
'femoral neck f score at flex baseline','C0016327','F-','Fluorides','true'
'femoral neck f score at flex baseline','C0449820','SCORE','Score','false'
'femoral neck f score at flex baseline','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'morphometric vertebral','C0549207','Vertebral','Bone structure of spine','true'
'pbo no o o ^','C0031962','PBO','Piperonyl Butoxide','true'
'pbo no o o ^','C0483204','O NOS','O NOS Ab','false'
'ain no','C0347129','AIN','Anal intraepithelial neoplasia','false'
'pbo no ^','C0031962','PBO','Piperonyl Butoxide','true'
'nvf at flex baseline $nmbr$ flex fn t score','C0168634','baseline','BaseLine dental cement','true'
'nvf at flex baseline $nmbr$ flex fn t score','C0449820','SCORE','Score','false'
'nvf at flex baseline $nmbr$ flex fn t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'nvf at flex baseline $nmbr$ flex fn t score','C1442488','Baseline','Baseline','false'
'$nmbr$ $nmbr$ flex fn f score $nmbr$','C0449820','SCORE','Score','false'
'$nmbr$ $nmbr$ flex fn f score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'flex fn f score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'flex fn f score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'p value for interaction vertebral fracture at flex baseline','C1709380','P-Value','P-Value','false'
'p value for interaction vertebral fracture at flex baseline','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'p value for interaction vertebral fracture at flex baseline','C0168634','baseline','BaseLine dental cement','true'
'p value for interaction vertebral fracture at flex baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ flex fn f score','C0449820','SCORE','Score','false'
'$nmbr$ flex fn f score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'nateglinide n $nmbr$','C0903898','NATEGLINIDE','nateglinide','true'
'race no i','C0034510','RACE','Racial group','true'
'race no i','C1706779','RACE','AMACR wt Allele','false'
'race no i','C3853635','Race','Race','false'
'race no i','C0021966','I-','Iodides','true'
'race no i','C0221138','I NOS','Blood group antibody I','false'
'body mass index^','C0005893','Body mass index','Body mass index procedure','false'
'body mass index^','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index^','C1305855','BODY MASS INDEX','Body mass index','true'
'waist circumference cmj','C0455829','Waist Circumference','Waist Circumference','true'
'blood pressure while seated mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure while seated mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure while seated mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'blood pressure while seated mm hg','C0277814','Seated','Sitting position','true'
'blood pressure while seated mm hg','C0439475','mmHG','mmHg','false'
'blood pressure while seated mm hg','C1283233','seated','Seating','false'
'cardiovascular risk factors no','C0850624','cardiovascular risk factor','cardiovascular risk factor','false'
'family history of premature heart disease','C0850707','family history of disease','history (of) disease family','false'
'reduced hdl cholesterol','C0151691','Reduced HDL cholesterol','Decreased HDL cholesterol concentration','false'
'elevated non hdl cholesterol','C0729627','Non-HDL cholesterol','Non-high density lipoprotein cholesterol (substance)','false'
'elevated non hdl cholesterol','C1535899','Non-HDL Cholesterol','Non-High Density Lipoprotein Cholesterol Measurement','false'
'history of cardiovascular disease no','C0455539','History of - cardiovascular disease','H/O: cardiovascular disease','false'
'angina or positive stress test','C0002962','ANGINA','Angina Pectoris','true'
'angina or positive stress test','C0015260','stress test','Exercise stress test','true'
'angina or positive stress test','C3494508','Stress Test','Stress Test','true'
'multivessel coronary artery bypass grafting','C0010055','Coronary Artery Bypass Grafting','Coronary Artery Bypass Surgery','true'
'intermittent claudication','C0021775','Claudication, Intermittent','Intermittent Claudication','true'
'peripheral arterial stenosis','C4025272','Peripheral arterial stenosis','Peripheral arterial stenosis','false'
'lower limb angioplasty or bypass surgery','C0745788','Lower Limb ANGIOPLASTY','Lower Limb ANGIOPLASTY','false'
'lower limb angioplasty or bypass surgery','C1536078','Bypass Surgery','Bypass Surgery','false'
'nontraumatic leg or foot amputation','C0023216','Leg','Lower Extremity','true'
'nontraumatic leg or foot amputation','C1140621','LEG','Leg','true'
'nontraumatic leg or foot amputation','C0188605','foot amputation','Amputation of the foot (procedure)','false'
'family history of diabetes mellitus no','C0260526','Family history of diabetes mellitus','Encounter due to family history of diabetes mellitus','false'
'family history of diabetes mellitus no','C1313937','Family history of diabetes mellitus','Family history of diabetes mellitus','false'
'plasma glucose mmol per liter','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'plasma glucose mmol per liter','C0439190','mmol','millimole','false'
'plasma glucose mmol per liter','C0455280','plasma glucose','Plasma glucose result','false'
'fasting','C0015663','FASTING','Fasting','true'
'$nmbr$ hr after glucose challenge','C3840385','Glucose challenge','Glucose challenge','false'
'metabolic syndrome no ^','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'lipids mg dl','C0023779','Lipids','Lipids','true'
'lipids mg dl','C0439269','mg dl','mg/dL','false'
'estimated gfr ml min $nmbr$ $nmbr$ m^','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min $nmbr$ $nmbr$ m^','C0439445','mL/min','mL/min','false'
'estimated gfr ml min $nmbr$ $nmbr$ m^','C1424601','GFR','RAPGEF5 gene','false'
'estimated gfr','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr','C1424601','GFR','RAPGEF5 gene','false'
'ratio of urinary albumin mg to creatinine g','C0456603','RATIO','Ratio','false'
'ratio of urinary albumin mg to creatinine g','C1547037','Ratio','data type - ratio','false'
'ratio of urinary albumin mg to creatinine g','C0010294','CREATININE','Creatinine','true'
'ratio of urinary albumin mg to creatinine g','C0439267','g%','Gram per Deciliter','false'
'ratio of urinary albumin mg to creatinine g','C1561535','Creatinine','Creatinine, CTCAE','false'
'medications no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications no','C4284232','Medications','Medications','false'
'last study visit','C0545082','Visit','Visit','false'
'last study visit','C1512346','visit','Patient Visit','false'
'last study visit','C2826704','VISIT','Visit Name','false'
'alpha blocker','C0001641','Alpha Blocker','Adrenergic alpha-Antagonists','true'
'aspirin or other antiplatelet drug','C0004057','ASPIRIN','Aspirin','true'
'aspirin or other antiplatelet drug','C0085826','Antiplatelet drug','Antiplatelet Agents','true'
'lipid modulating drug','C0023779','Lipid','Lipids','true'
'lipid modulating drug','C0443264','Modulating','Modulated','false'
'lipid modulating drug','C0013227','Drug','Pharmaceutical Preparations','true'
'lipid modulating drug','C1254351','DRUG','Pharmacologic Substance','false'
'antidiabetic drug i j','C0935929','antidiabetic drug','Antidiabetics','true'
'antidiabetic drug i j','C0021966','I-','Iodides','true'
'antidiabetic drug i j','C0221138','I NOS','Blood group antibody I','false'
'section $nmbr$ a','C0152060','Section, NOS','Transection (procedure)','false'
'section $nmbr$ a','C0700320','Section','Sectioning technique','false'
'section $nmbr$ a','C1522472','Section','section sample','false'
'section $nmbr$ a','C1552923','Section','Square Mile','false'
'section $nmbr$ a','C1705191','Section','Section (object)','false'
'section $nmbr$ a','C3714523','Section','Section - Geographic Area','false'
'nateglinide n n','C0903898','NATEGLINIDE','nateglinide','true'
'progression to diabetes','C1735364','Diabetes progression','Diabetes progression','false'
'hazard ratio $nmbr$ cl nateglinide vs placebo','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio $nmbr$ cl nateglinide vs placebo','C0903898','NATEGLINIDE','nateglinide','true'
'hazard ratio $nmbr$ cl nateglinide vs placebo','C0032042','Placebo','Placebos','true'
'hazard ratio $nmbr$ cl nateglinide vs placebo','C1696465','PLACEBO','placebo','false'
'hazard ratio $nmbr$ cl nateglinide vs placebo','C1706408','PLACEBO','Placebo Control','false'
'two sided p value for hetero geneity','C0205448','Two','Two','false'
'two sided p value for hetero geneity','C1709380','P-Value','P-Value','false'
'placebo n n','C0032042','Placebo','Placebos','true'
'placebo n n','C1696465','PLACEBO','placebo','false'
'placebo n n','C1706408','PLACEBO','Placebo Control','false'
'all patients p $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'$nmbr$ $nmbr$ years','C0439234','YEARS','year','false'
'fasting plasma glucose','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fasting plasma glucose','C0455280','plasma glucose','Plasma glucose result','false'
'$nmbr$ hr prandial glucose','C1998602','Meals','Meal (occasion for eating)','true'
'$nmbr$ hr prandial glucose','C0017725','GLUCOSE','Glucose','true'
'$nmbr$ hr prandial glucose','C4553624','Meals','With meals','false'
'[kg m^]','C0022718','KG','Kyrgyzstan','true'
'[kg m^]','C0439209','kg','Kilogram','false'
'[kg m^]','C4054209','/kg','Per Kilogram','false'
'waist circumference','C0455829','Waist Circumference','Waist Circumference','true'
'[cm female cm male ]','C0086582','MALE','Males','true'
'[cm female cm male ]','C1706180','Male','Male Gender, Self Report','false'
'[cm female cm male ]','C1706428','MALE','Male Phenotype','false'
'[cm female cm male ]','C1706429','Male','Male, Self-Reported','false'
'blood pressure control','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure control','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure control','C1272641','Blood pressure','Systemic arterial pressure','true'
'hypertension^','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension^','C1963138','Hypertension','Hypertension, CTCAE','false'
'history of cardiovascular disease','C0455539','History of - cardiovascular disease','H/O: cardiovascular disease','false'
'ace inhibitor treatment','C0039798','treatment','therapeutic aspects','true'
'ace inhibitor treatment','C0087111','Treatment','Therapeutic procedure','true'
'ace inhibitor treatment','C1522326','Treatment','Treating','false'
'ace inhibitor treatment','C1533734','Treatment','Administration procedure','false'
'ace inhibitor treatment','C1705169','Treatment','Biomaterial Treatment','false'
'ace inhibitor treatment','C3538994','TREATMENT','Treatment Epoch','false'
'ace inhibitor treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'section $nmbr$ b','C0152060','Section, NOS','Transection (procedure)','false'
'section $nmbr$ b','C0700320','Section','Sectioning technique','false'
'section $nmbr$ b','C1522472','Section','section sample','false'
'section $nmbr$ b','C1552923','Section','Square Mile','false'
'section $nmbr$ b','C1705191','Section','Section (object)','false'
'section $nmbr$ b','C3714523','Section','Section - Geographic Area','false'
'extended cardiovascular endpoint','C2349179','End Point','End Point','false'
'extended cardiovascular endpoint','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'section $nmbr$ c','C0152060','Section, NOS','Transection (procedure)','false'
'section $nmbr$ c','C0700320','Section','Sectioning technique','false'
'section $nmbr$ c','C1522472','Section','section sample','false'
'section $nmbr$ c','C1552923','Section','Square Mile','false'
'section $nmbr$ c','C1705191','Section','Section (object)','false'
'section $nmbr$ c','C3714523','Section','Section - Geographic Area','false'
'core cardiovascular endpoint','C2349179','End Point','End Point','false'
'core cardiovascular endpoint','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'valsartan n $nmbr$','C0216784','VALSARTAN','valsartan','true'
'sitting blood pressure mmhg','C0580946','Sitting blood pressure','Sitting blood pressure','false'
'sitting blood pressure mmhg','C0439475','mmHG','mmHg','false'
'peripheral artery stenosis','C0038449','artery stenosis','Stricture of artery','false'
'stroke of atherosclerotic origin','C0038454','STROKE','Cerebrovascular accident','true'
'stroke of atherosclerotic origin','C4554100','Stroke','Stroke, CTCAE','false'
'glycemic indexes','C1136206','Glycemic Index','Glycemic Index','true'
'fasting plasma glucose mmol liter','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fasting plasma glucose mmol liter','C0475211','Litre','liter','false'
'fasting plasma glucose mmol liter','C0455280','plasma glucose','Plasma glucose result','false'
'plasma glucose $nmbr$ hr after glucose load mmol liter','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'plasma glucose $nmbr$ hr after glucose load mmol liter','C0455280','plasma glucose','Plasma glucose result','false'
'metabolic syndrome no $nmbr$','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'estimated gfr^','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr^','C1424601','GFR','RAPGEF5 gene','false'
'mean ml min $nmbr$ $nmbr$ m^','C0444504','Mean','Statistical mean','false'
'mean ml min $nmbr$ $nmbr$ m^','C0439445','mL/min','mL/min','false'
'mean ml min $nmbr$ $nmbr$ m^','C2347634','Mean','Population Mean','false'
'mean ml min $nmbr$ $nmbr$ m^','C2348143','Mean','Sample Mean','false'
'ratio of urinary albumin mg to creatinine g median','C0456603','RATIO','Ratio','false'
'ratio of urinary albumin mg to creatinine g median','C1547037','Ratio','data type - ratio','false'
'ratio of urinary albumin mg to creatinine g median','C0549183','Median','Midline (qualifier value)','false'
'ratio of urinary albumin mg to creatinine g median','C0876920','Median','Median Statistical Measurement','false'
'ratio of urinary albumin mg to creatinine g median','C2347635','Median','Population Median','false'
'ratio of urinary albumin mg to creatinine g median','C2348144','Median','Sample Median','false'
'ratio of urinary albumin mg to creatinine g median','C2939193','Median','Median (qualifier value)','false'
'concomitant medication no ace inhibitor','C0013227','Medication','Pharmaceutical Preparations','true'
'concomitant medication no ace inhibitor','C3244316','medication','medication - HL7 publishing domain','false'
'concomitant medication no ace inhibitor','C4284232','Medication','Medications','false'
'concomitant medication no ace inhibitor','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'concomitant medication no ace inhibitor','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'any antihypertensive drug','C0003364','anti hypertensive drug','Antihypertensive Agents','true'
'aspirin orother antiplatelet drug','C0004057','aspirin antiplatelet','Aspirin','true'
'antidiabetic drug','C0935929','antidiabetic drug','Antidiabetics','true'
'valsartan n n','C0216784','VALSARTAN','valsartan','true'
'hazard ratio $nmbr$ cl valsartan vs placebo','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio $nmbr$ cl valsartan vs placebo','C0216784','VALSARTAN','valsartan','true'
'hazard ratio $nmbr$ cl valsartan vs placebo','C0032042','Placebo','Placebos','true'
'hazard ratio $nmbr$ cl valsartan vs placebo','C1696465','PLACEBO','placebo','false'
'hazard ratio $nmbr$ cl valsartan vs placebo','C1706408','PLACEBO','Placebo Control','false'
'all patients p','C0030705','Patients','Patients','true'
'all patients n $nmbr$','C0030705','Patients','Patients','true'
'fenofibrate n $nmbr$','C0033228','Phenofibrate','Fenofibrate','true'
'education no','C0013621','Education','Knowledge acquisition','true'
'education no','C0013622','education','Educational aspects','true'
'education no','C0013658','Education, NOS','Educational Status','true'
'education no','C0039401','Education','Educational process of instructing','true'
'high school graduate or ged','C0870649','High School Graduate','High School Graduate','false'
'high school graduate or ged','C1549971','High School Graduate','High School Graduate - Degree/license/certificate','false'
'high school graduate or ged','C1880947','GED','General Equivalency Diploma Completion','false'
'missing data','C4684714','Missing Data','Missing Data','false'
'previous cardiovascular event no','C0205156','Previous','Previous','false'
'previous cardiovascular event no','C1320716','Cardiovascular event','Cardiovascular event','false'
'previous cardiovascular event no','C1552607','previous','Act Relationship Subset - previous','false'
'previous congestive heart failure no','C0205156','Previous','Previous','false'
'previous congestive heart failure no','C0018802','CONGESTIVE HEART FAILURE','Congestive heart failure','true'
'previous congestive heart failure no','C1552607','previous','Act Relationship Subset - previous','false'
'cigarette smoking status no','C1519386','Smoking Status','Smoking Status','false'
'any lipid lowering agent','C0086440','Lipid lowering agent','Hypolipidemic Agents','true'
'duration of diabetes yr','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes yr','C2926735','Duration','Duration','false'
'fasting plasma glucose mg dl','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fasting plasma glucose mg dl','C0439269','mg dl','mg/dL','false'
'fasting plasma glucose mg dl','C0455280','plasma glucose','Plasma glucose result','false'
'amputation due to diabetes no','C0678226','Due To','Due to','false'
'amputation due to diabetes no','C0598284','diabetes amputation','diabetes amputation','false'
'estimated glomerular filtration rate no','C3811844','Estimated Glomerular Filtration Rate','Estimated Glomerular Filtration Rate','false'
'$nmbr$ $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'plasma cholesterol mg dl','C0858034','plasma cholesterol','plasma cholesterol','false'
'plasma cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'plasma triglyceride mg dl','C0032105','PLASMA','Plasma','true'
'plasma triglyceride mg dl','C0439269','mg dl','mg/dL','false'
'plasma triglyceride mg dl','C1550098','Plasma, NOS (not otherwise specified)','Plasma, NOS (not otherwise specified)','false'
'plasma triglyceride mg dl','C4521445','Plasma','Plasma Product','false'
'febuxostat $nmbr$ mg daily n $nmbr$','C0024671','MG','Mammography','true'
'febuxostat $nmbr$ mg daily n $nmbr$','C0026410','MG','Mongolia','true'
'febuxostat $nmbr$ mg daily n $nmbr$','C0439269','mg%','mg/dL','false'
'febuxostat $nmbr$ mg daily n $nmbr$','C1960952','mg %','Milligram percent','false'
'febuxostat $nmbr$ mg daily n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'febuxostat $nmbr$ mg daily n $nmbr$','C4321396','MG','MG','false'
'febuxostat $nmbr$ mg daily n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C0024671','MG','Mammography','true'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C0026410','MG','Mongolia','true'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C0439269','mg%','mg/dL','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C1960952','mg %','Milligram percent','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C2346927','Mg++','Magnesium Cation','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C4321396','MG','MG','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n','C4521761','MG','United States Military Commissioned Officer O8','false'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C0002144','ALLOPURINOL','Allopurinol','true'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C0024671','MG','Mammography','true'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C0026410','MG','Mongolia','true'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C0439269','mg%','mg/dL','false'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C1960952','mg %','Milligram percent','false'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C4321396','MG','MG','false'
'allopurinol $nmbr$ $nmbr$ mg daily n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'american indian or alaska native','C0002460','AMERICAN INDIAN','American Indians','true'
'american indian or alaska native','C0682125','ALASKA NATIVE','Alaska Natives','true'
'native hawaiian or other pacific','C0337920','Hawaiian, Native','Hawaiian population','true'
'not hispanic or latino','C1518424','Not Hispanic','Not Hispanic or Latino','false'
'not hispanic or latino','C0086528','Latino','Latinos','true'
'alcohol use','C0001948','ALCOHOL USE','Alcohol consumption','true'
'non ex drinker','C0457801','Non - drinker','Current non-drinker of alcohol','false'
'drinker $nmbr$ to $nmbr$ drinks week','C0556338','Drinker','Drinker','false'
'drinker $nmbr$ to $nmbr$ drinks week','C0332174','/week','Weekly','false'
'drinker $nmbr$ to $nmbr$ drinks week','C0439230','Week','week','false'
'serum urate mg dl','C0455272','Serum Urate','Serum urate measurement','false'
'serum urate mg dl','C0439269','mg dl','mg/dL','false'
'years with gout','C0439234','YEARS','year','false'
'years with gout','C0018099','GOUT','Gout','true'
'completed previous febuxostat study','C2348557','Completed Study','Study Completed','false'
'completed previous febuxostat study','C0205156','Previous','Previous','false'
'completed previous febuxostat study','C1552607','previous','Act Relationship Subset - previous','false'
'renal functionb','C0022646','Renal','Kidney','true'
'moderately impaired','C0205081','Moderately','Moderate (severity modifier)','false'
'moderately impaired','C0221099','Impaired','Impaired','false'
'moderately impaired','C1881878','Moderately','Moderation','false'
'moderately impaired','C4085643','Moderately','Moderate Response','false'
'moderately impaired','C4321491','Moderately','Moderately Able','false'
'mildly impaired','C0750532','MILDLY','MILDLY','false'
'mildly impaired','C0221099','Impaired','Impaired','false'
'mildly impaired','C2945599','Mildly','Mild (qualifier value)','false'
'normal','C0205307','NORMAL','Normal','false'
'normal','C0231683','Normal','Gait normal','false'
'normal','C0439166','% normal','Percent normal','false'
'normal','C2347086','% Normal','Mean Percent of Normal','false'
'normal','C4553972','Normal','How Often Felt Normal question','false'
'including hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'including hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'use of low dose aspirin $nmbr$','C1524063','Use of','Use of','false'
'use of low dose aspirin $nmbr$','C2608320','Low-Dose Aspirin','Low-Dose Aspirin','false'
'mg daily','C0024671','MG','Mammography','true'
'mg daily','C0332173','Daily','Daily','false'
'mg daily','C0026410','MG','Mongolia','true'
'mg daily','C0439269','mg%','mg/dL','false'
'mg daily','C1960952','mg %','Milligram percent','false'
'mg daily','C2346927','Mg++','Magnesium Cation','false'
'mg daily','C4321396','MG','MG','false'
'mg daily','C4521761','MG','United States Military Commissioned Officer O8','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C0024671','MG','Mammography','true'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C0026410','MG','Mongolia','true'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C0439269','mg%','mg/dL','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C1960952','mg %','Milligram percent','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C2346927','Mg++','Magnesium Cation','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C4321396','MG','MG','false'
'febuxostat $nmbr$ mg daily n $nmbr$ n n','C4521761','MG','United States Military Commissioned Officer O8','false'
'renal functiona','C0022646','Renal','Kidney','true'
'baseline serum urate mg dl a','C0455272','Serum Urate','Serum urate measurement','false'
'baseline serum urate mg dl a','C0439269','mg dl','mg/dL','false'
'baseline tophusa','C0168634','baseline','BaseLine dental cement','true'
'baseline tophusa','C1442488','Baseline','Baseline','false'
'completed prior febuxostat studya','C0205197','COMPLETED','Complete','false'
'completed prior febuxostat studya','C0249529','FEBUXOSTAT','febuxostat','true'
'completed prior febuxostat studya','C3854010','completed','completed - RoleLinkStatus','false'
'age $nmbr$ y n n','C0001779','AGE','Age','false'
'white n n','C0007457','WHITE','Caucasoid Race','true'
'white n n','C0043157','WHITE','Caucasians','true'
'white n n','C0220938','WHITE','White color','false'
'diabetes mellitus n n','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'hypertension n n','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension n n','C1963138','Hypertension','Hypertension, CTCAE','false'
'hyperlipidemia n n','C0020473','Hyperlipidaemia, NOS','Hyperlipidemia','true'
'hyperlipidemia n n','C0428465','Hyperlipidemia','Serum lipids high (finding)','false'
'hyperlipidemia n n','C4555212','Hyperlipidemia','Hyperlipidemia, CTCAE','false'
'metabolic syndrome n n','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'current smoker n n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker n n','C3241966','Current Smoker','Current Smoker','false'
'prior mi n n','C0332152','Prior','Before','false'
'prior mi n n','C2826257','PRIOR','Prior Medication Usage','false'
'prior coronary revascularization n n','C0332152','Prior','Before','false'
'prior coronary revascularization n n','C0877341','coronary revascularisation','coronary revascularization','false'
'prior coronary revascularization n n','C2826257','PRIOR','Prior Medication Usage','false'
'prior angina n n','C0332152','Prior','Before','false'
'prior angina n n','C0002962','ANGINA','Angina Pectoris','true'
'prior angina n n','C2826257','PRIOR','Prior Medication Usage','false'
'prior heart failure n n','C0018801','Failure, Heart','Heart failure','true'
'prior heart failure n n','C0018802','Heart Failure','Congestive heart failure','true'
'prior heart failure n n','C4554158','Heart failure','Heart Failure, CTCAE','false'
'timi risk score n n','C0035647','Risk','Risk','true'
'timi risk score n n','C0449820','SCORE','Score','false'
'timi risk score n n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score n n','C4552904','risk','Subject Risk','false'
'index event n n','C0600653','Index','Indexes','true'
'index event n n','C0441471','Event','Event','false'
'index event n n','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'index event n n','C0918012','Index','Index','true'
'index event n n','C1552854','index','Html Link Type - index','false'
'index event n n','C1637833','% index','% index','false'
'index event n n','C2986546','Index','Target Lesion Identification','false'
'ua','C0041580','UA','Ukraine','true'
'ua','C0042014','UA','Urinalysis','true'
'nstemi','C3537184','NSTEMI','Non-ST Elevation Myocardial Infarction by ECG Finding','false'
'nstemi','C4255010','NSTEMI','Non-ST Elevated Myocardial Infarction','true'
'time from symptoms to randomization h','C0040223','TIME','Time','true'
'time from symptoms to randomization h','C3541383','Time','Time (foundation metadata concept)','false'
'time from symptoms to randomization h','C0033727','H+','Protons','true'
'time from symptoms to randomization h','C0369286','H NOS','H NOS Antibodies','false'
'time from symptoms to randomization h','C0441932','H+','Hepatic Involvement','false'
'time from symptoms to randomization h','C0564385','/h','/hour','false'
'time from symptoms to randomization h','C4528284','h*%','Hour Times Percent','false'
'azathioprine n $nmbr$','C0004482','AZATHIOPRINE','Azathioprine','true'
'infliximab n $nmbr$','C0666743','INFLIXIMAB','infliximab','true'
'combination therapy n $nmbr$','C0009429','Combination Therapy','Combined Modality Therapy','true'
'combination therapy n $nmbr$','C0556895','Combination therapy','Combination electrotherapy','false'
'p valued','C0369773','P NOS','P Blood group antibodies','false'
'p valued','C2603361','P'','P prime','false'
'white race no t','C0007457','white race','Caucasoid Race','true'
'white race no t','C0043157','white race','Caucasians','true'
'white race no t','C2603360','T'','T prime','false'
'median age yr','C0001779','AGE','Age','false'
'median age yr','C0439234','yr','year','false'
'median body weight kg','C0022718','KG','Kyrgyzstan','true'
'median body weight kg','C0439209','kg','Kilogram','false'
'median body weight kg','C4054209','/kg','Per Kilogram','false'
'median disease duration yr','C0872146','disease duration','disease length','false'
'median disease duration yr','C0439234','yr','year','false'
'median c reactive protein mg dl^','C0006560','C Reactive Protein','C-reactive protein','true'
'median c reactive protein mg dl^','C0439269','mg dl','mg/dL','false'
'median c reactive protein mg dl^','C1413716','C-reactive protein','CRP gene','false'
'median c reactive protein mg dl^','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'crohn s disease activity index score]','C0010346','Crohn's','Crohn Disease','true'
'crohn s disease activity index score]','C4706353','Disease Activity Score','DAS - Disease Activity Score','false'
'crohn s disease activity index score]','C0600653','Index','Indexes','true'
'crohn s disease activity index score]','C0918012','Index','Index','true'
'crohn s disease activity index score]','C1552854','index','Html Link Type - index','false'
'crohn s disease activity index score]','C1637833','% index','% index','false'
'crohn s disease activity index score]','C2986546','Index','Target Lesion Identification','false'
'gastrointestinal area involved no total no','C0017446','Area','Geographic Locations','true'
'gastrointestinal area involved no total no','C0205146','AREA','Area','false'
'gastrointestinal area involved no total no','C1314939','Involved','Involvement with','false'
'gastrointestinal area involved no total no','C0439175','% total','% of total','false'
'gastrointestinal area involved no total no','C0439810','Total','Total','false'
'ileum or colon','C0020885','ILEUM','ileum','true'
'ileum or colon','C0009368','COLON','Colon structure (body structure)','true'
'ileum or colon','C3888384','Colon','Colon <insect>','false'
'ileum only','C0020885','ILEUM','ileum','true'
'colon only','C0009368','COLON','Colon structure (body structure)','true'
'colon only','C3888384','Colon','Colon <insect>','false'
'ileum and colon','C0020885','ILEUM','ileum','true'
'ileum and colon','C0009368','COLON','Colon structure (body structure)','true'
'ileum and colon','C3888384','Colon','Colon <insect>','false'
'proximal gastrointestinal tract','C0017189','GASTROINTESTINAL TRACT','Gastrointestinal tract structure','true'
'proximal gastrointestinal tract','C0521362','gastro Intestinal tract','gastrointestinal','false'
'systemic corticosteroids no','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'any type according to daily dose','C0332307','TYPE','Type - attribute','false'
'any type according to daily dose','C1547052','*Type','*Type - Kind of quantity','false'
'budesonide no','C0054201','BUDESONIDE','Budesonide','true'
'$nmbr$ aminosalicylic compounds no','C0205198','Compound','Compound','false'
'$nmbr$ aminosalicylic compounds no','C1706082','Compound','Compound (substance)','false'
'proportion of patients in corticosteroid free clinical remission at week $nmbr$','C1709707','Proportion','Proportion','false'
'proportion of patients in corticosteroid free clinical remission at week $nmbr$','C0030705','Patients','Patients','true'
'proportion of patients in corticosteroid free clinical remission at week $nmbr$','C0205210','Clinical','Clinical','false'
'proportion of patients in corticosteroid free clinical remission at week $nmbr$','C0544452','Remission','Disease remission','false'
'proportion of patients in corticosteroid free clinical remission at week $nmbr$','C0687702','remission','Cancer Remission','false'
'ifx aza n $nmbr$','C0020823','IFX','Ifosfamide','true'
'ifx aza n $nmbr$','C0004482','AZA','Azathioprine','true'
'aza n $nmbr$','C0004482','AZA','Azathioprine','true'
'odds ratio','C0028873','Odds Ratio','Odds Ratio','true'
'd value','C1522609','Value','Numerical value','false'
'crohn s disease related surgery','C0010346','Crohn's','Crohn Disease','true'
'crohn s disease related surgery','C0038894','Surgery','Surgery specialty','false'
'crohn s disease related surgery','C0038895','surgery','Surgical aspects','true'
'crohn s disease related surgery','C0543467','Surgery','Operative Surgical Procedures','true'
'crohn s disease related surgery','C1274039','Surgery','General surgery specialty','true'
'with previous surgery','C0038894','Surgery','Surgery specialty','false'
'with previous surgery','C0038895','surgery','Surgical aspects','true'
'with previous surgery','C0543467','Surgery','Operative Surgical Procedures','true'
'with previous surgery','C1274039','Surgery','General surgery specialty','true'
'without previous surgery','C0038894','Surgery','Surgery specialty','false'
'without previous surgery','C0038895','surgery','Surgical aspects','true'
'without previous surgery','C0543467','Surgery','Operative Surgical Procedures','true'
'without previous surgery','C1274039','Surgery','General surgery specialty','true'
'baseline corticosteroid use mg','C0024671','MG','Mammography','true'
'baseline corticosteroid use mg','C0026410','MG','Mongolia','true'
'baseline corticosteroid use mg','C0439269','mg%','mg/dL','false'
'baseline corticosteroid use mg','C1960952','mg %','Milligram percent','false'
'baseline corticosteroid use mg','C2346927','Mg++','Magnesium Cation','false'
'baseline corticosteroid use mg','C4321396','MG','MG','false'
'baseline corticosteroid use mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'with corticosteroid treatment $nmbr$','C0039798','treatment','therapeutic aspects','true'
'with corticosteroid treatment $nmbr$','C0087111','Treatment','Therapeutic procedure','true'
'with corticosteroid treatment $nmbr$','C1522326','Treatment','Treating','false'
'with corticosteroid treatment $nmbr$','C1533734','Treatment','Administration procedure','false'
'with corticosteroid treatment $nmbr$','C1705169','Treatment','Biomaterial Treatment','false'
'with corticosteroid treatment $nmbr$','C3538994','TREATMENT','Treatment Epoch','false'
'with corticosteroid treatment $nmbr$','C3887704','treatment','treatment - ActInformationManagementReason','false'
'duration of crohn s disease yrs','C0449238','Duration','Duration (temporal concept)','false'
'duration of crohn s disease yrs','C2926735','Duration','Duration','false'
'duration of crohn s disease yrs','C0012634','Disease','Disease','true'
'baseline crp mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline crp mg dl','C0439269','mg dl','mg/dL','false'
'baseline crp mg dl','C1442488','Baseline','Baseline','false'
'europe lsrael','C0015176','Europe','Europe','true'
'baseline $nmbr$ asa','C0004057','ASA','Aspirin','true'
'baseline $nmbr$ asa','C3853627','ASA','Arylsulfatase A, human','false'
'use $nmbr$ asa compounds','C0205198','Compound','Compound','false'
'use $nmbr$ asa compounds','C1706082','Compound','Compound (substance)','false'
'no use of $nmbr$ asa compounds','C1524063','Use of','Use of','false'
'no use of $nmbr$ asa compounds','C0004057','ASA','Aspirin','true'
'no use of $nmbr$ asa compounds','C3853627','ASA','Arylsulfatase A, human','false'
'total group','C0441833','Group','Groups','false'
'total group','C0687744','group','Social group','false'
'total group','C1257890','Group','Population Group','true'
'total group','C1519504','Group','Stage Grouping','false'
'total group','C1705428','Group','Group Object','false'
'total group','C1705429','Group','User Group','false'
'ifx n $nmbr$','C0020823','IFX','Ifosfamide','true'
'enox','C3147679','ENOX','JPX gene','false'
'location','C0450429','Location','Location','false'
'location','C1515974','Location','Anatomic Site','false'
'location','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'location','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'no dm','C0011816','DM','Dextromethorphan','true'
'no dm','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'dm','C0011816','DM','Dextromethorphan','true'
'dm','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'prior ml','C0439526','/mL','/mL','false'
'prior ml','C1705224','ML','THPO wt Allele','false'
'prior ml','C3887665','ML','Thrombopoietin, human','false'
'no prior ml','C0439526','/mL','/mL','false'
'no prior ml','C1705224','ML','THPO wt Allele','false'
'no prior ml','C3887665','ML','Thrombopoietin, human','false'
'fibrinolytic','C0040044','Fibrinolytic','Thrombolytic Therapy','true'
'fibrin specilic','C0015982','Fibrin','Fibrin','true'
'time to rx','C0040223','TIME','Time','true'
'time to rx','C3541383','Time','Time (foundation metadata concept)','false'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C1962523','AMLODIPINE/VALSARTAN','Amlodipine / valsartan','true'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'amlodipine valsartan $nmbr$ to $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'amlodipine $nmbr$ to $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age sd yrs','C0001779','AGE','Age','false'
'age sd yrs','C2699239','SD','SD, Rat Strain','false'
'age category n','C0001779','AGE','Age','false'
'age category n','C0683312','Category','Categories','false'
'age category n','C3889287','Category','Digital Content Category','false'
'mssbp mm hg','C0439475','mmHG','mmHg','false'
'msdbp mm hg','C0439475','mmHG','mmHg','false'
'hypertension severity at baseline n','C0439793','Severity','Severities','false'
'hypertension severity at baseline n','C0522510','Severity','With intensity','false'
'$nmbr$ mm hg','C0439475','mmHG','mmHg','false'
'diabetic status n','C0241863','DIABETIC','diabetic','false'
'diabetic status n','C0449438','Status','Status','false'
'ish status n','C0449438','Status','Status','false'
'bmi n','C0578022','BMI','Finding of body mass index','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C0030771','PEF','Pefloxacin','true'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C1518922','PEF','peak expiratory flow (procedure)','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C1542834','PEF','Peak expiratory flow rate','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C1707156','BARS','CTBP1 wt Allele','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C3274014','BARS','Brief Ataxia Rating Scale','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C3541345','BARS','Barnes Akathisia Rating Scale Questionnaire','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ change in am pef by bmi and treatment group bars represent the standard error of the mean','C1710181','Standard Error of the Mean','Standard Error','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C0392747','Change','Changing','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C0443172','change','Changed status','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C0578022','BMI','Finding of body mass index','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C1707156','BARS','CTBP1 wt Allele','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C3274014','BARS','Brief Ataxia Rating Scale','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C3541345','BARS','Barnes Akathisia Rating Scale Questionnaire','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ change in pm pef by bmi and treatment group bars represent the standard error of the mean','C1710181','Standard Error of the Mean','Standard Error','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C0436315','Symptom change','Symptom modification','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C0578022','BMI','Finding of body mass index','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C1707156','BARS','CTBP1 wt Allele','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C3274014','BARS','Brief Ataxia Rating Scale','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C3541345','BARS','Barnes Akathisia Rating Scale Questionnaire','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ change in $nmbr$ hour symptoms score by bmi and treatment group bars represent the standard error of the mean','C1710181','Standard Error of the Mean','Standard Error','false'
'nyha ll lll patients with lvef','C1275491','NYHA','New York Heart Association Classification','false'
'nyha ll lll patients with lvef','C0030705','Patients','Patients','true'
'nyha ll lll patients with lvef','C0428772','LVEF','Left ventricular ejection fraction','false'
'nyha ll lll patients with lvef','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'remaining patients','C1527428','Remaining','Remaining','false'
'remaining patients','C0030705','Patients','Patients','true'
'dronedarone n $nmbr$','C0766326','DRONEDARONE','dronedarone','true'
'age years sd','C1510829','Age-Years','Age-Years','false'
'age years sd','C2699239','SD','SD, Rat Strain','false'
'ischaemic dilated cardiomyopathy','C1960867','Ischemic Dilated Cardiomyopathy','Ischemic congestive cardiomyopathy','false'
'non rheumatic valvular heart disease','C1518422','Non','Negation','false'
'non rheumatic valvular heart disease','C0264757','rheumatic Valvular Heart Diseases','Rheumatic disease of heart valve','false'
'non ischaemic dilated cardiomyopathy','C1518422','Non','Negation','false'
'non ischaemic dilated cardiomyopathy','C1960867','Ischemic Dilated Cardiomyopathy','Ischemic congestive cardiomyopathy','false'
'pacemaker','C0030163','PACEMAKER','Artificial cardiac pacemaker','true'
'pacemaker','C0810633','Pacemaker','Pacemakers','false'
'pacemaker','C1546728','Pacemaker','Specimen Source Codes - Pacemaker','false'
'pacemaker','C3275122','PACEMAKER','Pacemaker Procedure','false'
'pacemaker','C3853703','Pacemaker','Pacemaker ECG Assessment','false'
'implanted cardioverter defibrillator','C0021102','Implanted','Implants','false'
'implanted cardioverter defibrillator','C0810516','Cardioverter-Defibrillator','defibrillator/cardioverters','false'
'implanted cardioverter defibrillator','C2828363','IMPLANTED','Implanted Medical Device (finding)','false'
'overall population','C0032659','Population','geographic population','true'
'overall population','C1257890','Population','Population Group','true'
'hr [ $nmbr$ ci','C0008107','CI','Chile','true'
'hr [ $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline','C0428772','LVEF','Left ventricular ejection fraction','false'
'lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'lvef^ $nmbr$ $nmbr$ and nyha class ii iii at baseline','C1882086','NYHA CLASS III','New York Heart Association Class III','false'
'outcome measure','C0086749','Outcome Measure','Outcome Measures','true'
'hazard ratio $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'time to first cv hospitalization or death from any cause','C0040223','TIME','Time','true'
'time to first cv hospitalization or death from any cause','C3541383','Time','Time (foundation metadata concept)','false'
'time to first cv hospitalization or death from any cause','C0007465','Death Cause','Cause of Death','true'
'first cv hospitalization','C0205435','First','First (number)','false'
'first cv hospitalization','C0019993','hospitalisation','Hospitalization','true'
'first cv hospitalization','C1279901','First','Firstly','false'
'death from any cause','C0007465','Death Cause','Cause of Death','true'
'first hospitalization for chf or cv death','C0019993','hospitalisation','Hospitalization','true'
'first hospitalization for chf or cv death','C0018802','CHF','Congestive heart failure','true'
'first hospitalization for chf or cv death','C0011065','DEATH','Cessation of life','true'
'first hospitalization for chf or cv death','C1306577','Death','Death (finding)','false'
'first hospitalization for chf or cv death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'first hospitalization for chf or cv death','C4552775','Death NOS','Death NOS, CTCAE','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0444506','Trough','Trough','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C3714541','FEV','Forced Vital Capacity','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1705242','Difference','Different','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1554093','Patient Treatment','HL7CommitteeIDInRIM <Patient Administration>','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C3242279','patient Treatment','healthcare operations <patient administration>','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C3242455','patient Treatment','HL7PublishingDomain <patient administration>','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0332849','Divided','Divide','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1442488','Baseline','Baseline','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0001779','AGE','Age','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1519386','Smoking Status','Smoking Status','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0004048','Inhaled','Inspiration function','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0239126','CORTICOSTEROID USE','corticosteroid use','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0009924','Contrast','Contrast Media','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1979874','Contrast','Contrast','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0032042','Placebo','Placebos','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C2825972','Cant','Cant','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0178602','Doses','Dosage','false'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C0213771','TIOTROPIUM','tiotropium','true'
'figure $nmbr$ trough fev $nmbr$ at $nmbr$ weeks differences between active and placebo treatments in patient subgroups divided according to baseline status for age smoking status and inhaled corticosteroid ics use all contrasts versus placebo signi cant at p $nmbr$ $nmbr$ indacaterol both doses was noninferior to tiotropium p $nmbr$ $nmbr$ in all subgroups','C1079230','subgroups','Subgroup A Nepoviruses','false'
'arm','C0446516','ARM','Upper arm','true'
'arm','C3715044','ARM','AKR1A1 wt Allele','false'
'arm','C4553528','arm','Sequence Arm','false'
'pad at baseline','C0182158','Pad','Pads','false'
'pad at baseline','C0332568','Pad','Pad Mass','false'
'pad at baseline','C3540603','PAD','PADI4 wt Allele','false'
'pad at baseline','C3669270','Pad','Strucure of thick cushion of skin','false'
'pad at baseline','C3814046','PAD','PAD Regimen','false'
'pad at baseline','C4319657','Pad','Pad (unit of presentation)','false'
'control','C0243148','control','control aspects','true'
'control','C1550141','Control','control substance','false'
'control','C1882979','Control','Scientific Control','false'
'control','C2587213','Control','Control function','false'
'control','C3274648','Control','True Control Status','false'
'control','C4553389','control','Study Control','false'
'no pad baseline','C0168634','baseline','BaseLine dental cement','true'
'no pad baseline','C1442488','Baseline','Baseline','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0024501','Maintenance','Maintenance','true'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0871261','Response','Response process','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C1704632','Response','Disease Response','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C1706817','Response','Response (statement)','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C2911692','Response','Response (communication)','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0544452','Remission','Disease remission','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0687702','remission','Cancer Remission','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0332152','Prior to','Before','false'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C0032659','Population','geographic population','true'
'figure $nmbr$ maintenance of a response and b remission at week $nmbr$ by prior in iximab use intent to treat population','C1257890','Population','Population Group','true'
'lce n $nmbr$','C1423759','LCE','ELOVL6 gene','false'
'lce n $nmbr$','C3273355','LCE','Laser Cryo Enrichment','false'
'age mean yr','C0001779','AGE','Age','false'
'age mean yr','C0439234','yr','year','false'
'men no','C0025266','Men','Male population group','true'
'mean duration of pd yr','C0449238','Duration','Duration (temporal concept)','false'
'mean duration of pd yr','C2926735','Duration','Duration','false'
'updrs total ii iii','C0439070','III','Roman Numeral III','false'
'updrs total ii iii','C1705160','III','III (suffix)','false'
'updrs part ii adl','C0001288','ADL','Activities of Daily Living (activity)','true'
'updrs part ii adl','C1420005','ADL','SGCA gene','false'
'updrs part iii motor','C1513492','Motor','motor movement','false'
'updrs part iii motor','C1705994','Motor','Device Motor','false'
'hoehn yahr stage','C0205390','Stage','Phase','false'
'hoehn yahr stage','C1300072','Stage','Tumor stage','false'
'hoehn yahr stage','C1306673','Stage','Stage','false'
'schwab england score','C0449820','SCORE','Score','false'
'schwab england score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'previous antiparkinson medication no','C0205156','Previous','Previous','false'
'previous antiparkinson medication no','C0003405','Antiparkinson Medication','Antiparkinson Agents','true'
'previous antiparkinson medication no','C1552607','previous','Act Relationship Subset - previous','false'
'dopamine agonist use no','C0042153','use','utilization qualifier','true'
'dopamine agonist use no','C0457083','Use','Usage','false'
'dopamine agonist use no','C1947944','Use','Use - dosing instruction imperative','false'
'lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire','C1292728','Disease activity','Condition activity','false'
'lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire','C0337645','Living Disease','Living Conditions','true'
'lce l dopa carbidopa entacapone lc l dopa carbidopa pd parkinson disease updrs rating scale adl activities of daily living pdq $nmbr$ parkinson disease questionnaire','C0034394','Questionnaire','Questionnaires','true'
'unified parkinson disease','C0030567','PARKINSON DISEASE','Parkinson Disease','true'
'unified parkinson disease','C1521736','Parkinson's Disease','Parkinson's Disease Pathway','false'
'olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$','C0386393','OLMESARTAN MEDOXOMIL','Olmesartan medoxomil','true'
'olmesartan medoxomil $nmbr$ mg hctz $nmbr$ $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C0386393','OLMESARTAN MEDOXOMIL','Olmesartan medoxomil','true'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'olmesartan medoxomil $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age y [mean sd]','C0001779','AGE','Age','false'
'age y [mean sd]','C0444504','Mean','Statistical mean','false'
'age y [mean sd]','C2699239','SD','SD, Rat Strain','false'
'age y [mean sd]','C2347634','Mean','Population Mean','false'
'age y [mean sd]','C2348143','Mean','Sample Mean','false'
'$nmbr$ [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ [n ]','C0441922','N+','N+ (tumor staging)','false'
'males [n ]','C0086582','Males','Males','true'
'males [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'males [n ]','C0441922','N+','N+ (tumor staging)','false'
'diabetes mellitus [n ]','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'diabetes mellitus [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'diabetes mellitus [n ]','C0441922','N+','N+ (tumor staging)','false'
'bmi kg m $nmbr$ [mean sd]','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ [mean sd]','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ [mean sd]','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ [mean sd]','C0444504','Mean','Statistical mean','false'
'bmi kg m $nmbr$ [mean sd]','C2699239','SD','SD, Rat Strain','false'
'bmi kg m $nmbr$ [mean sd]','C2347634','Mean','Population Mean','false'
'bmi kg m $nmbr$ [mean sd]','C2348143','Mean','Sample Mean','false'
'sedbp mmhg [mean_ sd]a','C0439475','mmHG','mmHg','false'
'sedbp mmhg [mean_ sd]a','C0444504','Mean','Statistical mean','false'
'sedbp mmhg [mean_ sd]a','C2699239','SD','SD, Rat Strain','false'
'sedbp mmhg [mean_ sd]a','C2347634','Mean','Population Mean','false'
'sedbp mmhg [mean_ sd]a','C2348143','Mean','Sample Mean','false'
'sesbp mmhg [mean _sd]a','C0439475','mmHG','mmHg','false'
'sesbp mmhg [mean _sd]a','C0444504','Mean','Statistical mean','false'
'sesbp mmhg [mean _sd]a','C2699239','SD','SD, Rat Strain','false'
'sesbp mmhg [mean _sd]a','C2347634','Mean','Population Mean','false'
'sesbp mmhg [mean _sd]a','C2348143','Mean','Sample Mean','false'
'severity ofhypertension [n ]b','C0439793','Severity','Severities','false'
'severity ofhypertension [n ]b','C0522510','Severity','With intensity','false'
'severity ofhypertension [n ]b','C0369718','N NOS','N not otherwise specified Antibody','false'
'severity ofhypertension [n ]b','C0441922','N+','N+ (tumor staging)','false'
'mild','C2945599','Mild','Mild (qualifier value)','false'
'pre treatedforhypertension [n ]','C0332152','Pre','Before','false'
'pre treatedforhypertension [n ]','C0740175','Pre','Before values','false'
'pre treatedforhypertension [n ]','C2257086','PRE','photoreactivating enzyme activity','false'
'pre treatedforhypertension [n ]','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'pre treatedforhypertension [n ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'pre treatedforhypertension [n ]','C0441922','N+','N+ (tumor staging)','false'
'pre treatment[n ]c','C1550147','Pretreatment','Pretreatment (substance)','false'
'pre treatment[n ]c','C2709094','pre treatment','pre treatment','false'
'pre treatment[n ]c','C3539075','Pretreatment','Pretreatment Period','false'
'pre treatment[n ]c','C3539076','Pretreatment','Pretreatment','false'
'pre treatment[n ]c','C2349138','N/C','Volt per Meter','false'
'calcium channelantagonist','C0006675','CALCIUM','Calcium','true'
'calcium channelantagonist','C0006726','Calcium','Calcium, Dietary','true'
'calcium channelantagonist','C2936886','Calcium','Calcium [EPC]','false'
'calcium channelantagonist','C3540037','CALCIUM','CALCIUM SUPPLEMENTS','false'
'calcium channelantagonist','C3714611','CALCIUM','Calcium Drug Class','false'
'low ceiling diuretic','C0205251','Low','low','false'
'low ceiling diuretic','C0012798','Diuretic','Diuretics','true'
'low ceiling diuretic','C1550472','low','low confidentiality','false'
'low ceiling diuretic','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low ceiling diuretic','C4048187','low','low exposure','false'
'low ceiling diuretic','C4321351','Low','Low Level','false'
'low ceiling diuretic','C4522223','Low','IPSS Risk Category Low','false'
'bp in pre treated patients','C0037623','BP','Solomon Islands','true'
'bp in pre treated patients','C1415692','Bp','HP gene','false'
'bp in pre treated patients','C1708288','BP','HP wt Allele','false'
'bp in pre treated patients','C4318478','BP','Base Pair Unit','false'
'sedbp mmhg [mean _sd]d','C0439475','mmHG','mmHg','false'
'sedbp mmhg [mean _sd]d','C0444504','Mean','Statistical mean','false'
'sedbp mmhg [mean _sd]d','C2699239','SD','SD, Rat Strain','false'
'sedbp mmhg [mean _sd]d','C2347634','Mean','Population Mean','false'
'sedbp mmhg [mean _sd]d','C2348143','Mean','Sample Mean','false'
'sesbp mmhg [mean sd]d','C0439475','mmHG','mmHg','false'
'sesbp mmhg [mean sd]d','C0444504','Mean','Statistical mean','false'
'sesbp mmhg [mean sd]d','C2699239','SD','SD, Rat Strain','false'
'sesbp mmhg [mean sd]d','C2347634','Mean','Population Mean','false'
'sesbp mmhg [mean sd]d','C2348143','Mean','Sample Mean','false'
'hradj $nmbr$ ci','C0008107','CI','Chile','true'
'hradj $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'$nmbr$ $nmbr$ referent','C1706462','Referent','Reference Object','false'
'no prior mi n $nmbr$','C0332152','Prior','Before','false'
'no prior mi n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'prior mi n $nmbr$','C0332152','Prior','Before','false'
'prior mi n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'no prior hf n $nmbr$','C0332152','Prior','Before','false'
'no prior hf n $nmbr$','C0018488','Hf','Hafnium','true'
'no prior hf n $nmbr$','C1313497','HF','GZMA protein, human','true'
'no prior hf n $nmbr$','C1538440','HF','CFH gene','false'
'no prior hf n $nmbr$','C3273279','HF','CFH wt Allele','false'
'no prior hf n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'prior hf n $nmbr$','C0332152','Prior','Before','false'
'prior hf n $nmbr$','C0018488','Hf','Hafnium','true'
'prior hf n $nmbr$','C1313497','HF','GZMA protein, human','true'
'prior hf n $nmbr$','C1538440','HF','CFH gene','false'
'prior hf n $nmbr$','C3273279','HF','CFH wt Allele','false'
'prior hf n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'bnp','C0054015','BNP','Nesiritide','true'
'bnp','C1095989','BNP','Brain natriuretic peptide measurement','false'
'bnp','C1417808','BNP','NPPB gene','false'
'bnp','C2982014','BNP','NPPB wt Allele','false'
'bnp $nmbr$ pg ml n $nmbr$','C0054015','BNP','Nesiritide','true'
'bnp $nmbr$ pg ml n $nmbr$','C0439297','pg/mL','Nanogram per Liter','false'
'bnp $nmbr$ pg ml n $nmbr$','C1095989','BNP','Brain natriuretic peptide measurement','false'
'bnp $nmbr$ pg ml n $nmbr$','C1417808','BNP','NPPB gene','false'
'bnp $nmbr$ pg ml n $nmbr$','C2982014','BNP','NPPB wt Allele','false'
'ranolazine n $nmbr$','C0073633','RANOLAZINE','ranolazine','true'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0428883','Diastolic Blood Pressure','Diastolic blood pressure','true'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C1305849','diastolic blood pressure','Diastolic blood pressure measurement','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0949236','Pulse Pressure','Pulse Pressure','true'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0439234','Year','year','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C1705117','Increment','Increment','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0439508','/Year','per year','false'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C0040223','TIME','Time','true'
'figure $nmbr$ systolic blood pressure a diastolic blood pressure b and pulse pressure c as a function of age in $nmbr$ year increments and time','C3541383','Time','Time (foundation metadata concept)','false'
'om $nmbr$ mg aml $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg aml $nmbr$ mg n $nmbr$','C0023465','AML','Acute monocytic leukemia','true'
'om $nmbr$ mg aml $nmbr$ mg n $nmbr$','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'om $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C0020261','HCTZ','Hydrochlorothiazide','true'
'aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C0020261','HCTZ','Hydrochlorothiazide','true'
'om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg n $nmbr$','C0020261','HCTZ','Hydrochlorothiazide','true'
'age group no','C0027362','Age Group','Human Age Group','true'
'age group no','C2348001','Age Group','Age Cohort','false'
'height mean sd cm','C0489786','Height','Height','false'
'height mean sd cm','C0444504','Mean','Statistical mean','false'
'height mean sd cm','C2347634','Mean','Population Mean','false'
'height mean sd cm','C2348143','Mean','Sample Mean','false'
'bmi mean sd kg m^','C0022718','KG','Kyrgyzstan','true'
'bmi mean sd kg m^','C0439209','kg','Kilogram','false'
'bmi mean sd kg m^','C4054209','/kg','Per Kilogram','false'
'bmi category no','C0683312','Category','Categories','false'
'bmi category no','C3889287','Category','Digital Content Category','false'
'$nmbr$ kg m^ obesity','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg m^ obesity','C0439209','kg','Kilogram','false'
'$nmbr$ kg m^ obesity','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg m^ obesity','C0028754','OBESITY','Obesity','true'
'$nmbr$ kg m^ obesity','C1963185','Obesity','Obesity, CTCAE','false'
'diabetes no','C0011847','Diabetes','Diabetes','false'
'diabetes no','C0011849','Diabetes','Diabetes Mellitus','true'
'chronic kidney disease no t','C1561643','Chronic Kidney Disease','Chronic Kidney Diseases','true'
'chronic kidney disease no t','C4553188','Chronic kidney disease','Chronic Kidney Disease, CTCAE','false'
'chronic kidney disease no t','C2603360','T'','T prime','false'
'chronic cardiovascular disease no','C1290380','Chronic Cardiovascular disease','Chronic disease of cardiovascular system','false'
'bp goal no','C0018017','Goal','objective (goal)','true'
'bp goal no','C1571704','Goal','Act Mood - Goal','false'
'baseline sesbp mean sd mm hg','C0168634','baseline','BaseLine dental cement','true'
'baseline sesbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'baseline sesbp mean sd mm hg','C1442488','Baseline','Baseline','false'
'baseline sedbp mean sd mm hg','C0168634','baseline','BaseLine dental cement','true'
'baseline sedbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'baseline sedbp mean sd mm hg','C1442488','Baseline','Baseline','false'
'om $nmbr$ mg aml $nmbr$ mg','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg aml $nmbr$ mg','C0023465','AML','Acute monocytic leukemia','true'
'om $nmbr$ mg aml $nmbr$ mg','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'om $nmbr$ mg hctz $nmbr$ mg','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg hctz $nmbr$ mg','C0020261','HCTZ','Hydrochlorothiazide','true'
'aml $nmbr$ mg hctz $nmbr$ mg','C1319635','mg/mg','mg/mg','false'
'aml $nmbr$ mg hctz $nmbr$ mg','C0020261','HCTZ','Hydrochlorothiazide','true'
'om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg','C1319635','mg/mg','mg/mg','false'
'om $nmbr$ mg aml $nmbr$ mg hctz $nmbr$ mg','C0020261','HCTZ','Hydrochlorothiazide','true'
'bp variable mm hg','C0037623','BP','Solomon Islands','true'
'bp variable mm hg','C0439475','mmHG','mmHg','false'
'bp variable mm hg','C1415692','Bp','HP gene','false'
'bp variable mm hg','C1708288','BP','HP wt Allele','false'
'bp variable mm hg','C4318478','BP','Base Pair Unit','false'
'moderate severe n $nmbr$ n $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate severe n $nmbr$ n $nmbr$','C0205082','Severe','Severe (severity modifier)','false'
'moderate severe n $nmbr$ n $nmbr$','C4050465','Severe','Severe Extremity Pain','false'
'moderate severe n $nmbr$ n $nmbr$','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'moderate severe n $nmbr$ n $nmbr$','C1881878','Moderate','Moderation','false'
'moderate severe n $nmbr$ n $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate severe n $nmbr$ n $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate severe n $nmbr$ n $nmbr$','C4085643','Moderate','Moderate Response','false'
'moderate severe n $nmbr$ n $nmbr$','C4321335','Moderate','Moderate Level','false'
'baseline bp mean sd','C0488053','BP mean','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'baseline bp mean sd','C2699239','SD','SD, Rat Strain','false'
'change in sesbp ls mean se','C0392747','Change','Changing','false'
'change in sesbp ls mean se','C0443172','change','Changed status','false'
'change in sesbp ls mean se','C1705241','Change','Delta (difference)','false'
'change in sesbp ls mean se','C4319952','Change','Change -- procedure','false'
'change in sedbp ls mean se','C0392747','Change','Changing','false'
'change in sedbp ls mean se','C0443172','change','Changed status','false'
'change in sedbp ls mean se','C1705241','Change','Delta (difference)','false'
'change in sedbp ls mean se','C4319952','Change','Change -- procedure','false'
'severe oab subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'severe oab subgroup','C1515021','Subgroup','Subgroup','false'
'solifenacin n $nmbr$','C1099677','SOLIFENACIN','Solifenacin','true'
'age year','C0439234','Year','year','false'
'age year','C0439508','/Year','per year','false'
'age cohort no','C2348001','Age Cohort','Age Cohort','false'
'diary variables mean sd','C0376660','Diary','Diary','true'
'diary variables mean sd','C2699239','SD','SD, Rat Strain','false'
'urgency episodes $nmbr$ h','C0033727','H+','Protons','true'
'urgency episodes $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'urgency episodes $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'urgency episodes $nmbr$ h','C0564385','/h','/hour','false'
'urgency episodes $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'incontinence episodes $nmbr$ h','C0033727','H+','Protons','true'
'incontinence episodes $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'incontinence episodes $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'incontinence episodes $nmbr$ h','C0564385','/h','/hour','false'
'incontinence episodes $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'micturitions $nmbr$ h','C0033727','H+','Protons','true'
'micturitions $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'micturitions $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'micturitions $nmbr$ h','C0564385','/h','/hour','false'
'micturitions $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'nocturia episodes $nmbr$ h','C0033727','H+','Protons','true'
'nocturia episodes $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'nocturia episodes $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'nocturia episodes $nmbr$ h','C0564385','/h','/hour','false'
'nocturia episodes $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'wt second median','C0549183','Median','Midline (qualifier value)','false'
'wt second median','C0876920','Median','Median Statistical Measurement','false'
'wt second median','C2347635','Median','Population Median','false'
'wt second median','C2348144','Median','Sample Median','false'
'wt second median','C2939193','Median','Median (qualifier value)','false'
'ppbc score mean sd','C0444504','Mean','Statistical mean','false'
'ppbc score mean sd','C2699239','SD','SD, Rat Strain','false'
'ppbc score mean sd','C2347634','Mean','Population Mean','false'
'ppbc score mean sd','C2348143','Mean','Sample Mean','false'
'iuss score mean sd','C0444504','Mean','Statistical mean','false'
'iuss score mean sd','C2699239','SD','SD, Rat Strain','false'
'iuss score mean sd','C2347634','Mean','Population Mean','false'
'iuss score mean sd','C2348143','Mean','Sample Mean','false'
'ups score mean sd','C0334463','UPS','Malignant Fibrous Histiocytoma','true'
'ups score mean sd','C2699239','SD','SD, Rat Strain','false'
'ups score mean sd','C3542434','UPS','Urgency Perception Scale Questionnaire','false'
'oab q score mean sd','C3641332','OAB-Q','The Overactive Bladder Questionnaire','false'
'oab q score mean sd','C2699239','SD','SD, Rat Strain','false'
'symptom bother','C1457887','Symptom','Symptoms','false'
'symptom bother','C3854129','Symptom','Symptom:Find:Pt:^Patient:Nom','false'
'hrql mean sd','C0444504','Mean','Statistical mean','false'
'hrql mean sd','C2699239','SD','SD, Rat Strain','false'
'hrql mean sd','C2347634','Mean','Population Mean','false'
'hrql mean sd','C2348143','Mean','Sample Mean','false'
'coping','C0009967','Coping','Coping Behavior','true'
'concern','C2699424','Concern','Concern','false'
'sleep','C0037313','Sleep','Sleep','true'
'social interaction','C0037420','Social Interaction','Social Interaction','true'
'all n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'all n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'bivalirudin n $nmbr$ $nmbr$','C0168273','BIVALIRUDIN','bivalirudin','true'
'heparin plus gpi n $nmbr$ $nmbr$','C0019134','HEPARIN','heparin','true'
'heparin plus gpi n $nmbr$ $nmbr$','C0770546','HEPARIN','heparin, porcine','false'
'symptom onset to pci h','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptom onset to pci h','C0033727','H+','Protons','true'
'symptom onset to pci h','C0369286','H NOS','H NOS Antibodies','false'
'symptom onset to pci h','C0441932','H+','Hepatic Involvement','false'
'symptom onset to pci h','C0564385','/h','/hour','false'
'symptom onset to pci h','C4528284','h*%','Hour Times Percent','false'
'killip class $nmbr$ $nmbr$','C1881332','Killip Class','Killip Class','false'
'anemia','C0002871','ANEMIA','Anemia','true'
'anemia','C1000483','Anemia','Genus Anemia','false'
'anemia','C4554633','Anemia','Anemia, CTCAE','false'
'$nmbr$ diseased vessels','C0005847','Vessels','Blood Vessel','true'
'anterior infarct location','C0450429','Location','Location','false'
'anterior infarct location','C1515974','Location','Anatomic Site','false'
'anterior infarct location','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'anterior infarct location','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'initial timi flow grade $nmbr$','C0441800','Grade','Grade','false'
'initial timi flow grade $nmbr$','C0919553','Grade','Histopathologic Grade','false'
'initial timi flow grade $nmbr$','C3244287','grade','School Grade','false'
'lvef','C0428772','LVEF','Left ventricular ejection fraction','false'
'lvef','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'stent implanted','C0522776','stent implant','Placement of stent','false'
'final timi flow grade','C0441800','Grade','Grade','false'
'final timi flow grade','C0919553','Grade','Histopathologic Grade','false'
'final timi flow grade','C3244287','grade','School Grade','false'
'heart rate group at baseline','C0441833','Group','Groups','false'
'heart rate group at baseline','C0687744','group','Social group','false'
'heart rate group at baseline','C1257890','Group','Population Group','true'
'heart rate group at baseline','C1519504','Group','Stage Grouping','false'
'heart rate group at baseline','C1705428','Group','Group Object','false'
'heart rate group at baseline','C1705429','Group','User Group','false'
'cardiac parameters','C0018787','Cardiac','Heart','true'
'cardiac parameters','C0449381','Parameters','Observation parameter','false'
'cardiac parameters','C1522601','Cardiac','Cardiac - anatomy qualifier','false'
'egfr ml min per $nmbr$ $nmbr$ kg m^','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min per $nmbr$ $nmbr$ kg m^','C0439402','(mL/min)/kg','mL/min/kg','false'
'egfr ml min per $nmbr$ $nmbr$ kg m^','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min per $nmbr$ $nmbr$ kg m^','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'duration of heart failure years','C0449238','Duration','Duration (temporal concept)','false'
'duration of heart failure years','C2926735','Duration','Duration','false'
'primary cause of heart failure','C0205225','Primary','Primary','false'
'primary cause of heart failure','C0015127','cause','Etiology aspects','true'
'primary cause of heart failure','C1524003','Cause','Science of Etiology','false'
'primary cause of heart failure','C0439612','Primary','True primary (qualifier value)','false'
'primary cause of heart failure','C0439631','Primary','Primary operation','false'
'ischaemic','C0475224','Ischemic','Ischemic','false'
'non ischaemic','C1518422','Non','Negation','false'
'non ischaemic','C0475224','Ischemic','Ischemic','false'
'history of atrial fibrillation and or flutter','C0729790','History of - atrial fibrillation','H/O: atrial fibrillation','false'
'history of atrial fibrillation and or flutter','C0016385','Flutter','Cardiac Flutter','false'
'history of atrial fibrillation and or flutter','C2242390','FLUTTER','Flutter (respiratory device)','false'
'treatment at randomisation','C0039798','treatment','therapeutic aspects','true'
'treatment at randomisation','C0087111','Treatment','Therapeutic procedure','true'
'treatment at randomisation','C1522326','Treatment','Treating','false'
'treatment at randomisation','C1533734','Treatment','Administration procedure','false'
'treatment at randomisation','C1705169','Treatment','Biomaterial Treatment','false'
'treatment at randomisation','C3538994','TREATMENT','Treatment Epoch','false'
'treatment at randomisation','C3887704','treatment','treatment - ActInformationManagementReason','false'
'p blocker','C0369773','P NOS','P Blood group antibodies','false'
'p blocker','C2603361','P'','P prime','false'
'arbs','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'diuretic agents excluding antialdosterone','C0450442','Agent','Agent','false'
'diuretic agents excluding antialdosterone','C1254351','Agent','Pharmacologic Substance','false'
'diuretic agents excluding antialdosterone','C1521826','Agent','Protocol Agent','false'
'antialdosterone agents','C0450442','Agent','Agent','false'
'antialdosterone agents','C1254351','Agent','Pharmacologic Substance','false'
'antialdosterone agents','C1521826','Agent','Protocol Agent','false'
'cardiac glycosides','C0007158','CARDIAC GLYCOSIDES','Cardiac Glycosides','true'
'devices','C0025080','DEVICES','Medical Devices','true'
'devices','C0220819','devices','device aspects','true'
'devices','C0699733','Devices','Devices','true'
'heart rate at baseline bpm','C0018810','Heart Rate','heart rate','true'
'heart rate at baseline bpm','C0168634','baseline','BaseLine dental cement','true'
'heart rate at baseline bpm','C1442488','Baseline','Baseline','false'
'ivabradine group','C0441833','Group','Groups','false'
'ivabradine group','C0687744','group','Social group','false'
'ivabradine group','C1257890','Group','Population Group','true'
'ivabradine group','C1519504','Group','Stage Grouping','false'
'ivabradine group','C1705428','Group','Group Object','false'
'ivabradine group','C1705429','Group','User Group','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0013806','ECT','Electroconvulsive Therapy','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C2199618','ECT','Ecarin Clotting Time Measurement','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C2363129','ECT','Benign Rolandic Epilepsy','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C4050504','ECT','Ectomesenchymal Chondromyxoid Tumor','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1707455','Compared','Comparison','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0032042','Placebo','Placebos','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C2986535','Primary Endpoint','Primary Endpoint','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0184666','HOSPITAL ADMISSIONS','Hospital admission','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0332271','Worsening','Worsening pattern','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1457868','Worsening','Worse','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1546960','Worsening','Patient Outcome - Worsening','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0018801','Failure, Heart','Heart failure','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0018802','Heart Failure','Congestive heart failure','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C4554158','Heart failure','Heart Failure, CTCAE','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0007226','Cardiovascular','Cardiovascular system','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1555024','Patient deaths','Patient Deceased','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1508496','Quintile','Quintile','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0018810','Heart Rate','heart rate','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0332257','include','Including (qualifier)','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1552866','include','include - SetOperator','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C2700399','Include','Include (action)','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0011065','deaths','Cessation of life','true'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1306577','DEATHS','Death (finding)','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0456081','Adjusted','Adjustment Action','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1512806','Intake','Intake','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0428876','Heart pressure','Intracardiac pressure','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0812399','Creatinine clearance','Creatinine clearance','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C2985465','Hazard Ratio','Hazard Ratio','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C0702093','/min','Per Minute','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C1524029','MIN NOS','Mouse MIN NOS','false'
'figure $nmbr$ e ect of ivabradine compared with placebo on a the primary composite endpoint b rst hospital admissions for worsening heart failure and c cardiovascular deaths in the whole patient population de ned by quintiles of baseline heart rate distribution primary composite endpoint includes cardiovascular deaths and hospital admissions for worsening heart failure adjusted for blocker intake at randomisation new york heart association class left ventricular ejection fraction ischaemic cause age systolic blood pressure and creatinine clearance at baseline hr hazard ratio bpm beats per min','C3813700','%/min','Percent per Minute','false'
'heparin dose regimen','C0019134','HEPARIN','heparin','true'
'heparin dose regimen','C2348331','Dose Regimen','Dose Regimen','false'
'heparin dose regimen','C0770546','HEPARIN','heparin, porcine','false'
'$nmbr$ standard n $nmbr$','C1442989','Standard','Standard (qualifier)','false'
'$nmbr$ standard n $nmbr$','C2828392','Standard','Standard (document)','false'
'$nmbr$ low n $nmbr$','C0205251','Low','low','false'
'$nmbr$ low n $nmbr$','C1550472','low','low confidentiality','false'
'$nmbr$ low n $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'$nmbr$ low n $nmbr$','C4048187','low','low exposure','false'
'$nmbr$ low n $nmbr$','C4321351','Low','Low Level','false'
'$nmbr$ low n $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'heart failure at entry no','C0018801','Failure, Heart','Heart failure','true'
'heart failure at entry no','C0018802','Heart Failure','Congestive heart failure','true'
'heart failure at entry no','C4554158','Heart failure','Heart Failure, CTCAE','false'
'previous events no','C0441471','Events','Event','false'
'previous events no','C3541888','EVENTS','CDISC Events Class','false'
'cabg surgery','C0038894','Surgery','Surgery specialty','false'
'cabg surgery','C0038895','surgery','Surgical aspects','true'
'cabg surgery','C0543467','Surgery','Operative Surgical Procedures','true'
'cabg surgery','C1274039','Surgery','General surgery specialty','true'
'pad','C0182158','Pad','Pads','false'
'pad','C0332568','Pad','Pad Mass','false'
'pad','C3540603','PAD','PADI4 wt Allele','false'
'pad','C3669270','Pad','Strucure of thick cushion of skin','false'
'pad','C3814046','PAD','PAD Regimen','false'
'pad','C4319657','Pad','Pad (unit of presentation)','false'
'cancer','C0006826','CANCER','Malignant Neoplasms','true'
'cancer','C0998265','Cancer','Cancer Genus','false'
'cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'electrocardiograph results no','C1274040','Result','Result','false'
'electrocardiograph results no','C1546471','Result','What subject filter - Result','false'
'electrocardiograph results no','C2825142','Result','Experimental Result','false'
'changes at baseline','C0392747','changes','Changing','false'
'changes at baseline','C0443172','changes','Changed status','false'
'st depression $nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'st depression $nmbr$ mm','C4554674','MM','MM genotype','false'
'any dynamic st segment shift','C0333051','Shift','shift displacement','false'
'any dynamic st segment shift','C2347509','Shift','Physical Shift','false'
'transient st elevation','C0040704','Transient','Transient Population Group','true'
'transient st elevation','C0520886','ST ELEVATION','ST segment elevation (finding)','false'
'transient st elevation','C0205374','Transient','Transitory','false'
'positive troponin i or t no','C0439178','% Positive','percent positive cells','false'
'positive troponin i or t no','C0077401','Troponin I','Troponin I','true'
'positive troponin i or t no','C1446409','Positive','Positive','false'
'positive troponin i or t no','C1514241','POSITIVE','Positive Finding','false'
'positive troponin i or t no','C2825490','Positive','Positive Charge','false'
'positive troponin i or t no','C3812269','Positive','Positive Number','false'
'positive troponin i or t no','C2603360','T'','T prime','false'
'time from median iqr h','C0040223','TIME','Time','true'
'time from median iqr h','C3541383','Time','Time (foundation metadata concept)','false'
'symptom onset to hospitalization','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptom onset to hospitalization','C0019993','hospitalisation','Hospitalization','true'
'hospitalization to enrollment','C0019993','hospitalisation','Hospitalization','true'
'hospitalization to enrollment','C1516879','Enrollment','Enrollment','false'
'hospitalization to enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'hospitalization to enrollment','C3888021','enrollment','enrollment - coverage','false'
'enrollment to randomization','C1516879','Enrollment','Enrollment','false'
'enrollment to randomization','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'enrollment to randomization','C3888021','enrollment','enrollment - coverage','false'
'symptom onset to enrollment','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptom onset to enrollment','C1516879','Enrollment','Enrollment','false'
'symptom onset to enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'symptom onset to enrollment','C3888021','enrollment','enrollment - coverage','false'
'symptom onset to randomization','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptom onset to randomization','C0034656','Randomization','Randomization','true'
'angiographic characteristics no','C1521970','Characteristics','Characteristics','false'
'single vessel disease','C0037179','Single','Unmarried person','true'
'single vessel disease','C0042373','Vessel disease','Vascular Diseases','true'
'single vessel disease','C0087136','single','Unmarried','true'
'single vessel disease','C0205171','SINGLE','Singular','false'
'multivessel disease','C0012634','Disease','Disease','true'
'antithrombotic use before enrollment no','C0042153','use','utilization qualifier','true'
'antithrombotic use before enrollment no','C0457083','Use','Usage','false'
'antithrombotic use before enrollment no','C1947944','Use','Use - dosing instruction imperative','false'
'non pci intravenous unfractionated heparin','C1518422','Non','Negation','false'
'non pci intravenous unfractionated heparin','C0354566','Intravenous Unfractionated Heparin','intravenous heparin','false'
'subcutaneous unfractionated heparin','C0353681','Subcutaneous Unfractionated Heparin','subcutaneous heparin','false'
'oral anticoagulants','C0354604','Oral anticoagulants','oral anticoagulants','false'
'lmwh','C0019139','LMWH','Heparin, Low-Molecular-Weight','true'
'lmwh','C3536766','LMWH','Low Molecular Weight Heparin [EPC]','false'
'gpiib iiia inhibitors','C0016011','GPIIB IIIA','Platelet Glycoprotein GPIIb-IIIa Complex','true'
'gpiib iiia inhibitors','C0243077','inhibitors','inhibitors','true'
'bivalirudin','C0168273','BIVALIRUDIN','bivalirudin','true'
'commercially available fondaparinux','C0470187','Available','Availability of','false'
'commercially available fondaparinux','C1098510','FONDAPARINUX','fondaparinux','true'
'medication use before enrollment no','C0240320','MEDICATION USE','medication use','false'
'medication use before enrollment no','C1516879','Enrollment','Enrollment','false'
'medication use before enrollment no','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'medication use before enrollment no','C3888021','enrollment','enrollment - coverage','false'
'g blockers','C0439267','g%','Gram per Deciliter','false'
'angiotensin receptor blockers','C0521942','Angiotensin Receptor Blockers','Angiotensin II receptor antagonist','true'
'angiotensin receptor blockers','C0815017','Angiotensin Receptor Blockers','Angiotensin Receptor Antagonists','true'
'oral hypoglycemic agents','C0359086','oral hypoglycemic agents','oral hypoglycemic','false'
'ticlopidine','C0040207','TICLOPIDINE','Ticlopidine','true'
'prasugrel','C1620287','PRASUGREL','prasugrel','true'
'aspirin dose mg d','C0024671','MG','Mammography','true'
'aspirin dose mg d','C0026410','MG','Mongolia','true'
'aspirin dose mg d','C0439269','mg%','mg/dL','false'
'aspirin dose mg d','C1960952','mg %','Milligram percent','false'
'aspirin dose mg d','C2346927','Mg++','Magnesium Cation','false'
'aspirin dose mg d','C4321396','MG','MG','false'
'aspirin dose mg d','C4521761','MG','United States Military Commissioned Officer O8','false'
'total time of fondaparinux treatment before','C0439175','% total','% of total','false'
'total time of fondaparinux treatment before','C0040223','TIME','Time','true'
'total time of fondaparinux treatment before','C3541383','Time','Time (foundation metadata concept)','false'
'total time of fondaparinux treatment before','C0439810','Total','Total','false'
'and after pci median iqr d','C0549183','Median','Midline (qualifier value)','false'
'and after pci median iqr d','C0876920','Median','Median Statistical Measurement','false'
'and after pci median iqr d','C2347635','Median','Population Median','false'
'and after pci median iqr d','C2348144','Median','Sample Median','false'
'and after pci median iqr d','C2939193','Median','Median (qualifier value)','false'
'supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups','C0598697','Hazard','hazard','false'
'supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups','C0456603','Ratios','Ratio','false'
'supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups','C1610540','*Ratios','Kind of quantity - Ratios','false'
'supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups','C0439064','MULTIPLE','Numerous','false'
'supplementary figure $nmbr$ hazard ratios for the composite gastrointestinal endpoint in multiple subgroups','C1079230','subgroups','Subgroup A Nepoviruses','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0598697','Hazard','hazard','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0456603','Ratios','Ratio','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C1610540','*Ratios','Kind of quantity - Ratios','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0439064','MULTIPLE','Numerous','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C1079230','subgroups','Subgroup A Nepoviruses','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0348078','forms','Qualitative form','false'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0042373','Disease, Vascular','Vascular Diseases','true'
'supplementary figure $nmbr$ hazard ratios for the composite cardiovascular endpoint in multiple subgroups with and without various forms of vascular disease','C0376315','Forms','Manufactured form','true'
'figure $nmbr$ a subgroup results for primary endpoint','C1274040','Result','Result','false'
'figure $nmbr$ a subgroup results for primary endpoint','C1546471','Result','What subject filter - Result','false'
'figure $nmbr$ a subgroup results for primary endpoint','C2825142','Result','Experimental Result','false'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C1274040','Result','Result','false'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C1546471','Result','What subject filter - Result','false'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C2825142','Result','Experimental Result','false'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C0007226','Cardiovascular','Cardiovascular system','true'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'figure $nmbr$ b subgroup results for death or cardiovascular or renal rehospitalizatiou','C0022646','Renal','Kidney','true'
'rosuvastatin n $nmbr$','C0965129','ROSUVASTATIN','rosuvastatin','true'
'fenofibric acid n $nmbr$','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'rosuvastain fenofibric acid n $nmbr$','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'type $nmbr$ diabetes mellitusa','C1320657','type diabetes','Diabetes type','false'
'metabolic syndromeb','C0311400','METABOLIC','Metabolic','false'
'metabolic syndromeb','C1524026','Metabolic','Metabolic Process, Cellular','false'
'metabolic syndromeb','C2707259','Metabolic','Metabolic:-:Point in time:^Patient:-','false'
'baseline lipids mg dl','C0023779','Lipids','Lipids','true'
'baseline lipids mg dl','C0439269','mg dl','mg/dL','false'
'hdl c mean sd','C0444504','Mean','Statistical mean','false'
'hdl c mean sd','C2699239','SD','SD, Rat Strain','false'
'hdl c mean sd','C2347634','Mean','Population Mean','false'
'hdl c mean sd','C2348143','Mean','Sample Mean','false'
'tg median min max','C0337445','TG','Thyroglobulin measurement','false'
'tg median min max','C0549183','Median','Midline (qualifier value)','false'
'tg median min max','C0876920','Median','Median Statistical Measurement','false'
'tg median min max','C2347635','Median','Population Median','false'
'tg median min max','C2348144','Median','Sample Median','false'
'tg median min max','C2939193','Median','Median (qualifier value)','false'
'ldl c mean sd','C0444504','Mean','Statistical mean','false'
'ldl c mean sd','C2699239','SD','SD, Rat Strain','false'
'ldl c mean sd','C2347634','Mean','Population Mean','false'
'ldl c mean sd','C2348143','Mean','Sample Mean','false'
'rosuvastatin','C0965129','ROSUVASTATIN','rosuvastatin','true'
'rosuvastatin fenofibric acid','C0965129','ROSUVASTATIN','rosuvastatin','true'
'rosuvastatin fenofibric acid','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'baseline mean mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline mean mg dl','C0439269','mg dl','mg/dL','false'
'baseline mean mg dl','C1442488','Baseline','Baseline','false'
'final mean mg dl','C0205088','Final','End-stage','false'
'final mean mg dl','C0439269','mg dl','mg/dL','false'
'final mean mg dl','C1546485','Final','Diagnosis Type - Final','false'
'final mean mg dl','C3853528','Final','Final','false'
'mean change se','C0392747','Change','Changing','false'
'mean change se','C0036919','SE','Seychelles','true'
'mean change se','C0443172','change','Changed status','false'
'mean change se','C1705241','Change','Delta (difference)','false'
'mean change se','C4319952','Change','Change -- procedure','false'
'hdl c high density lipoprotein cholesterol ldl c low density lipoprotein cholesterol sestandard error tg triglycerides','C0062152','hdl lipoprotein triglycerides','HDL-triglyceride','true'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C0002680','AP','Ampicillin','true'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1522609','Value','Numerical value','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C3887950','AP','Associated Persons Domain','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C0023779','Lipid','Lipids','true'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1280500','Effect','Effect','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1518681','effect','Outcome of Therapy','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C2348382','Effect','Effect, Appearance','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C0039798','treatment','therapeutic aspects','true'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C0087111','Treatment','Therapeutic procedure','true'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1522326','Treatment','Treating','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1533734','Treatment','Administration procedure','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C1705169','Treatment','Biomaterial Treatment','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C3538994','TREATMENT','Treatment Epoch','false'
'ap value from an ancova with corresponding baseline lipid value as the covariate and with a effect for treatment group','C3887704','treatment','treatment - ActInformationManagementReason','false'
'brandomization was stratified by diabetic status','C0205363','Stratified','Stratified','false'
'brandomization was stratified by diabetic status','C0241863','DIABETIC','diabetic','false'
'crosuvastatin fenofibric acid vs rosuvastatin monotherapy','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'crosuvastatin fenofibric acid vs rosuvastatin monotherapy','C0965129','ROSUVASTATIN','rosuvastatin','true'
'drosuvastatin fenofibric acid vs fenofibric acid monotherapy','C0060179','FENOFIBRIC ACID','fenofibric acid','true'
'all participants n $nmbr$','C0679646','participants','Participant','false'
'dha n $nmbr$','C0142831','dha's','sodium dehydroacetate','true'
'dha n $nmbr$','C2348308','DHA','doconexent','false'
'education mean sd ya','C0013621','Education','Knowledge acquisition','true'
'education mean sd ya','C0013622','education','Educational aspects','true'
'education mean sd ya','C0013658','Education, NOS','Educational Status','true'
'education mean sd ya','C0039401','Education','Educational process of instructing','true'
'apoe e $nmbr$ carriers no','C0003595','Apo E','Apolipoprotein E','true'
'apoe e $nmbr$ carriers no','C0007294','carriers','Genetic Carriers','true'
'apoe e $nmbr$ carriers no','C0523511','APOE','Apolipoproteins E measurement (procedure)','false'
'apoe e $nmbr$ carriers no','C1412481','APOE','APOE gene','false'
'body mass indexb','C0518010','body mass','body mass','false'
'modified hachinski ischemia scale mean sd c','C0022116','Ischaemia, NOS','Ischemia','true'
'modified hachinski ischemia scale mean sd c','C0175659','Scale','Weight measurement scales','true'
'modified hachinski ischemia scale mean sd c','C0349674','Scale','Intellectual scale','false'
'modified hachinski ischemia scale mean sd c','C1947916','Scale','Scaling','false'
'modified hachinski ischemia scale mean sd c','C4321499','Ischemia','Ischemia Procedure','false'
'smokers no','C0337664','Smokers','Smoker','true'
'blood pressure mean sd mm hg systolic','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure mean sd mm hg systolic','C0039155','Systolic','Systole','true'
'mini mental state examination mean sd d','C0451306','Mini Mental State Examination','Mini-mental state examination','true'
'mini mental state examination mean sd d','C2699239','SD','SD, Rat Strain','false'
'cognitive subscale on alzheimer s disease assessment scale mean sd e','C0450989','Alzheimer disease assessment scale','Alzheimer's disease assessment scale','false'
'clinical dementia rating sum of boxes mean sd f','C0451074','Clinical Dementia Rating','Clinical dementia rating scale','true'
'clinical dementia rating sum of boxes mean sd f','C1515051','Sum','Sum','false'
'dha intake on food frequency questionnaire mean sd mg d','C1286336','Food Intake frequency','Frequency of eating','false'
'plasma dha mean sd weight','C0005910','Weight','Body Weight','true'
'plasma dha mean sd weight','C0043100','Weight','Weight','true'
'plasma dha mean sd weight','C1305866','weight','Weighing patient','false'
'plasma dha mean sd weight','C1705104','Weight','Importance Weight','false'
'cholinesterase inhibitor use at baseline no','C0042153','use','utilization qualifier','true'
'cholinesterase inhibitor use at baseline no','C0457083','Use','Usage','false'
'cholinesterase inhibitor use at baseline no','C1947944','Use','Use - dosing instruction imperative','false'
'memantine use at baseline no','C0042153','use','utilization qualifier','true'
'memantine use at baseline no','C0457083','Use','Usage','false'
'memantine use at baseline no','C1947944','Use','Use - dosing instruction imperative','false'
'$nmbr$ mg dabigatran n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg dabigatran n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg dabigatran n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg dabigatran n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg dabigatran n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg dabigatran n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg dabigatran n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'previous stroke or tia n $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or tia n $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or tia n $nmbr$','C0007787','TIA','Transient Ischemic Attack','true'
'previous stroke or tia n $nmbr$','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous stroke or tia n $nmbr$','C1054154','tia','Tacca leontopetaloides','false'
'no previous stroke or tia n $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'no previous stroke or tia n $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'no previous stroke or tia n $nmbr$','C0007787','TIA','Transient Ischemic Attack','true'
'no previous stroke or tia n $nmbr$','C0917805','TIA','Transient Cerebral Ischemia','true'
'no previous stroke or tia n $nmbr$','C1054154','tia','Tacca leontopetaloides','false'
'on aspirin at baseline','C0004057','ASPIRIN','Aspirin','true'
'on aspirin at baseline','C0168634','baseline','BaseLine dental cement','true'
'on aspirin at baseline','C1442488','Baseline','Baseline','false'
'vitamin k antagonist naive','C1096489','vitamin k antagonist','Treatment with Vitamin K antagonist','false'
'vitamin k antagonist naive','C2267235','Vitamin K Antagonist','Vitamin K Antagonist [EPC]','false'
'on statins at baseline','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'on statins at baseline','C0168634','baseline','BaseLine dental cement','true'
'on statins at baseline','C1442488','Baseline','Baseline','false'
'rate per year','C0871208','Rate','Rating (action)','false'
'rate per year','C1521828','Rate','Rate','false'
'interaction p','C1704675','Interaction','Interaction','false'
'$nmbr$ mg dabigatran','C0024671','MG','Mammography','true'
'$nmbr$ mg dabigatran','C2348066','DABIGATRAN','dabigatran','true'
'$nmbr$ mg dabigatran','C0026410','MG','Mongolia','true'
'$nmbr$ mg dabigatran','C0439269','mg%','mg/dL','false'
'$nmbr$ mg dabigatran','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg dabigatran','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg dabigatran','C4321396','MG','MG','false'
'$nmbr$ mg dabigatran','C4521761','MG','United States Military Commissioned Officer O8','false'
'previous stroke or tl a','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or tl a','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or tl a','C0220928','TL','Tokelau','true'
'no previous stroke ortia','C0205156','Previous','Previous','false'
'no previous stroke ortia','C0038454','STROKE','Cerebrovascular accident','true'
'no previous stroke ortia','C4554100','Stroke','Stroke, CTCAE','false'
'no previous stroke ortia','C1552607','previous','Act Relationship Subset - previous','false'
'ischaemic or unknown stroke','C0475224','Ischemic','Ischemic','false'
'ischaemic or unknown stroke','C0038454','STROKE','Cerebrovascular accident','true'
'ischaemic or unknown stroke','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke ortia $nmbr$ $nmbr$','C0205156','Previous','Previous','false'
'previous stroke ortia $nmbr$ $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke ortia $nmbr$ $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke ortia $nmbr$ $nmbr$','C1552607','previous','Act Relationship Subset - previous','false'
'previous stroke ortia','C0205156','Previous','Previous','false'
'previous stroke ortia','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke ortia','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke ortia','C1552607','previous','Act Relationship Subset - previous','false'
'haemorrhagic stroke','C0553692','Haemorrhagic stroke','Brain hemorrhage','true'
'total bleeding','C0232100','Total Bleeding','Exsanguination','true'
'major bleeding','C0205082','Major','Severe (severity modifier)','false'
'major bleeding','C0019080','BLEEDING','Hemorrhage','true'
'major bleeding','C0205164','Major','Major','false'
'major bleeding','C4318856','Major','Major <insect>','false'
'major bleeding','C4521762','Major','United States Military Commissioned Officer O4','false'
'$nmbr$ gi','C1708130','Gi','GNAI1 wt Allele','false'
'$nmbr$ gi','C3539617','GI','Digestive System Findings Domain','false'
'$nmbr$ gi','C4050121','GI','Gastrointestinal studies and measurements','false'
'intracranial bleeding','C0151699','Bleeding, Intracranial','Intracranial Hemorrhage','true'
'gastrointestinal major bleed','C0017181','Gastrointestinal Bleed','Gastrointestinal Hemorrhage','true'
'gastrointestinal major bleed','C0205082','Major','Severe (severity modifier)','false'
'gastrointestinal major bleed','C0205164','Major','Major','false'
'gastrointestinal major bleed','C4318856','Major','Major <insect>','false'
'gastrointestinal major bleed','C4521762','Major','United States Military Commissioned Officer O4','false'
'previous stroke or tl a $nmbr$ $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or tl a $nmbr$ $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or tl a $nmbr$ $nmbr$','C0220928','TL','Tokelau','true'
'silodosin $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'silodosin $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'silodosin $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'silodosin $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'silodosin $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'silodosin $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'silodosin $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tamsulosin $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age yr n','C0001779','AGE','Age','false'
'age yr n','C0439234','yr','year','false'
'min max','C0702093','/min','Per Minute','false'
'min max','C1524029','MIN NOS','Mouse MIN NOS','false'
'min max','C3813700','%/min','Percent per Minute','false'
'not estimable','C1518422','Not','Negation','false'
'bmi kg m $nmbr$ n','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ n','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ n','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'bmi kg m $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'ipss total score','C1019118','Ips','Ips <Invertebrate>','false'
'ipss total score','C2964552','Total Score','Total score','false'
'ipss total score','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss total score','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss total score','C3811063','IPS','SLC27A4 wt Allele','false'
'ipss storage subscore','C1019118','Ips','Ips <Invertebrate>','false'
'ipss storage subscore','C0337174','Storage','Storage area','false'
'ipss storage subscore','C1698986','Storage','Storage','false'
'ipss storage subscore','C1753314','storage','cellular entity storage','false'
'ipss storage subscore','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss storage subscore','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss storage subscore','C3811063','IPS','SLC27A4 wt Allele','false'
'ipss voiding subscore','C1019118','Ips','Ips <Invertebrate>','false'
'ipss voiding subscore','C0042034','Voiding','Urination','true'
'ipss voiding subscore','C4067975','Voiding','Voids','false'
'ipss voiding subscore','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss voiding subscore','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss voiding subscore','C3811063','IPS','SLC27A4 wt Allele','false'
'qol due to urinary symptoms','C0518214','QOL','Perceived quality of life','false'
'qol due to urinary symptoms','C0426359','Urinary symptoms','Urinary symptoms','false'
'delighted','C3830544','Delighted','Delight','false'
'pleased','C3829994','Pleased','Generally Satisfied or Pleased','false'
'pleased','C4264468','Pleased','Pleased','false'
'mostly satisfied','C0242428','Satisfied','Satisfaction','true'
'mostly satisfied','C4049977','Satisfied','Emotionally Satisfied with Extremity','false'
'mostly satisfied','C4084799','Satisfied','Satisfied','false'
'mostly dissatisfied','C0870433','Dissatisfied','Dissatisfaction','false'
'mostly dissatisfied','C4085546','Dissatisfied','Dissatisfied - response','false'
'unhappy','C1688635','Unhappy','Feeling unhappy','false'
'terrible','C3827840','Terrible','Terrible','false'
'urine qmax ml s','C0439526','/mL','/mL','false'
'urine qmax ml s','C1705224','ML','THPO wt Allele','false'
'urine qmax ml s','C3887665','ML','Thrombopoietin, human','false'
'acute dvt study','C0557651','Study','Room of building - Study','false'
'acute dvt study','C2603343','Study','Study','false'
'continued treatment study','C0549178','Continued','Continuous','false'
'continued treatment study','C3161471','Treatment Study','Treatment Study','false'
'rivaroxaban n $nmbr$','C1739768','RIVAROXABAN','rivaroxaban','true'
'standard therapyy n $nmbr$','C1442989','Standard','Standard (qualifier)','false'
'standard therapyy n $nmbr$','C2828392','Standard','Standard (document)','false'
'male sex no weight no','C0086582','MALE SEX','Males','true'
'male sex no weight no','C0005910','Weight','Body Weight','true'
'male sex no weight no','C0043100','Weight','Weight','true'
'male sex no weight no','C1305866','weight','Weighing patient','false'
'male sex no weight no','C1705104','Weight','Importance Weight','false'
'missing data initial diagnosis no','C0011900','DIAGNOSIS','Diagnosis','true'
'missing data initial diagnosis no','C1704338','diagnosis','diagnosis aspect','true'
'missing data initial diagnosis no','C1704656','DIAGNOSIS','Diagnosis Study','false'
'dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'dvt','C3899446','DVT','Data Validation Test Document','false'
'$nmbr$ only $nmbr$ distal','C0205108','DISTAL','Distal (qualifier value)','false'
'$nmbr$ only $nmbr$ distal','C4522154','Distal','Distal Resection Margin','false'
'pe','C0070939','PE','phosphoethanolamine','true'
'pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'pe','C4284304','PE','PENK wt Allele','false'
'time from onset of symptoms to randomization days','C1320528','Time of symptom onset','Time of symptom onset','false'
'time from onset of symptoms to randomization days','C0034656','Randomization','Randomization','true'
'time from onset of symptoms to randomization days','C0439228','DAYS','day','false'
'cause of dvt or pe no','C0015127','cause','Etiology aspects','true'
'cause of dvt or pe no','C1524003','Cause','Science of Etiology','false'
'cause of dvt or pe no','C0070939','PE','phosphoethanolamine','true'
'cause of dvt or pe no','C1880476','PE','Etoposide-Platinol Regimen','false'
'cause of dvt or pe no','C4284304','PE','PENK wt Allele','false'
'recent surgery or trauma','C0038894','Surgery','Surgery specialty','false'
'recent surgery or trauma','C0038895','surgery','Surgical aspects','true'
'recent surgery or trauma','C0543467','Surgery','Operative Surgical Procedures','true'
'recent surgery or trauma','C1274039','Surgery','General surgery specialty','true'
'recent surgery or trauma','C0043251','Trauma','Wounds and Injuries','true'
'recent surgery or trauma','C1510467','trauma','trauma qualifier','true'
'recent surgery or trauma','C3263723','Trauma','Traumatic injury','true'
'recent surgery or trauma','C3714660','TRAUMA','Trauma','false'
'recent surgery or trauma','C4049136','Trauma','Trauma, nursing specialty','false'
'immobilization','C0020944','Immobilization','Immobilization','true'
'immobilization','C4048292','Immobilization','Immobilization test','false'
'estrogen therapy','C0279494','oestrogen therapy','Estrogen Therapy','false'
'active cancer','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer','C0998265','Cancer','Cancer Genus','false'
'active cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'puerperium','C0034042','Puerperium','Puerperium (time period)','true'
'puerperium','C0086839','Puerperium','Postpartum Period','true'
'puerperium','C1879329','Puerperium','Puerperium (physiologic function)','false'
'known thrombophilic condition no','C0012634','condition','Disease','true'
'known thrombophilic condition no','C0348080','Condition','Condition','false'
'known thrombophilic condition no','C1705253','Condition','Logical Condition','false'
'known thrombophilic condition no','C3864998','Condition','Condition:Find:Pt:^Patient:Nom','false'
'previous vte no','C0205156','Previous','Previous','false'
'previous vte no','C0630906','vte','vinyltriethoxysilane','true'
'previous vte no','C1552607','previous','Act Relationship Subset - previous','false'
'riva roxa ban n n $nmbr$ $nmbr$ $nmbr$','C0683610','ban','prohibition','false'
'riva roxa ban n n $nmbr$ $nmbr$ $nmbr$','C4553947','BAN','Breath Actuated Nebulizer','false'
'enoxaparin vka n n $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0206460','Enoxaparine','Enoxaparin','true'
'mae','C0286540','MAE','MAV protocol','true'
'mae','C4085238','MAE','MYOCLONIC-ATONIC EPILEPSY','false'
'renal fmclicn creatntoe clearance','C0232813','Renal clearance','Renal clearance function','false'
'renal fmclicn creatntoe clearance','C0699829','Renal Clearance','Renal clearance diagnostic test','false'
'cardiac disease','C0018799','Disease, Cardiac','Heart Diseases','true'
'ns cardiac cisease','C0038944','NS','Suriname','true'
'ns cardiac cisease','C0018787','Cardiac','Heart','true'
'ns cardiac cisease','C1522601','Cardiac','Cardiac - anatomy qualifier','false'
'ns cardiac cisease','C1112705','NS','Nuclear non-senile cataract','false'
'ns cardiac cisease','C1705982','NS','KRAS wt Allele','false'
'intended durat sm of antccagubficn','C0036154','SM','San Marino','true'
'intended durat sm of antccagubficn','C4553627','SM','Subject Disease Milestones Domain','false'
'$nmbr$ months','C0439231','MONTHS','month','false'
'pre rtous eptscde s d dvt pe','C0070939','PE','phosphoethanolamine','true'
'pre rtous eptscde s d dvt pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'pre rtous eptscde s d dvt pe','C4284304','PE','PENK wt Allele','false'
'kheeatne index dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'kheeatne index dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'kheeatne index dvt','C3899446','DVT','Data Validation Test Document','false'
'sco ita rojs dvt pe','C0070939','PE','phosphoethanolamine','true'
'sco ita rojs dvt pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'sco ita rojs dvt pe','C4284304','PE','PENK wt Allele','false'
'secondary dvt fe','C0027627','secondary','Neoplasm Metastasis','true'
'secondary dvt fe','C3848561','Fe+++','ferric cation','false'
'secondary dvt fe','C0175668','Secondary','Secondary to','false'
'secondary dvt fe','C0205436','Secondary','second (number)','false'
'ill','C0231218','Ill','Malaise','false'
'known t rc iitoji cccndilon','C0205309','Known','Known','false'
'known t rc iitoji cccndilon','C1167159','RC','replication compartment','false'
'known t rc iitoji cccndilon','C1419366','RC','RGN gene','false'
'known tiromtcch c ccndifeon','C0205309','Known','Known','false'
'p $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$','C2603361','P'','P prime','false'
'no known frtrontxtfufoc cond aon','C0205309','Known','Known','false'
'no known frtrontxtfufoc cond aon','C1856054','COND','HUTTERITE CEREBROOSTEONEPHRODYSPLASIA SYNDROME','true'
'no known frtrontxtfufoc cond aon','C2826243','COND','Protocol Test Conditions Met','false'
'no known frtrontxtfufoc cond aon','C4597943','Aon','Aon','false'
'locafon of index dvt','C0600653','Index','Indexes','true'
'locafon of index dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'locafon of index dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'locafon of index dvt','C3899446','DVT','Data Validation Test Document','false'
'locafon of index dvt','C0918012','Index','Index','true'
'locafon of index dvt','C1552854','index','Html Link Type - index','false'
'locafon of index dvt','C1637833','% index','% index','false'
'locafon of index dvt','C2986546','Index','Target Lesion Identification','false'
'extensive','C0205231','Extensive','Extensive','false'
'non extensive','C1518422','Non','Negation','false'
'non extensive','C0205231','Extensive','Extensive','false'
'ms ng','C0017887','NG','Nitroglycerin','true'
'ms ng','C0028074','NG','Niger','true'
'p o','C0369773','P NOS','P Blood group antibodies','false'
'p o','C2603361','P'','P prime','false'
'no adk e cancer','C0006826','CANCER','Malignant Neoplasms','true'
'no adk e cancer','C0998265','Cancer','Cancer Genus','false'
'no adk e cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'ac tve cancer','C0006826','CANCER','Malignant Neoplasms','true'
'ac tve cancer','C0998265','Cancer','Cancer Genus','false'
'ac tve cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'modmy al randcnxzaton','C0202311','Al','Aluminum measurement','false'
'miami k antagonist received','C0597277','K+','Potassium Ion','false'
'miami k antagonist received','C0231491','Antagonist','Antagonist muscle action','false'
'miami k antagonist received','C1708601','K'','K Prime','false'
'miami k antagonist received','C1514756','RECEIVED','Receive','false'
'western friroce','C1705493','Western','West (direction)','false'
'austrafca and new zealand','C0027978','NEW ZEALAND','New Zealand','true'
'austrafca and new zealand','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'kg','C0022718','KG','Kyrgyzstan','true'
'kg','C0439209','kg','Kilogram','false'
'kg','C4054209','/kg','Per Kilogram','false'
'sou ti africa','C0039247','TI','Tajikistan','true'
'sou ti africa','C0001737','Africa','Africa','true'
'sou ti africa','C0040302','Ti','Titanium','true'
'sou ti africa','C1553045','Ti','Tebi','false'
'sou ti africa','C1704756','TI','Trial Inclusion and Exclusion Criteria Submission Domain','false'
'rivaroxaban','C1739768','RIVAROXABAN','rivaroxaban','true'
'enoxaparin vka','C0206460','Enoxaparine','Enoxaparin','true'
'n n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'n n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'mate','C0682323','mate','Partner in relationship','false'
'mate','C1260875','Mate','mating','false'
'renal function creatinine clearance','C0232813','Renal clearance','Renal clearance function','false'
'renal function creatinine clearance','C0699829','Renal Clearance','Renal clearance diagnostic test','false'
'sd ml min','C2699239','SD','SD, Rat Strain','false'
'sd ml min','C0439445','mL/min','mL/min','false'
'intended duration of anticoagulation','C0449238','Duration','Duration (temporal concept)','false'
'intended duration of anticoagulation','C2926735','Duration','Duration','false'
'parenteral anticoagulalion before randomization','C0030547','parenteral','Parenteral Nutrition','true'
'parenteral anticoagulalion before randomization','C0034656','Randomization','Randomization','true'
'parenteral anticoagulalion before randomization','C4522267','Parenteral','Parenteral (intended site)','false'
'malignancy at randomization','C0006826','MALIGNANCY','Malignant Neoplasms','true'
'malignancy at randomization','C1306459','Malignancy','Primary malignant neoplasm','false'
'malignancy at randomization','C4282132','Malignancy','Malignancy','false'
'no active cancer','C0006826','CANCER','Malignant Neoplasms','true'
'no active cancer','C0998265','Cancer','Cancer Genus','false'
'no active cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'not available','C0686905','Not Available','Unavailability','false'
'never been on a vka','C2003901','NEVER','Never (frequency)','false'
'no vka at randomization','C0034656','Randomization','Randomization','true'
'vka at randomization','C0034656','Randomization','Randomization','true'
'total randomized','C0439175','% total','% of total','false'
'total randomized','C0439810','Total','Total','false'
'total randomized','C0034656','Randomized','Randomization','true'
'total randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'dabigatran $nmbr$ mg bid','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg bid','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg bid','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg bid','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg bid','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg bid','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg bid','C4521761','MG','United States Military Commissioned Officer O8','false'
'chads $nmbr$ scoret','C0007928','CHAD','Chad','true'
'chads $nmbr$ scoret','C1413373','CHAD','CHAD gene','false'
'prior transient ischemic attack','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'prior transient ischemic attack','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'baseline aspirin use','C0042153','use','utilization qualifier','true'
'baseline aspirin use','C0457083','Use','Usage','false'
'baseline aspirin use','C1947944','Use','Use - dosing instruction imperative','false'
'event','C0441471','Event','Event','false'
'event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'd $nmbr$ vs warfarin','C0043031','WARFARIN','Warfarin','true'
'interaction pf','C1704675','Interaction','Interaction','false'
'interaction pf','C3815179','PF','Pharmacogenomics Findings Domain','false'
'stroke or systemic embolism','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or systemic embolism','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or systemic embolism','C0013922','EMBOLISM','Embolism','true'
'stroke or systemic embolism','C1704212','Embolism, NOS','Embolus','true'
'life threatening bleeding disabling stroke and death','C1546953','Life threatening','Life threatening - Event Consequence','false'
'life threatening bleeding disabling stroke and death','C0019080','BLEEDING','Hemorrhage','true'
'life threatening bleeding disabling stroke and death','C2826244','Life Threatening','Life Threatening','false'
'life threatening bleeding disabling stroke and death','C3537125','LIFE THREATENING','Life Threatening or Disabling Adverse Event','false'
'life threatening bleeding disabling stroke and death','C0038454','STROKE','Cerebrovascular accident','true'
'life threatening bleeding disabling stroke and death','C4554100','Stroke','Stroke, CTCAE','false'
'life threatening bleeding disabling stroke and death','C0011065','DEATH','Cessation of life','true'
'life threatening bleeding disabling stroke and death','C1306577','Death','Death (finding)','false'
'life threatening bleeding disabling stroke and death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'life threatening bleeding disabling stroke and death','C4552775','Death NOS','Death NOS, CTCAE','false'
'gastrointestinal bleeding','C0017181','gastro intestinal bleeding','Gastrointestinal Hemorrhage','true'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C0024485','MR','Magnetic Resonance Imaging','true'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C1417249','MR','MRC1 gene','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C2347167','Mr.','Mr. - Title','false'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C3254418','MR','NR3C2 protein, human','true'
'dexlansoprazole mr $nmbr$ mg n $nmbr$','C4050513','MR','Minor Response','false'
'age at baseline years','C1510829','Age-Years','Age-Years','false'
'age at baseline years','C0168634','baseline','BaseLine dental cement','true'
'age at baseline years','C1442488','Baseline','Baseline','false'
'ppi use within $nmbr$ months of randomization','C1524063','Use of','Use of','false'
'ppi use within $nmbr$ months of randomization','C0034656','Randomization','Randomization','true'
'alcohol drinker','C0001962','ALCOHOL','Ethanol','true'
'alcohol drinker','C0556338','Drinker','Drinker','false'
'alcohol drinker','C0001975','Alcohol','Alcohols','true'
'smoker','C0337664','Smoker','Smoker','true'
'caffeine user','C3532939','Caffeine user','Caffeine user','false'
'indacaterol $nmbr$ gg qd','C0017454','GG','Georgia, Western Asia','true'
'indacaterol $nmbr$ gg qd','C0332173','QD','Daily','false'
'indacaterol $nmbr$ gg qd','C0018370','GG','Guernsey (geographic location)','true'
'formoterol $nmbr$ gg bid','C0017454','GG','Georgia, Western Asia','true'
'formoterol $nmbr$ gg bid','C0018370','GG','Guernsey (geographic location)','true'
'salmeterol $nmbr$ gg bid','C0017454','GG','Georgia, Western Asia','true'
'salmeterol $nmbr$ gg bid','C0018370','GG','Guernsey (geographic location)','true'
'tiotropium $nmbr$ gg qd','C0017454','GG','Georgia, Western Asia','true'
'tiotropium $nmbr$ gg qd','C0332173','QD','Daily','false'
'tiotropium $nmbr$ gg qd','C0018370','GG','Guernsey (geographic location)','true'
'male female','C0043210','female','Woman','true'
'male female','C0086287','FEMALE','Females','true'
'male female','C1705497','Female','Female, Self-Report','false'
'male female','C1705498','FEMALE','Female Phenotype','false'
'fev $nmbr$ la','C0023031','La','Lanthanum','true'
'fev $nmbr$ la','C0023749','LA','Linoleic Acid','true'
'fev $nmbr$ la','C0230347','LA','Left upper arm structure','false'
'fev $nmbr$ la','C2346906','LA','Lupus Anticoagulant Antibody','false'
'fev $nmbr$ la','C4553351','La','SSB wt Allele','false'
'fev $nmbr$ predicteda','C3714541','FEV','Forced Vital Capacity','true'
'ics use yes no','C0042153','use','utilization qualifier','true'
'ics use yes no','C0457083','Use','Usage','false'
'ics use yes no','C1947944','Use','Use - dosing instruction imperative','false'
'ics use yes no','C1512698','yes/no','Yes or No Response','false'
'ex smoker smoker','C0337671','Ex-smoker','Former smoker','false'
'ex smoker smoker','C4555205','Ex-Smoker','Ex-Smokers','true'
'history of or current cardiac disorders','C0019664','History','History','true'
'history of or current cardiac disorders','C0019665','history','Historical aspects qualifier','true'
'history of or current cardiac disorders','C0262512','History, NOS','History of present illness','false'
'history of or current cardiac disorders','C0262926','History','Medical History','false'
'history of or current cardiac disorders','C1705255','History','Concept History','false'
'history of or current cardiac disorders','C2004062','History','History of previous events','false'
'history of or current cardiac disorders','C0521116','CURRENT','Current (present time)','false'
'history of or current cardiac disorders','C0018799','Cardiac Disorders','Heart Diseases','true'
'history of or current cardiac disorders','C1705970','Current','Electrical Current','false'
'treatment duration days','C0444921','Treatment duration','Duration of treatment','false'
'treatment duration days','C0439228','DAYS','day','false'
'treatment duration days','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'patients treated for $nmbr$ weeks','C0030705','Patients','Patients','true'
'patients treated for $nmbr$ weeks','C1522326','Treated','Treating','false'
'patients treated for $nmbr$ weeks','C0439230','WEEKS','week','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C0439165','Percentage','Percent (qualifier value)','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C1549488','Percentage','Amount type - Percentage','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C1412268','AES','AES gene','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C1518422','Not','Negation','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C0850624','cardiovascular risk factor','cardiovascular risk factor','false'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ percentage of patients with ccv aes according to presence or not of cardiovascular risk factors at baseline','C1442488','Baseline','Baseline','false'
'ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus','C4049864','IND','Improvised Nuclear Device','false'
'ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus','C1722260','INDACATEROL','indacaterol','true'
'ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus','C0439272','mg kg','ug/g','false'
'ind z indacaterol $nmbr$ $nmbr$ and $nmbr$ z mg doses form z formoterol salm z salmeterol tio z tiotropium pbo z placebo bmi z body mass index kg m $nmbr$ dm z diabetes mellitus','C0011849','DM - Diabetes mellitus','Diabetes Mellitus','true'
'carisbamate $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'carisbamate $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'carisbamate $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'carisbamate $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'carisbamate $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'carisbamate $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'carisbamate $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'carisbamate $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'time since epilepsy diagnosis years','C0556970','time year','times/year','false'
'time since epilepsy diagnosis years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since epilepsy diagnosis years','C1704338','diagnosis','diagnosis aspect','true'
'time since epilepsy diagnosis years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'number of previous reported aeds','C0237753','*Number','Numbers','false'
'number of previous reported aeds','C0449788','Number','Count of entities','false'
'baseline monthly pos seizure rate','C0871208','Rate','Rating (action)','false'
'baseline monthly pos seizure rate','C1521828','Rate','Rate','false'
'number of co aeds n','C0237753','*Number','Numbers','false'
'number of co aeds n','C0449788','Number','Count of entities','false'
'patients with $nmbr$ co aed','C0030705','Patients','Patients','true'
'patients with $nmbr$ co aed','C0887457','AED','Cystamine Dihydrochloride','true'
'patients with $nmbr$ co aeds','C0030705','Patients','Patients','true'
'patients with $nmbr$ co aeds','C0180309','aeds','Automated External Defibrillators','true'
'ugt induction status as randomizeda n','C0205263','Induction','Induce (action)','false'
'ugt induction status as randomizeda n','C0449438','Status','Status','false'
'ugt induction status as randomizeda n','C0857127','induction','Induction procedure','false'
'inducing','C0205263','Inducing','Induce (action)','false'
'ugt induction status per aeda n','C0205263','Induction','Induce (action)','false'
'ugt induction status per aeda n','C0449438','Status','Status','false'
'ugt induction status per aeda n','C0857127','induction','Induction procedure','false'
'syndrome n','C0039082','Syndrome','Syndrome','true'
'symptomatic localization related','C0475264','Localization','localization','false'
'symptomatic localization related','C1744691','localization','establishment and maintenance of localization','false'
'symptomatic localization related','C0439849','Related','Relationships','false'
'symptomatic localization related','C0445223','Related','Related personal status','false'
'cryptogenic localization related','C0475264','Localization','localization','false'
'cryptogenic localization related','C1744691','localization','establishment and maintenance of localization','false'
'cryptogenic localization related','C0439849','Related','Relationships','false'
'cryptogenic localization related','C0445223','Related','Related personal status','false'
'undetermined','C0205258','Undetermined','Indeterminate','false'
'undetermined','C3536725','UNDETERMINED','Undetermined','false'
'undetermined','C4082977','UNDETERMINED','Undetermined finding','false'
'overall w $nmbr$ $nmbr$ $nmbr$','C0282416','Overall','Overall Publication Type','true'
'overall w $nmbr$ $nmbr$ $nmbr$','C1561607','Overall','Overall','false'
'combined therapy v $nmbr$ $nmbr$ $nmbr$','C0033972','Combined therapy','Psychotherapy, Multiple','true'
'dutasteride w $nmbr$ $nmbr$ $nmbr$','C0754659','DUTASTERIDE','Dutasteride','true'
'tamsulosin w $nmbr$ $nmbr$ $nmbr$','C0257343','TAMSULOSIN','tamsulosin','true'
'ipss o','C1019118','Ips','Ips <Invertebrate>','false'
'ipss o','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss o','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss o','C3811063','IPS','SLC27A4 wt Allele','false'
'pv ml','C0439526','/mL','/mL','false'
'pv ml','C1705224','ML','THPO wt Allele','false'
'pv ml','C3887665','ML','Thrombopoietin, human','false'
'psa level ng ml','C4086720','PSA Level','PSA Level','false'
'psa level ng ml','C0439275','ng/mL','Microgram per Liter','false'
'qmaxi rn l s','C2827110','RN','Saint Martin, French','false'
'qmaxi rn l s','C3540639','RN','U2AF1 wt Allele','false'
'qmaxi rn l s','C4281819','Rn','Rn','false'
'previous treatment','C0039798','treatment','therapeutic aspects','true'
'previous treatment','C0087111','Treatment','Therapeutic procedure','true'
'previous treatment','C1522326','Treatment','Treating','false'
'previous treatment','C1533734','Treatment','Administration procedure','false'
'previous treatment','C1705169','Treatment','Biomaterial Treatment','false'
'previous treatment','C3538994','TREATMENT','Treatment Epoch','false'
'previous treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'ipss hrql','C1019118','Ips','Ips <Invertebrate>','false'
'ipss hrql','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss hrql','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss hrql','C3811063','IPS','SLC27A4 wt Allele','false'
'at $nmbr$ years','C0439234','YEARS','year','false'
'rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl','C0301630','Reduction','Reduction (chemical)','false'
'rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl','C0392756','Reduction','Reduced','false'
'rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl','C1293152','Reduction','Reduction procedure','false'
'rr reduction $nmbr$ $nmbr$ $nmbr$ $nmbr$ cl','C4551656','Reduction','Surgical reduction','false'
'combined dutasteride ta msu losi n','C0039297','Ta','Tantalum','true'
'combined dutasteride ta msu losi n','C0024776','MSU','Maple Syrup Urine Disease','true'
'combined dutasteride ta msu losi n','C1412759','MSU','BCKDHA gene','false'
'combined dutasteride ta msu losi n','C1506978','Ta','Ma+Ta Antibody','false'
'combined dutasteride ta msu losi n','C1705538','TA','Trial Arms Domain','false'
'combined dutasteride ta msu losi n','C3272501','Ta','Ta Stage Finding','false'
'combined dutasteride ta msu losi n','C4553364','TA','TOR1A wt Allele','false'
'dutasteride','C0754659','DUTASTERIDE','Dutasteride','true'
'tamsulosin','C0257343','TAMSULOSIN','tamsulosin','true'
'no of events','C0441471','Events','Event','false'
'no of events','C3541888','EVENTS','CDISC Events Class','false'
'incidence o $nmbr$ $nmbr$ cl','C0021149','Incidence','Incidence','true'
'incidence o $nmbr$ $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'incidence o $nmbr$ $nmbr$ cl','C0220856','incidence','incidence of cases','true'
'combined therapy vsdutasteride','C0033972','Combined therapy','Psychotherapy, Multiple','true'
'combined therapy vsta msu iosin','C0033972','Combined therapy','Psychotherapy, Multiple','true'
'combined therapy vsta msu iosin','C0024776','MSU','Maple Syrup Urine Disease','true'
'combined therapy vsta msu iosin','C1412759','MSU','BCKDHA gene','false'
'ipss','C1019118','Ips','Ips <Invertebrate>','false'
'ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'non white','C0007457','WHITE','Caucasoid Race','true'
'non white','C0043157','WHITE','Caucasians','true'
'non white','C0220938','WHITE','White color','false'
'change in das $nmbr$ $nmbr$ $nmbr$','C0392747','Change','Changing','false'
'change in das $nmbr$ $nmbr$ $nmbr$','C0443172','change','Changed status','false'
'change in das $nmbr$ $nmbr$ $nmbr$','C1705241','Change','Delta (difference)','false'
'change in das $nmbr$ $nmbr$ $nmbr$','C4319952','Change','Change -- procedure','false'
'week $nmbr$ responders n $nmbr$','C0332174','/week','Weekly','false'
'week $nmbr$ responders n $nmbr$','C0439230','Week','week','false'
'acr $nmbr$ week $nmbr$ responders n $nmbr$','C0332174','/week','Weekly','false'
'acr $nmbr$ week $nmbr$ responders n $nmbr$','C0439230','Week','week','false'
'no previous dmard mean sd','C0205156','Previous','Previous','false'
'no previous dmard mean sd','C2699239','SD','SD, Rat Strain','false'
'no previous dmard mean sd','C1552607','previous','Act Relationship Subset - previous','false'
'disease duration yrs mean sd','C0872146','disease duration','disease length','false'
'disease duration yrs mean sd','C2699239','SD','SD, Rat Strain','false'
'mtx dose $nmbr$ mg week','C0332174','/week','Weekly','false'
'mtx dose $nmbr$ mg week','C0439230','Week','week','false'
'steroid use','C0281991','Steroid Use','steroid use','false'
'rf positive $nmbr$ iu ml','C0035448','RF','Rheumatoid Factor','true'
'rf positive $nmbr$ iu ml','C0439458','IU/mL','IU/mL','false'
'rf positive $nmbr$ iu ml','C0201660','RF','Rheumatoid Factor Measurement','false'
'rf positive $nmbr$ iu ml','C0748398','RF','RF','false'
'rf positive $nmbr$ iu ml','C1547111','RF','Radio fluoroscopy','false'
'sjc mean sd','C0444504','Mean','Statistical mean','false'
'sjc mean sd','C2699239','SD','SD, Rat Strain','false'
'sjc mean sd','C2347634','Mean','Population Mean','false'
'sjc mean sd','C2348143','Mean','Sample Mean','false'
'tjc mean sd','C0444504','Mean','Statistical mean','false'
'tjc mean sd','C2699239','SD','SD, Rat Strain','false'
'tjc mean sd','C2347634','Mean','Population Mean','false'
'tjc mean sd','C2348143','Mean','Sample Mean','false'
'mtss mean sd','C0444504','Mean','Statistical mean','false'
'mtss mean sd','C2699239','SD','SD, Rat Strain','false'
'mtss mean sd','C2347634','Mean','Population Mean','false'
'mtss mean sd','C2348143','Mean','Sample Mean','false'
'das $nmbr$ range $nmbr$ $nmbr$ mean sd','C0051767','DAS','amsonic acid','true'
'das $nmbr$ range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'das $nmbr$ range $nmbr$ $nmbr$ mean sd','C0057671','DAS','diacetoxyscirpenol','true'
'pain vas range $nmbr$ $nmbr$ mm mean sd','C0042815','Pain VAS','Visual Analog Pain Scale','true'
'pain vas range $nmbr$ $nmbr$ mm mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di range $nmbr$ $nmbr$ mean sd','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di range $nmbr$ $nmbr$ mean sd','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'fas range $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'fas range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'fas range $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'fas range $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'crp mean mg l sd','C0439268','mg/L','Microgram per Milliliter','false'
'crp mean mg l sd','C2699239','SD','SD, Rat Strain','false'
'olmesartan n $nmbr$','C1098320','OLMESARTAN','olmesartan','true'
'mean yr','C0444504','Mean','Statistical mean','false'
'mean yr','C0439234','yr','year','false'
'mean yr','C2347634','Mean','Population Mean','false'
'mean yr','C2348143','Mean','Sample Mean','false'
'duration yr','C0449238','Duration','Duration (temporal concept)','false'
'duration yr','C0439234','yr','year','false'
'duration yr','C2926735','Duration','Duration','false'
'prior treatment no','C1514463','Prior Treatment','Prior Therapy','false'
'smoking status no','C1519386','Smoking Status','Smoking Status','false'
'never smoked','C0037366','Smoke','Smoke','true'
'never smoked','C0439994','Smoke','Tobacco smoke','false'
'never smoked','C1881674','Smoke','Medical Device Emits Smoke','false'
'former smoker','C0337671','Former Smoker','Former smoker','false'
'metabolic syndrome no','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'cardiovascular history no','C1880008','Cardiovascular History','Cardiovascular History','false'
'stroke or tia','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or tia','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or tia','C0007787','TIA','Transient Ischemic Attack','true'
'stroke or tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'stroke or tia','C1054154','tia','Tacca leontopetaloides','false'
'glucose mmol liter','C0017725','GLUCOSE','Glucose','true'
'glucose mmol liter','C0475211','Litre','liter','false'
'overall freedom population n $nmbr$','C0016694','Freedom','Freedom','true'
'overall freedom population n $nmbr$','C0032659','Population','geographic population','true'
'overall freedom population n $nmbr$','C1257890','Population','Population Group','true'
'prevalent vertebral fracture status','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'prevalent vertebral fracture status','C0449438','Status','Status','false'
'femoral neck bmd t score','C0449820','SCORE','Score','false'
'femoral neck bmd t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C1881878','Moderate','Moderation','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C4085643','Moderate','Moderate Response','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C4321335','Moderate','Moderate Level','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0000768','Deformity','Congenital Abnormality','true'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0221430','Deformity, NOS','Acquired deformity','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0302142','Deformity','Deformity','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ and or $nmbr$ moderate or severe deformity or both n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'age yr mean sd bmd t score mean sd','C0001779','AGE','Age','false'
'age yr mean sd bmd t score mean sd','C3533236','Mean score','Mean score','false'
'subjects with prevalent vertebral fracture n prevalent vertebral fracture','C0681850','Subject','Study Subject','false'
'subjects with prevalent vertebral fracture n prevalent vertebral fracture','C1550501','{Subject}','Subject -direct target','false'
'subjects with prevalent vertebral fracture n prevalent vertebral fracture','C1706203','Subject','Subject - topic','false'
'subjects with prevalent vertebral fracture n prevalent vertebral fracture','C2349001','Subject','Human Study Subject','false'
'subjects with prevalent vertebral fracture n prevalent vertebral fracture','C2697811','Subject','Investigative Subject','false'
'tiotropium n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'salmeterol n $nmbr$','C0073992','SALMETEROL','salmeterol','true'
'smoking history pack yr','C1519384','Smoking History','Smoking History','false'
'smoking history pack yr','C0439234','yr','year','false'
'duration of copd yr f','C0449238','Duration','Duration (temporal concept)','false'
'duration of copd yr f','C2926735','Duration','Duration','false'
'gold stage c','C0018026','GOLD','Gold','true'
'gold stage c','C0441785','Stage C','Stage C','false'
'gold stage c','C1304897','Gold','Gold color','false'
'spirometry after bronchodilation','C0037981','SPIROMETRY','Spirometry','true'
'spirometry after bronchodilation','C1371299','Bronchodilation','Bronchodilation [PE]','false'
'spirometry after bronchodilation','C3537072','Bronchodilation','Bronchodilation','false'
'fev $nmbr$ liters','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ liters','C0475211','LITER','liter','false'
'fev $nmbr$ of predicted value','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ of predicted value','C0681842','Predicted','prediction','false'
'fev $nmbr$ of predicted value','C1522609','Value','Numerical value','false'
'fev $nmbr$ of predicted value','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fvc liters','C3714541','FVC','Forced Vital Capacity','true'
'fvc liters','C0475211','LITER','liter','false'
'ratio of fev $nmbr$ to fvc','C0456603','RATIO','Ratio','false'
'ratio of fev $nmbr$ to fvc','C1547037','Ratio','data type - ratio','false'
'ratio of fev $nmbr$ to fvc','C3714541','FVC','Forced Vital Capacity','true'
'pulmonary medications','C0013227','Medications','Pharmaceutical Preparations','true'
'pulmonary medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'pulmonary medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'pulmonary medications','C4284232','Medications','Medications','false'
'anticholinergic drug','C0242896','Anticholinergic drug','Anticholinergic Agents','true'
'short acting','C1282927','short','Shortened','false'
'short acting','C1806781','SHORT','Short','false'
'short acting','C2350002','Short','Short Value','false'
'js $nmbr$ agonists','C0243192','agonists','agonists','true'
'js $nmbr$ agonists','C2987634','agonists','Agonist','false'
'long acting^','C0205166','LONG','Long','false'
'long acting^','C1706317','Long','Long Variable','false'
'glucocorticoids','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'glucocorticoids','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'glucocorticoids','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'inhaled^','C0004048','Inhaled','Inspiration function','true'
'with tiotropium','C0213771','TIOTROPIUM','tiotropium','true'
'with long acting j $nmbr$ agonists','C0243192','agonists','agonists','true'
'with long acting j $nmbr$ agonists','C2987634','agonists','Agonist','false'
'oral','C0442027','Oral','Oral','false'
'oral','C4521986','Oral','Oral (intended site)','false'
'methylxanthines','C0066447','METHYLXANTHINES','methylxanthine','true'
'tiotropium salmeterol no of patients total no','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium salmeterol no of patients total no','C0073992','SALMETEROL','salmeterol','true'
'tiotropium salmeterol no of patients total no','C0030705','Patients','Patients','true'
'tiotropium salmeterol no of patients total no','C0439175','% total','% of total','false'
'tiotropium salmeterol no of patients total no','C0439810','Total','Total','false'
'hazard ratio $nmbr$ ci','C0008107','CI','Chile','true'
'hazard ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'copd severity stage gold','C0018026','GOLD','Gold','true'
'copd severity stage gold','C1304897','Gold','Gold color','false'
'stage ii','C0441767','Stage II','Stage level 2','false'
'stage iii','C0441771','Stage III','Stage level 3','false'
'stage iv','C0022326','IV','Ivory Coast','true'
'stage iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'noncurrent smoker','C0337664','Smoker','Smoker','true'
'use of inhaled glucocorticoids at baseline','C1524063','Use of','Use of','false'
'use of inhaled glucocorticoids at baseline','C0004048','Inhaled','Inspiration function','true'
'use of inhaled glucocorticoids at baseline','C0168634','baseline','BaseLine dental cement','true'
'use of inhaled glucocorticoids at baseline','C1442488','Baseline','Baseline','false'
'stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml min n $nmbr$','C0439445','mL/min','mL/min','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C0205390','Stage','Phase','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C0439526','/mL','/mL','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C1705224','ML','THPO wt Allele','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C3887665','ML','Thrombopoietin, human','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C1300072','Stage','Tumor stage','false'
'stage $nmbr$ ckd egfr $nmbr$ ml n $nmbr$','C1306673','Stage','Stage','false'
'years since menopause','C0439234','YEARS','year','false'
'years since menopause','C0025320','MENOPAUSE','Menopause','true'
'years since menopause','C0567312','Menopause','Menopause present (finding)','false'
'taking calcium supplements at baseline n','C3540037','CALCIUM SUPPLEMENTS','CALCIUM SUPPLEMENTS','false'
'taking calcium supplements at baseline n','C0168634','baseline','BaseLine dental cement','true'
'taking calcium supplements at baseline n','C1442488','Baseline','Baseline','false'
'no alcohol consumption on average','C0001948','ALCOHOL CONSUMPTION','Alcohol consumption','true'
'no alcohol consumption on average','C1510992','Average','Average','false'
'no alcohol consumption on average','C2825518','AVERAGE','Average of Value Derivation Technique','false'
'over past $nmbr$ years n','C0439234','YEARS','year','false'
'eq $nmbr$ da health index status score','C0449820','SCORE','Score','false'
'eq $nmbr$ da health index status score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'opaqb physical function score','C4483112','Physical score','Physical score','false'
'low trauma fracture since age $nmbr$ n','C0521170','Low-Trauma Fracture','Osteoporotic Fractures','true'
'low trauma fracture since age $nmbr$ n','C0001779','AGE','Age','false'
'prevalent vertebral fracture n','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'serum albumin adjusted calcium mg dl','C0036785','serum calcium','Serum Calcium Level','false'
'serum albumin adjusted calcium mg dl','C0439269','mg dl','mg/dL','false'
'serum albumin adjusted calcium mg dl','C0728876','Serum calcium','Serum calcium measurement','false'
'serum vitamin d nmol l','C0312532','Vitamin L','Vitamin L','false'
'lumbar spine bmd t score','C0449820','SCORE','Score','false'
'lumbar spine bmd t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'total hip bmd t score','C2964552','Total Score','Total score','false'
'total hip bmd t score','C0019552','HIP','Hip structure','true'
'total hip bmd t score','C0022122','Hip','Bone structure of ischium','true'
'total hip bmd t score','C1505163','HIP','HHIP protein, human','true'
'total hip bmd t score','C3538851','HIP','REG3A wt Allele','false'
'total hip bmd t score','C4284725','HIP','HHIP wt Allele','false'
'facilitated pci n $nmbr$','C4049621','PCI','Peritoneal Cancer Index','false'
'primary pci n $nmbr$','C0205225','Primary','Primary','false'
'primary pci n $nmbr$','C0439612','Primary','True primary (qualifier value)','false'
'primary pci n $nmbr$','C0439631','Primary','Primary operation','false'
'p vaiue','C0369773','P NOS','P Blood group antibodies','false'
'p vaiue','C2603361','P'','P prime','false'
'actual or estimated weight kg','C0237400','ACTUAL','Actual','false'
'actual or estimated weight kg','C0022718','KG','Kyrgyzstan','true'
'actual or estimated weight kg','C0439209','kg','Kilogram','false'
'actual or estimated weight kg','C4054209','/kg','Per Kilogram','false'
'killip class iv at randomization','C2697847','Killip Class 4','Killip Class IV','false'
'killip class iv at randomization','C0034656','Randomization','Randomization','true'
'prior cabg surgery','C0455610','Prior Surgery','H/O: surgery','false'
'prior cabg surgery','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'chronic treatment with aspirin','C0039798','treatment','therapeutic aspects','true'
'chronic treatment with aspirin','C0087111','Treatment','Therapeutic procedure','true'
'chronic treatment with aspirin','C1522326','Treatment','Treating','false'
'chronic treatment with aspirin','C1533734','Treatment','Administration procedure','false'
'chronic treatment with aspirin','C1705169','Treatment','Biomaterial Treatment','false'
'chronic treatment with aspirin','C3538994','TREATMENT','Treatment Epoch','false'
'chronic treatment with aspirin','C3887704','treatment','treatment - ActInformationManagementReason','false'
'infarct location anterior','C0021308','INFARCT','Infarction','true'
'infarct location anterior','C0205094','ANTERIOR','Anterior','false'
'time intervals','C0872291','Time Interval','Time Interval','false'
'symptoms onset to first balloon inflation min','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptoms onset to first balloon inflation min','C0021398','Inflation','Economic Inflation','true'
'symptoms onset to first balloon inflation min','C1318493','Inflation','Inflation procedure','false'
'randomization to first balloon inflation min','C0034656','Randomization','Randomization','true'
'randomization to first balloon inflation min','C0021398','Inflation','Economic Inflation','true'
'randomization to first balloon inflation min','C1318493','Inflation','Inflation procedure','false'
'treatment before catheterization','C0039798','treatment','therapeutic aspects','true'
'treatment before catheterization','C0087111','Treatment','Therapeutic procedure','true'
'treatment before catheterization','C1522326','Treatment','Treating','false'
'treatment before catheterization','C1533734','Treatment','Administration procedure','false'
'treatment before catheterization','C1705169','Treatment','Biomaterial Treatment','false'
'treatment before catheterization','C3538994','TREATMENT','Treatment Epoch','false'
'treatment before catheterization','C3887704','treatment','treatment - ActInformationManagementReason','false'
'bolus of heparin given','C1186706','Bolus','Bolus of ingested food','false'
'bolus of heparin given','C1511237','Bolus','bolus infusion','false'
'bolus of heparin given','C1705509','{Bolus}','Bolus Dosing Unit','false'
'bolus of heparin given','C3812160','Bolus','Radiotherapy Bolus','false'
'loading dose of clopidogrel or ticlopidine','C3714444','Loading dose','Loading dose','false'
'loading dose of clopidogrel or ticlopidine','C0070166','CLOPIDOGREL','clopidogrel','true'
'loading dose of clopidogrel or ticlopidine','C0040207','TICLOPIDINE','Ticlopidine','true'
'glycoprotein llb illa inhibitor','C0017968','Glycoprotein','Glycoproteins','true'
'glycoprotein llb illa inhibitor','C1999216','Inhibitor','Inhibitor','false'
'pci performed','C4049621','PCI','Peritoneal Cancer Index','false'
'pci performed','C0884358','PERFORMED','Performed','false'
'cabg performed during index hospitalization','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'cabg performed during index hospitalization','C0884358','PERFORMED','Performed','false'
'cabg performed during index hospitalization','C0019993','hospitalisation','Hospitalization','true'
'treatment during or after catheterization','C0039798','treatment','therapeutic aspects','true'
'treatment during or after catheterization','C0087111','Treatment','Therapeutic procedure','true'
'treatment during or after catheterization','C1522326','Treatment','Treating','false'
'treatment during or after catheterization','C1533734','Treatment','Administration procedure','false'
'treatment during or after catheterization','C1705169','Treatment','Biomaterial Treatment','false'
'treatment during or after catheterization','C3538994','TREATMENT','Treatment Epoch','false'
'treatment during or after catheterization','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment during or after catheterization','C0007430','Catheterization','Catheterization','true'
'additional heparin','C0019134','HEPARIN','heparin','true'
'additional heparin','C0770546','HEPARIN','heparin, porcine','false'
'glycoprotein llb llia inhibitor','C0017968','Glycoprotein','Glycoproteins','true'
'glycoprotein llb llia inhibitor','C1999216','Inhibitor','Inhibitor','false'
'$nmbr$ day mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'$nmbr$ day mortality','C0026566','mortality','Aspects of mortality statistics','true'
'$nmbr$ day cce','C0332173','/day','Daily','false'
'$nmbr$ day cce','C0439228','Day','day','false'
'$nmbr$ day cce','C0439505','/day','per day','false'
'assigned treatment by sex interaction','C0039798','treatment','therapeutic aspects','true'
'assigned treatment by sex interaction','C0087111','Treatment','Therapeutic procedure','true'
'assigned treatment by sex interaction','C1522326','Treatment','Treating','false'
'assigned treatment by sex interaction','C1533734','Treatment','Administration procedure','false'
'assigned treatment by sex interaction','C1705169','Treatment','Biomaterial Treatment','false'
'assigned treatment by sex interaction','C3538994','TREATMENT','Treatment Epoch','false'
'assigned treatment by sex interaction','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fpci vs ppci in women','C0043210','Women','Woman','true'
'fpci vs ppci in men','C0025266','Men','Male population group','true'
'or per unit for continuous variables','C0439148','Unit','Unit','false'
'or per unit for continuous variables','C0439453','Unit','International Unit','false'
'or per unit for continuous variables','C1509845','Unit','Unit device','false'
'or per unit for continuous variables','C1519795','Unit','Unit of Measure','false'
'or per unit for continuous variables','C1704753','Unit','Storage Unit','false'
'or per unit for continuous variables','C1880519','Unit','Enzyme Unit','false'
'or per unit for continuous variables','C3853603','Unit','Unit - NCI Thesaurus Property','false'
'or per unit for continuous variables','C0549178','CONTINUOUS','Continuous','false'
'or per unit for continuous variables','C0439828','variables','Variable (uniformity)','false'
'univariable or $nmbr$ ci p value','C0008107','CI','Chile','true'
'univariable or $nmbr$ ci p value','C1709380','P-Value','P-Value','false'
'univariable or $nmbr$ ci p value','C3259781','CI','Coagulation Index Measurement','false'
'multivariable or $nmbr$ ci p value','C0008107','CI','Chile','true'
'multivariable or $nmbr$ ci p value','C1709380','P-Value','P-Value','false'
'multivariable or $nmbr$ ci p value','C3259781','CI','Coagulation Index Measurement','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'baseline crcl ml min','C0168634','baseline','BaseLine dental cement','true'
'baseline crcl ml min','C0439445','mL/min','mL/min','false'
'baseline crcl ml min','C1442488','Baseline','Baseline','false'
'hemoglobin $nmbr$ men $nmbr$ women','C0019046','Hemoglobin','Hemoglobin','true'
'hemoglobin $nmbr$ men $nmbr$ women','C0043210','Women','Woman','true'
'total diuretic dose iv oral on day $nmbr$ mg','C0442027','Oral','Oral','false'
'total diuretic dose iv oral on day $nmbr$ mg','C4521986','Oral','Oral (intended site)','false'
'rolofylline rx','C1425688','RX','RAX gene','false'
'rolofylline rx','C1521941','Rx','prescription document','false'
'rolofylline rx','C2709207','Rx','Rx therapy','false'
'weight kg blood pressure mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'weight kg blood pressure mm hg','C0439475','mmHG','mmHg','false'
'weight kg blood pressure mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'weight kg blood pressure mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'previous stroke or transient ischemic attack no total no','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or transient ischemic attack no total no','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or transient ischemic attack no total no','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'previous stroke or transient ischemic attack no total no','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'previous stroke or transient ischemic attack no total no','C0439175','% total','% of total','false'
'previous stroke or transient ischemic attack no total no','C0439810','Total','Total','false'
'hypertension no total no medications in use at baseline no total no','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension no total no medications in use at baseline no total no','C1963138','Hypertension','Hypertension, CTCAE','false'
'hypertension no total no medications in use at baseline no total no','C0439175','% total','% of total','false'
'hypertension no total no medications in use at baseline no total no','C0439810','Total','Total','false'
'hypertension no total no medications in use at baseline no total no','C0013227','Medications','Pharmaceutical Preparations','true'
'hypertension no total no medications in use at baseline no total no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'hypertension no total no medications in use at baseline no total no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'hypertension no total no medications in use at baseline no total no','C4284232','Medications','Medications','false'
'hypertension no total no medications in use at baseline no total no','C0150312','In','Present','false'
'hypertension no total no medications in use at baseline no total no','C0042153','use','utilization qualifier','true'
'hypertension no total no medications in use at baseline no total no','C0457083','Use','Usage','false'
'hypertension no total no medications in use at baseline no total no','C1947944','Use','Use - dosing instruction imperative','false'
'hypertension no total no medications in use at baseline no total no','C0332285','In','Within','false'
'hypertension no total no medications in use at baseline no total no','C1707101','IN','CD44 wt Allele','false'
'long term vitamin k antagonist','C1096489','vitamin k antagonist','Treatment with Vitamin K antagonist','false'
'long term vitamin k antagonist','C2267235','Vitamin K Antagonist','Vitamin K Antagonist [EPC]','false'
'pts','C1419129','PTS','PTS gene','false'
'pts','C2698747','PTS','Patient Tracking System','false'
'war','C0043027','War','War','true'
'dabigatran $nmbr$ vs warfarin p inter','C2348066','DABIGATRAN','dabigatran','true'
'dabigatran $nmbr$ vs warfarin p inter','C0043031','WARFARIN','Warfarin','true'
'dabigatran $nmbr$ vs warfarin p inter','C0205103','Inter-','Intermediate','false'
'dabigatran $nmbr$ vs warfarin p inter','C1548610','Inter','Inter','false'
'age $nmbr$ $nmbr$','C0001779','AGE','Age','false'
'weight $nmbr$ $nmbr$','C0005910','Weight','Body Weight','true'
'weight $nmbr$ $nmbr$','C0043100','Weight','Weight','true'
'weight $nmbr$ $nmbr$','C1305866','weight','Weighing patient','false'
'weight $nmbr$ $nmbr$','C1705104','Weight','Importance Weight','false'
'weight $nmbr$','C0005910','Weight','Body Weight','true'
'weight $nmbr$','C0043100','Weight','Weight','true'
'weight $nmbr$','C1305866','weight','Weighing patient','false'
'weight $nmbr$','C1705104','Weight','Importance Weight','false'
'asa','C0004057','ASA','Aspirin','true'
'asa','C3853627','ASA','Arylsulfatase A, human','false'
'no asa','C0004057','ASA','Aspirin','true'
'no asa','C3853627','ASA','Arylsulfatase A, human','false'
'no amiodarone','C0002598','AMIODARONE','Amiodarone','true'
'ppi','C0358591','PPI','Proton Pump Inhibitors','true'
'ppi','C0871125','PPI','prepulse inhibition activity','true'
'ppi','C3811894','PPI','Pixels per Inch','false'
'p inter','C0369773','P NOS','P Blood group antibodies','false'
'p inter','C2603361','P'','P prime','false'
'p inter','C0205103','Inter-','Intermediate','false'
'p inter','C1548610','Inter','Inter','false'
'no ppi','C0358591','PPI','Proton Pump Inhibitors','true'
'no ppi','C0871125','PPI','prepulse inhibition activity','true'
'no ppi','C3811894','PPI','Pixels per Inch','false'
'figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients','C0040223','TIME','Time','true'
'figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients','C3541383','Time','Time (foundation metadata concept)','false'
'figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients','C1319635','mg/mg','mg/mg','false'
'figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients','C0439422','mg day','milligram/day','false'
'figure $nmbr$ time to first exacerbation in high dose ics $nmbr$ mg day medium dose ics $nmbr$ $nmbr$ mg day and low dose ics $nmbr$ mg day patients','C0030705','Patients','Patients','true'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C2986480','Subgroup Analysis','Subset Analysis','false'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C0040223','TIME','Time','true'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C3541383','Time','Time (foundation metadata concept)','false'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C1441672','Observed','Observed','false'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C0332283','Followed by','Followed by','false'
'in this subgroup analysis the shortest time to the first exacerbation was observed in the hd stratum followed by the md and ld strata figure $nmbr$','C0694649','LD','Left deltoid','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0392747','Change','Changing','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0443172','change','Changed status','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0439234','YEARS','year','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0017446','Region','Geographic Locations','true'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0205147','Region','regional','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1522326','Treated','Treating','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C4521536','SFC','United States Military enlisted E7','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0332272','Better','Better','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0018684','Health','Health','true'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C4522046','Better','Better than Others','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0022885','Test','Laboratory Procedures','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0039593','Test','Testing','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0392366','test','Tests (qualifier value)','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C0456984','Test','Test Result','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1515976','test','Anatomic Structure, System, or Substance','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C3831328','Test','Blood Products Laboratory Testing','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C4318744','Test','Test - temporal region','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1518681','Treatment Effect','Outcome of Therapy','false'
'figure $nmbr$ mean change in sgrq total score at $nmbr$ years by region for patients treated by placebo and sfc a lower score indicates better health a test for an interaction between region and treatment effect was not significant p $nmbr$ $nmbr$','C1273937','Not significant','Not significant','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C2045651','change relationship','Altered relationship','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C2964552','Total Score','Total score','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0392747','Change','Changing','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0443172','change','Changed status','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0683312','Category','Categories','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C3889287','Category','Digital Content Category','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0184511','Improved','Improved','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0018684','Health','Health','true'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0332272','Improved','Better','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C1561611','Improved','Admission Level of Care Code - Improved','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C4084203','Improved','Improved - answer to question','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C1524063','Using','Use of','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0814908','analysis of covariance','ancova','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C1705242','Difference','Different','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0598981','intercepts','Intercept Substance','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C3146232','Intercept','Point of Interception','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'figure $nmbr$ relationship between change in sgrq total score over the $nmbr$ year study period and change in fev $nmbr$ by age category a negative score indicates improved health using analysis of covariance difference in slopes p $nmbr$ $nmbr$ difference in intercepts p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'charm','C0849759','charm','charmed','false'
'adhere','C3714578','Adhere','Fix','false'
'week $nmbr$','C0332174','/week','Weekly','false'
'week $nmbr$','C0439230','Week','week','false'
'steroid free remission','C0544452','Remission','Disease remission','false'
'steroid free remission','C0687702','remission','Cancer Remission','false'
'steroid sparing remission','C0544452','Remission','Disease remission','false'
'steroid sparing remission','C0687702','remission','Cancer Remission','false'
'steroid free cr $nmbr$','C0201975','Cr','Creatinine measurement','false'
'steroid free cr $nmbr$','C3539604','CR','CR2 wt Allele','false'
'steroid free cr $nmbr$','C3711669','CR','CALB2 protein, human','true'
'steroid free cr $nmbr$','C4084730','CR','CALB2 wt Allele','false'
'steroid free cr $nmbr$','C4553336','CR','Lugano Lymphoma Response Classification Complete Remission by PET','false'
'steroid free cr $nmbr$','C4553337','CR','Lugano Lymphoma Response Classification Complete Remission by CT','false'
'remission by baseline steroid doses','C0544452','Remission','Disease remission','false'
'remission by baseline steroid doses','C0687702','remission','Cancer Remission','false'
'high','C0205250','High','High','false'
'high','C1299351','High','Abnormally high','false'
'high','C2700149','HIGH','Value Above Reference Range','false'
'high','C3887512','high','high - ActExposureLevelCode','false'
'high','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high','C4321237','High','High Level','false'
'high','C4522209','High','IPSS Risk Category High','false'
'low','C0205251','Low','low','false'
'low','C1550472','low','low confidentiality','false'
'low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low','C4048187','low','low exposure','false'
'low','C4321351','Low','Low Level','false'
'low','C4522223','Low','IPSS Risk Category Low','false'
'remission by baseline duration of steroid','C0814126','remission by duration','remission by duration','false'
'remission by baseline duration of steroid','C0038317','Steroid','Steroids','true'
'used','C1273517','used','Used by','false'
'$nmbr$ $nmbr$ months','C0439231','MONTHS','month','false'
'week $nmbr$ mayo endoscopy subscorea','C0332174','/week','Weekly','false'
'week $nmbr$ mayo endoscopy subscorea','C0014245','ENDOSCOPY','Endoscopy (procedure)','true'
'week $nmbr$ mayo endoscopy subscorea','C0439230','Week','week','false'
'symptomatic remissionb n n','C0231220','Symptomatic','Symptomatic','false'
'sustained mucosal healingc n n','C0443318','Sustained','Sustained','false'
'sustained mucosal healingc n n','C0026724','Mucosal','Mucous Membrane','true'
'mucosal healingc n n','C0026724','Mucosal','Mucous Membrane','true'
'sustained mucosal healingc','C0443318','Sustained','Sustained','false'
'sustained mucosal healingc','C0026724','Mucosal','Mucous Membrane','true'
'p value n n','C1709380','P-Value','P-Value','false'
'nesiritide n $nmbr$','C0054015','NESIRITIDE','Nesiritide','true'
'sex no total no','C0009253','Sex','Coitus','true'
'sex no total no','C0036864','Sex','Sex Behavior','true'
'sex no total no','C0079399','sex','Gender','true'
'sex no total no','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex no total no','C1314687','Sex','Sexual intercourse - finding','false'
'sex no total no','C1522384','SEX','sex','true'
'sex no total no','C0439175','% total','% of total','false'
'sex no total no','C0439810','Total','Total','false'
'race no total no f','C0034510','RACE','Racial group','true'
'race no total no f','C1706779','RACE','AMACR wt Allele','false'
'race no total no f','C3853635','Race','Race','false'
'race no total no f','C0439175','% total','% of total','false'
'race no total no f','C0439810','Total','Total','false'
'race no total no f','C0016327','F-','Fluorides','true'
'systolic pressure mm hg','C0871470','Pressure, Systolic','Systolic Pressure','true'
'systolic pressure mm hg','C0439475','mmHG','mmHg','false'
'heart rate at rest beats min','C0018810','Heart Rate','heart rate','true'
'bnp pg ml i','C0023806','ML I','Lipomucopolysaccharidosis','true'
'n terminal pro bnp pg ml','C0669479','N-terminal pro-BNP','pro-brain natriuretic peptide (1-76)','true'
'n terminal pro bnp pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'serum sodium mmol liter','C0523891','Serum sodium','Serum sodium measurement','false'
'serum sodium mmol liter','C0475211','Litre','liter','false'
'left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$','C0428772','Left Ventricular Ejection Fraction','Left ventricular ejection fraction','false'
'left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$','C0488728','Left ventricular Ejection fraction','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$','C0439175','% total','% of total','false'
'left ventricular ejection fraction within previous $nmbr$ mo no total no $nmbr$','C0439810','Total','Total','false'
'medical history no total no','C0262926','Medical History','Medical History','false'
'medical history no total no','C1704706','Medical History','Medical History Domain','false'
'medical history no total no','C0439175','% total','% of total','false'
'medical history no total no','C0439810','Total','Total','false'
'heart failure $nmbr$ yr before admission','C0018801','Failure, Heart','Heart failure','true'
'heart failure $nmbr$ yr before admission','C0439234','yr','year','false'
'heart failure $nmbr$ yr before admission','C0018802','Heart Failure','Congestive heart failure','true'
'heart failure $nmbr$ yr before admission','C4554158','Heart failure','Heart Failure, CTCAE','false'
'atrial fibrillation or flutter','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation or flutter','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation or flutter','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'atrial fibrillation or flutter','C0016385','Flutter','Cardiac Flutter','false'
'atrial fibrillation or flutter','C2242390','FLUTTER','Flutter (respiratory device)','false'
'medical therapy before randomization no total no','C0418981','Medical therapy','Medical therapy','false'
'medical therapy before randomization no total no','C0034656','Randomization','Randomization','true'
'medical therapy before randomization no total no','C0439175','% total','% of total','false'
'medical therapy before randomization no total no','C0439810','Total','Total','false'
'aldosterone blocker','C0002006','ALDOSTERONE','Aldosterone','true'
'nitrate oral or topical','C0442027','Oral','Oral','false'
'nitrate oral or topical','C4521986','Oral','Oral (intended site)','false'
'nitrate oral or topical','C0332237','Topical','Topical surface','false'
'digoxin or digitalis glycoside','C0012265','DIGOXIN','Digoxin','true'
'digoxin or digitalis glycoside','C0012253','Digitalis glycoside','Digitalis Glycosides','true'
'hydralazine','C0020223','Hydrallazine','Hydralazine','true'
'loop diuretic','C0354100','Loop Diuretic','Loop Diuretics','true'
'loop diuretic','C3536704','Loop Diuretic','Loop Diuretic [EPC]','false'
'inotropic agent','C0304509','Inotropic agent','Inotropic agent','false'
'vasodilator','C0042402','Vasodilator','Vasodilator Agents','true'
'vasodilator','C3537240','Vasodilator','Vasodilator [EPC]','false'
'use of medication from randomization through $nmbr$ hr no total no','C1524063','Use of','Use of','false'
'use of medication from randomization through $nmbr$ hr no total no','C0034656','Randomization','Randomization','true'
'use of medication from randomization through $nmbr$ hr no total no','C0439175','% total','% of total','false'
'use of medication from randomization through $nmbr$ hr no total no','C0439810','Total','Total','false'
'time from hospitalization to randomization hr','C0040223','TIME','Time','true'
'time from hospitalization to randomization hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from hospitalization to randomization hr','C0034656','Randomization','Randomization','true'
'time from randomization to study drug administration hr','C0040223','TIME','Time','true'
'time from randomization to study drug administration hr','C3541383','Time','Time (foundation metadata concept)','false'
'time from randomization to study drug administration hr','C0013175','study drug','Drug Evaluation','true'
'time from randomization to study drug administration hr','C0150270','Drug administration','Medication Management','false'
'time from randomization to study drug administration hr','C3469597','Drug administration','Administration of medication','false'
'administration of study drug bolus no total no','C0150270','Drug administration','Medication Management','false'
'administration of study drug bolus no total no','C0262754','Administration drug','drug management','false'
'administration of study drug bolus no total no','C3469597','Drug administration','Administration of medication','false'
'administration of study drug bolus no total no','C0439175','% total','% of total','false'
'administration of study drug bolus no total no','C0439810','Total','Total','false'
'duration of study drug administration hr','C0920470','drug administration duration','drug administration duration','false'
'duration of study drug administration hr','C2348354','Duration of Administration','Duration of Administration','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1707455','Comparison','Comparison','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C0772326','Clopidogrel bisulphate','Clopidogrel bisulfate','true'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C2353292','clopidogrel resinate','clopidogrel resinate','true'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1705242','Difference','Different','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1628982','Percent Inhibition','Percent inhibition','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C0013227','Drugs','Pharmaceutical Preparations','true'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C3687832','Drugs','Drugs - dental services','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C0030705','Patients','Patients','true'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C3538926','ED','Endocrine System Findings Domain','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1079230','subgroups','Subgroup A Nepoviruses','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1518422','Not','Negation','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C0439801','Limit','Limited (extensiveness)','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C1549649','Limit','Limit - Amount class','false'
'figure $nmbr$ noninferiority comparison of clopidogrel bisulfate and clopidogrel resinate by the difference in percent p $nmbr$ y $nmbr$ inhibition of the $nmbr$ drugs in all patients and the prespeci ed subgroups the difference in platelet inhibition between clopidogrel resinate and clopidogrel bisulfate did not exceed predetermined limit of noninferiority chd coronary heart disease dm diabetes mellitus','C2349209','Limit','Bound (value)','false'
'age yr mean sd','C0001779','AGE','Age','false'
'age yr mean sd','C2699239','SD','SD, Rat Strain','false'
'baseline total ipss mean sd','C0168634','baseline','BaseLine dental cement','true'
'baseline total ipss mean sd','C2699239','SD','SD, Rat Strain','false'
'baseline total ipss mean sd','C1442488','Baseline','Baseline','false'
'baseline bii mean sd','C0168634','baseline','BaseLine dental cement','true'
'baseline bii mean sd','C2699239','SD','SD, Rat Strain','false'
'baseline bii mean sd','C1442488','Baseline','Baseline','false'
'baseline luts severity n','C0168634','baseline','BaseLine dental cement','true'
'baseline luts severity n','C0439793','Severity','Severities','false'
'baseline luts severity n','C0522510','Severity','With intensity','false'
'baseline luts severity n','C1442488','Baseline','Baseline','false'
'mild ipss','C1019118','Ips','Ips <Invertebrate>','false'
'mild ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'mild ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'mild ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'moderate $nmbr$ ipss','C1019118','Ips','Ips <Invertebrate>','false'
'moderate $nmbr$ ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'moderate $nmbr$ ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'moderate $nmbr$ ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'severe ipss $nmbr$','C1019118','Ips','Ips <Invertebrate>','false'
'severe ipss $nmbr$','C1998280','IPSS','International Prostate Symptom Score','false'
'severe ipss $nmbr$','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'severe ipss $nmbr$','C3811063','IPS','SLC27A4 wt Allele','false'
'qmax category n','C0683312','Category','Categories','false'
'qmax category n','C3889287','Category','Digital Content Category','false'
'$nmbr$ ml s','C0439526','/mL','/mL','false'
'$nmbr$ ml s','C1705224','ML','THPO wt Allele','false'
'$nmbr$ ml s','C3887665','ML','Thrombopoietin, human','false'
'qmax ml s mean sd','C0439390','mL/s','Milliliter per Second','false'
'qmax ml s mean sd','C2699239','SD','SD, Rat Strain','false'
'pvr volume ml mean sd','C0242852','PVR','Proliferative vitreoretinopathy','true'
'pvr volume ml mean sd','C2699239','SD','SD, Rat Strain','false'
'pvr volume ml mean sd','C0456261','PVR','Pulmonary Vascular Resistance','true'
'pvr volume ml mean sd','C1419141','PVR','PVR gene','false'
'psa ng ml mean sd','C0439275','ng/mL','Microgram per Liter','false'
'psa ng ml mean sd','C2699239','SD','SD, Rat Strain','false'
'ed history n yes','C1549445','Yes','Yes - Yes/no indicator','false'
'ed history n yes','C1705108','YES','Yes (indicator)','false'
'ed history n yes','C1710701','Yes','YES1 wt Allele','false'
'ed severity n','C0439793','Severity','Severities','false'
'ed severity n','C0522510','Severity','With intensity','false'
'ed duration $nmbr$ yr n','C0449238','Duration','Duration (temporal concept)','false'
'ed duration $nmbr$ yr n','C0439234','yr','year','false'
'ed duration $nmbr$ yr n','C2926735','Duration','Duration','false'
'sexually active with female','C0241028','SEXUALLY ACTIVE','Sexually active','false'
'sexually active with female','C0043210','female','Woman','true'
'sexually active with female','C0086287','FEMALE','Females','true'
'sexually active with female','C1705497','Female','Female, Self-Report','false'
'sexually active with female','C1705498','FEMALE','Female Phenotype','false'
'partner n yes','C1549445','Yes','Yes - Yes/no indicator','false'
'partner n yes','C1705108','YES','Yes (indicator)','false'
'partner n yes','C1710701','Yes','YES1 wt Allele','false'
'pgi s n y','C0523816','PGI','Pepsinogen I measurement','false'
'pgi s n y','C1333690','PGI','GPI gene','false'
'pgi s n y','C1412792','PGI','BGN gene','false'
'pgi s n y','C1704947','PGI','GPI wt Allele','false'
'pgi s n y','C2975867','PGI','GPI protein, human','true'
'pgi s n y','C3810522','PGI','BGN wt Allele','false'
'pgi s n y','C4522133','PGI','Patient Global Impression Generic Modification Version Questionnaire','false'
'cgi s n z','C4526016','CGI','Clinical Global Impression Generic Modification Version Questionnaire','false'
'previous therapies n','C0205156','Previous','Previous','false'
'previous therapies n','C0087111','Therapies','Therapeutic procedure','true'
'previous therapies n','C1552607','previous','Act Relationship Subset - previous','false'
'other bph luts therapy','C0039798','therapy','therapeutic aspects','true'
'other bph luts therapy','C0087111','Therapy','Therapeutic procedure','true'
'other bph luts therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'oab therapy','C0039798','therapy','therapeutic aspects','true'
'oab therapy','C0087111','Therapy','Therapeutic procedure','true'
'oab therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'ed therapy','C0039798','therapy','therapeutic aspects','true'
'ed therapy','C0087111','Therapy','Therapeutic procedure','true'
'ed therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'placebo mean change sd','C0032042','Placebo','Placebos','true'
'placebo mean change sd','C2699239','SD','SD, Rat Strain','false'
'placebo mean change sd','C1696465','PLACEBO','placebo','false'
'placebo mean change sd','C1706408','PLACEBO','Placebo Control','false'
'tadalafil $nmbr$ mg mean change sd','C0024671','MG','Mammography','true'
'tadalafil $nmbr$ mg mean change sd','C2699239','SD','SD, Rat Strain','false'
'tadalafil $nmbr$ mg mean change sd','C0026410','MG','Mongolia','true'
'tadalafil $nmbr$ mg mean change sd','C0439269','mg%','mg/dL','false'
'tadalafil $nmbr$ mg mean change sd','C1960952','mg %','Milligram percent','false'
'tadalafil $nmbr$ mg mean change sd','C2346927','Mg++','Magnesium Cation','false'
'tadalafil $nmbr$ mg mean change sd','C4321396','MG','MG','false'
'tadalafil $nmbr$ mg mean change sd','C4521761','MG','United States Military Commissioned Officer O8','false'
'ls mean treatment difference $nmbr$ ci','C0008107','CI','Chile','true'
'ls mean treatment difference $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'baseline luts severity','C0439793','Severity','Severities','false'
'baseline luts severity','C0522510','Severity','With intensity','false'
'moderate n $nmbr$ $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate n $nmbr$ $nmbr$','C1881878','Moderate','Moderation','false'
'moderate n $nmbr$ $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate n $nmbr$ $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate n $nmbr$ $nmbr$','C4085643','Moderate','Moderate Response','false'
'moderate n $nmbr$ $nmbr$','C4321335','Moderate','Moderate Level','false'
'severe n $nmbr$ $nmbr$','C0205082','Severe','Severe (severity modifier)','false'
'severe n $nmbr$ $nmbr$','C4050465','Severe','Severe Extremity Pain','false'
'severe n $nmbr$ $nmbr$','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'baseline ed severity','C0439793','Severity','Severities','false'
'baseline ed severity','C0522510','Severity','With intensity','false'
'mild n $nmbr$ $nmbr$ $nmbr$','C2945599','Mild','Mild (qualifier value)','false'
'characteristic^','C1521970','Characteristic','Characteristics','false'
'bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$','C2700462','Bud','Bud - plant part','false'
'bud fm $nmbr$ $nmbr$ atg n ^ $nmbr$','C2945744','bud','Bud - CHV concept','false'
'bud $nmbr$ ptg n $nmbr$','C0039512','PTG','Teniposide','true'
'bud $nmbr$ ptg n $nmbr$','C1418830','PTG','PPP1R3C gene','false'
'self reported descent n','C0681906','self reported','Patient Self-Report','false'
'self reported descent n','C2700446','Self-reported','Self-Report','true'
'mexican','C0240339','MEXICAN','mexican','false'
'puerto rican','C0034043','PUERTO RICAN','Puerto Ricans','true'
'cuban','C1553379','CUBAN','Cuban','false'
'south or central american','C1710133','South','South','false'
'south or central american','C0238914','CENTRAL AMERICAN','Central American','false'
'caribbean','C0043122','Caribbean','Caribbean Islands','true'
'caribbean','C0206155','Caribbean','Caribbean region','true'
'caribbean','C1331005','CARIBBEAN','Caribbean natives','false'
'mixed hispanic','C0205430','MIXED','Mixed (qualifier value)','false'
'mixed hispanic','C0086409','HISPANIC','Hispanics','true'
'mixed hispanic','C3160715','Mixed','Mixed Cell Morphology','false'
'total ics dose at entry xg d','C2986497','Total Dose','Cumulative Dose','false'
'total ics dose at entry xg d','C0017209','XG','Gaza Strip','true'
'total ics dose at entry xg d','C1292284','XG','Xg blood group system','false'
'total ics dose at entry xg d','C1421532','XG','XG gene','false'
'predose fev^ at screening','C0439565','Pre-dose','Pre-dose','false'
'predose fev^ at screening','C3714541','FEV','Forced Vital Capacity','true'
'predose fev^ at screening','C3812758','Pre-dose','Pre-dose Measure','false'
'predose fev^ at screening','C0220908','Screening','Screening procedure','true'
'predose fev^ at screening','C0220909','screening','Aspects of disease screening','true'
'predose fev^ at screening','C1698960','screening','research subject screening','false'
'predose fev^ at screening','C1710031','Screening','Disease Screening','false'
'predose fev^ at screening','C1710032','Screening','Screening','false'
'predose fev^ at screening','C1710477','SCREENING','Trial Screening','false'
'predose fev^ at screening','C2348164','SCREENING','Screening Study','false'
'l','C0439394','l's','liter/second','false'
'l','C1706495','L-','upper case letter ell','false'
'l','C3642217','/L','Per Liter','false'
'predicted','C0681842','Predicted','prediction','false'
'predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'predose fev at randomization','C3714541','FEV','Forced Vital Capacity','true'
'predose fev at randomization','C0034656','Randomization','Randomization','true'
'predose fvc l','C0439565','Pre-dose','Pre-dose','false'
'predose fvc l','C3714541','FVC','Forced Vital Capacity','true'
'predose fvc l','C3812758','Pre-dose','Pre-dose Measure','false'
'at screening','C0220908','Screening','Screening procedure','true'
'at screening','C0220909','screening','Aspects of disease screening','true'
'at screening','C1698960','screening','research subject screening','false'
'at screening','C1710031','Screening','Disease Screening','false'
'at screening','C1710032','Screening','Screening','false'
'at screening','C1710477','SCREENING','Trial Screening','false'
'at screening','C2348164','SCREENING','Screening Study','false'
'at randomization','C0034656','Randomization','Randomization','true'
'predose fev fvc','C0439565','Pre-dose','Pre-dose','false'
'predose fev fvc','C3714541','FVC','Forced Vital Capacity','true'
'predose fev fvc','C3812758','Pre-dose','Pre-dose Measure','false'
'postdose fev fvc at screening','C3714541','FVC','Forced Vital Capacity','true'
'postdose fev fvc at screening','C0220908','Screening','Screening procedure','true'
'postdose fev fvc at screening','C0220909','screening','Aspects of disease screening','true'
'postdose fev fvc at screening','C1698960','screening','research subject screening','false'
'postdose fev fvc at screening','C1710031','Screening','Disease Screening','false'
'postdose fev fvc at screening','C1710032','Screening','Screening','false'
'postdose fev fvc at screening','C1710477','SCREENING','Trial Screening','false'
'postdose fev fvc at screening','C2348164','SCREENING','Screening Study','false'
'reversibility in fev^ at','C0449261','Reversibility','Reversibility','false'
'reversibility in fev^ at','C3714541','FEV','Forced Vital Capacity','true'
'screening l','C0220908','Screening','Screening procedure','true'
'screening l','C0220909','screening','Aspects of disease screening','true'
'screening l','C1698960','screening','research subject screening','false'
'screening l','C1710031','Screening','Disease Screening','false'
'screening l','C1710032','Screening','Screening','false'
'screening l','C1710477','SCREENING','Trial Screening','false'
'screening l','C2348164','SCREENING','Screening Study','false'
'pef at baseline l_ min','C0030771','PEF','Pefloxacin','true'
'pef at baseline l_ min','C1518922','PEF','peak expiratory flow (procedure)','false'
'pef at baseline l_ min','C1542834','PEF','Peak expiratory flow rate','false'
'morning','C0332170','Morning','Morning','false'
'evening','C0587117','Evening','Evening','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0687676','Post','Post','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0010992','Data Analysis','Data Analysis','true'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1704687','Post','Post Device','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C3469826','POST','SLC35G1 gene','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0205363','Stratified','Stratified','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0017446','Region','Geographic Locations','true'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0205147','Region','regional','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0392747','changes','Changing','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0443172','changes','Changed status','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0444504','Mean','Statistical mean','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C2347634','Mean','Population Mean','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C2348143','Mean','Sample Mean','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0030771','PEF','Pefloxacin','true'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1518922','PEF','peak expiratory flow (procedure)','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1542834','PEF','Peak expiratory flow rate','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0439230','WEEKS','week','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0016529','Forced expiratory volume','Forced expiratory volume function','true'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1306036','Forced Expiratory Volume','Forced expiratory volume procedure','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1511726','Data','Data','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C3245479','data','Data call receiving device','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C3714741','Data','Data (eukaryote)','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0849355','Removed','Removed','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0030705','*^patient','Patients','true'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C1522609','Value','Numerical value','false'
'figure $nmbr$ post hoc analysis of data stratified by region for a mean changes from baseline to the mean during the randomized treatment period for morning pef and bj mean change from baseline to $nmbr$ weeks for predose fey abbreviations bud budesonide fey forced expiratory volume in $nmbr$ second fm formoterol pef peak expiratory flow pmdi pressurized metered dose inhaler outlier data removed for $nmbr$ patient with baseline pef value of $nmbr$ l min in the bud fm group value with outlier included $nmbr$ $nmbr$ l min','C0441846','Group L','Group L','false'
'obese $nmbr$ kg m^ $nmbr$','C0022718','KG','Kyrgyzstan','true'
'obese $nmbr$ kg m^ $nmbr$','C0439209','kg','Kilogram','false'
'obese $nmbr$ kg m^ $nmbr$','C4054209','/kg','Per Kilogram','false'
'a aml n $nmbr$','C0023465','AML','Acute monocytic leukemia','true'
'a aml n $nmbr$','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'aml n $nmbr$','C0023465','AML','Acute monocytic leukemia','true'
'aml n $nmbr$','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'mets n','C0812270','METS','ETV3 gene','false'
'mets n','C1705694','METS','ETV3 wt Allele','false'
'mets n','C2939420','mets','Metastatic Neoplasm','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C0301630','reductions','Reduction (chemical)','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C4551656','reductions','Surgical reduction','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C0332174','/week','Weekly','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C0439230','Week','week','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C1319893','Sitting systolic blood pressure','Sitting systolic blood pressure','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C0005893','Body mass index','Body mass index procedure','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C0578022','Body Mass Index','Finding of body mass index','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in mean sitting systolic blood pressure mssbp in obese body mass index [bmi] $nmbr$ kg nr and nonobese bmi','C1305855','BODY MASS INDEX','Body mass index','true'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0301630','reductions','Reduction (chemical)','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C4551656','reductions','Surgical reduction','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0332174','/week','Weekly','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0439230','Week','week','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C1319893','Sitting systolic blood pressure','Sitting systolic blood pressure','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C1319894','Sitting diastolic blood pressure','Sitting diastolic blood pressure','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0812270','METS','ETV3 gene','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C1705694','METS','ETV3 wt Allele','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C2939420','mets','Metastatic Neoplasm','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C1710181','Standard Error of the Mean','Standard Error','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C1442488','Baseline','Baseline','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C2937472','ALISKIREN/AMLODIPINE','aliskiren / Amlodipine','false'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0023465','AML','Acute monocytic leukemia','true'
'figure $nmbr$ least square mean lsm reductions from baseline to week $nmbr$ in a mean sitting systolic blood pressure mssbp and b mean sitting diastolic blood pressure msdbp in subjects with and without the metabolic syndrome mets at baseline error bars repre sent standard error of the mean a aliskiren aml amlodipine','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0439165','Percentage','Percent (qualifier value)','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C1549488','Percentage','Amount type - Percentage','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0005823','BP - Blood pressure','Blood Pressure','true'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0018017','Goals','objective (goal)','true'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0681850','Subject','Study Subject','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C1550501','{Subject}','Subject -direct target','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C1706203','Subject','Subject - topic','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C2349001','Subject','Human Study Subject','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C2697811','Subject','Investigative Subject','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0812270','METS','ETV3 gene','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C1705694','METS','ETV3 wt Allele','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C2939420','mets','Metastatic Neoplasm','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C2937472','ALISKIREN/AMLODIPINE','aliskiren / Amlodipine','false'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0023465','AML','Acute monocytic leukemia','true'
'figure $nmbr$ percentage of subjects achieving blood pressure bp goals of $nmbr$ kg nr subjects and subjects with and without the metabolic syndrome mets a aliskiren aml amlodipine','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'oma oat n $nmbr$','C0028753','oat','Oats (Dietary)','false'
'oma oat n $nmbr$','C0331496','Oat','Avena (plant)','true'
'oma oat n $nmbr$','C0939905','oat','Oats preparation','false'
'oma oat n $nmbr$','C3539067','OAT','Oat (plant)','false'
'oma oat n $nmbr$','C3897364','OAT','Thermoacoustic Computed Tomography','false'
'oat n $nmbr$','C0028753','oat','Oats (Dietary)','false'
'oat n $nmbr$','C0331496','Oat','Avena (plant)','true'
'oat n $nmbr$','C0939905','oat','Oats preparation','false'
'oat n $nmbr$','C3539067','OAT','Oat (plant)','false'
'oat n $nmbr$','C3897364','OAT','Thermoacoustic Computed Tomography','false'
'age distribution years n','C1510829','Age-Years','Age-Years','false'
'serum total ige iu ml','C1441420','Serum.total','Serum.total','false'
'serum total ige iu ml','C0439458','IU/mL','IU/mL','false'
'fev $nmbr$ predicted at baseline','C0681842','Predicted','prediction','false'
'fev $nmbr$ predicted at baseline','C1882327','%{Predicted}','Percent of Predicted Value','false'
'number of clinically significant asthma exacerbations in last year prior to baseline','C0237753','*Number','Numbers','false'
'number of clinically significant asthma exacerbations in last year prior to baseline','C0449788','Number','Count of entities','false'
'number of clinically significant asthma exacerbations in last year prior to baseline','C0439234','Year','year','false'
'number of clinically significant asthma exacerbations in last year prior to baseline','C0439508','/Year','per year','false'
'number of er visits in last year prior to baseline','C3810541','ER','Adverse Event Emergency Room Visit','false'
'number of er visits in last year prior to baseline','C1549755','Visit Number','Visit Number','false'
'number of er visits in last year prior to baseline','C3811131','ER','Estrogen Receptor Measurement','false'
'number of er visits in last year prior to baseline','C0439234','Year','year','false'
'number of er visits in last year prior to baseline','C0439508','/Year','per year','false'
'number of hospitalizations in last year prior to baseline','C4086639','Number Of Hospitalizations','Number of Hospitalizations','false'
'number of hospitalizations in last year prior to baseline','C0439234','Year','year','false'
'number of hospitalizations in last year prior to baseline','C0439508','/Year','per year','false'
'night time awakenings in past $nmbr$ weeks prior to baseline','C0860510','Night time awakening','Night time awakening','false'
'night time awakenings in past $nmbr$ weeks prior to baseline','C0439230','WEEKS','week','false'
'night time awakenings in past $nmbr$ weeks prior to baseline','C0332152','Prior to','Before','false'
'ocs reduced stopped','C0392756','Reduced','Reduced','false'
'ocs reduced stopped','C1272691','stopped','To be stopped','false'
'ocs maintained increased','C0205217','Increased','Increased','false'
'ocs maintained increased','C0442805','Increased','Increase','false'
'oma oat','C0028753','oat','Oats (Dietary)','false'
'oma oat','C0331496','Oat','Avena (plant)','true'
'oma oat','C0939905','oat','Oats preparation','false'
'oma oat','C3539067','OAT','Oat (plant)','false'
'oma oat','C3897364','OAT','Thermoacoustic Computed Tomography','false'
'oat','C0028753','oat','Oats (Dietary)','false'
'oat','C0331496','Oat','Avena (plant)','true'
'oat','C0939905','oat','Oats preparation','false'
'oat','C3539067','OAT','Oat (plant)','false'
'oat','C3897364','OAT','Thermoacoustic Computed Tomography','false'
'mean change from baseline in fev $nmbr$ predicted sd','C0392747','Change','Changing','false'
'mean change from baseline in fev $nmbr$ predicted sd','C0443172','change','Changed status','false'
'mean change from baseline in fev $nmbr$ predicted sd','C1705241','Change','Delta (difference)','false'
'mean change from baseline in fev $nmbr$ predicted sd','C4319952','Change','Change -- procedure','false'
'mean change from baseline in fev $nmbr$ predicted sd','C0681842','Predicted','prediction','false'
'mean change from baseline in fev $nmbr$ predicted sd','C2699239','SD','SD, Rat Strain','false'
'mean change from baseline in fev $nmbr$ predicted sd','C1882327','%{Predicted}','Percent of Predicted Value','false'
'mean number of clinically significant asthma exacerbations','C0444504','Mean','Statistical mean','false'
'mean number of clinically significant asthma exacerbations','C0237753','*Number','Numbers','false'
'mean number of clinically significant asthma exacerbations','C0449788','Number','Count of entities','false'
'mean number of clinically significant asthma exacerbations','C2347634','Mean','Population Mean','false'
'mean number of clinically significant asthma exacerbations','C2348143','Mean','Sample Mean','false'
'mean number of combined visits hospitalizations','C4086639','Number Of Hospitalizations','Number of Hospitalizations','false'
'mean change from baseline in acq overall score sd','C0392747','Change','Changing','false'
'mean change from baseline in acq overall score sd','C0443172','change','Changed status','false'
'mean change from baseline in acq overall score sd','C1705241','Change','Delta (difference)','false'
'mean change from baseline in acq overall score sd','C4319952','Change','Change -- procedure','false'
'mean change from baseline in acq overall score sd','C0282416','Overall','Overall Publication Type','true'
'mean change from baseline in acq overall score sd','C2699239','SD','SD, Rat Strain','false'
'mean change from baseline in acq overall score sd','C1561607','Overall','Overall','false'
'mean change from baseline in the number of','C0392747','Change','Changing','false'
'mean change from baseline in the number of','C0443172','change','Changed status','false'
'mean change from baseline in the number of','C1705241','Change','Delta (difference)','false'
'mean change from baseline in the number of','C4319952','Change','Change -- procedure','false'
'mean change from baseline in the number of','C0237753','*Number','Numbers','false'
'mean change from baseline in the number of','C0449788','Number','Count of entities','false'
'night time awakenings in past $nmbr$ weeks sd','C0860510','Night time awakening','Night time awakening','false'
'night time awakenings in past $nmbr$ weeks sd','C0439230','WEEKS','week','false'
'night time awakenings in past $nmbr$ weeks sd','C2699239','SD','SD, Rat Strain','false'
'metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'no metabolic syndrome','C0524620','METABOLIC SYNDROME','Metabolic Syndrome X','true'
'canrenone n z $nmbr$','C0006882','CANRENONE','Canrenone','true'
'placebo n z $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n z $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n z $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'men n [ ]','C0025266','Men','Male population group','true'
'heart rate bpm $nmbr$','C0018810','Heart Rate','heart rate','true'
'systolic bp mmhg','C0871470','systolic bp','Systolic Pressure','true'
'systolic bp mmhg','C0439475','mmHG','mmHg','false'
'diastolic bp mmhg','C0428883','diastolic bp','Diastolic blood pressure','true'
'diastolic bp mmhg','C0439475','mmHG','mmHg','false'
'diabetes n [ ]','C0011847','Diabetes','Diabetes','false'
'diabetes n [ ]','C0011849','Diabetes','Diabetes Mellitus','true'
'placebo n $nmbr$ n','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ n','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ n','C1706408','PLACEBO','Placebo Control','false'
'denosumab n $nmbr$ n','C1690432','DENOSUMAB','denosumab','true'
'western europe australia new zealand','C0027978','NEW ZEALAND','New Zealand','true'
'western europe australia new zealand','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'prevalent vertebral fracture','C0080179','VERTEBRAL FRACTURE','Spinal Fractures','true'
'prior nonvertebral fracture at age $nmbr$ years','C0016658','FRACTURE','Fracture','true'
'prior nonvertebral fracture at age $nmbr$ years','C1510829','Age-Years','Age-Years','false'
'prior use of osteoporosis medications','C1524063','Use of','Use of','false'
'female subjects n $nmbr$','C0043210','female','Woman','true'
'female subjects n $nmbr$','C0086287','FEMALE','Females','true'
'female subjects n $nmbr$','C1705497','Female','Female, Self-Report','false'
'female subjects n $nmbr$','C1705498','FEMALE','Female Phenotype','false'
'male subjects n $nmbr$ $nmbr$','C0086582','MALE','Males','true'
'male subjects n $nmbr$ $nmbr$','C1706180','Male','Male Gender, Self Report','false'
'male subjects n $nmbr$ $nmbr$','C1706428','MALE','Male Phenotype','false'
'male subjects n $nmbr$ $nmbr$','C1706429','Male','Male, Self-Reported','false'
'african american black','C0005680','Black','Black race','true'
'african american black','C0027567','Black','African race','true'
'african american black','C0085756','BLACK','African American','true'
'african american black','C0439541','Black','Black color','false'
'american indian native alaskan','C0682125','Native Alaskan','Alaska Natives','true'
'serum creatinine level','C0600061','Serum creatinine level','Serum creatinine level','false'
'estimated creatinine clearancet','C0750572','Estimated','Estimated','false'
'estimated creatinine clearancet','C0010294','CREATININE','Creatinine','true'
'estimated creatinine clearancet','C1561535','Creatinine','Creatinine, CTCAE','false'
'$nmbr$ ml minute','C0439232','Minute','Minute of time','false'
'$nmbr$ ml minute','C0700321','minute','Small','false'
'$nmbr$ ml minute','C0702093','/minute','Per Minute','false'
'$nmbr$ ml minute','C1282918','Minute','Minute (diminutive)','false'
'$nmbr$ ml minute','C2347166','Minute','Minute Unit of Plane Angle','false'
'baseline sua mean sd mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline sua mean sd mg dl','C0439269','mg dl','mg/dL','false'
'baseline sua mean sd mg dl','C1442488','Baseline','Baseline','false'
'presence of tophi','C0150312','Presence','Present','false'
'presence of tophi','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of tophi','C3854307','Presence','Presence (property)','false'
'years since last gout flare','C0439234','YEARS','year','false'
'years since last gout flare','C0018099','GOUT','Gout','true'
'years with gout mean sd','C0439234','YEARS','year','false'
'years with gout mean sd','C0018099','GOUT','Gout','true'
'obesity bmi $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'obesity bmi $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'obesity bmi $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'baseline renal function eclcr','C0168634','baseline','BaseLine dental cement','true'
'baseline renal function eclcr','C0232804','Renal function','Renal function','false'
'baseline renal function eclcr','C1442488','Baseline','Baseline','false'
'febuxostat $nmbr$ mg','C0024671','MG','Mammography','true'
'febuxostat $nmbr$ mg','C0026410','MG','Mongolia','true'
'febuxostat $nmbr$ mg','C0439269','mg%','mg/dL','false'
'febuxostat $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'febuxostat $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'febuxostat $nmbr$ mg','C4321396','MG','MG','false'
'febuxostat $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'normal $nmbr$ ml minute','C0439232','Minute','Minute of time','false'
'normal $nmbr$ ml minute','C0700321','minute','Small','false'
'normal $nmbr$ ml minute','C0702093','/minute','Per Minute','false'
'normal $nmbr$ ml minute','C1282918','Minute','Minute (diminutive)','false'
'normal $nmbr$ ml minute','C2347166','Minute','Minute Unit of Plane Angle','false'
'mild impairment $nmbr$ to','C0221099','Impairment','Impaired','false'
'mild impairment $nmbr$ to','C0684336','Impairment','Impaired health','false'
'moderate or severe impairment','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate or severe impairment','C1881878','Moderate','Moderation','false'
'moderate or severe impairment','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate or severe impairment','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate or severe impairment','C4085643','Moderate','Moderate Response','false'
'moderate or severe impairment','C4321335','Moderate','Moderate Level','false'
'moderate or severe impairment','C0221099','Impairment','Impaired','false'
'moderate or severe impairment','C0684336','Impairment','Impaired health','false'
'vorapaxar n $nmbr$','C2974521','VORAPAXAR','vorapaxar','true'
'median q $nmbr$ q $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'median q $nmbr$ q $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'median q $nmbr$ q $nmbr$','C2347635','Median','Population Median','false'
'median q $nmbr$ q $nmbr$','C2348144','Median','Sample Median','false'
'median q $nmbr$ q $nmbr$','C2939193','Median','Median (qualifier value)','false'
'region of enrollment','C0017446','Region','Geographic Locations','true'
'region of enrollment','C0205147','Region','regional','false'
'cardiovascular risk factors','C0850624','cardiovascular risk factor','cardiovascular risk factor','false'
'tobacco use','C0040335','Tobacco use NOS','Encounter due to tobacco use','false'
'tobacco use','C0543414','TOBACCO USE','Tobacco use','true'
'tobacco use','C0841002','Tobacco use','History of tobacco use','false'
'tobacco use','C3853727','Tobacco use','Tobacco user','false'
'renal function ml min','C0232804','Renal function','Renal function','false'
'renal function ml min','C0439445','mL/min','mL/min','false'
'$nmbr$ $nmbr$ crcl','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'$nmbr$ crcl','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'cardiovascular disease history','C1880008','Cardiovascular History','Cardiovascular History','false'
'peripheral arterial disease','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'peripheral arterial disease','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'positive troponin or ck mb','C0439178','% Positive','percent positive cells','false'
'positive troponin or ck mb','C0041199','Troponin','Troponin','true'
'positive troponin or ck mb','C1446409','Positive','Positive','false'
'positive troponin or ck mb','C1514241','POSITIVE','Positive Finding','false'
'positive troponin or ck mb','C2825490','Positive','Positive Charge','false'
'positive troponin or ck mb','C3812269','Positive','Positive Number','false'
'positive troponin or ck mb','C0010290','CK-MB','Creatine Kinase MB Isoenzyme','true'
'ecg findings','C0438154','ecg findings','Electrocardiogram finding','false'
'symmetric t wave inversions','C0332516','Symmetric','Symmetrical','false'
'symmetric t wave inversions','C0520888','T Wave Inversion','Inverted T wave','false'
'symmetric t wave inversions','C2699744','Symmetric','Symmetric Relationship','false'
'iii iv','C0022326','IV','Ivory Coast','true'
'iii iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'stratification factors','C1514984','Stratification Factors','Stratification Factors','false'
'intent to use glycoprotein iib iiia inhibitor','C0162425','intent','Intention - mental process','true'
'intent to use glycoprotein iib iiia inhibitor','C1283828','Intent','intent','false'
'intent to use glycoprotein iib iiia inhibitor','C1550453','intent','Act Mood - intent','false'
'intent to use direct thrombin','C0162425','intent','Intention - mental process','true'
'intent to use direct thrombin','C1283828','Intent','intent','false'
'intent to use direct thrombin','C1550453','intent','Act Mood - intent','false'
'antiplatelet at randomization','C0034656','Randomization','Randomization','true'
'thienopyridine','C1120149','thienopyridine','thienopyridine','true'
'chads $nmbr$ score $nmbr$','C0449820','SCORE','Score','false'
'chads $nmbr$ score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients n','C0030705','Patients','Patients','true'
'mean age sd y','C0444504','Mean','Statistical mean','false'
'mean age sd y','C0001779','AGE','Age','false'
'mean age sd y','C2347634','Mean','Population Mean','false'
'mean age sd y','C2348143','Mean','Sample Mean','false'
'mean weight sd kg','C0022718','KG','Kyrgyzstan','true'
'mean weight sd kg','C0439209','kg','Kilogram','false'
'mean weight sd kg','C4054209','/kg','Per Kilogram','false'
'mean systolic blood pressure sd mm hg','C0428886','Mean blood pressure','Mean blood pressure','true'
'mean systolic blood pressure sd mm hg','C0439475','mmHG','mmHg','false'
'mean systolic blood pressure sd mm hg','C0488053','Mean blood pressure','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'mean diastolic blood pressure sd mm hg','C0428886','Mean blood pressure','Mean blood pressure','true'
'mean diastolic blood pressure sd mm hg','C0439475','mmHG','mmHg','false'
'mean diastolic blood pressure sd mm hg','C0488053','Mean blood pressure','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'men n','C0025266','Men','Male population group','true'
'type of atrial fibrillation n','C0332307','TYPE','Type - attribute','false'
'type of atrial fibrillation n','C1547052','*Type','*Type - Kind of quantity','false'
'chads $nmbr$ components n','C0007928','CHAD','Chad','true'
'chads $nmbr$ components n','C0449432','Components','Component object','false'
'chads $nmbr$ components n','C1413373','CHAD','CHAD gene','false'
'stroke or transient ischemic attack','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or transient ischemic attack','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or transient ischemic attack','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'stroke or transient ischemic attack','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'previous myocardial infarction n','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'previous myocardial infarction n','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'previous myocardial infarction n','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'previous myocardial infarction n','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'previous myocardial infarction n','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'medications in use at baseline n','C0013227','Medications','Pharmaceutical Preparations','true'
'medications in use at baseline n','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications in use at baseline n','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications in use at baseline n','C4284232','Medications','Medications','false'
'medications in use at baseline n','C0150312','In','Present','false'
'medications in use at baseline n','C0042153','use','utilization qualifier','true'
'medications in use at baseline n','C0457083','Use','Usage','false'
'medications in use at baseline n','C1947944','Use','Use - dosing instruction imperative','false'
'medications in use at baseline n','C0332285','In','Within','false'
'medications in use at baseline n','C1707101','IN','CD44 wt Allele','false'
'histamine $nmbr$ receptor antagonist','C0019590','Histamine receptor antagonist','Histamine Antagonists','true'
'histamine $nmbr$ receptor antagonist','C4521896','Histamine receptor antagonist','Histamine receptor antagonist (disposition)','false'
'median time in therapeutic range for warfarin recipients','C1554109','Time Range','Time Range','false'
'median time in therapeutic range for warfarin recipients','C0043031','WARFARIN','Warfarin','true'
'median time in therapeutic range for warfarin recipients','C1709854','Recipient','Recipient','false'
'chads $nmbr$ score per outcome stroke or systemic embolism','C0449820','SCORE','Score','false'
'chads $nmbr$ score per outcome stroke or systemic embolism','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'chads $nmbr$ score per outcome stroke or systemic embolism','C0013922','EMBOLISM','Embolism','true'
'chads $nmbr$ score per outcome stroke or systemic embolism','C1704212','Embolism, NOS','Embolus','true'
'rate in all participants y','C0871208','Rate','Rating (action)','false'
'rate in all participants y','C1521828','Rate','Rate','false'
'dabigatran $nmbr$ mg twice daily','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg twice daily','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg twice daily','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg twice daily','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg twice daily','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg twice daily','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg twice daily','C4521761','MG','United States Military Commissioned Officer O8','false'
'absolute risk reduction $nmbr$ ci y','C3179139','Absolute Risk Reduction','Absolute Risk Reduction','true'
'absolute risk reduction $nmbr$ ci y','C0008107','CI','Chile','true'
'absolute risk reduction $nmbr$ ci y','C3259781','CI','Coagulation Index Measurement','false'
'total events n','C0439175','% total','% of total','false'
'total events n','C0439810','Total','Total','false'
'rate y','C0871208','Rate','Rating (action)','false'
'rate y','C1521828','Rate','Rate','false'
'dabigatran $nmbr$ mg vs warfarin','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg vs warfarin','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg vs warfarin','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg vs warfarin','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg vs warfarin','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg vs warfarin','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg vs warfarin','C4521761','MG','United States Military Commissioned Officer O8','false'
'dabigatran $nmbr$ mg vs warfarin','C0043031','WARFARIN','Warfarin','true'
'vs warfarin','C0043031','WARFARIN','Warfarin','true'
'major bleeding $nmbr$ to $nmbr$','C0205082','Major','Severe (severity modifier)','false'
'major bleeding $nmbr$ to $nmbr$','C0019080','BLEEDING','Hemorrhage','true'
'major bleeding $nmbr$ to $nmbr$','C0205164','Major','Major','false'
'major bleeding $nmbr$ to $nmbr$','C4318856','Major','Major <insect>','false'
'major bleeding $nmbr$ to $nmbr$','C4521762','Major','United States Military Commissioned Officer O4','false'
'$nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'vascular death','C0011065','DEATH','Cessation of life','true'
'vascular death','C1306577','Death','Death (finding)','false'
'vascular death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'vascular death','C4552775','Death NOS','Death NOS, CTCAE','false'
'total death','C0011065','DEATH','Cessation of life','true'
'total death','C1306577','Death','Death (finding)','false'
'total death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'total death','C4552775','Death NOS','Death NOS, CTCAE','false'
'placebo plus statin n $nmbr$','C0032042','Placebo','Placebos','true'
'placebo plus statin n $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo plus statin n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'extended release niacin plus statin n $nmbr$','C0027996','NIACIN','Niacin','true'
'extended release niacin plus statin n $nmbr$','C1142562','Niacin','Vitamin B3 Assay','false'
'distribution no','C0520511','Distribution','Distributing','false'
'distribution no','C1704711','Distribution','Distribution','true'
'american indian alaskan native or aboriginal canadian','C0886378','American native','Native American Healing','false'
'american indian alaskan native or aboriginal canadian','C0935542','aboriginal','aborigines','false'
'american indian alaskan native or aboriginal canadian','C0238884','CANADIAN','Canadian','false'
'multiracial or other','C1881928','Multiracial','Multiracial','false'
'hispanic or non hispanic ethnic group no f','C0086409','HISPANIC','Hispanics','true'
'hispanic or non hispanic ethnic group no f','C0015031','Ethnic Group','Ethnic group','true'
'hispanic or non hispanic ethnic group no f','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'hispanic or non hispanic ethnic group no f','C0016327','F-','Fluorides','true'
'presenting history or diagnosis no','C0449450','Presenting','Presentation','false'
'presenting history or diagnosis no','C0019664','History','History','true'
'presenting history or diagnosis no','C0019665','history','Historical aspects qualifier','true'
'presenting history or diagnosis no','C0262512','History, NOS','History of present illness','false'
'presenting history or diagnosis no','C0262926','History','Medical History','false'
'presenting history or diagnosis no','C1705255','History','Concept History','false'
'presenting history or diagnosis no','C2004062','History','History of previous events','false'
'presenting history or diagnosis no','C0011900','DIAGNOSIS','Diagnosis','true'
'presenting history or diagnosis no','C1704338','diagnosis','diagnosis aspect','true'
'presenting history or diagnosis no','C1704656','DIAGNOSIS','Diagnosis Study','false'
'history of myocardial infarction','C1275835','History of - myocardial infarction','History of myocardial infarction','false'
'stroke or cerebrovascular disease','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or cerebrovascular disease','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or cerebrovascular disease','C0007820','CEREBROVASCULAR DISEASE','Cerebrovascular Disorders','true'
'laboratory values in patients with history of diabetes','C0022877','LABORATORY','Laboratory','true'
'laboratory values in patients with history of diabetes','C0042295','Values','Values','false'
'laboratory values in patients with history of diabetes','C3244292','laboratory','Laboratory domain','false'
'laboratory values in patients with history of diabetes','C4283904','Laboratory','Laboratory observation','false'
'laboratory values in patients with history of diabetes','C0019664','History','History','true'
'laboratory values in patients with history of diabetes','C0019665','history','Historical aspects qualifier','true'
'laboratory values in patients with history of diabetes','C0262512','History, NOS','History of present illness','false'
'laboratory values in patients with history of diabetes','C0262926','History','Medical History','false'
'laboratory values in patients with history of diabetes','C1705255','History','Concept History','false'
'laboratory values in patients with history of diabetes','C2004062','History','History of previous events','false'
'insulin tu ml','C0439526','/mL','/mL','false'
'insulin tu ml','C1705224','ML','THPO wt Allele','false'
'insulin tu ml','C3887665','ML','Thrombopoietin, human','false'
'concomitant medications no','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications no','C4284232','Medications','Medications','false'
'use at baseline','C0042153','use','utilization qualifier','true'
'use at baseline','C0457083','Use','Usage','false'
'use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'duration of prior statin therapy^','C0444917','Duration of therapy','Duration of therapy','false'
'previous use of niacin or niaspan','C1524063','Use of','Use of','false'
'previous use of niacin or niaspan','C0027996','NIACIN','Niacin','true'
'previous use of niacin or niaspan','C1142562','Niacin','Vitamin B3 Assay','false'
'previous use of niacin or niaspan','C1161310','Niaspan','Niaspan','false'
'aspirin or other antiplatelet or anticoagulant agent','C0004057','ASPIRIN','Aspirin','true'
'aspirin or other antiplatelet or anticoagulant agent','C0003280','Anticoagulant Agent','Anticoagulants','true'
'baseline hemoglobin aj^ values','C0004486','AJ','Azerbaijan','true'
'baseline hemoglobin aj^ values','C0042295','Values','Values','false'
'baseline hemoglobin aj^ values','C0230613','AJ','Zonula Adherens','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'hemoglobin aj^','C0004486','AJ','Azerbaijan','true'
'hemoglobin aj^','C0230613','AJ','Zonula Adherens','true'
'diabetes duration y','C0011847','Diabetes','Diabetes','false'
'diabetes duration y','C0011849','Diabetes','Diabetes Mellitus','true'
'baseline alc category','C0683312','Category','Categories','false'
'baseline alc category','C3889287','Category','Digital Content Category','false'
'liraglutide $nmbr$ $nmbr$ mg oad','C0024671','MG','Mammography','true'
'liraglutide $nmbr$ $nmbr$ mg oad','C0026410','MG','Mongolia','true'
'liraglutide $nmbr$ $nmbr$ mg oad','C0439269','mg%','mg/dL','false'
'liraglutide $nmbr$ $nmbr$ mg oad','C1960952','mg %','Milligram percent','false'
'liraglutide $nmbr$ $nmbr$ mg oad','C2346927','Mg++','Magnesium Cation','false'
'liraglutide $nmbr$ $nmbr$ mg oad','C4321396','MG','MG','false'
'liraglutide $nmbr$ $nmbr$ mg oad','C4521761','MG','United States Military Commissioned Officer O8','false'
'sitagliptin oad','C1565750','SITAGLIPTIN','sitagliptin','true'
'exenatide oad','C0167117','EXENATIDE','exenatide','true'
'alc at weeko','C1424945','ALC','ALLC gene','false'
'alc at weeko','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'l i $nmbr$ $nmbr$','C0021966','I-','Iodides','true'
'l i $nmbr$ $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'alc at week $nmbr$','C1424945','ALC','ALLC gene','false'
'alc at week $nmbr$','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'$nmbr$ $nmbr$ g l','C0439294','g l','Kilogram per Cubic Meter','false'
'$nmbr$ $nmbr$ g l','C0456615','G/L','Billion per Liter','false'
'alc $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1424945','ALC','ALLC gene','false'
'alc $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3811058','ALC','Absolute Blood Lymphocyte Count','false'
'of patients','C0030705','Patients','Patients','true'
'$nmbr$ $nmbr$ fi $nmbr$','C4050619','FI','Flexibility Index','false'
'value','C1522609','Value','Numerical value','false'
'white no','C0007457','WHITE','Caucasoid Race','true'
'white no','C0043157','WHITE','Caucasians','true'
'white no','C0220938','WHITE','White color','false'
'black no','C0005680','Black','Black race','true'
'black no','C0027567','Black','African race','true'
'black no','C0085756','BLACK','African American','true'
'black no','C0439541','Black','Black color','false'
'taking antihypertensive treatment at','C0003364','anti hypertensive','Antihypertensive Agents','true'
'taking antihypertensive treatment at','C0039798','treatment','therapeutic aspects','true'
'taking antihypertensive treatment at','C0087111','Treatment','Therapeutic procedure','true'
'taking antihypertensive treatment at','C1522326','Treatment','Treating','false'
'taking antihypertensive treatment at','C1533734','Treatment','Administration procedure','false'
'taking antihypertensive treatment at','C1705169','Treatment','Biomaterial Treatment','false'
'taking antihypertensive treatment at','C3538994','TREATMENT','Treatment Epoch','false'
'taking antihypertensive treatment at','C3887704','treatment','treatment - ActInformationManagementReason','false'
'baseline no','C0168634','baseline','BaseLine dental cement','true'
'baseline no','C1442488','Baseline','Baseline','false'
'treated at baseline mean sd mm hg','C1522326','Treated','Treating','false'
'treated at baseline mean sd mm hg','C0439475','mmHG','mmHg','false'
'untreated at baseline mean sd mm hg','C0332155','untreated','Did not receive therapy or drug for','false'
'untreated at baseline mean sd mm hg','C0439475','mmHG','mmHg','false'
'eligibility risk factorsa','C0013893','Eligibility','Eligibility Determination','true'
'eligibility risk factorsa','C0035647','Risk','Risk','true'
'eligibility risk factorsa','C4552904','risk','Subject Risk','false'
'eligibility risk factorsa','C1548635','Eligibility','Eligible','false'
'cigarette smoker no','C0337667','Cigarette Smoker','Cigarette smoker (finding)','false'
'ascvd b no','C3665365','ASCVD','Arteriosclerotic cardiovascular disease, NOS','false'
'history of mi or stroke no','C0019664','History','History','true'
'history of mi or stroke no','C0019665','history','Historical aspects qualifier','true'
'history of mi or stroke no','C0262512','History, NOS','History of present illness','false'
'history of mi or stroke no','C0262926','History','Medical History','false'
'history of mi or stroke no','C1705255','History','Concept History','false'
'history of mi or stroke no','C2004062','History','History of previous events','false'
'history of mi or stroke no','C0038454','STROKE','Cerebrovascular accident','true'
'history of mi or stroke no','C4554100','Stroke','Stroke, CTCAE','false'
'history of coronary revascularization no','C0019664','History','History','true'
'history of coronary revascularization no','C0019665','history','Historical aspects qualifier','true'
'history of coronary revascularization no','C0262512','History, NOS','History of present illness','false'
'history of coronary revascularization no','C0262926','History','Medical History','false'
'history of coronary revascularization no','C1705255','History','Concept History','false'
'history of coronary revascularization no','C2004062','History','History of previous events','false'
'other ascvd no','C3665365','ASCVD','Arteriosclerotic cardiovascular disease, NOS','false'
'st t wave no','C0036056','ST','Saint Lucia','true'
'st t wave no','C0429103','T wave','T wave feature','false'
'st t wave no','C3272372','ST','Character String Data Type','false'
'lvh by ecg or echocardiography no','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'lvh by ecg or echocardiography no','C0013516','ECHOCARDIOGRAPHY','Echocardiography','true'
'lvh by minnesota code no','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by minnesota code no','C0009219','code','Coding','true'
'lvh by minnesota code no','C0805701','CODE','Code','false'
'lvh by minnesota code no','C3889831','Code','eTMF Content Model Code','false'
'diabetes no c','C0011847','Diabetes','Diabetes','false'
'diabetes no c','C0011849','Diabetes','Diabetes Mellitus','true'
'history of chd at baseline no','C0019664','History','History','true'
'history of chd at baseline no','C0019665','history','Historical aspects qualifier','true'
'history of chd at baseline no','C0262512','History, NOS','History of present illness','false'
'history of chd at baseline no','C0262926','History','Medical History','false'
'history of chd at baseline no','C1705255','History','Concept History','false'
'history of chd at baseline no','C2004062','History','History of previous events','false'
'history of chd at baseline no','C0168634','baseline','BaseLine dental cement','true'
'history of chd at baseline no','C1442488','Baseline','Baseline','false'
'lipid trial participants no','C1997894','Trial participant','Clinical trial participant (person)','false'
'lipid trial participants no','C2242969','Trial participant','clinical trial participant (history)','false'
'non cardiovascular mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'non cardiovascular mortality','C0026566','mortality','Aspects of mortality statistics','true'
'fatal chd nonfatal ml','C0439526','/mL','/mL','false'
'fatal chd nonfatal ml','C1705224','ML','THPO wt Allele','false'
'fatal chd nonfatal ml','C3887665','ML','Thrombopoietin, human','false'
'fatal nonfatal ccvd','C1302234','Fatal','Fatal','false'
'fatal nonfatal ccvd','C1705232','FATAL','Death Related to Adverse Event','false'
'fatal nonfatal hospitalized heart failure','C0018801','Failure, Heart','Heart failure','true'
'fatal nonfatal hospitalized heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'fatal nonfatal hospitalized heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'fatal nonfatal hospitalized stroke','C0038454','STROKE','Cerebrovascular accident','true'
'fatal nonfatal hospitalized stroke','C4554100','Stroke','Stroke, CTCAE','false'
'kidney disease usrds','C0022658','KIDNEY DISEASE','Kidney Diseases','true'
'age $nmbr$ $nmbr$ y','C0001779','AGE','Age','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os','C0229090','OS','Left eye structure','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os','C0230028','Os','Oral region','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os','C0262950','Os','Skeletal bone','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os','C0393706','OS','Early infantile epileptic encephalopathy with suppression bursts','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ os','C1561953','Os','Supernumerary mandibular left central primary incisor','false'
'cangrelor','C1121991','CANGRELOR','cangrelor','true'
'comparator','C1707454','Comparator','Comparator Device','false'
'comparator','C4553389','comparator','Study Control','false'
'comparator','C4553390','Comparator','Comparator','false'
'or [ $nmbr$ cl]','C0596019','Cl -','Chloride Ion','false'
'death udmi idr','C0011065','DEATH','Cessation of life','true'
'death udmi idr','C1306577','Death','Death (finding)','false'
'death udmi idr','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death udmi idr','C4552775','Death NOS','Death NOS, CTCAE','false'
'death q mi idr','C0011065','DEATH','Cessation of life','true'
'death q mi idr','C1306577','Death','Death (finding)','false'
'death q mi idr','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death q mi idr','C4552775','Death NOS','Death NOS, CTCAE','false'
'death q ml stent thrombosis','C0011065','DEATH','Cessation of life','true'
'death q ml stent thrombosis','C3897493','Stent Thrombosis','Stent Thrombosis','false'
'death q ml stent thrombosis','C1306577','Death','Death (finding)','false'
'death q ml stent thrombosis','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death q ml stent thrombosis','C4552775','Death NOS','Death NOS, CTCAE','false'
'diabetic yes','C1549445','Yes','Yes - Yes/no indicator','false'
'diabetic yes','C1705108','YES','Yes (indicator)','false'
'diabetic yes','C1710701','Yes','YES1 wt Allele','false'
'diabetic no','C0241863','DIABETIC','diabetic','false'
'prior thienopyridine','C0332152','Prior','Before','false'
'prior thienopyridine','C1120149','thienopyridine','thienopyridine','true'
'prior thienopyridine','C2826257','PRIOR','Prior Medication Usage','false'
'gfr $nmbr$','C0017654','GFR','Glomerular Filtration Rate','true'
'gfr $nmbr$','C1424601','GFR','RAPGEF5 gene','false'
'parameter','C0549193','Parameter','Parameter Value','false'
'parameter','C1704769','Parameter','Programming Parameter','false'
'parameter','C2350001','Parameter','Population Parameter','false'
'subjects stratified by baseline pra','C0681850','Subject','Study Subject','false'
'subjects stratified by baseline pra','C1550501','{Subject}','Subject -direct target','false'
'subjects stratified by baseline pra','C1706203','Subject','Subject - topic','false'
'subjects stratified by baseline pra','C2349001','Subject','Human Study Subject','false'
'subjects stratified by baseline pra','C2697811','Subject','Investigative Subject','false'
'subjects stratified by baseline pra','C0205363','Stratified','Stratified','false'
'subjects stratified by baseline pra','C0168634','baseline','BaseLine dental cement','true'
'subjects stratified by baseline pra','C1442488','Baseline','Baseline','false'
'low renin pra','C0633231','PRA','S100A6 protein, human','true'
'low renin pra','C1141951','PRA','Panel-reactive antibody','false'
'low renin pra','C1419788','PRA','S100A6 gene','false'
'low renin pra','C3274822','PRA','S100A6 wt Allele','false'
'low renin pra','C3669212','PRA','Progressive retinal atrophy','false'
'low renin pra','C4283900','PRA','Progesterone Receptor Isoform A, Human','false'
'normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$','C1533072','ng/mL/h','Nanograms per milliliter per hour','false'
'normal high renin pra $nmbr$ $nmbr$ ng ml h n $nmbr$','C4050009','ng/mL/h','Microgram per Liter per Hour','false'
'received antihypertensive within last $nmbr$ days n','C0003364','anti hypertensive','Antihypertensive Agents','true'
'received antihypertensive within last $nmbr$ days n','C0439228','DAYS','day','false'
'diabetic n','C0241863','DIABETIC','diabetic','false'
'mssbp sd mmhg','C2699239','SD','SD, Rat Strain','false'
'mssbp sd mmhg','C0439475','mmHG','mmHg','false'
'msdbp sd mmhg','C2699239','SD','SD, Rat Strain','false'
'msdbp sd mmhg','C0439475','mmHG','mmHg','false'
'pra median min max ng ml h','C1533072','ng/mL/h','Nanograms per milliliter per hour','false'
'pra median min max ng ml h','C4050009','ng/mL/h','Microgram per Liter per Hour','false'
'african american n $nmbr$','C0085756','AFRICAN AMERICAN','African American','true'
'caucasian n $nmbr$ $nmbr$','C0007457','Caucasian','Caucasoid Race','true'
'caucasian n $nmbr$ $nmbr$','C0043157','Caucasian','Caucasians','true'
'alcohol use n','C0001948','ALCOHOL USE','Alcohol consumption','true'
'drinker $nmbr$ $nmbr$ drinks week','C0332174','/week','Weekly','false'
'drinker $nmbr$ $nmbr$ drinks week','C0439230','Week','week','false'
'non ex tobacco user','C1518422','Non','Negation','false'
'non ex tobacco user','C3853727','Tobacco user','Tobacco user','false'
'tobacco user','C3853727','Tobacco user','Tobacco user','false'
'tophi present n','C0221248','Tophi','Tophus','false'
'tophi present n','C0150312','PRESENT','Present','false'
'tophi present n','C0449450','Present','Presentation','false'
'renal function bn','C0005005','BN','Benin Republic','true'
'renal function bn','C0034700','BN','Rats, Inbred BN','true'
'renal function bn','C1706574','BN','GRP wt Allele','false'
'renal function bn','C4551963','BN','BULIMIA NERVOSA, SUSCEPTIBILITY TO','false'
'any cardiovascular disease','C0007222','Cardiovascular Disease','Cardiovascular Diseases','true'
'cardiac arrhythmia','C0003811','Arrhythmia, Cardiac','Cardiac Arrhythmia','true'
'cardiac arrhythmia','C0264886','CARDIAC Arrythmia','Conduction disorder of the heart','true'
'cardiac arrhythmia','C1560249','CARDIAC ARRHYTHMIA','Adverse Event Associated with Cardiac Arrhythmia','false'
'use of low dose aspirin $nmbr$ mg daily','C1524063','Use of','Use of','false'
'use of low dose aspirin $nmbr$ mg daily','C2608320','Low-Dose Aspirin','Low-Dose Aspirin','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C1280519','Efficacy','Effectiveness','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C1707887','EFFICACY','Efficacy Study','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C0085756','AFRICAN AMERICAN','African American','true'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C0681850','Subject','Study Subject','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C1550501','{Subject}','Subject -direct target','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C1706203','Subject','Subject - topic','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C2349001','Subject','Human Study Subject','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C2697811','Subject','Investigative Subject','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C2945599','Mild','Mild (qualifier value)','false'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C1565489','Renal Impairment','Renal Insufficiency','true'
'figure $nmbr$ comparative efficacy of urate lowering therapy between african american and caucasian subjects within treatment groups a all subjects b subjects with mild renal impairment eclcr $nmbr$ to $nmbr$ ml min and c subjects with moderate renal impairment eclcr $nmbr$ to $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'semuloparin n $nmbr$','C2700104','SEMULOPARIN','semuloparin','true'
'hazard ratio $nmbr$ ci j','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio $nmbr$ ci j','C0008107','CI','Chile','true'
'hazard ratio $nmbr$ ci j','C3259781','CI','Coagulation Index Measurement','false'
'any vte or vte related death no','C0630906','vte','vinyltriethoxysilane','true'
'any vte or vte related death no','C0011065','DEATH','Cessation of life','true'
'any vte or vte related death no','C1306577','Death','Death (finding)','false'
'any vte or vte related death no','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'any vte or vte related death no','C4552775','Death NOS','Death NOS, CTCAE','false'
'symptomatic deep vein thrombosis','C0231220','Symptomatic','Symptomatic','false'
'symptomatic deep vein thrombosis','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'upper limbs','C1140618','Upper Limbs','Upper Extremity','true'
'lower limbs','C0023216','Lower Limbs','Lower Extremity','true'
'proximal','C0205107','PROXIMAL','Proximal','false'
'proximal','C4489236','Proximal','Proximal Resection Margin','false'
'distal','C0205108','DISTAL','Distal (qualifier value)','false'
'distal','C4522154','Distal','Distal Resection Margin','false'
'pulmonary embolism','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'symptomatic','C0231220','Symptomatic','Symptomatic','false'
'detected during tumor evaluation','C0442726','Detected','Detected (finding)','false'
'detected during tumor evaluation','C1511790','Detected','Detection','false'
'ne','C0027608','Ne','Neon','true'
'ne','C0028219','NE','Niue','true'
'ne','C3538705','NE','ELANE wt Allele','false'
'any vte related death','C0011065','DEATH','Cessation of life','true'
'any vte related death','C1306577','Death','Death (finding)','false'
'any vte related death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'any vte related death','C4552775','Death NOS','Death NOS, CTCAE','false'
'outcome according to primary cancer site no total no','C1274040','Outcome','Result','false'
'outcome according to primary cancer site no total no','C0872338','primary cancer site','cancer location','false'
'outcome according to primary cancer site no total no','C0439175','% total','% of total','false'
'outcome according to primary cancer site no total no','C0439810','Total','Total','false'
'lung','C0024109','LUNG','Lung','true'
'pancreas','C0030274','PANCREAS','Pancreas','true'
'stomach','C0038351','STOMACH','Stomach','true'
'stomach','C3714551','Stomach','Stomach structure','false'
'colon or rectum','C0009368','COLON','Colon structure (body structure)','true'
'colon or rectum','C3888384','Colon','Colon <insect>','false'
'colon or rectum','C0034896','RECTUM','Rectum','true'
'bladder','C0005682','BLADDER','Urinary Bladder','true'
'bladder','C4319531','Bladder','Bladder Continence Question','false'
'ovary','C0029939','OVARY','Ovary','true'
'ovary','C0227898','ovary','Both ovaries','false'
'outcome according to stage of cancer no total no','C1274040','Outcome','Result','false'
'outcome according to stage of cancer no total no','C0027646','cancer stage','Diagnostic Neoplasm Staging','true'
'outcome according to stage of cancer no total no','C0439175','% total','% of total','false'
'outcome according to stage of cancer no total no','C0439810','Total','Total','false'
'metastatic','C0036525','Metastatic','Metastatic to','false'
'metastatic','C1522484','metastatic','metastatic qualifier','true'
'metastatic','C4085632','METASTATIC','Metastatic Disease Clinical Trial Setting','false'
'locally advanced','C1517927','Locally','Locally','false'
'locally advanced','C0205179','Advanced','Advanced phase','false'
'outcome according to no of risk factors for vte','C1274040','Outcome','Result','false'
'outcome according to no of risk factors for vte','C0035648','Risk Factors','risk factors','true'
'outcome according to no of risk factors for vte','C1553898','risk factors','risk factors - observation list','false'
'outcome according to no of risk factors for vte','C0630906','vte','vinyltriethoxysilane','true'
'total phase $nmbr$ pooled n $nmbr$','C0439175','% total','% of total','false'
'total phase $nmbr$ pooled n $nmbr$','C0205390','Phase','Phase','false'
'total phase $nmbr$ pooled n $nmbr$','C1710475','phase','Trial Phase','false'
'total phase $nmbr$ pooled n $nmbr$','C0439810','Total','Total','false'
'low complement anti dsdna positive n $nmbr$','C0432633','Anti N','Blood group antibody N','false'
'mean selena sledai score sd','C3533236','Mean score','Mean score','false'
'mean selena sledai score sd','C2699239','SD','SD, Rat Strain','false'
'selena sledai $nmbr$','C0451528','SLEDAI','Systemic lupus erythematosus disease activity index','false'
'proteinuria $nmbr$ g $nmbr$ h','C0033687','PROTEINURIA','Proteinuria','true'
'proteinuria $nmbr$ g $nmbr$ h','C0560020','g h','g/h','false'
'proteinuria $nmbr$ g $nmbr$ h','C1962972','Proteinuria','Proteinuria, CTCAE 3.0','false'
'proteinuria $nmbr$ g $nmbr$ h','C4554346','Proteinuria','Proteinuria, CTCAE 5.0','false'
'anti dsdna $nmbr$ iu ml','C0741099','anti ds dna','anti ds dna','false'
'anti dsdna $nmbr$ iu ml','C0439458','IU/mL','IU/mL','false'
'igg $nmbr$ $nmbr$ g l','C0439294','g l','Kilogram per Cubic Meter','false'
'igg $nmbr$ $nmbr$ g l','C0456615','G/L','Billion per Liter','false'
'low c $nmbr$','C0205251','Low','low','false'
'low c $nmbr$','C1550472','low','low confidentiality','false'
'low c $nmbr$','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low c $nmbr$','C4048187','low','low exposure','false'
'low c $nmbr$','C4321351','Low','Low Level','false'
'low c $nmbr$','C4522223','Low','IPSS Risk Category Low','false'
'corticosteroid use','C0239126','CORTICOSTEROID USE','corticosteroid use','false'
'$nmbr$ $nmbr$ mg day','C0439422','mg day','milligram/day','false'
'immunosuppressant use','C0042153','use','utilization qualifier','true'
'immunosuppressant use','C0457083','Use','Usage','false'
'immunosuppressant use','C1947944','Use','Use - dosing instruction imperative','false'
'mean slicc damage index score sd','C3533236','Mean score','Mean score','false'
'mean slicc damage index score sd','C2699239','SD','SD, Rat Strain','false'
'mean pga score sd','C3533236','Mean score','Mean score','false'
'mean pga score sd','C2699239','SD','SD, Rat Strain','false'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C0024141','SLE NOS','Lupus Erythematosus, Systemic','true'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C0600653','Index','Indexes','true'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C0918012','Index','Index','true'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C1552854','index','Html Link Type - index','false'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C1637833','% index','% index','false'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C2986546','Index','Target Lesion Identification','false'
'figure $nmbr$ or for sle responder index rates in univariate disease activity subgroup analysis','C0683962','univariate analysis','univariate statistics','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0205126','Horizontal','Horizontal','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0205132','lines','Linear','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0008107','CI','Chile','true'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0458097','Vertical reference line','Vertical reference line','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C3259781','CI','Coagulation Index Measurement','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1882932','Represent','Representation (action)','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1705241','*Difference','Delta (difference)','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1705242','Difference','Different','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0032042','Placebo','Placebos','true'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1696465','PLACEBO','placebo','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1706408','PLACEBO','Placebo Control','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1552961','POINT','point - UnitsOfMeasure','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C2347617','point','Point Name','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C3714763','Point','Point','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0205250','Higher','High','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0871261','responses','Response process','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0441994','LOWER','Lower - spatial qualifier','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1548802','Lower','Body Site Modifier - Lower','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C2003888','Lower','Lower (action)','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0750572','estimates','Estimated','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1518681','Treatment Effect','Outcome of Therapy','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0205128','Vertical','Vertical','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1723401','BELIMUMAB','belimumab','true'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C0439272','mg kg','ug/g','false'
'horizontal lines are $nmbr$ ci vertical dashed reference lines represent or of $nmbr$ which indicates no difference between belimumab and placebo while points to right of lines indicate higher responses for belimumab versus placebo and points to left of line indicate lower responses for belimumab versus placebo point estimates for or for overall treatment effect coloured solid vertical lines are $nmbr$ $nmbr$ for belimumab $nmbr$ mg kg and $nmbr$ $nmbr$ for $nmbr$ mg kg interaction p','C1704675','Interaction','Interaction','false'
'troponin positive n $nmbr$','C0041199','Troponin','Troponin','true'
'troponin positive n $nmbr$','C0439178','% Positive','percent positive cells','false'
'troponin positive n $nmbr$','C1446409','Positive','Positive','false'
'troponin positive n $nmbr$','C1514241','POSITIVE','Positive Finding','false'
'troponin positive n $nmbr$','C2825490','Positive','Positive Charge','false'
'troponin positive n $nmbr$','C3812269','Positive','Positive Number','false'
'troponin negative n $nmbr$','C0041199','Troponin','Troponin','true'
'troponin negative n $nmbr$','C0205160','Negative','Negative','false'
'troponin negative n $nmbr$','C1513916','NEGATIVE','Negative Finding','false'
'troponin negative n $nmbr$','C2825415','Negative','Negative Number','false'
'troponin negative n $nmbr$','C2825491','Negative','Negative Charge','false'
'troponin negative n $nmbr$','C3853545','Negative','Negative - answer','false'
'age median [iqr] y','C0549183','Median','Midline (qualifier value)','false'
'age median [iqr] y','C0876920','Median','Median Statistical Measurement','false'
'age median [iqr] y','C2347635','Median','Population Median','false'
'age median [iqr] y','C2348144','Median','Sample Median','false'
'age median [iqr] y','C2939193','Median','Median (qualifier value)','false'
'weight median [iqr] kg','C0549183','Median','Midline (qualifier value)','false'
'weight median [iqr] kg','C0876920','Median','Median Statistical Measurement','false'
'weight median [iqr] kg','C2347635','Median','Population Median','false'
'weight median [iqr] kg','C2348144','Median','Sample Median','false'
'weight median [iqr] kg','C2939193','Median','Median (qualifier value)','false'
'weight median [iqr] kg','C0022718','KG','Kyrgyzstan','true'
'weight median [iqr] kg','C0439209','kg','Kilogram','false'
'weight median [iqr] kg','C4054209','/kg','Per Kilogram','false'
'insulin treated diabetes','C0011847','Diabetes','Diabetes','false'
'insulin treated diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'high risk','C0332167','HIGH RISK','High risk of','false'
'high risk','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'high risk','C4050568','High Risk','High Risk Acute Leukemia','false'
'high risk','C4319571','High risk','High risk','false'
'cardiac biomarker elevation','C0439775','Elevation','Elevation procedure','false'
'cardiac biomarker elevation','C0702240','Elevation','Elevation','false'
'st segment deviation timi risk score','C0035647','Risk','Risk','true'
'st segment deviation timi risk score','C0449820','SCORE','Score','false'
'st segment deviation timi risk score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'st segment deviation timi risk score','C4552904','risk','Subject Risk','false'
'white blood cell count cellsx $nmbr$','C0023508','Blood Cell Count, White','White Blood Cell Count procedure','true'
'white blood cell count cellsx $nmbr$','C0427512','white blood cell count','White blood cell count laboratory result','false'
'hemoglobin g dl','C0439267','g/dL','Gram per Deciliter','false'
'golimumab $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'golimumab $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'golimumab $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'golimumab $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'golimumab $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'golimumab $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'golimumab $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'sex no male','C0009253','Sex','Coitus','true'
'sex no male','C0036864','Sex','Sex Behavior','true'
'sex no male','C0079399','sex','Gender','true'
'sex no male','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex no male','C1314687','Sex','Sexual intercourse - finding','false'
'sex no male','C1522384','SEX','sex','true'
'sex no male','C0086582','MALE','Males','true'
'sex no male','C1706180','Male','Male Gender, Self Report','false'
'sex no male','C1706428','MALE','Male Phenotype','false'
'sex no male','C1706429','Male','Male, Self-Reported','false'
'race no white','C0034510','RACE','Racial group','true'
'race no white','C1706779','RACE','AMACR wt Allele','false'
'race no white','C3853635','Race','Race','false'
'race no white','C0007457','WHITE','Caucasoid Race','true'
'race no white','C0043157','WHITE','Caucasians','true'
'race no white','C0220938','WHITE','White color','false'
'psa duration years','C0449238','Duration','Duration (temporal concept)','false'
'psa duration years','C0439234','YEARS','year','false'
'psa duration years','C2926735','Duration','Duration','false'
'number of swollen joints $nmbr$ assessed','C0449813','Number of joints','Number of joints','false'
'number of tender joints $nmbr$ assessed','C0449813','Number of joints','Number of joints','false'
'das $nmbr$ crp','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'das $nmbr$ crp','C4048285','CRP','C-Reactive Protein, human','false'
'psa modified shs of hands and feet','C0392747','Modified','Changing','false'
'psa modified shs of hands and feet','C0018563','Hands','Hand','true'
'psa modified shs of hands and feet','C1552914','hand','hand - unit of measure','false'
'psa modified shs of hands and feet','C3889737','Modified','Data Change Date','false'
'psa modified shs of hands and feet','C0016504','Feet','Foot','true'
'psa modified shs of hands and feet','C0347981','feet','Feet, unit of measurement','false'
'erosion score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'erosion score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'erosion score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'jsn score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'jsn score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'jsn score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'total score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'total score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'total score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'no of patients with $nmbr$ bsa affected','C0030705','Patients','Patients','true'
'no of patients with $nmbr$ bsa affected','C0392760','Affected','Affecting','false'
'no of patients with $nmbr$ bsa affected','C1314939','Affected','Involvement with','false'
'bsa affected','C0392760','Affected','Affecting','false'
'bsa affected','C1314939','Affected','Involvement with','false'
'pasi score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'pasi score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'pasi score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'no of patients with fingernail involvement','C0030705','Patients','Patients','true'
'no of patients with fingernail involvement','C0222001','Finger Nail','Structure of nail of finger','true'
'no of patients with fingernail involvement','C1314939','Involvement','Involvement with','false'
'no fingernails','C0222001','Fingernails','Structure of nail of finger','true'
'target nail napsi score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'target nail napsi score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'target nail napsi score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'patients with dactylitis no','C0030705','Patients','Patients','true'
'patients with dactylitis no','C0239161','DACTYLITIS','Dactylitis','false'
'dactylitis score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'dactylitis score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'dactylitis score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'patients with enthesitis no','C0030705','Patients','Patients','true'
'patients with enthesitis no','C1282952','Enthesitis','Enthesitis','false'
'psa modified mases score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'psa modified mases score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'psa modified mases score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'haq score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'haq score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'haq score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'sf $nmbr$ health survey','C0037712','SF','South Africa','true'
'sf $nmbr$ health survey','C0018762','Survey, Health','Health Surveys','true'
'pcs score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'pcs score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'pcs score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'mcs score $nmbr$ $nmbr$ scale','C0175659','Scale','Weight measurement scales','true'
'mcs score $nmbr$ $nmbr$ scale','C0349674','Scale','Intellectual scale','false'
'mcs score $nmbr$ $nmbr$ scale','C1947916','Scale','Scaling','false'
'patients taking mtx no','C0025677','MTX','Methotrexate','true'
'patients taking mtx no','C1417487','MTX','MTX1 gene','false'
'mean median mtx dose mg week','C0332174','/week','Weekly','false'
'mean median mtx dose mg week','C0439230','Week','week','false'
'golimumab combined n $nmbr$','C2353893','GOLIMUMAB','golimumab','true'
'golimumab combined n $nmbr$','C0205195','Combined','Combined','false'
'change in psa modified shs baseline to week $nmbr$','C0392747','Change','Changing','false'
'change in psa modified shs baseline to week $nmbr$','C0443172','change','Changed status','false'
'change in psa modified shs baseline to week $nmbr$','C1705241','Change','Delta (difference)','false'
'change in psa modified shs baseline to week $nmbr$','C4319952','Change','Change -- procedure','false'
'change in psa modified shs baseline to week $nmbr$','C0332174','/week','Weekly','false'
'change in psa modified shs baseline to week $nmbr$','C0439230','Week','week','false'
'total score','C2964552','Total Score','Total score','false'
'mtx at baseline','C0025677','MTX','Methotrexate','true'
'mtx at baseline','C1417487','MTX','MTX1 gene','false'
'p vs placebo','C0369773','P NOS','P Blood group antibodies','false'
'p vs placebo','C2603361','P'','P prime','false'
'p vs placebo','C0032042','Placebo','Placebos','true'
'p vs placebo','C1696465','PLACEBO','placebo','false'
'p vs placebo','C1706408','PLACEBO','Placebo Control','false'
'no mtx at baseline','C0025677','MTX','Methotrexate','true'
'no mtx at baseline','C1417487','MTX','MTX1 gene','false'
'hands','C0018563','Hands','Hand','true'
'hands','C1552914','hand','hand - unit of measure','false'
'erosion score','C0449820','SCORE','Score','false'
'erosion score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'jsn score','C0449820','SCORE','Score','false'
'jsn score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'total hands score','C2964552','Total Score','Total score','false'
'total hands score','C0018563','Hands','Hand','true'
'total hands score','C1552914','hand','hand - unit of measure','false'
'feet','C0016504','Feet','Foot','true'
'feet','C0347981','feet','Feet, unit of measurement','false'
'total feet score','C2964552','Total Score','Total score','false'
'total feet score','C0016504','Feet','Foot','true'
'total feet score','C0347981','feet','Feet, unit of measurement','false'
'additional radiographic findings at week $nmbr$','C2607943','findings','findings aspects','true'
'additional radiographic findings at week $nmbr$','C2926606','Findings','Procedure findings:Finding:Point in time:^Patient:Narrative','false'
'additional radiographic findings at week $nmbr$','C3539655','FINDINGS','CDISC Findings Class','false'
'no new erosions among patients with $nmbr$ uninvolved joint at baseline','C0333307','erosions','Superficial ulcer','false'
'no new erosions among patients with $nmbr$ uninvolved joint at baseline','C1959609','Erosions','Erosion lesion','false'
'no new erosions among patients with $nmbr$ uninvolved joint at baseline','C0022417','JOINT','Joints','true'
'no new erosions among patients with $nmbr$ uninvolved joint at baseline','C0392905','Joint, NOS','Articular system','false'
'no new erosions among patients with $nmbr$ uninvolved joint at baseline','C1706309','Joint','Joint Device','false'
'no new jsn among patients with $nmbr$ uninvolved joint at baseline','C0205314','New','New','false'
'no new jsn among patients with $nmbr$ uninvolved joint at baseline','C0030705','Patients','Patients','true'
'no new jsn among patients with $nmbr$ uninvolved joint at baseline','C0022417','JOINT','Joints','true'
'no new jsn among patients with $nmbr$ uninvolved joint at baseline','C0392905','Joint, NOS','Articular system','false'
'no new jsn among patients with $nmbr$ uninvolved joint at baseline','C1706309','Joint','Joint Device','false'
'radiographic progression based on change from baseline sdc','C0242656','Progression','Disease Progression','true'
'radiographic progression based on change from baseline sdc','C0449258','Progression','Progression','false'
'radiographic progression based on change from baseline sdc','C1527178','Based','Basis - conceptual entity','false'
'radiographic progression based on change from baseline sdc','C1705938','Based','Base - General Qualifier','false'
'radiographic progression based on change from baseline sdc','C1419891','SDC','SDC1 gene','false'
'radiographic progression based on change from baseline sdc','C3273112','SDC','SDC1 wt Allele','false'
'total psa modified shs','C2986589','Total PSA','Total PSA','false'
'total psa modified shs','C0392747','Modified','Changing','false'
'total psa modified shs','C3889737','Modified','Data Change Date','false'
'patients with change from baseline in total psa modified shs $nmbr$','C0030705','Patients','Patients','true'
'patients with change from baseline in total psa modified shs $nmbr$','C0392747','Change','Changing','false'
'patients with change from baseline in total psa modified shs $nmbr$','C0443172','change','Changed status','false'
'patients with change from baseline in total psa modified shs $nmbr$','C1705241','Change','Delta (difference)','false'
'patients with change from baseline in total psa modified shs $nmbr$','C4319952','Change','Change -- procedure','false'
'patients with change from baseline in total psa modified shs $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'patients with change from baseline in total psa modified shs $nmbr$','C1442488','Baseline','Baseline','false'
'diabetes bl','C0005918','BL','Bolivia','true'
'diabetes bl','C0006413','BL','Burkitt Lymphoma','true'
'diabetes bl','C1552663','BL','Boolean','false'
'diabetes bl','C2827109','BL','Saint Barthelemy','false'
'idm','C0270221','IDM','Syndrome of infant of diabetic mother','false'
'no diabetes','C0011847','Diabetes','Diabetes','false'
'no diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'no pts','C1419129','PTS','PTS gene','false'
'no pts','C2698747','PTS','Patient Tracking System','false'
'ascvd','C3665365','ASCVD','Arteriosclerotic cardiovascular disease, NOS','false'
'lvh by ecgt blood pressure mm hg','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by ecgt blood pressure mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'lvh by ecgt blood pressure mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'lvh by ecgt blood pressure mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'sbp','C0085805','SBP','Androgen Binding Protein','true'
'dbp','C0536221','DBP','HSD17B4 protein, human','true'
'dbp','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'bmi kg m $nmbr$ cholesterol mg dl','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ cholesterol mg dl','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ cholesterol mg dl','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ cholesterol mg dl','C0008377','CHOLESTEROL','Cholesterol','true'
'bmi kg m $nmbr$ cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'total no of events participants','C0439175','% total','% of total','false'
'total no of events participants','C0439810','Total','Total','false'
'total no of events participants','C0441471','Events','Event','false'
'total no of events participants','C0679646','participants','Participant','false'
'total no of events participants','C3541888','EVENTS','CDISC Events Class','false'
'unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate','C0242444','risk population','Population at Risk','true'
'unadjusted $nmbr$ y risk per $nmbr$ population se adjusted rate','C2987720','Population Risk','Population risk','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0008107','CI','Chile','true'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C3259781','CI','Coagulation Index Measurement','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C1707455','Compared','Comparison','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0011847','Diabetes','Diabetes','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0011849','Diabetes','Diabetes Mellitus','true'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0005918','BL','Bolivia','true'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0006413','BL','Burkitt Lymphoma','true'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C1552663','BL','Boolean','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C2827109','BL','Saint Barthelemy','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0439234','Year','year','false'
'adjusted hr $nmbr$ ci compared with no diabetes at bl or at year $nmbr$','C0439508','/Year','per year','false'
'adjusted hr $nmbr$ ci comparing idm with bl','C0008107','CI','Chile','true'
'adjusted hr $nmbr$ ci comparing idm with bl','C3259781','CI','Coagulation Index Measurement','false'
'adjusted hr $nmbr$ ci comparing idm with bl','C1707455','Compare','Comparison','false'
'adjusted hr $nmbr$ ci comparing idm with bl','C0270221','IDM','Syndrome of infant of diabetic mother','false'
'adjusted hr $nmbr$ ci comparing idm with bl','C0005918','BL','Bolivia','true'
'adjusted hr $nmbr$ ci comparing idm with bl','C0006413','BL','Burkitt Lymphoma','true'
'adjusted hr $nmbr$ ci comparing idm with bl','C1552663','BL','Boolean','false'
'adjusted hr $nmbr$ ci comparing idm with bl','C2827109','BL','Saint Barthelemy','false'
'cvd mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'cvd mortality','C0026566','mortality','Aspects of mortality statistics','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p','C2603361','P'','P prime','false'
'non cvd mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'non cvd mortality','C0026566','mortality','Aspects of mortality statistics','true'
'nonfatal mi fatal chdt','C1302234','Fatal','Fatal','false'
'nonfatal mi fatal chdt','C1705232','FATAL','Death Related to Adverse Event','false'
'lisinopril cvd total','C0439175','% total','% of total','false'
'lisinopril cvd total','C0439810','Total','Total','false'
'no cases','C0868928','Cases','Case (situation)','false'
'no cases','C1533148','Cases','Case unit dose','false'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C0002144','ALLOPURINOL','Allopurinol','true'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'allopurinol $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'participated in a previous febuxostat studyb n','C0205156','Previous','Previous','false'
'participated in a previous febuxostat studyb n','C0249529','FEBUXOSTAT','febuxostat','true'
'participated in a previous febuxostat studyb n','C1552607','previous','Act Relationship Subset - previous','false'
'prior urate lowering therapies n','C1514463','Prior Therapy','Prior Therapy','false'
'prior urate lowering therapies n','C0441994','lowering','Lower - spatial qualifier','false'
'prior urate lowering therapies n','C2003888','Lowering','Lower (action)','false'
'yes any','C1549445','Yes','Yes - Yes/no indicator','false'
'yes any','C1705108','YES','Yes (indicator)','false'
'yes any','C1710701','Yes','YES1 wt Allele','false'
'febuxostat','C0249529','FEBUXOSTAT','febuxostat','true'
'allopurinol','C0002144','ALLOPURINOL','Allopurinol','true'
'probenecid','C0033209','PROBENECID','Probenecid','true'
'renal functionc n','C0022646','Renal','Kidney','true'
'any cardiovascular diseased','C0007226','Cardiovascular','Cardiovascular system','true'
'any cardiovascular diseased','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'use of low dose aspirin','C1524063','Use of','Use of','false'
'use of low dose aspirin','C2608320','Low-Dose Aspirin','Low-Dose Aspirin','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C0444504','Mean','Statistical mean','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C3272907','Percent Change From Baseline','Percent Change From Baseline','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C2347634','Mean','Population Mean','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C2348143','Mean','Sample Mean','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C0455272','Serum Urate','Serum urate measurement','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C0086960','Scheduled','Schedule (document type)','true'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C0205539','SCHEDULED','Scheduled - procedure status','false'
'figure $nmbr$ mean percent change from baseline in serum urate at each scheduled visit','C1571999','Scheduled','Scheduled - priority','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C2603361','P'','P prime','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0002144','ALLOPURINOL','Allopurinol','true'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0024671','MG','Mammography','true'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0026410','MG','Mongolia','true'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0439269','mg%','mg/dL','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C1960952','mg %','Milligram percent','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C2346927','Mg++','Magnesium Cation','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C4321396','MG','MG','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C4521761','MG','United States Military Commissioned Officer O8','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0743559','Error','error','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C1608199','Error','Act Reason - Error','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C1882932','Represent','Representation (action)','false'
'p $nmbr$ $nmbr$ vs allopurinol p $nmbr$ $nmbr$ vs febuxostat $nmbr$ mg p $nmbr$ $nmbr$ vs allopurinol error bars represent standard deviation','C0871420','Standard Deviation','Standard deviation','false'
'vorapaxar n $nmbr$ $nmbr$','C2974521','VORAPAXAR','vorapaxar','true'
'demographic','C0011298','demographic','Demography','true'
'qualifying type of atherosclerosis no','C1514624','Qualifying','Qualifying','false'
'qualifying type of atherosclerosis no','C0332307','TYPE','Type - attribute','false'
'qualifying type of atherosclerosis no','C1547052','*Type','*Type - Kind of quantity','false'
'ischemic stroke','C0948008','Ischaemic stroke','Ischemic stroke','false'
'selected clinical characteristics no total no','C1707391','Selected','Choose (action)','false'
'selected clinical characteristics no total no','C0683325','clinical characteristics','clinical aspects','false'
'selected clinical characteristics no total no','C0439175','% total','% of total','false'
'selected clinical characteristics no total no','C0439810','Total','Total','false'
'any coronary artery disease','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'any coronary artery disease','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'any coronary artery disease','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'any peripheral arterial disease','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'any peripheral arterial disease','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'previous cerebrovascular event','C0441471','Event','Event','false'
'previous cerebrovascular event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'use of antiplatelet agents no total no','C1524063','Use of','Use of','false'
'use of antiplatelet agents no total no','C0085826','Antiplatelet Agents','Antiplatelet Agents','true'
'use of antiplatelet agents no total no','C0439175','% total','% of total','false'
'use of antiplatelet agents no total no','C0439810','Total','Total','false'
'qualifying myocardial infarction','C1514624','Qualifying','Qualifying','false'
'qualifying myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'qualifying myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'qualifying myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'qualifying myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'qualifying myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'qualifying peripheral arterial disease','C1514624','Qualifying','Qualifying','false'
'qualifying peripheral arterial disease','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'qualifying peripheral arterial disease','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'qualifying stroke','C1514624','Qualifying','Qualifying','false'
'qualifying stroke','C0038454','STROKE','Cerebrovascular accident','true'
'qualifying stroke','C4554100','Stroke','Stroke, CTCAE','false'
'dipyridamole','C0012582','DIPYRIDAMOLE','Dipyridamole','true'
'use of other medications no','C1524063','Use of','Use of','false'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C0003015','Angiotensin-Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C2757044','Angiotensin Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors [MoA]','false'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C3536837','Angiotensin Converting Enzyme Inhibitor','Angiotensin Converting Enzyme Inhibitor [EPC]','false'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C4541021','Angiotensin-converting enzyme inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C0034787','Angiotensin Receptor','Angiotensin Receptor','true'
'angiotensin converting enzyme inhibitor or angiotensin receptor blocker','C1622222','Angiotensin Receptor','MAS1 protein, human','true'
'subgroup overall','C1079230','subgroup','Subgroup A Nepoviruses','false'
'subgroup overall','C1515021','Subgroup','Subgroup','false'
'subgroup overall','C0282416','Overall','Overall Publication Type','true'
'subgroup overall','C1561607','Overall','Overall','false'
'total no $nmbr$','C0439175','% total','% of total','false'
'total no $nmbr$','C0439810','Total','Total','false'
'vorapaxar placebo $nmbr$ yr','C0032042','Placebo','Placebos','true'
'vorapaxar placebo $nmbr$ yr','C0439234','yr','year','false'
'vorapaxar placebo $nmbr$ yr','C1696465','PLACEBO','placebo','false'
'vorapaxar placebo $nmbr$ yr','C1706408','PLACEBO','Placebo Control','false'
'hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0596019','Cl -','Chloride Ion','false'
'body weight','C0005910','Body Weight','Body Weight','true'
'body weight','C1305866','body weight','Weighing patient','false'
'qualifying atherosclerosis','C1514624','Qualifying','Qualifying','false'
'qualifying atherosclerosis','C0003850','ATHEROSCLEROSIS','Arteriosclerosis','true'
'qualifying atherosclerosis','C0004153','ATHEROSCLEROSIS','Atherosclerosis','true'
'history of stroke','C0019664','History','History','true'
'history of stroke','C0019665','history','Historical aspects qualifier','true'
'history of stroke','C0262512','History, NOS','History of present illness','false'
'history of stroke','C0262926','History','Medical History','false'
'history of stroke','C1705255','History','Concept History','false'
'history of stroke','C2004062','History','History of previous events','false'
'aspirin at enrollment','C0004057','ASPIRIN','Aspirin','true'
'aspirin at enrollment','C1516879','Enrollment','Enrollment','false'
'aspirin at enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'aspirin at enrollment','C3888021','enrollment','enrollment - coverage','false'
'thienopyridine at enrollment','C1120149','thienopyridine','thienopyridine','true'
'thienopyridine at enrollment','C1516879','Enrollment','Enrollment','false'
'thienopyridine at enrollment','C1696073','enrollment','enrollment - ResearchSubjectRoleBasis','false'
'thienopyridine at enrollment','C3888021','enrollment','enrollment - coverage','false'
'egfr mumin $nmbr$ $nmbr$ m $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr mumin $nmbr$ $nmbr$ m $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr mumin $nmbr$ $nmbr$ m $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'europe i','C0021966','I-','Iodides','true'
'europe i','C0221138','I NOS','Blood group antibody I','false'
'europe ii','C1710602','II','VIPR1 wt Allele','false'
'europe ii','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'australia nz','C0004340','AUSTRALIA','Australia','true'
'australia nz','C0027978','NZ','New Zealand','true'
'vorapaxar placebo','C0032042','Placebo','Placebos','true'
'vorapaxar placebo','C1696465','PLACEBO','placebo','false'
'vorapaxar placebo','C1706408','PLACEBO','Placebo Control','false'
'overall $nmbr$','C0282416','Overall','Overall Publication Type','true'
'overall $nmbr$','C1561607','Overall','Overall','false'
'estimated glomerular filtration','C0750572','Estimated','Estimated','false'
'estimated glomerular filtration','C0232809','Glomerular filtration','Glomerular filtration','false'
'sample size n by treatment','C0242618','Sample Size','Sample Size','true'
'american indian alaskan native n','C0886378','American native','Native American Healing','false'
'asian pacific islander n','C0078988','ASIAN','Asians','true'
'asian pacific islander n','C0242191','Pacific Islander','Pacific Islander Americans','true'
'other n','C0369718','N NOS','N not otherwise specified Antibody','false'
'other n','C0441922','N+','N+ (tumor staging)','false'
'on antihypertensive treatment n','C0003364','anti hypertensive','Antihypertensive Agents','true'
'on antihypertensive treatment n','C0039798','treatment','therapeutic aspects','true'
'on antihypertensive treatment n','C0087111','Treatment','Therapeutic procedure','true'
'on antihypertensive treatment n','C1522326','Treatment','Treating','false'
'on antihypertensive treatment n','C1533734','Treatment','Administration procedure','false'
'on antihypertensive treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'on antihypertensive treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'on antihypertensive treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'blood pressure at baseline','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure at baseline','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure at baseline','C1272641','Blood pressure','Systemic arterial pressure','true'
'all participants mm hg sbp mean sd','C0439475','mmHG','mmHg','false'
'all participants mm hg sbp mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mean sd','C0444504','Mean','Statistical mean','false'
'dbp mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mean sd','C2347634','Mean','Population Mean','false'
'dbp mean sd','C2348143','Mean','Sample Mean','false'
'treated at baseline mm hg sbp mean sd','C1522326','Treated','Treating','false'
'treated at baseline mm hg sbp mean sd','C0439475','mmHG','mmHg','false'
'untreated at baseline mm hg sbp mean sd','C0332155','untreated','Did not receive therapy or drug for','false'
'untreated at baseline mm hg sbp mean sd','C0439475','mmHG','mmHg','false'
'current cigarette smoker n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current cigarette smoker n','C3241966','Current Smoker','Current Smoker','false'
'type $nmbr$ diabetes n','C1320657','type diabetes','Diabetes type','false'
'hdl c $nmbr$ mg dl n','C3715113','HDL','HSD11B1 wt Allele','false'
'hdl c $nmbr$ mg dl n','C0439269','mg dl','mg/dL','false'
'lvh by electrocardiogram n','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by electrocardiogram n','C0013798','Electrocardiogram','Electrocardiogram','true'
'lvh by electrocardiogram n','C1547122','Electro-Cardiogram','Electro-Cardiogram','false'
'lvh by electrocardiogram n','C1623258','Electrocardiogram','Electrocardiography','true'
'fasting glucose mean sd mg dl','C0015663','FASTING','Fasting','true'
'fasting glucose mean sd mg dl','C0439269','mg dl','mg/dL','false'
'total cholesterol mean sd mg dl','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol mean sd mg dl','C0439269','mg dl','mg/dL','false'
'total cholesterol mean sd mg dl','C0543421','Total cholesterol','Total cholesterol','false'
'fasting triglycerides mean sd mg dl','C0015663','FASTING','Fasting','true'
'fasting triglycerides mean sd mg dl','C0041004','TRIGLYCERIDES','Triglycerides','true'
'fasting triglycerides mean sd mg dl','C0439269','mg dl','mg/dL','false'
'nos $nmbr$ $nmbr$ c t n','C0326287','NOS','Ant-thrush (organism)','false'
'nos $nmbr$ $nmbr$ c t n','C1518425','{NOS}','Not Otherwise Specified','false'
'cc','C0008318','CC','Cholecalciferol','true'
'cc','C3538933','CC','C-Circle','false'
'ct','C0007673','CT','Central African Republic','true'
'ct','C3540513','CT','PCYT1A wt Allele','false'
'ct','C3813556','CT','Cancer/Testis Antigen','false'
'ct','C3888140','CT','Computed Tomography Study File','false'
'tt','C1452561','TT','East Timor','true'
'tt','C4554543','TT','TT genotype','false'
'nos $nmbr$ $nmbr$ a g n','C0326287','NOS','Ant-thrush (organism)','false'
'nos $nmbr$ $nmbr$ a g n','C1518425','{NOS}','Not Otherwise Specified','false'
'nos $nmbr$ $nmbr$ a g n','C0439267','g%','Gram per Deciliter','false'
'aa','C0282379','AA','Aruba','true'
'aa','C1235746','Aa','Aa (Plant)','false'
'aa','C1882141','aa','Of Each','false'
'aa','C4554792','AA','AA genotype','false'
'ag','C0002037','AG','Algeria','true'
'ag','C0051080','AG','alanylglutamine','true'
'ag','C0152305','AG','Structure of angular gyrus','true'
'ag','C3888235','AG','Procedure Agents Domain','false'
'gg','C0017454','GG','Georgia, Western Asia','true'
'gg','C0018370','GG','Guernsey (geographic location)','true'
'nos $nmbr$ glu $nmbr$ asp g t n','C0326287','NOS','Ant-thrush (organism)','false'
'nos $nmbr$ glu $nmbr$ asp g t n','C0125690','Glu-Asp','gamma-Glu-Asp','true'
'nos $nmbr$ glu $nmbr$ asp g t n','C1518425','{NOS}','Not Otherwise Specified','false'
'gt','C1435727','GT','FABP6 protein, human','true'
'gt','C1704693','GT','ITGB3 wt Allele','false'
'gt','C2697657','GT','ITGA2B wt Allele','false'
'number of events event per $nmbr$ person years','C4330837','Number of Events','Number of Events','false'
'number of events event per $nmbr$ person years','C0027361','Person','Persons','true'
'number of events event per $nmbr$ person years','C0439234','YEARS','year','false'
'number of events event per $nmbr$ person years','C2347489','Person','Person Observer','false'
'rates','C0871208','Rate','Rating (action)','false'
'rates','C1521828','Rate','Rate','false'
'genotype specific treatment effect hazard ratio $nmbr$ ci','C0008107','CI','Chile','true'
'genotype specific treatment effect hazard ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'genotype by treatment interaction p values','C0017431','Genotype','Genotype','true'
'genotype by treatment interaction p values','C1709380','P-Value','P-Value','false'
'outcome variant','C1274040','Outcome','Result','false'
'outcome variant','C0205419','Variant','Variant','false'
'genotype','C0017431','Genotype','Genotype','true'
'aml','C0023465','AML','Acute monocytic leukemia','true'
'aml','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'lis','C2247545','LIS','S-linalool synthase activity','false'
'chl','C0019829','CHL','Hodgkin Disease','true'
'aml vs lis','C0023465','AML','Acute monocytic leukemia','true'
'aml vs lis','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'aml vs lis','C2247545','LIS','S-linalool synthase activity','false'
'aml vs chl','C0023465','AML','Acute monocytic leukemia','true'
'aml vs chl','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'aml vs chl','C0019829','CHL','Hodgkin Disease','true'
'chd primary outcome','C0205225','Primary','Primary','false'
'chd primary outcome','C1274040','Outcome','Result','false'
'chd primary outcome','C0439612','Primary','True primary (qualifier value)','false'
'chd primary outcome','C0439631','Primary','Primary operation','false'
'ct tt','C1452561','TT','East Timor','true'
'ct tt','C4554543','TT','TT genotype','false'
'$nmbr$ a g','C0439267','g%','Gram per Deciliter','false'
'ag gg','C0017454','GG','Georgia, Western Asia','true'
'ag gg','C0018370','GG','Guernsey (geographic location)','true'
'glu $nmbr$ asp g t','C0125690','Glu-Asp','gamma-Glu-Asp','true'
'glu $nmbr$ asp g t','C0439267','g%','Gram per Deciliter','false'
'gt tt','C1452561','TT','East Timor','true'
'gt tt','C4554543','TT','TT genotype','false'
'end stage renal disease','C0022661','End Stage Renal Disease','Kidney Failure, Chronic','true'
'end stage renal disease','C2316810','End Stage Renal Disease','Chronic kidney disease stage 5','false'
'normal or increased egfr','C0205307','NORMAL','Normal','false'
'normal or increased egfr','C0231683','Normal','Gait normal','false'
'normal or increased egfr','C0439166','% normal','Percent normal','false'
'normal or increased egfr','C2347086','% Normal','Mean Percent of Normal','false'
'normal or increased egfr','C4553972','Normal','How Often Felt Normal question','false'
'normal or increased egfr','C1739039','EGFR','EGFR protein, human','true'
'normal or increased egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'normal or increased egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'mild reduction in egfr','C0301630','Reduction','Reduction (chemical)','false'
'mild reduction in egfr','C0392756','Reduction','Reduced','false'
'mild reduction in egfr','C1293152','Reduction','Reduction procedure','false'
'mild reduction in egfr','C4551656','Reduction','Surgical reduction','false'
'moderate severe reduction in egfr','C0301630','Reduction','Reduction (chemical)','false'
'moderate severe reduction in egfr','C0392756','Reduction','Reduced','false'
'moderate severe reduction in egfr','C1293152','Reduction','Reduction procedure','false'
'moderate severe reduction in egfr','C4551656','Reduction','Surgical reduction','false'
'$nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'$nmbr$ $nmbr$ ml min per $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'sample size','C0242618','Sample Size','Sample Size','true'
'sbp mmghg mean sd','C0085805','SBP','Androgen Binding Protein','true'
'sbp mmghg mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mmghg mean sd','C0444504','Mean','Statistical mean','false'
'dbp mmghg mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mmghg mean sd','C2347634','Mean','Population Mean','false'
'dbp mmghg mean sd','C2348143','Mean','Sample Mean','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'follow up in trial at $nmbr$ yr','C0589120','Follow-up','Follow-up status','false'
'follow up in trial at $nmbr$ yr','C1522577','Followup','follow-up','false'
'follow up in trial at $nmbr$ yr','C1704685','Follow-Up','Follow-Up Report','false'
'follow up in trial at $nmbr$ yr','C3274571','FOLLOW-UP','Clinical Study Follow-up','false'
'follow up in trial at $nmbr$ yr','C0150312','In','Present','false'
'follow up in trial at $nmbr$ yr','C0008976','Trial','Clinical Trials','true'
'follow up in trial at $nmbr$ yr','C0332285','In','Within','false'
'follow up in trial at $nmbr$ yr','C1707101','IN','CD44 wt Allele','false'
'sample sizea','C0370003','Sample','Specimen','false'
'sample sizea','C2347026','Sample','Biospecimen','false'
'taking statins n a','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'mean sd d','C0444504','Mean','Statistical mean','false'
'mean sd d','C2699239','SD','SD, Rat Strain','false'
'mean sd d','C2347634','Mean','Population Mean','false'
'mean sd d','C2348143','Mean','Sample Mean','false'
'egfr','C1739039','EGFR','EGFR protein, human','true'
'egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'total number of events participants','C4330837','Number of Events','Number of Events','false'
'$nmbr$ yr rate $nmbr$ participants','C0439234','yr','year','false'
'$nmbr$ yr rate $nmbr$ participants','C0679646','participants','Participant','false'
'a compared wi','C0043193','WI','Wisconsin','true'
'a compared wi','C1520135','WI','Western Sahara','false'
'th c','C0039725','TH','Thailand','true'
'th c','C0039738','Th','Thallium','true'
'th c','C1420718','TH','TH gene','false'
'th c','C4282123','TH','TH','false'
'th c','C4285344','TH','Tyrosine 3-Monooxygenase, human','false'
'l compared wit','C0439394','l's','liter/second','false'
'l compared wit','C0043197','Wit','Wit','true'
'l compared wit','C1706495','L-','upper case letter ell','false'
'l compared wit','C3642217','/L','Per Liter','false'
'hc','C0020268','HC','Hydrocortisone','true'
'hc','C0262499','HC','Head circumference','false'
'hc','C1413512','Hc','CLTC gene','false'
'chd total','C0439175','% total','% of total','false'
'chd total','C0439810','Total','Total','false'
'cvd total','C0439175','% total','% of total','false'
'cvd total','C0439810','Total','Total','false'
'stroke total','C0439175','% total','% of total','false'
'stroke total','C0439810','Total','Total','false'
'hf total','C0439175','% total','% of total','false'
'hf total','C0439810','Total','Total','false'
'a compared w','C1707455','Compared','Comparison','false'
'l compared wi','C0043193','WI','Wisconsin','true'
'l compared wi','C1520135','WI','Western Sahara','false'
'option','C1518601','Option','Options','false'
'option','C1550456','option','option - ActMoodPredicate','false'
'ambition','C0870128','ambition','ambition','false'
'radiate','C0332301','radiate','Radiating to','false'
'all trials','C0008976','Trial','Clinical Trials','true'
'patient population','C0032659','Population','geographic population','true'
'patient population','C1257890','Population','Population Group','true'
'mtx ir','C0022065','IR','Iran','true'
'mtx ir','C0022071','Ir','Iridium','true'
'mtx ir','C1448132','IR','INSR protein, human','true'
'mtx naive or free','C0025677','MTX','Methotrexate','true'
'mtx naive or free','C1417487','MTX','MTX1 gene','false'
'mtx naive or free','C0332296','free','Free of (attribute)','false'
'mtx naive or free','C1880497','Free','Empty (qualifier)','false'
'mtx naive or free','C1996904','Free','Free (available (qualifier))','false'
'anti tnf ir','C0022065','IR','Iran','true'
'anti tnf ir','C0022071','Ir','Iridium','true'
'anti tnf ir','C1448132','IR','INSR protein, human','true'
'dmard ir','C0022065','IR','Iran','true'
'dmard ir','C0022071','Ir','Iridium','true'
'dmard ir','C1448132','IR','INSR protein, human','true'
'dmard ir anti tnf ir','C0022065','IR','Iran','true'
'dmard ir anti tnf ir','C0022071','Ir','Iridium','true'
'dmard ir anti tnf ir','C1448132','IR','INSR protein, human','true'
'$nmbr$ tcz mtx','C0025677','MTX','Methotrexate','true'
'$nmbr$ tcz mtx','C1417487','MTX','MTX1 gene','false'
'mtx','C0025677','MTX','Methotrexate','true'
'mtx','C1417487','MTX','MTX1 gene','false'
'$nmbr$ tcz mtx mtx','C0025677','MTX','Methotrexate','true'
'$nmbr$ tcz mtx mtx','C1417487','MTX','MTX1 gene','false'
'total n','C0439175','% total','% of total','false'
'total n','C0439810','Total','Total','false'
'tcz mtx n','C0025677','MTX','Methotrexate','true'
'tcz mtx n','C1417487','MTX','MTX1 gene','false'
'$nmbr$ mono','C1551432','Mono','Mono Indians','false'
'$nmbr$ mono','C1551969','Mono','Mono language','false'
'mtx n','C0025677','MTX','Methotrexate','true'
'mtx n','C1417487','MTX','MTX1 gene','false'
'white tcz mtx n','C0007457','WHITE','Caucasoid Race','true'
'white tcz mtx n','C0025677','MTX','Methotrexate','true'
'white tcz mtx n','C1417487','MTX','MTX1 gene','false'
'white tcz mtx n','C0043157','WHITE','Caucasians','true'
'white tcz mtx n','C0220938','WHITE','White color','false'
'white mtx n','C0007457','WHITE','Caucasoid Race','true'
'white mtx n','C0025677','MTX','Methotrexate','true'
'white mtx n','C1417487','MTX','MTX1 gene','false'
'white mtx n','C0043157','WHITE','Caucasians','true'
'white mtx n','C0220938','WHITE','White color','false'
'age mean s e','C0444504','Mean','Statistical mean','false'
'age mean s e','C2347634','Mean','Population Mean','false'
'age mean s e','C2348143','Mean','Sample Mean','false'
'sex female','C0086287','Sex Female','Females','true'
'height cm mean s e','C0444504','Mean','Statistical mean','false'
'height cm mean s e','C2347634','Mean','Population Mean','false'
'height cm mean s e','C2348143','Mean','Sample Mean','false'
'weight kg mean s e','C0444504','Mean','Statistical mean','false'
'weight kg mean s e','C2347634','Mean','Population Mean','false'
'weight kg mean s e','C2348143','Mean','Sample Mean','false'
'ra duration years mean s e','C0444504','Mean','Statistical mean','false'
'ra duration years mean s e','C2347634','Mean','Population Mean','false'
'ra duration years mean s e','C2348143','Mean','Sample Mean','false'
'rf positive','C0439178','% Positive','percent positive cells','false'
'rf positive','C1446409','Positive','Positive','false'
'rf positive','C1514241','POSITIVE','Positive Finding','false'
'rf positive','C2825490','Positive','Positive Charge','false'
'rf positive','C3812269','Positive','Positive Number','false'
'baseline das $nmbr$ mean s e','C0444504','Mean','Statistical mean','false'
'baseline das $nmbr$ mean s e','C2347634','Mean','Population Mean','false'
'baseline das $nmbr$ mean s e','C2348143','Mean','Sample Mean','false'
'baseline haq mean s e','C0444504','Mean','Statistical mean','false'
'baseline haq mean s e','C2347634','Mean','Population Mean','false'
'baseline haq mean s e','C2348143','Mean','Sample Mean','false'
'baseline sjc mean s e','C0444504','Mean','Statistical mean','false'
'baseline sjc mean s e','C2347634','Mean','Population Mean','false'
'baseline sjc mean s e','C2348143','Mean','Sample Mean','false'
'baseline tjc mean s e','C0444504','Mean','Statistical mean','false'
'baseline tjc mean s e','C2347634','Mean','Population Mean','false'
'baseline tjc mean s e','C2348143','Mean','Sample Mean','false'
'shared epitope a positive','C0237876','shared','Sharing (Social Behavior)','false'
'shared epitope a positive','C0003316','Epitope','Epitopes','true'
'shared epitope a positive','C1522138','Shared','shared attribute','false'
'shared epitope a positive','C0439178','% Positive','percent positive cells','false'
'shared epitope a positive','C1446409','Positive','Positive','false'
'shared epitope a positive','C1514241','POSITIVE','Positive Finding','false'
'shared epitope a positive','C2825490','Positive','Positive Charge','false'
'shared epitope a positive','C3812269','Positive','Positive Number','false'
'high dose arb n $nmbr$','C0444956','High dose','High dose','false'
'high dose arb n $nmbr$','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'arb ccb n $nmbr$','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'arb ccb n $nmbr$','C0006684','CCB','Calcium Channel Blockers','true'
'body height cm','C0005890','Body Height','Body Height','true'
'body height cm','C0487985','Body height','Body height:Length:Point in time:^Patient:Quantitative','false'
'bmi $nmbr$ n','C0578022','BMI','Finding of body mass index','false'
'egfr $nmbr$ n','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ n','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ n','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'serum values','C0229671','SERUM','Serum','true'
'serum values','C0042295','Values','Values','false'
'serum values','C1546774','Serum','Specimen Source Codes - Serum','false'
'serum values','C1550100','Serum','Specimen Type - Serum','false'
'potassium mmol l','C0032821','POTASSIUM','Potassium','true'
'potassium mmol l','C1532563','mmol/L','Millimole per Liter','false'
'potassium mmol l','C0202194','Potassium+','Potassium measurement','false'
'potassium mmol l','C0304475','POTASSIUM','Potassium supplement','false'
'potassium mmol l','C0597277','Potassium','Potassium Ion','false'
'potassium mmol l','C3714637','POTASSIUM','Potassium Drug Class','false'
'hdl cholesterol mg dl','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'hdl cholesterol mg dl','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'casual plasma glucose mg dl','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'casual plasma glucose mg dl','C0439269','mg dl','mg/dL','false'
'casual plasma glucose mg dl','C0455280','plasma glucose','Plasma glucose result','false'
'current alcohol n','C0001962','ALCOHOL','Ethanol','true'
'current alcohol n','C0001975','Alcohol','Alcohols','true'
'drug therapy n','C0013216','Drug Therapy','Pharmacotherapy','true'
'drug therapy n','C0013217','drug therapy','pharmacotherapeutic','true'
'previous antihypertensive treatment','C0003364','anti hypertensive','Antihypertensive Agents','true'
'previous antihypertensive treatment','C0039798','treatment','therapeutic aspects','true'
'previous antihypertensive treatment','C0087111','Treatment','Therapeutic procedure','true'
'previous antihypertensive treatment','C1522326','Treatment','Treating','false'
'previous antihypertensive treatment','C1533734','Treatment','Administration procedure','false'
'previous antihypertensive treatment','C1705169','Treatment','Biomaterial Treatment','false'
'previous antihypertensive treatment','C3538994','TREATMENT','Treatment Epoch','false'
'previous antihypertensive treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'insulin treatment','C0745343','insulin treatment','insulin treatment','false'
'antiplatelet agents','C0085826','Antiplatelet Agents','Antiplatelet Agents','true'
'arb angiotensin ii receptor blocker ccb','C0521942','Angiotensin II Receptor Blocker','Angiotensin II receptor antagonist','true'
'arb angiotensin ii receptor blocker ccb','C0006684','CCB','Calcium Channel Blockers','true'
'arb angiotensin ii receptor blocker ccb','C3536793','Angiotensin II Receptor Blocker','Angiotensin 2 Receptor Blocker [EPC]','false'
'calcium channel blocker bmi body','C0242821','body','Human body','true'
'calcium channel blocker bmi body','C0460148','Body','Human body structure','false'
'calcium channel blocker bmi body','C1268086','Body','Body structure','false'
'calcium channel blocker bmi body','C4082212','Body','Adult human body','false'
'mass index','C0600653','Index','Indexes','true'
'mass index','C0918012','Index','Index','true'
'mass index','C1552854','index','Html Link Type - index','false'
'mass index','C1637833','% index','% index','false'
'mass index','C2986546','Index','Target Lesion Identification','false'
'bp blood pressure egfr estimated glomerular filtration rate men $nmbr$ en $nmbr$ x cr $nmbr$ $nmbr$ x age $nmbr$ $nmbr$ x $nmbr$ $nmbr$ hdl high density lipoprotein','C1363845','blood lipoprotein','Blood lipoproteins','false'
'x cr $nmbr$ $nmbr$ x age','C0201975','Cr','Creatinine measurement','false'
'x cr $nmbr$ $nmbr$ x age','C0001779','AGE','Age','false'
'x cr $nmbr$ $nmbr$ x age','C3539604','CR','CR2 wt Allele','false'
'x cr $nmbr$ $nmbr$ x age','C3711669','CR','CALB2 protein, human','true'
'x cr $nmbr$ $nmbr$ x age','C4084730','CR','CALB2 wt Allele','false'
'x cr $nmbr$ $nmbr$ x age','C4553336','CR','Lugano Lymphoma Response Classification Complete Remission by PET','false'
'x cr $nmbr$ $nmbr$ x age','C4553337','CR','Lugano Lymphoma Response Classification Complete Remission by CT','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C1511726','Data','Data','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C3245479','data','Data call receiving device','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C3714741','Data','Data (eukaryote)','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C0871420','Standard Deviation','Standard deviation','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C0237753','*Number','Numbers','false'
'data are mean standard deviation for continuous variables and number for categoric variables p','C0449788','Number','Count of entities','false'
'values were calculated using t tests for continuous variables and chi square','C0042295','Values','Values','false'
'values were calculated using t tests for continuous variables and chi square','C0444686','Calculated','Calculated','false'
'values were calculated using t tests for continuous variables and chi square','C1441506','Calculated','Calculation','false'
'values were calculated using t tests for continuous variables and chi square','C1524063','Using','Use of','false'
'values were calculated using t tests for continuous variables and chi square','C0871472','t tests','t test','false'
'values were calculated using t tests for continuous variables and chi square','C0439828','variables','Variable (uniformity)','false'
'values were calculated using t tests for continuous variables and chi square','C1552646','chi square','chi square','false'
'tests for categoric','C0022885','Tests','Laboratory Procedures','false'
'tests for categoric','C0392366','Tests','Tests (qualifier value)','false'
'variables','C0439828','variables','Variable (uniformity)','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C2986480','Subgroup Analysis','Subset Analysis','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C0237629','rate responses','Frequency of Responses','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C0205263','Induction','Induce (action)','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C0439531','/period','per period (qualifier value)','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C1948053','Period','Period (temporal qualifier)','false'
'supplementary figure $nmbr$ subgroup analyses for the rate of primary clinical responses during the induction period','C0857127','induction','Induction procedure','false'
'non hispanic latino','C1518424','Non-Hispanic','Not Hispanic or Latino','false'
'non hispanic latino','C0086528','Latino','Latinos','true'
'baseline data','C1511726','Data','Data','false'
'baseline data','C3245479','data','Data call receiving device','false'
'baseline data','C3714741','Data','Data (eukaryote)','false'
'gender m f','C0079399','Gender','Gender','true'
'gender m f','C1522384','Gender','sex','true'
'gender m f','C0016327','F-','Fluorides','true'
'at c data','C1511726','Data','Data','false'
'at c data','C3245479','data','Data call receiving device','false'
'at c data','C3714741','Data','Data (eukaryote)','false'
'final a $nmbr$ c','C0205088','Final','End-stage','false'
'final a $nmbr$ c','C1546485','Final','Diagnosis Type - Final','false'
'final a $nmbr$ c','C3853528','Final','Final','false'
'at c change','C0392747','Change','Changing','false'
'at c change','C0443172','change','Changed status','false'
'at c change','C1705241','Change','Delta (difference)','false'
'at c change','C4319952','Change','Change -- procedure','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'fpg data','C1511726','Data','Data','false'
'fpg data','C3245479','data','Data call receiving device','false'
'fpg data','C3714741','Data','Data (eukaryote)','false'
'final mg dl','C0205088','Final','End-stage','false'
'final mg dl','C0439269','mg dl','mg/dL','false'
'final mg dl','C1546485','Final','Diagnosis Type - Final','false'
'final mg dl','C3853528','Final','Final','false'
'fpg change mg dl','C0392747','Change','Changing','false'
'fpg change mg dl','C0439269','mg dl','mg/dL','false'
'fpg change mg dl','C0443172','change','Changed status','false'
'fpg change mg dl','C1705241','Change','Delta (difference)','false'
'fpg change mg dl','C4319952','Change','Change -- procedure','false'
'withdrawals n n','C1710677','withdrawal','Withdrawal by Subject','false'
'withdrawals n n','C2349954','Withdrawal','Withdraw (activity)','false'
'withdrawals n n','C2825032','Withdrawal','Withdrawal (dysfunction)','false'
'withdrawals n n','C3812880','Withdrawal','Withdrawal - birth control','false'
'withdrawals n n','C4049634','Withdrawal','Withdrawal Scale (BASC-2)','false'
'voluntary','C0439656','Voluntary','Voluntary','false'
'voluntary','C3543419','Voluntary','Voluntary Report','false'
'noncompliant','C0457432','Non-compliant','Non-compliance','false'
'no men','C0025266','Men','Male population group','true'
'no women','C0043210','Women','Woman','true'
'known duration','C0449238','Duration','Duration (temporal concept)','false'
'known duration','C2926735','Duration','Duration','false'
'of t $nmbr$ dm years','C0011816','DM','Dextromethorphan','true'
'of t $nmbr$ dm years','C0439234','YEARS','year','false'
'of t $nmbr$ dm years','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'hba $nmbr$ c range','C1514721','Range','Range','false'
'hba $nmbr$ c range','C2348147','Range','Sample Range','false'
'hba $nmbr$ c range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'hba $nmbr$ c distribution at baseline','C0520511','Distribution','Distributing','false'
'hba $nmbr$ c distribution at baseline','C1704711','Distribution','Distribution','true'
'fpg mmol l','C1532563','mmol/L','Millimole per Liter','false'
'$nmbr$ h pmg mmol l','C2827804','h*mmol/L','Hour Times Micromole per Milliliter','false'
'metformin dose','C0178602','DOSE','Dosage','false'
'metformin dose','C0869039','Dose','Unit dose','false'
'metformin dose','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1705242','Difference','Different','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1442488','Baseline','Baseline','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C3875154','Relative to','Relative to','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0023668','LS','Liechtenstein','true'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0205132','Line','Linear','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0700221','Line','Intravascular line','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1550648','Line','Line Specimen','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1552960','Line','Line Unit of Length','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0369718','N NOS','N not otherwise specified Antibody','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0042295','Values','Values','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0441922','N+','N+ (tumor staging)','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C2360800','Number of patients','Number of patients','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C0032042','Placebo','Placebos','true'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1305855','BMI - Body mass index','Body mass index','true'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ difference in hba $nmbr$ c least squares ls mean change from baseline at week $nmbr$ by subgroup categories relative to ls mean change for all patients vertical line the n values in parentheses show the number of patients in the sitagliptin group number of patients in the placebo group bmi body mass index','C1706408','PLACEBO','Placebo Control','false'
'dabigatran $nmbr$ mg bid n $nmbr$','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg bid n $nmbr$','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg bid n $nmbr$','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg bid n $nmbr$','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg bid n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg bid n $nmbr$','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg bid n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'prior oac','C0332152','Prior','Before','false'
'prior oac','C2826257','PRIOR','Prior Medication Usage','false'
'crcl sd ml min','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl sd ml min','C0439445','mL/min','mL/min','false'
'prior history of bleeding on oac','C0019664','History','History','true'
'prior history of bleeding on oac','C0019665','history','Historical aspects qualifier','true'
'prior history of bleeding on oac','C0262512','History, NOS','History of present illness','false'
'prior history of bleeding on oac','C0262926','History','Medical History','false'
'prior history of bleeding on oac','C1705255','History','Concept History','false'
'prior history of bleeding on oac','C2004062','History','History of previous events','false'
'type of surgery','C0332307','TYPE','Type - attribute','false'
'type of surgery','C1547052','*Type','*Type - Kind of quantity','false'
'pacemaker or icd','C0030163','PACEMAKER','Artificial cardiac pacemaker','true'
'pacemaker or icd','C0810633','Pacemaker','Pacemakers','false'
'pacemaker or icd','C1546728','Pacemaker','Specimen Source Codes - Pacemaker','false'
'pacemaker or icd','C3275122','PACEMAKER','Pacemaker Procedure','false'
'pacemaker or icd','C3853703','Pacemaker','Pacemaker ECG Assessment','false'
'pacemaker or icd','C0021122','ICD','Disruptive, Impulse Control, and Conduct Disorders','true'
'dental procedure','C0011331','Dental Procedure','Dental Procedures','true'
'other diagnostic procedure','C0430022','Diagnostic Procedure','diagnostic procedure','false'
'other diagnostic procedure','C1546908','Diagnostic procedure','Procedure Functional Type - Diagnostic procedure','false'
'cataract removal','C0007389','cataract removal','Cataract Extraction','true'
'colonoscopy','C0009378','Colonoscopy','colonoscopy','true'
'colonoscopy','C1548837','Colonoscopy','Consent Type - Colonoscopy','false'
'total hip or knee replacement','C0019552','HIP','Hip structure','true'
'total hip or knee replacement','C0022122','Hip','Bone structure of ischium','true'
'total hip or knee replacement','C1505163','HIP','HHIP protein, human','true'
'total hip or knee replacement','C3538851','HIP','REG3A wt Allele','false'
'total hip or knee replacement','C4284725','HIP','HHIP wt Allele','false'
'total hip or knee replacement','C0086511','Knee Replacement','Knee Replacement Arthroplasty (procedure)','true'
'cystoscopic procedure','C0184661','Procedure','Interventional procedure','true'
'cystoscopic procedure','C2700391','Procedure','Procedure (set of actions)','false'
'cystoscopic procedure','C3274430','PROCEDURE','Physical Medical Procedure','false'
'cystoscopic procedure','C3539779','Procedure','CDISC SDTM Procedure Terminology','false'
'inguinal hernia repair','C0021446','INGUINAL HERNIA REPAIR','Repair of inguinal hernia','false'
'laparoscopic cholecystectomy','C0162522','Cholecystectomy, Laparoscopic','Cholecystectomy, Laparoscopic','true'
'cabg or valve','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'cabg or valve','C0184252','VALVE','Medical Valves','false'
'cabg or valve','C1186983','Valve','anatomic valve','false'
'cabg or valve','C1704414','Valve','Valve Device','false'
'cabg or valve','C3888056','Valve','Valve (physical object)','false'
'colectomy partial or total','C0728938','PARTIAL','Partial','false'
'colectomy partial or total','C1550516','partial','Target Awareness - partial','false'
'colectomy partial or total','C0439175','% total','% of total','false'
'colectomy partial or total','C0439810','Total','Total','false'
'peripheral angioplasty','C0162577','Angioplasty','Angioplasty','true'
'peripheral angioplasty','C1548817','Angioplasty','Angioplasty - Consent Type','false'
'prostate biopsy','C0194804','Prostate Biopsy','Biopsy of prostate','false'
'carotid endarterectomy','C0014099','CAROTID ENDARTERECTOMY','Carotid Endarterectomy','true'
'limb amputation','C0002689','Limb amputation','Amputation of limb','false'
'd $nmbr$ n n','C0369718','N NOS','N not otherwise specified Antibody','false'
'd $nmbr$ n n','C0441922','N+','N+ (tumor staging)','false'
'warfarin n n','C0043031','WARFARIN','Warfarin','true'
'd $nmbr$ vs warfarin rr $nmbr$ ci p value','C0008107','CI','Chile','true'
'd $nmbr$ vs warfarin rr $nmbr$ ci p value','C1709380','P-Value','P-Value','false'
'd $nmbr$ vs warfarin rr $nmbr$ ci p value','C3259781','CI','Coagulation Index Measurement','false'
'urgent surgery','C2188405','urgent Surgery','urgent Operation','false'
'elective surgery','C0206058','Elective Surgery','Elective Surgical Procedures','true'
'major surgery','C0679637','major surgery','major surgery','false'
'minor surgery','C0038904','Surgery, Minor','Minor Surgical Procedures','true'
'original dabigatran protocol','C0442711','Protocol','Protocols documentation','false'
'original dabigatran protocol','C1507394','Protocol','Clinical trial protocol document','false'
'original dabigatran protocol','C1522729','Protocol','Library Protocol','false'
'original dabigatran protocol','C2348563','Protocol','Study Protocol','false'
'original dabigatran protocol','C2599718','protocol','Clinical trial protocol','true'
'original dabigatran protocol','C3715209','Protocol','Protocol - answer to question','false'
'original dabigatran protocol','C4282383','Protocol','REMS Protocol','false'
'amended dabigatran protocol','C0442711','Protocol','Protocols documentation','false'
'amended dabigatran protocol','C1507394','Protocol','Clinical trial protocol document','false'
'amended dabigatran protocol','C1522729','Protocol','Library Protocol','false'
'amended dabigatran protocol','C2348563','Protocol','Study Protocol','false'
'amended dabigatran protocol','C2599718','protocol','Clinical trial protocol','true'
'amended dabigatran protocol','C3715209','Protocol','Protocol - answer to question','false'
'amended dabigatran protocol','C4282383','Protocol','REMS Protocol','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0205210','Clinical','Clinical','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0544452','Remission','Disease remission','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0687702','remission','Cancer Remission','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0332174','/week','Weekly','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0872146','disease duration','disease length','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0439230','Week','week','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0042295','Values','Values','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0022885','Test','Laboratory Procedures','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0039593','Test','Testing','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0392366','test','Tests (qualifier value)','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C0456984','Test','Test Result','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C1515976','test','Anatomic Structure, System, or Substance','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C3831328','Test','Blood Products Laboratory Testing','false'
'figure $nmbr$ clinical remission at week $nmbr$ a and week $nmbr$ b by disease duration all patients randomised itt population p values from fisher s exact test','C4318744','Test','Test - temporal region','false'
'general anaesthesia','C0002915','General anaesthesia','General Anesthesia','true'
'general anaesthesia','C2930406','General Anesthesia','General Anesthesia [PE]','false'
'neuraxial anaesthesia','C0002903','anaesthesia','Anesthesia procedures','true'
'neuraxial anaesthesia','C0002912','Anesthesia','Dental anesthesia','true'
'neuraxial anaesthesia','C0002930','Anaesthesia','Anesthesiology','true'
'neuraxial anaesthesia','C4049933','Anesthesia','Anesthesia substance','false'
'combination','C0205195','Combination','Combined','false'
'combination','C1947911','Combination','combination of objects','false'
'combination','C3811910','Combination','combination - answer to question','false'
'number of patients','C2360800','Number of patients','Number of patients','false'
'mean age years sd','C1510829','Age-Years','Age-Years','false'
'mean age years sd','C2699239','SD','SD, Rat Strain','false'
'mean bmi kg m $nmbr$ sd','C0022718','KG','Kyrgyzstan','true'
'mean bmi kg m $nmbr$ sd','C0439209','kg','Kilogram','false'
'mean bmi kg m $nmbr$ sd','C4054209','/kg','Per Kilogram','false'
'mean bmi kg m $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'minimum','C1524031','Minimum','Minimum','false'
'minimum','C1552614','minimum','ActRelationshipSubset - minimum','false'
'minimum','C2826545','MINIMUM','Minimum Value Derivation Technique','false'
'maximum','C0806909','Maximum','Maximum','false'
'maximum','C1552615','maximum','Act Relationship Subset - maximum','false'
'maximum','C2826546','MAXIMUM','Maximum Value Derivation Technique','false'
'smoker or ex smoker n','C0337664','Smoker','Smoker','true'
'smoker or ex smoker n','C0337671','Ex-smoker','Former smoker','false'
'smoker or ex smoker n','C4555205','Ex-Smoker','Ex-Smokers','true'
'$nmbr$ years n','C0439234','YEARS','year','false'
'$nmbr$ years or','C0439234','YEARS','year','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1707455','Comparison','Comparison','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0024671','MG','Mammography','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0026410','MG','Mongolia','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0439269','mg%','mg/dL','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1960952','mg %','Milligram percent','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C2346927','Mg++','Magnesium Cation','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C4321396','MG','MG','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C4521761','MG','United States Military Commissioned Officer O8','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1571583','DABIGATRAN ETEXILATE','dabigatran etexilate','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0205449','Three','Three','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1274040','Outcome','Result','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0680240','according','Agreement','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1305863','Anesthesia type','Anesthesia type','false'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C1861172','VENOUS THROMBOEMBOLISM','Venous Thromboembolism','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0630906','vte','vinyltriethoxysilane','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0026565','Mortality','Mortality Vital Statistics','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0019080','BLEEDING','Hemorrhage','true'
'figure $nmbr$ comparison of $nmbr$ mg and $nmbr$ mg dabigatran etexilate with enoxaparin treatments for the three outcomes analysed according to the type of anaesthesia a major venous thromboembolism vte and vte related mortality b major bleeding events c major bleeding events plus clinically relevant bleeding events','C0026566','mortality','Aspects of mortality statistics','true'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C1511726','Data','Data','false'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C3245479','data','Data call receiving device','false'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C3714741','Data','Data (eukaryote)','false'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C0449450','Presented','Presentation','false'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C0028873','Odds Ratio','Odds Ratio','true'
'data are presented as the odds ratio with $nmbr$ confidence intervals','C0009667','Confidence Intervals','Confidence Intervals','true'
't $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml','C2603360','T'','T prime','false'
't $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ ng ml','C0439275','ng/mL','Microgram per Liter','false'
'no patients','C0030705','Patients','Patients','true'
'sbp dbp mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp dbp mmhg','C0439475','mmHG','mmHg','false'
'ischaemic aetiology','C0015127','etiology','Etiology aspects','true'
'ischaemic aetiology','C1314792','Etiology','Etiology','true'
'ischaemic aetiology','C1524003','Etiology','Science of Etiology','false'
'nyha classes iii iv','C0278962','NYHA Class III/IV','New York Heart Association class III/IV','false'
'laboratory values','C0022877','LABORATORY','Laboratory','true'
'laboratory values','C0042295','Values','Values','false'
'laboratory values','C3244292','laboratory','Laboratory domain','false'
'laboratory values','C4283904','Laboratory','Laboratory observation','false'
'ldl cholesterol mg dl','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'ldl cholesterol mg dl','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'co morbidities','C0009488','co-morbidity','Comorbidity','true'
'atrial fibrillation flutter','C0155709','Atrial fibrillation/flutter','Atrial fibrillation and flutter','false'
'pharmacological therapy for hf','C0039798','therapy','therapeutic aspects','true'
'pharmacological therapy for hf','C0087111','Therapy','Therapeutic procedure','true'
'pharmacological therapy for hf','C1363945','Therapy','Therapy Object (animal model)','false'
'aldosterone receptor antagonists','C1579268','Aldosterone Receptor Antagonists','Mineralocorticoid Receptor Antagonists','true'
'biomarkers at baseline','C0005516','Biomarkers','Biological Markers','true'
'biomarkers at baseline','C0168634','baseline','BaseLine dental cement','true'
'biomarkers at baseline','C1442488','Baseline','Baseline','false'
'ptx $nmbr$ ng ml','C0030899','PTX','Pentoxifylline','true'
'ptx $nmbr$ ng ml','C0439275','ng/mL','Microgram per Liter','false'
'hscrp mg l','C0439268','mg/L','Microgram per Milliliter','false'
'nt probnp pg ml','C0669479','NTproBNP','pro-brain natriuretic peptide (1-76)','true'
'nt probnp pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'nt probnp pg ml','C0754710','NT-proBNP','Amino-terminal pro-brain natriuretic peptide','true'
'all cause mortality per $nmbr$ person years','C0015127','cause','Etiology aspects','true'
'all cause mortality per $nmbr$ person years','C0026565','Mortality','Mortality Vital Statistics','true'
'all cause mortality per $nmbr$ person years','C0026566','mortality','Aspects of mortality statistics','true'
'all cause mortality per $nmbr$ person years','C1524003','Cause','Science of Etiology','false'
'cardiovascular mortality per $nmbr$ person years','C0026565','Mortality','Mortality Vital Statistics','true'
'cardiovascular mortality per $nmbr$ person years','C0026566','mortality','Aspects of mortality statistics','true'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C0683150','concentrations plasma','plasma concentration','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C0683325','clinical characteristics','clinical aspects','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C1547282','Show','Show','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C0086045','Concentration','Mental concentration','true'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C1446561','Concentration','Concentration measurement','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C3827302','Concentration','Able to Concentrate Question','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C1527178','Based','Basis - conceptual entity','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C1705938','Based','Base - General Qualifier','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C0750572','Estimated','Estimated','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C1739039','EGFR','EGFR protein, human','true'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'figure $nmbr$ baseline plasma pentraxin $nmbr$ ptx $nmbr$ concentrations in relation to selected clinical characteristics box plots showing the baseline median ptx $nmbr$ concentration in clinical subgroups based on sex age body mass index bmi and estimated glom erular filtration rate egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C0441833','Groups','Groups','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C0687744','groups','Social group','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1257890','Group','Population Group','true'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1519504','Group','Stage Grouping','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1552839','groups','Table Rules - groups','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1705428','Group','Group Object','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1705429','Group','User Group','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1707455','Compared','Comparison','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1708930','Mann-Whitney Test','Mann-Whitney Test','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C2360800','Number of patients','Number of patients','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C0683312','Category','Categories','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C3889287','Category','Digital Content Category','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1444656','Indicated','Indicated','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C1707156','BARS','CTBP1 wt Allele','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C3274014','BARS','Brief Ataxia Rating Scale','false'
'groups were compared with the kruskall wallis or mann whitney tests the number of patients in each category is indicated below the bars','C3541345','BARS','Barnes Akathisia Rating Scale Questionnaire','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0376674','Postprandial','Postprandial Period','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0017725','GLUCOSE','Glucose','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0021641','INSULIN','Insulin','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1533581','INSULIN','Recombinant Insulin','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1579433','Insulin','Insulin [EPC]','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C3714501','INSULIN','Insulin Drug Class','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0870536','test f','f test','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1275991','test e','E test (procedure)','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C2827788','E-Test','Epsilometry','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1442488','Baseline','Baseline','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0444930','End','End','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0557651','Study','Room of building - Study','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C2603343','Study','Study','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C2746065','End','Stop (qualifier value)','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0030705','Patients','Patients','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0439375','mEq/L','mEq/L','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0597277','K+','Potassium Ion','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1708601','K'','K Prime','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0023465','AML','Acute monocytic leukemia','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0743559','Error','error','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1608199','Error','Act Reason - Error','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ postprandial glucose a b c and insulin d e f after oral glucose tolerance test ogtt challenge at baseline and at the end of the study eos in patients with baseline potassium k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ meq l and baseline k $nmbr$ $nmbr$ meq l and eos k $nmbr$ $nmbr$ or $nmbr$ $nmbr$ meq l respectively aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1710181','Standard Error','Standard Error','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0392747','Change','Changing','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0443172','change','Changed status','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0444930','End','End','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C2746065','End','Stop (qualifier value)','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0455280','plasma glucose','Plasma glucose result','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0428357','Serum insulin','Serum insulin measurement','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0376690','Area under the curve','Area Under Curve','true'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1261415','serum insulin','Serum insulin result','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0023465','AML','Acute monocytic leukemia','true'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0023467','AML','Leukemia, Myelocytic, Acute','true'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C0743559','Error','error','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1608199','Error','Act Reason - Error','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1882932','Represent','Representation (action)','false'
'figure $nmbr$ mean change from baseline to end of the study eos week $nmbr$ in postprandial plasma glucose a and postprandial serum insulin b area under the curve auc from $nmbr$ to $nmbr$ minutes auc $nmbr$ $nmbr$ min aml indicates amlodipine hctz hydrochlorothiazide val valsartan error bars represent standard error','C1710181','Standard Error','Standard Error','false'
'tofacitinib $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tofacitinib $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tofacitinib $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tofacitinib $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tofacitinib $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tofacitinib $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tofacitinib $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'white race no f','C0007457','white race','Caucasoid Race','true'
'white race no f','C0043157','white race','Caucasians','true'
'white race no f','C0016327','F-','Fluorides','true'
'duration of rheumatoid arthritis yr','C0449238','Duration','Duration (temporal concept)','false'
'duration of rheumatoid arthritis yr','C2926735','Duration','Duration','false'
'tender and swollen joints mean no','C0234234','Tender','Tender','false'
'tender and swollen joints mean no','C0444504','Mean','Statistical mean','false'
'tender and swollen joints mean no','C2347634','Mean','Population Mean','false'
'tender and swollen joints mean no','C2348143','Mean','Sample Mean','false'
'tender','C0234234','Tender','Tender','false'
'swollen','C0038999','Swollen','Swelling','false'
'mean score on haq di','C3533236','Mean score','Mean score','false'
'mean score on haq di','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'mean score on haq di','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'das $nmbr$ $nmbr$ esr $nmbr$','C0051767','DAS','amsonic acid','true'
'das $nmbr$ $nmbr$ esr $nmbr$','C3811131','ESR','Estrogen Receptor Measurement','false'
'das $nmbr$ $nmbr$ esr $nmbr$','C0057671','DAS','diacetoxyscirpenol','true'
'score of $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'score of $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'mean score on das $nmbr$ $nmbr$ crp ^','C3533236','Mean score','Mean score','false'
'mean score on das $nmbr$ $nmbr$ crp ^','C0051767','DAS','amsonic acid','true'
'mean score on das $nmbr$ $nmbr$ crp ^','C0057671','DAS','diacetoxyscirpenol','true'
'erythrocyte sedimentation rate mm hr','C1176468','Erythrocyte Sedimentation Rate','Erythrocyte sedimentation rate measurement','false'
'erythrocyte sedimentation rate mm hr','C1619634','Erythrocyte sedimentation rate','erythrocyte sedimentation rate result','true'
'c reactive protein mg liter','C0006560','C Reactive Protein','C-reactive protein','true'
'c reactive protein mg liter','C0475211','Litre','liter','false'
'c reactive protein mg liter','C1413716','C-reactive protein','CRP gene','false'
'c reactive protein mg liter','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff','C0741132','positive antibody','antibody positive','false'
'positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff','C1829901','Rheumatoid factor & Cyclic citrullinated peptide','Rheumatoid factor & Cyclic citrullinated peptide','false'
'positive for rheumatoid factor anti cyclic citrullinated peptide antibodies or both ff','C4554348','FF','FF genotype','false'
'prior treatment','C1514463','Prior Treatment','Prior Therapy','false'
'tnf inhibitor','C1448177','TNF','TNF protein, human','true'
'tnf inhibitor','C1999216','Inhibitor','Inhibitor','false'
'other biologic agent','C0005515','Biologic agent','Biological Factors','true'
'methotrexate','C0025677','METHOTREXATE','Methotrexate','true'
'nonbiologic disease modifying drug other than methotrexate','C0392747','MODIFY','Changing','false'
'nonbiologic disease modifying drug other than methotrexate','C4036059','Drug-disease','Drug-disease','false'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0012634','Disease','Disease','true'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0013227','Drugs','Pharmaceutical Preparations','true'
'prior disease modifying drugs resulting in inadequate response mean no patient','C3687832','Drugs','Drugs - dental services','false'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0332294','Resulting in','Resulting in','false'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0205412','Inadequate','Inadequate (qualifier)','false'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0439856','Inadequate','Unsatisfactory','false'
'prior disease modifying drugs resulting in inadequate response mean no patient','C0030705','*^patient','Patients','true'
'tofacitinib','C2930696','TOFACITINIB','tofacitinib','true'
'gender female','C0043210','female','Woman','true'
'gender female','C0086287','FEMALE','Females','true'
'gender female','C1705497','Female','Female, Self-Report','false'
'gender female','C1705498','FEMALE','Female Phenotype','false'
'rheumatoid factor positive','C0439178','% Positive','percent positive cells','false'
'rheumatoid factor positive','C1446409','Positive','Positive','false'
'rheumatoid factor positive','C1514241','POSITIVE','Positive Finding','false'
'rheumatoid factor positive','C2825490','Positive','Positive Charge','false'
'rheumatoid factor positive','C3812269','Positive','Positive Number','false'
'anti ccp positive','C0439178','% Positive','percent positive cells','false'
'anti ccp positive','C1446409','Positive','Positive','false'
'anti ccp positive','C1514241','POSITIVE','Positive Finding','false'
'anti ccp positive','C2825490','Positive','Positive Charge','false'
'anti ccp positive','C3812269','Positive','Positive Number','false'
'dmard biologic ir','C0022065','IR','Iran','true'
'dmard biologic ir','C0022071','Ir','Iridium','true'
'dmard biologic ir','C1448132','IR','INSR protein, human','true'
'region united states','C0017446','Region','Geographic Locations','true'
'region united states','C0041703','UNITED STATES','United States','true'
'region united states','C0205147','Region','regional','false'
'europe $nmbr$','C0015176','Europe','Europe','true'
'colesevelam n $nmbr$','C0541155','COLESEVELAM','colesevelam','true'
'country n','C0454664','COUNTRY','Country','false'
'country n','C1511538','Country','Country Code','false'
'mexico','C0025885','MEXICO','Mexico','true'
'colombia','C3245499','COLOMBIA','Colombia','true'
'hba $nmbr$ ca mean sd','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ ca mean sd','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ ca mean sd','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ ca mean sd','C0444504','Mean','Statistical mean','false'
'hba $nmbr$ ca mean sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ ca mean sd','C2347634','Mean','Population Mean','false'
'hba $nmbr$ ca mean sd','C2348143','Mean','Sample Mean','false'
'fpg mg dl mean sd','C0439269','mg dl','mg/dL','false'
'fpg mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ hour postload glucose','C0439227','HOUR','Hour','false'
'$nmbr$ hour postload glucose','C0017725','GLUCOSE','Glucose','true'
'$nmbr$ hour postload glucose','C0564385','/hour','/hour','false'
'mg dl mean sd','C0439269','mg dl','mg/dL','false'
'mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'fasting insulin iiiu ml mean sd','C0015663','FASTING','Fasting','true'
'fasting insulin iiiu ml mean sd','C0021641','INSULIN','Insulin','true'
'fasting insulin iiiu ml mean sd','C2699239','SD','SD, Rat Strain','false'
'fasting insulin iiiu ml mean sd','C1533581','INSULIN','Recombinant Insulin','false'
'fasting insulin iiiu ml mean sd','C1579433','Insulin','Insulin [EPC]','false'
'fasting insulin iiiu ml mean sd','C3714501','INSULIN','Insulin Drug Class','false'
'ldl c mg dl mean sd','C0439269','mg dl','mg/dL','false'
'ldl c mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'aspirin plus placebo n $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'aspirin plus placebo n $nmbr$','C0032042','Placebo','Placebos','true'
'aspirin plus placebo n $nmbr$','C1696465','PLACEBO','placebo','false'
'aspirin plus placebo n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'aspirin plus clopidogrel n $nmbr$','C0004057','ASPIRIN','Aspirin','true'
'aspirin plus clopidogrel n $nmbr$','C0070166','CLOPIDOGREL','clopidogrel','true'
'mean age yr','C0001779','AGE','Age','false'
'mean age yr','C0439234','yr','year','false'
'male sex race or ethnic group f','C0034510','RACE','Racial group','true'
'male sex race or ethnic group f','C1706779','RACE','AMACR wt Allele','false'
'male sex race or ethnic group f','C3853635','Race','Race','false'
'male sex race or ethnic group f','C0441840','Group F','Group F','false'
'black region or country','C0017446','Region','Geographic Locations','true'
'black region or country','C0205147','Region','regional','false'
'black region or country','C0454664','COUNTRY','Country','false'
'black region or country','C1511538','Country','Country Code','false'
'spain','C0037747','SPAIN','Spain','true'
'mean blood pressure at screening visit mm hg','C0428886','Mean blood pressure','Mean blood pressure','true'
'mean blood pressure at screening visit mm hg','C0488053','Mean blood pressure','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'previous clinical stroke or transient ischemic attack','C0038454','STROKE','Cerebrovascular accident','true'
'previous clinical stroke or transient ischemic attack','C4554100','Stroke','Stroke, CTCAE','false'
'previous clinical stroke or transient ischemic attack','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'previous clinical stroke or transient ischemic attack','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'current tobacco smoker qualifying event','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current tobacco smoker qualifying event','C3241966','Current Smoker','Current Smoker','false'
'current tobacco smoker qualifying event','C1514624','Qualifying','Qualifying','false'
'current tobacco smoker qualifying event','C0441471','Event','Event','false'
'current tobacco smoker qualifying event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'transient ischemic attack type of lacunar syndrome','C0455703','Transient type','Temporary type','false'
'pure motor hemiparesis','C1513492','Motor','motor movement','false'
'pure motor hemiparesis','C0018989','HEMIPARESIS','Hemiparesis','true'
'pure motor hemiparesis','C1705994','Motor','Device Motor','false'
'pure sensory stroke','C0445254','Sensory','Sensory (qualifier value)','false'
'pure sensory stroke','C0038454','STROKE','Cerebrovascular accident','true'
'pure sensory stroke','C4554100','Stroke','Stroke, CTCAE','false'
'sensorimotor stroke','C0038454','STROKE','Cerebrovascular accident','true'
'sensorimotor stroke','C4554100','Stroke','Stroke, CTCAE','false'
'use of aspirin at time of qualifying event','C1524063','Use of','Use of','false'
'use of aspirin at time of qualifying event','C0004057','ASPIRIN','Aspirin','true'
'use of aspirin at time of qualifying event','C0040223','TIME','Time','true'
'use of aspirin at time of qualifying event','C3541383','Time','Time (foundation metadata concept)','false'
'use of aspirin at time of qualifying event','C1514624','Qualifying','Qualifying','false'
'use of aspirin at time of qualifying event','C0441471','Event','Event','false'
'use of aspirin at time of qualifying event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'use of statin at any follow up visit','C1524063','Use of','Use of','false'
'use of statin at any follow up visit','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'use of statin at any follow up visit','C0589121','Follow-up visit','Follow-up visit','false'
'vorapaxar group n $nmbr$','C2974521','VORAPAXAR','vorapaxar','true'
'vorapaxar group n $nmbr$','C0441848','Group N','Group N','false'
'median age iqr years','C0549183','Median','Midline (qualifier value)','false'
'median age iqr years','C1510829','Age-Years','Age-Years','false'
'median age iqr years','C0876920','Median','Median Statistical Measurement','false'
'median age iqr years','C2347635','Median','Population Median','false'
'median age iqr years','C2348144','Median','Sample Median','false'
'median age iqr years','C2939193','Median','Median (qualifier value)','false'
'white ethnic origin','C0007457','WHITE','Caucasoid Race','true'
'white ethnic origin','C0015031','Ethnic Origin','Ethnic group','true'
'white ethnic origin','C0043157','WHITE','Caucasians','true'
'white ethnic origin','C0220938','WHITE','White color','false'
'time from qualifying myocardial infarction','C0040223','TIME','Time','true'
'time from qualifying myocardial infarction','C3541383','Time','Time (foundation metadata concept)','false'
'time from qualifying myocardial infarction','C1514624','Qualifying','Qualifying','false'
'time from qualifying myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'time from qualifying myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'time from qualifying myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'time from qualifying myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'time from qualifying myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'hyperlipidaemia','C0020473','Hyperlipidaemia, NOS','Hyperlipidemia','true'
'hyperlipidaemia','C0428465','Hyperlipidemia','Serum lipids high (finding)','false'
'hyperlipidaemia','C4555212','Hyperlipidemia','Hyperlipidemia, CTCAE','false'
'previous coronary revascularisation','C0205156','Previous','Previous','false'
'previous coronary revascularisation','C0877341','coronary revascularisation','coronary revascularization','false'
'previous coronary revascularisation','C1552607','previous','Act Relationship Subset - previous','false'
'concomitant drugs','C0013227','Drugs','Pharmaceutical Preparations','true'
'concomitant drugs','C3687832','Drugs','Drugs - dental services','false'
'total no','C0439175','% total','% of total','false'
'total no','C0439810','Total','Total','false'
'vorapaxar placebo $nmbr$ yr km','C0032042','Placebo','Placebos','true'
'vorapaxar placebo $nmbr$ yr km','C3887676','KM','Kathy Mercer','false'
'vorapaxar placebo $nmbr$ yr km','C1696465','PLACEBO','placebo','false'
'vorapaxar placebo $nmbr$ yr km','C1706408','PLACEBO','Placebo Control','false'
'hr $nmbr$ ci p value for interaction','C0008107','CI','Chile','true'
'hr $nmbr$ ci p value for interaction','C1709380','P-Value','P-Value','false'
'hr $nmbr$ ci p value for interaction','C3259781','CI','Coagulation Index Measurement','false'
'prior stroke or tia','C0038454','STROKE','Cerebrovascular accident','true'
'prior stroke or tia','C4554100','Stroke','Stroke, CTCAE','false'
'prior stroke or tia','C0007787','TIA','Transient Ischemic Attack','true'
'prior stroke or tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'prior stroke or tia','C1054154','tia','Tacca leontopetaloides','false'
'planned thienopyridine at enrollment','C1709561','Planned Enrollment','Planned Subject Number','false'
'planned thienopyridine at enrollment','C1120149','thienopyridine','thienopyridine','true'
'prior stent','C0332152','Prior','Before','false'
'prior stent','C0038257','Stent','Stent, device','true'
'prior stent','C2826257','PRIOR','Prior Medication Usage','false'
'stemi','C1536220','STEMI','ST segment elevation myocardial infarction','true'
'stemi','C3538872','STEMI','ST Elevation Myocardial Infarction by ECG Finding','false'
'azl m hctz n $nmbr$','C0020261','HCTZ','Hydrochlorothiazide','true'
'$nmbr$ f','C0016327','F-','Fluorides','true'
'age categories y n','C2916832','Age Categories','Age Categories [Disease/Finding]','false'
'multiple','C0439064','MULTIPLE','Numerous','false'
'egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n','C0683312','Category','Categories','false'
'egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n','C0439445','mL/min','mL/min','false'
'egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n','C3889287','Category','Digital Content Category','false'
'egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'egfr category ml min $nmbr$ $nmbr$ m $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'moderate impairment','C0221099','Impairment','Impaired','false'
'moderate impairment','C0684336','Impairment','Impaired health','false'
'mild impairment','C0221099','Impairment','Impaired','false'
'mild impairment','C0684336','Impairment','Impaired health','false'
'chronic kidney disease n','C1561643','Chronic Kidney Disease','Chronic Kidney Diseases','true'
'chronic kidney disease n','C4553188','Chronic kidney disease','Chronic Kidney Disease, CTCAE','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1705242','Difference','Different','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0032042','Placebo','Placebos','true'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1511728','Data Component','Data Element','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0032659','Population','geographic population','true'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1257890','Population','Population Group','true'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0205132','Line','Linear','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0700221','Line','Intravascular line','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1550648','Line','Line Specimen','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1552960','Line','Line Unit of Length','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0441889','Level','Levels (qualifier value)','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0456079','Level','Disease classification level','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1547707','Level','Floor - story of building','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C2946261','Level','Level','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0023189','Least Squares','Least-Squares Analysis','true'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0444504','Mean','Statistical mean','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C2347634','Mean','Population Mean','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C2348143','Mean','Sample Mean','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0162425','intent','Intention - mental process','true'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1283828','Intent','intent','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1550453','intent','Act Mood - intent','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C0521346','RESPIRATORY','respiratory','false'
'figure $nmbr$ least squares mean $nmbr$ ci treatment differences versus placebo in sgrq total score symptoms activity and impacts component scores data at week $nmbr$ itt population the dotted line indicates the pre speci ed level of clinical relevance data are least squares mean with $nmbr$ con dence intervals lsm [ $nmbr$ ci] itt z intent to treat sgrq z st george s respiratory ques tionnaire ind z indacaterol p $nmbr$ $nmbr$ p $nmbr$ $nmbr$ versus placebo','C1546767','Respiratory','Specimen Source Codes - Respiratory','false'
'bivalirudin n $nmbr$','C0168273','BIVALIRUDIN','bivalirudin','true'
'heparin plus a gpi n $nmbr$','C0019134','HEPARIN','heparin','true'
'heparin plus a gpi n $nmbr$','C0770546','HEPARIN','heparin, porcine','false'
'treated with insulin','C0332293','Treated with','Treated with','false'
'treated with insulin','C0021641','INSULIN','Insulin','true'
'treated with insulin','C1533581','INSULIN','Recombinant Insulin','false'
'treated with insulin','C1579433','Insulin','Insulin [EPC]','false'
'treated with insulin','C3714501','INSULIN','Insulin Drug Class','false'
'arterial hypertension no','C0020538','Arterial hypertension','Hypertensive disease','true'
'hypercholesterolemia no','C0020443','HYPERCHOLESTEROLEMIA','Hypercholesterolemia','true'
'hypercholesterolemia no','C1522133','Hypercholesterolemia','Hypercholesterolemia result','false'
'coronary artery treated no','C0205042','Artery, Coronary','Coronary artery','true'
'coronary artery treated no','C1522326','Treated','Treating','false'
'multivessel disease no','C0012634','Disease','Disease','true'
'previous myocardial infarction no','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'previous myocardial infarction no','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'previous myocardial infarction no','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'previous myocardial infarction no','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'previous myocardial infarction no','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'previous percutaneous coronary intervention','C0205156','Previous','Previous','false'
'previous percutaneous coronary intervention','C1532338','Intervention, Percutaneous Coronary','Percutaneous Coronary Intervention','true'
'previous percutaneous coronary intervention','C1552607','previous','Act Relationship Subset - previous','false'
'previous coronary artery bypass surgery no','C2144990','previous Coronary Artery Bypass Surgery','previous Aortocoronary Bypass','false'
'estimated gfr ml min','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min','C0439445','mL/min','mL/min','false'
'estimated gfr ml min','C1424601','GFR','RAPGEF5 gene','false'
'time point','C2348792','Timepoint','Timepoint','false'
'ckd','C1561643','CKD','Chronic Kidney Diseases','true'
'chronic cvd','C0205191','CHRONIC','chronic','false'
'chronic cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'to goal','C0018017','Goal','objective (goal)','true'
'to goal','C1571704','Goal','Act Mood - Goal','false'
'week $nmbr$ et','C0332174','/week','Weekly','false'
'week $nmbr$ et','C0040028','ET','Thrombocythemia, Essential','true'
'week $nmbr$ et','C0439230','Week','week','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C0024671','MG','Mammography','true'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C0026410','MG','Mongolia','true'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C0439269','mg%','mg/dL','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C4321396','MG','MG','false'
'om $nmbr$ aml $nmbr$ hctz $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'sitagliptin $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'sitagliptin $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'sitagliptin $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'sitagliptin $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'sitagliptin $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'sitagliptin $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'sitagliptin $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'american indian alaska native','C0886378','American native','Native American Healing','false'
'body weight kg mean sd','C0005910','Body Weight','Body Weight','true'
'body weight kg mean sd','C2699239','SD','SD, Rat Strain','false'
'body weight kg mean sd','C1305866','body weight','Weighing patient','false'
'known duration of type $nmbr$ diabetes','C0449238','Duration','Duration (temporal concept)','false'
'known duration of type $nmbr$ diabetes','C2926735','Duration','Duration','false'
'years mean sd','C0439234','YEARS','year','false'
'years mean sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c mean sd [range]','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c mean sd [range]','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c mean sd [range]','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c mean sd [range]','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c mean sd [range]','C1514721','Range','Range','false'
'hba $nmbr$ c mean sd [range]','C2348147','Range','Sample Range','false'
'hba $nmbr$ c mean sd [range]','C3542016','Range','Concept model range (foundation metadata concept)','false'
'hba $nmbr$ c distribution at baseline n','C0520511','Distribution','Distributing','false'
'hba $nmbr$ c distribution at baseline n','C1704711','Distribution','Distribution','true'
'fpg mmol l mean sd','C1532563','mmol/L','Millimole per Liter','false'
'fpg mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ h pmg mmol l mean sd','C2827804','h*mmol/L','Hour Times Micromole per Milliliter','false'
'$nmbr$ h pmg mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'fasting insulin pmol l mean sd','C0015663','FASTING','Fasting','true'
'fasting insulin pmol l mean sd','C0439284','pmol/L','Picomole per Liter','false'
'fasting insulin pmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'canakinumab dose per mo','C0178602','DOSE','Dosage','false'
'canakinumab dose per mo','C0869039','Dose','Unit dose','false'
'canakinumab dose per mo','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'total group n $nmbr$','C0439175','% total','% of total','false'
'total group n $nmbr$','C0441848','Group N','Group N','false'
'total group n $nmbr$','C0439810','Total','Total','false'
'blood pressure mm','C4330985','/mm','Per Millimeter','false'
'blood pressure mm','C4554674','MM','MM genotype','false'
'geographic site','C0017446','geographic site','Geographic Locations','true'
'duration of diabetes mellitus y','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes mellitus y','C2926735','Duration','Duration','false'
'previous metformin use','C0042153','use','utilization qualifier','true'
'previous metformin use','C0457083','Use','Usage','false'
'previous metformin use','C1947944','Use','Use - dosing instruction imperative','false'
'metformin dose mg','C0024671','MG','Mammography','true'
'metformin dose mg','C0026410','MG','Mongolia','true'
'metformin dose mg','C0439269','mg%','mg/dL','false'
'metformin dose mg','C1960952','mg %','Milligram percent','false'
'metformin dose mg','C2346927','Mg++','Magnesium Cation','false'
'metformin dose mg','C4321396','MG','MG','false'
'metformin dose mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'glucose mmol l','C0017725','GLUCOSE','Glucose','true'
'glucose mmol l','C1532563','mmol/L','Millimole per Liter','false'
'insulin pmol l','C0021641','INSULIN','Insulin','true'
'insulin pmol l','C0439284','pmol/L','Picomole per Liter','false'
'insulin pmol l','C1533581','INSULIN','Recombinant Insulin','false'
'insulin pmol l','C1579433','Insulin','Insulin [EPC]','false'
'insulin pmol l','C3714501','INSULIN','Insulin Drug Class','false'
'ldl c mmol l','C1532563','mmol/L','Millimole per Liter','false'
'hdl c mmol l','C3715113','HDL','HSD11B1 wt Allele','false'
'hdl c mmol l','C1532563','mmol/L','Millimole per Liter','false'
'non hdl c mmol l','C1518422','Non','Negation','false'
'non hdl c mmol l','C1532563','mmol/L','Millimole per Liter','false'
'triglyceride mmol l','C0041004','Triglyceride','Triglycerides','true'
'triglyceride mmol l','C1532563','mmol/L','Millimole per Liter','false'
'il $nmbr$ ng l','C0020898','IL','Illinois (geographic location)','true'
'il $nmbr$ ng l','C0439297','ng/L','Nanogram per Liter','false'
'il $nmbr$ ng l','C0021764','IL','Interleukins','true'
'il $nmbr$ ng l','C0022271','IL','Israel','true'
'fibrinogen g l','C0439294','g l','Kilogram per Cubic Meter','false'
'fibrinogen g l','C0456615','G/L','Billion per Liter','false'
'canakinumab dose per month','C0178602','DOSE','Dosage','false'
'canakinumab dose per month','C0869039','Dose','Unit dose','false'
'canakinumab dose per month','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'crp','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp','C4048285','CRP','C-Reactive Protein, human','false'
'change median baseline crp $nmbr$ mg l','C0168634','baseline','BaseLine dental cement','true'
'change median baseline crp $nmbr$ mg l','C0439268','mg/L','Microgram per Milliliter','false'
'change median baseline crp $nmbr$ mg l','C1442488','Baseline','Baseline','false'
'baseline crp','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'baseline crp','C4048285','CRP','C-Reactive Protein, human','false'
'il $nmbr$','C0020898','IL','Illinois (geographic location)','true'
'il $nmbr$','C0021764','IL','Interleukins','true'
'il $nmbr$','C0022271','IL','Israel','true'
'fibrinogen','C0016006','FIBRINOGEN','Fibrinogen','true'
'fibrinogen','C1167394','fibrinogen','fibrinogen complex location','false'
'fibrinogen','C2587184','FIBRINOGEN','fibrinogen concentrate (human)','false'
'fibrinogen','C3540039','Fibrinogen','Fibrinogen containing hemostatics','false'
'parameters','C0449381','Parameters','Observation parameter','false'
'n v n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'n v n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'v $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'v $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'race asian n','C0034510','RACE','Racial group','true'
'race asian n','C0078988','ASIAN','Asians','true'
'race asian n','C1706779','RACE','AMACR wt Allele','false'
'race asian n','C3853635','Race','Race','false'
'mean sd kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean sd kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean sd kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'nonsmoker n','C0337672','nonsmoker','Non-smoker','false'
'nonsmoker n','C0425293','Non-Smoker','Never smoked tobacco','false'
'nonsmoker n','C4554605','Nonsmoker','Non-Smokers -- population group','true'
'baseline sbp','C0168634','baseline','BaseLine dental cement','true'
'baseline sbp','C0085805','SBP','Androgen Binding Protein','true'
'baseline sbp','C1442488','Baseline','Baseline','false'
'mean sd mmhg','C0444504','Mean','Statistical mean','false'
'mean sd mmhg','C0439475','mmHG','mmHg','false'
'mean sd mmhg','C2347634','Mean','Population Mean','false'
'mean sd mmhg','C2348143','Mean','Sample Mean','false'
'baseline dbp','C0536221','DBP','HSD17B4 protein, human','true'
'baseline dbp','C3813197','DBP','HSD17B4 wt Allele','false'
'baseline dbp','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'metabolism and nutrition','C0025519','Metabolism','Metabolism','true'
'metabolism and nutrition','C0025520','metabolism','metabolic aspects','true'
'metabolism and nutrition','C0028707','Nutrition','Science of nutrition','true'
'metabolism and nutrition','C0392209','nutrition','Nutritional status','true'
'metabolism and nutrition','C0518896','Nutrition','Nutrition outcomes','false'
'metabolism and nutrition','C1442959','Nutrition','Nutrition function','false'
'disorders soc','C0012634','Disorders','Disease','true'
'cardiac disorders soc','C0018799','Cardiac Disorders','Heart Diseases','true'
'cerebral infarction','C0007785','CEREBRAL INFARCTION','Cerebral Infarction','true'
'cerebral ischemia','C0007785','Cerebral Ischemia','Cerebral Infarction','true'
'cerebral ischemia','C0917798','Cerebral ischaemia','Cerebral Ischemia','true'
'cerebrovascular accident','C0038454','CEREBROVASCULAR ACCIDENT','Cerebrovascular accident','true'
'normal weight bmi','C4229017','Normal BMI','Normal BMI','false'
'overweight bmi $nmbr$ to','C0497406','OVERWEIGHT','Overweight','true'
'overweight bmi $nmbr$ to','C0578022','BMI','Finding of body mass index','false'
'obese bmi $nmbr$','C0028754','OBESE','Obesity','true'
'obese bmi $nmbr$','C0578022','BMI','Finding of body mass index','false'
'b h n $nmbr$','C0033727','H+','Protons','true'
'b h n $nmbr$','C0369286','H NOS','H NOS Antibodies','false'
'b h n $nmbr$','C0441932','H+','Hepatic Involvement','false'
'b h n $nmbr$','C0564385','/h','/hour','false'
'b h n $nmbr$','C4528284','h*%','Hour Times Percent','false'
'sex men women','C0009253','Sex','Coitus','true'
'sex men women','C0043210','Women','Woman','true'
'sex men women','C0036864','Sex','Sex Behavior','true'
'sex men women','C0079399','sex','Gender','true'
'sex men women','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex men women','C1314687','Sex','Sexual intercourse - finding','false'
'sex men women','C1522384','SEX','sex','true'
'previous coronary heart disease','C0010054','coronary heart disease','Coronary Arteriosclerosis','true'
'previous coronary heart disease','C0010068','Coronary Heart Disease','Coronary heart disease','true'
'previous coronary heart disease','C1956346','coronary heart disease','Coronary Artery Disease','true'
'previous chronic kidney disease','C1561643','Chronic Kidney Disease','Chronic Kidney Diseases','true'
'previous chronic kidney disease','C4553188','Chronic kidney disease','Chronic Kidney Disease, CTCAE','false'
'change in retinal pathology','C0392747','Change','Changing','false'
'change in retinal pathology','C0443172','change','Changed status','false'
'change in retinal pathology','C1705241','Change','Delta (difference)','false'
'change in retinal pathology','C4319952','Change','Change -- procedure','false'
'$nmbr$ step','C1261552','Step','Step (specific stage)','false'
'$nmbr$ step','C1704379','Step','Treatment Step','false'
'$nmbr$ step','C1705117','Step','Increment','false'
'$nmbr$ step','C2825408','Step','Stair (equipment)','false'
'$nmbr$ step','C3814463','{Step}','Step Unit of Distance','false'
'$nmbr$ or $nmbr$ step','C1261552','Step','Step (specific stage)','false'
'$nmbr$ or $nmbr$ step','C1704379','Step','Treatment Step','false'
'$nmbr$ or $nmbr$ step','C1705117','Step','Increment','false'
'$nmbr$ or $nmbr$ step','C2825408','Step','Stair (equipment)','false'
'$nmbr$ or $nmbr$ step','C3814463','{Step}','Step Unit of Distance','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C1261552','Step','Step (specific stage)','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C1704379','Step','Treatment Step','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C1705117','Step','Increment','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C2825408','Step','Stair (equipment)','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C3814463','{Step}','Step Unit of Distance','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C1551358','Incident','Incident','false'
'$nmbr$ step or incident vitrectomy or photocoagulation','C0042903','Vitrectomy','Vitrectomy','true'
'$nmbr$ step or incident vitrectomy or photocoagulation','C0023694','Photocoagulation','Light Coagulation','true'
'$nmbr$ step or incident vitrectomy or photocoagulation','C1328010','photocoagulation','Infrared Photocoagulation Therapy','false'
'baseline a $nmbr$ c','C0168634','baseline','BaseLine dental cement','true'
'baseline a $nmbr$ c','C1442488','Baseline','Baseline','false'
'baseline sbp mm','C4330985','/mm','Per Millimeter','false'
'baseline sbp mm','C4554674','MM','MM genotype','false'
'baseline ldl mg','C0024671','MG','Mammography','true'
'baseline ldl mg','C0026410','MG','Mongolia','true'
'baseline ldl mg','C0439269','mg%','mg/dL','false'
'baseline ldl mg','C1960952','mg %','Milligram percent','false'
'baseline ldl mg','C2346927','Mg++','Magnesium Cation','false'
'baseline ldl mg','C4321396','MG','MG','false'
'baseline ldl mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'outcomes during accord','C1274040','Outcome','Result','false'
'outcomes during accord','C0680240','accord','Agreement','false'
'accord primary n','C0205225','Primary','Primary','false'
'accord primary n','C0439612','Primary','True primary (qualifier value)','false'
'accord primary n','C0439631','Primary','Primary operation','false'
'fatal nonfatal mi n','C1302234','Fatal','Fatal','false'
'fatal nonfatal mi n','C1705232','FATAL','Death Related to Adverse Event','false'
'fatal nonfatal stroke n','C1302234','Fatal','Fatal','false'
'fatal nonfatal stroke n','C0038454','STROKE','Cerebrovascular accident','true'
'fatal nonfatal stroke n','C4554100','Stroke','Stroke, CTCAE','false'
'fatal nonfatal stroke n','C1705232','FATAL','Death Related to Adverse Event','false'
'concomitant antiplatelet','C0521115','Concomitant','Simultaneous','false'
'no concomitant antiplatelet','C0521115','Concomitant','Simultaneous','false'
'de $nmbr$ n $nmbr$','C0011198','DE','Delaware','true'
'de $nmbr$ n $nmbr$','C0017480','DE','Germany','true'
'de $nmbr$ n $nmbr$','C3541240','DE','Device Events Domain','false'
'previous htn n','C0205156','Previous','Previous','false'
'previous htn n','C0020538','HTN','Hypertensive disease','true'
'previous htn n','C1552607','previous','Act Relationship Subset - previous','false'
'previous dm n','C0205156','Previous','Previous','false'
'previous dm n','C0011816','DM','Dextromethorphan','true'
'previous dm n','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'previous dm n','C1552607','previous','Act Relationship Subset - previous','false'
'previous mi n','C0205156','Previous','Previous','false'
'previous mi n','C1552607','previous','Act Relationship Subset - previous','false'
'previous cad n','C0205156','Previous','Previous','false'
'previous cad n','C1504769','CAD','DFFB protein, human','true'
'previous cad n','C2239547','CAD','ACOD1 gene','false'
'previous cad n','C3813548','CAD','CALD1 wt Allele','false'
'previous cad n','C4284121','CAD','DFFB wt Allele','false'
'previous cad n','C1552607','previous','Act Relationship Subset - previous','false'
'previous chf n','C0205156','Previous','Previous','false'
'previous chf n','C0018802','CHF','Congestive heart failure','true'
'previous chf n','C1552607','previous','Act Relationship Subset - previous','false'
'previous stroke n','C0205156','Previous','Previous','false'
'previous stroke n','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke n','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke n','C1552607','previous','Act Relationship Subset - previous','false'
'chads score n','C0449820','SCORE','Score','false'
'chads score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'previous renal disease n','C0205156','Previous','Previous','false'
'previous renal disease n','C0022658','RENAL DISEASE, NOS','Kidney Diseases','true'
'previous renal disease n','C1552607','previous','Act Relationship Subset - previous','false'
'type of af n','C0332307','TYPE','Type - attribute','false'
'type of af n','C1547052','*Type','*Type - Kind of quantity','false'
'duration antiplatelet use as of study duration sd','C1881378','DURATION OF USE','Limitation of Use Based on Duration of Use','false'
'duration antiplatelet use as of study duration sd','C2826775','Duration of Use','Duration of Use','false'
'rate year','C0439234','Year','year','false'
'rate year','C0439508','/Year','per year','false'
'stroke embolism','C0013922','EMBOLISM','Embolism','true'
'stroke embolism','C1704212','Embolism, NOS','Embolus','true'
'all stroke','C0038454','STROKE','Cerebrovascular accident','true'
'all stroke','C4554100','Stroke','Stroke, CTCAE','false'
'cv death','C0011065','DEATH','Cessation of life','true'
'cv death','C1306577','Death','Death (finding)','false'
'cv death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cv death','C4552775','Death NOS','Death NOS, CTCAE','false'
'major bleed','C0205082','Major','Severe (severity modifier)','false'
'major bleed','C0019080','bleed','Hemorrhage','true'
'major bleed','C0205164','Major','Major','false'
'major bleed','C4318856','Major','Major <insect>','false'
'major bleed','C4521762','Major','United States Military Commissioned Officer O4','false'
'minor bleed','C0026193','Minor','Minor (person)','true'
'minor bleed','C0019080','bleed','Hemorrhage','true'
'minor bleed','C0205165','Minor','Minor (value)','false'
'all bleed','C0019080','bleed','Hemorrhage','true'
'intracranial','C0524466','Intracranial','Intracranial','false'
'extracranial','C0580586','Extracranial','Extracranial','false'
'with mets','C0812270','METS','ETV3 gene','false'
'with mets','C1705694','METS','ETV3 wt Allele','false'
'with mets','C2939420','mets','Metastatic Neoplasm','false'
'ez simva $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'ez simva $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'ez simva $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'ez simva $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'ez simva $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'ez simva $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'ez simva $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'doubling statin dose','C0178602','DOSE','Dosage','false'
'doubling statin dose','C0869039','Dose','Unit dose','false'
'doubling statin dose','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'rosuvastatin $nmbr$ mg','C0024671','MG','Mammography','true'
'rosuvastatin $nmbr$ mg','C0026410','MG','Mongolia','true'
'rosuvastatin $nmbr$ mg','C0439269','mg%','mg/dL','false'
'rosuvastatin $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'rosuvastatin $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'rosuvastatin $nmbr$ mg','C4321396','MG','MG','false'
'rosuvastatin $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'multi racial','C0439064','Multi','Numerous','false'
'multi racial','C3266262','Multi','Multiple Chronic Conditions','true'
'without mets','C0812270','METS','ETV3 gene','false'
'without mets','C1705694','METS','ETV3 wt Allele','false'
'without mets','C2939420','mets','Metastatic Neoplasm','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0392747','Change','Changing','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0443172','change','Changed status','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1274040','Result','Result','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1546471','Result','What subject filter - Result','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C2825142','Result','Experimental Result','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0449450','Presented','Presentation','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0084844','MENT','trestolone','true'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1538994','MENT','C1orf56 gene','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0332174','/week','Weekly','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0439230','Week','week','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0007447','Cation','Cations','true'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0162425','intent','Intention - mental process','true'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1283828','Intent','intent','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1550453','intent','Act Mood - intent','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0032659','Population','geographic population','true'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C0042295','Values','Values','false'
'figure $nmbr$ change in $nmbr$ minute walk distance $nmbr$ mwd by covariates results presented as hodges lehmann median estimate of treat ment effect for the change in $nmbr$ mwd at week $nmbr$ by covariate classi cation for the modi ed intent to treat mitt population subgroup interaction probability values provided for covariates p','C1257890','Population','Population Group','true'
'subgoup_name','C0027365','Name','Name','true'
'subgoup_name','C1547383','Name','Person Name','false'
'subgoup_name','C4522128','Name','Name (property) (qualifier value)','false'
'subgroup_level','C0441889','Level','Levels (qualifier value)','false'
'subgroup_level','C0456079','Level','Disease classification level','false'
'subgroup_level','C1547707','Level','Floor - story of building','false'
'subgroup_level','C2946261','Level','Level','false'
'image only','C1704254','Image','Medical Image','false'
'image only','C1704922','Image','Image','false'
'image only','C3542466','Image','Image (foundation metadata concept)','false'
'chads $nmbr$','C0007928','CHAD','Chad','true'
'chads $nmbr$','C1413373','CHAD','CHAD gene','false'
'r $nmbr$','C0205090','R-','Right','false'
'r $nmbr$','C0684010','R.','Rabbi','true'
'r $nmbr$','C2603358','R'','R prime','false'
'af pattern','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'af pattern','C0449774','Pattern','Patterns','false'
'af pattern','C4049859','AF','PSMD4 wt Allele','false'
'laa ostium','C0444567','Ostium','Ostium','false'
'$nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'$nmbr$ mm','C4554674','MM','MM genotype','false'
'laa length','C1444754','Length','Length','false'
'laa length','C1706316','LENGTH','Length of Trial','false'
'device watchman filter','C0180860','Filter, device','Filters','false'
'device watchman filter','C0335390','Watchman','Watchman','false'
'control warfarin','C0243148','control','control aspects','true'
'control warfarin','C0043031','WARFARIN','Warfarin','true'
'control warfarin','C1550141','Control','control substance','false'
'control warfarin','C1882979','Control','Scientific Control','false'
'control warfarin','C2587213','Control','Control function','false'
'control warfarin','C3274648','Control','True Control Status','false'
'control warfarin','C4553389','control','Study Control','false'
'age y $nmbr$ th $nmbr$ th percentiles','C0001779','AGE','Age','false'
'age y $nmbr$ th $nmbr$ th percentiles','C1264641','percentiles','Percentile','false'
'months from qualifying stroke','C0439231','MONTHS','month','false'
'months from qualifying stroke','C1514624','Qualifying','Qualifying','false'
'months from qualifying stroke','C0038454','STROKE','Cerebrovascular accident','true'
'months from qualifying stroke','C4554100','Stroke','Stroke, CTCAE','false'
'selected clinical characteristics','C1707391','Selected','Choose (action)','false'
'selected clinical characteristics','C0683325','clinical characteristics','clinical aspects','false'
'rankin scale $nmbr$','C0451405','Rankin scale','Rankin scale','false'
'aspirin alone','C0004057','ASPIRIN','Aspirin','true'
'aspirin alone','C0205171','Alone','Singular','false'
'aspirin alone','C0439044','Alone','Living Alone','false'
'aspirin alone','C0679994','alone','alone - group size','false'
'thienopyridine alone','C1120149','thienopyridine','thienopyridine','true'
'thienopyridine alone','C0205171','Alone','Singular','false'
'thienopyridine alone','C0439044','Alone','Living Alone','false'
'thienopyridine alone','C0679994','alone','alone - group size','false'
'dipyridamole alone','C0012582','DIPYRIDAMOLE','Dipyridamole','true'
'dipyridamole alone','C0205171','Alone','Singular','false'
'dipyridamole alone','C0439044','Alone','Living Alone','false'
'dipyridamole alone','C0679994','alone','alone - group size','false'
'aspirin thienopyridine','C0004057','ASPIRIN','Aspirin','true'
'aspirin thienopyridine','C1120149','thienopyridine','thienopyridine','true'
'aspirin dipyridamole','C0732279','ASPIRIN/DIPYRIDAMOLE','Aspirin / Dipyridamole','true'
'thienopyridine dipyridamole','C1120149','thienopyridine','thienopyridine','true'
'thienopyridine dipyridamole','C0012582','DIPYRIDAMOLE','Dipyridamole','true'
'other medications at enrollment','C0013227','Medications','Pharmaceutical Preparations','true'
'other medications at enrollment','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'other medications at enrollment','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'other medications at enrollment','C4284232','Medications','Medications','false'
'vorapaxar no $nmbr$ y km','C2974521','VORAPAXAR','vorapaxar','true'
'vorapaxar no $nmbr$ y km','C3887676','KM','Kathy Mercer','false'
'placebo no $nmbr$ y km','C0032042','Placebo','Placebos','true'
'placebo no $nmbr$ y km','C1696465','PLACEBO','placebo','false'
'placebo no $nmbr$ y km','C1706408','PLACEBO','Placebo Control','false'
'placebo no $nmbr$ y km','C3887676','KM','Kathy Mercer','false'
'efficacy end points','C1280519','Efficacy','Effectiveness','false'
'efficacy end points','C2349179','End Point','End Point','false'
'efficacy end points','C1707887','EFFICACY','Efficacy Study','false'
'cv death mi or stroke','C0011065','DEATH','Cessation of life','true'
'cv death mi or stroke','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'cv death mi or stroke','C1306577','Death','Death (finding)','false'
'cv death mi or stroke','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cv death mi or stroke','C4552775','Death NOS','Death NOS, CTCAE','false'
'cv death mi or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'cv death mi or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'cv death mi stroke or urgent coronary revascularization','C0038454','STROKE','Cerebrovascular accident','true'
'cv death mi stroke or urgent coronary revascularization','C4554100','Stroke','Stroke, CTCAE','false'
'cv death mi stroke or urgent coronary revascularization','C0439609','Urgent','Urgent','false'
'cv death mi stroke or urgent coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'cv death mi stroke or urgent coronary revascularization','C3272275','URGENT','Urgent Procedure','false'
'any stroke','C0038454','STROKE','Cerebrovascular accident','true'
'any stroke','C4554100','Stroke','Stroke, CTCAE','false'
'urgent coronary revascularization','C0439609','Urgent','Urgent','false'
'urgent coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'urgent coronary revascularization','C3272275','URGENT','Urgent Procedure','false'
'all cause death','C0011065','DEATH','Cessation of life','true'
'all cause death','C1306577','Death','Death (finding)','false'
'all cause death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'all cause death','C4552775','Death NOS','Death NOS, CTCAE','false'
'bleeding end points','C0019080','BLEEDING','Hemorrhage','true'
'bleeding end points','C2349179','End Point','End Point','false'
'gusto moderate or severe','C0205081','Moderate','Moderate (severity modifier)','false'
'gusto moderate or severe','C1881878','Moderate','Moderation','false'
'gusto moderate or severe','C4049705','Moderate','Moderate Extremity Pain','false'
'gusto moderate or severe','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'gusto moderate or severe','C4085643','Moderate','Moderate Response','false'
'gusto moderate or severe','C4321335','Moderate','Moderate Level','false'
'gusto moderate or severe','C0205082','Severe','Severe (severity modifier)','false'
'gusto moderate or severe','C4050465','Severe','Severe Extremity Pain','false'
'gusto moderate or severe','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'gusto severe','C0205082','Severe','Severe (severity modifier)','false'
'gusto severe','C4050465','Severe','Severe Extremity Pain','false'
'gusto severe','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'timi clinically significant','C0237881','significant','Statistical Significance','false'
'timi clinically significant','C0750502','Significant','Significant','false'
'timi clinically significant','C1546944','Significant','Event Seriousness - Significant','false'
'timi non cabg major','C0205082','Major','Severe (severity modifier)','false'
'timi non cabg major','C0205164','Major','Major','false'
'timi non cabg major','C4318856','Major','Major <insect>','false'
'timi non cabg major','C4521762','Major','United States Military Commissioned Officer O4','false'
'timi minor','C0026193','Minor','Minor (person)','true'
'timi minor','C0205165','Minor','Minor (value)','false'
'fatal bleeding','C1302234','Fatal','Fatal','false'
'fatal bleeding','C0019080','BLEEDING','Hemorrhage','true'
'fatal bleeding','C1705232','FATAL','Death Related to Adverse Event','false'
'intracranial hemorrhage','C0151699','Intracranial haemorrhage','Intracranial Hemorrhage','true'
'intracranial hemorrhage','C4554169','Intracranial hemorrhage','Intracranial Hemorrhage, CTCAE','false'
'intracerebral','C0442111','Intracerebral','Intracerebral','false'
'subdural epidural','C0228134','epidural','Spinal epidural space','true'
'subdural epidural','C0812144','epidural','Medication administration: epidural','false'
'active control study','C2347179','Active Study','Active Study','false'
'placebo control study','C0683952','Placebo Control study','placebo study','false'
'estimated creatinine clearance ml min i','C0023806','ML I','Lipomucopolysaccharidosis','true'
'neither deep vein thrombosis nor pulmonary embolism','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'neither deep vein thrombosis nor pulmonary embolism','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'immobilization no','C0020944','Immobilization','Immobilization','true'
'immobilization no','C4048292','Immobilization','Immobilization test','false'
'transient','C0040704','Transient','Transient Population Group','true'
'transient','C0205374','Transient','Transitory','false'
'known thrombophilia no','C0205309','Known','Known','false'
'known thrombophilia no','C0398623','Thrombophilia','Thrombophilia','true'
'active cancer no','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer no','C0998265','Cancer','Cancer Genus','false'
'active cancer no','C1306459','Cancer','Primary malignant neoplasm','false'
'previous cancer no','C0006826','CANCER','Malignant Neoplasms','true'
'previous cancer no','C0998265','Cancer','Cancer Genus','false'
'previous cancer no','C1306459','Cancer','Primary malignant neoplasm','false'
'coronary artery disease no','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'coronary artery disease no','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'coronary artery disease no','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'treatment duration before randomization days','C0444921','Treatment duration','Duration of treatment','false'
'treatment duration before randomization days','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'enrolled from re cover study no','C4684790','enrolled','Study Subject Enrolled','false'
'enrolled from re cover study no','C0556581','{RE}','Retinol equivalents','false'
'enrolled from re cover study no','C0180153','Cover','Covers (device)','false'
'enrolled from re cover study no','C1999244','Cover','Cover - action','false'
'enrolled from re cover study no','C3888055','Cover','Cover (physical object)','false'
'enrolled from re cover study no','C2986904','RE','Respiratory Domain','false'
'enrolled from re cover study no','C0557651','Study','Room of building - Study','false'
'enrolled from re cover study no','C2603343','Study','Study','false'
'dabigatran group','C0441833','Group','Groups','false'
'dabigatran group','C0687744','group','Social group','false'
'dabigatran group','C1257890','Group','Population Group','true'
'dabigatran group','C1519504','Group','Stage Grouping','false'
'dabigatran group','C1705428','Group','Group Object','false'
'dabigatran group','C1705429','Group','User Group','false'
'warfarin group','C0441833','Group','Groups','false'
'warfarin group','C0687744','group','Social group','false'
'warfarin group','C1257890','Group','Population Group','true'
'warfarin group','C1519504','Group','Stage Grouping','false'
'warfarin group','C1705428','Group','Group Object','false'
'warfarin group','C1705429','Group','User Group','false'
'enrolled from re cover ii study no','C4684790','enrolled','Study Subject Enrolled','false'
'enrolled from re cover ii study no','C0556581','{RE}','Retinol equivalents','false'
'enrolled from re cover ii study no','C0180153','Cover','Covers (device)','false'
'enrolled from re cover ii study no','C1999244','Cover','Cover - action','false'
'enrolled from re cover ii study no','C3888055','Cover','Cover (physical object)','false'
'enrolled from re cover ii study no','C2986904','RE','Respiratory Domain','false'
'enrolled from re cover ii study no','C0557651','Study','Room of building - Study','false'
'enrolled from re cover ii study no','C2603343','Study','Study','false'
'adherence to study regimen no ff','C1510802','Adherence','Adherence (attribute)','false'
'adherence to study regimen no ff','C0040808','Regimen','Treatment Protocols','true'
'adherence to study regimen no ff','C2945654','regimen','Regimen - CHV concept','false'
'adherence to study regimen no ff','C4554348','FF','FF genotype','false'
'factors dabigatran event incidence n','C0021149','Incidence','Incidence','true'
'factors dabigatran event incidence n','C0220856','incidence','incidence of cases','true'
'wafarin event incidence n','C0021149','Incidence','Incidence','true'
'wafarin event incidence n','C0220856','incidence','incidence of cases','true'
'age category','C0683312','Category','Categories','false'
'age category','C3889287','Category','Digital Content Category','false'
'geographical region','C0017446','Region','Geographic Locations','true'
'geographical region','C0205147','Region','regional','false'
'creatine clearance category $nmbr$ to','C0683312','Category','Categories','false'
'creatine clearance category $nmbr$ to','C3889287','Category','Digital Content Category','false'
'smoking history','C1519384','Smoking History','Smoking History','false'
'ex smoker','C0337671','Ex-smoker','Former smoker','false'
'ex smoker','C4555205','Ex-Smoker','Ex-Smokers','true'
'currently smokes','C0521116','Currently','Current (present time)','false'
'currently smokes','C0037369','smokes','Smoking','true'
'subgroup w r t re cover','C0180153','Cover','Covers (device)','false'
'subgroup w r t re cover','C1999244','Cover','Cover - action','false'
'subgroup w r t re cover','C3888055','Cover','Cover (physical object)','false'
're cover $nmbr$ dabigatran','C0556581','{RE}','Retinol equivalents','false'
're cover $nmbr$ dabigatran','C0180153','Cover','Covers (device)','false'
're cover $nmbr$ dabigatran','C1999244','Cover','Cover - action','false'
're cover $nmbr$ dabigatran','C3888055','Cover','Cover (physical object)','false'
're cover $nmbr$ dabigatran','C2986904','RE','Respiratory Domain','false'
're cover $nmbr$ dabigatran','C2348066','DABIGATRAN','dabigatran','true'
're cover $nmbr$ warfarin','C0556581','{RE}','Retinol equivalents','false'
're cover $nmbr$ warfarin','C0180153','Cover','Covers (device)','false'
're cover $nmbr$ warfarin','C1999244','Cover','Cover - action','false'
're cover $nmbr$ warfarin','C3888055','Cover','Cover (physical object)','false'
're cover $nmbr$ warfarin','C2986904','RE','Respiratory Domain','false'
're cover $nmbr$ warfarin','C0043031','WARFARIN','Warfarin','true'
're cover ii','C0556581','{RE}','Retinol equivalents','false'
're cover ii','C0180153','Cover','Covers (device)','false'
're cover ii','C1999244','Cover','Cover - action','false'
're cover ii','C3888055','Cover','Cover (physical object)','false'
're cover ii','C2986904','RE','Respiratory Domain','false'
'non rollover','C0517067','roll over','Rolls over, 6 month child development','false'
'non rollover','C0543436','roll over','Does roll over','false'
'symptomatic pe','C0070939','PE','phosphoethanolamine','true'
'symptomatic pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'symptomatic pe','C4284304','PE','PENK wt Allele','false'
'history of $nmbr$ previous vte excluding index event','C0019664','History','History','true'
'history of $nmbr$ previous vte excluding index event','C0019665','history','Historical aspects qualifier','true'
'history of $nmbr$ previous vte excluding index event','C0262512','History, NOS','History of present illness','false'
'history of $nmbr$ previous vte excluding index event','C0262926','History','Medical History','false'
'history of $nmbr$ previous vte excluding index event','C1705255','History','Concept History','false'
'history of $nmbr$ previous vte excluding index event','C2004062','History','History of previous events','false'
'history of $nmbr$ previous vte excluding index event','C0441471','Event','Event','false'
'history of $nmbr$ previous vte excluding index event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'history of non hemor rhagic stroke','C0019664','History','History','true'
'history of non hemor rhagic stroke','C0019665','history','Historical aspects qualifier','true'
'history of non hemor rhagic stroke','C0262512','History, NOS','History of present illness','false'
'history of non hemor rhagic stroke','C0262926','History','Medical History','false'
'history of non hemor rhagic stroke','C1705255','History','Concept History','false'
'history of non hemor rhagic stroke','C2004062','History','History of previous events','false'
'history of coronary artery disease','C1881055','History of Coronary Artery Disease','Personal History of Coronary Artery Disease','false'
'factors dabigatran','C1521761','Factor','Factor','false'
'factors dabigatran','C2348066','DABIGATRAN','dabigatran','true'
'factors dabigatran','C2827422','Factor','Mathematical Factor','false'
'p value for','C1709380','P-Value','P-Value','false'
'event incidence n','C0021149','Incidence','Incidence','true'
'event incidence n','C0220856','incidence','incidence of cases','true'
'black or asian','C0005680','Black','Black race','true'
'black or asian','C0027567','Black','African race','true'
'black or asian','C0085756','BLACK','African American','true'
'black or asian','C0439541','Black','Black color','false'
'black or asian','C0078988','ASIAN','Asians','true'
'rest of the world','C0035253','Rest','Rest','true'
'rest of the world','C1622890','ResT','site-specific telomere resolvase activity','false'
'l $nmbr$ kg','C1637390','L/kg','Milliliter per gram','false'
'creatine clearance category','C0683312','Category','Categories','false'
'creatine clearance category','C3889287','Category','Digital Content Category','false'
'$nmbr$ m b m in','C0369637','M NOS','M NOS ANTIBODY','false'
'$nmbr$ m b m in','C0441923','M+','M+ (tumor staging)','false'
'$nmbr$ ^ $nmbr$ t $nmbr$ c u','C2603360','T'','T prime','false'
'$nmbr$ ^ $nmbr$ t $nmbr$ c u','C0439148','{U}','Unit','false'
'qualifying index event as pe','C1514624','Qualifying','Qualifying','false'
'qualifying index event as pe','C0441471','Event','Event','false'
'qualifying index event as pe','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'budesonide mmx $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'budesonide mmx $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'budesonide mmx $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'budesonide mmx $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'budesonide mmx $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'budesonide mmx $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'budesonide mmx $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'entocort ec n $nmbr$','C1170256','entocort ec','entocort ec','false'
'mean age years range','C1514721','Range','Range','false'
'mean age years range','C2348147','Range','Sample Range','false'
'mean age years range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'uc history','C0019664','History','History','true'
'uc history','C0019665','history','Historical aspects qualifier','true'
'uc history','C0262512','History, NOS','History of present illness','false'
'uc history','C0262926','History','Medical History','false'
'uc history','C1705255','History','Concept History','false'
'uc history','C2004062','History','History of previous events','false'
'mean disease duration years','C0872146','disease duration','disease length','false'
'mean disease duration years','C0439234','YEARS','year','false'
'duration','C0449238','Duration','Duration (temporal concept)','false'
'duration','C2926735','Duration','Duration','false'
'duration $nmbr$ to','C0449238','Duration','Duration (temporal concept)','false'
'duration $nmbr$ to','C2926735','Duration','Duration','false'
'duration $nmbr$ years n','C0449238','Duration','Duration (temporal concept)','false'
'duration $nmbr$ years n','C0439234','YEARS','year','false'
'duration $nmbr$ years n','C2926735','Duration','Duration','false'
'disease extent n','C0012634','Disease','Disease','true'
'disease extent n','C0439792','Extent','Extent','false'
'proctosigmoiditis','C0033252','Proctosigmoiditis','Proctosigmoiditis','true'
'left sided colitis','C2887821','Left sided colitis','Left sided colitis','false'
'extensive pancolitis','C0205231','Extensive','Extensive','false'
'extensive pancolitis','C0868908','Pancolitis','pancolitis','false'
'mean baseline ucdai score','C3533236','Mean score','Mean score','false'
'mean baseline ucdai score','C0168634','baseline','BaseLine dental cement','true'
'mean baseline ucdai score','C1442488','Baseline','Baseline','false'
'mean baseline ei score','C3533236','Mean score','Mean score','false'
'mean baseline ei score','C0022067','EI','Ireland','true'
'mean baseline ei score','C1414370','EI','SERPINB1 gene','false'
'mean baseline ei score','C2348481','Ei','Exbi','false'
'prior mesalazine use','C0042153','use','utilization qualifier','true'
'prior mesalazine use','C0457083','Use','Usage','false'
'prior mesalazine use','C1947944','Use','Use - dosing instruction imperative','false'
'prior sulfasalazine use','C0042153','use','utilization qualifier','true'
'prior sulfasalazine use','C0457083','Use','Usage','false'
'prior sulfasalazine use','C1947944','Use','Use - dosing instruction imperative','false'
'eo','C0332120','EO','Evidence of (contextual qualifier)','false'
'gender male n','C0079399','Gender','Gender','true'
'gender male n','C0086582','MALE','Males','true'
'gender male n','C1706180','Male','Male Gender, Self Report','false'
'gender male n','C1706428','MALE','Male Phenotype','false'
'gender male n','C1706429','Male','Male, Self-Reported','false'
'gender male n','C1522384','Gender','sex','true'
'american indian alaskan native','C0886378','American native','Native American Healing','false'
'native hawaiian pacific islander','C0337920','Hawaiian, Native','Hawaiian population','true'
'native hawaiian pacific islander','C0242191','Pacific Islander','Pacific Islander Americans','true'
'alcohol drinker n','C0001962','ALCOHOL','Ethanol','true'
'alcohol drinker n','C0001975','Alcohol','Alcohols','true'
'smoker n','C0337664','Smoker','Smoker','true'
'caffeine user n','C3532939','Caffeine user','Caffeine user','false'
'h pylori status n','C0079488','H. pylori','Helicobacter pylori','true'
'h pylori status n','C0449438','Status','Status','false'
'baseline los angeles grade of eo n','C0441800','Grade','Grade','false'
'baseline los angeles grade of eo n','C0919553','Grade','Histopathologic Grade','false'
'baseline los angeles grade of eo n','C3244287','grade','School Grade','false'
'n a','C1272460','N/A','Not Applicable','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0376249','Frequency','With frequency','true'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0439603','Frequency','Frequencies (time pattern)','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0871396','Frequency','Spatial Frequency','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C1561548','Frequency','Kind of quantity - Frequency','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C1705502','Frequency','Statistical Frequency','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C3898838','Frequency','How Often','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C4321352','Frequency','Frequency','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C1522326','Treatment','Treating','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0267055','Erosive oesophagitis','Erosive esophagitis','false'
'figure $nmbr$ frequency of $nmbr$ h heartburn free days during treatment in a non erosive oesophageal reflux disease nerd and b erosive oesophagitis eo patients','C0030705','Patients','Patients','true'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1705241','*Difference','Delta (difference)','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1705242','Difference','Different','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C0039798','treatment','therapeutic aspects','true'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C0087111','Treatment','Therapeutic procedure','true'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1522326','Treatment','Treating','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1533734','Treatment','Administration procedure','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1705169','Treatment','Biomaterial Treatment','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C3538994','TREATMENT','Treatment Epoch','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C3887704','treatment','treatment - ActInformationManagementReason','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C0521095','Determined','Determined by','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1524063','Using','Use of','false'
'statistically significant differences among bmi categories within treatment group were determined using kruskal wallis test','C1708614','Kruskal-Wallis Test','Kruskal-Wallis Test','false'
'figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency','C2986480','Subgroup Analysis','Subset Analysis','false'
'figure $nmbr$ subgroup analyses of the primary endpoint of weekly angina frequency','C3695257','Frequency of angina','Frequency of angina','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0456603','RATIO','Ratio','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C1547037','Ratio','data type - ratio','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C1705241','*Difference','Delta (difference)','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C1705242','Difference','Different','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0023732','Model, Linear','Linear Models','true'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0332152','Pre','Before','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0007447','Cations','Cations','true'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0740175','Pre','Before values','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C2257086','PRE','photoreactivating enzyme activity','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C1079231','Subgroup B','Subgroup B','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C1547282','Show','Show','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C2986480','Subgroup Analysis','Subset Analysis','false'
'incidence density ratio or the relative difference in the incidence rates of weekly angina frequency according to the generalized linear model with nega tive binomial distribution within pre speci ed strati cations and categorical subgroups a b shows the exploratory analysis of subgroups of hba $nmbr$ c by var ious thresholds cabg coronary artery bypass graft surgery pci percuta neous coronary intervention','C0397581','Artery Intervention','Procedures on Arteries','false'
'clinical characteristics n','C0683325','clinical characteristics','clinical aspects','false'
'egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr crcl ml min $nmbr$ $nmbr$ $nmbr$ m $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'pervious cerebrovascular event','C0441471','Event','Event','false'
'pervious cerebrovascular event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'pad details n','C0182158','Pad','Pads','false'
'pad details n','C0332568','Pad','Pad Mass','false'
'pad details n','C3540603','PAD','PADI4 wt Allele','false'
'pad details n','C3669270','Pad','Strucure of thick cushion of skin','false'
'pad details n','C3814046','PAD','PAD Regimen','false'
'pad details n','C4319657','Pad','Pad (unit of presentation)','false'
'peripheral arterial revascularization','C0003842','Arterial','Arteries','true'
'peripheral arterial revascularization','C0581603','Revascularization','Revascularization - action','false'
'peripheral arterial revascularization','C0221464','Arterial','Arterial','false'
'prior amputation','C0002688','AMPUTATION','Amputation','true'
'prior amputation','C0332840','Amputation','Amputated structure (morphologic abnormality)','false'
'prior amputation','C1546539','Amputation','Amputation Specimen Code','false'
'prior carotid intervention','C0184661','Intervention','Interventional procedure','true'
'prior carotid intervention','C0886296','intervention','Nursing interventions','false'
'prior carotid intervention','C1273869','Intervention','Intervention regimes','false'
'abi','C1328319','ABI','Ankle brachial pressure index (observable entity)','true'
'abi','C3888326','ABI','Intravascular systolic.tibial artery/Brachial artery:PresRto:Pt:Arterial system:Qn','false'
'abi $nmbr$ $nmbr$','C1328319','ABI','Ankle brachial pressure index (observable entity)','true'
'abi $nmbr$ $nmbr$','C3888326','ABI','Intravascular systolic.tibial artery/Brachial artery:PresRto:Pt:Arterial system:Qn','false'
'claudication fontaine class $nmbr$','C0456387','Class','Class','false'
'claudication fontaine class $nmbr$','C1518526','class','Object Class','false'
'claudication fontaine class $nmbr$','C1705943','Class','Class (taxonomic)','false'
'baseline medical therapy n','C0168634','baseline','BaseLine dental cement','true'
'baseline medical therapy n','C0418981','Medical therapy','Medical therapy','false'
'baseline medical therapy n','C1442488','Baseline','Baseline','false'
'no antiplatelet therapy','C1096021','antiplatelet therapy','antiplatelet therapy','false'
'aspirin and thienopyridine therapy','C0004057','ASPIRIN','Aspirin','true'
'aspirin and thienopyridine therapy','C0039798','therapy','therapeutic aspects','true'
'aspirin and thienopyridine therapy','C0087111','Therapy','Therapeutic procedure','true'
'aspirin and thienopyridine therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'cilostazol','C0055729','CILOSTAZOL','cilostazol','true'
'vorapaxar n $nmbr$ n','C2974521','VORAPAXAR','vorapaxar','true'
'overall efficacy','C1280519','Efficacy','Effectiveness','false'
'overall efficacy','C1707887','EFFICACY','Efficacy Study','false'
'cvd mi stroke','C0038454','STROKE','Cerebrovascular accident','true'
'cvd mi stroke','C4554100','Stroke','Stroke, CTCAE','false'
'cvd mi stroke urgent coronary revascularization','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'cvd mi stroke urgent coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'cvd mi stroke urgent vascular hospitalization','C0005847','Vascular','Blood Vessel','true'
'cvd mi stroke urgent vascular hospitalization','C0019993','hospitalisation','Hospitalization','true'
'cvd mi stroke urgent vascular hospitalization','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'cvd mi stroke urgent vascular hospitalization','C1801960','Vascular','Vascular','false'
'cvd mi stroke revascularization urgent vascular hospitalization','C0005847','Vascular','Blood Vessel','true'
'cvd mi stroke revascularization urgent vascular hospitalization','C0019993','hospitalisation','Hospitalization','true'
'cvd mi stroke revascularization urgent vascular hospitalization','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'cvd mi stroke revascularization urgent vascular hospitalization','C1801960','Vascular','Vascular','false'
'peripheral limb vascular efficacy','C1280519','Efficacy','Effectiveness','false'
'peripheral limb vascular efficacy','C1707887','EFFICACY','Efficacy Study','false'
'hospitalization for acute limb ischemia','C0019993','hospitalisation','Hospitalization','true'
'hospitalization for acute limb ischemia','C2945695','Limb ischemia','Limb ischemia','false'
'any peripheral revascularization','C0205100','PERIPHERAL','Peripheral','false'
'any peripheral revascularization','C0581603','Revascularization','Revascularization - action','false'
'urgent peripheral revascularization','C0205100','PERIPHERAL','Peripheral','false'
'urgent peripheral revascularization','C0581603','Revascularization','Revascularization - action','false'
'elective peripheral revascularization','C0205100','PERIPHERAL','Peripheral','false'
'elective peripheral revascularization','C0581603','Revascularization','Revascularization - action','false'
'any vascular efficacy','C1280519','Efficacy','Effectiveness','false'
'any vascular efficacy','C1707887','EFFICACY','Efficacy Study','false'
'urgent vascular hospitalization','C0005847','Vascular','Blood Vessel','true'
'urgent vascular hospitalization','C0019993','hospitalisation','Hospitalization','true'
'urgent vascular hospitalization','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'urgent vascular hospitalization','C1801960','Vascular','Vascular','false'
'any revascularization','C0581603','Revascularization','Revascularization - action','false'
'bleeding','C0019080','BLEEDING','Hemorrhage','true'
'gusto moderate severe bleed','C0205081','Moderate','Moderate (severity modifier)','false'
'gusto moderate severe bleed','C0019080','bleed','Hemorrhage','true'
'gusto moderate severe bleed','C1881878','Moderate','Moderation','false'
'gusto moderate severe bleed','C4049705','Moderate','Moderate Extremity Pain','false'
'gusto moderate severe bleed','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'gusto moderate severe bleed','C4085643','Moderate','Moderate Response','false'
'gusto moderate severe bleed','C4321335','Moderate','Moderate Level','false'
'gusto severe bleed','C0205082','Severe','Severe (severity modifier)','false'
'gusto severe bleed','C0019080','bleed','Hemorrhage','true'
'gusto severe bleed','C4050465','Severe','Severe Extremity Pain','false'
'gusto severe bleed','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'fatal bleed','C1302234','Fatal','Fatal','false'
'fatal bleed','C0019080','bleed','Hemorrhage','true'
'fatal bleed','C1705232','FATAL','Death Related to Adverse Event','false'
'nebivolol n $nmbr$','C0068475','NEBIVOLOL','nebivolol','true'
'age years a','C1510829','Age-Years','Age-Years','false'
'trough seated sbp mmhg a','C0085805','SBP','Androgen Binding Protein','true'
'trough seated sbp mmhg a','C0439475','mmHG','mmHg','false'
'trough seated dbp mmhg a','C0277814','Seated','Sitting position','true'
'trough seated dbp mmhg a','C0439475','mmHG','mmHg','false'
'trough seated dbp mmhg a','C1283233','seated','Seating','false'
'trough seated hr bpm a','C0444506','Trough','Trough','false'
'trough seated hr bpm a','C0277814','Seated','Sitting position','true'
'trough seated hr bpm a','C1283233','seated','Seating','false'
'all men','C0025266','Men','Male population group','true'
'all women','C0043210','Women','Woman','true'
'ethnicity t','C0015031','Ethnicity','Ethnic group','true'
'ethnicity t','C0243103','ethnicity','Ethnicity aspects','true'
'education y mean sd','C0013621','Education','Knowledge acquisition','true'
'education y mean sd','C2699239','SD','SD, Rat Strain','false'
'education y mean sd','C0013622','education','Educational aspects','true'
'education y mean sd','C0013658','Education, NOS','Educational Status','true'
'education y mean sd','C0039401','Education','Educational process of instructing','true'
'treatment n','C0039798','treatment','therapeutic aspects','true'
'treatment n','C0087111','Treatment','Therapeutic procedure','true'
'treatment n','C1522326','Treatment','Treating','false'
'treatment n','C1533734','Treatment','Administration procedure','false'
'treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'blood pressure mm hg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure mm hg mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd','C0439269','mg dl','mg/dL','false'
'dbp $nmbr$ $nmbr$ $nmbr$ $nmbr$ baseline lipid profile mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'total glucose mg dl','C0017725','GLUCOSE','Glucose','true'
'total glucose mg dl','C0439269','mg dl','mg/dL','false'
'diabetes mellitus classification','C0008902','Classification','Classification','true'
'diabetes mellitus classification','C0008903','classification','Taxonomic','true'
'diabetes mellitus classification','C0678229','classification','Classification of information','false'
'diabetes mellitust','C0011847','Diabetes','Diabetes','false'
'diabetes mellitust','C0011849','Diabetes','Diabetes Mellitus','true'
'normoglycemic^','C0580545','Normoglycemic','Blood glucose normal','false'
'history of chd','C0019664','History','History','true'
'history of chd','C0019665','history','Historical aspects qualifier','true'
'history of chd','C0262512','History, NOS','History of present illness','false'
'history of chd','C0262926','History','Medical History','false'
'history of chd','C1705255','History','Concept History','false'
'history of chd','C2004062','History','History of previous events','false'
'history of mi or stroke','C0019664','History','History','true'
'history of mi or stroke','C0019665','history','Historical aspects qualifier','true'
'history of mi or stroke','C0262512','History, NOS','History of present illness','false'
'history of mi or stroke','C0262926','History','Medical History','false'
'history of mi or stroke','C1705255','History','Concept History','false'
'history of mi or stroke','C2004062','History','History of previous events','false'
'history of mi or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'history of mi or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'st t wavett','C0036056','ST','Saint Lucia','true'
'st t wavett','C3272372','ST','Character String Data Type','false'
'$nmbr$ $nmbr$ $nmbr$ continued','C0549178','Continued','Continuous','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C0439445','mL/min','mL/min','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C1424601','GFR','RAPGEF5 gene','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'estimated gfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'atrial fibrillation flutter n','C0155709','Atrial fibrillation/flutter','Atrial fibrillation and flutter','false'
'outcomes','C1274040','Outcome','Result','false'
'$nmbr$ y rate per $nmbr$ persons se n','C0871208','Rate','Rating (action)','false'
'$nmbr$ y rate per $nmbr$ persons se n','C1521828','Rate','Rate','false'
'hazard ratio and $nmbr$ confidence interval','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio and $nmbr$ confidence interval','C0009667','Confidence Interval','Confidence Intervals','true'
'l c','C0439394','l's','liter/second','false'
'l c','C1706495','L-','upper case letter ell','false'
'l c','C3642217','/L','Per Liter','false'
'total randomized n','C0439175','% total','% of total','false'
'total randomized n','C0034656','Randomized','Randomization','true'
'total randomized n','C3815594','RANDOMIZED','Subject is Randomized','false'
'total randomized n','C0439810','Total','Total','false'
'primary end point','C2986535','Primary Endpoint','Primary Endpoint','false'
'chd nonfatal mi fatal chd','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'chd nonfatal mi fatal chd','C1302234','Fatal','Fatal','false'
'chd nonfatal mi fatal chd','C1705232','FATAL','Death Related to Adverse Event','false'
'chd nonfatal mi fatal chd','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'secondary end points','C0027627','secondary','Neoplasm Metastasis','true'
'secondary end points','C2349179','End Point','End Point','false'
'secondary end points','C0175668','Secondary','Secondary to','false'
'secondary end points','C0205436','Secondary','second (number)','false'
'mortality outcomes','C0026565','Mortality','Mortality Vital Statistics','true'
'mortality outcomes','C1274040','Outcome','Result','false'
'mortality outcomes','C0026566','mortality','Aspects of mortality statistics','true'
'combined fatal nonfatal outcomes','C1548228','Combined Outcome','Combined result','false'
'heart failure treated hospitalized fatal','C1302234','Fatal','Fatal','false'
'heart failure treated hospitalized fatal','C1705232','FATAL','Death Related to Adverse Event','false'
'hospitalized fatal heart failure','C0018801','Failure, Heart','Heart failure','true'
'hospitalized fatal heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'hospitalized fatal heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'hospitalized angina','C0701159','HOSPITALIZED','Patient in hospital','false'
'hospitalized angina','C0002962','ANGINA','Angina Pectoris','true'
'coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'insulin glargin arm','C0446516','ARM','Upper arm','true'
'insulin glargin arm','C3715044','ARM','AKR1A1 wt Allele','false'
'insulin glargin arm','C4553528','arm','Sequence Arm','false'
'insulin glargine slope lsm se mm year','C0439234','Year','year','false'
'insulin glargine slope lsm se mm year','C0439508','/Year','per year','false'
'standard care slope lsm se mm year','C0439234','Year','year','false'
'standard care slope lsm se mm year','C0439508','/Year','per year','false'
'difference glargine standard care lsm se mm year','C0439234','Year','year','false'
'difference glargine standard care lsm se mm year','C0439508','/Year','per year','false'
'p value for interaction by region','C1709380','P-Value','P-Value','false'
'p value for interaction by region','C1704675','Interaction','Interaction','false'
'p value for interaction by region','C0017446','Region','Geographic Locations','true'
'p value for interaction by region','C0205147','Region','regional','false'
'north america n $nmbr$','C0028405','North America','North America','true'
'south america n $nmbr$','C0037713','South America','South America','true'
'n $nmbr$ fatty acit','C0369718','N NOS','N not otherwise specified Antibody','false'
'n $nmbr$ fatty acit','C0441922','N+','N+ (tumor staging)','false'
's arm','C0446516','ARM','Upper arm','true'
's arm','C3715044','ARM','AKR1A1 wt Allele','false'
's arm','C4553528','arm','Sequence Arm','false'
'n $nmbr$ fatty acids slope lsm se mm year','C0439234','Year','year','false'
'n $nmbr$ fatty acids slope lsm se mm year','C0439508','/Year','per year','false'
'placebo slope lsm se mm year','C0439234','Year','year','false'
'placebo slope lsm se mm year','C0439508','/Year','per year','false'
'difference n $nmbr$ fa placebo lsm se mm year','C0439234','Year','year','false'
'difference n $nmbr$ fa placebo lsm se mm year','C0439508','/Year','per year','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C0015176','Europe','Europe','true'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C0004340','AUSTRALIA','Australia','true'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C0021201','INDIA','India','true'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C2700456','India','India - zebrafish','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C1511726','Data','Data','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C3245479','data','Data call receiving device','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C3714741','Data','Data (eukaryote)','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C0344329','collapsed','Collapse (finding)','false'
'other europe n $nmbr$ australia n $nmbr$ and india n $nmbr$ the data from these regions were collapsed due to the small numbers','C0392748','Collapsed','Collapsed','false'
'sita $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'sita $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'sita $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'sita $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'sita $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'sita $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'sita $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'cana $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'cana $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'cana $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'cana $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'cana $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'cana $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'cana $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'other i','C0021966','I-','Iodides','true'
'other i','C0221138','I NOS','Blood group antibody I','false'
'a $nmbr$ c mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'fpg mmol l mg dl','C1532980','mmol/dL','mmol/dL','false'
'duration of type $nmbr$ diabetes years','C0449238','Duration','Duration (temporal concept)','false'
'duration of type $nmbr$ diabetes years','C2926735','Duration','Duration','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C0392747','Change','Changing','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C0443172','change','Changed status','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C1705241','Change','Delta (difference)','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C4319952','Change','Change -- procedure','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C0168634','baseline','BaseLine dental cement','true'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C1442488','Baseline','Baseline','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'supplementary figure $nmbr$ change in a $nmbr$ c from baseline to week $nmbr$ by baseline a $nmbr$ c subgroup','C1515021','Subgroup','Subgroup','false'
'ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$','C0023189','Least Squares','Least-Squares Analysis','true'
'ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$','C1710181','Standard Error','Standard Error','false'
'ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$','C1319635','mg/mg','mg/mg','false'
'ls least squares se standard error sita sitagliptin cana canagliflozin a $nmbr$ c $nmbr$ $nmbr$ to $nmbr$ $nmbr$ sita $nmbr$ mg n $nmbr$ cana $nmbr$ mg n $nmbr$','C1418845','CANA','PPP3CA gene','false'
'cluster $nmbr$ diuretic n $nmbr$','C1555715','Cluster','entry - cluster','false'
'cluster $nmbr$ diuretic n $nmbr$','C0012798','Diuretic','Diuretics','true'
'cluster $nmbr$ diuretic n $nmbr$','C1704332','Cluster','Cluster','false'
'cluster $nmbr$ reversible no diuretic n $nmbr$','C1555715','Cluster','entry - cluster','false'
'cluster $nmbr$ reversible no diuretic n $nmbr$','C0205343','Reversible','Reversible','false'
'cluster $nmbr$ reversible no diuretic n $nmbr$','C1704332','Cluster','Cluster','false'
'cluster $nmbr$ reversible no diuretic n $nmbr$','C0012798','Diuretic','Diuretics','true'
'cluster $nmbr$ not reversible no diuretic n $nmbr$','C1555715','Cluster','entry - cluster','false'
'cluster $nmbr$ not reversible no diuretic n $nmbr$','C1704332','Cluster','Cluster','false'
'cluster $nmbr$ not reversible no diuretic n $nmbr$','C1518422','Not','Negation','false'
'cluster $nmbr$ not reversible no diuretic n $nmbr$','C0205343','Reversible','Reversible','false'
'cluster $nmbr$ not reversible no diuretic n $nmbr$','C0012798','Diuretic','Diuretics','true'
'age median years','C1510829','Age-Years','Age-Years','false'
'age median years','C0549183','Median','Midline (qualifier value)','false'
'age median years','C0876920','Median','Median Statistical Measurement','false'
'age median years','C2347635','Median','Population Median','false'
'age median years','C2348144','Median','Sample Median','false'
'age median years','C2939193','Median','Median (qualifier value)','false'
'median m kg $nmbr$ iqr','C0549183','Median','Midline (qualifier value)','false'
'median m kg $nmbr$ iqr','C0876920','Median','Median Statistical Measurement','false'
'median m kg $nmbr$ iqr','C2347635','Median','Population Median','false'
'median m kg $nmbr$ iqr','C2348144','Median','Sample Median','false'
'median m kg $nmbr$ iqr','C2939193','Median','Median (qualifier value)','false'
'median m kg $nmbr$ iqr','C0022718','KG','Kyrgyzstan','true'
'median m kg $nmbr$ iqr','C0439209','kg','Kilogram','false'
'median m kg $nmbr$ iqr','C4054209','/kg','Per Kilogram','false'
'smoking mean','C0444504','Mean','Statistical mean','false'
'smoking mean','C2347634','Mean','Population Mean','false'
'smoking mean','C2348143','Mean','Sample Mean','false'
'pack years iqr','C1277691','Pack years','Pack years','false'
'fev $nmbr$ predicted sd','C0681842','Predicted','prediction','false'
'fev $nmbr$ predicted sd','C2699239','SD','SD, Rat Strain','false'
'fev $nmbr$ predicted sd','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fev $nmbr$ reversibility sd','C0449261','Reversibility','Reversibility','false'
'fev $nmbr$ reversibility sd','C2699239','SD','SD, Rat Strain','false'
'reversibility stratum','C0449261','Reversibility','Reversibility','false'
'[no yes]','C1549445','Yes','Yes - Yes/no indicator','false'
'[no yes]','C1705108','YES','Yes (indicator)','false'
'[no yes]','C1710701','Yes','YES1 wt Allele','false'
'exacerbations requiring hospitalisation past year','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations requiring hospitalisation past year','C0019993','hospitalisation','Hospitalization','true'
'exacerbations requiring hospitalisation past year','C0439234','Year','year','false'
'exacerbations requiring hospitalisation past year','C0439508','/Year','per year','false'
'exacerbations requiring oral steroids antibiotics past year','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations requiring oral steroids antibiotics past year','C0003232','Antibiotics','Antibiotics','true'
'exacerbations requiring oral steroids antibiotics past year','C0003237','Antibiotics','Antibiotics, Antitubercular','true'
'exacerbations requiring oral steroids antibiotics past year','C3540704','Antibiotics','Antibiotics for systemic use','false'
'exacerbations requiring oral steroids antibiotics past year','C3540705','Antibiotics','Antifungal Antibiotics, Topical','false'
'exacerbations requiring oral steroids antibiotics past year','C3540706','Antibiotics','Antibiotic throat preparations','false'
'exacerbations requiring oral steroids antibiotics past year','C3540707','Antibiotics','Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE','false'
'exacerbations requiring oral steroids antibiotics past year','C3540708','Antibiotics','Antibiotics, Gynecological','false'
'exacerbations requiring oral steroids antibiotics past year','C3540709','Antibiotics','antibiotics, intestinal','false'
'exacerbations requiring oral steroids antibiotics past year','C3540710','Antibiotics','Antibiotics, ophthalmologic','false'
'baseline medications','C0013227','Medications','Pharmaceutical Preparations','true'
'baseline medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'baseline medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'baseline medications','C4284232','Medications','Medications','false'
'anti thrombotics','C0087086','Thrombotic','Thrombus','true'
'lipid modifiers','C0023779','Lipid','Lipids','true'
'lipid modifiers','C4284280','Modifiers','Modifiers','false'
'psycholeptics','C3653516','PSYCHOLEPTICS','PSYCHOLEPTICS','false'
'anti histamines','C0019590','anti histamines','Histamine Antagonists','true'
'cardiac therapy','C3654025','CARDIAC THERAPY','CARDIAC THERAPY DRUGS','false'
'anti anaemics','C0857322','anaemic','anaemic','false'
'anti hypertensives','C0003364','Anti-Hypertensives','Antihypertensive Agents','true'
'or $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'p for interaction','C0369773','P NOS','P Blood group antibodies','false'
'p for interaction','C2603361','P'','P prime','false'
'age median','C0549183','Median','Midline (qualifier value)','false'
'age median','C0876920','Median','Median Statistical Measurement','false'
'age median','C2347635','Median','Population Median','false'
'age median','C2348144','Median','Sample Median','false'
'age median','C2939193','Median','Median (qualifier value)','false'
'alcohol','C0001962','ALCOHOL','Ethanol','true'
'alcohol','C0001975','Alcohol','Alcohols','true'
'alcohol $nmbr$ wk','C0332174','/wk','Weekly','false'
'alcohol $nmbr$ wk','C0439230','wk','week','false'
'no depression','C0011570','DEPRESSION','Mental Depression','true'
'no depression','C0011581','Depression','Depressive disorder','true'
'no depression','C0344315','depression','Depressed mood','false'
'no depression','C0460137','Depression','Depression motion','false'
'no depression','C4049644','Depression','Depression Scale (BASC-2)','false'
'no depression','C4084909','Depression','Depression Subordinate Domain','false'
'no depression','C4085311','DEPRESSION','Depression - recess','false'
'no depression','C4553827','Depression','Depression Visual Analogue Scale','false'
'depression','C0011570','DEPRESSION','Mental Depression','true'
'depression','C0011581','Depression','Depressive disorder','true'
'depression','C0344315','depression','Depressed mood','false'
'depression','C0460137','Depression','Depression motion','false'
'depression','C4049644','Depression','Depression Scale (BASC-2)','false'
'depression','C4084909','Depression','Depression Subordinate Domain','false'
'depression','C4085311','DEPRESSION','Depression - recess','false'
'depression','C4553827','Depression','Depression Visual Analogue Scale','false'
'a $nmbr$ c median','C0549183','Median','Midline (qualifier value)','false'
'a $nmbr$ c median','C0876920','Median','Median Statistical Measurement','false'
'a $nmbr$ c median','C2347635','Median','Population Median','false'
'a $nmbr$ c median','C2348144','Median','Sample Median','false'
'a $nmbr$ c median','C2939193','Median','Median (qualifier value)','false'
'waist hip median','C0549183','Median','Midline (qualifier value)','false'
'waist hip median','C0876920','Median','Median Statistical Measurement','false'
'waist hip median','C2347635','Median','Population Median','false'
'waist hip median','C2348144','Median','Sample Median','false'
'waist hip median','C2939193','Median','Median (qualifier value)','false'
'waisvhip median','C0549183','Median','Midline (qualifier value)','false'
'waisvhip median','C0876920','Median','Median Statistical Measurement','false'
'waisvhip median','C2347635','Median','Population Median','false'
'waisvhip median','C2348144','Median','Sample Median','false'
'waisvhip median','C2939193','Median','Median (qualifier value)','false'
'grip strength meidan','C0429271','Grip Strength','Grip strength','false'
'grip strength meidan','C2598165','Grip strength','Grip Strength:-:Point in time:^Patient:-','false'
'grip strength median','C0549183','Median','Midline (qualifier value)','false'
'grip strength median','C0876920','Median','Median Statistical Measurement','false'
'grip strength median','C2347635','Median','Population Median','false'
'grip strength median','C2348144','Median','Sample Median','false'
'grip strength median','C2939193','Median','Median (qualifier value)','false'
'urine acr median','C0549183','Median','Midline (qualifier value)','false'
'urine acr median','C0876920','Median','Median Statistical Measurement','false'
'urine acr median','C2347635','Median','Population Median','false'
'urine acr median','C2348144','Median','Sample Median','false'
'urine acr median','C2939193','Median','Median (qualifier value)','false'
'diabetic subjects n $nmbr$','C0241863','DIABETIC','diabetic','false'
'diabetic subjects n $nmbr$','C0681850','Subject','Study Subject','false'
'diabetic subjects n $nmbr$','C1550501','{Subject}','Subject -direct target','false'
'diabetic subjects n $nmbr$','C1706203','Subject','Subject - topic','false'
'diabetic subjects n $nmbr$','C2349001','Subject','Human Study Subject','false'
'diabetic subjects n $nmbr$','C2697811','Subject','Investigative Subject','false'
'non diabetic subjects n $nmbr$','C1518422','Non','Negation','false'
'non diabetic subjects n $nmbr$','C0241863','DIABETIC','diabetic','false'
'alcohol usef n','C0001962','ALCOHOL','Ethanol','true'
'alcohol usef n','C0001975','Alcohol','Alcohols','true'
'serum urate mg dl n','C0455272','Serum Urate','Serum urate measurement','false'
'serum urate mg dl n','C0439269','mg dl','mg/dL','false'
'years with gouty arthritis','C0439234','YEARS','year','false'
'years with gouty arthritis','C0003868','ARTHRITIS, GOUTY','Arthritis, Gouty','true'
'presence of tophi n','C0150312','Presence','Present','false'
'presence of tophi n','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of tophi n','C3854307','Presence','Presence (property)','false'
'renal function n','C0232804','Renal function','Renal function','false'
'figure $nmbr$ achievement of sua','C0001072','Achievement','Achievement','true'
'higher target group n $nmbr$','C0441848','Group N','Group N','false'
'lower target group n $nmbr$','C0441848','Group N','Group N','false'
'blood pressure at entry mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'blood pressure at entry mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'blood pressure at entry mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'ischaemic heart disease','C0010054','ischaemic heart disease','Coronary Arteriosclerosis','true'
'ischaemic heart disease','C0151744','Ischaemic heart disease, NOS','Myocardial Ischemia','true'
'previous clinical stroke or tia','C0038454','STROKE','Cerebrovascular accident','true'
'previous clinical stroke or tia','C4554100','Stroke','Stroke, CTCAE','false'
'previous clinical stroke or tia','C0007787','TIA','Transient Ischemic Attack','true'
'previous clinical stroke or tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous clinical stroke or tia','C1054154','tia','Tacca leontopetaloides','false'
'current tobacco smoker','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current tobacco smoker','C3241966','Current Smoker','Current Smoker','false'
'qualifying event','C1514624','Qualifying','Qualifying','false'
'qualifying event','C0441471','Event','Event','false'
'qualifying event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'ischaemic stroke','C0948008','Ischaemic stroke','Ischemic stroke','false'
'tia','C0007787','TIA','Transient Ischemic Attack','true'
'tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'tia','C1054154','tia','Tacca leontopetaloides','false'
'number of antihypertensive medications at study entry','C1718138','Number of medications','Number of medications','false'
'number of antihypertensive medications at study entry','C0557651','Study','Room of building - Study','false'
'number of antihypertensive medications at study entry','C1705654','Entry','Entry (data)','false'
'number of antihypertensive medications at study entry','C2603343','Study','Study','false'
'mean number of antihypertensive medications at $nmbr$ year','C0444504','Mean','Statistical mean','false'
'mean number of antihypertensive medications at $nmbr$ year','C1718138','Number of medications','Number of medications','false'
'mean number of antihypertensive medications at $nmbr$ year','C2347634','Mean','Population Mean','false'
'mean number of antihypertensive medications at $nmbr$ year','C2348143','Mean','Sample Mean','false'
'mean number of antihypertensive medications at $nmbr$ year','C0439234','Year','year','false'
'mean number of antihypertensive medications at $nmbr$ year','C0439508','/Year','per year','false'
'types of antihypertensive medications at $nmbr$ year','C0457591','Medication types','Type of drug','false'
'types of antihypertensive medications at $nmbr$ year','C0439234','Year','year','false'
'types of antihypertensive medications at $nmbr$ year','C0439508','/Year','per year','false'
'ace inhibitor arb','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'ace inhibitor arb','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'mean number of antihypertensive medication at last visit','C0444504','Mean','Statistical mean','false'
'mean number of antihypertensive medication at last visit','C0237753','*Number','Numbers','false'
'mean number of antihypertensive medication at last visit','C0449788','Number','Count of entities','false'
'mean number of antihypertensive medication at last visit','C2347634','Mean','Population Mean','false'
'mean number of antihypertensive medication at last visit','C2348143','Mean','Sample Mean','false'
'mean number of antihypertensive medication at last visit','C0545082','Visit','Visit','false'
'mean number of antihypertensive medication at last visit','C1512346','visit','Patient Visit','false'
'mean number of antihypertensive medication at last visit','C2826704','VISIT','Visit Name','false'
'types of antihypertensive medications at last visit','C0457591','Medication types','Type of drug','false'
'types of antihypertensive medications at last visit','C0545082','Visit','Visit','false'
'types of antihypertensive medications at last visit','C1512346','visit','Patient Visit','false'
'types of antihypertensive medications at last visit','C2826704','VISIT','Visit Name','false'
'statins used during follow up','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statins used during follow up','C1273517','used','Used by','false'
'statins used during follow up','C0589120','Follow-up','Follow-up status','false'
'statins used during follow up','C1522577','Followup','follow-up','false'
'statins used during follow up','C1704685','Follow-Up','Follow-Up Report','false'
'statins used during follow up','C3274571','FOLLOW-UP','Clinical Study Follow-up','false'
'number of events annualised rate [ ]','C4330837','Number of Events','Number of Events','false'
'$nmbr$ o i $nmbr$ mm hg','C0021966','I-','Iodides','true'
'$nmbr$ o i $nmbr$ mm hg','C0439475','mmHG','mmHg','false'
'$nmbr$ o i $nmbr$ mm hg','C0221138','I NOS','Blood group antibody I','false'
'age p o $nmbr$','C0001779','AGE','Age','false'
'$nmbr$ years n $nmbr$','C0439234','YEARS','year','false'
'sex p $nmbr$','C0009253','Sex','Coitus','true'
'sex p $nmbr$','C0036864','Sex','Sex Behavior','true'
'sex p $nmbr$','C0079399','sex','Gender','true'
'sex p $nmbr$','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex p $nmbr$','C1314687','Sex','Sexual intercourse - finding','false'
'sex p $nmbr$','C1522384','SEX','sex','true'
'male n $nmbr$','C0086582','MALE','Males','true'
'male n $nmbr$','C1706180','Male','Male Gender, Self Report','false'
'male n $nmbr$','C1706428','MALE','Male Phenotype','false'
'male n $nmbr$','C1706429','Male','Male, Self-Reported','false'
'female n lll $nmbr$','C0043210','female','Woman','true'
'female n lll $nmbr$','C1261077','LLL','Structure of left lower lobe of lung','false'
'female n lll $nmbr$','C0086287','FEMALE','Females','true'
'female n lll $nmbr$','C1705497','Female','Female, Self-Report','false'
'female n lll $nmbr$','C1705498','FEMALE','Female Phenotype','false'
'history of diabetes p $nmbr$ $nmbr$','C0019664','History','History','true'
'history of diabetes p $nmbr$ $nmbr$','C0019665','history','Historical aspects qualifier','true'
'history of diabetes p $nmbr$ $nmbr$','C0262512','History, NOS','History of present illness','false'
'history of diabetes p $nmbr$ $nmbr$','C0262926','History','Medical History','false'
'history of diabetes p $nmbr$ $nmbr$','C1705255','History','Concept History','false'
'history of diabetes p $nmbr$ $nmbr$','C2004062','History','History of previous events','false'
'non diabetic n $nmbr$','C1518422','Non','Negation','false'
'non diabetic n $nmbr$','C0241863','DIABETIC','diabetic','false'
'diabetes n $nmbr$','C0011847','Diabetes','Diabetes','false'
'diabetes n $nmbr$','C0011849','Diabetes','Diabetes Mellitus','true'
'race p o $nmbr$','C0034510','RACE','Racial group','true'
'race p o $nmbr$','C1706779','RACE','AMACR wt Allele','false'
'race p o $nmbr$','C3853635','Race','Race','false'
'hispanic n $nmbr$ l $nmbr$','C0086409','HISPANIC','Hispanics','true'
'other mixed n $nmbr$','C0205430','MIXED','Mixed (qualifier value)','false'
'other mixed n $nmbr$','C3160715','Mixed','Mixed Cell Morphology','false'
'region of residence p $nmbr$ $nmbr$','C0017446','Region','Geographic Locations','true'
'region of residence p $nmbr$ $nmbr$','C0205147','Region','regional','false'
'latin america n $nmbr$','C0023122','Latin America','Latin America','true'
'spain n $nmbr$','C0037747','SPAIN','Spain','true'
'baseline sbp p o $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline sbp p o $nmbr$','C0085805','SBP','Androgen Binding Protein','true'
'baseline sbp p o $nmbr$','C1442488','Baseline','Baseline','false'
'normotensive n $nmbr$','C2712122','Normotensive','Normal blood pressure','false'
'sbp median n $nmbr$','C0085805','SBP','Androgen Binding Protein','true'
'sbp median n $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'sbp median n $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'sbp median n $nmbr$','C2347635','Median','Population Median','false'
'sbp median n $nmbr$','C2348144','Median','Sample Median','false'
'sbp median n $nmbr$','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ i $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'$nmbr$ $nmbr$ mga n $nmbr$','C0065879','MGA','Megestrol Acetate','true'
'all n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'all n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'male patients n','C0150904','male patients','patient is male','false'
'median iqr','C0549183','Median','Midline (qualifier value)','false'
'median iqr','C0876920','Median','Median Statistical Measurement','false'
'median iqr','C2347635','Median','Population Median','false'
'median iqr','C2348144','Median','Sample Median','false'
'median iqr','C2939193','Median','Median (qualifier value)','false'
'uc disease duration y','C0872146','disease duration','disease length','false'
'extent of disease n','C0449279','Extent of disease','Extent of disease','false'
'extent of disease n','C4553144','Extent of Disease','Intergroup Rhabdomyosarcoma Clinical Group Extent of Disease','false'
'limited to left side of colon','C0439801','Limited','Limited (extensiveness)','false'
'limited to left side of colon','C2674459','Limited','Limited Walking Ability','false'
'limited to left side of colon','C3542948','Limited','Limited component (foundation metadata concept)','false'
'limited to left side of colon','C4050251','Limited','Limited Lifting Ability','false'
'mayo score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'mayo score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'endoscopy subscore n','C0014245','ENDOSCOPY','Endoscopy (procedure)','true'
'moderate disease','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate disease','C0012634','Disease','Disease','true'
'moderate disease','C1881878','Moderate','Moderation','false'
'moderate disease','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate disease','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate disease','C4085643','Moderate','Moderate Response','false'
'moderate disease','C4321335','Moderate','Moderate Level','false'
'severe disease','C1836348','Severe Disease','Severe disorder','false'
'crp mg l n','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp mg l n','C0439268','mg/L','Microgram per Milliliter','false'
'crp mg l n','C4048285','CRP','C-Reactive Protein, human','false'
'patients receiving any uc medication n','C0030705','Patients','Patients','true'
'patients receiving any uc medication n','C1514756','RECEIVING','Receive','false'
'patients receiving any uc medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'patients receiving any uc medication n','C3244316','medication','medication - HL7 publishing domain','false'
'patients receiving any uc medication n','C4284232','Medication','Medications','false'
'corticosteroids excluding budesonide','C0001617','Corticosteroids','Adrenal Cortex Hormones','true'
'corticosteroids excluding budesonide','C3539185','Corticosteroids','Corticosteroid nasal preparations for topical use','false'
'corticosteroids excluding budesonide','C3540725','CORTICOSTEROIDS','Corticosteroid otologicals','false'
'corticosteroids excluding budesonide','C3540726','CORTICOSTEROIDS','Corticosteroid ophthalmologic and otologic preparations','false'
'corticosteroids excluding budesonide','C3540727','Corticosteroids','Corticosteroids, topical for treatment of hemorrhoids and anal fissures','false'
'$nmbr$ mg d peq','C0024671','MG','Mammography','true'
'$nmbr$ mg d peq','C0026410','MG','Mongolia','true'
'$nmbr$ mg d peq','C0439269','mg%','mg/dL','false'
'$nmbr$ mg d peq','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg d peq','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg d peq','C4321396','MG','MG','false'
'$nmbr$ mg d peq','C4521761','MG','United States Military Commissioned Officer O8','false'
'budesonide','C0054201','BUDESONIDE','Budesonide','true'
'immunomodulatory drugs','C0013227','Drugs','Pharmaceutical Preparations','true'
'immunomodulatory drugs','C3687832','Drugs','Drugs - dental services','false'
'$nmbr$ mercaptopurine azathioprine','C0000618','MERCAPTOPURINE','mercaptopurine','true'
'$nmbr$ mercaptopurine azathioprine','C0004482','AZATHIOPRINE','Azathioprine','true'
'golimumab $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'golimumab $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'golimumab $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'golimumab $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'golimumab $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'golimumab $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'golimumab $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'ne ne','C0027608','Ne','Neon','true'
'ne ne','C0028219','NE','Niue','true'
'ne ne','C3538705','NE','ELANE wt Allele','false'
'normonatremic $nmbr$ meq l at baseline','C0439375','mEq/L','mEq/L','false'
'normonatremic $nmbr$ meq l at baseline','C0168634','baseline','BaseLine dental cement','true'
'normonatremic $nmbr$ meq l at baseline','C1442488','Baseline','Baseline','false'
'hyponatremic','C0857122','hyponatremic','hyponatremic','false'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C1709380','P-Value','P-Value','false'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C1176308','TOLVAPTAN','tolvaptan','true'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C0857122','hyponatremic','hyponatremic','false'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C0032042','Placebo','Placebos','true'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C1696465','PLACEBO','placebo','false'
'p value placebo group p value hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo','C1706408','PLACEBO','Placebo Control','false'
'placebo n $nmbr$ $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'placebo tolvaptan $nmbr$ mg n $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age y sd','C0001779','AGE','Age','false'
'age y sd','C2699239','SD','SD, Rat Strain','false'
'systolic blood pressure mm hg sd','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic blood pressure mm hg sd','C2699239','SD','SD, Rat Strain','false'
'systolic blood pressure mm hg sd','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'systolic blood pressure mm hg sd','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'diastolic blood pressure mm hg sd','C0428883','Diastolic Blood Pressure','Diastolic blood pressure','true'
'diastolic blood pressure mm hg sd','C2699239','SD','SD, Rat Strain','false'
'diastolic blood pressure mm hg sd','C1305849','diastolic blood pressure','Diastolic blood pressure measurement','false'
'heart rate sd','C0018810','Heart Rate','heart rate','true'
'heart rate sd','C2699239','SD','SD, Rat Strain','false'
'history of htn','C0019664','History','History','true'
'history of htn','C0019665','history','Historical aspects qualifier','true'
'history of htn','C0262512','History, NOS','History of present illness','false'
'history of htn','C0262926','History','Medical History','false'
'history of htn','C1705255','History','Concept History','false'
'history of htn','C2004062','History','History of previous events','false'
'intravenous vasoactive drugs y','C0683092','intravenous drug','intravenous drug','false'
'intravenous vasoactive drugs y','C1980011','Vasoactive','Vasoactive','false'
'nesiritide z','C0054015','NESIRITIDE','Nesiritide','true'
'edema z','C0013604','OEDEMA','Edema','true'
'edema z','C1717255','Edema','Edema:Finding:Point in time:^Patient:Ordinal','false'
'jvd $nmbr$ cm h $nmbr$ o','C0425687','JVD','Jugular venous engorgement','false'
'jvd $nmbr$ cm h $nmbr$ o','C0455483','h o','history of - * (non-specific)','false'
'duration of hf y','C0449238','Duration','Duration (temporal concept)','false'
'duration of hf y','C2926735','Duration','Duration','false'
'prior hospitalization for hf','C0019993','hospitalisation','Hospitalization','true'
'prior hospitalization for hf','C0018488','Hf','Hafnium','true'
'prior hospitalization for hf','C1313497','HF','GZMA protein, human','true'
'prior hospitalization for hf','C1538440','HF','CFH gene','false'
'prior hospitalization for hf','C3273279','HF','CFH wt Allele','false'
'nyha iv','C0022326','IV','Ivory Coast','true'
'nyha iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'blood urea nitrogen mg dl','C0005845','Urea Nitrogen, Blood','Blood urea nitrogen measurement','true'
'blood urea nitrogen mg dl','C0439269','mg dl','mg/dL','false'
'blood urea nitrogen mg dl','C0600137','Blood Urea Nitrogen','Blood Urea Nitrogen','false'
'non asian n $nmbr$ $nmbr$','C1518422','Non','Negation','false'
'non asian n $nmbr$ $nmbr$','C0078988','ASIAN','Asians','true'
'$nmbr$ $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ n weight kg','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ n weight kg','C0439209','kg','Kilogram','false'
'$nmbr$ n weight kg','C4054209','/kg','Per Kilogram','false'
'systolic mean sd','C0039155','Systolic','Systole','true'
'systolic mean sd','C2699239','SD','SD, Rat Strain','false'
'diastolic mean sd','C0012000','Diastolic','Diastole','true'
'diastolic mean sd','C2699239','SD','SD, Rat Strain','false'
'type of atrial fibrillation','C0332307','TYPE','Type - attribute','false'
'type of atrial fibrillation','C1547052','*Type','*Type - Kind of quantity','false'
'paroxysmal n','C0205311','Paroxysmal','Paroxysmal','false'
'persistent n','C0205322','Persistent','Persistent','false'
'persistent n','C0332996','PERSISTENT','Persistent embryonic structure','false'
'permanent n','C0205355','Permanent','Permanent','false'
'$nmbr$ n chads $nmbr$ score','C0449820','SCORE','Score','false'
'$nmbr$ n chads $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'previous stroke yes n previous myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'previous stroke yes n previous myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'previous stroke yes n previous myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'previous stroke yes n previous myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'previous stroke yes n previous myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'yes n','C1549445','Yes','Yes - Yes/no indicator','false'
'yes n','C1705108','YES','Yes (indicator)','false'
'yes n','C1710701','Yes','YES1 wt Allele','false'
'heat failure','C0231174','FAILURE','Failure (biologic function)','false'
'heat failure','C0680095','failure','Personal failure','false'
'diabetes mellitus yes n hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'diabetes mellitus yes n hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'medication in use at the baseline','C0013227','Medication','Pharmaceutical Preparations','true'
'medication in use at the baseline','C3244316','medication','medication - HL7 publishing domain','false'
'medication in use at the baseline','C4284232','Medication','Medications','false'
'medication in use at the baseline','C0150312','In','Present','false'
'medication in use at the baseline','C0042153','use','utilization qualifier','true'
'medication in use at the baseline','C0457083','Use','Usage','false'
'medication in use at the baseline','C1947944','Use','Use - dosing instruction imperative','false'
'medication in use at the baseline','C0332285','In','Within','false'
'medication in use at the baseline','C1707101','IN','CD44 wt Allele','false'
'aspirin n','C0004057','ASPIRIN','Aspirin','true'
'arb n','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'ace i n','C0021966','I-','Iodides','true'
'ace i n','C0221138','I NOS','Blood group antibody I','false'
'amiodarone n','C0002598','AMIODARONE','Amiodarone','true'
'verapamil n','C0042523','VERAPAMIL','Verapamil','true'
'proton pump inhibitor n','C0358591','Proton Pump Inhibitor','Proton Pump Inhibitors','true'
'proton pump inhibitor n','C3536754','Proton Pump Inhibitor','Proton Pump Inhibitor [EPC]','false'
'proton pump inhibitor n','C4521480','Proton pump inhibitor','H+/K+-exchanging ATPase inhibitor (disposition)','false'
'h $nmbr$ blocker n long term vka therapy','C0039798','therapy','therapeutic aspects','true'
'h $nmbr$ blocker n long term vka therapy','C0087111','Therapy','Therapeutic procedure','true'
'h $nmbr$ blocker n long term vka therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'experience n','C0237607','experience','Practice Experience','false'
'experience n','C0596545','Experience','Experience','false'
'non asian','C1518422','Non','Negation','false'
'non asian','C0078988','ASIAN','Asians','true'
'event number','C0237753','*Number','Numbers','false'
'event number','C0449788','Number','Count of entities','false'
'stroke or','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or','C4554100','Stroke','Stroke, CTCAE','false'
'systemic embolism','C0013922','EMBOLISM','Embolism','true'
'systemic embolism','C1704212','Embolism, NOS','Embolus','true'
'hemorrhagic','C0333275','Hemorrhagic','Hemorrhagic','false'
'death from','C0011065','DEATH','Cessation of life','true'
'death from','C1306577','Death','Death (finding)','false'
'death from','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death from','C4552775','Death NOS','Death NOS, CTCAE','false'
'any cause','C0015127','cause','Etiology aspects','true'
'any cause','C1524003','Cause','Science of Etiology','false'
'tcz $nmbr$ mg kg n $nmbr$','C0439272','mg kg','ug/g','false'
'geographical region n','C0017446','Region','Geographic Locations','true'
'geographical region n','C0205147','Region','regional','false'
'rest of world','C0035253','Rest','Rest','true'
'rest of world','C1622890','ResT','site-specific telomere resolvase activity','false'
'positive hla b $nmbr$ status n','C1426226','HLA-N','HLA-N gene','false'
'as duration y mean sd','C0444504','Mean','Statistical mean','false'
'as duration y mean sd','C2699239','SD','SD, Rat Strain','false'
'as duration y mean sd','C2347634','Mean','Population Mean','false'
'as duration y mean sd','C2348143','Mean','Sample Mean','false'
'swollen joints $nmbr$ n','C0152031','SWOLLEN JOINTS','Joint swelling','false'
'basdai score mean sd','C0444504','Mean','Statistical mean','false'
'basdai score mean sd','C2699239','SD','SD, Rat Strain','false'
'basdai score mean sd','C2347634','Mean','Population Mean','false'
'basdai score mean sd','C2348143','Mean','Sample Mean','false'
'crp mg dl mean sd','C0439269','mg dl','mg/dL','false'
'crp mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'crp mg dl median','C0549183','Median','Midline (qualifier value)','false'
'crp mg dl median','C0876920','Median','Median Statistical Measurement','false'
'crp mg dl median','C2347635','Median','Population Median','false'
'crp mg dl median','C2348144','Median','Sample Median','false'
'crp mg dl median','C2939193','Median','Median (qualifier value)','false'
'rvalue for interaction','C1704675','Interaction','Interaction','false'
'favors dabigatran','C0309049','FAVOR','favor','false'
'favors dabigatran','C2348066','DABIGATRAN','dabigatran','true'
'no heart failure','C0018801','Failure, Heart','Heart failure','true'
'no heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'no heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'prior stroke tia','C0007787','TIA','Transient Ischemic Attack','true'
'prior stroke tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'prior stroke tia','C1054154','tia','Tacca leontopetaloides','false'
'no prior stroke tia','C0007787','TIA','Transient Ischemic Attack','true'
'no prior stroke tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'no prior stroke tia','C1054154','tia','Tacca leontopetaloides','false'
'cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$','C1420648','CHA','TCFL5 gene','false'
'cha $nmbr$ ds $nmbr$ vasc $nmbr$ $nmbr$','C3714751','DS','Disease Steps Questionnaire','false'
'has bledo','C1019275','bledo','Amaranthus viridis','false'
'has bled $nmbr$ $nmbr$','C0019080','bleed','Hemorrhage','true'
'has bled $nmbr$','C0019080','bleed','Hemorrhage','true'
'sbp $nmbr$ mm hg','C0085805','SBP','Androgen Binding Protein','true'
'sbp $nmbr$ mm hg','C0439475','mmHG','mmHg','false'
'crcl','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl $nmbr$ ml min','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'history of cad mi','C0019664','History','History','true'
'history of cad mi','C0019665','history','Historical aspects qualifier','true'
'history of cad mi','C0262512','History, NOS','History of present illness','false'
'history of cad mi','C0262926','History','Medical History','false'
'history of cad mi','C1705255','History','Concept History','false'
'history of cad mi','C2004062','History','History of previous events','false'
'no cad mi','C1504769','CAD','DFFB protein, human','true'
'no cad mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'no cad mi','C2239547','CAD','ACOD1 gene','false'
'no cad mi','C3813548','CAD','CALD1 wt Allele','false'
'no cad mi','C4284121','CAD','DFFB wt Allele','false'
'sbp $nmbr$ mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp $nmbr$ mmhg','C0439475','mmHG','mmHg','false'
'nocad mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'age s $nmbr$','C0001779','AGE','Age','false'
'$nmbr$ e h','C0033727','H+','Protons','true'
'$nmbr$ e h','C0369286','H NOS','H NOS Antibodies','false'
'$nmbr$ e h','C0441932','H+','Hepatic Involvement','false'
'$nmbr$ e h','C0564385','/h','/hour','false'
'$nmbr$ e h','C4528284','h*%','Hour Times Percent','false'
'chad $nmbr$ $nmbr$','C0007928','CHAD','Chad','true'
'chad $nmbr$ $nmbr$','C1413373','CHAD','CHAD gene','false'
'h $nmbr$','C0033727','H+','Protons','true'
'h $nmbr$','C0369286','H NOS','H NOS Antibodies','false'
'h $nmbr$','C0441932','H+','Hepatic Involvement','false'
'h $nmbr$','C0564385','/h','/hour','false'
'h $nmbr$','C4528284','h*%','Hour Times Percent','false'
'cha $nmbr$ ds $nmbr$ vasc $nmbr$','C1420648','CHA','TCFL5 gene','false'
'cha $nmbr$ ds $nmbr$ vasc $nmbr$','C3714751','DS','Disease Steps Questionnaire','false'
'sbp $nmbr$ mnn hg','C0025424','Hg','Mercury','true'
'sbp $nmbr$ mnn hg','C0428257','Hg','Mercury measurement','false'
'sbp $nmbr$ mnn hg','C2347108','Hg+','Mercury(1+)','false'
'sbp $nmbr$ mnn hg','C2347109','Hg++','Mercury 2+','false'
'sbp $nmbr$ mnn hg','C2348272','Hg','Dietary Mercury','false'
'normal cognitive','C0205307','NORMAL','Normal','false'
'normal cognitive','C0231683','Normal','Gait normal','false'
'normal cognitive','C0439166','% normal','Percent normal','false'
'normal cognitive','C2347086','% Normal','Mean Percent of Normal','false'
'normal cognitive','C4553972','Normal','How Often Felt Normal question','false'
'normal cognitive','C1516691','Cognitive','Cognitive','false'
'impaired cognitive','C0221099','Impaired','Impaired','false'
'impaired cognitive','C1516691','Cognitive','Cognitive','false'
'status spmsq','C0449438','Status','Status','false'
'status spmsq $nmbr$','C0449438','Status','Status','false'
'female gender','C0086287','Female Gender','Females','true'
'treatment arm zoledronate','C1522541','Treatment Arm','Protocol Treatment Arm','false'
'treatment arm zoledronate','C0392938','Zoledronate','zoledronate','true'
'bmi kg m $nmbr$ sd','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ sd','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ sd','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C0019552','HIP','Hip structure','true'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C0022122','Hip','Bone structure of ischium','true'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C1505163','HIP','HHIP protein, human','true'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C3538851','HIP','REG3A wt Allele','false'
'total hip n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C4284725','HIP','HHIP wt Allele','false'
'femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C0015815','Femoral Neck','Structure of neck of femur','true'
'femoral neck n $nmbr$ $nmbr$ bmd g cm $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'fn t score','C0449820','SCORE','Score','false'
'fn t score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'op concomitant medications','C0013227','Medications','Pharmaceutical Preparations','true'
'op concomitant medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'op concomitant medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'op concomitant medications','C4284232','Medications','Medications','false'
'charlson index','C0600653','Index','Indexes','true'
'charlson index','C0918012','Index','Index','true'
'charlson index','C1552854','index','Html Link Type - index','false'
'charlson index','C1637833','% index','% index','false'
'charlson index','C2986546','Index','Target Lesion Identification','false'
'normal cognitive function spmsq','C4296962','Normal function','Normal function','false'
'impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest','C0009240','Cognitive function','Cognition','true'
'impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest','C0679646','participants','Participant','false'
'impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest','C0392335','Cognitive function','Cognitive functions','false'
'impaired cognitive function spmsq $nmbr$ n $nmbr$ n participants with the event of interest','C4050130','Cognitive Function','Cognitive Function Subordinate Domain','false'
'chi square p value','C1552646','chi square','chi square','false'
'chi square p value','C1709380','P-Value','P-Value','false'
'clinical fracture','C0205210','Clinical','Clinical','false'
'clinical fracture','C0016658','FRACTURE','Fracture','true'
'zoledronic acid arm','C0446516','ARM','Upper arm','true'
'zoledronic acid arm','C3715044','ARM','AKR1A1 wt Allele','false'
'zoledronic acid arm','C4553528','arm','Sequence Arm','false'
'placebo arm','C0446516','ARM','Upper arm','true'
'placebo arm','C3715044','ARM','AKR1A1 wt Allele','false'
'placebo arm','C4553528','arm','Sequence Arm','false'
'death','C0011065','DEATH','Cessation of life','true'
'death','C1306577','Death','Death (finding)','false'
'death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death','C4552775','Death NOS','Death NOS, CTCAE','false'
'vedolizumab','C2742797','VEDOLIZUMAB','vedolizumab','true'
'cohort $nmbr$ n $nmbr$ f','C0009247','COHORT','Cohort Studies','true'
'cohort $nmbr$ n $nmbr$ f','C0016327','F-','Fluorides','true'
'cohort $nmbr$ n $nmbr$ f','C0599755','Cohort','Cohort','false'
'cohort $nmbr$ n $nmbr$','C0009247','COHORT','Cohort Studies','true'
'cohort $nmbr$ n $nmbr$','C0599755','Cohort','Cohort','false'
'combined n $nmbr$','C0205195','Combined','Combined','false'
'white race no','C0007457','white race','Caucasoid Race','true'
'white race no','C0043157','white race','Caucasians','true'
'duration of disease yr','C0872146','disease duration','disease length','false'
'duration of disease yr','C0439234','yr','year','false'
'mayo clinic score','C0449820','SCORE','Score','false'
'mayo clinic score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'partial mayo clinic scored','C0002424','Clinic','Ambulatory Care Facilities','true'
'partial mayo clinic scored','C0442592','Clinic','Clinic','false'
'partial mayo clinic scored','C0449820','scored','Score','false'
'ibdq score','C0449820','SCORE','Score','false'
'ibdq score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'fecal calprotectin pg g','C0015733','Fecal','Feces','true'
'fecal calprotectin pg g','C1638318','pg/g','ng/kg','false'
'site of disease no','C2945843','Site of','Site of','false'
'site of disease no','C0012634','Disease','Disease','true'
'rectum and sigmoid colon only','C0034896','RECTUM','Rectum','true'
'rectum and sigmoid colon only','C0227391','Sigmoid Colon','Sigmoid colon','true'
'left side of colon','C0227388','Left side of colon','Left colon','false'
'proximal to the splenic flexure','C0205107','PROXIMAL','Proximal','false'
'proximal to the splenic flexure','C4489236','Proximal','Proximal Resection Margin','false'
'all of the colon','C0009368','COLON','Colon structure (body structure)','true'
'all of the colon','C3888384','Colon','Colon <insect>','false'
'concomitant medications for ulcerative colitis no','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications for ulcerative colitis no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications for ulcerative colitis no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications for ulcerative colitis no','C4284232','Medications','Medications','false'
'immunosuppressants onlyff','C0021081','IMMUNOSUPPRESSANTS','Immunosuppressive Agents','true'
'glucocorticoids and immunosuppressants','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'glucocorticoids and immunosuppressants','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'glucocorticoids and immunosuppressants','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'glucocorticoids and immunosuppressants','C0021081','IMMUNOSUPPRESSANTS','Immunosuppressive Agents','true'
'no glucocorticoids or immunosuppressants','C0017710','GLUCOCORTICOIDS','Glucocorticoids','true'
'no glucocorticoids or immunosuppressants','C3540777','Glucocorticoids','Glucocorticoids, Systemic','false'
'no glucocorticoids or immunosuppressants','C3540778','Glucocorticoids','Glucocorticoid inhalants for obstructive airway disease','false'
'no glucocorticoids or immunosuppressants','C0021081','IMMUNOSUPPRESSANTS','Immunosuppressive Agents','true'
'prednisone equivalent dose mg','C0024671','MG','Mammography','true'
'prednisone equivalent dose mg','C0026410','MG','Mongolia','true'
'prednisone equivalent dose mg','C0439269','mg%','mg/dL','false'
'prednisone equivalent dose mg','C1960952','mg %','Milligram percent','false'
'prednisone equivalent dose mg','C2346927','Mg++','Magnesium Cation','false'
'prednisone equivalent dose mg','C4321396','MG','MG','false'
'prednisone equivalent dose mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'prior anti tnf therapy no','C1514463','Prior Therapy','Prior Therapy','false'
'prior failure of anti tnf therapy no','C0231174','FAILURE','Failure (biologic function)','false'
'prior failure of anti tnf therapy no','C0680095','failure','Personal failure','false'
'prior failure of anti tnf therapy no','C0279936','therapy, TNF','tumor necrosis factor therapy','false'
'$nmbr$ failure','C0231174','FAILURE','Failure (biologic function)','false'
'$nmbr$ failure','C0680095','failure','Personal failure','false'
'inadequate response','C0871261','Response','Response process','false'
'inadequate response','C1704632','Response','Disease Response','false'
'inadequate response','C1706817','Response','Response (statement)','false'
'inadequate response','C2911692','Response','Response (communication)','false'
'loss of response','C1517945','Loss','Loss','false'
'loss of response','C0871261','Response','Response process','false'
'loss of response','C1704632','Response','Disease Response','false'
'loss of response','C1706817','Response','Response (statement)','false'
'loss of response','C2911692','Response','Response (communication)','false'
'unacceptable adverse events','C0877248','adverse events','Adverse event','false'
'unacceptable adverse events','C1705413','Adverse Events','Adverse Event Domain','false'
'hemoglobin concentration g liter','C1319312','Hemoglobin G','Hemoglobin G','false'
'hemoglobin concentration g liter','C0475211','Litre','liter','false'
'white cell count x $nmbr$ _ $nmbr$ liter','C0023508','White Cell count','White Blood Cell Count procedure','true'
'white cell count x $nmbr$ _ $nmbr$ liter','C0475211','Litre','liter','false'
'white cell count x $nmbr$ _ $nmbr$ liter','C0427512','White Cell count','White blood cell count laboratory result','false'
'estimated difference','C1705241','*Difference','Delta (difference)','false'
'estimated difference','C1705242','Difference','Different','false'
'duration of ulcerative colitis','C0449238','Duration','Duration (temporal concept)','false'
'duration of ulcerative colitis','C2926735','Duration','Duration','false'
'extent of disease','C0449279','Extent of disease','Extent of disease','false'
'extent of disease','C4553144','Extent of Disease','Intergroup Rhabdomyosarcoma Clinical Group Extent of Disease','false'
'extensive colitis','C0009319','COLITIS','Colitis','true'
'extensive colitis','C1963084','Colitis','Colitis, CTCAE','false'
'pancolitis','C0868908','Pancolitis','pancolitis','false'
'baseline composite mayo clinic score','C4055211','Composite Score','Composite Score','false'
'baseline composite mayo clinic score','C0002424','Clinic','Ambulatory Care Facilities','true'
'baseline composite mayo clinic score','C0442592','Clinic','Clinic','false'
'baseline fecal caicrctectin','C0168634','baseline','BaseLine dental cement','true'
'baseline fecal caicrctectin','C0015733','Fecal','Feces','true'
'baseline fecal caicrctectin','C1442488','Baseline','Baseline','false'
'$nmbr$ ug g','C0439272','ug/g','ug/g','false'
'prior treatment history $nmbr$','C0019664','History','History','true'
'prior treatment history $nmbr$','C0019665','history','Historical aspects qualifier','true'
'prior treatment history $nmbr$','C0262512','History, NOS','History of present illness','false'
'prior treatment history $nmbr$','C0262926','History','Medical History','false'
'prior treatment history $nmbr$','C1705255','History','Concept History','false'
'prior treatment history $nmbr$','C2004062','History','History of previous events','false'
'any prior anti tnf treatment failure','C1514463','Prior Treatment','Prior Therapy','false'
'prior immunnosupressive failure but no anti tnf failure','C0332152','Prior','Before','false'
'prior immunnosupressive failure but no anti tnf failure','C0231174','FAILURE','Failure (biologic function)','false'
'prior immunnosupressive failure but no anti tnf failure','C0680095','failure','Personal failure','false'
'prior immunnosupressive failure but no anti tnf failure','C2826257','PRIOR','Prior Medication Usage','false'
'prior corticosteroid failure only','C0231174','FAILURE','Failure (biologic function)','false'
'prior corticosteroid failure only','C0680095','failure','Personal failure','false'
'stratification variables','C1514983','Stratification','Stratification','false'
'stratification variables','C0439828','variables','Variable (uniformity)','false'
'concomitant corticosteroid use','C0521115','Concomitant','Simultaneous','false'
'concomitant corticosteroid use','C0239126','CORTICOSTEROID USE','corticosteroid use','false'
'no concomitant cortcosteroid use','C0042153','use','utilization qualifier','true'
'no concomitant cortcosteroid use','C0457083','Use','Usage','false'
'no concomitant cortcosteroid use','C1947944','Use','Use - dosing instruction imperative','false'
'concomitant immunosuppressive and or prior anti tnf use','C0521115','Concomitant','Simultaneous','false'
'concomitant immunosuppressive and or prior anti tnf use','C0021081','immunosuppressive','Immunosuppressive Agents','true'
'concomitant immunosuppressive and or prior anti tnf use','C0332152','Prior','Before','false'
'concomitant immunosuppressive and or prior anti tnf use','C2826257','PRIOR','Prior Medication Usage','false'
'no concomitant immunosuppressive and or prior anti tnf use','C0521115','Concomitant','Simultaneous','false'
'no concomitant immunosuppressive and or prior anti tnf use','C0021081','immunosuppressive','Immunosuppressive Agents','true'
'no concomitant immunosuppressive and or prior anti tnf use','C0332152','Prior','Before','false'
'no concomitant immunosuppressive and or prior anti tnf use','C2826257','PRIOR','Prior Medication Usage','false'
'patients with deep vein thrombosis only','C0030705','Patients','Patients','true'
'patients with deep vein thrombosis only','C0149871','DEEP VEIN THROMBOSIS','Deep Vein Thrombosis','true'
'patients with pulmonary embolism','C0030705','Patients','Patients','true'
'patients with pulmonary embolism','C0034065','PULMONARY EMBOLISM','Pulmonary Embolism','true'
'edoxaban n $nmbr$','C2975435','EDOXABAN','edoxaban','true'
'creatinine clearance $nmbr$ to','C0812399','Creatinine clearance','Creatinine clearance','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0030705','Patients','Patients','true'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C1514756','RECEIVING','Receive','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0024671','MG','Mammography','true'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0026410','MG','Mongolia','true'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0439269','mg%','mg/dL','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C1960952','mg %','Milligram percent','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C2346927','Mg++','Magnesium Cation','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C4321396','MG','MG','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C4521761','MG','United States Military Commissioned Officer O8','false'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0034656','Randomization','Randomization','true'
'patients receiving $nmbr$ mg of edoxaban at randomization no f','C0016327','F-','Fluorides','true'
'anatomical extent of qualifying event no t','C0220784','Anatomical','anatomic','false'
'anatomical extent of qualifying event no t','C0439792','Extent','Extent','false'
'anatomical extent of qualifying event no t','C1514624','Qualifying','Qualifying','false'
'anatomical extent of qualifying event no t','C0441471','Event','Event','false'
'anatomical extent of qualifying event no t','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'anatomical extent of qualifying event no t','C2603360','T'','T prime','false'
'limited','C0439801','Limited','Limited (extensiveness)','false'
'limited','C2674459','Limited','Limited Walking Ability','false'
'limited','C3542948','Limited','Limited component (foundation metadata concept)','false'
'limited','C4050251','Limited','Limited Lifting Ability','false'
'intermediate','C0205103','INTERMEDIATE','Intermediate','false'
'intermediate','C1550465','Intermediate','Observation Interpretation - intermediate','false'
'intermediate','C2827755','INTERMEDIATE','Antimicrobial Intermediate Susceptibility Result','false'
'intermediate','C3889971','Intermediate','Intermediate Mitosis-Karyorrhexis Index','false'
'not assessable','C1883425','Not Assessable','Unevaluable','false'
'concomitant dvt no baseline nt probnp no','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'concomitant dvt no baseline nt probnp no','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'concomitant dvt no baseline nt probnp no','C3899446','DVT','Data Validation Test Document','false'
'concomitant dvt no baseline nt probnp no','C0669479','NTproBNP','pro-brain natriuretic peptide (1-76)','true'
'concomitant dvt no baseline nt probnp no','C0754710','NT-proBNP','Amino-terminal pro-brain natriuretic peptide','true'
'patients with measurement','C0030705','Patients','Patients','true'
'patients with measurement','C0242485','MEASUREMENT','Measurement','false'
'patients with level $nmbr$ pg ml','C0030705','Patients','Patients','true'
'patients with level $nmbr$ pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'right ventricular dysfunction no total no','C0242707','Right Ventricular Dysfunction','Right Ventricular Dysfunction','true'
'right ventricular dysfunction no total no','C1556315','Right ventricular dysfunction','Right Ventricular Dysfunction, CTCAE','false'
'right ventricular dysfunction no total no','C0439175','% total','% of total','false'
'right ventricular dysfunction no total no','C0439810','Total','Total','false'
'causes of dvt or pe no ^','C0015127','causes','Etiology aspects','true'
'causes of dvt or pe no ^','C1314792','Causes','Etiology','true'
'causes of dvt or pe no ^','C0070939','PE','phosphoethanolamine','true'
'causes of dvt or pe no ^','C1880476','PE','Etoposide-Platinol Regimen','false'
'causes of dvt or pe no ^','C4284304','PE','PENK wt Allele','false'
'temporary risk factor','C0205374','Temporary','Transitory','false'
'temporary risk factor','C0035648','Risk Factor','risk factors','true'
'temporary risk factor','C1548539','Temporary','Job Status - Temporary','false'
'temporary risk factor','C3245481','temporary','EntityNameUseR2 <temporary>','false'
'edoxaban','C2975435','EDOXABAN','edoxaban','true'
'presenting diagnosis','C0449450','Presenting','Presentation','false'
'presenting diagnosis','C0011900','DIAGNOSIS','Diagnosis','true'
'presenting diagnosis','C1704338','diagnosis','diagnosis aspect','true'
'presenting diagnosis','C1704656','DIAGNOSIS','Diagnosis Study','false'
'pe with without dvt','C0070939','PE','phosphoethanolamine','true'
'pe with without dvt','C1880476','PE','Etoposide-Platinol Regimen','false'
'pe with without dvt','C4284304','PE','PENK wt Allele','false'
'pe with without dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'pe with without dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'pe with without dvt','C3899446','DVT','Data Validation Test Document','false'
'dvt only','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'dvt only','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'dvt only','C3899446','DVT','Data Validation Test Document','false'
'aga group','C0441833','Group','Groups','false'
'aga group','C0687744','group','Social group','false'
'aga group','C1257890','Group','Population Group','true'
'aga group','C1519504','Group','Stage Grouping','false'
'aga group','C1705428','Group','Group Object','false'
'aga group','C1705429','Group','User Group','false'
'baseline risk factors','C0035648','Risk Factors','risk factors','true'
'baseline risk factors','C1553898','risk factors','risk factors - observation list','false'
'temporary factors','C1521761','Factor','Factor','false'
'temporary factors','C2827422','Factor','Mathematical Factor','false'
'all others eteed for $nmbr$ mg edoxaban dose at','C1955473','Others','Others - Allergy','false'
'all others eteed for $nmbr$ mg edoxaban dose at','C4086581','mg/dose','Milligram per Dose','false'
'all others eteed for $nmbr$ mg edoxaban dose at','C3539125','others','other medicated shampoos in ATC','false'
'ra ndosii zat ion','C0022023','Ion','Ions','true'
'ra ndosii zat ion','C1700702','ION','Iontophoresis Route of Drug Administration','false'
'no body weight at randomization ixrs','C0005910','Body Weight','Body Weight','true'
'no body weight at randomization ixrs','C1305866','body weight','Weighing patient','false'
'$nmbr$ kg body weight at randomization','C0005910','Body Weight','Body Weight','true'
'$nmbr$ kg body weight at randomization','C1305866','body weight','Weighing patient','false'
'creatinine clearance at randomization','C0812399','Creatinine clearance','Creatinine clearance','false'
'creatinine clearance at randomization','C0034656','Randomization','Randomization','true'
'fl $nmbr$ b','C1300812','FL','Femur length','false'
'fl $nmbr$ b','C1708024','FL','FLT3LG wt Allele','false'
'southern europe','C0037724','Southern Europe','Southern Europe','true'
'nordic','C0331873','Nordic','nordic','false'
'china japan','C0008115','CHINA','China','true'
'china japan','C0022341','JAPAN','Japan','true'
'other asian','C0078988','ASIAN','Asians','true'
'south africa south america','C0037713','South America','South America','true'
'usa canada','C0041703','USA','United States','true'
'usa canada','C0006823','CANADA','Canada','true'
'$nmbr$ t $nmbr$ $nmbr$','C2603360','T'','T prime','false'
'american indian or','C0002460','AMERICAN INDIAN','American Indians','true'
'alaska native','C0682125','ALASKA NATIVE','Alaska Natives','true'
'native hawaiian or','C0337920','Hawaiian, Native','Hawaiian population','true'
'other pacific islander','C0242191','Pacific Islander','Pacific Islander Americans','true'
'medical history cancer','C0006826','CANCER','Malignant Neoplasms','true'
'medical history cancer','C0998265','Cancer','Cancer Genus','false'
'medical history cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'no history of cancer','C0455471','History of Cancer','H/O: malignant neoplasm','false'
'active cancer at randomisation','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer at randomisation','C0998265','Cancer','Cancer Genus','false'
'active cancer at randomisation','C1306459','Cancer','Primary malignant neoplasm','false'
'no active cancer center level inr percent time','C0040223','TIME','Time','true'
'no active cancer center level inr percent time','C3541383','Time','Time (foundation metadata concept)','false'
'in therapeutic range for warfarin subjects','C0460097','therapeutic range','Within therapeutic range','false'
'in therapeutic range for warfarin subjects','C0043031','WARFARIN','Warfarin','true'
'$nmbr$ ^ initial heparin treatment duration','C0444921','Treatment duration','Duration of treatment','false'
'$nmbr$ ^ initial heparin treatment duration','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'$nmbr$ $nmbr$ days','C0439228','DAYS','day','false'
'$nmbr$ days','C0439228','DAYS','day','false'
'$nmbr$ day s initial heparin treatment duration','C0332173','/day','Daily','false'
'$nmbr$ day s initial heparin treatment duration','C0439228','Day','day','false'
'$nmbr$ day s initial heparin treatment duration','C0439505','/day','per day','false'
'$nmbr$ day s initial heparin treatment duration','C0444921','Treatment duration','Duration of treatment','false'
'$nmbr$ day s initial heparin treatment duration','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'medion $nmbr$ days','C0439228','DAYS','day','false'
'initial type of heparin treatment received','C0019134','HEPARIN','heparin','true'
'initial type of heparin treatment received','C0455708','Treatment type','Administration type','false'
'initial type of heparin treatment received','C0770546','HEPARIN','heparin, porcine','false'
'initial type of heparin treatment received','C1514756','RECEIVED','Receive','false'
'concomitant aspirin use','C0042153','use','utilization qualifier','true'
'concomitant aspirin use','C0457083','Use','Usage','false'
'concomitant aspirin use','C1947944','Use','Use - dosing instruction imperative','false'
'hazard ratio with','C2985465','Hazard Ratio','Hazard Ratio','false'
'n t','C0369718','N NOS','N not otherwise specified Antibody','false'
'n t','C0441922','N+','N+ (tumor staging)','false'
'warfarin s $nmbr$ cl','C0043031','WARFARIN','Warfarin','true'
'warfarin s $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'all others','C1955473','Others','Others - Allergy','false'
'all others','C3539125','others','other medicated shampoos in ATC','false'
'need for $nmbr$ ng edoxaban dose at','C0017887','NG','Nitroglycerin','true'
'need for $nmbr$ ng edoxaban dose at','C0028074','NG','Niger','true'
'body weight at randonization ixrs','C0005910','Body Weight','Body Weight','true'
'body weight at randonization ixrs','C1305866','body weight','Weighing patient','false'
'body weight at randomization','C0005910','Body Weight','Body Weight','true'
'body weight at randomization','C1305866','body weight','Weighing patient','false'
'creatinine clearance at randomization ixrs','C0812399','Creatinine clearance','Creatinine clearance','false'
'creatinine clearance at randomization ixrs','C0034656','Randomization','Randomization','true'
'$nmbr$ $nmbr$ ml rain','C0439526','/mL','/mL','false'
'$nmbr$ $nmbr$ ml rain','C0034640','Rain','Rain','true'
'$nmbr$ $nmbr$ ml rain','C1705224','ML','THPO wt Allele','false'
'$nmbr$ $nmbr$ ml rain','C3887665','ML','Thrombopoietin, human','false'
'ho','C0019905','HO','Honduras','true'
'ho','C1832110','HO','HORNS IN SHEEP','false'
'ho','C3889614','HO','Healthcare Encounters Domain','false'
'china tjapan','C0008115','CHINA','China','true'
'fl $nmbr$ $nmbr$','C1300812','FL','Femur length','false'
'fl $nmbr$ $nmbr$','C1708024','FL','FLT3LG wt Allele','false'
'active cancer at randomization','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer at randomization','C0998265','Cancer','Cancer Genus','false'
'active cancer at randomization','C1306459','Cancer','Primary malignant neoplasm','false'
'ho active cancer','C0006826','CANCER','Malignant Neoplasms','true'
'ho active cancer','C0998265','Cancer','Cancer Genus','false'
'ho active cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C1554109','Time Range','Time Range','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C0681850','Subject','Study Subject','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C1550501','{Subject}','Subject -direct target','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C1706203','Subject','Subject - topic','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C2349001','Subject','Human Study Subject','false'
'center level ihr percent time in therapeutic range for warfarin subjects','C2697811','Subject','Investigative Subject','false'
'initial heparin treatment duration on or after randomization','C0444921','Treatment duration','Duration of treatment','false'
'initial heparin treatment duration on or after randomization','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'initial heparin treatment duration on or after randomization','C0034656','Randomization','Randomization','true'
'initial heparin treatment duration','C0444921','Treatment duration','Duration of treatment','false'
'initial heparin treatment duration','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'median $nmbr$ days','C0549183','Median','Midline (qualifier value)','false'
'median $nmbr$ days','C0439228','DAYS','day','false'
'median $nmbr$ days','C0876920','Median','Median Statistical Measurement','false'
'median $nmbr$ days','C2347635','Median','Population Median','false'
'median $nmbr$ days','C2348144','Median','Sample Median','false'
'median $nmbr$ days','C2939193','Median','Median (qualifier value)','false'
'ib $nmbr$ $nmbr$','C2744579','IB','ATP8A2 protein, human','true'
'ib $nmbr$ $nmbr$','C3890035','IB','Clinical Trial Investigator Brochure','false'
'ib $nmbr$ $nmbr$','C4283819','IB','Imipramine Blue','false'
'saxagliptin n $nmbr$','C1611934','SAXAGLIPTIN','saxagliptin','true'
'hispanic ethnic group no i','C0015031','Ethnic Group','Ethnic group','true'
'hispanic ethnic group no i','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'hispanic ethnic group no i','C0021966','I-','Iodides','true'
'hispanic ethnic group no i','C0221138','I NOS','Blood group antibody I','false'
'weight^','C0005910','Weight','Body Weight','true'
'weight^','C0043100','Weight','Weight','true'
'weight^','C1305866','weight','Weighing patient','false'
'weight^','C1705104','Weight','Importance Weight','false'
'mean kg','C0022718','KG','Kyrgyzstan','true'
'mean kg','C0439209','kg','Kilogram','false'
'mean kg','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg no','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg no','C0439209','kg','Kilogram','false'
'$nmbr$ kg no','C4054209','/kg','Per Kilogram','false'
'duration of diabetes yr^','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes yr^','C2926735','Duration','Duration','false'
'established atherosclerotic disease no','C0333482','Atherosclerotic','atherosclerotic','false'
'established atherosclerotic disease no','C0012634','Disease','Disease','true'
'dyslipidemia no','C0242339','Dyslipidemia','Dyslipidemias','true'
'prior myocardial infarction no','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'prior myocardial infarction no','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'prior myocardial infarction no','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'prior myocardial infarction no','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'prior myocardial infarction no','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'prior heart failure no','C0018801','Failure, Heart','Heart failure','true'
'prior heart failure no','C0018802','Heart Failure','Congestive heart failure','true'
'prior heart failure no','C4554158','Heart failure','Heart Failure, CTCAE','false'
'prior coronary revascularization no','C0332152','Prior','Before','false'
'prior coronary revascularization no','C0877341','coronary revascularisation','coronary revascularization','false'
'prior coronary revascularization no','C2826257','PRIOR','Prior Medication Usage','false'
'mean ml min','C0444504','Mean','Statistical mean','false'
'mean ml min','C0439445','mL/min','mL/min','false'
'mean ml min','C2347634','Mean','Population Mean','false'
'mean ml min','C2348143','Mean','Sample Mean','false'
'albumin to creatinine ratio i','C0021966','I-','Iodides','true'
'albumin to creatinine ratio i','C0221138','I NOS','Blood group antibody I','false'
'$nmbr$ yr km rate','C0871208','Rate','Rating (action)','false'
'$nmbr$ yr km rate','C1521828','Rate','Rate','false'
'saxagliptin','C1611934','SAXAGLIPTIN','saxagliptin','true'
'atherosclerosis','C0003850','ATHEROSCLEROSIS','Arteriosclerosis','true'
'atherosclerosis','C0004153','ATHEROSCLEROSIS','Atherosclerosis','true'
'established','C0443211','Established','Established','false'
'established','C1272684','Established','Accepted','false'
'multiple risk factors','C0035648','Risk Factors','risk factors','true'
'multiple risk factors','C1553898','risk factors','risk factors - observation list','false'
'a $nmbr$ years','C0439234','YEARS','year','false'
'region north america','C0017446','Region','Geographic Locations','true'
'region north america','C0028405','North America','North America','true'
'region north america','C0205147','Region','regional','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ i','C0221138','I NOS','Blood group antibody I','false'
'prior heart failure','C0018801','Failure, Heart','Heart failure','true'
'prior heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'prior heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'duration of diabetes','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes','C2926735','Duration','Duration','false'
'baseline glycated','C0168634','baseline','BaseLine dental cement','true'
'baseline glycated','C1442488','Baseline','Baseline','false'
'baseline glycated','C3666909','Glycate','Glycate','false'
'hemoglobin','C0019046','Hemoglobin','Hemoglobin','true'
'baseline insulin','C0021641','INSULIN','Insulin','true'
'baseline insulin','C1533581','INSULIN','Recombinant Insulin','false'
'baseline insulin','C1579433','Insulin','Insulin [EPC]','false'
'baseline insulin','C3714501','INSULIN','Insulin Drug Class','false'
'baseline sulfonylurea yes','C1549445','Yes','Yes - Yes/no indicator','false'
'baseline sulfonylurea yes','C1705108','YES','Yes (indicator)','false'
'baseline sulfonylurea yes','C1710701','Yes','YES1 wt Allele','false'
'baseline metformin','C0168634','baseline','BaseLine dental cement','true'
'baseline metformin','C0025598','METFORMIN','Metformin','true'
'baseline metformin','C1442488','Baseline','Baseline','false'
'thiazolidinedione','C0289779','Thiazolidinedione','2,4-thiazolidinedione','true'
'thiazolidinedione','C1257987','Thiazolidinedione','Thiazolidinediones','true'
'thiazolidinedione','C3537039','Thiazolidinedione','Thiazolidinedione [EPC]','false'
'baseline microalbumin','C0201838','Microalbumin','Albumin measurement','false'
'baseline microalbumin','C2362049','Microalbumin','Microalbumin','false'
'creatinine ratio','C0456603','RATIO','Ratio','false'
'creatinine ratio','C1547037','Ratio','data type - ratio','false'
'p vaiue interaction','C0369773','P NOS','P Blood group antibodies','false'
'p vaiue interaction','C1704675','Interaction','Interaction','false'
'p vaiue interaction','C2603361','P'','P prime','false'
'non hishnic','C1518422','Non','Negation','false'
'$nmbr$ $nmbr$ to $nmbr$ i iot','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ to $nmbr$ i iot','C0006196','IOT','British Indian Ocean Territory','true'
'$nmbr$ $nmbr$ to $nmbr$ i iot','C0221138','I NOS','Blood group antibody I','false'
'prior hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'prior hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0016327','F-','Fluorides','true'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0033727','H+','Protons','true'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C0564385','/h','/hour','false'
'$nmbr$ $nmbr$ f $nmbr$ $nmbr$ $nmbr$ $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'baseiine aspirin','C0004057','ASPIRIN','Aspirin','true'
'baseiine statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'baseiine acei arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'$nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'baseiine ccb','C0006684','CCB','Calcium Channel Blockers','true'
'baseiine diuretic','C0012798','Diuretic','Diuretics','true'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'alogliptin n $nmbr$','C1958126','ALOGLIPTIN','alogliptin','true'
'race or ethnic group no t','C0034510','RACE','Racial group','true'
'race or ethnic group no t','C1706779','RACE','AMACR wt Allele','false'
'race or ethnic group no t','C3853635','Race','Race','false'
'race or ethnic group no t','C0015031','Ethnic Group','Ethnic group','true'
'race or ethnic group no t','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'race or ethnic group no t','C2603360','T'','T prime','false'
'region of world no','C0017446','Region','Geographic Locations','true'
'region of world no','C0205147','Region','regional','false'
'united states and canada','C0041703','UNITED STATES','United States','true'
'united states and canada','C0006823','CANADA','Canada','true'
'western europe australia new zealand and middle east','C0027978','NEW ZEALAND','New Zealand','true'
'western europe australia new zealand and middle east','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'western europe australia new zealand and middle east','C0026068','MIDDLE EAST','Middle East','true'
'central and south america and mexico','C0205099','CENTRAL','Central','false'
'central and south america and mexico','C1879652','Central -','Central Minus','false'
'central and south america and mexico','C0037713','South America','South America','true'
'central and south america and mexico','C0025885','MEXICO','Mexico','true'
'eastern europe and africa','C0015177','Eastern Europe','Europe, Eastern','true'
'eastern europe and africa','C0001737','Africa','Africa','true'
'asia and pacific islands','C0003980','Asia','Asia','true'
'asia and pacific islands','C0030168','Pacific Islands','Pacific Islands','true'
'cardiovascular risk factors and history no','C0850624','cardiovascular risk factor','cardiovascular risk factor','false'
'cardiovascular risk factors and history no','C0019664','History','History','true'
'cardiovascular risk factors and history no','C0019665','history','Historical aspects qualifier','true'
'cardiovascular risk factors and history no','C0262512','History, NOS','History of present illness','false'
'cardiovascular risk factors and history no','C0262926','History','Medical History','false'
'cardiovascular risk factors and history no','C1705255','History','Concept History','false'
'cardiovascular risk factors and history no','C2004062','History','History of previous events','false'
'estimated glomerular filtration rate^','C3811844','Estimated Glomerular Filtration Rate','Estimated Glomerular Filtration Rate','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C2347635','Median','Population Median','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C2348144','Median','Sample Median','false'
'median ml min $nmbr$ $nmbr$ m $nmbr$','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ no','C0439445','mL/min','mL/min','false'
'index acs no','C0742343','ACS','Acute Chest Syndrome','true'
'index acs no','C4318612','ACS','ACS - Activity Card Sort','false'
'unstable angina requiring hospitalization','C0002965','Angina, Unstable','Angina, Unstable','true'
'unstable angina requiring hospitalization','C0019993','hospitalisation','Hospitalization','true'
'time between index acs and randomization days','C0040223','TIME','Time','true'
'time between index acs and randomization days','C3541383','Time','Time (foundation metadata concept)','false'
'time between index acs and randomization days','C0034656','Randomization','Randomization','true'
'time between index acs and randomization days','C0439228','DAYS','day','false'
'alogliptin','C1958126','ALOGLIPTIN','alogliptin','true'
'hazard','C0598697','Hazard','hazard','false'
'with treatment','C0039798','treatment','therapeutic aspects','true'
'with treatment','C0087111','Treatment','Therapeutic procedure','true'
'with treatment','C1522326','Treatment','Treating','false'
'with treatment','C1533734','Treatment','Administration procedure','false'
'with treatment','C1705169','Treatment','Biomaterial Treatment','false'
'with treatment','C3538994','TREATMENT','Treatment Epoch','false'
'with treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'overall treatment effect','C0282416','Overall','Overall Publication Type','true'
'overall treatment effect','C1518681','Treatment Effect','Outcome of Therapy','false'
'overall treatment effect','C1561607','Overall','Overall','false'
'index event','C0441471','Event','Event','false'
'index event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'history of ml before index event','C0019664','History','History','true'
'history of ml before index event','C0019665','history','Historical aspects qualifier','true'
'history of ml before index event','C0262512','History, NOS','History of present illness','false'
'history of ml before index event','C0262926','History','Medical History','false'
'history of ml before index event','C1705255','History','Concept History','false'
'history of ml before index event','C2004062','History','History of previous events','false'
'history of ml before index event','C0441471','Event','Event','false'
'history of ml before index event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'history of pci or cabg before index event','C0019664','History','History','true'
'history of pci or cabg before index event','C0019665','history','Historical aspects qualifier','true'
'history of pci or cabg before index event','C0262512','History, NOS','History of present illness','false'
'history of pci or cabg before index event','C0262926','History','Medical History','false'
'history of pci or cabg before index event','C1705255','History','Concept History','false'
'history of pci or cabg before index event','C2004062','History','History of previous events','false'
'history of pci or cabg before index event','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'history of pci or cabg before index event','C0441471','Event','Event','false'
'history of pci or cabg before index event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'history of chf before index event','C0019664','History','History','true'
'history of chf before index event','C0019665','history','Historical aspects qualifier','true'
'history of chf before index event','C0262512','History, NOS','History of present illness','false'
'history of chf before index event','C0262926','History','Medical History','false'
'history of chf before index event','C1705255','History','Concept History','false'
'history of chf before index event','C2004062','History','History of previous events','false'
'history of chf before index event','C0441471','Event','Event','false'
'history of chf before index event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'baseline bmi','C0168634','baseline','BaseLine dental cement','true'
'baseline bmi','C0578022','BMI','Finding of body mass index','false'
'baseline bmi','C1442488','Baseline','Baseline','false'
'$nmbr$ and $nmbr$ years','C0439234','YEARS','year','false'
'baseline glycemic control','C0243148','control','control aspects','true'
'baseline glycemic control','C1550141','Control','control substance','false'
'baseline glycemic control','C1882979','Control','Scientific Control','false'
'baseline glycemic control','C2587213','Control','Control function','false'
'baseline glycemic control','C3274648','Control','True Control Status','false'
'baseline glycemic control','C4553389','control','Study Control','false'
'hba $nmbr$ c $nmbr$ level','C0441889','Level','Levels (qualifier value)','false'
'hba $nmbr$ c $nmbr$ level','C0456079','Level','Disease classification level','false'
'hba $nmbr$ c $nmbr$ level','C1547707','Level','Floor - story of building','false'
'hba $nmbr$ c $nmbr$ level','C2946261','Level','Level','false'
'insulin use at baseline','C0240016','INSULIN USE','Insulin used','false'
'insulin use at baseline','C0168634','baseline','BaseLine dental cement','true'
'insulin use at baseline','C1442488','Baseline','Baseline','false'
'biguanide use at baseline','C0042153','use','utilization qualifier','true'
'biguanide use at baseline','C0457083','Use','Usage','false'
'biguanide use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'thiazolidinedione use at baseline','C0042153','use','utilization qualifier','true'
'thiazolidinedione use at baseline','C0457083','Use','Usage','false'
'thiazolidinedione use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'sulfonylurea use at baseline','C0042153','use','utilization qualifier','true'
'sulfonylurea use at baseline','C0457083','Use','Usage','false'
'sulfonylurea use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'united states canada','C0041703','UNITED STATES','United States','true'
'united states canada','C0006823','CANADA','Canada','true'
'mexico central south america','C0007674','Central America','Central America','true'
'western europe australia new zealand middle east','C0043128','Western Australia','Western Australia','true'
'western europe australia new zealand middle east','C0026068','MIDDLE EAST','Middle East','true'
'eastern europe africa','C0001741','Africa, Eastern','Africa, Eastern','true'
'renal function','C0232804','Renal function','Renal function','false'
'normalfunction or mild impairment','C0221099','Impairment','Impaired','false'
'normalfunction or mild impairment','C0684336','Impairment','Impaired health','false'
'placebo mtx','C0025677','MTX','Methotrexate','true'
'placebo mtx','C1417487','MTX','MTX1 gene','false'
'golimumab $nmbr$ mg kg mtx','C0025677','MTX','Methotrexate','true'
'golimumab $nmbr$ mg kg mtx','C1417487','MTX','MTX1 gene','false'
'randomised patients n','C0030705','Patients','Patients','true'
'median iq range','C1514721','Range','Range','false'
'median iq range','C2348147','Range','Sample Range','false'
'median iq range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'total vdh s score $nmbr$ $nmbr$ n','C2964552','Total Score','Total score','false'
'erosion score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'erosion score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'jsn score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'jsn score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'crp normal','C0205307','NORMAL','Normal','false'
'crp normal','C0231683','Normal','Gait normal','false'
'crp normal','C0439166','% normal','Percent normal','false'
'crp normal','C2347086','% Normal','Mean Percent of Normal','false'
'crp normal','C4553972','Normal','How Often Felt Normal question','false'
'cdai $nmbr$ $nmbr$','C0683448','CDAI','Codependency Assessment Inventory','false'
'cdai $nmbr$ $nmbr$','C1413248','CDAI','CDAN1 gene','false'
'cdai $nmbr$ $nmbr$','C3273706','CDAI','CDAN1 wt Allele','false'
'disease activity n','C1292728','Disease activity','Condition activity','false'
'low $nmbr$ $nmbr$ and','C0205251','Low','low','false'
'low $nmbr$ $nmbr$ and','C1550472','low','low confidentiality','false'
'low $nmbr$ $nmbr$ and','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'low $nmbr$ $nmbr$ and','C4048187','low','low exposure','false'
'low $nmbr$ $nmbr$ and','C4321351','Low','Low Level','false'
'low $nmbr$ $nmbr$ and','C4522223','Low','IPSS Risk Category Low','false'
'moderate $nmbr$ and','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate $nmbr$ and','C1881878','Moderate','Moderation','false'
'moderate $nmbr$ and','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate $nmbr$ and','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate $nmbr$ and','C4085643','Moderate','Moderate Response','false'
'moderate $nmbr$ and','C4321335','Moderate','Moderate Level','false'
'high $nmbr$','C0205250','High','High','false'
'high $nmbr$','C1299351','High','Abnormally high','false'
'high $nmbr$','C2700149','HIGH','Value Above Reference Range','false'
'high $nmbr$','C3887512','high','high - ActExposureLevelCode','false'
'high $nmbr$','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high $nmbr$','C4321237','High','High Level','false'
'high $nmbr$','C4522209','High','IPSS Risk Category High','false'
'sdai $nmbr$ $nmbr$','C3871128','SDAI','SDAI','false'
'haq di $nmbr$ $nmbr$','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di $nmbr$ $nmbr$','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'direction of hr','C0449738','Direction','Direction','false'
'all subjects','C0681850','Subject','Study Subject','false'
'all subjects','C1550501','{Subject}','Subject -direct target','false'
'all subjects','C1706203','Subject','Subject - topic','false'
'all subjects','C2349001','Subject','Human Study Subject','false'
'all subjects','C2697811','Subject','Investigative Subject','false'
'right','C0205090','RIGHT','Right','false'
'right','C0444532','Right','Right sided','false'
'centre','C0205099','Centre','Central','false'
'centre','C3810851','Center','Center of town','false'
'left','C0205091','LEFT','Left','false'
'left','C0443246','Left','Left sided','false'
'left','C1552822','left','Table Cell Horizontal Align - left','false'
'middle','C0444598','Middle','Middle','false'
'middle','C0549183','middle','Midline (qualifier value)','false'
'middle','C1552826','middle','Table Cell Vertical Align - middle','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0242492','Relative Risk','Relative Risk','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C4554402','RR','RR genotype','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0557651','Study','Room of building - Study','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C2603343','Study','Study','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0205195','Combined','Combined','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0947630','studies','Scientific Study','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0008107','CI','Chile','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C3259781','CI','Coagulation Index Measurement','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0026175','mine','Mining','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0338297','MINE','Etoposide/Ifosfamide/Mesna/Mitoxantrone','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0032042','Placebo','Placebos','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0031962','PBO','Piperonyl Butoxide','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0030705','Patients','Patients','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C3272598','WHO','WHO Temperature/Humidity Storage Condition','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C1448177','TNF Alpha','TNF protein, human','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C1456820','TNFalpha','Tumor Necrosis Factor-alpha','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C1522669','TNF-Alpha','Recombinant Tumor Necrosis Factor-Alpha','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0008976','Trial','Clinical Trials','true'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0205171','Alone','Singular','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0439044','Alone','Living Alone','false'
'figure $nmbr$ patient based relative risk rr of hospi talization by study and for the combined studies a the rr and corresponding $nmbr$ ci of all cause hos pitalization was deter mined for adalimumab ada vs placebo pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both trials combined b the rr and corresponding $nmbr$ ci of uc related hospitalization was deter mined for ada vs pbo during the $nmbr$ week period of ultra $nmbr$ alone ultra $nmbr$ alone prior anti tnf users patients who were anti tnf alpha na ve and both','C0679994','alone','alone - group size','false'
'predictive factor','C0683956','predictive factor','predictive factor','false'
'age yr range','C1514721','Range','Range','false'
'age yr range','C2348147','Range','Sample Range','false'
'age yr range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'bmi no','C0578022','BMI','Finding of body mass index','false'
'lifestyle behaviors','C0004927','Behaviors','Behavior','true'
'lifestyle behaviors','C0677505','behaviors','Behaviors and observations relating to behavior','false'
'alcohol consumption no','C0001948','ALCOHOL CONSUMPTION','Alcohol consumption','true'
'comorbidities concomitant medications','C0013227','Medications','Pharmaceutical Preparations','true'
'comorbidities concomitant medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'comorbidities concomitant medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'comorbidities concomitant medications','C4284232','Medications','Medications','false'
'comorbidities no','C0009488','comorbidities','Comorbidity','true'
'cardiovascular disorder','C0007222','CARDIOVASCULAR DISORDER (NOS)','Cardiovascular Diseases','true'
'cardiac disorder','C0018799','Cardiac disorder','Heart Diseases','true'
'no antihypertensive medication','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'one antihypertensive medication','C0205447','ONE','One','false'
'one antihypertensive medication','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'two or more antihypertensive medications','C0205448','Two','Two','false'
'two or more antihypertensive medications','C0003364','Antihypertensive Medications','Antihypertensive Agents','true'
'statin s','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'ed characteristics','C3538926','ED','Endocrine System Findings Domain','false'
'ed characteristics','C1521970','Characteristics','Characteristics','false'
'ed $nmbr$ yr no','C3538926','ED','Endocrine System Findings Domain','false'
'ed $nmbr$ yr no','C0439234','yr','year','false'
'ed etiology no','C0015127','etiology','Etiology aspects','true'
'ed etiology no','C1314792','Etiology','Etiology','true'
'ed etiology no','C1524003','Etiology','Science of Etiology','false'
'ed severity no a','C0439793','Severity','Severities','false'
'ed severity no a','C0522510','Severity','With intensity','false'
'mild iief ef $nmbr$ $nmbr$','C2945599','Mild','Mild (qualifier value)','false'
'mild iief ef $nmbr$ $nmbr$','C3641331','IIEF','International Index of Erectile Function Questionnaire','false'
'moderate iief ef $nmbr$ $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate iief ef $nmbr$ $nmbr$','C1881878','Moderate','Moderation','false'
'moderate iief ef $nmbr$ $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate iief ef $nmbr$ $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate iief ef $nmbr$ $nmbr$','C4085643','Moderate','Moderate Response','false'
'moderate iief ef $nmbr$ $nmbr$','C4321335','Moderate','Moderate Level','false'
'severe iief ef','C0205082','Severe','Severe (severity modifier)','false'
'severe iief ef','C3641331','IIEF','International Index of Erectile Function Questionnaire','false'
'severe iief ef','C4050465','Severe','Severe Extremity Pain','false'
'severe iief ef','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'previous pde $nmbr$ i therapy no','C0039798','therapy','therapeutic aspects','true'
'previous pde $nmbr$ i therapy no','C0087111','Therapy','Therapeutic procedure','true'
'previous pde $nmbr$ i therapy no','C1363945','Therapy','Therapy Object (animal model)','false'
'tadalafil $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'tadalafil $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'tadalafil $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tadalafil $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tadalafil $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tadalafil $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'tadalafil $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'tadalafil $nmbr$ mg','C0024671','MG','Mammography','true'
'tadalafil $nmbr$ mg','C0026410','MG','Mongolia','true'
'tadalafil $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tadalafil $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tadalafil $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tadalafil $nmbr$ mg','C4321396','MG','MG','false'
'tadalafil $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'ls mean change','C0392747','Change','Changing','false'
'ls mean change','C0443172','change','Changed status','false'
'ls mean change','C1705241','Change','Delta (difference)','false'
'ls mean change','C4319952','Change','Change -- procedure','false'
'pbo adjusted ls mean change','C0392747','Change','Changing','false'
'pbo adjusted ls mean change','C0443172','change','Changed status','false'
'pbo adjusted ls mean change','C1705241','Change','Delta (difference)','false'
'pbo adjusted ls mean change','C4319952','Change','Change -- procedure','false'
'alcohol consumption at baseline','C0001948','ALCOHOL CONSUMPTION','Alcohol consumption','true'
'alcohol consumption at baseline','C0168634','baseline','BaseLine dental cement','true'
'alcohol consumption at baseline','C1442488','Baseline','Baseline','false'
'smoker at baseline','C0337664','Smoker','Smoker','true'
'smoker at baseline','C0168634','baseline','BaseLine dental cement','true'
'smoker at baseline','C1442488','Baseline','Baseline','false'
'antihypertensive use','C0042153','use','utilization qualifier','true'
'antihypertensive use','C0457083','Use','Usage','false'
'antihypertensive use','C1947944','Use','Use - dosing instruction imperative','false'
'none at baseline','C0168634','baseline','BaseLine dental cement','true'
'none at baseline','C1442488','Baseline','Baseline','false'
'one at baseline','C0205447','ONE','One','false'
'one at baseline','C0168634','baseline','BaseLine dental cement','true'
'one at baseline','C1442488','Baseline','Baseline','false'
'two or more at baseline','C0205448','Two','Two','false'
'two or more at baseline','C0168634','baseline','BaseLine dental cement','true'
'two or more at baseline','C1442488','Baseline','Baseline','false'
'statin use','C0042153','use','utilization qualifier','true'
'statin use','C0457083','Use','Usage','false'
'statin use','C1947944','Use','Use - dosing instruction imperative','false'
'ed duration','C0449238','Duration','Duration (temporal concept)','false'
'ed duration','C2926735','Duration','Duration','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C0444504','Mean','Statistical mean','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C2347634','Mean','Population Mean','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C2348143','Mean','Sample Mean','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C0032042','Placebo','Placebos','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C2599594','Post-bronchodilator','post bronchodilator','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C3714541','FEV','Forced Vital Capacity','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C0032659','Population','geographic population','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1257890','Population','Population Group','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C0016529','Forced expiratory volume','Forced expiratory volume function','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1306036','Forced Expiratory Volume','Forced expiratory volume procedure','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C0162425','intent','Intention - mental process','true'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1283828','Intent','intent','false'
'figure $nmbr$ least squares ls mean differences between ro umilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting b $nmbr$ agonist','C1550453','intent','Act Mood - intent','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C0444504','Mean','Statistical mean','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C2347634','Mean','Population Mean','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C2348143','Mean','Sample Mean','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C0032042','Placebo','Placebos','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C2599594','Post-bronchodilator','post bronchodilator','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C3714541','FEV','Forced Vital Capacity','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C0032659','Population','geographic population','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1257890','Population','Population Group','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C0016529','Forced expiratory volume','Forced expiratory volume function','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1306036','Forced Expiratory Volume','Forced expiratory volume procedure','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C0162425','intent','Intention - mental process','true'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1283828','Intent','intent','false'
'figure $nmbr$ least squares ls mean differences between roflumilast and placebo in a pre and b postbronchodilator fev $nmbr$ in the itt population and subpopulations copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long acting $nmbr$ agonist','C1550453','intent','Act Mood - intent','false'
'risedronate n $nmbr$','C0246719','RISEDRONATE','Risedronate','true'
'denosumab n $nmbr$','C1690432','DENOSUMAB','denosumab','true'
'history of osteoporotic fracture n a','C4075937','History of osteoporotic fracture','History of osteoporotic fracture','false'
'serum $nmbr$ hydroxyvitamin d ng ml','C0020337','hydroxyvitamin d','Hydroxycholecalciferols','true'
'serum $nmbr$ hydroxyvitamin d ng ml','C0439275','ng/mL','Microgram per Liter','false'
'duration of prior alendronate use months','C1881378','DURATION OF USE','Limitation of Use Based on Duration of Use','false'
'duration of prior alendronate use months','C2826775','Duration of Use','Duration of Use','false'
'$nmbr$ tob $nmbr$ months n','C1420851','TOB','TOB1 gene','false'
'$nmbr$ tob $nmbr$ months n','C0439231','MONTHS','month','false'
'$nmbr$ months n','C0439231','MONTHS','month','false'
'time since prior alendronate use n','C1279919','Prior time','Early','false'
'time since prior alendronate use n','C2362777','Prior time','Before time','false'
'$nmbr$ tob $nmbr$ months','C1420851','TOB','TOB1 gene','false'
'$nmbr$ tob $nmbr$ months','C0439231','MONTHS','month','false'
'never took alendronate','C2003901','NEVER','Never (frequency)','false'
'never took alendronate','C1515187','Take','Take','false'
'never took alendronate','C0102118','ALENDRONATE','Alendronate','true'
'still taking alendronate at study entry n','C0102118','ALENDRONATE','Alendronate','true'
'still taking alendronate at study entry n','C0557651','Study','Room of building - Study','false'
'still taking alendronate at study entry n','C2603343','Study','Study','false'
'serum ctx $nmbr$ ng ml median iqr','C0010377','CTX','Crotoxin','true'
'serum ctx $nmbr$ ng ml median iqr','C0439275','ng/mL','Microgram per Liter','false'
'serum ctx $nmbr$ ng ml median iqr','C0631180','CTX','C-telopeptide','true'
'serum ctx $nmbr$ ng ml median iqr','C3539598','CTX','CYP27A1 wt Allele','false'
'lower tertile b $nmbr$ $nmbr$','C0441994','LOWER','Lower - spatial qualifier','false'
'lower tertile b $nmbr$ $nmbr$','C1548802','Lower','Body Site Modifier - Lower','false'
'lower tertile b $nmbr$ $nmbr$','C2003888','Lower','Lower (action)','false'
'middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$','C0444598','Middle','Middle','false'
'middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$','C0549183','middle','Midline (qualifier value)','false'
'middle tertile $nmbr$ $nmbr$ to b $nmbr$ $nmbr$','C1552826','middle','Table Cell Vertical Align - middle','false'
'upper tertile $nmbr$ $nmbr$','C1282910','UPPER','Upper','false'
'high dose edoxaban n $nmbr$','C0444956','High dose','High dose','false'
'high dose edoxaban n $nmbr$','C2975435','EDOXABAN','edoxaban','true'
'low dose edoxaban n $nmbr$','C0445550','Low dose','Low dose','false'
'low dose edoxaban n $nmbr$','C1708745','Low-Dose','Low-Dose Treatment','false'
'asia pacific region and south africa','C0017446','Region','Geographic Locations','true'
'asia pacific region and south africa','C0205147','Region','regional','false'
'asia pacific region and south africa','C0037712','SOUTH AFRICA','South Africa','true'
'paroxysmal atrial fibrillation no','C0235480','ATRIAL FIBRILLATION, PAROXYSMAL','Paroxysmal atrial fibrillation','true'
'paroxysmal atrial fibrillation no','C4050122','PAROXYSMAL ATRIAL FIBRILLATION','Paroxysmal Atrial Fibrillation by ECG Finding','false'
'qualifying risk factor no','C1514624','Qualifying','Qualifying','false'
'qualifying risk factor no','C0035648','Risk Factor','risk factors','true'
'prior stroke or transient ischemic attack','C0038454','STROKE','Cerebrovascular accident','true'
'prior stroke or transient ischemic attack','C4554100','Stroke','Stroke, CTCAE','false'
'prior stroke or transient ischemic attack','C0007787','Transient ischaemic attack','Transient Ischemic Attack','true'
'prior stroke or transient ischemic attack','C0917805','Transient ischemic attack','Transient Cerebral Ischemia','true'
'hypertension requiring treatment','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension requiring treatment','C1963138','Hypertension','Hypertension, CTCAE','false'
'hypertension requiring treatment','C0039798','treatment','therapeutic aspects','true'
'hypertension requiring treatment','C0087111','Treatment','Therapeutic procedure','true'
'hypertension requiring treatment','C1522326','Treatment','Treating','false'
'hypertension requiring treatment','C1533734','Treatment','Administration procedure','false'
'hypertension requiring treatment','C1705169','Treatment','Biomaterial Treatment','false'
'hypertension requiring treatment','C3538994','TREATMENT','Treatment Epoch','false'
'hypertension requiring treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'dose reduction at randomization no i','C0301630','Reduction','Reduction (chemical)','false'
'dose reduction at randomization no i','C0392756','Reduction','Reduced','false'
'dose reduction at randomization no i','C1293152','Reduction','Reduction procedure','false'
'dose reduction at randomization no i','C4551656','Reduction','Surgical reduction','false'
'dose reduction at randomization no i','C0021966','I-','Iodides','true'
'dose reduction at randomization no i','C0221138','I NOS','Blood group antibody I','false'
'use of verapamil or quinidine','C1524063','Use of','Use of','false'
'use of verapamil or quinidine','C0042523','VERAPAMIL','Verapamil','true'
'use of verapamil or quinidine','C0034414','QUINIDINE','Quinidine','true'
'previous use of vitamin k antagonist for $nmbr$ days no','C1524063','Use of','Use of','false'
'previous use of vitamin k antagonist for $nmbr$ days no','C1096489','vitamin k antagonist','Treatment with Vitamin K antagonist','false'
'previous use of vitamin k antagonist for $nmbr$ days no','C2267235','Vitamin K Antagonist','Vitamin K Antagonist [EPC]','false'
'previous use of vitamin k antagonist for $nmbr$ days no','C0439228','DAYS','day','false'
'medication at time of randomization no','C0013227','Medication','Pharmaceutical Preparations','true'
'medication at time of randomization no','C3244316','medication','medication - HL7 publishing domain','false'
'medication at time of randomization no','C4284232','Medication','Medications','false'
'digoxin or digitalis preparation','C0012265','DIGOXIN','Digoxin','true'
'digoxin or digitalis preparation','C0304520','Digitalis preparation','Digitalis preparation','false'
'hazard ratio with high $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio with high $nmbr$ cl','C0205250','High','High','false'
'hazard ratio with high $nmbr$ cl','C1299351','High','Abnormally high','false'
'hazard ratio with high $nmbr$ cl','C2700149','HIGH','Value Above Reference Range','false'
'hazard ratio with high $nmbr$ cl','C3887512','high','high - ActExposureLevelCode','false'
'hazard ratio with high $nmbr$ cl','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'hazard ratio with high $nmbr$ cl','C4321237','High','High Level','false'
'hazard ratio with high $nmbr$ cl','C4522209','High','IPSS Risk Category High','false'
'hazard ratio with low $nmbr$ cl','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio with low $nmbr$ cl','C0205251','Low','low','false'
'hazard ratio with low $nmbr$ cl','C1550472','low','low confidentiality','false'
'hazard ratio with low $nmbr$ cl','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'hazard ratio with low $nmbr$ cl','C4048187','low','low exposure','false'
'hazard ratio with low $nmbr$ cl','C4321351','Low','Low Level','false'
'hazard ratio with low $nmbr$ cl','C4522223','Low','IPSS Risk Category Low','false'
'high dose edoxaban vs warfarin','C0444956','High dose','High dose','false'
'high dose edoxaban vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'high dose edoxaban vs warfarin','C0043031','WARFARIN','Warfarin','true'
'low dose edoxaban vs warfarin','C0445550','Low dose','Low dose','false'
'low dose edoxaban vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'low dose edoxaban vs warfarin','C1708745','Low-Dose','Low-Dose Treatment','false'
'low dose edoxaban vs warfarin','C0043031','WARFARIN','Warfarin','true'
'af type','C0332307','TYPE','Type - attribute','false'
'af type','C1547052','*Type','*Type - Kind of quantity','false'
'prior stroke or tza','C0038454','STROKE','Cerebrovascular accident','true'
'prior stroke or tza','C4554100','Stroke','Stroke, CTCAE','false'
'prior stroke or tza','C0039298','TZA','Tanzania','true'
'$nmbr$ p $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ p $nmbr$','C2603361','P'','P prime','false'
'congestive heart','C0742742','Congestive','congestive','false'
'congestive heart','C0018787','HEART','Heart','true'
'failure','C0231174','FAILURE','Failure (biologic function)','false'
'failure','C0680095','failure','Personal failure','false'
'cha $nmbr$ s $nmbr$ score','C1420648','CHA','TCFL5 gene','false'
'cha $nmbr$ s $nmbr$ score','C0449820','SCORE','Score','false'
'cha $nmbr$ s $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'dose adjusted','C0178602','DOSE','Dosage','false'
'dose adjusted','C0869039','Dose','Unit dose','false'
'dose adjusted','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'dose adjusted','C0456081','Adjusted','Adjustment Action','false'
'amiodarone use at baseline','C0042153','use','utilization qualifier','true'
'amiodarone use at baseline','C0457083','Use','Usage','false'
'amiodarone use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'center level ttr','C0032923','TTR','Prealbumin','true'
'center level ttr','C1421224','TTR','TTR gene','false'
'amiodarone ote at baseline','C0002598','AMIODARONE','Amiodarone','true'
'amiodarone ote at baseline','C0168634','baseline','BaseLine dental cement','true'
'amiodarone ote at baseline','C1442488','Baseline','Baseline','false'
'ff $nmbr$ ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'ff $nmbr$ ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'ff $nmbr$ ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'ff vi $nmbr$ $nmbr$ ig n $nmbr$','C0205999','VI','British Virgin Islands','true'
'ff vi $nmbr$ $nmbr$ ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'ff vi $nmbr$ $nmbr$ ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'ff vi $nmbr$ $nmbr$ ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'never smoked n','C2003901','NEVER','Never (frequency)','false'
'never smoked n','C0037366','Smoke','Smoke','true'
'never smoked n','C0439994','Smoke','Tobacco smoke','false'
'never smoked n','C1881674','Smoke','Medical Device Emits Smoke','false'
'former smoker n','C0337671','Former Smoker','Former smoker','false'
'number of exacerbations in last $nmbr$ months','C0237753','*Number','Numbers','false'
'number of exacerbations in last $nmbr$ months','C0449788','Number','Count of entities','false'
'number of exacerbations in last $nmbr$ months','C0439231','MONTHS','month','false'
'duration of asthma years','C0449238','Duration','Duration (temporal concept)','false'
'duration of asthma years','C2926735','Duration','Duration','false'
'screening prebronchodilator fev $nmbr$ l','C0220908','Screening','Screening procedure','true'
'screening prebronchodilator fev $nmbr$ l','C0220909','screening','Aspects of disease screening','true'
'screening prebronchodilator fev $nmbr$ l','C1698960','screening','research subject screening','false'
'screening prebronchodilator fev $nmbr$ l','C1710031','Screening','Disease Screening','false'
'screening prebronchodilator fev $nmbr$ l','C1710032','Screening','Screening','false'
'screening prebronchodilator fev $nmbr$ l','C1710477','SCREENING','Trial Screening','false'
'screening prebronchodilator fev $nmbr$ l','C2348164','SCREENING','Screening Study','false'
'screening predicted fev $nmbr$','C0220908','Screening','Screening procedure','true'
'screening predicted fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'screening predicted fev $nmbr$','C0220909','screening','Aspects of disease screening','true'
'screening predicted fev $nmbr$','C1698960','screening','research subject screening','false'
'screening predicted fev $nmbr$','C1710031','Screening','Disease Screening','false'
'screening predicted fev $nmbr$','C1710032','Screening','Screening','false'
'screening predicted fev $nmbr$','C1710477','SCREENING','Trial Screening','false'
'screening predicted fev $nmbr$','C2348164','SCREENING','Screening Study','false'
'screening reversibility fev $nmbr$','C0220908','Screening','Screening procedure','true'
'screening reversibility fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'screening reversibility fev $nmbr$','C0220909','screening','Aspects of disease screening','true'
'screening reversibility fev $nmbr$','C1698960','screening','research subject screening','false'
'screening reversibility fev $nmbr$','C1710031','Screening','Disease Screening','false'
'screening reversibility fev $nmbr$','C1710032','Screening','Screening','false'
'screening reversibility fev $nmbr$','C1710477','SCREENING','Trial Screening','false'
'screening reversibility fev $nmbr$','C2348164','SCREENING','Screening Study','false'
'screening absolute reversibility fev $nmbr$ ml','C0439526','/mL','/mL','false'
'screening absolute reversibility fev $nmbr$ ml','C1705224','ML','THPO wt Allele','false'
'screening absolute reversibility fev $nmbr$ ml','C3887665','ML','Thrombopoietin, human','false'
'baseline acq $nmbr$ score','C0449820','SCORE','Score','false'
'baseline acq $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'percentage of patients using ics or ics laba on entry','C0439165','Percentage','Percent (qualifier value)','false'
'percentage of patients using ics or ics laba on entry','C1549488','Percentage','Amount type - Percentage','false'
'percentage of patients using ics or ics laba on entry','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'percentage of patients using ics or ics laba on entry','C1524063','Using','Use of','false'
'percentage of patients using ics or ics laba on entry','C0815320','ICS','Impaired Control Scale','false'
'percentage of patients using ics or ics laba on entry','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'percentage of patients using ics or ics laba on entry','C1705654','Entry','Entry (data)','false'
'ics only','C0815320','ICS','Impaired Control Scale','false'
'ics only','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics laba','C0815320','ICS','Impaired Control Scale','false'
'ics laba','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ff $nmbr$ gg n $nmbr$ $nmbr$','C0017454','GG','Georgia, Western Asia','true'
'ff $nmbr$ gg n $nmbr$ $nmbr$','C0018370','GG','Guernsey (geographic location)','true'
'ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$','C0017454','GG','Georgia, Western Asia','true'
'ff vi $nmbr$ $nmbr$ gg n $nmbr$ $nmbr$','C0018370','GG','Guernsey (geographic location)','true'
'total n $nmbr$ $nmbr$','C0439175','% total','% of total','false'
'total n $nmbr$ $nmbr$','C0439810','Total','Total','false'
'african american','C0085756','AFRICAN AMERICAN','African American','true'
'russia','C0035970','RUSSIA','Russia','true'
'ukraine','C0041580','UKRAINE','Ukraine','true'
'germany','C0017480','GERMANY','Germany','true'
'argentina','C0003761','ARGENTINA','Country of Argentina','true'
'argentina','C1504311','Argentina','Argentina genus','false'
'poland','C0032356','POLAND','Country of Poland','true'
'philippines','C0031529','PHILIPPINES','Philippines','true'
'romania','C0035826','Rumania','Romania','true'
'japan','C0022341','JAPAN','Japan','true'
'australia','C0004340','AUSTRALIA','Australia','true'
'baseline fev l','C0168634','baseline','BaseLine dental cement','true'
'baseline fev l','C1442488','Baseline','Baseline','false'
'f','C0016327','F-','Fluorides','true'
'grouped region','C0017446','Region','Geographic Locations','true'
'grouped region','C0205147','Region','regional','false'
'australasia','C0282279','Australasia','Oceania','true'
'australasia','C1257882','Australasia','Australasia','true'
'participants no','C0679646','participants','Participant','false'
'gi bleed','C1708130','Gi','GNAI1 wt Allele','false'
'gi bleed','C0019080','bleed','Hemorrhage','true'
'gi bleed','C3539617','GI','Digestive System Findings Domain','false'
'gi bleed','C4050121','GI','Gastrointestinal studies and measurements','false'
'no gi bleed','C1708130','Gi','GNAI1 wt Allele','false'
'no gi bleed','C0019080','bleed','Hemorrhage','true'
'no gi bleed','C3539617','GI','Digestive System Findings Domain','false'
'no gi bleed','C4050121','GI','Gastrointestinal studies and measurements','false'
'participants randomized','C0679646','participants','Participant','false'
'participants randomized','C0034656','Randomized','Randomization','true'
'participants randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'black non black','C0005680','Black','Black race','true'
'black non black','C0027567','Black','African race','true'
'black non black','C0085756','BLACK','African American','true'
'black non black','C0439541','Black','Black color','false'
'hispanic non hispanic','C0086409','HISPANIC','Hispanics','true'
'hispanic non hispanic','C1518422','Non','Negation','false'
'women taking estrogen','C0014939','Oestrogen, NOS','Estrogens','true'
'women taking estrogen','C2936882','Estrogen','Estrogen [EPC]','false'
'women taking estrogen','C4542544','Estrogen','Estrogen (disposition)','false'
'hdl mean sd mg dl','C0444504','Mean','Statistical mean','false'
'hdl mean sd mg dl','C0439269','mg dl','mg/dL','false'
'hdl mean sd mg dl','C2347634','Mean','Population Mean','false'
'hdl mean sd mg dl','C2348143','Mean','Sample Mean','false'
'diabetes classificationa','C0011847','Diabetes','Diabetes','false'
'diabetes classificationa','C0011849','Diabetes','Diabetes Mellitus','true'
'mean sd mg kg $nmbr$','C0444504','Mean','Statistical mean','false'
'mean sd mg kg $nmbr$','C0439272','mg kg','ug/g','false'
'mean sd mg kg $nmbr$','C2347634','Mean','Population Mean','false'
'mean sd mg kg $nmbr$','C2348143','Mean','Sample Mean','false'
'yes no','C1512698','yes/no','Yes or No Response','false'
'history mi or stroke','C0019664','History','History','true'
'history mi or stroke','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'history mi or stroke','C0019665','history','Historical aspects qualifier','true'
'history mi or stroke','C0262512','History, NOS','History of present illness','false'
'history mi or stroke','C0262926','History','Medical History','false'
'history mi or stroke','C1705255','History','Concept History','false'
'history mi or stroke','C2004062','History','History of previous events','false'
'history mi or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'history mi or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'history coronary','C0019664','History','History','true'
'history coronary','C0018787','coronary','Heart','true'
'history coronary','C0019665','history','Historical aspects qualifier','true'
'history coronary','C0262512','History, NOS','History of present illness','false'
'history coronary','C0262926','History','Medical History','false'
'history coronary','C1705255','History','Concept History','false'
'history coronary','C2004062','History','History of previous events','false'
'other atherosclerotic','C0333482','Atherosclerotic','atherosclerotic','false'
'cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'lvh by minnesota code','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by minnesota code','C0009219','code','Coding','true'
'lvh by minnesota code','C0805701','CODE','Code','false'
'lvh by minnesota code','C3889831','Code','eTMF Content Model Code','false'
'unadjusted hr $nmbr$ ci a','C0008107','CI','Chile','true'
'unadjusted hr $nmbr$ ci a','C3259781','CI','Coagulation Index Measurement','false'
'lisinopril vs chlorthalidone','C0065374','Lysinopril','Lisinopril','true'
'lisinopril vs chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'lisinopril vs amlodipineb','C0065374','Lysinopril','Lisinopril','true'
'aspirin at baseline','C0004057','ASPIRIN','Aspirin','true'
'aspirin at baseline','C0168634','baseline','BaseLine dental cement','true'
'aspirin at baseline','C1442488','Baseline','Baseline','false'
'no aspirin at baseline','C0004057','ASPIRIN','Aspirin','true'
'no aspirin at baseline','C0168634','baseline','BaseLine dental cement','true'
'no aspirin at baseline','C1442488','Baseline','Baseline','false'
'qva $nmbr$ $nmbr$ pg once daily n $nmbr$','C0030827','PG','Penicillin G','true'
'qva $nmbr$ $nmbr$ pg once daily n $nmbr$','C0072225','PG','Propylene glycol','true'
'qva $nmbr$ $nmbr$ pg once daily n $nmbr$','C1266240','PG','Prostaglandin measurement','false'
'qva $nmbr$ $nmbr$ pg once daily n $nmbr$','C0332173','Daily','Daily','false'
'sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$','C0030827','PG','Penicillin G','true'
'sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$','C0585361','Twice Daily','Twice a day','false'
'sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$','C0072225','PG','Propylene glycol','true'
'sfc $nmbr$ $nmbr$ pg twice daily n $nmbr$','C1266240','PG','Prostaglandin measurement','false'
'duration of copd years','C0449238','Duration','Duration (temporal concept)','false'
'duration of copd years','C2926735','Duration','Duration','false'
'copd severity n','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'copd severity n','C0439793','Severity','Severities','false'
'copd severity n','C0522510','Severity','With intensity','false'
'copd severity n','C1412502','COPD','ARCN1 gene','false'
'copd severity n','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'ics users at baseline','C1706077','Users','user - individual','false'
'ics users at baseline','C0168634','baseline','BaseLine dental cement','true'
'ics users at baseline','C1442488','Baseline','Baseline','false'
'smoking history r','C0205090','R-','Right','false'
'smoking history r','C0684010','R.','Rabbi','true'
'smoking history r','C2603358','R'','R prime','false'
'ex smokers','C0337671','ex smokers','Former smoker','false'
'ex smokers','C4555205','Ex-Smokers','Ex-Smokers','true'
'estimated number of pack years','C0237753','*Number','Numbers','false'
'estimated number of pack years','C0449788','Number','Count of entities','false'
'copd exacerbation history in the previous year n','C0019664','History','History','true'
'copd exacerbation history in the previous year n','C0019665','history','Historical aspects qualifier','true'
'copd exacerbation history in the previous year n','C0262512','History, NOS','History of present illness','false'
'copd exacerbation history in the previous year n','C0262926','History','Medical History','false'
'copd exacerbation history in the previous year n','C1705255','History','Concept History','false'
'copd exacerbation history in the previous year n','C2004062','History','History of previous events','false'
'pre bronchodilator fev l','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'pre bronchodilator fev l','C3714541','FEV','Forced Vital Capacity','true'
'post bronchodilator fev l','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev l','C3714541','FEV','Forced Vital Capacity','true'
'pre bronchodilator fev predicted','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'pre bronchodilator fev predicted','C3714541','FEV','Forced Vital Capacity','true'
'pre bronchodilator fev predicted','C0681842','Predicted','prediction','false'
'pre bronchodilator fev predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'post bronchodilator fev predicted','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev predicted','C3714541','FEV','Forced Vital Capacity','true'
'post bronchodilator fev predicted','C0681842','Predicted','prediction','false'
'post bronchodilator fev predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'post bronchodilator fev reversibility','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev reversibility','C0449261','Reversibility','Reversibility','false'
'post bronchodilator fev fvc','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev fvc','C3714541','FVC','Forced Vital Capacity','true'
'lsm $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'overall qvai $nmbr$ sfc','C0282416','Overall','Overall Publication Type','true'
'overall qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'overall qvai $nmbr$ sfc','C1561607','Overall','Overall','false'
'ex smokers qvai $nmbr$ sfc','C0337671','ex smokers','Former smoker','false'
'ex smokers qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'ex smokers qvai $nmbr$ sfc','C4555205','Ex-Smokers','Ex-Smokers','true'
'$nmbr$ o o $nmbr$ o $nmbr$','C0483204','O NOS','O NOS Ab','false'
'smokers qva $nmbr$ $nmbr$ fc','C0337664','Smokers','Smoker','true'
'smokers qva $nmbr$ $nmbr$ fc','C2983605','FC','Food Consumption','false'
'moderate cord qva $nmbr$ sfc','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate cord qva $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'moderate cord qva $nmbr$ sfc','C1881878','Moderate','Moderation','false'
'moderate cord qva $nmbr$ sfc','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate cord qva $nmbr$ sfc','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate cord qva $nmbr$ sfc','C4085643','Moderate','Moderate Response','false'
'moderate cord qva $nmbr$ sfc','C4321335','Moderate','Moderate Level','false'
'severe cord qvai $nmbr$ sfc','C0205082','Severe','Severe (severity modifier)','false'
'severe cord qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'severe cord qvai $nmbr$ sfc','C4050465','Severe','Severe Extremity Pain','false'
'severe cord qvai $nmbr$ sfc','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'o $nmbr$ o oo $nmbr$ o $nmbr$ o','C0483204','O NOS','O NOS Ab','false'
'men qvai $nmbr$ sfc','C0025266','Men','Male population group','true'
'men qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'women qva $nmbr$ sfc','C0043210','Women','Woman','true'
'women qva $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'ics non users qvai $nmbr$ sfc','C0815320','ICS','Impaired Control Scale','false'
'ics non users qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'ics non users qvai $nmbr$ sfc','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics users qvai $nmbr$ sfc','C0815320','ICS','Impaired Control Scale','false'
'ics users qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'ics users qvai $nmbr$ sfc','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'age $nmbr$ qvai $nmbr$ sfc','C0001779','AGE','Age','false'
'age $nmbr$ qvai $nmbr$ sfc','C4521536','SFC','United States Military enlisted E7','false'
'$nmbr$ ml min n $nmbr$','C0439445','mL/min','mL/min','false'
'median $nmbr$ th $nmbr$ th percentile','C0039725','TH','Thailand','true'
'median $nmbr$ th $nmbr$ th percentile','C1264641','Percentile','Percentile','false'
'median $nmbr$ th $nmbr$ th percentile','C0039738','Th','Thallium','true'
'median $nmbr$ th $nmbr$ th percentile','C1420718','TH','TH gene','false'
'median $nmbr$ th $nmbr$ th percentile','C4282123','TH','TH','false'
'median $nmbr$ th $nmbr$ th percentile','C4285344','TH','Tyrosine 3-Monooxygenase, human','false'
'af duration n','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'af duration n','C0449238','Duration','Duration (temporal concept)','false'
'af duration n','C2926735','Duration','Duration','false'
'af duration n','C4049859','AF','PSMD4 wt Allele','false'
'$nmbr$ mo $nmbr$ y','C0026544','MO','Morocco','true'
'$nmbr$ mo $nmbr$ y','C0332177','/mo','Monthly (qualifier value)','false'
'chads $nmbr$ risk factors n','C0035648','Risk Factors','risk factors','true'
'chads $nmbr$ risk factors n','C1553898','risk factors','risk factors - observation list','false'
'previous stroke or tia','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or tia','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or tia','C0007787','TIA','Transient Ischemic Attack','true'
'previous stroke or tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous stroke or tia','C1054154','tia','Tacca leontopetaloides','false'
'chads $nmbr$ score n','C0449820','SCORE','Score','false'
'chads $nmbr$ score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'any anticoagulant','C0003280','Anticoagulant','Anticoagulants','true'
'any anticoagulant','C0848112','anti coagulant','on anti-coagulants','false'
'any anticoagulant','C3536711','Anticoagulant','Anti-coagulant [EPC]','false'
'events n y','C0441471','Events','Event','false'
'events n y','C3541888','EVENTS','CDISC Events Class','false'
'dabigatran $nmbr$ mg bid vs warfarin','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg bid vs warfarin','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg bid vs warfarin','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg bid vs warfarin','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg bid vs warfarin','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg bid vs warfarin','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg bid vs warfarin','C4521761','MG','United States Military Commissioned Officer O8','false'
'dabigatran $nmbr$ mg bid vs warfarin','C0043031','WARFARIN','Warfarin','true'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C2348066','DABIGATRAN','dabigatran','true'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C4321396','MG','MG','false'
'dabigatran $nmbr$ vs dabigatran $nmbr$ mg bid','C4521761','MG','United States Military Commissioned Officer O8','false'
'outcome according to renal function level in ml min','C1274040','Outcome','Result','false'
'outcome according to renal function level in ml min','C0232804','Renal function','Renal function','false'
'outcome according to renal function level in ml min','C0439445','mL/min','mL/min','false'
'dabigatran $nmbr$ mg bid events n y','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg bid events n y','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg bid events n y','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg bid events n y','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg bid events n y','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg bid events n y','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg bid events n y','C4521761','MG','United States Military Commissioned Officer O8','false'
'warfarin events n y','C0043031','WARFARIN','Warfarin','true'
'warfarin events n y','C0441471','Events','Event','false'
'warfarin events n y','C3541888','EVENTS','CDISC Events Class','false'
'p value inter','C1709380','P-Value','P-Value','false'
'p value inter','C0205103','Inter-','Intermediate','false'
'p value inter','C1548610','Inter','Inter','false'
'life threatening bleed','C1546953','Life threatening','Life threatening - Event Consequence','false'
'life threatening bleed','C0019080','bleed','Hemorrhage','true'
'life threatening bleed','C2826244','Life Threatening','Life Threatening','false'
'life threatening bleed','C3537125','LIFE THREATENING','Life Threatening or Disabling Adverse Event','false'
'intracranial bleed','C0151699','Intracranial bleed','Intracranial Hemorrhage','true'
'net clinical benefit','C1456447','NET','SLC6A2 protein, human','true'
'net clinical benefit','C4684590','Clinical Benefit','Clinical Benefit','false'
'net clinical benefit','C3853572','NET','Ephrin Type-B Receptor 1, human','false'
'net clinical benefit','C3887809','Net','Net (qualifier)','false'
'net clinical benefit','C3890893','NET','SLC6A2 wt Allele','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C0024671','MG','Mammography','true'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C0026410','MG','Mongolia','true'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C0439269','mg%','mg/dL','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C1960952','mg %','Milligram percent','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C4321396','MG','MG','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'czp $nmbr$ mg every $nmbr$ weeks n $nmbr$','C0439230','WEEKS','week','false'
'arthritis characteristics','C0003864','ARTHRITIS','Arthritis','true'
'arthritis characteristics','C1521970','Characteristics','Characteristics','false'
'arthritis characteristics','C4552845','Arthritis','Arthritis, CTCAE','false'
'crp median range mg literl','C0024671','MG','Mammography','true'
'crp median range mg literl','C0026410','MG','Mongolia','true'
'crp median range mg literl','C0439269','mg%','mg/dL','false'
'crp median range mg literl','C1960952','mg %','Milligram percent','false'
'crp median range mg literl','C2346927','Mg++','Magnesium Cation','false'
'crp median range mg literl','C4321396','MG','MG','false'
'crp median range mg literl','C4521761','MG','United States Military Commissioned Officer O8','false'
'esr median range mm hour','C0439227','HOUR','Hour','false'
'esr median range mm hour','C0564385','/hour','/hour','false'
'tender joint count range $nmbr$ $nmbr$ joints','C0451530','Tender joint count','Tender joint count','false'
'tender joint count range $nmbr$ $nmbr$ joints','C1514721','Range','Range','false'
'tender joint count range $nmbr$ $nmbr$ joints','C2348147','Range','Sample Range','false'
'tender joint count range $nmbr$ $nmbr$ joints','C3542016','Range','Concept model range (foundation metadata concept)','false'
'swollen joint count range $nmbr$ $nmbr$ joints','C0451521','Swollen joint count','Swollen joint count','false'
'swollen joint count range $nmbr$ $nmbr$ joints','C1514721','Range','Range','false'
'swollen joint count range $nmbr$ $nmbr$ joints','C2348147','Range','Sample Range','false'
'swollen joint count range $nmbr$ $nmbr$ joints','C3542016','Range','Concept model range (foundation metadata concept)','false'
'modified total sharp score','C0392747','Modified','Changing','false'
'modified total sharp score','C2964552','Total Score','Total score','false'
'modified total sharp score','C3889737','Modified','Data Change Date','false'
'joint space narrowing score','C0449820','SCORE','Score','false'
'joint space narrowing score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'physician s assessment of disease activity vas mm','C0031831','PHYSICIAN','Physicians','true'
'physician s assessment of disease activity vas mm','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'physician s assessment of disease activity vas mm','C1261322','Assessment','Evaluation procedure','false'
'physician s assessment of disease activity vas mm','C1516048','Assessment','Assessed','false'
'enthesitis','C1282952','Enthesitis','Enthesitis','false'
'lei $nmbr$','C0023401','Leu','Leucine','true'
'lei $nmbr$','C0428209','LEU','Leucine measurement','false'
'dactylitis','C0239161','DACTYLITIS','Dactylitis','false'
'psoriasis characteristics','C0033860','PSORIASIS','Psoriasis','true'
'psoriasis characteristics','C1521970','Characteristics','Characteristics','false'
'$nmbr$ bsa psoriasis no','C0033860','PSORIASIS','Psoriasis','true'
'pasi median range','C1514721','Range','Range','false'
'pasi median range','C2348147','Range','Sample Range','false'
'pasi median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'nail involvement','C0027342','NAIL','Nail plate','true'
'nail involvement','C1314939','Involvement','Involvement with','false'
'nail involvement','C1432728','NAIL','CD244 protein, human','true'
'nail involvement','C3538766','NAIL','CD244 wt Allele','false'
'patient reported outcomes','C2987124','Reported Outcomes, Patient','Patient Reported Outcome','true'
'patient assessment of disease activity mm','C0679830','patient assessment','patient assessment','false'
'patient assessment of disease activity mm','C1292728','Disease activity','Condition activity','false'
'patient assessment of arthritis pain mm','C0679830','patient assessment','patient assessment','false'
'fatigue range $nmbr$ $nmbr$','C1514721','Range','Range','false'
'fatigue range $nmbr$ $nmbr$','C2348147','Range','Sample Range','false'
'fatigue range $nmbr$ $nmbr$','C3542016','Range','Concept model range (foundation metadata concept)','false'
'haq di range $nmbr$ $nmbr$','C1514721','Range','Range','false'
'haq di range $nmbr$ $nmbr$','C2348147','Range','Sample Range','false'
'haq di range $nmbr$ $nmbr$','C3542016','Range','Concept model range (foundation metadata concept)','false'
'sf $nmbr$ pcs','C1864389','PCS','PREMATURE CHROMATID SEPARATION TRAIT','false'
'sf $nmbr$ pcs','C1882368','PCS','Photon Correlation Spectroscopy','true'
'sf $nmbr$ mcs','C0037712','SF','South Africa','true'
'dlqi','C3899393','DLQI','Dermatology Life Quality Index Questionnaire','false'
'dlqi patients with $nmbr$ bsa psoriasis','C0030705','Patients','Patients','true'
'dlqi patients with $nmbr$ bsa psoriasis','C0033860','PSORIASIS','Psoriasis','true'
'prior tnf inhibitor exposure no','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'prior tnf inhibitor exposure no','C0332157','Exposure','Exposure to','false'
'adalimumab','C1122087','ADALIMUMAB','adalimumab','true'
'etanercept','C0717758','ETANERCEPT','Etanercept','true'
'no prior tnf inhibitor exposure','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'no prior tnf inhibitor exposure','C0332157','Exposure','Exposure to','false'
'prior tnf inhibitor exposure','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'prior tnf inhibitor exposure','C0332157','Exposure','Exposure to','false'
'czp combined arms n $nmbr$','C0054841','CZP','carzinophilin','true'
'czp combined arms n $nmbr$','C0205195','Combined','Combined','false'
'czp combined arms n $nmbr$','C1861828','CZP','Cataract, Zonular Pulverulent 1','true'
'czp combined arms n $nmbr$','C1872109','CZP','certolizumab pegol','true'
'pain mm','C4330985','/mm','Per Millimeter','false'
'pain mm','C4554674','MM','MM genotype','false'
'fatigue','C0015672','FATIGUE','Fatigue','true'
'fatigue','C3463815','Fatigue','Feel Fatigue','false'
'fatigue','C4050243','Fatigue','Fatigue Subordinate Domain','false'
'fatigue','C4554645','Fatigue','Fatigue, CTCAE 5.0','false'
'haq di','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1709707','Proportion','Proportion','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0681850','Subject','Study Subject','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1550501','{Subject}','Subject -direct target','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1706203','Subject','Subject - topic','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C2349001','Subject','Human Study Subject','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C2697811','Subject','Investigative Subject','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1521840','Target','Target','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C2986546','TARGET','Target Lesion Identification','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1704788','Defined','Definition','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C3539106','Defined','Sufficiently defined concept definition status (core metadata concept)','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0332167','HIGH RISK','High risk of','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0442804','Very high','Very high','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C4050568','High Risk','High Risk Acute Leukemia','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C4319571','High risk','High risk','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C4321397','Very high','Very High Level','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0596269','cardiovascular disease prevention','cardiovascular disorder prevention','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0205210','Clinical','Clinical','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0205195','Combination','Combined','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1947911','Combination','combination of objects','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C3811910','Combination','combination - answer to question','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C0332257','include','Including (qualifier)','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C1552866','include','include - SetOperator','false'
'figure $nmbr$ proportion of all and very high risk subjects achieving targets defined by european guidelines a all subjects b very high risk subjects with avd error bars standard error european guidelines on cardiovascular disease prevention in clinical practice version $nmbr$ [ $nmbr$ ] triple combination includes ldl c','C2700399','Include','Include (action)','false'
'abatacept $nmbr$ $nmbr$ n $nmbr$','C1619966','ABATACEPT','abatacept','true'
'class iv glomerulonephritis','C0441888','Class IV','Class 4','false'
'class iv glomerulonephritis','C0017658','GLOMERULONEPHRITIS','Glomerulonephritis','true'
'class iv glomerulonephritis','C2698970','Class IV','Canadian Cardiovascular Society Grading Scale Class IV','false'
'duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$','C0449238','Duration','Duration (temporal concept)','false'
'duration of current flare median range months n $nmbr$ $nmbr$ $nmbr$','C2926735','Duration','Duration','false'
'baseline creatinine median range mg dl','C0010294','CREATININE','Creatinine','true'
'baseline creatinine median range mg dl','C0439269','mg dl','mg/dL','false'
'baseline creatinine median range mg dl','C1561535','Creatinine','Creatinine, CTCAE','false'
'baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$','C0567349','mg/mmol','milligram/millimole (mg/mmol)','false'
'baseline upgr mg mmole n $nmbr$ $nmbr$ $nmbr$','C2348885','mg/mmol','Gram per Mole (g/mol)','false'
'baseline upgr $nmbr$ gm gm $nmbr$ mg mmole','C0567349','mg/mmol','milligram/millimole (mg/mmol)','false'
'baseline upgr $nmbr$ gm gm $nmbr$ mg mmole','C2348885','mg/mmol','Gram per Mole (g/mol)','false'
'prestudy treatment status','C0749659','Treatment Status','Treatment Status','false'
'naive no treatment for current flare','C2827774','Current Treatment','Current Therapy','false'
'naive no treatment for current flare','C1517205','Flare','Flare','false'
'naive no treatment for current flare','C3540542','Flare','Exacerbation of cGVHD','false'
'recent treatment','C0039798','treatment','therapeutic aspects','true'
'recent treatment','C0087111','Treatment','Therapeutic procedure','true'
'recent treatment','C1522326','Treatment','Treating','false'
'recent treatment','C1533734','Treatment','Administration procedure','false'
'recent treatment','C1705169','Treatment','Biomaterial Treatment','false'
'recent treatment','C3538994','TREATMENT','Treatment Epoch','false'
'recent treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'inadequate response $nmbr$ months mmf ggs','C0205412','Inadequate','Inadequate (qualifier)','false'
'inadequate response $nmbr$ months mmf ggs','C0083765','MMF','fluorouracil/methotrexate/mitoxantrone protocol','true'
'inadequate response $nmbr$ months mmf ggs','C0209368','MMF','mycophenolate mofetil','true'
'inadequate response $nmbr$ months mmf ggs','C3848524','MMF','monomethyl fumarate','true'
'inadequate response $nmbr$ months mmf ggs','C0439856','Inadequate','Unsatisfactory','false'
'baseline prednisone or oral prednisone equivalent daily dose','C0168634','baseline','BaseLine dental cement','true'
'baseline prednisone or oral prednisone equivalent daily dose','C0032952','PREDNISONE','Prednisone','true'
'baseline prednisone or oral prednisone equivalent daily dose','C1442488','Baseline','Baseline','false'
'baseline prednisone or oral prednisone equivalent daily dose','C2348070','Daily Dose','Daily Dose','false'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C4321396','MG','MG','false'
'mean sd mg n $nmbr$ $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'goncomitant treatment with age inhibitors angiotensin','C0039798','treatment','therapeutic aspects','true'
'goncomitant treatment with age inhibitors angiotensin','C0087111','Treatment','Therapeutic procedure','true'
'goncomitant treatment with age inhibitors angiotensin','C1522326','Treatment','Treating','false'
'goncomitant treatment with age inhibitors angiotensin','C1533734','Treatment','Administration procedure','false'
'goncomitant treatment with age inhibitors angiotensin','C1705169','Treatment','Biomaterial Treatment','false'
'goncomitant treatment with age inhibitors angiotensin','C3538994','TREATMENT','Treatment Epoch','false'
'goncomitant treatment with age inhibitors angiotensin','C3887704','treatment','treatment - ActInformationManagementReason','false'
'receptor blockers','C0597357','Receptor','receptor','false'
'premature discontinuation','C0457454','Discontinuation','Discontinuation (procedure)','false'
'premature discontinuation','C1444662','Discontinuation','Discontinued','false'
'premature discontinuation','C4552847','discontinuation','Clinical Trial Discontinuation','false'
'adverse event','C0877248','ADVERSE EVENT','Adverse event','false'
'lack of efficacy','C0235828','LACK OF EFFICACY','Lack of Efficacy','false'
'withdrew consent','C2349954','Withdraw','Withdraw (activity)','false'
'withdrew consent','C1511481','Consent','Consent','false'
'withdrew consent','C1554192','consent','ActClass - consent','false'
'withdrew consent','C2923685','Consent','Consent:Finding:Point in time:{Setting}:Document:Patient','false'
'no longer met study criteria','C0428210','MET','Methionine measurement','false'
'no longer met study criteria','C0243161','Criteria','criteria','true'
'no longer met study criteria','C1550543','Met','Fulfill','false'
'no longer met study criteria','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'poor compliance noncompliance','C0376405','Noncompliance','Patient Non-Compliance','true'
'poor compliance noncompliance','C0457432','Non-compliance','Non-compliance','false'
'pregnancy','C0032961','PREGNANCY','Pregnancy','true'
'revive i','C0021966','I-','Iodides','true'
'revive i','C0221138','I NOS','Blood group antibody I','false'
'levosimendan n $nmbr$','C0246904','Levosimendan','Levosimendan','true'
'lv ejection fraction','C0489482','ejection fraction','Ejection fraction (procedure)','false'
'lv ejection fraction','C2700378','Ejection fraction','Ejection fraction (finding)','false'
'pulmonary rales','C0034642','Pulmonary Rales','Rales','true'
'basal only','C0205112','BASAL','Basal','false'
'$nmbr$ $nmbr$ lung fields','C0225759','Lung field','Lung field','false'
'peripheral edema','C0085649','Peripheral oedema','Peripheral edema','false'
'legs only','C1140621','Legs','Leg','true'
'sacral and or lumbar','C0036037','Sacral','Bone structure of sacrum','true'
'sacral and or lumbar','C0024090','Lumbar','Lumbar Region','true'
'diastolic bp mm hg','C0428883','diastolic bp','Diastolic blood pressure','true'
'diastolic bp mm hg','C0439475','mmHG','mmHg','false'
'iv vasodilator','C0042402','Vasodilator','Vasodilator Agents','true'
'iv vasodilator','C3537240','Vasodilator','Vasodilator [EPC]','false'
'iv inotropic drug','C1971835','IV Drugs','IV medication','false'
'both iv vasodilator and inotrope','C0042402','Vasodilator','Vasodilator Agents','true'
'both iv vasodilator and inotrope','C3537240','Vasodilator','Vasodilator [EPC]','false'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C2985465','Hazard Ratio','Hazard Ratio','false'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C0015127','cause','Etiology aspects','true'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C1524003','Cause','Science of Etiology','false'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C0032042','Placebo','Placebos','true'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C0005811','function blood','Blood Physiological Phenomena','true'
'figure $nmbr$ hazard ratio for all cause mortality hazard ratio for all cause mortality levosimendan placebo at $nmbr$ days as a function of the systolic blood pressure at randomization','C0034656','Randomization','Randomization','true'
'table $nmbr$ selected baseline characteristics of the study patients','C4684572','Baseline Characteristics','Baseline Characteristics','false'
'spironolactone n $nmbr$','C0037982','SPIRONOLACTONE','Spironolactone','true'
'nyha functional classification no','C1275491','NYHA classification','New York Heart Association Classification','false'
'nyha functional classification no','C0205245','Functional','Functional','false'
'nyha functional classification no','C0542341','Functional','Function (attribute)','false'
'nyha functional classification no','C2700217','Functional','Functional Relationship','false'
'eligibility stratum','C0013893','Eligibility','Eligibility Determination','true'
'eligibility stratum','C1548635','Eligibility','Eligible','false'
'hospitalization in previous year with management of heart failure as major component no','C0019993','hospitalisation','Hospitalization','true'
'hospitalization in previous year with management of heart failure as major component no','C0205156','Previous','Previous','false'
'hospitalization in previous year with management of heart failure as major component no','C1552607','previous','Act Relationship Subset - previous','false'
'hospitalization in previous year with management of heart failure as major component no','C0001554','Management','Administration occupational activities','true'
'hospitalization in previous year with management of heart failure as major component no','C0376636','management','Disease Management','true'
'hospitalization in previous year with management of heart failure as major component no','C1273870','Management','Management procedure','false'
'hospitalization in previous year with management of heart failure as major component no','C3273539','Management','Management Occupations','false'
'hospitalization in previous year with management of heart failure as major component no','C0449432','Component','Component object','false'
'hospitalization in previous year with management of heart failure as major component no','C1705248','Component','Component (part)','false'
'elevated natriuretic peptides in previous $nmbr$ days no','C1144709','Natriuretic Peptides','Natriuretic Peptides','true'
'elevated natriuretic peptides in previous $nmbr$ days no','C0205156','Previous','Previous','false'
'elevated natriuretic peptides in previous $nmbr$ days no','C1552607','previous','Act Relationship Subset - previous','false'
'bnp pg ml','C0054015','BNP','Nesiritide','true'
'bnp pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'bnp pg ml','C1095989','BNP','Brain natriuretic peptide measurement','false'
'bnp pg ml','C1417808','BNP','NPPB gene','false'
'bnp pg ml','C2982014','BNP','NPPB wt Allele','false'
'current smoker no blood pressure mm hg','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker no blood pressure mm hg','C3241966','Current Smoker','Current Smoker','false'
'current smoker no blood pressure mm hg','C0005823','BLOOD PRESSURE','Blood Pressure','true'
'current smoker no blood pressure mm hg','C0439475','mmHG','mmHg','false'
'current smoker no blood pressure mm hg','C1271104','Blood Pressure','Blood pressure finding','false'
'current smoker no blood pressure mm hg','C1272641','Blood pressure','Systemic arterial pressure','true'
'serum potassium mmol liter','C0302353','Serum Potassium','Serum potassium measurement','false'
'serum potassium mmol liter','C0475211','Litre','liter','false'
'serum potassium mmol liter','C0543465','serum potassium','Serum Potassium result','false'
'region of enrollment no','C0017446','Region','Geographic Locations','true'
'region of enrollment no','C0205147','Region','regional','false'
'russia and georgia','C0035970','RUSSIA','Russia','true'
'russia and georgia','C0017452','Georgia','Georgia, USA','true'
'russia and georgia','C0017454','GEORGIA','Georgia, Western Asia','true'
'quartiles of fgf $nmbr$ ru ml','C2828255','Quartile','Quartile','false'
'quartiles of fgf $nmbr$ ru ml','C0016026','FGF','Fibroblast Growth Factor','true'
'quartiles of fgf $nmbr$ ru ml','C0919505','FGF','Fibroblast Growth Factor Gene Family','false'
'p value for trend','C1709380','P-Value','P-Value','false'
'p value for trend','C1521798','Trend','trend','false'
'p value for trend','C4554533','Trend','Trend:Type:Point in time:^Patient:Nominal','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'$nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'current tobacco use','C0040335','Tobacco use NOS','Encounter due to tobacco use','false'
'current tobacco use','C0543414','TOBACCO USE','Tobacco use','true'
'current tobacco use','C0841002','Tobacco use','History of tobacco use','false'
'current tobacco use','C3853727','Tobacco use','Tobacco user','false'
'prior pci or cabg','C0332152','Prior','Before','false'
'prior pci or cabg','C4049621','PCI','Peritoneal Cancer Index','false'
'prior pci or cabg','C2826257','PRIOR','Prior Medication Usage','false'
'prior pci or cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'apo a $nmbr$ mg dl','C0003592','Apo A','Apolipoproteins A','true'
'apo a $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'apo a $nmbr$ mg dl','C0523508','APOA','Apolipoproteins A measurement','false'
'apo a $nmbr$ mg dl','C4553344','APOA','LPA wt Allele','false'
'apo a $nmbr$ mg dl','C4553379','Apo(a)','Apolipoprotein(a), human','false'
'$nmbr$ year km','C0439234','Year','year','false'
'$nmbr$ year km','C3887676','KM','Kathy Mercer','false'
'$nmbr$ year km','C0439508','/Year','per year','false'
't $nmbr$ $nmbr$','C2603360','T'','T prime','false'
'$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0008107','CI','Chile','true'
'$nmbr$ ci $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3259781','CI','Coagulation Index Measurement','false'
'risk categories','C0035647','Risk','Risk','true'
'risk categories','C0683312','Categories','Categories','false'
'risk categories','C4552904','risk','Subject Risk','false'
'fgf $nmbr$ low egfr $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'fgf $nmbr$ low egfr $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'fgf $nmbr$ low egfr $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'fgf $nmbr$ low egfr','C1739039','EGFR','EGFR protein, human','true'
'fgf $nmbr$ low egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'fgf $nmbr$ low egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'fgf $nmbr$ high egfr $nmbr$','C1739039','EGFR','EGFR protein, human','true'
'fgf $nmbr$ high egfr $nmbr$','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'fgf $nmbr$ high egfr $nmbr$','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'fgf $nmbr$ high egfr','C1739039','EGFR','EGFR protein, human','true'
'fgf $nmbr$ high egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'fgf $nmbr$ high egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'fgf $nmbr$ low','C0205251','Low','low','false'
'fgf $nmbr$ low','C1550472','low','low confidentiality','false'
'fgf $nmbr$ low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'fgf $nmbr$ low','C4048187','low','low exposure','false'
'fgf $nmbr$ low','C4321351','Low','Low Level','false'
'fgf $nmbr$ low','C4522223','Low','IPSS Risk Category Low','false'
'fgf $nmbr$ low $nmbr$ elevated biomarkers','C0016026','FGF','Fibroblast Growth Factor','true'
'fgf $nmbr$ low $nmbr$ elevated biomarkers','C0005516','Biomarkers','Biological Markers','true'
'fgf $nmbr$ low $nmbr$ elevated biomarkers','C0919505','FGF','Fibroblast Growth Factor Gene Family','false'
'fgf $nmbr$ high','C0205250','High','High','false'
'fgf $nmbr$ high','C1299351','High','Abnormally high','false'
'fgf $nmbr$ high','C2700149','HIGH','Value Above Reference Range','false'
'fgf $nmbr$ high','C3887512','high','high - ActExposureLevelCode','false'
'fgf $nmbr$ high','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'fgf $nmbr$ high','C4321237','High','High Level','false'
'fgf $nmbr$ high','C4522209','High','IPSS Risk Category High','false'
'fgf $nmbr$ high $nmbr$ elevated biomarkers','C0016026','FGF','Fibroblast Growth Factor','true'
'fgf $nmbr$ high $nmbr$ elevated biomarkers','C0005516','Biomarkers','Biological Markers','true'
'fgf $nmbr$ high $nmbr$ elevated biomarkers','C0919505','FGF','Fibroblast Growth Factor Gene Family','false'
'p interaction $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'p interaction $nmbr$ $nmbr$','C1704675','Interaction','Interaction','false'
'p interaction $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'$nmbr$ mw distance m','C0024548','MW','Malawi','true'
'$nmbr$ mw distance m','C0012751','Distance','Distance','false'
'$nmbr$ mw distance m','C0026385','mw','Molecular Weight','true'
'$nmbr$ mw distance m','C0556966','mW','milliwatt','false'
'randomized treatment','C0039798','treatment','therapeutic aspects','true'
'randomized treatment','C0087111','Treatment','Therapeutic procedure','true'
'randomized treatment','C1522326','Treatment','Treating','false'
'randomized treatment','C1533734','Treatment','Administration procedure','false'
'randomized treatment','C1705169','Treatment','Biomaterial Treatment','false'
'randomized treatment','C3538994','TREATMENT','Treatment Epoch','false'
'randomized treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'nonwhite race','C0034510','RACE','Racial group','true'
'nonwhite race','C1706779','RACE','AMACR wt Allele','false'
'nonwhite race','C3853635','Race','Race','false'
'weight lbs','C0439219','lbs','Pounds','false'
'weight lbs','C3161851','LBS','liquid-based cytology (procedure)','false'
'ischemic hf etiology','C0015127','etiology','Etiology aspects','true'
'ischemic hf etiology','C1314792','Etiology','Etiology','true'
'ischemic hf etiology','C1524003','Etiology','Science of Etiology','false'
'pulmonary disease','C0024115','PULMONARY DISEASE','Lung diseases','true'
'ace i or arb','C0021966','I-','Iodides','true'
'ace i or arb','C0221138','I NOS','Blood group antibody I','false'
'ace i or arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'$nmbr$ yr km mortality rate','C0026565','Mortality rate','Mortality Vital Statistics','true'
'$nmbr$ yr km mortality rate','C0205848','Mortality Rate','Death Rate','true'
'icd vs placebo','C0021122','ICD','Disruptive, Impulse Control, and Conduct Disorders','true'
'icd vs placebo','C0032042','Placebo','Placebos','true'
'icd vs placebo','C1696465','PLACEBO','placebo','false'
'icd vs placebo','C1706408','PLACEBO','Placebo Control','false'
'amiodarone vs placebo','C0002598','AMIODARONE','Amiodarone','true'
'amiodarone vs placebo','C0032042','Placebo','Placebos','true'
'amiodarone vs placebo','C1696465','PLACEBO','placebo','false'
'amiodarone vs placebo','C1706408','PLACEBO','Placebo Control','false'
'patients $nmbr$ y','C0030705','Patients','Patients','true'
'pbo n $nmbr$','C0031962','PBO','Piperonyl Butoxide','true'
'duration of diabetes y','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes y','C2926735','Duration','Duration','false'
'patients with cardiac disorders n','C0741926','cardiac patients','cardiac patient','false'
'patients on antihypertensive medications n','C0030705','Patients','Patients','true'
'patients on antihypertensive medications n','C0003364','Antihypertensive Medications','Antihypertensive Agents','true'
'number of patients randomized','C2360800','Number of patients','Number of patients','false'
'number of patients randomized','C0034656','Randomized','Randomization','true'
'number of patients randomized','C3815594','RANDOMIZED','Subject is Randomized','false'
'number of swollen joints $nmbr$ $nmbr$','C0449813','Number of joints','Number of joints','false'
'number of tender joints $nmbr$ $nmbr$','C0449813','Number of joints','Number of joints','false'
'psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$','C0018563','Hands','Hand','true'
'psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$','C0016504','Feet','Foot','true'
'psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$','C0347981','feet','Feet, unit of measurement','false'
'psa modified shs of hands feet $nmbr$ $nmbr$ $nmbr$','C1552914','hand','hand - unit of measure','false'
'all patients n','C0030705','Patients','Patients','true'
'patients receiving mtx n','C0030705','Patients','Patients','true'
'patients receiving mtx n','C1514756','RECEIVING','Receive','false'
'patients receiving mtx n','C0025677','MTX','Methotrexate','true'
'patients receiving mtx n','C1417487','MTX','MTX1 gene','false'
'patients not receiving mtx n','C0030705','Patients','Patients','true'
'patients not receiving mtx n','C1518422','Not','Negation','false'
'patients not receiving mtx n','C1514756','RECEIVING','Receive','false'
'patients not receiving mtx n','C0025677','MTX','Methotrexate','true'
'patients not receiving mtx n','C1417487','MTX','MTX1 gene','false'
'patients with dactylitis','C0030705','Patients','Patients','true'
'patients with dactylitis','C0239161','DACTYLITIS','Dactylitis','false'
'dactylitis score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'dactylitis score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients with enthesitis','C0030705','Patients','Patients','true'
'patients with enthesitis','C1282952','Enthesitis','Enthesitis','false'
'psa modified mases score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'psa modified mases score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients with $nmbr$ bsa','C0030705','Patients','Patients','true'
'pasi score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'pasi score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'haq di score $nmbr$ $nmbr$','C0449820','SCORE','Score','false'
'haq di score $nmbr$ $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients with fingernail involvement','C0522476','Involvement patients','Patient affected','false'
'napsi score $nmbr$ $nmbr$ of target fingernail','C0449820','SCORE','Score','false'
'napsi score $nmbr$ $nmbr$ of target fingernail','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'napsi score $nmbr$ $nmbr$ of target fingernail','C1521840','Target','Target','false'
'napsi score $nmbr$ $nmbr$ of target fingernail','C0222001','Finger Nail','Structure of nail of finger','true'
'napsi score $nmbr$ $nmbr$ of target fingernail','C2986546','TARGET','Target Lesion Identification','false'
'sf $nmbr$ summary scores','C0037712','SF','South Africa','true'
'sf $nmbr$ summary scores','C0449820','Scores','Score','false'
'pcs score','C0449820','SCORE','Score','false'
'pcs score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'mcs score','C0449820','SCORE','Score','false'
'mcs score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients receiving mtx','C0030705','Patients','Patients','true'
'patients receiving mtx','C1514756','RECEIVING','Receive','false'
'patients receiving mtx','C0025677','MTX','Methotrexate','true'
'patients receiving mtx','C1417487','MTX','MTX1 gene','false'
'eplerenone n $nmbr$','C0961485','EPLERENONE','eplerenone','true'
'race no b','C0034510','RACE','Racial group','true'
'race no b','C1706779','RACE','AMACR wt Allele','false'
'race no b','C3853635','Race','Race','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C0439445','mL/min','mL/min','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C1424601','GFR','RAPGEF5 gene','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ of body surface area','C0005902','Body Surface Area','Body Surface Area','true'
'serum potassium mmol l','C0302353','Serum Potassium','Serum potassium measurement','false'
'serum potassium mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum potassium mmol l','C0543465','serum potassium','Serum Potassium result','false'
'anterior mi','C3536746','Anterior MI','Anterior Myocardial Infarction by ECG Finding','false'
'history of mi','C0019664','History','History','true'
'history of mi','C0019665','history','Historical aspects qualifier','true'
'history of mi','C0262512','History, NOS','History of present illness','false'
'history of mi','C0262926','History','Medical History','false'
'history of mi','C1705255','History','Concept History','false'
'history of mi','C2004062','History','History of previous events','false'
'concomitant treatments at randomization','C0087111','Treatments','Therapeutic procedure','true'
'concomitant treatments at randomization','C0034656','Randomization','Randomization','true'
'acetylsalicylic acid','C0004057','Acetylsalicylic Acid','Aspirin','true'
'p $nmbr$ y $nmbr$ antagonists','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$ y $nmbr$ antagonists','C0243076','antagonists','antagonists','true'
'p $nmbr$ y $nmbr$ antagonists','C2603361','P'','P prime','false'
'heparins and fondaparinux','C0019134','heparins','heparin','true'
'heparins and fondaparinux','C1098510','FONDAPARINUX','fondaparinux','true'
'gp iib iiia inhibitors','C0016011','GPIIB IIIA','Platelet Glycoprotein GPIIb-IIIa Complex','true'
'gp iib iiia inhibitors','C0243077','inhibitors','inhibitors','true'
'fibrinolytics','C0040044','fibrinolytics','Thrombolytic Therapy','true'
'pci thrombolysis at randomization','C0520997','Thrombolysis','Thrombolysis, function','false'
'pci thrombolysis at randomization','C0034656','Randomization','Randomization','true'
'thrombolysis','C0520997','Thrombolysis','Thrombolysis, function','false'
'no reperfusion','C0035124','Reperfusion','Reperfusion Therapy','true'
'no reperfusion','C0684253','reperfusion','Physiological reperfusion','false'
'subgroup level','C0441889','Level','Levels (qualifier value)','false'
'subgroup level','C0456079','Level','Disease classification level','false'
'subgroup level','C1547707','Level','Floor - story of building','false'
'subgroup level','C2946261','Level','Level','false'
'n participants','C0369718','N NOS','N not otherwise specified Antibody','false'
'n participants','C0679646','participants','Participant','false'
'n participants','C0441922','N+','N+ (tumor staging)','false'
'age group $nmbr$','C0027362','Age Group','Human Age Group','true'
'age group $nmbr$','C2348001','Age Group','Age Cohort','false'
'systolic blood pressure median $nmbr$ $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'systolic blood pressure median $nmbr$ $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'systolic blood pressure median $nmbr$ $nmbr$','C2347635','Median','Population Median','false'
'systolic blood pressure median $nmbr$ $nmbr$','C2348144','Median','Sample Median','false'
'systolic blood pressure median $nmbr$ $nmbr$','C2939193','Median','Median (qualifier value)','false'
'pulse pressure median $nmbr$ $nmbr$ ]','C0549183','Median','Midline (qualifier value)','false'
'pulse pressure median $nmbr$ $nmbr$ ]','C0876920','Median','Median Statistical Measurement','false'
'pulse pressure median $nmbr$ $nmbr$ ]','C2347635','Median','Population Median','false'
'pulse pressure median $nmbr$ $nmbr$ ]','C2348144','Median','Sample Median','false'
'pulse pressure median $nmbr$ $nmbr$ ]','C2939193','Median','Median (qualifier value)','false'
'heart rate median $nmbr$ $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'heart rate median $nmbr$ $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'heart rate median $nmbr$ $nmbr$','C2347635','Median','Population Median','false'
'heart rate median $nmbr$ $nmbr$','C2348144','Median','Sample Median','false'
'heart rate median $nmbr$ $nmbr$','C2939193','Median','Median (qualifier value)','false'
'prior bb plus acbi plus arb use','C0004739','BB','Barbados','true'
'prior bb plus acbi plus arb use','C0332297','BB','Bounded by','false'
'prior bb plus acbi plus arb use','C0042153','use','utilization qualifier','true'
'prior bb plus acbi plus arb use','C0457083','Use','Usage','false'
'prior bb plus acbi plus arb use','C1947944','Use','Use - dosing instruction imperative','false'
'prior acbi or arb use','C0332152','Prior','Before','false'
'prior acbi or arb use','C2826257','PRIOR','Prior Medication Usage','false'
'prior acbi or arb use','C0042153','use','utilization qualifier','true'
'prior acbi or arb use','C0457083','Use','Usage','false'
'prior acbi or arb use','C1947944','Use','Use - dosing instruction imperative','false'
'history of atrial fibrillation','C0729790','History of - atrial fibrillation','H/O: atrial fibrillation','false'
'history of diabetes mellitus','C0455488','History of - diabetes mellitus','H/O: diabetes mellitus','false'
'anterior or non anterior ml','C0205094','ANTERIOR','Anterior','false'
'anterior or non anterior ml','C0439526','/mL','/mL','false'
'anterior or non anterior ml','C1705224','ML','THPO wt Allele','false'
'anterior or non anterior ml','C3887665','ML','Thrombopoietin, human','false'
'non anterior','C1518422','Non','Negation','false'
'non anterior','C0205094','ANTERIOR','Anterior','false'
'previous ml','C0439526','/mL','/mL','false'
'previous ml','C1705224','ML','THPO wt Allele','false'
'previous ml','C3887665','ML','Thrombopoietin, human','false'
'acute reperfusion','C0035124','Reperfusion','Reperfusion Therapy','true'
'acute reperfusion','C0684253','reperfusion','Physiological reperfusion','false'
'$nmbr$ $nmbr$ h','C0033727','H+','Protons','true'
'$nmbr$ $nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'$nmbr$ $nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'$nmbr$ $nmbr$ h','C0564385','/h','/hour','false'
'$nmbr$ $nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'not perfused','C1518422','Not','Negation','false'
'not perfused','C1549542','Perfuse','Perfuse','false'
'use of pci or thrombolysis within one day of randomization','C1524063','Use of','Use of','false'
'use of pci or thrombolysis within one day of randomization','C4049621','PCI','Peritoneal Cancer Index','false'
'use of pci or thrombolysis within one day of randomization','C0520997','Thrombolysis','Thrombolysis, function','false'
'use of pci or thrombolysis within one day of randomization','C3844320','One day','One day','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0178602','DOSE','Dosage','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0033727','H+','Protons','true'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0369286','H NOS','H NOS Antibodies','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0441932','H+','Hepatic Involvement','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0564385','/h','/hour','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C4528284','h*%','Hour Times Percent','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0869039','Dose','Unit dose','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C0687676','Post','Post','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C1704687','Post','Post Device','false'
'first dose admin $nmbr$ $nmbr$ h $nmbr$ $nmbr$ h post onset of symptoms','C3469826','POST','SLC35G1 gene','false'
'$nmbr$ $nmbr$ hours','C0439227','HOURS','Hour','false'
'cardiac enzyates raised','C0018787','Cardiac','Heart','true'
'cardiac enzyates raised','C1522601','Cardiac','Cardiac - anatomy qualifier','false'
'cardiac enzyates raised','C0442818','Raised','Raised','false'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C2986535','Primary Endpoint','Primary Endpoint','false'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C0205199','Composite','Composite','false'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C1547335','Composite','Data types- Composite','false'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C0961485','EPLERENONE','eplerenone','true'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C0032042','Placebo','Placebos','true'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ forrest plot on the primary composite endpoint with eplerenone vs placebo according to pre speci ed subgroups webplotdig','C1706408','PLACEBO','Placebo Control','false'
'zoledronic acid n $nmbr$','C0257685','ZOLEDRONIC ACID','zoledronic acid','true'
'age groups n','C0441848','Group N','Group N','false'
'baseline bmi kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'baseline bmi kg m $nmbr$','C0439209','kg','Kilogram','false'
'baseline bmi kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'baseline t score at femoral neck n','C0449820','SCORE','Score','false'
'baseline t score at femoral neck n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'entry hip fracture location n','C3260017','Hip fracture location','Hip fracture location','false'
'intertrochanteric','C0745355','Intertrochanteric','intertrochanteric','false'
'fracture history n','C0016658','FRACTURE','Fracture','true'
'fracture history n','C0019664','History','History','true'
'fracture history n','C0019665','history','Historical aspects qualifier','true'
'fracture history n','C0262512','History, NOS','History of present illness','false'
'fracture history n','C0262926','History','Medical History','false'
'fracture history n','C1705255','History','Concept History','false'
'fracture history n','C2004062','History','History of previous events','false'
'hip fracture only','C0019557','HIP FRACTURE','Hip Fractures','true'
'hip fracture only','C0149531','Hip Fracture','Fracture of pelvis','false'
'hip fracture only','C4552776','Hip fracture','Hip Fracture, CTCAE','false'
'hip other nonvertebral fractures','C0019552','HIP','Hip structure','true'
'hip other nonvertebral fractures','C0022122','Hip','Bone structure of ischium','true'
'hip other nonvertebral fractures','C1505163','HIP','HHIP protein, human','true'
'hip other nonvertebral fractures','C3538851','HIP','REG3A wt Allele','false'
'hip other nonvertebral fractures','C4284725','HIP','HHIP wt Allele','false'
'hip other nonvertebral fractures','C0016658','FRACTURES','Fracture','true'
'hip $nmbr$ vertebral fractures','C0019557','Hip Fractures','Hip Fractures','true'
'hip nonvertebral vertebral','C0019552','HIP','Hip structure','true'
'hip nonvertebral vertebral','C0549207','Vertebral','Bone structure of spine','true'
'hip nonvertebral vertebral','C0022122','Hip','Bone structure of ischium','true'
'hip nonvertebral vertebral','C1505163','HIP','HHIP protein, human','true'
'hip nonvertebral vertebral','C3538851','HIP','REG3A wt Allele','false'
'hip nonvertebral vertebral','C4284725','HIP','HHIP wt Allele','false'
'fractures','C0016658','FRACTURES','Fracture','true'
'time to first infusion from hip surgery days n','C0040223','TIME','Time','true'
'time to first infusion from hip surgery days n','C3541383','Time','Time (foundation metadata concept)','false'
'time to first infusion from hip surgery days n','C0596706','hip surgery','hip surgery','false'
'time to first infusion from hip surgery days n','C0439228','DAYS','day','false'
'$nmbr$ weeks','C0439230','WEEKS','week','false'
'baseline serum calcium level n','C0036785','Serum Calcium Level','Serum Calcium Level','false'
'baseline serum calcium level n','C0728876','Serum calcium level','Serum calcium measurement','false'
'prior use of osteoporosis medications n','C1524063','Use of','Use of','false'
'bone mineral density g cm $nmbr$ mean sd','C0005938','Bone Mineral Density','Bone Density','true'
'bone mineral density g cm $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'bone mineral density g cm $nmbr$ mean sd','C0177804','Bone Mineral Density','Bone Mineral Density Test','false'
'eq $nmbr$ dprofile mobility n','C0205163','EQ','Equal','false'
'eq $nmbr$ dprofile mobility n','C0080078','Mobility','Range of Motion, Articular','true'
'eq $nmbr$ dprofile mobility n','C0425245','Mobility','Mobility as a finding','false'
'eq $nmbr$ dprofile mobility n','C0449580','Mobility','Qualitative mobility','false'
'eq $nmbr$ dprofile mobility n','C4318935','Mobility','Mobility Ability','false'
'eq $nmbr$ dprofile mobility n','C0439185','eq','Equivalent Weight','false'
'walking','C0080331','Walking','Walking (activity)','true'
'walking','C4283795','Walking','Symptoms Interfered with Walking','false'
'walking','C4321241','Walking','Usually Need Help from Another Person for Walking','false'
'walking','C4321242','Walking','Hard to Walk More Than One Block','false'
'some walking','C0080331','Walking','Walking (activity)','true'
'some walking','C4283795','Walking','Symptoms Interfered with Walking','false'
'some walking','C4321241','Walking','Usually Need Help from Another Person for Walking','false'
'some walking','C4321242','Walking','Hard to Walk More Than One Block','false'
'mental status baseline spmsq scores n','C0278060','Mental status','Mental state','false'
'mental status baseline spmsq scores n','C0168634','baseline','BaseLine dental cement','true'
'mental status baseline spmsq scores n','C1442488','Baseline','Baseline','false'
'charlson comobility score n','C0449820','SCORE','Score','false'
'charlson comobility score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'between treatment comparison of percentage change from baseline in total hip bmd','C1299575','Treatment change','Treatment modification','false'
'between treatment comparison of percentage change from baseline in total hip bmd','C1707455','Comparison','Comparison','false'
'between treatment comparison of percentage change from baseline in total hip bmd','C0168634','baseline','BaseLine dental cement','true'
'between treatment comparison of percentage change from baseline in total hip bmd','C1442488','Baseline','Baseline','false'
'month $nmbr$ subgroup x treatment interaction p value','C0039798','treatment','therapeutic aspects','true'
'month $nmbr$ subgroup x treatment interaction p value','C1709380','P-Value','P-Value','false'
'month $nmbr$ subgroup x treatment interaction p value','C0087111','Treatment','Therapeutic procedure','true'
'month $nmbr$ subgroup x treatment interaction p value','C1522326','Treatment','Treating','false'
'month $nmbr$ subgroup x treatment interaction p value','C1533734','Treatment','Administration procedure','false'
'month $nmbr$ subgroup x treatment interaction p value','C1705169','Treatment','Biomaterial Treatment','false'
'month $nmbr$ subgroup x treatment interaction p value','C3538994','TREATMENT','Treatment Epoch','false'
'month $nmbr$ subgroup x treatment interaction p value','C3887704','treatment','treatment - ActInformationManagementReason','false'
'age groups','C0027362','Age groups','Human Age Group','true'
't score at femoral neck','C3854607','T-Score','T-Score','false'
't score at femoral neck','C0015815','Femoral Neck','Structure of neck of femur','true'
'hip fracture','C0019557','HIP FRACTURE','Hip Fractures','true'
'hip fracture','C0149531','Hip Fracture','Fracture of pelvis','false'
'hip fracture','C4552776','Hip fracture','Hip Fracture, CTCAE','false'
'fracture','C0016658','FRACTURE','Fracture','true'
'history','C0019664','History','History','true'
'history','C0019665','history','Historical aspects qualifier','true'
'history','C0262512','History, NOS','History of present illness','false'
'history','C0262926','History','Medical History','false'
'history','C1705255','History','Concept History','false'
'history','C2004062','History','History of previous events','false'
'hip fracture $nmbr$','C0019557','HIP FRACTURE','Hip Fractures','true'
'hip fracture $nmbr$','C0149531','Hip Fracture','Fracture of pelvis','false'
'hip fracture $nmbr$','C4552776','Hip fracture','Hip Fracture, CTCAE','false'
'time to first infusion','C0040223','TIME','Time','true'
'time to first infusion','C3541383','Time','Time (foundation metadata concept)','false'
'calcium level','C0201925','Calcium level','Calcium measurement','false'
'calcium level','C0428302','calcium level','Calcium level result','false'
'prior medications','C0013227','Medications','Pharmaceutical Preparations','true'
'prior medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'prior medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'prior medications','C4284232','Medications','Medications','false'
'mental status','C0278060','Mental status','Mental state','false'
'eq $nmbr$ d mobility','C0205163','EQ','Equal','false'
'eq $nmbr$ d mobility','C0439185','eq','Equivalent Weight','false'
'eq $nmbr$ d mobility','C0080078','Mobility','Range of Motion, Articular','true'
'eq $nmbr$ d mobility','C0425245','Mobility','Mobility as a finding','false'
'eq $nmbr$ d mobility','C0449580','Mobility','Qualitative mobility','false'
'eq $nmbr$ d mobility','C4318935','Mobility','Mobility Ability','false'
'age mean sd years n','C1510829','Age-Years','Age-Years','false'
'age mean sd years n','C0444504','Mean','Statistical mean','false'
'age mean sd years n','C2347634','Mean','Population Mean','false'
'age mean sd years n','C2348143','Mean','Sample Mean','false'
'education mean sd years','C0013621','Education','Knowledge acquisition','true'
'education mean sd years','C0439234','YEARS','year','false'
'education mean sd years','C0013622','education','Educational aspects','true'
'education mean sd years','C0013658','Education, NOS','Educational Status','true'
'education mean sd years','C0039401','Education','Educational process of instructing','true'
'weight mean sd lbs','C0439219','lbs','Pounds','false'
'weight mean sd lbs','C3161851','LBS','liquid-based cytology (procedure)','false'
'antihypertensive treatment n','C0003364','anti hypertensive','Antihypertensive Agents','true'
'antihypertensive treatment n','C0039798','treatment','therapeutic aspects','true'
'antihypertensive treatment n','C0087111','Treatment','Therapeutic procedure','true'
'antihypertensive treatment n','C1522326','Treatment','Treating','false'
'antihypertensive treatment n','C1533734','Treatment','Administration procedure','false'
'antihypertensive treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'antihypertensive treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'antihypertensive treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'st t wave n','C0036056','ST','Saint Lucia','true'
'st t wave n','C0429103','T wave','T wave feature','false'
'st t wave n','C3272372','ST','Character String Data Type','false'
'lvh by ecg or echo n','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'lvh by ecg or echo n','C0058928','ECHO','ECHO protocol','true'
'lvh by ecg or echo n','C1655045','Echo','Echo (insect)','false'
'visit $nmbr$ blood pressures','C0545082','Visit','Visit','false'
'visit $nmbr$ blood pressures','C1272641','blood pressures','Systemic arterial pressure','true'
'visit $nmbr$ blood pressures','C1512346','visit','Patient Visit','false'
'visit $nmbr$ blood pressures','C2826704','VISIT','Visit Name','false'
'sbp mean sd mm hg','C0085805','SBP','Androgen Binding Protein','true'
'sbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'dbp mean sd mm hg','C0444504','Mean','Statistical mean','false'
'dbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'dbp mean sd mm hg','C2347634','Mean','Population Mean','false'
'dbp mean sd mm hg','C2348143','Mean','Sample Mean','false'
'bp','C0037623','BP','Solomon Islands','true'
'bp','C1415692','Bp','HP gene','false'
'bp','C1708288','BP','HP wt Allele','false'
'bp','C4318478','BP','Base Pair Unit','false'
'serum potassium mean sd mmol l','C0302353','Serum Potassium','Serum potassium measurement','false'
'serum potassium mean sd mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum potassium mean sd mmol l','C0543465','serum potassium','Serum Potassium result','false'
'fasting serum glucose mean sd mg dl','C0202041','Serum Glucose','Glucose measurement, serum','false'
'fasting serum glucose mean sd mg dl','C0439269','mg dl','mg/dL','false'
'fasting serum glucose mean sd mg dl','C3534430','Serum glucose','Serum glucose','false'
'serum cholesterol mean sd mg dl','C0587184','Serum cholesterol NOS','Serum cholesterol measurement','false'
'serum cholesterol mean sd mg dl','C0439269','mg dl','mg/dL','false'
'treatment groups n','C0039798','treatment','therapeutic aspects','true'
'treatment groups n','C0441848','Group N','Group N','false'
'treatment groups n','C0087111','Treatment','Therapeutic procedure','true'
'treatment groups n','C1522326','Treatment','Treating','false'
'treatment groups n','C1533734','Treatment','Administration procedure','false'
'treatment groups n','C1705169','Treatment','Biomaterial Treatment','false'
'treatment groups n','C3538994','TREATMENT','Treatment Epoch','false'
'treatment groups n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'history of mi or stroke n','C0019664','History','History','true'
'history of mi or stroke n','C0019665','history','Historical aspects qualifier','true'
'history of mi or stroke n','C0262512','History, NOS','History of present illness','false'
'history of mi or stroke n','C0262926','History','Medical History','false'
'history of mi or stroke n','C1705255','History','Concept History','false'
'history of mi or stroke n','C2004062','History','History of previous events','false'
'history of mi or stroke n','C0038454','STROKE','Cerebrovascular accident','true'
'history of mi or stroke n','C4554100','Stroke','Stroke, CTCAE','false'
'amlodipine vs chlorthalidone normal','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine vs chlorthalidone normal','C0205307','NORMAL','Normal','false'
'amlodipine vs chlorthalidone normal','C0231683','Normal','Gait normal','false'
'amlodipine vs chlorthalidone normal','C0439166','% normal','Percent normal','false'
'amlodipine vs chlorthalidone normal','C2347086','% Normal','Mean Percent of Normal','false'
'amlodipine vs chlorthalidone normal','C4553972','Normal','How Often Felt Normal question','false'
'amlodipine vs chlorthalidone overweight','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine vs chlorthalidone overweight','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine vs chlorthalidone overweight','C0497406','OVERWEIGHT','Overweight','true'
'amlodipine vs chlorthalidone obese','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine vs chlorthalidone obese','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine vs chlorthalidone obese','C0028754','OBESE','Obesity','true'
'favors amlodipine favors chlorthalidone','C0051696','AMLODIPINE','Amlodipine','true'
'favors amlodipine favors chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'favors favors amlodipine chlorthalidone','C0051696','AMLODIPINE','Amlodipine','true'
'favors favors amlodipine chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'lisinopril vs chlorthalidone normal','C0065374','Lysinopril','Lisinopril','true'
'lisinopril vs chlorthalidone normal','C0205307','NORMAL','Normal','false'
'lisinopril vs chlorthalidone normal','C0231683','Normal','Gait normal','false'
'lisinopril vs chlorthalidone normal','C0439166','% normal','Percent normal','false'
'lisinopril vs chlorthalidone normal','C2347086','% Normal','Mean Percent of Normal','false'
'lisinopril vs chlorthalidone normal','C4553972','Normal','How Often Felt Normal question','false'
'lisinopril vs chlorthalidone overweight','C0065374','Lysinopril','Lisinopril','true'
'lisinopril vs chlorthalidone overweight','C0008294','Chlortalidone','Chlorthalidone','true'
'lisinopril vs chlorthalidone overweight','C0497406','OVERWEIGHT','Overweight','true'
'lisinopril vs chlorthalidone obese','C0065374','Lysinopril','Lisinopril','true'
'lisinopril vs chlorthalidone obese','C0008294','Chlortalidone','Chlorthalidone','true'
'lisinopril vs chlorthalidone obese','C0028754','OBESE','Obesity','true'
'favors lisinopril favors chlorthalidone','C0065374','Lysinopril','Lisinopril','true'
'favors lisinopril favors chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'favors favors lisinopril chlorthalidone','C0065374','Lysinopril','Lisinopril','true'
'favors favors lisinopril chlorthalidone','C0008294','Chlortalidone','Chlorthalidone','true'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'dulaglutide $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'metformin n $nmbr$','C0025598','METFORMIN','Metformin','true'
'hba $nmbr$ c mmol mol','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'hba $nmbr$ c mmol mol','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c mmol mol','C3538758','HBA','SCN2A wt Allele','false'
'fsg mg dl','C0439269','mg dl','mg/dL','false'
'prestudy treatment a','C0039798','treatment','therapeutic aspects','true'
'prestudy treatment a','C0087111','Treatment','Therapeutic procedure','true'
'prestudy treatment a','C1522326','Treatment','Treating','false'
'prestudy treatment a','C1533734','Treatment','Administration procedure','false'
'prestudy treatment a','C1705169','Treatment','Biomaterial Treatment','false'
'prestudy treatment a','C3538994','TREATMENT','Treatment Epoch','false'
'prestudy treatment a','C3887704','treatment','treatment - ActInformationManagementReason','false'
'dulaglutide $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'dulaglutide $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'dulaglutide $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'dulaglutide $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'dulaglutide $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'dulaglutide $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'dulaglutide $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'overall population n $nmbr$','C0282416','Overall','Overall Publication Type','true'
'overall population n $nmbr$','C0032659','Population','geographic population','true'
'overall population n $nmbr$','C1257890','Population','Population Group','true'
'overall population n $nmbr$','C1561607','Overall','Overall','false'
'tnf antagonist failure population n $nmbr$','C0231174','FAILURE','Failure (biologic function)','false'
'tnf antagonist failure population n $nmbr$','C0032659','Population','geographic population','true'
'tnf antagonist failure population n $nmbr$','C1257890','Population','Population Group','true'
'tnf antagonist failure population n $nmbr$','C0680095','failure','Personal failure','false'
'tnf antagonist naive subgroup n $nmbr$','C0231491','Antagonist','Antagonist muscle action','false'
'tnf antagonist naive subgroup n $nmbr$','C1079230','subgroup','Subgroup A Nepoviruses','false'
'tnf antagonist naive subgroup n $nmbr$','C1515021','Subgroup','Subgroup','false'
'median age y range','C1514721','Range','Range','false'
'median age y range','C2348147','Range','Sample Range','false'
'median age y range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'mean body weight kg range','C1514721','Range','Range','false'
'mean body weight kg range','C2348147','Range','Sample Range','false'
'mean body weight kg range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'median body mass index kg m $nmbr$ range','C0022718','KG','Kyrgyzstan','true'
'median body mass index kg m $nmbr$ range','C0439209','kg','Kilogram','false'
'median body mass index kg m $nmbr$ range','C4054209','/kg','Per Kilogram','false'
'median body mass index kg m $nmbr$ range','C1514721','Range','Range','false'
'median body mass index kg m $nmbr$ range','C2348147','Range','Sample Range','false'
'median body mass index kg m $nmbr$ range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'median crohn s disease duration y range','C0549183','Median','Midline (qualifier value)','false'
'median crohn s disease duration y range','C0010346','Crohn's','Crohn Disease','true'
'median crohn s disease duration y range','C0876920','Median','Median Statistical Measurement','false'
'median crohn s disease duration y range','C2347635','Median','Population Median','false'
'median crohn s disease duration y range','C2348144','Median','Sample Median','false'
'median crohn s disease duration y range','C2939193','Median','Median (qualifier value)','false'
'median crohn s disease duration y range','C1514721','Range','Range','false'
'median crohn s disease duration y range','C2348147','Range','Sample Range','false'
'median crohn s disease duration y range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'mean cdai score sd','C3533236','Mean score','Mean score','false'
'mean cdai score sd','C2699239','SD','SD, Rat Strain','false'
'mean crp level mg l sd','C0439268','mg/L','Microgram per Milliliter','false'
'mean crp level mg l sd','C2699239','SD','SD, Rat Strain','false'
'mean fecal calprotectin level mg g stool sd','C1300563','mg/g','Gram per Kilogram','false'
'mean fecal calprotectin level mg g stool sd','C2699239','SD','SD, Rat Strain','false'
'disease localization n','C0012634','Disease','Disease','true'
'disease localization n','C0475264','Localization','localization','false'
'disease localization n','C1744691','localization','establishment and maintenance of localization','false'
'ileocolonic both ileum and colon','C0020885','ILEUM','ileum','true'
'ileocolonic both ileum and colon','C0009368','COLON','Colon structure (body structure)','true'
'ileocolonic both ileum and colon','C3888384','Colon','Colon <insect>','false'
'history of crohn s disease surgery n','C0019664','History','History','true'
'history of crohn s disease surgery n','C0019665','history','Historical aspects qualifier','true'
'history of crohn s disease surgery n','C0262512','History, NOS','History of present illness','false'
'history of crohn s disease surgery n','C0262926','History','Medical History','false'
'history of crohn s disease surgery n','C1705255','History','Concept History','false'
'history of crohn s disease surgery n','C2004062','History','History of previous events','false'
'history of crohn s disease surgery n','C0012634','Disease','Disease','true'
'history of crohn s disease surgery n','C0038894','Surgery','Surgery specialty','false'
'history of crohn s disease surgery n','C0038895','surgery','Surgical aspects','true'
'history of crohn s disease surgery n','C0543467','Surgery','Operative Surgical Procedures','true'
'history of crohn s disease surgery n','C1274039','Surgery','General surgery specialty','true'
'history of fistulizing disease n','C0019664','History','History','true'
'history of fistulizing disease n','C0019665','history','Historical aspects qualifier','true'
'history of fistulizing disease n','C0262512','History, NOS','History of present illness','false'
'history of fistulizing disease n','C0262926','History','Medical History','false'
'history of fistulizing disease n','C1705255','History','Concept History','false'
'history of fistulizing disease n','C2004062','History','History of previous events','false'
'history of fistulizing disease n','C0012634','Disease','Disease','true'
'corticosteroid use n','C0239126','CORTICOSTEROID USE','corticosteroid use','false'
'immunosuppressive use n','C0021081','immunosuppressive','Immunosuppressive Agents','true'
'immunosuppressive use n','C0042153','use','utilization qualifier','true'
'immunosuppressive use n','C0457083','Use','Usage','false'
'immunosuppressive use n','C1947944','Use','Use - dosing instruction imperative','false'
'mesalamine use n a','C0127615','MESALAMINE','mesalamine','true'
'mesalamine use n a','C0042153','use','utilization qualifier','true'
'mesalamine use n a','C0457083','Use','Usage','false'
'mesalamine use n a','C1947944','Use','Use - dosing instruction imperative','false'
'prior immunosuppressive exposure n','C0021081','immunosuppressive','Immunosuppressive Agents','true'
'prior immunosuppressive exposure n','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'prior immunosuppressive exposure n','C0332157','Exposure','Exposure to','false'
'prior tnf antagonist failure n b','C3887647','TNF-b','Lymphotoxin-Alpha, human','false'
'prior tnf antagonist failure n b','C0231174','FAILURE','Failure (biologic function)','false'
'prior tnf antagonist failure n b','C0680095','failure','Personal failure','false'
'$nmbr$ prior tnf antagonist failure n b','C3887647','TNF-b','Lymphotoxin-Alpha, human','false'
'$nmbr$ prior tnf antagonist failure n b','C0231174','FAILURE','Failure (biologic function)','false'
'$nmbr$ prior tnf antagonist failure n b','C0680095','failure','Personal failure','false'
'$nmbr$ prior tnf antagonist failures n b','C3887647','TNF-b','Lymphotoxin-Alpha, human','false'
'$nmbr$ prior tnf antagonist failures n b','C0231174','failures','Failure (biologic function)','false'
'$nmbr$ prior tnf antagonist failures n b','C0680095','failures','Personal failure','false'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C0051767','DAS','amsonic acid','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C1279919','Early','Early','false'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C0057671','DAS','diacetoxyscirpenol','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C0012634','Disease','Disease','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C3900351','Lara','Lara','false'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C0032659','Population','geographic population','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara a $nmbr$ years disease duration population','C1257890','Population','Population Group','true'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0369718','N NOS','N not otherwise specified Antibody','false'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0441922','N+','N+ (tumor staging)','false'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0014758','ETN','Erythrityl Tetranitrate','true'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0025677','MTX','Methotrexate','true'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C1417487','MTX','MTX1 gene','false'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0717758','ETN','Etanercept','true'
'n $nmbr$ for etn mtx n $nmbr$ for dmards','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population','C0051767','DAS','amsonic acid','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population','C1279919','Early','Early','false'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population','C0057671','DAS','diacetoxyscirpenol','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population','C0032659','Population','geographic population','true'
'supplementary figure s $nmbr$ das $nmbr$ early vs late disease appeal lara b $nmbr$ years disease duration population','C1257890','Population','Population Group','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0005918','BL','Bolivia','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0006413','BL','Burkitt Lymphoma','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C1552663','BL','Boolean','false'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C2827109','BL','Saint Barthelemy','false'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0014758','ETN','Erythrityl Tetranitrate','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0025677','MTX','Methotrexate','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C1417487','MTX','MTX1 gene','false'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0717758','ETN','Etanercept','true'
'bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C0205081','Moderate','Moderate (severity modifier)','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C1881878','Moderate','Moderation','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C4049705','Moderate','Moderate Extremity Pain','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C4085643','Moderate','Moderate Response','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C4321335','Moderate','Moderate Level','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C1836348','Severe Disease','Severe disorder','false'
'supplementary figure s $nmbr$ das $nmbr$ moderate vs severe disease appeal lara','C3900351','Lara','Lara','false'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0012634','Disease','Disease','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0032659','Population','geographic population','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C1257890','Population','Population Group','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0014758','ETN','Erythrityl Tetranitrate','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0025677','MTX','Methotrexate','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C1417487','MTX','MTX1 gene','false'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0717758','ETN','Etanercept','true'
'a das $nmbr$ moderate disease population n $nmbr$ for etn mtx n $nmbr$ for dmards','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C1836348','Severe Disease','Severe disorder','false'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0005918','BL','Bolivia','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0006413','BL','Burkitt Lymphoma','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C1552663','BL','Boolean','false'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C2827109','BL','Saint Barthelemy','false'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0014758','ETN','Erythrityl Tetranitrate','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0025677','MTX','Methotrexate','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C1417487','MTX','MTX1 gene','false'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0717758','ETN','Etanercept','true'
'a das $nmbr$ severe disease population bl baseline etn etanercept csdmards conventional synthetic dmards n $nmbr$ for etn mtx n $nmbr$ for dmards','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'race n a','C0034510','RACE','Racial group','true'
'race n a','C1706779','RACE','AMACR wt Allele','false'
'race n a','C3853635','Race','Race','false'
'region n a','C0017446','Region','Geographic Locations','true'
'region n a','C0205147','Region','regional','false'
'central south america','C0007674','Central America','Central America','true'
'mean sd hba $nmbr$ c level','C0441889','Level','Levels (qualifier value)','false'
'mean sd hba $nmbr$ c level','C0456079','Level','Disease classification level','false'
'mean sd hba $nmbr$ c level','C1547707','Level','Floor - story of building','false'
'mean sd hba $nmbr$ c level','C2946261','Level','Level','false'
'mean sd bmi kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean sd bmi kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean sd bmi kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$','C0444504','Mean','Statistical mean','false'
'mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$','C2347634','Mean','Population Mean','false'
'mean sd egfr ml min $nmbr$ $nmbr$ m $nmbr$','C2348143','Mean','Sample Mean','false'
'mean sd duration of t $nmbr$ dm y','C0449238','Duration','Duration (temporal concept)','false'
'mean sd duration of t $nmbr$ dm y','C2926735','Duration','Duration','false'
'patients with microvascular complications n','C0030705','Patients','Patients','true'
'patients with microvascular complications n','C0009566','Complications','Complication','false'
'patients with microvascular complications n','C1171258','complications','Complication Aspects','true'
'patients with cardiac disorders n c','C0741926','cardiac patients','cardiac patient','false'
'mean treatment exposure wk','C0332174','/wk','Weekly','false'
'mean treatment exposure wk','C0439230','wk','week','false'
'$nmbr$ st tertile','C0036056','ST','Saint Lucia','true'
'$nmbr$ st tertile','C3272372','ST','Character String Data Type','false'
'$nmbr$ rd tertile $nmbr$ mg dl [ $nmbr$ $nmbr$ mmol l] d','C0439422','mg/d','milligram/day','false'
'pbo','C0031962','PBO','Piperonyl Butoxide','true'
'cana $nmbr$ mg','C0024671','MG','Mammography','true'
'cana $nmbr$ mg','C0026410','MG','Mongolia','true'
'cana $nmbr$ mg','C0439269','mg%','mg/dL','false'
'cana $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'cana $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'cana $nmbr$ mg','C4321396','MG','MG','false'
'cana $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'baseline mg dl mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'ls mean se','C0023668','LS','Liechtenstein','true'
'ls mean se','C0036919','SE','Seychelles','true'
'change mg dl mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'difference vs pbo $nmbr$ ci','C1705241','*Difference','Delta (difference)','false'
'difference vs pbo $nmbr$ ci','C1705242','Difference','Different','false'
'difference vs pbo $nmbr$ ci','C0008107','CI','Chile','true'
'difference vs pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'percent change','C0392747','Change','Changing','false'
'percent change','C0443172','change','Changed status','false'
'percent change','C1705241','Change','Delta (difference)','false'
'percent change','C4319952','Change','Change -- procedure','false'
'difference vs pbo','C1705241','*Difference','Delta (difference)','false'
'difference vs pbo','C1705242','Difference','Different','false'
'difference vs pbo','C0031962','PBO','Piperonyl Butoxide','true'
'tcz sc $nmbr$ mg every other week n $nmbr$','C0024671','MG','Mammography','true'
'tcz sc $nmbr$ mg every other week n $nmbr$','C0026410','MG','Mongolia','true'
'tcz sc $nmbr$ mg every other week n $nmbr$','C0439269','mg%','mg/dL','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C1960952','mg %','Milligram percent','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C4321396','MG','MG','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C0332174','/week','Weekly','false'
'tcz sc $nmbr$ mg every other week n $nmbr$','C0439230','Week','week','false'
'pbo sc every other week n $nmbr$','C0031962','PBO','Piperonyl Butoxide','true'
'pbo sc every other week n $nmbr$','C0282380','SC','Saint Kitts and Nevis','true'
'pbo sc every other week n $nmbr$','C0332174','/week','Weekly','false'
'pbo sc every other week n $nmbr$','C0439230','Week','week','false'
'weight group no','C0441833','Group','Groups','false'
'weight group no','C0687744','group','Social group','false'
'weight group no','C1257890','Group','Population Group','true'
'weight group no','C1519504','Group','Stage Grouping','false'
'weight group no','C1705428','Group','Group Object','false'
'weight group no','C1705429','Group','User Group','false'
'concomitant medication no','C0013227','Medication','Pharmaceutical Preparations','true'
'concomitant medication no','C3244316','medication','medication - HL7 publishing domain','false'
'concomitant medication no','C4284232','Medication','Medications','false'
'other dmards','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'previous dmards mean sd','C0205156','Previous','Previous','false'
'previous dmards mean sd','C2699239','SD','SD, Rat Strain','false'
'previous dmards mean sd','C1552607','previous','Act Relationship Subset - previous','false'
'previously failed anti tnf treatment no','C0231175','Failed','failed','false'
'previously failed anti tnf treatment no','C0039798','treatment','therapeutic aspects','true'
'previously failed anti tnf treatment no','C0087111','Treatment','Therapeutic procedure','true'
'previously failed anti tnf treatment no','C1522326','Treatment','Treating','false'
'previously failed anti tnf treatment no','C1533734','Treatment','Administration procedure','false'
'previously failed anti tnf treatment no','C1705169','Treatment','Biomaterial Treatment','false'
'previously failed anti tnf treatment no','C3538994','TREATMENT','Treatment Epoch','false'
'previously failed anti tnf treatment no','C3887704','treatment','treatment - ActInformationManagementReason','false'
'laboratory tests','C0022885','Laboratory Tests','Laboratory Procedures','false'
'rf positive no','C0439178','% Positive','percent positive cells','false'
'rf positive no','C1446409','Positive','Positive','false'
'rf positive no','C1514241','POSITIVE','Positive Finding','false'
'rf positive no','C2825490','Positive','Positive Charge','false'
'rf positive no','C3812269','Positive','Positive Number','false'
'acpa positive no','C0439178','% Positive','percent positive cells','false'
'acpa positive no','C1446409','Positive','Positive','false'
'acpa positive no','C1514241','POSITIVE','Positive Finding','false'
'acpa positive no','C2825490','Positive','Positive Charge','false'
'acpa positive no','C3812269','Positive','Positive Number','false'
'crp level mean sd mg dl','C0441889','Level','Levels (qualifier value)','false'
'crp level mean sd mg dl','C0439269','mg dl','mg/dL','false'
'crp level mean sd mg dl','C0456079','Level','Disease classification level','false'
'crp level mean sd mg dl','C1547707','Level','Floor - story of building','false'
'crp level mean sd mg dl','C2946261','Level','Level','false'
'esr mean sd mg dl','C0444504','Mean','Statistical mean','false'
'esr mean sd mg dl','C0439269','mg dl','mg/dL','false'
'esr mean sd mg dl','C2347634','Mean','Population Mean','false'
'esr mean sd mg dl','C2348143','Mean','Sample Mean','false'
'disease activity','C1292728','Disease activity','Condition activity','false'
'duration of ra mean sd years','C0449238','Duration','Duration (temporal concept)','false'
'duration of ra mean sd years','C2926735','Duration','Duration','false'
'tender joints $nmbr$ joint count mean sd','C0451530','Tender joint count','Tender joint count','false'
'tender joints $nmbr$ joint count mean sd','C2699239','SD','SD, Rat Strain','false'
'swollen joints $nmbr$ joint count mean sd','C0451521','Swollen joint count','Swollen joint count','false'
'swollen joints $nmbr$ joint count mean sd','C2699239','SD','SD, Rat Strain','false'
'das $nmbr$ mean sd','C0051767','DAS','amsonic acid','true'
'das $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'das $nmbr$ mean sd','C0057671','DAS','diacetoxyscirpenol','true'
'shs mean sd','C0444504','Mean','Statistical mean','false'
'shs mean sd','C2699239','SD','SD, Rat Strain','false'
'shs mean sd','C2347634','Mean','Population Mean','false'
'shs mean sd','C2348143','Mean','Sample Mean','false'
'jsn mean sd','C0444504','Mean','Statistical mean','false'
'jsn mean sd','C2699239','SD','SD, Rat Strain','false'
'jsn mean sd','C2347634','Mean','Population Mean','false'
'jsn mean sd','C2348143','Mean','Sample Mean','false'
'erosion mean sd','C0333307','Erosion','Superficial ulcer','false'
'erosion mean sd','C2699239','SD','SD, Rat Strain','false'
'erosion mean sd','C1880549','Erosion','Erosion of Medical Device Material','false'
'erosion mean sd','C1959609','EROSION','Erosion lesion','false'
'erosion mean sd','C3887524','Erosion','Skin Erosion','false'
'quality of life','C0034380','Quality of Life','Quality of life','true'
'quality of life','C0518214','Quality of life','Perceived quality of life','false'
'haq di score range $nmbr$ $nmbr$ mean sd','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di score range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di score range $nmbr$ $nmbr$ mean sd','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'pain vas range $nmbr$ $nmbr$ mean sd','C0042815','Pain VAS','Visual Analog Pain Scale','true'
'pain vas range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'patient global assessment of disease','C4054229','Patient Global Assessment','Patient Assessment of Overall Well-Being','false'
'activity range $nmbr$ $nmbr$ mean sd','C0205177','Activity','Active','false'
'activity range $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'activity range $nmbr$ $nmbr$ mean sd','C0439167','% Activity','Percent Activity','false'
'activity range $nmbr$ $nmbr$ mean sd','C0441655','ACTIVITY','Activities','false'
'activity range $nmbr$ $nmbr$ mean sd','C1561536','*Activity','*Activity (kind of quantity)','false'
'activity range $nmbr$ $nmbr$ mean sd','C3668946','Activity','Activity (animal life circumstance)','false'
'activity range $nmbr$ $nmbr$ mean sd','C4049938','ACTIVITY','Physical Activity Measurement','false'
'activity range $nmbr$ $nmbr$ mean sd','C4049939','ACTIVITY','FDA Establishment Activity Terminology','false'
'physician global assessment of disease','C4050369','Physician's Global Assessment','Physician Global Assessment of Disease Activity','false'
'study $nmbr$ $nmbr$','C0557651','Study','Room of building - Study','false'
'study $nmbr$ $nmbr$','C2603343','Study','Study','false'
'olodaterol','C2934193','OLODATEROL','olodaterol','true'
'$nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'mean sd age years','C0444504','Mean','Statistical mean','false'
'mean sd age years','C1510829','Age-Years','Age-Years','false'
'mean sd age years','C2347634','Mean','Population Mean','false'
'mean sd age years','C2348143','Mean','Sample Mean','false'
'pre bronchodilator mean sd fev $nmbr$ l','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'pre bronchodilator mean sd fev $nmbr$ l','C0444504','Mean','Statistical mean','false'
'pre bronchodilator mean sd fev $nmbr$ l','C2347634','Mean','Population Mean','false'
'pre bronchodilator mean sd fev $nmbr$ l','C2348143','Mean','Sample Mean','false'
'post bronchodilator','C2599594','Post-bronchodilator','post bronchodilator','false'
'mean sd fev $nmbr$ l','C0444504','Mean','Statistical mean','false'
'mean sd fev $nmbr$ l','C2347634','Mean','Population Mean','false'
'mean sd fev $nmbr$ l','C2348143','Mean','Sample Mean','false'
'mean sd predicted normal fev $nmbr$','C0205307','NORMAL','Normal','false'
'mean sd predicted normal fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'mean sd predicted normal fev $nmbr$','C0231683','Normal','Gait normal','false'
'mean sd predicted normal fev $nmbr$','C0439166','% normal','Percent normal','false'
'mean sd predicted normal fev $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'mean sd predicted normal fev $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'mean sd fev $nmbr$ fvc','C0444504','Mean','Statistical mean','false'
'mean sd fev $nmbr$ fvc','C3714541','FVC','Forced Vital Capacity','true'
'mean sd fev $nmbr$ fvc','C2347634','Mean','Population Mean','false'
'mean sd fev $nmbr$ fvc','C2348143','Mean','Sample Mean','false'
'mean sd change from pre to post bronchodilator fev $nmbr$ l','C0392747','Change','Changing','false'
'mean sd change from pre to post bronchodilator fev $nmbr$ l','C0443172','change','Changed status','false'
'mean sd change from pre to post bronchodilator fev $nmbr$ l','C1705241','Change','Delta (difference)','false'
'mean sd change from pre to post bronchodilator fev $nmbr$ l','C4319952','Change','Change -- procedure','false'
'gold stage n','C0018026','GOLD','Gold','true'
'gold stage n','C0205390','Stage','Phase','false'
'gold stage n','C1300072','Stage','Tumor stage','false'
'gold stage n','C1306673','Stage','Stage','false'
'gold stage n','C1304897','Gold','Gold color','false'
'baseline pulmonary medications','C0013227','Medications','Pharmaceutical Preparations','true'
'baseline pulmonary medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'baseline pulmonary medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'baseline pulmonary medications','C4284232','Medications','Medications','false'
'any pulmonary medication n','C0024109','pulmonary','Lung','true'
'any pulmonary medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'any pulmonary medication n','C3244316','medication','medication - HL7 publishing domain','false'
'any pulmonary medication n','C4284232','Medication','Medications','false'
'any pulmonary medication n','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'any pulmonary medication n','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'any pulmonary medication n','C4522268','Pulmonary','Pulmonary (intended site)','false'
'sama b n','C1075468','sama','Echinochloa frumentacea','false'
'lama tiotropium b n','C0999593','Lama','Lama','false'
'lama tiotropium b n','C0213771','TIOTROPIUM','tiotropium','true'
'lama tiotropium b n','C1416775','LAMA','LAMA1 gene','false'
'saba inhaled c n','C0004048','Inhaled','Inspiration function','true'
'laba inhaled d n','C0004048','Inhaled','Inspiration function','true'
'laba inhaled d n','C0369718','N NOS','N not otherwise specified Antibody','false'
'laba inhaled d n','C0441922','N+','N+ (tumor staging)','false'
'oral adrenergics n','C0442027','Oral','Oral','false'
'oral adrenergics n','C0001637','Adrenergics','Adrenergic Agents','true'
'oral adrenergics n','C4521986','Oral','Oral (intended site)','false'
'steroids n','C0038317','Steroids','Steroids','true'
'xanthines b n','C0043318','Xanthines','Xanthines','true'
'xanthines b n','C3541955','Xanthines','Xanthines, systemic for obstructive airway disease','false'
'mean se auc^p l','C0036919','SE','Seychelles','true'
'mean se auc^p l','C0376690','AUC','Area Under Curve','true'
'olodaterol $nmbr$ jig','C2934193','OLODATEROL','olodaterol','true'
'tiotropium n $nmbr$ non tiotropium n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium n $nmbr$ non tiotropium n $nmbr$','C1518422','Non','Negation','false'
'non tiotropium','C1518422','Non','Negation','false'
'non tiotropium','C0213771','TIOTROPIUM','tiotropium','true'
'mean se trough l','C0444504','Mean','Statistical mean','false'
'mean se trough l','C0036919','SE','Seychelles','true'
'mean se trough l','C2347634','Mean','Population Mean','false'
'mean se trough l','C2348143','Mean','Sample Mean','false'
'tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium n $nmbr$ non tiotropium n $nmbr$ $nmbr$','C1518422','Non','Negation','false'
'n unless otherwise specified','C0369718','N NOS','N not otherwise specified Antibody','false'
'n unless otherwise specified','C0441922','N+','N+ (tumor staging)','false'
'n unless otherwise specified','C0205369','Specified','Specific qualifier value','false'
'l vs c','C0439394','l's','liter/second','false'
'l vs c','C1706495','L-','upper case letter ell','false'
'l vs c','C3642217','/L','Per Liter','false'
'education years mean sd','C0013621','Education','Knowledge acquisition','true'
'education years mean sd','C2699239','SD','SD, Rat Strain','false'
'education years mean sd','C0013622','education','Educational aspects','true'
'education years mean sd','C0013658','Education, NOS','Educational Status','true'
'education years mean sd','C0039401','Education','Educational process of instructing','true'
'type ii diabetes','C0011860','Type II Diabetes','Diabetes Mellitus, Non-Insulin-Dependent','true'
'hx cabg','C0262926','Hx','Medical History','false'
'hx cabg','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'hx cabg','C3814444','HX','HPX wt Allele','false'
'hx mi or stroke','C0262926','Hx','Medical History','false'
'hx mi or stroke','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'hx mi or stroke','C3814444','HX','HPX wt Allele','false'
'hx mi or stroke','C0038454','STROKE','Cerebrovascular accident','true'
'hx mi or stroke','C4554100','Stroke','Stroke, CTCAE','false'
'antihypertensive medication $nmbr$','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'estrogen','C0014939','Oestrogen, NOS','Estrogens','true'
'estrogen','C2936882','Estrogen','Estrogen [EPC]','false'
'estrogen','C4542544','Estrogen','Estrogen (disposition)','false'
'heart rate mean sd','C0018810','Heart Rate','heart rate','true'
'heart rate mean sd','C2699239','SD','SD, Rat Strain','false'
'lvh by ecg minnesota code','C0232306','ECG LVH','Electrocardiogram: left ventricle hypertrophy (finding)','false'
'lvh by ecg minnesota code','C0009219','code','Coding','true'
'lvh by ecg minnesota code','C0805701','CODE','Code','false'
'lvh by ecg minnesota code','C3889831','Code','eTMF Content Model Code','false'
'cholesterol mg dl mean sd','C0439269','mg dl','mg/dL','false'
'cholesterol mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'fasting glucose mg dl mean sd','C0439269','mg dl','mg/dL','false'
'fasting glucose mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C0439445','mL/min','mL/min','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'egfr ml min per $nmbr$ $nmbr$ m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'blood pressure mmhg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'systolic total','C0439175','% total','% of total','false'
'systolic total','C0439810','Total','Total','false'
'diastolic total','C0439175','% total','% of total','false'
'diastolic total','C0439810','Total','Total','false'
'systolic treated at baseline','C0039155','Systolic','Systole','true'
'systolic treated at baseline','C1522326','Treated','Treating','false'
'systolic treated at baseline','C0168634','baseline','BaseLine dental cement','true'
'systolic treated at baseline','C1442488','Baseline','Baseline','false'
'diastolic treated at baseline','C0012000','Diastolic','Diastole','true'
'diastolic treated at baseline','C1522326','Treated','Treating','false'
'diastolic treated at baseline','C0168634','baseline','BaseLine dental cement','true'
'diastolic treated at baseline','C1442488','Baseline','Baseline','false'
'pulse pressure','C0949236','Pulse Pressure','Pulse Pressure','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C1704675','Interaction','Interaction','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C1709380','P-Value','P-Value','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0332283','follows','Followed by','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C1719822','Follow','Follow - dosing instruction imperative','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C4281991','Follow','Follow','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0051696','AMLODIPINE','Amlodipine','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0008294','Chlortalidone','Chlorthalidone','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0001779','AGE','Age','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0011847','Diabetes','Diabetes','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0065374','Lysinopril','Lisinopril','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0011849','Diabetes','Diabetes Mellitus','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0008976','Trial','Clinical Trials','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0019993','hospitalisation','Hospitalization','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C0184661','Procedure','Interventional procedure','true'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C2700391','Procedure','Procedure (set of actions)','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C3274430','PROCEDURE','Physical Medical Procedure','false'
'interaction p values are as follows amlodipine vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ lisinopril vs chlorthalidone age p $nmbr$ $nmbr$ gender p $nmbr$ $nmbr$ race p $nmbr$ $nmbr$ history of chd p $nmbr$ $nmbr$ history of diabetes p $nmbr$ $nmbr$ peripheral arterial disease refers to in trial hospitalization or lower extremity revascularization procedure','C3539779','Procedure','CDISC SDTM Procedure Terminology','false'
'no chd','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'no chd','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'$nmbr$ mg mtx','C0025677','MTX','Methotrexate','true'
'$nmbr$ mg mtx','C1417487','MTX','MTX1 gene','false'
'patients with prior dmard use n a','C0030705','Patients','Patients','true'
'patients with prior dmard use n a','C0042153','use','utilization qualifier','true'
'patients with prior dmard use n a','C0457083','Use','Usage','false'
'patients with prior dmard use n a','C1947944','Use','Use - dosing instruction imperative','false'
'hydroxychloroquine','C0020336','HYDROXYCHLOROQUINE','Hydroxychloroquine','true'
'sulfasalazine','C0036078','Sulphasalazine','Sulfasalazine','true'
'patients taking oral corticosteroids at baseline n','C0442027','Oral','Oral','false'
'patients taking oral corticosteroids at baseline n','C0001617','Corticosteroids','Adrenal Cortex Hormones','true'
'patients taking oral corticosteroids at baseline n','C3539185','Corticosteroids','Corticosteroid nasal preparations for topical use','false'
'patients taking oral corticosteroids at baseline n','C3540725','CORTICOSTEROIDS','Corticosteroid otologicals','false'
'patients taking oral corticosteroids at baseline n','C3540726','CORTICOSTEROIDS','Corticosteroid ophthalmologic and otologic preparations','false'
'patients taking oral corticosteroids at baseline n','C3540727','Corticosteroids','Corticosteroids, topical for treatment of hemorrhoids and anal fissures','false'
'patients taking oral corticosteroids at baseline n','C4521986','Oral','Oral (intended site)','false'
'prednisone or equivalent dose mg day','C0032952','PREDNISONE','Prednisone','true'
'prednisone or equivalent dose mg day','C0178602','DOSE','Dosage','false'
'prednisone or equivalent dose mg day','C0439422','mg day','milligram/day','false'
'prednisone or equivalent dose mg day','C0869039','Dose','Unit dose','false'
'prednisone or equivalent dose mg day','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'anti ccp antibody positive n','C0432633','Anti N','Blood group antibody N','false'
'total vdh s score','C2964552','Total Score','Total score','false'
'olodaterol $nmbr$ gg n $nmbr$','C0017454','GG','Georgia, Western Asia','true'
'olodaterol $nmbr$ gg n $nmbr$','C0018370','GG','Guernsey (geographic location)','true'
'formoterol $nmbr$ gg n $nmbr$','C0017454','GG','Georgia, Western Asia','true'
'formoterol $nmbr$ gg n $nmbr$','C0018370','GG','Guernsey (geographic location)','true'
'pre bronchodilator screening','C0220908','Screening','Screening procedure','true'
'pre bronchodilator screening','C0220909','screening','Aspects of disease screening','true'
'pre bronchodilator screening','C1698960','screening','research subject screening','false'
'pre bronchodilator screening','C1710031','Screening','Disease Screening','false'
'pre bronchodilator screening','C1710032','Screening','Screening','false'
'pre bronchodilator screening','C1710477','SCREENING','Trial Screening','false'
'pre bronchodilator screening','C2348164','SCREENING','Screening Study','false'
'post bronchodilator screening','C0220908','Screening','Screening procedure','true'
'post bronchodilator screening','C0220909','screening','Aspects of disease screening','true'
'post bronchodilator screening','C1698960','screening','research subject screening','false'
'post bronchodilator screening','C1710031','Screening','Disease Screening','false'
'post bronchodilator screening','C1710032','Screening','Screening','false'
'post bronchodilator screening','C1710477','SCREENING','Trial Screening','false'
'post bronchodilator screening','C2348164','SCREENING','Screening Study','false'
'mean sd of predicted normal fev $nmbr$','C2699239','SD','SD, Rat Strain','false'
'mean sd of predicted normal fev $nmbr$','C0520835','FEV normal','FEV normal','false'
'baseline pulmonary medication b n','C0024109','pulmonary','Lung','true'
'baseline pulmonary medication b n','C0013227','Medication','Pharmaceutical Preparations','true'
'baseline pulmonary medication b n','C3244316','medication','medication - HL7 publishing domain','false'
'baseline pulmonary medication b n','C4284232','Medication','Medications','false'
'baseline pulmonary medication b n','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'baseline pulmonary medication b n','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'baseline pulmonary medication b n','C4522268','Pulmonary','Pulmonary (intended site)','false'
'mean se auc $nmbr$ $nmbr$ l','C0036919','SE','Seychelles','true'
'mean se auc $nmbr$ $nmbr$ l','C0376690','AUC','Area Under Curve','true'
'placebo tiotropium n $nmbr$ non tiotropium n $nmbr$','C0032042','Placebo','Placebos','true'
'placebo tiotropium n $nmbr$ non tiotropium n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'placebo tiotropium n $nmbr$ non tiotropium n $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo tiotropium n $nmbr$ non tiotropium n $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C4032878','OLODATEROL/TIOTROPIUM','olodaterol / tiotropium','true'
'olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0021027','IG','Immunoglobulins','true'
'olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'olodaterol $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C4032878','OLODATEROL/TIOTROPIUM','olodaterol / tiotropium','true'
'olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0021027','IG','Immunoglobulins','true'
'olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'olodaterol $nmbr$ $nmbr$ ig tiotropium n $nmbr$ non tiotropium n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$','C0060657','FORMOTEROL','formoterol','true'
'formoterol tiotropium n $nmbr$ non tiotropium n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'omalizumab','C0966225','OMALIZUMAB','omalizumab','true'
'age group n','C0441848','Group N','Group N','false'
'x $nmbr$ years','C0439234','YEARS','year','false'
'o $nmbr$ kg n','C0022718','KG','Kyrgyzstan','true'
'o $nmbr$ kg n','C0439209','kg','Kilogram','false'
'o $nmbr$ kg n','C4054209','/kg','Per Kilogram','false'
'body mass index kgm _ $nmbr$','C0005893','Body mass index','Body mass index procedure','false'
'body mass index kgm _ $nmbr$','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index kgm _ $nmbr$','C1305855','BODY MASS INDEX','Body mass index','true'
'time since diagnosis of ciu csu years $nmbr$','C0556970','time year','times/year','false'
'time since diagnosis of ciu csu years $nmbr$','C0011900','DIAGNOSIS','Diagnosis','true'
'time since diagnosis of ciu csu years $nmbr$','C1704338','diagnosis','diagnosis aspect','true'
'time since diagnosis of ciu csu years $nmbr$','C1704656','DIAGNOSIS','Diagnosis Study','false'
'cu index test n $nmbr$','C0022885','Test','Laboratory Procedures','false'
'cu index test n $nmbr$','C0039593','Test','Testing','false'
'cu index test n $nmbr$','C0392366','test','Tests (qualifier value)','false'
'cu index test n $nmbr$','C0456984','Test','Test Result','false'
'cu index test n $nmbr$','C1515976','test','Anatomic Structure, System, or Substance','false'
'cu index test n $nmbr$','C3831328','Test','Blood Products Laboratory Testing','false'
'cu index test n $nmbr$','C4318744','Test','Test - temporal region','false'
'no of previous ciu csu medications','C0205156','Previous','Previous','false'
'no of previous ciu csu medications','C0013227','Medications','Pharmaceutical Preparations','true'
'no of previous ciu csu medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'no of previous ciu csu medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'no of previous ciu csu medications','C4284232','Medications','Medications','false'
'no of previous ciu csu medications','C1552607','previous','Act Relationship Subset - previous','false'
'median range total ige level iuml $nmbr$','C0439175','% total','% of total','false'
'median range total ige level iuml $nmbr$','C0439810','Total','Total','false'
'in clinic uas $nmbr$','C0150312','In','Present','false'
'in clinic uas $nmbr$','C0002424','Clinic','Ambulatory Care Facilities','true'
'in clinic uas $nmbr$','C0442592','Clinic','Clinic','false'
'in clinic uas $nmbr$','C0332285','In','Within','false'
'in clinic uas $nmbr$','C1707101','IN','CD44 wt Allele','false'
'weekly iss $nmbr$','C1740819','ISS','Idiopathic short stature','false'
'weekly iss $nmbr$','C1845118','ISS','SHORT STATURE, IDIOPATHIC, X-LINKED','false'
'weekly number of hives score $nmbr$','C0237753','*Number','Numbers','false'
'weekly number of hives score $nmbr$','C0449788','Number','Count of entities','false'
'overall dlqi score $nmbr$','C0282416','Overall','Overall Publication Type','true'
'overall dlqi score $nmbr$','C3897059','DLQI - Score','DLQI - Score','false'
'overall dlqi score $nmbr$','C1561607','Overall','Overall','false'
'angioedema present n $nmbr$','C0002994','Angiooedema','Angioedema','true'
'angioedema present n $nmbr$','C0150312','PRESENT','Present','false'
'angioedema present n $nmbr$','C0449450','Present','Presentation','false'
'lsm difference $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'lsm difference $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'lsm difference $nmbr$ cl','C1705242','Difference','Different','false'
'sia','C1225105','Sia','Sia','false'
'sia','C1551538','Zia','Zia','false'
'non united states','C1518422','Non','Negation','false'
'non united states','C0041703','UNITED STATES','United States','true'
'baseline weekly iss','C1740819','ISS','Idiopathic short stature','false'
'baseline weekly iss','C1845118','ISS','SHORT STATURE, IDIOPATHIC, X-LINKED','false'
'baseline uas $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline uas $nmbr$','C1442488','Baseline','Baseline','false'
'a median','C0549183','Median','Midline (qualifier value)','false'
'a median','C0876920','Median','Median Statistical Measurement','false'
'a median','C2347635','Median','Population Median','false'
'a median','C2348144','Median','Sample Median','false'
'a median','C2939193','Median','Median (qualifier value)','false'
'body weiqht','C0242821','body','Human body','true'
'body weiqht','C0460148','Body','Human body structure','false'
'body weiqht','C1268086','Body','Body structure','false'
'body weiqht','C4082212','Body','Adult human body','false'
'positive cu index test','C0022885','Test','Laboratory Procedures','false'
'positive cu index test','C0039593','Test','Testing','false'
'positive cu index test','C0392366','test','Tests (qualifier value)','false'
'positive cu index test','C0456984','Test','Test Result','false'
'positive cu index test','C1515976','test','Anatomic Structure, System, or Substance','false'
'positive cu index test','C3831328','Test','Blood Products Laboratory Testing','false'
'positive cu index test','C4318744','Test','Test - temporal region','false'
'presence of angioedema at baseline','C0150312','Presence','Present','false'
'presence of angioedema at baseline','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of angioedema at baseline','C3854307','Presence','Presence (property)','false'
'presence of angioedema at baseline','C0168634','baseline','BaseLine dental cement','true'
'presence of angioedema at baseline','C1442488','Baseline','Baseline','false'
'previous use of systemic steroids for ciu csu','C0281991','use of steroids','steroid use','false'
'previous use of systemic steroids for ciu csu','C0578870','CIU','Chronic idiopathic urticaria','false'
'level of thyroperoxidase antibody at baseline','C0428536','Antibody level','Immunoglobulin level - finding','false'
'level of thyroperoxidase antibody at baseline','C0168634','baseline','BaseLine dental cement','true'
'level of thyroperoxidase antibody at baseline','C1442488','Baseline','Baseline','false'
'high $nmbr$ $nmbr$ u ml','C0439340','U/mL','Kilounit per Liter','false'
'high $nmbr$ $nmbr$ u ml','C1880521','U/mL','Enzyme Unit per Milliliter','false'
'high $nmbr$ $nmbr$ u ml','C2945590','U/mL','Unit per Milliliter','false'
'duration of disease before baseline','C0872146','disease duration','disease length','false'
'duration of disease before baseline','C0168634','baseline','BaseLine dental cement','true'
'duration of disease before baseline','C1442488','Baseline','Baseline','false'
'previous number of ciu csu medications','C0205156','Previous','Previous','false'
'previous number of ciu csu medications','C1718138','Number of medications','Number of medications','false'
'previous number of ciu csu medications','C1552607','previous','Act Relationship Subset - previous','false'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0018623','Model, Hazard','Hazards Models','true'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0456603','Ratios','Ratio','false'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C1610540','*Ratios','Kind of quantity - Ratios','false'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0030705','Patients','Patients','true'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0441767','Phase II','Stage level 2','false'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C1706317','Long Value','Long Variable','false'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0009667','Confidence Interval','Confidence Intervals','true'
'b hazard ratios for serious infections cox proportional hazards model in tofacitinib treated patients in the pooled phase ii phase iii and long term extension study population values are the mean $nmbr$ confidence interval [ $nmbr$ ci] dmard disease modifying antirheumatic drug','C0242708','Disease-Modifying Antirheumatic Drug','Antirheumatic Drugs, Disease-Modifying','true'
'baseline high density lipoprotein cholesterol mg dl','C0023822','High Density Lipoprotein Cholesterol','High Density Lipoprotein Cholesterol','true'
'baseline high density lipoprotein cholesterol mg dl','C0439269','mg dl','mg/dL','false'
'no of cardiovascular events cardiovascular events $nmbr$ person years','C1320716','cardiovascular events','Cardiovascular event','false'
'no of cardiovascular events cardiovascular events $nmbr$ person years','C0027361','Person','Persons','true'
'no of cardiovascular events cardiovascular events $nmbr$ person years','C2347489','Person','Person Observer','false'
'hazard ratio','C2985465','Hazard Ratio','Hazard Ratio','false'
'pfor trend','C1521798','Trend','trend','false'
'pfor trend','C4554533','Trend','Trend:Type:Point in time:^Patient:Nominal','false'
'chd plus cerebral infarction','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'chd plus cerebral infarction','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'total deaths','C0011065','deaths','Cessation of life','true'
'total deaths','C1306577','DEATHS','Death (finding)','false'
'prehospital ticagrelor n $nmbr$','C1999375','TICAGRELOR','Ticagrelor','true'
'in hospital ticagrelor n $nmbr$','C0019994','HOSPITAL','Hospitals','true'
'in hospital ticagrelor n $nmbr$','C1510665','Hospital','Hospital environment','false'
'bmi $nmbr$ no f','C0578022','BMI','Finding of body mass index','false'
'bmi $nmbr$ no f','C0016327','F-','Fluorides','true'
'timi risk score no t','C0035647','Risk','Risk','true'
'timi risk score no t','C0449820','SCORE','Score','false'
'timi risk score no t','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score no t','C4552904','risk','Subject Risk','false'
'timi risk score no t','C2603360','T'','T prime','false'
'killip class i no','C2697844','Killip Class 1','Killip Class I','false'
'first medical contact no','C0332158','contact','Contact with','false'
'first medical contact no','C0337611','Contact','contact person','false'
'first medical contact no','C1705415','Contact','Communication Contact','false'
'first medical contact no','C3812666','Contact','Personal Contact','false'
'in ambulance','C0002422','Ambulance','Ambulances','true'
'in ambulance','C3846685','Ambulance, not otherwise specified','Ambulance, not otherwise specified','false'
'in emergency department before ambulance transfer','C0562508','Emergency Department','Accident and Emergency department','true'
'in emergency department before ambulance transfer','C0002422','Ambulance','Ambulances','true'
'in emergency department before ambulance transfer','C3846685','Ambulance, not otherwise specified','Ambulance, not otherwise specified','false'
'procedures for index event','C0025664','procedures','Methods aspects','true'
'procedures for index event','C0184661','PROCEDURES','Interventional procedure','true'
'procedures for index event','C2700391','Procedures','Procedure (set of actions)','false'
'procedures for index event','C3538935','Procedures','Procedure Domain','false'
'coronary angiography no','C0085532','CORONARY ANGIOGRAPHY','Coronary angiography','true'
'coronary angiography no','C1548829','Coronary Angiography','Consent Type - Coronary Angiography','false'
'femoral access no total no','C0444454','Access','Access','false'
'femoral access no total no','C1554204','access','Role Class - access','false'
'femoral access no total no','C0439175','% total','% of total','false'
'femoral access no total no','C0439810','Total','Total','false'
'radial access no total no','C0444454','Access','Access','false'
'radial access no total no','C1554204','access','Role Class - access','false'
'radial access no total no','C0439175','% total','% of total','false'
'radial access no total no','C0439810','Total','Total','false'
'missing data no total no','C4684714','Missing Data','Missing Data','false'
'missing data no total no','C0439175','% total','% of total','false'
'missing data no total no','C0439810','Total','Total','false'
'with stent^l','C0038257','Stent','Stent, device','true'
'drug eluting stent','C1322815','Drug Eluting Stent','Drug-Eluting Stents','true'
'bare metal stent','C2825200','Bare Metal Stent','Bare metal stent','false'
'without stent','C0038257','Stent','Stent, device','true'
'no pci or cabg no','C4049621','PCI','Peritoneal Cancer Index','false'
'no pci or cabg no','C0010055','CABG','Coronary Artery Bypass Surgery','true'
'study medication no','C0013227','Medication','Pharmaceutical Preparations','true'
'study medication no','C3244316','medication','medication - HL7 publishing domain','false'
'study medication no','C4284232','Medication','Medications','false'
'first loading dose','C0205435','First','First (number)','false'
'first loading dose','C3714444','Loading dose','Loading dose','false'
'first loading dose','C1279901','First','Firstly','false'
'second loading dose','C0205436','Second','second (number)','false'
'second loading dose','C3714444','Loading dose','Loading dose','false'
'second loading dose','C0457385','Second','seconds','false'
'second loading dose','C0565930','/second','per second','false'
'second loading dose','C1561503','second','Precision - second','false'
'second loading dose','C1705190','Second','Second Suffix','false'
'maintenance dose','C3714445','Maintenance dose','Maintenance dose','false'
'aspirin no','C0004057','ASPIRIN','Aspirin','true'
'any use','C0042153','use','utilization qualifier','true'
'any use','C0457083','Use','Usage','false'
'any use','C1947944','Use','Use - dosing instruction imperative','false'
'other antithrombotic medication for index event no','C0013227','Medication','Pharmaceutical Preparations','true'
'other antithrombotic medication for index event no','C3244316','medication','medication - HL7 publishing domain','false'
'other antithrombotic medication for index event no','C4284232','Medication','Medications','false'
'glycoprotein ilb iiia inhibitor before pci]','C0017968','Glycoprotein','Glycoproteins','true'
'glycoprotein ilb iiia inhibitor before pci]','C1999216','Inhibitor','Inhibitor','false'
'intravenous anticoagulant during hospitalization','C0003280','Anticoagulant','Anticoagulants','true'
'intravenous anticoagulant during hospitalization','C0848112','anti coagulant','on anti-coagulants','false'
'intravenous anticoagulant during hospitalization','C3536711','Anticoagulant','Anti-coagulant [EPC]','false'
'heparin','C0019134','HEPARIN','heparin','true'
'heparin','C0770546','HEPARIN','heparin, porcine','false'
'combination therapy','C0009429','Combination Therapy','Combined Modality Therapy','true'
'combination therapy','C0556895','Combination therapy','Combination electrotherapy','false'
'total patients','C0439175','% total','% of total','false'
'total patients','C0030705','Patients','Patients','true'
'total patients','C0439810','Total','Total','false'
'endpoint rate','C0871208','Rate','Rating (action)','false'
'endpoint rate','C1521828','Rate','Rate','false'
'p value int','C1709380','P-Value','P-Value','false'
'p value int','C3272375','INT','Integer Data Type','false'
'pre h','C0033727','H+','Protons','true'
'pre h','C0369286','H NOS','H NOS Antibodies','false'
'pre h','C0441932','H+','Hepatic Involvement','false'
'pre h','C0564385','/h','/hour','false'
'pre h','C4528284','h*%','Hour Times Percent','false'
'in h','C0033727','H+','Protons','true'
'in h','C0369286','H NOS','H NOS Antibodies','false'
'in h','C0441932','H+','Hepatic Involvement','false'
'in h','C0564385','/h','/hour','false'
'in h','C4528284','h*%','Hour Times Percent','false'
'n nt','C0332126','NT','No treatment required for','false'
'n nt','C1449832','NT','Nuchal Translucency Screen','true'
'n nt','C3889152','NT','NT5E wt Allele','false'
'n nt','C4050156','NT','Tyrosine Nitration','false'
'n nt','C4283901','NT','Neurotensin, human','false'
'n nt','C4284038','NT','NTS wt Allele','false'
'location of ml','C0450429','Location','Location','false'
'location of ml','C1515974','Location','Anatomic Site','false'
'location of ml','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'location of ml','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'tim $nmbr$ nsk score','C0449820','SCORE','Score','false'
'tim $nmbr$ nsk score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'highest killip classiciation pre pci','C1522410','Highest','Highest','false'
'highest killip classiciation pre pci','C0332152','Pre','Before','false'
'highest killip classiciation pre pci','C0740175','Pre','Before values','false'
'highest killip classiciation pre pci','C2257086','PRE','photoreactivating enzyme activity','false'
'highest killip classiciation pre pci','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'$nmbr$ ix','C0015491','IX','factor IX','true'
'prior asa use','C0042153','use','utilization qualifier','true'
'prior asa use','C0457083','Use','Usage','false'
'prior asa use','C1947944','Use','Use - dosing instruction imperative','false'
'gpifeellla inhibitor use before angography','C0042153','use','utilization qualifier','true'
'gpifeellla inhibitor use before angography','C0457083','Use','Usage','false'
'gpifeellla inhibitor use before angography','C1947944','Use','Use - dosing instruction imperative','false'
'morphine use for index event pci','C0242000','MORPHINE USE','morphine use','false'
'morphine use for index event pci','C0441471','Event','Event','false'
'morphine use for index event pci','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'heparin ondaparinux or brvalirudin use between rxjex event','C0019134','HEPARIN','heparin','true'
'heparin ondaparinux or brvalirudin use between rxjex event','C0770546','HEPARIN','heparin, porcine','false'
'heparin ondaparinux or brvalirudin use between rxjex event','C0042153','use','utilization qualifier','true'
'heparin ondaparinux or brvalirudin use between rxjex event','C0457083','Use','Usage','false'
'heparin ondaparinux or brvalirudin use between rxjex event','C1947944','Use','Use - dosing instruction imperative','false'
'total atients','C0439175','% total','% of total','false'
'total atients','C0439810','Total','Total','false'
'tlmi risk score','C0035647','Risk','Risk','true'
'tlmi risk score','C0449820','SCORE','Score','false'
'tlmi risk score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'tlmi risk score','C4552904','risk','Subject Risk','false'
'gpifo llia inhibitor use before angography','C0042153','use','utilization qualifier','true'
'gpifo llia inhibitor use before angography','C0457083','Use','Usage','false'
'gpifo llia inhibitor use before angography','C1947944','Use','Use - dosing instruction imperative','false'
'heparin fondaparinux or brvalirudin use between oex event','C0019134','HEPARIN','heparin','true'
'heparin fondaparinux or brvalirudin use between oex event','C1098510','FONDAPARINUX','fondaparinux','true'
'heparin fondaparinux or brvalirudin use between oex event','C0770546','HEPARIN','heparin, porcine','false'
'heparin fondaparinux or brvalirudin use between oex event','C0042153','use','utilization qualifier','true'
'heparin fondaparinux or brvalirudin use between oex event','C0457083','Use','Usage','false'
'heparin fondaparinux or brvalirudin use between oex event','C1947944','Use','Use - dosing instruction imperative','false'
'total by treatment','C0439175','% total','% of total','false'
'total by treatment','C0439810','Total','Total','false'
'early','C1279919','Early','Early','false'
'delayed','C0205421','Delayed','Deferred','false'
'delayed','C1545665','Delayed','Views delayed','false'
'delayed','C3272602','Delayed','Delayed Testing','false'
'creatinine clearance an','C0812399','Creatinine clearance','Creatinine clearance','false'
'prior non cns se','C0332152','Prior','Before','false'
'prior non cns se','C0036919','SE','Seychelles','true'
'prior non cns se','C2826257','PRIOR','Prior Medication Usage','false'
'prior tia','C0007787','TIA','Transient Ischemic Attack','true'
'prior tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'prior tia','C1054154','tia','Tacca leontopetaloides','false'
'congestive hf','C0018488','Hf','Hafnium','true'
'congestive hf','C1313497','HF','GZMA protein, human','true'
'congestive hf','C1538440','HF','CFH gene','false'
'congestive hf','C3273279','HF','CFH wt Allele','false'
'nyha class iii iv','C0278962','NYHA Class III/IV','New York Heart Association class III/IV','false'
'arterial hypertension','C0020538','Arterial hypertension','Hypertensive disease','true'
'vascular disease','C0042373','Disease, Vascular','Vascular Diseases','true'
'first diagnosed','C0205435','First','First (number)','false'
'first diagnosed','C1279901','First','Firstly','false'
'first diagnosed','C0011900','Diagnosed','Diagnosis','true'
'long standing persistent','C0205322','Persistent','Persistent','false'
'long standing persistent','C0332996','PERSISTENT','Persistent embryonic structure','false'
'cha $nmbr$ ds $nmbr$ vasc score n','C1420648','CHA','TCFL5 gene','false'
'cha $nmbr$ ds $nmbr$ vasc score n','C0449820','SCORE','Score','false'
'cha $nmbr$ ds $nmbr$ vasc score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ or $nmbr$ if female only','C0043210','female','Woman','true'
'$nmbr$ or $nmbr$ if female only','C0086287','FEMALE','Females','true'
'$nmbr$ or $nmbr$ if female only','C1705497','Female','Female, Self-Report','false'
'$nmbr$ or $nmbr$ if female only','C1705498','FEMALE','Female Phenotype','false'
'$nmbr$ except for female alone','C0043210','female','Woman','true'
'$nmbr$ except for female alone','C0086287','FEMALE','Females','true'
'$nmbr$ except for female alone','C1705497','Female','Female, Self-Report','false'
'$nmbr$ except for female alone','C1705498','FEMALE','Female Phenotype','false'
'$nmbr$ except for female alone','C0205171','Alone','Singular','false'
'$nmbr$ except for female alone','C0439044','Alone','Living Alone','false'
'$nmbr$ except for female alone','C0679994','alone','alone - group size','false'
'oac experienced bn','C0005005','BN','Benin Republic','true'
'oac experienced bn','C0034700','BN','Rats, Inbred BN','true'
'oac experienced bn','C1706574','BN','GRP wt Allele','false'
'oac experienced bn','C4551963','BN','BULIMIA NERVOSA, SUSCEPTIBILITY TO','false'
'antiarrhythmic drugs n','C0003195','ANTIARRHYTHMIC DRUGS','Anti-Arrhythmia Agents','true'
'dronedarone','C0766326','DRONEDARONE','dronedarone','true'
'flecainide','C0016229','FLECAINIDE','Flecainide','true'
'propafenone','C0033429','PROPAFENONE','Propafenone','true'
'others classes i and iiic','C0441885','Class I','Class 1','false'
'others classes i and iiic','C1319793','Class I','New York Heart Association Classification - Class I','false'
'others classes i and iiic','C2698967','Class I','Canadian Cardiovascular Society Grading Scale Class I','false'
'efficacy n a','C1280519','Efficacy','Effectiveness','false'
'efficacy n a','C1707887','EFFICACY','Efficacy Study','false'
'se','C0036919','SE','Seychelles','true'
'cardiovascular death','C0011065','DEATH','Cessation of life','true'
'cardiovascular death','C1306577','Death','Death (finding)','false'
'cardiovascular death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cardiovascular death','C4552775','Death NOS','Death NOS, CTCAE','false'
'safety n b','C0036043','Safety','Safety','true'
'safety n b','C1705187','SAFETY','Safety Study','false'
'fatal','C1302234','Fatal','Fatal','false'
'fatal','C1705232','FATAL','Death Related to Adverse Event','false'
'critical site','C0205145','Site','Site','false'
'critical site','C1515974','Site','Anatomic Site','false'
'critical site','C2825164','Site','Study Site','false'
'ich','C0019191','ICH','Infectious Canine Hepatitis','true'
'ich','C3272597','ICH','ICH Temperature/Humidity Storage Condition','false'
'ich','C3281105','ICH','HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO','false'
'hb decrease $nmbr$ g dl','C0439267','g/dL','Gram per Deciliter','false'
'transfusion $nmbr$ units rbcs or whole blood','C0005841','Transfusion','Blood Transfusion','true'
'transfusion $nmbr$ units rbcs or whole blood','C0014792','RBCs','Erythrocytes','true'
'transfusion $nmbr$ units rbcs or whole blood','C0199960','Transfusion','Transfusion - action','false'
'transfusion $nmbr$ units rbcs or whole blood','C1879316','Transfusion','Transfusion (procedure)','false'
'transfusion $nmbr$ units rbcs or whole blood','C0229664','Whole Blood','peripheral blood','false'
'transfusion $nmbr$ units rbcs or whole blood','C0370231','Whole blood','whole blood','false'
'transfusion $nmbr$ units rbcs or whole blood','C1546552','Blood, Whole','Specimen Source Codes - Whole blood','false'
'transfusion $nmbr$ units rbcs or whole blood','C1608383','Blood, Whole','whole blood specimen','false'
'mepolizumab','C0969324','MEPOLIZUMAB','mepolizumab','true'
'intravenous n $nmbr$','C0348016','Intravenous','Intravenous','false'
'subcutaneous n $nmbr$','C0443315','Subcutaneous','subcutaneous','false'
'mean age range yr','C0001779','AGE','Age','false'
'mean age range yr','C0439234','yr','year','false'
'former smoker no','C0337671','Former Smoker','Former smoker','false'
'duration of asthma yr','C0449238','Duration','Duration (temporal concept)','false'
'duration of asthma yr','C2926735','Duration','Duration','false'
'use of oral glucocorticoids','C1524063','Use of','Use of','false'
'maintenance use no','C0042153','use','utilization qualifier','true'
'maintenance use no','C0457083','Use','Usage','false'
'maintenance use no','C1947944','Use','Use - dosing instruction imperative','false'
'mean daily dose range mg i','C0024671','MG','Mammography','true'
'mean daily dose range mg i','C0021966','I-','Iodides','true'
'mean daily dose range mg i','C0221138','I NOS','Blood group antibody I','false'
'mean daily dose range mg i','C0026410','MG','Mongolia','true'
'mean daily dose range mg i','C0439269','mg%','mg/dL','false'
'mean daily dose range mg i','C1960952','mg %','Milligram percent','false'
'mean daily dose range mg i','C2346927','Mg++','Magnesium Cation','false'
'mean daily dose range mg i','C4321396','MG','MG','false'
'mean daily dose range mg i','C4521761','MG','United States Military Commissioned Officer O8','false'
'allergic rhinitis no','C1334103','allergic rhinitis','IL13 gene','false'
'allergic rhinitis no','C2607914','ALLERGIC RHINITIS','Allergic rhinitis (disorder)','true'
'allergic rhinitis no','C4552864','Allergic rhinitis','Allergic Rhinitis, CTCAE','false'
'fev $nmbr$','C3714541','FEV','Forced Vital Capacity','true'
'before bronchodilation liters','C1371299','Bronchodilation','Bronchodilation [PE]','false'
'before bronchodilation liters','C0475211','LITER','liter','false'
'before bronchodilation liters','C3537072','Bronchodilation','Bronchodilation','false'
'percent of predicted value before bronchodilation^','C1882327','Percent of Predicted Value','Percent of Predicted Value','false'
'percent of predicted value before bronchodilation^','C1371299','Bronchodilation','Bronchodilation [PE]','false'
'percent of predicted value before bronchodilation^','C3537072','Bronchodilation','Bronchodilation','false'
'reversibility','C0449261','Reversibility','Reversibility','false'
'fevt fvc ratio','C0456603','RATIO','Ratio','false'
'fevt fvc ratio','C1547037','Ratio','data type - ratio','false'
'morning peak expiratory flow liters min','C0702093','/min','Per Minute','false'
'morning peak expiratory flow liters min','C1524029','MIN NOS','Mouse MIN NOS','false'
'morning peak expiratory flow liters min','C3813700','%/min','Percent per Minute','false'
'score on asthma control questionnaire','C4706265','Asthma Control Questionnaire score','Asthma Control Questionnaire score','false'
'score on st george s respiratory questionnaire^^','C0449820','SCORE','Score','false'
'score on st george s respiratory questionnaire^^','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'score on st george s respiratory questionnaire^^','C0521346','RESPIRATORY','respiratory','false'
'score on st george s respiratory questionnaire^^','C0034394','Questionnaire','Questionnaires','true'
'score on st george s respiratory questionnaire^^','C1546767','Respiratory','Specimen Source Codes - Respiratory','false'
'geometric mean ige on loge scale u ml','C0439340','U/mL','Kilounit per Liter','false'
'geometric mean ige on loge scale u ml','C1880521','U/mL','Enzyme Unit per Milliliter','false'
'geometric mean ige on loge scale u ml','C2945590','U/mL','Unit per Milliliter','false'
'geometric mean blood eosinophil count on loge scale cells ^ljj','C2986759','Geometric Mean','Geometric Mean','false'
'geometric mean blood eosinophil count on loge scale cells ^ljj','C0200638','Blood cell count, eosinophil','Eosinophil count procedure','false'
'asthma exacerbations','C0349790','asthma exacerbations','Exacerbation of asthma','false'
'severe episodes in previous year no patient','C0205082','Severe','Severe (severity modifier)','false'
'severe episodes in previous year no patient','C0332189','Episodes','Episode of','false'
'severe episodes in previous year no patient','C4050465','Severe','Severe Extremity Pain','false'
'severe episodes in previous year no patient','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'severe episodes in previous year no patient','C0030705','*^patient','Patients','true'
'necessitating hospitalization in previous year no','C0019993','hospitalisation','Hospitalization','true'
'necessitating hospitalization in previous year no','C0205156','Previous','Previous','false'
'necessitating hospitalization in previous year no','C1552607','previous','Act Relationship Subset - previous','false'
'history of asthma related intubation no','C0455544','History of - asthma','H/O: asthma','false'
'history of asthma related intubation no','C0021925','INTUBATION','Intubation','true'
'p $nmbr$ z $nmbr$ n $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$ z $nmbr$ n $nmbr$','C2603361','P'','P prime','false'
'$nmbr$ to $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ to $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'north america oceania','C0282279','Oceania','Oceania','true'
'north america oceania','C4085681','Oceania','Oceania <genus>','false'
'femoral neck t score mean sd','C0015815','Femoral Neck','Structure of neck of femur','true'
'femoral neck t score mean sd','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'mean bmd sd g cm $nmbr$','C0444504','Mean','Statistical mean','false'
'mean bmd sd g cm $nmbr$','C0439267','g%','Gram per Deciliter','false'
'mean bmd sd g cm $nmbr$','C2347634','Mean','Population Mean','false'
'mean bmd sd g cm $nmbr$','C2348143','Mean','Sample Mean','false'
'lumbar','C0024090','Lumbar','Lumbar Region','true'
'prior medication use n','C0332152','Prior','Before','false'
'prior medication use n','C0240320','MEDICATION USE','medication use','false'
'prior medication use n','C2826257','PRIOR','Prior Medication Usage','false'
'hormone therapy','C0279025','Hormone Therapy','Hormone Therapy','false'
'bisphosphonates','C0012544','Bisphosphonates','Diphosphonates','true'
'bisphosphonates','C3541401','Bisphosphonates','Bisphosphonate drugs affecting bone structure and mineralization','false'
'calcitonin','C0006668','CALCITONIN','Calcitonin','true'
'calcitonin','C0770558','CALCITONIN','Human calcitonin','false'
'calcitonin','C1704385','Calcitonin','Recombinant Calcitonin','false'
'calcitonin','C2825090','Calcitonin','Calcitonin [EPC]','false'
'calcitonin','C4520796','Calcitonin','Calcitonin Precursor, human','false'
'serms','C0732611','SERMs','Selective Estrogen Receptor Modulators','true'
'other osteoporosis medication','C0013227','Medication','Pharmaceutical Preparations','true'
'other osteoporosis medication','C3244316','medication','medication - HL7 publishing domain','false'
'other osteoporosis medication','C4284232','Medication','Medications','false'
'mean sd days since','C0444504','Mean','Statistical mean','false'
'mean sd days since','C0439228','DAYS','day','false'
'mean sd days since','C2347634','Mean','Population Mean','false'
'mean sd days since','C2348143','Mean','Sample Mean','false'
'last infusion in the horizon pft','C0574032','Infusion','Infusion procedures','false'
'last infusion in the horizon pft','C1827465','Infusion','Infusion route','false'
'core study to first infusion','C0557651','Study','Room of building - Study','false'
'core study to first infusion','C2603343','Study','Study','false'
'in extension study','C0557651','Study','Room of building - Study','false'
'in extension study','C2603343','Study','Study','false'
'with ckd intensive n $nmbr$','C1561643','CKD','Chronic Kidney Diseases','true'
'with ckd standard n $nmbr$','C1561643','CKD','Chronic Kidney Diseases','true'
'with ckd standard n $nmbr$','C1442989','Standard','Standard (qualifier)','false'
'with ckd standard n $nmbr$','C2828392','Standard','Standard (document)','false'
'no ckd intensive n $nmbr$','C1561643','CKD','Chronic Kidney Diseases','true'
'no ckd standard n $nmbr$','C1561643','CKD','Chronic Kidney Diseases','true'
'no ckd standard n $nmbr$','C1442989','Standard','Standard (qualifier)','false'
'no ckd standard n $nmbr$','C2828392','Standard','Standard (document)','false'
'o $nmbr$ $nmbr$','C0483204','O NOS','O NOS Ab','false'
'race ethnicity','C0015031','Ethnicity','Ethnic group','true'
'race ethnicity','C0243103','ethnicity','Ethnicity aspects','true'
'waist cm','C0230097','WAIST','Structure of waist (surface region)','false'
'uacr mg g','C1300563','mg/g','Gram per Kilogram','false'
'o $nmbr$','C0483204','O NOS','O NOS Ab','false'
'no ckd','C1561643','CKD','Chronic Kidney Diseases','true'
'ckd stage $nmbr$','C0205390','Stage','Phase','false'
'ckd stage $nmbr$','C1300072','Stage','Tumor stage','false'
'ckd stage $nmbr$','C1306673','Stage','Stage','false'
'serum glucose mg dl','C0202041','Serum Glucose','Glucose measurement, serum','false'
'serum glucose mg dl','C0439269','mg dl','mg/dL','false'
'serum glucose mg dl','C3534430','Serum glucose','Serum glucose','false'
'duration of dm years','C0449238','Duration','Duration (temporal concept)','false'
'duration of dm years','C2926735','Duration','Duration','false'
'heart rate','C0018810','Heart Rate','heart rate','true'
'history of cvd','C0019664','History','History','true'
'history of cvd','C0019665','history','Historical aspects qualifier','true'
'history of cvd','C0262512','History, NOS','History of present illness','false'
'history of cvd','C0262926','History','Medical History','false'
'history of cvd','C1705255','History','Concept History','false'
'history of cvd','C2004062','History','History of previous events','false'
'history of chf','C0019664','History','History','true'
'history of chf','C0019665','history','Historical aspects qualifier','true'
'history of chf','C0262512','History, NOS','History of present illness','false'
'history of chf','C0262926','History','Medical History','false'
'history of chf','C1705255','History','Concept History','false'
'history of chf','C2004062','History','History of previous events','false'
'any anti hypertensive agent','C0003364','Antihypertensive Agent','Antihypertensive Agents','true'
'dihydropyridine ccbs','C0012315','Dihydropyridine','Dihydropyridines','true'
'dihydropyridine ccbs','C0006684','CCB','Calcium Channel Blockers','true'
'dihydropyridine ccbs','C0220821','dihydropyridine','dihydropyridine','true'
'non dihydropyridine ccbs','C0012315','Dihydropyridine','Dihydropyridines','true'
'non dihydropyridine ccbs','C0006684','CCB','Calcium Channel Blockers','true'
'non dihydropyridine ccbs','C0220821','dihydropyridine','dihydropyridine','true'
'potassium','C0032821','POTASSIUM','Potassium','true'
'potassium','C0202194','Potassium+','Potassium measurement','false'
'potassium','C0304475','POTASSIUM','Potassium supplement','false'
'potassium','C0597277','Potassium','Potassium Ion','false'
'potassium','C3714637','POTASSIUM','Potassium Drug Class','false'
'hdl female','C0043210','female','Woman','true'
'hdl female','C0086287','FEMALE','Females','true'
'hdl female','C1705497','Female','Female, Self-Report','false'
'hdl female','C1705498','FEMALE','Female Phenotype','false'
'hdl male','C0086582','MALE','Males','true'
'hdl male','C1706180','Male','Male Gender, Self Report','false'
'hdl male','C1706428','MALE','Male Phenotype','false'
'hdl male','C1706429','Male','Male, Self-Reported','false'
'ohs graduate','C0588053','Graduate','Graduate (person)','false'
'ohs graduate','C1547183','Graduate','School type - Graduate','false'
'hs graduate ged','C0588053','Graduate','Graduate (person)','false'
'hs graduate ged','C1880947','GED','General Equivalency Diploma Completion','false'
'hs graduate ged','C1547183','Graduate','School type - Graduate','false'
'some college tech','C0557806','College','College','false'
'some college tech','C1826596','Tech','PLEKHG5 gene','false'
'college graduate or more','C0682187','college graduate','college completed','false'
'network','C0150775','network','Social Networks','true'
'network','C1513822','Network','Consortium or Network','false'
'network','C1705739','Network','Network Device','false'
'network','C1882071','Network','Network','false'
'$nmbr$ mg empagliflozin','C0024671','MG','Mammography','true'
'$nmbr$ mg empagliflozin','C3490348','EMPAGLIFLOZIN','empagliflozin','true'
'$nmbr$ mg empagliflozin','C0026410','MG','Mongolia','true'
'$nmbr$ mg empagliflozin','C0439269','mg%','mg/dL','false'
'$nmbr$ mg empagliflozin','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg empagliflozin','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg empagliflozin','C4321396','MG','MG','false'
'$nmbr$ mg empagliflozin','C4521761','MG','United States Military Commissioned Officer O8','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd','C0439445','mL/min','mL/min','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd','C3839656','MDRD','Modification of diet in renal disease formula','false'
'hba $nmbr$ c [mmol mol]','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c [mmol mol]','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c [mmol mol]','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c [mmol mol]','C3829066','mmol/mol','Millimole per Mole','false'
'years since diagnosis of type $nmbr$ diabetes n','C0439234','YEARS','year','false'
'years since diagnosis of type $nmbr$ diabetes n','C1320657','type diabetes','Diabetes type','false'
'sbp office measurement mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp office measurement mmhg','C0439475','mmHG','mmHg','false'
'sbp mean over $nmbr$ h mmhg','C0444504','Mean','Statistical mean','false'
'sbp mean over $nmbr$ h mmhg','C2347634','Mean','Population Mean','false'
'sbp mean over $nmbr$ h mmhg','C2348143','Mean','Sample Mean','false'
'dbp office measurement mmhg','C0242485','MEASUREMENT','Measurement','false'
'dbp office measurement mmhg','C0439475','mmHG','mmHg','false'
'dbp mean over $nmbr$ h mmhg','C0444504','Mean','Statistical mean','false'
'dbp mean over $nmbr$ h mmhg','C2347634','Mean','Population Mean','false'
'dbp mean over $nmbr$ h mmhg','C2348143','Mean','Sample Mean','false'
'pulse rate mean $nmbr$ h bpm','C0232117','Pulse Rate','Pulse Rate','true'
'pulse rate mean $nmbr$ h bpm','C0033727','H+','Protons','true'
'pulse rate mean $nmbr$ h bpm','C0369286','H NOS','H NOS Antibodies','false'
'pulse rate mean $nmbr$ h bpm','C0441932','H+','Hepatic Involvement','false'
'pulse rate mean $nmbr$ h bpm','C0564385','/h','/hour','false'
'pulse rate mean $nmbr$ h bpm','C4528284','h*%','Hour Times Percent','false'
'number of antihypertensive medications n','C1718138','Number of medications','Number of medications','false'
'daytime mean sbp abpm at week $nmbr$ mmhg','C0332169','Daytime','Daytime','false'
'daytime mean sbp abpm at week $nmbr$ mmhg','C0085805','SBP','Androgen Binding Protein','true'
'change from baseline mmhg','C0392747','Change','Changing','false'
'change from baseline mmhg','C0443172','change','Changed status','false'
'change from baseline mmhg','C1705241','Change','Delta (difference)','false'
'change from baseline mmhg','C4319952','Change','Change -- procedure','false'
'difference vs placebo','C1705241','*Difference','Delta (difference)','false'
'difference vs placebo','C1705242','Difference','Different','false'
'difference vs placebo','C0032042','Placebo','Placebos','true'
'difference vs placebo','C1696465','PLACEBO','placebo','false'
'difference vs placebo','C1706408','PLACEBO','Placebo Control','false'
'nighttime mean sbp abpm at week $nmbr$ mmhg','C0240526','Night Time','Night time','false'
'nighttime mean sbp abpm at week $nmbr$ mmhg','C0085805','SBP','Androgen Binding Protein','true'
'daytime mean dbp abpm at week $nmbr$ mmhg','C0332169','Daytime','Daytime','false'
'daytime mean dbp abpm at week $nmbr$ mmhg','C0332174','/week','Weekly','false'
'daytime mean dbp abpm at week $nmbr$ mmhg','C0439230','Week','week','false'
'nighttime mean dbp abpm at week $nmbr$ mmhg','C0240526','Night Time','Night time','false'
'nighttime mean dbp abpm at week $nmbr$ mmhg','C0332174','/week','Weekly','false'
'nighttime mean dbp abpm at week $nmbr$ mmhg','C0439230','Week','week','false'
'mean $nmbr$ h sbp','C0033727','H+','Protons','true'
'mean $nmbr$ h sbp','C0085805','SBP','Androgen Binding Protein','true'
'mean $nmbr$ h sbp','C0369286','H NOS','H NOS Antibodies','false'
'mean $nmbr$ h sbp','C0441932','H+','Hepatic Involvement','false'
'mean $nmbr$ h sbp','C0564385','/h','/hour','false'
'mean $nmbr$ h sbp','C4528284','h*%','Hour Times Percent','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C0030705','Patients','Patients','true'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C0037623','BP','Solomon Islands','true'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1415692','Bp','HP gene','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1708288','BP','HP wt Allele','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C4318478','BP','Base Pair Unit','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C0332126','NT','No treatment required for','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1449832','NT','Nuchal Translucency Screen','true'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C3889152','NT','NT5E wt Allele','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C4050156','NT','Tyrosine Nitration','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C4283901','NT','Neurotensin, human','false'
'patients with bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C4284038','NT','NTS wt Allele','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0392747','Change','Changing','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0443172','change','Changed status','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C1705241','Change','Delta (difference)','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C4319952','Change','Change -- procedure','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0033727','H+','Protons','true'
'change from baseline in mean $nmbr$ h sbp mmhg','C0439475','mmHG','mmHg','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0369286','H NOS','H NOS Antibodies','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0441932','H+','Hepatic Involvement','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C0564385','/h','/hour','false'
'change from baseline in mean $nmbr$ h sbp mmhg','C4528284','h*%','Hour Times Percent','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C0037623','BP','Solomon Islands','true'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C0168634','baseline','BaseLine dental cement','true'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C1442488','Baseline','Baseline','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C1415692','Bp','HP gene','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C1708288','BP','HP wt Allele','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline n','C4318478','BP','Base Pair Unit','false'
'mean $nmbr$ h dbp','C0536221','DBP','HSD17B4 protein, human','true'
'mean $nmbr$ h dbp','C3813197','DBP','HSD17B4 wt Allele','false'
'mean $nmbr$ h dbp','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C0037623','BP','Solomon Islands','true'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C0168634','baseline','BaseLine dental cement','true'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1442488','Baseline','Baseline','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1415692','Bp','HP gene','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C1708288','BP','HP wt Allele','false'
'patientswith bp $nmbr$ $nmbr$ mmhg abpm at baseline nt','C4318478','BP','Base Pair Unit','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0392747','Change','Changing','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0443172','change','Changed status','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C1705241','Change','Delta (difference)','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C4319952','Change','Change -- procedure','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0033727','H+','Protons','true'
'change from baseline in mean $nmbr$ h dbp mmhg','C0439475','mmHG','mmHg','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0369286','H NOS','H NOS Antibodies','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0441932','H+','Hepatic Involvement','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C0564385','/h','/hour','false'
'change from baseline in mean $nmbr$ h dbp mmhg','C4528284','h*%','Hour Times Percent','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C0243132','occurrence','occurrence characteristics','true'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C1554210','occurrence','Act Relationship Type - occurrence','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C2745955','Occurrence','Occurrence','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C0332152','Pre','Before','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C1079230','subgroups','Subgroup A Nepoviruses','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C0740175','Pre','Before values','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C2257086','PRE','photoreactivating enzyme activity','false'
'figure $nmbr$ occurrence of primary endpoint in pre speci ed subgroups','C3669034','PRE','Pure Spanish horse breed (organism)','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1522326','Treatment','Treating','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0032042','Placebo','Placebos','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1442488','Baseline','Baseline','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0332174','/week','Weekly','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0439230','Week','week','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0871236','Association Therapy','Association Therapy','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0086045','Concentrations','Mental concentration','true'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0178602','Doses','Dosage','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1521801','Administered','Having administered','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0743559','Error','error','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1608199','Error','Act Reason - Error','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0597484','Na+','Sodium Cation','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1272460','{NA}','Not Applicable','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1546968','NA','No Application Type','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C1879645','NA','Adverse Event by CTCAE Category','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C4049872','NA','Package Type Not Applicable','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C4552882','NA','XK wt Allele','false'
'figure $nmbr$ treatment di erences between evolocumab and placebo in mean percentage changes from baseline in ldl cholesterol at week $nmbr$ and the associations with sex age bmi lipid lowering therapy and baseline ldl cholesterol concentrations a doses administered every $nmbr$ weeks b doses administered monthly error bars are $nmbr$ ci bmi body mass index na not available','C0686905','Not Available','Unavailability','false'
'black or african','C0005680','Black','Black race','true'
'black or african','C0027567','Black','African race','true'
'black or african','C0085756','BLACK','African American','true'
'black or african','C0439541','Black','Black color','false'
'american','C0596070','American','Americas Ethnicity','false'
'region no c','C0017446','Region','Geographic Locations','true'
'region no c','C0205147','Region','regional','false'
'central south','C0205099','CENTRAL','Central','false'
'central south','C1710133','South','South','false'
'central south','C1879652','Central -','Central Minus','false'
'america','C0002454','America','Americas','true'
'duration of t $nmbr$ dm y','C0449238','Duration','Duration (temporal concept)','false'
'duration of t $nmbr$ dm y','C2926735','Duration','Duration','false'
'taking antihypertensive medication at baseline no e','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'dbp $nmbr$ mmhg','C0536221','DBP','HSD17B4 protein, human','true'
'dbp $nmbr$ mmhg','C0439475','mmHG','mmHg','false'
'dbp $nmbr$ mmhg','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp $nmbr$ mmhg','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'on antihypertensive medication at baseline n','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'on antihypertensive medication at baseline n','C0168634','baseline','BaseLine dental cement','true'
'on antihypertensive medication at baseline n','C1442488','Baseline','Baseline','false'
'secukinumab $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'secukinumab $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'secukinumab $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'secukinumab $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'secukinumab $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'secukinumab $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'secukinumab $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age years $nmbr$','C1510829','Age-Years','Age-Years','false'
'weight kg $nmbr$','C0022718','KG','Kyrgyzstan','true'
'weight kg $nmbr$','C0439209','kg','Kilogram','false'
'weight kg $nmbr$','C4054209','/kg','Per Kilogram','false'
'time since psoriasis diagnosis years $nmbr$','C0556970','time year','times/year','false'
'time since psoriasis diagnosis years $nmbr$','C0011900','DIAGNOSIS','Diagnosis','true'
'time since psoriasis diagnosis years $nmbr$','C1704338','diagnosis','diagnosis aspect','true'
'time since psoriasis diagnosis years $nmbr$','C1704656','DIAGNOSIS','Diagnosis Study','false'
'pasi score $nmbr$','C0449820','SCORE','Score','false'
'pasi score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'bsa involved $nmbr$','C1314939','Involved','Involvement with','false'
'iga mod $nmbr$ score n','C0011860','MOD','Diabetes Mellitus, Non-Insulin-Dependent','true'
'iga mod $nmbr$ score n','C0449820','SCORE','Score','false'
'iga mod $nmbr$ score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'$nmbr$ moderate disease','C0205081','Moderate','Moderate (severity modifier)','false'
'$nmbr$ moderate disease','C0012634','Disease','Disease','true'
'$nmbr$ moderate disease','C1881878','Moderate','Moderation','false'
'$nmbr$ moderate disease','C4049705','Moderate','Moderate Extremity Pain','false'
'$nmbr$ moderate disease','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'$nmbr$ moderate disease','C4085643','Moderate','Moderate Response','false'
'$nmbr$ moderate disease','C4321335','Moderate','Moderate Level','false'
'$nmbr$ severe disease','C1836348','Severe Disease','Severe disorder','false'
'psa reported n','C0684224','Reported','Report (document)','true'
'psa reported n','C0700287','Reported','Reporting','false'
'psa reported n','C4319718','Reported','Reported','false'
'conventional agents','C0450442','Agent','Agent','false'
'conventional agents','C1254351','Agent','Pharmacologic Substance','false'
'conventional agents','C1521826','Agent','Protocol Agent','false'
'topical','C0332237','Topical','Topical surface','false'
'phototherapy previous systemic treatment n','C0031765','Phototherapy','Phototherapy','true'
'phototherapy previous systemic treatment n','C0678812','systemic Treatment','systemic administration','false'
'biologic','C0005515','BIOLOGIC','Biological Factors','true'
'biologic','C0205460','Biologic','biological','false'
'anti tnf','C1448177','TNF','TNF protein, human','true'
'efficacy endpoints','C1280519','Efficacy','Effectiveness','false'
'efficacy endpoints','C2349179','endpoints','End Point','false'
'efficacy endpoints','C1707887','EFFICACY','Efficacy Study','false'
'visit','C0545082','Visit','Visit','false'
'visit','C1512346','visit','Patient Visit','false'
'visit','C2826704','VISIT','Visit Name','false'
'japanese subpopulation','C0376247','Japanese','Japanese language','false'
'japanese subpopulation','C1257890','Subpopulation','Population Group','true'
'japanese subpopulation','C1556094','JAPANESE','Japanese race','true'
'week','C0332174','/week','Weekly','false'
'week','C0439230','Week','week','false'
'secukinumab $nmbr$ mg','C0024671','MG','Mammography','true'
'secukinumab $nmbr$ mg','C0026410','MG','Mongolia','true'
'secukinumab $nmbr$ mg','C0439269','mg%','mg/dL','false'
'secukinumab $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'secukinumab $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'secukinumab $nmbr$ mg','C4321396','MG','MG','false'
'secukinumab $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'pasi $nmbr$','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'iga $nmbr$ $nmbr$','C2825347','IgA','Immunoglobulin A, Human','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1274040','Result','Result','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1546471','Result','What subject filter - Result','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C2825142','Result','Experimental Result','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0021641','INSULIN','Insulin','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0008976','Trial','Clinical Trials','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1533581','INSULIN','Recombinant Insulin','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1579433','Insulin','Insulin [EPC]','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C3714501','INSULIN','Insulin Drug Class','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0392747','changes','Changing','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0443172','changes','Changed status','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1709707','Proportion','Proportion','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0030705','Patients','Patients','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0019016','HBA','Hemoglobin A','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C2825507','LOCF','Last Observation Carried Forward Imputation Technique','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1825777','HBA','KRT90P gene','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C3538758','HBA','SCN2A wt Allele','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0005910','Body Weight','Body Weight','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1305866','body weight','Weighing patient','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0679831','history patients','Patient History','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0019664','History','History','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0019665','history','Historical aspects qualifier','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0262512','History, NOS','History of present illness','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0262926','History','Medical History','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1705255','History','Concept History','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C2004062','History','History of previous events','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C3538987','CV','Cardiovascular System Findings Domain','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0035648','Risk Factor','risk factors','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C4048877','CV','Dinner','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C4318503','CV','ciliary vesicle','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0020538','HYPERTENSION','Hypertensive disease','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1963138','Hypertension','Hypertension, CTCAE','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0042153','use','utilization qualifier','true'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C0457083','Use','Usage','false'
'figure $nmbr$ results of the saxagliptin add on to insulin metformin trial a adjusted mean changes from baseline hba $nmbr$ c level locf at week $nmbr$ b adjusted mean changes from baseline fpg locf at week $nmbr$ c proportions of patients achieving hba $nmbr$ c level $nmbr$ locf at week $nmbr$ d adjusted mean changes from baseline in body weight locf at week $nmbr$ in patients with cvd history versus no cvd history with $nmbr$ and $nmbr$ cv risk factor with and without hypertension and with and without statin use','C1947944','Use','Use - dosing instruction imperative','false'
'abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error','C0019045','Disease hemoglobin','Hemoglobinopathies','true'
'abbreviations cv cardiovascular cvd cardiovascular disease glip glipizide hba $nmbr$ c glycated hemoglobin met metformin saxa saxagliptin se standard error','C1710181','Standard Error','Standard Error','false'
'amlodipine lisinopril chlorthalidone comparison','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine lisinopril chlorthalidone comparison','C1707455','Comparison','Comparison','false'
'no in trial stroke n $nmbr$ $nmbr$','C0008976','Trial','Clinical Trials','true'
'no in trial stroke n $nmbr$ $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'no in trial stroke n $nmbr$ $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C0150312','In','Present','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C0008976','Trial','Clinical Trials','true'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C0332285','In','Within','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C1707101','IN','CD44 wt Allele','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C1302234','Fatal','Fatal','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'in trial nonfatal or fatal stroke n $nmbr$ $nmbr$','C1705232','FATAL','Death Related to Adverse Event','false'
'education in years mean sd','C0013621','Education','Knowledge acquisition','true'
'education in years mean sd','C0013622','education','Educational aspects','true'
'education in years mean sd','C0013658','Education, NOS','Educational Status','true'
'education in years mean sd','C0039401','Education','Educational process of instructing','true'
'lipids medications','C0013227','Medications','Pharmaceutical Preparations','true'
'lipids medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'lipids medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'lipids medications','C4284232','Medications','Medications','false'
'blood pressure in mm hg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'blood pressure in mm hg mean sd','C0488053','Mean blood pressure','Intravascular mean:Pressure:Point in time:Arterial system:Quantitative','false'
'sbp at visit $nmbr$','C0085805','SBP','Androgen Binding Protein','true'
'sbp at visit $nmbr$','C0545082','Visit','Visit','false'
'sbp at visit $nmbr$','C1512346','visit','Patient Visit','false'
'sbp at visit $nmbr$','C2826704','VISIT','Visit Name','false'
'dbp at visit $nmbr$','C0536221','DBP','HSD17B4 protein, human','true'
'dbp at visit $nmbr$','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp at visit $nmbr$','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'pulse in beats minute mean sd','C0232117','PULSE','Pulse Rate','true'
'pulse in beats minute mean sd','C0391850','Pulse','Physiologic pulse','false'
'pulse in beats minute mean sd','C1947910','Pulse','Pulse phenomenon','false'
'eligibility risk factors n','C0035648','Risk Factors','risk factors','true'
'eligibility risk factors n','C1553898','risk factors','risk factors - observation list','false'
'history coronary revascularization','C0019664','History','History','true'
'history coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'history coronary revascularization','C0019665','history','Historical aspects qualifier','true'
'history coronary revascularization','C0262512','History, NOS','History of present illness','false'
'history coronary revascularization','C0262926','History','Medical History','false'
'history coronary revascularization','C1705255','History','Concept History','false'
'history coronary revascularization','C2004062','History','History of previous events','false'
'major st depression or t wave inversion','C0041696','Major Depression','Unipolar Depression','true'
'major st depression or t wave inversion','C1269683','MAJOR DEPRESSION','Major Depressive Disorder','true'
'major st depression or t wave inversion','C0520888','T Wave Inversion','Inverted T wave','false'
'hdl c $nmbr$ mg dl','C3715113','HDL','HSD11B1 wt Allele','false'
'hdl c $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'lvh by echo or ecg','C0149721','LVH','Left Ventricular Hypertrophy','true'
'lvh by echo or ecg','C0058928','ECHO','ECHO protocol','true'
'lvh by echo or ecg','C1655045','Echo','Echo (insect)','false'
'lvh by echo or ecg','C1623258','ECG NOS','Electrocardiography','true'
'history chd','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'history chd','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'atrial fibrillation on baseline ecg n','C0344434','atrial fibrillation ecg','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation on baseline ecg n','C0168634','baseline','BaseLine dental cement','true'
'atrial fibrillation on baseline ecg n','C1442488','Baseline','Baseline','false'
'baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0017654','GFR','Glomerular Filtration Rate','true'
'baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0439445','mL/min','mL/min','false'
'baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C1424601','GFR','RAPGEF5 gene','false'
'baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'baseline gfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'biochemical measures mean sd','C0079809','Measures','Measures','true'
'biochemical measures mean sd','C2699239','SD','SD, Rat Strain','false'
'biochemical measures mean sd','C1879489','Measures','Measures (attribute)','false'
'in trial $nmbr$ year rates per $nmbr$ se total events number at risk','C1264674','rate number','Number rate','false'
'in trial $nmbr$ year rates per $nmbr$ se total events number at risk','C1444641','At risk','At risk','false'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C0150312','In','Present','false'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C0008976','Trial','Clinical Trials','true'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C0332285','In','Within','false'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C1707101','IN','CD44 wt Allele','false'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C1264674','rate number','Number rate','false'
'in trial and post trial $nmbr$ year rates per $nmbr$ se total events number at risk','C1444641','At risk','At risk','false'
'chlor','C0308648','CHLOR','chlor','false'
'$nmbr$ fe black','C0005680','Black','Black race','true'
'$nmbr$ fe black','C0027567','Black','African race','true'
'$nmbr$ fe black','C0085756','BLACK','African American','true'
'$nmbr$ fe black','C0439541','Black','Black color','false'
'ment','C0084844','MENT','trestolone','true'
'ment','C1538994','MENT','C1orf56 gene','false'
'women t','C0043210','Women','Woman','true'
'no atrial fibrillation','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'no atrial fibrillation','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'no atrial fibrillation','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'chd at baseline','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'chd at baseline','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'no chd at baseline','C0280604','CHD','altretamine/cisplatin/cyclophosphamide protocol','false'
'no chd at baseline','C3542407','CHD','Choline Dehydrogenase, Mitochondrial','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C4684572','Baseline Characteristics','Baseline Characteristics','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C0034656','Randomized','Randomization','true'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C3815594','RANDOMIZED','Subject is Randomized','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C1524063','Using','Use of','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C0021641','INSULIN','Insulin','true'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C0439465','IU/day','IU/day','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C1533581','INSULIN','Recombinant Insulin','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C1579433','Insulin','Insulin [EPC]','false'
'table $nmbr$ baseline characteristics of randomized participants using insulin $nmbr$ iu day at baseline','C3714501','INSULIN','Insulin Drug Class','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0439165','Percentage','Percent (qualifier value)','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1549488','Percentage','Amount type - Percentage','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0439175','% total','% of total','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0439810','Total','Total','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0332490','ROUND','Round shape','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0002460','AMERICAN INDIAN','American Indians','true'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0238611','ALASKAN','alaskan','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0337920','Hawaiian, Native','Hawaiian population','true'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1165245','paci','Pacis','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0439064','MULTIPLE','Numerous','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1511726','Data','Data','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C3245479','data','Data call receiving device','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C3714741','Data','Data (eukaryote)','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1551393','Missing','Container status - Missing','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1705492','Missing','Missing','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C3272743','MISSING','Missing Study Animal','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0679646','participants','Participant','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0205447','ONE','One','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0457464','type disease','types of diseases','false'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C0168634','baseline','BaseLine dental cement','true'
'acr albumin to creatinine ratio dbp diastolic blood pressure fpg fasting plasma glucose sbp systolic blood pressure percentages may not total $nmbr$ due to rounding including american indian or alaskan native native hawaiian or other paci c islander multiple other and unknown data on dosing regimen are missing for $nmbr$ $nmbr$ of individuals some participants had more than one type of atherosclerotic disease at baseline','C1442488','Baseline','Baseline','false'
'canagliflozin $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'canagliflozin $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'canagliflozin $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'canagliflozin $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'canagliflozin $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'canagliflozin $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'canagliflozin $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age years median range','C1514721','Range','Range','false'
'age years median range','C2348147','Range','Sample Range','false'
'age years median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'duration of diabetes years mean sd','C0449238','Duration','Duration (temporal concept)','false'
'duration of diabetes years mean sd','C2926735','Duration','Duration','false'
'insulin dose iu day median','C0549183','Median','Midline (qualifier value)','false'
'insulin dose iu day median','C0876920','Median','Median Statistical Measurement','false'
'insulin dose iu day median','C2347635','Median','Population Median','false'
'insulin dose iu day median','C2348144','Median','Sample Median','false'
'insulin dose iu day median','C2939193','Median','Median (qualifier value)','false'
'insulin therapy n','C0021641','INSULIN','Insulin','true'
'insulin therapy n','C0039798','therapy','therapeutic aspects','true'
'insulin therapy n','C0087111','Therapy','Therapeutic procedure','true'
'insulin therapy n','C1363945','Therapy','Therapy Object (animal model)','false'
'insulin therapy n','C1533581','INSULIN','Recombinant Insulin','false'
'insulin therapy n','C1579433','Insulin','Insulin [EPC]','false'
'insulin therapy n','C3714501','INSULIN','Insulin Drug Class','false'
'basal plus bolus','C0205112','BASAL','Basal','false'
'basal plus bolus','C1186706','Bolus','Bolus of ingested food','false'
'basal plus bolus','C1511237','Bolus','bolus infusion','false'
'basal plus bolus','C1705509','{Bolus}','Bolus Dosing Unit','false'
'basal plus bolus','C3812160','Bolus','Radiotherapy Bolus','false'
'basal alone','C0205112','BASAL','Basal','false'
'basal alone','C0205171','Alone','Singular','false'
'basal alone','C0439044','Alone','Living Alone','false'
'basal alone','C0679994','alone','alone - group size','false'
'bolus alone','C1186706','Bolus','Bolus of ingested food','false'
'bolus alone','C1511237','Bolus','bolus infusion','false'
'bolus alone','C1705509','{Bolus}','Bolus Dosing Unit','false'
'bolus alone','C3812160','Bolus','Radiotherapy Bolus','false'
'bolus alone','C0205171','Alone','Singular','false'
'bolus alone','C0439044','Alone','Living Alone','false'
'bolus alone','C0679994','alone','alone - group size','false'
'other drug therapy n','C0013216','Drug Therapy','Pharmacotherapy','true'
'other drug therapy n','C0013217','drug therapy','pharmacotherapeutic','true'
'microvascular disease n','C0443258','Microvascular','Microvascular','false'
'microvascular disease n','C0012634','Disease','Disease','true'
'retinopathy','C0035309','RETINOPATHY','Retinal Diseases','true'
'retinopathy','C1962966','Retinopathy','Retinopathy, CTCAE','false'
'nephropathy','C0022658','Nephropathy','Kidney Diseases','true'
'neuropathy','C0442874','NEUROPATHY','Neuropathy','false'
'atherosclerotic vascular disease n','C0004153','ATHEROSCLEROTIC VASCULAR DISEASE','Atherosclerosis','true'
'coronary','C0018787','coronary','Heart','true'
'cerebrovascular','C1880018','Cerebrovascular','Cerebrovascular','false'
'peripheral','C0205100','PERIPHERAL','Peripheral','false'
'sbp mmhg mean sd','C0085805','SBP','Androgen Binding Protein','true'
'sbp mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mmhg mean sd','C0439475','mmHG','mmHg','false'
'dbp mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c mean sd','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c mean sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c mean sd','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c mean sd','C3538758','HBA','SCN2A wt Allele','false'
'mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'total cholesterol mmol l mean sd','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'total cholesterol mmol l mean sd','C0543421','Total cholesterol','Total cholesterol','false'
'triglycerides mmol l mean sd','C1532563','mmol/L','Millimole per Liter','false'
'triglycerides mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'hdl cholesterol mmol l mean sd','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'hdl cholesterol mmol l mean sd','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'ldl cholesterol mmol l mean sd','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol mmol l mean sd','C2699239','SD','SD, Rat Strain','false'
'ldl cholesterol mmol l mean sd','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'ldl to hdl cholesterol ratio mean sd','C0428621','ldl hdl ratio','High density/low density lipoprotein ratio result','false'
'ldl to hdl cholesterol ratio mean sd','C1171408','HDL/LDL ratio','High density/low density lipoprotein ratio measurement','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C0439445','mL/min','mL/min','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0439445','mL/min','mL/min','false'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'acr mg g mean sd','C1300563','mg/g','Gram per Kilogram','false'
'acr mg g mean sd','C2699239','SD','SD, Rat Strain','false'
'microalbuminuria n','C0730345','Microalbuminuria','Microalbuminuria','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1280500','Effects','Effect','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C0178602','DOSE','Dosage','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C0869039','Dose','Unit dose','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1707455','Compared','Comparison','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C0032042','Placebo','Placebos','true'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C0019016','HBA','Hemoglobin A','true'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1079232','Subgroup C','Subgroup C','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C1825777','HBA','KRT90P gene','false'
'figure $nmbr$ supplement effects of each dose of canagliflozin compared to placebo on hba $nmbr$ c in patient subgroups at $nmbr$ weeks','C3538758','HBA','SCN2A wt Allele','false'
'open label phase baseline week $nmbr$','C0332174','/week','Weekly','false'
'open label phase baseline week $nmbr$','C0439230','Week','week','false'
'randomized double blind reversal phase baseline week $nmbr$','C0332174','/week','Weekly','false'
'randomized double blind reversal phase baseline week $nmbr$','C0439230','Week','week','false'
'total cohort','C0009247','COHORT','Cohort Studies','true'
'total cohort','C0599755','Cohort','Cohort','false'
'azl ma','C0024443','MA','Madagascar','true'
'azl ma','C3887485','MA','MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1','false'
'race no c','C0034510','RACE','Racial group','true'
'race no c','C1706779','RACE','AMACR wt Allele','false'
'race no c','C3853635','Race','Race','false'
'baseline dbp mean sd mm hg','C0168634','baseline','BaseLine dental cement','true'
'baseline dbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'baseline dbp mean sd mm hg','C1442488','Baseline','Baseline','false'
'baseline sbp mean sd mm hg','C0085805','SBP','Androgen Binding Protein','true'
'baseline sbp mean sd mm hg','C0439475','mmHG','mmHg','false'
'table $nmbr$ baseline demographics and clinical characteristics','C0011298','Demographics','Demography','true'
'table $nmbr$ baseline demographics and clinical characteristics','C1704791','Demographics','Demographics Domain','false'
'table $nmbr$ baseline demographics and clinical characteristics','C0683325','clinical characteristics','clinical aspects','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0030705','Patients','Patients','true'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C3272598','WHO','WHO Temperature/Humidity Storage Condition','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0332293','Treated with','Treated with','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0013175','Medication study','Drug Evaluation','true'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0168634','baseline','BaseLine dental cement','true'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C1442488','Baseline','Baseline','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C1299575','Treatment modification','Treatment modification','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0457987','diet renal disease','Renal disease diet','false'
'all patients who were treated with $nmbr$ dose of study medication yall patients who had a baseline and $nmbr$ on treatment hba $nmbr$ c measurement egfr estimated glomerular filtration rate fpg fasting plasma glucose hba $nmbr$ c glycated hemoglobin mdrd modification of diet in renal disease nph neutral protamine hagedorn oads oral antidiabetes drugs sd standard deviation','C0871420','Standard Deviation','Standard deviation','false'
'linagliptin','C2746078','LINAGLIPTIN','Linagliptin','true'
'patients treated set n','C0030705','Patients','Patients','true'
'patients treated set n','C0036849','Set','Set (Psychology)','true'
'patients treated set n','C1442518','Set','Set scale','false'
'patients treated set n','C1705195','Set','set (group)','false'
'males n','C0086582','Males','Males','true'
'renal function egfr according to mdrd n','C1739039','EGFR','EGFR protein, human','true'
'renal function egfr according to mdrd n','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'renal function egfr according to mdrd n','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'normal $nmbr$ ml min','C0205307','NORMAL','Normal','false'
'normal $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'normal $nmbr$ ml min','C0231683','Normal','Gait normal','false'
'normal $nmbr$ ml min','C0439166','% normal','Percent normal','false'
'normal $nmbr$ ml min','C2347086','% Normal','Mean Percent of Normal','false'
'normal $nmbr$ ml min','C4553972','Normal','How Often Felt Normal question','false'
'mild impairment $nmbr$ to $nmbr$ ml min','C0221099','Impairment','Impaired','false'
'mild impairment $nmbr$ to $nmbr$ ml min','C0684336','Impairment','Impaired health','false'
'mild impairment $nmbr$ to $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'moderate impairment $nmbr$ to $nmbr$ ml min','C0221099','Impairment','Impaired','false'
'moderate impairment $nmbr$ to $nmbr$ ml min','C0684336','Impairment','Impaired health','false'
'moderate impairment $nmbr$ to $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'severe to end stage impairment $nmbr$ ml min','C0205082','Severe','Severe (severity modifier)','false'
'severe to end stage impairment $nmbr$ ml min','C4050465','Severe','Severe Extremity Pain','false'
'severe to end stage impairment $nmbr$ ml min','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'patients full analysis sety n','C0030705','Patients','Patients','true'
'patients full analysis sety n','C0002778','Analysis','Analysis of substances','false'
'patients full analysis sety n','C0936012','ANALYSIS','Analysis','false'
'patients full analysis sety n','C1524024','analysis','analysis aspect','true'
'hba $nmbr$ c mmol mol mean sd','C3829066','mmol/mol','Millimole per Mole','false'
'hba $nmbr$ c mmol mol mean sd','C2699239','SD','SD, Rat Strain','false'
'time since diagnosis of diabetes mean sd','C0040223','TIME','Time','true'
'time since diagnosis of diabetes mean sd','C3541383','Time','Time (foundation metadata concept)','false'
'type of basal insulin n','C0457592','Insulin type','types of insulin','false'
'insulin glargine','C0907402','INSULIN GLARGINE','Insulin Glargine','true'
'insulin detemir','C0537270','INSULIN DETEMIR','insulin detemir','true'
'nph','C0020258','NPH','Hydrocephalus, Normal Pressure','true'
'nph','C0027442','Nph','Nasopharynx','true'
'concomitant oads n','C0521115','Concomitant','Simultaneous','false'
'pioglitazone only','C0071097','PIOGLITAZONE','pioglitazone','true'
'metformin pioglitazone','C1635037','METFORMIN/PIOGLITAZONE','Metformin / pioglitazone','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0392747','Change','Changing','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0443172','change','Changed status','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0332174','/week','Weekly','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0439230','Week','week','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0457592','Insulin type','types of insulin','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0001779','AGE','Age','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C2986798','Stage Analysis','Phase Analysis','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0020258','NPH','Hydrocephalus, Normal Pressure','true'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0332173','QD','Daily','false'
'figure $nmbr$ mean hba $nmbr$ c change from baseline at week $nmbr$ by type of basal insulin a by age b and by renal impairment stage c fas locf egfr estimated glomerular filtration rate fas full analysis set hba $nmbr$ c glycated hemoglobin locf last observation carried forward nph neutral protamine hagedorn qd once daily','C0027442','Nph','Nasopharynx','true'
'included in this study n $nmbr$','C0332257','included','Including (qualifier)','false'
'included in this study n $nmbr$','C0557651','Study','Room of building - Study','false'
'included in this study n $nmbr$','C2603343','Study','Study','false'
'patients with early cd n $nmbr$','C0030705','Patients','Patients','true'
'patients with early cd n $nmbr$','C0007928','CD','Chad','true'
'patients with early cd n $nmbr$','C0034283','CD','Pyrimethamine','true'
'patients with early cd n $nmbr$','C4552032','CD','With lunch','false'
'age year median','C0549183','Median','Midline (qualifier value)','false'
'age year median','C0876920','Median','Median Statistical Measurement','false'
'age year median','C2347635','Median','Population Median','false'
'age year median','C2348144','Median','Sample Median','false'
'age year median','C2939193','Median','Median (qualifier value)','false'
'disease duration year median','C0549183','Median','Midline (qualifier value)','false'
'disease duration year median','C0876920','Median','Median Statistical Measurement','false'
'disease duration year median','C2347635','Median','Population Median','false'
'disease duration year median','C2348144','Median','Sample Median','false'
'disease duration year median','C2939193','Median','Median (qualifier value)','false'
'crp median mg dl','C0549183','Median','Midline (qualifier value)','false'
'crp median mg dl','C0439269','mg dl','mg/dL','false'
'crp median mg dl','C0876920','Median','Median Statistical Measurement','false'
'crp median mg dl','C2347635','Median','Population Median','false'
'crp median mg dl','C2348144','Median','Sample Median','false'
'crp median mg dl','C2939193','Median','Median (qualifier value)','false'
'crp $nmbr$ $nmbr$ mg dl n','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp $nmbr$ $nmbr$ mg dl n','C0439269','mg dl','mg/dL','false'
'crp $nmbr$ $nmbr$ mg dl n','C4048285','CRP','C-Reactive Protein, human','false'
'cdai score mean s d','C0449820','SCORE','Score','false'
'cdai score mean s d','C0444504','Mean','Statistical mean','false'
'cdai score mean s d','C2347634','Mean','Population Mean','false'
'cdai score mean s d','C2348143','Mean','Sample Mean','false'
'cdai score mean s d','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'gastrointestinal area involved n total n','C0017446','Area','Geographic Locations','true'
'gastrointestinal area involved n total n','C0205146','AREA','Area','false'
'upper gastrointestinal tract','C3203348','Gastrointestinal tract, upper','Upper Gastrointestinal Tract','true'
'baseline crohn s disease medications','C0168634','baseline','BaseLine dental cement','true'
'baseline crohn s disease medications','C0010346','Crohn's','Crohn Disease','true'
'baseline crohn s disease medications','C1442488','Baseline','Baseline','false'
'baseline crohn s disease medications','C0013227','Medications','Pharmaceutical Preparations','true'
'baseline crohn s disease medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'baseline crohn s disease medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'baseline crohn s disease medications','C4284232','Medications','Medications','false'
'systemic corticosteroids n','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'budesonide n','C0054201','BUDESONIDE','Budesonide','true'
'$nmbr$ asa compounds n','C0004057','ASA','Aspirin','true'
'$nmbr$ asa compounds n','C3853627','ASA','Arylsulfatase A, human','false'
'history of bowel resections n','C0019664','History','History','true'
'history of bowel resections n','C0019665','history','Historical aspects qualifier','true'
'history of bowel resections n','C0262512','History, NOS','History of present illness','false'
'history of bowel resections n','C0262926','History','Medical History','false'
'history of bowel resections n','C1705255','History','Concept History','false'
'history of bowel resections n','C2004062','History','History of previous events','false'
'early crohn s disease','C1279919','Early','Early','false'
'early crohn s disease','C0010346','Crohn's','Crohn Disease','true'
'early crohn s disease','C0012634','Disease','Disease','true'
'non early crohn s disease','C1279919','Early','Early','false'
'non early crohn s disease','C0010346','Crohn's','Crohn Disease','true'
'non early crohn s disease','C0012634','Disease','Disease','true'
'remission component of variable','C0449432','Component','Component object','false'
'remission component of variable','C1705248','Component','Component (part)','false'
'azathioprine monotherapy','C0004482','AZATHIOPRINE','Azathioprine','true'
'infliximab monotherapy','C0666743','INFLIXIMAB','infliximab','true'
'infliximab combination therapy','C4076075','Infliximab therapy','Infliximab therapy','false'
'p valuer','C0369773','P NOS','P Blood group antibodies','false'
'p valuer','C0401806','Valuer','Valuer','false'
'p valuer','C2603361','P'','P prime','false'
'cr mh','C0026514','MH','Montserrat','true'
'cr mh','C2930980','MH','Malignant hyperthermia susceptibility type 1','true'
'cr crpnorr','C0201975','Cr','Creatinine measurement','false'
'cr crpnorr','C3539604','CR','CR2 wt Allele','false'
'cr crpnorr','C3711669','CR','CALB2 protein, human','true'
'cr crpnorr','C4084730','CR','CALB2 wt Allele','false'
'cr crpnorr','C4553336','CR','Lugano Lymphoma Response Classification Complete Remission by PET','false'
'cr crpnorr','C4553337','CR','Lugano Lymphoma Response Classification Complete Remission by CT','false'
'mh crpnorr','C0026514','MH','Montserrat','true'
'mh crpnorr','C2930980','MH','Malignant hyperthermia susceptibility type 1','true'
'cr mh crpnorr','C0201975','Cr','Creatinine measurement','false'
'cr mh crpnorr','C0026514','MH','Montserrat','true'
'cr mh crpnorr','C2930980','MH','Malignant hyperthermia susceptibility type 1','true'
'cr mh crpnorr','C3539604','CR','CR2 wt Allele','false'
'cr mh crpnorr','C3711669','CR','CALB2 protein, human','true'
'cr mh crpnorr','C4084730','CR','CALB2 wt Allele','false'
'cr mh crpnorr','C4553336','CR','Lugano Lymphoma Response Classification Complete Remission by PET','false'
'cr mh crpnorr','C4553337','CR','Lugano Lymphoma Response Classification Complete Remission by CT','false'
'[ $nmbr$ ci]','C0008107','CI','Chile','true'
'[ $nmbr$ ci]','C3259781','CI','Coagulation Index Measurement','false'
'a aza treatment ref','C0004482','AZA','Azathioprine','true'
'a aza treatment ref','C1425988','REF','ALYREF gene','false'
'ifx treatment','C0039798','treatment','therapeutic aspects','true'
'ifx treatment','C0087111','Treatment','Therapeutic procedure','true'
'ifx treatment','C1522326','Treatment','Treating','false'
'ifx treatment','C1533734','Treatment','Administration procedure','false'
'ifx treatment','C1705169','Treatment','Biomaterial Treatment','false'
'ifx treatment','C3538994','TREATMENT','Treatment Epoch','false'
'ifx treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'combination treatment ifx aza','C0020823','IFX','Ifosfamide','true'
'combination treatment ifx aza','C0004482','AZA','Azathioprine','true'
'previous cd related surgery ref a','C0007928','CD','Chad','true'
'previous cd related surgery ref a','C1425988','REF','ALYREF gene','false'
'previous cd related surgery ref a','C0034283','CD','Pyrimethamine','true'
'previous cd related surgery ref a','C4552032','CD','With lunch','false'
'no previous cd related surgery $nmbr$','C0038894','Surgery','Surgery specialty','false'
'no previous cd related surgery $nmbr$','C0038895','surgery','Surgical aspects','true'
'no previous cd related surgery $nmbr$','C0543467','Surgery','Operative Surgical Procedures','true'
'no previous cd related surgery $nmbr$','C1274039','Surgery','General surgery specialty','true'
'b aza treatment ref','C0004482','AZA','Azathioprine','true'
'b aza treatment ref','C1425988','REF','ALYREF gene','false'
'history of bowel resection ref','C0019664','History','History','true'
'history of bowel resection ref','C0019665','history','Historical aspects qualifier','true'
'history of bowel resection ref','C0262512','History, NOS','History of present illness','false'
'history of bowel resection ref','C0262926','History','Medical History','false'
'history of bowel resection ref','C1705255','History','Concept History','false'
'history of bowel resection ref','C2004062','History','History of previous events','false'
'no history of bowel resections','C0019664','History','History','true'
'no history of bowel resections','C0019665','history','Historical aspects qualifier','true'
'no history of bowel resections','C0262512','History, NOS','History of present illness','false'
'no history of bowel resections','C0262926','History','Medical History','false'
'no history of bowel resections','C1705255','History','Concept History','false'
'no history of bowel resections','C2004062','History','History of previous events','false'
'c kza treatment ref','C0039798','treatment','therapeutic aspects','true'
'c kza treatment ref','C1425988','REF','ALYREF gene','false'
'c kza treatment ref','C0087111','Treatment','Therapeutic procedure','true'
'c kza treatment ref','C1522326','Treatment','Treating','false'
'c kza treatment ref','C1533734','Treatment','Administration procedure','false'
'c kza treatment ref','C1705169','Treatment','Biomaterial Treatment','false'
'c kza treatment ref','C3538994','TREATMENT','Treatment Epoch','false'
'c kza treatment ref','C3887704','treatment','treatment - ActInformationManagementReason','false'
'no hospitalization in the past $nmbr$ months prior to baseline ref','C0019993','hospitalisation','Hospitalization','true'
'no hospitalization in the past $nmbr$ months prior to baseline ref','C0439231','MONTHS','month','false'
'no hospitalization in the past $nmbr$ months prior to baseline ref','C0168634','baseline','BaseLine dental cement','true'
'no hospitalization in the past $nmbr$ months prior to baseline ref','C1425988','REF','ALYREF gene','false'
'no hospitalization in the past $nmbr$ months prior to baseline ref','C1442488','Baseline','Baseline','false'
'hospitalization in the past $nmbr$ months prior to baseline','C0019993','hospitalisation','Hospitalization','true'
'hospitalization in the past $nmbr$ months prior to baseline','C0439231','MONTHS','month','false'
'hospitalization in the past $nmbr$ months prior to baseline','C0168634','baseline','BaseLine dental cement','true'
'hospitalization in the past $nmbr$ months prior to baseline','C1442488','Baseline','Baseline','false'
'no history of extra intestinal manifestations of ibd ref','C0019664','History','History','true'
'no history of extra intestinal manifestations of ibd ref','C0019665','history','Historical aspects qualifier','true'
'no history of extra intestinal manifestations of ibd ref','C0262512','History, NOS','History of present illness','false'
'no history of extra intestinal manifestations of ibd ref','C0262926','History','Medical History','false'
'no history of extra intestinal manifestations of ibd ref','C1705255','History','Concept History','false'
'no history of extra intestinal manifestations of ibd ref','C2004062','History','History of previous events','false'
'history of extra intestinal manifestations of ibd','C0019664','History','History','true'
'history of extra intestinal manifestations of ibd','C0019665','history','Historical aspects qualifier','true'
'history of extra intestinal manifestations of ibd','C0262512','History, NOS','History of present illness','false'
'history of extra intestinal manifestations of ibd','C0262926','History','Medical History','false'
'history of extra intestinal manifestations of ibd','C1705255','History','Concept History','false'
'history of extra intestinal manifestations of ibd','C2004062','History','History of previous events','false'
'd aza treatment ref','C0004482','AZA','Azathioprine','true'
'd aza treatment ref','C1425988','REF','ALYREF gene','false'
'no steroid use at baseline ref','C0281991','Steroid Use','steroid use','false'
'no steroid use at baseline ref','C0168634','baseline','BaseLine dental cement','true'
'no steroid use at baseline ref','C1442488','Baseline','Baseline','false'
'on steroid at baseline','C0038317','Steroid','Steroids','true'
'on steroid at baseline','C0168634','baseline','BaseLine dental cement','true'
'on steroid at baseline','C1442488','Baseline','Baseline','false'
'e aza treatment ref','C0004482','AZA','Azathioprine','true'
'e aza treatment ref','C1425988','REF','ALYREF gene','false'
'study $nmbr$','C0557651','Study','Room of building - Study','false'
'study $nmbr$','C2603343','Study','Study','false'
'placebo $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'reslizumab n $nmbr$','C1869620','RESLIZUMAB','reslizumab','true'
'median age years iqr','C0549183','Median','Midline (qualifier value)','false'
'median age years iqr','C1510829','Age-Years','Age-Years','false'
'median age years iqr','C0876920','Median','Median Statistical Measurement','false'
'median age years iqr','C2347635','Median','Population Median','false'
'median age years iqr','C2348144','Median','Sample Median','false'
'median age years iqr','C2939193','Median','Median (qualifier value)','false'
'mean body mass index kg mq','C0005893','Body mass index','Body mass index procedure','false'
'mean body mass index kg mq','C0024853','MQ','Martinique','true'
'mean body mass index kg mq','C0578022','Body Mass Index','Finding of body mass index','false'
'mean body mass index kg mq','C1305855','BODY MASS INDEX','Body mass index','true'
'$nmbr$ $nmbr$ $nmbr$ i','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ $nmbr$ i','C0221138','I NOS','Blood group antibody I','false'
'mean time since diagnosis years','C0556970','time year','times/year','false'
'mean time since diagnosis years','C0011900','DIAGNOSIS','Diagnosis','true'
'mean time since diagnosis years','C1704338','diagnosis','diagnosis aspect','true'
'mean time since diagnosis years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'mean ics use at enrolment pg','C0042153','use','utilization qualifier','true'
'mean ics use at enrolment pg','C0457083','Use','Usage','false'
'mean ics use at enrolment pg','C1947944','Use','Use - dosing instruction imperative','false'
'oral corticosteroid use at enrolmentt','C0239126','CORTICOSTEROID USE','corticosteroid use','false'
'laba use at enrolment','C0042153','use','utilization qualifier','true'
'laba use at enrolment','C0457083','Use','Usage','false'
'laba use at enrolment','C1947944','Use','Use - dosing instruction imperative','false'
'mean prebronchodilation l','C0444504','Mean','Statistical mean','false'
'mean prebronchodilation l','C2347634','Mean','Population Mean','false'
'mean prebronchodilation l','C2348143','Mean','Sample Mean','false'
'mean predicted value prebronchodilation','C0444504','Mean','Statistical mean','false'
'mean predicted value prebronchodilation','C0681842','Predicted','prediction','false'
'mean predicted value prebronchodilation','C1882327','%{Predicted}','Percent of Predicted Value','false'
'mean predicted value prebronchodilation','C2347634','Mean','Population Mean','false'
'mean predicted value prebronchodilation','C2348143','Mean','Sample Mean','false'
'mean reversibility','C0444504','Mean','Statistical mean','false'
'mean reversibility','C0449261','Reversibility','Reversibility','false'
'mean reversibility','C2347634','Mean','Population Mean','false'
'mean reversibility','C2348143','Mean','Sample Mean','false'
'mean aqlq total score t','C3533236','Mean score','Mean score','false'
'mean acq $nmbr$ scores','C3533236','Mean score','Mean score','false'
'mean acq $nmbr$ scores','C2919686','ACQ','Asthma control questionnaire','false'
'mean asui scored','C0444504','Mean','Statistical mean','false'
'mean asui scored','C2347634','Mean','Population Mean','false'
'mean asui scored','C2348143','Mean','Sample Mean','false'
'mean asui scored','C0449820','scored','Score','false'
'saba use in past $nmbr$ days','C0042153','use','utilization qualifier','true'
'saba use in past $nmbr$ days','C0457083','Use','Usage','false'
'saba use in past $nmbr$ days','C1947944','Use','Use - dosing instruction imperative','false'
'saba use in past $nmbr$ days','C0439228','DAYS','day','false'
'mean number of puffs per day','C0444504','Mean','Statistical mean','false'
'mean number of puffs per day','C0237753','*Number','Numbers','false'
'mean number of puffs per day','C0449788','Number','Count of entities','false'
'mean number of puffs per day','C2347634','Mean','Population Mean','false'
'mean number of puffs per day','C2348143','Mean','Sample Mean','false'
'mean number of puffs per day','C0332173','/day','Daily','false'
'mean number of puffs per day','C0439228','Day','day','false'
'mean number of puffs per day','C0439505','/day','per day','false'
'mean blood eosinophil count cells per pl','C0444504','Mean','Statistical mean','false'
'mean blood eosinophil count cells per pl','C0200638','Blood cell count, eosinophil','Eosinophil count procedure','false'
'mean blood eosinophil count cells per pl','C2347634','Mean','Population Mean','false'
'mean blood eosinophil count cells per pl','C2348143','Mean','Sample Mean','false'
'mean number of caes in past $nmbr$ months number per patient ]','C0444504','Mean','Statistical mean','false'
'mean number of caes in past $nmbr$ months number per patient ]','C0237753','*Number','Numbers','false'
'mean number of caes in past $nmbr$ months number per patient ]','C0449788','Number','Count of entities','false'
'mean number of caes in past $nmbr$ months number per patient ]','C2347634','Mean','Population Mean','false'
'mean number of caes in past $nmbr$ months number per patient ]','C2348143','Mean','Sample Mean','false'
'mean number of caes in past $nmbr$ months number per patient ]','C0439231','MONTHS','month','false'
'mean number of caes in past $nmbr$ months number per patient ]','C0030705','*^patient','Patients','true'
'reslizumab','C1869620','RESLIZUMAB','reslizumab','true'
'place','C0442504','Place','Place','false'
'place','C1533810','Place','Placement action','false'
'place','C1704765','Place','Place - dosing instruction imperative','false'
'place','C1882509','Place','put - instruction imperative','false'
'rate ratio $nmbr$ cl','C0456603','RATIO','Ratio','false'
'rate ratio $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'rate ratio $nmbr$ cl','C1547037','Ratio','data type - ratio','false'
'ocs at baseline','C0168634','baseline','BaseLine dental cement','true'
'ocs at baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ $nmbr$ o $nmbr$ o $nmbr$','C0483204','O NOS','O NOS Ab','false'
'ics plus laba','C0815320','ICS','Impaired Control Scale','false'
'ics plus laba','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics no laba','C0815320','ICS','Impaired Control Scale','false'
'ics no laba','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'age s $nmbr$ years n $nmbr$ $nmbr$','C1510829','Age-Years','Age-Years','false'
'baseline tg level n $nmbr$ $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline tg level n $nmbr$ $nmbr$','C0337445','TG','Thyroglobulin measurement','false'
'baseline tg level n $nmbr$ $nmbr$','C1442488','Baseline','Baseline','false'
'baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'baseline tg level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'statin only n $nmbr$ $nmbr$','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statin only n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'statin only n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'statin ezetimibe n $nmbr$ $nmbr$','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statin ezetimibe n $nmbr$ $nmbr$','C1142985','EZETIMIBE','ezetimibe','true'
'other n $nmbr$ $nmbr$ ]','C0369718','N NOS','N not otherwise specified Antibody','false'
'other n $nmbr$ $nmbr$ ]','C0441922','N+','N+ (tumor staging)','false'
'simvastatin n $nmbr$ $nmbr$','C0074554','SIMVASTATIN','Simvastatin','true'
'atorvastatin n $nmbr$ $nmbr$','C0286651','ATORVASTATIN','atorvastatin','true'
'rosuvastatin n $nmbr$ $nmbr$','C0965129','ROSUVASTATIN','rosuvastatin','true'
'diabetics yes n $nmbr$ $nmbr$','C0241863','diabetics','diabetic','false'
'diabetics yes n $nmbr$ $nmbr$','C1549445','Yes','Yes - Yes/no indicator','false'
'diabetics yes n $nmbr$ $nmbr$','C1705108','YES','Yes (indicator)','false'
'diabetics yes n $nmbr$ $nmbr$','C1710701','Yes','YES1 wt Allele','false'
'diabetics no n $nmbr$ $nmbr$','C0241863','diabetics','diabetic','false'
'diabetics no n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'diabetics no n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'baseline ldlc level n $nmbr$ $nmbr$ ^ $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C0168634','baseline','BaseLine dental cement','true'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C0441889','Level','Levels (qualifier value)','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C0456079','Level','Disease classification level','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C1547707','Level','Floor - story of building','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C2946261','Level','Level','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mgzdl','C1442488','Baseline','Baseline','false'
'baseline hdl c level n s $nmbr$ $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline hdl c level n s $nmbr$ $nmbr$','C0441889','Level','Levels (qualifier value)','false'
'baseline hdl c level n s $nmbr$ $nmbr$','C0456079','Level','Disease classification level','false'
'baseline hdl c level n s $nmbr$ $nmbr$','C1547707','Level','Floor - story of building','false'
'baseline hdl c level n s $nmbr$ $nmbr$','C2946261','Level','Level','false'
'baseline hdl c level n s $nmbr$ $nmbr$','C1442488','Baseline','Baseline','false'
'baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'baseline hdl c level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0337445','TG','Thyroglobulin measurement','false'
'baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline tg level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'other n $nmbr$ $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'other n $nmbr$ $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0441889','Level','Levels (qualifier value)','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0456079','Level','Disease classification level','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C1547707','Level','Floor - story of building','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C2946261','Level','Level','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline ldlc level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'baseline ldlc level n $nmbr$ $nmbr$ $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0441889','Level','Levels (qualifier value)','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0456079','Level','Disease classification level','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C1547707','Level','Floor - story of building','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C2946261','Level','Level','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C1442488','Baseline','Baseline','false'
'baseline hdl c level n $nmbr$ $nmbr$ s $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'history of heart failure at baseline','C0455531','History of - heart failure','H/O: heart failure','false'
'history of heart failure at baseline','C0168634','baseline','BaseLine dental cement','true'
'history of heart failure at baseline','C1442488','Baseline','Baseline','false'
'no history of heart failure at baseline','C0455531','History of - heart failure','H/O: heart failure','false'
'no history of heart failure at baseline','C0168634','baseline','BaseLine dental cement','true'
'no history of heart failure at baseline','C1442488','Baseline','Baseline','false'
'baseline hba $nmbr$ c concentration','C0086045','Concentration','Mental concentration','true'
'baseline hba $nmbr$ c concentration','C1446561','Concentration','Concentration measurement','false'
'baseline hba $nmbr$ c concentration','C3827302','Concentration','Able to Concentrate Question','false'
'bodyweight kg','C0022718','KG','Kyrgyzstan','true'
'bodyweight kg','C0439209','kg','Kilogram','false'
'bodyweight kg','C4054209','/kg','Per Kilogram','false'
'cardiovascular risk factors and history','C0850624','cardiovascular risk factor','cardiovascular risk factor','false'
'cardiovascular risk factors and history','C0019664','History','History','true'
'cardiovascular risk factors and history','C0019665','history','Historical aspects qualifier','true'
'cardiovascular risk factors and history','C0262512','History, NOS','History of present illness','false'
'cardiovascular risk factors and history','C0262926','History','Medical History','false'
'cardiovascular risk factors and history','C1705255','History','Concept History','false'
'cardiovascular risk factors and history','C2004062','History','History of previous events','false'
'egfr ml min per $nmbr$ ^ $nmbr$ m','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min per $nmbr$ ^ $nmbr$ m','C0439445','mL/min','mL/min','false'
'egfr ml min per $nmbr$ ^ $nmbr$ m','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min per $nmbr$ ^ $nmbr$ m','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m','C0439445','mL/min','mL/min','false'
'egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ ml min per $nmbr$ ^ $nmbr$ m','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'index acs event','C0441471','Event','Event','false'
'index acs event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'time from index acs event to randomisation days','C0040223','TIME','Time','true'
'time from index acs event to randomisation days','C3541383','Time','Time (foundation metadata concept)','false'
'time from index acs event to randomisation days','C0034656','Randomization','Randomization','true'
'time from index acs event to randomisation days','C0439228','DAYS','day','false'
'nyha chf class','C1882083','NYHA Class','New York Heart Association Class','false'
'nyha chf class','C0018802','CHF','Congestive heart failure','true'
'baseline bnp concentration pg ml','C0054015','BNP','Nesiritide','true'
'baseline bnp concentration pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'baseline bnp concentration pg ml','C1095989','BNP','Brain natriuretic peptide measurement','false'
'baseline bnp concentration pg ml','C1417808','BNP','NPPB gene','false'
'baseline bnp concentration pg ml','C2982014','BNP','NPPB wt Allele','false'
'baseline concomitant cardiovascular medications','C0168634','baseline','BaseLine dental cement','true'
'baseline concomitant cardiovascular medications','C0007220','CARDIOVASCULAR MEDICATIONS','Cardiovascular Agents','true'
'baseline concomitant cardiovascular medications','C1442488','Baseline','Baseline','false'
'ace inhibitor arb or both','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor arb or both','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'ace inhibitor arb or both','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'thiazide diuretics','C0012802','Diuretics, Thiazide','Thiazide Diuretics','true'
'loop diuretics','C0354100','Diuretics, Loop','Loop Diuretics','true'
'mras','C1335594','MRAS','MRAS protein, human','true'
'mras','C1367476','MRAS','MRAS gene','false'
'primary mace endpoint','C2986535','Primary Endpoint','Primary Endpoint','false'
'primary mace endpoint','C0349381','MACE','Mace Spice','false'
'primary mace endpoint','C0949745','mace','Myristica fragrans','true'
'primary mace endpoint','C1445339','MACE','Mace extract','false'
'non fatal myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'non fatal myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'non fatal myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'non fatal myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'non fatal myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'non fatal stroke','C0038454','STROKE','Cerebrovascular accident','true'
'non fatal stroke','C4554100','Stroke','Stroke, CTCAE','false'
'$nmbr$ $nmbr$ s $nmbr$ $nmbr$ t','C2603360','T'','T prime','false'
'pinteraction for treatment and history of heart failure','C0039798','treatment','therapeutic aspects','true'
'pinteraction for treatment and history of heart failure','C0087111','Treatment','Therapeutic procedure','true'
'pinteraction for treatment and history of heart failure','C1522326','Treatment','Treating','false'
'pinteraction for treatment and history of heart failure','C1533734','Treatment','Administration procedure','false'
'pinteraction for treatment and history of heart failure','C1705169','Treatment','Biomaterial Treatment','false'
'pinteraction for treatment and history of heart failure','C3538994','TREATMENT','Treatment Epoch','false'
'pinteraction for treatment and history of heart failure','C3887704','treatment','treatment - ActInformationManagementReason','false'
'pinteraction for treatment and history of heart failure','C0455531','History of - heart failure','H/O: heart failure','false'
'secondary mace endpoint','C4528314','Secondary Endpoint','Secondary Endpoint','false'
'secondary mace endpoint','C0349381','MACE','Mace Spice','false'
'secondary mace endpoint','C0949745','mace','Myristica fragrans','true'
'secondary mace endpoint','C1445339','MACE','Mace extract','false'
'urgent revascularisation due to unstable angina','C0581603','Revascularization','Revascularization - action','false'
'urgent revascularisation due to unstable angina','C0002965','Angina, Unstable','Angina, Unstable','true'
'cardiovascular death and hospital admission for heart failure','C0011065','DEATH','Cessation of life','true'
'cardiovascular death and hospital admission for heart failure','C1306577','Death','Death (finding)','false'
'cardiovascular death and hospital admission for heart failure','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cardiovascular death and hospital admission for heart failure','C4552775','Death NOS','Death NOS, CTCAE','false'
'cardiovascular death and hospital admission for heart failure','C0184666','Hospital Admission','Hospital admission','false'
'cardiovascular death and hospital admission for heart failure','C0018801','Failure, Heart','Heart failure','true'
'cardiovascular death and hospital admission for heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'cardiovascular death and hospital admission for heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'hospital admission for heart failure','C0184666','Hospital Admission','Hospital admission','false'
'hospital admission for heart failure','C0018801','Failure, Heart','Heart failure','true'
'hospital admission for heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'hospital admission for heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'normal responder n $nmbr$','C0205307','NORMAL','Normal','false'
'normal responder n $nmbr$','C0231683','Normal','Gait normal','false'
'normal responder n $nmbr$','C0439166','% normal','Percent normal','false'
'normal responder n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'normal responder n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'sensitive responder n $nmbr$','C0020517','Sensitive','Hypersensitivity','true'
'sensitive responder n $nmbr$','C0332324','Sensitive','Sensitive','false'
'sensitive responder n $nmbr$','C1522640','Sensitive','stimulus sensitivity','false'
'highly sensitive responder n $nmbr$','C0439822','Highly sensitive','Highly sensitive','false'
'median age [interquartile range] yr','C0549183','Median','Midline (qualifier value)','false'
'median age [interquartile range] yr','C0001779','AGE','Age','false'
'median age [interquartile range] yr','C0876920','Median','Median Statistical Measurement','false'
'median age [interquartile range] yr','C2347635','Median','Population Median','false'
'median age [interquartile range] yr','C2348144','Median','Sample Median','false'
'median age [interquartile range] yr','C2939193','Median','Median (qualifier value)','false'
'median age [interquartile range] yr','C1711350','Interquartile Range','Interquartile Range','false'
'median age [interquartile range] yr','C0439234','yr','year','false'
'atrial fibrillation no','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation no','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation no','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'qualifying risk factors no','C1514624','Qualifying','Qualifying','false'
'qualifying risk factors no','C0035648','Risk Factors','risk factors','true'
'qualifying risk factors no','C1553898','risk factors','risk factors - observation list','false'
'chads $nmbr$ score mean sd','C0444504','Mean','Statistical mean','false'
'chads $nmbr$ score mean sd','C2699239','SD','SD, Rat Strain','false'
'chads $nmbr$ score mean sd','C2347634','Mean','Population Mean','false'
'chads $nmbr$ score mean sd','C2348143','Mean','Sample Mean','false'
'previous exposure to a vitamin k antagonist no current or former never','C0332157','Exposure to','Exposure to','false'
'previous exposure to a vitamin k antagonist no current or former never','C1096489','vitamin k antagonist','Treatment with Vitamin K antagonist','false'
'previous exposure to a vitamin k antagonist no current or former never','C2267235','Vitamin K Antagonist','Vitamin K Antagonist [EPC]','false'
'previous exposure to a vitamin k antagonist no current or former never','C0521116','CURRENT','Current (present time)','false'
'previous exposure to a vitamin k antagonist no current or former never','C1705970','Current','Electrical Current','false'
'previous exposure to a vitamin k antagonist no current or former never','C0205156','FORMER','Previous','false'
'previous exposure to a vitamin k antagonist no current or former never','C0750523','FORMER','FORMER','false'
'medications at time of randomization no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications at time of randomization no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications at time of randomization no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications at time of randomization no','C4284232','Medications','Medications','false'
'digoxin or digitalis preparations','C0012265','DIGOXIN','Digoxin','true'
'digoxin or digitalis preparations','C0304520','digitalis preparations','Digitalis preparation','false'
'asia pacific and south africa','C0003980','Asia','Asia','true'
'asia pacific and south africa','C0037712','SOUTH AFRICA','South Africa','true'
'edoxaban higher dose vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'edoxaban higher dose vs warfarin','C0444956','High dose','High dose','false'
'edoxaban higher dose vs warfarin','C0043031','WARFARIN','Warfarin','true'
'edoxaban lower dose vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'edoxaban lower dose vs warfarin','C0445550','Low dose','Low dose','false'
'edoxaban lower dose vs warfarin','C1708745','Low-Dose','Low-Dose Treatment','false'
'edoxaban lower dose vs warfarin','C0043031','WARFARIN','Warfarin','true'
'higher dose','C0444956','High dose','High dose','false'
'lower dose','C0445550','Low dose','Low dose','false'
'lower dose','C1708745','Low-Dose','Low-Dose Treatment','false'
'any overt bleed','C0019080','bleed','Hemorrhage','true'
'normal responder','C0205307','NORMAL','Normal','false'
'normal responder','C0231683','Normal','Gait normal','false'
'normal responder','C0439166','% normal','Percent normal','false'
'normal responder','C2347086','% Normal','Mean Percent of Normal','false'
'normal responder','C4553972','Normal','How Often Felt Normal question','false'
'sensitive','C0020517','Sensitive','Hypersensitivity','true'
'sensitive','C0332324','Sensitive','Sensitive','false'
'sensitive','C1522640','Sensitive','stimulus sensitivity','false'
'highly sensitive','C0439822','Highly sensitive','Highly sensitive','false'
'major or clinically relevant non major bleed','C0205082','Major','Severe (severity modifier)','false'
'major or clinically relevant non major bleed','C0205164','Major','Major','false'
'major or clinically relevant non major bleed','C4318856','Major','Major <insect>','false'
'major or clinically relevant non major bleed','C4521762','Major','United States Military Commissioned Officer O4','false'
'major or clinically relevant non major bleed','C0019080','bleed','Hemorrhage','true'
'clinically relevant non','C2347946','Relevant','Relevance','false'
'clinically relevant non','C1518422','Non','Negation','false'
'background therapy','C0039798','therapy','therapeutic aspects','true'
'background therapy','C0087111','Therapy','Therapeutic procedure','true'
'background therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'su','C0038642','SU','Sudan','true'
'su','C1705534','SU','Substance Use Domain','false'
'biguanide','C0005382','biguanide','Biguanides','true'
'biguanide','C3537187','Biguanide','Biguanide [EPC]','false'
'biguanide','C4317165','Biguanide','biguanide','false'
'agi','C1299007','AGI','alpha-Glucosidase Inhibitors','true'
'dpp $nmbr$ inhibitor','C1414174','DPP','DSPP gene','false'
'dpp $nmbr$ inhibitor','C1999216','Inhibitor','Inhibitor','false'
'glinide','C2266929','Glinide','Glinide [EPC]','false'
'study drug','C0013175','study drug','Drug Evaluation','true'
'empagliflozin','C3490348','EMPAGLIFLOZIN','empagliflozin','true'
'metformin open label','C0025598','METFORMIN','Metformin','true'
'metformin open label','C1709323','OPEN LABEL','Open Label Study','false'
'time since diagnosis of t $nmbr$ dm','C0040223','TIME','Time','true'
'time since diagnosis of t $nmbr$ dm','C3541383','Time','Time (foundation metadata concept)','false'
'$nmbr$ year','C0439234','Year','year','false'
'$nmbr$ year','C0439508','/Year','per year','false'
'$nmbr$ to $nmbr$ years','C0439234','YEARS','year','false'
'systolic blood pressure mmhg','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic blood pressure mmhg','C0439475','mmHG','mmHg','false'
'systolic blood pressure mmhg','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'systolic blood pressure mmhg','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'diastolic blood pressure mmhg','C0428883','Diastolic Blood Pressure','Diastolic blood pressure','true'
'diastolic blood pressure mmhg','C0439475','mmHG','mmHg','false'
'diastolic blood pressure mmhg','C1305849','diastolic blood pressure','Diastolic blood pressure measurement','false'
'figure must be in supplement is not in paper','C0242295','Supplement','Dietary Supplements','true'
'figure must be in supplement is not in paper','C1947943','Supplement','Supplement (document)','false'
'figure must be in supplement is not in paper','C2348609','Supplement','Supplement','false'
'figure must be in supplement is not in paper','C1518422','Not','Negation','false'
'figure must be in supplement is not in paper','C0030351','Paper','Paper','true'
'figure must be in supplement is not in paper','C1547566','Paper','Paper Authorization','false'
'heparin alone n $nmbr$','C0019134','HEPARIN','heparin','true'
'heparin alone n $nmbr$','C0205171','Alone','Singular','false'
'heparin alone n $nmbr$','C0439044','Alone','Living Alone','false'
'heparin alone n $nmbr$','C0679994','alone','alone - group size','false'
'heparin alone n $nmbr$','C0770546','HEPARIN','heparin, porcine','false'
'heparin plus tirofiban n $nmbr$','C0019134','HEPARIN','heparin','true'
'heparin plus tirofiban n $nmbr$','C0770546','HEPARIN','heparin, porcine','false'
'type of ml no','C0332307','TYPE','Type - attribute','false'
'type of ml no','C1547052','*Type','*Type - Kind of quantity','false'
'symptom onset to hospital arrival median iqr h','C4086878','SYMPTOM ONSET','Symptom Onset','false'
'symptom onset to hospital arrival median iqr h','C0019994','HOSPITAL','Hospitals','true'
'symptom onset to hospital arrival median iqr h','C1510665','Hospital','Hospital environment','false'
'killip class $nmbr$ no','C1881332','Killip Class','Killip Class','false'
'anemia no total','C0002871','ANEMIA','Anemia','true'
'anemia no total','C1000483','Anemia','Genus Anemia','false'
'anemia no total','C4554633','Anemia','Anemia, CTCAE','false'
'anemia no total','C0439175','% total','% of total','false'
'anemia no total','C0439810','Total','Total','false'
'crusade bleeding score mean sd ^','C0019080','BLEEDING','Hemorrhage','true'
'crusade bleeding score mean sd ^','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ moderate or high bleeding risk no total','C0205081','Moderate','Moderate (severity modifier)','false'
'$nmbr$ moderate or high bleeding risk no total','C1881878','Moderate','Moderation','false'
'$nmbr$ moderate or high bleeding risk no total','C4049705','Moderate','Moderate Extremity Pain','false'
'$nmbr$ moderate or high bleeding risk no total','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'$nmbr$ moderate or high bleeding risk no total','C4085643','Moderate','Moderate Response','false'
'$nmbr$ moderate or high bleeding risk no total','C4321335','Moderate','Moderate Level','false'
'$nmbr$ moderate or high bleeding risk no total','C0332167','HIGH RISK','High risk of','false'
'$nmbr$ moderate or high bleeding risk no total','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'$nmbr$ moderate or high bleeding risk no total','C4050568','High Risk','High Risk Acute Leukemia','false'
'$nmbr$ moderate or high bleeding risk no total','C4319571','High risk','High risk','false'
'$nmbr$ moderate or high bleeding risk no total','C0439175','% total','% of total','false'
'$nmbr$ moderate or high bleeding risk no total','C0439810','Total','Total','false'
'heparin tirofiban n $nmbr$','C0019134','HEPARIN','heparin','true'
'heparin tirofiban n $nmbr$','C0247025','TIROFIBAN','tirofiban','true'
'heparin tirofiban n $nmbr$','C0770546','HEPARIN','heparin, porcine','false'
'relative risk $nmbr$ ci','C0008107','CI','Chile','true'
'relative risk $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'no of events total no $nmbr$','C0439175','% total','% of total','false'
'no of events total no $nmbr$','C0439810','Total','Total','false'
'$nmbr$ years old','C0439234','YEARS','year','false'
'$nmbr$ years old','C0580836','Old','Old','false'
'class ll iv','C0456387','Class','Class','false'
'class ll iv','C1518526','class','Object Class','false'
'class ll iv','C1705943','Class','Class (taxonomic)','false'
'class ll iv','C0022326','IV','Ivory Coast','true'
'class ll iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'arterial access','C0444454','Access','Access','false'
'arterial access','C1554204','access','Role Class - access','false'
'previous cv events','C0441471','Events','Event','false'
'previous cv events','C3541888','EVENTS','CDISC Events Class','false'
'crusade score','C0449820','SCORE','Score','false'
'crusade score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'target vessel','C0449618','Target vessel','Target vessel','false'
'lad artery','C0003842','ARTERY','Arteries','true'
'lad artery','C0226004','artery','Arterial system','false'
'non lad artery','C0003842','ARTERY','Arteries','true'
'non lad artery','C0226004','artery','Arterial system','false'
'no of events total no','C0439175','% total','% of total','false'
'no of events total no','C0439810','Total','Total','false'
'ciass ll iv','C0022326','IV','Ivory Coast','true'
'ciass ll iv','C4265176','IV #','IV number:ID:Pt:^Patient:Nom','false'
'ciass i','C0021966','I-','Iodides','true'
'ciass i','C0221138','I NOS','Blood group antibody I','false'
'creatinine ciearance','C0010294','CREATININE','Creatinine','true'
'creatinine ciearance','C1561535','Creatinine','Creatinine, CTCAE','false'
'$nmbr$ mi min','C0702093','/min','Per Minute','false'
'$nmbr$ mi min','C1524029','MIN NOS','Mouse MIN NOS','false'
'$nmbr$ mi min','C3813700','%/min','Percent per Minute','false'
'arteriai access','C0444454','Access','Access','false'
'arteriai access','C1554204','access','Role Class - access','false'
'no of events totol no','C0441471','Events','Event','false'
'no of events totol no','C3541888','EVENTS','CDISC Events Class','false'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C0024671','MG','Mammography','true'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C0026410','MG','Mongolia','true'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C0439269','mg%','mg/dL','false'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C1960952','mg %','Milligram percent','false'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C2346927','Mg++','Magnesium Cation','false'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C4321396','MG','MG','false'
'placebo golimumab $nmbr$ mg $nmbr$ mga b','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg $nmbr$ mgc','C0024671','MG','Mammography','true'
'$nmbr$ mg $nmbr$ mgc','C3888239','MGC','HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1','false'
'$nmbr$ mg $nmbr$ mgc','C0026410','MG','Mongolia','true'
'$nmbr$ mg $nmbr$ mgc','C0439269','mg%','mg/dL','false'
'$nmbr$ mg $nmbr$ mgc','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg $nmbr$ mgc','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg $nmbr$ mgc','C4321396','MG','MG','false'
'$nmbr$ mg $nmbr$ mgc','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg $nmbr$ mgb','C0024671','MG','Mammography','true'
'$nmbr$ mg $nmbr$ mgb','C0373680','MGB','Myoglobin measurement','false'
'$nmbr$ mg $nmbr$ mgb','C0026410','MG','Mongolia','true'
'$nmbr$ mg $nmbr$ mgb','C0439269','mg%','mg/dL','false'
'$nmbr$ mg $nmbr$ mgb','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg $nmbr$ mgb','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg $nmbr$ mgb','C4321396','MG','MG','false'
'$nmbr$ mg $nmbr$ mgb','C4521761','MG','United States Military Commissioned Officer O8','false'
'randomized patients','C0034656','Randomized','Randomization','true'
'randomized patients','C0030705','Patients','Patients','true'
'randomized patients','C3815594','RANDOMIZED','Subject is Randomized','false'
'psa modified shs $nmbr$ $nmbr$','C3810537','PSA','PSAT1 wt Allele','false'
'psa modified shs $nmbr$ $nmbr$','C0392747','Modified','Changing','false'
'psa modified shs $nmbr$ $nmbr$','C3889737','Modified','Data Change Date','false'
'psa modified shs $nmbr$ $nmbr$','C3813209','PSA','PROS1 wt Allele','false'
'ptga $nmbr$ $nmbr$ cm vas','C0042815','VAS','Visual Analog Pain Scale','true'
'ptga $nmbr$ $nmbr$ cm vas','C3536884','VAS','Visual Analog Scale','true'
'ptga $nmbr$ $nmbr$ cm vas','C3827561','VAS','Vibroacoustic Stimulation','false'
'pasi score $nmbr$ $nmbr$ d','C0449820','SCORE','Score','false'
'pasi score $nmbr$ $nmbr$ d','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'methotrexate use at baseline','C0042153','use','utilization qualifier','true'
'methotrexate use at baseline','C0457083','Use','Usage','false'
'methotrexate use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C0024671','MG','Mammography','true'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C0026410','MG','Mongolia','true'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C0439269','mg%','mg/dL','false'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C1960952','mg %','Milligram percent','false'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C2346927','Mg++','Magnesium Cation','false'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C4321396','MG','MG','false'
'placebofigolimumab $nmbr$ mg $nmbr$ mgt','C4521761','MG','United States Military Commissioned Officer O8','false'
'golimumab $nmbr$ mg $nmbr$ mgt','C0024671','MG','Mammography','true'
'golimumab $nmbr$ mg $nmbr$ mgt','C0026410','MG','Mongolia','true'
'golimumab $nmbr$ mg $nmbr$ mgt','C0439269','mg%','mg/dL','false'
'golimumab $nmbr$ mg $nmbr$ mgt','C1960952','mg %','Milligram percent','false'
'golimumab $nmbr$ mg $nmbr$ mgt','C2346927','Mg++','Magnesium Cation','false'
'golimumab $nmbr$ mg $nmbr$ mgt','C4321396','MG','MG','false'
'golimumab $nmbr$ mg $nmbr$ mgt','C4521761','MG','United States Military Commissioned Officer O8','false'
'mtx use at baseline','C0042153','use','utilization qualifier','true'
'mtx use at baseline','C0457083','Use','Usage','false'
'mtx use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'no mtx use at baseline','C0042153','use','utilization qualifier','true'
'no mtx use at baseline','C0457083','Use','Usage','false'
'no mtx use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'no patients with','C0030705','Patients','Patients','true'
'available data','C1511726','Data','Data','false'
'available data','C3245479','data','Data call receiving device','false'
'available data','C3714741','Data','Data (eukaryote)','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C0021149','Incidence','Incidence','true'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C0220856','incidence','incidence of cases','true'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C0446516','ARM','Upper arm','true'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C3715044','ARM','AKR1A1 wt Allele','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C4553528','arm','Sequence Arm','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C0441833','Panel','Groups','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C1706365','Panel','Device Panel','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C1999270','Panel','Laboratory Order Panels','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C0155626','Acute Myocardial Infarction','Acute myocardial infarction','false'
'figure $nmbr$ cumulative incidence of stent thrombosis according to randomization arm for patients with panel a and without panel b acute myocardial infarction','C3541950','Acute Myocardial Infarction','Acute Myocardial Infarction by ECG Finding','false'
'mitt population n $nmbr$','C0032659','Population','geographic population','true'
'mitt population n $nmbr$','C1257890','Population','Population Group','true'
'bmi $nmbr$ kg m $nmbr$ population n $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi $nmbr$ kg m $nmbr$ population n $nmbr$','C0439209','kg','Kilogram','false'
'bmi $nmbr$ kg m $nmbr$ population n $nmbr$','C4054209','/kg','Per Kilogram','false'
'bmi $nmbr$ kg m $nmbr$ population n $nmbr$','C0032659','Population','geographic population','true'
'bmi $nmbr$ kg m $nmbr$ population n $nmbr$','C1257890','Population','Population Group','true'
'race ethnicity no','C0015031','Ethnicity','Ethnic group','true'
'race ethnicity no','C0243103','ethnicity','Ethnicity aspects','true'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C0024671','MG','Mammography','true'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C0026410','MG','Mongolia','true'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C0439269','mg%','mg/dL','false'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C4321396','MG','MG','false'
'canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl','C0967300','MM-LDL','minimally modified oxidized-LDL','true'
'hba $nmbr$ c $nmbr$ $nmbr$ bp $nmbr$ $nmbr$ mm hg ldl c $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'insulin lispro mix $nmbr$','C0205430','Mix','Mixed (qualifier value)','false'
'insulin lispro mix $nmbr$','C1421951','MIX','MIXL1 gene','false'
'insulin lispro mix $nmbr$','C1720722','Mix','Mix','false'
'insulin lispro mix $nmbr$','C4553942','Mix','Mix (transformation)','false'
'caucasians n $nmbr$','C0007457','Caucasians','Caucasoid Race','true'
'caucasians n $nmbr$','C0043157','CAUCASIANS','Caucasians','true'
'asians n $nmbr$','C0078988','Asians','Asians','true'
'mg dl fpg mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0871261','responses','Response process','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0168634','baseline','BaseLine dental cement','true'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C1442488','Baseline','Baseline','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C2349179','End Point','End Point','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0205430','Mix','Mixed (qualifier value)','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C1421951','MIX','MIXL1 gene','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C1720722','Mix','Mix','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C4553942','Mix','Mix (transformation)','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0019016','HBA','Hemoglobin A','true'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C2828255','Quartile','Quartile','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C1825777','HBA','KRT90P gene','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C3538758','HBA','SCN2A wt Allele','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0015663','FASTING','Fasting','true'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0020456','HYPERGLYCEMIA','Hyperglycemia','true'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C0376690','Area under the curve','Area Under Curve','true'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C4552833','Hyperglycemia','Hyperglycemia, CTCAE','false'
'fig $nmbr$ responses at baseline and endpoint to insulin glargine and insulin lispro mix $nmbr$ by baseline hba $nmbr$ c quartiles a fasting hyperglycaemia fhg area under the curve auc and b postprandial hyperglycaemia phg auc','C1855520','Hyperglycemia, Postprandial','Hyperglycemia, Postprandial','true'
'ranolazine n $nmbr$ $nmbr$','C0073633','RANOLAZINE','ranolazine','true'
'age years mean $nmbr$ sd','C1510829','Age-Years','Age-Years','false'
'age years mean $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'not reported','C0684224','Reported','Report (document)','true'
'not reported','C0700287','Reported','Reporting','false'
'not reported','C4319718','Reported','Reported','false'
'weight kg mean $nmbr$ sd','C0005910','Weight','Body Weight','true'
'weight kg mean $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'weight kg mean $nmbr$ sd','C0043100','Weight','Weight','true'
'weight kg mean $nmbr$ sd','C1305866','weight','Weighing patient','false'
'weight kg mean $nmbr$ sd','C1705104','Weight','Importance Weight','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ mean $nmbr$ sd','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C0444504','Mean','Statistical mean','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C2347634','Mean','Population Mean','false'
'bmi kg m $nmbr$ mean $nmbr$ sd','C2348143','Mean','Sample Mean','false'
'hba $nmbr$ c mean $nmbr$ sd','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c mean $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c mean $nmbr$ sd','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c mean $nmbr$ sd','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c mmol mol mean','C0444504','Mean','Statistical mean','false'
'hba $nmbr$ c mmol mol mean','C2347634','Mean','Population Mean','false'
'hba $nmbr$ c mmol mol mean','C2348143','Mean','Sample Mean','false'
'fsg mg dl mean sd','C0439269','mg dl','mg/dL','false'
'fsg mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'diabetes duration years mean sd','C0011847','Diabetes','Diabetes','false'
'diabetes duration years mean sd','C2699239','SD','SD, Rat Strain','false'
'diabetes duration years mean sd','C0011849','Diabetes','Diabetes Mellitus','true'
'took prior antihyperglycemic agent any','C1515187','Take','Take','false'
'took prior antihyperglycemic agent any','C0450442','Agent','Agent','false'
'took prior antihyperglycemic agent any','C1254351','Agent','Pharmacologic Substance','false'
'took prior antihyperglycemic agent any','C1521826','Agent','Protocol Agent','false'
'sulfonylureas','C0038766','SULFONYLUREAS','Sulfonylurea Compounds','true'
'sulfonylureas','C3653359','Sulfonylureas','Sulfonylureas for blood glucose lowering','false'
'concomitant lipid lowering therapy any','C0585943','Lipid-lowering therapy','Lipid-lowering therapy','false'
'fibrates','C1449704','Fibrates','Fibrates','true'
'fibrates','C3540783','Fibrates','Fibrates, lipid modifying drugs, plain','false'
'niacin','C0027996','NIACIN','Niacin','true'
'niacin','C1142562','Niacin','Vitamin B3 Assay','false'
'asteria i ii','C1710602','II','VIPR1 wt Allele','false'
'asteria i ii','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'placebo n [ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo n [ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo n [ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'omalizumab $nmbr$ mg n [ $nmbr$','C0024671','MG','Mammography','true'
'omalizumab $nmbr$ mg n [ $nmbr$','C0026410','MG','Mongolia','true'
'omalizumab $nmbr$ mg n [ $nmbr$','C0439269','mg%','mg/dL','false'
'omalizumab $nmbr$ mg n [ $nmbr$','C1960952','mg %','Milligram percent','false'
'omalizumab $nmbr$ mg n [ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'omalizumab $nmbr$ mg n [ $nmbr$','C4321396','MG','MG','false'
'omalizumab $nmbr$ mg n [ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'time since diagnosis of ciu csuf y','C0040223','TIME','Time','true'
'time since diagnosis of ciu csuf y','C3541383','Time','Time (foundation metadata concept)','false'
'positive cu index test z n','C0022885','Test','Laboratory Procedures','false'
'positive cu index test z n','C0039593','Test','Testing','false'
'positive cu index test z n','C0392366','test','Tests (qualifier value)','false'
'positive cu index test z n','C0456984','Test','Test Result','false'
'positive cu index test z n','C1515976','test','Anatomic Structure, System, or Substance','false'
'positive cu index test z n','C3831328','Test','Blood Products Laboratory Testing','false'
'positive cu index test z n','C4318744','Test','Test - temporal region','false'
'no of previous ciu csu medications mean median','C0205156','Previous','Previous','false'
'no of previous ciu csu medications mean median','C0013227','Medications','Pharmaceutical Preparations','true'
'no of previous ciu csu medications mean median','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'no of previous ciu csu medications mean median','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'no of previous ciu csu medications mean median','C4284232','Medications','Medications','false'
'no of previous ciu csu medications mean median','C1552607','previous','Act Relationship Subset - previous','false'
'previous use of systemic steroids n','C0281991','use of steroids','steroid use','false'
'total ige levelx iu ml median range','C1514721','Range','Range','false'
'total ige levelx iu ml median range','C2348147','Range','Sample Range','false'
'total ige levelx iu ml median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'in clinic uask','C0150312','In','Present','false'
'in clinic uask','C0002424','Clinic','Ambulatory Care Facilities','true'
'in clinic uask','C0442592','Clinic','Clinic','false'
'in clinic uask','C0332285','In','Within','false'
'in clinic uask','C1707101','IN','CD44 wt Allele','false'
'weekly iss','C1740819','ISS','Idiopathic short stature','false'
'weekly iss','C1845118','ISS','SHORT STATURE, IDIOPATHIC, X-LINKED','false'
'weekly number of hives score','C0237753','*Number','Numbers','false'
'weekly number of hives score','C0449788','Number','Count of entities','false'
'weekly size of largest hives score','C0456389','Size','size','false'
'weekly size of largest hives score','C0042109','HIVES','Urticaria','true'
'overall dlqi score','C0282416','Overall','Overall Publication Type','true'
'overall dlqi score','C3897059','DLQI - Score','DLQI - Score','false'
'overall dlqi score','C1561607','Overall','Overall','false'
'angioedema present n','C0002994','Angiooedema','Angioedema','true'
'angioedema present n','C0150312','PRESENT','Present','false'
'angioedema present n','C0449450','Present','Presentation','false'
'primary key efficacy endpoint','C2986535','Primary Endpoint','Primary Endpoint','false'
'change from baseline to week $nmbr$ in weekly iss','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$ in weekly iss','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$ in weekly iss','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$ in weekly iss','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$ in weekly iss','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$ in weekly iss','C0439230','Week','week','false'
'change from baseline to week $nmbr$ in weekly iss','C1740819','ISS','Idiopathic short stature','false'
'change from baseline to week $nmbr$ in weekly iss','C1845118','ISS','SHORT STATURE, IDIOPATHIC, X-LINKED','false'
'additional endpoints','C1524062','Additional','Additional','false'
'additional endpoints','C2349179','endpoints','End Point','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$ in uas $nmbr$','C0439230','Week','week','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C0439230','Week','week','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C0042109','HIVES','Urticaria','true'
'change from baseline to week $nmbr$ in weekly no of hives score','C0449820','SCORE','Score','false'
'change from baseline to week $nmbr$ in weekly no of hives score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C0040223','TIME','Time','true'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C3541383','Time','Time (foundation metadata concept)','false'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C0871261','Response','Response process','false'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C1704632','Response','Disease Response','false'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C1706817','Response','Response (statement)','false'
'median $nmbr$ ci time to weekly iss mid response up to week $nmbr$ wk f','C2911692','Response','Response (communication)','false'
'$nmbr$ $nmbr$ ne ne','C0027608','Ne','Neon','true'
'$nmbr$ $nmbr$ ne ne','C0028219','NE','Niue','true'
'$nmbr$ $nmbr$ ne ne','C3538705','NE','ELANE wt Allele','false'
'hr vs placebo $nmbr$ ci','C0008107','CI','Chile','true'
'hr vs placebo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'patients with weekly iss mid response n v','C0030705','Patients','Patients','true'
'patients with weekly iss mid response n v','C0332174','Weekly','Weekly','false'
'patients with weekly iss mid response n v','C0871261','Response','Response process','false'
'patients with weekly iss mid response n v','C1704632','Response','Disease Response','false'
'patients with weekly iss mid response n v','C1706817','Response','Response (statement)','false'
'patients with weekly iss mid response n v','C2911692','Response','Response (communication)','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0439230','Week','week','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0456389','Size','size','false'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0042109','Hive','Urticaria','true'
'change from baseline to week $nmbr$ in weekly size of largest hive score','C0221232','Hive','Welts','false'
'change from baseline to week $nmbr$ in dlqi scorez','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$ in dlqi scorez','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$ in dlqi scorez','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$ in dlqi scorez','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$ in dlqi scorez','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$ in dlqi scorez','C0439230','Week','week','false'
'change from baseline to week $nmbr$ in dlqi scorez','C3899393','DLQI','Dermatology Life Quality Index Questionnaire','false'
'proportion of angioedema free days from week $nmbr$ to week $nmbr$ x','C1709707','Proportion','Proportion','false'
'proportion of angioedema free days from week $nmbr$ to week $nmbr$ x','C0002994','Angiooedema','Angioedema','true'
'proportion of angioedema free days from week $nmbr$ to week $nmbr$ x','C0332174','/week','Weekly','false'
'proportion of angioedema free days from week $nmbr$ to week $nmbr$ x','C0439230','Week','week','false'
'ranotazine vs placebo km failure rate','C0231174','FAILURE','Failure (biologic function)','false'
'ranotazine vs placebo km failure rate','C0680095','failure','Personal failure','false'
'hr $nmbr$ s ci','C0008107','CI','Chile','true'
'hr $nmbr$ s ci','C3259781','CI','Coagulation Index Measurement','false'
'primary ep cvd mi ri','C0035487','RI','Rhode Island','true'
'primary ep cvd mi ri','C1826843','RI','RNH1 gene','false'
'no pci','C4049621','PCI','Peritoneal Cancer Index','false'
'$nmbr$ $nmbr$ vi $nmbr$ $nmbr$','C0205999','VI','British Virgin Islands','true'
'recurrent ischemia','C0022116','Ischaemia, NOS','Ischemia','true'
'recurrent ischemia','C4321499','Ischemia','Ischemia Procedure','false'
'ranolazine vs placebo km failure rate','C0073633','RANOLAZINE','ranolazine','true'
'ranolazine vs placebo km failure rate','C0231174','FAILURE','Failure (biologic function)','false'
'ranolazine vs placebo km failure rate','C0680095','failure','Personal failure','false'
'rec ischemia requiring revasc','C0022116','Ischaemia, NOS','Ischemia','true'
'rec ischemia requiring revasc','C4321499','Ischemia','Ischemia Procedure','false'
'rec ischemia requiring revasc','C0378365','Revasc','Revasc','true'
'rec ischemia leading to hosp','C0022116','Ischaemia, NOS','Ischemia','true'
'rec ischemia leading to hosp','C4321499','Ischemia','Ischemia Procedure','false'
'rec ischemia leading to hosp','C0332152','Leading','Before','false'
'rec ischemia leading to hosp','C1522538','Leading','Leading','false'
'rec ischemia','C0022116','Ischaemia, NOS','Ischemia','true'
'rec ischemia','C4321499','Ischemia','Ischemia Procedure','false'
'due to ecg changes','C0855329','ecg change','Electrocardiographic changes','false'
'due worsening angina','C0678226','due','Due to','false'
'due worsening angina','C3146286','Due','Due','false'
'due worsening angina','C0332271','Worsening','Worsening pattern','false'
'due worsening angina','C1457868','Worsening','Worse','false'
'due worsening angina','C1546960','Worsening','Patient Outcome - Worsening','false'
'due worsening angina','C0002962','ANGINA','Angina Pectoris','true'
'de $nmbr$ mg bid n $nmbr$ $nmbr$','C0011198','DE','Delaware','true'
'de $nmbr$ mg bid n $nmbr$ $nmbr$','C0017480','DE','Germany','true'
'de $nmbr$ mg bid n $nmbr$ $nmbr$','C3541240','DE','Device Events Domain','false'
'warfarin n $nmbr$ $nmbr$','C0043031','WARFARIN','Warfarin','true'
'gfr ckd epi','C1561643','CKD','Chronic Kidney Diseases','true'
'gfr ckd epi','C0162734','EPI','Echo-Planar Imaging','true'
'gfr ckd epi','C4281721','EPI','Tissue Factor Pathway Inhibitor, human','false'
'ckd stages','C1561643','CKD','Chronic Kidney Diseases','true'
'ckd stages','C1306673','Stages','Stage','false'
'$nmbr$ $nmbr$ to $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'history of stroke see tia','C0019664','History','History','true'
'history of stroke see tia','C0019665','history','Historical aspects qualifier','true'
'history of stroke see tia','C0262512','History, NOS','History of present illness','false'
'history of stroke see tia','C0262926','History','Medical History','false'
'history of stroke see tia','C1705255','History','Concept History','false'
'history of stroke see tia','C2004062','History','History of previous events','false'
'history of heart failure','C0455531','History of - heart failure','H/O: heart failure','false'
'documented coronary artery disease','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'documented coronary artery disease','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'documented coronary artery disease','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'hypertension requiring medical treatment','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension requiring medical treatment','C1963138','Hypertension','Hypertension, CTCAE','false'
'hypertension requiring medical treatment','C0679624','medical Treatment','medical treatment method','false'
'previous vka use stratified randomization','C0042153','use','utilization qualifier','true'
'previous vka use stratified randomization','C4687737','Stratified Randomization','Stratified Randomization','false'
'previous vka use stratified randomization','C0457083','Use','Usage','false'
'previous vka use stratified randomization','C1947944','Use','Use - dosing instruction imperative','false'
'duration of previous use of vka months','C1881378','DURATION OF USE','Limitation of Use Based on Duration of Use','false'
'duration of previous use of vka months','C2826775','Duration of Use','Duration of Use','false'
'normal study termination','C1549081','Termination','Termination - Inactive Reason Code','false'
'normal study termination','C1692758','termination','termination - ActReason','false'
'concomitant medication $nmbr$','C0013227','Medication','Pharmaceutical Preparations','true'
'concomitant medication $nmbr$','C3244316','medication','medication - HL7 publishing domain','false'
'concomitant medication $nmbr$','C4284232','Medication','Medications','false'
'p gp inhibitor','C3898062','P-gp inhibitor','P-glycoprotein Inhibitor','false'
'vitamins','C0042890','VITAMINS','Vitamins','true'
'vitamins','C3540032','Vitamins','Vitamin IV solution additives','false'
'vitamins','C3714649','VITAMINS','VITAMINS [VA Class]','false'
'oral hypoglycemic','C0359086','Oral hypoglycemic','oral hypoglycemic','false'
'alpha blocker other vasodilator','C0001641','Alpha Blocker','Adrenergic alpha-Antagonists','true'
'alpha blocker other vasodilator','C0042402','Vasodilator','Vasodilator Agents','true'
'alpha blocker other vasodilator','C3537240','Vasodilator','Vasodilator [EPC]','false'
'previous vka use','C0042153','use','utilization qualifier','true'
'previous vka use','C0457083','Use','Usage','false'
'previous vka use','C1947944','Use','Use - dosing instruction imperative','false'
'mean se','C0444504','Mean','Statistical mean','false'
'mean se','C0036919','SE','Seychelles','true'
'mean se','C2347634','Mean','Population Mean','false'
'mean se','C2348143','Mean','Sample Mean','false'
'adjusted mean se change from baseline','C0392747','Change','Changing','false'
'adjusted mean se change from baseline','C0443172','change','Changed status','false'
'adjusted mean se change from baseline','C1705241','Change','Delta (difference)','false'
'adjusted mean se change from baseline','C4319952','Change','Change -- procedure','false'
'p value vs previous time point','C1709380','P-Value','P-Value','false'
'p value vs previous time point','C0205156','Previous','Previous','false'
'p value vs previous time point','C2348792','Timepoint','Timepoint','false'
'p value vs previous time point','C1552607','previous','Act Relationship Subset - previous','false'
'calculated annual decline mean se','C0332181','Annual','Annual','false'
'calculated annual decline mean se','C0036919','SE','Seychelles','true'
'adjusted mean _ se change from baseline','C0392747','Change','Changing','false'
'adjusted mean _ se change from baseline','C0443172','change','Changed status','false'
'adjusted mean _ se change from baseline','C1705241','Change','Delta (difference)','false'
'adjusted mean _ se change from baseline','C4319952','Change','Change -- procedure','false'
'elderly patients n $nmbr$','C0870602','Elderly patients','geriatric patients','false'
'very elderly patients n $nmbr$','C0442824','Very','Very','false'
'very elderly patients n $nmbr$','C0870602','Elderly patients','geriatric patients','false'
'very elderly patients n $nmbr$','C2984081','Very','Very Much','false'
'p between age groups','C0441849','Group P','Group P (alphabetic group)','false'
'p between age groups','C1959644','P group','P group','false'
'olmesartan along with ccb n $nmbr$','C1098320','OLMESARTAN','olmesartan','true'
'olmesartan along with ccb n $nmbr$','C0006684','CCB','Calcium Channel Blockers','true'
'olmesartan along with diuretic n $nmbr$','C1098320','OLMESARTAN','olmesartan','true'
'olmesartan along with diuretic n $nmbr$','C0012798','Diuretic','Diuretics','true'
'grade of hypertension','C0441800','Grade','Grade','false'
'grade of hypertension','C0919553','Grade','Histopathologic Grade','false'
'grade of hypertension','C3244287','grade','School Grade','false'
'grade $nmbr$','C0441800','Grade','Grade','false'
'grade $nmbr$','C0919553','Grade','Histopathologic Grade','false'
'grade $nmbr$','C3244287','grade','School Grade','false'
'previous history of cardiovascular events','C2004062','History of previous events','History of previous events','false'
'drinking','C0001948','Drinking','Alcohol consumption','true'
'drinking','C0684271','Drinking','Drinking function','true'
'number of visits median','C1549755','Visit Number','Visit Number','false'
'number of visits median','C0549183','Median','Midline (qualifier value)','false'
'number of visits median','C0876920','Median','Median Statistical Measurement','false'
'number of visits median','C2347635','Median','Population Median','false'
'number of visits median','C2348144','Median','Sample Median','false'
'number of visits median','C2939193','Median','Median (qualifier value)','false'
'number of visits mean sd','C1549755','Visit Number','Visit Number','false'
'number of visits mean sd','C0444504','Mean','Statistical mean','false'
'number of visits mean sd','C2347634','Mean','Population Mean','false'
'number of visits mean sd','C2348143','Mean','Sample Mean','false'
'sbp during the follow up period mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp during the follow up period mmhg','C0589120','Follow-up','Follow-up status','false'
'sbp during the follow up period mmhg','C1522577','Followup','follow-up','false'
'sbp during the follow up period mmhg','C1704685','Follow-Up','Follow-Up Report','false'
'sbp during the follow up period mmhg','C3274571','FOLLOW-UP','Clinical Study Follow-up','false'
'dbp during the follow up period mmhg','C0536221','DBP','HSD17B4 protein, human','true'
'dbp during the follow up period mmhg','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp during the follow up period mmhg','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'etanercept n $nmbr$','C0717758','ETANERCEPT','Etanercept','true'
'ixekizumab every $nmbr$ weeks n $nmbr$','C3489764','IXEKIZUMAB','ixekizumab','true'
'ixekizumab every $nmbr$ weeks n $nmbr$','C0439230','WEEKS','week','false'
'nx','C0445085','NX','NX category','false'
'bmi kg per m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi kg per m $nmbr$','C0439209','kg','Kilogram','false'
'bmi kg per m $nmbr$','C4054209','/kg','Per Kilogram','false'
'psoriasis duration years','C0033860','PSORIASIS','Psoriasis','true'
'psoriasis duration years','C0439234','YEARS','year','false'
'percentage of bsa involved','C0439165','Percentage','Percent (qualifier value)','false'
'percentage of bsa involved','C1549488','Percentage','Amount type - Percentage','false'
'percentage of bsa involved','C1561533','Percentage','Money or percentage indicator - Percentage','false'
'percentage of bsa involved','C1314939','Involved','Involvement with','false'
'pasi','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'qids sr $nmbr$','C4331197','QIDS-SR','Quick Inventory of Depressive Symptomatology Self-Report Version Questionnaire','false'
'itch nrs','C2240043','nrs','SPNS1 gene','false'
'itch nrs','C4050142','NRS','Numeric Rating Scale','false'
'previous therapy','C0039798','therapy','therapeutic aspects','true'
'previous therapy','C0087111','Therapy','Therapeutic procedure','true'
'previous therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'topical prescription','C0033080','Prescription','Prescription procedure','true'
'topical prescription','C1521941','Prescription','prescription document','false'
'topical non prescription','C0332237','Topical','Topical surface','false'
'topical non prescription','C1518422','Non','Negation','false'
'topical non prescription','C0033080','Prescription','Prescription procedure','true'
'topical non prescription','C1521941','Prescription','prescription document','false'
'phototherapy','C0031765','Phototherapy','Phototherapy','true'
'non biological systemic','C0445097','Non-biological','Non-biological','false'
'non biological systemic','C0205373','Systemic','Systemic','false'
'biological','C0005532','Biological','biology (field)','true'
'biological','C0205460','Biological','biological','false'
'diabetics n $nmbr$','C0241863','diabetics','diabetic','false'
'non diabetics n $nmbr$','C1518422','Non','Negation','false'
'non diabetics n $nmbr$','C0241863','diabetics','diabetic','false'
'patients with dm n $nmbr$','C0030705','Patients','Patients','true'
'patients with dm n $nmbr$','C0011816','DM','Dextromethorphan','true'
'patients with dm n $nmbr$','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'patients without dm n $nmbr$','C0030705','Patients','Patients','true'
'patients without dm n $nmbr$','C0011816','DM','Dextromethorphan','true'
'patients without dm n $nmbr$','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'patients with dm vs patients without dm','C0030705','Patients','Patients','true'
'patients with dm vs patients without dm','C0011816','DM','Dextromethorphan','true'
'patients with dm vs patients without dm','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'age\\yr','C0001779','AGE','Age','false'
'age\\yr','C0439234','yr','year','false'
'year','C0439234','Year','year','false'
'year','C0439508','/Year','per year','false'
'male sex \ no','C0086582','MALE SEX','Males','true'
'body mass index \ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'body mass index \ kg m $nmbr$','C0439209','kg','Kilogram','false'
'body mass index \ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'ischemic stroke incl uncertain','C0948008','Ischaemic stroke','Ischemic stroke','false'
'ischemic stroke incl uncertain','C0087130','Uncertain','Uncertainty','true'
'ischemic stroke incl uncertain','C4085655','Uncertain','Uncertain - Response','false'
'hba $nmbr$ c \n','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c \n','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c \n','C3538758','HBA','SCN2A wt Allele','false'
'hemorrhagic stroke','C0553692','Haemorrhagic stroke','Brain hemorrhage','true'
'\mean sd','C0444504','Mean','Statistical mean','false'
'\mean sd','C2699239','SD','SD, Rat Strain','false'
'\mean sd','C2347634','Mean','Population Mean','false'
'\mean sd','C2348143','Mean','Sample Mean','false'
'af type no','C0332307','TYPE','Type - attribute','false'
'af type no','C1547052','*Type','*Type - Kind of quantity','false'
'median crcl ml min','C0549183','Median','Midline (qualifier value)','false'
'median crcl ml min','C0439445','mL/min','mL/min','false'
'median crcl ml min','C0876920','Median','Median Statistical Measurement','false'
'median crcl ml min','C2347635','Median','Population Median','false'
'median crcl ml min','C2348144','Median','Sample Median','false'
'median crcl ml min','C2939193','Median','Median (qualifier value)','false'
'peripheral arterial disease no','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'peripheral arterial disease no','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'baseline chads $nmbr$ a c','C0168634','baseline','BaseLine dental cement','true'
'baseline chads $nmbr$ a c','C1442488','Baseline','Baseline','false'
'baseline cha $nmbr$ ds $nmbr$ vascb c','C0168634','baseline','BaseLine dental cement','true'
'baseline cha $nmbr$ ds $nmbr$ vascb c','C1420648','CHA','TCFL5 gene','false'
'baseline cha $nmbr$ ds $nmbr$ vascb c','C1442488','Baseline','Baseline','false'
'patients without dm n $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'patients without dm n $nmbr$ $nmbr$','C0011816','DM','Dextromethorphan','true'
'patients without dm n $nmbr$ $nmbr$','C3250443','DM','MYOTONIC DYSTROPHY 1','false'
'stroke or systemic','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or systemic','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or systemic','C0205373','Systemic','Systemic','false'
'embolism','C0013922','EMBOLISM','Embolism','true'
'embolism','C1704212','Embolism, NOS','Embolus','true'
'incl uncertain','C0087130','Uncertain','Uncertainty','true'
'incl uncertain','C4085655','Uncertain','Uncertain - Response','false'
'ustekinumab $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'ustekinumab $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'ustekinumab $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'ustekinumab $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'ustekinumab $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'ustekinumab $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'ustekinumab $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'duration of disease years','C0872146','disease duration','disease length','false'
'duration of disease years','C0439234','YEARS','year','false'
'psoriatic arthritis','C0003872','ARTHRITIS, PSORIATIC','Arthritis, Psoriatic','true'
'psoriasis','C0033860','PSORIASIS','Psoriasis','true'
'patients with psoriasis $nmbr$ of body surface area','C0030705','Patients','Patients','true'
'patients with psoriasis $nmbr$ of body surface area','C0005902','Body Surface Area','Body Surface Area','true'
'pasi score','C0449820','SCORE','Score','false'
'pasi score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'dlqi score','C3897059','DLQI - Score','DLQI - Score','false'
'swollen joint count','C0451521','Swollen joint count','Swollen joint count','false'
'tender joint count','C0451530','Tender joint count','Tender joint count','false'
'crp mg l','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'crp mg l','C0439268','mg/L','Microgram per Milliliter','false'
'crp mg l','C4048285','CRP','C-Reactive Protein, human','false'
'haq di score','C0449820','SCORE','Score','false'
'haq di score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'dactylitis in $nmbr$ digit','C0239161','DACTYLITIS','Dactylitis','false'
'dactylitis in $nmbr$ digit','C0582802','Digit','Digit structure','false'
'dactylitis in $nmbr$ digit','C3241971','Digit','Digit - number character','false'
'dactylitis score','C0449820','SCORE','Score','false'
'dactylitis score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'enthesitis score','C0449820','SCORE','Score','false'
'enthesitis score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'mental component','C0449432','Component','Component object','false'
'mental component','C1705248','Component','Component (part)','false'
'physical component','C0449432','Component','Component object','false'
'physical component','C1705248','Component','Component (part)','false'
'dose mg week','C0332174','/week','Weekly','false'
'dose mg week','C0439230','Week','week','false'
'mean dose sd mg week','C0332174','/week','Weekly','false'
'mean dose sd mg week','C0439230','Week','week','false'
'oral corticosteroid','C0442027','Oral','Oral','false'
'oral corticosteroid','C0001617','Corticosteroid','Adrenal Cortex Hormones','true'
'oral corticosteroid','C3536709','Corticosteroid','Corticosteroid [EPC]','false'
'oral corticosteroid','C4521986','Oral','Oral (intended site)','false'
'dose mg day','C0178602','DOSE','Dosage','false'
'dose mg day','C0439422','mg day','milligram/day','false'
'dose mg day','C0869039','Dose','Unit dose','false'
'dose mg day','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'mean dose sd mg day','C0178602','DOSE','Dosage','false'
'mean dose sd mg day','C0439422','mg day','milligram/day','false'
'mean dose sd mg day','C0869039','Dose','Unit dose','false'
'mean dose sd mg day','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'non steroidal anti inflammatory drugs','C0003211','Non Steroidal Anti Inflammatory Drugs','Anti-Inflammatory Agents, Non-Steroidal','true'
'placebo to ustekinumab $nmbr$ mgt','C0032042','Placebo','Placebos','true'
'placebo to ustekinumab $nmbr$ mgt','C1696465','PLACEBO','placebo','false'
'placebo to ustekinumab $nmbr$ mgt','C1706408','PLACEBO','Placebo Control','false'
'ustekinumab','C1608841','USTEKINUMAB','ustekinumab','true'
'patients randomized no','C0030705','Patients','Patients','true'
'patients randomized no','C0034656','Randomized','Randomization','true'
'patients randomized no','C3815594','RANDOMIZED','Subject is Randomized','false'
'clinical efficacy at week $nmbr$','C0087113','Efficacy, Clinical','Treatment Effectiveness','true'
'clinical efficacy at week $nmbr$','C0332174','/week','Weekly','false'
'clinical efficacy at week $nmbr$','C0439230','Week','week','false'
'patients no','C0030705','Patients','Patients','true'
'acr $nmbr$','C1412134','ACR','ACR gene','false'
'acr $nmbr$','C1515941','ACR','American College of Radiology','false'
'acr response by baseline weight','C0871261','Response','Response process','false'
'acr response by baseline weight','C1704632','Response','Disease Response','false'
'acr response by baseline weight','C1706817','Response','Response (statement)','false'
'acr response by baseline weight','C2911692','Response','Response (communication)','false'
'no total no','C0439175','% total','% of total','false'
'no total no','C0439810','Total','Total','false'
'acr response by baseline mtx use no total no acr $nmbr$','C0871261','Response','Response process','false'
'acr response by baseline mtx use no total no acr $nmbr$','C1704632','Response','Disease Response','false'
'acr response by baseline mtx use no total no acr $nmbr$','C1706817','Response','Response (statement)','false'
'acr response by baseline mtx use no total no acr $nmbr$','C2911692','Response','Response (communication)','false'
'acr response by baseline mtx use no total no acr $nmbr$','C0439175','% total','% of total','false'
'acr response by baseline mtx use no total no acr $nmbr$','C0439810','Total','Total','false'
'acr response by baseline mtx use no total no acr $nmbr$','C1412134','ACR','ACR gene','false'
'acr response by baseline mtx use no total no acr $nmbr$','C1515941','ACR','American College of Radiology','false'
'good moderate response','C0205170','Good','Good','false'
'good moderate response','C4085643','Moderate Response','Moderate Response','false'
'remission','C0544452','Remission','Disease remission','false'
'remission','C0687702','remission','Cancer Remission','false'
'change from baseline median iqr','C0392747','Change','Changing','false'
'change from baseline median iqr','C0443172','change','Changed status','false'
'change from baseline median iqr','C1705241','Change','Delta (difference)','false'
'change from baseline median iqr','C4319952','Change','Change -- procedure','false'
'patients with improvement $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'patients with improvement $nmbr$ $nmbr$','C2986411','Improvement','Improvement','false'
'patients with $nmbr$ bsa at baseline no','C0030705','Patients','Patients','true'
'patients with $nmbr$ bsa at baseline no','C0168634','baseline','BaseLine dental cement','true'
'patients with $nmbr$ bsa at baseline no','C1442488','Baseline','Baseline','false'
'pasi $nmbr$ at week $nmbr$','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'pasi $nmbr$ at week $nmbr$','C0332174','/week','Weekly','false'
'pasi $nmbr$ at week $nmbr$','C0439230','Week','week','false'
'no total no t','C0439175','% total','% of total','false'
'no total no t','C0439810','Total','Total','false'
'no total no t','C2603360','T'','T prime','false'
'pasi $nmbr$ no total no $nmbr$','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'pasi $nmbr$ no total no $nmbr$','C0439175','% total','% of total','false'
'pasi $nmbr$ no total no $nmbr$','C0439810','Total','Total','false'
'pasi response by baseline weight no total no pasi $nmbr$','C0871261','Response','Response process','false'
'pasi response by baseline weight no total no pasi $nmbr$','C1704632','Response','Disease Response','false'
'pasi response by baseline weight no total no pasi $nmbr$','C1706817','Response','Response (statement)','false'
'pasi response by baseline weight no total no pasi $nmbr$','C2911692','Response','Response (communication)','false'
'pasi response by baseline weight no total no pasi $nmbr$','C0439175','% total','% of total','false'
'pasi response by baseline weight no total no pasi $nmbr$','C0439810','Total','Total','false'
'pasi response by baseline weight no total no pasi $nmbr$','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C0871261','Response','Response process','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C1704632','Response','Disease Response','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C1706817','Response','Response (statement)','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C2911692','Response','Response (communication)','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C0439175','% total','% of total','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C0439810','Total','Total','false'
'pasi response by baseline mtx use no total no pasi $nmbr$','C4528685','PASI','Psoriasis Area and Severity Index Clinical Classification','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ continued','C0549178','Continued','Continuous','false'
'patients with dactylitis at baseline no','C0030705','Patients','Patients','true'
'patients with dactylitis at baseline no','C0239161','DACTYLITIS','Dactylitis','false'
'patients with dactylitis at baseline no','C0168634','baseline','BaseLine dental cement','true'
'patients with dactylitis at baseline no','C1442488','Baseline','Baseline','false'
'dactylitis score at baseline median iqr week $nmbr$','C0449820','SCORE','Score','false'
'dactylitis score at baseline median iqr week $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'score improvement baseline to week $nmbr$ median iqr','C0168634','baseline','BaseLine dental cement','true'
'score improvement baseline to week $nmbr$ median iqr','C1442488','Baseline','Baseline','false'
'percent improvement baseline to week $nmbr$ median iqr','C0168634','baseline','BaseLine dental cement','true'
'percent improvement baseline to week $nmbr$ median iqr','C1442488','Baseline','Baseline','false'
'patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis','C0030705','Patients','Patients','true'
'patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis','C0239161','DACTYLITIS','Dactylitis','false'
'patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis','C0332174','/week','Weekly','false'
'patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis','C1282952','Enthesitis','Enthesitis','false'
'patients with $nmbr$ dactylitis digit at week $nmbr$ enthesitis','C0439230','Week','week','false'
'patients with enthesitis at baseline no','C0030705','Patients','Patients','true'
'patients with enthesitis at baseline no','C1282952','Enthesitis','Enthesitis','false'
'patients with enthesitis at baseline no','C0168634','baseline','BaseLine dental cement','true'
'patients with enthesitis at baseline no','C1442488','Baseline','Baseline','false'
'enthesitis score at baseline median iqr week $nmbr$','C0449820','SCORE','Score','false'
'enthesitis score at baseline median iqr week $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C0030705','Patients','Patients','true'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C1282952','Enthesitis','Enthesitis','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C0392747','Change','Changing','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C0443172','change','Changed status','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C1705241','Change','Delta (difference)','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C4319952','Change','Change -- procedure','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C0332174','/week','Weekly','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C0439230','Week','week','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C2964552','Total Score','Total score','false'
'patients with enthesitis at week $nmbr$ radiographic progression change from baseline to week $nmbr$ in psa modified total shs score','C3889737','Modified','Data Change Date','false'
'mean $nmbr$ sd','C0444504','Mean','Statistical mean','false'
'mean $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'mean $nmbr$ sd','C2347634','Mean','Population Mean','false'
'mean $nmbr$ sd','C2348143','Mean','Sample Mean','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C0392747','Change','Changing','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C0443172','change','Changed status','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C1705241','Change','Delta (difference)','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C4319952','Change','Change -- procedure','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C0332174','/week','Weekly','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C0439230','Week','week','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C2964552','Total Score','Total score','false'
'median iqr change from baseline to week $nmbr$ in psa modified total shs score','C3889737','Modified','Data Change Date','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0444504','Mean','Statistical mean','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0168634','baseline','BaseLine dental cement','true'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1442488','Baseline','Baseline','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C2347634','Mean','Population Mean','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C2348143','Mean','Sample Mean','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0332174','/week','Weekly','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0439230','Week','week','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0441833','Group','Groups','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0687744','group','Social group','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1257890','Group','Population Group','true'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1519504','Group','Stage Grouping','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1705428','Group','Group Object','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1705429','Group','User Group','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0005910','Weight','Body Weight','true'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C0043100','Weight','Weight','true'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1305866','weight','Weighing patient','false'
'median iqr mean $nmbr$ sdchange from baseline to week $nmbr$ by weight group and mtx use weight','C1705104','Weight','Importance Weight','false'
'$nmbr$ kg mtx use','C0042153','use','utilization qualifier','true'
'$nmbr$ kg mtx use','C0457083','Use','Usage','false'
'$nmbr$ kg mtx use','C1947944','Use','Use - dosing instruction imperative','false'
'patients with change from baseline in psa modified total shs score $nmbr$','C0030705','Patients','Patients','true'
'patients with change from baseline in psa modified total shs score $nmbr$','C0392747','Change','Changing','false'
'patients with change from baseline in psa modified total shs score $nmbr$','C0443172','change','Changed status','false'
'patients with change from baseline in psa modified total shs score $nmbr$','C1705241','Change','Delta (difference)','false'
'patients with change from baseline in psa modified total shs score $nmbr$','C4319952','Change','Change -- procedure','false'
'patients with change from baseline in psa modified total shs score $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'patients with change from baseline in psa modified total shs score $nmbr$','C1442488','Baseline','Baseline','false'
'low risk n $nmbr$ $nmbr$','C3272281','Low Risk','American College of Cardiology/American Heart Association Lesion Complexity Score A','false'
'low risk n $nmbr$ $nmbr$','C3538919','LOW RISK','Low Risk','false'
'high risk n $nmbr$ $nmbr$','C0332167','HIGH RISK','High risk of','false'
'high risk n $nmbr$ $nmbr$','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'high risk n $nmbr$ $nmbr$','C4050568','High Risk','High Risk Acute Leukemia','false'
'high risk n $nmbr$ $nmbr$','C4319571','High risk','High risk','false'
'time since diagnosis of copd years','C0556970','time year','times/year','false'
'time since diagnosis of copd years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since diagnosis of copd years','C1704338','diagnosis','diagnosis aspect','true'
'time since diagnosis of copd years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'spirometry','C0037981','SPIROMETRY','Spirometry','true'
'fev $nmbr$ l','C3714541','FEV','Forced Vital Capacity','true'
'respiratory medication taken at baseline n','C0418986','Respiratory medication','Respiratory medication','false'
'respiratory medication taken at baseline n','C1883727','Taken','Taken','false'
'respiratory medication taken at baseline n','C0168634','baseline','BaseLine dental cement','true'
'respiratory medication taken at baseline n','C1442488','Baseline','Baseline','false'
'anticholinergics','C0242896','Anticholinergics','Anticholinergic Agents','true'
'anticholinergics','C3537307','Anticholinergics','Anticholinergics inhalants for obstructive airway diseases','false'
'anticholinergics','C3540711','Anticholinergics','Anticholinergic mydriatics and cycloplegics','false'
'ics','C0815320','ICS','Impaired Control Scale','false'
'ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'other steroids','C0038317','Steroids','Steroids','true'
'ics laba free or fdc','C0332296','free','Free of (attribute)','false'
'ics laba free or fdc','C1880497','Free','Empty (qualifier)','false'
'ics laba free or fdc','C1996904','Free','Free (available (qualifier))','false'
'ics laba free or fdc','C0340427','FDC','Familial dilated cardiomyopathy','true'
'ics laba free or fdc','C1413520','FDC','CMD1B gene','false'
'ics laba free or fdc','C3539652','FDC','LAG3 wt Allele','false'
'patient classification','C0008902','Classification','Classification','true'
'patient classification','C0008903','classification','Taxonomic','true'
'patient classification','C0678229','classification','Classification of information','false'
'salmeterol','C0073992','SALMETEROL','salmeterol','true'
'tiotropium vs salmeterol','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium vs salmeterol','C0073992','SALMETEROL','salmeterol','true'
'number of patients with events','C2360800','Number of patients','Number of patients','false'
'number of patients with events','C0441471','Events','Event','false'
'number of patients with events','C3541888','EVENTS','CDISC Events Class','false'
'low risk','C3272281','Low Risk','American College of Cardiology/American Heart Association Lesion Complexity Score A','false'
'low risk','C3538919','LOW RISK','Low Risk','false'
'infrequent exacerbator','C0521114','Infrequent','Infrequent','false'
'frequent exacerbator','C0332183','Frequent','Frequently','false'
'low risk ics','C0815320','ICS','Impaired Control Scale','false'
'low risk ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'high risk ics','C0815320','ICS','Impaired Control Scale','false'
'high risk ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'olodaterol $nmbr$ pg','C0030827','PG','Penicillin G','true'
'olodaterol $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'olodaterol $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'tiotropium $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'tiotropium $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'tiotropium $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'tiotropium $nmbr$ pg','C0030827','PG','Penicillin G','true'
'tiotropium $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'tiotropium $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'tiotropium olodaterol $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'tiotropium olodaterol $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'tiotropium olodaterol $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'gold $nmbr$ $nmbr$','C0018026','GOLD','Gold','true'
'gold $nmbr$ $nmbr$','C1304897','Gold','Gold color','false'
'participants n','C0679646','participants','Participant','false'
'current smoker n post bronchodilator screening','C0220908','Screening','Screening procedure','true'
'current smoker n post bronchodilator screening','C0220909','screening','Aspects of disease screening','true'
'current smoker n post bronchodilator screening','C1698960','screening','research subject screening','false'
'current smoker n post bronchodilator screening','C1710031','Screening','Disease Screening','false'
'current smoker n post bronchodilator screening','C1710032','Screening','Screening','false'
'current smoker n post bronchodilator screening','C1710477','SCREENING','Trial Screening','false'
'current smoker n post bronchodilator screening','C2348164','SCREENING','Screening Study','false'
'mean sd fevi ml','C0439526','/mL','/mL','false'
'mean sd fevi ml','C1705224','ML','THPO wt Allele','false'
'mean sd fevi ml','C3887665','ML','Thrombopoietin, human','false'
'mean sd change from pre to post bronchodilator fevi ml','C2599594','Post-bronchodilator','post bronchodilator','false'
'mean sd change from pre to post bronchodilator fevi ml','C3481639','FEV1 % change','Volume expired during 1.0 s of forced expiration percent change:VPctDiff:Pt:Respiratory system:Qn','false'
'mean sd fevi fvc','C0802741','FEV1/FVC','Volume at 1.0 s post forced expiration/Vital capacity.forced:Volume Ratio:Point in time:Respiratory system:Quantitative','false'
'mean sd fevi fvc','C3815113','FEV1/FVC','Forced Expiratory Volume in 1 Second to Forced Vital Capacity Ratio Measurement','false'
'mean sd of predicted normal fevi','C2699239','SD','SD, Rat Strain','false'
'mean sd of predicted normal fevi','C0205307','NORMAL','Normal','false'
'mean sd of predicted normal fevi','C0231683','Normal','Gait normal','false'
'mean sd of predicted normal fevi','C0439166','% normal','Percent normal','false'
'mean sd of predicted normal fevi','C2347086','% Normal','Mean Percent of Normal','false'
'mean sd of predicted normal fevi','C4553972','Normal','How Often Felt Normal question','false'
'gold $nmbr$ $nmbr$ n $nmbr$','C0018026','GOLD','Gold','true'
'gold $nmbr$ $nmbr$ n $nmbr$','C1304897','Gold','Gold color','false'
'olodaterol sgg','C2934193','OLODATEROL','olodaterol','true'
'tiotropium olodaterol $nmbr$ $nmbr$','C4032878','tiotropium-olodaterol','olodaterol / tiotropium','true'
'mean sd change from pre to post bronchodilator fevi nil','C2599594','Post-bronchodilator','post bronchodilator','false'
'mean sd change from pre to post bronchodilator fevi nil','C3481639','FEV1 % change','Volume expired during 1.0 s of forced expiration percent change:VPctDiff:Pt:Respiratory system:Qn','false'
'gold $nmbr$ $nmbr$ $nmbr$','C0018026','GOLD','Gold','true'
'gold $nmbr$ $nmbr$ $nmbr$','C1304897','Gold','Gold color','false'
'mean sd eevi ml','C0439526','/mL','/mL','false'
'mean sd eevi ml','C1705224','ML','THPO wt Allele','false'
'mean sd eevi ml','C3887665','ML','Thrombopoietin, human','false'
'mean sd fevi evc','C0013903','EVC','Ellis-Van Creveld Syndrome','true'
'mean sd fevi evc','C0429711','EVC','Expiratory vital capacity','false'
'mean sd fevi evc','C1414479','EVC','EVC gene','false'
'mean sd of predicted normal eevi','C2699239','SD','SD, Rat Strain','false'
'mean sd of predicted normal eevi','C0205307','NORMAL','Normal','false'
'mean sd of predicted normal eevi','C0231683','Normal','Gait normal','false'
'mean sd of predicted normal eevi','C0439166','% normal','Percent normal','false'
'mean sd of predicted normal eevi','C2347086','% Normal','Mean Percent of Normal','false'
'mean sd of predicted normal eevi','C4553972','Normal','How Often Felt Normal question','false'
'treatment comparison','C0039798','treatment','therapeutic aspects','true'
'treatment comparison','C1707455','Comparison','Comparison','false'
'treatment comparison','C0087111','Treatment','Therapeutic procedure','true'
'treatment comparison','C1522326','Treatment','Treating','false'
'treatment comparison','C1533734','Treatment','Administration procedure','false'
'treatment comparison','C1705169','Treatment','Biomaterial Treatment','false'
'treatment comparison','C3538994','TREATMENT','Treatment Epoch','false'
'treatment comparison','C3887704','treatment','treatment - ActInformationManagementReason','false'
'adjusted mean se fevi auco_ $nmbr$ ml','C0439526','/mL','/mL','false'
'adjusted mean se fevi auco_ $nmbr$ ml','C1705224','ML','THPO wt Allele','false'
'adjusted mean se fevi auco_ $nmbr$ ml','C3887665','ML','Thrombopoietin, human','false'
'adjusted mean se trough fevi ml','C0439526','/mL','/mL','false'
'adjusted mean se trough fevi ml','C1705224','ML','THPO wt Allele','false'
'adjusted mean se trough fevi ml','C3887665','ML','Thrombopoietin, human','false'
'gold $nmbr$','C0018026','GOLD','Gold','true'
'gold $nmbr$','C1304897','Gold','Gold color','false'
'versus olodaterol $nmbr$ pg','C0030827','PG','Penicillin G','true'
'versus olodaterol $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'versus olodaterol $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C4032878','tiotropium-olodaterol','olodaterol / tiotropium','true'
'versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'versus tiotropium $nmbr$ pg tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'versus tiotropium $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'versus tiotropium $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'versus tiotropium $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'versus tiotropium $nmbr$ pg','C0030827','PG','Penicillin G','true'
'versus tiotropium $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'versus tiotropium $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'bosentan','C0252643','BOSENTAN','bosentan','true'
'median interquartile range','C0549183','Median','Midline (qualifier value)','false'
'median interquartile range','C1711350','Interquartile Range','Interquartile Range','false'
'median interquartile range','C0876920','Median','Median Statistical Measurement','false'
'median interquartile range','C2347635','Median','Population Median','false'
'median interquartile range','C2348144','Median','Sample Median','false'
'median interquartile range','C2939193','Median','Median (qualifier value)','false'
'brazil','C0006137','BRAZIL','Brazil','true'
'saudi arabia','C0036243','SAUDI ARABIA','Saudi Arabia','true'
'time from pah diagnosis months','C0011900','DIAGNOSIS','Diagnosis','true'
'time from pah diagnosis months','C0556969','months time','times/month','false'
'time from pah diagnosis months','C1704338','diagnosis','diagnosis aspect','true'
'time from pah diagnosis months','C1704656','DIAGNOSIS','Diagnosis Study','false'
'aetiology of pah','C0015127','etiology','Etiology aspects','true'
'aetiology of pah','C1314792','Etiology','Etiology','true'
'aetiology of pah','C1524003','Etiology','Science of Etiology','false'
'familial','C0015576','Familial','Family','true'
'familial','C0241888','FAMILIAL','Familial','false'
'repaired congenital shunts','C0232180','Shunt','Cardiac shunt','false'
'repaired congenital shunts','C0542331','Shunt','Shunt Device','false'
'repaired congenital shunts','C1442858','Shunt','Surgical fistula','false'
'drugs and toxins','C0013227','Drugs','Pharmaceutical Preparations','true'
'drugs and toxins','C3687832','Drugs','Drugs - dental services','false'
'drugs and toxins','C0040549','Toxins','Toxin','true'
'$nmbr$ min walk distance m','C0702093','/min','Per Minute','false'
'$nmbr$ min walk distance m','C0429886','Walk distance','Walking distance','false'
'$nmbr$ min walk distance m','C1524029','MIN NOS','Mouse MIN NOS','false'
'$nmbr$ min walk distance m','C3813700','%/min','Percent per Minute','false'
'who functional class','C0205245','Functional','Functional','false'
'who functional class','C0456387','Class','Class','false'
'who functional class','C1518526','class','Object Class','false'
'who functional class','C1705943','Class','Class (taxonomic)','false'
'who functional class','C0542341','Functional','Function (attribute)','false'
'who functional class','C2700217','Functional','Functional Relationship','false'
'nt probnp $nmbr$ pmol l $nmbr$','C0669479','NTproBNP','pro-brain natriuretic peptide (1-76)','true'
'nt probnp $nmbr$ pmol l $nmbr$','C0439284','pmol/L','Picomole per Liter','false'
'nt probnp $nmbr$ pmol l $nmbr$','C0754710','NT-proBNP','Amino-terminal pro-brain natriuretic peptide','true'
'baseline sildenafil dose mg','C0024671','MG','Mammography','true'
'baseline sildenafil dose mg','C0026410','MG','Mongolia','true'
'baseline sildenafil dose mg','C0439269','mg%','mg/dL','false'
'baseline sildenafil dose mg','C1960952','mg %','Milligram percent','false'
'baseline sildenafil dose mg','C2346927','Mg++','Magnesium Cation','false'
'baseline sildenafil dose mg','C4321396','MG','MG','false'
'baseline sildenafil dose mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'east asian','C1707877','East','East','false'
'east asian','C0078988','ASIAN','Asians','true'
'non east asian','C1518422','Non','Negation','false'
'non east asian','C0078988','ASIAN','Asians','true'
'p value for east asian versus non east asian','C1709380','P-Value','P-Value','false'
'p value for east asian versus non east asian','C0078988','ASIAN','Asians','true'
'p value for east asian versus non east asian','C1518422','Non','Negation','false'
'age years mean _ sd','C1510829','Age-Years','Age-Years','false'
'age years mean _ sd','C2699239','SD','SD, Rat Strain','false'
'weight of $nmbr$ kg n','C0005910','Weight','Body Weight','true'
'weight of $nmbr$ kg n','C0043100','Weight','Weight','true'
'weight of $nmbr$ kg n','C1305866','weight','Weighing patient','false'
'weight of $nmbr$ kg n','C1705104','Weight','Importance Weight','false'
'crcl of $nmbr$ $nmbr$ ml min n','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl of $nmbr$ $nmbr$ ml min n','C0439445','mL/min','mL/min','false'
'patients meeting the criteria to receive $nmbr$ mg of','C0030705','Patients','Patients','true'
'patients meeting the criteria to receive $nmbr$ mg of','C0556656','Meeting','Meetings','false'
'patients meeting the criteria to receive $nmbr$ mg of','C0243161','Criteria','criteria','true'
'patients meeting the criteria to receive $nmbr$ mg of','C1514756','Receive','Receive','false'
'patients meeting the criteria to receive $nmbr$ mg of','C0024671','MG','Mammography','true'
'patients meeting the criteria to receive $nmbr$ mg of','C0026410','MG','Mongolia','true'
'patients meeting the criteria to receive $nmbr$ mg of','C0439269','mg%','mg/dL','false'
'patients meeting the criteria to receive $nmbr$ mg of','C1960952','mg %','Milligram percent','false'
'patients meeting the criteria to receive $nmbr$ mg of','C2346927','Mg++','Magnesium Cation','false'
'patients meeting the criteria to receive $nmbr$ mg of','C4321396','MG','MG','false'
'patients meeting the criteria to receive $nmbr$ mg of','C4521761','MG','United States Military Commissioned Officer O8','false'
'edoxaban at randomization n','C2975435','EDOXABAN','edoxaban','true'
'edoxaban at randomization n','C0034656','Randomization','Randomization','true'
'anatomic extent of qualifying event n x','C0220784','Anatomic','anatomic','false'
'anatomic extent of qualifying event n x','C0439792','Extent','Extent','false'
'anatomic extent of qualifying event n x','C1514624','Qualifying','Qualifying','false'
'anatomic extent of qualifying event n x','C0441471','Event','Event','false'
'anatomic extent of qualifying event n x','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'concomitant dvt n','C0521115','Concomitant','Simultaneous','false'
'concomitant dvt n','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'concomitant dvt n','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'concomitant dvt n','C3899446','DVT','Data Validation Test Document','false'
'right ventricular dysfunction n n j','C0242707','Right Ventricular Dysfunction','Right Ventricular Dysfunction','true'
'right ventricular dysfunction n n j','C1556315','Right ventricular dysfunction','Right Ventricular Dysfunction, CTCAE','false'
'causes of dvt or pe n','C0015127','causes','Etiology aspects','true'
'causes of dvt or pe n','C1314792','Causes','Etiology','true'
'causes of dvt or pe n','C0070939','PE','phosphoethanolamine','true'
'causes of dvt or pe n','C1880476','PE','Etoposide-Platinol Regimen','false'
'causes of dvt or pe n','C4284304','PE','PENK wt Allele','false'
'index event n','C0600653','Index','Indexes','true'
'index event n','C0441471','Event','Event','false'
'index event n','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'index event n','C0918012','Index','Index','true'
'index event n','C1552854','index','Html Link Type - index','false'
'index event n','C1637833','% index','% index','false'
'index event n','C2986546','Index','Target Lesion Identification','false'
'non east asianf','C1518422','Non','Negation','false'
'non east asianf','C1707877','East','East','false'
'edoxaban n $nmbr$ n n','C2975435','EDOXABAN','edoxaban','true'
'warfarin n $nmbr$ n n','C0043031','WARFARIN','Warfarin','true'
'hr with edoxaban $nmbr$ ci','C2975435','EDOXABAN','edoxaban','true'
'hr with edoxaban $nmbr$ ci','C0008107','CI','Chile','true'
'hr with edoxaban $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'event during overall','C0441471','Event','Event','false'
'event during overall','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'study period fatal pe','C0070939','PE','phosphoethanolamine','true'
'study period fatal pe','C1880476','PE','Etoposide-Platinol Regimen','false'
'study period fatal pe','C4284304','PE','PENK wt Allele','false'
'death with pe not','C0011065','DEATH','Cessation of life','true'
'death with pe not','C1306577','Death','Death (finding)','false'
'death with pe not','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death with pe not','C4552775','Death NOS','Death NOS, CTCAE','false'
'death with pe not','C1518422','Not','Negation','false'
'ruled out non fatal pe with or','C1446409','ruled','Positive','false'
'ruled out non fatal pe with or','C0070939','PE','phosphoethanolamine','true'
'ruled out non fatal pe with or','C1880476','PE','Etoposide-Platinol Regimen','false'
'ruled out non fatal pe with or','C4284304','PE','PENK wt Allele','false'
'without dvt dvt alone','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'without dvt dvt alone','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'without dvt dvt alone','C3899446','DVT','Data Validation Test Document','false'
'without dvt dvt alone','C0205171','Alone','Singular','false'
'without dvt dvt alone','C0439044','Alone','Living Alone','false'
'without dvt dvt alone','C0679994','alone','alone - group size','false'
'event during on','C0441471','Event','Event','false'
'event during on','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'treatment period index dvt event','C0441471','Event','Event','false'
'treatment period index dvt event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'during overall study period','C0439531','/period','per period (qualifier value)','false'
'during overall study period','C1948053','Period','Period (temporal qualifier)','false'
'index pe event during','C0441471','Event','Event','false'
'index pe event during','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'overall study period','C0439531','/period','per period (qualifier value)','false'
'overall study period','C1948053','Period','Period (temporal qualifier)','false'
'gaviscon da n $nmbr$','C0061146','Gaviscon','Gaviscon','true'
'gaviscon da n $nmbr$','C0011318','DA','Denmark','true'
'gaviscon da n $nmbr$','C3668815','DA','Displacement of abomasum','false'
'bmi kg m $nmbr$ median range','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ median range','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ median range','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ median range','C1514721','Range','Range','false'
'bmi kg m $nmbr$ median range','C2348147','Range','Sample Range','false'
'bmi kg m $nmbr$ median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'la grade a n f','C0441800','Grade','Grade','false'
'la grade a n f','C0919553','Grade','Histopathologic Grade','false'
'la grade a n f','C3244287','grade','School Grade','false'
'la grade a n f','C0369718','N NOS','N not otherwise specified Antibody','false'
'la grade a n f','C0016327','F-','Fluorides','true'
'la grade a n f','C0441922','N+','N+ (tumor staging)','false'
'la grade b n f','C1881342','LA Grade B','LA Grade B','false'
'la grade b n f','C0016327','F-','Fluorides','true'
'fdc $nmbr$ $nmbr$ g n $nmbr$','C0340427','FDC','Familial dilated cardiomyopathy','true'
'fdc $nmbr$ $nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'fdc $nmbr$ $nmbr$ g n $nmbr$','C1413520','FDC','CMD1B gene','false'
'fdc $nmbr$ $nmbr$ g n $nmbr$','C3539652','FDC','LAG3 wt Allele','false'
'aclidinium $nmbr$ g n $nmbr$','C2699757','ACLIDINIUM','aclidinium','false'
'aclidinium $nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'formoterol $nmbr$ g n $nmbr$','C0060657','FORMOTEROL','formoterol','true'
'formoterol $nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'post bronchodilator fev $nmbr$ predicted','C0681842','Predicted','prediction','false'
'post bronchodilator fev $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'number of exacerbations in previous $nmbr$ months','C0237753','*Number','Numbers','false'
'number of exacerbations in previous $nmbr$ months','C0449788','Number','Count of entities','false'
'number of exacerbations in previous $nmbr$ months','C0205156','Previous','Previous','false'
'number of exacerbations in previous $nmbr$ months','C0439231','MONTHS','month','false'
'number of exacerbations in previous $nmbr$ months','C1552607','previous','Act Relationship Subset - previous','false'
'prior copd medicationa n','C0332152','Prior','Before','false'
'prior copd medicationa n','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'prior copd medicationa n','C1412502','COPD','ARCN1 gene','false'
'prior copd medicationa n','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'prior copd medicationa n','C2826257','PRIOR','Prior Medication Usage','false'
'any copd medication','C0013227','Medication','Pharmaceutical Preparations','true'
'any copd medication','C3244316','medication','medication - HL7 publishing domain','false'
'any copd medication','C4284232','Medication','Medications','false'
'laba ics','C0815320','ICS','Impaired Control Scale','false'
'laba ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'lama','C0999593','Lama','Lama','false'
'lama','C1416775','LAMA','LAMA1 gene','false'
'bdi focal score','C0449820','SCORE','Score','false'
'bdi focal score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'e rs total scoreb','C0035970','RS','Russia','true'
'e rs total scoreb','C0439175','% total','% of total','false'
'e rs total scoreb','C0439810','Total','Total','false'
'e rs total scoreb','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'e rs total scoreb','C3813325','RS','Disease Response Domain','false'
'overall night time copd symptom severity scorec','C0240526','Night Time','Night time','false'
'overall night time copd symptom severity scorec','C1319166','Symptom severity NOS','Symptom severity level','false'
'overall early morning copd symptom severity scorec','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'overall early morning copd symptom severity scorec','C1319166','Symptom severity NOS','Symptom severity level','false'
'overall early morning copd symptom severity scorec','C1412502','COPD','ARCN1 gene','false'
'overall early morning copd symptom severity scorec','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'gold group n','C0018026','GOLD','Gold','true'
'gold group n','C0441848','Group N','Group N','false'
'gold group n','C1304897','Gold','Gold color','false'
'gold group','C0441833','Group','Groups','false'
'gold group','C0687744','group','Social group','false'
'gold group','C1257890','Group','Population Group','true'
'gold group','C1519504','Group','Stage Grouping','false'
'gold group','C1705428','Group','Group Object','false'
'gold group','C1705429','Group','User Group','false'
'fdc $nmbr$ $nmbr$ pg vs placebo','C0030827','PG','Penicillin G','true'
'fdc $nmbr$ $nmbr$ pg vs placebo','C0072225','PG','Propylene glycol','true'
'fdc $nmbr$ $nmbr$ pg vs placebo','C1266240','PG','Prostaglandin measurement','false'
'fdc $nmbr$ $nmbr$ pg vs placebo','C0032042','Placebo','Placebos','true'
'fdc $nmbr$ $nmbr$ pg vs placebo','C1696465','PLACEBO','placebo','false'
'fdc $nmbr$ $nmbr$ pg vs placebo','C1706408','PLACEBO','Placebo Control','false'
'fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg','C0030827','PG','Penicillin G','true'
'fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'fdc $nmbr$ $nmbr$ pg vs aclidinium $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg','C0030827','PG','Penicillin G','true'
'fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'fdc $nmbr$ $nmbr$ pg vs formoterol $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'aclidinium $nmbr$ pg vs placebo','C0030827','PG','Penicillin G','true'
'aclidinium $nmbr$ pg vs placebo','C0072225','PG','Propylene glycol','true'
'aclidinium $nmbr$ pg vs placebo','C1266240','PG','Prostaglandin measurement','false'
'aclidinium $nmbr$ pg vs placebo','C0032042','Placebo','Placebos','true'
'aclidinium $nmbr$ pg vs placebo','C1696465','PLACEBO','placebo','false'
'aclidinium $nmbr$ pg vs placebo','C1706408','PLACEBO','Placebo Control','false'
'formoterol $nmbr$ pg vs placebo','C0030827','PG','Penicillin G','true'
'formoterol $nmbr$ pg vs placebo','C0072225','PG','Propylene glycol','true'
'formoterol $nmbr$ pg vs placebo','C1266240','PG','Prostaglandin measurement','false'
'formoterol $nmbr$ pg vs placebo','C0032042','Placebo','Placebos','true'
'formoterol $nmbr$ pg vs placebo','C1696465','PLACEBO','placebo','false'
'formoterol $nmbr$ pg vs placebo','C1706408','PLACEBO','Placebo Control','false'
'fdc $nmbr$ $nmbr$ pg','C0030827','PG','Penicillin G','true'
'fdc $nmbr$ $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'fdc $nmbr$ $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'rr $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C4554402','RR','RR genotype','false'
'aclidinium $nmbr$ pg','C0030827','PG','Penicillin G','true'
'aclidinium $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'aclidinium $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'formoterol $nmbr$ pg','C0030827','PG','Penicillin G','true'
'formoterol $nmbr$ pg','C0072225','PG','Propylene glycol','true'
'formoterol $nmbr$ pg','C1266240','PG','Prostaglandin measurement','false'
'exact b','C2828393','Exact','Exact (qualifier)','false'
'exact b','C4050514','EXACT','Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire','false'
'outcome type','C0332307','TYPE','Type - attribute','false'
'outcome type','C1547052','*Type','*Type - Kind of quantity','false'
'outcome severity','C0439793','Severity','Severities','false'
'outcome severity','C0522510','Severity','With intensity','false'
'any severity','C0439793','Severity','Severities','false'
'any severity','C0522510','Severity','With intensity','false'
'moderate severity','C0439793','Severity','Severities','false'
'moderate severity','C0522510','Severity','With intensity','false'
'baseline ics','C0815320','ICS','Impaired Control Scale','false'
'baseline ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'with concomitant ics','C0815320','ICS','Impaired Control Scale','false'
'with concomitant ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'without concomitant ics','C0815320','ICS','Impaired Control Scale','false'
'without concomitant ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'rr $nmbr$ $nmbr$','C4554402','RR','RR genotype','false'
'teaes cases per $nmbr$ patient years ci','C0868928','Cases','Case (situation)','false'
'teaes cases per $nmbr$ patient years ci','C1533148','Cases','Case unit dose','false'
'mtx $nmbr$ mg week','C0332174','/week','Weekly','false'
'mtx $nmbr$ mg week','C0439230','Week','week','false'
'mtx $nmbr$ $nmbr$ mg week','C0332174','/week','Weekly','false'
'mtx $nmbr$ $nmbr$ mg week','C0439230','Week','week','false'
'czp $nmbr$ mg','C0024671','MG','Mammography','true'
'czp $nmbr$ mg','C0026410','MG','Mongolia','true'
'czp $nmbr$ mg','C0439269','mg%','mg/dL','false'
'czp $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'czp $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'czp $nmbr$ mg','C4321396','MG','MG','false'
'czp $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'related to study druga','C0439849','Related','Relationships','false'
'related to study druga','C0445223','Related','Related personal status','false'
'leading to study withdrawal','C0332152','Leading','Before','false'
'leading to study withdrawal','C0557651','Study','Room of building - Study','false'
'leading to study withdrawal','C2603343','Study','Study','false'
'leading to study withdrawal','C1522538','Leading','Leading','false'
'leading to death','C0332152','Leading','Before','false'
'leading to death','C0011065','DEATH','Cessation of life','true'
'leading to death','C1306577','Death','Death (finding)','false'
'leading to death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'leading to death','C4552775','Death NOS','Death NOS, CTCAE','false'
'leading to death','C1522538','Leading','Leading','false'
'gastrointestinal gi disorders','C0017178','GASTROINTESTINAL DISORDERS','Gastrointestinal Diseases','true'
'gastrointestinal gi disorders','C1708130','Gi','GNAI1 wt Allele','false'
'gastrointestinal gi disorders','C3539617','GI','Digestive System Findings Domain','false'
'gastrointestinal gi disorders','C4050121','GI','Gastrointestinal studies and measurements','false'
'infections','C3714514','Infections','Infection','true'
'serious teaes','C0205404','Serious','Serious','false'
'most frequent gi disorders','C0332183','Frequent','Frequently','false'
'most frequent gi disorders','C0012634','Disorders','Disease','true'
'nausea','C0027497','NAUSEA','Nausea','true'
'nausea','C1963179','Nausea','Nausea, CTCAE 3.0','false'
'nausea','C2984057','Nausea','Have Nausea','false'
'nausea','C3829611','Nausea','How Much Nausea During This Period','false'
'nausea','C4084796','Nausea','How Often Nausea','false'
'nausea','C4085222','Nausea','How Much Distress Nausea','false'
'nausea','C4085661','Nausea','Usual Severity Nausea','false'
'nausea','C4085862','Nausea','Bothered by Nausea','false'
'nausea','C4255480','Nausea','Nausea:Presence or Threshold:Point in time:^Patient:Ordinal','false'
'nausea','C4552888','Nausea','Nausea Visual Analogue Scale','false'
'nausea','C4552889','Nausea','Feel Nausea','false'
'nausea','C4553767','Nausea','Nausea, CTCAE 5.0','false'
'most frequent infections','C0239998','Frequent infections','Recurrent infections','false'
'urinary tract infection','C0042029','URINARY TRACT INFECTION','Urinary tract infection','true'
'urinary tract infection','C0262655','Urinary tract infection','Recurrent urinary tract infection','false'
'urinary tract infection','C4554638','Urinary tract infection','Urinary Tract Infection, CTCAE','false'
'nasopharyngitis','C0027441','NASOPHARYNGITIS','Nasopharyngitis','true'
'upper respiratory tract infection','C0041912','Infection, Upper Respiratory Tract','Upper Respiratory Infections','true'
'most frequent non infectious teaesb','C0332183','Frequent','Frequently','false'
'most frequent non infectious teaesb','C1518422','Non','Negation','false'
'back pain','C0004604','BACKPAIN','Back Pain','true'
'back pain','C1963071','Back pain','Back Pain, CTCAE 3.0','false'
'back pain','C4553945','Back pain','Back Pain, CTCAE 5.0','false'
'rheumatoid arthritis','C0003873','RHEUMATOID ARTHRITIS','Rheumatoid Arthritis','true'
'headache','C0018681','HEADACHE','Headache','true'
'headache','C4553197','Headache','Headache, CTCAE','false'
'pyrexia','C0015967','PYREXIA','Fever','true'
'rash','C0015230','RASH','Exanthema','true'
'contusion','C0009938','CONTUSION','Contusions','true'
'cough','C0010200','COUGH','Coughing','true'
'cough','C1961131','Cough','Cough, CTCAE','false'
'cough','C3274924','Cough','Have Been Coughing','false'
'cough','C4084725','Cough','Usual Severity Cough','false'
'cough','C4084726','Cough','How Much Distress Cough','false'
'cough','C4084727','Cough','Cough Frequency','false'
'most frequent serious teaes','C0332183','Frequent','Frequently','false'
'most frequent serious teaes','C0205404','Serious','Serious','false'
'serious infections','C0205404','Serious','Serious','false'
'serious infections','C3714514','Infections','Infection','true'
'serious gi disorder','C0205404','Serious','Serious','false'
'serious gi disorder','C0012634','Disorder','Disease','true'
'pneumonia','C0032285','PNEUMONIA','Pneumonia','true'
'erysipelas','C0014733','ERYSIPELAS','Erysipelas','true'
'disseminated tuberculosis','C0152915','Disseminated tuberculosis','Acute miliary tuberculosis','false'
'investigations','C1261322','Investigations','Evaluation procedure','false'
'alanine aminotransferase increased','C0001899','Alanine Aminotransferase','Alanine Transaminase','true'
'alanine aminotransferase increased','C0057041','Alanine amino transferase','D-Alanine Transaminase','true'
'alanine aminotransferase increased','C1415274','alanine aminotransferase','GPT gene','false'
'alanine aminotransferase increased','C3887708','Alanine Aminotransferase','Alanine Aminotransferase 1, human','false'
'alanine aminotransferase increased','C0205217','Increased','Increased','false'
'alanine aminotransferase increased','C0442805','Increased','Increase','false'
'aspartate aminotransferase increased','C0004002','Aspartate Aminotransferase','Aspartate Transaminase','true'
'aspartate aminotransferase increased','C0205217','Increased','Increased','false'
'aspartate aminotransferase increased','C0442805','Increased','Increase','false'
'c group n $nmbr$','C0441848','Group N','Group N','false'
'nc group n $nmbr$','C0027964','NC','New Caledonia','true'
'nc group n $nmbr$','C0441848','Group N','Group N','false'
'nc group n $nmbr$','C0028407','NC','North Carolina','true'
'nc group n $nmbr$','C0067895','NC','Chimerin 1','true'
'nc group n $nmbr$','C0265987','NC','Nevus comedonicus','false'
'systolic blood pressure mmhg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'systolic blood pressure mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'diastolic blood pressure mmhg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'diastolic blood pressure mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'diabetes mellitus n','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'left ventricular systolic dysfunction n','C1277187','LEFT VENTRICULAR SYSTOLIC DYSFUNCTION','Left ventricular systolic dysfunction','false'
'left ventricular systolic dysfunction n','C1963159','Left ventricular systolic dysfunction','Left Ventricular Systolic Dysfunction, CTCAE 3.0','false'
'left ventricular systolic dysfunction n','C4553199','Left ventricular systolic dysfunction','Left Ventricular Systolic Dysfunction, CTCAE 5.0','false'
'serum creatinine mg dl mean sd','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'serum creatinine mg dl mean sd','C0600061','serum creatinine','Serum creatinine level','false'
'ldl cholesterol mg dl mean sd','C0023824','LDL Cholesterol','LDL Cholesterol Lipoproteins','true'
'ldl cholesterol mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'ldl cholesterol mg dl mean sd','C0202117','LDL Cholesterol','Low density lipoprotein cholesterol measurement','false'
'hdl cholesterol mg dl mean sd','C0023822','HDL Cholesterol','High Density Lipoprotein Cholesterol','true'
'hdl cholesterol mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'hdl cholesterol mg dl mean sd','C0392885','HDL Cholesterol','High density lipoprotein measurement','false'
'triglyceride mg dl mean sd','C0439269','mg dl','mg/dL','false'
'triglyceride mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'concomitant medications after randomization','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications after randomization','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications after randomization','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications after randomization','C4284232','Medications','Medications','false'
'ca channel blockers n','C3887642','CA','Hippocampus Proper','true'
'ca channel blockers n','C0870261','channel blockers','channel blockers','false'
'nitrates n','C0028125','Nitrates','Nitrates','true'
'statins n','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'number of diseased vessels mean sd','C0237753','*Number','Numbers','false'
'number of diseased vessels mean sd','C0449788','Number','Count of entities','false'
'left main disease n','C0205091','LEFT','Left','false'
'left main disease n','C0012634','Disease','Disease','true'
'left main disease n','C0443246','Left','Left sided','false'
'left main disease n','C1552822','left','Table Cell Horizontal Align - left','false'
'type b $nmbr$ c lesions n','C4264484','Type C','Type C','false'
'type b $nmbr$ c lesions n','C0221198','lesions','Lesion','false'
'des implantation for restenosis n','C0021107','Implantation','Implantation procedure','false'
'des implantation for restenosis n','C0029976','Implantation','Blastocyst Implantation, natural','true'
'sirolimus eluting stent use n','C0038257','Stent','Stent, device','true'
'sirolimus eluting stent use n','C0042153','use','utilization qualifier','true'
'sirolimus eluting stent use n','C0457083','Use','Usage','false'
'sirolimus eluting stent use n','C1947944','Use','Use - dosing instruction imperative','false'
'paclitaxel eluting stent use n','C0038257','Stent','Stent, device','true'
'paclitaxel eluting stent use n','C0042153','use','utilization qualifier','true'
'paclitaxel eluting stent use n','C0457083','Use','Usage','false'
'paclitaxel eluting stent use n','C1947944','Use','Use - dosing instruction imperative','false'
'number of implanted stents n mean sd','C0237753','*Number','Numbers','false'
'number of implanted stents n mean sd','C0449788','Number','Count of entities','false'
'total length of implanted stents mm mean sd','C0439175','% total','% of total','false'
'total length of implanted stents mm mean sd','C0449462','Length of stent','Length of stent','false'
'total length of implanted stents mm mean sd','C0439810','Total','Total','false'
'rotablator use n','C0042153','use','utilization qualifier','true'
'rotablator use n','C0457083','Use','Usage','false'
'rotablator use n','C1947944','Use','Use - dosing instruction imperative','false'
'aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan','C0003015','Angiotensin converting enzyme--Inhibitors','Angiotensin-Converting Enzyme Inhibitors','true'
'aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan','C0151691','high low density lipoprotein','Decreased HDL cholesterol concentration','false'
'aceis angiotensin converting enzyme inhibitors c candesartan des drug eluting stent egfr estimated glomerular filtration rate hdl high density lipoprotein ldl low density lipoprotein nc non candesartan','C2757044','Angiotensin-converting Enzyme Inhibitors','Angiotensin-Converting Enzyme Inhibitors [MoA]','false'
'total ipss','C1019118','Ips','Ips <Invertebrate>','false'
'total ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'total ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'total ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'age category n $nmbr$ years','C1510829','Age-Years','Age-Years','false'
'age category n $nmbr$ years','C0683312','Category','Categories','false'
'age category n $nmbr$ years','C3889287','Category','Digital Content Category','false'
'baseline subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'baseline subgroup','C1515021','Subgroup','Subgroup','false'
'baseline sd','C0168634','baseline','BaseLine dental cement','true'
'baseline sd','C2699239','SD','SD, Rat Strain','false'
'baseline sd','C1442488','Baseline','Baseline','false'
'end point sd','C2349179','End Point','End Point','false'
'end point sd','C2699239','SD','SD, Rat Strain','false'
'end point sd','C2826544','ENDPOINT','Endpoint Value Derivation Technique','false'
'ls mean change se','C0023668','LS','Liechtenstein','true'
'ls mean change se','C0036919','SE','Seychelles','true'
'pbo adjusted ls mean change se','C0023668','LS','Liechtenstein','true'
'pbo adjusted ls mean change se','C0036919','SE','Seychelles','true'
'luts severity','C0439793','Severity','Severities','false'
'luts severity','C0522510','Severity','With intensity','false'
'mild moderate ipss $nmbr$','C1019118','Ips','Ips <Invertebrate>','false'
'mild moderate ipss $nmbr$','C1998280','IPSS','International Prostate Symptom Score','false'
'mild moderate ipss $nmbr$','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'mild moderate ipss $nmbr$','C3811063','IPS','SLC27A4 wt Allele','false'
'mean age sd','C0001779','AGE','Age','false'
'mean age sd','C2699239','SD','SD, Rat Strain','false'
'severe ipss $nmbr$ age group','C0027362','Age Group','Human Age Group','true'
'severe ipss $nmbr$ age group','C2348001','Age Group','Age Cohort','false'
'lifestyle behaviours','C0004927','Behaviours','Behavior','true'
'lifestyle behaviours','C0677505','behaviours','Behaviors and observations relating to behavior','false'
'body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'body mass index bmi kg m $nmbr$ n $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'$nmbr$ years bmi','C0439234','YEARS','year','false'
'$nmbr$ years bmi','C0578022','BMI','Finding of body mass index','false'
'mean bmi sd','C0444504','Mean','Statistical mean','false'
'mean bmi sd','C2699239','SD','SD, Rat Strain','false'
'mean bmi sd','C2347634','Mean','Population Mean','false'
'mean bmi sd','C2348143','Mean','Sample Mean','false'
'comorbidities and concomitant medications','C0009488','comorbidities','Comorbidity','true'
'comorbidities and concomitant medications','C0013227','Medications','Pharmaceutical Preparations','true'
'comorbidities and concomitant medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'comorbidities and concomitant medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'comorbidities and concomitant medications','C4284232','Medications','Medications','false'
'diabetes mellitus n yes','C1549445','Yes','Yes - Yes/no indicator','false'
'diabetes mellitus n yes','C1705108','YES','Yes (indicator)','false'
'diabetes mellitus n yes','C1710701','Yes','YES1 wt Allele','false'
'$nmbr$ kg m $nmbr$ smokers','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg m $nmbr$ smokers','C0439209','kg','Kilogram','false'
'$nmbr$ kg m $nmbr$ smokers','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg m $nmbr$ smokers','C0337664','Smokers','Smoker','true'
'glycaemic control hba $nmbr$ c n','C0243148','control','control aspects','true'
'glycaemic control hba $nmbr$ c n','C0019016','HBA','Hemoglobin A','true'
'glycaemic control hba $nmbr$ c n','C1825777','HBA','KRT90P gene','false'
'glycaemic control hba $nmbr$ c n','C3538758','HBA','SCN2A wt Allele','false'
'glycaemic control hba $nmbr$ c n','C1550141','Control','control substance','false'
'glycaemic control hba $nmbr$ c n','C1882979','Control','Scientific Control','false'
'glycaemic control hba $nmbr$ c n','C2587213','Control','Control function','false'
'glycaemic control hba $nmbr$ c n','C3274648','Control','True Control Status','false'
'glycaemic control hba $nmbr$ c n','C4553389','control','Study Control','false'
'diabetic therapy use n no therapy','C0039798','therapy','therapeutic aspects','true'
'diabetic therapy use n no therapy','C0042153','use','utilization qualifier','true'
'diabetic therapy use n no therapy','C0457083','Use','Usage','false'
'diabetic therapy use n no therapy','C1947944','Use','Use - dosing instruction imperative','false'
'diabetic therapy use n no therapy','C0087111','Therapy','Therapeutic procedure','true'
'diabetic therapy use n no therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'oral agent','C0450442','Agent','Agent','false'
'oral agent','C1254351','Agent','Pharmacologic Substance','false'
'oral agent','C1521826','Agent','Protocol Agent','false'
'glycaemic control group','C0009932','Control Group','Control Groups','true'
'oral agent and or insulin therapy','C0450442','Agent','Agent','false'
'oral agent and or insulin therapy','C1254351','Agent','Pharmacologic Substance','false'
'oral agent and or insulin therapy','C1521826','Agent','Protocol Agent','false'
'oral agent and or insulin therapy','C0021641','INSULIN','Insulin','true'
'oral agent and or insulin therapy','C0039798','therapy','therapeutic aspects','true'
'oral agent and or insulin therapy','C0087111','Therapy','Therapeutic procedure','true'
'oral agent and or insulin therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'oral agent and or insulin therapy','C1533581','INSULIN','Recombinant Insulin','false'
'oral agent and or insulin therapy','C1579433','Insulin','Insulin [EPC]','false'
'oral agent and or insulin therapy','C3714501','INSULIN','Insulin Drug Class','false'
'hba $nmbr$ c $nmbr$ $nmbr$','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c $nmbr$ $nmbr$','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c $nmbr$ $nmbr$','C3538758','HBA','SCN2A wt Allele','false'
'hyperlipidaemia n yes','C1549445','Yes','Yes - Yes/no indicator','false'
'hyperlipidaemia n yes','C1705108','YES','Yes (indicator)','false'
'hyperlipidaemia n yes','C1710701','Yes','YES1 wt Allele','false'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C0020473','Hyperlipidaemia, NOS','Hyperlipidemia','true'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C0039798','therapy','therapeutic aspects','true'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C0087111','Therapy','Therapeutic procedure','true'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C0428465','Hyperlipidemia','Serum lipids high (finding)','false'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C4555212','Hyperlipidemia','Hyperlipidemia, CTCAE','false'
'hyperlipidaemia therapy use n no lipid lowering agent therapy','C0585943','Lipid-lowering therapy','Lipid-lowering therapy','false'
'combined insulin oral hypoglycaemic agent use','C0240016','INSULIN USE','Insulin used','false'
'statin medication','C0013227','Medication','Pharmaceutical Preparations','true'
'statin medication','C3244316','medication','medication - HL7 publishing domain','false'
'statin medication','C4284232','Medication','Medications','false'
'other lipid lowering medication','C0023779','Lipid','Lipids','true'
'other lipid lowering medication','C0441994','lowering','Lower - spatial qualifier','false'
'other lipid lowering medication','C2003888','Lowering','Lower (action)','false'
'other lipid lowering medication','C0013227','Medication','Pharmaceutical Preparations','true'
'other lipid lowering medication','C3244316','medication','medication - HL7 publishing domain','false'
'other lipid lowering medication','C4284232','Medication','Medications','false'
'statin and or other lipid lowering agent therapy','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statin and or other lipid lowering agent therapy','C0585943','Lipid-lowering therapy','Lipid-lowering therapy','false'
'hypertension n yes','C1549445','Yes','Yes - Yes/no indicator','false'
'hypertension n yes','C1705108','YES','Yes (indicator)','false'
'hypertension n yes','C1710701','Yes','YES1 wt Allele','false'
'antihypertensive medication use n','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'antihypertensive medication use n','C0240320','MEDICATION USE','medication use','false'
'number of antihypertensive medications used n no antihypertensive therapy','C1718138','Number of medications','Number of medications','false'
'number of antihypertensive medications used n no antihypertensive therapy','C0585941','Antihypertensive therapy','Antihypertensive therapy','false'
'combined statin and other lipid lowering agent use','C0205195','Combined','Combined','false'
'combined statin and other lipid lowering agent use','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'combined statin and other lipid lowering agent use','C0042153','use','utilization qualifier','true'
'combined statin and other lipid lowering agent use','C0457083','Use','Usage','false'
'combined statin and other lipid lowering agent use','C1947944','Use','Use - dosing instruction imperative','false'
'type of antihypertensive medication use among patients using antihypertensive medications n','C0457591','Medication type','Type of drug','false'
'type of antihypertensive medication use among patients using antihypertensive medications n','C0030705','Patients','Patients','true'
'type of antihypertensive medication use among patients using antihypertensive medications n','C1524063','Using','Use of','false'
'type of antihypertensive medication use among patients using antihypertensive medications n','C0003364','Antihypertensive Medications','Antihypertensive Agents','true'
'antihypertensive agent use','C0042153','use','utilization qualifier','true'
'antihypertensive agent use','C0457083','Use','Usage','false'
'antihypertensive agent use','C1947944','Use','Use - dosing instruction imperative','false'
'centrally acting sympathomimetics','C3653511','Centrally acting sympathomimetics','Centrally acting sympathomimetics','false'
'number of antihypertensive agent reported','C0237753','*Number','Numbers','false'
'number of antihypertensive agent reported','C0449788','Number','Count of entities','false'
'number of antihypertensive agent reported','C0684224','Reported','Report (document)','true'
'number of antihypertensive agent reported','C0700287','Reported','Reporting','false'
'number of antihypertensive agent reported','C4319718','Reported','Reported','false'
'$nmbr$ med at baseline','C4321267','MED','COMP wt Allele','false'
'$nmbr$ med at baseline','C0168634','baseline','BaseLine dental cement','true'
'$nmbr$ med at baseline','C1442488','Baseline','Baseline','false'
'other antihypertensive agents','C0003364','Antihypertensive Agents','Antihypertensive Agents','true'
'$nmbr$ med at baseline cardiac disorder','C4321267','MED','COMP wt Allele','false'
'$nmbr$ med at baseline cardiac disorder','C0018799','Cardiac disorder','Heart Diseases','true'
'cardiac disorder n','C0018799','Cardiac disorder','Heart Diseases','true'
'cardiovascular disorder n','C0007222','CARDIOVASCULAR DISORDER (NOS)','Cardiovascular Diseases','true'
'no cardiovascular disorder $nmbr$','C0007222','CARDIOVASCULAR DISORDER (NOS)','Cardiovascular Diseases','true'
'ischaemic heart disease or cerebrovascular disorder n','C0010054','ischaemic heart disease','Coronary Arteriosclerosis','true'
'ischaemic heart disease or cerebrovascular disorder n','C0151744','Ischaemic heart disease, NOS','Myocardial Ischemia','true'
'ischaemic heart disease or cerebrovascular disorder n','C0007820','CEREBROVASCULAR DISORDER (NOS)','Cerebrovascular Disorders','true'
'cardiac arrhythmia n','C0003811','Arrhythmia, Cardiac','Cardiac Arrhythmia','true'
'cardiac arrhythmia n','C0264886','CARDIAC Arrythmia','Conduction disorder of the heart','true'
'cardiac arrhythmia n','C1560249','CARDIAC ARRHYTHMIA','Adverse Event Associated with Cardiac Arrhythmia','false'
'luts bph characteristics','C0005001','BPH','Benign prostatic hypertrophy','true'
'luts bph characteristics','C1521970','Characteristics','Characteristics','false'
'luts bph characteristics','C1704272','BPH','Benign Prostatic Hyperplasia','true'
'combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n','C0018801','CARDIAC FAILURE','Heart failure','true'
'combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n','C0878544','CARDIOMYOPATHY','Cardiomyopathies','true'
'combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n','C0018802','Cardiac Failure','Congestive heart failure','true'
'combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n','C0521117','Disorder severity','Severity of illness','false'
'combined cardiac failure cardiomyopathy or other cardiac disorder n luts severity n','C1292730','Disorder severity','Condition severity','false'
'combined ischaemic heart disease and or cerebrovascular disorder','C0010054','ischaemic heart disease','Coronary Arteriosclerosis','true'
'combined ischaemic heart disease and or cerebrovascular disorder','C0151744','Ischaemic heart disease, NOS','Myocardial Ischemia','true'
'combined ischaemic heart disease and or cerebrovascular disorder','C0007820','CEREBROVASCULAR DISORDER (NOS)','Cerebrovascular Disorders','true'
'mild to moderate ipss $nmbr$','C1019118','Ips','Ips <Invertebrate>','false'
'mild to moderate ipss $nmbr$','C1998280','IPSS','International Prostate Symptom Score','false'
'mild to moderate ipss $nmbr$','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'mild to moderate ipss $nmbr$','C3811063','IPS','SLC27A4 wt Allele','false'
'mean total ipss sd','C0439175','% total','% of total','false'
'mean total ipss sd','C2699239','SD','SD, Rat Strain','false'
'mean total ipss sd','C0439810','Total','Total','false'
'mean ipss voiding subscore sd','C0042034','Voiding','Urination','true'
'mean ipss voiding subscore sd','C2699239','SD','SD, Rat Strain','false'
'mean ipss voiding subscore sd','C4067975','Voiding','Voids','false'
'mean ipss storage sub score sd','C3533236','Mean score','Mean score','false'
'mean ipss storage sub score sd','C2699239','SD','SD, Rat Strain','false'
'mean ipss qol sd','C0444504','Mean','Statistical mean','false'
'mean ipss qol sd','C2699239','SD','SD, Rat Strain','false'
'mean ipss qol sd','C2347634','Mean','Population Mean','false'
'mean ipss qol sd','C2348143','Mean','Sample Mean','false'
'combined cardiac failure cardiomyopathy or other cardiac disorders','C0018801','CARDIAC FAILURE','Heart failure','true'
'combined cardiac failure cardiomyopathy or other cardiac disorders','C0878544','CARDIOMYOPATHY','Cardiomyopathies','true'
'combined cardiac failure cardiomyopathy or other cardiac disorders','C0018802','Cardiac Failure','Congestive heart failure','true'
'combined cardiac failure cardiomyopathy or other cardiac disorders','C0018799','Cardiac Disorders','Heart Diseases','true'
'$nmbr$ uln','C1519815','ULN','Upper Limit of Normal','false'
'pi','C0122626','PI','human pancreatic eicosapeptide','true'
'pi','C0429863','PI','Pulsatility index, arterial velocity waveform','false'
'pi','C3537219','PI','SERPINA1 wt Allele','false'
'pi','C3539772','PI','STANDARDS Pain Intensity Questionnaire','false'
'prior chf','C0332152','Prior','Before','false'
'prior chf','C0018802','CHF','Congestive heart failure','true'
'prior chf','C2826257','PRIOR','Prior Medication Usage','false'
'systolic blood pressure','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'systolic blood pressure','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'systolic blood pressure','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'mm hg','C0439475','mmHG','mmHg','false'
'killip class i','C2697844','Killip Class 1','Killip Class I','false'
'timi risk score $nmbr$','C0035647','Risk','Risk','true'
'timi risk score $nmbr$','C0449820','SCORE','Score','false'
'timi risk score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'timi risk score $nmbr$','C4552904','risk','Subject Risk','false'
'inferior mi','C0340305','inferior mi','Inferior Wall Myocardial Infarction','true'
'inferior mi','C3542426','Inferior MI','Inferior Myocardial Infarction by ECG Finding','false'
'baseline rst segment elevation mm','C4330985','/mm','Per Millimeter','false'
'baseline rst segment elevation mm','C4554674','MM','MM genotype','false'
'baseline rst segment','C0168634','baseline','BaseLine dental cement','true'
'baseline rst segment','C0441635','SEGMENT','Anatomical segmentation','false'
'baseline rst segment','C1442488','Baseline','Baseline','false'
'deviation mm','C4330985','/mm','Per Millimeter','false'
'deviation mm','C4554674','MM','MM genotype','false'
'q waves in the infarct territory at baseline','C0429089','q waves','Electrocardiogram Q waves test','false'
'q waves in the infarct territory at baseline','C1305738','q waves','Q wave','false'
'q waves in the infarct territory at baseline','C0168634','baseline','BaseLine dental cement','true'
'q waves in the infarct territory at baseline','C1442488','Baseline','Baseline','false'
'figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf','C0242492','Relative Risk','Relative Risk','true'
'figure $nmbr$ relative risk plot of the $nmbr$ day composite endpoint of shock chf','C0018802','CHF','Congestive heart failure','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0441833','Groups','Groups','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0687744','groups','Social group','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1257890','Group','Population Group','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1519504','Group','Stage Grouping','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1552839','groups','Table Rules - groups','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1705428','Group','Group Object','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1705429','Group','User Group','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0013806','shock treatment','Electroconvulsive Therapy','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0018802','CHF','Congestive heart failure','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0449244','onset time','Time of onset','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0034656','Randomization','Randomization','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C1442160','Cutoff','Cutoff','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0456081','Adjusted','Adjustment Action','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0205307','NORMAL','Normal','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0231683','Normal','Gait normal','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C0439166','% normal','Percent normal','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C2347086','% Normal','Mean Percent of Normal','false'
'upper panel infarct size groups and $nmbr$ day shock chf by treatment strategy lower panel infarct size groups and $nmbr$ day shock chf by treatment strategy and pre speci ed $nmbr$ hour time from symptom onset to treatment randomization cut off adjusted for thrombolysis in myocardial infarction risk score chf indicates congestive heart failure pi pharmacoinvasive ppci primary percutaneous coronary intervention uln upper limit normal','C4553972','Normal','How Often Felt Normal question','false'
'race n y','C0034510','RACE','Racial group','true'
'race n y','C1706779','RACE','AMACR wt Allele','false'
'race n y','C3853635','Race','Race','false'
'known duration of t $nmbr$ dm y','C0449238','Duration','Duration (temporal concept)','false'
'known duration of t $nmbr$ dm y','C2926735','Duration','Duration','false'
'history of cvd n','C0019664','History','History','true'
'history of cvd n','C0019665','history','Historical aspects qualifier','true'
'history of cvd n','C0262512','History, NOS','History of present illness','false'
'history of cvd n','C0262926','History','Medical History','false'
'history of cvd n','C1705255','History','Concept History','false'
'history of cvd n','C2004062','History','History of previous events','false'
'goal','C0018017','Goal','objective (goal)','true'
'goal','C1571704','Goal','Act Mood - Goal','false'
'baseline n','C0168634','baseline','BaseLine dental cement','true'
'baseline n','C1442488','Baseline','Baseline','false'
'week $nmbr$ n','C0332174','/week','Weekly','false'
'week $nmbr$ n','C0439230','Week','week','false'
'or for cana vs pbo $nmbr$ ci','C1418845','CANA','PPP3CA gene','false'
'or for cana vs pbo $nmbr$ ci','C0008107','CI','Chile','true'
'or for cana vs pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'p value nominal','C1709380','P-Value','P-Value','false'
'body weight reduction $nmbr$','C1262477','Weight Reduction','Weight decreased','true'
'week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci','C0332174','/week','Weekly','false'
'week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci','C0439230','Week','week','false'
'week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci','C1418845','CANA','PPP3CA gene','false'
'week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci','C0008107','CI','Chile','true'
'week $nmbr$ n $nmbr$ or for cana vs pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'week $nmbr$ n or for cana vs pbo $nmbr$ ci','C0332174','/week','Weekly','false'
'week $nmbr$ n or for cana vs pbo $nmbr$ ci','C0439230','Week','week','false'
'week $nmbr$ n or for cana vs pbo $nmbr$ ci','C1418845','CANA','PPP3CA gene','false'
'week $nmbr$ n or for cana vs pbo $nmbr$ ci','C0008107','CI','Chile','true'
'week $nmbr$ n or for cana vs pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'hdl c $nmbr$ mg dl $nmbr$ $nmbr$ mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'composite endpoint a $nmbr$ c','C0205199','Composite','Composite','false'
'composite endpoint a $nmbr$ c','C1547335','Composite','Data types- Composite','false'
'[ $nmbr$ $nmbr$ mmol l]','C1532563','mmol/L','Millimole per Liter','false'
'week $nmbr$ n ^','C0332174','/week','Weekly','false'
'week $nmbr$ n ^','C0439230','Week','week','false'
'male patients','C0150904','male patients','patient is male','false'
'female patients^','C0150905','female patients','patient is female','false'
'week $nmbr$ n j','C0332174','/week','Weekly','false'
'week $nmbr$ n j','C0439230','Week','week','false'
'week $nmbr$ n $nmbr$','C0332174','/week','Weekly','false'
'week $nmbr$ n $nmbr$','C0439230','Week','week','false'
'black race','C0005680','BLACK RACE','Black race','true'
'russia georgia','C0017452','Georgia','Georgia, USA','true'
'russia georgia','C0017454','GEORGIA','Georgia, Western Asia','true'
'history of hf hospitalization','C0551577','History of Hospitalization','History of hospitalizations:Finding:Point in time:^Patient:Nominal:Reported','false'
'history of hf hospitalization','C0018488','Hf','Hafnium','true'
'history of hf hospitalization','C1313497','HF','GZMA protein, human','true'
'history of hf hospitalization','C1538440','HF','CFH gene','false'
'history of hf hospitalization','C3273279','HF','CFH wt Allele','false'
'history of diabetes nyha class','C0019664','History','History','true'
'history of diabetes nyha class','C0019665','history','Historical aspects qualifier','true'
'history of diabetes nyha class','C0262512','History, NOS','History of present illness','false'
'history of diabetes nyha class','C0262926','History','Medical History','false'
'history of diabetes nyha class','C1705255','History','Concept History','false'
'history of diabetes nyha class','C2004062','History','History of previous events','false'
'heart rate b p m','C0018810','Heart Rate','heart rate','true'
'body mass index mg m $nmbr$','C0024671','MG','Mammography','true'
'body mass index mg m $nmbr$','C0026410','MG','Mongolia','true'
'body mass index mg m $nmbr$','C0439269','mg%','mg/dL','false'
'body mass index mg m $nmbr$','C1960952','mg %','Milligram percent','false'
'body mass index mg m $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'body mass index mg m $nmbr$','C4321396','MG','MG','false'
'body mass index mg m $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'ace arb','C1452534','ACE','ACE protein, human','true'
'ace arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'ace arb','C4284014','ACE','Adverse Childhood Experience Survey','false'
'all patients n $nmbr$ $nmbr$','C0030705','Patients','Patients','true'
'ejection fraction group','C0441833','Group','Groups','false'
'ejection fraction group','C0687744','group','Social group','false'
'ejection fraction group','C1257890','Group','Population Group','true'
'ejection fraction group','C1519504','Group','Stage Grouping','false'
'ejection fraction group','C1705428','Group','Group Object','false'
'ejection fraction group','C1705429','Group','User Group','false'
'continuous lvef $nmbr$ treatment interaction','C0039798','treatment','therapeutic aspects','true'
'continuous lvef $nmbr$ treatment interaction','C1704675','Interaction','Interaction','false'
'continuous lvef $nmbr$ treatment interaction','C0087111','Treatment','Therapeutic procedure','true'
'continuous lvef $nmbr$ treatment interaction','C1522326','Treatment','Treating','false'
'continuous lvef $nmbr$ treatment interaction','C1533734','Treatment','Administration procedure','false'
'continuous lvef $nmbr$ treatment interaction','C1705169','Treatment','Biomaterial Treatment','false'
'continuous lvef $nmbr$ treatment interaction','C3538994','TREATMENT','Treatment Epoch','false'
'continuous lvef $nmbr$ treatment interaction','C3887704','treatment','treatment - ActInformationManagementReason','false'
'primary endpoint','C2986535','Primary Endpoint','Primary Endpoint','false'
'event rate per $nmbr$','C0871208','Rate','Rating (action)','false'
'event rate per $nmbr$','C1521828','Rate','Rate','false'
'patient years hr unadjusted','C0030705','*^patient','Patients','true'
'patient years hr unadjusted','C0439234','YEARS','year','false'
'patient years hr unadjusted','C1439367','unadjusted','unadjusted','false'
'referent','C1706462','Referent','Reference Object','false'
'treatment effect hr','C1518681','Treatment Effect','Outcome of Therapy','false'
'hf hospitalization','C0018488','Hf','Hafnium','true'
'hf hospitalization','C0019993','hospitalisation','Hospitalization','true'
'hf hospitalization','C1313497','HF','GZMA protein, human','true'
'hf hospitalization','C1538440','HF','CFH gene','false'
'hf hospitalization','C3273279','HF','CFH wt Allele','false'
'no of hospitalised patients','C0030705','Patients','Patients','true'
'aplxaban $nmbr$ $nmbr$ mg bid','C0024671','MG','Mammography','true'
'aplxaban $nmbr$ $nmbr$ mg bid','C0026410','MG','Mongolia','true'
'aplxaban $nmbr$ $nmbr$ mg bid','C0439269','mg%','mg/dL','false'
'aplxaban $nmbr$ $nmbr$ mg bid','C1960952','mg %','Milligram percent','false'
'aplxaban $nmbr$ $nmbr$ mg bid','C2346927','Mg++','Magnesium Cation','false'
'aplxaban $nmbr$ $nmbr$ mg bid','C4321396','MG','MG','false'
'aplxaban $nmbr$ $nmbr$ mg bid','C4521761','MG','United States Military Commissioned Officer O8','false'
'apixaban $nmbr$ mg bid','C0024671','MG','Mammography','true'
'apixaban $nmbr$ mg bid','C0026410','MG','Mongolia','true'
'apixaban $nmbr$ mg bid','C0439269','mg%','mg/dL','false'
'apixaban $nmbr$ mg bid','C1960952','mg %','Milligram percent','false'
'apixaban $nmbr$ mg bid','C2346927','Mg++','Magnesium Cation','false'
'apixaban $nmbr$ mg bid','C4321396','MG','MG','false'
'apixaban $nmbr$ mg bid','C4521761','MG','United States Military Commissioned Officer O8','false'
'pe with or without dvt','C0070939','PE','phosphoethanolamine','true'
'pe with or without dvt','C1880476','PE','Etoposide-Platinol Regimen','false'
'pe with or without dvt','C4284304','PE','PENK wt Allele','false'
'pe with or without dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'pe with or without dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'pe with or without dvt','C3899446','DVT','Data Validation Test Document','false'
'apixaban $nmbr$ $nmbr$ mg bid','C0024671','MG','Mammography','true'
'apixaban $nmbr$ $nmbr$ mg bid','C0026410','MG','Mongolia','true'
'apixaban $nmbr$ $nmbr$ mg bid','C0439269','mg%','mg/dL','false'
'apixaban $nmbr$ $nmbr$ mg bid','C1960952','mg %','Milligram percent','false'
'apixaban $nmbr$ $nmbr$ mg bid','C2346927','Mg++','Magnesium Cation','false'
'apixaban $nmbr$ $nmbr$ mg bid','C4321396','MG','MG','false'
'apixaban $nmbr$ $nmbr$ mg bid','C4521761','MG','United States Military Commissioned Officer O8','false'
'level of renal impairment','C0441889','Level','Levels (qualifier value)','false'
'level of renal impairment','C0456079','Level','Disease classification level','false'
'level of renal impairment','C1547707','Level','Floor - story of building','false'
'level of renal impairment','C2946261','Level','Level','false'
'severe or moderate','C0205082','Severe','Severe (severity modifier)','false'
'severe or moderate','C4050465','Severe','Severe Extremity Pain','false'
'severe or moderate','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'severe or moderate','C0205081','Moderate','Moderate (severity modifier)','false'
'severe or moderate','C1881878','Moderate','Moderation','false'
'severe or moderate','C4049705','Moderate','Moderate Extremity Pain','false'
'severe or moderate','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'severe or moderate','C4085643','Moderate','Moderate Response','false'
'severe or moderate','C4321335','Moderate','Moderate Level','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C4684572','Baseline Characteristics','Baseline Characteristics','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C0205363','Stratified','Stratified','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C0039798','treatment','therapeutic aspects','true'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C0087111','Treatment','Therapeutic procedure','true'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C1522326','Treatment','Treating','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C1533734','Treatment','Administration procedure','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C1705169','Treatment','Biomaterial Treatment','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C3538994','TREATMENT','Treatment Epoch','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C3887704','treatment','treatment - ActInformationManagementReason','false'
'table $nmbr$ baseline characteristics of total study sample and stratified by treatment assignment and testosterone levela','C0039601','TESTOSTERONE','Testosterone','true'
'main effect baseline hormone','C0019932','Hormone','Hormones','true'
'main effect baseline hormone','C4521914','Hormone','Hormone (disposition)','false'
'baseline total ipss','C1019118','Ips','Ips <Invertebrate>','false'
'baseline total ipss','C1998280','IPSS','International Prostate Symptom Score','false'
'baseline total ipss','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'baseline total ipss','C3811063','IPS','SLC27A4 wt Allele','false'
'unadjusteda beta se','C0330390','Beta','Beta plant','false'
'unadjusteda beta se','C0036919','SE','Seychelles','true'
'unadjusteda beta se','C0439096','Beta','Beta greek letter','false'
'unadjusteda beta se','C2004068','Beta','Beta (qualifier)','false'
'adjustedb c beta se','C0330390','Beta','Beta plant','false'
'adjustedb c beta se','C0036919','SE','Seychelles','true'
'adjustedb c beta se','C0439096','Beta','Beta greek letter','false'
'adjustedb c beta se','C2004068','Beta','Beta (qualifier)','false'
'stratified by','C0205363','Stratified','Stratified','false'
'linear regression','C0023733','Linear Regression','Linear Regression','true'
'linear regression','C2346679','Linear Regression','Linear Regression Body Surface Area Formula for Infants and Children','false'
'treatment randomization','C0039798','treatment','therapeutic aspects','true'
'treatment randomization','C0034656','Randomization','Randomization','true'
'treatment randomization','C0087111','Treatment','Therapeutic procedure','true'
'treatment randomization','C1522326','Treatment','Treating','false'
'treatment randomization','C1533734','Treatment','Administration procedure','false'
'treatment randomization','C1705169','Treatment','Biomaterial Treatment','false'
'treatment randomization','C3538994','TREATMENT','Treatment Epoch','false'
'treatment randomization','C3887704','treatment','treatment - ActInformationManagementReason','false'
'testosterone level nmol l','C0428412','testosterone level','Testosterone level result','false'
'testosterone level nmol l','C0439282','nmol/L','Nanomole/liter','false'
'testosterone level nmol l','C0523912','Testosterone level','Testosterone measurement','false'
'testosterone nmol l','C0039601','TESTOSTERONE','Testosterone','true'
'testosterone nmol l','C0439282','nmol/L','Nanomole/liter','false'
'continuous','C0549178','CONTINUOUS','Continuous','false'
'low tt','C1452561','TT','East Timor','true'
'low tt','C4554543','TT','TT genotype','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C0205250','High','High','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C1299351','High','Abnormally high','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C2700149','HIGH','Value Above Reference Range','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C3887512','high','high - ActExposureLevelCode','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C4321237','High','High Level','false'
'high tt $nmbr$ $nmbr$ n $nmbr$','C4522209','High','IPSS Risk Category High','false'
'estradiol pmol l','C0014912','Oestradiol','Estradiol','true'
'estradiol pmol l','C0439284','pmol/L','Picomole per Liter','false'
'baseline outcomes','C0168634','baseline','BaseLine dental cement','true'
'baseline outcomes','C1274040','Outcome','Result','false'
'baseline outcomes','C1442488','Baseline','Baseline','false'
'logistic regression','C0206031','Logistic Regression','Logistic Regression','true'
'odds ratios $nmbr$ ci','C0008107','CI','Chile','true'
'odds ratios $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'ipss v','C1019118','Ips','Ips <Invertebrate>','false'
'ipss v','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss v','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss v','C3811063','IPS','SLC27A4 wt Allele','false'
'moderate $nmbr$ $nmbr$','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate $nmbr$ $nmbr$','C1881878','Moderate','Moderation','false'
'moderate $nmbr$ $nmbr$','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate $nmbr$ $nmbr$','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate $nmbr$ $nmbr$','C4085643','Moderate','Moderate Response','false'
'moderate $nmbr$ $nmbr$','C4321335','Moderate','Moderate Level','false'
'ipss s','C1019118','Ips','Ips <Invertebrate>','false'
'ipss s','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss s','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss s','C3811063','IPS','SLC27A4 wt Allele','false'
'severe $nmbr$','C0205082','Severe','Severe (severity modifier)','false'
'severe $nmbr$','C4050465','Severe','Severe Extremity Pain','false'
'severe $nmbr$','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'ipss categories','C1019118','Ips','Ips <Invertebrate>','false'
'ipss categories','C0683312','Categories','Categories','false'
'ipss categories','C1998280','IPSS','International Prostate Symptom Score','false'
'ipss categories','C2827405','IPSS','International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes','false'
'ipss categories','C3811063','IPS','SLC27A4 wt Allele','false'
'hormones','C0019932','Hormones','Hormones','true'
'testosterone tt nmol l','C0039601','TESTOSTERONE','Testosterone','true'
'testosterone tt nmol l','C0439282','nmol/L','Nanomole/liter','false'
'estradiol e $nmbr$ pmol l','C0014912','Oestradiol','Estradiol','true'
'estradiol e $nmbr$ pmol l','C0439284','pmol/L','Picomole per Liter','false'
'estradiol quartiles','C0014912','Oestradiol','Estradiol','true'
'estradiol quartiles','C2828255','Quartile','Quartile','false'
'$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l','C0036056','ST','Saint Lucia','true'
'$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l','C0439284','pmol/L','Picomole per Liter','false'
'$nmbr$ st $nmbr$ $nmbr$ $nmbr$ pmol l','C3272372','ST','Character String Data Type','false'
'$nmbr$ nd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l','C0439284','pmol/L','Picomole per Liter','false'
'$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l','C0694666','RD','Right deltoid','false'
'$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l','C0439284','pmol/L','Picomole per Liter','false'
'$nmbr$ rd $nmbr$ $nmbr$ $nmbr$ $nmbr$ pmol l','C4553350','RD','NELFE wt Allele','false'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C0039725','TH','Thailand','true'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C0439284','pmol/L','Picomole per Liter','false'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C0039738','Th','Thallium','true'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C1420718','TH','TH gene','false'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C4282123','TH','TH','false'
'$nmbr$ th $nmbr$ $nmbr$ $nmbr$ pmol l','C4285344','TH','Tyrosine 3-Monooxygenase, human','false'
'american indian or alaskan','C0002460','AMERICAN INDIAN','American Indians','true'
'american indian or alaskan','C0238611','ALASKAN','alaskan','false'
'alcohol useb','C0001962','ALCOHOL','Ethanol','true'
'alcohol useb','C0001975','Alcohol','Alcohols','true'
'obese $nmbr$ kg m $nmbr$ b','C0028754','OBESE','Obesity','true'
'obese $nmbr$ kg m $nmbr$ b','C1532718','kg-m','kg-m','false'
'cardiac diseasec','C0018787','Cardiac','Heart','true'
'cardiac diseasec','C1522601','Cardiac','Cardiac - anatomy qualifier','false'
'medication useb','C0013227','Medication','Pharmaceutical Preparations','true'
'medication useb','C3244316','medication','medication - HL7 publishing domain','false'
'medication useb','C4284232','Medication','Medications','false'
'other lipid lowering drugs','C0086440','Lipid lowering drug','Hypolipidemic Agents','true'
'alpha blockers','C0001641','alpha blockers','Adrenergic alpha-Antagonists','true'
'angiotensin receptive blocker','C0003018','Angiotensin','Angiotensins','true'
'angiotensin receptive blocker','C4521302','Angiotensin','Angiotensin-1, human','false'
'other antihypertensive medications','C0003364','Antihypertensive Medications','Antihypertensive Agents','true'
'cyp $nmbr$ a $nmbr$ inhibitors','C1418793','CYPA','PPIA gene','false'
'cyp $nmbr$ a $nmbr$ inhibitors','C0243077','inhibitors','inhibitors','true'
'cyp $nmbr$ a $nmbr$ inhibitors','C2634343','Cypa','Cypa (invertebrate)','false'
'alpha reductase inhibitors','C0597153','Reductase inhibitor','oxidoreductase inhibitor','false'
'alpha reductase inhibitors','C1655741','Reductase inhibitor','negative regulation of oxidoreductase activity','false'
'previous pde $nmbr$ inhibitors','C0205156','Previous','Previous','false'
'previous pde $nmbr$ inhibitors','C0031638','PDE Inhibitor','Phosphodiesterase Inhibitors','true'
'previous pde $nmbr$ inhibitors','C1552607','previous','Act Relationship Subset - previous','false'
'laboratory measurements','C0681902','laboratory measurements','laboratory measurement','false'
'hemoglobin a $nmbr$ c','C0019020','Hemoglobin C','Hemoglobin C','true'
'hemoglobin a $nmbr$ c','C3889898','HEMOGLOBIN C','HEMOGLOBIN C PHENOTYPE','false'
'good control','C0243148','control','control aspects','true'
'good control','C1550141','Control','control substance','false'
'good control','C1882979','Control','Scientific Control','false'
'good control','C2587213','Control','Control function','false'
'good control','C3274648','Control','True Control Status','false'
'good control','C4553389','control','Study Control','false'
'fair control $nmbr$ $nmbr$ $nmbr$','C0243148','control','control aspects','true'
'fair control $nmbr$ $nmbr$ $nmbr$','C1550141','Control','control substance','false'
'fair control $nmbr$ $nmbr$ $nmbr$','C1882979','Control','Scientific Control','false'
'fair control $nmbr$ $nmbr$ $nmbr$','C2587213','Control','Control function','false'
'fair control $nmbr$ $nmbr$ $nmbr$','C3274648','Control','True Control Status','false'
'fair control $nmbr$ $nmbr$ $nmbr$','C4553389','control','Study Control','false'
'cholesterol nmol l','C0008377','CHOLESTEROL','Cholesterol','true'
'cholesterol nmol l','C0439282','nmol/L','Nanomole/liter','false'
'glucose non fasting or random nmol l','C0017725','GLUCOSE','Glucose','true'
'glucose non fasting or random nmol l','C1518422','Non','Negation','false'
'glucose non fasting or random nmol l','C0015663','FASTING','Fasting','true'
'glucose non fasting or random nmol l','C0034656','RANDOM','Randomization','true'
'glucose non fasting or random nmol l','C0439282','nmol/L','Nanomole/liter','false'
'glucose non fasting or random nmol l','C0439605','Random','Random','false'
'standard bp lowering','C1442989','Standard','Standard (qualifier)','false'
'standard bp lowering','C2828392','Standard','Standard (document)','false'
'standard bp lowering','C0037623','BP','Solomon Islands','true'
'standard bp lowering','C0441994','lowering','Lower - spatial qualifier','false'
'standard bp lowering','C2003888','Lowering','Lower (action)','false'
'standard bp lowering','C1415692','Bp','HP gene','false'
'standard bp lowering','C1708288','BP','HP wt Allele','false'
'standard bp lowering','C4318478','BP','Base Pair Unit','false'
'intensive bp lowering','C0037623','BP','Solomon Islands','true'
'intensive bp lowering','C0441994','lowering','Lower - spatial qualifier','false'
'intensive bp lowering','C2003888','Lowering','Lower (action)','false'
'intensive bp lowering','C1415692','Bp','HP gene','false'
'intensive bp lowering','C1708288','BP','HP wt Allele','false'
'intensive bp lowering','C4318478','BP','Base Pair Unit','false'
'latino','C0086528','Latino','Latinos','true'
'intensive glycemia lowering','C0005802','glycemia','Blood Glucose','true'
'intensive glycemia lowering','C0441994','lowering','Lower - spatial qualifier','false'
'intensive glycemia lowering','C2003888','Lowering','Lower (action)','false'
'cornell index pv','C0030840','PV','Penicillin V','true'
'cornell index pv','C0032463','PV','Polycythemia Vera','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C2986480','Subgroup Analysis','Subset Analysis','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0032664','population reduction','Population Decrease','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0149775','SEIZURE FREQUENCY','Fit frequency','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0332152','Prior','Before','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0023556','LEV','Levamisole','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C2826257','PRIOR','Prior Medication Usage','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0030705','Patients','Patients','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0871208','Rate','Rating (action)','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C1521828','Rate','Rate','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0168634','baseline','BaseLine dental cement','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C1442488','Baseline','Baseline','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0301630','Reduction','Reduction (chemical)','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0392756','Reduction','Reduced','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C1293152','Reduction','Reduction procedure','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C4551656','Reduction','Surgical reduction','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0392360','Reason','Indication of (contextual qualifier)','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0444930','End','End','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C2746065','End','Stop (qualifier value)','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C1264674','rate number','Number rate','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0237753','*Number','Numbers','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0449788','Number','Count of entities','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0332293','Treated with','Treated with','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0377265','LEVETIRACETAM','Levetiracetam','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C3693636','Levetiracetam','Measurement of levetiracetam','false'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0657912','PREGABALIN','pregabalin','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0003299','Drugs, Antiepileptic','Antiepileptic Agents','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0751495','Partial Seizure','Seizures, Focal','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0206132','Onset','Age of Onset','true'
'subgroup analysis itt population percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period in prior lev and lev naive patients a $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period in prior lev and lev naive patients b percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to reason for prior discontinuation of lev c $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to reason for prior discontinuation of lev d percent reduction over placebo in $nmbr$ day adjusted partial onset seizure frequency during the treatment period according to number of prior aeds e $nmbr$ responder rate for partial onset seizure frequency from baseline to the end of treatment period according to number of prior aeds f analysis by reason for prior discontinuation of lev excluded one patient who was previously treated with either levetiracetam or pregabalin in a blinded study aeds antiepileptic drugs brv brivaracetam itt intention to treat lev levetiracetam pbo placebo pos partial onset seizure','C0332162','Onset','Onset of (contextual qualifier)','false'
'enrollment strata prior hospitalization','C0332152','Prior','Before','false'
'enrollment strata prior hospitalization','C0019993','hospitalisation','Hospitalization','true'
'enrollment strata prior hospitalization','C2826257','PRIOR','Prior Medication Usage','false'
'physical characteristics','C0031809','Physical','Physical Examination','true'
'physical characteristics','C1521970','Characteristics','Characteristics','false'
'physical characteristics','C0205485','Physical','Physical','false'
'physical characteristics','C1509143','Physical','Physical assessment findings','false'
'heart rate beats per minute','C0439385','Heart Beats per Minute','beats per minute','false'
'hematocrit','C0018935','Hematocrit','Hematocrit procedure','true'
'hematocrit','C0518014','Hematocrit','Hematocrit level','false'
'prior hf hospitalization n $nmbr$','C0018488','Hf','Hafnium','true'
'prior hf hospitalization n $nmbr$','C0019993','hospitalisation','Hospitalization','true'
'prior hf hospitalization n $nmbr$','C1313497','HF','GZMA protein, human','true'
'prior hf hospitalization n $nmbr$','C1538440','HF','CFH gene','false'
'prior hf hospitalization n $nmbr$','C3273279','HF','CFH wt Allele','false'
'elevated natriuretic peptide level n $nmbr$','C1144709','natriuretic peptide','Natriuretic Peptides','true'
'elevated natriuretic peptide level n $nmbr$','C2709270','Natriuretic peptide','Natriuretic peptide','false'
'elevated natriuretic peptide level n $nmbr$','C3537020','Natriuretic Peptide','Natriuretic Peptide [EPC]','false'
'p for inter act','C0369773','P NOS','P Blood group antibodies','false'
'p for inter act','C2603361','P'','P prime','false'
'p for inter act','C0205103','Inter-','Intermediate','false'
'p for inter act','C1548610','Inter','Inter','false'
'p for inter act','C0079613','ACT','Adoptive Immunotherapy','true'
'p for inter act','C1704930','ACT','ACTG2 wt Allele','false'
'p for inter act','C1869853','ACT','SERPINA3 protein, human','true'
'p for inter act','C3890007','ACT','SERPINA3 wt Allele','false'
'p for inter act','C4048375','ACT','Asthma Control Test Questionnaire','false'
'lv heart structure','C0023128','LV','Latvia','true'
'lv heart structure','C0018787','Heart structure','Heart','true'
'lv heart structure','C0731033','LV','Leucovorin Calcium','true'
'lv heart structure','C1881413','LV','Liposome Vesicle','false'
'lvedv ml','C0439526','/mL','/mL','false'
'lvedv ml','C1705224','ML','THPO wt Allele','false'
'lvedv ml','C3887665','ML','Thrombopoietin, human','false'
'lvesv ml','C0439526','/mL','/mL','false'
'lvesv ml','C1705224','ML','THPO wt Allele','false'
'lvesv ml','C3887665','ML','Thrombopoietin, human','false'
'mean wall thickness cm','C4054557','Mean Thickness','Mean Thickness','false'
'mean wall thickness cm','C0677535','Wall','Walls of a building','false'
'lv mass index mg m $nmbr$','C0024671','MG','Mammography','true'
'lv mass index mg m $nmbr$','C0026410','MG','Mongolia','true'
'lv mass index mg m $nmbr$','C0439269','mg%','mg/dL','false'
'lv mass index mg m $nmbr$','C1960952','mg %','Milligram percent','false'
'lv mass index mg m $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'lv mass index mg m $nmbr$','C4321396','MG','MG','false'
'lv mass index mg m $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'relative wall thickness','C0080103','RELATIVE','Relative (related person)','true'
'relative wall thickness','C0205345','Relative','Relative','false'
'relative wall thickness','C1547039','*Relative','*Relative','false'
'lav ml','C0439526','/mL','/mL','false'
'lav ml','C1705224','ML','THPO wt Allele','false'
'lav ml','C3887665','ML','Thrombopoietin, human','false'
'la diameter','C0023031','La','Lanthanum','true'
'la diameter','C1301886','DIAMETER','Diameter (qualifier value)','false'
'la diameter','C0023749','LA','Linoleic Acid','true'
'la diameter','C0230347','LA','Left upper arm structure','false'
'la diameter','C2346906','LA','Lupus Anticoagulant Antibody','false'
'la diameter','C4553351','La','SSB wt Allele','false'
'lv function','C0031843','function','physiological aspects','true'
'lv function','C0542341','Function','Function (attribute)','false'
'lv function','C0700205','FUNCTION','Function Axis','false'
'lv function','C1705273','Function','Mathematical Operator','false'
'e a ratio','C0456603','RATIO','Ratio','false'
'e a ratio','C1547037','Ratio','data type - ratio','false'
'tdi e septal cm sec','C0205976','TDI','Tolylene Diisocyanate','true'
'tdi e septal cm sec','C0439392','cm/sec','cm/s','false'
'tdi e septal cm sec','C2674784','TDI','TLX1NB gene','false'
'tdi e septal cm sec','C3714807','TDI','Transition Dyspnea Index Questionnaire','false'
'e e septal','C0442004','Septal','Septal','false'
'rv and pulmonary vascular','C0035190','RV','Residual volume','true'
'rv and pulmonary vascular','C3889272','RV','Randomization Validation','false'
'rv and pulmonary vascular','C0459963','Pulmonary Vascular','Structure of pulmonary blood vessel','false'
'rv and pulmonary vascular','C1508661','Pulmonary Vascular','Pulmonary vessels','false'
'tr jet velocity m sec','C0439830','Velocity','Velocity','false'
'tr jet velocity m sec','C1547053','*Velocity','*Velocity','false'
'tr jet velocity m sec','C0565930','/sec','per second','false'
'enrolled in the americas','C4684790','enrolled','Study Subject Enrolled','false'
'enrolled in the americas','C0002454','Americas','Americas','true'
'enrolled in the americas','C0596070','Americas','Americas Ethnicity','false'
'enrolled in russia or georgia','C4684790','enrolled','Study Subject Enrolled','false'
'enrolled in russia or georgia','C0035970','RUSSIA','Russia','true'
'enrolled in russia or georgia','C0017452','Georgia','Georgia, USA','true'
'enrolled in russia or georgia','C0017454','GEORGIA','Georgia, Western Asia','true'
'baseline adjusted hr','C0168634','baseline','BaseLine dental cement','true'
'baseline adjusted hr','C0456081','Adjusted','Adjustment Action','false'
'baseline adjusted hr','C1442488','Baseline','Baseline','false'
'alvedv per ml','C0439526','/mL','/mL','false'
'alvedv per ml','C1705224','ML','THPO wt Allele','false'
'alvedv per ml','C3887665','ML','Thrombopoietin, human','false'
'alvesv per ml','C0439526','/mL','/mL','false'
'alvesv per ml','C1705224','ML','THPO wt Allele','false'
'alvesv per ml','C3887665','ML','Thrombopoietin, human','false'
'alvmi per g m $nmbr$','C0439267','g%','Gram per Deciliter','false'
'ae a ratio per $nmbr$ $nmbr$ unit','C3887670','AE','AE synonym fragment','false'
'ae a ratio per $nmbr$ $nmbr$ unit','C0456603','RATIO','Ratio','false'
'ae a ratio per $nmbr$ $nmbr$ unit','C1547037','Ratio','data type - ratio','false'
'ae per cm s','C3887670','AE','AE synonym fragment','false'
'ae e ratio per $nmbr$ unit','C0456603','RATIO','Ratio','false'
'ae e ratio per $nmbr$ unit','C1547037','Ratio','data type - ratio','false'
'alav per ml','C0439526','/mL','/mL','false'
'alav per ml','C1705224','ML','THPO wt Allele','false'
'alav per ml','C3887665','ML','Thrombopoietin, human','false'
'apasp per mmhg','C0439475','mmHG','mmHg','false'
'sbp at baseline','C0085805','SBP','Androgen Binding Protein','true'
'sbp at baseline','C0168634','baseline','BaseLine dental cement','true'
'sbp at baseline','C1442488','Baseline','Baseline','false'
'sd of sbp','C2699239','SD','SD, Rat Strain','false'
'sd of sbp','C0085805','SBP','Androgen Binding Protein','true'
'range of sbp','C1514721','Range','Range','false'
'range of sbp','C2348147','Range','Sample Range','false'
'range of sbp','C3542016','Range','Concept model range (foundation metadata concept)','false'
'change in sbp','C0392747','Change','Changing','false'
'change in sbp','C0443172','change','Changed status','false'
'change in sbp','C1705241','Change','Delta (difference)','false'
'change in sbp','C4319952','Change','Change -- procedure','false'
'bp lowering treatment n $nmbr$','C0037623','BP','Solomon Islands','true'
'bp lowering treatment n $nmbr$','C0039798','treatment','therapeutic aspects','true'
'bp lowering treatment n $nmbr$','C0087111','Treatment','Therapeutic procedure','true'
'bp lowering treatment n $nmbr$','C1522326','Treatment','Treating','false'
'bp lowering treatment n $nmbr$','C1533734','Treatment','Administration procedure','false'
'bp lowering treatment n $nmbr$','C1705169','Treatment','Biomaterial Treatment','false'
'bp lowering treatment n $nmbr$','C3538994','TREATMENT','Treatment Epoch','false'
'bp lowering treatment n $nmbr$','C3887704','treatment','treatment - ActInformationManagementReason','false'
'bp lowering treatment n $nmbr$','C1415692','Bp','HP gene','false'
'bp lowering treatment n $nmbr$','C1708288','BP','HP wt Allele','false'
'bp lowering treatment n $nmbr$','C4318478','BP','Base Pair Unit','false'
'treatment arm','C1522541','Treatment Arm','Protocol Treatment Arm','false'
'r tpa','C0032143','r-tPA','alteplase','true'
'time to treatment h','C3494202','Time-to-Treatment','Time-to-Treatment','true'
'time to treatment h','C0033727','H+','Protons','true'
'time to treatment h','C0369286','H NOS','H NOS Antibodies','false'
'time to treatment h','C0441932','H+','Hepatic Involvement','false'
'time to treatment h','C0564385','/h','/hour','false'
'time to treatment h','C4528284','h*%','Hour Times Percent','false'
'nihss score','C0449820','SCORE','Score','false'
'nihss score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'stroke subtype','C0038454','STROKE','Cerebrovascular accident','true'
'stroke subtype','C0449560','Subtype','Subtype (attribute)','false'
'stroke subtype','C4554100','Stroke','Stroke, CTCAE','false'
'taci','C0666480','TACI','TNFRSF13B protein, human','true'
'taci','C1425349','TACI','TNFRSF13B gene','false'
'taci','C4284230','TACI','TNFRSF13B wt Allele','false'
'paci','C1165245','paci','Pacis','false'
'laci','C1420705','LACI','TFPI gene','false'
'laci','C3273314','LACI','TFPI wt Allele','false'
'laci','C4281721','LACI','Tissue Factor Pathway Inhibitor, human','false'
'infarct size','C0021308','INFARCT','Infarction','true'
'infarct size','C0456389','Size','size','false'
'no infarct visible','C0021308','INFARCT','Infarction','true'
'no infarct visible','C0205379','Visible','Visible','false'
'small medium','C0009458','Medium','Communications Media','true'
'small medium','C0439536','MEDIUM','Medium','false'
'small medium','C1705217','Medium','Medium (Substance)','false'
'small medium','C3244283','medium','medium exposure','false'
'small medium','C4085196','Medium','Medium Growth Rate','false'
'small medium','C4522282','Medium','A Medium Amount of Time','false'
'small medium','C4522283','Medium','A Medium Amount','false'
'large very large','C0549177','LARGE','Large','false'
'large very large','C0442824','Very','Very','false'
'large very large','C2984081','Very','Very Much','false'
'symptomatic infarct swelling','C0013604','SWELLING','Edema','true'
'symptomatic infarct swelling','C0038999','SWELLING','Swelling','false'
'symptomatic ich','C0019191','ICH','Infectious Canine Hepatitis','true'
'symptomatic ich','C3272597','ICH','ICH Temperature/Humidity Storage Condition','false'
'symptomatic ich','C3281105','ICH','HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO','false'
'nd not due to swelling or ich','C0678226','Due To','Due to','false'
'nd not due to swelling or ich','C0013604','SWELLING','Edema','true'
'nd not due to swelling or ich','C0038999','SWELLING','Swelling','false'
'nd not due to swelling or ich','C0019191','ICH','Infectious Canine Hepatitis','true'
'nd not due to swelling or ich','C3272597','ICH','ICH Temperature/Humidity Storage Condition','false'
'nd not due to swelling or ich','C3281105','ICH','HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO','false'
'early ichaem ic stroke','C0038454','STROKE','Cerebrovascular accident','true'
'early ichaem ic stroke','C4554100','Stroke','Stroke, CTCAE','false'
'any early adverse event','C1279919','Early','Early','false'
'any early adverse event','C0877248','ADVERSE EVENT','Adverse event','false'
'early death','C1836407','Early death','Early death','false'
'poor outcome at $nmbr$ months','C3806166','Poor outcome','Poor outcome','false'
'poor outcome at $nmbr$ months','C0439231','MONTHS','month','false'
'numbers of events','C4330837','Number of Events','Number of Events','false'
'ors $nmbr$ cis','C1504308','Cis','Genus Cis','false'
'ors $nmbr$ cis','C1742862','CIS','CISH protein, human','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0038454','STROKE','Cerebrovascular accident','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C4554100','Stroke','Stroke, CTCAE','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0178602','Doses','Dosage','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0439542','PURPLE','Purple','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C1707455','Compared','Comparison','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0032042','Placebo','Placebos','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C1706408','PLACEBO','Placebo Control','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0030705','Patients','Patients','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0424092','Withdrawn','Withdrawn','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C2349954','Withdrawn','Withdraw (activity)','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C2825032','Withdrawn','Withdrawal (dysfunction)','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C3853865','withdrawn','Withdrawn - HL7ApprovalStatus','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0439228','DAYS','day','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0034656','Randomization','Randomization','true'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C1514624','Qualifying','Qualifying','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0439231','MONTHS','month','false'
'figure $nmbr$ cardiovascular death myocardial infarction or stroke at $nmbr$ years with ticagrelor doses pooled purple compared with placebo in patients withdrawn from p $nmbr$ y $nmbr$ inhibitor therapy within $nmbr$ days of randomization strati ed by a qualifying myocardial infarction $nmbr$ months prior to randomization left and $nmbr$ months prior to randomization right','C0332152','Prior to','Before','false'
'western europe and other','C0043129','Western Europe','Western Europe','true'
'creatinine mol l','C0010294','CREATININE','Creatinine','true'
'creatinine mol l','C0347982','mol/L','Mole per Liter','false'
'creatinine mol l','C1561535','Creatinine','Creatinine, CTCAE','false'
'hemoglobin g l','C0635222','hemoglobin L','hemoglobin L','true'
'median bnp iqr pg ml','C0054015','BNP','Nesiritide','true'
'median bnp iqr pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'median bnp iqr pg ml','C1095989','BNP','Brain natriuretic peptide measurement','false'
'median bnp iqr pg ml','C1417808','BNP','NPPB gene','false'
'median bnp iqr pg ml','C2982014','BNP','NPPB wt Allele','false'
'median nt probnp iqr pg ml','C0669479','NTproBNP','pro-brain natriuretic peptide (1-76)','true'
'median nt probnp iqr pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'median nt probnp iqr pg ml','C0754710','NT-proBNP','Amino-terminal pro-brain natriuretic peptide','true'
'ischaemic etiology n','C0475224','Ischemic','Ischemic','false'
'ischaemic etiology n','C0015127','etiology','Etiology aspects','true'
'ischaemic etiology n','C1314792','Etiology','Etiology','true'
'ischaemic etiology n','C1524003','Etiology','Science of Etiology','false'
'nyha','C1275491','NYHA','New York Heart Association Classification','false'
'kccq score','C0449820','SCORE','Score','false'
'kccq score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'hospitalization for heart failure n','C3898876','HEART FAILURE HOSPITALIZATION','Hospitalization Due to Heart Failure','false'
'myocardial infarction n','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'myocardial infarction n','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'myocardial infarction n','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'myocardial infarction n','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'myocardial infarction n','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'stroke n','C0038454','STROKE','Cerebrovascular accident','true'
'stroke n','C4554100','Stroke','Stroke, CTCAE','false'
'coronary artery bypass grafting n','C0010055','Coronary Artery Bypass Grafting','Coronary Artery Bypass Surgery','true'
'percutaneous coronary intervention n','C1532338','Intervention, Percutaneous Coronary','Percutaneous Coronary Intervention','true'
'diuretic n','C0012798','Diuretic','Diuretics','true'
'beta blocker n','C0001645','Beta Blocker','Adrenergic beta-Antagonists','true'
'mineralocorticoid receptor antagonist n','C1579268','Mineralocorticoid Receptor Antagonist','Mineralocorticoid Receptor Antagonists','true'
'oral anticoagulant n','C0354604','oral anticoagulant','oral anticoagulants','false'
'antiplatelet agent n','C0085826','Antiplatelet Agent','Antiplatelet Agents','true'
'lipid lowering agent n','C0086440','Lipid lowering agent','Hypolipidemic Agents','true'
'implantable cardioverter defibrillator n','C0162589','Implantable Cardioverter-Defibrillator','Implantable defibrillator','true'
'implantable cardioverter defibrillator n','C2825184','IMPLANTABLE CARDIOVERTER DEFIBRILLATOR','Implantable Cardioverter-Defibrillator Placement','false'
'cardiac resynchronization therapy n','C1167956','CARDIAC RESYNCHRONIZATION THERAPY','Cardiac Resynchronization Therapy','true'
'enalapril','C0014025','ENALAPRIL','Enalapril','true'
'cv death or hf hosp','C0011065','DEATH','Cessation of life','true'
'cv death or hf hosp','C1306577','Death','Death (finding)','false'
'cv death or hf hosp','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cv death or hf hosp','C4552775','Death NOS','Death NOS, CTCAE','false'
'cv death or hf hosp','C0018488','Hf','Hafnium','true'
'cv death or hf hosp','C1313497','HF','GZMA protein, human','true'
'cv death or hf hosp','C1538440','HF','CFH gene','false'
'cv death or hf hosp','C3273279','HF','CFH wt Allele','false'
'hf hosp','C0018488','Hf','Hafnium','true'
'hf hosp','C1313497','HF','GZMA protein, human','true'
'hf hosp','C1538440','HF','CFH gene','false'
'hf hosp','C3273279','HF','CFH wt Allele','false'
'acd','C4554601','ACD','Amyloidosis cutis dyschromia','false'
'bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure','C0488055','Systolic blood pressure','Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative','false'
'bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure','C0871470','Systolic Blood Pressure','Systolic Pressure','true'
'bmi body mass index bnp brain natriuretic peptide dbp diastolic blood pressure gfr glomerular filtration rate hr heart rate iqr interquartile range kccq kansas city cardiomyopathy questionnaire n number nt n terminal nyha new york heart association sbp systolic blood pressure','C1306620','systolic blood pressure','Systolic blood pressure measurement','false'
'fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy','C0237629','rates response','Frequency of Responses','false'
'fig $nmbr$ pasi $nmbr$ pasi $nmbr$ and pasi $nmbr$ response rates at week $nmbr$ overall and by type of prior failed systemic therapy','C1515119','Systemic Therapy','systemic therapy','false'
'tiotropium $nmbr$ g n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium $nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'tiotropium $nmbr$ $nmbr$ g n $nmbr$','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium $nmbr$ $nmbr$ g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'median range duration of asthma y','C0449238','Duration','Duration (temporal concept)','false'
'median range duration of asthma y','C2926735','Duration','Duration','false'
'fev $nmbr$ at screening','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ at screening','C0220908','Screening','Screening procedure','true'
'fev $nmbr$ at screening','C0220909','screening','Aspects of disease screening','true'
'fev $nmbr$ at screening','C1698960','screening','research subject screening','false'
'fev $nmbr$ at screening','C1710031','Screening','Disease Screening','false'
'fev $nmbr$ at screening','C1710032','Screening','Screening','false'
'fev $nmbr$ at screening','C1710477','SCREENING','Trial Screening','false'
'fev $nmbr$ at screening','C2348164','SCREENING','Screening Study','false'
'actual l','C0237400','ACTUAL','Actual','false'
'of predicted','C0681842','Predicted','prediction','false'
'of predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fev $nmbr$ at baseline randomization','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ at baseline randomization','C0168634','baseline','BaseLine dental cement','true'
'fev $nmbr$ at baseline randomization','C0034656','Randomization','Randomization','true'
'fev $nmbr$ at baseline randomization','C1442488','Baseline','Baseline','false'
'fvc','C3714541','FVC','Forced Vital Capacity','true'
'fev $nmbr$ fvc at baseline randomization','C3714541','FVC','Forced Vital Capacity','true'
'fev $nmbr$ fvc at baseline randomization','C0034656','Randomization','Randomization','true'
'pefam l min','C0702093','/min','Per Minute','false'
'pefam l min','C1524029','MIN NOS','Mouse MIN NOS','false'
'pefam l min','C3813700','%/min','Percent per Minute','false'
'pefpm l min','C0702093','/min','Per Minute','false'
'pefpm l min','C1524029','MIN NOS','Mouse MIN NOS','false'
'pefpm l min','C3813700','%/min','Percent per Minute','false'
'acq $nmbr$ total score','C2919686','ACQ','Asthma control questionnaire','false'
'acq $nmbr$ total score','C2964552','Total Score','Total score','false'
'ics dose of stable maintenance treatment g','C3714445','Maintenance dose','Maintenance dose','false'
'treatment and parameter','C0039798','treatment','therapeutic aspects','true'
'treatment and parameter','C0087111','Treatment','Therapeutic procedure','true'
'treatment and parameter','C1522326','Treatment','Treating','false'
'treatment and parameter','C1533734','Treatment','Administration procedure','false'
'treatment and parameter','C1705169','Treatment','Biomaterial Treatment','false'
'treatment and parameter','C3538994','TREATMENT','Treatment Epoch','false'
'treatment and parameter','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment and parameter','C0549193','Parameter','Parameter Value','false'
'treatment and parameter','C1704769','Parameter','Programming Parameter','false'
'treatment and parameter','C2350001','Parameter','Population Parameter','false'
'adjusted mean se ml','C0439526','/mL','/mL','false'
'adjusted mean se ml','C1705224','ML','THPO wt Allele','false'
'adjusted mean se ml','C3887665','ML','Thrombopoietin, human','false'
'active vs placebo','C0205177','Active','Active','false'
'active vs placebo','C3853793','active','active (HL7 RoleLink)','false'
'active vs placebo','C3888249','Active','Active License','false'
'active vs placebo','C0032042','Placebo','Placebos','true'
'active vs placebo','C1696465','PLACEBO','placebo','false'
'active vs placebo','C1706408','PLACEBO','Placebo Control','false'
'adjusted mean of difference se ml','C0444504','Mean','Statistical mean','false'
'adjusted mean of difference se ml','C2347634','Mean','Population Mean','false'
'adjusted mean of difference se ml','C2348143','Mean','Sample Mean','false'
'peak fev $nmbr$ $nmbr$ $nmbr$ h response','C0871261','Response','Response process','false'
'peak fev $nmbr$ $nmbr$ $nmbr$ h response','C1704632','Response','Disease Response','false'
'peak fev $nmbr$ $nmbr$ $nmbr$ h response','C1706817','Response','Response (statement)','false'
'peak fev $nmbr$ $nmbr$ $nmbr$ h response','C2911692','Response','Response (communication)','false'
'trough fev $nmbr$ response','C0871261','Response','Response process','false'
'trough fev $nmbr$ response','C1704632','Response','Disease Response','false'
'trough fev $nmbr$ response','C1706817','Response','Response (statement)','false'
'trough fev $nmbr$ response','C2911692','Response','Response (communication)','false'
'fev $nmbr$ of predicted normal post bronchodilator','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ of predicted normal post bronchodilator','C0205307','NORMAL','Normal','false'
'fev $nmbr$ of predicted normal post bronchodilator','C0231683','Normal','Gait normal','false'
'fev $nmbr$ of predicted normal post bronchodilator','C0439166','% normal','Percent normal','false'
'fev $nmbr$ of predicted normal post bronchodilator','C2347086','% Normal','Mean Percent of Normal','false'
'fev $nmbr$ of predicted normal post bronchodilator','C4553972','Normal','How Often Felt Normal question','false'
'fev $nmbr$ of predicted normal post bronchodilator','C2599594','Post-bronchodilator','post bronchodilator','false'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'enoxaparin $nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'number of treated patients','C2360800','Number of patients','Number of patients','false'
'number of treated patients','C1522326','Treated','Treating','false'
'females n','C0086287','Females','Females','true'
'body mass indexa','C0518010','body mass','body mass','false'
'previous vte n','C0205156','Previous','Previous','false'
'previous vte n','C0630906','vte','vinyltriethoxysilane','true'
'previous vte n','C1552607','previous','Act Relationship Subset - previous','false'
'creatinine clearanceb ml min','C0010294','CREATININE','Creatinine','true'
'creatinine clearanceb ml min','C0439445','mL/min','mL/min','false'
'creatinine clearanceb ml min','C1561535','Creatinine','Creatinine, CTCAE','false'
'racec n','C4287599','RACEC','CDISC SDTM Collected Race Terminology','false'
'india','C0021201','INDIA','India','true'
'india','C2700456','India','India - zebrafish','false'
'australia new zealand south africa','C0027978','NEW ZEALAND','New Zealand','true'
'australia new zealand south africa','C0037712','SOUTH AFRICA','South Africa','true'
'australia new zealand south africa','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'patients treated and operated n','C0030705','Patients','Patients','true'
'patients treated and operated n','C1522326','Treated','Treating','false'
'patients treated and operated n','C3242339','operate','operate','false'
'general alone','C0205246','General','Generalized','false'
'general alone','C3812897','General','General medical service','false'
'general alone','C3891294','General','Safety Reporting Documentation','false'
'general alone','C4521767','General','United States Military Commissioned Officer O10','false'
'general alone','C0205171','Alone','Singular','false'
'general alone','C0439044','Alone','Living Alone','false'
'general alone','C0679994','alone','alone - group size','false'
'mean duration of surgery sd min','C0449238','Duration','Duration (temporal concept)','false'
'mean duration of surgery sd min','C2926735','Duration','Duration','false'
'study treatment','C1521826','study treatment','Protocol Agent','false'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C0040223','TIME','Time','true'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C3541383','Time','Time (foundation metadata concept)','false'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C0038894','Surgery','Surgery specialty','false'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C0038895','surgery','Surgical aspects','true'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C0543467','Surgery','Operative Surgical Procedures','true'
'mean time to first subcutaneous injectiong h in relation to surgery hr','C1274039','Surgery','General surgery specialty','true'
'mean time to first oral dose postsurgeryh hr','C0040223','TIME','Time','true'
'mean time to first oral dose postsurgeryh hr','C3541383','Time','Time (foundation metadata concept)','false'
'median range duration of hospital stayi d','C0449238','Duration','Duration (temporal concept)','false'
'median range duration of hospital stayi d','C2926735','Duration','Duration','false'
'median range treatment duration d','C0444921','Treatment duration','Duration of treatment','false'
'median range treatment duration d','C3259042','Treatment duration','Treatment duration:Time:Pt:^Patient:Qn','false'
'add on to met $nmbr$','C1883712','Add','Add - instruction imperative','false'
'add on to met $nmbr$','C0428210','MET','Methionine measurement','false'
'add on to met $nmbr$','C1550543','Met','Fulfill','false'
'add on to met $nmbr$','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'add on to met su $nmbr$','C1883712','Add','Add - instruction imperative','false'
'add on to met su $nmbr$','C0038642','SU','Sudan','true'
'add on to met su $nmbr$','C1705534','SU','Substance Use Domain','false'
'mean sd age y race n','C0001779','AGE','Age','false'
'mean sd age y race n','C0034510','RACE','Racial group','true'
'mean sd age y race n','C1706779','RACE','AMACR wt Allele','false'
'mean sd age y race n','C3853635','Race','Race','false'
'othery ethnicity n','C0015031','Ethnicity','Ethnic group','true'
'othery ethnicity n','C0243103','ethnicity','Ethnicity aspects','true'
'mean sd hba $nmbr$ c','C0444504','Mean','Statistical mean','false'
'mean sd hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'mean sd hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'mean sd hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'mean sd hba $nmbr$ c','C2347634','Mean','Population Mean','false'
'mean sd hba $nmbr$ c','C2348143','Mean','Sample Mean','false'
'latin american subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'latin american subgroup','C1515021','Subgroup','Subgroup','false'
'add on to met','C1883712','Add','Add - instruction imperative','false'
'add on to met','C0428210','MET','Methionine measurement','false'
'add on to met','C1550543','Met','Fulfill','false'
'add on to met','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'add on to met su','C1883712','Add','Add - instruction imperative','false'
'add on to met su','C0038642','SU','Sudan','true'
'add on to met su','C1705534','SU','Substance Use Domain','false'
'cana','C1418845','CANA','PPP3CA gene','false'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C1268766','bp change','Blood pressure alteration (finding)','false'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C0032659','Populations','geographic population','true'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C1257890','Population','Population Group','true'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C1553378','LATIN AMERICAN','Latin American','false'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C1079230','subgroups','Subgroup A Nepoviruses','false'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C0031962','PBO','Piperonyl Butoxide','true'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C0681867','Controlled Study','Controlled Study','false'
'figure $nmbr$ changes in systolic bp for the overall populations and latin american subgroups of the a pbo controlled studies at week $nmbr$ and b active controlled studies at week $nmbr$','C1706449','Active Control','Active Control','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C0038944','NS','Suriname','true'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1112705','NS','Nuclear non-senile cataract','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1705982','NS','KRAS wt Allele','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1273937','Not significant','Not significant','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C0031962','PBO','Piperonyl Butoxide','true'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1707455','Comparison','Comparison','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C0884358','PERFORMED','Performed','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C0002778','Analysis','Analysis of substances','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C0936012','ANALYSIS','Analysis','false'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1524024','analysis','analysis aspect','true'
'bp blood pressure pbo placebo met metformin su sulfonylurea ls least squares se standard error ci confidence interval cana canagliflozin sita sitagliptin glim glimepiride ns not significant p $nmbr$ $nmbr$ versus pbo sita ystatistical comparisons were not performed in the post hoc analysis of patients from latin america zp ns versus pbo xstatistical comparisons were not performed not prespecified','C1518422','Not','Negation','false'
'bp and fasting glucose results','C0037623','BP','Solomon Islands','true'
'bp and fasting glucose results','C1415692','Bp','HP gene','false'
'bp and fasting glucose results','C1708288','BP','HP wt Allele','false'
'bp and fasting glucose results','C4318478','BP','Base Pair Unit','false'
'bp and fasting glucose results','C1274040','Result','Result','false'
'bp and fasting glucose results','C1546471','Result','What subject filter - Result','false'
'bp and fasting glucose results','C2825142','Result','Experimental Result','false'
'ethnicity $nmbr$','C0015031','Ethnicity','Ethnic group','true'
'ethnicity $nmbr$','C0243103','ethnicity','Ethnicity aspects','true'
'mean change in sbp from baseline mmhg mean sd','C0392747','Change','Changing','false'
'mean change in sbp from baseline mmhg mean sd','C0443172','change','Changed status','false'
'mean change in sbp from baseline mmhg mean sd','C1705241','Change','Delta (difference)','false'
'mean change in sbp from baseline mmhg mean sd','C4319952','Change','Change -- procedure','false'
'mean change in sbp from baseline mmhg mean sd','C0168634','baseline','BaseLine dental cement','true'
'mean change in sbp from baseline mmhg mean sd','C2699239','SD','SD, Rat Strain','false'
'mean change in sbp from baseline mmhg mean sd','C1442488','Baseline','Baseline','false'
'education yrs mean sd','C0013621','Education','Knowledge acquisition','true'
'education yrs mean sd','C2699239','SD','SD, Rat Strain','false'
'education yrs mean sd','C0013622','education','Educational aspects','true'
'education yrs mean sd','C0013658','Education, NOS','Educational Status','true'
'education yrs mean sd','C0039401','Education','Educational process of instructing','true'
'receiving antihypertensive treatment n blood pressure mm hg mean sd','C1514756','RECEIVING','Receive','false'
'receiving antihypertensive treatment n blood pressure mm hg mean sd','C0428886','blood Pressure mean','Mean blood pressure','true'
'receiving antihypertensive treatment n blood pressure mm hg mean sd','C2699239','SD','SD, Rat Strain','false'
'mean change in dbp from baseline mg dl mean sd','C0392747','Change','Changing','false'
'mean change in dbp from baseline mg dl mean sd','C0443172','change','Changed status','false'
'mean change in dbp from baseline mg dl mean sd','C1705241','Change','Delta (difference)','false'
'mean change in dbp from baseline mg dl mean sd','C4319952','Change','Change -- procedure','false'
'mean change in dbp from baseline mg dl mean sd','C0439269','mg dl','mg/dL','false'
'mean change in dbp from baseline mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'baseline lipid profile mg dl mean sd','C0439269','mg dl','mg/dL','false'
'baseline lipid profile mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'participants at baseline n','C0679646','participants','Participant','false'
'participants at baseline n','C0168634','baseline','BaseLine dental cement','true'
'participants at baseline n','C1442488','Baseline','Baseline','false'
'fasting glucose mg dl diabetes classification','C0008902','Classification','Classification','true'
'fasting glucose mg dl diabetes classification','C0008903','classification','Taxonomic','true'
'fasting glucose mg dl diabetes classification','C0678229','classification','Classification of information','false'
'mean sd baseline','C0168634','baseline','BaseLine dental cement','true'
'mean sd baseline','C1442488','Baseline','Baseline','false'
'impaired fasting glucosex','C0221099','Impaired','Impaired','false'
'impaired fasting glucosex','C0015663','FASTING','Fasting','true'
'baseline if have $nmbr$ yr follow up','C0168634','baseline','BaseLine dental cement','true'
'baseline if have $nmbr$ yr follow up','C1442488','Baseline','Baseline','false'
'baseline if have $nmbr$ yr follow up','C0589120','Follow-up','Follow-up status','false'
'baseline if have $nmbr$ yr follow up','C1522577','Followup','follow-up','false'
'baseline if have $nmbr$ yr follow up','C1704685','Follow-Up','Follow-Up Report','false'
'baseline if have $nmbr$ yr follow up','C3274571','FOLLOW-UP','Clinical Study Follow-up','false'
'lipid trial participantsk','C0023779','Lipid','Lipids','true'
'lipid trial participantsk','C0008976','Trial','Clinical Trials','true'
'change from baseline mg dl mean sd','C0392747','Change','Changing','false'
'change from baseline mg dl mean sd','C0443172','change','Changed status','false'
'change from baseline mg dl mean sd','C1705241','Change','Delta (difference)','false'
'change from baseline mg dl mean sd','C4319952','Change','Change -- procedure','false'
'fasting glucose $nmbr$ mg dl n','C0015663','FASTING','Fasting','true'
'fasting glucose $nmbr$ mg dl n','C0439269','mg dl','mg/dL','false'
'st t waveft','C0036056','ST','Saint Lucia','true'
'st t waveft','C3272372','ST','Character String Data Type','false'
'history of lvh on electrocardiogram','C0019664','History','History','true'
'history of lvh on electrocardiogram','C0019665','history','Historical aspects qualifier','true'
'history of lvh on electrocardiogram','C0262512','History, NOS','History of present illness','false'
'history of lvh on electrocardiogram','C0262926','History','Medical History','false'
'history of lvh on electrocardiogram','C1705255','History','Concept History','false'
'history of lvh on electrocardiogram','C2004062','History','History of previous events','false'
'history of lvh on electrocardiogram','C0013798','Electrocardiogram','Electrocardiogram','true'
'history of lvh on electrocardiogram','C1547122','Electro-Cardiogram','Electro-Cardiogram','false'
'history of lvh on electrocardiogram','C1623258','Electrocardiogram','Electrocardiography','true'
'history of lvh on echocardiogram','C0019664','History','History','true'
'history of lvh on echocardiogram','C0019665','history','Historical aspects qualifier','true'
'history of lvh on echocardiogram','C0262512','History, NOS','History of present illness','false'
'history of lvh on echocardiogram','C0262926','History','Medical History','false'
'history of lvh on echocardiogram','C1705255','History','Concept History','false'
'history of lvh on echocardiogram','C2004062','History','History of previous events','false'
'history of lvh on echocardiogram','C0013516','Echocardiogram','Echocardiography','true'
'history of lvh on echocardiogram','C2243117','Echocardiogram','Echocardiogram (image)','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C0017654','GFR','Glomerular Filtration Rate','true'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C0439445','mL/min','mL/min','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C1424601','GFR','RAPGEF5 gene','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'estimated gfr ml min $nmbr$ $nmbr$ m $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'additional antihypertensive subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'additional antihypertensive subgroup','C1515021','Subgroup','Subgroup','false'
'thiazide diuretic','C0012802','Thiazide Diuretic','Thiazide Diuretics','true'
'thiazide diuretic','C3536861','Thiazide Diuretic','Thiazide Diuretic [EPC]','false'
'dapagliflozin n $nmbr$','C2353951','DAPAGLIFLOZIN','dapagliflozin','true'
'placebo n $nmbr$ l','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ l','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ l','C1706408','PLACEBO','Placebo Control','false'
'women ethnic origin','C0043210','Women','Woman','true'
'women ethnic origin','C0015031','Ethnic Origin','Ethnic group','true'
'$nmbr$ $nmbr$ l','C0439394','l's','liter/second','false'
'$nmbr$ $nmbr$ l','C1706495','L-','upper case letter ell','false'
'$nmbr$ $nmbr$ l','C3642217','/L','Per Liter','false'
'hbaj mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'fasting plasma glucose mmol l','C0202042','Plasma glucose','Plasma Glucose Measurement','false'
'fasting plasma glucose mmol l','C1532563','mmol/L','Millimole per Liter','false'
'fasting plasma glucose mmol l','C0455280','plasma glucose','Plasma glucose result','false'
'participants taking insulin','C0679646','participants','Participant','false'
'participants taking insulin','C3842788','Taking insulin','Taking insulin','false'
'l $nmbr$ $nmbr$','C0439394','l's','liter/second','false'
'l $nmbr$ $nmbr$','C1706495','L-','upper case letter ell','false'
'l $nmbr$ $nmbr$','C3642217','/L','Per Liter','false'
'duration of hypertension years','C0449238','Duration','Duration (temporal concept)','false'
'duration of hypertension years','C2926735','Duration','Duration','false'
'selective vascular history','C0019664','History','History','true'
'selective vascular history','C0019665','history','Historical aspects qualifier','true'
'selective vascular history','C0262512','History, NOS','History of present illness','false'
'selective vascular history','C0262926','History','Medical History','false'
'selective vascular history','C1705255','History','Concept History','false'
'selective vascular history','C2004062','History','History of previous events','false'
'stable angina','C0340288','Angina, Stable','Stable angina','true'
'carotid artery disease','C0007273','CAROTID ARTERY DISEASE','Carotid Artery Diseases','true'
'amputation','C0002688','AMPUTATION','Amputation','true'
'amputation','C0332840','Amputation','Amputated structure (morphologic abnormality)','false'
'amputation','C1546539','Amputation','Amputation Specimen Code','false'
'history of dyslipidaemia','C0019664','History','History','true'
'history of dyslipidaemia','C0019665','history','Historical aspects qualifier','true'
'history of dyslipidaemia','C0262512','History, NOS','History of present illness','false'
'history of dyslipidaemia','C0262926','History','Medical History','false'
'history of dyslipidaemia','C1705255','History','Concept History','false'
'history of dyslipidaemia','C2004062','History','History of previous events','false'
'recent cardiovascular eventf','C0332185','Recent','Recent','false'
'recent cardiovascular eventf','C0007226','Cardiovascular','Cardiovascular system','true'
'recent cardiovascular eventf','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'egfr ml min per $nmbr$ $nmbr$ m','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min per $nmbr$ $nmbr$ m','C0439445','mL/min','mL/min','false'
'egfr ml min per $nmbr$ $nmbr$ m','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min per $nmbr$ $nmbr$ m','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'seated sbp n','C0277814','Seated','Sitting position','true'
'seated sbp n','C0085805','SBP','Androgen Binding Protein','true'
'seated sbp n','C1283233','seated','Seating','false'
'baseline mean seated sbp mm hg sd','C0439475','mmHG','mmHg','false'
'baseline mean seated sbp mm hg sd','C2699239','SD','SD, Rat Strain','false'
'sbp difference vs placebo $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'sbp difference vs placebo $nmbr$ cl','C1705242','Difference','Different','false'
'sbp difference vs placebo $nmbr$ cl','C0032042','Placebo','Placebos','true'
'sbp difference vs placebo $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'sbp difference vs placebo $nmbr$ cl','C1696465','PLACEBO','placebo','false'
'sbp difference vs placebo $nmbr$ cl','C1706408','PLACEBO','Placebo Control','false'
'hba $nmbr$ c n','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c n','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c n','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c baseline mean hba $nmbr$ c sd','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c baseline mean hba $nmbr$ c sd','C2699239','SD','SD, Rat Strain','false'
'hba $nmbr$ c baseline mean hba $nmbr$ c sd','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c baseline mean hba $nmbr$ c sd','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C1705242','Difference','Different','false'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C0032042','Placebo','Placebos','true'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C1696465','PLACEBO','placebo','false'
'hba $nmbr$ c difference vs placebo $nmbr$ cl','C1706408','PLACEBO','Placebo Control','false'
'ambulatory sbp n','C0439841','Ambulatory','Ambulatory - qualifier value','false'
'ambulatory sbp n','C0085805','SBP','Androgen Binding Protein','true'
'baseline mean ambulatory sbp mm hg sd','C0439475','mmHG','mmHg','false'
'baseline mean ambulatory sbp mm hg sd','C2699239','SD','SD, Rat Strain','false'
'ambulatory sbp difference vs placebo $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'ambulatory sbp difference vs placebo $nmbr$ cl','C1705242','Difference','Different','false'
'ambulatory sbp difference vs placebo $nmbr$ cl','C0032042','Placebo','Placebos','true'
'ambulatory sbp difference vs placebo $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'ambulatory sbp difference vs placebo $nmbr$ cl','C1696465','PLACEBO','placebo','false'
'ambulatory sbp difference vs placebo $nmbr$ cl','C1706408','PLACEBO','Placebo Control','false'
'serum uric acid n','C0455272','Serum uric acid','Serum urate measurement','false'
'serum uric acid n','C0700634','Serum uric acid','Serum uric acid observed','false'
'baseline mean serum uric acid pmol l sd','C0455272','Serum uric acid','Serum urate measurement','false'
'baseline mean serum uric acid pmol l sd','C2699239','SD','SD, Rat Strain','false'
'baseline mean serum uric acid pmol l sd','C0700634','Serum uric acid','Serum uric acid observed','false'
'serum uric acid difference vs placebo $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'serum uric acid difference vs placebo $nmbr$ cl','C1705242','Difference','Different','false'
'serum uric acid difference vs placebo $nmbr$ cl','C0032042','Placebo','Placebos','true'
'serum uric acid difference vs placebo $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'serum uric acid difference vs placebo $nmbr$ cl','C1696465','PLACEBO','placebo','false'
'serum uric acid difference vs placebo $nmbr$ cl','C1706408','PLACEBO','Placebo Control','false'
'dapagliflozin','C2353951','DAPAGLIFLOZIN','dapagliflozin','true'
'p blockersubgroup','C0369773','P NOS','P Blood group antibodies','false'
'p blockersubgroup','C2603361','P'','P prime','false'
'o $nmbr$ o $nmbr$ loto $nmbr$ $nmbr$','C0483204','O NOS','O NOS Ab','false'
'calcium channel blockersubgroup','C0006685','Calcium Channel','Calcium Channel','true'
'diuretic subgroup','C1079230','subgroup','Subgroup A Nepoviruses','false'
'diuretic subgroup','C1515021','Subgroup','Subgroup','false'
'lixisenatide n $nmbr$','C2973895','LIXISENATIDE','Lixisenatide','true'
'retinopathy no','C0035309','RETINOPATHY','Retinal Diseases','true'
'retinopathy no','C1962966','Retinopathy','Retinopathy, CTCAE','false'
'neuropathy no','C0442874','NEUROPATHY','Neuropathy','false'
'race no t','C0034510','RACE','Racial group','true'
'race no t','C1706779','RACE','AMACR wt Allele','false'
'race no t','C3853635','Race','Race','false'
'race no t','C2603360','T'','T prime','false'
'hispanic ethnic group no t','C0015031','Ethnic Group','Ethnic group','true'
'hispanic ethnic group no t','C1879937','Ethnic Group','CDISC SDTM Patient Ethnic Group Terminology','false'
'hispanic ethnic group no t','C2603360','T'','T prime','false'
'geographic region no','C0017446','Geographic Region','Geographic Locations','true'
'africa or near east','C0001737','Africa','Africa','true'
'africa or near east','C1707877','East','East','false'
'south or central america','C1710133','South','South','false'
'south or central america','C0007674','Central America','Central America','true'
'current smoking no','C0037369','SMOKING','Smoking','true'
'current smoking no','C0453996','Smoking','Tobacco smoking behavior','true'
'current smoking no','C1881674','Smoking','Medical Device Emits Smoke','false'
'myocardial infarction before index acs no','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'myocardial infarction before index acs no','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'myocardial infarction before index acs no','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'myocardial infarction before index acs no','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'myocardial infarction before index acs no','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'medical history at randomization no','C0262926','Medical History','Medical History','false'
'medical history at randomization no','C1704706','Medical History','Medical History Domain','false'
'qualifying acs event no','C1514624','Qualifying','Qualifying','false'
'qualifying acs event no','C0441471','Event','Event','false'
'qualifying acs event no','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'unclassified','C0205426','Unclassified','Unclassified general adjectival modifiers','false'
'unclassified','C1546437','Unclassified','No Information Available','false'
'unclassified','C2347854','Unclassified','Conditionally Related to Intervention','false'
'unclassified','C4085229','UNCLASSIFIED','Unclassified Abnormality','false'
'days from acs to randomization','C0439228','DAYS','day','false'
'days from acs to randomization','C0742343','ACS','Acute Chest Syndrome','true'
'days from acs to randomization','C4318612','ACS','ACS - Activity Card Sort','false'
'days from acs to randomization','C0034656','Randomization','Randomization','true'
'urinary albumin creatinine ratio^','C0486293','Albumin/creatinine ratio','Albumin To Creatinine Protein Ratio Measurement','false'
'urinary albumin creatinine ratio^','C1318293','albumin creatinine ratio','Albumin/creatinine ration result','false'
'less than $nmbr$ y ears','C0013443','Ears','Ear structure','true'
'less than $nmbr$ y ears','C0521421','EARS','Entire ear','false'
'$nmbr$ years or older','C0439234','YEARS','year','false'
'$nmbr$ years or older','C0580836','Old','Old','false'
'racial category','C0683312','Category','Categories','false'
'racial category','C3889287','Category','Digital Content Category','false'
'not hispanic','C1518424','Not Hispanic','Not Hispanic or Latino','false'
'africa near east','C0001741','East Africa','Africa, Eastern','true'
'south central america','C0037713','South America','South America','true'
'days between acs and rand','C0439228','DAYS','day','false'
'days between acs and rand','C0742343','ACS','Acute Chest Syndrome','true'
'days between acs and rand','C4318612','ACS','ACS - Activity Card Sort','false'
'days between acs and rand','C1555436','Rand','Rand','false'
'$nmbr$ or greater','C1704243','Greater','Greater','false'
'region us','C0815353','US','Male external urethral sphincter','false'
'region us','C3889164','US','Ultrasound Study File','false'
'non us','C0815353','US','Male external urethral sphincter','false'
'non us','C3889164','US','Ultrasound Study File','false'
'dm duration','C0449238','Duration','Duration (temporal concept)','false'
'dm duration','C2926735','Duration','Duration','false'
'$nmbr$ years or more','C0439234','YEARS','year','false'
'less than $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'less than $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'less than $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'$nmbr$ kg m $nmbr$ or more','C0022718','KG','Kyrgyzstan','true'
'$nmbr$ kg m $nmbr$ or more','C0439209','kg','Kilogram','false'
'$nmbr$ kg m $nmbr$ or more','C4054209','/kg','Per Kilogram','false'
'acs event','C0441471','Event','Event','false'
'acs event','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'pcr after acs','C0032520','PCR','Polymerase Chain Reaction','true'
'pcr after acs','C3853643','PCR','Probe with target amplification technique','false'
'pcr after acs','C4050242','pCR','Pathologic Complete Response','false'
'ace arb use','C0042153','use','utilization qualifier','true'
'ace arb use','C0457083','Use','Usage','false'
'ace arb use','C1947944','Use','Use - dosing instruction imperative','false'
'history of hf','C0019664','History','History','true'
'history of hf','C0019665','history','Historical aspects qualifier','true'
'history of hf','C0262512','History, NOS','History of present illness','false'
'history of hf','C0262926','History','Medical History','false'
'history of hf','C1705255','History','Concept History','false'
'history of hf','C2004062','History','History of previous events','false'
'$nmbr$ $nmbr$ mg g','C1300563','mg/g','Gram per Kilogram','false'
'$nmbr$ mg g','C1300563','mg/g','Gram per Kilogram','false'
'no previous diagnosis of diabetes mellitus','C0332132','Previous diagnosis','Prior diagnosis','false'
'no previous diagnosis of diabetes mellitus','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'previous diabetes mellitus','C0205156','Previous','Previous','false'
'previous diabetes mellitus','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'previous diabetes mellitus','C1552607','previous','Act Relationship Subset - previous','false'
'hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3538758','HBA','SCN2A wt Allele','false'
'any hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'any hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'any hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'age mean','C0444504','Mean','Statistical mean','false'
'age mean','C2347634','Mean','Population Mean','false'
'age mean','C2348143','Mean','Sample Mean','false'
'lcz $nmbr$ treatment n','C0039798','treatment','therapeutic aspects','true'
'lcz $nmbr$ treatment n','C0087111','Treatment','Therapeutic procedure','true'
'lcz $nmbr$ treatment n','C1522326','Treatment','Treating','false'
'lcz $nmbr$ treatment n','C1533734','Treatment','Administration procedure','false'
'lcz $nmbr$ treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'lcz $nmbr$ treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'lcz $nmbr$ treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C2347635','Median','Population Median','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C2348144','Median','Sample Median','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C2939193','Median','Median (qualifier value)','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c median q $nmbr$ q $nmbr$','C3538758','HBA','SCN2A wt Allele','false'
'hf duration y n','C0018488','Hf','Hafnium','true'
'hf duration y n','C0449238','Duration','Duration (temporal concept)','false'
'hf duration y n','C2926735','Duration','Duration','false'
'hf duration y n','C1313497','HF','GZMA protein, human','true'
'hf duration y n','C1538440','HF','CFH gene','false'
'hf duration y n','C3273279','HF','CFH wt Allele','false'
'nyha class n','C1882083','NYHA Class','New York Heart Association Class','false'
'jugular venous distension n','C0425687','Jugular venous distension','Jugular venous engorgement','false'
'edema n','C0013604','OEDEMA','Edema','true'
'edema n','C1717255','Edema','Edema:Finding:Point in time:^Patient:Ordinal','false'
'rales n','C0034642','RALES','Rales','true'
'rales n','C0240859','Rales','Basilar Rales','false'
'third heart sound n','C0232237','HEART SOUND, THIRD','S3 - Third heart sound','false'
'third heart sound n','C0232278','Third Heart Sound','Protodiastolic gallop with abnormally audible third heart sound','false'
'heart rate beats per min','C0425583','heart beats','Heart beat','false'
'heart rate beats per min','C0439385','beats/min','beats per minute','false'
'ckd egfr','C1739039','EGFR','EGFR protein, human','true'
'ckd egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'ckd egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'icd crt d n','C0021122','ICD','Disruptive, Impulse Control, and Conduct Disorders','true'
'crt p d n','C0369718','N NOS','N not otherwise specified Antibody','false'
'crt p d n','C0441922','N+','N+ (tumor staging)','false'
'ischemic cause','C0015127','cause','Etiology aspects','true'
'ischemic cause','C1524003','Cause','Science of Etiology','false'
'previous af','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'previous af','C4049859','AF','PSMD4 wt Allele','false'
'medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'medication n','C3244316','medication','medication - HL7 publishing domain','false'
'medication n','C4284232','Medication','Medications','false'
'mra','C0243032','MRA','Magnetic Resonance Angiography','true'
'mra','C1609165','MRA','tocilizumab','true'
'mra','C3891069','MRA','MRI-Based Angiogram','false'
'hypoglycemic agent','C0020616','Hypoglycemic agent','Hypoglycemic Agents','true'
'pre diabetes mellitus','C0362046','Prediabetes','Prediabetes syndrome','true'
'undiagnosed diabetes mellitus','C1408353','Undiagnosed','Undiagnosed','false'
'undiagnosed diabetes mellitus','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'p values for interaction','C1709380','P-Value','P-Value','false'
'p values for interaction','C1704675','Interaction','Interaction','false'
'hf hospitalization or cardiovascular death','C0018488','Hf','Hafnium','true'
'hf hospitalization or cardiovascular death','C0019993','hospitalisation','Hospitalization','true'
'hf hospitalization or cardiovascular death','C1313497','HF','GZMA protein, human','true'
'hf hospitalization or cardiovascular death','C1538440','HF','CFH gene','false'
'hf hospitalization or cardiovascular death','C3273279','HF','CFH wt Allele','false'
'hf hospitalization or cardiovascular death','C0011065','DEATH','Cessation of life','true'
'hf hospitalization or cardiovascular death','C1306577','Death','Death (finding)','false'
'hf hospitalization or cardiovascular death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'hf hospitalization or cardiovascular death','C4552775','Death NOS','Death NOS, CTCAE','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0237881','significant','Statistical Significance','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0750502','Significant','Significant','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C1546944','Significant','Event Seriousness - Significant','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0332271','Worsening','Worsening pattern','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0205210','Clinical','Clinical','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C1457868','Worsening','Worse','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C1546960','Worsening','Patient Outcome - Worsening','false'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0026544','MO','Morocco','true'
'significant worsening in kccq clinical score $nmbr$ at $nmbr$ mo','C0332177','/mo','Monthly (qualifier value)','false'
'normal hba $nmbr$ c n $nmbr$','C0205307','NORMAL','Normal','false'
'normal hba $nmbr$ c n $nmbr$','C0019016','HBA','Hemoglobin A','true'
'normal hba $nmbr$ c n $nmbr$','C1825777','HBA','KRT90P gene','false'
'normal hba $nmbr$ c n $nmbr$','C3538758','HBA','SCN2A wt Allele','false'
'normal hba $nmbr$ c n $nmbr$','C0231683','Normal','Gait normal','false'
'normal hba $nmbr$ c n $nmbr$','C0439166','% normal','Percent normal','false'
'normal hba $nmbr$ c n $nmbr$','C2347086','% Normal','Mean Percent of Normal','false'
'normal hba $nmbr$ c n $nmbr$','C4553972','Normal','How Often Felt Normal question','false'
'pre diabetes mellitus n $nmbr$','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'pre diabetes mellitus n $nmbr$','C0362046','Prediabetes','Prediabetes syndrome','true'
'undiagnosed diabetes mellitus n $nmbr$','C1408353','Undiagnosed','Undiagnosed','false'
'undiagnosed diabetes mellitus n $nmbr$','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'diabetes mellitus n $nmbr$','C0011849','DIABETES MELLITUS','Diabetes Mellitus','true'
'p values of interaction','C1709380','P-Value','P-Value','false'
'p values of interaction','C1704675','Interaction','Interaction','false'
'hypotension n','C0020649','HYPOTENSION','Hypotension','true'
'hypotension n','C3163620','Hypotension','Hypotension, CTCAE','false'
'symptomatic hypotension','C0020649','HYPOTENSION','Hypotension','true'
'symptomatic hypotension','C3163620','Hypotension','Hypotension, CTCAE','false'
'symptomatic hypotension with sbp','C0020649','HYPOTENSION','Hypotension','true'
'symptomatic hypotension with sbp','C3163620','Hypotension','Hypotension, CTCAE','false'
'leading to study drug discontinuation','C0332152','Leading','Before','false'
'leading to study drug discontinuation','C0013175','study drug','Drug Evaluation','true'
'leading to study drug discontinuation','C1522538','Leading','Leading','false'
'renal impairment n','C1565489','Renal Impairment','Renal Insufficiency','true'
'serum creatinine $nmbr$ $nmbr$ mg dl','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine $nmbr$ $nmbr$ mg dl','C0439269','mg dl','mg/dL','false'
'serum creatinine $nmbr$ $nmbr$ mg dl','C0600061','serum creatinine','Serum creatinine level','false'
'hyperkalemia n','C0020461','HYPERKALEMIA','Hyperkalemia','true'
'hyperkalemia n','C4552983','Hyperkalemia','Hyperkalemia, CTCAE','false'
'serum potassium $nmbr$ $nmbr$ mmol l','C0302353','Serum Potassium','Serum potassium measurement','false'
'serum potassium $nmbr$ $nmbr$ mmol l','C1532563','mmol/L','Millimole per Liter','false'
'serum potassium $nmbr$ $nmbr$ mmol l','C0543465','serum potassium','Serum Potassium result','false'
'cough n','C0010200','COUGH','Coughing','true'
'cough n','C1961131','Cough','Cough, CTCAE','false'
'cough n','C3274924','Cough','Have Been Coughing','false'
'cough n','C4084725','Cough','Usual Severity Cough','false'
'cough n','C4084726','Cough','How Much Distress Cough','false'
'cough n','C4084727','Cough','Cough Frequency','false'
'any cough','C0010200','COUGH','Coughing','true'
'any cough','C1961131','Cough','Cough, CTCAE','false'
'any cough','C3274924','Cough','Have Been Coughing','false'
'any cough','C4084725','Cough','Usual Severity Cough','false'
'any cough','C4084726','Cough','How Much Distress Cough','false'
'any cough','C4084727','Cough','Cough Frequency','false'
'angioedema adjudicated n','C0002994','Angiooedema','Angioedema','true'
'no treatment or antihistamines only','C0039798','treatment','therapeutic aspects','true'
'no treatment or antihistamines only','C0087111','Treatment','Therapeutic procedure','true'
'no treatment or antihistamines only','C1522326','Treatment','Treating','false'
'no treatment or antihistamines only','C1533734','Treatment','Administration procedure','false'
'no treatment or antihistamines only','C1705169','Treatment','Biomaterial Treatment','false'
'no treatment or antihistamines only','C3538994','TREATMENT','Treatment Epoch','false'
'no treatment or antihistamines only','C3887704','treatment','treatment - ActInformationManagementReason','false'
'no treatment or antihistamines only','C0019590','ANTIHISTAMINES','Histamine Antagonists','true'
'catecholamines or corticosteroids without hospitalization','C0007412','Catecholamines','Catecholamines','true'
'catecholamines or corticosteroids without hospitalization','C0001617','Corticosteroids','Adrenal Cortex Hormones','true'
'catecholamines or corticosteroids without hospitalization','C3539185','Corticosteroids','Corticosteroid nasal preparations for topical use','false'
'catecholamines or corticosteroids without hospitalization','C3540725','CORTICOSTEROIDS','Corticosteroid otologicals','false'
'catecholamines or corticosteroids without hospitalization','C3540726','CORTICOSTEROIDS','Corticosteroid ophthalmologic and otologic preparations','false'
'catecholamines or corticosteroids without hospitalization','C3540727','Corticosteroids','Corticosteroids, topical for treatment of hemorrhoids and anal fissures','false'
'hospitalized without airway compromise','C0701159','HOSPITALIZED','Patient in hospital','false'
'hospitalized without airway compromise','C4055482','Airway Compromise','Airway Compromise','false'
'airway compromise','C4055482','Airway Compromise','Airway Compromise','false'
'any adverse event leading to study drug discontinuation n','C0877248','ADVERSE EVENT','Adverse event','false'
'any adverse event leading to study drug discontinuation n','C0332152','Leading','Before','false'
'any adverse event leading to study drug discontinuation n','C0013175','study drug','Drug Evaluation','true'
'any adverse event leading to study drug discontinuation n','C1522538','Leading','Leading','false'
'$nmbr$ $nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'$nmbr$ $nmbr$ mm','C4554674','MM','MM genotype','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ mm','C4554674','MM','MM genotype','false'
'$nmbr$ $nmbr$ $nmbr$ mm','C4330985','/mm','Per Millimeter','false'
'$nmbr$ $nmbr$ $nmbr$ mm','C4554674','MM','MM genotype','false'
'baseline ^ste mm','C4330985','/mm','Per Millimeter','false'
'baseline ^ste mm','C4554674','MM','MM genotype','false'
'baseline ste in worst lead mm','C1420459','STE','SULT1E1 gene','false'
'baseline ste in worst lead mm','C3811127','STE','SULT1E1 wt Allele','false'
'baseline std mm','C4330985','/mm','Per Millimeter','false'
'baseline std mm','C4554674','MM','MM genotype','false'
'q wave in the infarct territory at baseline','C0429089','q wave','Electrocardiogram Q waves test','false'
'q wave in the infarct territory at baseline','C1305738','Q wave','Q wave','false'
'q wave in the infarct territory at baseline','C0168634','baseline','BaseLine dental cement','true'
'q wave in the infarct territory at baseline','C1442488','Baseline','Baseline','false'
'time from sx onset to baseline ecg min','C1519428','SX','South Georgia and the South Sandwich Islands','false'
'time from sx onset to baseline ecg min','C0449244','onset time','Time of onset','false'
'time from sx onset to baseline ecg min','C3539997','SX','Sint Maarten (Dutch Part)','true'
'time from sx onset to baseline ecg min','C3815196','SX','Testicular Cancer Serum Markers Test Result SX','false'
'time from sx onset to baseline ecg min','C0702093','/min','Per Minute','false'
'time from sx onset to baseline ecg min','C1524029','MIN NOS','Mouse MIN NOS','false'
'time from sx onset to baseline ecg min','C3813700','%/min','Percent per Minute','false'
'cana $nmbr$ met n $nmbr$','C1418845','CANA','PPP3CA gene','false'
'cana $nmbr$ met n $nmbr$','C0428210','MET','Methionine measurement','false'
'cana $nmbr$ met n $nmbr$','C1550543','Met','Fulfill','false'
'cana $nmbr$ met n $nmbr$','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'cana $nmbr$ n $nmbr$','C1418845','CANA','PPP3CA gene','false'
'met n $nmbr$','C0428210','MET','Methionine measurement','false'
'met n $nmbr$','C1550543','Met','Fulfill','false'
'met n $nmbr$','C4317104','MET','Metabolic Equivalent of Task Unit','false'
'race n t','C0034510','RACE','Racial group','true'
'race n t','C1706779','RACE','AMACR wt Allele','false'
'race n t','C3853635','Race','Race','false'
'baseline hba $nmbr$ c n','C0168634','baseline','BaseLine dental cement','true'
'baseline hba $nmbr$ c n','C0019016','HBA','Hemoglobin A','true'
'baseline hba $nmbr$ c n','C1825777','HBA','KRT90P gene','false'
'baseline hba $nmbr$ c n','C3538758','HBA','SCN2A wt Allele','false'
'baseline hba $nmbr$ c n','C1442488','Baseline','Baseline','false'
'$nmbr$ $nmbr$ $nmbr$ mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'type $nmbr$ diabetes duration years','C1320657','type diabetes','Diabetes type','false'
'type $nmbr$ diabetes duration years','C0439234','YEARS','year','false'
'figure $nmbr$ effects on ef cacy parameters','C1280500','Effects','Effect','false'
'figure $nmbr$ effects on ef cacy parameters','C0449381','Parameters','Observation parameter','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C0392747','Change','Changing','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C0443172','change','Changed status','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C1705241','Change','Delta (difference)','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C4319952','Change','Change -- procedure','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C1079230','subgroups','Subgroup A Nepoviruses','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C3829066','mmol/mol','Millimole per Mole','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C0332174','/week','Weekly','false'
'c change from baseline in hba $nmbr$ c in subgroups with baseline hba $nmbr$ c $nmbr$ $nmbr$ $nmbr$ mmol mol or $nmbr$ $nmbr$ $nmbr$ mmol mol at week $nmbr$','C0439230','Week','week','false'
'apremilast','C1678805','APREMILAST','apremilast','true'
'$nmbr$ mg twice daily n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg twice daily n $nmbr$','C0585361','Twice Daily','Twice a day','false'
'$nmbr$ mg twice daily n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg twice daily n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg twice daily n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg twice daily n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg twice daily n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg twice daily n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'duration mean sd years','C0444504','Mean','Statistical mean','false'
'duration mean sd years','C0439234','YEARS','year','false'
'duration mean sd years','C2347634','Mean','Population Mean','false'
'duration mean sd years','C2348143','Mean','Sample Mean','false'
'prior use of conventional dmards only biologic nai ve n','C1524063','Use of','Use of','false'
'prior use of conventional dmards only biologic nai ve n','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'prior use of conventional dmards only biologic nai ve n','C0005515','BIOLOGIC','Biological Factors','true'
'prior use of conventional dmards only biologic nai ve n','C3537218','NAI','Neuraminidase Inhibitor [EPC]','false'
'prior use of conventional dmards only biologic nai ve n','C0205460','Biologic','biological','false'
'prior use of conventional dmards only biologic nai ve n','C0369718','N NOS','N not otherwise specified Antibody','false'
'prior use of conventional dmards only biologic nai ve n','C0441922','N+','N+ (tumor staging)','false'
'prior use of biologics n','C1524063','Use of','Use of','false'
'prior use of biologics n','C0005515','Biologics','Biological Factors','true'
'prior use of biologics n','C0005522','Biologics','Biological Products','true'
'prior use of biologics n','C4553887','Biologics','Biopharmaceuticals','true'
'prior biologic therapeutic failures n','C0005515','BIOLOGIC','Biological Factors','true'
'prior biologic therapeutic failures n','C0087111','Therapeutic','Therapeutic procedure','true'
'prior biologic therapeutic failures n','C0302350','Therapeutic','Therapeutic','false'
'prior biologic therapeutic failures n','C0205460','Biologic','biological','false'
'baseline dmard use n','C0168634','baseline','BaseLine dental cement','true'
'baseline dmard use n','C0042153','use','utilization qualifier','true'
'baseline dmard use n','C0457083','Use','Usage','false'
'baseline dmard use n','C1947944','Use','Use - dosing instruction imperative','false'
'baseline dmard use n','C1442488','Baseline','Baseline','false'
'mtx mean dose $nmbr$ $nmbr$ mg wk','C0366550','MTX Dose','Methotrexate:Mass:Pt:Dose:Qn','false'
'mtx mean dose $nmbr$ $nmbr$ mg wk','C1881833','mg/wk','Milligram per Week','false'
'leflunomide mean dose $nmbr$ $nmbr$ mg day','C0063041','LEFLUNOMIDE','leflunomide','true'
'leflunomide mean dose $nmbr$ $nmbr$ mg day','C0439422','mg day','milligram/day','false'
'sulfasalazine mean dose $nmbr$ $nmbr$ g day','C0036078','Sulphasalazine','Sulfasalazine','true'
'sulfasalazine mean dose $nmbr$ $nmbr$ g day','C0439417','g/day','g/24h','false'
'baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n','C0168634','baseline','BaseLine dental cement','true'
'baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n','C0439422','mg day','milligram/day','false'
'baseline corticosteroidst mean dose $nmbr$ $nmbr$ mg day n','C1442488','Baseline','Baseline','false'
'sjc $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'sjc $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'sjc $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'sjc $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'tjc $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'tjc $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'tjc $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'tjc $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'haq di $nmbr$ $nmbr$ mean sd','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di $nmbr$ $nmbr$ mean sd','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd','C0086715','Normal Range','Normal Range','true'
'crp normal range $nmbr$ $nmbr$ $nmbr$ mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C0030705','*^patient','Patients','true'
'patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C0281858','Global Assessment','global assessment','false'
'patient s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C1292728','Disease activity','Condition activity','false'
'physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C0031831','PHYSICIAN','Physicians','true'
'physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C0281858','Global Assessment','global assessment','false'
'physician s global assessment of disease activity $nmbr$ $nmbr$ mm vas mean sd','C1292728','Disease activity','Condition activity','false'
'das $nmbr$ crp mean sd','C0051767','DAS','amsonic acid','true'
'das $nmbr$ crp mean sd','C2699239','SD','SD, Rat Strain','false'
'das $nmbr$ crp mean sd','C0057671','DAS','diacetoxyscirpenol','true'
'pasi score $nmbr$ $nmbr$ t mean sd','C0444504','Mean','Statistical mean','false'
'pasi score $nmbr$ $nmbr$ t mean sd','C2699239','SD','SD, Rat Strain','false'
'pasi score $nmbr$ $nmbr$ t mean sd','C2347634','Mean','Population Mean','false'
'pasi score $nmbr$ $nmbr$ t mean sd','C2348143','Mean','Sample Mean','false'
'presence of enthesitis n','C0150312','Presence','Present','false'
'presence of enthesitis n','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of enthesitis n','C3854307','Presence','Presence (property)','false'
'mases $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'mases $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'mases $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'mases $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'presence of dactylitis n','C0150312','Presence','Present','false'
'presence of dactylitis n','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of dactylitis n','C3854307','Presence','Presence (property)','false'
'dactylitis count $nmbr$ $nmbr$ mean sd','C0239161','DACTYLITIS','Dactylitis','false'
'dactylitis count $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'week $nmbr$ itt population','C0032659','Population','geographic population','true'
'week $nmbr$ itt population','C1257890','Population','Population Group','true'
'apremilast $nmbr$ mg bid n $nmbr$','C0024671','MG','Mammography','true'
'apremilast $nmbr$ mg bid n $nmbr$','C0026410','MG','Mongolia','true'
'apremilast $nmbr$ mg bid n $nmbr$','C0439269','mg%','mg/dL','false'
'apremilast $nmbr$ mg bid n $nmbr$','C1960952','mg %','Milligram percent','false'
'apremilast $nmbr$ mg bid n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'apremilast $nmbr$ mg bid n $nmbr$','C4321396','MG','MG','false'
'apremilast $nmbr$ mg bid n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'concomitant conventional dmard use','C0042153','use','utilization qualifier','true'
'concomitant conventional dmard use','C0457083','Use','Usage','false'
'concomitant conventional dmard use','C1947944','Use','Use - dosing instruction imperative','false'
'prior biologic exposure','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'prior biologic exposure','C0332157','Exposure','Exposure to','false'
'biologic naive','C0005515','BIOLOGIC','Biological Factors','true'
'biologic naive','C0205460','Biologic','biological','false'
'prior biologic use','C0042153','use','utilization qualifier','true'
'prior biologic use','C0457083','Use','Usage','false'
'prior biologic use','C1947944','Use','Use - dosing instruction imperative','false'
'biologic therapeutic failure','C0231174','FAILURE','Failure (biologic function)','false'
'biologic therapeutic failure','C0680095','failure','Personal failure','false'
'trial','C0008976','Trial','Clinical Trials','true'
'trial $nmbr$','C0008976','Trial','Clinical Trials','true'
'scale obesity and prediabetes','C0028754','OBESITY','Obesity','true'
'scale obesity and prediabetes','C1963185','Obesity','Obesity, CTCAE','false'
'scale obesity and prediabetes','C0362046','Prediabetes','Prediabetes syndrome','true'
'scale diabetes','C0011847','Diabetes','Diabetes','false'
'scale diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'phase $nmbr$ dose finding trial','C0037088','Finding','Signs and Symptoms','true'
'phase $nmbr$ dose finding trial','C0008976','Trial','Clinical Trials','true'
'phase $nmbr$ dose finding trial','C0243095','Finding','Finding','false'
'phase $nmbr$ dose finding trial','C2825141','Finding','Experimental Finding','false'
'biometric parameters','C0449381','Parameters','Observation parameter','false'
'[sd]','C2699239','SD','SD, Rat Strain','false'
'mean bmi kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean bmi kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean bmi kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'glycaemic parameters','C0449381','Parameters','Observation parameter','false'
'mean hba $nmbr$ c','C0444504','Mean','Statistical mean','false'
'mean hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'mean hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'mean hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'mean hba $nmbr$ c','C2347634','Mean','Population Mean','false'
'mean hba $nmbr$ c','C2348143','Mean','Sample Mean','false'
'mean hba $nmbr$ c mmol mol','C0019016','HBA','Hemoglobin A','true'
'mean hba $nmbr$ c mmol mol','C3829066','mmol/mol','Millimole per Mole','false'
'mean hba $nmbr$ c mmol mol','C1825777','HBA','KRT90P gene','false'
'mean hba $nmbr$ c mmol mol','C3538758','HBA','SCN2A wt Allele','false'
'individuals with pre diabetes n','C0027361','Individual','Persons','true'
'individuals with pre diabetes n','C0237401','Individual','Individual','false'
'individuals with type $nmbr$ diabetes n','C0027361','Individual','Persons','true'
'individuals with type $nmbr$ diabetes n','C0237401','Individual','Individual','false'
'normoglycaemic individuals n','C0580545','Normoglycemic','Blood glucose normal','false'
'normoglycaemic individuals n','C0027361','Individual','Persons','true'
'normoglycaemic individuals n','C0237401','Individual','Individual','false'
'figure $nmbr$ liraglutide exposure and body weight loss in men and women','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'figure $nmbr$ liraglutide exposure and body weight loss in men and women','C0332157','Exposure','Exposure to','false'
'figure $nmbr$ liraglutide exposure and body weight loss in men and women','C2911645','body weight loss','Weight Loss, CTCAE','false'
'figure $nmbr$ liraglutide exposure and body weight loss in men and women','C0025266','Men','Male population group','true'
'figure $nmbr$ liraglutide exposure and body weight loss in men and women','C0043210','Women','Woman','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0332157','Exposure','Exposure to','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0017446','Area','Geographic Locations','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0205146','AREA','Area','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0376690','AUC','Area Under Curve','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0678587','steady state','steady state','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0005911','Weight Change, Body','Body Weight Changes','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0025266','Men','Male population group','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0043210','Women','Woman','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0042295','Values','Values','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1180280','Women body','Female adult human body','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0444504','Mean','Statistical mean','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C2347634','Mean','Population Mean','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C2348143','Mean','Sample Mean','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0205120','SQUARE','Square shape','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0205119','triangles','Triangular','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1552595','Square','Style Type - Square','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1882932','Represent','Representation (action)','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0549183','Median','Midline (qualifier value)','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0876920','Median','Median Statistical Measurement','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C2347635','Median','Population Median','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C2348144','Median','Sample Median','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C2939193','Median','Median (qualifier value)','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1514721','*Ranges','Range','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0178602','Dose Level','Dosage','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0205132','lines','Linear','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0750572','estimates','Estimated','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0032659','Populations','geographic population','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1257890','Population','Population Group','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0205452','Six','Six','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0032042','Placebo','Placebos','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1696465','PLACEBO','placebo','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1706408','PLACEBO','Placebo Control','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1456408','LIRAGLUTIDE','liraglutide','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0023693','Light','Light','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1306462','Light','Light color','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1570446','LIGHT','TNFSF14 protein, human','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1881376','Light','Light (qualifier)','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C3842678','Light','Light - subjective measurement','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C4050248','Light','Borg Scale Rating of Perceived Exertion Score 11','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C4521367','LIGHT','TNFSF14 wt Allele','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0028754','OBESITY','Obesity','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C1963185','Obesity','Obesity, CTCAE','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0008976','Trial','Clinical Trials','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0011847','Diabetes','Diabetes','false'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0011849','Diabetes','Diabetes Mellitus','true'
'liraglutide exposure expressed as model derived area under the curve auc at steady state versus body weight change from baseline a for men and women in trials $nmbr$ $nmbr$ combined covariate adjusted values b for men and women at the extremes of exposure body weight data are mean values with $nmbr$ confidence intervals horizontal bars with cir cles squares triangles represent median and $nmbr$ exposure ranges from each dose level a or from men and women at the extremes of expo sure b sigmoidal curved lines represent covariate adjusted model based estimates for defined populations a exposure expressed as six quantiles of auc values plus placebo b exposure and weight change for the placebo or liraglutide treated heaviest men and lightest women as well as the overall cohort mean in trial $nmbr$ trial $nmbr$ scale obesity and prediabetes trial $nmbr$ scale diabetes trial $nmbr$ the phase ii trial','C0282460','PHASE II TRIAL','Phase 2 Clinical Trials','false'
'figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c','C0332157','Exposure','Exposure to','false'
'figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c','C0019020','Hemoglobin C','Hemoglobin C','true'
'figure $nmbr$ liraglutide exposure and glycated haemoglobin hba $nmbr$ c','C3889898','HEMOGLOBIN C','HEMOGLOBIN C PHENOTYPE','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0332157','Exposure','Exposure to','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0017446','Area','Geographic Locations','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0205146','AREA','Area','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0376690','AUC','Area Under Curve','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0678587','steady state','steady state','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0392747','Change','Changing','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0443172','change','Changed status','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1705241','Change','Delta (difference)','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C4319952','Change','Change -- procedure','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0027361','Individual','Persons','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0237401','Individual','Individual','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0497406','OVERWEIGHT','Overweight','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0028754','OBESITY','Obesity','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1963185','Obesity','Obesity, CTCAE','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1320657','type diabetes','Diabetes type','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0205363','Stratified','Stratified','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0008976','Trial','Clinical Trials','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0444504','Mean','Statistical mean','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0042295','Values','Values','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C2347634','Mean','Population Mean','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C2348143','Mean','Sample Mean','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0205423','Sure','Certain (qualifier value)','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0032042','Placebo','Placebos','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0205132','lines','Linear','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1696465','PLACEBO','placebo','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1706408','PLACEBO','Placebo Control','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1882932','Represent','Representation (action)','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0750572','estimates','Estimated','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0057717','Diamonds','Diamond','true'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0549183','Median','Midline (qualifier value)','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0876920','Median','Median Statistical Measurement','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C2347635','Median','Population Median','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C2348144','Median','Sample Median','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C2939193','Median','Median (qualifier value)','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C1514721','*Ranges','Range','false'
'exposure expressed as model derived area under the curve auc at steady state versus hba $nmbr$ c change from baseline a in individuals with overweight or obesity and type $nmbr$ diabetes trial $nmbr$ b in individuals with overweight or obesity and type $nmbr$ diabetes stratified by baseline hba $nmbr$ c trial $nmbr$ data are mean values with $nmbr$ confidence interval versus expo sure expressed as six quantiles of auc values plus placebo sigmoidal curved lines represent covariate adjusted model based estimates for each trial population horizontal bars with diamonds represent median and $nmbr$ exposure ranges from each dose level t $nmbr$ d type $nmbr$ diabetes','C0178602','Dose Level','Dosage','false'
'$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ $nmbr$ to $nmbr$ $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'mean lvef','C0428772','LVEF','Left ventricular ejection fraction','false'
'mean lvef','C0488728','LV EF','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'new york heart association class','C1882083','New York Heart Association Class','New York Heart Association Class','false'
'prior hf hospitalization','C0018488','Hf','Hafnium','true'
'prior hf hospitalization','C0019993','hospitalisation','Hospitalization','true'
'prior hf hospitalization','C1313497','HF','GZMA protein, human','true'
'prior hf hospitalization','C1538440','HF','CFH gene','false'
'prior hf hospitalization','C3273279','HF','CFH wt Allele','false'
'ischemic cardiomyopathy','C0349782','Ischemic cardiomyopathy','Ischemic cardiomyopathy','false'
'history of af','C0019664','History','History','true'
'history of af','C0019665','history','Historical aspects qualifier','true'
'history of af','C0262512','History, NOS','History of present illness','false'
'history of af','C0262926','History','Medical History','false'
'history of af','C1705255','History','Concept History','false'
'history of af','C2004062','History','History of previous events','false'
'icd or crt d','C0021122','ICD','Disruptive, Impulse Control, and Conduct Disorders','true'
'hf hospitalisation','C0018488','Hf','Hafnium','true'
'hf hospitalisation','C0019993','hospitalisation','Hospitalization','true'
'hf hospitalisation','C1313497','HF','GZMA protein, human','true'
'hf hospitalisation','C1538440','HF','CFH gene','false'
'hf hospitalisation','C3273279','HF','CFH wt Allele','false'
'evening mealb','C0587117','Evening','Evening','false'
'lm $nmbr$ bid n $nmbr$','C1261082','LM','Left coronary artery structure','false'
'lm $nmbr$ bid n $nmbr$','C1551056','lm','Units Of Measure - lumen','false'
'igl n $nmbr$','C0021037','IGL','Immunoglobulin lambda-Chains','true'
'igl n $nmbr$','C0314619','IGL','IGL gene','false'
'igl n $nmbr$','C2247518','IGL','indole-3-glycerol-phosphate lyase activity','false'
'glycemic variability mmol lc','C2827666','Variability','Variability','false'
'glycemic variability mmol lc','C0439190','mmol','millimole','false'
'insulin glargine dose at screening visit iu','C0366513','Insulin Dose','Insulin regular:Mass:Pt:Dose:Qn','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0392747','Change','Changing','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0443172','change','Changed status','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1442488','Baseline','Baseline','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1550335','Patient Type','Patient type','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0332293','Treated with','Treated with','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0982221','Insulin lispro protamine','Insulin, Protamine Lispro, Human','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0907402','INSULIN GLARGINE','Insulin Glargine','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0332173','Daily','Daily','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0293359','INSULIN LISPRO','Insulin Lispro','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0021037','IGL','Immunoglobulin lambda-Chains','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0314619','IGL','IGL gene','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C2247518','IGL','indole-3-glycerol-phosphate lyase activity','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0439745','Grouped','Grouped (qualifier value)','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C4319846','Grouped','Grouped (foundation metadata concept)','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1998602','Meal','Meal (occasion for eating)','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0020456','high blood glucose level','Hyperglycemia','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0521095','Determined','Determined by','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0205449','Three','Three','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0005803','Self-monitoring of blood glucose','Blood Glucose Self-Monitoring','true'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1979963','Profile','Profile (lab procedure)','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C2003903','Profile','Profiling (action)','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0237881','significant','Statistical Significance','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C0750502','Significant','Significant','false'
'figure $nmbr$ change in glycosylated hemoglobin hba $nmbr$ c from baseline to $nmbr$ weeks in patients with type $nmbr$ diabetes treated with insulin lispro protamine suspension $nmbr$ insulin lispro solution $nmbr$ lm $nmbr$ or basal insulin glargine once daily plus prandial insulin lispro once daily igl grouped according to main meal the meal with the highest $nmbr$ hour postprandial blood glucose level as determined from three separate $nmbr$ point self monitoring of blood glucose profiles all changes significant versus baseline p $nmbr$ $nmbr$','C1546944','Significant','Event Seriousness - Significant','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C1511726','Data','Data','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C3245479','data','Data call receiving device','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C3714741','Data','Data (eukaryote)','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C0449450','Presented','Presentation','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C1706992','Box Plot','Box Plot','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C0683607','allow','allowing','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C0444504','Statistical Mean','Statistical mean','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C0039725','TH','Thailand','true'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C1532337','Percentile value','Percentile value','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C0039738','Th','Thallium','true'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C1420718','TH','TH gene','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C4282123','TH','TH','false'
'data are presented as box plots which allow presentation of multiple statistical endpoints diamonds mean horizontal lines median end margins of boxes $nmbr$ th and $nmbr$ th percentile values','C4285344','TH','Tyrosine 3-Monooxygenase, human','false'
'table $nmbr$ characteristics of the patients at baseline','C0039224','Table','Table - furniture','false'
'table $nmbr$ characteristics of the patients at baseline','C0815172','patient characteristics','patient characteristics','false'
'table $nmbr$ characteristics of the patients at baseline','C1706074','Table','Data Table','true'
'table $nmbr$ characteristics of the patients at baseline','C0168634','baseline','BaseLine dental cement','true'
'table $nmbr$ characteristics of the patients at baseline','C1442488','Baseline','Baseline','false'
'fluticasone salmeterol n $nmbr$','C0939232','FLUTICASONE/SALMETEROL','fluticasone / salmeterol','true'
'fluticasone alone n $nmbr$','C0082607','FLUTICASONE','fluticasone','true'
'fluticasone alone n $nmbr$','C0205171','Alone','Singular','false'
'fluticasone alone n $nmbr$','C0439044','Alone','Living Alone','false'
'fluticasone alone n $nmbr$','C0679994','alone','alone - group size','false'
'africa','C0001737','Africa','Africa','true'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0475224','Ischemic','Ischemic','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0085415','outcomes treatment','Treatment outcome','true'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C1518681','Treatment Effect','Outcome of Therapy','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0749659','Treatment Status','Treatment Status','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0439231','MONTHS','month','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0030705','Patients','Patients','true'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C1274040','Outcome','Result','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C3897493','Stent Thrombosis','Stent Thrombosis','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0441471','Events','Event','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C3541888','EVENTS','CDISC Events Class','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0205082','Severe','Severe (severity modifier)','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4050465','Severe','Severe Extremity Pain','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0205081','Moderate','Moderate (severity modifier)','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C0019080','BLEEDING','Hemorrhage','true'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C1881878','Moderate','Moderation','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4049705','Moderate','Moderate Extremity Pain','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4085643','Moderate','Moderate Response','false'
'figure $nmbr$ ischemic and bleeding outcomes by randomized treatment arm according to diabetes mellitus status treatment effect according to diabetes status at $nmbr$ to $nmbr$ months in all randomly assigned patients n $nmbr$ $nmbr$ for the outcomes of stent thrombosis major adverse cardiovascular and cerebrovascular events and severe or moderate bleeding','C4321335','Moderate','Moderate Level','false'
'reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$','C1869620','RESLIZUMAB','reslizumab','true'
'reslizumab $nmbr$ $nmbr$ mg kg n $nmbr$','C0439272','mg kg','ug/g','false'
'bmi mean kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi mean kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi mean kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'years since diagnosis mean','C0439234','YEARS','year','false'
'years since diagnosis mean','C0011900','DIAGNOSIS','Diagnosis','true'
'years since diagnosis mean','C1704338','diagnosis','diagnosis aspect','true'
'years since diagnosis mean','C1704656','DIAGNOSIS','Diagnosis Study','false'
'ics use at enrollment mean mg d','C0042153','use','utilization qualifier','true'
'ics use at enrollment mean mg d','C0457083','Use','Usage','false'
'ics use at enrollment mean mg d','C1947944','Use','Use - dosing instruction imperative','false'
'exacerbation within previous $nmbr$ mo no','C4086268','EXACERBATION','Exacerbation','false'
'exacerbation within previous $nmbr$ mo no','C0026544','MO','Morocco','true'
'exacerbation within previous $nmbr$ mo no','C0332177','/mo','Monthly (qualifier value)','false'
'acq score mean','C0444504','Mean','Statistical mean','false'
'acq score mean','C2347634','Mean','Population Mean','false'
'acq score mean','C2348143','Mean','Sample Mean','false'
'airway reversibility','C0178987','Airway, NOS','Artificial Airways','false'
'airway reversibility','C0449261','Reversibility','Reversibility','false'
'airway reversibility','C0458827','Airway','Airway structure','false'
'fev $nmbr$ mean l','C0444504','Mean','Statistical mean','false'
'fev $nmbr$ mean l','C2347634','Mean','Population Mean','false'
'fev $nmbr$ mean l','C2348143','Mean','Sample Mean','false'
'rescue medication use mean inhalations previous $nmbr$ d','C0004048','inhalations','Inspiration function','true'
'rescue medication use mean inhalations previous $nmbr$ d','C0354922','Inhalations','Inhalation preparations','false'
'rescue medication use mean inhalations previous $nmbr$ d','C0205156','Previous','Previous','false'
'rescue medication use mean inhalations previous $nmbr$ d','C1552607','previous','Act Relationship Subset - previous','false'
'blood eosinophils mean range cells ml','C2699156','Cells/mL','Cells per Milliliter','false'
'treated with laba','C0332293','Treated with','Treated with','false'
'baricitinib $nmbr$ mg daily n $nmbr$','C0024671','MG','Mammography','true'
'baricitinib $nmbr$ mg daily n $nmbr$','C0026410','MG','Mongolia','true'
'baricitinib $nmbr$ mg daily n $nmbr$','C0439269','mg%','mg/dL','false'
'baricitinib $nmbr$ mg daily n $nmbr$','C1960952','mg %','Milligram percent','false'
'baricitinib $nmbr$ mg daily n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'baricitinib $nmbr$ mg daily n $nmbr$','C4321396','MG','MG','false'
'baricitinib $nmbr$ mg daily n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'positive for anti cyclic citrullinated peptide antibody no f','C0741132','positive antibody','antibody positive','false'
'positive for anti cyclic citrullinated peptide antibody no f','C1320283','Anti-cyclic citrullinated peptide','Anti-cyclic citrullinated peptide','false'
'positive for anti cyclic citrullinated peptide antibody no f','C0016327','F-','Fluorides','true'
'positive for rheumatoid factor no t','C0439178','% Positive','percent positive cells','false'
'positive for rheumatoid factor no t','C1446409','Positive','Positive','false'
'positive for rheumatoid factor no t','C1514241','POSITIVE','Positive Finding','false'
'positive for rheumatoid factor no t','C2825490','Positive','Positive Charge','false'
'positive for rheumatoid factor no t','C3812269','Positive','Positive Number','false'
'positive for rheumatoid factor no t','C2603360','T'','T prime','false'
'no of previous biologic dmards no','C0205156','Previous','Previous','false'
'no of previous biologic dmards no','C4055380','Biologic DMARD','Biologic Disease-Modifying Antirheumatic Drug','false'
'no of previous biologic dmards no','C1552607','previous','Act Relationship Subset - previous','false'
'tnf inhibitors','C1448177','TNF','TNF protein, human','true'
'tnf inhibitors','C0243077','inhibitors','inhibitors','true'
'non tnf inhibitors','C1448177','TNF','TNF protein, human','true'
'non tnf inhibitors','C0243077','inhibitors','inhibitors','true'
'swollen joint count of $nmbr$ joints examined','C0451521','Swollen joint count','Swollen joint count','false'
'swollen joint count of $nmbr$ joints examined','C0332128','Examined','Examined','false'
'tender joint count of $nmbr$ joints examined','C0451530','Tender joint count','Tender joint count','false'
'tender joint count of $nmbr$ joints examined','C0332128','Examined','Examined','false'
'scores for global and pain assessments','C0449820','Scores','Score','false'
'scores for global and pain assessments','C0205246','Global','Generalized','false'
'scores for global and pain assessments','C2348867','Global','Global','false'
'scores for global and pain assessments','C0030198','Pain Assessments','Pain Measurement','true'
'physician s global assessment','C0031831','PHYSICIAN','Physicians','true'
'physician s global assessment','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'physician s global assessment','C0281858','Global Assessment','global assessment','false'
'patient s global assessment','C0030705','*^patient','Patients','true'
'patient s global assessment','C0281858','Global Assessment','global assessment','false'
'patient s assessment of pain','C0030705','*^patient','Patients','true'
'patient s assessment of pain','C0030198','Pain Assessment','Pain Measurement','true'
'haq di scored','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di scored','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'haq di scored','C0449820','scored','Score','false'
'high sensitivity crp mg liter','C1441604','High sensitivity','High sensitivity','false'
'high sensitivity crp mg liter','C0475211','Litre','liter','false'
'esr mm hr','C3811131','ESR','Estrogen Receptor Measurement','false'
'esr mm hr','C4330985','/mm','Per Millimeter','false'
'esr mm hr','C4554674','MM','MM genotype','false'
'das $nmbr$ esr','C0051767','DAS','amsonic acid','true'
'das $nmbr$ esr','C3811131','ESR','Estrogen Receptor Measurement','false'
'das $nmbr$ esr','C0057671','DAS','diacetoxyscirpenol','true'
'simplified disease activity index score','C4706353','Disease Activity Score','DAS - Disease Activity Score','false'
'n n','C0369718','N NOS','N not otherwise specified Antibody','false'
'n n','C0441922','N+','N+ (tumor staging)','false'
'baricitinib $nmbr$ mg','C0024671','MG','Mammography','true'
'baricitinib $nmbr$ mg','C0026410','MG','Mongolia','true'
'baricitinib $nmbr$ mg','C0439269','mg%','mg/dL','false'
'baricitinib $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'baricitinib $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'baricitinib $nmbr$ mg','C4321396','MG','MG','false'
'baricitinib $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'of prior bdmards','C0332152','Prior','Before','false'
'of prior bdmards','C2826257','PRIOR','Prior Medication Usage','false'
'of prior tnfi among non tnfi naive','C0332152','Prior','Before','false'
'of prior tnfi among non tnfi naive','C1518422','Non','Negation','false'
'of prior tnfi among non tnfi naive','C2826257','PRIOR','Prior Medication Usage','false'
'of prior non tnfi bdmards','C0332152','Prior','Before','false'
'of prior non tnfi bdmards','C1518422','Non','Negation','false'
'of prior non tnfi bdmards','C2826257','PRIOR','Prior Medication Usage','false'
'white race no y left ventricular ejection fraction','C0007457','white race','Caucasoid Race','true'
'white race no y left ventricular ejection fraction','C0043157','white race','Caucasians','true'
'white race no y left ventricular ejection fraction','C0428772','Left Ventricular Ejection Fraction','Left ventricular ejection fraction','false'
'white race no y left ventricular ejection fraction','C0488728','Left ventricular Ejection fraction','Ejection fraction:Volume Fraction:Point in time:Heart.ventricle.left:Quantitative','false'
'nyha functional classification no i','C1275491','NYHA classification','New York Heart Association Classification','false'
'nyha functional classification no i','C0205245','Functional','Functional','false'
'nyha functional classification no i','C0542341','Functional','Function (attribute)','false'
'nyha functional classification no i','C2700217','Functional','Functional Relationship','false'
'nyha functional classification no i','C0021966','I-','Iodides','true'
'nyha functional classification no i','C0221138','I NOS','Blood group antibody I','false'
'hospitalization in previous year with management of heart failure','C0019993','hospitalisation','Hospitalization','true'
'hospitalization in previous year with management of heart failure','C0205156','Previous','Previous','false'
'hospitalization in previous year with management of heart failure','C1552607','previous','Act Relationship Subset - previous','false'
'hospitalization in previous year with management of heart failure','C0001554','Management','Administration occupational activities','true'
'hospitalization in previous year with management of heart failure','C0376636','management','Disease Management','true'
'hospitalization in previous year with management of heart failure','C1273870','Management','Management procedure','false'
'hospitalization in previous year with management of heart failure','C3273539','Management','Management Occupations','false'
'as major component no','C0449432','Component','Component object','false'
'as major component no','C1705248','Component','Component (part)','false'
'qrs $nmbr$ ms $nmbr$ cl n $nmbr$','C2349943','Ms.','Ms. - Title','false'
'qrs $nmbr$ ms $nmbr$ cl n $nmbr$','C0596019','Cl -','Chloride Ion','false'
'qrs $nmbr$ ms $nmbr$ cl n $nmbr$','C3539704','MS','MTR wt Allele','false'
'qrs $nmbr$ ms $nmbr$ cl n $nmbr$','C3713294','MS','MTR protein, human','true'
'hr $nmbr$ cl pvalue','C0596019','Cl -','Chloride Ion','false'
'adjusted hr $nmbr$ cl pvalue','C0456081','Adjusted','Adjustment Action','false'
'adjusted hr $nmbr$ cl pvalue','C0596019','Cl -','Chloride Ion','false'
'primary outcome','C0205225','Primary','Primary','false'
'primary outcome','C1274040','Outcome','Result','false'
'primary outcome','C0439612','Primary','True primary (qualifier value)','false'
'primary outcome','C0439631','Primary','Primary operation','false'
'$nmbr$ events','C0441471','Events','Event','false'
'$nmbr$ events','C3541888','EVENTS','CDISC Events Class','false'
'$nmbr$ $nmbr$ per $nmbr$ py','C0030428','PY','Paraguay','true'
'$nmbr$ $nmbr$ per $nmbr$ py','C3538810','PY','Nonclinical Pregnancy Results Domain','false'
'aborted cardiac arrest','C0018790','Arrest, Cardiac','Cardiac Arrest','true'
'aborted cardiac arrest','C4553105','Cardiac arrest','Cardiac Arrest, CTCAE 5','false'
'$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0441471','Events','Event','false'
'$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3541888','EVENTS','CDISC Events Class','false'
'$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0030428','PY','Paraguay','true'
'$nmbr$ events $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3538810','PY','Nonclinical Pregnancy Results Domain','false'
'$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0441471','Event','Event','false'
'$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0030428','PY','Paraguay','true'
'$nmbr$ event $nmbr$ $nmbr$ per $nmbr$ py $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3538810','PY','Nonclinical Pregnancy Results Domain','false'
'heart failure hospitalizations','C3898876','HEART FAILURE HOSPITALIZATION','Hospitalization Due to Heart Failure','false'
'persistent faol n [ $nmbr$','C0205322','Persistent','Persistent','false'
'persistent faol n [ $nmbr$','C0332996','PERSISTENT','Persistent embryonic structure','false'
'persistent faod n [ $nmbr$','C0205322','Persistent','Persistent','false'
'persistent faod n [ $nmbr$','C0332996','PERSISTENT','Persistent embryonic structure','false'
'inconsistent fao n [ $nmbr$','C0442809','Inconsistent','Inconsistent','false'
'inconsistent fao n [ $nmbr$','C0016457','FAO','Food and Agriculture Organization of the United Nations','false'
'total n [ $nmbr$','C0439175','% total','% of total','false'
'total n [ $nmbr$','C0439810','Total','Total','false'
'duration of asthma y','C0449238','Duration','Duration (temporal concept)','false'
'duration of asthma y','C2926735','Duration','Duration','false'
'predose fev $nmbr$ l','C0439565','Pre-dose','Pre-dose','false'
'predose fev $nmbr$ l','C3714541','FEV','Forced Vital Capacity','true'
'predose fev $nmbr$ l','C3812758','Pre-dose','Pre-dose Measure','false'
'fevj predicted t','C0681842','Predicted','prediction','false'
'fevj predicted t','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fvc predicted t','C0681842','Predicted','prediction','false'
'fvc predicted t','C1882327','%{Predicted}','Percent of Predicted Value','false'
'baseline ics dose n','C0168634','baseline','BaseLine dental cement','true'
'baseline ics dose n','C0178602','DOSE','Dosage','false'
'baseline ics dose n','C0869039','Dose','Unit dose','false'
'baseline ics dose n','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'baseline ics dose n','C1442488','Baseline','Baseline','false'
'rescue medication use inh d','C0240320','MEDICATION USE','medication use','false'
'rescue medication use inh d','C0022209','ISONIAZID','isoniazid','true'
'asthma control days','C0004096','ASTHMA','Asthma','true'
'asthma control days','C0439228','DAYS','day','false'
'asthma control days','C2984299','Asthma','Asthma Pathway','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C0439565','Pre-dose','Pre-dose','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C2986411','Improvement','Improvement','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C3812758','Pre-dose','Pre-dose Measure','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C0039798','treatment','therapeutic aspects','true'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C0087111','Treatment','Therapeutic procedure','true'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C1522326','Treatment','Treating','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C1533734','Treatment','Administration procedure','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C1705169','Treatment','Biomaterial Treatment','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C3538994','TREATMENT','Treatment Epoch','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C0016457','FAO','Food and Agriculture Organization of the United Nations','false'
'figure $nmbr$ predose fev $nmbr$ improvements in l by treatment and fao status','C0449438','Status','Status','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0168634','baseline','BaseLine dental cement','true'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1442488','Baseline','Baseline','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1704788','Defined','Definition','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C3539106','Defined','Sufficiently defined concept definition status (core metadata concept)','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0444706','Measured','Measured','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C3541902','MEASURED','Measured Tumor Identification','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0220908','Screening','Screening procedure','true'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1522609','Value','Numerical value','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0220909','screening','Aspects of disease screening','true'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1698960','screening','research subject screening','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1710031','Screening','Disease Screening','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1710032','Screening','Screening','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1710477','SCREENING','Trial Screening','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C2348164','SCREENING','Screening Study','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1551351','Available Volume','Available Volume','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0205436','Second','second (number)','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0060657','FORMOTEROL','formoterol','true'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0457385','Second','seconds','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C0565930','/second','per second','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1561503','second','Precision - second','false'
'baseline was defined as the predose fev $nmbr$ value measured on the day of randomization visit $nmbr$ or the screening predose value if no value was available at visit $nmbr$ bid twice daily bud budesonide fao fixed airflow obstruction fev $nmbr$ forced expiratory volume l in $nmbr$ second fm formoterol','C1705190','Second','Second Suffix','false'
'prior mi n $nmbr$ $nmbr$','C0332152','Prior','Before','false'
'prior mi n $nmbr$ $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'index mi n $nmbr$ $nmbr$','C0600653','Index','Indexes','true'
'index mi n $nmbr$ $nmbr$','C0918012','Index','Index','true'
'index mi n $nmbr$ $nmbr$','C1552854','index','Html Link Type - index','false'
'index mi n $nmbr$ $nmbr$','C1637833','% index','% index','false'
'index mi n $nmbr$ $nmbr$','C2986546','Index','Target Lesion Identification','false'
'any mi n $nmbr$ $nmbr$','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'no mi n $nmbr$ $nmbr$','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'pvaluefor any mi versus no mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'race nonwhitet','C0034510','RACE','Racial group','true'
'race nonwhitet','C1706779','RACE','AMACR wt Allele','false'
'race nonwhitet','C3853635','Race','Race','false'
'oral medications','C0304289','Oral Medications','Oral drug preparation, NOS','false'
'diet controlled or no','C0743195','diet controlled','diet controlled','false'
'stroke tia','C0007787','TIA','Transient Ischemic Attack','true'
'stroke tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'stroke tia','C1054154','tia','Tacca leontopetaloides','false'
'history of major bleeding','C0019664','History','History','true'
'history of major bleeding','C0019665','history','Historical aspects qualifier','true'
'history of major bleeding','C0262512','History, NOS','History of present illness','false'
'history of major bleeding','C0262926','History','Medical History','false'
'history of major bleeding','C1705255','History','Concept History','false'
'history of major bleeding','C2004062','History','History of previous events','false'
'peripheral artery disease','C1704436','Peripheral Artery Disease','Peripheral Arterial Diseases','true'
'peripheral artery disease','C4025272','Peripheral artery disease','Peripheral arterial stenosis','false'
'indication for index procedure','C2315323','Indication for procedure','Indication for procedure','false'
'indication for index procedure','C0600653','Index','Indexes','true'
'indication for index procedure','C0918012','Index','Index','true'
'indication for index procedure','C1552854','index','Html Link Type - index','false'
'indication for index procedure','C1637833','% index','% index','false'
'indication for index procedure','C2986546','Index','Target Lesion Identification','false'
'unstable anginat','C0443343','Unstable','Unstable status','false'
'unstable anginat','C1883468','Unstable','Unstable Medical Device Problem','false'
'any mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'ischemic outcomes','C0475224','Ischemic','Ischemic','false'
'ischemic outcomes','C1274040','Outcome','Result','false'
'continue thienopyridine n $nmbr$','C0549178','Continue','Continuous','false'
'continue thienopyridine n $nmbr$','C1120149','thienopyridine','thienopyridine','true'
'stratified hazard ratio $nmbr$ ci','C0008107','CI','Chile','true'
'stratified hazard ratio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'stratified log rank p value','C0205363','Stratified','Stratified','false'
'stratified log rank p value','C1709380','P-Value','P-Value','false'
'stent thrombosis arc definite probable','C0033204','Probable','Probability','true'
'stent thrombosis arc definite probable','C0332148','Probable','Probable diagnosis','false'
'macce death mi stroke','C0038454','STROKE','Cerebrovascular accident','true'
'macce death mi stroke','C4554100','Stroke','Stroke, CTCAE','false'
'stent thrombosis related mi','C3897493','Stent Thrombosis','Stent Thrombosis','false'
'stent thrombosis related mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'non stent thrombosis related mi','C3897493','Stent Thrombosis','Stent Thrombosis','false'
'non stent thrombosis related mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'bleeding outcomes','C0019080','BLEEDING','Hemorrhage','true'
'bleeding outcomes','C1274040','Outcome','Result','false'
'log rank p value','C0667477','RANK','TNFRSF11A protein, human','true'
'log rank p value','C1709380','P-Value','P-Value','false'
'log rank p value','C0699794','Rank','Rank','false'
'gusto severe moderate','C1299393','severe moderate','Moderate to severe','false'
'gusto moderate','C0205081','Moderate','Moderate (severity modifier)','false'
'gusto moderate','C1881878','Moderate','Moderation','false'
'gusto moderate','C4049705','Moderate','Moderate Extremity Pain','false'
'gusto moderate','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'gusto moderate','C4085643','Moderate','Moderate Response','false'
'gusto moderate','C4321335','Moderate','Moderate Level','false'
'barc types $nmbr$ $nmbr$ or $nmbr$','C0332307','Types','Type - attribute','false'
'no mi','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'log rank','C0667477','RANK','TNFRSF11A protein, human','true'
'log rank','C0699794','Rank','Rank','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C0871208','Rate','Rating (action)','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C1521828','Rate','Rate','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C1709595','Pooled','Pooled Sample','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C1999375','TICAGRELOR','Ticagrelor','true'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C2349200','Pooled','Pool (action)','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C4522255','Pooled','Pooled Blood Products','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C0206655','ARMS','Alveolar rhabdomyosarcoma','true'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C0446516','Arms','Upper arm','true'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C2681631','ARMS','KIDINS220 gene','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C3715044','ARM','AKR1A1 wt Allele','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C4553528','arm','Sequence Arm','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C0011847','Diabetes','Diabetes','false'
'figure $nmbr$ rates of mace in the pooled ticagrelor versus placebo arms for patients with and without diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C1999375','TICAGRELOR','Ticagrelor','true'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C0030705','Patients','Patients','true'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C0182158','Pad','Pads','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C0332568','Pad','Pad Mass','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C3540603','PAD','PADI4 wt Allele','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C3669270','Pad','Strucure of thick cushion of skin','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C3814046','PAD','PAD Regimen','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C4319657','Pad','Pad (unit of presentation)','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C1274040','Result','Result','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C1546471','Result','What subject filter - Result','false'
'central illustration ticagrelor in patients with pad and prior mi $nmbr$ year results','C2825142','Result','Experimental Result','false'
'peripheral artery disease pad','C0182158','Pad','Pads','false'
'peripheral artery disease pad','C0332568','Pad','Pad Mass','false'
'peripheral artery disease pad','C3540603','PAD','PADI4 wt Allele','false'
'peripheral artery disease pad','C3669270','Pad','Strucure of thick cushion of skin','false'
'peripheral artery disease pad','C3814046','PAD','PAD Regimen','false'
'peripheral artery disease pad','C4319657','Pad','Pad (unit of presentation)','false'
'adolescents aged $nmbr$ $nmbr$ y no','C0001779','Aged','Age','false'
'adolescents aged $nmbr$ $nmbr$ y no','C0001792','Aged','Elderly (population group)','true'
'adolescents aged $nmbr$ $nmbr$ y no','C1999167','aged','Old age','false'
'adults aged $nmbr$ y no','C0001675','Adults','Adult','true'
'adults aged $nmbr$ y no','C0001779','Aged','Age','false'
'adults aged $nmbr$ y no','C0001792','Aged','Elderly (population group)','true'
'adults aged $nmbr$ y no','C1999167','aged','Old age','false'
'non hispanic non latino','C1518424','Non-Hispanic','Not Hispanic or Latino','false'
'non hispanic non latino','C0086528','Latino','Latinos','true'
'disease characteristics','C0599878','disease characteristic','disease characteristic','false'
'mean time since diagnosis y','C0040223','TIME','Time','true'
'mean time since diagnosis y','C3541383','Time','Time (foundation metadata concept)','false'
'exacerbation within $nmbr$ mo','C4086268','EXACERBATION','Exacerbation','false'
'exacerbation within $nmbr$ mo','C0026544','MO','Morocco','true'
'exacerbation within $nmbr$ mo','C0332177','/mo','Monthly (qualifier value)','false'
'aqlq score mean','C0444504','Mean','Statistical mean','false'
'aqlq score mean','C2347634','Mean','Population Mean','false'
'aqlq score mean','C2348143','Mean','Sample Mean','false'
'asui score mean','C0444504','Mean','Statistical mean','false'
'asui score mean','C2347634','Mean','Population Mean','false'
'asui score mean','C2348143','Mean','Sample Mean','false'
'airway reversibility mean','C0444504','Mean','Statistical mean','false'
'airway reversibility mean','C2347634','Mean','Population Mean','false'
'airway reversibility mean','C2348143','Mean','Sample Mean','false'
'fev $nmbr$ mean predicted','C0444504','Mean','Statistical mean','false'
'fev $nmbr$ mean predicted','C2347634','Mean','Population Mean','false'
'fev $nmbr$ mean predicted','C2348143','Mean','Sample Mean','false'
'fev $nmbr$ mean predicted','C0681842','Predicted','prediction','false'
'fev $nmbr$ mean predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'rescue use mean no of inhalations d','C0444504','Mean','Statistical mean','false'
'rescue use mean no of inhalations d','C2347634','Mean','Population Mean','false'
'rescue use mean no of inhalations d','C2348143','Mean','Sample Mean','false'
'rescue use mean no of inhalations d','C0004048','inhalations','Inspiration function','true'
'rescue use mean no of inhalations d','C0354922','Inhalations','Inhalation preparations','false'
'blood eosinophils mean range cells mlb','C0005773','Blood Cells','Blood Cells','true'
'total daily dose of ics mean gc','C2348070','Total Daily Dose','Daily Dose','false'
'total daily dose of ics mean gc','C0444504','Mean','Statistical mean','false'
'total daily dose of ics mean gc','C2347634','Mean','Population Mean','false'
'total daily dose of ics mean gc','C2348143','Mean','Sample Mean','false'
'a reslizumab $nmbr$ $nmbr$ mg kg n n','C1869620','RESLIZUMAB','reslizumab','true'
'a reslizumab $nmbr$ $nmbr$ mg kg n n','C0439272','mg kg','ug/g','false'
'b reslizumab $nmbr$ $nmbr$ mg kg n n','C1869620','RESLIZUMAB','reslizumab','true'
'b reslizumab $nmbr$ $nmbr$ mg kg n n','C0439272','mg kg','ug/g','false'
'eos count cells pl','C3897966','/pL','Per Picoliter','false'
'eos count cells pl','C4049765','PL','Infusion pump Alert priority PL','false'
'prior oma use','C0042153','use','utilization qualifier','true'
'prior oma use','C0457083','Use','Usage','false'
'prior oma use','C1947944','Use','Use - dosing instruction imperative','false'
'no prior oma use','C0042153','use','utilization qualifier','true'
'no prior oma use','C0457083','Use','Usage','false'
'no prior oma use','C1947944','Use','Use - dosing instruction imperative','false'
'prior oma use n $nmbr$','C0332152','Prior','Before','false'
'prior oma use n $nmbr$','C0042153','use','utilization qualifier','true'
'prior oma use n $nmbr$','C0457083','Use','Usage','false'
'prior oma use n $nmbr$','C1947944','Use','Use - dosing instruction imperative','false'
'prior oma use n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'no prior oma use n $nmbr$','C0332152','Prior','Before','false'
'no prior oma use n $nmbr$','C0042153','use','utilization qualifier','true'
'no prior oma use n $nmbr$','C0457083','Use','Usage','false'
'no prior oma use n $nmbr$','C1947944','Use','Use - dosing instruction imperative','false'
'no prior oma use n $nmbr$','C2826257','PRIOR','Prior Medication Usage','false'
'annual exacerbation rate','C0871208','Rate','Rating (action)','false'
'annual exacerbation rate','C1521828','Rate','Rate','false'
'age mean range years','C1510829','Age-Years','Age-Years','false'
'age mean range years','C0444504','Mean','Statistical mean','false'
'age mean range years','C2347634','Mean','Population Mean','false'
'age mean range years','C2348143','Mean','Sample Mean','false'
'rate ratio mepo pbo $nmbr$ ci','C0008107','CI','Chile','true'
'rate ratio mepo pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'female n race n','C0043210','female','Woman','true'
'female n race n','C0034510','RACE','Racial group','true'
'female n race n','C1706779','RACE','AMACR wt Allele','false'
'female n race n','C3853635','Race','Race','false'
'female n race n','C0086287','FEMALE','Females','true'
'female n race n','C1705497','Female','Female, Self-Report','false'
'female n race n','C1705498','FEMALE','Female Phenotype','false'
'change from baseline in acq $nmbr$','C0392747','Change','Changing','false'
'change from baseline in acq $nmbr$','C0443172','change','Changed status','false'
'change from baseline in acq $nmbr$','C1705241','Change','Delta (difference)','false'
'change from baseline in acq $nmbr$','C4319952','Change','Change -- procedure','false'
'change from baseline in acq $nmbr$','C2919686','ACQ','Asthma control questionnaire','false'
'score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci','C3533236','Mean score','Mean score','false'
'score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci','C0008107','CI','Chile','true'
'score at week $nmbr$ mean se difference mepo pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'change from baseline in sgrq','C0392747','Change','Changing','false'
'change from baseline in sgrq','C0443172','change','Changed status','false'
'change from baseline in sgrq','C1705241','Change','Delta (difference)','false'
'change from baseline in sgrq','C4319952','Change','Change -- procedure','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C0392747','Change','Changing','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C0443172','change','Changed status','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C1705241','Change','Delta (difference)','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C4319952','Change','Change -- procedure','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C0030771','PEF','Pefloxacin','true'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C1518922','PEF','peak expiratory flow (procedure)','false'
'change from baseline in morning pef during weeks $nmbr$ $nmbr$ mean l min se','C1542834','PEF','Peak expiratory flow rate','false'
'hispanic ethnicity n','C0086409','HISPANIC','Hispanics','true'
'hispanic ethnicity n','C0015031','Ethnicity','Ethnic group','true'
'hispanic ethnicity n','C0243103','ethnicity','Ethnicity aspects','true'
'difference mepo pbo $nmbr$ ci','C0008107','CI','Chile','true'
'difference mepo pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'change from baseline in pre bd','C0392747','Change','Changing','false'
'change from baseline in pre bd','C0443172','change','Changed status','false'
'change from baseline in pre bd','C1705241','Change','Delta (difference)','false'
'change from baseline in pre bd','C4319952','Change','Change -- procedure','false'
'change from baseline in pre bd','C0005126','BD','Bermuda','true'
'change from baseline in pre bd','C2344255','BD','BD Alcohol','false'
'change from baseline in pre bd','C4050145','BD','Block Design Subtest (WPPSI-IV)','false'
'fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci','C3714541','FEV','Forced Vital Capacity','true'
'fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci','C0008107','CI','Chile','true'
'fev $nmbr$ at week $nmbr$ mean ml se difference mepo pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'duration of asthma','C0449238','Duration','Duration (temporal concept)','false'
'duration of asthma','C2926735','Duration','Duration','false'
'change from baseline in post bd','C0392747','Change','Changing','false'
'change from baseline in post bd','C0443172','change','Changed status','false'
'change from baseline in post bd','C1705241','Change','Delta (difference)','false'
'change from baseline in post bd','C4319952','Change','Change -- procedure','false'
'change from baseline in post bd','C0005126','BD','Bermuda','true'
'change from baseline in post bd','C2344255','BD','BD Alcohol','false'
'change from baseline in post bd','C4050145','BD','Block Design Subtest (WPPSI-IV)','false'
'mean sd years daily ocs use n','C0332173','Daily','Daily','false'
'mean sd years daily ocs use n','C0042153','use','utilization qualifier','true'
'mean sd years daily ocs use n','C0457083','Use','Usage','false'
'mean sd years daily ocs use n','C1947944','Use','Use - dosing instruction imperative','false'
'ocs dose mean sd','C0178602','DOSE','Dosage','false'
'ocs dose mean sd','C2699239','SD','SD, Rat Strain','false'
'ocs dose mean sd','C0869039','Dose','Unit dose','false'
'ocs dose mean sd','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C0456603','RATIO','Ratio','false'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C1547037','Ratio','data type - ratio','false'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C0200638','Eosinophil Count','Eosinophil count procedure','false'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C0750879','Eosinophil count NOS','Eosinophil count result','false'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C0007584','CELLS','Cell Count','true'
'ratio to baseline in eosinophil count at week $nmbr$ geometric mean se on loge scale cells ll','C0007634','Cells','Cells','true'
'mg day','C0439422','mg day','milligram/day','false'
'ratio mepo pbo $nmbr$ ci','C0008107','CI','Chile','true'
'ratio mepo pbo $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'eosinophils cells ll inclusion criteria n','C0007584','CELLS','Cell Count','true'
'eosinophils cells ll inclusion criteria n','C0007634','Cells','Cells','true'
'eosinophils cells ll inclusion criteria n','C1512693','Inclusion Criteria','Inclusion','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C0456603','RATIO','Ratio','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C1547037','Ratio','data type - ratio','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C0806481','IgE.total','IgE.total','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C2986759','Geometric Mean','Geometric Mean','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C0439340','U/mL','Kilounit per Liter','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C1880521','U/mL','Enzyme Unit per Milliliter','false'
'ratio to baseline in total ige at week $nmbr$ geometric mean se on loge scale u ml','C2945590','U/mL','Unit per Milliliter','false'
'$nmbr$ in previous','C0205156','Previous','Previous','false'
'$nmbr$ in previous','C1552607','previous','Act Relationship Subset - previous','false'
'$nmbr$ at screening','C0220908','Screening','Screening procedure','true'
'$nmbr$ at screening','C0220909','screening','Aspects of disease screening','true'
'$nmbr$ at screening','C1698960','screening','research subject screening','false'
'$nmbr$ at screening','C1710031','Screening','Disease Screening','false'
'$nmbr$ at screening','C1710032','Screening','Screening','false'
'$nmbr$ at screening','C1710477','SCREENING','Trial Screening','false'
'$nmbr$ at screening','C2348164','SCREENING','Screening Study','false'
'predicted pre bd','C0005126','BD','Bermuda','true'
'predicted pre bd','C2344255','BD','BD Alcohol','false'
'predicted pre bd','C4050145','BD','Block Design Subtest (WPPSI-IV)','false'
'fev $nmbr$ mean sd pre bd fev $nmbr$ fvc','C0005126','BD','Bermuda','true'
'fev $nmbr$ mean sd pre bd fev $nmbr$ fvc','C3714541','FVC','Forced Vital Capacity','true'
'fev $nmbr$ mean sd pre bd fev $nmbr$ fvc','C2344255','BD','BD Alcohol','false'
'fev $nmbr$ mean sd pre bd fev $nmbr$ fvc','C4050145','BD','Block Design Subtest (WPPSI-IV)','false'
'mean sd reversibility fev $nmbr$ at','C0444504','Mean','Statistical mean','false'
'mean sd reversibility fev $nmbr$ at','C3714541','FEV','Forced Vital Capacity','true'
'mean sd reversibility fev $nmbr$ at','C2347634','Mean','Population Mean','false'
'mean sd reversibility fev $nmbr$ at','C2348143','Mean','Sample Mean','false'
'screening mean sd morning pef mean','C0220908','Screening','Screening procedure','true'
'screening mean sd morning pef mean','C0030771','PEF','Pefloxacin','true'
'screening mean sd morning pef mean','C1518922','PEF','peak expiratory flow (procedure)','false'
'screening mean sd morning pef mean','C1542834','PEF','Peak expiratory flow rate','false'
'screening mean sd morning pef mean','C0220909','screening','Aspects of disease screening','true'
'screening mean sd morning pef mean','C1698960','screening','research subject screening','false'
'screening mean sd morning pef mean','C1710031','Screening','Disease Screening','false'
'screening mean sd morning pef mean','C1710032','Screening','Screening','false'
'screening mean sd morning pef mean','C1710477','SCREENING','Trial Screening','false'
'screening mean sd morning pef mean','C2348164','SCREENING','Screening Study','false'
'sd l min acq $nmbr$ score mean sd','C0449820','SCORE','Score','false'
'sd l min acq $nmbr$ score mean sd','C0444504','Mean','Statistical mean','false'
'sd l min acq $nmbr$ score mean sd','C2347634','Mean','Population Mean','false'
'sd l min acq $nmbr$ score mean sd','C2348143','Mean','Sample Mean','false'
'sd l min acq $nmbr$ score mean sd','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'sgrq score mean sd','C0444504','Mean','Statistical mean','false'
'sgrq score mean sd','C2699239','SD','SD, Rat Strain','false'
'sgrq score mean sd','C2347634','Mean','Population Mean','false'
'sgrq score mean sd','C2348143','Mean','Sample Mean','false'
'total ige geometric','C0439175','% total','% of total','false'
'total ige geometric','C0439810','Total','Total','false'
'mean sd on loge scale u ml','C2699239','SD','SD, Rat Strain','false'
'mean sd on loge scale u ml','C0439340','U/mL','Kilounit per Liter','false'
'mean sd on loge scale u ml','C1880521','U/mL','Enzyme Unit per Milliliter','false'
'mean sd on loge scale u ml','C2945590','U/mL','Unit per Milliliter','false'
'blood eosinophil count geometric mean sd loge scale cells ll','C0005773','Blood Cells','Blood Cells','true'
'severe exacerbations','C0205082','Severe','Severe (severity modifier)','false'
'severe exacerbations','C4086268','EXACERBATION','Exacerbation','false'
'severe exacerbations','C4050465','Severe','Severe Extremity Pain','false'
'severe exacerbations','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'in previous year mean sd','C0205156','Previous','Previous','false'
'in previous year mean sd','C2699239','SD','SD, Rat Strain','false'
'in previous year mean sd','C1552607','previous','Act Relationship Subset - previous','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C0205156','Previous','Previous','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C1552607','previous','Act Relationship Subset - previous','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C0019993','hospitalisation','Hospitalization','true'
'exacerbations in previous year requiring hospitalization and or ed visit n','C0545082','Visit','Visit','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C1512346','visit','Patient Visit','false'
'exacerbations in previous year requiring hospitalization and or ed visit n','C2826704','VISIT','Visit Name','false'
'exacerbations in previous year requiring hospitalization n','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in previous year requiring hospitalization n','C0205156','Previous','Previous','false'
'exacerbations in previous year requiring hospitalization n','C1552607','previous','Act Relationship Subset - previous','false'
'exacerbations in previous year requiring hospitalization n','C0019993','hospitalisation','Hospitalization','true'
'spondylitis','C0038012','Spondylitis','Spondylitis','true'
'non spondylitis','C1518422','Non','Negation','false'
'non spondylitis','C0038012','Spondylitis','Spondylitis','true'
'ustekinumab combined','C1608841','USTEKINUMAB','ustekinumab','true'
'ustekinumab combined','C0205195','Combined','Combined','false'
'randomised patients with spondylitis at baseline n','C0030705','Patients','Patients','true'
'randomised patients with spondylitis at baseline n','C0038012','Spondylitis','Spondylitis','true'
'randomised patients with spondylitis at baseline n','C0168634','baseline','BaseLine dental cement','true'
'randomised patients with spondylitis at baseline n','C1442488','Baseline','Baseline','false'
'patients randomised n','C0030705','Patients','Patients','true'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C1998004','BASDAI','Bath ankylosing spondylitis disease activity index','false'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C0679830','assessment patients','patient assessment','false'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C0168634','baseline','BaseLine dental cement','true'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C1442488','Baseline','Baseline','false'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C0332174','/week','Weekly','false'
'randomised patients with basdai assessment at baseline and week $nmbr$ n','C0439230','Week','week','false'
'mean sd improvement from baseline to week $nmbr$ in basdai','C2986411','Improvement','Improvement','false'
'mean sd improvement from baseline to week $nmbr$ in basdai','C0168634','baseline','BaseLine dental cement','true'
'mean sd improvement from baseline to week $nmbr$ in basdai','C1442488','Baseline','Baseline','false'
'mean sd improvement from baseline to week $nmbr$ in basdai','C0332174','/week','Weekly','false'
'mean sd improvement from baseline to week $nmbr$ in basdai','C0439230','Week','week','false'
'mean sd improvement from baseline to week $nmbr$ in basdai','C1998004','BASDAI','Bath ankylosing spondylitis disease activity index','false'
'number of swollen joints $nmbr$ $nmbr$ mean sd','C0449813','Number of joints','Number of joints','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C2986411','Improvement','Improvement','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C0168634','baseline','BaseLine dental cement','true'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C1442488','Baseline','Baseline','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C0332174','/week','Weekly','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C0439230','Week','week','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C1998004','BASDAI','Bath ankylosing spondylitis disease activity index','false'
'mean sd improvement from baseline to week $nmbr$ in basdai questions','C1522634','Question','Question (inquiry)','false'
'number of tender joints $nmbr$ $nmbr$ mean sd','C0449813','Number of joints','Number of joints','false'
'question $nmbr$ fatigue tiredness','C0015672','TIREDNESS','Fatigue','true'
'question $nmbr$ fatigue tiredness','C4553152','Tiredness','Tiredness Visual Analogue Scale','false'
'haq di score $nmbr$ $nmbr$ mean sd','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di score $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di score $nmbr$ $nmbr$ mean sd','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'question $nmbr$ neck back hip pain','C0007859','NECK PAIN','Neck Pain','true'
'question $nmbr$ neck back hip pain','C1963180','Neck pain','Neck Pain, CTCAE 3.0','false'
'question $nmbr$ neck back hip pain','C4553909','Neck pain','Neck Pain, CTCAE 5.0','false'
'crp mg l mean sd','C0439268','mg/L','Microgram per Milliliter','false'
'crp mg l mean sd','C2699239','SD','SD, Rat Strain','false'
'question $nmbr$ pain swelling in joints other than neck back hips','C0152031','JOINT SWELLING','Joint swelling','false'
'question $nmbr$ pain swelling in joints other than neck back hips','C0004600','BACK','Back','true'
'question $nmbr$ pain swelling in joints other than neck back hips','C0019552','HIPS','Hip structure','true'
'question $nmbr$ pain swelling in joints other than neck back hips','C0205095','BACK','Dorsal','false'
'question $nmbr$ pain swelling in joints other than neck back hips','C0460009','Back','Back structure, including back of neck','false'
'question $nmbr$ pain swelling in joints other than neck back hips','C1995000','Back, NOS','Back structure, excluding neck','false'
'psa subtypes n','C3810537','PSA','PSAT1 wt Allele','false'
'psa subtypes n','C0449560','subtypes','Subtype (attribute)','false'
'psa subtypes n','C3813209','PSA','PROS1 wt Allele','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C2364135','DISCOMFORT','Discomfort','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C0205146','areas','Area','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C4319729','Areas','Areas <moth>','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C0033095','Pressure','Pressure- physical agent','true'
'question $nmbr$ discomfort from any areas tender to touch pressure','C0460139','Pressure','Pressure (finding)','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C1306345','Pressure','Pressure - action','false'
'question $nmbr$ discomfort from any areas tender to touch pressure','C4284008','Pressure','Pressure (property)','false'
'dip joint arthritis','C0003864','ARTHRITIS','Arthritis','true'
'dip joint arthritis','C4552845','Arthritis','Arthritis, CTCAE','false'
'question $nmbr$ morning stiffness since arising','C1522634','Question','Question (inquiry)','false'
'question $nmbr$ morning stiffness since arising','C0457086','MORNING STIFFNESS','Morning stiffness - joint','false'
'question $nmbr$ morning stiffness since arising','C0332284','arising','Arising in','false'
'question $nmbr$ morning stiffness since arising','C4019053','Arising','Arising','false'
'question $nmbr$ morning stiffness since arising','C4318616','Arising','Usually Need Help from Another Person for Arising','false'
'arthritis mutilans','C0702102','Arthritis mutilans','Arthritis mutilans','false'
'question $nmbr$ length of morning stiffness since arising','C1444754','Length','Length','false'
'question $nmbr$ length of morning stiffness since arising','C1706316','LENGTH','Length of Trial','false'
'question $nmbr$ length of morning stiffness since arising','C0332284','arising','Arising in','false'
'question $nmbr$ length of morning stiffness since arising','C4019053','Arising','Arising','false'
'question $nmbr$ length of morning stiffness since arising','C4318616','Arising','Usually Need Help from Another Person for Arising','false'
'asymmetric peripheral arthritis','C0332514','Asymmetric','Asymmetry','false'
'asymmetric peripheral arthritis','C0238694','ARTHRITIS, PERIPHERAL','ARTHRITIS, PERIPHERAL','false'
'basdai responses at week $nmbr$','C0871261','responses','Response process','false'
'basdai responses at week $nmbr$','C0332174','/week','Weekly','false'
'basdai responses at week $nmbr$','C0439230','Week','week','false'
'polyarticular arthritis no rheumatoid nodules','C0162323','Polyarticular Arthritis','Polyarthritis','true'
'polyarticular arthritis no rheumatoid nodules','C0035450','Rheumatoid Nodules','Rheumatoid Nodule','true'
'basdai $nmbr$ n','C1998004','BASDAI','Bath ankylosing spondylitis disease activity index','false'
'spondylitis with peripheral arthritis','C0038012','Spondylitis','Spondylitis','true'
'spondylitis with peripheral arthritis','C0238694','ARTHRITIS, PERIPHERAL','ARTHRITIS, PERIPHERAL','false'
'psa duration years mean sd','C0439234','YEARS','year','false'
'psa duration years mean sd','C2699239','SD','SD, Rat Strain','false'
'psoriasis duration years mean sd','C0033860','PSORIASIS','Psoriasis','true'
'psoriasis duration years mean sd','C2699239','SD','SD, Rat Strain','false'
'patients taking mtx n','C0030705','Patients','Patients','true'
'patients taking mtx n','C0025677','MTX','Methotrexate','true'
'patients taking mtx n','C1417487','MTX','MTX1 gene','false'
'patients with digits with dactylitis n','C0030705','Patients','Patients','true'
'patients with digits with dactylitis n','C0582802','Digits','Digit structure','false'
'patients with digits with dactylitis n','C0239161','DACTYLITIS','Dactylitis','false'
'haq di improvement from baseline to week $nmbr$','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di improvement from baseline to week $nmbr$','C2986411','Improvement','Improvement','false'
'haq di improvement from baseline to week $nmbr$','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'haq di improvement from baseline to week $nmbr$','C0332174','/week','Weekly','false'
'haq di improvement from baseline to week $nmbr$','C0439230','Week','week','false'
'dactylitis score $nmbr$ $nmbr$ mean sd','C0239161','DACTYLITIS','Dactylitis','false'
'dactylitis score $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'patients with enthesitis n','C0030705','Patients','Patients','true'
'patients with enthesitis n','C1282952','Enthesitis','Enthesitis','false'
'enthesitis score mases $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'enthesitis score mases $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'enthesitis score mases $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'enthesitis score mases $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'patients with radiographic erosion n n','C0030705','Patients','Patients','true'
'patients with radiographic erosion n n','C0333307','Erosion','Superficial ulcer','false'
'patients with radiographic erosion n n','C1880549','Erosion','Erosion of Medical Device Material','false'
'patients with radiographic erosion n n','C1959609','EROSION','Erosion lesion','false'
'patients with radiographic erosion n n','C3887524','Erosion','Skin Erosion','false'
'randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline','C0522476','Involvement patients','Patient affected','false'
'randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline','C0168634','baseline','BaseLine dental cement','true'
'randomised patients with $nmbr$ bsa psoriasis skin involvement at baseline','C1442488','Baseline','Baseline','false'
'basdai score $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'basdai score $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'basdai score $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'basdai score $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'dlqi improvement from baseline to week $nmbr$','C2986411','Improvement','Improvement','false'
'dlqi improvement from baseline to week $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'dlqi improvement from baseline to week $nmbr$','C1442488','Baseline','Baseline','false'
'dlqi improvement from baseline to week $nmbr$','C0332174','/week','Weekly','false'
'dlqi improvement from baseline to week $nmbr$','C0439230','Week','week','false'
'basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'basdai question $nmbr$ score $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'patients with $nmbr$ bsa psoriasis skin involvement n','C0522476','Involvement patients','Patient affected','false'
'bsa mean sd','C0444504','Mean','Statistical mean','false'
'bsa mean sd','C2699239','SD','SD, Rat Strain','false'
'bsa mean sd','C2347634','Mean','Population Mean','false'
'bsa mean sd','C2348143','Mean','Sample Mean','false'
'pasi score $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'pasi score $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'pasi score $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'pasi score $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'randomised patients with dactylitis at baseline','C0030705','Patients','Patients','true'
'randomised patients with dactylitis at baseline','C0239161','DACTYLITIS','Dactylitis','false'
'randomised patients with dactylitis at baseline','C0168634','baseline','BaseLine dental cement','true'
'randomised patients with dactylitis at baseline','C1442488','Baseline','Baseline','false'
'dlqi $nmbr$ $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'dlqi $nmbr$ $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'dlqi $nmbr$ $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'dlqi $nmbr$ $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'improvement in dactylitis score at week $nmbr$ n','C2986411','Improvement','Improvement','false'
'improvement in dactylitis score at week $nmbr$ n','C0239161','DACTYLITIS','Dactylitis','false'
'improvement in dactylitis score at week $nmbr$ n','C0332174','/week','Weekly','false'
'improvement in dactylitis score at week $nmbr$ n','C0439230','Week','week','false'
'patients with dactylitis at week $nmbr$ n','C0030705','Patients','Patients','true'
'patients with dactylitis at week $nmbr$ n','C0239161','DACTYLITIS','Dactylitis','false'
'patients with dactylitis at week $nmbr$ n','C0332174','/week','Weekly','false'
'patients with dactylitis at week $nmbr$ n','C0439230','Week','week','false'
'randomised patients with enthesitis at baselinet','C0030705','Patients','Patients','true'
'randomised patients with enthesitis at baselinet','C1282952','Enthesitis','Enthesitis','false'
'improvement in enthesitis score at week $nmbr$ n','C2986411','Improvement','Improvement','false'
'improvement in enthesitis score at week $nmbr$ n','C0449820','SCORE','Score','false'
'improvement in enthesitis score at week $nmbr$ n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'improvement in enthesitis score at week $nmbr$ n','C0332174','/week','Weekly','false'
'improvement in enthesitis score at week $nmbr$ n','C0439230','Week','week','false'
'patients with enthesitis at week $nmbr$ n','C0030705','Patients','Patients','true'
'patients with enthesitis at week $nmbr$ n','C1282952','Enthesitis','Enthesitis','false'
'patients with enthesitis at week $nmbr$ n','C0332174','/week','Weekly','false'
'patients with enthesitis at week $nmbr$ n','C0439230','Week','week','false'
'standard treatment n $nmbr$','C4684780','Standard Treatment','Standard Treatment','false'
'mra regimen n $nmbr$','C0243032','MRA','Magnetic Resonance Angiography','true'
'mra regimen n $nmbr$','C0040808','Regimen','Treatment Protocols','true'
'mra regimen n $nmbr$','C2945654','regimen','Regimen - CHV concept','false'
'mra regimen n $nmbr$','C1609165','MRA','tocilizumab','true'
'mra regimen n $nmbr$','C3891069','MRA','MRI-Based Angiogram','false'
'risk factors and medical history','C0035648','Risk Factors','risk factors','true'
'risk factors and medical history','C1553898','risk factors','risk factors - observation list','false'
'risk factors and medical history','C0262926','Medical History','Medical History','false'
'risk factors and medical history','C1704706','Medical History','Medical History Domain','false'
'prior cancer','C0006826','CANCER','Malignant Neoplasms','true'
'prior cancer','C0998265','Cancer','Cancer Genus','false'
'prior cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'presentation','C0449450','Presentation','Presentation','false'
'creatinine clearance ml min $nmbr$','C0812399','Creatinine clearance','Creatinine clearance','false'
'creatinine clearance ml min $nmbr$','C0439445','mL/min','mL/min','false'
'potassium at admission mmol l $nmbr$','C0032821','POTASSIUM','Potassium','true'
'potassium at admission mmol l $nmbr$','C0202194','Potassium+','Potassium measurement','false'
'potassium at admission mmol l $nmbr$','C0304475','POTASSIUM','Potassium supplement','false'
'potassium at admission mmol l $nmbr$','C0597277','Potassium','Potassium Ion','false'
'potassium at admission mmol l $nmbr$','C3714637','POTASSIUM','Potassium Drug Class','false'
'admission grace score','C0449820','SCORE','Score','false'
'admission grace score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'in hospital medication','C0013227','Medication','Pharmaceutical Preparations','true'
'in hospital medication','C3244316','medication','medication - HL7 publishing domain','false'
'in hospital medication','C4284232','Medication','Medications','false'
'p $nmbr$ y $nmbr$ antagonist','C0369773','P NOS','P Blood group antibodies','false'
'p $nmbr$ y $nmbr$ antagonist','C0231491','Antagonist','Antagonist muscle action','false'
'p $nmbr$ y $nmbr$ antagonist','C2603361','P'','P prime','false'
'glycoprotein iib iiia inhibitort','C0016011','Glycoprotein IIb/IIIa','Platelet Glycoprotein GPIIb-IIIa Complex','true'
'interventional or surgical procedures','C0184661','Interventional','Interventional procedure','true'
'interventional or surgical procedures','C3274035','INTERVENTIONAL','Interventional Study','false'
'interventional or surgical procedures','C0543467','Surgical Procedures','Operative Surgical Procedures','true'
'primary pcit','C0205225','Primary','Primary','false'
'primary pcit','C0439612','Primary','True primary (qualifier value)','false'
'primary pcit','C0439631','Primary','Primary operation','false'
'demographic characteristic','C0011298','demographic','Demography','true'
'demographic characteristic','C1521970','Characteristic','Characteristics','false'
'umec $nmbr$ $nmbr$ ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'umec $nmbr$ $nmbr$ ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'umec $nmbr$ $nmbr$ ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'tio $nmbr$ ig n $nmbr$','C0021027','IG','Immunoglobulins','true'
'tio $nmbr$ ig n $nmbr$','C0305052','IG','Gamma globulin serum','false'
'tio $nmbr$ ig n $nmbr$','C0360506','IG','Intramuscular immunoglobulin','false'
'umec $nmbr$ $nmbr$ mcg n $nmbr$','C0439211','mcg','microgram','false'
'umec $nmbr$ $nmbr$ mcg n $nmbr$','C3463985','MCG','miscellaneous Crenarchaeota group','false'
'tio i $nmbr$ mcg n $nmbr$','C0021966','I-','Iodides','true'
'tio i $nmbr$ mcg n $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'treatment diff vs tio $nmbr$ ci','C0039798','treatment','therapeutic aspects','true'
'treatment diff vs tio $nmbr$ ci','C0087111','Treatment','Therapeutic procedure','true'
'treatment diff vs tio $nmbr$ ci','C1522326','Treatment','Treating','false'
'treatment diff vs tio $nmbr$ ci','C1533734','Treatment','Administration procedure','false'
'treatment diff vs tio $nmbr$ ci','C1705169','Treatment','Biomaterial Treatment','false'
'treatment diff vs tio $nmbr$ ci','C3538994','TREATMENT','Treatment Epoch','false'
'treatment diff vs tio $nmbr$ ci','C3887704','treatment','treatment - ActInformationManagementReason','false'
'treatment diff vs tio $nmbr$ ci','C0008107','CI','Chile','true'
'treatment diff vs tio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'gold grade $nmbr$','C0441800','Grade','Grade','false'
'gold grade $nmbr$','C0919553','Grade','Histopathologic Grade','false'
'gold grade $nmbr$','C3244287','grade','School Grade','false'
'ls mean change from baseline ml se a','C0392747','Change','Changing','false'
'ls mean change from baseline ml se a','C0443172','change','Changed status','false'
'ls mean change from baseline ml se a','C1705241','Change','Delta (difference)','false'
'ls mean change from baseline ml se a','C4319952','Change','Change -- procedure','false'
'$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'$nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'current smoker at screening n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker at screening n','C3241966','Current Smoker','Current Smoker','false'
'smoking pack yearsa','C0037369','SMOKING','Smoking','true'
'smoking pack yearsa','C0453996','Smoking','Tobacco smoking behavior','true'
'smoking pack yearsa','C1881674','Smoking','Medical Device Emits Smoke','false'
'post salbutamol fev $nmbr$ l b mean sd','C0001927','Salbutamol','Albuterol','true'
'post salbutamol fev $nmbr$ l b mean sd','C2699239','SD','SD, Rat Strain','false'
'gold group b','C0018026','GOLD','Gold','true'
'gold group b','C4522078','Group B','Group B','false'
'gold group b','C1304897','Gold','Gold color','false'
'post salbutamol fev $nmbr$ fvcb mean sd','C0001927','Salbutamol','Albuterol','true'
'post salbutamol fev $nmbr$ fvcb mean sd','C2699239','SD','SD, Rat Strain','false'
'reversibility to salbutamolc d mean sd','C0449261','Reversibility','Reversibility','false'
'reversibility to salbutamolc d mean sd','C0444504','Mean','Statistical mean','false'
'reversibility to salbutamolc d mean sd','C2699239','SD','SD, Rat Strain','false'
'reversibility to salbutamolc d mean sd','C2347634','Mean','Population Mean','false'
'reversibility to salbutamolc d mean sd','C2348143','Mean','Sample Mean','false'
'gold group d','C0441833','Group','Groups','false'
'gold group d','C0687744','group','Social group','false'
'gold group d','C1257890','Group','Population Group','true'
'gold group d','C1519504','Group','Stage Grouping','false'
'gold group d','C1705428','Group','Group Object','false'
'gold group d','C1705429','Group','User Group','false'
'reversible','C0205343','Reversible','Reversible','false'
'ics users at screening','C1706077','Users','user - individual','false'
'ics users at screening','C0220908','Screening','Screening procedure','true'
'ics users at screening','C0220909','screening','Aspects of disease screening','true'
'ics users at screening','C1698960','screening','research subject screening','false'
'ics users at screening','C1710031','Screening','Disease Screening','false'
'ics users at screening','C1710032','Screening','Screening','false'
'ics users at screening','C1710477','SCREENING','Trial Screening','false'
'ics users at screening','C2348164','SCREENING','Screening Study','false'
'gold grades $nmbr$ $nmbr$ percent predicted fev n','C0018026','GOLD','Gold','true'
'gold grades $nmbr$ $nmbr$ percent predicted fev n','C0439165','PERCENT','Percent (qualifier value)','false'
'gold grades $nmbr$ $nmbr$ percent predicted fev n','C1304897','Gold','Gold color','false'
'grade $nmbr$ moderate copd n','C0205081','Moderate','Moderate (severity modifier)','false'
'grade $nmbr$ moderate copd n','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'grade $nmbr$ moderate copd n','C1412502','COPD','ARCN1 gene','false'
'grade $nmbr$ moderate copd n','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'grade $nmbr$ moderate copd n','C1881878','Moderate','Moderation','false'
'grade $nmbr$ moderate copd n','C4049705','Moderate','Moderate Extremity Pain','false'
'grade $nmbr$ moderate copd n','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'grade $nmbr$ moderate copd n','C4085643','Moderate','Moderate Response','false'
'grade $nmbr$ moderate copd n','C4321335','Moderate','Moderate Level','false'
'ics non users at screening','C1518422','Non','Negation','false'
'ics non users at screening','C1706077','Users','user - individual','false'
'grade $nmbr$ severe copd n','C0205082','Severe','Severe (severity modifier)','false'
'grade $nmbr$ severe copd n','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'grade $nmbr$ severe copd n','C1412502','COPD','ARCN1 gene','false'
'grade $nmbr$ severe copd n','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'grade $nmbr$ severe copd n','C4050465','Severe','Severe Extremity Pain','false'
'grade $nmbr$ severe copd n','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'gold groups a d using mmrcb','C0441838','Group D','Group D','false'
'gold groups a d using mmrcb','C1524063','Using','Use of','false'
'gold grade $nmbr$ and ics users at screening','C0441800','Grade','Grade','false'
'gold grade $nmbr$ and ics users at screening','C0919553','Grade','Histopathologic Grade','false'
'gold grade $nmbr$ and ics users at screening','C3244287','grade','School Grade','false'
'gold grade $nmbr$ and ics users at screening','C1706077','Users','user - individual','false'
'gold grade $nmbr$ and ics users at screening','C0220908','Screening','Screening procedure','true'
'gold grade $nmbr$ and ics users at screening','C0220909','screening','Aspects of disease screening','true'
'gold grade $nmbr$ and ics users at screening','C1698960','screening','research subject screening','false'
'gold grade $nmbr$ and ics users at screening','C1710031','Screening','Disease Screening','false'
'gold grade $nmbr$ and ics users at screening','C1710032','Screening','Screening','false'
'gold grade $nmbr$ and ics users at screening','C1710477','SCREENING','Trial Screening','false'
'gold grade $nmbr$ and ics users at screening','C2348164','SCREENING','Screening Study','false'
'group b low risk more symptoms n','C3272281','Low Risk','American College of Cardiology/American Heart Association Lesion Complexity Score A','false'
'group b low risk more symptoms n','C3538919','LOW RISK','Low Risk','false'
'group b low risk more symptoms n','C0683368','symptoms','Symptoms aspect','true'
'group b low risk more symptoms n','C1457887','SYMPTOMS','Symptoms','false'
'group d high risk more symptoms n','C0441833','Group','Groups','false'
'group d high risk more symptoms n','C0687744','group','Social group','false'
'group d high risk more symptoms n','C1257890','Group','Population Group','true'
'group d high risk more symptoms n','C1519504','Group','Stage Grouping','false'
'group d high risk more symptoms n','C1705428','Group','Group Object','false'
'group d high risk more symptoms n','C1705429','Group','User Group','false'
'group d high risk more symptoms n','C0332167','HIGH RISK','High risk of','false'
'group d high risk more symptoms n','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'group d high risk more symptoms n','C4050568','High Risk','High Risk Acute Leukemia','false'
'group d high risk more symptoms n','C4319571','High risk','High risk','false'
'group d high risk more symptoms n','C0683368','symptoms','Symptoms aspect','true'
'group d high risk more symptoms n','C1457887','SYMPTOMS','Symptoms','false'
'gold grade $nmbr$ and ics non users at screening','C0441800','Grade','Grade','false'
'gold grade $nmbr$ and ics non users at screening','C0919553','Grade','Histopathologic Grade','false'
'gold grade $nmbr$ and ics non users at screening','C3244287','grade','School Grade','false'
'gold grade $nmbr$ and ics non users at screening','C1518422','Non','Negation','false'
'gold grade $nmbr$ and ics non users at screening','C1706077','Users','user - individual','false'
'ics use at screening','C0042153','use','utilization qualifier','true'
'ics use at screening','C0457083','Use','Usage','false'
'ics use at screening','C1947944','Use','Use - dosing instruction imperative','false'
'ics users n','C0815320','ICS','Impaired Control Scale','false'
'ics users n','C1706077','Users','user - individual','false'
'ics users n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'ics nonusers n','C0815320','ICS','Impaired Control Scale','false'
'ics nonusers n','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'proportion of patients with trough fevi $nmbr$ ml above baseline n','C1709707','Proportion','Proportion','false'
'proportion of patients with trough fevi $nmbr$ ml above baseline n','C0030705','Patients','Patients','true'
'proportion of patients with trough fevi $nmbr$ ml above baseline n','C0439526','/mL','/mL','false'
'proportion of patients with trough fevi $nmbr$ ml above baseline n','C1705224','ML','THPO wt Allele','false'
'proportion of patients with trough fevi $nmbr$ ml above baseline n','C3887665','ML','Thrombopoietin, human','false'
'or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C0369773','P NOS','P Blood group antibodies','false'
'or $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$ p $nmbr$ $nmbr$','C2603361','P'','P prime','false'
'odds ratio $nmbr$ cl','C0028873','Odds Ratio','Odds Ratio','true'
'odds ratio $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'heterogeneity test','C0022885','Test','Laboratory Procedures','false'
'heterogeneity test','C0039593','Test','Testing','false'
'heterogeneity test','C0392366','test','Tests (qualifier value)','false'
'heterogeneity test','C0456984','Test','Test Result','false'
'heterogeneity test','C1515976','test','Anatomic Structure, System, or Substance','false'
'heterogeneity test','C3831328','Test','Blood Products Laboratory Testing','false'
'heterogeneity test','C4318744','Test','Test - temporal region','false'
'previous statin use','C0042153','use','utilization qualifier','true'
'previous statin use','C0457083','Use','Usage','false'
'previous statin use','C1947944','Use','Use - dosing instruction imperative','false'
'troponin $nmbr$ at baseline','C0041199','Troponin','Troponin','true'
'troponin $nmbr$ at baseline','C0168634','baseline','BaseLine dental cement','true'
'troponin $nmbr$ at baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ $nmbr$ ng ml','C0439275','ng/mL','Microgram per Liter','false'
'duration of assigned regimen before surgery','C0449238','Duration','Duration (temporal concept)','false'
'duration of assigned regimen before surgery','C2926735','Duration','Duration','false'
'duration of assigned regimen before surgery','C0038894','Surgery','Surgery specialty','false'
'duration of assigned regimen before surgery','C0038895','surgery','Surgical aspects','true'
'duration of assigned regimen before surgery','C0543467','Surgery','Operative Surgical Procedures','true'
'duration of assigned regimen before surgery','C1274039','Surgery','General surgery specialty','true'
'surgical technique','C0683469','surgical Technique','surgical methods','false'
'on pump','C3842462','On pump','On pump','false'
'off pump','C1518543','Off','Off','false'
'off pump','C0182537','Pump','pump (device)','false'
'procedure','C0184661','Procedure','Interventional procedure','true'
'procedure','C2700391','Procedure','Procedure (set of actions)','false'
'procedure','C3274430','PROCEDURE','Physical Medical Procedure','false'
'procedure','C3539779','Procedure','CDISC SDTM Procedure Terminology','false'
'aortic valve replacement','C0003506','AORTIC VALVE REPLACEMENT','Replacement of aortic valve (procedure)','false'
'postoperative glucocorticoid use','C0042153','use','utilization qualifier','true'
'postoperative glucocorticoid use','C0457083','Use','Usage','false'
'postoperative glucocorticoid use','C1947944','Use','Use - dosing instruction imperative','false'
'postoperative nsaid or glucocorticoid use','C0003211','NSAID','Anti-Inflammatory Agents, Non-Steroidal','true'
'postoperative nsaid or glucocorticoid use','C3536840','NSAID','Nonsteroidal Anti-inflammatory Drug [EPC]','false'
'postoperative nsaid or glucocorticoid use','C0042153','use','utilization qualifier','true'
'postoperative nsaid or glucocorticoid use','C0457083','Use','Usage','false'
'postoperative nsaid or glucocorticoid use','C1947944','Use','Use - dosing instruction imperative','false'
'dulaglutide $nmbr$ $nmbr$ mgf','C1366394','MGF','STAT5A protein, human','true'
'dulaglutide $nmbr$ $nmbr$ mgf','C3712803','MGF','IGF1 protein, human','true'
'dulaglutide $nmbr$ $nmbr$ mgf','C3887684','MGF','Kit Ligand, human','false'
'age $nmbr$ vears n $nmbr$','C0001779','AGE','Age','false'
'previous oral antidiabetic medication use n','C1527415','Oral use','Oral Route of Drug administration','false'
'no oral antidiabetic medication','C0175795','ORAL MEDICATION','oral medication','false'
'$nmbr$ oral antidiabetic medication','C0175795','ORAL MEDICATION','oral medication','false'
'insulin oral antidiabetic medication s','C0175795','ORAL MEDICATION','oral medication','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C0392747','Change','Changing','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C0443172','change','Changed status','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C1705241','Change','Delta (difference)','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C4319952','Change','Change -- procedure','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C0439230','WEEKS','week','false'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C0027361','Individual','Persons','true'
'figure $nmbr$ glycated haemoglobin hba $nmbr$ c change from baseline to $nmbr$ weeks by individual study','C0237401','Individual','Individual','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C1511726','Data','Data','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C3245479','data','Data call receiving device','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C3714741','Data','Data (eukaryote)','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C0449450','Presented','Presentation','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C0023668','LS','Liechtenstein','true'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C2708217','Assessment administration','Assessment administration:-:Point in time:^Patient:-','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C2708218','Assessment administration','Assessment administration','false'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C0017853','Glycated hemoglobin','Hemoglobin, Glycosylated','true'
'data presented as ls means and $nmbr$ cis award assessment of weekly administration of ly $nmbr$ dulaglutide in diabetes bl baseline hbalc glycated haemoglobin met metformin su sulphonylurea tzd thiazolidinedione yrs years','C0439234','YEARS','year','false'
'pbo mtx n $nmbr$','C0031962','PBO','Piperonyl Butoxide','true'
'pbo mtx n $nmbr$','C0025677','MTX','Methotrexate','true'
'pbo mtx n $nmbr$','C1417487','MTX','MTX1 gene','false'
'czp mtx n $nmbr$','C0054841','CZP','carzinophilin','true'
'czp mtx n $nmbr$','C0025677','MTX','Methotrexate','true'
'czp mtx n $nmbr$','C1417487','MTX','MTX1 gene','false'
'czp mtx n $nmbr$','C1861828','CZP','Cataract, Zonular Pulverulent 1','true'
'czp mtx n $nmbr$','C1872109','CZP','certolizumab pegol','true'
'europe and australia','C0015176','Europe','Europe','true'
'europe and australia','C0004340','AUSTRALIA','Australia','true'
'latin and north america','C0028405','North America','North America','true'
'systemic corticosteroids n a','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'das $nmbr$ esr mean sd','C0051767','DAS','amsonic acid','true'
'das $nmbr$ esr mean sd','C2699239','SD','SD, Rat Strain','false'
'das $nmbr$ esr mean sd','C0057671','DAS','diacetoxyscirpenol','true'
'moderate disease activity $nmbr$ $nmbr$ to','C1513375','Moderate Activity','Moderate Exercise','false'
'moderate disease activity $nmbr$ $nmbr$ to','C3833417','Moderate activity','Moderate activity','false'
'high disease activity $nmbr$ $nmbr$ n','C4699623','High activity','High activity','false'
'sdai mean sd','C0444504','Mean','Statistical mean','false'
'sdai mean sd','C2699239','SD','SD, Rat Strain','false'
'sdai mean sd','C2347634','Mean','Population Mean','false'
'sdai mean sd','C2348143','Mean','Sample Mean','false'
'cdai mean sd','C0444504','Mean','Statistical mean','false'
'cdai mean sd','C2699239','SD','SD, Rat Strain','false'
'cdai mean sd','C2347634','Mean','Population Mean','false'
'cdai mean sd','C2348143','Mean','Sample Mean','false'
'haq di mean sd','C3826998','HAQ-DI','Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire','false'
'haq di mean sd','C2699239','SD','SD, Rat Strain','false'
'haq di mean sd','C4321476','HAQ-DI','Health Assessment Questionnaire Disability Index','false'
'tjc $nmbr$ joints mean sd','C0022417','Joints','Joints','true'
'tjc $nmbr$ joints mean sd','C2699239','SD','SD, Rat Strain','false'
'tjc $nmbr$ joints mean sd','C0392905','Joints','Articular system','false'
'sjc $nmbr$ joints mean sd','C0022417','Joints','Joints','true'
'sjc $nmbr$ joints mean sd','C2699239','SD','SD, Rat Strain','false'
'sjc $nmbr$ joints mean sd','C0392905','Joints','Articular system','false'
'esr mm h median min max','C3642211','mm/min','Millimeter Per Minute','false'
'crp mg l median min max','C0439420','mg/min','mg/min','false'
'months since ra was first diagnosed mean sd','C0439231','MONTHS','month','false'
'months since ra was first diagnosed mean sd','C3538806','Ra','Axial R','false'
'months since ra was first diagnosed mean sd','C4048756','RA','Right arm','false'
'months since ra was first diagnosed mean sd','C0011900','Diagnosed','Diagnosis','true'
'months since ra was first diagnosed mean sd','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ months mean sd','C0439231','MONTHS','month','false'
'$nmbr$ months mean sd','C2699239','SD','SD, Rat Strain','false'
'months since first ra symptom mean sd f','C0439231','MONTHS','month','false'
'months since first ra symptom mean sd f','C0016327','F-','Fluorides','true'
'rf positive $nmbr$ iu ml n','C0035448','RF','Rheumatoid Factor','true'
'rf positive $nmbr$ iu ml n','C0439458','IU/mL','IU/mL','false'
'rf positive $nmbr$ iu ml n','C0201660','RF','Rheumatoid Factor Measurement','false'
'rf positive $nmbr$ iu ml n','C0748398','RF','RF','false'
'rf positive $nmbr$ iu ml n','C1547111','RF','Radio fluoroscopy','false'
'acpa positive $nmbr$ iu ml n','C0439178','% Positive','percent positive cells','false'
'acpa positive $nmbr$ iu ml n','C0439458','IU/mL','IU/mL','false'
'acpa positive $nmbr$ iu ml n','C1446409','Positive','Positive','false'
'acpa positive $nmbr$ iu ml n','C1514241','POSITIVE','Positive Finding','false'
'acpa positive $nmbr$ iu ml n','C2825490','Positive','Positive Charge','false'
'acpa positive $nmbr$ iu ml n','C3812269','Positive','Positive Number','false'
'mtss median min max','C0549183','Median','Midline (qualifier value)','false'
'mtss median min max','C0702093','/min','Per Minute','false'
'mtss median min max','C1524029','MIN NOS','Mouse MIN NOS','false'
'mtss median min max','C3813700','%/min','Percent per Minute','false'
'mtss median min max','C0876920','Median','Median Statistical Measurement','false'
'mtss median min max','C2347635','Median','Population Median','false'
'mtss median min max','C2348144','Median','Sample Median','false'
'mtss median min max','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ months median min max','C0439231','MONTHS','month','false'
'$nmbr$ months median min max','C0549183','Median','Midline (qualifier value)','false'
'$nmbr$ months median min max','C0876920','Median','Median Statistical Measurement','false'
'$nmbr$ months median min max','C2347635','Median','Population Median','false'
'$nmbr$ months median min max','C2348144','Median','Sample Median','false'
'$nmbr$ months median min max','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ l','C0439394','l's','liter/second','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ l','C1706495','L-','upper case letter ell','false'
'$nmbr$ $nmbr$ $nmbr$ $nmbr$ l','C3642217','/L','Per Liter','false'
'erosion score median min max','C0333307','Erosion','Superficial ulcer','false'
'erosion score median min max','C0449820','SCORE','Score','false'
'erosion score median min max','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'erosion score median min max','C1880549','Erosion','Erosion of Medical Device Material','false'
'erosion score median min max','C1959609','EROSION','Erosion lesion','false'
'erosion score median min max','C3887524','Erosion','Skin Erosion','false'
'jsn median min max','C0549183','Median','Midline (qualifier value)','false'
'jsn median min max','C0702093','/min','Per Minute','false'
'jsn median min max','C1524029','MIN NOS','Mouse MIN NOS','false'
'jsn median min max','C3813700','%/min','Percent per Minute','false'
'jsn median min max','C0876920','Median','Median Statistical Measurement','false'
'jsn median min max','C2347635','Median','Population Median','false'
'jsn median min max','C2348144','Median','Sample Median','false'
'jsn median min max','C2939193','Median','Median (qualifier value)','false'
'presence of erosions n','C0150312','Presence','Present','false'
'presence of erosions n','C0392148','Presence','Providing presence (regime/therapy)','false'
'presence of erosions n','C3854307','Presence','Presence (property)','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C2986480','Subgroup Analysis','Subset Analysis','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0205363','Stratified','Stratified','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0040223','TIME','Time','true'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C3541383','Time','Time (foundation metadata concept)','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0011900','DIAGNOSIS','Diagnosis','true'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C1704338','diagnosis','diagnosis aspect','true'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C1704656','DIAGNOSIS','Diagnosis Study','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0025677','MTX','Methotrexate','true'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C1417487','MTX','MTX1 gene','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0441837','Group C','Group C','false'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0028873','Odds Ratios','Odds Ratio','true'
'supplementary figure $nmbr$ subgroup analysis stratified by time since ra diagnosis for week $nmbr$ outcomes in the a pbo mtx and b czp mtx groups c odds ratios for week $nmbr$ outcomes stratified by time since ra diagnosis forest plot','C0086312','Forest','Forests','true'
'included in analysis','C0332257','included','Including (qualifier)','false'
'included in analysis','C0002778','Analysis','Analysis of substances','false'
'included in analysis','C0936012','ANALYSIS','Analysis','false'
'included in analysis','C1524024','analysis','analysis aspect','true'
'total sample $nmbr$','C0370003','Sample','Specimen','false'
'total sample $nmbr$','C2347026','Sample','Biospecimen','false'
'age at baseline in years mean sd','C0001779','AGE','Age','false'
'age at baseline in years mean sd','C0168634','baseline','BaseLine dental cement','true'
'age at baseline in years mean sd','C1442488','Baseline','Baseline','false'
'age at baseline in years mean sd','C0439234','YEARS','year','false'
'age at baseline in years mean sd','C2699239','SD','SD, Rat Strain','false'
'$nmbr$ $nmbr$ lo i','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ lo i','C0221138','I NOS','Blood group antibody I','false'
'time from parkinson s disease diagnosis in months mean sd','C0040223','TIME','Time','true'
'time from parkinson s disease diagnosis in months mean sd','C3541383','Time','Time (foundation metadata concept)','false'
'time from parkinson s disease diagnosis in months mean sd','C0439231','MONTHS','month','false'
'time from parkinson s disease diagnosis in months mean sd','C2699239','SD','SD, Rat Strain','false'
'total updrs score baseline mean sd','C2964552','Total Score','Total score','false'
'total updrs score baseline mean sd','C2699239','SD','SD, Rat Strain','false'
'activities of daily living updrs subscore baseline mean sd','C0001288','Activities of Daily Living','Activities of Daily Living (activity)','true'
'activities of daily living updrs subscore baseline mean sd','C4050548','Activities of Daily Living','Activities of Daily Living Scale (BASC-2)','false'
'motor updrs subscore baseline mean sd','C0168634','baseline','BaseLine dental cement','true'
'motor updrs subscore baseline mean sd','C2699239','SD','SD, Rat Strain','false'
'motor updrs subscore baseline mean sd','C1442488','Baseline','Baseline','false'
'mental activities updrs subscore baseline mean sd','C0168634','baseline','BaseLine dental cement','true'
'mental activities updrs subscore baseline mean sd','C2699239','SD','SD, Rat Strain','false'
'mental activities updrs subscore baseline mean sd','C1442488','Baseline','Baseline','false'
'hoehn and yahr stage baseline mean sd','C0168634','baseline','BaseLine dental cement','true'
'hoehn and yahr stage baseline mean sd','C2699239','SD','SD, Rat Strain','false'
'hoehn and yahr stage baseline mean sd','C1442488','Baseline','Baseline','false'
'initial treatment randomization','C0039798','treatment','therapeutic aspects','true'
'initial treatment randomization','C0034656','Randomization','Randomization','true'
'initial treatment randomization','C0087111','Treatment','Therapeutic procedure','true'
'initial treatment randomization','C1522326','Treatment','Treating','false'
'initial treatment randomization','C1533734','Treatment','Administration procedure','false'
'initial treatment randomization','C1705169','Treatment','Biomaterial Treatment','false'
'initial treatment randomization','C3538994','TREATMENT','Treatment Epoch','false'
'initial treatment randomization','C3887704','treatment','treatment - ActInformationManagementReason','false'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg $nmbr$ $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'placebo $nmbr$ $nmbr$ $nmbr$','C0032042','Placebo','Placebos','true'
'placebo $nmbr$ $nmbr$ $nmbr$','C1696465','PLACEBO','placebo','false'
'placebo $nmbr$ $nmbr$ $nmbr$','C1706408','PLACEBO','Placebo Control','false'
'weeks','C0439230','WEEKS','week','false'
'weeks_measured','C0444706','Measured','Measured','false'
'weeks_measured','C3541902','MEASURED','Measured Tumor Identification','false'
'mean change in total updrs scores adjusted according to baseline updrs','C0392747','Change','Changing','false'
'mean change in total updrs scores adjusted according to baseline updrs','C0443172','change','Changed status','false'
'mean change in total updrs scores adjusted according to baseline updrs','C1705241','Change','Delta (difference)','false'
'mean change in total updrs scores adjusted according to baseline updrs','C4319952','Change','Change -- procedure','false'
'mean change in total updrs scores adjusted according to baseline updrs','C0456081','Adjusted','Adjustment Action','false'
'mean change in total updrs scores adjusted according to baseline updrs','C0168634','baseline','BaseLine dental cement','true'
'mean change in total updrs scores adjusted according to baseline updrs','C1442488','Baseline','Baseline','false'
'event rate vr','C0441471','Event','Event','false'
'event rate vr','C3476815','VR','VR - Veterans Rand Health Survey','false'
'event rate vr','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'edoxaban vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'edoxaban vs warfarin','C0043031','WARFARIN','Warfarin','true'
'p int','C0369773','P NOS','P Blood group antibodies','false'
'p int','C3272375','INT','Integer Data Type','false'
'p int','C2603361','P'','P prime','false'
'stroke see','C0042789','see','Vision','true'
'stroke see','C1947903','See','See','false'
'type of af','C0332307','TYPE','Type - attribute','false'
'type of af','C1547052','*Type','*Type - Kind of quantity','false'
'fatal stroke','C0038454','STROKE','Cerebrovascular accident','true'
'fatal stroke','C4554100','Stroke','Stroke, CTCAE','false'
'crcl ml min at randomization','C0439445','mL/min','mL/min','false'
'crcl ml min at randomization','C0034656','Randomization','Randomization','true'
'cha $nmbr$ ds $nmbr$ vasc score','C0449820','SCORE','Score','false'
'cha $nmbr$ ds $nmbr$ vasc score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'has bled score $nmbr$','C0449820','SCORE','Score','false'
'has bled score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'major gl bleeding','C0018229','GL','Greenland','true'
'major gl bleeding','C0019080','BLEEDING','Hemorrhage','true'
'major gl bleeding','C1423073','GL','PPP1R3B gene','false'
'major gl bleeding','C1427674','GL','OSTM1 gene','false'
'time in therapeutic range','C1554109','Time Range','Time Range','false'
'dose reduction at randomization','C0301630','Reduction','Reduction (chemical)','false'
'dose reduction at randomization','C0392756','Reduction','Reduced','false'
'dose reduction at randomization','C1293152','Reduction','Reduction procedure','false'
'dose reduction at randomization','C4551656','Reduction','Surgical reduction','false'
'prior vka experience','C0237607','experience','Practice Experience','false'
'prior vka experience','C0596545','Experience','Experience','false'
'medication at time of randomization','C0013227','Medication','Pharmaceutical Preparations','true'
'medication at time of randomization','C3244316','medication','medication - HL7 publishing domain','false'
'medication at time of randomization','C4284232','Medication','Medications','false'
'gly $nmbr$ $nmbr$ mg b i d n $nmbr$','C0439422','mg/d','milligram/day','false'
'ind $nmbr$ mg q d n $nmbr$','C4049864','IND','Improvised Nuclear Device','false'
'ind $nmbr$ mg q d n $nmbr$','C0439422','mg/d','milligram/day','false'
'smoking history n','C1519384','Smoking History','Smoking History','false'
'number of pack years','C0237753','*Number','Numbers','false'
'number of pack years','C0449788','Number','Count of entities','false'
'severity of copd airflow limitation n','C0439793','Severity','Severities','false'
'severity of copd airflow limitation n','C0522510','Severity','With intensity','false'
'moderate gold $nmbr$','C0018026','GOLD','Gold','true'
'moderate gold $nmbr$','C1304897','Gold','Gold color','false'
'severe gold $nmbr$','C0018026','GOLD','Gold','true'
'severe gold $nmbr$','C1304897','Gold','Gold color','false'
'very severe gold $nmbr$','C0018026','GOLD','Gold','true'
'very severe gold $nmbr$','C1304897','Gold','Gold color','false'
'severity of copd combined assessment n','C0439793','Severity','Severities','false'
'severity of copd combined assessment n','C0522510','Severity','With intensity','false'
'group b','C4522078','Group B','Group B','false'
'group c','C0441837','Group C','Group C','false'
'group d','C0441833','Group','Groups','false'
'group d','C0687744','group','Social group','false'
'group d','C1257890','Group','Population Group','true'
'group d','C1519504','Group','Stage Grouping','false'
'group d','C1705428','Group','Group Object','false'
'group d','C1705429','Group','User Group','false'
'copd exacerbation history n','C0740304','copd exacerbation','copd exacerbation','false'
'copd exacerbation history n','C0019664','History','History','true'
'copd exacerbation history n','C0019665','history','Historical aspects qualifier','true'
'copd exacerbation history n','C0262512','History, NOS','History of present illness','false'
'copd exacerbation history n','C0262926','History','Medical History','false'
'copd exacerbation history n','C1705255','History','Concept History','false'
'copd exacerbation history n','C2004062','History','History of previous events','false'
'ics use at baseline n','C0042153','use','utilization qualifier','true'
'ics use at baseline n','C0457083','Use','Usage','false'
'ics use at baseline n','C1947944','Use','Use - dosing instruction imperative','false'
'mmrc dyspnea scale n','C0013404','DYSPNOEA','Dyspnea','true'
'mmrc dyspnea scale n','C0175659','Scale','Weight measurement scales','true'
'mmrc dyspnea scale n','C0349674','Scale','Intellectual scale','false'
'mmrc dyspnea scale n','C1947916','Scale','Scaling','false'
'mmrc dyspnea scale n','C1963100','Dyspnea','Dyspnea, CTCAE','false'
'copd assessment test cat score','C0237855','test score','Test scores','false'
'copd assessment test cat score','C0237856','test score','Scoring of tests','false'
'pre bronchodilator fev $nmbr$ l','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'pre bronchodilator fev $nmbr$ l','C3714541','FEV','Forced Vital Capacity','true'
'post bronchodilator fev $nmbr$ l','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ l','C3714541','FEV','Forced Vital Capacity','true'
'post bronchodilator fev $nmbr$ reversibility a','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ reversibility a','C0449261','Reversibility','Reversibility','false'
'ccv history condition','C0683519','history condition','disease history','false'
'gly $nmbr$ $nmbr$ gg b i d n n','C1415124','GLY B+','GLYB gene','false'
'gly $nmbr$ $nmbr$ gg b i d n n','C0152277','i d','Incision and drainage','false'
'ind $nmbr$ gg q d n n','C0017454','GG','Georgia, Western Asia','true'
'ind $nmbr$ gg q d n n','C0018370','GG','Guernsey (geographic location)','true'
'severity of airflow obstruction','C0439793','Severity','Severities','false'
'severity of airflow obstruction','C0522510','Severity','With intensity','false'
'mild or moderate copd','C2945599','Mild','Mild (qualifier value)','false'
'mild or moderate copd','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'mild or moderate copd','C1412502','COPD','ARCN1 gene','false'
'mild or moderate copd','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'severe or very severe copd','C0205082','Severe','Severe (severity modifier)','false'
'severe or very severe copd','C4050465','Severe','Severe Extremity Pain','false'
'severe or very severe copd','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'severe or very severe copd','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'severe or very severe copd','C1412502','COPD','ARCN1 gene','false'
'severe or very severe copd','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'ics use at baseline','C0042153','use','utilization qualifier','true'
'ics use at baseline','C0457083','Use','Usage','false'
'ics use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'ccv history condition at baseline','C0683519','history condition','disease history','false'
'ccv history condition at baseline','C0168634','baseline','BaseLine dental cement','true'
'ccv history condition at baseline','C1442488','Baseline','Baseline','false'
'history of atrial fibrillation flutter','C0729790','History of - atrial fibrillation','H/O: atrial fibrillation','false'
'history of cardiac arrhythmia','C3494593','History of cardiac arrhythmia','History of cardiac arrhythmia','false'
'long acting bronchodilator use at screening','C0042153','use','utilization qualifier','true'
'long acting bronchodilator use at screening','C0457083','Use','Usage','false'
'long acting bronchodilator use at screening','C1947944','Use','Use - dosing instruction imperative','false'
'augment copd','C0205217','augment','Increased','false'
'augment copd','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'augment copd','C1412502','COPD','ARCN1 gene','false'
'augment copd','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'pooled analysis sample','C1709595','Pooled Sample','Pooled Sample','false'
'aclidinium $nmbr$ g n $nmbr$ a','C2699757','ACLIDINIUM','aclidinium','false'
'aclidinium $nmbr$ g n $nmbr$ a','C0439267','g%','Gram per Deciliter','false'
'placebo n $nmbr$ a','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ a','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ a','C1706408','PLACEBO','Placebo Control','false'
'aclidinium $nmbr$ g n $nmbr$ b','C2699757','ACLIDINIUM','aclidinium','false'
'aclidinium $nmbr$ g n $nmbr$ b','C0439267','g%','Gram per Deciliter','false'
'placebo n $nmbr$ b','C0032042','Placebo','Placebos','true'
'placebo n $nmbr$ b','C1696465','PLACEBO','placebo','false'
'placebo n $nmbr$ b','C1706408','PLACEBO','Placebo Control','false'
'all patients n $nmbr$ b','C0030705','Patients','Patients','true'
'caucasian n','C0007457','Caucasian','Caucasoid Race','true'
'caucasian n','C0043157','Caucasian','Caucasians','true'
'smoking history pack years mean sd','C1277691','Pack years','Pack years','false'
'smoking history pack years mean sd','C2699239','SD','SD, Rat Strain','false'
'post bronchodilator fev $nmbr$ l mean sd c','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ l mean sd c','C0444504','Mean','Statistical mean','false'
'post bronchodilator fev $nmbr$ l mean sd c','C2347634','Mean','Population Mean','false'
'post bronchodilator fev $nmbr$ l mean sd c','C2348143','Mean','Sample Mean','false'
'post bronchodilator fev $nmbr$ predicted mean sd c','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ predicted mean sd c','C0444504','Mean','Statistical mean','false'
'post bronchodilator fev $nmbr$ predicted mean sd c','C2347634','Mean','Population Mean','false'
'post bronchodilator fev $nmbr$ predicted mean sd c','C2348143','Mean','Sample Mean','false'
'bronchial reversibility sd','C0205039','Bronchial','Bronchial','false'
'bronchial reversibility sd','C2699239','SD','SD, Rat Strain','false'
'bronchial reversibility sd','C1442216','Bronchial','Bronchial system','false'
'number of exacerbations in previous year mean sd','C0237753','*Number','Numbers','false'
'number of exacerbations in previous year mean sd','C0449788','Number','Count of entities','false'
'number of exacerbations in previous year mean sd','C0205156','Previous','Previous','false'
'number of exacerbations in previous year mean sd','C2699239','SD','SD, Rat Strain','false'
'number of exacerbations in previous year mean sd','C1552607','previous','Act Relationship Subset - previous','false'
'rs breathlessnessb','C0035970','RS','Russia','true'
'rs breathlessnessb','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'rs breathlessnessb','C3813325','RS','Disease Response Domain','false'
'rs cough sputumc','C0035970','RS','Russia','true'
'rs cough sputumc','C0010200','COUGH','Coughing','true'
'rs cough sputumc','C1961131','Cough','Cough, CTCAE','false'
'rs cough sputumc','C3274924','Cough','Have Been Coughing','false'
'rs cough sputumc','C4084725','Cough','Usual Severity Cough','false'
'rs cough sputumc','C4084726','Cough','How Much Distress Cough','false'
'rs cough sputumc','C4084727','Cough','Cough Frequency','false'
'rs cough sputumc','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'rs cough sputumc','C3813325','RS','Disease Response Domain','false'
'rs chest symptomsd','C0035970','RS','Russia','true'
'rs chest symptomsd','C0817096','CHEST','Chest','true'
'rs chest symptomsd','C1527391','Chest','Anterior thoracic region','false'
'rs chest symptomsd','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'rs chest symptomsd','C3813325','RS','Disease Response Domain','false'
'rs totala','C0035970','RS','Russia','true'
'rs totala','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'rs totala','C3813325','RS','Disease Response Domain','false'
'aclidinium $nmbr$ g bid n $nmbr$','C2699757','ACLIDINIUM','aclidinium','false'
'aclidinium $nmbr$ g bid n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'gold group a','C0441835','Group A','Group A (qualifier value)','false'
'gold group a','C4522145','Group A','Group A (blood group)','false'
'gold group c','C0018026','GOLD','Gold','true'
'gold group c','C0441837','Group C','Group C','false'
'gold group c','C1304897','Gold','Gold color','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0392747','Change','Changing','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0443172','change','Changed status','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C1705241','Change','Delta (difference)','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C4319952','Change','Change -- procedure','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0035970','RS','Russia','true'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0449820','Scores','Score','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C3813325','RS','Disease Response Domain','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C1709707','Proportion','Proportion','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0282416','Overall','Overall Publication Type','true'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C1561607','Overall','Overall','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0441835','Group A','Group A (qualifier value)','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C4522145','Group A','Group A (blood group)','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C2964552','Total Score','Total score','false'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0013404','BREATHLESSNESS','Dyspnea','true'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0119082','Domain E','gephyrin','true'
'fig $nmbr$ change from baseline in e rs scores and proportion of e rs responders at week $nmbr$ overall and by gold group a and b rs total score c and d rs breathlessness domain e and f','C0016327','F-','Fluorides','true'
'rs cough sputum domain g and h rs chest symptoms domain p','C0370205','cough sputum','Specimen Type - Sputum - coughed','false'
'rs cough sputum domain g and h rs chest symptoms domain p','C0119082','Domain G','gephyrin','true'
'rs cough sputum domain g and h rs chest symptoms domain p','C0150618','H&P','History and physical examination','false'
'rs cough sputum domain g and h rs chest symptoms domain p','C0035970','RS','Russia','true'
'rs cough sputum domain g and h rs chest symptoms domain p','C3714753','RS','RETINOSCHISIS 1, X-LINKED, JUVENILE','false'
'rs cough sputum domain g and h rs chest symptoms domain p','C3813325','RS','Disease Response Domain','false'
'lixisenatide','C2973895','LIXISENATIDE','Lixisenatide','true'
'high i $nmbr$ baseline hba $nmbr$ c','C0021966','I-','Iodides','true'
'high i $nmbr$ baseline hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'high i $nmbr$ baseline hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'high i $nmbr$ baseline hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'high i $nmbr$ baseline hba $nmbr$ c','C0221138','I NOS','Blood group antibody I','false'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C0022718','KG','Kyrgyzstan','true'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C0439209','kg','Kilogram','false'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C4054209','/kg','Per Kilogram','false'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C0168634','baseline','BaseLine dental cement','true'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C0578022','BMI','Finding of body mass index','false'
'high i $nmbr$ kg m $nmbr$ baseline bmi','C1442488','Baseline','Baseline','false'
'short','C1282927','short','Shortened','false'
'short','C1806781','SHORT','Short','false'
'short','C2350002','Short','Short Value','false'
'long i $nmbr$ years duration of diabetes','C0439591','Long duration','Long duration','false'
'long i $nmbr$ years duration of diabetes','C0011847','Diabetes','Diabetes','false'
'long i $nmbr$ years duration of diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'i $nmbr$ years of age','C0021966','I-','Iodides','true'
'i $nmbr$ years of age','C1510829','Age-Years','Age-Years','false'
'i $nmbr$ years of age','C0221138','I NOS','Blood group antibody I','false'
'getgoal l asia','C0003980','Asia','Asia','true'
'high $nmbr$ baseline hbalc','C0205250','High','High','false'
'high $nmbr$ baseline hbalc','C0168634','baseline','BaseLine dental cement','true'
'high $nmbr$ baseline hbalc','C1442488','Baseline','Baseline','false'
'high $nmbr$ baseline hbalc','C1299351','High','Abnormally high','false'
'high $nmbr$ baseline hbalc','C2700149','HIGH','Value Above Reference Range','false'
'high $nmbr$ baseline hbalc','C3887512','high','high - ActExposureLevelCode','false'
'high $nmbr$ baseline hbalc','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'high $nmbr$ baseline hbalc','C4321237','High','High Level','false'
'high $nmbr$ baseline hbalc','C4522209','High','IPSS Risk Category High','false'
'high $nmbr$ kg m^ baseline bmi','C0022718','KG','Kyrgyzstan','true'
'high $nmbr$ kg m^ baseline bmi','C0439209','kg','Kilogram','false'
'high $nmbr$ kg m^ baseline bmi','C4054209','/kg','Per Kilogram','false'
'high $nmbr$ kg m^ baseline bmi','C0168634','baseline','BaseLine dental cement','true'
'high $nmbr$ kg m^ baseline bmi','C0578022','BMI','Finding of body mass index','false'
'high $nmbr$ kg m^ baseline bmi','C1442488','Baseline','Baseline','false'
'long $nmbr$ years duration of diabetes','C0439591','Long duration','Long duration','false'
'long $nmbr$ years duration of diabetes','C0011847','Diabetes','Diabetes','false'
'long $nmbr$ years duration of diabetes','C0011849','Diabetes','Diabetes Mellitus','true'
'$nmbr$ years of age','C1510829','Age-Years','Age-Years','false'
'suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$','C1532564','nmol/mmol','Micromole per mole','false'
'suit quartile $nmbr$ b $nmbr$ $nmbr$ nmol mmol n $nmbr$','C1533073','nmol/mmol','Nanomole per millimole','false'
'suit quartile $nmbr$ $nmbr$ $nmbr$','C2828255','Quartile','Quartile','false'
'suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$','C1532564','nmol/mmol','Micromole per mole','false'
'suit quartile $nmbr$ $nmbr$ $nmbr$ nmol mmol n $nmbr$','C1533073','nmol/mmol','Nanomole per millimole','false'
't $nmbr$ d duration years','C2603360','T'','T prime','false'
't $nmbr$ d duration years','C0449238','Duration','Duration (temporal concept)','false'
't $nmbr$ d duration years','C0439234','YEARS','year','false'
't $nmbr$ d duration years','C2926735','Duration','Duration','false'
'oad use n','C0042153','use','utilization qualifier','true'
'oad use n','C0457083','Use','Usage','false'
'oad use n','C1947944','Use','Use - dosing instruction imperative','false'
'oad history years','C0019664','History','History','true'
'oad history years','C0439234','YEARS','year','false'
'oad history years','C0019665','history','Historical aspects qualifier','true'
'oad history years','C0262512','History, NOS','History of present illness','false'
'oad history years','C0262926','History','Medical History','false'
'oad history years','C1705255','History','Concept History','false'
'oad history years','C2004062','History','History of previous events','false'
'ppg post meal test mmol l','C0376674','post meal','Postprandial Period','true'
'ppg post meal test mmol l','C1532563','mmol/L','Millimole per Liter','false'
'suit index nmol mmol','C1532564','nmol/mmol','Micromole per mole','false'
'suit index nmol mmol','C1533073','nmol/mmol','Nanomole per millimole','false'
'no cv event n $nmbr$ $nmbr$','C3538987','CV','Cardiovascular System Findings Domain','false'
'no cv event n $nmbr$ $nmbr$','C0441471','Event','Event','false'
'no cv event n $nmbr$ $nmbr$','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'no cv event n $nmbr$ $nmbr$','C4048877','CV','Dinner','true'
'no cv event n $nmbr$ $nmbr$','C4318503','CV','ciliary vesicle','false'
'nonfatal mi n $nmbr$','C3810814','MI','Myocardial Infarction ECG Assessment','false'
'nonfatal stroke n $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'nonfatal stroke n $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'ua n $nmbr$','C0041580','UA','Ukraine','true'
'ua n $nmbr$','C0042014','UA','Urinalysis','true'
'baseline glycated hemoglobin','C0168634','baseline','BaseLine dental cement','true'
'baseline glycated hemoglobin','C0017853','Glycated hemoglobin','Hemoglobin, Glycosylated','true'
'baseline glycated hemoglobin','C1442488','Baseline','Baseline','false'
'cv risk factors and history','C0035648','Risk Factors','risk factors','true'
'cv risk factors and history','C1553898','risk factors','risk factors - observation list','false'
'cv risk factors and history','C0019664','History','History','true'
'cv risk factors and history','C0019665','history','Historical aspects qualifier','true'
'cv risk factors and history','C0262512','History, NOS','History of present illness','false'
'cv risk factors and history','C0262926','History','Medical History','false'
'cv risk factors and history','C1705255','History','Concept History','false'
'cv risk factors and history','C2004062','History','History of previous events','false'
'coronary artery bypass graft','C0010055','Coronary Artery Bypass Graft','Coronary Artery Bypass Surgery','true'
'coronary artery bypass graft','C1260596','coronary artery bypass graft','coronary artery graft device','false'
'placebo n','C0032042','Placebo','Placebos','true'
'placebo n','C1696465','PLACEBO','placebo','false'
'placebo n','C1706408','PLACEBO','Placebo Control','false'
'alogliptin n','C1958126','ALOGLIPTIN','alogliptin','true'
'$nmbr$ kg ma $nmbr$','C0024443','MA','Madagascar','true'
'$nmbr$ kg ma $nmbr$','C3887485','MA','MIGRAINE WITH OR WITHOUT AURA, SUSCEPTIBILITY TO, 1','false'
'$nmbr$ years and $nmbr$ years','C0439234','YEARS','year','false'
'hba $nmbr$ c $nmbr$','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c $nmbr$','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c $nmbr$','C3538758','HBA','SCN2A wt Allele','false'
'western europe australia new zealand middle eai','C0043128','Western Australia','Western Australia','true'
'western europe australia new zealand middle eai','C0027978','NEW ZEALAND','New Zealand','true'
'western europe australia new zealand middle eai','C0324547','NEW ZEALAND','New Zealand Rabbits','true'
'normal function or mild impairment','C4296962','Normal function','Normal function','false'
'normal function or mild impairment','C0221099','Impairment','Impaired','false'
'normal function or mild impairment','C0684336','Impairment','Impaired health','false'
'table $nmbr$ characteristics of the patients at baseline according','C0039224','Table','Table - furniture','false'
'table $nmbr$ characteristics of the patients at baseline according','C0815172','patient characteristics','patient characteristics','false'
'table $nmbr$ characteristics of the patients at baseline according','C1706074','Table','Data Table','true'
'table $nmbr$ characteristics of the patients at baseline according','C0168634','baseline','BaseLine dental cement','true'
'table $nmbr$ characteristics of the patients at baseline according','C1442488','Baseline','Baseline','false'
'table $nmbr$ characteristics of the patients at baseline according','C0680240','according','Agreement','false'
'to the estimated glomerular filtration r','C0205090','R-','Right','false'
'to the estimated glomerular filtration r','C0684010','R.','Rabbi','true'
'to the estimated glomerular filtration r','C2603358','R'','R prime','false'
'ate egfr','C1739039','EGFR','EGFR protein, human','true'
'ate egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'ate egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1709380','P-Value','P-Value','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1704970','Means','Means','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C2699239','SD','SD, Rat Strain','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0017654','GFR','Glomerular Filtration Rate','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1424601','GFR','RAPGEF5 gene','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0750572','Estimated','Estimated','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3839656','Modification of diet in renal disease formula','Modification of diet in renal disease formula','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1739039','EGFR','EGFR protein, human','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0686905','Not Available','Unavailability','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0030705','Patients','Patients','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0441833','Group','Groups','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0687744','group','Social group','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1257890','Group','Population Group','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1519504','Group','Stage Grouping','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705428','Group','Group Object','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705429','Group','User Group','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0237881','significant','Statistical Significance','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0750502','Significant','Significant','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1546944','Significant','Event Seriousness - Significant','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0041420','tween','Tweens','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0681848','Group Study','Panel Study','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0023822','High Density Lipoprotein Cholesterol','High Density Lipoprotein Cholesterol','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1704436','Peripheral Artery Disease','Peripheral Arterial Diseases','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C4025272','Peripheral artery disease','Peripheral arterial stenosis','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0439232','Minute','Minute of time','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0700321','minute','Small','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0702093','/minute','Per Minute','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1282918','Minute','Minute (diminutive)','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C2347166','Minute','Minute Unit of Plane Angle','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0042295','Values','Values','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0008377','CHOLESTEROL','Cholesterol','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1532563','Millimole per Liter','Millimole per Liter','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1719797','Multiply','Multiply - dosing instruction fragment','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C2911648','Multiply','Multiplication','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0041004','TRIGLYCERIDES','Triglycerides','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0005893','Body mass index','Body mass index procedure','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0578022','Body Mass Index','Finding of body mass index','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1305855','BODY MASS INDEX','Body mass index','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0005910','Weight','Body Weight','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0043100','Weight','Weight','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1305866','weight','Weighing patient','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705104','Weight','Importance Weight','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0332849','Divided','Divide','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0205120','SQUARE','Square shape','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1552595','Square','Style Type - Square','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0017853','Glycated hemoglobin','Hemoglobin, Glycosylated','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1522609','Value','Numerical value','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1551393','Missing','Container status - Missing','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705492','Missing','Missing','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3272743','MISSING','Missing Study Animal','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0456603','RATIO','Ratio','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1547037','Ratio','data type - ratio','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0444706','Measured','Measured','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3541902','MEASURED','Measured Tumor Identification','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0439208','grams','gram','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0065055','lipoprotein cholesterol','lipoprotein cholesterol','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0032042','Placebo','Placebos','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1696465','PLACEBO','placebo','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1706408','PLACEBO','Placebo Control','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0017351','IGH','IGH gene','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0021034','IGH','Immunoglobulin Heavy Chains','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0019664','History','History','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0019665','history','Historical aspects qualifier','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0262512','History, NOS','History of present illness','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0262926','History','Medical History','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705255','History','Concept History','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C2004062','History','History of previous events','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0205447','ONE','One','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0439526','/mL','/mL','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705224','ML','THPO wt Allele','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3887665','ML','Thrombopoietin, human','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0231174','FAILURE','Failure (biologic function)','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0680095','failure','Personal failure','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0521095','Determined','Determined by','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1140263','Medical Dictionary for Regulatory Activities','Medical Dictionary for Regulatory Activities Terminology (MedDRA)','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0012634','condition','Disease','true'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C0348080','Condition','Condition','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C1705253','Condition','Logical Condition','false'
'p lus minus values are means sd the gfr at baseline was estimated according to the four variable modification of diet in renal disease formula data on egfr at baseline were not available for two patients in the empagliflozin group there were no significant differences be tween the study groups except with respect to high density lipoprotein cholesterol p $nmbr$ $nmbr$ and peripheral artery disease p $nmbr$ $nmbr$ in pa tients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less to convert the values for cholesterol to millimoles per liter multiply by $nmbr$ $nmbr$ to convert the values for triglycerides to millimoles per liter multiply by $nmbr$ $nmbr$ t he body mass index is the weight in kilograms divided by the square of the height in meters t he glycated hemoglobin value was missing for one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more t his ratio was measured in milligrams of albumin per grams of creatinine l ow density lipoprotein cholesterol was measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more h igh density lipoprotein cholesterol and triglycerides were measured in $nmbr$ patients in the placebo group and $nmbr$ in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less and in $nmbr$ patients in the placebo group and $nmbr$ in the empa gliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on stroke history was not available for one patient in the placebo group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more i nformation on peripheral artery disease was not available for one patient in the placebo group and one patient in the empagliflozin group in patients with an egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or more c ardiac failure was determined according to the narrow standardized medical dictionary for regulatory activities query for the condition','C3864998','Condition','Condition:Find:Pt:^Patient:Nom','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C0030705','Patients','Patients','true'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C0439526','/mL','/mL','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C1705224','ML','THPO wt Allele','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C3887665','ML','Thrombopoietin, human','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C0439232','Minute','Minute of time','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C0700321','minute','Small','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C0702093','/minute','Per Minute','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C1282918','Minute','Minute (diminutive)','false'
'patients with egfr of $nmbr$ ml per minute per $nmbr$ $nmbr$ m $nmbr$ or less','C2347166','Minute','Minute Unit of Plane Angle','false'
'patients with minute per','C0030705','Patients','Patients','true'
'patients with minute per','C0439232','Minute','Minute of time','false'
'patients with minute per','C0700321','minute','Small','false'
'patients with minute per','C0702093','/minute','Per Minute','false'
'patients with minute per','C1282918','Minute','Minute (diminutive)','false'
'patients with minute per','C2347166','Minute','Minute Unit of Plane Angle','false'
'egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more','C1739039','EGFR','EGFR protein, human','true'
'egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr of $nmbr$ ml per $nmbr$ $nmbr$ m $nmbr$ or more','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'empagliflozin n $nmbr$ $nmbr$ $nmbr$ $nmbr$ $nmbr$','C3490348','EMPAGLIFLOZIN','empagliflozin','true'
'interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no','C1272706','Interval','Interval','false'
'interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no','C1552654','Interval','Parameterized Data Type - Interval','false'
'interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no','C1552713','Interval','Data Type Interval','false'
'interval of $nmbr$ yr since diagnosis of type $nmbr$ diabetes no','C1550351','Diagnosis Type','Diagnosis Type','false'
'estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$','C3811844','Estimated Glomerular Filtration Rate','Estimated Glomerular Filtration Rate','false'
'estimated glomerular filtration rate ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'urinary albumin to creatinine ratio no','C0486293','Albumin/creatinine ratio','Albumin To Creatinine Protein Ratio Measurement','false'
'urinary albumin to creatinine ratio no','C1318293','albumin creatinine ratio','Albumin/creatinine ration result','false'
'low density lipoprotein^','C0023823','LOW DENSITY LIPOPROTEIN','Low-Density Lipoproteins','true'
'high density lipoprotein]','C0023821','High Density Lipoprotein','High Density Lipoproteins','true'
'cardiac failure','C0018801','CARDIAC FAILURE','Heart failure','true'
'cardiac failure','C0018802','Cardiac Failure','Congestive heart failure','true'
'angiotensin converting enzyme inhibitor or angiotensin','C0003015','Angiotensin-Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'angiotensin converting enzyme inhibitor or angiotensin','C2757044','Angiotensin Converting Enzyme Inhibitor','Angiotensin-Converting Enzyme Inhibitors [MoA]','false'
'angiotensin converting enzyme inhibitor or angiotensin','C3536837','Angiotensin Converting Enzyme Inhibitor','Angiotensin Converting Enzyme Inhibitor [EPC]','false'
'angiotensin converting enzyme inhibitor or angiotensin','C4541021','Angiotensin-converting enzyme inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'angiotensin converting enzyme inhibitor or angiotensin','C0003018','Angiotensin','Angiotensins','true'
'angiotensin converting enzyme inhibitor or angiotensin','C4521302','Angiotensin','Angiotensin-1, human','false'
'receptor blocker','C0597357','Receptor','receptor','false'
'urine albumin to creatinine ratio','C0455271','Urine albumin/creatinine ratio','Urine albumin/creatinine ratio measurement','false'
'urine albumin to creatinine ratio','C1318330','urine albumin creatinine ratio','Urine albumin:creatinine ratio result','false'
'time since diagnosis of type $nmbr$ diabetes','C0040223','TIME','Time','true'
'time since diagnosis of type $nmbr$ diabetes','C3541383','Time','Time (foundation metadata concept)','false'
'sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg','C0085805','SBP','Androgen Binding Protein','true'
'sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg','C0439475','mmHG','mmHg','false'
'sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg','C0536221','DBP','HSD17B4 protein, human','true'
'sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg','C3813197','DBP','HSD17B4 wt Allele','false'
'sbp $nmbr$ mmhg and or dbp $nmbr$ mmhg','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'cardiovascular risk','C0007226','Cardiovascular','Cardiovascular system','true'
'cardiovascular risk','C0035647','Risk','Risk','true'
'cardiovascular risk','C4552904','risk','Subject Risk','false'
'cardiovascular risk','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'only cerebrovascular disease','C0007820','CEREBROVASCULAR DISEASE','Cerebrovascular Disorders','true'
'only coronary artery disease','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'only coronary artery disease','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'only coronary artery disease','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'only peripheral artery disease','C1704436','Peripheral Artery Disease','Peripheral Arterial Diseases','true'
'only peripheral artery disease','C4025272','Peripheral artery disease','Peripheral arterial stenosis','false'
'$nmbr$ or $nmbr$ high cardiovascular risk categories','C0332167','HIGH RISK','High risk of','false'
'$nmbr$ or $nmbr$ high cardiovascular risk categories','C0683312','Categories','Categories','false'
'$nmbr$ or $nmbr$ high cardiovascular risk categories','C3272283','High Risk','American College of Cardiology/American Heart Association Lesion Complexity Score C','false'
'$nmbr$ or $nmbr$ high cardiovascular risk categories','C4050568','High Risk','High Risk Acute Leukemia','false'
'$nmbr$ or $nmbr$ high cardiovascular risk categories','C4319571','High risk','High risk','false'
'statin and or ezetimibe','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statin and or ezetimibe','C1142985','EZETIMIBE','ezetimibe','true'
'anti hypertensive therapy','C0585941','Antihypertensive therapy','Antihypertensive therapy','false'
'ace inhibitor and or arb','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor and or arb','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'ace inhibitor and or arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C3714541','FEV','Forced Vital Capacity','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0376690','AUC','Area Under Curve','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0444506','Trough','Trough','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C2964552','Total Score','Total score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0449820','SCORE','Score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0039798','treatment','therapeutic aspects','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0087111','Treatment','Therapeutic procedure','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1522326','Treatment','Treating','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1533734','Treatment','Administration procedure','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1705169','Treatment','Biomaterial Treatment','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C3538994','TREATMENT','Treatment Epoch','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C2603360','T'','T prime','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0439267','g%','Gram per Deciliter','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0032042','Placebo','Placebos','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1696465','PLACEBO','placebo','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1706408','PLACEBO','Placebo Control','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0018026','GOLD','Gold','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C1304897','Gold','Gold color','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold $nmbr$ and $nmbr$ disease','C0012634','Disease','Disease','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C3714541','FEV','Forced Vital Capacity','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0376690','AUC','Area Under Curve','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0444506','Trough','Trough','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C2964552','Total Score','Total score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0449820','SCORE','Score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0039798','treatment','therapeutic aspects','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0087111','Treatment','Therapeutic procedure','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1522326','Treatment','Treating','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1533734','Treatment','Administration procedure','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1705169','Treatment','Biomaterial Treatment','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C3538994','TREATMENT','Treatment Epoch','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C2603360','T'','T prime','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0439267','g%','Gram per Deciliter','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0032042','Placebo','Placebos','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1696465','PLACEBO','placebo','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1706408','PLACEBO','Placebo Control','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0018026','GOLD','Gold','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C0012634','Disease','Disease','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score all at $nmbr$ weeks treatment comparisons for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients with gold a d disease','C1304897','Gold','Gold color','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C3714541','FEV','Forced Vital Capacity','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0376690','AUC','Area Under Curve','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0444506','Trough','Trough','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C2964552','Total Score','Total score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0039798','treatment','therapeutic aspects','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1707455','Comparison','Comparison','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0087111','Treatment','Therapeutic procedure','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1522326','Treatment','Treating','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1533734','Treatment','Administration procedure','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1705169','Treatment','Biomaterial Treatment','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C3538994','TREATMENT','Treatment Epoch','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C2603360','T'','T prime','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0439267','g%','Gram per Deciliter','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C0032042','Placebo','Placebos','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1696465','PLACEBO','placebo','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were treatment naive not treatment naive at baseline','C1706408','PLACEBO','Placebo Control','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0349966','FIG','Figs - dietary','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1337208','FIG','Fig Flavor','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C3714541','FEV','Forced Vital Capacity','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0376690','AUC','Area Under Curve','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0444506','Trough','Trough','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C2964552','Total Score','Total score','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0039798','treatment','therapeutic aspects','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1707455','Comparison','Comparison','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0087111','Treatment','Therapeutic procedure','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1522326','Treatment','Treating','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1533734','Treatment','Administration procedure','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1705169','Treatment','Biomaterial Treatment','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C3538994','TREATMENT','Treatment Epoch','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C3887704','treatment','treatment - ActInformationManagementReason','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C2603360','T'','T prime','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0439267','g%','Gram per Deciliter','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C0032042','Placebo','Placebos','true'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1696465','PLACEBO','placebo','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1706408','PLACEBO','Placebo Control','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1514756','RECEIVING','Receive','false'
'fig $nmbr$ a fev $nmbr$ auc $nmbr$ $nmbr$ and trough fev $nmbr$ responses b sgrq total score and c tdi focal score treatment comparisons at $nmbr$ weeks for t o $nmbr$ $nmbr$ g versus t $nmbr$ g and versus placebo in patients who were receiving not receiving ics treatment at baseline','C1518422','Not','Negation','false'
'rotigotine n $nmbr$','C1700683','ROTIGOTINE','Rotigotine','true'
'rotigotine n $nmbr$','C4318637','rotigotine, (+)-','rotigotine, (+)-','true'
'stage of pda','C0205390','Stage','Phase','false'
'stage of pda','C1300072','Stage','Tumor stage','false'
'stage of pda','C1306673','Stage','Stage','false'
'early n','C1279919','Early','Early','false'
'advanced n','C0205179','Advanced','Advanced phase','false'
'time since pd diagnosis mean sd','C0040223','TIME','Time','true'
'time since pd diagnosis mean sd','C3541383','Time','Time (foundation metadata concept)','false'
'years modified hoehn and yahr stage n','C0439234','YEARS','year','false'
'years modified hoehn and yahr stage n','C0679846','Modified stage','stages of change','false'
'renal function at randomization','C0232804','Renal function','Renal function','false'
'renal function at randomization','C0034656','Randomization','Randomization','true'
'moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C3274776','MODERATE DYSFUNCTION','Moderately Abnormal Ejection Fraction','false'
'moderate dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C0439445','mL/min','mL/min','false'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C2945599','Mild','Mild (qualifier value)','false'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C0031847','dysfunction','physiopathological','true'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C0439445','mL/min','mL/min','false'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C0277785','Dysfunction','Functional disorder','false'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C3887504','Dysfunction','Dysfunction','false'
'mild or no dysfunction crcl $nmbr$ ml min n $nmbr$ $nmbr$ [ $nmbr$ $nmbr$ ]','C3887505','DYSFUNCTION','DYSFUNCTION - SKIN DISORDERS','false'
'mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C3274775','MILD DYSFUNCTION','Mildly Abnormal Ejection Fraction','false'
'mild dysfunction crcl $nmbr$ $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C0439445','mL/min','mL/min','false'
'normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C4296962','Normal function','Normal function','false'
'normal function crcl $nmbr$ ml min n $nmbr$ [ $nmbr$ $nmbr$ ]','C0439445','mL/min','mL/min','false'
'weight median iqr kg','C0022718','KG','Kyrgyzstan','true'
'weight median iqr kg','C0439209','kg','Kilogram','false'
'weight median iqr kg','C4054209','/kg','Per Kilogram','false'
'bmi median iqr kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi median iqr kg m $nmbr$','C0439209','kg','Kilogram','false'
'bmi median iqr kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'crcl median iqr ml min','C0549183','Median','Midline (qualifier value)','false'
'crcl median iqr ml min','C0439445','mL/min','mL/min','false'
'crcl median iqr ml min','C0876920','Median','Median Statistical Measurement','false'
'crcl median iqr ml min','C2347635','Median','Population Median','false'
'crcl median iqr ml min','C2348144','Median','Sample Median','false'
'crcl median iqr ml min','C2939193','Median','Median (qualifier value)','false'
'current or prior smoking','C0521116','CURRENT','Current (present time)','false'
'current or prior smoking','C1705970','Current','Electrical Current','false'
'current or prior smoking','C0037369','SMOKING','Smoking','true'
'current or prior smoking','C0453996','Smoking','Tobacco smoking behavior','true'
'current or prior smoking','C1881674','Smoking','Medical Device Emits Smoke','false'
'other vascular disease cvd or pad','C0042373','Disease, Vascular','Vascular Diseases','true'
'other vascular disease cvd or pad','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'other vascular disease cvd or pad','C0182158','Pad','Pads','false'
'other vascular disease cvd or pad','C0332568','Pad','Pad Mass','false'
'other vascular disease cvd or pad','C3540603','PAD','PADI4 wt Allele','false'
'other vascular disease cvd or pad','C3669270','Pad','Strucure of thick cushion of skin','false'
'other vascular disease cvd or pad','C3814046','PAD','PAD Regimen','false'
'other vascular disease cvd or pad','C4319657','Pad','Pad (unit of presentation)','false'
'asia pacific and africa','C0003980','Asia','Asia','true'
'asia pacific and africa','C0001737','Africa','Africa','true'
'chads $nmbr$ mean sd','C0444504','Mean','Statistical mean','false'
'chads $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'chads $nmbr$ mean sd','C2347634','Mean','Population Mean','false'
'chads $nmbr$ mean sd','C2348143','Mean','Sample Mean','false'
'cha $nmbr$ ds $nmbr$ vasc mean sd','C0444504','Mean','Statistical mean','false'
'cha $nmbr$ ds $nmbr$ vasc mean sd','C2699239','SD','SD, Rat Strain','false'
'cha $nmbr$ ds $nmbr$ vasc mean sd','C2347634','Mean','Population Mean','false'
'cha $nmbr$ ds $nmbr$ vasc mean sd','C2348143','Mean','Sample Mean','false'
'modified has bled score mean sd','C0392747','Modified','Changing','false'
'modified has bled score mean sd','C3889737','Modified','Data Change Date','false'
'modified has bled score mean sd','C0444504','Mean','Statistical mean','false'
'modified has bled score mean sd','C2699239','SD','SD, Rat Strain','false'
'modified has bled score mean sd','C2347634','Mean','Population Mean','false'
'modified has bled score mean sd','C2348143','Mean','Sample Mean','false'
'intermediate $nmbr$','C0205103','INTERMEDIATE','Intermediate','false'
'intermediate $nmbr$','C1550465','Intermediate','Observation Interpretation - intermediate','false'
'intermediate $nmbr$','C2827755','INTERMEDIATE','Antimicrobial Intermediate Susceptibility Result','false'
'intermediate $nmbr$','C3889971','Intermediate','Intermediate Mitosis-Karyorrhexis Index','false'
'potent phosphorylated glycoprotein inhibitor use','C0042153','use','utilization qualifier','true'
'potent phosphorylated glycoprotein inhibitor use','C0457083','Use','Usage','false'
'potent phosphorylated glycoprotein inhibitor use','C1947944','Use','Use - dosing instruction imperative','false'
'prior vka use for $nmbr$ d','C0042153','use','utilization qualifier','true'
'prior vka use for $nmbr$ d','C0457083','Use','Usage','false'
'prior vka use for $nmbr$ d','C1947944','Use','Use - dosing instruction imperative','false'
'medication at randomization','C0013227','Medication','Pharmaceutical Preparations','true'
'medication at randomization','C3244316','medication','medication - HL7 publishing domain','false'
'medication at randomization','C4284232','Medication','Medications','false'
'time in therapeutic range median iqr','C1554109','Time Range','Time Range','false'
'n n yr','C0369718','N NOS','N not otherwise specified Antibody','false'
'n n yr','C0439234','yr','year','false'
'n n yr','C0441922','N+','N+ (tumor staging)','false'
'warf','C0043031','WARF','Warfarin','true'
'hder','C3898895','HDER','Hemodialysis Extraction Ratio','false'
'stroke or se s se','C0038454','STROKE','Cerebrovascular accident','true'
'stroke or se s se','C4554100','Stroke','Stroke, CTCAE','false'
'stroke or se s se','C0036919','SE','Seychelles','true'
'crcl $nmbr$ $nmbr$','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'major bleeding mb','C0019080','BLEEDING','Hemorrhage','true'
'major bleeding mb','C0024853','MB','Martinique','true'
's se mb or death','C0036919','SE','Seychelles','true'
's se mb or death','C0024853','MB','Martinique','true'
's se mb or death','C0011065','DEATH','Cessation of life','true'
's se mb or death','C1306577','Death','Death (finding)','false'
's se mb or death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
's se mb or death','C4552775','Death NOS','Death NOS, CTCAE','false'
'previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$','C0948008','Ischaemic stroke','Ischemic stroke','false'
'previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$','C0007787','TIA','Transient Ischemic Attack','true'
'previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$','C1054154','tia','Tacca leontopetaloides','false'
'no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0948008','Ischaemic stroke','Ischemic stroke','false'
'no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0007787','TIA','Transient Ischemic Attack','true'
'no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0917805','TIA','Transient Cerebral Ischemia','true'
'no previous ischemic stroke tia n $nmbr$ $nmbr$ $nmbr$ $nmbr$','C1054154','tia','Tacca leontopetaloides','false'
'warfarin n $nmbr$ n y','C0043031','WARFARIN','Warfarin','true'
'higher dose edoxaban n $nmbr$ n y','C0444956','High dose','High dose','false'
'higher dose edoxaban n $nmbr$ n y','C2975435','EDOXABAN','edoxaban','true'
'higher dose edoxaban vs warfarin','C0444956','High dose','High dose','false'
'higher dose edoxaban vs warfarin','C2975435','EDOXABAN','edoxaban','true'
'higher dose edoxaban vs warfarin','C0043031','WARFARIN','Warfarin','true'
'ard per $nmbr$ $nmbr$ patient years $nmbr$ ci','C1817569','ARD'','acireductone dioxygenase [iron(II)-requiring] activity','false'
'ard per $nmbr$ $nmbr$ patient years $nmbr$ ci','C1826411','ARD','ADI1 gene','false'
'previous stroke tia','C0007787','TIA','Transient Ischemic Attack','true'
'previous stroke tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous stroke tia','C1054154','tia','Tacca leontopetaloides','false'
'no previous stroke tia','C0007787','TIA','Transient Ischemic Attack','true'
'no previous stroke tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'no previous stroke tia','C1054154','tia','Tacca leontopetaloides','false'
'cvd stroke see','C0042789','see','Vision','true'
'cvd stroke see','C1947903','See','See','false'
'all cause death stroke see','C0042789','see','Vision','true'
'all cause death stroke see','C1947903','See','See','false'
'atrial fibrillation type n','C0004238','ATRIAL FIBRILLATION','Atrial Fibrillation','true'
'atrial fibrillation type n','C0344434','Atrial Fibrillation','Atrial Fibrillation by ECG Finding','false'
'atrial fibrillation type n','C1963067','Atrial fibrillation','Atrial Fibrillation, CTCAE','false'
'mace','C0349381','MACE','Mace Spice','false'
'mace','C0949745','mace','Myristica fragrans','true'
'mace','C1445339','MACE','Mace extract','false'
'paroxysmal af','C0235480','Paroxysmal AF','Paroxysmal atrial fibrillation','true'
'persistent af','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'persistent af','C4049859','AF','PSMD4 wt Allele','false'
'permanent af','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'permanent af','C4049859','AF','PSMD4 wt Allele','false'
'qualifying risk factor n','C1514624','Qualifying','Qualifying','false'
'qualifying risk factor n','C0035648','Risk Factor','risk factors','true'
'chads $nmbr$ score $nmbr$ $nmbr$ n','C0449820','SCORE','Score','false'
'chads $nmbr$ score $nmbr$ $nmbr$ n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'nonfatal stroke','C0038454','STROKE','Cerebrovascular accident','true'
'nonfatal stroke','C4554100','Stroke','Stroke, CTCAE','false'
'dose reduction n','C0178602','DOSE','Dosage','false'
'dose reduction n','C0301630','Reduction','Reduction (chemical)','false'
'dose reduction n','C0392756','Reduction','Reduced','false'
'dose reduction n','C1293152','Reduction','Reduction procedure','false'
'dose reduction n','C4551656','Reduction','Surgical reduction','false'
'dose reduction n','C0869039','Dose','Unit dose','false'
'dose reduction n','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'renal impairment crcl','C1565489','Renal Impairment','Renal Insufficiency','true'
'renal impairment crcl','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'low body weight','C0041667','Low body weight','Underweight','true'
'nondisabling nonfatal stroke','C0038454','STROKE','Cerebrovascular accident','true'
'nondisabling nonfatal stroke','C4554100','Stroke','Stroke, CTCAE','false'
'medication at randomization n','C0013227','Medication','Pharmaceutical Preparations','true'
'medication at randomization n','C3244316','medication','medication - HL7 publishing domain','false'
'medication at randomization n','C4284232','Medication','Medications','false'
'disabling stroke','C0038454','STROKE','Cerebrovascular accident','true'
'disabling stroke','C4554100','Stroke','Stroke, CTCAE','false'
'disabling or fatal stroke','C0038454','STROKE','Cerebrovascular accident','true'
'disabling or fatal stroke','C4554100','Stroke','Stroke, CTCAE','false'
'primary hemorrhagic stroke','C0205225','Primary','Primary','false'
'primary hemorrhagic stroke','C0553692','Haemorrhagic stroke','Brain hemorrhage','true'
'primary hemorrhagic stroke','C0439612','Primary','True primary (qualifier value)','false'
'primary hemorrhagic stroke','C0439631','Primary','Primary operation','false'
'primary ischemic stroke','C0205225','Primary','Primary','false'
'primary ischemic stroke','C0948008','Ischaemic stroke','Ischemic stroke','false'
'primary ischemic stroke','C0439612','Primary','True primary (qualifier value)','false'
'primary ischemic stroke','C0439631','Primary','Primary operation','false'
'figure $nmbr$ treatment effect of sacubitril valsartan therapy','C1518681','Treatment Effect','Outcome of Therapy','false'
'note have already got interaction values from the paper itself','C1316572','Note','Evaluation and management note:Finding:Point in time:{Setting}:Document:{Provider}','false'
'note have already got interaction values from the paper itself','C1317574','Note','Note (document)','false'
'note have already got interaction values from the paper itself','C0042295','Values','Values','false'
'note have already got interaction values from the paper itself','C0030351','Paper','Paper','true'
'note have already got interaction values from the paper itself','C1547566','Paper','Paper Authorization','false'
'vildagliptin metformin vldm','C1570906','VILDAGLIPTIN','vildagliptin','true'
'vildagliptin metformin vldm','C0025598','METFORMIN','Metformin','true'
'metformin hdm','C0025598','METFORMIN','Metformin','true'
'mean s d age years','C0444504','Mean','Statistical mean','false'
'mean s d age years','C1510829','Age-Years','Age-Years','false'
'mean s d age years','C2347634','Mean','Population Mean','false'
'mean s d age years','C2348143','Mean','Sample Mean','false'
'mean s d weight kg','C0022718','KG','Kyrgyzstan','true'
'mean s d weight kg','C0439209','kg','Kilogram','false'
'mean s d weight kg','C4054209','/kg','Per Kilogram','false'
'mean s d bmi kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean s d bmi kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean s d bmi kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'age distribution n','C0001782','Age Distribution','Age Distribution','true'
'bmi distribution n','C0578022','BMI','Finding of body mass index','false'
'bmi distribution n','C0520511','Distribution','Distributing','false'
'bmi distribution n','C1704711','Distribution','Distribution','true'
'mean s d duration of t $nmbr$ dm years','C0449238','Duration','Duration (temporal concept)','false'
'mean s d duration of t $nmbr$ dm years','C2926735','Duration','Duration','false'
'mean s d baseline hba $nmbr$ c','C0168634','baseline','BaseLine dental cement','true'
'mean s d baseline hba $nmbr$ c','C0019016','HBA','Hemoglobin A','true'
'mean s d baseline hba $nmbr$ c','C1825777','HBA','KRT90P gene','false'
'mean s d baseline hba $nmbr$ c','C3538758','HBA','SCN2A wt Allele','false'
'mean s d baseline hba $nmbr$ c','C1442488','Baseline','Baseline','false'
'mean s d baseline fpg mmol l','C0168634','baseline','BaseLine dental cement','true'
'mean s d baseline fpg mmol l','C1532563','mmol/L','Millimole per Liter','false'
'mean s d baseline fpg mmol l','C1442488','Baseline','Baseline','false'
'mean s d metformin dose mg day','C0025598','METFORMIN','Metformin','true'
'mean s d metformin dose mg day','C0439422','mg day','milligram/day','false'
'age $nmbr$ years and bmi','C1510829','Age-Years','Age-Years','false'
'age $nmbr$ years and bmi','C0578022','BMI','Finding of body mass index','false'
'age $nmbr$ years and bmi $nmbr$ kg m $nmbr$','C1510829','Age-Years','Age-Years','false'
'age $nmbr$ years and bmi $nmbr$ kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'age $nmbr$ years and bmi $nmbr$ kg m $nmbr$','C0439209','kg','Kilogram','false'
'age $nmbr$ years and bmi $nmbr$ kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'hba $nmbr$ c $nmbr$ weeks','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c $nmbr$ weeks','C0439230','WEEKS','week','false'
'hba $nmbr$ c $nmbr$ weeks','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c $nmbr$ weeks','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C3538758','HBA','SCN2A wt Allele','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C1708130','Gi','GNAI1 wt Allele','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C0559546','Adverse reactions','Adverse reactions','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C3539617','GI','Digestive System Findings Domain','false'
'hba $nmbr$ c $nmbr$ $nmbr$ without gi adverse reactions','C4050121','GI','Gastrointestinal studies and measurements','false'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C0301630','Reduction','Reduction (chemical)','false'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C0392756','Reduction','Reduced','false'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C1293152','Reduction','Reduction procedure','false'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C4551656','Reduction','Surgical reduction','false'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'reduction of hba $nmbr$ c from baseline $nmbr$ $nmbr$','C1442488','Baseline','Baseline','false'
'mean age y median range','C1514721','Range','Range','false'
'mean age y median range','C2348147','Range','Sample Range','false'
'mean age y median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'systolic blood pressure mm hg median range','C1514721','Range','Range','false'
'systolic blood pressure mm hg median range','C2348147','Range','Sample Range','false'
'systolic blood pressure mm hg median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'diastolic blood pressure mm hg median range','C1514721','Range','Range','false'
'diastolic blood pressure mm hg median range','C2348147','Range','Sample Range','false'
'diastolic blood pressure mm hg median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'previous ischemic stroke n','C0205156','Previous','Previous','false'
'previous ischemic stroke n','C0948008','Ischaemic stroke','Ischemic stroke','false'
'previous ischemic stroke n','C1552607','previous','Act Relationship Subset - previous','false'
'previous coronary artery disease n','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'previous coronary artery disease n','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'previous coronary artery disease n','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'history of diabetes mellitus n','C0455488','History of - diabetes mellitus','H/O: diabetes mellitus','false'
'history of hypercholesterolemia n','C1533076','History of hypercholesterolemia','History of hypercholesterolemia','false'
'baseline scales median range','C1514721','Range','Range','false'
'baseline scales median range','C2348147','Range','Sample Range','false'
'baseline scales median range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'nihss at randomization','C1697238','NIHSS','NIH stroke scale','false'
'nihss at randomization','C0034656','Randomization','Randomization','true'
'stroke subtype n','C0038454','STROKE','Cerebrovascular accident','true'
'stroke subtype n','C0449560','Subtype','Subtype (attribute)','false'
'stroke subtype n','C4554100','Stroke','Stroke, CTCAE','false'
'extracranial carotid stenosis n','C0580586','Extracranial','Extracranial','false'
'extracranial carotid stenosis n','C0007282','CAROTID STENOSIS','Carotid Stenosis','true'
'medications at timing of randomization n','C2359859','Medication timing','Medication timing','false'
'medications at timing of randomization n','C0034656','Randomization','Randomization','true'
'antiplatelet within $nmbr$ mo before randomization','C0026544','MO','Morocco','true'
'antiplatelet within $nmbr$ mo before randomization','C0332177','/mo','Monthly (qualifier value)','false'
'antiplatelet within $nmbr$ mo before randomization','C0034656','Randomization','Randomization','true'
'antihypertensive agents','C0003364','Antihypertensive Agents','Antihypertensive Agents','true'
'antidiabetic agents','C0935929','Antidiabetic Agents','Antidiabetics','true'
'time from onset to randomization h mean sd','C0449244','onset time','Time of onset','false'
'time from onset to randomization h mean sd','C0033727','H+','Protons','true'
'time from onset to randomization h mean sd','C2699239','SD','SD, Rat Strain','false'
'time from onset to randomization h mean sd','C0369286','H NOS','H NOS Antibodies','false'
'time from onset to randomization h mean sd','C0441932','H+','Hepatic Involvement','false'
'time from onset to randomization h mean sd','C0564385','/h','/hour','false'
'time from onset to randomization h mean sd','C4528284','h*%','Hour Times Percent','false'
'time from onset to medication h mean sd','C0449244','onset time','Time of onset','false'
'time from onset to medication h mean sd','C0013227','Medication','Pharmaceutical Preparations','true'
'time from onset to medication h mean sd','C2699239','SD','SD, Rat Strain','false'
'time from onset to medication h mean sd','C3244316','medication','medication - HL7 publishing domain','false'
'time from onset to medication h mean sd','C4284232','Medication','Medications','false'
'event rates','C0871208','Rate','Rating (action)','false'
'event rates','C1521828','Rate','Rate','false'
'p value for variance','C1709380','P-Value','P-Value','false'
'p value for variance','C1711260','Variance','Variance','false'
'p value for variance','C2348152','Variance','Sample Variance','false'
'clopidogrel plus aspirin','C0070166','CLOPIDOGREL','clopidogrel','true'
'clopidogrel plus aspirin','C0004057','ASPIRIN','Aspirin','true'
'placebo plus aspirin','C0032042','Placebo','Placebos','true'
'placebo plus aspirin','C1696465','PLACEBO','placebo','false'
'placebo plus aspirin','C1706408','PLACEBO','Placebo Control','false'
'history of hypercholesterolemia','C1533076','History of hypercholesterolemia','History of hypercholesterolemia','false'
'history of ischemic stroke','C0019664','History','History','true'
'history of ischemic stroke','C0019665','history','Historical aspects qualifier','true'
'history of ischemic stroke','C0262512','History, NOS','History of present illness','false'
'history of ischemic stroke','C0262926','History','Medical History','false'
'history of ischemic stroke','C1705255','History','Concept History','false'
'history of ischemic stroke','C2004062','History','History of previous events','false'
'time to treatment','C3494202','Time-to-Treatment','Time-to-Treatment','true'
'hospital factor $nmbr$','C1521761','Factor','Factor','false'
'hospital factor $nmbr$','C2827422','Factor','Mathematical Factor','false'
'$nmbr$ beds','C0004916','Beds','Beds','true'
'lesion location','C0450429','Location','Location','false'
'lesion location','C1515974','Location','Anatomic Site','false'
'lesion location','C4284930','Location','Location of Pharyngeal Residue Following Swallowing','false'
'lesion location','C4284931','Location','Location of Oral Residue Following Swallowing','false'
'cortical only','C0001613','Cortical','Adrenal Cortex','true'
'cortical only','C0007776','Cortical','Cerebral cortex','true'
'cortical only','C0022655','Cortical','Structure of cortex of kidney','true'
'non cortical','C0001613','Cortical','Adrenal Cortex','true'
'non cortical','C0007776','Cortical','Cerebral cortex','true'
'non cortical','C0022655','Cortical','Structure of cortex of kidney','true'
'vascular territory $nmbr$','C1301808','Territory','Geographic state','false'
'vascular territory $nmbr$','C2983136','Territory','Territory','false'
'anterior circulation','C0005775','Circulation','Blood Circulation','true'
'anterior circulation','C1516559','Circulation','Circulatory Process','false'
'posterior circulation','C0005775','Circulation','Blood Circulation','true'
'posterior circulation','C1516559','Circulation','Circulatory Process','false'
'mca','C0149566','MCA','Structure of middle cerebral artery','true'
'aclidinium formoterol $nmbr$ $nmbr$ pg twice daily','C0030827','PG','Penicillin G','true'
'aclidinium formoterol $nmbr$ $nmbr$ pg twice daily','C0072225','PG','Propylene glycol','true'
'aclidinium formoterol $nmbr$ $nmbr$ pg twice daily','C1266240','PG','Prostaglandin measurement','false'
'salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily','C0030827','PG','Penicillin G','true'
'salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily','C0072225','PG','Propylene glycol','true'
'salmeterol fluticasone $nmbr$ $nmbr$ pg twice daily','C1266240','PG','Prostaglandin measurement','false'
'caucasians','C0007457','Caucasians','Caucasoid Race','true'
'caucasians','C0043157','CAUCASIANS','Caucasians','true'
'gold classification','C0008902','Classification','Classification','true'
'gold classification','C0008903','classification','Taxonomic','true'
'gold classification','C0678229','classification','Classification of information','false'
'smoking consumption pack years','C0425291','Smoking consumption','Tobacco smoking consumption','false'
'smoking consumption pack years','C1277691','Pack years','Pack years','false'
'exacerbation in previous year','C4086268','EXACERBATION','Exacerbation','false'
'exacerbation in previous year','C0205156','Previous','Previous','false'
'exacerbation in previous year','C1552607','previous','Act Relationship Subset - previous','false'
'exacerbations in previous year','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in previous year','C0205156','Previous','Previous','false'
'exacerbations in previous year','C1552607','previous','Act Relationship Subset - previous','false'
'prior copd medication','C0013227','Medication','Pharmaceutical Preparations','true'
'prior copd medication','C3244316','medication','medication - HL7 publishing domain','false'
'prior copd medication','C4284232','Medication','Medications','false'
'laba lama','C0999593','Lama','Lama','false'
'laba lama','C1416775','LAMA','LAMA1 gene','false'
'laba lama ics','C0815320','ICS','Impaired Control Scale','false'
'laba lama ics','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'fevi $nmbr$ l','C0429706','FEV 1.0','Forced expiratory volume in 1 second finding','false'
'fevi $nmbr$ l','C0849974','fev 1','Pulmonary Function Test/Forced Expiratory Volume 1','false'
'fevi $nmbr$ l','C1561566','FEV(1)','FEV1, CTCAE','false'
'fevi $nmbr$ l','C4528367','FEV_1','Forced Expiratory Volume in 0.1 Second','false'
'post bronchodilator fevi $nmbr$ predicted','C0681842','Predicted','prediction','false'
'post bronchodilator fevi $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'bronchial reversibility','C0205039','Bronchial','Bronchial','false'
'bronchial reversibility','C0449261','Reversibility','Reversibility','false'
'bronchial reversibility','C1442216','Bronchial','Bronchial system','false'
'bdi focal score $nmbr$','C0449820','SCORE','Score','false'
'bdi focal score $nmbr$','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'cat total score $nmbr$','C0007450','CAT','Felis catus','true'
'cat total score $nmbr$','C2964552','Total Score','Total score','false'
'cat total score $nmbr$','C0325090','Cat','Felis silvestris','false'
'cat total score $nmbr$','C0524517','Cat','Genus Felis','true'
'cat total score $nmbr$','C1443200','Cat','Cat hair antigen','false'
'cat total score $nmbr$','C3665481','Cat','Cat (organism)','false'
'cat total score $nmbr$','C4050461','CAT','Cutaneous Assessment Tool','false'
'cat total score $nmbr$','C4284282','CAT','COPD Assessment Test Questionnaire','false'
'sgrq total score $nmbr$','C2964552','Total Score','Total score','false'
'figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p','C4055223','Clinical Response','Clinical Response','false'
'figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p','C0030705','Patients','Patients','true'
'figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p','C1279919','Early','Early','false'
'figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p','C3538806','Ra','Axial R','false'
'figure $nmbr$ clinical response in patients with early and established ra at month $nmbr$ p','C4048756','RA','Right arm','false'
'acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis','C0035452','Rheumatology','Rheumatology specialty','true'
'acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis','C4706353','DAS - Disease Activity Score','DAS - Disease Activity Score','false'
'acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis','C0014779','Index, Erythrocyte','Erythrocyte Indices','true'
'acr american college of rheumatology response criteria das $nmbr$ $nmbr$ esr disease activity score in $nmbr$ joints erythrocyte sedimentation rate haq di health assessment questionnaire disability index ls least squares mtx methotrexate ra rheumatoid arthritis','C0003873','RA - Rheumatoid arthritis','Rheumatoid Arthritis','true'
'c right sided vhd n $nmbr$','C0205090','right sided','Right','false'
'c right sided vhd n $nmbr$','C0444532','RIGHT-SIDED','Right sided','false'
'd mitral stenosis vhd n $nmbr$','C0026269','MITRAL STENOSIS','Mitral Valve Stenosis','true'
'd mitral stenosis vhd n $nmbr$','C0264766','Mitral stenosis','Rheumatic mitral stenosis','false'
'bonferroni adjusted p value b vs a','C0456081','Adjusted','Adjustment Action','false'
'bonferroni adjusted p value b vs a','C1709380','P-Value','P-Value','false'
'bonferroni adjusted p value c vs a','C0456081','Adjusted','Adjustment Action','false'
'bonferroni adjusted p value c vs a','C1709380','P-Value','P-Value','false'
'bonferroni adjusted p value d vs a','C0456081','Adjusted','Adjustment Action','false'
'bonferroni adjusted p value d vs a','C1709380','P-Value','P-Value','false'
'vhd event rate year n','C0439234','Year','year','false'
'vhd event rate year n','C0439508','/Year','per year','false'
'no vhd event rate year n','C0439234','Year','year','false'
'no vhd event rate year n','C0439508','/Year','per year','false'
'adiusted hazard ratio','C2985465','Hazard Ratio','Hazard Ratio','false'
'persistent af n','C0205322','Persistent','Persistent','false'
'persistent af n','C0332996','PERSISTENT','Persistent embryonic structure','false'
'[ $nmbr$ cl]','C0596019','Cl -','Chloride Ion','false'
'crcl at baseline ml min','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl at baseline ml min','C0439445','mL/min','mL/min','false'
'moderate renal impairment n','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate renal impairment n','C1565489','Renal Impairment','Renal Insufficiency','true'
'moderate renal impairment n','C1881878','Moderate','Moderation','false'
'moderate renal impairment n','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate renal impairment n','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate renal impairment n','C4085643','Moderate','Moderate Response','false'
'moderate renal impairment n','C4321335','Moderate','Moderate Level','false'
'history of heart failure n','C0455531','History of - heart failure','H/O: heart failure','false'
'coronary artery disease n','C0010054','coronary artery disease','Coronary Arteriosclerosis','true'
'coronary artery disease n','C0010068','Coronary (artery) disease','Coronary heart disease','true'
'coronary artery disease n','C1956346','CORONARY ARTERY DISEASE','Coronary Artery Disease','true'
'history of myocardial infarction n','C1275835','History of - myocardial infarction','History of myocardial infarction','false'
'vitamin k antagonist experienced n','C1096489','vitamin k antagonist','Treatment with Vitamin K antagonist','false'
'vitamin k antagonist experienced n','C2267235','Vitamin K Antagonist','Vitamin K Antagonist [EPC]','false'
'history of stroke see tia n','C0019664','History','History','true'
'history of stroke see tia n','C0019665','history','Historical aspects qualifier','true'
'history of stroke see tia n','C0262512','History, NOS','History of present illness','false'
'history of stroke see tia n','C0262926','History','Medical History','false'
'history of stroke see tia n','C1705255','History','Concept History','false'
'history of stroke see tia n','C2004062','History','History of previous events','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C1705241','*Difference','Delta (difference)','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C1705242','Difference','Different','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0024671','MG','Mammography','true'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0026410','MG','Mongolia','true'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0439269','mg%','mg/dL','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C1960952','mg %','Milligram percent','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C2346927','Mg++','Magnesium Cation','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C4321396','MG','MG','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C4521761','MG','United States Military Commissioned Officer O8','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0168634','baseline','BaseLine dental cement','true'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C1442488','Baseline','Baseline','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0439230','WEEKS','week','false'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0021966','I-','Iodides','true'
'fig $nmbr$ treatment differences by baseline median subgroups $nmbr$ mg vs $nmbr$ mg for time weighted change from baseline in efficacy endpoints over $nmbr$ weeks in part i','C0221138','I NOS','Blood group antibody I','false'
'colchicine n $nmbr$','C0009262','COLCHICINE','Colchicine','true'
'no colchicine n $nmbr$','C0009262','COLCHICINE','Colchicine','true'
'age y mean range','C1514721','Range','Range','false'
'age y mean range','C2348147','Range','Sample Range','false'
'age y mean range','C3542016','Range','Concept model range (foundation metadata concept)','false'
'creatinine mg dl mean sd','C0439269','mg dl','mg/dL','false'
'creatinine mg dl mean sd','C2699239','SD','SD, Rat Strain','false'
'ef mean sd','C0444504','Mean','Statistical mean','false'
'ef mean sd','C2699239','SD','SD, Rat Strain','false'
'ef mean sd','C2347634','Mean','Population Mean','false'
'ef mean sd','C2348143','Mean','Sample Mean','false'
'valvular heart disease','C0018824','Heart Disease, Valvular','Heart valve disease','true'
'valvular heart disease','C1963123','Valvular heart disease','Valvular Heart Disease, CTCAE','false'
'$nmbr$ $nmbr$ range $nmbr$ $nmbr$','C1514721','Range','Range','false'
'$nmbr$ $nmbr$ range $nmbr$ $nmbr$','C2348147','Range','Sample Range','false'
'$nmbr$ $nmbr$ range $nmbr$ $nmbr$','C3542016','Range','Concept model range (foundation metadata concept)','false'
'age y n $nmbr$','C0001779','AGE','Age','false'
'age $nmbr$ $nmbr$ y n $nmbr$','C0001779','AGE','Age','false'
'age $nmbr$ y n $nmbr$','C0001779','AGE','Age','false'
'$nmbr$ y kaplan meier rate $nmbr$ ci','C0008107','CI','Chile','true'
'$nmbr$ y kaplan meier rate $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'female race white','C0007457','WHITE','Caucasoid Race','true'
'female race white','C0043157','WHITE','Caucasians','true'
'female race white','C0220938','WHITE','White color','false'
'vorapaxar','C2974521','VORAPAXAR','vorapaxar','true'
'cv death mi stroke recurrent ischemia','C0022116','Ischaemia, NOS','Ischemia','true'
'cv death mi stroke recurrent ischemia','C4321499','Ischemia','Ischemia Procedure','false'
'with rehospitalization urgent coronary revascularization','C0439609','Urgent','Urgent','false'
'with rehospitalization urgent coronary revascularization','C0877341','coronary revascularisation','coronary revascularization','false'
'with rehospitalization urgent coronary revascularization','C3272275','URGENT','Urgent Procedure','false'
'age b $nmbr$ y n $nmbr$','C0001779','AGE','Age','false'
'cv death mi stroke','C0038454','STROKE','Cerebrovascular accident','true'
'cv death mi stroke','C4554100','Stroke','Stroke, CTCAE','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C2347635','Median','Population Median','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C2348144','Median','Sample Median','false'
'bmi kg m $nmbr$ median q $nmbr$ q $nmbr$','C2939193','Median','Median (qualifier value)','false'
'gusto moderate severe bleeding','C0205081','Moderate','Moderate (severity modifier)','false'
'gusto moderate severe bleeding','C0019080','BLEEDING','Hemorrhage','true'
'gusto moderate severe bleeding','C1881878','Moderate','Moderation','false'
'gusto moderate severe bleeding','C4049705','Moderate','Moderate Extremity Pain','false'
'gusto moderate severe bleeding','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'gusto moderate severe bleeding','C4085643','Moderate','Moderate Response','false'
'gusto moderate severe bleeding','C4321335','Moderate','Moderate Level','false'
'gusto moderate bleeding ich','C0019191','ICH','Infectious Canine Hepatitis','true'
'gusto moderate bleeding ich','C3272597','ICH','ICH Temperature/Humidity Storage Condition','false'
'gusto moderate bleeding ich','C3281105','ICH','HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO','false'
'net clinical benefit cv death mi stroke gusto moderate severe bleeding','C4684590','Clinical Benefit','Clinical Benefit','false'
'net clinical benefit cv death mi stroke gusto moderate severe bleeding','C0019080','BLEEDING','Hemorrhage','true'
'thienopyridine at baseline','C1120149','thienopyridine','thienopyridine','true'
'thienopyridine at baseline','C0168634','baseline','BaseLine dental cement','true'
'thienopyridine at baseline','C1442488','Baseline','Baseline','false'
'aspirin dose at baseline mg','C4696290','Aspirin dose','Aspirin dose','false'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'secukinumab $nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'range race n','C1514721','Range','Range','false'
'range race n','C0034510','RACE','Racial group','true'
'range race n','C1706779','RACE','AMACR wt Allele','false'
'range race n','C3853635','Race','Race','false'
'range race n','C2348147','Range','Sample Range','false'
'range race n','C3542016','Range','Concept model range (foundation metadata concept)','false'
'height cm mean sd a','C0444504','Mean','Statistical mean','false'
'height cm mean sd a','C2699239','SD','SD, Rat Strain','false'
'height cm mean sd a','C2347634','Mean','Population Mean','false'
'height cm mean sd a','C2348143','Mean','Sample Mean','false'
'bmi kg m $nmbr$ mean sd a','C0022718','KG','Kyrgyzstan','true'
'bmi kg m $nmbr$ mean sd a','C0439209','kg','Kilogram','false'
'bmi kg m $nmbr$ mean sd a','C4054209','/kg','Per Kilogram','false'
'bmi kg m $nmbr$ mean sd a','C0444504','Mean','Statistical mean','false'
'bmi kg m $nmbr$ mean sd a','C2699239','SD','SD, Rat Strain','false'
'bmi kg m $nmbr$ mean sd a','C2347634','Mean','Population Mean','false'
'bmi kg m $nmbr$ mean sd a','C2348143','Mean','Sample Mean','false'
'pasi score mean sd','C0444504','Mean','Statistical mean','false'
'pasi score mean sd','C2699239','SD','SD, Rat Strain','false'
'pasi score mean sd','C2347634','Mean','Population Mean','false'
'pasi score mean sd','C2348143','Mean','Sample Mean','false'
'range iga modified $nmbr$ score n','C0392747','Modified','Changing','false'
'range iga modified $nmbr$ score n','C0449820','SCORE','Score','false'
'range iga modified $nmbr$ score n','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'range iga modified $nmbr$ score n','C3889737','Modified','Data Change Date','false'
'time since first psoriasis diagnosis y mean sd','C0040223','TIME','Time','true'
'time since first psoriasis diagnosis y mean sd','C3541383','Time','Time (foundation metadata concept)','false'
'previous exposure to systemic psoriasis therapyb yes n','C0332157','Exposure to','Exposure to','false'
'previous exposure to systemic psoriasis therapyb yes n','C0033860','PSORIASIS','Psoriasis','true'
'previous exposure to biologic systemic psoriasis therapyb yes n','C0332157','Exposure to','Exposure to','false'
'previous exposure to biologic systemic psoriasis therapyb yes n','C0005515','BIOLOGIC','Biological Factors','true'
'previous exposure to biologic systemic psoriasis therapyb yes n','C0205460','Biologic','biological','false'
'previous exposure to non biologic systemic psoriasis therapyb yes n','C0332157','Exposure to','Exposure to','false'
'previous exposure to non biologic systemic psoriasis therapyb yes n','C0005515','BIOLOGIC','Biological Factors','true'
'previous exposure to non biologic systemic psoriasis therapyb yes n','C0205460','Biologic','biological','false'
'no stroke n $nmbr$ $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'no stroke n $nmbr$ $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'stroke n $nmbr$','C0038454','STROKE','Cerebrovascular accident','true'
'stroke n $nmbr$','C4554100','Stroke','Stroke, CTCAE','false'
'age median iqr','C0001779','AGE','Age','false'
'age median iqr','C0549183','Median','Midline (qualifier value)','false'
'age median iqr','C0876920','Median','Median Statistical Measurement','false'
'age median iqr','C2347635','Median','Population Median','false'
'age median iqr','C2348144','Median','Sample Median','false'
'age median iqr','C2939193','Median','Median (qualifier value)','false'
'weight in kg median iqr','C0005910','Weight','Body Weight','true'
'weight in kg median iqr','C0043100','Weight','Weight','true'
'weight in kg median iqr','C1305866','weight','Weighing patient','false'
'weight in kg median iqr','C1705104','Weight','Importance Weight','false'
'bmi median iqr','C0578022','BMI','Finding of body mass index','false'
'bmi median iqr','C0549183','Median','Midline (qualifier value)','false'
'bmi median iqr','C0876920','Median','Median Statistical Measurement','false'
'bmi median iqr','C2347635','Median','Population Median','false'
'bmi median iqr','C2348144','Median','Sample Median','false'
'bmi median iqr','C2939193','Median','Median (qualifier value)','false'
'sbp mm hg median iqr','C0085805','SBP','Androgen Binding Protein','true'
'sbp mm hg median iqr','C0439475','mmHG','mmHg','false'
'dbp mm hg median iqr','C0536221','DBP','HSD17B4 protein, human','true'
'dbp mm hg median iqr','C0439475','mmHG','mmHg','false'
'dbp mm hg median iqr','C3813197','DBP','HSD17B4 wt Allele','false'
'dbp mm hg median iqr','C4281799','DBP','Vitamin D-Binding Protein, human','false'
'hypercholesterolemia n','C0020443','HYPERCHOLESTEROLEMIA','Hypercholesterolemia','true'
'hypercholesterolemia n','C1522133','Hypercholesterolemia','Hypercholesterolemia result','false'
'current smoking n','C0037369','SMOKING','Smoking','true'
'current smoking n','C0453996','Smoking','Tobacco smoking behavior','true'
'current smoking n','C1881674','Smoking','Medical Device Emits Smoke','false'
'cardiovascular history','C1880008','Cardiovascular History','Cardiovascular History','false'
'history of second prior mi n','C0019664','History','History','true'
'history of second prior mi n','C0019665','history','Historical aspects qualifier','true'
'history of second prior mi n','C0262512','History, NOS','History of present illness','false'
'history of second prior mi n','C0262926','History','Medical History','false'
'history of second prior mi n','C1705255','History','Concept History','false'
'history of second prior mi n','C2004062','History','History of previous events','false'
'multivessel cad n','C1504769','CAD','DFFB protein, human','true'
'multivessel cad n','C2239547','CAD','ACOD1 gene','false'
'multivessel cad n','C3813548','CAD','CALD1 wt Allele','false'
'multivessel cad n','C4284121','CAD','DFFB wt Allele','false'
'history of cabg n','C0019664','History','History','true'
'history of cabg n','C0019665','history','Historical aspects qualifier','true'
'history of cabg n','C0262512','History, NOS','History of present illness','false'
'history of cabg n','C0262926','History','Medical History','false'
'history of cabg n','C1705255','History','Concept History','false'
'history of cabg n','C2004062','History','History of previous events','false'
'history of pci n','C0019664','History','History','true'
'history of pci n','C0019665','history','Historical aspects qualifier','true'
'history of pci n','C0262512','History, NOS','History of present illness','false'
'history of pci n','C0262926','History','Medical History','false'
'history of pci n','C1705255','History','Concept History','false'
'history of pci n','C2004062','History','History of previous events','false'
'qualifying nstemi n','C1514624','Qualifying','Qualifying','false'
'qualifying nstemi n','C3537184','NSTEMI','Non-ST Elevation Myocardial Infarction by ECG Finding','false'
'qualifying nstemi n','C4255010','NSTEMI','Non-ST Elevated Myocardial Infarction','true'
'history of chf n','C0019664','History','History','true'
'history of chf n','C0019665','history','Historical aspects qualifier','true'
'history of chf n','C0262512','History, NOS','History of present illness','false'
'history of chf n','C0262926','History','Medical History','false'
'history of chf n','C1705255','History','Concept History','false'
'history of chf n','C2004062','History','History of previous events','false'
'history of atrial fibrillation n','C0729790','History of - atrial fibrillation','H/O: atrial fibrillation','false'
'history of tia n','C0019664','History','History','true'
'history of tia n','C0019665','history','Historical aspects qualifier','true'
'history of tia n','C0262512','History, NOS','History of present illness','false'
'history of tia n','C0262926','History','Medical History','false'
'history of tia n','C1705255','History','Concept History','false'
'history of tia n','C2004062','History','History of previous events','false'
'history of stroke n','C0019664','History','History','true'
'history of stroke n','C0019665','history','Historical aspects qualifier','true'
'history of stroke n','C0262512','History, NOS','History of present illness','false'
'history of stroke n','C0262926','History','Medical History','false'
'history of stroke n','C1705255','History','Concept History','false'
'history of stroke n','C2004062','History','History of previous events','false'
'medical therapies','C0418981','Medical therapies','Medical therapy','false'
'ace inhibitor n','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'ace inhibitor n','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C0024671','MG','Mammography','true'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C3887676','KM','Kathy Mercer','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C0026410','MG','Mongolia','true'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C0439269','mg%','mg/dL','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C1960952','mg %','Milligram percent','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C2346927','Mg++','Magnesium Cation','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C4321396','MG','MG','false'
'ticagrelor $nmbr$ mg $nmbr$ yr km','C4521761','MG','United States Military Commissioned Officer O8','false'
'placebo $nmbr$ yr km','C0032042','Placebo','Placebos','true'
'placebo $nmbr$ yr km','C3887676','KM','Kathy Mercer','false'
'placebo $nmbr$ yr km','C1696465','PLACEBO','placebo','false'
'placebo $nmbr$ yr km','C1706408','PLACEBO','Placebo Control','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C0024671','MG','Mammography','true'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C0026410','MG','Mongolia','true'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C0439269','mg%','mg/dL','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C1960952','mg %','Milligram percent','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C2346927','Mg++','Magnesium Cation','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C4321396','MG','MG','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C4521761','MG','United States Military Commissioned Officer O8','false'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C0008107','CI','Chile','true'
'ticagrelor $nmbr$ mg vs placebo hr $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'p interactio n','C0369773','P NOS','P Blood group antibodies','false'
'p interactio n','C2603361','P'','P prime','false'
'no renal dysfunction','C1565489','Renal dysfunction','Renal Insufficiency','true'
'no renal dysfunction','C3279454','Renal dysfunction','Renal dysfunction','false'
'renal dysfunction','C1565489','Renal dysfunction','Renal Insufficiency','true'
'renal dysfunction','C3279454','Renal dysfunction','Renal dysfunction','false'
'no history of chf','C0019664','History','History','true'
'no history of chf','C0019665','history','Historical aspects qualifier','true'
'no history of chf','C0262512','History, NOS','History of present illness','false'
'no history of chf','C0262926','History','Medical History','false'
'no history of chf','C1705255','History','Concept History','false'
'no history of chf','C2004062','History','History of previous events','false'
'no history of af','C0019664','History','History','true'
'no history of af','C0019665','history','Historical aspects qualifier','true'
'no history of af','C0262512','History, NOS','History of present illness','false'
'no history of af','C0262926','History','Medical History','false'
'no history of af','C1705255','History','Concept History','false'
'no history of af','C2004062','History','History of previous events','false'
'low dose','C0445550','Low dose','Low dose','false'
'low dose','C1708745','Low-Dose','Low-Dose Treatment','false'
'high dose','C0444956','High dose','High dose','false'
'budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$','C1276807','BUDESONIDE/FORMOTEROL','Budesonide / formoterol','false'
'budesonide formoterol $nmbr$ $nmbr$ $nmbr$ ^g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'budesonide $nmbr$ ^g n $nmbr$','C0054201','BUDESONIDE','Budesonide','true'
'budesonide $nmbr$ ^g n $nmbr$','C0439267','g%','Gram per Deciliter','false'
'budesonide formoterol $nmbr$ ^g $nmbr$ $nmbr$ ^g n $nmbr$','C1276807','BUDESONIDE/FORMOTEROL','Budesonide / formoterol','false'
'budesonide formoterol n $nmbr$','C1276807','BUDESONIDE/FORMOTEROL','Budesonide / formoterol','false'
'budesonide n $nmbr$','C0054201','BUDESONIDE','Budesonide','true'
'age yr age group no','C0027362','Age Group','Human Age Group','true'
'age yr age group no','C2348001','Age Group','Age Cohort','false'
'female sex no race no f','C0086287','FEMALE SEX','Females','true'
'female sex no race no f','C0034510','RACE','Racial group','true'
'female sex no race no f','C1706779','RACE','AMACR wt Allele','false'
'female sex no race no f','C3853635','Race','Race','false'
'female sex no race no f','C0016327','F-','Fluorides','true'
'mean time since asthma','C0040223','TIME','Time','true'
'mean time since asthma','C3541383','Time','Time (foundation metadata concept)','false'
'diagnosis yr','C0011900','DIAGNOSIS','Diagnosis','true'
'diagnosis yr','C0439234','yr','year','false'
'diagnosis yr','C1704338','diagnosis','diagnosis aspect','true'
'diagnosis yr','C1704656','DIAGNOSIS','Diagnosis Study','false'
'mean acq $nmbr$ score at randomization','C3533236','Mean score','Mean score','false'
'mean acq $nmbr$ score at randomization','C0034656','Randomization','Randomization','true'
'asthma control status at randomization no','C0004096','ASTHMA','Asthma','true'
'asthma control status at randomization no','C0449438','Status','Status','false'
'asthma control status at randomization no','C2984299','Asthma','Asthma Pathway','false'
'controlled acq $nmbr$','C2587213','Controlled','Control function','false'
'controlled acq $nmbr$','C2919686','ACQ','Asthma control questionnaire','false'
'controlled acq $nmbr$','C2911690','Controlled','Disease Controlled','false'
'uncontrolled acq $nmbr$ $nmbr$ $nmbr$','C0205318','Uncontrolled','Uncontrolled','false'
'uncontrolled acq $nmbr$ $nmbr$ $nmbr$','C2919686','ACQ','Asthma control questionnaire','false'
'exacerbations in past $nmbr$ mo no','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in past $nmbr$ mo no','C0026544','MO','Morocco','true'
'exacerbations in past $nmbr$ mo no','C0332177','/mo','Monthly (qualifier value)','false'
'daily dose of inhaled glucocorticoid no','C2348070','Daily Dose','Daily Dose','false'
'daily dose of inhaled glucocorticoid no','C0004048','Inhaled','Inspiration function','true'
'medium','C0009458','Medium','Communications Media','true'
'medium','C0439536','MEDIUM','Medium','false'
'medium','C1705217','Medium','Medium (Substance)','false'
'medium','C3244283','medium','medium exposure','false'
'medium','C4085196','Medium','Medium Growth Rate','false'
'medium','C4522282','Medium','A Medium Amount of Time','false'
'medium','C4522283','Medium','A Medium Amount','false'
'monitoring group n $nmbr$','C0150369','Monitoring','Preventive monitoring','false'
'monitoring group n $nmbr$','C0441848','Group N','Group N','false'
'monitoring group n $nmbr$','C1283169','Monitoring','Monitoring - action','false'
'body mass index kg m','C0022718','KG','Kyrgyzstan','true'
'body mass index kg m','C0439209','kg','Kilogram','false'
'body mass index kg m','C4054209','/kg','Per Kilogram','false'
'medical history and risk factors','C0262926','Medical History','Medical History','false'
'medical history and risk factors','C1704706','Medical History','Medical History Domain','false'
'medical history and risk factors','C0035648','Risk Factors','risk factors','true'
'medical history and risk factors','C1553898','risk factors','risk factors - observation list','false'
'dyslipidaemia','C0242339','Dyslipidemia','Dyslipidemias','true'
'previous cancer','C0006826','CANCER','Malignant Neoplasms','true'
'previous cancer','C0998265','Cancer','Cancer Genus','false'
'previous cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'chronic respiratory failure','C0264492','Chronic respiratory failure','Chronic respiratory failure','false'
'inflammatory disease','C1290884','Inflammatory Disease','Inflammatory disorder','false'
'previous cardiovascular events','C0205156','Previous','Previous','false'
'previous cardiovascular events','C1320716','cardiovascular events','Cardiovascular event','false'
'previous cardiovascular events','C1552607','previous','Act Relationship Subset - previous','false'
'concomitant medication after randomisation','C0013227','Medication','Pharmaceutical Preparations','true'
'concomitant medication after randomisation','C3244316','medication','medication - HL7 publishing domain','false'
'concomitant medication after randomisation','C4284232','Medication','Medications','false'
'mra spironolactone or eplerenone','C0243032','MRA','Magnetic Resonance Angiography','true'
'mra spironolactone or eplerenone','C0037982','SPIRONOLACTONE','Spironolactone','true'
'mra spironolactone or eplerenone','C1609165','MRA','tocilizumab','true'
'mra spironolactone or eplerenone','C3891069','MRA','MRI-Based Angiogram','false'
'mra spironolactone or eplerenone','C0961485','EPLERENONE','eplerenone','true'
'clinical presentation','C2708283','Clinical presentation','Clinical presentation','false'
'secondary pci','C0027627','secondary','Neoplasm Metastasis','true'
'secondary pci','C4049621','PCI','Peritoneal Cancer Index','false'
'secondary pci','C0175668','Secondary','Secondary to','false'
'secondary pci','C0205436','Secondary','second (number)','false'
'coronary angiography and intervention','C0085532','CORONARY ANGIOGRAPHY','Coronary angiography','true'
'coronary angiography and intervention','C1548829','Coronary Angiography','Consent Type - Coronary Angiography','false'
'coronary angiography and intervention','C0184661','Intervention','Interventional procedure','true'
'coronary angiography and intervention','C0886296','intervention','Nursing interventions','false'
'coronary angiography and intervention','C1273869','Intervention','Intervention regimes','false'
'radial access','C0444454','Access','Access','false'
'radial access','C1554204','access','Role Class - access','false'
'one vessel disease','C3275121','ONE VESSEL DISEASE','One Vessel Coronary Disease','false'
'two vessel disease','C0581375','TWO VESSEL DISEASE','Double coronary vessel disease','false'
'three vessel disease','C3272265','THREE VESSEL DISEASE','Three Vessel Coronary Disease','false'
'left main','C0205091','LEFT','Left','false'
'left main','C0205225','Main','Primary','false'
'left main','C1542147','Main','Main','false'
'left main','C0443246','Left','Left sided','false'
'left main','C1552822','left','Table Cell Horizontal Align - left','false'
'multivessel two vessel three vessel or left main','C0205448','Two','Two','false'
'multivessel two vessel three vessel or left main','C0005847','Vessel','Blood Vessel','true'
'multivessel two vessel three vessel or left main','C0205091','LEFT','Left','false'
'multivessel two vessel three vessel or left main','C0205225','Main','Primary','false'
'multivessel two vessel three vessel or left main','C1542147','Main','Main','false'
'multivessel two vessel three vessel or left main','C0443246','Left','Left sided','false'
'multivessel two vessel three vessel or left main','C1552822','left','Table Cell Horizontal Align - left','false'
'number of stents implanted','C0237753','*Number','Numbers','false'
'number of stents implanted','C0449788','Number','Count of entities','false'
'number of stents implanted','C0021102','Implanted','Implants','false'
'number of stents implanted','C2828363','IMPLANTED','Implanted Medical Device (finding)','false'
'drug eluting stent implanted at least one','C1322815','Drug Eluting Stent','Drug-Eluting Stents','true'
'drug eluting stent implanted at least one','C0205447','ONE','One','false'
'stented vessels','C0038257','stented','Stent, device','true'
'stented vessels','C0005847','Vessels','Blood Vessel','true'
'left main artery','C0205091','LEFT','Left','false'
'left main artery','C0003842','ARTERY','Arteries','true'
'left main artery','C0226004','artery','Arterial system','false'
'left main artery','C0443246','Left','Left sided','false'
'left main artery','C1552822','left','Table Cell Horizontal Align - left','false'
'left anterior descending coronary artery','C0226032','Left Anterior Descending Coronary Artery','Anterior descending branch of left coronary artery','false'
'left circumflex coronary artery','C0226037','LEFT CIRCUMFLEX CORONARY ARTERY','Structure of circumflex branch of left coronary artery','false'
'right coronary artery','C1261316','Right Coronary Artery','Right coronary artery structure','false'
'coronary bypass graft','C1260596','Coronary bypass graft','coronary artery graft device','false'
'creatinine clearance at admission ml min','C0184666','Admission','Hospital admission','false'
'creatinine clearance at admission ml min','C0151280','Creatinine clearance, ml/min','Creatinine clearance, ml/min','false'
'creatinine clearance at admission ml min','C0809949','Admission','Admission activity','false'
'haemoglobin g dl','C0439267','g/dL','Gram per Deciliter','false'
'monitoring treatment','C0039798','treatment','therapeutic aspects','true'
'monitoring treatment','C0087111','Treatment','Therapeutic procedure','true'
'monitoring treatment','C1522326','Treatment','Treating','false'
'monitoring treatment','C1533734','Treatment','Administration procedure','false'
'monitoring treatment','C1705169','Treatment','Biomaterial Treatment','false'
'monitoring treatment','C3538994','TREATMENT','Treatment Epoch','false'
'monitoring treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'conventional treatment','C2945704','Conventional Treatment','Conventional Treatment','false'
'full population','C0032659','Population','geographic population','true'
'full population','C1257890','Population','Population Group','true'
't $nmbr$','C2603360','T'','T prime','false'
'weight $nmbr$ kg','C0022718','KG','Kyrgyzstan','true'
'weight $nmbr$ kg','C0439209','kg','Kilogram','false'
'weight $nmbr$ kg','C4054209','/kg','Per Kilogram','false'
'no hypertension','C0020538','HYPERTENSION','Hypertensive disease','true'
'no hypertension','C1963138','Hypertension','Hypertension, CTCAE','false'
'no current smoking','C0037369','SMOKING','Smoking','true'
'no current smoking','C0453996','Smoking','Tobacco smoking behavior','true'
'no current smoking','C1881674','Smoking','Medical Device Emits Smoke','false'
'st','C0036056','ST','Saint Lucia','true'
'st','C3272372','ST','Character String Data Type','false'
'creat clearance','C0449297','Clearance','Clearance','false'
'creat clearance','C1382187','Clearance','Clearance of substance','false'
'creat clearance','C2825073','Clearance','Clearance [PK]','false'
'creat clearance','C4554548','Clearance','Clearance procedure','false'
'creat clearance $nmbr$ ml min','C0201975','CREAT','Creatinine measurement','false'
'creat clearance $nmbr$ ml min','C0439445','mL/min','mL/min','false'
'no prior cancer','C0006826','CANCER','Malignant Neoplasms','true'
'no prior cancer','C0998265','Cancer','Cancer Genus','false'
'no prior cancer','C1306459','Cancer','Primary malignant neoplasm','false'
'no prior heart failure','C0018801','Failure, Heart','Heart failure','true'
'no prior heart failure','C0018802','Heart Failure','Congestive heart failure','true'
'no prior heart failure','C4554158','Heart failure','Heart Failure, CTCAE','false'
'one vessel','C0205447','ONE','One','false'
'one vessel','C0005847','Vessel','Blood Vessel','true'
'multi vessel or left main','C0439064','Multi','Numerous','false'
'multi vessel or left main','C0005847','Vessel','Blood Vessel','true'
'multi vessel or left main','C3266262','Multi','Multiple Chronic Conditions','true'
'multi vessel or left main','C0205091','LEFT','Left','false'
'multi vessel or left main','C0205225','Main','Primary','false'
'multi vessel or left main','C1542147','Main','Main','false'
'multi vessel or left main','C0443246','Left','Left sided','false'
'multi vessel or left main','C1552822','left','Table Cell Horizontal Align - left','false'
'des','C0011702','Des','Desmosine','true'
'des','C4551552','DES','Cerebellar Ataxia, Mental Retardation, And Dysequilibrium Syndrome 1','true'
'length of stent median','C0449462','Length of stent','Length of stent','false'
'length of stent median','C0549183','Median','Midline (qualifier value)','false'
'length of stent median','C0876920','Median','Median Statistical Measurement','false'
'length of stent median','C2347635','Median','Population Median','false'
'length of stent median','C2348144','Median','Sample Median','false'
'length of stent median','C2939193','Median','Median (qualifier value)','false'
'number of stent l or $nmbr$ or $nmbr$','C0237753','*Number','Numbers','false'
'number of stent l or $nmbr$ or $nmbr$','C0449788','Number','Count of entities','false'
'number stent $nmbr$','C0237753','*Number','Numbers','false'
'number stent $nmbr$','C0038257','Stent','Stent, device','true'
'number stent $nmbr$','C0449788','Number','Count of entities','false'
'roflumilast n $nmbr$ $nmbr$','C0965618','ROFLUMILAST','Roflumilast','true'
'age mean sd yr','C0001779','AGE','Age','false'
'age mean sd yr','C0439234','yr','year','false'
'total cigarette pack years mean sd','C1303175','Cigarette pack-years','Cigarette pack-years','false'
'total cigarette pack years mean sd','C2699239','SD','SD, Rat Strain','false'
'very severe','C3641272','Very severe','Very severe','false'
'very severe','C4050419','Very severe','Borg Category-Ratio 10 Perceived Exertion Score 7','false'
'copd duration mean sd yr','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'copd duration mean sd yr','C0439234','yr','year','false'
'copd duration mean sd yr','C1412502','COPD','ARCN1 gene','false'
'copd duration mean sd yr','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'prebronchodilator fev $nmbr$ mean sd l','C0444504','Mean','Statistical mean','false'
'prebronchodilator fev $nmbr$ mean sd l','C2347634','Mean','Population Mean','false'
'prebronchodilator fev $nmbr$ mean sd l','C2348143','Mean','Sample Mean','false'
'post bronchodilator fev $nmbr$ mean sd l','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ mean sd l','C0444504','Mean','Statistical mean','false'
'post bronchodilator fev $nmbr$ mean sd l','C2347634','Mean','Population Mean','false'
'post bronchodilator fev $nmbr$ mean sd l','C2348143','Mean','Sample Mean','false'
'predicted prebronchodilator fev $nmbr$ mean sd l','C0681842','Predicted','prediction','false'
'predicted prebronchodilator fev $nmbr$ mean sd l','C0444504','Mean','Statistical mean','false'
'predicted prebronchodilator fev $nmbr$ mean sd l','C2347634','Mean','Population Mean','false'
'predicted prebronchodilator fev $nmbr$ mean sd l','C2348143','Mean','Sample Mean','false'
'predicted prebronchodilator fev $nmbr$ mean sd l','C1882327','%{Predicted}','Percent of Predicted Value','false'
'predicted post bronchodilator fev $nmbr$ mean sd l','C2599594','Post-bronchodilator','post bronchodilator','false'
'predicted post bronchodilator fev $nmbr$ mean sd l','C0444504','Mean','Statistical mean','false'
'predicted post bronchodilator fev $nmbr$ mean sd l','C2347634','Mean','Population Mean','false'
'predicted post bronchodilator fev $nmbr$ mean sd l','C2348143','Mean','Sample Mean','false'
'post bronchodilator fev $nmbr$ fvc ratio mean sd','C2599594','Post-bronchodilator','post bronchodilator','false'
'post bronchodilator fev $nmbr$ fvc ratio mean sd','C2699239','SD','SD, Rat Strain','false'
'no of moderate or severe exacerbations in previous','C0205081','Moderate','Moderate (severity modifier)','false'
'no of moderate or severe exacerbations in previous','C1881878','Moderate','Moderation','false'
'no of moderate or severe exacerbations in previous','C4049705','Moderate','Moderate Extremity Pain','false'
'no of moderate or severe exacerbations in previous','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'no of moderate or severe exacerbations in previous','C4085643','Moderate','Moderate Response','false'
'no of moderate or severe exacerbations in previous','C4321335','Moderate','Moderate Level','false'
'no of moderate or severe exacerbations in previous','C0205082','Severe','Severe (severity modifier)','false'
'no of moderate or severe exacerbations in previous','C4086268','EXACERBATION','Exacerbation','false'
'no of moderate or severe exacerbations in previous','C4050465','Severe','Severe Extremity Pain','false'
'no of moderate or severe exacerbations in previous','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'$nmbr$ mo mean sd x','C0026544','MO','Morocco','true'
'$nmbr$ mo mean sd x','C0332177','/mo','Monthly (qualifier value)','false'
'year n','C0439234','Year','year','false'
'year n','C0439508','/Year','per year','false'
'prior hospitalizations n','C0332152','Prior','Before','false'
'prior hospitalizations n','C0019993','Hospitalizations','Hospitalization','true'
'prior hospitalizations n','C2826257','PRIOR','Prior Medication Usage','false'
'cat score mean sd','C0007450','CAT','Felis catus','true'
'cat score mean sd','C2699239','SD','SD, Rat Strain','false'
'cat score mean sd','C0325090','Cat','Felis silvestris','false'
'cat score mean sd','C0524517','Cat','Genus Felis','true'
'cat score mean sd','C1443200','Cat','Cat hair antigen','false'
'cat score mean sd','C3665481','Cat','Cat (organism)','false'
'cat score mean sd','C4050461','CAT','Cutaneous Assessment Tool','false'
'cat score mean sd','C4284282','CAT','COPD Assessment Test Questionnaire','false'
'exact pro total score mean sd','C2964552','Total Score','Total score','false'
'exact pro total score mean sd','C2699239','SD','SD, Rat Strain','false'
'ics laba therapy n','C0039798','therapy','therapeutic aspects','true'
'ics laba therapy n','C0087111','Therapy','Therapeutic procedure','true'
'ics laba therapy n','C1363945','Therapy','Therapy Object (animal model)','false'
'fluticasone propionate salmeterol fdc','C0340427','FDC','Familial dilated cardiomyopathy','true'
'fluticasone propionate salmeterol fdc','C1413520','FDC','CMD1B gene','false'
'fluticasone propionate salmeterol fdc','C3539652','FDC','LAG3 wt Allele','false'
'budesonide formoterol fdc','C0340427','FDC','Familial dilated cardiomyopathy','true'
'budesonide formoterol fdc','C1413520','FDC','CMD1B gene','false'
'budesonide formoterol fdc','C3539652','FDC','LAG3 wt Allele','false'
'lama use n','C0042153','use','utilization qualifier','true'
'lama use n','C0457083','Use','Usage','false'
'lama use n','C1947944','Use','Use - dosing instruction imperative','false'
'brv $nmbr$ mg day','C0155502','BRV','Benign Paroxysmal Positional Vertigo','true'
'brv $nmbr$ mg day','C0439422','mg day','milligram/day','false'
'brv overall','C0155502','BRV','Benign Paroxysmal Positional Vertigo','true'
'brv overall','C0282416','Overall','Overall Publication Type','true'
'brv overall','C1561607','Overall','Overall','false'
'mean bmi sd kg m $nmbr$','C0022718','KG','Kyrgyzstan','true'
'mean bmi sd kg m $nmbr$','C0439209','kg','Kilogram','false'
'mean bmi sd kg m $nmbr$','C4054209','/kg','Per Kilogram','false'
'etiology n','C0015127','etiology','Etiology aspects','true'
'etiology n','C1314792','Etiology','Etiology','true'
'etiology n','C1524003','Etiology','Science of Etiology','false'
'cryptogenic','C0332240','Cryptogenic','Unknown (origin) (qualifier value)','false'
'mean sd [range] duration of epilepsy years','C0444504','Mean','Statistical mean','false'
'mean sd [range] duration of epilepsy years','C2699239','SD','SD, Rat Strain','false'
'mean sd [range] duration of epilepsy years','C2347634','Mean','Population Mean','false'
'mean sd [range] duration of epilepsy years','C2348143','Mean','Sample Mean','false'
'mean sd [range] duration of epilepsy years','C1514721','Range','Range','false'
'mean sd [range] duration of epilepsy years','C2348147','Range','Sample Range','false'
'mean sd [range] duration of epilepsy years','C3542016','Range','Concept model range (foundation metadata concept)','false'
'mean sd [range] duration of epilepsy years','C0449238','Duration','Duration (temporal concept)','false'
'mean sd [range] duration of epilepsy years','C2926735','Duration','Duration','false'
'median minimum maximum focal seizure frequency $nmbr$ days at baseline','C0149775','SEIZURE FREQUENCY','Fit frequency','false'
'median minimum maximum focal seizure frequency $nmbr$ days at baseline','C0439228','DAYS','day','false'
'number of prior aeds n','C0237753','*Number','Numbers','false'
'number of prior aeds n','C0449788','Number','Count of entities','false'
'prior lev treatment n','C1514463','Prior Treatment','Prior Therapy','false'
'prior lev treatment n','C0023556','LEV','Levamisole','true'
'concomitant aedsb n','C0521115','Concomitant','Simultaneous','false'
'oxcarbazepine','C0069751','OXCARBAZEPINE','oxcarbazepine','true'
'carbamazepine','C0006949','Carbamazepin','Carbamazepine','true'
'carbamazepine','C0006950','Carbamazepine','Carbamazepine measurement','false'
'carbamazepine','C0682993','carbamazepin','carbamazepin (benzodiazepine)','false'
'lamotrigine','C0064636','LAMOTRIGINE','lamotrigine','true'
'lamotrigine','C0524166','lamotrigine','Lamotrigine measurement','false'
'lacosamide','C0893761','LACOSAMIDE','lacosamide','true'
'teaes leading to discontinuation of study drug','C0332152','Leading','Before','false'
'teaes leading to discontinuation of study drug','C0013175','study drug','Drug Evaluation','true'
'teaes leading to discontinuation of study drug','C1522538','Leading','Leading','false'
'drug related teaes','C0013227','Drug','Pharmaceutical Preparations','true'
'drug related teaes','C0439849','Related','Relationships','false'
'drug related teaes','C0445223','Related','Related personal status','false'
'drug related teaes','C1254351','DRUG','Pharmacologic Substance','false'
'saes','C1519255','SAE','Serious Adverse Event','false'
'saes','C1622657','SAE','SUMO activating enzyme complex','false'
'saes','C4553214','SAE','Serious Adverse Experience','false'
'drug related saes','C1519255','SAE','Serious Adverse Event','false'
'drug related saes','C1622657','SAE','SUMO activating enzyme complex','false'
'drug related saes','C4553214','SAE','Serious Adverse Experience','false'
'deaths','C0011065','deaths','Cessation of life','true'
'deaths','C1306577','DEATHS','Death (finding)','false'
'teaes reported by $nmbr$ patients in the overall brv group n','C1709908','Reported By','Reported By','false'
'teaes reported by $nmbr$ patients in the overall brv group n','C0155502','BRV','Benign Paroxysmal Positional Vertigo','true'
'teaes reported by $nmbr$ patients in the overall brv group n','C0441848','Group N','Group N','false'
'paresthesia','C0030554','parasthesia','Paresthesia','true'
'paresthesia','C4553220','Paresthesia','Paresthesia, CTCAE','false'
'somnolence','C0013144','Somnolence','Drowsiness','false'
'somnolence','C2830004','SOMNOLENCE','Somnolence','true'
'somnolence','C4553740','Somnolence','Somnolence, CTCAE','false'
'cataract','C0086543','CATARACT','Cataract','true'
'cataract','C4555209','Cataract','Cataract, CTCAE 5.0','false'
'constipation','C0009806','CONSTIPATION','Constipation','true'
'constipation','C1963087','Constipation','Constipation, CTCAE','false'
'constipation','C3641755','Constipation','Have Constipation','false'
'constipation','C4084722','Constipation','How Often Constipation','false'
'constipation','C4084723','Constipation','How Much Distress Constipation','false'
'constipation','C4084724','Constipation','Usual Severity Constipation','false'
'convulsion','C0036572','CONVULSION (NOS)','Seizures','true'
'convulsion','C4048158','Convulsion','Convulsions','true'
'cystitis','C0010692','CYSTITIS','Cystitis','true'
'cystitis','C0600041','Cystitis','Infective cystitis','false'
'cystitis','C1963088','Cystitis','Cystitis, CTCAE 3','false'
'hyponatremia','C0020625','HYPONATREMIA','Hyponatremia','true'
'hyponatremia','C4553967','Hyponatremia','Hyponatremia, CTCAE','false'
'hot climate subset','C0178683','hot climate','hot climate','false'
'hot climate subset','C1515021','Subset','Subgroup','false'
'other climate subset','C0008946','Climate','Climate','true'
'other climate subset','C1515021','Subset','Subgroup','false'
'sex n b','C0009253','Sex','Coitus','true'
'sex n b','C0036864','Sex','Sex Behavior','true'
'sex n b','C0079399','sex','Gender','true'
'sex n b','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'sex n b','C1314687','Sex','Sexual intercourse - finding','false'
'sex n b','C1522384','SEX','sex','true'
'race n b','C0034510','RACE','Racial group','true'
'race n b','C1706779','RACE','AMACR wt Allele','false'
'race n b','C3853635','Race','Race','false'
'duration of t $nmbr$ dm years','C0449238','Duration','Duration (temporal concept)','false'
'duration of t $nmbr$ dm years','C2926735','Duration','Duration','false'
'high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$','C0815320','ICS','Impaired Control Scale','false'
'high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'high dosage ics plus laba with baseline blood eosinophils a $nmbr$ cells per pl n $nmbr$','C0005773','Blood Cells','Blood Cells','true'
'high dosage ics plus laba with baseline blood eosinophils','C0815320','ICS','Impaired Control Scale','false'
'high dosage ics plus laba with baseline blood eosinophils','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'high dosage ics plus laba with baseline blood eosinophils','C0168634','baseline','BaseLine dental cement','true'
'high dosage ics plus laba with baseline blood eosinophils','C0014467','blood eosinophils','eosinophil','true'
'high dosage ics plus laba with baseline blood eosinophils','C1442488','Baseline','Baseline','false'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C0024671','MG','Mammography','true'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C0026410','MG','Mongolia','true'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C0439269','mg%','mg/dL','false'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C1960952','mg %','Milligram percent','false'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C4321396','MG','MG','false'
'benralizumab $nmbr$ mg q $nmbr$ w n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'age group years','C1510829','Age-Years','Age-Years','false'
'body mass index kg m $nmbr$ t','C0005893','Body mass index','Body mass index procedure','false'
'body mass index kg m $nmbr$ t','C1532718','kg-m','kg-m','false'
'body mass index kg m $nmbr$ t','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index kg m $nmbr$ t','C1305855','BODY MASS INDEX','Body mass index','true'
'local eosinophil count cells per pl t','C0007584','Cell Count','Cell Count','true'
'central eosinophil count cells per pl t','C0007584','Cell Count','Cell Count','true'
'prebronchodilator fev $nmbr$ l t','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'prebronchodilator fev $nmbr$ l t','C3714541','FEV','Forced Vital Capacity','true'
'prebronchodilator fev $nmbr$ predicted normal t','C0520835','FEV normal','FEV normal','false'
'prebronchodilator fev $nmbr$ predicted normal t','C0681842','Predicted','prediction','false'
'prebronchodilator fev $nmbr$ predicted normal t','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fev $nmbr$ fvc prebronchodilatort','C3714541','FEV','Forced Vital Capacity','true'
'reversibility t','C0449261','Reversibility','Reversibility','false'
'acq $nmbr$ score','C0449820','SCORE','Score','false'
'acq $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'time since asthma diagnosis years','C0556970','time year','times/year','false'
'time since asthma diagnosis years','C0004096','ASTHMA','Asthma','true'
'time since asthma diagnosis years','C2984299','Asthma','Asthma Pathway','false'
'number of exacerbations in the past $nmbr$ months','C0237753','*Number','Numbers','false'
'number of exacerbations in the past $nmbr$ months','C0449788','Number','Count of entities','false'
'number of exacerbations in the past $nmbr$ months','C0439231','MONTHS','month','false'
'number resulting in emergency department visit','C0237753','*Number','Numbers','false'
'number resulting in emergency department visit','C0449788','Number','Count of entities','false'
'number resulting in emergency department visit','C0332294','Resulting in','Resulting in','false'
'number resulting in emergency department visit','C0562508','Emergency Department','Accident and Emergency department','true'
'patients with $nmbr$ exacerbations resulting in emergency department visit','C0030705','Patients','Patients','true'
'patients with $nmbr$ exacerbations resulting in emergency department visit','C4086268','EXACERBATION','Exacerbation','false'
'patients with $nmbr$ exacerbations resulting in emergency department visit','C0332294','Resulting in','Resulting in','false'
'patients with $nmbr$ exacerbations resulting in emergency department visit','C0562508','Emergency Department','Accident and Emergency department','true'
'number resulting in hospital admission','C0237753','*Number','Numbers','false'
'number resulting in hospital admission','C0449788','Number','Count of entities','false'
'number resulting in hospital admission','C0184666','admission In Hospital','Hospital admission','false'
'patients with $nmbr$ exacerbations resulting in hospital admission','C0030705','Patients','Patients','true'
'patients with $nmbr$ exacerbations resulting in hospital admission','C4086268','EXACERBATION','Exacerbation','false'
'patients with $nmbr$ exacerbations resulting in hospital admission','C0184666','admission In Hospital','Hospital admission','false'
'total asthma symptom score','C3533163','Total symptom score','Total symptom score','false'
'total asthma symptom score','C0004096','ASTHMA','Asthma','true'
'total asthma symptom score','C2984299','Asthma','Asthma Pathway','false'
'diagnosis of allergic rhinitis','C0011900','DIAGNOSIS','Diagnosis','true'
'diagnosis of allergic rhinitis','C1704338','diagnosis','diagnosis aspect','true'
'diagnosis of allergic rhinitis','C1704656','DIAGNOSIS','Diagnosis Study','false'
'nasal polyps','C0027430','Nasal Polyps','Nasal Polyps','true'
'atopic based on phadiatop test','C0392707','atopic','Atopy','false'
'atopic based on phadiatop test','C1527178','Based','Basis - conceptual entity','false'
'atopic based on phadiatop test','C1705938','Based','Base - General Qualifier','false'
'history of omalizumab treatment','C0019664','History','History','true'
'history of omalizumab treatment','C0019665','history','Historical aspects qualifier','true'
'history of omalizumab treatment','C0262512','History, NOS','History of present illness','false'
'history of omalizumab treatment','C0262926','History','Medical History','false'
'history of omalizumab treatment','C1705255','History','Concept History','false'
'history of omalizumab treatment','C2004062','History','History of previous events','false'
'aqlq s $nmbr$ scorets','C4055434','AQLQ','Asthma Quality of Life Questionnaire','false'
'smoking pack year years fl','C1300812','FL','Femur length','false'
'smoking pack year years fl','C1708024','FL','FLT3LG wt Allele','false'
'empty','C1880497','Empty','Empty (qualifier)','false'
'b benralizumab $nmbr$ mg q $nmbr$ w','C0024671','MG','Mammography','true'
'b benralizumab $nmbr$ mg q $nmbr$ w','C0026410','MG','Mongolia','true'
'b benralizumab $nmbr$ mg q $nmbr$ w','C0439269','mg%','mg/dL','false'
'b benralizumab $nmbr$ mg q $nmbr$ w','C1960952','mg %','Milligram percent','false'
'b benralizumab $nmbr$ mg q $nmbr$ w','C2346927','Mg++','Magnesium Cation','false'
'b benralizumab $nmbr$ mg q $nmbr$ w','C4321396','MG','MG','false'
'b benralizumab $nmbr$ mg q $nmbr$ w','C4521761','MG','United States Military Commissioned Officer O8','false'
'estimate $nmbr$ ci','C0008107','CI','Chile','true'
'estimate $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'baseline ocs use yes','C1549445','Yes','Yes - Yes/no indicator','false'
'baseline ocs use yes','C1705108','YES','Yes (indicator)','false'
'baseline ocs use yes','C1710701','Yes','YES1 wt Allele','false'
'age groiro','C0001779','AGE','Age','false'
'geo graphic region asia','C0017446','Region','Geographic Locations','true'
'geo graphic region asia','C0003980','Asia','Asia','true'
'geo graphic region asia','C0205147','Region','regional','false'
'$nmbr$ kg nr','C0027496','NR','Nauru','true'
'$nmbr$ kg nr','C3844738','NR','No Response - Disease Response','false'
'exacerbations in the prev year $nmbr$','C4086268','EXACERBATION','Exacerbation','false'
'exacerbations in the prev year $nmbr$','C0439234','Year','year','false'
'exacerbations in the prev year $nmbr$','C0439508','/Year','per year','false'
'nasal polyps at baseline yes','C0027430','Nasal Polyps','Nasal Polyps','true'
'nasal polyps at baseline yes','C0168634','baseline','BaseLine dental cement','true'
'nasal polyps at baseline yes','C1442488','Baseline','Baseline','false'
'iee at baseline','C0168634','baseline','BaseLine dental cement','true'
'iee at baseline','C1442488','Baseline','Baseline','false'
'$nmbr$ iu l','C0439457','IU/L','International Unit per Liter','false'
'atopic at baseline yes','C0392707','atopic','Atopy','false'
'atopic at baseline yes','C0168634','baseline','BaseLine dental cement','true'
'atopic at baseline yes','C1442488','Baseline','Baseline','false'
'prior therapy with omalizumab yes','C1514463','Prior Therapy','Prior Therapy','false'
'prior therapy with omalizumab yes','C0966225','OMALIZUMAB','omalizumab','true'
'high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$','C0815320','ICS','Impaired Control Scale','false'
'high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$','C4551720','ICS','Primary Ciliary Dyskinesia','true'
'high dosage ics plus laba with baseline blood eosinophils $nmbr$ cells per pl n $nmbr$','C0005773','Blood Cells','Blood Cells','true'
'eosinophil count cells per pl','C0007584','Cell Count','Cell Count','true'
'central eosinophil count cells per pl','C0007584','Cell Count','Cell Count','true'
'prebronchodilator fev $nmbr$ l','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'prebronchodilator fev $nmbr$ l','C3714541','FEV','Forced Vital Capacity','true'
'predicted normal','C0205307','NORMAL','Normal','false'
'predicted normal','C0231683','Normal','Gait normal','false'
'predicted normal','C0439166','% normal','Percent normal','false'
'predicted normal','C2347086','% Normal','Mean Percent of Normal','false'
'predicted normal','C4553972','Normal','How Often Felt Normal question','false'
'prebronchodilator fev $nmbr$ fvc','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'prebronchodilator fev $nmbr$ fvc','C3714541','FVC','Forced Vital Capacity','true'
'acq $nmbr$ scoret','C2919686','ACQ','Asthma control questionnaire','false'
'number resulting in ed visit','C0237753','*Number','Numbers','false'
'number resulting in ed visit','C0449788','Number','Count of entities','false'
'number resulting in ed visit','C0332294','Resulting in','Resulting in','false'
'patients with $nmbr$ exacerbations resulting in ed visit','C0030705','Patients','Patients','true'
'patients with $nmbr$ exacerbations resulting in ed visit','C4086268','EXACERBATION','Exacerbation','false'
'patients with $nmbr$ exacerbations resulting in ed visit','C0332294','Resulting in','Resulting in','false'
'aqlq s $nmbr$ scored','C4055434','AQLQ','Asthma Quality of Life Questionnaire','false'
'aqlq s $nmbr$ scored','C0449820','scored','Score','false'
'nicotine pack years','C0028040','NICOTINE','Nicotine','true'
'nicotine pack years','C1277691','Pack years','Pack years','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C0871208','Rate','Rating (action)','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C0456603','RATIO','Ratio','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1547037','Ratio','data type - ratio','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1521828','Rate','Rate','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1079230','subgroup','Subgroup A Nepoviruses','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1515021','Subgroup','Subgroup','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C0032042','Placebo','Placebos','true'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1696465','PLACEBO','placebo','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1706408','PLACEBO','Placebo Control','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C2982078','BENRALIZUMAB','benralizumab','true'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C1514756','RECEIVING','Receive','false'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C0014467','blood eosinophils','eosinophil','true'
'appendix $nmbr$ figure $nmbr$ annual asthma exacerbation rate ratio at $nmbr$ weeks by subgroup for a benralizumab q $nmbr$ w vs placebo and b benralizumab q $nmbr$ w vs placebo for patients receiving high dosage ics laba with blood eosinophils $nmbr$ cells l','C0347983','Cells/L','cells/L','false'
'at increased fall risk n $nmbr$','C4699158','Increased risk','Increased risk','false'
'notatincreased fall risk n $nmbr$ $nmbr$','C1268740','Fall risk','At risk for falls','false'
'randomization group','C0441833','Group','Groups','false'
'randomization group','C0687744','group','Social group','false'
'randomization group','C1257890','Group','Population Group','true'
'randomization group','C1519504','Group','Stage Grouping','false'
'randomization group','C1705428','Group','Group Object','false'
'randomization group','C1705429','Group','User Group','false'
'higher dose edoxaban regimen','C2348331','Dose Regimen','Dose Regimen','false'
'lower dose edoxaban regimen','C2348331','Dose Regimen','Dose Regimen','false'
'age $nmbr$ yrs','C0001779','AGE','Age','false'
'has bled score','C0449820','SCORE','Score','false'
'has bled score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'history of stroke or tia','C0019664','History','History','true'
'history of stroke or tia','C0019665','history','Historical aspects qualifier','true'
'history of stroke or tia','C0262512','History, NOS','History of present illness','false'
'history of stroke or tia','C0262926','History','Medical History','false'
'history of stroke or tia','C1705255','History','Concept History','false'
'history of stroke or tia','C2004062','History','History of previous events','false'
'history of stroke or tia','C0007787','TIA','Transient Ischemic Attack','true'
'history of stroke or tia','C0917805','TIA','Transient Cerebral Ischemia','true'
'history of stroke or tia','C1054154','tia','Tacca leontopetaloides','false'
'crcl at randomization ml min','C1846718','CRCL','CREATININE CLEARANCE QUANTITATIVE TRAIT LOCUS','false'
'crcl at randomization ml min','C0439445','mL/min','mL/min','false'
'aspirin use at randomization','C0042153','use','utilization qualifier','true'
'aspirin use at randomization','C0457083','Use','Usage','false'
'aspirin use at randomization','C1947944','Use','Use - dosing instruction imperative','false'
'dose reduced at randomization','C0178602','DOSE','Dosage','false'
'dose reduced at randomization','C0869039','Dose','Unit dose','false'
'dose reduced at randomization','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'dose reduced at randomization','C0392756','Reduced','Reduced','false'
'dose reduced at randomization','C0034656','Randomization','Randomization','true'
'ttr warfarin arm only','C0446516','ARM','Upper arm','true'
'ttr warfarin arm only','C3715044','ARM','AKR1A1 wt Allele','false'
'ttr warfarin arm only','C4553528','arm','Sequence Arm','false'
'charlson comorbidity index','C4546361','Charlson Comorbidity Index','Charlson Comorbidity Index','false'
'increased risk for falls','C4699158','Increased risk','Increased risk','false'
'no increased risk for falls','C4699158','Increased risk','Increased risk','false'
'bone fracture','C0016658','BONE FRACTURE','Fracture','true'
'bone fracture due to fall','C0016658','BONE FRACTURE','Fracture','true'
'bone fracture due to fall','C0678226','Due To','Due to','false'
'malignancy death','C0011065','DEATH','Cessation of life','true'
'malignancy death','C1306577','Death','Death (finding)','false'
'malignancy death','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'malignancy death','C4552775','Death NOS','Death NOS, CTCAE','false'
'net ep $nmbr$','C1880476','EP','Etoposide-Platinol Regimen','false'
'net ep $nmbr$','C4321526','EP','EP -- route of administration','false'
'major crnm bleed','C0205082','Major','Severe (severity modifier)','false'
'major crnm bleed','C0019080','bleed','Hemorrhage','true'
'major crnm bleed','C0205164','Major','Major','false'
'major crnm bleed','C4318856','Major','Major <insect>','false'
'major crnm bleed','C4521762','Major','United States Military Commissioned Officer O4','false'
'death or ich','C0011065','DEATH','Cessation of life','true'
'death or ich','C1306577','Death','Death (finding)','false'
'death or ich','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'death or ich','C4552775','Death NOS','Death NOS, CTCAE','false'
'death or ich','C0019191','ICH','Infectious Canine Hepatitis','true'
'death or ich','C3272597','ICH','ICH Temperature/Humidity Storage Condition','false'
'death or ich','C3281105','ICH','HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO','false'
'abaloparatide sc n','C4042342','ABALOPARATIDE','abaloparatide','true'
'abaloparatide sc n','C0282380','SC','Saint Kitts and Nevis','true'
't score categories lumbar spineb','C3854607','T-Score','T-Score','false'
'total hipc','C0439175','% total','% of total','false'
'total hipc','C0439810','Total','Total','false'
'femoral neckc','C0015811','Femoral','Femur','true'
'fracture status prevalent vertebral fractured','C0016658','FRACTURE','Fracture','true'
'fracture status prevalent vertebral fractured','C0549207','Vertebral','Bone structure of spine','true'
'fracture status prevalent vertebral fractured','C4554413','Fractured','Fractured','false'
'prior nonvertebral fracture','C0332152','Prior','Before','false'
'prior nonvertebral fracture','C0016658','FRACTURE','Fracture','true'
'prior nonvertebral fracture','C2826257','PRIOR','Prior Medication Usage','false'
'age categories','C2916832','Age Categories','Age Categories [Disease/Finding]','false'
'abl sc n n','C0023139','ABL','lauric acid','true'
'abl sc n n','C0282380','SC','Saint Kitts and Nevis','true'
'abl sc n n','C1704928','ABL','ABL1 wt Allele','false'
'abl sc n n','C3890208','ABL','MTTP wt Allele','false'
'\bl sc n n','C0439394','l's','liter/second','false'
'\bl sc n n','C0282380','SC','Saint Kitts and Nevis','true'
'\bl sc n n','C1706495','L-','upper case letter ell','false'
'\bl sc n n','C3642217','/L','Per Liter','false'
'interaction j $nmbr$ valuet','C1704675','Interaction','Interaction','false'
'lumbar spine bmd t','C0024091','Lumbar spine','Bone structure of lumbar vertebra','true'
'lumbar spine bmd t','C3887615','LUMBAR SPINE','Lumbar spine structure','false'
'score','C0449820','SCORE','Score','false'
'score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'total hip bmi t score','C2964552','Total Score','Total score','false'
'total hip bmi t score','C0019552','HIP','Hip structure','true'
'total hip bmi t score','C0022122','Hip','Bone structure of ischium','true'
'total hip bmi t score','C1505163','HIP','HHIP protein, human','true'
'total hip bmi t score','C3538851','HIP','REG3A wt Allele','false'
'total hip bmi t score','C4284725','HIP','HHIP wt Allele','false'
'placebo mean','C0444504','Mean','Statistical mean','false'
'placebo mean','C2347634','Mean','Population Mean','false'
'placebo mean','C2348143','Mean','Sample Mean','false'
'abl sc mean','C0444504','Mean','Statistical mean','false'
'abl sc mean','C2347634','Mean','Population Mean','false'
'abl sc mean','C2348143','Mean','Sample Mean','false'
'least squares mean difference $nmbr$ ci','C0008107','CI','Chile','true'
'least squares mean difference $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'interaction p valuef','C1704675','Interaction','Interaction','false'
'o os','C2673162',''O'os','Moho (bird)','false'
'lavolta ii','C1710602','II','VIPR1 wt Allele','false'
'lavolta ii','C4082587','Ii','HLA Class II Histocompatibility Antigen Gamma Chain, human','false'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'lebrikizumab $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'lebrikizumab $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'lebrikizumab $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'lebrikizumab $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'lebrikizumab $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'lebrikizumab $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'lebrikizumab $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'lebrikizumab $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'body mass index kg mq','C0005893','Body mass index','Body mass index procedure','false'
'body mass index kg mq','C0024853','MQ','Martinique','true'
'body mass index kg mq','C0578022','Body Mass Index','Finding of body mass index','false'
'body mass index kg mq','C1305855','BODY MASS INDEX','Body mass index','true'
'median range duration of asthma years','C0449238','Duration','Duration (temporal concept)','false'
'median range duration of asthma years','C2926735','Duration','Duration','false'
'baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba','C2827928','pg/day','Picogram per Day','false'
'baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba','C0117996','FLUTICASONE PROPIONATE','Fluticasone propionate','true'
'baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba','C0205163','Equivalent','Equal','false'
'baseline ics $nmbr$ pg per day fluticasone propionate dpi or equivalent and laba','C0439185','equivalent','Equivalent Weight','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C0444504','Mean','Statistical mean','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C0117996','FLUTICASONE PROPIONATE','Fluticasone propionate','true'
'mean ics fluticasone propionate dpi or equivalent pg per day','C2347634','Mean','Population Mean','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C2348143','Mean','Sample Mean','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C0205163','Equivalent','Equal','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C2827928','pg/day','Picogram per Day','false'
'mean ics fluticasone propionate dpi or equivalent pg per day','C0439185','equivalent','Equivalent Weight','false'
'pre bronchodilator fevj','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'absolute l','C0205344','ABSOLUTE','Absolute','false'
't jj $nmbr$ $nmbr$','C2603360','T'','T prime','false'
'median serum periostin ng ml t','C0219433','Periostin','POSTN protein, human','true'
'median serum periostin ng ml t','C0439275','ng/mL','Microgram per Liter','false'
'median serum periostin ng ml t','C1424662','PERIOSTIN','POSTN gene','false'
'median serum periostin ng ml t','C3812270','Periostin','Periostin Measurement','false'
'median feno ppb f','C0549183','Median','Midline (qualifier value)','false'
'median feno ppb f','C0016327','F-','Fluorides','true'
'median feno ppb f','C0876920','Median','Median Statistical Measurement','false'
'median feno ppb f','C2347635','Median','Population Median','false'
'median feno ppb f','C2348144','Median','Sample Median','false'
'median feno ppb f','C2939193','Median','Median (qualifier value)','false'
'tj $nmbr$ $nmbr$','C0039247','TJ','Tajikistan','true'
'median blood eosinophil count cells per pl t','C0549183','Median','Midline (qualifier value)','false'
'median blood eosinophil count cells per pl t','C0200638','Blood cell count, eosinophil','Eosinophil count procedure','false'
'median blood eosinophil count cells per pl t','C0876920','Median','Median Statistical Measurement','false'
'median blood eosinophil count cells per pl t','C2347635','Median','Population Median','false'
'median blood eosinophil count cells per pl t','C2348144','Median','Sample Median','false'
'median blood eosinophil count cells per pl t','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ i $nmbr$ $nmbr$','C0021966','I-','Iodides','true'
'$nmbr$ i $nmbr$ $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t','C0005516','Biomarker','Biological Markers','true'
'biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t','C0439275','ng/mL','Microgram per Liter','false'
'biomarker high periostin $nmbr$ ng ml or blood eosinophils $nmbr$ cells per pl t','C0005773','Blood Cells','Blood Cells','true'
'patients with $nmbr$ exacerbation in previous $nmbr$ months','C0030705','Patients','Patients','true'
'patients with $nmbr$ exacerbation in previous $nmbr$ months','C4086268','EXACERBATION','Exacerbation','false'
'patients with $nmbr$ exacerbation in previous $nmbr$ months','C0205156','Previous','Previous','false'
'patients with $nmbr$ exacerbation in previous $nmbr$ months','C0439231','MONTHS','month','false'
'patients with $nmbr$ exacerbation in previous $nmbr$ months','C1552607','previous','Act Relationship Subset - previous','false'
'adjusted exacerbation rate per patient peryear','C0871208','Rate','Rating (action)','false'
'adjusted exacerbation rate per patient peryear','C1521828','Rate','Rate','false'
'rate difference lebrikizumab placebo','C0032042','Placebo','Placebos','true'
'rate difference lebrikizumab placebo','C1696465','PLACEBO','placebo','false'
'rate difference lebrikizumab placebo','C1706408','PLACEBO','Placebo Control','false'
'rate reduction','C0301630','Reduction','Reduction (chemical)','false'
'rate reduction','C0392756','Reduction','Reduced','false'
'rate reduction','C1293152','Reduction','Reduction procedure','false'
'rate reduction','C4551656','Reduction','Surgical reduction','false'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C0456603','RATIO','Ratio','false'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C2981360','LEBRIKIZUMAB','lebrikizumab','true'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C1547037','Ratio','data type - ratio','false'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C0032042','Placebo','Placebos','true'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C1696465','PLACEBO','placebo','false'
'rate ratio lebrikizumab vs placebo $nmbr$ cl','C1706408','PLACEBO','Placebo Control','false'
'biomarker high','C0205250','High','High','false'
'biomarker high','C1299351','High','Abnormally high','false'
'biomarker high','C2700149','HIGH','Value Above Reference Range','false'
'biomarker high','C3887512','high','high - ActExposureLevelCode','false'
'biomarker high','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'biomarker high','C4321237','High','High Level','false'
'biomarker high','C4522209','High','IPSS Risk Category High','false'
'lebrikizumab $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'lebrikizumab $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'lebrikizumab $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'lebrikizumab $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'lebrikizumab $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'lebrikizumab $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'lebrikizumab $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'lebrikizumab $nmbr$ mg','C0024671','MG','Mammography','true'
'lebrikizumab $nmbr$ mg','C0026410','MG','Mongolia','true'
'lebrikizumab $nmbr$ mg','C0439269','mg%','mg/dL','false'
'lebrikizumab $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'lebrikizumab $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'lebrikizumab $nmbr$ mg','C4321396','MG','MG','false'
'lebrikizumab $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'biomarker low','C0205251','Low','low','false'
'biomarker low','C1550472','low','low confidentiality','false'
'biomarker low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'biomarker low','C4048187','low','low exposure','false'
'biomarker low','C4321351','Low','Low Level','false'
'biomarker low','C4522223','Low','IPSS Risk Category Low','false'
'periostin high','C0205250','High','High','false'
'periostin high','C1299351','High','Abnormally high','false'
'periostin high','C2700149','HIGH','Value Above Reference Range','false'
'periostin high','C3887512','high','high - ActExposureLevelCode','false'
'periostin high','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'periostin high','C4321237','High','High Level','false'
'periostin high','C4522209','High','IPSS Risk Category High','false'
'periostin low','C0205251','Low','low','false'
'periostin low','C1550472','low','low confidentiality','false'
'periostin low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'periostin low','C4048187','low','low exposure','false'
'periostin low','C4321351','Low','Low Level','false'
'periostin low','C4522223','Low','IPSS Risk Category Low','false'
'eosinophil high','C0205250','High','High','false'
'eosinophil high','C1299351','High','Abnormally high','false'
'eosinophil high','C2700149','HIGH','Value Above Reference Range','false'
'eosinophil high','C3887512','high','high - ActExposureLevelCode','false'
'eosinophil high','C3889660','High','High Mitosis-Karyorrhexis Index','false'
'eosinophil high','C4321237','High','High Level','false'
'eosinophil high','C4522209','High','IPSS Risk Category High','false'
'eosinophil low','C0205251','Low','low','false'
'eosinophil low','C1550472','low','low confidentiality','false'
'eosinophil low','C3890211','Low','Low Mitosis-Karyorrhexis Index','false'
'eosinophil low','C4048187','low','low exposure','false'
'eosinophil low','C4321351','Low','Low Level','false'
'eosinophil low','C4522223','Low','IPSS Risk Category Low','false'
'change from baseline in fevj mb','C0392747','Change','Changing','false'
'change from baseline in fevj mb','C0443172','change','Changed status','false'
'change from baseline in fevj mb','C1705241','Change','Delta (difference)','false'
'change from baseline in fevj mb','C4319952','Change','Change -- procedure','false'
'change from baseline in fevj mb','C0024853','MB','Martinique','true'
'adjusted mean se','C0444504','Mean','Statistical mean','false'
'adjusted mean se','C0036919','SE','Seychelles','true'
'adjusted mean se','C2347634','Mean','Population Mean','false'
'adjusted mean se','C2348143','Mean','Sample Mean','false'
'difference in means $nmbr$ cl','C1705241','*Difference','Delta (difference)','false'
'difference in means $nmbr$ cl','C1705242','Difference','Different','false'
'time to first exacerbation','C0040223','TIME','Time','true'
'time to first exacerbation','C3541383','Time','Time (foundation metadata concept)','false'
'patients with event n','C0030705','Patients','Patients','true'
'patients with event n','C0441471','Event','Event','false'
'patients with event n','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'median time to event weeks','C0040223','TIME','Time','true'
'median time to event weeks','C3541383','Time','Time (foundation metadata concept)','false'
'asthma related health','C0004096','ASTHMA','Asthma','true'
'asthma related health','C0018684','Health','Health','true'
'asthma related health','C2984299','Asthma','Asthma Pathway','false'
'care use','C0042153','use','utilization qualifier','true'
'care use','C0457083','Use','Usage','false'
'care use','C1947944','Use','Use - dosing instruction imperative','false'
'health care use rate peryear','C0814514','health care use','health care use','false'
'health care use rate peryear','C0871208','Rate','Rating (action)','false'
'health care use rate peryear','C1521828','Rate','Rate','false'
'rate difference events year','C0439234','Year','year','false'
'rate difference events year','C0439508','/Year','per year','false'
'oil','C0028908','Oil','Oils','true'
'oil','C0032085','Oil','Plant Oils','true'
'oil','C1517288','Oil','Food Oil','false'
'oil','C3541397','oil','oil ingredients','false'
'change from baseline in aqlq s score','C0392747','Change','Changing','false'
'change from baseline in aqlq s score','C0443172','change','Changed status','false'
'change from baseline in aqlq s score','C1705241','Change','Delta (difference)','false'
'change from baseline in aqlq s score','C4319952','Change','Change -- procedure','false'
'change from baseline in aqlq s score','C0449820','SCORE','Score','false'
'change from baseline in aqlq s score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'change from baseline in rescue medication use puffs per day','C0392747','Change','Changing','false'
'change from baseline in rescue medication use puffs per day','C0443172','change','Changed status','false'
'change from baseline in rescue medication use puffs per day','C1705241','Change','Delta (difference)','false'
'change from baseline in rescue medication use puffs per day','C4319952','Change','Change -- procedure','false'
'change from baseline in rescue medication use puffs per day','C0240320','MEDICATION USE','medication use','false'
'change from baseline in rescue medication use puffs per day','C1533107','Puffs','Puff unit dose','false'
'change from baseline in acq $nmbr$ score','C0392747','Change','Changing','false'
'change from baseline in acq $nmbr$ score','C0443172','change','Changed status','false'
'change from baseline in acq $nmbr$ score','C1705241','Change','Delta (difference)','false'
'change from baseline in acq $nmbr$ score','C4319952','Change','Change -- procedure','false'
'change from baseline in acq $nmbr$ score','C0449820','SCORE','Score','false'
'change from baseline in acq $nmbr$ score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'difference in means','C1705241','*Difference','Delta (difference)','false'
'difference in means','C1705242','Difference','Different','false'
'evolocumab','C3529352','EVOLOCUMAB','evolocumab','true'
'p value $nmbr$','C1709380','P-Value','P-Value','false'
'safety','C0036043','Safety','Safety','true'
'safety','C1705187','SAFETY','Safety Study','false'
'dysglycaemia or mets','C1960636','Dysglycemia','Dysglycemia','false'
'dysglycaemia or mets','C0812270','METS','ETV3 gene','false'
'dysglycaemia or mets','C1705694','METS','ETV3 wt Allele','false'
'dysglycaemia or mets','C2939420','mets','Metastatic Neoplasm','false'
'no dysglycaemia or mets','C1960636','Dysglycemia','Dysglycemia','false'
'no dysglycaemia or mets','C0812270','METS','ETV3 gene','false'
'no dysglycaemia or mets','C1705694','METS','ETV3 wt Allele','false'
'no dysglycaemia or mets','C2939420','mets','Metastatic Neoplasm','false'
'all subjects n','C0681850','Subject','Study Subject','false'
'all subjects n','C1550501','{Subject}','Subject -direct target','false'
'all subjects n','C1706203','Subject','Subject - topic','false'
'all subjects n','C2349001','Subject','Human Study Subject','false'
'all subjects n','C2697811','Subject','Investigative Subject','false'
'postbaseline new onset diabetes n','C0746890','new onset','new onset','false'
'postbaseline new onset diabetes n','C0011847','Diabetes','Diabetes','false'
'postbaseline new onset diabetes n','C0011849','Diabetes','Diabetes Mellitus','true'
'any adverse event ae','C0877248','ADVERSE EVENT','Adverse event','false'
'any adverse event ae','C3887670','AE','AE synonym fragment','false'
'baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n','C0168634','baseline','BaseLine dental cement','true'
'baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n','C1532563','mmol/L','Millimole per Liter','false'
'baseline normoglycaemia fpg $nmbr$ $nmbr$ mmol l n','C1442488','Baseline','Baseline','false'
'most common aes in any group','C1412268','AES','AES gene','false'
'most common aes in any group','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n','C0168634','baseline','BaseLine dental cement','true'
'baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n','C1532563','mmol/L','Millimole per Liter','false'
'baseline ifg fpg $nmbr$ $nmbr$ $nmbr$ $nmbr$ mmol l n','C1442488','Baseline','Baseline','false'
'influenza','C0021400','INFLUENZA','Influenza','true'
'influenza','C0021403','INFLUENZA','Influenza virus vaccine','true'
'serious','C0205404','Serious','Serious','false'
'leading to discontinuation','C0332152','Leading','Before','false'
'leading to discontinuation','C0457454','Discontinuation','Discontinuation (procedure)','false'
'leading to discontinuation','C1444662','Discontinuation','Discontinued','false'
'leading to discontinuation','C4552847','discontinuation','Clinical Trial Discontinuation','false'
'leading to discontinuation','C1522538','Leading','Leading','false'
'ck $nmbr$ x uln $nmbr$','C0009212','CK','Cocos (Keeling) Islands','true'
'ck $nmbr$ x uln $nmbr$','C1519815','ULN','Upper Limit of Normal','false'
'ck $nmbr$ x uln $nmbr$','C0010287','CK','Creatine Kinase','true'
'ck $nmbr$ x uln $nmbr$','C1872855','CK','CHKA protein, human','true'
'alt or ast $nmbr$ x uln $nmbr$','C1266129','ALT','Atypical Lipoma','false'
'alt or ast $nmbr$ x uln $nmbr$','C4553172','ALT','Antibiotic Lock Therapy','false'
'alt or ast $nmbr$ x uln $nmbr$','C1415181','AST','GOT1 gene','false'
'alt or ast $nmbr$ x uln $nmbr$','C1519815','ULN','Upper Limit of Normal','false'
'alt or ast $nmbr$ x uln $nmbr$','C3891303','AST','Atlantic Standard Time','false'
'total bilirubin $nmbr$ x uln $nmbr$','C0005437','Bilirubin, total','Bilirubin','true'
'total bilirubin $nmbr$ x uln $nmbr$','C1519815','ULN','Upper Limit of Normal','false'
'total bilirubin $nmbr$ x uln $nmbr$','C0368753','total bilirubin','Total bilirubin level','false'
'potential injection site reactions','C3245505','Potential','potential','false'
'potential injection site reactions','C0151735','Injection Site Reactions','Injection Site Reaction','true'
'postbaseline binding antibodies','C1145667','Binding','Binding action','false'
'postbaseline binding antibodies','C0003241','Antibodies','Antibodies','true'
'postbaseline binding antibodies','C1167622','Binding','Binding (Molecular Function)','false'
'semaglutide n $nmbr$','C3885068','SEMAGLUTIDE','semaglutide','true'
'low density lipoprotein cholesterol mg dlf','C0023824','Low Density Lipoprotein Cholesterol','LDL Cholesterol Lipoproteins','true'
'low density lipoprotein cholesterol mg dlf','C0024671','MG','Mammography','true'
'low density lipoprotein cholesterol mg dlf','C0026410','MG','Mongolia','true'
'low density lipoprotein cholesterol mg dlf','C0439269','mg%','mg/dL','false'
'low density lipoprotein cholesterol mg dlf','C1960952','mg %','Milligram percent','false'
'low density lipoprotein cholesterol mg dlf','C2346927','Mg++','Magnesium Cation','false'
'low density lipoprotein cholesterol mg dlf','C4321396','MG','MG','false'
'low density lipoprotein cholesterol mg dlf','C4521761','MG','United States Military Commissioned Officer O8','false'
'never smoked no','C0037366','Smoke','Smoke','true'
'never smoked no','C0439994','Smoke','Tobacco smoke','false'
'never smoked no','C1881674','Smoke','Medical Device Emits Smoke','false'
'tnf naive patientsa','C1448177','TNF','TNF protein, human','true'
'tnf failure patientsa','C0231174','FAILURE','Failure (biologic function)','false'
'tnf failure patientsa','C0680095','failure','Personal failure','false'
'vedolizumab cohort $nmbr$ n $nmbr$','C0009247','COHORT','Cohort Studies','true'
'vedolizumab cohort $nmbr$ n $nmbr$','C0599755','Cohort','Cohort','false'
'disease duration y mean sd','C0872146','disease duration','disease length','false'
'disease duration y mean sd','C2699239','SD','SD, Rat Strain','false'
'mayo clinic score mean sd','C0002424','Clinic','Ambulatory Care Facilities','true'
'mayo clinic score mean sd','C2699239','SD','SD, Rat Strain','false'
'mayo clinic score mean sd','C0442592','Clinic','Clinic','false'
'fcal mg g mean sd','C1300563','mg/g','Gram per Kilogram','false'
'fcal mg g mean sd','C2699239','SD','SD, Rat Strain','false'
'concomitant medications n','C0521115','Concomitant','Simultaneous','false'
'concomitant medications n','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications n','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications n','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications n','C4284232','Medications','Medications','false'
'cs only','C0010182','CS','Costa Rica','true'
'cs only','C0271160','CS','Cortical cataract','false'
'cs only','C3540510','cs','Centisecond','false'
'cs only','C4085345','cs','Condylion superiore','false'
'cs and is','C0010182','CS','Costa Rica','true'
'cs and is','C0271160','CS','Cortical cataract','false'
'cs and is','C3540510','cs','Centisecond','false'
'cs and is','C4085345','cs','Condylion superiore','false'
'no cs and is','C0010182','CS','Costa Rica','true'
'no cs and is','C0271160','CS','Cortical cataract','false'
'no cs and is','C3540510','cs','Centisecond','false'
'no cs and is','C4085345','cs','Condylion superiore','false'
'median min max','C0549183','Median','Midline (qualifier value)','false'
'median min max','C0702093','/min','Per Minute','false'
'median min max','C1524029','MIN NOS','Mouse MIN NOS','false'
'median min max','C3813700','%/min','Percent per Minute','false'
'median min max','C0876920','Median','Median Statistical Measurement','false'
'median min max','C2347635','Median','Population Median','false'
'median min max','C2348144','Median','Sample Median','false'
'median min max','C2939193','Median','Median (qualifier value)','false'
'type of tnf failure n b','C0332307','TYPE','Type - attribute','false'
'type of tnf failure n b','C1547052','*Type','*Type - Kind of quantity','false'
'intolerance','C0231199','Intolerance','intolerance function','false'
'intolerance','C1744706','intolerance','intolerance to substance','false'
'intolerance','C2355652','INTOLERANCE','Intolerance - biological effect of chemicals','false'
'tnf naivea','C1448177','TNF','TNF protein, human','true'
'tnf failurea','C1448177','TNF','TNF protein, human','true'
'point difference $nmbr$ ci c','C1552961','POINT','point - UnitsOfMeasure','false'
'point difference $nmbr$ ci c','C0008107','CI','Chile','true'
'point difference $nmbr$ ci c','C3259781','CI','Coagulation Index Measurement','false'
'point difference $nmbr$ ci c','C2347617','point','Point Name','false'
'point difference $nmbr$ ci c','C3714763','Point','Point','false'
'rr $nmbr$ ci c','C0008107','CI','Chile','true'
'rr $nmbr$ ci c','C3259781','CI','Coagulation Index Measurement','false'
'clinical responsed','C0205210','Clinical','Clinical','false'
'clinical remissione','C0205210','Clinical','Clinical','false'
'mucosal healingf','C0026724','Mucosal','Mucous Membrane','true'
'durable clinical responseg','C0205210','Clinical','Clinical','false'
'durable clinical remissionh','C0205210','Clinical','Clinical','false'
'corticosteroid free remissioni','C0001617','Corticosteroid','Adrenal Cortex Hormones','true'
'corticosteroid free remissioni','C0332296','free','Free of (attribute)','false'
'corticosteroid free remissioni','C1880497','Free','Empty (qualifier)','false'
'corticosteroid free remissioni','C1996904','Free','Free (available (qualifier))','false'
'corticosteroid free remissioni','C3536709','Corticosteroid','Corticosteroid [EPC]','false'
'patients not receiving statin','C0030705','Patients','Patients','true'
'patients not receiving statin','C1518422','Not','Negation','false'
'patients not receiving statin','C1514756','RECEIVING','Receive','false'
'patients not receiving statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'patients receiving statin','C0030705','Patients','Patients','true'
'patients receiving statin','C1514756','RECEIVING','Receive','false'
'patients receiving statin','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'alirocumab','C3491162','ALIROCUMAB','alirocumab','true'
'baseline demographics','C0011298','Demographics','Demography','true'
'baseline demographics','C1704791','Demographics','Demographics Domain','false'
'race white n','C0034510','RACE','Racial group','true'
'race white n','C0007457','WHITE','Caucasoid Race','true'
'race white n','C0043157','WHITE','Caucasians','true'
'race white n','C0220938','WHITE','White color','false'
'race white n','C1706779','RACE','AMACR wt Allele','false'
'race white n','C3853635','Race','Race','false'
'race black or african american n','C0005680','Black','Black race','true'
'race black or african american n','C0027567','Black','African race','true'
'race black or african american n','C0085756','BLACK','African American','true'
'race black or african american n','C0439541','Black','Black color','false'
'ethnicity hispanic latino n','C0015031','Ethnicity','Ethnic group','true'
'ethnicity hispanic latino n','C0086409','HISPANIC','Hispanics','true'
'ethnicity hispanic latino n','C0243103','ethnicity','Ethnicity aspects','true'
'diagnosis of hefh n','C0011900','DIAGNOSIS','Diagnosis','true'
'diagnosis of hefh n','C1704338','diagnosis','diagnosis aspect','true'
'diagnosis of hefh n','C1704656','DIAGNOSIS','Diagnosis Study','false'
'by genotyping','C1285573','Genotyping','Genotype determination','false'
'by who simon broome criteria','C0443058','Simon','Simon','false'
'by who simon broome criteria','C0243161','Criteria','criteria','true'
'diabetes mellitus type $nmbr$ n','C1320657','Diabetes Mellitus type','Diabetes type','false'
'cardiovascular risk n','C0007226','Cardiovascular','Cardiovascular system','true'
'cardiovascular risk n','C0035647','Risk','Risk','true'
'cardiovascular risk n','C4552904','risk','Subject Risk','false'
'cardiovascular risk n','C3887460','CARDIOVASCULAR','Cardiovascular','false'
'very high','C0442804','Very high','Very high','false'
'very high','C4321397','Very high','Very High Level','false'
'lipid treatment','C0039798','treatment','therapeutic aspects','true'
'lipid treatment','C0087111','Treatment','Therapeutic procedure','true'
'lipid treatment','C1522326','Treatment','Treating','false'
'lipid treatment','C1533734','Treatment','Administration procedure','false'
'lipid treatment','C1705169','Treatment','Biomaterial Treatment','false'
'lipid treatment','C3538994','TREATMENT','Treatment Epoch','false'
'lipid treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'patients on atorvastatin rosuvastatin or simvastatin at','C0030705','Patients','Patients','true'
'patients on atorvastatin rosuvastatin or simvastatin at','C0286651','ATORVASTATIN','atorvastatin','true'
'patients on atorvastatin rosuvastatin or simvastatin at','C0074554','SIMVASTATIN','Simvastatin','true'
'randomization n','C0034656','Randomization','Randomization','true'
'any llt other than statins n b','C2347090','LLT','MedDRA Low Level Term','false'
'any llt other than statins n b','C0360714','Statins','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'any llt other than nutraceuticals n','C2347090','LLT','MedDRA Low Level Term','false'
'any llt other than nutraceuticals n','C1518478','Nutraceuticals','Nutraceuticals','true'
'ezetimibe n','C1142985','EZETIMIBE','ezetimibe','true'
'nutraceuticals n','C1518478','Nutraceuticals','Nutraceuticals','true'
'baseline lipid parameters mg dl mmol l or g l','C0439268','mg/L','Microgram per Milliliter','false'
'baseline lipid parameters mg dl mmol l or g l','C0439294','g l','Kilogram per Cubic Meter','false'
'baseline lipid parameters mg dl mmol l or g l','C0456615','G/L','Billion per Liter','false'
'ldl c calculated mean sd','C0444504','Mean','Statistical mean','false'
'ldl c calculated mean sd','C2699239','SD','SD, Rat Strain','false'
'ldl c calculated mean sd','C2347634','Mean','Population Mean','false'
'ldl c calculated mean sd','C2348143','Mean','Sample Mean','false'
'ldl c measured mean sd','C0444504','Mean','Statistical mean','false'
'ldl c measured mean sd','C2699239','SD','SD, Rat Strain','false'
'ldl c measured mean sd','C2347634','Mean','Population Mean','false'
'ldl c measured mean sd','C2348143','Mean','Sample Mean','false'
'non hdl c mean sd','C0444504','Mean','Statistical mean','false'
'non hdl c mean sd','C2699239','SD','SD, Rat Strain','false'
'non hdl c mean sd','C2347634','Mean','Population Mean','false'
'non hdl c mean sd','C2348143','Mean','Sample Mean','false'
'total cholesterol mean sd','C0201950','Total Cholesterol','Cholesterol measurement test','false'
'total cholesterol mean sd','C2699239','SD','SD, Rat Strain','false'
'total cholesterol mean sd','C0543421','Total cholesterol','Total cholesterol','false'
'apo b mean sd','C0003593','Apo B','Apolipoproteins B','true'
'apo b mean sd','C2699239','SD','SD, Rat Strain','false'
'apo b mean sd','C3252643','APOB','APOB protein, human','true'
'lp a median q $nmbr$ q $nmbr$','C0065058','Lp(a)','Lipoprotein (a)','true'
'lp a median q $nmbr$ q $nmbr$','C1439335','Lp(a)','LPA gene','false'
'lp a median q $nmbr$ q $nmbr$','C4553379','Lp(a)','Apolipoprotein(a), human','false'
'fasting tgs median q $nmbr$ q $nmbr$','C0015663','FASTING','Fasting','true'
'fasting tgs median q $nmbr$ q $nmbr$','C0549183','Median','Midline (qualifier value)','false'
'fasting tgs median q $nmbr$ q $nmbr$','C0876920','Median','Median Statistical Measurement','false'
'fasting tgs median q $nmbr$ q $nmbr$','C2347635','Median','Population Median','false'
'fasting tgs median q $nmbr$ q $nmbr$','C2348144','Median','Sample Median','false'
'fasting tgs median q $nmbr$ q $nmbr$','C2939193','Median','Median (qualifier value)','false'
'apo a $nmbr$ mean sd','C0003592','Apo A','Apolipoproteins A','true'
'apo a $nmbr$ mean sd','C2699239','SD','SD, Rat Strain','false'
'apo a $nmbr$ mean sd','C0523508','APOA','Apolipoproteins A measurement','false'
'apo a $nmbr$ mean sd','C4553344','APOA','LPA wt Allele','false'
'apo a $nmbr$ mean sd','C4553379','Apo(a)','Apolipoprotein(a), human','false'
'change from baseline to week $nmbr$','C0392747','Change','Changing','false'
'change from baseline to week $nmbr$','C0443172','change','Changed status','false'
'change from baseline to week $nmbr$','C1705241','Change','Delta (difference)','false'
'change from baseline to week $nmbr$','C4319952','Change','Change -- procedure','false'
'change from baseline to week $nmbr$','C0332174','/week','Weekly','false'
'change from baseline to week $nmbr$','C0439230','Week','week','false'
'no statin group','C0441833','Group','Groups','false'
'no statin group','C0687744','group','Social group','false'
'no statin group','C1257890','Group','Population Group','true'
'no statin group','C1519504','Group','Stage Grouping','false'
'no statin group','C1705428','Group','Group Object','false'
'no statin group','C1705429','Group','User Group','false'
'statin group','C0441833','Group','Groups','false'
'statin group','C0687744','group','Social group','false'
'statin group','C1257890','Group','Population Group','true'
'statin group','C1519504','Group','Stage Grouping','false'
'statin group','C1705428','Group','Group Object','false'
'statin group','C1705429','Group','User Group','false'
'$nmbr$ mg q $nmbr$ w','C0024671','MG','Mammography','true'
'$nmbr$ mg q $nmbr$ w','C0026410','MG','Mongolia','true'
'$nmbr$ mg q $nmbr$ w','C0439269','mg%','mg/dL','false'
'$nmbr$ mg q $nmbr$ w','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg q $nmbr$ w','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg q $nmbr$ w','C4321396','MG','MG','false'
'$nmbr$ mg q $nmbr$ w','C4521761','MG','United States Military Commissioned Officer O8','false'
'not hispanic latino','C1518424','Not Hispanic','Not Hispanic or Latino','false'
'not hispanic latino','C0086528','Latino','Latinos','true'
'moderate chronic kidney disease','C1561643','Chronic Kidney Disease','Chronic Kidney Diseases','true'
'moderate chronic kidney disease','C4553188','Chronic kidney disease','Chronic Kidney Disease, CTCAE','false'
'baseline total pcsk $nmbr$ level','C0441889','Level','Levels (qualifier value)','false'
'baseline total pcsk $nmbr$ level','C0456079','Level','Disease classification level','false'
'baseline total pcsk $nmbr$ level','C1547707','Level','Floor - story of building','false'
'baseline total pcsk $nmbr$ level','C2946261','Level','Level','false'
'below median','C0549183','Median','Midline (qualifier value)','false'
'below median','C0876920','Median','Median Statistical Measurement','false'
'below median','C2347635','Median','Population Median','false'
'below median','C2348144','Median','Sample Median','false'
'below median','C2939193','Median','Median (qualifier value)','false'
'baseline free pcsk $nmbr$ level','C0441889','Level','Levels (qualifier value)','false'
'baseline free pcsk $nmbr$ level','C0456079','Level','Disease classification level','false'
'baseline free pcsk $nmbr$ level','C1547707','Level','Floor - story of building','false'
'baseline free pcsk $nmbr$ level','C2946261','Level','Level','false'
'statin intolerant','C0360714','Statin','Hydroxymethylglutaryl-CoA Reductase Inhibitors','true'
'statin intolerant','C0231200','Intolerant','intolerant','false'
'baseline ldl c mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline ldl c mg dl','C0439269','mg dl','mg/dL','false'
'baseline ldl c mg dl','C1442488','Baseline','Baseline','false'
'baseline hdl c mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline hdl c mg dl','C0439269','mg dl','mg/dL','false'
'baseline hdl c mg dl','C1442488','Baseline','Baseline','false'
'baseline fasting tgs mg dl','C0168634','baseline','BaseLine dental cement','true'
'baseline fasting tgs mg dl','C1442488','Baseline','Baseline','false'
'baseline fasting tgs mg dl','C0015663','FASTING','Fasting','true'
'baseline fasting tgs mg dl','C1156212','TGS','chromatin silencing','false'
'baseline fasting tgs mg dl','C0439269','mg dl','mg/dL','false'
'baseline fasting tgs mg dl','C1537574','TGS','LIN9 gene','false'
'baseline lp a mg dl','C0065058','Lp(a)','Lipoprotein (a)','true'
'baseline lp a mg dl','C0439269','mg dl','mg/dL','false'
'baseline lp a mg dl','C1439335','Lp(a)','LPA gene','false'
'baseline lp a mg dl','C4553379','Lp(a)','Apolipoprotein(a), human','false'
'inter p value','C0205103','Inter-','Intermediate','false'
'inter p value','C1548610','Inter','Inter','false'
'inter p value','C1709380','P-Value','P-Value','false'
'any gusto bleeding','C0019080','BLEEDING','Hemorrhage','true'
'acs','C0742343','ACS','Acute Chest Syndrome','true'
'acs','C4318612','ACS','ACS - Activity Card Sort','false'
'severe life ttireatening','C0205082','Severe','Severe (severity modifier)','false'
'severe life ttireatening','C0376558','Life','Life','true'
'severe life ttireatening','C4050465','Severe','Severe Extremity Pain','false'
'severe life ttireatening','C4050466','Severe','Borg Category-Ratio 10 Perceived Exertion Score 5','false'
'sa acs','C0742343','ACS','Acute Chest Syndrome','true'
'sa acs','C4318612','ACS','ACS - Activity Card Sort','false'
'severe moderate','C1299393','severe moderate','Moderate to severe','false'
'any timi bleeding','C0019080','BLEEDING','Hemorrhage','true'
'major','C0205082','Major','Severe (severity modifier)','false'
'major','C0205164','Major','Major','false'
'major','C4318856','Major','Major <insect>','false'
'major','C4521762','Major','United States Military Commissioned Officer O4','false'
'any acuity bleeding','C0750509','acuity','acuity','false'
'any acuity bleeding','C0019080','BLEEDING','Hemorrhage','true'
'any blood product transfusion','C0005841','BLOOD TRANSFUSION','Blood Transfusion','true'
'any blood product transfusion','C0281867','Blood transfusion','History of - blood transfusion','false'
'fvc $nmbr$ predicted','C0681842','Predicted','prediction','false'
'fvc $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'nintedanib n $nmbr$','C2930789','NINTEDANIB','nintedanib','true'
'time since diagnosis years','C0556970','time year','times/year','false'
'time since diagnosis years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since diagnosis years','C1704338','diagnosis','diagnosis aspect','true'
'time since diagnosis years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'centrilobular emphysema','C0221227','Centrilobular emphysema','Centriacinar Emphysema','true'
'fvc ml','C0439526','/mL','/mL','false'
'fvc ml','C1705224','ML','THPO wt Allele','false'
'fvc ml','C3887665','ML','Thrombopoietin, human','false'
'fvc predicted','C3714541','FVC','Forced Vital Capacity','true'
'fvc predicted','C0681842','Predicted','prediction','false'
'fvc predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'fev $nmbr$ fvc ratio','C0456603','RATIO','Ratio','false'
'fev $nmbr$ fvc ratio','C1547037','Ratio','data type - ratio','false'
'diffusion capacity of the lung for carbon monoxide predicted','C0231971','Diffusion capacity of lung','Diffusion capacity of lung, function','false'
'diffusion capacity of the lung for carbon monoxide predicted','C0007018','CARBON MONOXIDE','Carbon Monoxide','true'
'diffusion capacity of the lung for carbon monoxide predicted','C4520712','Carbon Monoxide','Carbon Monoxide Measurement','false'
'diffusion capacity of the lung for carbon monoxide predicted','C0681842','Predicted','prediction','false'
'diffusion capacity of the lung for carbon monoxide predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'st george s respiratory questionnaire total score','C1553316','St. George','St. George Aleuts','false'
'st george s respiratory questionnaire total score','C0034394','Questionnaire','Questionnaires','true'
'st george s respiratory questionnaire total score','C2964552','Total Score','Total score','false'
'composite physiologic index','C0600653','Index','Indexes','true'
'composite physiologic index','C0918012','Index','Index','true'
'composite physiologic index','C1552854','index','Html Link Type - index','false'
'composite physiologic index','C1637833','% index','% index','false'
'composite physiologic index','C2986546','Index','Target Lesion Identification','false'
'absolute decline in fvc $nmbr$ predicted or death n','C0205344','ABSOLUTE','Absolute','false'
'absolute decline in fvc $nmbr$ predicted or death n','C0681842','Predicted','prediction','false'
'absolute decline in fvc $nmbr$ predicted or death n','C1882327','%{Predicted}','Percent of Predicted Value','false'
'absolute decline in fvc $nmbr$ predicted or death n','C0011065','DEATH','Cessation of life','true'
'absolute decline in fvc $nmbr$ predicted or death n','C1306577','Death','Death (finding)','false'
'absolute decline in fvc $nmbr$ predicted or death n','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'absolute decline in fvc $nmbr$ predicted or death n','C4552775','Death NOS','Death NOS, CTCAE','false'
'treatment by subgroup interaction','C0039798','treatment','therapeutic aspects','true'
'treatment by subgroup interaction','C0087111','Treatment','Therapeutic procedure','true'
'treatment by subgroup interaction','C1522326','Treatment','Treating','false'
'treatment by subgroup interaction','C1533734','Treatment','Administration procedure','false'
'treatment by subgroup interaction','C1705169','Treatment','Biomaterial Treatment','false'
'treatment by subgroup interaction','C3538994','TREATMENT','Treatment Epoch','false'
'treatment by subgroup interaction','C3887704','treatment','treatment - ActInformationManagementReason','false'
'criterion reached first n','C0243161','Criterion','criteria','true'
'criterion reached first n','C0205435','First','First (number)','false'
'criterion reached first n','C1279901','First','Firstly','false'
'absolute decline in fvc $nmbr$ predicted','C0205344','ABSOLUTE','Absolute','false'
'absolute decline in fvc $nmbr$ predicted','C0681842','Predicted','prediction','false'
'absolute decline in fvc $nmbr$ predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'baricitinib $nmbr$ mg qd n $nmbr$','C0024671','MG','Mammography','true'
'baricitinib $nmbr$ mg qd n $nmbr$','C0026410','MG','Mongolia','true'
'baricitinib $nmbr$ mg qd n $nmbr$','C0439269','mg%','mg/dL','false'
'baricitinib $nmbr$ mg qd n $nmbr$','C1960952','mg %','Milligram percent','false'
'baricitinib $nmbr$ mg qd n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'baricitinib $nmbr$ mg qd n $nmbr$','C4321396','MG','MG','false'
'baricitinib $nmbr$ mg qd n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'duration of rheumatoid arthritis year','C0449238','Duration','Duration (temporal concept)','false'
'duration of rheumatoid arthritis year','C2926735','Duration','Duration','false'
'anticyclic citrullinated peptide positive^ n','C1320283','Anti-cyclic citrullinated peptide','Anti-cyclic citrullinated peptide','false'
'anticyclic citrullinated peptide positive^ n','C0439178','% Positive','percent positive cells','false'
'anticyclic citrullinated peptide positive^ n','C1446409','Positive','Positive','false'
'anticyclic citrullinated peptide positive^ n','C1514241','POSITIVE','Positive Finding','false'
'anticyclic citrullinated peptide positive^ n','C2825490','Positive','Positive Charge','false'
'anticyclic citrullinated peptide positive^ n','C3812269','Positive','Positive Number','false'
'rheumatoid factor positive n','C0035448','RHEUMATOID FACTOR','Rheumatoid Factor','true'
'rheumatoid factor positive n','C0201660','Rheumatoid factor NOS','Rheumatoid Factor Measurement','false'
'$nmbr$ erosion n','C0333307','Erosion','Superficial ulcer','false'
'$nmbr$ erosion n','C1880549','Erosion','Erosion of Medical Device Material','false'
'$nmbr$ erosion n','C1959609','EROSION','Erosion lesion','false'
'$nmbr$ erosion n','C3887524','Erosion','Skin Erosion','false'
'mtss units','C0439148','UNITS','Unit','false'
'mtss units','C1519795','Units','Unit of Measure','false'
'mtss units','C3853603','Units','Unit - NCI Thesaurus Property','false'
'prior conventional synthetic dmards n','C0332152','Prior','Before','false'
'prior conventional synthetic dmards n','C0242708','dmards','Antirheumatic Drugs, Disease-Modifying','true'
'prior conventional synthetic dmards n','C2826257','PRIOR','Prior Medication Usage','false'
'swollen joint count of $nmbr$','C0451521','Swollen joint count','Swollen joint count','false'
'tender joint count of $nmbr$','C0451530','Tender joint count','Tender joint count','false'
'high sensitivity c reactive protein mg ltt','C0006560','C Reactive Protein','C-reactive protein','true'
'high sensitivity c reactive protein mg ltt','C1413716','C-reactive protein','CRP gene','false'
'high sensitivity c reactive protein mg ltt','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'erythrocyte sedimentation rate mm hour','C0439227','HOUR','Hour','false'
'erythrocyte sedimentation rate mm hour','C0564385','/hour','/hour','false'
'simplified disease activity index','C3869582','Simplified disease activity index','Simplified disease activity index','false'
'a acr $nmbr$','C1412134','ACR','ACR gene','false'
'a acr $nmbr$','C1515941','ACR','American College of Radiology','false'
'week $nmbr$ overall population','C0032659','Population','geographic population','true'
'week $nmbr$ overall population','C1257890','Population','Population Group','true'
'background csdmard category','C0683312','Category','Categories','false'
'background csdmard category','C3889287','Category','Digital Content Category','false'
'mtx only','C0025677','MTX','Methotrexate','true'
'mtx only','C1417487','MTX','MTX1 gene','false'
'non mtx csdmards','C0025677','MTX','Methotrexate','true'
'non mtx csdmards','C1417487','MTX','MTX1 gene','false'
'mtx other csdmards','C0025677','MTX','Methotrexate','true'
'mtx other csdmards','C1417487','MTX','MTX1 gene','false'
'$nmbr$ $nmbr$ i','C0021966','I-','Iodides','true'
'$nmbr$ $nmbr$ i','C0221138','I NOS','Blood group antibody I','false'
'b acr $nmbr$','C1412134','ACR','ACR gene','false'
'b acr $nmbr$','C1515941','ACR','American College of Radiology','false'
'nteraction p value','C1709380','P-Value','P-Value','false'
'c das $nmbr$ crp','C3890735','CRp','Complete Response with Incomplete Platelet Recovery','false'
'c das $nmbr$ crp','C4048285','CRP','C-Reactive Protein, human','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C0086312','Forest','Forests','true'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C0039798','treatment','therapeutic aspects','true'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C0087111','Treatment','Therapeutic procedure','true'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C1522326','Treatment','Treating','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C1533734','Treatment','Administration procedure','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C1705169','Treatment','Biomaterial Treatment','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C3538994','TREATMENT','Treatment Epoch','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C3887704','treatment','treatment - ActInformationManagementReason','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C0332174','/week','Weekly','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C0439230','Week','week','false'
'figure forest plot of the treatment di erence in trough fev l at week across di erent subgroups of the lantern study ind gly indacaterol glycopyrronium sfc salmeterol uticasone','C1079230','subgroups','Subgroup A Nepoviruses','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C1280500','Effect','Effect','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C1518681','effect','Outcome of Therapy','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C2348382','Effect','Effect, Appearance','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0669479','NTproBNP','pro-brain natriuretic peptide (1-76)','true'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C3538926','ED','Endocrine System Findings Domain','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0754710','NT-proBNP','Amino-terminal pro-brain natriuretic peptide','true'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C1709380','P-Value','P-Value','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0022885','Test','Laboratory Procedures','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0039593','Test','Testing','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0392366','test','Tests (qualifier value)','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C0456984','Test','Test Result','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C1515976','test','Anatomic Structure, System, or Substance','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C3831328','Test','Blood Products Laboratory Testing','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C4318744','Test','Test - temporal region','false'
'fig $nmbr$ relative effect of tocilizumab on hstnt and nt probnp strati ed by key baseline variables with p values for test for interaction','C1704675','Interaction','Interaction','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C0871208','Rate','Rating (action)','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C1521828','Rate','Rate','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C0589120','Follow-up','Follow-up status','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C1522577','Followup','follow-up','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C1704685','Follow-Up','Follow-Up Report','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C3274571','FOLLOW-UP','Clinical Study Follow-up','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C0002688','AMPUTATION','Amputation','true'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C0332840','Amputation','Amputated structure (morphologic abnormality)','false'
'figure $nmbr$ rates of peripheral revascularization during follow up by history of revascularization or amputation at baseline','C1546539','Amputation','Amputation Specimen Code','false'
'mod sev exacerbation rate','C0871208','Rate','Rating (action)','false'
'mod sev exacerbation rate','C1521828','Rate','Rate','false'
'ff vi $nmbr$ $nmbr$','C4554348','FF','FF genotype','false'
'ff vi $nmbr$ $nmbr$','C0205999','VI','British Virgin Islands','true'
'current smoker n $nmbr$ $nmbr$','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker n $nmbr$ $nmbr$','C3241966','Current Smoker','Current Smoker','false'
'former smoker n $nmbr$ $nmbr$','C0337671','Former Smoker','Former smoker','false'
'cv entry criteria','C1705654','Entry','Entry (data)','false'
'cv entry criteria','C0243161','Criteria','criteria','true'
'$nmbr$ $nmbr$ cv disease n $nmbr$ $nmbr$','C0007222','CV Disease','Cardiovascular Diseases','true'
'$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$','C0035647','Risk','Risk','true'
'$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$','C4552904','risk','Subject Risk','false'
'$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$','C1518422','Not','Negation','false'
'$nmbr$ $nmbr$ risk not disease n $nmbr$ $nmbr$','C0012634','Disease','Disease','true'
'hispanic latino n $nmbr$','C0086409','HISPANIC','Hispanics','true'
'hispanic latino n $nmbr$','C0086528','Latino','Latinos','true'
'not hispanic latino n $nmbr$ $nmbr$','C1518424','Not Hispanic','Not Hispanic or Latino','false'
'not hispanic latino n $nmbr$ $nmbr$','C0086528','Latino','Latinos','true'
'asian n $nmbr$ $nmbr$','C0078988','ASIAN','Asians','true'
'african american african heritage n $nmbr$','C0085756','AFRICAN AMERICAN','African American','true'
'african american african heritage n $nmbr$','C2986513','Heritage','Heritage','false'
'usa n $nmbr$ $nmbr$','C0041703','USA','United States','true'
'asia n $nmbr$ $nmbr$','C0003980','Asia','Asia','true'
'europe $nmbr$ n $nmbr$ $nmbr$','C0015176','Europe','Europe','true'
'rest of world n $nmbr$','C0035253','Rest','Rest','true'
'rest of world n $nmbr$','C1622890','ResT','site-specific telomere resolvase activity','false'
'moderate severe exacerbation','C0205081','Moderate','Moderate (severity modifier)','false'
'moderate severe exacerbation','C4086268','EXACERBATION','Exacerbation','false'
'moderate severe exacerbation','C1881878','Moderate','Moderation','false'
'moderate severe exacerbation','C4049705','Moderate','Moderate Extremity Pain','false'
'moderate severe exacerbation','C4049706','Moderate','Borg Category-Ratio 10 Perceived Exertion Score 3','false'
'moderate severe exacerbation','C4085643','Moderate','Moderate Response','false'
'moderate severe exacerbation','C4321335','Moderate','Moderate Level','false'
'hospitalized for an exacerbation','C0701159','HOSPITALIZED','Patient in hospital','false'
'hospitalized for an exacerbation','C4086268','EXACERBATION','Exacerbation','false'
'hospitalized exacerbation rates','C0871208','Rate','Rating (action)','false'
'hospitalized exacerbation rates','C1521828','Rate','Rate','false'
'mod sev exacerbation rates','C0871208','Rate','Rating (action)','false'
'mod sev exacerbation rates','C1521828','Rate','Rate','false'
'favors ffa i favors placebo','C0032042','Placebo','Placebos','true'
'favors ffa i favors placebo','C1696465','PLACEBO','placebo','false'
'favors ffa i favors placebo','C1706408','PLACEBO','Placebo Control','false'
'ff vi','C4554348','FF','FF genotype','false'
'ff vi','C0205999','VI','British Virgin Islands','true'
'$nmbr$ h','C0033727','H+','Protons','true'
'$nmbr$ h','C0369286','H NOS','H NOS Antibodies','false'
'$nmbr$ h','C0441932','H+','Hepatic Involvement','false'
'$nmbr$ h','C0564385','/h','/hour','false'
'$nmbr$ h','C4528284','h*%','Hour Times Percent','false'
'h $nmbr$ $nmbr$','C0033727','H+','Protons','true'
'h $nmbr$ $nmbr$','C0369286','H NOS','H NOS Antibodies','false'
'h $nmbr$ $nmbr$','C0441932','H+','Hepatic Involvement','false'
'h $nmbr$ $nmbr$','C0564385','/h','/hour','false'
'h $nmbr$ $nmbr$','C4528284','h*%','Hour Times Percent','false'
'$nmbr$ t i','C0021966','I-','Iodides','true'
'$nmbr$ t i','C0221138','I NOS','Blood group antibody I','false'
'predicted fev','C0681842','Predicted','prediction','false'
'predicted fev','C3714541','FEV','Forced Vital Capacity','true'
'predicted fev','C1882327','%{Predicted}','Percent of Predicted Value','false'
't n $nmbr$ $nmbr$','C2986835','T/N','Tumor to Normal','false'
'favors ff vi favors placebo','C0032042','Placebo','Placebos','true'
'favors ff vi favors placebo','C1696465','PLACEBO','placebo','false'
'favors ff vi favors placebo','C1706408','PLACEBO','Placebo Control','false'
'current smoker n $nmbr$ $nmbr$ former smoker n $nmbr$ $nmbr$','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker n $nmbr$ $nmbr$ former smoker n $nmbr$ $nmbr$','C3241966','Current Smoker','Current Smoker','false'
'$nmbr$ bh i','C0021966','I-','Iodides','true'
'$nmbr$ bh i','C0221138','I NOS','Blood group antibody I','false'
'i ^w i $nmbr$','C0021966','I-','Iodides','true'
'i ^w i $nmbr$','C0221138','I NOS','Blood group antibody I','false'
'predicted fev^','C0681842','Predicted','prediction','false'
'predicted fev^','C3714541','FEV','Forced Vital Capacity','true'
'predicted fev^','C1882327','%{Predicted}','Percent of Predicted Value','false'
'itt population','C0032659','Population','geographic population','true'
'itt population','C1257890','Population','Population Group','true'
'mn population','C0032659','Population','geographic population','true'
'mn population','C1257890','Population','Population Group','true'
'umec vi $nmbr$ $nmbr$ $nmbr$ n $nmbr$ $nmbr$','C0205999','VI','British Virgin Islands','true'
'current smoker at screeninga n','C3173209','Current smoker','Current smoker:Finding:Point in time:^Patient:Ordinal','false'
'current smoker at screeninga n','C3241966','Current Smoker','Current Smoker','false'
'smoking pack yearsb n','C0037369','SMOKING','Smoking','true'
'smoking pack yearsb n','C0453996','Smoking','Tobacco smoking behavior','true'
'smoking pack yearsb n','C1881674','Smoking','Medical Device Emits Smoke','false'
'reversible to albuterolc d n','C0205343','Reversible','Reversible','false'
'reversible to albuterolc d n','C0369718','N NOS','N not otherwise specified Antibody','false'
'reversible to albuterolc d n','C0441922','N+','N+ (tumor staging)','false'
'post albuterol predicted fev $nmbr$ mean sd e','C0001927','ALBUTEROL','Albuterol','true'
'post albuterol predicted fev $nmbr$ mean sd e','C0444504','Mean','Statistical mean','false'
'post albuterol predicted fev $nmbr$ mean sd e','C2347634','Mean','Population Mean','false'
'post albuterol predicted fev $nmbr$ mean sd e','C2348143','Mean','Sample Mean','false'
'gold stage nf','C0018026','GOLD','Gold','true'
'gold stage nf','C0205390','Stage','Phase','false'
'gold stage nf','C1300072','Stage','Tumor stage','false'
'gold stage nf','C1306673','Stage','Stage','false'
'gold stage nf','C1304897','Gold','Gold color','false'
'ics use at screeningg n','C0042153','use','utilization qualifier','true'
'ics use at screeningg n','C0457083','Use','Usage','false'
'ics use at screeningg n','C1947944','Use','Use - dosing instruction imperative','false'
'exacerbation historyh n','C4086268','EXACERBATION','Exacerbation','false'
'required corticosteroid and or antibiotic without hospitalization','C0001617','Corticosteroid','Adrenal Cortex Hormones','true'
'required corticosteroid and or antibiotic without hospitalization','C3536709','Corticosteroid','Corticosteroid [EPC]','false'
'required corticosteroid and or antibiotic without hospitalization','C0003232','Antibiotic','Antibiotics','true'
'required corticosteroid and or antibiotic without hospitalization','C0019993','hospitalisation','Hospitalization','true'
'required hospitalization','C1708385','Required hospitalization','Hospitalization Required','false'
'components of the first cid','C0449432','Components','Component object','false'
'components of the first cid','C0205435','First','First (number)','false'
'components of the first cid','C1279901','First','Firstly','false'
'umec vi $nmbr$ $nmbr$ $nmbr$','C0205999','VI','British Virgin Islands','true'
'hazard ratio umec vi vs tio $nmbr$ ci','C2985465','Hazard Ratio','Hazard Ratio','false'
'hazard ratio umec vi vs tio $nmbr$ ci','C0205999','VI','British Virgin Islands','true'
'hazard ratio umec vi vs tio $nmbr$ ci','C0008107','CI','Chile','true'
'hazard ratio umec vi vs tio $nmbr$ ci','C3259781','CI','Coagulation Index Measurement','false'
'itt population n','C0032659','Population','geographic population','true'
'itt population n','C1257890','Population','Population Group','true'
'c $nmbr$ ml decrease in trough fev $nmbr$','C0392756','Decrease','Reduced','false'
'c $nmbr$ ml decrease in trough fev $nmbr$','C0547047','Decrease','Decrease','false'
'c $nmbr$ unit sgrq total score increase','C2964552','Total Score','Total score','false'
'c $nmbr$ unit sgrq total score increase','C0442805','Increase','Increase','false'
'moderate to severe copd exacerbation','C1299393','Moderate to severe','Moderate to severe','false'
'moderate to severe copd exacerbation','C0740304','copd exacerbation','copd exacerbation','false'
'mn population n','C0026327','MN','MNSs Blood-Group System','true'
'mn population n','C0026405','MN','Monaco','true'
'mn population n','C4285072','mN','Millinewton','false'
're cover re cover ii','C0556581','{RE}','Retinol equivalents','false'
're cover re cover ii','C0180153','Cover','Covers (device)','false'
're cover re cover ii','C1999244','Cover','Cover - action','false'
're cover re cover ii','C3888055','Cover','Cover (physical object)','false'
're cover re cover ii','C2986904','RE','Respiratory Domain','false'
'thrombophilia','C0398623','Thrombophilia','Thrombophilia','true'
'not tested','C1518422','Not','Negation','false'
'not tested','C0392366','tested','Tests (qualifier value)','false'
'de n $nmbr$','C0011198','DE','Delaware','true'
'de n $nmbr$','C0017480','DE','Germany','true'
'de n $nmbr$','C3541240','DE','Device Events Domain','false'
'age mean years sd','C1510829','Age-Years','Age-Years','false'
'age mean years sd','C2699239','SD','SD, Rat Strain','false'
'bmi mean kg m $nmbr$ sd','C0022718','KG','Kyrgyzstan','true'
'bmi mean kg m $nmbr$ sd','C0439209','kg','Kilogram','false'
'bmi mean kg m $nmbr$ sd','C4054209','/kg','Per Kilogram','false'
'bmi mean kg m $nmbr$ sd','C2699239','SD','SD, Rat Strain','false'
'crcl mean ml min sd','C0439445','mL/min','mL/min','false'
'crcl mean ml min sd','C2699239','SD','SD, Rat Strain','false'
'qualifying symptomatic event n a','C1514624','Qualifying','Qualifying','false'
'qualifying symptomatic event n a','C0231220','Symptomatic','Symptomatic','false'
'qualifying symptomatic event n a','C0441471','Event','Event','false'
'qualifying symptomatic event n a','C4019010','Event','National reporting jurisdiction:Loc:Pt:^Event:Nom','false'
'pe and dvt','C0070939','PE','phosphoethanolamine','true'
'pe and dvt','C1880476','PE','Etoposide-Platinol Regimen','false'
'pe and dvt','C4284304','PE','PENK wt Allele','false'
'pe and dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'pe and dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'pe and dvt','C3899446','DVT','Data Validation Test Document','false'
'pe only','C0070939','PE','phosphoethanolamine','true'
'pe only','C1880476','PE','Etoposide-Platinol Regimen','false'
'pe only','C4284304','PE','PENK wt Allele','false'
'neither pe nor dvt','C0070939','PE','phosphoethanolamine','true'
'neither pe nor dvt','C1880476','PE','Etoposide-Platinol Regimen','false'
'neither pe nor dvt','C4284304','PE','PENK wt Allele','false'
'neither pe nor dvt','C0149871','DVT NOS','Deep Vein Thrombosis','true'
'neither pe nor dvt','C2926618','DVT','Ever told by doctor that you had deep venous thrombosis:Finding:Point in time:^Patient:Ordinal','false'
'neither pe nor dvt','C3899446','DVT','Data Validation Test Document','false'
'non transient risk factors for recurrent vte n','C0035648','Risk Factors','risk factors','true'
'non transient risk factors for recurrent vte n','C1553898','risk factors','risk factors - observation list','false'
'active cancer at any timeb','C0006826','CANCER','Malignant Neoplasms','true'
'active cancer at any timeb','C0998265','Cancer','Cancer Genus','false'
'active cancer at any timeb','C1306459','Cancer','Primary malignant neoplasm','false'
'concomitant anticoagulant antithrombotic or nsaid n','C0521115','Concomitant','Simultaneous','false'
'concomitant anticoagulant antithrombotic or nsaid n','C0003280','Anticoagulant','Anticoagulants','true'
'concomitant anticoagulant antithrombotic or nsaid n','C0848112','anti coagulant','on anti-coagulants','false'
'concomitant anticoagulant antithrombotic or nsaid n','C3536711','Anticoagulant','Anti-coagulant [EPC]','false'
'concomitant anticoagulant antithrombotic or nsaid n','C0003211','NSAID','Anti-Inflammatory Agents, Non-Steroidal','true'
'concomitant anticoagulant antithrombotic or nsaid n','C3536840','NSAID','Nonsteroidal Anti-inflammatory Drug [EPC]','false'
'vte vte related deathsa n n','C0439849','Related','Relationships','false'
'vte vte related deathsa n n','C0445223','Related','Related personal status','false'
'pulmonary embolisma n n','C0024109','pulmonary','Lung','true'
'pulmonary embolisma n n','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'pulmonary embolisma n n','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'pulmonary embolisma n n','C4522268','Pulmonary','Pulmonary (intended site)','false'
'vte vte related deathsb n n','C0439849','Related','Relationships','false'
'vte vte related deathsb n n','C0445223','Related','Related personal status','false'
'pulmonary embolismb n n','C0024109','pulmonary','Lung','true'
'pulmonary embolismb n n','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'pulmonary embolismb n n','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'pulmonary embolismb n n','C4522268','Pulmonary','Pulmonary (intended site)','false'
'de','C0011198','DE','Delaware','true'
'de','C0017480','DE','Germany','true'
'de','C3541240','DE','Device Events Domain','false'
'total study population','C3258257','Total population','Total population','false'
'treatment de vs warfarin by thrombophilia interaction','C0011198','DE','Delaware','true'
'treatment de vs warfarin by thrombophilia interaction','C0017480','DE','Germany','true'
'treatment de vs warfarin by thrombophilia interaction','C3541240','DE','Device Events Domain','false'
'treatment de vs warfarin by thrombophilia interaction','C0043031','WARFARIN','Warfarin','true'
'treatment de vs warfarin by thrombophilia interaction','C0398623','Thrombophilia','Thrombophilia','true'
'chlorthalidone $nmbr$','C0008294','Chlortalidone','Chlorthalidone','true'
'amlodipine lisinopril $nmbr$','C0051696','AMLODIPINE','Amlodipine','true'
'amlodipine lisinopril $nmbr$','C0065374','Lysinopril','Lisinopril','true'
'total $nmbr$','C0439175','% total','% of total','false'
'total $nmbr$','C0439810','Total','Total','false'
'white non hispanic n','C1533020','Hispanic, white','Hispanic white finding','false'
'white non hispanic n','C1533021','Hispanic, white','Hispanic white racial group','false'
'black non hispanic n','C1533017','Hispanic, black','Hispanic black finding','false'
'black non hispanic n','C1533018','Hispanic, black','Hispanic black racial group','false'
'white hispanic n','C1533020','Hispanic, white','Hispanic white finding','false'
'white hispanic n','C1533021','Hispanic, white','Hispanic white racial group','false'
'black hispanic n','C1533017','Hispanic, black','Hispanic black finding','false'
'black hispanic n','C1533018','Hispanic, black','Hispanic black racial group','false'
'receiving antihypertensive treatment','C1514756','RECEIVING','Receive','false'
'receiving antihypertensive treatment','C0003364','anti hypertensive','Antihypertensive Agents','true'
'receiving antihypertensive treatment','C0039798','treatment','therapeutic aspects','true'
'receiving antihypertensive treatment','C0087111','Treatment','Therapeutic procedure','true'
'receiving antihypertensive treatment','C1522326','Treatment','Treating','false'
'receiving antihypertensive treatment','C1533734','Treatment','Administration procedure','false'
'receiving antihypertensive treatment','C1705169','Treatment','Biomaterial Treatment','false'
'receiving antihypertensive treatment','C3538994','TREATMENT','Treatment Epoch','false'
'receiving antihypertensive treatment','C3887704','treatment','treatment - ActInformationManagementReason','false'
'n blood pressure mean sd mm hg','C0428886','blood Pressure mean','Mean blood pressure','true'
'n blood pressure mean sd mm hg','C0439475','mmHG','mmHg','false'
'major st depression or t wave','C0041696','Major Depression','Unipolar Depression','true'
'major st depression or t wave','C1269683','MAJOR DEPRESSION','Major Depressive Disorder','true'
'major st depression or t wave','C0429103','T wave','T wave feature','false'
'inversion','C0021943','Inversion','Chromosome inversion','true'
'inversion','C0021945','Inversion','Body part inversion','false'
'inversion','C1705687','Inversion','Inversion Mutation Abnormality','false'
'inversion','C2349984','Inversion','Inversion','false'
'diabetes t','C0011847','Diabetes','Diabetes','false'
'diabetes t','C0011849','Diabetes','Diabetes Mellitus','true'
'medication use at baseline n','C0240320','MEDICATION USE','medication use','false'
'medication use at baseline n','C0168634','baseline','BaseLine dental cement','true'
'medication use at baseline n','C1442488','Baseline','Baseline','false'
'females only','C0086287','Females','Females','true'
'atenolol use at $nmbr$ month','C0042153','use','utilization qualifier','true'
'atenolol use at $nmbr$ month','C0457083','Use','Usage','false'
'atenolol use at $nmbr$ month','C1947944','Use','Use - dosing instruction imperative','false'
'cholesterol mean sd n','C0008377','CHOLESTEROL','Cholesterol','true'
'cholesterol mean sd n','C0444504','Mean','Statistical mean','false'
'cholesterol mean sd n','C2347634','Mean','Population Mean','false'
'cholesterol mean sd n','C2348143','Mean','Sample Mean','false'
'serum creatinine mean sd n','C0201976','Serum Creatinine','Creatinine measurement, serum (procedure)','false'
'serum creatinine mean sd n','C0600061','serum creatinine','Serum creatinine level','false'
'egfr mean sd n','C1739039','EGFR','EGFR protein, human','true'
'egfr mean sd n','C0444504','Mean','Statistical mean','false'
'egfr mean sd n','C2347634','Mean','Population Mean','false'
'egfr mean sd n','C2348143','Mean','Sample Mean','false'
'egfr mean sd n','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr mean sd n','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'baseline mdrd','C0168634','baseline','BaseLine dental cement','true'
'baseline mdrd','C3839656','MDRD','Modification of diet in renal disease formula','false'
'baseline mdrd','C1442488','Baseline','Baseline','false'
'baseline ckd epi','C1561643','CKD','Chronic Kidney Diseases','true'
'baseline ckd epi','C0162734','EPI','Echo-Planar Imaging','true'
'baseline ckd epi','C4281721','EPI','Tissue Factor Pathway Inhibitor, human','false'
'lipid trial participants n','C1997894','Trial participant','Clinical trial participant (person)','false'
'lipid trial participants n','C2242969','Trial participant','clinical trial participant (history)','false'
'baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'baseline mdrd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C1442488','Baseline','Baseline','false'
'baseline mdrd egfr','C1739039','EGFR','EGFR protein, human','true'
'baseline mdrd egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'baseline mdrd egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C0439445','mL/min','mL/min','false'
'baseline ckd egfr $nmbr$ ml min $nmbr$ $nmbr$ m $nmbr$','C1442488','Baseline','Baseline','false'
'baseline ckd egfr','C1739039','EGFR','EGFR protein, human','true'
'baseline ckd egfr','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'baseline ckd egfr','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'no cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'prevalent cvd','C0007222','CVD, NOS','Cardiovascular Diseases','true'
'healthy weight','C0005910','Weight','Body Weight','true'
'healthy weight','C0043100','Weight','Weight','true'
'healthy weight','C1305866','weight','Weighing patient','false'
'healthy weight','C1705104','Weight','Importance Weight','false'
'overweight','C0497406','OVERWEIGHT','Overweight','true'
'obese','C0028754','OBESE','Obesity','true'
'no estrogen','C0014939','Oestrogen, NOS','Estrogens','true'
'no estrogen','C2936882','Estrogen','Estrogen [EPC]','false'
'no estrogen','C4542544','Estrogen','Estrogen (disposition)','false'
'budesonide symptom days a week','C0054201','BUDESONIDE','Budesonide','true'
'budesonide symptom days a week','C0439228','DAYS','day','false'
'budesonide symptom days a week','C0332174','/week','Weekly','false'
'budesonide symptom days a week','C0439230','Week','week','false'
'placebo symptom days a week','C0032042','Placebo','Placebos','true'
'placebo symptom days a week','C0439228','DAYS','day','false'
'placebo symptom days a week','C1696465','PLACEBO','placebo','false'
'placebo symptom days a week','C1706408','PLACEBO','Placebo Control','false'
'placebo symptom days a week','C0332174','/week','Weekly','false'
'placebo symptom days a week','C0439230','Week','week','false'
'$nmbr$ n $nmbr$ l $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ n $nmbr$ l $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'age mean age years sex','C0009253','Sex','Coitus','true'
'age mean age years sex','C0036864','Sex','Sex Behavior','true'
'age mean age years sex','C0079399','sex','Gender','true'
'age mean age years sex','C0804628','Sex','Gender:Type:Point in time:^Patient:Nominal','false'
'age mean age years sex','C1314687','Sex','Sexual intercourse - finding','false'
'age mean age years sex','C1522384','SEX','sex','true'
'$nmbr$ u','C0439148','{U}','Unit','false'
'oriental','C0078988','ORIENTAL','Asians','true'
'oriental','C0699027','oriental','Oriental Herbs and Botanicals','false'
'passive smoker','C0425309','Passive smoker','Passive smoker','false'
'prebronchodilator fevj predicted','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'prebronchodilator fevj predicted','C0681842','Predicted','prediction','false'
'prebronchodilator fevj predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'postbronchodilator fevj predicted','C2599594','Post-bronchodilator','post bronchodilator','false'
'postbronchodilator fevj predicted','C0681842','Predicted','prediction','false'
'postbronchodilator fevj predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'controllertreatment before entry','C1705654','Entry','Entry (data)','false'
'inhaled corticosteroid','C0004048','Inhaled','Inspiration function','true'
'inhaled corticosteroid','C0001617','Corticosteroid','Adrenal Cortex Hormones','true'
'inhaled corticosteroid','C3536709','Corticosteroid','Corticosteroid [EPC]','false'
'oral or other systemic corticosteroid','C0442027','Oral','Oral','false'
'oral or other systemic corticosteroid','C4521986','Oral','Oral (intended site)','false'
'oral or other systemic corticosteroid','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'xanthine','C0043314','XANTHINE','xanthine','true'
'xanthine','C0043318','xanthine','Xanthines','true'
'cromoglicate','C0010347','Cromoglycate','Cromoglycate','true'
'leukotriene modifier','C0205349','Modifier','Modified By','false'
'leukotriene modifier','C1514623','Modifier','Qualifier (concept)','false'
'leukotriene modifier','C1516451','Modifier','Chemical Modifier','false'
'leukotriene modifier','C3542952','Modifier','Modifier (core metadata concept)','false'
'$nmbr$ to $nmbr$ n $nmbr$','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ to $nmbr$ n $nmbr$','C0441922','N+','N+ (tumor staging)','false'
'time to first sare','C0040223','TIME','Time','true'
'time to first sare','C3541383','Time','Time (foundation metadata concept)','false'
'cumulative incidence lyear','C0021149','Incidence','Incidence','true'
'cumulative incidence lyear','C0220856','incidence','incidence of cases','true'
'cumulative incidence $nmbr$ years','C0021149','Incidence','Incidence','true'
'cumulative incidence $nmbr$ years','C0439234','YEARS','year','false'
'cumulative incidence $nmbr$ years','C0220856','incidence','incidence of cases','true'
'rate of sares','C0871208','Rate','Rating (action)','false'
'rate of sares','C1521828','Rate','Rate','false'
'rate per $nmbr$ patient years','C0871208','Rate','Rating (action)','false'
'rate per $nmbr$ patient years','C1521828','Rate','Rate','false'
'$nmbr$ year mean change from baseline','C0392747','Change','Changing','false'
'$nmbr$ year mean change from baseline','C0443172','change','Changed status','false'
'$nmbr$ year mean change from baseline','C1705241','Change','Delta (difference)','false'
'$nmbr$ year mean change from baseline','C4319952','Change','Change -- procedure','false'
'prebronchodilator fevi predicted','C0849974','fev 1','Pulmonary Function Test/Forced Expiratory Volume 1','false'
'prebronchodilator fevi predicted','C1561566','FEV(1)','FEV1, CTCAE','false'
'prebronchodilator fevi predicted','C4528367','FEV_1','Forced Expiratory Volume in 0.1 Second','false'
'prebronchodilator fevi predicted','C0681842','Predicted','prediction','false'
'prebronchodilator fevi predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'lyear mean change from baseline','C0392747','Change','Changing','false'
'lyear mean change from baseline','C0443172','change','Changed status','false'
'lyear mean change from baseline','C1705241','Change','Delta (difference)','false'
'lyear mean change from baseline','C4319952','Change','Change -- procedure','false'
'time to first inhaled corticosteroid','C0040223','TIME','Time','true'
'time to first inhaled corticosteroid','C3541383','Time','Time (foundation metadata concept)','false'
'time to first oral or systemic corticosteroid','C0040223','TIME','Time','true'
'time to first oral or systemic corticosteroid','C3541383','Time','Time (foundation metadata concept)','false'
'time to first oral or systemic corticosteroid','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'rate of oral or systemic corticosteroid','C0871208','Rate','Rating (action)','false'
'rate of oral or systemic corticosteroid','C1521828','Rate','Rate','false'
'rate of oral or systemic corticosteroid','C4053960','Systemic Corticosteroid','Systemic Corticosteroid Therapy','false'
'asthma symptoms in the past $nmbr$ weeks','C0683368','symptoms','Symptoms aspect','true'
'asthma symptoms in the past $nmbr$ weeks','C1457887','SYMPTOMS','Symptoms','false'
'mean proportion','C0444504','Mean','Statistical mean','false'
'mean proportion','C1709707','Proportion','Proportion','false'
'mean proportion','C2347634','Mean','Population Mean','false'
'mean proportion','C2348143','Mean','Sample Mean','false'
'restriction in normal activities in the past $nmbr$ weeks','C0443288','Restriction','Restricted','false'
'restriction in normal activities in the past $nmbr$ weeks','C4697852','Normal Activity','Normal Activity','false'
'restriction in normal activities in the past $nmbr$ weeks','C0439230','WEEKS','week','false'
'sleeping problems in the past $nmbr$ weeks','C0037313','Sleeping','Sleep','true'
'sleeping problems in the past $nmbr$ weeks','C0424522','Sleeping','Asleep','false'
'sleeping problems in the past $nmbr$ weeks','C4050403','Sleeping','Ability to Sleep After Treatment question','false'
'sleeping problems in the past $nmbr$ weeks','C1546466','Problems','Problems - What subject filter','false'
'sleeping problems in the past $nmbr$ weeks','C0439230','WEEKS','week','false'
'symptom free days in the past $nmbr$ weeks','C0332296','free','Free of (attribute)','false'
'symptom free days in the past $nmbr$ weeks','C0677547','days week','days/week','false'
'symptom free days in the past $nmbr$ weeks','C1880497','Free','Empty (qualifier)','false'
'symptom free days in the past $nmbr$ weeks','C1996904','Free','Free (available (qualifier))','false'
'$nmbr$ to $nmbr$ symptom days per week','C1457887','Symptom','Symptoms','false'
'$nmbr$ to $nmbr$ symptom days per week','C0677547','days per week','days/week','false'
'$nmbr$ to $nmbr$ symptom days per week','C3854129','Symptom','Symptom:Find:Pt:^Patient:Nom','false'
'lto $nmbr$ symptom days per week','C1457887','Symptom','Symptoms','false'
'lto $nmbr$ symptom days per week','C0677547','days per week','days/week','false'
'lto $nmbr$ symptom days per week','C3854129','Symptom','Symptom:Find:Pt:^Patient:Nom','false'
'$nmbr$ symptom days per week','C1457887','Symptom','Symptoms','false'
'$nmbr$ symptom days per week','C0677547','days per week','days/week','false'
'$nmbr$ symptom days per week','C3854129','Symptom','Symptom:Find:Pt:^Patient:Nom','false'
'hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$','C0596019','Cl -','Chloride Ion','false'
'hr $nmbr$ $nmbr$ $nmbr$ cl $nmbr$ $nmbr$ $nmbr$ $nmbr$','C0596019','Cl -','Chloride Ion','false'
'a prebronchodilator fevl predicted','C2599602','Pre-bronchodilator','pre bronchodilator','false'
'a prebronchodilator fevl predicted','C0681842','Predicted','prediction','false'
'a prebronchodilator fevl predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'baseline symptom days perweek','C0168634','baseline','BaseLine dental cement','true'
'baseline symptom days perweek','C0439228','DAYS','day','false'
'baseline symptom days perweek','C1442488','Baseline','Baseline','false'
'mean difference $nmbr$ cl','C0444504','Mean','Statistical mean','false'
'mean difference $nmbr$ cl','C0596019','Cl -','Chloride Ion','false'
'mean difference $nmbr$ cl','C2347634','Mean','Population Mean','false'
'mean difference $nmbr$ cl','C2348143','Mean','Sample Mean','false'
'b postbronchodilator fevl predicted','C2599594','Post-bronchodilator','post bronchodilator','false'
'b postbronchodilator fevl predicted','C0681842','Predicted','prediction','false'
'b postbronchodilator fevl predicted','C1882327','%{Predicted}','Percent of Predicted Value','false'
'baseline feature','C1521970','Feature','Characteristics','false'
'baseline feature','C1706388','Feature','Array Feature','false'
'baseline feature','C2346469','Feature','Image Feature','false'
'baseline feature','C2348519','Feature','Feature','false'
'pioglitazone','C0071097','PIOGLITAZONE','pioglitazone','true'
'hispanic ethnicity','C0015031','Ethnicity','Ethnic group','true'
'hispanic ethnicity','C0243103','ethnicity','Ethnicity aspects','true'
'lived alone','C0205171','Alone','Singular','false'
'lived alone','C0439044','Alone','Living Alone','false'
'lived alone','C0679994','alone','alone - group size','false'
'stroke at entry','C0038454','STROKE','Cerebrovascular accident','true'
'stroke at entry','C4554100','Stroke','Stroke, CTCAE','false'
'nih stroke scale','C1697238','NIH stroke scale','NIH stroke scale','false'
'nih stroke scale','C3484372','NIH Stroke Scale','NIH stroke scale:-:Point in time:^Patient:-:NIHSS','false'
'modified rankin score','C0392747','Modified','Changing','false'
'modified rankin score','C0449820','SCORE','Score','false'
'modified rankin score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'modified rankin score','C3889737','Modified','Data Change Date','false'
'health practices','C0018684','Health','Health','true'
'health practices','C0237607','practices','Practice Experience','false'
'$nmbr$ $nmbr$ drinks day if male female','C0332173','/day','Daily','false'
'$nmbr$ $nmbr$ drinks day if male female','C0439228','Day','day','false'
'$nmbr$ $nmbr$ drinks day if male female','C0439505','/day','per day','false'
'$nmbr$ $nmbr$ drinks day if male female','C0043210','female','Woman','true'
'$nmbr$ $nmbr$ drinks day if male female','C0086287','FEMALE','Females','true'
'$nmbr$ $nmbr$ drinks day if male female','C1705497','Female','Female, Self-Report','false'
'$nmbr$ $nmbr$ drinks day if male female','C1705498','FEMALE','Female Phenotype','false'
'aerobic exercise','C0001701','Aerobic Exercise','Exercise, Aerobic','true'
'cognitive','C1516691','Cognitive','Cognitive','false'
'and physical examination','C0031809','PHYSICAL EXAMINATION','Physical Examination','true'
'and physical examination','C1744699','Physical Examination','Physical Exam Domain','false'
'$nmbr$ ms score','C0449820','SCORE','Score','false'
'$nmbr$ ms score','C4050231','Score','ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated','false'
'antidepressant','C0003289','Antidepressant','Antidepressive Agents','true'
'benzodiazepine or bzra','C0005064','Benzodiazepine','Benzodiazepines','true'
'benzodiazepine or bzra','C3536850','Benzodiazepine','Benzodiazepine [EPC]','false'
'benzodiazepine or bzra','C4048284','Benzodiazepine','Benzodiazepine','true'
'epilepsy drug','C0013227','Drug','Pharmaceutical Preparations','true'
'epilepsy drug','C1254351','DRUG','Pharmacologic Substance','false'
'osteoporosis drug','C0013227','Drug','Pharmaceutical Preparations','true'
'osteoporosis drug','C1254351','DRUG','Pharmacologic Substance','false'
'vitamin d','C0014695','Vitamin D','Ergocalciferol','true'
'vitamin d','C0042866','VITAMIN D','Vitamin D','true'
'vitamin d','C2936842','Vitamin D','Vitamin D [EPC]','false'
'vitamin d','C3537249','Vitamin D','D Vitamin','false'
'vitamin d','C3714503','VITAMIN D','Vitamin D Drug Class','false'
'group','C0441833','Group','Groups','false'
'group','C0687744','group','Social group','false'
'group','C1257890','Group','Population Group','true'
'group','C1519504','Group','Stage Grouping','false'
'group','C1705428','Group','Group Object','false'
'group','C1705429','Group','User Group','false'
'risk at','C0035647','Risk','Risk','true'
'risk at','C4552904','risk','Subject Risk','false'
'fxs','C0016667','FXS','Fragile X Syndrome','true'
'risk','C0035647','Risk','Risk','true'
'risk','C4552904','risk','Subject Risk','false'
'any site','C0205145','Site','Site','false'
'any site','C1515974','Site','Anatomic Site','false'
'any site','C2825164','Site','Study Site','false'
'upper limb','C1140618','LIMB, UPPER','Upper Extremity','true'
'distal lower','C0441994','LOWER','Lower - spatial qualifier','false'
'distal lower','C1548802','Lower','Body Site Modifier - Lower','false'
'distal lower','C2003888','Lower','Lower (action)','false'
'limb','C0015385','LIMB','Limb structure','true'
'hip femur','C0019552','HIP','Hip structure','true'
'hip femur','C0015811','FEMUR','Femur','true'
'hip femur','C0022122','Hip','Bone structure of ischium','true'
'hip femur','C1505163','HIP','HHIP protein, human','true'
'hip femur','C3538851','HIP','REG3A wt Allele','false'
'hip femur','C4284725','HIP','HHIP wt Allele','false'
'rib','C0035561','RIB','Bone structure of rib','true'
'id','C0009450','ID','Communicable Diseases','true'
'id','C0600091','ID','Identifier','false'
'id','C1441613','ID','Immune diffusion','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1705241','*Difference','Delta (difference)','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1705242','Difference','Different','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C0008107','CI','Chile','true'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C3259781','CI','Coagulation Index Measurement','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1079231','Subgroup B','Subgroup B','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1079232','Subgroup C','Subgroup C','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C3715113','HDL','HSD11B1 wt Allele','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C0024671','MG','Mammography','true'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C0026410','MG','Mongolia','true'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C0439269','mg%','mg/dL','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1960952','mg %','Milligram percent','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C2346927','Mg++','Magnesium Cation','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C4321396','MG','MG','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C4521761','MG','United States Military Commissioned Officer O8','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C0032042','Placebo','Placebos','true'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1707455','Comparison','Comparison','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1696465','PLACEBO','placebo','false'
'figure $nmbr$ least square mean difference of percent change from baseline $nmbr$ ci at week $nmbr$ presented by patient subgroup for a ldl c b quanti cation and b hdl c for anacetrapib $nmbr$ mg versus placebo comparison','C1706408','PLACEBO','Placebo Control','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0205132','Line','Linear','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0700221','Line','Intravascular line','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1550648','Line','Line Specimen','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1552960','Line','Line Unit of Length','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0282416','Overall','Overall Publication Type','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1518681','Treatment Effect','Outcome of Therapy','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1561607','Overall','Overall','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C2360800','Number of patients','Number of patients','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0024671','MG','Mammography','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0441848','Group N','Group N','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0026410','MG','Mongolia','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0439269','mg%','mg/dL','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1960952','mg %','Milligram percent','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C2346927','Mg++','Magnesium Cation','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C4321396','MG','MG','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C4521761','MG','United States Military Commissioned Officer O8','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0441833','Group','Groups','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C0687744','group','Social group','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1257890','Group','Population Group','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1519504','Group','Stage Grouping','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1705428','Group','Group Object','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebc group','C1705429','Group','User Group','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0205132','Line','Linear','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0700221','Line','Intravascular line','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1550648','Line','Line Specimen','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1552960','Line','Line Unit of Length','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0282416','Overall','Overall Publication Type','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1518681','Treatment Effect','Outcome of Therapy','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1561607','Overall','Overall','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C2360800','Number of patients','Number of patients','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0024671','MG','Mammography','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0441848','Group N','Group N','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0026410','MG','Mongolia','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0439269','mg%','mg/dL','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1960952','mg %','Milligram percent','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C2346927','Mg++','Magnesium Cation','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C4321396','MG','MG','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C4521761','MG','United States Military Commissioned Officer O8','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0032042','Placebo','Placebos','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0441833','Group','Groups','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C0687744','group','Social group','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1257890','Group','Population Group','true'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1519504','Group','Stage Grouping','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1705428','Group','Group Object','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1705429','Group','User Group','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1696465','PLACEBO','placebo','false'
'the vertical dashed line indicates the overall treatment effect $nmbr$ $nmbr$ n n $nmbr$ n $nmbr$ n $nmbr$ the number of patients in the anacetrapib $nmbr$ mg group n $nmbr$ the number of patients in the placebo group','C1706408','PLACEBO','Placebo Control','false'
'mab','C0003250','MAb','Monoclonal Antibodies','true'
'mab','C0369637','M Ab','M NOS ANTIBODY','false'
'$nmbr$ mg kgf n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg kgf n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg kgf n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg kgf n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg kgf n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg kgf n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg kgf n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg $nmbr$ wk n $nmbr$','C1881833','mg/wk','Milligram per Week','false'
'duration of disease yr t','C0872146','disease duration','disease length','false'
'duration of disease yr t','C0439234','yr','year','false'
'cdai','C0683448','CDAI','Codependency Assessment Inventory','false'
'cdai','C1413248','CDAI','CDAN1 gene','false'
'cdai','C3273706','CDAI','CDAN1 wt Allele','false'
'median c reactive protein mg liter','C0006560','C Reactive Protein','C-reactive protein','true'
'median c reactive protein mg liter','C0475211','Litre','liter','false'
'median c reactive protein mg liter','C1413716','C-reactive protein','CRP gene','false'
'median c reactive protein mg liter','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'median fecal calprotectin mg kg gi areas involved no','C0205146','areas','Area','false'
'median fecal calprotectin mg kg gi areas involved no','C4319729','Areas','Areas <moth>','false'
'median fecal calprotectin mg kg gi areas involved no','C1314939','Involved','Involvement with','false'
'proximal gi tract','C0205107','PROXIMAL','Proximal','false'
'proximal gi tract','C0017189','GI Tract','Gastrointestinal tract structure','true'
'proximal gi tract','C4489236','Proximal','Proximal Resection Margin','false'
'perianal gi tract','C0442158','Perianal','Perianal','false'
'perianal gi tract','C0017189','GI Tract','Gastrointestinal tract structure','true'
'medications for crohn s disease taken at baseline no','C0013227','Medications','Pharmaceutical Preparations','true'
'medications for crohn s disease taken at baseline no','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'medications for crohn s disease taken at baseline no','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'medications for crohn s disease taken at baseline no','C4284232','Medications','Medications','false'
'medications for crohn s disease taken at baseline no','C0012634','Disease','Disease','true'
'medications for crohn s disease taken at baseline no','C1883727','Taken','Taken','false'
'medications for crohn s disease taken at baseline no','C0168634','baseline','BaseLine dental cement','true'
'medications for crohn s disease taken at baseline no','C1442488','Baseline','Baseline','false'
'one or more medications','C0205447','ONE','One','false'
'one or more medications','C0013227','Medications','Pharmaceutical Preparations','true'
'one or more medications','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'one or more medications','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'one or more medications','C4284232','Medications','Medications','false'
'immunosuppressant^','C0021081','Immunosuppressant','Immunosuppressive Agents','true'
'aminosalicylate','C0368663','Aminosalicylate','aminosalicylate','false'
'aminosalicylate','C2825094','Aminosalicylate','Aminosalicylate [EPC]','false'
'glucocorticoid]','C0017710','Glucocorticoid','Glucocorticoids','true'
'history of disease refractory to treatment with tnf antagonist no','C0683519','History of disease','disease history','false'
'history of disease refractory to treatment with tnf antagonist no','C0730226','History of Disease','H/O: Disorder','false'
'history of disease refractory to treatment with tnf antagonist no','C0850708','History of disease','History of disease','false'
'history of disease refractory to treatment with tnf antagonist no','C0944983','History of Disease','History of symptoms & diseases:Finding:Point in time:^Patient:Nominal:Observed','false'
'history of disease refractory to treatment with tnf antagonist no','C0039798','treatment','therapeutic aspects','true'
'history of disease refractory to treatment with tnf antagonist no','C0087111','Treatment','Therapeutic procedure','true'
'history of disease refractory to treatment with tnf antagonist no','C1522326','Treatment','Treating','false'
'history of disease refractory to treatment with tnf antagonist no','C1533734','Treatment','Administration procedure','false'
'history of disease refractory to treatment with tnf antagonist no','C1705169','Treatment','Biomaterial Treatment','false'
'history of disease refractory to treatment with tnf antagonist no','C3538994','TREATMENT','Treatment Epoch','false'
'history of disease refractory to treatment with tnf antagonist no','C3887704','treatment','treatment - ActInformationManagementReason','false'
'no history of tnf antagonist treatment no','C0019664','History','History','true'
'no history of tnf antagonist treatment no','C0019665','history','Historical aspects qualifier','true'
'no history of tnf antagonist treatment no','C0262512','History, NOS','History of present illness','false'
'no history of tnf antagonist treatment no','C0262926','History','Medical History','false'
'no history of tnf antagonist treatment no','C1705255','History','Concept History','false'
'no history of tnf antagonist treatment no','C2004062','History','History of previous events','false'
'history of tnf antagonist treatment failure no','C0019664','History','History','true'
'history of tnf antagonist treatment failure no','C0019665','history','Historical aspects qualifier','true'
'history of tnf antagonist treatment failure no','C0262512','History, NOS','History of present illness','false'
'history of tnf antagonist treatment failure no','C0262926','History','Medical History','false'
'history of tnf antagonist treatment failure no','C1705255','History','Concept History','false'
'history of tnf antagonist treatment failure no','C2004062','History','History of previous events','false'
'patients who received $nmbr$ drug','C0013227','Drug','Pharmaceutical Preparations','true'
'patients who received $nmbr$ drug','C1254351','DRUG','Pharmacologic Substance','false'
'patients who received $nmbr$ or $nmbr$ drugs','C0030705','Patients','Patients','true'
'patients who received $nmbr$ or $nmbr$ drugs','C3272598','WHO','WHO Temperature/Humidity Storage Condition','false'
'patients who received $nmbr$ or $nmbr$ drugs','C1514756','RECEIVED','Receive','false'
'patients who received $nmbr$ or $nmbr$ drugs','C0013227','Drugs','Pharmaceutical Preparations','true'
'patients who received $nmbr$ or $nmbr$ drugs','C3687832','Drugs','Drugs - dental services','false'
'primary nonresponse','C0205225','Primary','Primary','false'
'primary nonresponse','C0439612','Primary','True primary (qualifier value)','false'
'primary nonresponse','C0439631','Primary','Primary operation','false'
'secondary nonresponse','C0027627','secondary','Neoplasm Metastasis','true'
'secondary nonresponse','C0175668','Secondary','Secondary to','false'
'secondary nonresponse','C0205436','Secondary','second (number)','false'
'unacceptable side effects','C0001688','side effects','aspects of adverse effects','true'
'unacceptable side effects','C0877248','side effects','Adverse event','false'
'unacceptable side effects','C0879626','Side effects','Adverse effects','false'
'$nmbr$ mq kq','C0024853','MQ','Martinique','true'
'weight at baseline','C1303013','Baseline weight','Baseline weight','false'
'$nmbr$ st quartile','C0036056','ST','Saint Lucia','true'
'$nmbr$ st quartile','C2828255','Quartile','Quartile','false'
'$nmbr$ st quartile','C3272372','ST','Character String Data Type','false'
'$nmbr$ st and $nmbr$ nd quartile','C0036056','ST','Saint Lucia','true'
'$nmbr$ st and $nmbr$ nd quartile','C3272372','ST','Character String Data Type','false'
'$nmbr$ st and $nmbr$ nd quartile','C2828255','Quartile','Quartile','false'
'$nmbr$ nd and $nmbr$ rd quartile','C0694666','RD','Right deltoid','false'
'$nmbr$ nd and $nmbr$ rd quartile','C2828255','Quartile','Quartile','false'
'$nmbr$ nd and $nmbr$ rd quartile','C4553350','RD','NELFE wt Allele','false'
'$nmbr$ rd quartile','C0694666','RD','Right deltoid','false'
'$nmbr$ rd quartile','C2828255','Quartile','Quartile','false'
'$nmbr$ rd quartile','C4553350','RD','NELFE wt Allele','false'
'crohn s disease duration','C0010346','Crohn's','Crohn Disease','true'
'crohn s disease duration','C0872146','disease duration','disease length','false'
'involved gastrointestinal','C1314939','Involved','Involvement with','false'
'involved gastrointestinal','C0521362','Gastrointestinal','gastrointestinal','false'
'areas','C0205146','areas','Area','false'
'areas','C4319729','Areas','Areas <moth>','false'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'secukinumab intravenous $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'time since as diagnosis mean sd years','C0040223','TIME','Time','true'
'time since as diagnosis mean sd years','C3541383','Time','Time (foundation metadata concept)','false'
'time since as diagnosis mean sd years','C0011900','DIAGNOSIS','Diagnosis','true'
'time since as diagnosis mean sd years','C0439234','YEARS','year','false'
'time since as diagnosis mean sd years','C1704338','diagnosis','diagnosis aspect','true'
'time since as diagnosis mean sd years','C1704656','DIAGNOSIS','Diagnosis Study','false'
'hla b $nmbr$ positive n','C1426226','HLA-N','HLA-N gene','false'
'anti tnf naive n','C1448177','TNF','TNF protein, human','true'
'hscrp median min max mg l','C0549183','Median','Midline (qualifier value)','false'
'hscrp median min max mg l','C2827895','min*mg/L','Minute Times Microgram per Milliliter','false'
'hscrp median min max mg l','C0876920','Median','Median Statistical Measurement','false'
'hscrp median min max mg l','C2347635','Median','Population Median','false'
'hscrp median min max mg l','C2348144','Median','Sample Median','false'
'hscrp median min max mg l','C2939193','Median','Median (qualifier value)','false'
'elevated hscrp $nmbr$ mg l n','C0205250','Elevated','High','false'
'elevated hscrp $nmbr$ mg l n','C0439268','mg/L','Microgram per Milliliter','false'
'elevated hscrp $nmbr$ mg l n','C3163633','Elevated','Elevated','false'
'total basdai mean sd','C0439175','% total','% of total','false'
'total basdai mean sd','C2699239','SD','SD, Rat Strain','false'
'total basdai mean sd','C0439810','Total','Total','false'
'basfi mean sd','C0444504','Mean','Statistical mean','false'
'basfi mean sd','C2699239','SD','SD, Rat Strain','false'
'basfi mean sd','C2347634','Mean','Population Mean','false'
'basfi mean sd','C2348143','Mean','Sample Mean','false'
'basmi linear mean sd','C0205132','Linear','Linear','false'
'basmi linear mean sd','C2699239','SD','SD, Rat Strain','false'
'msasss mean sd','C0444504','Mean','Statistical mean','false'
'msasss mean sd','C2699239','SD','SD, Rat Strain','false'
'msasss mean sd','C2347634','Mean','Population Mean','false'
'msasss mean sd','C2348143','Mean','Sample Mean','false'
'syndesmophyte present n','C0221690','Syndesmophyte','Syndesmophyte','false'
'syndesmophyte present n','C0150312','PRESENT','Present','false'
'syndesmophyte present n','C0449450','Present','Presentation','false'
'total back pain mean sd','C0004604','BACKPAIN','Back Pain','true'
'total back pain mean sd','C2699239','SD','SD, Rat Strain','false'
'total back pain mean sd','C1963071','Back pain','Back Pain, CTCAE 3.0','false'
'total back pain mean sd','C4553945','Back pain','Back Pain, CTCAE 5.0','false'
'patient s global assessment of disease activity mean sd','C0030705','*^patient','Patients','true'
'patient s global assessment of disease activity mean sd','C0281858','Global Assessment','global assessment','false'
'patient s global assessment of disease activity mean sd','C1292728','Disease activity','Condition activity','false'
'placebo secukinumab $nmbr$ mg','C0024671','MG','Mammography','true'
'placebo secukinumab $nmbr$ mg','C0026410','MG','Mongolia','true'
'placebo secukinumab $nmbr$ mg','C0439269','mg%','mg/dL','false'
'placebo secukinumab $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'placebo secukinumab $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'placebo secukinumab $nmbr$ mg','C4321396','MG','MG','false'
'placebo secukinumab $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'placebo secukinumab pooled','C0032042','Placebo','Placebos','true'
'placebo secukinumab pooled','C3179547','SECUKINUMAB','secukinumab','true'
'placebo secukinumab pooled','C1696465','PLACEBO','placebo','false'
'placebo secukinumab pooled','C1706408','PLACEBO','Placebo Control','false'
'placebo secukinumab pooled','C1709595','Pooled','Pooled Sample','false'
'placebo secukinumab pooled','C2349200','Pooled','Pool (action)','false'
'placebo secukinumab pooled','C4522255','Pooled','Pooled Blood Products','false'
'change at week $nmbr$','C0392747','Change','Changing','false'
'change at week $nmbr$','C0443172','change','Changed status','false'
'change at week $nmbr$','C1705241','Change','Delta (difference)','false'
'change at week $nmbr$','C4319952','Change','Change -- procedure','false'
'patients with syndesmophytes at baseline','C0030705','Patients','Patients','true'
'patients with syndesmophytes at baseline','C0221690','Syndesmophytes','Syndesmophyte','false'
'patients with syndesmophytes at baseline','C0168634','baseline','BaseLine dental cement','true'
'patients with syndesmophytes at baseline','C1442488','Baseline','Baseline','false'
'patients without syndesmophytes at baseline','C0030705','Patients','Patients','true'
'patients without syndesmophytes at baseline','C0221690','Syndesmophytes','Syndesmophyte','false'
'patients without syndesmophytes at baseline','C0168634','baseline','BaseLine dental cement','true'
'patients without syndesmophytes at baseline','C1442488','Baseline','Baseline','false'
'elevated hscrp','C0205250','Elevated','High','false'
'elevated hscrp','C3163633','Elevated','Elevated','false'
'normal hscrp','C0205307','NORMAL','Normal','false'
'normal hscrp','C0231683','Normal','Gait normal','false'
'normal hscrp','C0439166','% normal','Percent normal','false'
'normal hscrp','C2347086','% Normal','Mean Percent of Normal','false'
'normal hscrp','C4553972','Normal','How Often Felt Normal question','false'
'smokers at baseline','C0337664','Smokers','Smoker','true'
'smokers at baseline','C0168634','baseline','BaseLine dental cement','true'
'smokers at baseline','C1442488','Baseline','Baseline','false'
'non smokers at baseline','C0337672','non smokers','Non-smoker','false'
'non smokers at baseline','C4554605','Non-Smokers','Non-Smokers -- population group','true'
'empagliflozin $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'empagliflozin $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'empagliflozin $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'empagliflozin $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'empagliflozin $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'empagliflozin $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'empagliflozin $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C1739039','EGFR','EGFR protein, human','true'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C0439445','mL/min','mL/min','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C0444504','Mean','Statistical mean','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C2699239','SD','SD, Rat Strain','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C2347634','Mean','Population Mean','false'
'egfr ml min $nmbr$ $nmbr$ m $nmbr$ mdrd mean sd','C2348143','Mean','Sample Mean','false'
'sbp mm hg office measurement mean sd','C0439475','mmHG','mmHg','false'
'sbp mm hg office measurement mean sd','C2699239','SD','SD, Rat Strain','false'
'sbp mm hg mean $nmbr$ h mean sd','C0456680','mm/h','mm/h','false'
'sbp mm hg mean $nmbr$ h mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mm hg office measurement mean sd','C0439475','mmHG','mmHg','false'
'dbp mm hg office measurement mean sd','C2699239','SD','SD, Rat Strain','false'
'dbp mm hg mean $nmbr$ h mean sd','C0456680','mm/h','mm/h','false'
'dbp mm hg mean $nmbr$ h mean sd','C2699239','SD','SD, Rat Strain','false'
'pulse rate bpm mean $nmbr$ h mean sd','C0232117','Pulse Rate','Pulse Rate','true'
'pulse rate bpm mean $nmbr$ h mean sd','C2699239','SD','SD, Rat Strain','false'
'time since diagnosis of t $nmbr$ dm y n','C0040223','TIME','Time','true'
'time since diagnosis of t $nmbr$ dm y n','C3541383','Time','Time (foundation metadata concept)','false'
'use of diuretics n','C1524063','Use of','Use of','false'
'use of diuretics n','C0012798','DIURETICS','Diuretics','true'
'use of ace inhibitors arbs n','C1524063','Use of','Use of','false'
'use of ace inhibitors arbs n','C0003015','ACE INHIBITORS','Angiotensin-Converting Enzyme Inhibitors','true'
'$nmbr$ antihypertensive medication','C0003364','Antihypertensive Medication','Antihypertensive Agents','true'
'$nmbr$ antihypertensive medications','C0003364','Antihypertensive Medications','Antihypertensive Agents','true'
'$nmbr$ aes','C1412268','AES','AES gene','false'
'$nmbr$ aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'$nmbr$ drug related aes','C1412268','AES','AES gene','false'
'$nmbr$ drug related aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'$nmbr$ aes leading to discontinuation','C1412268','AES','AES gene','false'
'$nmbr$ aes leading to discontinuation','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'$nmbr$ aes leading to discontinuation','C0332152','Leading','Before','false'
'$nmbr$ aes leading to discontinuation','C0457454','Discontinuation','Discontinuation (procedure)','false'
'$nmbr$ aes leading to discontinuation','C1444662','Discontinuation','Discontinued','false'
'$nmbr$ aes leading to discontinuation','C4552847','discontinuation','Clinical Trial Discontinuation','false'
'$nmbr$ aes leading to discontinuation','C1522538','Leading','Leading','false'
'$nmbr$ serious aes','C1412268','AES','AES gene','false'
'$nmbr$ serious aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'special interest categories','C0205555','Special','Special','false'
'special interest categories','C0683312','Categories','Categories','false'
'events requiring assistance','C0441471','Events','Event','false'
'events requiring assistance','C3541888','EVENTS','CDISC Events Class','false'
'events requiring assistance','C0018896','Assistance','Helping Behavior','true'
'events requiring assistance','C1269765','Assistance','Assisted (qualifier value)','false'
'events consistent with uti','C0441471','Events','Event','false'
'events consistent with uti','C3541888','EVENTS','CDISC Events Class','false'
'events consistent with uti','C0332290','Consistent with','Consistent with','false'
'events consistent with uti','C0042029','UTI','Urinary tract infection','true'
'events consistent with uti','C0077906','UTI','urinastatin','true'
'events consistent with uti','C1412376','UTI','AMBP gene','false'
'events consistent with genital infection','C0441471','Events','Event','false'
'events consistent with genital infection','C3541888','EVENTS','CDISC Events Class','false'
'events consistent with genital infection','C0332290','Consistent with','Consistent with','false'
'events consistent with genital infection','C0729552','Genital infection','Genital infection','false'
'events consistent with volume depletion','C0441471','Events','Event','false'
'events consistent with volume depletion','C3541888','EVENTS','CDISC Events Class','false'
'events consistent with volume depletion','C0332290','Consistent with','Consistent with','false'
'events consistent with volume depletion','C0546884','Volume depletion','Hypovolemia','true'
'positive orthostatic test','C0022885','Test','Laboratory Procedures','false'
'positive orthostatic test','C0039593','Test','Testing','false'
'positive orthostatic test','C0392366','test','Tests (qualifier value)','false'
'positive orthostatic test','C0456984','Test','Test Result','false'
'positive orthostatic test','C1515976','test','Anatomic Structure, System, or Substance','false'
'positive orthostatic test','C3831328','Test','Blood Products Laboratory Testing','false'
'positive orthostatic test','C4318744','Test','Test - temporal region','false'
'no diuretic therapy','C0948575','Diuretic therapy','Diuretic therapy','false'
'diuretic therapy','C0948575','Diuretic therapy','Diuretic therapy','false'
'no ace inhibitor arb','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'no ace inhibitor arb','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'no ace inhibitor arb','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'ace inhibitor arb therapy','C1444755','ACE inhibitor therapy','Angiotensin converting enzyme inhibitor therapy','false'
'ace inhibitor arb therapy','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'therapy','C0039798','therapy','therapeutic aspects','true'
'therapy','C0087111','Therapy','Therapeutic procedure','true'
'therapy','C1363945','Therapy','Therapy Object (animal model)','false'
'empa','C2699863','EMPA','Electron Microprobe Analysis','false'
'$nmbr$ drug related','C0013227','Drug','Pharmaceutical Preparations','true'
'$nmbr$ drug related','C0439849','Related','Relationships','false'
'$nmbr$ drug related','C0445223','Related','Related personal status','false'
'$nmbr$ drug related','C1254351','DRUG','Pharmacologic Substance','false'
'aes','C1412268','AES','AES gene','false'
'aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'hypoglycemia^','C0020615','HYPOGLYCEMIA','Hypoglycemia','true'
'hypoglycemia^','C4553659','Hypoglycemia','Hypoglycemia, CTCAE','false'
'requiring assistance','C0018896','Assistance','Helping Behavior','true'
'requiring assistance','C1269765','Assistance','Assisted (qualifier value)','false'
'orthostatic test','C0022885','Test','Laboratory Procedures','false'
'orthostatic test','C0039593','Test','Testing','false'
'orthostatic test','C0392366','test','Tests (qualifier value)','false'
'orthostatic test','C0456984','Test','Test Result','false'
'orthostatic test','C1515976','test','Anatomic Structure, System, or Substance','false'
'orthostatic test','C3831328','Test','Blood Products Laboratory Testing','false'
'orthostatic test','C4318744','Test','Test - temporal region','false'
'non cana n $nmbr$','C1518422','Non','Negation','false'
'non cana n $nmbr$','C1418845','CANA','PPP3CA gene','false'
'baseline hbalc','C0168634','baseline','BaseLine dental cement','true'
'baseline hbalc','C1442488','Baseline','Baseline','false'
'baseline hbalc $nmbr$ to','C0168634','baseline','BaseLine dental cement','true'
'baseline hbalc $nmbr$ to','C1442488','Baseline','Baseline','false'
'baseline hbalc $nmbr$','C0168634','baseline','BaseLine dental cement','true'
'baseline hbalc $nmbr$','C1442488','Baseline','Baseline','false'
'genital mycotic infections male $nmbr$','C0564768','genital infections male','Male genital infection','false'
'female $nmbr$','C0043210','female','Woman','true'
'female $nmbr$','C0086287','FEMALE','Females','true'
'female $nmbr$','C1705497','Female','Female, Self-Report','false'
'female $nmbr$','C1705498','FEMALE','Female Phenotype','false'
'utis','C0042029','utis','Urinary tract infection','true'
'osmotic diuresis related aes','C1412268','AES','AES gene','false'
'osmotic diuresis related aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'volume depletion related aes','C1412268','AES','AES gene','false'
'volume depletion related aes','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'olodaterol $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'olodaterol $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'olodaterol $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'olodaterol $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'olodaterol $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'olodaterol $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'olodaterol $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'tiotropium $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tiotropium $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tiotropium $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tiotropium $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tiotropium $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tiotropium $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tiotropium $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C4032878','tiotropium-olodaterol','olodaterol / tiotropium','true'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'co morbidities a n','C0009488','co-morbidity','Comorbidity','true'
'co morbidities a n','C0369718','N NOS','N not otherwise specified Antibody','false'
'co morbidities a n','C0441922','N+','N+ (tumor staging)','false'
'cardiac history','C0019664','History','History','true'
'cardiac history','C0019665','history','Historical aspects qualifier','true'
'cardiac history','C0262512','History, NOS','History of present illness','false'
'cardiac history','C0262926','History','Medical History','false'
'cardiac history','C1705255','History','Concept History','false'
'cardiac history','C2004062','History','History of previous events','false'
'cardiac rhythm disorders','C0264886','cardiac rhythm disorder','Conduction disorder of the heart','true'
'vascular disordersb','C0005847','Vascular','Blood Vessel','true'
'vascular disordersb','C1558950','VASCULAR','Adverse Event Associated with Vascular','false'
'vascular disordersb','C1801960','Vascular','Vascular','false'
'gold n','C0018026','GOLD','Gold','true'
'gold n','C1304897','Gold','Gold color','false'
'baseline pulmonary medication n','C0024109','pulmonary','Lung','true'
'baseline pulmonary medication n','C0013227','Medication','Pharmaceutical Preparations','true'
'baseline pulmonary medication n','C3244316','medication','medication - HL7 publishing domain','false'
'baseline pulmonary medication n','C4284232','Medication','Medications','false'
'baseline pulmonary medication n','C2707265','Pulmonary','Pulmonary:-:Point in time:^Patient:-','false'
'baseline pulmonary medication n','C2709248','Pulmonary','Pulmonary (qualifier value)','false'
'baseline pulmonary medication n','C4522268','Pulmonary','Pulmonary (intended site)','false'
'sama','C1075468','sama','Echinochloa frumentacea','false'
'xanthines','C0043318','Xanthines','Xanthines','true'
'xanthines','C3541955','Xanthines','Xanthines, systemic for obstructive airway disease','false'
'baseline cardiovascular medication c n','C0168634','baseline','BaseLine dental cement','true'
'baseline cardiovascular medication c n','C0007220','Cardiovascular Medication','Cardiovascular Agents','true'
'baseline cardiovascular medication c n','C1442488','Baseline','Baseline','false'
'mean sd extent of exposure days','C0439792','Extent','Extent','false'
'mean sd extent of exposure days','C0274281','Exposure NOS','Injury due to exposure to external cause','false'
'mean sd extent of exposure days','C0332157','Exposure','Exposure to','false'
'cardiac rhythm disorder at baseline no','C0264886','cardiac rhythm disorder','Conduction disorder of the heart','true'
'cardiac rhythm disorder at baseline no','C0168634','baseline','BaseLine dental cement','true'
'cardiac rhythm disorder at baseline no','C1442488','Baseline','Baseline','false'
'cardiac rhythm disorder at baseline yes','C0264886','cardiac rhythm disorder','Conduction disorder of the heart','true'
'cardiac rhythm disorder at baseline yes','C0168634','baseline','BaseLine dental cement','true'
'cardiac rhythm disorder at baseline yes','C1442488','Baseline','Baseline','false'
'meddra smq','C1140263','MedDRA','Medical Dictionary for Regulatory Activities Terminology (MedDRA)','false'
'olodaterol $nmbr$ m g','C2934193','OLODATEROL','olodaterol','true'
'olodaterol $nmbr$ m g','C0439267','g%','Gram per Deciliter','false'
'tiotropium $nmbr$ m g','C0213771','TIOTROPIUM','tiotropium','true'
'tiotropium $nmbr$ m g','C0439267','g%','Gram per Deciliter','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'tiotropium olodaterol $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'total patients n','C0439175','% total','% of total','false'
'total patients n','C0030705','Patients','Patients','true'
'total patients n','C0439810','Total','Total','false'
'any aes n','C1412268','AES','AES gene','false'
'any aes n','C2699274','AES','Scanning Auger Spectrometer (device)','false'
'tachyarrhythmias n','C0080203','Tachyarrhythmias','Tachyarrhythmia','true'
'supraventricular tachyarrhythmias incl atrial','C1698480','Supraventricular tachyarrhythmias','Supraventricular tachyarrhythmia','false'
'supraventricular tachyarrhythmias incl atrial','C3853833','Supraventricular Tachyarrhythmias','Supraventricular Tachyarrhythmia ECG Assessment','false'
'fibrillation flutter','C0016385','Flutter','Cardiac Flutter','false'
'fibrillation flutter','C2242390','FLUTTER','Flutter (respiratory device)','false'
'ventricular tachyarrhythmias','C3827656','Ventricular Tachyarrhythmias','Ventricular Tachyarrhythmia ECG Assessment','false'
'ischaemic heart disease n','C0010054','ischaemic heart disease','Coronary Arteriosclerosis','true'
'ischaemic heart disease n','C0151744','Ischaemic heart disease, NOS','Myocardial Ischemia','true'
'other ischaemic heart disease non infarction','C0027051','HEART INFARCTION','Myocardial Infarction','true'
'other ischaemic heart disease non infarction','C1518422','Non','Negation','false'
'cardiac failure n','C0018801','CARDIAC FAILURE','Heart failure','true'
'cardiac failure n','C0018802','Cardiac Failure','Congestive heart failure','true'
'cerebrovascular disorders n','C0007820','Cerebrovascular Disorders','Cerebrovascular Disorders','true'
'haemorrhagic','C0333275','Hemorrhagic','Hemorrhagic','false'
'olodaterol $nmbr$ mg','C0024671','MG','Mammography','true'
'olodaterol $nmbr$ mg','C0026410','MG','Mongolia','true'
'olodaterol $nmbr$ mg','C0439269','mg%','mg/dL','false'
'olodaterol $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'olodaterol $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'olodaterol $nmbr$ mg','C4321396','MG','MG','false'
'olodaterol $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'tiotropium $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'tiotropium $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'tiotropium $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tiotropium $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tiotropium $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tiotropium $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'tiotropium $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'tiotropium $nmbr$ mg','C0024671','MG','Mammography','true'
'tiotropium $nmbr$ mg','C0026410','MG','Mongolia','true'
'tiotropium $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tiotropium $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tiotropium $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tiotropium $nmbr$ mg','C4321396','MG','MG','false'
'tiotropium $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C0024671','MG','Mammography','true'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C0026410','MG','Mongolia','true'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C0439269','mg%','mg/dL','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C1960952','mg %','Milligram percent','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C2346927','Mg++','Magnesium Cation','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C4321396','MG','MG','false'
'tiotropium olodaterol $nmbr$ $nmbr$ $nmbr$ mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'copd disease severity','C0024117','COPD NOS','Chronic Obstructive Airway Disease','true'
'copd disease severity','C0521117','disease severity','Severity of illness','false'
'copd disease severity','C1412502','COPD','ARCN1 gene','false'
'copd disease severity','C3714496','COPD','Chronic obstructive pulmonary disease of horses','false'
'vonoprazan $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'vonoprazan $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'vonoprazan $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'vonoprazan $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'vonoprazan $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'vonoprazan $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'vonoprazan $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'previous smoker','C0337671','Previous smoker','Former smoker','false'
'every day','C0332173','/day','Daily','false'
'every day','C0439228','Day','day','false'
'every day','C0439505','/day','per day','false'
'$nmbr$ or $nmbr$ d wk','C0332174','/wk','Weekly','false'
'$nmbr$ or $nmbr$ d wk','C0439230','wk','week','false'
'$nmbr$ or $nmbr$ d mo','C0026544','MO','Morocco','true'
'$nmbr$ or $nmbr$ d mo','C0332177','/mo','Monthly (qualifier value)','false'
'never drink','C2003901','NEVER','Never (frequency)','false'
'never drink','C0452428','Drink','Drink (dietary substance)','false'
'caffeine consumption','C0948365','caffeine consumption','caffeine consumption','false'
'modi fied la grade','C0441800','Grade','Grade','false'
'modi fied la grade','C0919553','Grade','Histopathologic Grade','false'
'modi fied la grade','C3244287','grade','School Grade','false'
'heartburn severity during the run in periodt','C0439793','Severity','Severities','false'
'heartburn severity during the run in periodt','C0522510','Severity','With intensity','false'
'esophageal hiatal hernia','C3489393','Oesophageal hiatal hernia','Hiatal Hernia','true'
'yes z $nmbr$ cm','C1549445','Yes','Yes - Yes/no indicator','false'
'yes z $nmbr$ cm','C1705108','YES','Yes (indicator)','false'
'yes z $nmbr$ cm','C1710701','Yes','YES1 wt Allele','false'
'yes o $nmbr$ cm','C1549445','Yes','Yes - Yes/no indicator','false'
'yes o $nmbr$ cm','C1705108','YES','Yes (indicator)','false'
'yes o $nmbr$ cm','C1710701','Yes','YES1 wt Allele','false'
'h pylori serology','C0036745','Serology','Study of serum','true'
'h pylori serology','C0220911','Serology','Serological aspects','false'
'h pylori serology','C0455278','Serology','Sample serology (procedure)','false'
'history of h pylori eradication','C0019664','History','History','true'
'history of h pylori eradication','C0019665','history','Historical aspects qualifier','true'
'history of h pylori eradication','C0262512','History, NOS','History of present illness','false'
'history of h pylori eradication','C0262926','History','Medical History','false'
'history of h pylori eradication','C1705255','History','Concept History','false'
'history of h pylori eradication','C2004062','History','History of previous events','false'
'yes r $nmbr$ y','C1549445','Yes','Yes - Yes/no indicator','false'
'yes r $nmbr$ y','C1705108','YES','Yes (indicator)','false'
'yes r $nmbr$ y','C1710701','Yes','YES1 wt Allele','false'
'yes r $nmbr$ y','C0205090','R-','Right','false'
'yes r $nmbr$ y','C0684010','R.','Rabbi','true'
'yes r $nmbr$ y','C2603358','R'','R prime','false'
'yes $nmbr$ $nmbr$ y','C1549445','Yes','Yes - Yes/no indicator','false'
'yes $nmbr$ $nmbr$ y','C1705108','YES','Yes (indicator)','false'
'yes $nmbr$ $nmbr$ y','C1710701','Yes','YES1 wt Allele','false'
'serum gastrint pg ml','C0229671','SERUM','Serum','true'
'serum gastrint pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'serum gastrint pg ml','C1546774','Serum','Specimen Source Codes - Serum','false'
'serum gastrint pg ml','C1550100','Serum','Specimen Type - Serum','false'
'serum pepsinogen i iit','C0077923','Pepsinogen I','Pepsinogen A','true'
'serum pepsinogen i iit','C0523816','Pepsinogen I','Pepsinogen I measurement','false'
'czp mtx^mtx','C0054841','CZP','carzinophilin','true'
'czp mtx^mtx','C0025677','MTX','Methotrexate','true'
'czp mtx^mtx','C1417487','MTX','MTX1 gene','false'
'czp mtx^mtx','C1861828','CZP','Cataract, Zonular Pulverulent 1','true'
'czp mtx^mtx','C1872109','CZP','certolizumab pegol','true'
'pbo mtx^mtx','C0031962','PBO','Piperonyl Butoxide','true'
'pbo mtx^mtx','C0025677','MTX','Methotrexate','true'
'pbo mtx^mtx','C1417487','MTX','MTX1 gene','false'
'total patients n $nmbr$','C0439175','% total','% of total','false'
'total patients n $nmbr$','C0030705','Patients','Patients','true'
'total patients n $nmbr$','C0439810','Total','Total','false'
'patients entering pt period n $nmbr$','C0030705','Patients','Patients','true'
'patients entering pt period n $nmbr$','C1522196','ENTER','Enteral Route of Drug Administration','false'
'patients entering pt period n $nmbr$','C0032743','PT','Positron-Emission Tomography','true'
'patients entering pt period n $nmbr$','C0439531','/period','per period (qualifier value)','false'
'patients entering pt period n $nmbr$','C1948053','Period','Period (temporal qualifier)','false'
'patients entering pt period n $nmbr$','C0699718','PT','Physical therapy (field)','false'
'db baseline week $nmbr$','C0332174','/week','Weekly','false'
'db baseline week $nmbr$','C0439230','Week','week','false'
'pt baseline week $nmbr$','C0332174','/week','Weekly','false'
'pt baseline week $nmbr$','C0439230','Week','week','false'
'ra duration months','C0449238','Duration','Duration (temporal concept)','false'
'ra duration months','C0439231','MONTHS','month','false'
'ra duration months','C2926735','Duration','Duration','false'
'rf positive n','C0035448','RF','Rheumatoid Factor','true'
'rf positive n','C0201660','RF','Rheumatoid Factor Measurement','false'
'rf positive n','C0748398','RF','RF','false'
'rf positive n','C1547111','RF','Radio fluoroscopy','false'
'bone erosion judged by physician n','C0587240','bone erosion','bone erosion','false'
'bone erosion judged by physician n','C0221191','Judge','Judge','false'
'bone erosion judged by physician n','C0031831','PHYSICIAN','Physicians','true'
'bone erosion judged by physician n','C0804815','Physician','Physician:Identifier:Point in time:^Patient:Nominal','false'
'tjc $nmbr$ joints','C0022417','Joints','Joints','true'
'tjc $nmbr$ joints','C0392905','Joints','Articular system','false'
'sjc $nmbr$ joints','C0022417','Joints','Joints','true'
'sjc $nmbr$ joints','C0392905','Joints','Articular system','false'
'mmp $nmbr$ ng ml','C0623362','MMP','Matrix Metalloproteinases','true'
'mmp $nmbr$ ng ml','C0439275','ng/mL','Microgram per Liter','false'
'mmp $nmbr$ ng ml','C0919336','MMP','MMP gene','false'
'sdai','C3871128','SDAI','SDAI','false'
'average weekly mtx dose mg week t','C0366550','MTX Dose','Methotrexate:Mass:Pt:Dose:Qn','false'
'average weekly mtx dose mg week t','C0024671','MG','Mammography','true'
'average weekly mtx dose mg week t','C0026410','MG','Mongolia','true'
'average weekly mtx dose mg week t','C0439269','mg%','mg/dL','false'
'average weekly mtx dose mg week t','C1960952','mg %','Milligram percent','false'
'average weekly mtx dose mg week t','C2346927','Mg++','Magnesium Cation','false'
'average weekly mtx dose mg week t','C4321396','MG','MG','false'
'average weekly mtx dose mg week t','C4521761','MG','United States Military Commissioned Officer O8','false'
'czp mtx to mtx','C0054841','CZP','carzinophilin','true'
'czp mtx to mtx','C0025677','MTX','Methotrexate','true'
'czp mtx to mtx','C1417487','MTX','MTX1 gene','false'
'czp mtx to mtx','C1861828','CZP','Cataract, Zonular Pulverulent 1','true'
'czp mtx to mtx','C1872109','CZP','certolizumab pegol','true'
'pbo mtx to mtx','C0031962','PBO','Piperonyl Butoxide','true'
'pbo mtx to mtx','C0025677','MTX','Methotrexate','true'
'pbo mtx to mtx','C1417487','MTX','MTX1 gene','false'
'mtss cfb','C0009002','CFB','Clofibrate','true'
'mtss cfb','C1824728','CFB','CFB gene','false'
'baseline factor','C1521761','Factor','Factor','false'
'baseline factor','C2827422','Factor','Mathematical Factor','false'
'baseline erosion','C0333307','Erosion','Superficial ulcer','false'
'baseline erosion','C1880549','Erosion','Erosion of Medical Device Material','false'
'baseline erosion','C1959609','EROSION','Erosion lesion','false'
'baseline erosion','C3887524','Erosion','Skin Erosion','false'
'das $nmbr$','C0051767','DAS','amsonic acid','true'
'das $nmbr$','C0057671','DAS','diacetoxyscirpenol','true'
'rf iu ml','C0035448','RF','Rheumatoid Factor','true'
'rf iu ml','C0439458','IU/mL','IU/mL','false'
'rf iu ml','C0201660','RF','Rheumatoid Factor Measurement','false'
'rf iu ml','C0748398','RF','RF','false'
'rf iu ml','C1547111','RF','Radio fluoroscopy','false'
'tnf alpha pg ml','C1448177','TNF Alpha','TNF protein, human','true'
'tnf alpha pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'tnf alpha pg ml','C1456820','TNFalpha','Tumor Necrosis Factor-alpha','true'
'tnf alpha pg ml','C1522669','TNF-Alpha','Recombinant Tumor Necrosis Factor-Alpha','false'
'il $nmbr$ pg ml','C0020898','IL','Illinois (geographic location)','true'
'il $nmbr$ pg ml','C0439297','pg/mL','Nanogram per Liter','false'
'il $nmbr$ pg ml','C0021764','IL','Interleukins','true'
'il $nmbr$ pg ml','C0022271','IL','Israel','true'
'baseline steroids','C0168634','baseline','BaseLine dental cement','true'
'baseline steroids','C0038317','Steroids','Steroids','true'
'baseline steroids','C1442488','Baseline','Baseline','false'
'mtx exposure mg week','C0332174','/week','Weekly','false'
'mtx exposure mg week','C0439230','Week','week','false'
'age of onset','C0206132','Age of Onset','Age of Onset','true'
'age of onset','C3175530','Age of onset','Age of onset of symptoms:Time:Pt:^Patient:Qn','false'
'age of onset $nmbr$ years n $nmbr$','C0206132','Age of Onset','Age of Onset','true'
'age of onset $nmbr$ years n $nmbr$','C3175530','Age of onset','Age of onset of symptoms:Time:Pt:^Patient:Qn','false'
'geographical location n','C4545686','Geographical location','Geographical location (property)','false'
'fev $nmbr$ l mean sd','C0444504','Mean','Statistical mean','false'
'fev $nmbr$ l mean sd','C2699239','SD','SD, Rat Strain','false'
'fev $nmbr$ l mean sd','C2347634','Mean','Population Mean','false'
'fev $nmbr$ l mean sd','C2348143','Mean','Sample Mean','false'
'fev $nmbr$ predicted mean sd','C0444504','Mean','Statistical mean','false'
'fev $nmbr$ predicted mean sd','C2699239','SD','SD, Rat Strain','false'
'fev $nmbr$ predicted mean sd','C2347634','Mean','Population Mean','false'
'fev $nmbr$ predicted mean sd','C2348143','Mean','Sample Mean','false'
'acq $nmbr$ score mean sd','C0444504','Mean','Statistical mean','false'
'acq $nmbr$ score mean sd','C2699239','SD','SD, Rat Strain','false'
'acq $nmbr$ score mean sd','C2347634','Mean','Population Mean','false'
'acq $nmbr$ score mean sd','C2348143','Mean','Sample Mean','false'
'aqlq score mean sd','C0444504','Mean','Statistical mean','false'
'aqlq score mean sd','C2699239','SD','SD, Rat Strain','false'
'aqlq score mean sd','C2347634','Mean','Population Mean','false'
'aqlq score mean sd','C2348143','Mean','Sample Mean','false'
'asui score mean sd','C0444504','Mean','Statistical mean','false'
'asui score mean sd','C2699239','SD','SD, Rat Strain','false'
'asui score mean sd','C2347634','Mean','Population Mean','false'
'asui score mean sd','C2348143','Mean','Sample Mean','false'
'blood eosinophils cells ml','C2699156','Cells/mL','Cells per Milliliter','false'
'allergic disease by historyb n','C0020517','Allergic Disease','Hypersensitivity','true'
'allergic disease by historyb n','C0851444','Allergic Disease','Allergic condition','false'
'atopy specific ige c n','C0392707','ATOPY','Atopy','false'
'atopy specific ige c n','C0205369','Specific','Specific qualifier value','false'
'atopy specific ige c n','C1552740','specific','Entity Determiner - specific','false'
'atopy specific ige c n','C3539705','ATOPY','MS4A2 wt Allele','false'
'chronic sinusitis nasal polypsd n','C0149516','CHRONIC SINUSITIS','Chronic sinusitis','false'
'chronic sinusitis nasal polypsd n','C0028429','NASAL','Nose','true'
'chronic sinusitis nasal polypsd n','C4520890','Nasal','Nasal (intended site)','false'
'age of asthma onset years','C0206132','Age of Onset','Age of Onset','true'
'age of asthma onset years','C3175530','Age of onset','Age of onset of symptoms:Time:Pt:^Patient:Qn','false'
'demographic data','C4684639','Demographic Data','Demographic Data','false'
'alprostadil n $nmbr$','C0002335','ALPROSTADIL','Alprostadil','true'
'gender male female number','C0237753','*Number','Numbers','false'
'gender male female number','C0449788','Number','Count of entities','false'
'risk factors and diabetes status','C0035648','Risk Factors','risk factors','true'
'risk factors and diabetes status','C1553898','risk factors','risk factors - observation list','false'
'risk factors and diabetes status','C1317301','Diabetes status','diabetes status','false'
'caffeine','C0006644','CAFFEINE','Caffeine','true'
'caffeine','C0236734','caffeine','Caffeine related disorders','false'
'complete healinga','C0205197','COMPLETE','Complete','false'
'complete healinga','C0725685','COMPLEAT','Compleat Liquid Nutrition','false'
'complete healinga','C3853530','complete','Data operation - complete','false'
'complete healinga','C4283785','Complete','Complete Pharyngeal Contraction','false'
'major amputationsb','C0205082','Major','Severe (severity modifier)','false'
'major amputationsb','C0205164','Major','Major','false'
'major amputationsb','C4318856','Major','Major <insect>','false'
'major amputationsb','C4521762','Major','United States Military Commissioned Officer O4','false'
'alprostadil n n','C0002335','ALPROSTADIL','Alprostadil','true'
'interim analysis','C4684691','Interim Analysis','Interim Analysis','false'
'diabetics','C0241863','diabetics','diabetic','false'
'non diabetics','C1518422','Non','Negation','false'
'non diabetics','C0241863','diabetics','diabetic','false'
'overall analysis','C0002778','Analysis','Analysis of substances','false'
'overall analysis','C0936012','ANALYSIS','Analysis','false'
'overall analysis','C1524024','analysis','analysis aspect','true'
'cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c','C0205341','Repeated','Repeat','false'
'cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c','C0008107','CI','Chile','true'
'cochranemantelehaenszel repeated $nmbr$ $nmbr$ ci c','C3259781','CI','Coagulation Index Measurement','false'
'statistic','C2348149','Statistic','Sample Statistic','false'
'statistic','C2828391','Statistic','Statistic (data)','false'
'interim analysis all patients','C4684691','Interim Analysis','Interim Analysis','false'
'interim analysis all patients','C0030705','Patients','Patients','true'
'final analysis all patients','C0002778','Analysis','Analysis of substances','false'
'final analysis all patients','C0936012','ANALYSIS','Analysis','false'
'final analysis all patients','C1524024','analysis','analysis aspect','true'
'final analysis all patients','C0030705','Patients','Patients','true'
'serum mg','C0024671','MG','Mammography','true'
'serum mg','C0026410','MG','Mongolia','true'
'serum mg','C0439269','mg%','mg/dL','false'
'serum mg','C1960952','mg %','Milligram percent','false'
'serum mg','C2346927','Mg++','Magnesium Cation','false'
'serum mg','C4321396','MG','MG','false'
'serum mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'serum mg $nmbr$ $nmbr$ mmol l normal mg hvpermagnesemia','C2827881','mg/L/mg','Milligram per Liter per Milligram','false'
'pbo n $nmbr$ $nmbr$','C0031962','PBO','Piperonyl Butoxide','true'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C0024671','MG','Mammography','true'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C0026410','MG','Mongolia','true'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C0439269','mg%','mg/dL','false'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C1960952','mg %','Milligram percent','false'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C4321396','MG','MG','false'
'cana $nmbr$ mg n $nmbr$ $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'ethnicity n b','C0015031','Ethnicity','Ethnic group','true'
'ethnicity n b','C0243103','ethnicity','Ethnicity aspects','true'
'hba $nmbr$ c mmol mole','C0019016','HBA','Hemoglobin A','true'
'hba $nmbr$ c mmol mole','C3829066','mmol/mol','Millimole per Mole','false'
'hba $nmbr$ c mmol mole','C1825777','HBA','KRT90P gene','false'
'hba $nmbr$ c mmol mole','C3538758','HBA','SCN2A wt Allele','false'
'baseline serum mg','C0024671','MG','Mammography','true'
'baseline serum mg','C0026410','MG','Mongolia','true'
'baseline serum mg','C0439269','mg%','mg/dL','false'
'baseline serum mg','C1960952','mg %','Milligram percent','false'
'baseline serum mg','C2346927','Mg++','Magnesium Cation','false'
'baseline serum mg','C4321396','MG','MG','false'
'baseline serum mg','C4521761','MG','United States Military Commissioned Officer O8','false'
'baseline serum mg $nmbr$ $nmbr$ mmol l','C0439268','mg/L','Microgram per Milliliter','false'
'baseline mmol l','C0168634','baseline','BaseLine dental cement','true'
'baseline mmol l','C1532563','mmol/L','Millimole per Liter','false'
'baseline mmol l','C1442488','Baseline','Baseline','false'
'week $nmbr$ mmol l','C0332174','/week','Weekly','false'
'week $nmbr$ mmol l','C1532563','mmol/L','Millimole per Liter','false'
'week $nmbr$ mmol l','C0439230','Week','week','false'
'total number of patients','C2360800','Number of patients','Number of patients','false'
'egfr mean sd','C0444504','Mean','Statistical mean','false'
'egfr mean sd','C2699239','SD','SD, Rat Strain','false'
'egfr mean sd','C2347634','Mean','Population Mean','false'
'egfr mean sd','C2348143','Mean','Sample Mean','false'
'egfr $nmbr$ to','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ to','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ to','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'egfr $nmbr$ ml min n','C1739039','EGFR','EGFR protein, human','true'
'egfr $nmbr$ ml min n','C0439445','mL/min','mL/min','false'
'egfr $nmbr$ ml min n','C3811844','eGFR','Estimated Glomerular Filtration Rate','false'
'egfr $nmbr$ ml min n','C3812682','EGFR','Epidermal Growth Factor Receptor Measurement','false'
'af first diagnosis $nmbr$ years n','C0205435','First','First (number)','false'
'af first diagnosis $nmbr$ years n','C0011900','DIAGNOSIS','Diagnosis','true'
'af first diagnosis $nmbr$ years n','C1704338','diagnosis','diagnosis aspect','true'
'af first diagnosis $nmbr$ years n','C1704656','DIAGNOSIS','Diagnosis Study','false'
'af first diagnosis $nmbr$ years n','C1279901','First','Firstly','false'
'af on baseline ecg n','C0344434','AF','Atrial Fibrillation by ECG Finding','false'
'af on baseline ecg n','C4049859','AF','PSMD4 wt Allele','false'
'$nmbr$ or $nmbr$ n','C0369718','N NOS','N not otherwise specified Antibody','false'
'$nmbr$ or $nmbr$ n','C0441922','N+','N+ (tumor staging)','false'
'cha $nmbr$ ds $nmbr$ vasc score mean sd','C0444504','Mean','Statistical mean','false'
'cha $nmbr$ ds $nmbr$ vasc score mean sd','C2699239','SD','SD, Rat Strain','false'
'cha $nmbr$ ds $nmbr$ vasc score mean sd','C2347634','Mean','Population Mean','false'
'cha $nmbr$ ds $nmbr$ vasc score mean sd','C2348143','Mean','Sample Mean','false'
'risk factors for stroke','C0035648','Risk Factors','risk factors','true'
'risk factors for stroke','C1553898','risk factors','risk factors - observation list','false'
'previous stroke or tia n','C0038454','STROKE','Cerebrovascular accident','true'
'previous stroke or tia n','C4554100','Stroke','Stroke, CTCAE','false'
'previous stroke or tia n','C0007787','TIA','Transient Ischemic Attack','true'
'previous stroke or tia n','C0917805','TIA','Transient Cerebral Ischemia','true'
'previous stroke or tia n','C1054154','tia','Tacca leontopetaloides','false'
'heart failure n','C0018801','Failure, Heart','Heart failure','true'
'heart failure n','C0018802','Heart Failure','Congestive heart failure','true'
'heart failure n','C4554158','Heart failure','Heart Failure, CTCAE','false'
'hypertension receiving treatment n','C0020538','HYPERTENSION','Hypertensive disease','true'
'hypertension receiving treatment n','C1963138','Hypertension','Hypertension, CTCAE','false'
'hypertension receiving treatment n','C1514756','RECEIVING','Receive','false'
'hypertension receiving treatment n','C0039798','treatment','therapeutic aspects','true'
'hypertension receiving treatment n','C0087111','Treatment','Therapeutic procedure','true'
'hypertension receiving treatment n','C1522326','Treatment','Treating','false'
'hypertension receiving treatment n','C1533734','Treatment','Administration procedure','false'
'hypertension receiving treatment n','C1705169','Treatment','Biomaterial Treatment','false'
'hypertension receiving treatment n','C3538994','TREATMENT','Treatment Epoch','false'
'hypertension receiving treatment n','C3887704','treatment','treatment - ActInformationManagementReason','false'
'peripheral arterial disease n','C0085096','peripheral arterial disease','Peripheral Vascular Diseases','true'
'peripheral arterial disease n','C1704436','Peripheral Arterial Disease','Peripheral Arterial Diseases','true'
'valvular heart disease n','C0018824','Heart Disease, Valvular','Heart valve disease','true'
'valvular heart disease n','C1963123','Valvular heart disease','Valvular Heart Disease, CTCAE','false'
'concomitant medications at baseline','C0013227','Medications','Pharmaceutical Preparations','true'
'concomitant medications at baseline','C0802604','Medications','Medications:Presence or Identity:Duration of the study:^Patient:Nominal','false'
'concomitant medications at baseline','C2598133','Medications','Medications:-:Point in time:^Patient:-','false'
'concomitant medications at baseline','C4284232','Medications','Medications','false'
'arb or ace inhibitor n','C3888198','ARB','BESTROPHINOPATHY, AUTOSOMAL RECESSIVE','false'
'arb or ace inhibitor n','C0003015','ACE Inhibitor','Angiotensin-Converting Enzyme Inhibitors','true'
'arb or ace inhibitor n','C4541021','ACE inhibitor','Angiotensin-converting enzyme inhibitor (disposition)','false'
'ppi or h $nmbr$ receptor antagonist n','C0358591','PPI','Proton Pump Inhibitors','true'
'ppi or h $nmbr$ receptor antagonist n','C0871125','PPI','prepulse inhibition activity','true'
'ppi or h $nmbr$ receptor antagonist n','C3811894','PPI','Pixels per Inch','false'
'ppi or h $nmbr$ receptor antagonist n','C0033727','H+','Protons','true'
'ppi or h $nmbr$ receptor antagonist n','C4543207','Receptor antagonist','Receptor antagonist (disposition)','false'
'ppi or h $nmbr$ receptor antagonist n','C0369286','H NOS','H NOS Antibodies','false'
'ppi or h $nmbr$ receptor antagonist n','C0441932','H+','Hepatic Involvement','false'
'ppi or h $nmbr$ receptor antagonist n','C0564385','/h','/hour','false'
'ppi or h $nmbr$ receptor antagonist n','C4528284','h*%','Hour Times Percent','false'
'on oac at time of randomisation n','C0040223','TIME','Time','true'
'on oac at time of randomisation n','C0034656','Randomization','Randomization','true'
'on oac at time of randomisation n','C3541383','Time','Time (foundation metadata concept)','false'
'dabigatran $nmbr$ mg n $nmbr$','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg n $nmbr$','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg n $nmbr$','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg n $nmbr$','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg n $nmbr$','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'dabigatran $nmbr$ mg versus warfarin','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg versus warfarin','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg versus warfarin','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg versus warfarin','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg versus warfarin','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg versus warfarin','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg versus warfarin','C4521761','MG','United States Military Commissioned Officer O8','false'
'dabigatran $nmbr$ mg versus warfarin','C0043031','WARFARIN','Warfarin','true'
'dabigatran $nmbr$ mg versu swarfarin','C0024671','MG','Mammography','true'
'dabigatran $nmbr$ mg versu swarfarin','C0026410','MG','Mongolia','true'
'dabigatran $nmbr$ mg versu swarfarin','C0439269','mg%','mg/dL','false'
'dabigatran $nmbr$ mg versu swarfarin','C1960952','mg %','Milligram percent','false'
'dabigatran $nmbr$ mg versu swarfarin','C2346927','Mg++','Magnesium Cation','false'
'dabigatran $nmbr$ mg versu swarfarin','C4321396','MG','MG','false'
'dabigatran $nmbr$ mg versu swarfarin','C4521761','MG','United States Military Commissioned Officer O8','false'
'clinical outcome','C0205210','Clinical','Clinical','false'
'clinical outcome','C1274040','Outcome','Result','false'
'number of events','C4330837','Number of Events','Number of Events','false'
'event rate year','C0439234','Year','year','false'
'event rate year','C0439508','/Year','per year','false'
'p value for interaction age groups','C1709380','P-Value','P-Value','false'
'p value for interaction age continuous','C1709380','P-Value','P-Value','false'
'p value for interaction age continuous','C0001779','AGE','Age','false'
'p value for interaction age continuous','C0549178','CONTINUOUS','Continuous','false'
'stroke non','C0038454','STROKE','Cerebrovascular accident','true'
'stroke non','C1518422','Non','Negation','false'
'stroke non','C4554100','Stroke','Stroke, CTCAE','false'
'cns systemic embolism','C0013922','EMBOLISM','Embolism','true'
'cns systemic embolism','C1704212','Embolism, NOS','Embolus','true'
'all cause','C0015127','cause','Etiology aspects','true'
'all cause','C1524003','Cause','Science of Etiology','false'
'mortality','C0026565','Mortality','Mortality Vital Statistics','true'
'mortality','C0026566','mortality','Aspects of mortality statistics','true'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C0024671','MG','Mammography','true'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C3254570','Sirukumab','sirukumab','true'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C0026410','MG','Mongolia','true'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C0439269','mg%','mg/dL','false'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C1960952','mg %','Milligram percent','false'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C2346927','Mg++','Magnesium Cation','false'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C4321396','MG','MG','false'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C4521761','MG','United States Military Commissioned Officer O8','false'
'$nmbr$ mg sirukumab every $nmbr$ weeks n $nmbr$','C0439230','WEEKS','week','false'
'age range years','C1510829','Age-Years','Age-Years','false'
'age range years','C1514721','Range','Range','false'
'age range years','C2348147','Range','Sample Range','false'
'age range years','C3542016','Range','Concept model range (foundation metadata concept)','false'
'duration of rheumatoid arthritis years','C0449238','Duration','Duration (temporal concept)','false'
'duration of rheumatoid arthritis years','C2926735','Duration','Duration','false'
'anti ccp antibody positive','C0741132','antibody positive','antibody positive','false'
'das $nmbr$ c reactive protein','C0006560','C Reactive Protein','C-reactive protein','true'
'das $nmbr$ c reactive protein','C1413716','C-reactive protein','CRP gene','false'
'das $nmbr$ c reactive protein','C4048285','C-Reactive Protein','C-Reactive Protein, human','false'
'clinical disease activity index score $nmbr$ $nmbr$','C4706353','Disease Activity Score','DAS - Disease Activity Score','false'
'simplified disease activity index score $nmbr$ $nmbr$','C4706353','Disease Activity Score','DAS - Disease Activity Score','false'
'duration of morning','C0449238','Duration','Duration (temporal concept)','false'
'duration of morning','C2926735','Duration','Duration','false'
'stiffness min','C0702093','/min','Per Minute','false'
'stiffness min','C1524029','MIN NOS','Mouse MIN NOS','false'
'stiffness min','C3813700','%/min','Percent per Minute','false'
'conventional synthetic dmard use at baseline','C0042153','use','utilization qualifier','true'
'conventional synthetic dmard use at baseline','C0457083','Use','Usage','false'
'conventional synthetic dmard use at baseline','C1947944','Use','Use - dosing instruction imperative','false'
'methotrexate dose at baseline','C0178602','DOSE','Dosage','false'
'methotrexate dose at baseline','C0869039','Dose','Unit dose','false'
'methotrexate dose at baseline','C1114758','Dose #','Dose number:Number:Point in time:^Patient:Quantitative','false'
'$nmbr$ $nmbr$ mg week','C0332174','/week','Weekly','false'
'$nmbr$ $nmbr$ mg week','C0439230','Week','week','false'
'sirukumab $nmbr$ mg q $nmbr$ w','C0024671','MG','Mammography','true'
'sirukumab $nmbr$ mg q $nmbr$ w','C0026410','MG','Mongolia','true'
'sirukumab $nmbr$ mg q $nmbr$ w','C0439269','mg%','mg/dL','false'
'sirukumab $nmbr$ mg q $nmbr$ w','C1960952','mg %','Milligram percent','false'
'sirukumab $nmbr$ mg q $nmbr$ w','C2346927','Mg++','Magnesium Cation','false'
'sirukumab $nmbr$ mg q $nmbr$ w','C4321396','MG','MG','false'
'sirukumab $nmbr$ mg q $nmbr$ w','C4521761','MG','United States Military Commissioned Officer O8','false'
'evaluable for acr $nmbr$ at week $nmbr$ n','C1516986','Evaluable','Evaluable Disease','false'
'evaluable for acr $nmbr$ at week $nmbr$ n','C1412134','ACR','ACR gene','false'
'evaluable for acr $nmbr$ at week $nmbr$ n','C1515941','ACR','American College of Radiology','false'
'evaluable for acr $nmbr$ at week $nmbr$ n','C0332174','/week','Weekly','false'
'evaluable for acr $nmbr$ at week $nmbr$ n','C0439230','Week','week','false'
'acr $nmbr$ response at week $nmbr$ n','C0871261','Response','Response process','false'
'acr $nmbr$ response at week $nmbr$ n','C1704632','Response','Disease Response','false'
'acr $nmbr$ response at week $nmbr$ n','C1706817','Response','Response (statement)','false'
'acr $nmbr$ response at week $nmbr$ n','C2911692','Response','Response (communication)','false'
'prior anti tnf therapy','C1514463','Prior Therapy','Prior Therapy','false'
'received $nmbr$ prior anti tnf therapy n','C1514463','Prior Therapy','Prior Therapy','false'
'received $nmbr$ prior anti tnf therapies n','C1514463','Prior Therapy','Prior Therapy','false'
'prior biologic therapy including anti tnfs','C0278947','Prior Biologic Therapy','prior biologic therapy','false'
'prior biologic therapy including anti tnfs','C1448177','TNF','TNF protein, human','true'
'received $nmbr$ prior biologic therapy n','C1514756','RECEIVED','Receive','false'
'received $nmbr$ prior biologic therapy n','C0278947','Prior Biologic Therapy','prior biologic therapy','false'
'received $nmbr$ prior biologic therapies n','C1514756','RECEIVED','Receive','false'
'received $nmbr$ prior biologic therapies n','C0278947','Prior Biologic Therapy','prior biologic therapy','false'
'baseline hstni','C0168634','baseline','BaseLine dental cement','true'
'baseline hstni','C1442488','Baseline','Baseline','false'
'$nmbr$ ng l n $nmbr$','C0439297','ng/L','Nanogram per Liter','false'
'p value trend','C1521798','Trend','trend','false'
'p value trend','C4554533','Trend','Trend:Type:Point in time:^Patient:Nominal','false'
'glycohemoglobin','C0202054','Glycohemoglobin','Glucohemoglobin measurement','false'
'glycohemoglobin','C0696092','glyco hemoglobin','glyco hemoglobin','false'
'prior coronary intervention or coronary artery bypass grafting','C0184661','Intervention','Interventional procedure','true'
'prior coronary intervention or coronary artery bypass grafting','C0886296','intervention','Nursing interventions','false'
'prior coronary intervention or coronary artery bypass grafting','C1273869','Intervention','Intervention regimes','false'
'prior coronary intervention or coronary artery bypass grafting','C0010055','Coronary Artery Bypass Grafting','Coronary Artery Bypass Surgery','true'
'index inclusion acute coronary syndrome','C0007637','INCLUSION','Inclusion Bodies','true'
'index inclusion acute coronary syndrome','C0948089','Acute Coronary Syndrome','Acute Coronary Syndrome','true'
'index inclusion acute coronary syndrome','C1512693','INCLUSION','Inclusion','false'
'time from acute coronary syndrome to randomization days','C0040223','TIME','Time','true'
'time from acute coronary syndrome to randomization days','C3541383','Time','Time (foundation metadata concept)','false'
'time from acute coronary syndrome to randomization days','C0034656','Randomization','Randomization','true'
'time from acute coronary syndrome to randomization days','C0439228','DAYS','day','false'
'median egfr interquartile range','C0549183','Median','Midline (qualifier value)','false'
'median egfr interquartile range','C1711350','Interquartile Range','Interquartile Range','false'
'median egfr interquartile range','C0876920','Median','Median Statistical Measurement','false'
'median egfr interquartile range','C2347635','Median','Population Median','false'
'median egfr interquartile range','C2348144','Median','Sample Median','false'
'median egfr interquartile range','C2939193','Median','Median (qualifier value)','false'
'$nmbr$ ng l n $nmbr$ n','C0439297','ng/L','Nanogram per Liter','false'
'cardiovascular death nonfatal myocardial infarction nonfatal stroke','C0027051','Cardiovascular Stroke','Myocardial Infarction','true'
'cardiovascular death nonfatal myocardial infarction nonfatal stroke','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'cardiovascular death nonfatal myocardial infarction nonfatal stroke','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'cardiovascular death nonfatal myocardial infarction nonfatal stroke','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'cardiovascular death nonfatal myocardial infarction nonfatal stroke','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'nonfatal myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'nonfatal myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'nonfatal myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'nonfatal myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'nonfatal myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'cardiovascular death or hospitalization for heart failure','C0011065','DEATH','Cessation of life','true'
'cardiovascular death or hospitalization for heart failure','C1306577','Death','Death (finding)','false'
'cardiovascular death or hospitalization for heart failure','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cardiovascular death or hospitalization for heart failure','C4552775','Death NOS','Death NOS, CTCAE','false'
'cardiovascular death or hospitalization for heart failure','C3898876','HEART FAILURE HOSPITALIZATION','Hospitalization Due to Heart Failure','false'
'hospitalization for heart failure','C3898876','HEART FAILURE HOSPITALIZATION','Hospitalization Due to Heart Failure','false'
'cardiovascular death or nonfatal myocardial infarction','C0011065','DEATH','Cessation of life','true'
'cardiovascular death or nonfatal myocardial infarction','C1306577','Death','Death (finding)','false'
'cardiovascular death or nonfatal myocardial infarction','C4082313','Death NOS','Death Adverse Event Not Associated with More Specific CTCAE Term NOS','false'
'cardiovascular death or nonfatal myocardial infarction','C4552775','Death NOS','Death NOS, CTCAE','false'
'cardiovascular death or nonfatal myocardial infarction','C0027051','Infarction, Myocardial','Myocardial Infarction','true'
'cardiovascular death or nonfatal myocardial infarction','C0428953','MYOCARDIAL INFARCTION','Electrocardiogram: myocardial infarction (finding)','false'
'cardiovascular death or nonfatal myocardial infarction','C2926063','Myocardial infarction','Myocardial infarction:Finding:Point in time:^Patient:Ordinal','false'
'cardiovascular death or nonfatal myocardial infarction','C3810814','Myocardial Infarction','Myocardial Infarction ECG Assessment','false'
'cardiovascular death or nonfatal myocardial infarction','C4552959','Myocardial infarction','Myocardial Infarction, CTCAE','false'
'number of prior aeds','C0237753','*Number','Numbers','false'
'number of prior aeds','C0449788','Number','Count of entities','false'
'lev exposed','C0023556','LEV','Levamisole','true'
'lev exposed','C0332157','Exposed','Exposure to','false'
'$nmbr$ responder rate n','C0871208','Rate','Rating (action)','false'
'$nmbr$ responder rate n','C1521828','Rate','Rate','false'
'lev naive','C0023556','LEV','Levamisole','true'
